<SEC-DOCUMENT>0001121404-25-000022.txt : 20250731
<SEC-HEADER>0001121404-25-000022.hdr.sgml : 20250731
<ACCEPTANCE-DATETIME>20250731113308
ACCESSION NUMBER:		0001121404-25-000022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250731
DATE AS OF CHANGE:		20250731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		251170323

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sny-20250630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161,d:1cb661ddc7f946a1a069c8c0a6ccf94f-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sny="http://www.sanofi.com/20250630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-4">0001121404</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-5">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-6">6/30/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-7">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-8">Q2</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sny-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>sny:proceeding</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-27</xbrli:startDate><xbrli:endDate>2025-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VigilNeuroscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-22</xbrli:startDate><xbrli:endDate>2025-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VigilNeuroscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-30</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-29</xbrli:startDate><xbrli:endDate>2025-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-02</xbrli:startDate><xbrli:endDate>2025-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionFiveHundredMillionBondsIssuedInMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionFiveHundredMillionBondsIssuedInJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingJune2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromApril2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromApril2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:UKZONEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:EUROZONEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichSanofiAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VicebioLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-82 f-84 f-86 f-88 f-90 f-92 f-94 f-96 f-98 f-100 f-102 f-104 f-106 f-108 f-110 f-112 f-114 f-116 f-118 f-120 f-122 f-124 f-126 f-128 f-130 f-132 f-134 f-136 f-138 f-140 f-142 f-144 f-618 f-1258 f-1260 f-1301 f-1582 f-1673 f-1676 f-1678 f-1680 f-1682 f-1684" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-146 f-148 f-150 f-152 f-154 f-156 f-158 f-160 f-162 f-164 f-166 f-168 f-170 f-172 f-174 f-176 f-178 f-180 f-182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-213 f-214 f-215 f-260 f-261 f-262 f-331 f-332 f-333 f-345 f-346 f-347 f-348 f-349 f-350" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-338 f-339 f-340" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="4"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-232 f-233 f-234" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-5" order="5"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-357 f-358 f-359" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-6" order="6"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-360 f-361 f-362 f-363" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-7" order="7"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-374 f-376 f-378 f-380 f-382 f-384 f-386 f-388 f-390 f-392 f-394 f-396 f-398 f-400 f-402 f-404 f-406 f-408 f-410 f-412 f-414 f-416 f-418 f-420 f-422 f-424 f-426 f-428 f-430 f-432 f-434 f-436 f-438 f-440 f-442 f-444 f-446 f-448 f-450 f-452 f-454 f-456 f-458 f-460 f-462" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-8" order="8"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-383 f-384" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-9" order="9"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-387 f-388" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-10" order="10"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-393 f-394" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-11" order="11"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-405 f-406 f-407 f-408 f-409 f-410" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-12" order="12"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-413 f-414" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-13" order="13"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-417 f-418" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-14" order="14"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-427 f-428" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-15" order="15"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-443 f-444" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-16" order="16"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-542 f-543 f-544 f-545 f-570 f-571 f-572 f-573" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-17" order="17"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-526 f-527 f-528 f-529" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-18" order="18"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-558 f-559 f-560 f-561" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-19" order="19"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-596 f-597 f-598 f-613" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-20" order="20"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-599 f-600 f-601" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-21" order="21"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-602 f-603 f-604" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-22" order="22"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-605 f-606 f-607" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-23" order="23"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-627 f-628" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-24" order="24"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-629 f-630" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-25" order="25"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-621 f-622 f-623 f-624 f-625 f-626" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-26" order="26"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-621 f-622 f-623 f-624 f-625 f-626" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-27" order="27"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-636 f-637" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-28" order="28"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-723" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-29" order="29"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-726 f-728" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-30" order="30"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-803 f-804" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-31" order="31"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-809 f-810" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-32" order="32"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-815 f-816" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-33" order="33"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-842 f-843" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-34" order="34"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-877 f-878 f-879 f-880 f-881" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-35" order="35"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-892" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-36" order="36"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1059" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-37" order="37"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1063" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-38" order="38"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1073" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-39" order="39"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1156 f-1160 f-1164 f-1168 f-1172 f-1173 f-1174" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-40" order="40"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1161 f-1162 f-1163 f-1164" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-41" order="41"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1184 f-1185" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-42" order="42"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1197 f-1202 f-1207" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-43" order="43"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1212 f-1213 f-1214 f-1215 f-1216" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-44" order="44"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1241" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-45" order="45"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1242" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-46" order="46"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1239 f-1240 f-1241 f-1242" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-47" order="47"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1288 f-1289 f-1290 f-1291 f-1292 f-1293 f-1294 f-1295 f-1296 f-1297" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-48" order="48"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1290 f-1291" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-49" order="49"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1305 f-1307 f-1309 f-1311 f-1313 f-1315 f-1317 f-1319 f-1321 f-1323 f-1325" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-50" order="50"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1304 f-1305" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-51" order="51"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1306 f-1307" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-52" order="52"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1312 f-1313" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-53" order="53"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1318 f-1319" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-54" order="54"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1335 f-1337 f-1339 f-1341" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-55" order="55"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1344 f-1346 f-1348 f-1350 f-1352" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-56" order="56"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1343 f-1344 f-1345 f-1346 f-1347 f-1348 f-1349 f-1350 f-1351 f-1352" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-57" order="57"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1345 f-1346" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-58" order="58"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1349 f-1350" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-59" order="59"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1364 f-1372 f-1380 f-1388 f-1396 f-1404 f-1412 f-1420 f-1428 f-1436 f-1444 f-1452 f-1460 f-1468 f-1476 f-1484" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-60" order="60"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1487 f-1489 f-1491 f-1493 f-1495 f-1497 f-1499" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-61" order="61"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1488 f-1489" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-62" order="62"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1492 f-1493" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-63" order="63"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1496 f-1497" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-64" order="64"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1503 f-1506 f-1509 f-1512 f-1515 f-1518 f-1521 f-1524 f-1527" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-65" order="65"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1529 f-1530 f-1531 f-1532 f-1533 f-1534 f-1535 f-1536 f-1537 f-1538 f-1539 f-1540 f-1541 f-1542 f-1543 f-1544 f-1545 f-1546 f-1547 f-1548 f-1549 f-1550 f-1551 f-1552 f-1553 f-1554 f-1555" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-66" order="66"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1558 f-1560 f-1562 f-1564 f-1566 f-1568 f-1570 f-1572 f-1574 f-1576 f-1578 f-1580" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-67" order="67"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1559 f-1560" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-68" order="68"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1561 f-1562" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-69" order="69"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1563 f-1564" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-70" order="70"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1567 f-1568" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-71" order="71"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1569 f-1570" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-72" order="72"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1571 f-1572" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-73" order="73"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1584 f-1585" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-74" order="74"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1591 f-1593 f-1595 f-1597 f-1599 f-1601" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-75" order="75"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1662 f-1663 f-1664 f-1665" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-76" order="76"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1670 f-1671" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-77" order="77"/></ix:resources></ix:header></div><div id="i1cb661ddc7f946a1a069c8c0a6ccf94f_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of July 2025</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;001-31368</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">SANOFI</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46 avenue de la Grande Arm&#233;e &#8211; 75017 Paris</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, Sanofi issued the financial statements and half year management report attached hereto as Exhibit 99.1 and 99.2 which are incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i1cb661ddc7f946a1a069c8c0a6ccf94f_7"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed half-year consolidated financial statements for 2025</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Half-year management report, Statutory Auditors&#8217; Report and Responsibility Statement</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.635%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: July&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Securities Law and Capital Markets</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sny-20250630_d2.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161,d:4cb00d616bf34e7c9407f3fd7baa4584-->
<html xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:sny="http://www.sanofi.com/20250630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20250630_d2</title></head><body><div id="i4cb00d616bf34e7c9407f3fd7baa4584_4"></div><div style="min-height:56.69pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:0 1pt"/></tr></table></div></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div><div style="margin-bottom:5pt;margin-top:70pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"/><td style="width:3.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.997%"><tr><td style="width:1.0%"/><td style="width:88.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i0b4f8d7495f44e3d9a5f1ec2ced15103">1. Condensed half-year consolidated financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i0b4f8d7495f44e3d9a5f1ec2ced15103">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2df58f8d717d480f874b66e0f95ebc81">Consolidated balance sheets - assets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2df58f8d717d480f874b66e0f95ebc81">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib702841f245447d490c4416353f6fea4">Consolidated balance sheets - equity and liabilities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib702841f245447d490c4416353f6fea4">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#iaf9c7ab76228428f87d4f5edfcf61953">Consolidated income statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#iaf9c7ab76228428f87d4f5edfcf61953">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8e2058dfe19849b1bffcf8a8c7dd53a0">Consolidated statements of comprehensive income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8e2058dfe19849b1bffcf8a8c7dd53a0">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib45757957f5948ecb40023f34e3d4090">Consolidated statements of changes in equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib45757957f5948ecb40023f34e3d4090">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1bc67c61177f44aba5c0b502fab30cdf">Consolidated statement of cash flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1bc67c61177f44aba5c0b502fab30cdf">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i92fd164f2ed74f06ba367042f9317c9e">Notes to the condensed half-year consolidated financial statements as of June 30, 2025 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i92fd164f2ed74f06ba367042f9317c9e">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i06f57da0e5ba4e0c866be66a8e0b007c">Introduction</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i06f57da0e5ba4e0c866be66a8e0b007c">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#iff95aeb1cacb4d618b9870fd263c70dd">A/ Basis of preparation of the half-year financial statements and accounting policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#iff95aeb1cacb4d618b9870fd263c70dd">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic819263516be4986b3d2686dbb9cb5bc">B/ Significant information for the first half of 2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic819263516be4986b3d2686dbb9cb5bc">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i23ea087f4ae74ebaa993bb45daf2618f">C/ Events subsequent to June 30, 2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i23ea087f4ae74ebaa993bb45daf2618f">34</a></span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_7"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:15pt"><span id="i0b4f8d7495f44e3d9a5f1ec2ced15103"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_10"></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i2df58f8d717d480f874b66e0f95ebc81"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated balance sheets - assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-9">9,574</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-10">10,091</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-11">1,433</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-12">1,510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-13">40,283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-14">43,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-15">20,431</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-16">22,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.5.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-17">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-18">316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-19">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-20">3,753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-21">541</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-22">560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-23">8,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-24">7,967</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-25">87,942</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-26">90,210</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-27">9,618</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-28">9,431</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-29">7,810</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-30">7,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-31">3,595</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-32">3,826</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-33">397</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-34">724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-35">15,359</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-36">7,441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets held for sale</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.22.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-37">238</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-38">13,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-39">37,017</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-40">42,588</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-41">124,959</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-42">132,798</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_103">34</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_13"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="ib702841f245447d490c4416353f6fea4"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated balance sheets - equity and liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-43">70,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-44">77,507</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-45">271</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-46">350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-47">70,279</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-48">77,857</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-49">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-50">11,791</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current lease liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-51">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-52">1,645</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-53">564</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-54">569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.12.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-55">7,116</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-56">8,096</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-57">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-58">1,512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-59">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-60">2,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-61">25,621</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-62">25,779</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-63">7,075</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-64">7,551</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-66">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-67">13,697</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-68">14,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-69">724</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-70">697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current lease liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-71">252</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-72">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-73">7,309</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-74">4,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.22.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-75">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-76">2,131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-77">29,059</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-78">29,162</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></div></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-79">124,959</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-80">132,798</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_103">34</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_16"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="iaf9c7ab76228428f87d4f5edfcf61953"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated income statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.20.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-81">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-82">18,360</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.20.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-83">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-84">1,529</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-85">5,881</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-86">5,966</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-87">15,460</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-88">13,923</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-89">3,717</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-90">3,335</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-91">4,506</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-92">4,303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-93">533</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-94">563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-95">2,476</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-96">1,977</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-97">777</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-98">898</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-99">210</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-100">371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.  B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-101">61</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-102">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.16.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-103">430</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-104">1,060</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.17.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-105">57</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-106">450</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-107">3,759</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-108">2,768</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-109">361</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-110">583</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-111">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-112">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-113">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-114">2,462</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.19.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-115">711</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-116">379</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the&#160;equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-117">85</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-118">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-119">2,956</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-120">2,061</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations </span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.22</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-121">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" scale="6" id="f-122">202</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-123">5,837</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-124">2,263</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-125">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-126">17</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-127">5,812</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-128">2,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-129">1,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-130">1,249.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-131">1,230.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-132">1,253.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-133">2.40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-134">1.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-135">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-136">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (&#8364;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-137">4.74</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-138">1.80</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-139">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-140">1.63</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-141">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-142">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (&#8364;)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-143">4.72</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-144">1.79</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_103">34</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_19"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i8e2058dfe19849b1bffcf8a8c7dd53a0"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statements of comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-145">5,837</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-146">2,263</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-147">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-148">2,246</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-149">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-150">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-151">111</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-152">235</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of equity instruments included in financial assets and financial liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-153">222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-154">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-155">92</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-156">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subtotal: items not subsequently reclassifiable to profit or loss from continuing operations (A)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-157">241</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-158">166</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of debt instruments included in financial assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-159">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-160">5</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of cash flow hedges</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-161">23</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-162">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in currency translation differences</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-163">5,203</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-164">1,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-165">95</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-166">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subtotal: items subsequently reclassifiable to profit or loss from continuing operations (B)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-167">5,318</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-168">1,067</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income/(loss) from continuing operations  for the period, net of taxes (A+B)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherComprehensiveIncomeFromContinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-169">5,077</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherComprehensiveIncomeFromContinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-170">1,233</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherComprehensiveIncomeFromDiscontinuedOperations" scale="6" id="f-171">303</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherComprehensiveIncomeFromDiscontinuedOperations" scale="6" id="f-172">23</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-173">1,063</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-174">3,496</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-175">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-176">3,471</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Continuing operations</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-177">2,097</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-178">3,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Discontinued operations</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-179">3,173</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" scale="6" id="f-180">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #200f45;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-181">13</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #200f45;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #200f45;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-182">25</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #200f45;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_103">34</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_22"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="ib45757957f5948ecb40023f34e3d4090"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statements of changes in equity</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:21.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.299%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.299%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other compre-hensive income</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-183">2,530</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-184">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-185">1,184</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-186">67,499</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-187">4,944</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-188">62</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-189">74,040</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-190">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-191">74,353</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-192">166</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-193">1,059</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-194">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-195">8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-196">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-197">2,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-198">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-199">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-200">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-201">2,412</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-202">1,059</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-203">3,471</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-204">25</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-205">3,496</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2023 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-206">3.76</ix:nonFraction> per share)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-207">4,704</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-208">4,704</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-209">4,704</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-211">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-212">31</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-213">302</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-214">302</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-215">302</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="6" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-217">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-218">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-219">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-220">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-221">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-222">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-223">115</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-226">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-227">173</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-228">173</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-229">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-230">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-231">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-232">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-233">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-234">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2024 </span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-235">2,533</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-236">317</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-237">1,371</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-238">65,093</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-239">5,121</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-240">997</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-241">72,690</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-242">307</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-243">72,997</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-244">194</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-245">1,379</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-246">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-247">14</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-248">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-249">3,314</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-250">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-251">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-252">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the&#160;period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-253">3,120</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-254">1,379</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-255">4,499</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-256">55</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-257">4,554</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-258">13</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-259">13</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:fixed-zero" scale="6" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:fixed-zero" scale="6" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:fixed-zero" scale="6" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-263">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-264">492</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-265">530</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-266">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-269">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-270">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-271">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-272">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-275">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-276">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Employee share ownership plan</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-278">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-279">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-280">154</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-281">154</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-282">132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-283">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-284">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-285">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-286">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-287">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in non-controlling interests without loss of control</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="6" id="f-288">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="6" id="f-289">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="6" id="f-290">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" format="ixt:fixed-zero" scale="6" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at&#160;December&#160;31,&#160;2024</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-292">2,526</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="6" id="f-293">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-294">840</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-295">68,185</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-296">5,260</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-297">2,376</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-298">77,507</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-299">350</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-300">77,857</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;padding-left:14.2pt;text-align:justify;text-indent:-14.2pt"><span><br/></span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.200%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other compre-hensive income</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-301">2,526</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="6" id="f-302">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-303">840</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-304">68,185</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-305">5,260</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-306">2,376</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-307">77,507</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-308">350</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-309">77,857</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-310">243</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-311">4,979</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-312">4,736</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-313">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-314">4,774</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-315">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-316">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-317">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-318">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the&#160;period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-319">6,055</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-320">4,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-321">1,076</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-322">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-323">1,063</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2024 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-324">3.92</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-325">4,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-326">4,772</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-327">4,772</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-329">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-330">32</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-331">3,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-332">3,988</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-333">3,988</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-334">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-335">3,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-336">3,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax on share cancellations  </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-338">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-339">15</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-340">15</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-341">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-342">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-343">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-344">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and vesting of existing restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-345">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-346">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-351">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-352">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-353">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-354">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-355">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-356">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-357">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-358">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-359">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes in non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" format="ixt:fixed-zero" scale="6" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-362">34</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-363">34</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-364">2,456</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-365">11</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-366">975</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-367">65,689</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-368">5,430</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-369">2,603</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-370">70,008</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-371">271</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-372">70,279</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-6" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</span></ix:footnote></div><ix:footnote id="fn-7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).</span></div></ix:footnote><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4cb00d616bf34e7c9407f3fd7baa4584_103">34</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_25"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i1bc67c61177f44aba5c0b502fab30cdf"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statement of cash flows</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.275%"><tr><td style="width:1.0%"/><td style="width:62.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.321%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-373">5,812</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-374">2,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (income)/loss from the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:AdjustmentsForLossesGainsOnTransferOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-375">2,881</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:AdjustmentsForLossesGainsOnTransferOfBusiness" scale="6" id="f-376">202</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-377">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-378">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of undistributed earnings from investments accounted for using the equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-379">15</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-380">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-381">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-382">1,242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains and losses on disposals of non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-383">266</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-384">229</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-385">539</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-386">749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in non-current provisions and other non-current liabilities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-387">212</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-388">1,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of employee benefits (stock options and other share-based payments)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-389">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-390">157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of the workdown of acquired inventories remeasured at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-392">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profit or loss items with no cash effect on cash flows generated </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">by operating activities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-393">106</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-394">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating cash flow before changes in working capital</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-395">3,980</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-396">3,608</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-397">635</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-398">917</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-399">785</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-400">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-401">187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-402">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other current assets and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" scale="6" id="f-403">620</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-404">1,612</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing operating activities </span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-405">3,367</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-406">1,238</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="f-407">188</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="f-408">184</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-409">3,555</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-410">1,422</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2. - B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-411">1,420</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-412">1,804</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (f)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-413">538</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-414">1,885</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other equity investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-415">423</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-416">208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-417">434</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-418">516</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals of consolidated undertakings and investments accounted for using the equity method </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-420">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-421">32</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-422">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing investing activities</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInContinuingInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-423">1,979</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInContinuingInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-424">3,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInDiscontinuingInvestingActivities" scale="6" id="f-425">36</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInDiscontinuingInvestingActivities" scale="6" id="f-426">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash inflow from the Opella transaction </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.1.</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetCashInflowFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-427">10,742</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetCashInflowFromDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-428">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-429">8,727</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-430">3,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-431">29</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-432">21</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends paid:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to equity holders of Sanofi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-433">4,772</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-434">4,704</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to non-controlling interests</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-435">27</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-436">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional long-term debt contracted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-437">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-439">1,859</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" scale="6" id="f-440">638</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-441">124</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-442">136</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt and other financial instruments </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-443">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-444">5,876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of treasury shares and related tax effect</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.2</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:num-dot-decimal" scale="6" id="f-445">4,003</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-446">302</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing financing activities</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-447">4,441</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" scale="6" id="f-448">92</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="f-449">48</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="f-450">3</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-451">4,489</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-452">89</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-453">42</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-454">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%">Cash and cash equivalents reclassified to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;letter-spacing:-0.01em;line-height:100%"> Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%"> as of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" scale="6" id="f-455">167</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-456">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-457">7,918</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-458">1,915</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-459">7,441</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-460">8,710</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-461">15,359</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-462">6,795</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-8" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-9" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes non-current financial assets.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-10" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-11" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-12" continuedAt="fn-12-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Of which:</span></ix:footnote></div><ix:continuation id="fn-12-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-463">1,355</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-464">1,434</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-465">206</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-466">320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-467">170</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-468">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-469">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="6" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><ix:footnote id="fn-13" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><ix:footnote id="fn-14" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025 and June 30, 2024, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(h)</span><ix:footnote id="fn-15" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2025, this amount includes &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-471">667</ix:nonFraction>)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(i)</span><ix:footnote id="fn-16" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-472">3,353</ix:nonFraction>&#160;million, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-473">6,060</ix:nonFraction> million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></ix:footnote></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_28"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i92fd164f2ed74f06ba367042f9317c9e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes to the condensed half-year consolidated financial statements as of June 30, 2025 </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_31"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-474" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i06f57da0e5ba4e0c866be66a8e0b007c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2025 were reviewed by the Sanofi Board of Directors at the Board meeting on July 30, 2025.</span></div></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_34"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-475" continuedAt="f-475-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iff95aeb1cacb4d618b9870fd263c70dd"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A/ Basis of preparation of the half-year financial statements and accounting policies</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7688eda8a7014a69b04b189c74427e4d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-476" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2025 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2025 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2025 are identical to those presented in the consolidated financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment became applicable on January 1, 2025, and does not have a material impact on the Sanofi financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2025 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. The effective tax rate also includes a one-off impact from the 2024 component of the exceptional contribution in respect of French corporate income taxes (see Note B.19.).</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span id="i3ba3e8d2d67d4839a3ee18f4455ccac9"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2. Use of estimates and judgments</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-477" continuedAt="f-477-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-477-1">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ix:continuation> </span></div></ix:nonNumeric><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi&#8217;s audited consolidated financial statements as of December 31, 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-475-1" continuedAt="f-475-2"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0833d134ca4f467aa2d44022496a4589"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3. Seasonal trends</span></div><ix:nonNumeric contextRef="c-1" name="sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" id="f-478" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5d091607f6cd4770b1e2ba57b80d1097"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory" id="f-479" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2025, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-480">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-481">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1d2d8abdbdca4cb1ad5f11223ac03852"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.5. Fair value of financial instruments</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-482" continuedAt="f-482-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="f-483" escape="true"><ix:continuation id="f-482-1"><ix:continuation id="f-475-2" continuedAt="f-475-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:3.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.996%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-475-3"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i594cdfc2671541919a399905ebafffb7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.6. New pronouncements issued by the IASB and applicable from 2026</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-484" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026. Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments clarify the application of the &#8216;own use&#8217; exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and will not early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in Note D.21. to the consolidated financial statements included in the 2024 Form 20-F for the year ended December 31, 2024 (the &#8220;2024 20-F&#8221;).</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="ic819263516be4986b3d2686dbb9cb5bc"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B/ Significant information for the first half of 2025</span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_40"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" id="f-485" continuedAt="f-485-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i59b3a64f982a4997abb93c9d6139ad1b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Significant transactions for the first half of 2025</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i59a51ad9042b4cd4977c803f9630832f"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.1. Opella - Loss of control and equity interest in OPAL JV Co</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, Sanofi and CD&amp;R closed the Opella transaction following the signature of the share purchase agreement (SPA) on February 18, 2025. Sanofi retains a significant shareholding in Opella, through a 48.2% equity interest in OPAL JV Co (formed in Luxembourg), which indirectly holds 100% of Opella. Bpifrance owns a 1.8% equity interest, and is represented on Opella&#8217;s Board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Completion of the deal resulted in the loss of control of Opella by Sanofi and the derecognition of Opella&#8217;s assets and liabilities. This resulted in a net gain of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-5" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="9" id="f-486">2.7</ix:nonFraction>&#160;billion, reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated income statement. The proceeds from the divestment of Opella, determined on the basis of a &#8364;16 billion enterprise value, reflected the estimated share price. That price is subject to adjustments following finalization of the Opella completion accounts, expected at the earliest in the fourth quarter of 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the closing date of the transaction, the carrying amount of Opella&#8217;s assets and liabilities in the Sanofi consolidated balance sheet was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-5" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-487">11.3</ix:nonFraction>&#160;billion. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The gain took into account the following components: (i) a reclassification of unrealized foreign exchange losses amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="9" id="f-488">0.5</ix:nonFraction>&#160;billion associated with Opella operations, in accordance with IAS 21 (&#8220;The Effects of Changes in Foreign Exchange Rates&#8221;); (ii) recognition of the retained 48.2% equity interest in OPAL JV Co (over which Sanofi exercises significant influence as defined in IAS 28 &#8220;Investments in Associates and Joint Ventures&#8221;), reported within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> at an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-5" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="9" id="f-489">3.2</ix:nonFraction>&#160;billion (representing the fair value of the equity interest at the date of initial recognition in accordance with IFRS 10 and included in the estimated share price, plus capitalized transaction costs); and (iii) other items, mainly comprising compensation as agreed under the separation agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella transaction generated a net cash inflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-8" name="sny:NetCashInflowFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="9" id="f-490">10.7</ix:nonFraction>&#160;billion, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash inflow from the Opella transaction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a reminder, on October 21, 2024, Sanofi and CD&amp;R entered into exclusive negotiations for the transfer of a controlling interest in Opella. As of December 31, 2024, completion of the transaction was considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), all assets of Opella and all liabilities directly related to those assets were classified from October 21, 2024 in the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, respectively, in the consolidated balance sheet (see Notes D.8. and D.36. to the consolidated financial statements for the year ended December 31, 2024). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information" to the consolidated financial statements for the year ended December 31, 2024). Consequently, Opella met the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), as a result of which the net income from that business was presented separately within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated income statement. This presentation in a separate income statement line item applied to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business were also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_380"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i3396abf3da3841f7862a4b88f11b0550"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:continuation id="f-485-1" continuedAt="f-485-2">B.1.2. Acquisition of Dren-0201, Inc.</ix:continuation></span></div><ix:continuation id="f-485-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 27, 2025, Sanofi announced the completion of the acquisition of 100% of Dren-0201, Inc.<ix:nonNumeric contextRef="c-1" name="ifrs-full:NameOfAcquiree" id="f-491">,</ix:nonNumeric> adding SAR448501 (formerly DR-0201) to Sanofi&#8217;s immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. This potential first-in-class targeted bispecific myeloid cell engager targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent pre-clinical and early clinical study data in autoimmune diseases suggest that deep B-cell depletion has the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price was $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-492">600</ix:nonFraction>&#160;million. Of that amount (plus acquisition-related costs), $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-493">562</ix:nonFraction>&#160;million was allocated to in-process development in respect of SAR448501, and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, potential future payments totalling $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-8" name="sny:PotentialFuturePayments" format="ixt:num-dot-decimal" scale="9" id="f-494">1.3</ix:nonFraction>&#160;billion contingent on attainment of certain development and launch milestones have been recognized as off balance sheet commitments. These milestones will be added to the value of the SAR448501 intangible asset if and when attained.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-495">602</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ie03a56ead74e44b3aa28ab44ba3c23df"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.3. Agreed transactions expected to be finalized in the second half of 2025</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieed73ef4674a4d15af5f8915f5773e86"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Vigil Neuroscience, Inc. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vigil Neuroscience, Inc. (&#8220;Vigil&#8221;), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi&#8217;s four strategic disease areas, enhances Sanofi&#8217;s early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer&#8217;s disease. VG-3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer&#8217;s disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of a share purchase agreement (including the exclusive right of first negotiation for an exclusive license to VG-3927 or for transfer of the rights to research, develop, manufacture, and commercialize VG-3927) entered into by Sanofi and Vigil in June 2024 for an amount of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-496">40</ix:nonFraction>&#160;million, Sanofi already held an equity interest in Vigil Neuroscience, Inc., representing approximately <ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-497">12</ix:nonFraction>% of Vigil&#8217;s share capital. That equity interest was remeasured at market value as at June 30, 2025 through </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VGL101, Vigil&#8217;s second molecule program, is not being acquired by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash at closing. Based on $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="sny:EquityInterestsOfAcquirerPerShare" scale="0" id="f-498">8.00</ix:nonFraction> per share, the total equity value of Vigil represents approximately $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="ifrs-full:EquityInterestsOfAcquirer" format="ixt:num-dot-decimal" scale="6" id="f-499">470</ix:nonFraction>&#160;million (on a fully diluted basis).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Vigil&#8217;s shareholders will receive one non-transferable and non-tradeable contractual contingent value right (CVR) per Vigil share entitling the holder to receive a deferred cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="sny:DeferredCashPayments" scale="0" id="f-500">2.00</ix:nonFraction>, contingent upon the first commercial sales of VG-3927.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition is expected to close in the third quarter of 2025 subject to closing conditions.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i10b85b18c19a4029849164666a084b38"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Blueprint Medicines Corporation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 2, 2025, Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, entered into an agreement under which Sanofi agreed to acquire Blueprint.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition included a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint&#8217;s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi&#8217;s growing immunology pipeline.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the acquisition, Sanofi agreed to pay $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="INF" name="sny:CashTransferredPerShare" scale="0" id="f-501">129.00</ix:nonFraction> per share in cash at closing, representing an equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-8" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="f-502">9.1</ix:nonFraction>&#160;billion for <ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-503">100</ix:nonFraction>% of the shares. Blueprint shareholders also received one non-tradable contractual contingent value right (CVR) per share which entitles the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-8" name="ifrs-full:EquityInterestsOfAcquirer" format="ixt:num-dot-decimal" scale="9" id="f-504">9.5</ix:nonFraction>&#160;billion on a fully diluted basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2025, Sanofi obtained control of Blueprint after all tender offer and merger conditions had been met.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_43"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-505" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ied518a2a4a454270b2de2daf0c8e1b8d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Property, plant and equipment</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" id="f-506" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-507">702</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-508">591</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-509">663</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-510">535</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-511">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-512">366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation, see Note B.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-513">39</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-514">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-515">22</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-516">22</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-517">732</ix:nonFraction>&#160;million as of June 30, 2025.</span></div></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_46"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="f-518" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if2b2a5097a884347b340e8351a4610b7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Goodwill and other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-519">40,283</ix:nonFraction>&#160;million as of June 30, 2025, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-520">43,384</ix:nonFraction> million as of December&#160;31, 2024. The movement during the period was mainly due to the impact of changes in exchange rates.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" id="f-521" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2025 were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"/><td style="width:45.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-522">12,866</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-523">66,348</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-524">1,852</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-525">81,066</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-526">500</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-529">500</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-530">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-531">302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-532">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-533">676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-534">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-535">199</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-536">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-537">228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-538">1,339</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-539">5,159</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-540">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-541">6,547</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-542">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-543">244</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-544">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-545">292</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-546">12,297</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-547">61,048</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-94" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-548">1,830</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-549">75,175</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-550">4,497</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-551">52,507</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-552">1,433</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-553">58,437</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-555">800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-556">52</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-557">852</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-558">201</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-559">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-561">210</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-562">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-563">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-564">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-565">229</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-566">427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-567">3,772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-568">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-569">4,239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-571">281</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-572">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-573">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-574">4,249</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-575">49,064</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-576">1,431</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-577">54,744</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-578">8,369</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-579">13,841</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-110" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-580">419</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-581">22,629</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2025</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-582">8,048</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-583">11,984</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-6" name="ifrs-full:OtherIntangibleAssets" scale="6" id="f-584">399</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-585">20,431</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-17" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-18" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"><ix:footnote id="fn-19" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note B.4</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-111" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-586">11.0</ix:nonFraction> bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2025 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-112" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-587">12.7</ix:nonFraction> billion as of December 31, 2024) and a weighted average amortization period of approximately</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-113" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-588">10</ix:nonNumeric> years</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-114" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-589">1.0</ix:nonFraction> billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-115" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-590">1.1</ix:nonFraction> billion as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-116" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-591">18</ix:nonNumeric> years.</span></div></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_49"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" id="f-592" continuedAt="f-592-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5cb600bbe3954f83a819a319c757b93a"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Impairment of intangible assets</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-592-1">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-593">210</ix:nonFraction>&#160;million in the first half of 2025 linked to research and development projects.</ix:continuation> </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_52"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" id="f-594" continuedAt="f-594-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i087622ce136040f7a63e1598eff62e6b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5. Investments accounted for using the equity method</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="f-595" continuedAt="f-595-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2024), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:55.910%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-596">48.2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-597">3,239</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-598">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-599">29.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-122" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-600">82</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-601">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-602">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-603">93</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-604">102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-605">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-606">79</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-607">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" format="ixt:fixed-zero" scale="-2" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-609">70</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-610">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-611">3,563</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-612">316</ix:nonFraction></span></td></tr></table></div><ix:footnote id="fn-20" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-6" name="sny:LoansToAssociates" format="ixt:num-dot-decimal" scale="6" id="f-613">241</ix:nonFraction>&#160;million loan to OPAL JV Co being in substance part of the investment.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-21" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-133" decimals="INF" name="sny:StockPrice" format="ixt:num-dot-decimal" id="f-614">2.89</ix:nonFraction> as of June 30, 2025, and &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-134" decimals="INF" name="sny:StockPrice" scale="-2" id="f-615">2.88</ix:nonFraction> as of December 31, 2024). </span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-22" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"><ix:footnote id="fn-23" footnoteRole="http://www.xbrl.org/2003/role/footnote">Joint venture. MSP Vaccine Company owns <ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-616">100</ix:nonFraction>% of MCM Vaccine BV</ix:footnote>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><ix:continuation id="f-595-1" continuedAt="f-595-2"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><ix:continuation id="f-594-1" continuedAt="f-594-2"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span></ix:continuation><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-594-2"> showed net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-617">85</ix:nonFraction>&#160;million for the first half of 2025 (versus a net loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-618">22</ix:nonFraction> million for the first half of 2024), including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-619">11</ix:nonFraction>&#160;million for Sanofi&#8217;s share of profits from OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-620" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-621">29</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-622">59</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-623">63</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-624">33</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-625">371</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-626">333</ix:nonFraction></span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-627">299</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-628">184</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-629">189</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-630">189</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-631">637</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-632">160</ix:nonFraction></span></td></tr></table></div><ix:footnote id="fn-24" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div></ix:footnote><ix:footnote id="fn-25" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:SubordinateHybridBondRelatedPartyTransactions" scale="6" id="f-633">200</ix:nonFraction> million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-634">189</ix:nonFraction>&#160;million (and was also &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-635">189</ix:nonFraction> million as of December 31, 2024).</span></div></ix:footnote><ix:footnote id="fn-26" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:footnote><ix:footnote id="fn-27" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div></ix:footnote></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key items from the OPAL JV Co 2025 unaudited half-year consolidated financial statements, as provided in accordance with Sanofi&#8217;s consolidation timelines, are presented below: </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:83.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated income statement</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net sales and other revenues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures" scale="6" id="f-636">887</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="sny:NetIncomeRelatedPartyDisclosures" scale="6" id="f-637">24</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated statement of comprehensive income</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" sign="-" name="sny:OtherComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-638">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="sny:ComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-639">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) <ix:footnote id="fn-28" footnoteRole="http://www.xbrl.org/2003/role/footnote">With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</ix:footnote></span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-595-2"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:83.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated balance sheet</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:NonCurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-640">16,179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:CurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-641">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:AssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-642">19,116</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of OPAL JV Co</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:EquityAttributableToEquityHoldersRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-643">5,754</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions" scale="6" id="f-644">541</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:EquityRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-645">6,295</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-646">11,039</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:CurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-647">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:LiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-648">12,821</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:EquityAndLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-649">19,116</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div id="i4cb00d616bf34e7c9407f3fd7baa4584_55"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" id="f-650" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib826488bd111450d94e97cf9c6e8d771"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6. Other non-current assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" id="f-651" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-652">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-653">1,559</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-654">362</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-655">357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-656">965</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-657">1,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-658">146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-659">156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-660">143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-661">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLoansAndReceivables" scale="6" id="f-662">382</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLoansAndReceivables" scale="6" id="f-663">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" scale="6" id="f-664">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-666">4,109</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-667">3,753</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_58"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfTradeReceivablesTextBlock" id="f-668" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iaf6d41da42f0471b8c814bb674ed84ba"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.7. Accounts receivable</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCurrentTradeReceivablesTableTextBlock" id="f-669" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-670">7,896</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-671">7,777</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-672">86</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-673">100</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-674">7,810</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-675">7,677</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2025 was a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-676">4</ix:nonFraction> million (versus a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-677">3</ix:nonFraction> million for the first half of 2024).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock" id="f-678" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:18.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-679">386</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-680">122</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-681">103</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-682">73</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-683">48</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-684">40</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As of December&#160;31, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-685">650</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-686">316</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-687">194</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-688">87</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-689">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-690">44</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2024 and hence were derecognized was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DerecognizedReceivables" scale="6" id="f-691">12</ix:nonFraction> million as of June&#160;30, 2025 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DerecognizedReceivables" scale="6" id="f-692">14</ix:nonFraction> million as of December 31, 2024). The residual guarantees relating to those transfers were immaterial as of June 30, 2025.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_61"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-693" continuedAt="f-693-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-694" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7de095be9bd34777b07065d8d9446fb6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieb1db694e9274ef49646dccbed6532bf"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="f-695">2,455,512,548</ix:nonFraction> and consisted of <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-696">1,227,756,274</ix:nonFraction> shares (the total number of shares outstanding) with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-2" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-697">2</ix:nonFraction>.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-698">10.66</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-699">0.868</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-700">9.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-701">0.755</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-702">15.33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-30" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-703">1.211</ix:nonFraction></span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-704">13.45</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-705">1.063</ix:nonFraction></span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-706">171,150</ix:nonFraction> shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-707">2,682,051</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2025, of which <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-708">1,156,205</ix:nonFraction>&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-709">1,525,846</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i25296d69bf8543698f51f58a59381631"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.2. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2024, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-159" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-710">18</ix:nonNumeric> months. Under that program, Sanofi repurchased <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-711">39,344,633</ix:nonFraction> of its own shares during the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-6" name="sny:AmountOfSharesRepurchased" format="ixt:num-dot-decimal" scale="6" id="f-712">3,988</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#8364;<ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-9" name="sny:AmountOfSharesRepurchased" format="ixt:num-dot-decimal" scale="9" id="f-713">5</ix:nonFraction>&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#233;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#8217;s share capital, equivalent to <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-714">29,556,650</ix:nonFraction> shares, for a total amount of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-163" decimals="-9" name="sny:AmountOfSharesRepurchased" format="ixt:num-dot-decimal" scale="9" id="f-715">3</ix:nonFraction>&#160;billion, representing a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-163" decimals="INF" name="sny:PerShareValueOfSharesRepurchased" scale="0" id="f-716">101.50</ix:nonFraction> per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-164" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-717">18</ix:nonNumeric> months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2025.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="iab53d79b00614867aa54dfaeaac8fdef"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.3. Reduction in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, treasury shares amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CancellationOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-718">3,868</ix:nonFraction> million were cancelled further to decisions taken by the Sanofi Board of Directors on March 13, 2025 and April 23, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity, except for the impact of the tax on share cancellations.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i8f51ca431f464eb6984626bf2fabb13e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.4. Restricted share plans</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" id="f-719" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2024. The principal features of the plans awarded in 2025 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:82.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.541%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 April, 2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a <ix:nonNumeric contextRef="c-165" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-720">3</ix:nonNumeric>-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-721">4,021,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-722">2,599,478</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-167" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-723">83.94</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-724">1,421,892</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-725">1,331,892</ix:nonFraction> shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-169" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-726">79.25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-727">90,000</ix:nonFraction> shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-170" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-728">75.10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-729">331</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-29" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></ix:footnote></div><ix:footnote id="fn-30" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div></ix:footnote></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-693-1" continuedAt="f-693-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" id="f-730" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-731">146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-732">128</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-733">11,550,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-734">11,192,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-735">4,020,451</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-737">4,110,089</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-738">4,498,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-739">3,313,588</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-740">3,652,352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-741">106,219</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-742">3,031,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-744">11,463</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="idc68e16f4a53438286d6b02e26a98749"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.5. Capital increases</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 29, 2025, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-185" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-745">72.97</ix:nonFraction> per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-746">2,260,776</ix:nonFraction> shares, and this capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-747">116,794</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2025 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-748">31</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-188" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-749">72.87</ix:nonFraction> per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-750">2,124,445</ix:nonFraction> shares, and this capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-751">119,951</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-752">45</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="if776696deda84ae0905c147f47bfbc13"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.6. Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2025 or in 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No further stock option plan expenses were recognized through equity in either the first half of 2025 or 2024.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" id="f-753" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:26.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-191" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-754">60.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-192" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-755">70.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-756">168,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-194" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-757">2.84</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-193" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-758">65.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-759">168,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-193" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-760">65.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-195" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-761">70.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-196" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-762">80.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-763">299,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-198" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-764">2.98</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-197" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-765">76.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-766">299,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-197" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-767">76.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-199" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-768">80.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-200" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-769">90.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-770">257,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-202" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-771">1.86</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-201" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-772">88.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-773">257,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-201" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-774">88.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-775">725,044</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-776">725,044</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i92d70e7ae645487f86bdd2b833ba9524"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.7. Number of shares used to compute diluted earnings per share</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" id="f-777" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-778">1,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-779">1,249.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-780">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-781">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-782">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-783">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-784">1,230.7</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-785">1,253.8</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, December 31, 2024 and June 30, 2024, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-693-2"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i2ea5e4740dbf4078bbff62d9a657d829"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.8. Other comprehensive income</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" id="f-786" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-787">105</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-788">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-789">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-791">25</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-792">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-793">222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" sign="-" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-794">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-799">60</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-800">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-801">243</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-802">166</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-803">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" sign="-" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-804">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" format="ixt:fixed-zero" scale="6" id="f-807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" scale="6" id="f-808">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-809">23</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-810">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-812">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-813">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-814">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-815">5,266</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-816">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-817">26</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-818">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-819">390</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-820">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-821">101</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-822">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-823">5,017</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-824">1,067</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-31" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-32" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-825">2</ix:nonFraction>&#160;million in the first half of 2025, immaterial in the first half of 2024.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-33" continuedAt="fn-33-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></ix:footnote></div><ix:continuation id="fn-33-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-826">459</ix:nonFraction> million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-827">5</ix:nonFraction>&#160;million profit in 2024, and immaterial in the first half of 2024.</span></div></ix:continuation></ix:nonNumeric></ix:continuation><div id="i4cb00d616bf34e7c9407f3fd7baa4584_64"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" id="f-828" continuedAt="f-828-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5d93f704479c4f44b67be7e205d2d7a8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9. Debt, cash and cash equivalents</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInFinancialPositionTableTextBlock" id="f-829" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-830">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-831">11,791</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-832">7,309</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-833">4,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-834">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-835">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-836">20,519</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-837">16,137</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-838">15,359</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-839">7,441</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-840">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-841">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-842">5,102</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-843">8,772</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"><ix:footnote id="fn-34" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-844">1,776</ix:nonFraction> million as of June 30, 2025 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-845">1,906</ix:nonFraction> million as of December&#160;31, 2024</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-828-1" continuedAt="f-828-2"><div style="margin-bottom:3pt;margin-top:9pt"><span id="ic4f08bedb155434a888a0d64f5305f78"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.1. Net debt at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" id="f-846" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2025 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:28.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-847">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-848">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-849">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-850">13,317</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-851">11,940</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-852">7,309</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-853">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-855">7,311</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-856">4,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-857">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-859">78</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-860">68</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-861">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-862">20,519</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-863">41</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="6" id="f-864">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-865">20,560</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-866">16,171</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-867">15,359</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-869">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-870">15,359</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-871">7,441</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-872">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-875">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-876">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-877">5,102</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-878">41</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-879">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-880">5,143</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-881">8,806</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"><ix:footnote id="fn-35" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-882">1,776</ix:nonFraction> million as of June 30, 2025 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-883">1,906</ix:nonFraction> million as of December&#160;31, 2024</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" id="f-884" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-885">13,259</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-886">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-887">15,581</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-888">11,876</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-889">2,716</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-890">14,592</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-891">58</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-892">4,847</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-893">4,905</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-894">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-895">1,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-896">1,354</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-898">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-899">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-900">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-901">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-902">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-904">141</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-905">141</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-907">209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-908">209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-910">68</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-911">68</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-913">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-914">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-915">13,317</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-916">7,243</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-917">20,560</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-918">11,940</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-919">4,231</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-920">16,171</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-921">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-922">15,359</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-923">15,359</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-925">7,441</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-926">7,441</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-928">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-929">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-930">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-931">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-932">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-933">13,317</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-934">8,174</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-935">5,143</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-936">11,940</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-937">3,134</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-938">8,806</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:footnote id="fn-36" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, 2025, current other bank borrowings include &#8364;<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-939">4,535</ix:nonFraction>&#160;million related to the US commercial paper program and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-940">230</ix:nonFraction>&#160;million related to the Negotiable European Commercial Paper program in France.</span></div></ix:footnote></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-828-2"><div style="margin-bottom:3pt;margin-top:6pt"><span id="idb1ea718ea754a00bb46d85600fe6342"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi carried out the following bond issues during the period:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">March 2025: a bond issue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-8" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-941">1.5</ix:nonFraction>&#160;billion in <ix:nonFraction unitRef="eur" contextRef="c-229" decimals="INF" name="sny:NumberOfTranches" format="ixt-sec:numwordsen" id="f-942">two</ix:nonFraction> tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;<ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-943">850</ix:nonFraction>&#160;million of floating-rate bonds maturing March 2027, with quarterly coupons and bearing interest at an annual rate of 3-month Euribor plus 30 basis points; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-944">650</ix:nonFraction>&#160;million of fixed-rate bonds maturing March 2031, with annual coupons and bearing interest at an annual rate of 2.750%.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">June 2025: a bond issue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-8" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-945">1.5</ix:nonFraction>&#160;billion in <ix:nonFraction unitRef="eur" contextRef="c-232" decimals="INF" name="sny:NumberOfTranches" format="ixt-sec:numwordsen" id="f-946">two</ix:nonFraction> tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-947">750</ix:nonFraction>&#160;million of fixed-rate bonds maturing June 2029, with annual coupons and bearing interest at an annual rate of 2.625%; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;<ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-948">750</ix:nonFraction>&#160;million of fixed-rate bonds maturing June 2032, with annual coupons and bearing interest at an annual rate of 3.000%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Two bond issues were redeemed in 2025:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-949">1</ix:nonFraction>&#160;billion fixed-rate bond issue from April 2020, which was redeemed at maturity on April 1, 2025; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-950">850</ix:nonFraction>&#160;million fixed-rate bond issue from April 2022, which was redeemed at maturity on April 6, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-951">4</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-952">4</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, neither facility was drawn down.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two short-term debt programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-9" name="ifrs-full:CommercialPapersIssued" scale="9" id="f-953">6</ix:nonFraction> billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-9" name="ifrs-full:CommercialPapersIssued" format="ixt:num-dot-decimal" scale="9" id="f-954">10</ix:nonFraction>&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">the average drawdown under the US Commercial Paper program was $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-7" name="sny:BorrowingAverageDrawdown" scale="9" id="f-955">2.63</ix:nonFraction> billion; and </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-7" name="sny:BorrowingAverageDrawdown" scale="9" id="f-956">0.02</ix:nonFraction> billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2025 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="icd19a6965fa84d6a8acb50e70115a9d2"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.2. Market value of net debt</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMarketValueOfNetDebtTableTextBlock" id="f-957" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-958">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-959">8,165</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-960">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-961">8,806</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_67"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-963" continuedAt="f-963-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-962" continuedAt="f-962-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5ee764af394a41d98996a14bec414e96"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10. Derivative financial instruments</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i850ed5d10c524593866e3ac094f18038"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.1 Currency derivatives used to manage operating risk exposures</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" id="f-964" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:26.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-965">6,619</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-966">133</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-967">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-968">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-969">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-970">6,619</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-971">133</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-972">3,351</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-973">100</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-975">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-977">3,351</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-978">100</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-979">539</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-980">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-981">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-982">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-983">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-984">539</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-985">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-986">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-987">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-988">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-991">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-992">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-993">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-994">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-996">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-997">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-998">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-999">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which pound sterling</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1000">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1001">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1002">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1003">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1004">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1005">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1006">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1007">4,418</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1008">84</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1009">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1010">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1011">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1012">4,418</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1013">84</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1014">2,540</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1015">55</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1016">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1017">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1018">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1019">2,540</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1020">55</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1021">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1022">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1023">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1024">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1026">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1027">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1028">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1029">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1030">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1031">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1033">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1034">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1035">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1036">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1037">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1039">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1040">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1041">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1042">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1043">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1044">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1045">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1046">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1047">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1048">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1049">11,037</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1050">49</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1052">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1053">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1054">11,037</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1055">49</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="id95d9cb34ad843deb2eeb9cd2820d2ca"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.2. Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" id="f-1056" continuedAt="f-1056-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:53.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1057">1,476</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1058">5</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1059">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1060">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1061">7,723</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1062">176</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1063">6,007</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1064">148</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1065">601</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1066">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;of which Japanese yen </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1067">303</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1068">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1069">3,609</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1070">44</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1071">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1072">14</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1073">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1074">33</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1075">639</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1076">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1077">12,808</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1078">137</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-37" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $<ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1079">870</ix:nonFraction>&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $<ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1080">870</ix:nonFraction>&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1081">5</ix:nonFraction>&#160;million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1082">18</ix:nonFraction>&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment.</span></ix:footnote></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-963-1"><ix:continuation id="f-962-1"><ix:continuation id="f-1056-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-38" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1083">3,615</ix:nonFraction> million expiring in 2025, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1084">77</ix:nonFraction> million; the opposite entry was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, with the impact on financial income and expense being immaterial.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-39" continuedAt="fn-39-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1085">1,000</ix:nonFraction> million expiring in 2025, designated as a fair value hedge of the exposure of $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1086">1,000</ix:nonFraction> million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1087">25</ix:nonFraction> million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-1088">0</ix:nonFraction> million&#160;credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="fn-39-1"> to recognize the hedging cost</ix:continuation>.</span></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" id="f-1089" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:24.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and beyond</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive 1.17%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1090"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1091">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1092"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1093">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1094"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1095">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1096"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1097">848</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-365" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1098"></ix:nonFraction><ix:nonFraction unitRef="eur" contextRef="c-365" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1099"></ix:nonFraction></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1100"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1101">848</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1102"><ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1103">54</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1104"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1105">848</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1106"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1107">54</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-370" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1108"></ix:nonFraction><ix:nonFraction unitRef="eur" contextRef="c-370" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1109"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-371" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1110"></ix:nonFraction><ix:nonFraction unitRef="eur" contextRef="c-371" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1111"></ix:nonFraction></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1112"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3m</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1114">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-374" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1115"></ix:nonFraction></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1116">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1118">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1119">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1120">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-380" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1121"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-381" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1122"></ix:nonFraction></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1123">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1124">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1125">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive <ix:nonFraction unitRef="number" contextRef="c-385" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1126">0.92</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-386" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1128">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1130">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1131">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1132">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1133">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1134">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1135">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1138">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1139">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1140">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1141">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1142">848</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1143">650</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1144">2,348</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1145">88</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1146">1,498</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1147">81</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1148">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1149">7</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1150">3</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div id="i4cb00d616bf34e7c9407f3fd7baa4584_70"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" id="f-1151" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iaa43e806f1aa45c983dc11f10a287070"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.11. Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" id="f-1152" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:45.279%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1153">72</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1154">568</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1155">1</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1156">641</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1157">72</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1160">72</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1161">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1162">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-1163">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1164">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1165">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1166">76</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1167">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1168">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1169">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1170">563</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1171">1</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1172">564</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1174">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-40" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1175">569</ix:nonFraction> million and a current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1176">72</ix:nonFraction> million.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-41" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1177">563</ix:nonFraction> million as of June&#160;30, 2025, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1178">568</ix:nonFraction> million as of December 31, 2024. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-412" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-1179">10</ix:nonFraction>%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture was extinguished during 2024 in accordance with the contractual terms. Sanofi has no further liability in respect of this contingent consideration following settlement of the milestone linked to 2024 sales.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_73"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" id="f-1180" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i66ef10b1748b4d4696f08a72f348bef5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.12. Non-current provisions and other non-current liabilities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" id="f-1181" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.099%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1182">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1183">5,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1184">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1185">2,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1186">7,116</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1187">8,096</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(<ix:footnote id="fn-42" footnoteRole="http://www.xbrl.org/2003/role/footnote">a)&#160;&#160;&#160;&#160;Includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1188">1,756</ix:nonFraction> million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1189">1,027</ix:nonFraction>&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1190">2,293</ix:nonFraction> million</ix:footnote>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNonCurrentProvisionsTableTextBlock" id="f-1191" escape="true"><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:29.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1192">1,992</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1193">821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1194">799</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1195">2,150</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1196">5,762</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1197">69</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1198">78</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1199">175</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1200">293</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1201">615</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1202">167</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1203">61</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1204">10</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1205">378</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1206">616</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1207">17</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1208">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1209">2</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1210">178</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1211">197</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1212">4</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1213">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1214">158</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1215">93</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1216">255</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1217">37</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1218">1</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1219">2</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1220">20</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1221">60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1222">94</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1223">74</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1224">4</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1225">83</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1226">255</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1227">111</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1228">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1229">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1230">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1231">111</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1232">1,705</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1233">765</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1234">802</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1235">1,731</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1236">5,003</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-43" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-44" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i298b3c160c444f929e628ff6396043d5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2024, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2025 to take into account changes during the first half of the year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, Sanofi completed a further buy-in (amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-1237">101</ix:nonFraction>&#160;million) to cover the remaining uninsured liabilities arising under the main defined benefit pension scheme in the United Kingdom. Consequently, all scheme members are now fully insured as a result of buy-in transactions, except for liabilities rising from guaranteed minimum pension equalization (as described in Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" id="f-1238" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.114%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025     (6&#160;months)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024     (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1239">45</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1240">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1241">152</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1242">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-45" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between <ix:nonFraction unitRef="number" contextRef="c-434" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="f-1243">0.00</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-435" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1244">0.30</ix:nonFraction>%) and (ii) the -<ix:nonFraction unitRef="number" contextRef="c-436" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1245">0.30</ix:nonFraction>% change in the inflation rate in the United Kingdom in the first half of 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-46" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between +<ix:nonFraction unitRef="number" contextRef="c-437" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1246">0.40</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-438" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1247">0.65</ix:nonFraction>%) and (ii) the +<ix:nonFraction unitRef="number" contextRef="c-439" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1248">0.10</ix:nonFraction>% change in the inflation rate in the United Kingdom in the first half of 2024.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"><ix:footnote id="fn-47" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes actuarial gains/ (losses) related to Opella of &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1249">4</ix:nonFraction>)&#160;million for the first half of 2025 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1250">6</ix:nonFraction>)&#160;million for the first half of 2024 </ix:footnote>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_76"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" id="f-1251" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if13b4d11bd91484d826b9b625505475d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13. Off balance sheet commitments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2024 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into, amended or discontinued during the period are described below: </span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In April 2025, Sanofi entered into a license and collaboration agreement with Earendil Labs for two bispecific antibodies in the field of autoimmune and inflammatory bowel diseases: HXN-1002 (targeting &#945;4&#946;7 and TL1A for potential treatment of moderate to severe ulcerative colitis and Crohn's disease) and HXN-1003 (targeting TL1A and IL23 for potential treatment of colitis and skin inflammation). Under the terms of the agreement, Earendil Labs received an upfront payment of $125 million, is eligible to receive up to a total of $1.7 billion in development and commercial milestone payments, and is eligible to receive tiered royalties on product sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2024 Form 20-F.</span></div></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_79"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLegalAndArbitralProceedingsTextBlock" id="f-1252" continuedAt="f-1252-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1c221f089c9a4af9901d6cb4e4acaee3"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14. Litigation and arbitration proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i562e9106bf0241498655b78496fddfab"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.1. Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="iee905ab161554e27ac58988037567eef"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zantac product litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards the ongoing Zantac product  litigation in the US, the Separation Agreement (see Notes D.1 and D.22 to the consolidated financial statements in the 2024 Form 20-F) entered into between Sanofi and Opella specifies that Sanofi will indemnify the Opella group in respect of liabilities relating to (i) the commercialization of any Zantac branded products (i.e. products containing ranitidine as their active pharmaceutical ingredient) prior to closing, and (ii) all personal injury claims resulting from the manufacturing or handling of Zantac prior to closing.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2025, Sanofi reached several settlement deals that in total resolve a majority of the Delaware State Court consolidated litigation. In addition, in May 2025, Sanofi reached settlements with the City of Baltimore and the New Mexico Attorney General, amicably resolving both those matters. Other cases are pending in various state courts.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 10, 2025, the Delaware Supreme Court unanimously reversed the Superior Court&#8217;s denial of Defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">motion based on the lack of reliability of plaintiff&#8217;s experts on causation and remanded its findings back to the Superior Court for proceedings consistent with the rulings in the opinion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i705e5b570c5f4f11b9bf3e2e13c2c5f8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talc product litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi was named as a defendant in approximately 9<ix:nonFraction unitRef="proceeding" contextRef="c-442" decimals="INF" name="sny:NumberOfClassActionLawsuits" id="f-1253">00</ix:nonFraction> ongoing product liability actions. To date, no cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i3b1346ea9ebb45569d3dcaf9303a1d2e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.2. Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="ic6e991b615794cb48c76d24520e17825"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Praluent (alirocumab)-related Amgen patent litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Regarding Amgen&#8217;s EP 3 666 797, in April 2025, the Opposition Division of the European Patent Office ruled in Amgen&#8217;s favor and decided to maintain the patent as granted. Sanofi has appealed this decision to the Technical Board of Appeals of the European Patent Office, and the appeal hearing is scheduled for April 2026. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="ia6627e68f8924c1fbed2173501177e82"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) Litigation (Commonwealth) Litigation in Australia </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This matter has been finalized with no possibility of appeal. The matter is closed.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i3a96cd4646e3420c91ee3a27281ff538"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.3. Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i9d56b9e5932441cf91443bf4641a4ec5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) - Attorney General action in Hawaii</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2025, the parties agreed to settle the Hawaii action, with Sanofi US to pay $<ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-6" name="sny:PaymentOfDamagesClaimedByCounterparty" format="ixt:num-dot-decimal" scale="6" id="f-1254">350</ix:nonFraction>&#160;million pursuant to its settlement agreement and Bristol-Myers Squibb to pay $<ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-6" name="sny:PenaltyFeeIncurred" format="ixt:num-dot-decimal" scale="6" id="f-1255">350</ix:nonFraction>&#160;million pursuant to its separate settlement agreement. The appeal and the underlying case were dismissed pursuant to the settlement. This matter is closed.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1252-1"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i5d5243e109504bcd98fabc418f1c66c3"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel)-related litigation in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the claim filed by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Caisse Nationale d&#8217;Assurance Maladie</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8211; CNAM</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (French Social Security), hearings were held in June 2025. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="id7f1b070fc274121b83d6d00bc45251c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B drug pricing program in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the action filed by Sanofi against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA) and their respective administrators, following a joint hearing held on April 29, 2025 in Sanofi&#8217;s case and the similar cases filed by Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos, the district court held on May 15, 2025 that, although Section 340B does not categorically prohibit the use of manufacturer rebates, it does not allow HRSA to require preapproval of a manufacturer rebate program. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The district court also held that HRSA&#8217;s letter determining that Sanofi would violate Section 340B if it launched its Credit (rebate) Model was arbitrary and capricious and remanded the Sanofi matter back to HRSA for further consideration. Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos appealed the district court&#8217;s decision to the Circuit Court. Those appeals, along with a similar appeal by Johnson &amp; Johnson, have been expedited and consolidated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2025, Sanofi received notice that Hudson Headwaters Health Network (Hudson Headwaters) had filed a petition for monetary relief against Sanofi before the HRSA ADR (Administrative Dispute Resolution) Panel. Hudson Headwaters alleges that Sanofi has violated Section 340B by allowing only one contract pharmacy to be selected and utilized per covered entity, if the covered entity does not have an in-house pharmacy capable of dispensing its drug. Hudson Headwaters alleges that this Sanofi policy is an &#8220;overcharge&#8221; under Section 340B. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">State Litigation in the US </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In lawsuits filed by PhRMA and certain other manufacturers challenging a contract pharmacy law passed by the State of Mississippi, the court denied for each of the plaintiffs their preliminary injunctions in their respective lawsuits. The plaintiffs appealed the denials of the preliminary injunction motions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Various other challenges to similar state laws have been filed by PhRMA and/or certain manufacturers in a number of other states, including in Colorado, Kansas, Louisiana, Maryland, Minnesota, Missouri, Nebraska, North Dakota, Oklahoma, Tennessee, Utah, South Dakota, and Vermont.</span></div></ix:continuation><div id="i4cb00d616bf34e7c9407f3fd7baa4584_82"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" id="f-1256" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7c36aaced6214a41ba3422866e6c16dd"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.15. Other operating income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1257">533</ix:nonFraction> million in the first half of 2025 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1258">563</ix:nonFraction> million in the first half of 2024), and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1259">2,476</ix:nonFraction> million (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">versus</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8364; <ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1260">1,977</ix:nonFraction> million in the first half of 2024).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main items included in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were: in the first half of 2025, (i) income from pharmaceutical partners of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1261">87</ix:nonFraction>&#160;million (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1262">121</ix:nonFraction> million in the first half of 2024), of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1263">70</ix:nonFraction> million came from Regeneron (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1264">96</ix:nonFraction> million in the first half of 2024, see table below) and (ii) gains on disposals of assets and operations of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-6" name="sny:GainsOnDivestmentOfProducts" scale="6" id="f-1265">344</ix:nonFraction> million, primarily on divestments of non strategic products (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-6" name="sny:GainsOnDivestmentOfProducts" scale="6" id="f-1266">319</ix:nonFraction> million in the first half of 2024). </span></div><ix:nonNumeric contextRef="c-1" name="sny:OtherOperatingExpensesTableTextBlock" id="f-1267" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1268">2,331</ix:nonFraction> million of expenses related to Regeneron (compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1269">1,841</ix:nonFraction> million in the first half of 2024), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024       (6 months)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1270">2,475</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1271">1,934</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-452" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1272">494</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1273">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-454" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1274">346</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1275">292</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1276">2,327</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-457" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1277">1,837</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1278">66</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1279">92</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1280">2,261</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1281">1,745</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1282">70</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1283">96</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_85"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringTextBlock" id="f-1284" continuedAt="f-1284-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i006acb851dac4f99bae83d4ef197fbbd"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16. Restructuring costs and similar items</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsDetailsTableTextBlock" id="f-1287" escape="true"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-1286" continuedAt="f-1286-1" escape="true"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-1285" continuedAt="f-1285-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1288">201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1289">810</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1290">109</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1291">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1292">80</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1293">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1294">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1295">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1296">430</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1297">1,060</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-48" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:footnote><ix:footnote id="fn-49" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div></ix:footnote></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-1286-1"><ix:continuation id="f-1285-1"><ix:continuation id="f-1284-1">Restructuring and similar costs decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-6" sign="-" name="sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities" scale="6" id="f-1298">630</ix:nonFraction> million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;D operations to make Sanofi a leader in immunology</ix:continuation></ix:continuation></ix:continuation>.</span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_88"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" id="f-1299" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7ee99a522aa34d97b31f94cdb6dc313a"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17. Other gains and losses, and litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2025, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1300">57</ix:nonFraction> million, mainly related to major litigation. That compares with a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1301">450</ix:nonFraction> m</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_91"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-1302" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i3f2720f484d742c9ae4964b2d83dbd0c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.18. Financial expenses and income</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" id="f-1303" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1304">219</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1305">306</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1306">162</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1307">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1308">57</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1309">67</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1310">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NonOperatingForeignExchangeGainsLosses" format="ixt:fixed-zero" scale="6" id="f-1311">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1312">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1313">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1314">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1315">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1316">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1317">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1318">40</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1319">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1320">177</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1321">306</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1322">361</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1323">583</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1324">184</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1325">277</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-50" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-51" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1326">25</ix:nonFraction>) million in the first half of 2025 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-462" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1327">24</ix:nonFraction>) million in the first half of 2024.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-52" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1328">4</ix:nonFraction>) million in the first half of 2025 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-462" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1329">18</ix:nonFraction>)&#160;million in the first half of 2024.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-53" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-54" continuedAt="fn-54-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Includes a financial expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1330">50</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="fn-54-1">million for the six months ended June 30, 2025 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1331">176</ix:nonFraction> million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US</ix:continuation>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2025 or 2024.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_94"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-1332" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5300777f87c6406e8545c0c1004331b2"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.19. Income tax expense</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" id="f-1333" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1334">1,202</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1335">1,108</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1336">491</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1337">729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1338">711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1339">379</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1340">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1341">2,462</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-55" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:footnote></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" id="f-1342" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1343">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1344">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1345">7.3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1346">15.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1347">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1348">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1349">1.0</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1350">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1351">19.8</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1352">15.4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-56" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-57" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-58" continuedAt="fn-58-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></ix:footnote></div><ix:continuation id="fn-58-1"><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-59" continuedAt="fn-59-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"><ix:continuation id="fn-59-1">For the six months ended June 30, 2025, this line includes a tax expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CurrentTaxExpenseRelatedToPillarTwo" format="ixt:num-dot-decimal" scale="6" id="f-1353">17</ix:nonFraction>&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CurrentTaxExpenseRelatedToPillarTwo" format="ixt:num-dot-decimal" scale="6" id="f-1354">52</ix:nonFraction>&#160;million for the six months ended June 30, 2024</ix:continuation>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_340"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-1355" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i52a8186c44054bbe8274d7f029df5eba"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20. Revenue from contracts with customers</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i5a65fe3ac5364662bb96cd50b9aad65c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1. Analysis of net sales</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-1356" escape="true"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2025 and June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.690%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="42" style="display:none"/></tr><tr><td colspan="6" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-463" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1357">4,144</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1358">9,535</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1359">6,210</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1360">19,889</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1361">4,072</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1362">8,292</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1363">5,996</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1364">18,360</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1365">944</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1366">5,283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1367">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-473" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1368">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-474" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1369">770</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-475" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1370">4,437</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-476" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1371">931</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-477" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1372">6,138</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-478" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-479" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1374">456</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-480" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1375">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-481" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1376">542</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-482" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1377">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-483" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1378">259</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-484" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1379">21</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-485" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1380">280</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-486" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1381">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-487" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1382">195</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1383">60</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1384">387</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1385">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1386">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1387">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1388">320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1389">55</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1390">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1391">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1392">136</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1393">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1394">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-500" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1395">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1396">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-502" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1397">44</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-503" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1398">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-504" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1399">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1400">110</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-506" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1401">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-507" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1402">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1403">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1404">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1405">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1406">76</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-512" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1407">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-513" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1408">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-514" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1409">95</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1410">96</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1411">18</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1412">209</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1413">83</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1414">119</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-520" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1415">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-521" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1416">276</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-522" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1417">64</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-523" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1418">100</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-524" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1419">63</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-525" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1420">227</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1421">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-527" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1422">220</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-528" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1423">20</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1424">263</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-530" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1425">12</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-531" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1426">188</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-532" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1427">7</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-533" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1428">207</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-534" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1429">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-535" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1430">27</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1431">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1432">29</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1433">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-539" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1434">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-540" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1435">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-541" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1436">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1437">241</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1438">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1439">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1440">251</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1441">273</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1442">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1443">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-549" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1444">274</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1445">223</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1446">320</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1447">818</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-553" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1448">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-554" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1449">248</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-555" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1450">311</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1451">789</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-557" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1452">1,348</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1453">96</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1454">319</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1455">194</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1456">609</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1457">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1458">301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1459">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1460">583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccine (Beyfortus) </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1461">85</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1462">68</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1463">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1464">356</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1465">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1466">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1467">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1468">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1469">52</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-575" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1470">54</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1471">108</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1472">214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1473">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1474">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1475">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1476">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1477">4,144</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1478">9,535</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1479">6,210</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1480">19,889</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1481">4,072</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1482">8,292</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1483">5,996</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1484">18,360</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-60" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i159fef8eaf084bf697cb00fb8e4ea868"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.2. Other revenues</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherRevenueTextBlock" id="f-1485" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="sny:RevenueFromVaxServeSalesOfNonSanofiProducts" scale="6" id="f-1486">842</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="sny:RevenueFromVaxServeSalesOfNonSanofiProducts" scale="6" id="f-1487">854</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" scale="6" id="f-1488">61</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" scale="6" id="f-1489">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:RevenueFromRoyalties" scale="6" id="f-1490">68</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:RevenueFromRoyalties" scale="6" id="f-1491">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="sny:MiscellaneousOtherRevenue" scale="6" id="f-1492">275</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="sny:MiscellaneousOtherRevenue" scale="6" id="f-1493">341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1494">1,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1495">1,352</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1496">206</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1497">177</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1498">1,452</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1499">1,529</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-61" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:footnote><ix:footnote id="fn-62" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div></ix:footnote><ix:footnote id="fn-63" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div></ix:footnote><ix:footnote id="fn-64" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div></ix:footnote></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_97"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-1500" continuedAt="f-1500-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i557cf676139c4011ad72a0e3d410b685"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21. Segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment: Biopharma.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella, which constitutes a related party with effect from the deconsolidation date (April 30, 2025). Those revenues, which before that date represented intragroup transactions classified within continuing operations, are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ice051a960b0f48668ab8553db2de5368"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the portion attributable to non-controlling interests related to continuing operations and excluding the effects of the above reconciliation items, is deducted.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1500-1" continuedAt="f-1500-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="f-1501" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"/><td style="width:27.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1502">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-590" xsi:nil="true" name="ifrs-full:RevenueFromSaleOfGoods" id="f-1503"></ix:nonFraction></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1504">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1505">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-7.8</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1506">206</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+15.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1507">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-5.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-3.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1508">5,753</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.6</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-0.1</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1509">128</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+14.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1510">5,881</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+0.2</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1511">3,716</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1512">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1513">3,717</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1514">4,447</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1515">59</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1516">4,506</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1517">1,941</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1518">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1519">1,943</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1520">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1522">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1523">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1525">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1526">5,347</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.0</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1527">16</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1528">5,363</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.6</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+10.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.9</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">27.0</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><ix:footnote id="fn-65" footnoteRole="http://www.xbrl.org/2003/role/footnote"></ix:footnote><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:50.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6 months) (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1529">18,360</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-592" xsi:nil="true" name="ifrs-full:RevenueFromSaleOfGoods" id="f-1530"></ix:nonFraction></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1531">18,360</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1532">1,352</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1533">177</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1534">1,529</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1535">5,849</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1536">110</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1537">5,959</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1538">3,334</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1539">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1540">3,335</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1541">4,247</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1542">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1543">4,303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1544">1,426</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1545">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1546">1,414</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1547">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1548">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1549">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1550">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1551">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1552">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1553">4,916</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1554">22</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1555">4,938</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-66" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" id="f-1556" escape="true"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-594" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1557">5,363</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-595" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1558">4,938</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1559">77</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1560">66</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1561">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1562">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1563">987</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1564">527</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1565">61</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1566">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" format="ixt:fixed-zero" scale="6" id="f-1567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-1568">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1569">430</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1570">1,060</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1571">57</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1572">450</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1573">3,759</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1574">2,768</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1575">361</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1576">583</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1577">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1578">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1579">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1580">2,462</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-67" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-68" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-69" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-70" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1581">210</ix:nonFraction>&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1582">371</ix:nonFraction>&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. </span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-71" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><ix:footnote id="fn-72" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.16.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"><ix:footnote id="fn-73" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note B.17</ix:footnote>.</span></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1500-2" continuedAt="f-1500-3"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i742dec16cfa84e3b9d7429184f7f1072"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments in joint ventures and associates accounted for using the equity method with which Sanofi has entered into a collaboration agreement; (ii)&#160;acquisitions of property, plant and equipment; and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" id="f-1583" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:61.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.699%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-598" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1584">483</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-599" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1585">229</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1586">845</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1587">882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1588">575</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1589">922</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-74" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div></ix:footnote></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i7e465b35c3514c8eba9eaaae5e6df42e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.3. Information by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:60.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (a)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1590">4,144</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1591">4,072</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-600" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1592">835</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1593">855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1594">9,535</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1595">8,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-602" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1596">6,210</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-603" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1597">5,996</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-604" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1598">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-605" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1599">1,406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-606" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1600">19,889</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-607" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1601">18,360</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><ix:footnote id="fn-75" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-1602" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"/><td style="width:30.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.169%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1603">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1605">3,167</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1606">5,550</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1607">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1608">3,307</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1609">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1612">3,112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1613">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1614">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1615">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1617">16,725</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1618">2,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1619">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1620">18,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1621">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1623">539</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1624">2,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1625">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1626">611</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1627">83</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1630">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1631">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1632">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1633">9,574</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1634">40,283</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1635">20,431</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1636">10,091</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1637">43,384</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1638">22,629</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2024, goodwill is not allocated by geographical region.</span></div></ix:continuation><div id="i4cb00d616bf34e7c9407f3fd7baa4584_100"></div><ix:continuation id="f-1500-3"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i118884e44be846e89e084fafd4dfd51b"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.4. Disclosures about major customers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented <ix:nonFraction unitRef="number" contextRef="c-620" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1639">35</ix:nonFraction>% of net sales in the first half of 2025. Sanofi&#8217;s three largest customers respectively accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-621" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1640">18</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-622" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1641">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-623" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1642">5</ix:nonFraction>% of consolidated net sales in the first half of 2025 (versus approximately <ix:nonFraction unitRef="number" contextRef="c-624" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1643">13</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-625" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1644">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-626" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1645">7</ix:nonFraction>% in the first half of 2024).</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33</span></div></td></tr></table></div></div></div><div id="i4cb00d616bf34e7c9407f3fd7baa4584_333"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="f-1646" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1731ee5f715a4ab4931699f4917632dc"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.22. Information related to Opella, presented within assets held for sale and discontinued operations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30 2025, the Opella transaction was closed (see Note B.1.) triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" id="f-1647" continuedAt="f-1647-1" escape="true">As of December 31, 2024, all Opella assets and associated liabilities were classified as held for sale, in accordance with IFRS 5.</ix:nonNumeric></span></div><ix:continuation id="f-1647-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.658%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1648">760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1649">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:GoodwillDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1650">7,255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1651">2,928</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InventoriesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1652">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1653">989</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherAssetsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1654">841</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total  assets held for sale</span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:AssetsOfDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1655">13,489</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1656">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1657">204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:AccountsPayableDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1658">797</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1659">570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1660">448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale </span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1661">2,131</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, were measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.  </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1662">1,736</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1663">2,645</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1664">266</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1665">277</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1666">2,781</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-1667">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1668">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1669">278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1670">158</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1671">85</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1672">2,881</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" scale="6" id="f-1673">202</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-76" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).</span></div></ix:footnote><ix:footnote id="fn-77" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-6" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1674">88</ix:nonFraction>&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div></ix:footnote><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below presents basic and diluted earnings per share from discontinued operations (Opella), in accordance with IAS 33 (Earnings per Share):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1675">2,881</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" scale="6" id="f-1676">202</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-1677">1,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-1678">1,249.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-1679">1,230.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-1680">1,253.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-1681">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-1682">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diluted earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-1683">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-1684">0.16</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4cb00d616bf34e7c9407f3fd7baa4584_103"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-1685" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i23ea087f4ae74ebaa993bb45daf2618f"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C/ Events subsequent to June 30, 2025</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vicebio Ltd (&#8220;Vicebio&#8221;), a privately held biotechnology company headquartered in London, UK. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands Sanofi&#8217;s capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology. Under the terms of the agreement, Sanofi would acquire all of Vicebio&#8217;s share capital for a total upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-7" name="sny:UpfrontPayments" format="ixt:num-dot-decimal" scale="9" id="f-1686">1.15</ix:nonFraction>&#160;billion, with potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-6" name="sny:TotalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1687">450</ix:nonFraction>&#160;million based on development and regulatory achievements. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-2025halfyearman.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0f074ff5ccee4c41adecb7b0b757aded_1"></div><div style="min-height:56.69pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:32pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="margin-bottom:5pt;margin-top:70pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.997%"><tr><td style="width:1.0%"></td><td style="width:88.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0a2d3742832b49d1a3b29154f99eb87a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">2. Half-year management report</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0a2d3742832b49d1a3b29154f99eb87a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i1ee9d7ddda5441e3b2fe9390def9e3f1" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">A&#47; Significant events of the first half of 2025</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i1ee9d7ddda5441e3b2fe9390def9e3f1" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i33aac9174e9a4098abd57e68034bfb2f" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">B&#47; Progress on implementation of the corporate social responsibility strategy</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i33aac9174e9a4098abd57e68034bfb2f" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i3aefdd6f51d74346a6617bf82d69f584" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">C&#47; Events subsequent to June 30, 2025</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i3aefdd6f51d74346a6617bf82d69f584" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#iae677d8f3ec8485dbf38911dafb0bce4" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">D&#47; Consolidated financial statements for the first half of 2025</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#iae677d8f3ec8485dbf38911dafb0bce4" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i8d9aa26ca019415ba2bce351212c354a" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">E&#47; Risk factors and related party transactions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i8d9aa26ca019415ba2bce351212c354a" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i614aaf8b759a4182af7e9c5e8920184a" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">F&#47; Outlook</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i614aaf8b759a4182af7e9c5e8920184a" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#ifb57349444f24112a34d8c3272a137f0" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">G&#47; Appendix - research and development pipeline</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#ifb57349444f24112a34d8c3272a137f0" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie292f622033442c2969a1679079d01cf" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">3. Statutory auditors&#8217; review report on the half-yearly financial information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie292f622033442c2969a1679079d01cf" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie70311e4382e43369c27dcdcf4689f56" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">4. Responsibility statement of the certifying officer&#58; half-year financial report</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie70311e4382e43369c27dcdcf4689f56" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">63</a></font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_4"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="i0a2d3742832b49d1a3b29154f99eb87a"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">2. Half-year management report</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_7"></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i1ee9d7ddda5441e3b2fe9390def9e3f1"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A&#47; Significant events of the first half of 2025</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i4df9415549e24664b2bac5433ce6a104"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. First-half overview</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, Sanofi continued to implement its growth and innovation strategy, focused on launching major innovations, reallocating resources and developing cutting-edge R&#38;D. Significant events connected with the implementation of this strategy are described below (for additional information on developments related to Research and Development see also section &#34;A.2. Research and Development&#34;).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">repurchase the Company's shares</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, for an amount not exceeding &#8364;5&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#233;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#8217;s share capital, equivalent to 29,556,650 shares, for a total amount of approximately &#8364;3&#160;billion, representing a price of &#8364;101.50 per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code. In addition, on February 6, 2025 Sanofi entered into a mandate with an investment services provider to repurchase its own shares for a maximum amount of &#8364;2&#160;billion, between February 7, 2025 and December 31, 2025. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of the Euro Medium Term Note program, Sanofi carried out</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> two bond</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> issues in the first half of 2025. On March 5, a first issue of &#8364;1.5 billion was completed, comprising &#8364;850 million of floating-rate bonds (3-month Euribor + 0.300%) maturing in March 2027, and &#8364;650 million of fixed-rate bonds (2.750% per annum) maturing in March 2031. On June 17, a second issue of &#8364;1.5 billion was completed, consisting of two tranches of &#8364;750 million each&#58; one at a fixed rate of 2.625% per annum) maturing in June 2029, and the other at a fixed rate of 3.000% per annum maturing in June 2032. Sanofi will use the net proceeds from the issuance of these bonds for general corporate purposes.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, Sanofi announced the completion of the transaction with Clayton, Dubilier &#38; Rice (CD&#38;R) relating to Sanofi&#8217;s consumer healthcare business, </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Opella</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Sanofi retains a 48.2% equity interest in OPAL JV Co, which indirectly holds 100% of Opella.. Bpifrance holds a minority stake of 1.8% and will be represented on Opella&#8217;s Board. As a result of the transaction, Sanofi has recognized a net gain of &#8364;2.7 billion, reported within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated income statement. Sanofi has received total net cash proceeds of &#8364;10.7 billion, presented within the line item</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash inflow from the Opella transaction</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the statement of cash flows.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 22, 2025, Sanofi announced that it had entered into an agreement to acquire </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Vigil Neuroscience, Inc.</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8220;Vigil&#8221;), a US-based publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology enhances Sanofi&#8217;s early-stage pipeline and includes VG-3927, an oral small molecule TREM2 agonist currently in development for Alzheimer&#8217;s disease. Sanofi had previously invested $40 million in June 2024, including a pre-emptive right to VG-3927. Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing. Based on $8.00 per share, the total equity value of Vigil represents approximately $470 million (on a fully diluted basis). Closing of the transaction is expected in the third quarter of 2025 subject to conditions customary for such a transaction, including the approval of holders of a majority of the outstanding shares of Vigil common stock&#59; the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976&#59; and other customary conditions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 27, 2025, Sanofi announced the completion of the acquisition of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">DR-0201</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a targeted bispecific antibody developed by Dren Bio, Inc., a privately held clinical-stage biopharmaceutical company. The definitive agreement was signed on March 19, 2025. DR-0201, now named SAR448501, engages myeloid cells for robust B-cell depletion, as demonstrated in preclinical and early clinical studies. Under the merger agreement, Sanofi acquired Dren-0201, a subsidiary of Dren Bio, for an upfront payment of $600 million, supplemented by potential milestone payments of up to $1.3 billion contingent upon attainment of development and commercialization milestones.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 2, 2025, Sanofi and </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Blueprint Medicines Corporation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, entered into an agreement under which Sanofi agreed to acquire Blueprint.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition included a rare immunology disease medicine, Ayvakit&#47;Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint&#8217;s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi&#8217;s growing immunology pipeline.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the acquisition, Sanofi agreed to pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1&#160;billion for 100% of the shares. Blueprint shareholders also received one non-tradable contractual contingent value right (CVR) per share which entitles the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5&#160;billion on a fully diluted basis. In July 2025, Sanofi obtained control of Blueprint after all tender offer and merger conditions had been met.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">36</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2025 amounted to &#8364;19,889&#160;million, 8.3% higher than in the first half of 2024. At constant exchange rates (CER)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales rose by 9.9%, driven mainly by strong performances for Dupixent, ALTUVIIIO and Beyfortus.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:112%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">amounted to &#8364;5,812&#160;million in the first half of 2025, versus &#8364;2,246 million in the first half of 2024. Earnings per share was &#8364;4.74 for the first half of 2025, versus &#8364;1.80 for the first half of 2024. Business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:112%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"> was &#8364;4,152 million, up 7.6% on the first half of 2024, while business earnings per share (business EPS</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:112%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">) was &#8364;3.39, 9.7% up on the first half of 2024.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_10"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="if68ab577ef4949e3b851995f99d98cdb"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. Research and development</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, Sanofi maintained its R&#38;D efforts with the aim of improving quality of life for people around the globe by developing innovative vaccines and medicines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Progress made in R&#38;D during the period is described in detail below, and an update on the R&#38;D pipeline is presented in Section G&#47; of this half-year management report.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="iec21c0c8b5be4c44be24505597d06a3e"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i7b638359f55b4821ba6027c126167893"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dupixent (dupilumab)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After evaluation under priority review by the US Food and Drug Administration (FDA), Dupixent was approved for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">bullous pemphigoid</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (BP), a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population. The approval is based on data from the pivotal ADEPT phase 2&#47;3 study that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Additional regulatory applications are under review around the world, including in the European Union (EU), Japan, and China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dupixent was granted marketing and manufacturing authorization in Japan for the treatment of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">chronic obstructive pulmonary disease</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (COPD) in adults whose disease is not adequately controlled with existing therapy. The approval in Japan was based on data from the BOREAS phase 3 study. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i40fc1151970a4f559bc2bf2761b35a4f"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">itepekimab (IL33 mAb)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant reduction in moderate or severe acute exacerbations compared to placebo of 27% at week 52, a clinically meaningful benefit. With a reduction of only 2% at week 52, the AERIFY-2 phase 3 study did not meet the same primary endpoint. In the studies, patients were randomized to receive itepekimab every two weeks, every four weeks, or placebo, which was added to inhaled triple or double standard-of-care therapy. The safety of itepekimab was consistent across the studies, and adverse events were generally comparable between treatment and placebo groups. Sanofi and Regeneron are reviewing the data, including the apparent loss of benefit in AERIFY-2, and will discuss with regulatory authorities to evaluate next steps. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The CEREN 1 and CEREN 2 phase 3 studies of two dose regimens of itepekimab compared with placebo as add-on therapy to intranasal corticosteroids in patients with inadequately controlled </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CRSwNP </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">commenced dosing the first patients.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i1ea5a068b25d480192d052b6f6179c29"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">amlitelimab (CD40 mAb)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The COAST 1 and SHORE phase 3 studies, part of the OCEANA study program in atopic dermatitis (</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AD), </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have completed patient recruitment ahead of schedule. Patient recruitment proceeded efficiently, providing an opportunity to optimize the overall sample sizes and robustness of the studies. The OCEANA program is anticipated to read out in 2025 (initial data) and 2026 (full data) and will provide the foundation for potential regulatory submissions.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ic42e2e8567474fbcaa3e1c0632614c13"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rezurock (belumosudil) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on a pre-specified interim analysis, a decision was made to discontinue the ROCKnrol-1 phase 3 study evaluating belumosudil in first-line chronic graft-versus-host disease. No major safety concerns were identified.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ia7e26d59a5cd42e19027ed00d3cee962"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">riliprubart (C1s mAb) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US FDA granted orphan drug designation to riliprubart for the treatment of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">antibody-mediated rejection </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(AMR) in solid organ transplantation. This designation reflects Sanofi&#8217;s commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie672b8b083b44cf5a17cb9d11fa4aab2"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rare diseases</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="idd710b3ec6d649fab82abdd15eab61c4"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qfitlia (fitusiran)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US FDA approved Qfitlia, the first antithrombin (AT)-lowering medicine for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">hemophilia A or B </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">with or without factor VIII or IX inhibitors. The approval is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates across hemophilia patients with or without inhibitors. In conjunction with </font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure&#58; see definition in D.3., &#8220;Net sales&#8221;.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure&#58; see definition in D.2., &#8220;Business net income&#8221;.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">the Qfitlia approval, the FDA also cleared Siemens Healthineers&#8217; INNOVANCE&#174; AT assay as a companion diagnostic for Qfitlia to measure AT levels. The medicine is also under regulatory review in China.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="if60b2bb658a349e082e8f2470d6071d9"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cerezyme (imiglucerase)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US FDA accepted for review the submission of a supplemental biologics license application (sBLA) for Cerezyme to treat patients with Gaucher disease type 3 (GD3), with no age limitation, for patients with GD1 and GD3. The FDA decision is expected in the first quarter of 2026.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ia05bcc6575ce49afbac629805aebd67a"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rilzabrutinib (BTK inhibitor)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US FDA granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation to target a reduction in vaso-occlusive crises (which may occur via inflammation), in sickle cell disease.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i00e4319997f64cb599d2e5ecd286a90a"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Neurology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ie4cb99d5e3864383819292c1b912e63d"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">tolebrutinib (BTK inhibitor)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US FDA is evaluating under priority review the regulatory submission of tolebrutinib, the submission of which was accepted in the first half 2025, to treat </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">non-relapsing secondary progressive multiple sclerosis </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(nrSPMS) and to slow disability accumulation independent of relapse activity. The FDA decision is expected before the end of 2025. A regulatory submission has also been accepted and is under review in the EU. The positive results from the HERCULES phase 3 study that form the basis for these regulatory submissions were published in the </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (NEJM) in April 2025. As part of the ongoing regulatory review, discussions with the FDA and the EMA are continuing with respect to efficacy and safety, including liver safety, from the clinical studies.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ia04acc710e96484aa9f261b30023a83c"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">riliprubart (C1s mAb)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Japan, riliprubart was granted orphan drug designation for people with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite available therapies, many CIDP patients are left with residual symptoms, including weakness, numbness, and fatigue that can lead to long-term morbidity and diminished quality of life. Approximately 30% of people with CIDP do not respond to standard therapies. The orphan drug designation is granted to medicines that address rare medical diseases or conditions with unmet medical needs. There are currently approximately 4,000 people diagnosed with CIDP in Japan.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i9258ba06bea440a38227ad9723fd1881"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Oncology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i5892f8fb449d4e4085742e7f1e84f84e"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarclisa (isatuximab)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Following the adoption of a positive opinion by the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use (CHMP), Sarclisa in combination with the standard-of-care regimen bortezomib, lenalidomide, and dexamethasone (VRd) was approved in January in the EU for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">newly diagnosed multiple myeloma ineligible for autologous stem cell transplant</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (NDMM, TI). Sarclisa in combination with VRd was also approved in Japan and China for the treatment of adult patients with NDMM, TI. These approvals are based on data from the IMROZ phase&#160;3 study.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January, Sarclisa in combination with pomalidomide and dexamethasone was approved in China for the treatment of adult patients with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MM who have received at least one prior line of therapy</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, including lenalidomide and a proteasome inhibitor. This approval is based on results from the pivotal ICARIA-MM phase 3 study, using the China-based IsaFiRsT real-world study as bridging data.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Following the positive opinion by the CHMP, Sarclisa in combination with VRd was approved in the EU for the induction treatment of adult patients with NDMM who are eligible for autologous stem cell transplant. The positive CHMP opinion was based on part one results from the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 study.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Results from the IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system in combination with pomalidomide and dexamethasone (Pd) met its co-primary endpoints of non-inferior objective response rate and observed concentration before dosing at steady state compared to intravenous Sarclisa administered at a weight-based dose in combination with Pd in patients with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">relapsed or refractory (R&#47;R) MM</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These results will be the basis for regulatory submissions in the US and in the EU in 2025. Additional studies evaluating Sarclisa SC formulations across different combinations and lines of therapy are ongoing. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib323fb331cf04860945e036f080fb3d6"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i4f719695d83f4be08a27938d8b0c068f"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MenQuadfi (meningitis, six weeks+)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May, the US FDA updated MenQuadfi&#8217;s approval, which now includes active immunization in children aged six weeks to 23 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">38</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i7cb6d056426e4062bc6bbb10954ed0d5"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nuvaxovid (COVID-19)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s collaboration partner Novavax, Inc. announced that the US FDA had approved the biologics license application (BLA) for Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, diabetes, obesity, smoking). Nuvaxovid has been available for use in the US under Emergency Use Authorization since July 2022 and has full market approvals in the EU, UK and other countries. Under a May 2024 agreement, Sanofi has a co-exclusive license to co-commercialize Nuvaxovid in most countries worldwide and a sole license to Nuvaxovid for use in combination with Sanofi&#8217;s flu vaccines, currently in phase 1 clinical studies.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i0a5e62afbb1043d9b43832c3f8a890d3"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0087 (rabies)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The phase 3 study of the vero cell vaccine for the prevention of rabies read out positively on safety and immunogenicity. It is intended for use as a vaccine, and as a booster after two to three years. This study and previous studies support a US regulatory submission for prevention of rabies before and after exposure in all populations in the second half of 2025.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i8732f1e0b24f48d28838b2f03b6e5685"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0282 (E. coli sepsis)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February, a scheduled review of the E.mbrace phase 3 study conducted by an independent data monitoring committee (IDMC) determined that Sanofi&#8217;s and Johnson &#38; Johnson&#8217;s vaccine candidate for extraintestinal pathogenic E. coli was not sufficiently effective at preventing invasive </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">E. coli disease </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(IED) compared to placebo. No safety signals related to the vaccine candidate were identified and, throughout the study, investigators ensured that participants who developed IED received prompt treatment and care. As a result of the IDMC&#8217;s determination, the E.mbrace study was discontinued.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ic6328118c21747aeae98ab4bc690a48e"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0218 (yellow fever)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A vaccine candidate is in development to prevent </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">yellow fever </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">infection in populations aged nine months and older. A phase 3 study in adults has commenced dosing the first patient.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_397"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i8e720381b23c46a0b81c37fe97bb21fa"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. Other significant events</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i0ef82d8d91c34e87914b6b3e924a3777"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.1 Corporate governance</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Combined General Shareholders&#8217; Meeting of Sanofi was held on April 30, 2025 at the Palais des Congr&#232;s in Paris, and was chaired by Fr&#233;d&#233;ric Oud&#233;a. All resolutions submitted to the vote were adopted by the shareholders. Decisions taken by the General Meeting included approving the individual company and consolidated financial statements for the year ended December 31, 2024 and distributing an ordinary annual dividend of &#8364;3.92 per share. The meeting also approved the reappointment of Carole Ferrand, Barbara Lavernos, Emile Voest and Antoine Yver as directors, and ratified the co-opting of Jean-Paul Kress. On a proposal from the Appointments, Governance and CSR Committee, the Board of Directors appointed Clotilde Delbos, independent director, as Chairwoman of the Compensation Committee&#59; she succeeds Patrick Kron, who will remain as a member of the Committee. Following the expiry of Fabienne Lecorvaisier's term of office at the close of the Annual General Meeting of April 30, 2025, the Board of Directors now comprises 16 members, of whom six are women and two are directors representing employees. The Board of Directors retains a large majority of independent directors.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i48f32f2148344c2493ebdeb02c63dfe7"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.2. Legal and arbitration proceedings</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the most significant developments in legal and arbitration proceedings since publication of the financial statements for the year ended December 31, 2024, refer to Note B.14. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font id="i53e6d8d5fd0849d08e3b2ea93d4a6a5d"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">US Department of Health and Human Services (HHS), Office of Inspector General (OIG) Philadelphia Subpoena</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2025, Sanofi US received a subpoena from the Philadelphia Office of the US Department of Health and Human Services Office of Inspector General (HHS-OIG). The subpoena seeks information about Sanofi&#8217;s agreements with pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs), particularly regarding the provision of drug utilization data from 2020 to the present. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The investigation is being conducted jointly by the US Department of Justice (DOJ), the US Attorney&#8217;s Office for the Eastern District of Pennsylvania, and the HHS-OIG. Sanofi is cooperating with this investigation.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font id="i40d728120a834be18ce5fe35a86319df"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">US Department of Justice (DOJ) - Civil Investigative Demand (CID) - Beyfortus </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2025, Sanofi US received a CID (Civil Investigative Demand) from the US Department of Justice under the False Claims Act. The CID requests information related to the RSV (Respiratory Syncytial Virus) vaccine Beyfortus, which Sanofi co-develops and co-commercializes with a partner company. The CID specifically references a May 2024 FDA inspection of a manufacturing facility in North Carolina where Beyfortus was filled into syringes. Sanofi is cooperating fully and providing the requested information.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">39</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_16"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i7d9e08ba687544d292dfe4393ed27c2c"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.3. Other events</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 5, 2025. Sanofi announced the launch of Action 2025, a global employee share ownership plan open to around 70,000 employees in 55 countries. Now in its eleventh year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to ensuring that employees benefit from the company&#8217;s growth and success.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The shares were offered at a subscription price of &#8364;72.97, representing a 20% discount to the average of the 20 opening prices of Sanofi shares from May 7 to June 3, 2025. For every five shares subscribed, employees were entitled to receive one free share (up to a maximum of four free shares per employee). Every eligible employee was able to purchase up to 1,500 Sanofi shares, subject to the maximum legal limit set at 25% of their gross annual salary, minus any voluntary deductions already made under employee savings schemes such as the Company Savings Plan and&#47;or Group Savings Plan and&#47;or Group Retirement Savings Plan (PERCO) during 2025&#59; the above limit does not apply to voluntary contributions to the &#8220;PERCOL&#8221; retirement savings plan.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_19"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">40</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i33aac9174e9a4098abd57e68034bfb2f"></font><font style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">B&#47; Progress on implementation of the corporate social responsibility strategy</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i449b96f5bc7c478d88b279937fcd83eb"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introducing AIR&#58; Sanofi's updated sustainability strategy</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Building on a foundation in corporate social responsibility, Sanofi is introducing an updated sustainability strategy focused on the critical nexus between health and the environment. The AIR strategy addresses three key dimensions&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Access to healthcare&#58; expanding sustainable and equitable access to care programs for conditions impacted by environmental challenges, with initial focus on respiratory health and diabetes&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Environmental impact&#58; reducing the environmental impact of Sanofi&#8217;s medicines and vaccines and activities across the value chain while adapting to climate- and nature-related changes, with the ambition to reach Net Zero greenhouse gas emissions by 2045&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Resilience of healthcare systems&#58; transforming the delivery of care through treatments and collective efforts that reduce the environmental footprint of healthcare systems.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This strategic focus recognizes that 70% of Sanofi&#8217;s medicine and vaccine portfolio, and more than 75% of Sanofi&#8217;s pipeline, target diseases that are impacted by climate and environmental challenges. It also puts Sanofi in a position to make a meaningful difference through access to care programs and actions to reduce the environmental footprint of healthcare. In these ways, Sanofi can help break the vicious circle between environmental degradation and declining human health.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i27046987a1474003b932b386f93a2108"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reducing the environmental footprint of healthcare&#58; from ambition to results </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With 3.6 billion people living in areas sensitive to climate change globally</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, Sanofi aims to reduce the environmental footprint of its medicines and vaccines via an eco-design approach, spanning the entire lifecycle - from raw materials, manufacturing, device and packaging, all the way to distribution, patient use, and end of life.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Starting in 2025, all new medicines and vaccines are adopting an eco-design approach, and by 2030, so will Sanofi&#8217;s 20 top sellers. Leveraging a science-based life cycle assessment methodology</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and its own ISO-compliant eco-design digital intelligence tool, Sanofi has already achieved results in some of its top-selling medicines and vaccines&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">For Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carbon footprint was reduced by 53%, water use cut by 62% and resource depletion reduced by 30%, by optimizing the active ingredient manufacturing process with the partner Regeneron.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">For Toujeo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 27% carbon footprint reduction, 11% water savings, and 18% resource reduction were achieved through improved manufacturing, packaging, and device production.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">For Hexaxim</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, production and packaging were also optimized, resulting in 17% lower carbon footprint, 19% less water use, and 6% fewer resources used.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All measures were compared to the previous generation of those medicines and vaccines. These improvements demonstrate our commitment to reducing environmental impact across ours product range.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie560397e3af14a039a2a43595978cd40"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Decarbonizing patient care pathways</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The healthcare sector generates approximately 5% of global greenhouse gas emissions, with about half of that attributable to the patient care pathway</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. As a key player, Sanofi has the capacity to lead efforts to reduce emissions related to the patient journey.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is intensifying its efforts to generate and analyze data that examine how its treatments can help decarbonize patient care pathways. Sanofi has already identified several ways to reduce environmental impact across patient care such as prioritizing prevention, optimizing treatments, and improving care settings. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a recent study conducted in Spain using real-world evidence, Sanofi demonstrated the positive environmental impact of the all-infant 2023-2024 immunization program against RSV with Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. With immunization coverage exceeding 90% for in-season births and approaching 90% for out-of-season births</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, RSV prevention contributed to lower greenhouse gas emissions through reduced healthcare system utilization and decreased patient transportation, as evidenced by fewer visits to primary care  physicians, emergency rooms, and specialists, as well as reduced hospitalizations. The program reduced RSV-related CO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> emissions by 47% compared to the previous year&#8217;s standard of care, equivalent to 4.9 kilotons of CO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="icbb74af44ebc4644b03b944ca1e11b57"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sustainability dashboard for the second quarter of 2025 </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Please refer to the sustainability dashboard provided as an appendix to the Sanofi second-quarter 2025 results press release. </font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> World Health Organization newsroom&#47;fact sheet on climate change&#47;key facts&#58; October 12, 2023.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> European Platform on environmental life cycle assessment&#58; https&#58;&#47;&#47;eplca.jrc.ec.europa.eu&#47;EnvironmentalFootprint.html.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Based on an ISO-compliant life cycle assessment study peer-reviewed by independent panels, ensuring transparent and accurate results.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Information from White Paper issued by the Sustainable Markets Initiative health systems task force, https&#58;&#47;&#47;a.storyblok.com&#47;f&#47;109506&#47;x&#47;88fe7ea368&#47;smi-hstf-pcp-whitepaper.pdf.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Sanofi Beyfortus health-economic model, Gil-Prieto et al. 2024, CVA analysis&#58; ICAO 2024 data, CVA.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Data from the Spanish Ministry of Health (2024), https&#58;&#47;&#47;www.sanidad.gob.es&#47;areas&#47;promocionPrevencion&#47;vacunaciones&#47;comoTrabajamos&#47;docs&#47;VRS_infantil.pdfb.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">41</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_22"></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i3aefdd6f51d74346a6617bf82d69f584"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C&#47; Events subsequent to June 30, 2025</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main events related to research and development that occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were reviewed by the Board of Directors are described in section 'A.2. Research and Development'. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vicebio Ltd (&#8220;Vicebio&#8221;), a privately held biotechnology company headquartered in London, UK. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands Sanofi&#8217;s capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology. Under the terms of the agreement, Sanofi would acquire all of Vicebio&#8217;s share capital for a total upfront payment of $1.15&#160;billion, with potential milestone payments of up to $450&#160;million based on development and regulatory achievements. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">42</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_25"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="iae677d8f3ec8485dbf38911dafb0bce4"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">D&#47; Consolidated financial statements for the first half of 2025</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unless otherwise indicated, all financial data in this report are presented in accordance with international financial reporting standards (IFRS), including international accounting standards and interpretations (see Note A.1. to our condensed half-year consolidated financial statements). </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i8bea6178306149d590e0c0edb4ef63c1"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated income statements for the six months ended June 30, 2024 and&#160;June&#160;30,&#160;2025</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:46.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as % of net sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as % of net sales</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.3</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.3</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,966)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-32.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,460</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77.7</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,923</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75.8</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.7&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,335)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,303)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,476)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,977)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(777)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(898)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,060)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(450)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.9</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,768</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.1</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(583)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.0</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,462</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.4</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(711)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(379)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from continuing operations</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,956</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.9</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,061</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11.2</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,881&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.5</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.1</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,837</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29.3</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,263</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12.3</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29.2</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,246</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12.2</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,230.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,253.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.40&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;) </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.74&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.39&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.63&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;) </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.72&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.79&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_28"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i48970ee47947470fac10016ee30014fd"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.1. Segment information</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i2d4be471c1634e739b1e3a56342fc92d"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.1. Operating segments</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of the single operating segment is monitored individually using internal reports and common indicators. The operating segment disclosures required under IFRS 8 are provided in Note B.21. to our condensed half-year consolidated financial statements. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment&#58; Biopharma.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella, which constitutes a related party with effect from the deconsolidation date (April 30, 2025). Those revenues, which before that date represented intragroup transactions classified within continuing operations, are presented within </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028&#59; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement)&#59; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i62080865c12042d6a4ce582744bacff7"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.2. Business operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We report segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources. For a definition of &#8220;Business operating income&#8221;, and a reconciliation between that indicator and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.21.1. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, &#8220;Business operating income&#8221; amounted to &#8364;5,363 million (versus &#8364;4,938 million for the first half of 2024), while &#8220;Business operating income margin&#8221; was 27.0% (versus 26.9% for the first half of 2024). &#8220;Business operating income margin&#8221; is a non-IFRS financial measure that we define as the ratio of &#8220;Business net income&#8221; to our consolidated net sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business operating income&#8221; and &#8220;Business operating income margin&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-IFRS measures by management in setting goals and measuring performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_31"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ic25432f9a35442eb9c84a0b9d90a155c"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. Business net income (non-IFRS financial measure)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 was to &#8364;5,812 million, 157.9% higher than the first half of 2024 (&#8364;2,246 million). &#8220;Business net income&#8221; for the first half of 2025 amounted to &#8364;4,152 million, 7.6% up on the first half of 2024 (&#8364;3,859 million). That represents 20.9% of net sales, versus 21.0% for the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also report &#8220;Business earnings per share&#8221; (business EPS), a non-IFRS financial measure which we define as business net income divided by the weighted average number of shares outstanding. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business EPS was &#8364;3.39 for the first half of 2025, 9.7% up on the 2024 first-half figure of &#8364;3.09, based on an average number of shares outstanding of 1,225.5 million for the first half of 2025 and 1,249.4&#160;million for the first half of 2024. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">44</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We define &#8220;Business net income&#8221; as </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">determined under IFRS, excluding the following items&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income from discontinued operations, including Opella&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3), or to divestments of operations meeting the definition of a business&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">restructuring costs and similar items (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">(income)&#47;expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9 (Financial Instruments)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">tax effects related to the items listed above as well as effects of major tax disputes&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the portion attributable to non-controlling interests of the items listed above.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to our  &#8220;Business net income&#8221; &#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months) (a)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi (IFRS)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,246</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (income)&#47;loss from the discontinued Opella business </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,881)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(202)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets </font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(371)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,060&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial (income)&#47;expenses relating to financial liabilities accounted for at amortized cost and subject to periodic remeasurement</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effects of the items listed above&#58;</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(384)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(577)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">amortization and impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(48)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">tax effects of restructuring costs and similar items</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(113)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(343)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">other items</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(84)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(169)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income (non-IFRS)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,152</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,859</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (IFRS) (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.74&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reconciling items per share (in euros) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.35)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (non-IFRS) (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.39&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.09&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In 2025, this line includes &#8364;2,693&#160;million related to the net gain on the Opella divestment, recognized on the date of loss of control (refer to Note B1.1 to our condensed half-year statements).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of&#8364;210&#160;million in the first half of 2025 linked to research and development projects. <br>For the six months ended June 30, 2024, this line corresponds to a net reversal of impairment losses amounting to &#8364;371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;For the first half of 2025, Other gains and losses, and litigation is a charge of &#8364;57 million, mainly related to major litigation. That compares with a charge of &#8364;450 m</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">illion in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii. </font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;This line corresponds to the financial expense arising from remeasurement of the financial liability recognized in the balance sheet to reflect estimated future royalties on sales of Beyfortus in the United States.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;In the first half of 2024, this line mainly comprised an impairment loss taken against the equity interest in EUROAPI, based on the quoted market price&#58; &#8364;2.89 as of June 30, 2025, &#8364;2.55 as of June 30, 2024.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g) Corresponds to the reconciliation between basic earnings per share (IFRS) and business earnings per share (non-IFRS)&#58; sum total of reconciling items divided by the weighted average number of shares outstanding.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The most significant reconciling items between &#8220;Business net income&#8221; and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> relate to&#160;(i)&#160;the purchase accounting effects of our acquisitions of groups of assets and business combinations, particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or operational nature)&#59; (ii)&#160;the impacts of restructuring actions or transactions regarded as non-recurring, where the amounts involved are particularly significant&#59; (iii)&#160;the remeasurements recognized through profit or loss in respect of (a)&#160;amounts receivable in respect of business divestments and accounted for at fair value, (b)&#160;liabilities arising from business combinations (IFRS&#160;3) and accounted for at fair value, (c)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement under IFRS&#160;9&#59; and (iv) the net income from discontinued operations, including Opella. We believe that excluding those impacts enhances an investor&#8217;s understanding of our underlying economic performance, because it gives a better representation of our recurring operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating charges related to the purchase accounting effects (particularly amortization and impairment of some intangible assets) enhances comparability of our ongoing operating performance relative to our peers. Those intangible assets (principally rights relating to research and development, technology platforms and commercialization of products) are accounted for in accordance with IAS&#160;38 (Intangible Assets) and IFRS&#160;3 (Business Combinations).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our recurring operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in connection with reorganization and transformation Company&#8217;s programs, integration or separation as part of material deals.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major non-recurring items) improves comparability from one period to the next.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, remeasurements recognized in profit or loss during the period in respect of (i)&#160;assets or liabilities accounted for at fair value and recognized in the balance sheet in connection with business acquisitions or divestments or (ii)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement, generally determined on the basis of revised sales forecasts, are not reflective of our operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the items mentioned above relating to our continuing operations, &#8220;Business net income&#8221; excludes net income from the Opella discontinued operation, the results of which have been presented separately in the consolidated income statement since October 2024 (comparative figures have been re-presented on a consistent basis). Under IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), a discontinued operation is defined as a component of an entity that has been disposed of or is classified as held for sale, and represents a separate major line of business. With effect from October 2024, &#8220;Business net income&#8221; from continuing operations is used by management to measure Sanofi&#8217;s financial performance on an ongoing basis. We believe that providing a performance measure aligned with our management approach is useful for investors and analysts.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We remind investors, however, that &#8220;Business net income&#8221; should not be considered in isolation from, or as a substitute for, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reported in accordance with IFRS. In addition, we strongly encourage investors and potential investors not to rely on any single financial measure but to review our financial statements, including the notes thereto, carefully and in their entirety.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We compensate for the material limitations described above by using &#8220;Business net income&#8221; only to supplement our IFRS financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments included in&#160;&#8220;Business net income.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business net income&#8221; and &#8220;Business EPS&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_34"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">46</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i2feaf37aa304411aa54afa3ac9a14f77"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.3. Net sales</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2025 amounted to &#8364;19,889&#160;million, 8.3% higher than in the first half of 2024. Exchange rate fluctuations had a negative effect of 1.6 percentage points overall, due mainly to adverse trends in the euro exchange rate against the US dollar, Brazilian real and Mexican peso. At constant exchange rates (CER, see definition below), net sales rose by 9.9%, driven mainly by strong performances for Dupixent, ALTUVIIIO and Beyfortus. Divestments and medicines&#47;portfolio streamlining had a negative impact of 0.4 percentage points on sales growth.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="id27286cbbe1c45c694d3e51a7e526973"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net sales (IFRS) to net sales at constant exchange&#160;rates (non-IFRS)</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales at constant exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,175</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.9</font></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When we refer to changes in our net sales at constant exchange rates (CER), that means we have excluded the effect of exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous period, with the exception of countries treated as hyperinflationary economies under IAS 29 (i.e. Argentina and Turkey, see Note A.4 to our condensed half-year consolidated financial statements).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie5ac8ab661c045d3af32ed7a4c406e80"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Net sales by segment</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our net sales comprise the net sales generated by our Biopharma segment.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on<br>a reported<br>basis</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at<br>constant<br>exchange rates</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma segment</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.9</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ide0cd070950b4abba446d2e889483293"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Net sales by medicine, vaccine and geography</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales by main product and geographical region break down as follows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.020%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of the&#160;world</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,312&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.1</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.7</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,283&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.7</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.3</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,085&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.2</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+30.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.8</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.5</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+93.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+95.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+78.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+304.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme &#47; Nexviadyme (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">305&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-28.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-40.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+52.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+54.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+83.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+81.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Qfitlia (Fitusiran) (*) </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-34.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.8</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-57.9</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.2</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.6</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.5</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.7</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-50.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.4</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.7</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+47.8</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.9</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.9</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">692&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-19.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+91.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+185.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+35.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-65.2</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-63.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-60.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-82.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,971&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.7</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,211&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.6</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial Sales</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccine (Beyfortus) (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+78.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+79.0</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-43.1</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1114.3</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+168.8</font></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio &#47; Pertussis &#47; Hib Vaccines &#38;&#160;Boosters</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,361&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.0</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.4</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+237.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+73.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, Travel and Endemics Vaccines</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.1</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.5</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.9</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+16.4</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+1.8</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+6.4</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Launches (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,100&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+45.8</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.9</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,204&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.1</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+71.5</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100.0</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation, forming the basis for the percentage change data calculated in the above table.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">48</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="if1061b3b89ea4084bf82569e7c875679"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.3. Biopharma segment </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, revenue from the Biopharma business (see &#8220;Chapter D.1. Segment Information&#8221; for detailed segment information) was &#8364;19,889 million, up 8.3% on a reported basis and 9.9% at constant exchange rates (CER), driven by Dupixent and new launches.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Comments on the performances of our major Biopharma segment products are provided below.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ia702a07cf2b1454d9344728905df92f7"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New pharma launches</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (hemophilia A) generated sales of &#8364;542 million in the first half of 2025, primarily in the United States, driven by continued patient switches from older plasma-derived and recombinant factor medicines and to a lesser extent from non-factor treatments. Sales in the Rest of the World region, at &#8364;86 million, benefited from the launch in Japan and sales of supplies to Sanof'&#8217;s collaboration partner Sobi in Europe. Sales of the hemophilia A franchise (ALTUVIIIO + Eloctate) reached &#8364;683 million (+45% CER versus the first half of 2024), due to the strong commercial performance of ALTUVIIIO. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Nexviazyme&#47;Nexviadyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Pompe disease) sales reached &#8364;387 million, up 21.6% CER, driven by Europe (+38.9% CER) and the United States (+13.2% CER at &#8364;195 million) where all eligible&#47;non-pediatric patients have converted from Myozyme&#47;Lumizyme. Sales of the Pompe disease franchise (Nexviazyme&#47;Nexviadyme and Myozyme&#47;Lumizyme combined) reached &#8364;668 million, down 3.3% CER. Nexviazyme&#47;Nexviadyme sales now represent 58% of the Pompe disease franchise. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Over the same period, sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (multiple myeloma) reached &#8364;276 million, up 22.5% CER, driven by increased use in the front-line setting and market share gains globally.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rezurock</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (chronic graft-versus-host disease, third line) reached &#8364;263 million in the first half, up 28.0% CER, driven by the United States (+18.1% CER) and by a significant increase in volumes in Europe (&#8364;23 million) and the Rest of the World (&#8364;20&#160;million). </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cablivi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acquired thrombotic thrombocytopenic purpura) reached &#8364;136 million (+20.4% CER) in the first half, driven by an increase in the number of patients identified for this treatment (aided by artificial intelligence in the United States), and by launches in Europe and the Rest of the World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Xenpozyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acid sphingomyelinase deficiency) were &#8364;110 million in the first half, up 54.2% CER, reflecting an increase in the number of patients identified for this treatment across all regions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Tzield</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (delayed onset of type 1 diabetes) reached &#8364;29 million (+38.1% CER) with sales benefiting from ongoing investment in education and progress in screening. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Qfitlia</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (hemophilia A and B) received marketing authorization in the United States on March 28, 2025, with sales in the first half of 2025 amounting to &#8364;1 million.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="id9942a0f074746338589b52710a46d16"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> generated net sales of &#8364;7,312 million in the first half of 2025, up 19.1% on a reported basis and 20.7% at constant exchange rates. Global sales were driven by increased use in all approved indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis and chronic spontaneous urticaria, plus emerging use in COPD and bullous pemphigoid. In the United States, sales of Dupixent reached &#8364;5,283 million in the first half of 2025, driven by volume across all established and newly approved indications. In Europe, the product&#8217;s net sales for the first half of 2025 totaled &#8364;944 million, up 22.3% CER, reflecting strong momentum in all approved indications. In the Rest of the World region, Dupixent posted net sales of &#8364;1,085 million (+19.2% CER).</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="if01b2ff78c2c4dfda94c411d142bd28d"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other main medicines</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lantus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;876 million (+17.7% CER) in the first half of 2025. In the United States, sales were up 47.8% CER, benefiting from windfall sales due to the unavailability of competing medicines. In the Rest of the World region, sales were up 9.9% CER&#59; conversely, sales in Europe decreased by 14.9% CER.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Toujeo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales rose by 10.3% CER to &#8364;692 million, driven by the Rest of the World region (+17.4% CER), where the product continued to increase its share of the buoyant basal insulin market.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of the Fabry disease treatment </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fabrazyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;525 million in the first half of 2025 (+1.0% CER), reflecting slight growth in the number of patients.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Plavix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were up 1.9% CER at &#8364;473 million, reflecting volume growth in the Rest of the World region offset by volume-based procurement in China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lovenox</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales decreased by 11.0% CER to &#8364;447 million, mainly as a result of the impact from biosimilar competition in Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cerezyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales decreased by 8.6% CER to &#8364;363 million, due to the absence of inflationary pressure in 2025 and the cessation of treatment by some patients. Sales for the Gaucher disease franchise (Cerezyme and Cerdelga) were &#8364;539 million, down 5.8% CER.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Alprolix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;305 million, up 13.7% CER, driven by the Rest of the Word region and the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> decreased by 24.8% CER in the first half of 2025 to &#8364;275 million, due to the ongoing shift to Nexviazyme&#47;Nexviadyme as mentioned above.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">First-half net sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Praluent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;267 million, an increase of 8.5% CER driven by higher sales in Europe, partly offset by lower sales in the Rest of the World region.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Thymoglobulin</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales rose by 2.4% CER in the first half of 2025 to &#8364;248 million, driven by the Rest of the World region.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cerdelga</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;166 million, up 1.2% CER, reflecting continued growth in Europe but a decline in sales in the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Eloctate</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> posted sales of &#8364;135 million in the first half of 2025, down 28.8% CER, reflecting switches to ALTUVIIIO.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Aubagio</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were down 33.0% CER at &#8364;138 million, in line with the loss of exclusivity in the United States and Europe in 2023. Aubagio sales are expected to continue to decline.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i5499b8f612424fa7aa6771a4c950164b"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaccines</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, Vaccines sales were up 9.5% on a reported basis and 10.9% CER at &#8364;2,540 million, driven by expansion of Beyfortus into new markets.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Polio&#47;Pertussis&#47;Hib (PPH) Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, including Boosters, rose by 2.4% CER to &#8364;1,361 million, primarily driven by demand for boosters to re-vaccinate adolescents and adults and by pediatric combos in the United States and international markets.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Meningitis, Travel and Endemics Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales increased by 5.5% CER to &#8364;609 million, reflecting a favorable ordering pattern in meningitis in the United States and the Rest of the World region, partly offset by phasing of travel and endemics vaccines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales reached &#8364;356 million, driven by additional sales in the Northern Hemisphere, in particular Germany. In the Rest of the World region, sales were driven by the roll-out in Japan and Brazil, and by expansion in Australia. Beyfortus is routinely protecting babies in more than 25 countries.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Influenza</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;214 million, up 15.4% CER, due to one-offs from late-season immunizations in the US and Europe, while sales in the Rest of the World region decreased by 21.8% CER due to increased competition.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i2b9002fe910c4b238f19c382f7b05ae1"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.4. Net sales by geographical region</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:41.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on a reported basis</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at constant exchange rates </font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,535&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,292&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.0&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+16.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,072&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,210&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,996&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,388&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.9</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation, forming the basis for the percentage change data calculated in the above table.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, net sales in the </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">United States</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;9,535 million, up 15.0% on a reported basis and 16.4% at constant exchange rates, driven strong growth for Dupixent, pharma launches and a temporary increase in demand for Lantus, although sales of some legacy medicines were lower. Vaccines sales were broadly stable, though Beyfortus sales decreased.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Europe</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 2025 first-half net sales rose by 1.8% both on a reported basis and at constant exchange rates, to &#8364;4,144&#160;million. Growth was driven by Dupixent and launches, partially offset by lower sales of other main medicines and vaccines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World region</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, first-half net sales were up 3.6% on a reported basis and 6.4% at constant exchange rates at &#8364;6,210 million, driven mainly by Dupixent, Beyfortus, pharma launches, insulins, and PPH and booster vaccines, while other medicines and flu vaccines declined. Sales in China were down 1.3% on a reported basis but up 0.1% CER at &#8364;1,388 million, and were generally impacted by the declining market and by lower prices as a result of the renewed national reimbursement drug list and volume-based procurement.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">50</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="iae32eecf75c3455e9af061795fb2a881"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.4. Other income statement items</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i13714b576296400eb639dc78f1c932bc"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.1. Other revenues</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> decreased by 5.0% to &#8364;1,452&#160;million in the first half of 2025 (versus &#8364;1,529&#160;million in the first half of 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> line item includes VaxServe sales of non-Sanofi products, amounting to &#8364;842 million (versus &#8364;854&#160;million in 2024). In addition, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes sales of Opella products in markets retained by Sanofi (&#8364;206 million)&#59; sales to Opella (&#8364;61 million)&#59; royalties (&#8364;68 million)&#59; and sales of other services&#47;manufacturing services (&#8364;275 million).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i145b0426c4fc45a2971f1d12201925df"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.2. Gross profit</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Gross profit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 was &#8364;15,460 million, versus &#8364;13,923 million for the first half of 2024, a rise of 11.0%, driven by a portfolio shift towards specialty care and an enhanced product mix. Gross margin (the ratio of gross profit to net sales) also increased, reaching 77.7% in the first half of 2025 (versus 75.9% in the first half of 2024).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i20e9975cc07441dfb6021910915164fd"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.3. Research and development expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (R&#38;D expenses) in the first half of 2025 totaled &#8364;3,717&#160;million (versus &#8364;3,335&#160;million in the first half of 2024). The increase is explained mainly by (i) a one-time reimbursement in the first half of 2024 (the comparative period) for past ALTUVIIIO development, and (ii) wind-down costs for the discontinued E. coli sepsis vaccine candidate.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">R&#38;D expenses represent 18.7% of net sales, compared with 18.2% in the first half of 2024, and a year-on-year increase of 11.5%.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="if2f296b27e31425ca6f40556378ab931"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.4. Selling and general expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;4,506 million in the first half of 2025 (22.7%&#160;of net sales), versus &#8364;4,303&#160;million in the first half of 2024 (23.4% of net sales). The overall increase of 4.7% reflects continued support for launches and newer medicines in specialty care and vaccines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ratio of selling and general expenses to net sales was 0.8 of a percentage point lower than in the first half of 2024.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib4ec515f901949e1959647b0ec210b0e"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.5. Other operating income and expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;533 million, slightly lower than in the first half of 2024, and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> increased to &#8364;2,476 million (versus &#8364;1,977&#160;million in the first half of 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">other operating income and expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net expense of &#8364;1,943 million in the first half of 2025, compared with a net expense of &#8364;1,414 million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:60.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,476)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,977)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(499)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income&#47;(expenses), net</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,943)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,414)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(529)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2025, this item included &#8364;2,261 million of net expenses related to Regeneron (versus &#8364;1,745 million in the first half of 2024), as shown in the table below.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &#38; expense related to (profit)&#47;loss sharing under the Monoclonal Antibody&#160;Alliance</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#58; Monoclonal Antibody Alliance</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,327)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,837)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly Zaltrap and Libtayo)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income&#47;(expenses), net related to Regeneron Alliance</font></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,261)</font></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,745)</font></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which amount presented in &#8220;Other operating income&#8221;</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">96</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income and expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net) also includes gains on divestments of assets and operations totalling &#8364;344&#160;million, mainly related to portfolio rationalization (versus &#8364;319 million for the first half of 2024).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="id83055170a9b427e9489c9ecff5a0a29"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.6. Amortization of intangible assets</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization charged against intangible assets in the first half of 2025 amounted to &#8364;777 million, versus &#8364;898 million in the first half of 2024. This decrease was mainly driven by intangible assets reaching the end of their amortization periods.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">51</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i105c47e6461247489578c94ee465e96c"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.7. Impairment of intangible assets</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;210&#160;million in the first half of 2025 linked to research and development projects. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, the results of impairment tests on other intangible assets led to a net reversal of impairment losses amounting to &#8364;371 million recognized in connection with the divestments of the ProXTen technology platform and of the marketed product Enjaymo, for which some related assets had been subject to impairment losses in previous years.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="id01ffc462d8b403abe4c3f573971def0"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.8. Fair value remeasurement of contingent consideration</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fair value remeasurements of contingent consideration assets and liabilities relating to business combinations (recognized in accordance with IFRS 3) represented a net expense of &#8364;61 million in the first half of 2025, versus a net expense of &#8364;66 million in the first half of 2024. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i8b5320b2f6d54af8b884f24f4b94d9ed"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.9. Restructuring costs and similar items</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to a charge of &#8364;430&#160;million in the first half of 2025, compared with a charge of &#8364;1,060&#160;million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring and similar costs decreased by &#8364;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&#38;D operations to make Sanofi a leader in immunology.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i02ac74b26ccd44d0bf2337a40d556fda"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.10. Other gains and losses, and litigation</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2025, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;57 million, mainly related to major litigation. That compares with a charge of &#8364;450 m</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i6b9b52b2af33401d8c4e26ad50c55bd0"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.11. Operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;3,759 million in the first half of 2025, versus &#8364;2,768 million in the first half of 2024. The year-on-year change was mainly due to the increase in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Gross profit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i5654eb4c46de432cb07f72d571bea036"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.12. Financial income and expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net financial expenses were &#8364;177 million in the first half of 2025, &#8364;129 million lower than the 2024 first-half figure of &#8364;306 million. The 2025 first-half figure includes a financial expense of &#8364;50 million (&#8364;176 million for the first half of 2024) in respect of the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our cost of net debt (see&#160;the definition in Section D.7., &#8220;Consolidated balance sheet&#8221; below) was &#8364;57 million in the first half of 2025, compared with &#8364;67 million in the first half of 2024.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i97f9d3c4f72d4de3835623c0e8d96bfb"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.13. Income before tax and investments accounted for using the equity method</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 was &#8364;3,582&#160;million, versus &#8364;2,462&#160;million for the first half of 2024. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i5d353c46cdf64507a1b7c31a6fbb3bf9"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.14. Income tax expense</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled &#8364;711 million in the first half of 2025, versus &#8364;379 million in the first half of 2024, giving an effective tax rate (based on consolidated net income) of 19.8%, versus 15.4% in the first half of 2024. The increase in income tax expense was mainly due to a year-on-year decrease in restructuring costs relating to severance plans announced in the first half of 2025 and to Sanofi&#8217;s ongoing transformation projects (&#8364;113 million in the first half of 2025, versus &#8364;343 million in the first half of 2024). This was partly offset by a rise in the tax effects of amortization and impairment of intangible assets (&#8364;173 million in the first half of 2025, versus &#8364;48 million in the first half of 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effective tax rate on our &#8220;Business net income&#8221;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a non-IFRS financial measure. It is calculated on the basis of business operating income, minus net financial expenses and before (i) the share of profit&#47;loss from investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. We believe the presentation of this measure, used by our management, is also useful for investors as it provides a mean of analyzing the effective tax cost of our current business activities. It should not be seen as a substitute for the effective tax rate based on consolidated net income. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When calculated on business net income, our effective tax rate was 21.0% in the first half of 2025, compared with 20.0% in the first half of 2024 and 19.8% for 2024 as a whole. The main factors in this year-on-year change were (i) the impact of the OECD Pillar Two model rules, which aim to ensure that large multinationals pay a minimum level of tax on the income arising in each jurisdiction where they operate&#59; and (ii) the full effect of the 2024 portion of the temporary exceptional corporate income tax </font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> See definition in section D.2., &#8220;Business net income&#8221;.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">contribution introduced under the 2025 French Finance Bill. This latter item is excluded from the annual average effective tax rate calculation in accordance with IAS 34.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i7a4d644a40ee421488c2c48b94486910"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.15. Share of profit&#47;(loss) from investments accounted for using the equity method</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit&#47;(loss) from investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed net income of &#8364;85&#160;million for the first half of 2025 (versus a net loss of &#8364;22 million for the first half of 2024), including &#8364;11 million for Sanofi&#8217;s share of profits from OPAL JV Co for the period starting May 1st, 2025 until June 30, 2025. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i9b0fecb245904315b360ddc70fd4e0a7"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.16. Net income from continuing operations</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from continuing operations </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;2,956&#160;million in the first half of 2025, compared with &#8364;2,061&#160;million in the first half of 2024.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i98af03a99aba49738ee723e018ecbbad"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.17. Net income from discontinued operations</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to (i) the classification of Opella's assets and liabilities as held for sale since the announcement on October 21, 2024 of the opening of exclusive negotiations with CD&#38;R for the transfer of those assets and liabilities and (ii) the assessment that Opella qualifies as a principal line of business within the meaning of IFRS 5, the net income or loss of Opella is presented in a separate line item, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Notes B.1. and B.22. to our condensed half-year consolidated financial statements). </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;2,881 million, reflecting the net income of Opella until the date of loss of control and also including a net gain of &#8364;2,693&#160;million resulting from the divestment of Opella as of the date of loss of control.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364; 202 million.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ia10c0278c821448584aef4858ddcdda3"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.18. Net income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;5,837&#160;million in the first half of 2025, including a gain of &#8364;2,693&#160;million on the divestment of Opella, versus &#8364;2,263&#160;million in the first half of 2024.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib0315b056e274f53aaf5c07f3f7c4da1"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.19. Net income attributable to non-controlling interests</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 was &#8364;25&#160;million, against &#8364;17 million for the first half of 2024. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib1e24cc566b04295a3fc3cc7cbfc20eb"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.20. Net income attributable to equity holders of Sanofi</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;5,812&#160;million in the first half of 2025, versus &#8364;2,246&#160;million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) was &#8364;4.74, compared with &#8364;1.80 for the first half of 2024, based on an average number of shares outstanding of 1,225.5&#160;million for the first half of 2025 and 1,249.4&#160;million for the first half of 2024. Diluted earnings per share was &#8364;4.72, versus &#8364;1.79 for the first half of 2024, based on an average number of shares after dilution of 1,230.7&#160;million for the first half of 2025 and 1,253.8&#160;million for the first half of 2024.</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_40"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i33134d4a56244663a70ce64170c0afff"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.5. Segment results</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2025, our &#8220;Business operating income&#8221; (see Note B.21.1. to our condensed half-year consolidated financial statements for a definition and further details) was &#8364;5,363 million, versus &#8364;4,938 million for the first half of 2024, an increase of 8.6%. Our &#8220;Business operating income margin&#8221; was 27.0% (versus 26.9% for the first half of 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business operating income (non-IFRS) is reconciled with our operating income (IFRS) in Note &#34;B.21. Segment information &#8212; B.21.1. Segment results&#8221; to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth our business operating income &#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:58.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma segment operating income (IFRS)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,347&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,916&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+8.8</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As percentage of sales</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.9&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.8</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-27.3</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income (non-IFRS)</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,938</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.6</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As percentage of sales</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">27.0</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.9</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">53</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_43"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="idcae9e79a7d94f1c8f1e57321932c2fb"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.6. Consolidated statements of cash flows</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Summarized consolidated statements of cash flows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing operating activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,367&#160;</font></td><td style="background-color:#e7e7e8;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238&#160;</font></td><td style="border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,555</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,422</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing investing activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,979)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,355)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) investing activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash inflow from the Opella transaction </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,742&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) investing activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,727</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,413)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing financing activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,441)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) financing activities of the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) financing activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,489)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%">Cash and cash equivalents reported as held for sale as of December 31, 2024</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,918</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,915)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,441</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,710</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,359</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,795</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this amount includes &#8364;(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash inflow of &#8364;3,367&#160;million in the first half of 2025, against &#8364;1,238&#160;million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating cash flow before changes in working capital for the first half of 2025 was &#8364;3,980&#160;million, versus &#8364;3,608&#160;million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Working capital requirements decreased by &#8364;613&#160;million in the first half of 2025, versus a decrease of &#8364;2,370&#160;million in the first half of 2024&#59; the year-on-year change mainly reflects a reduction in provisions for rebates in the United States as a consequence of the reduction in the list price of Lantus from January 1, 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing investing activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">represented a net cash outflow of &#8364;1,979&#160;million in the first half of 2025, including the impact of the acquisition of Dren-0201, Inc. for $602&#160;million (see Note B.1.2. to our condensed half-year consolidated financial statements). That compares with a net cash outflow of &#8364;3,355&#160;million in the first half of 2024, resulting mainly from the acquisition of Inhibrx, Inc. for $2,035 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment and intangible assets totaled &#8364;1,420 million, versus &#8364;1,804 million in the first half of 2024. There were &#8364;845 million of acquisitions of property, plant and equipment (versus &#8364;882&#160;million in the first half of 2024), corresponding primarily to investments in industrial facilities. Acquisitions of intangible assets (&#8364;575&#160;million, versus &#8364;922&#160;million in the first half of 2024) mainly comprised contractual payments for intangible rights, primarily under license and collaboration agreements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After-tax proceeds from disposals (excluding disposals of consolidated entities and investments in joint ventures and associates) amounted to &#8364;434&#160;million in the first half of 2025, compared with &#8364;516 million for the first half of 2024, and related mainly to divestments of assets and operations relating to portfolio streamlining and to disposals of equity and debt instruments.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing financing activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash outflow of &#8364;4,441 million in the first half of 2025, compared with a net inflow of &#8364;92&#160;million in the first half of 2024. The 2025 first-half figure includes (i) the dividend payout to our shareholders of &#8364;4,772&#160;million (versus &#8364;4,704&#160;million in the first half of&#160;2024)&#59; (ii) &#8364;4,332 million of net external debt contracted (versus net external debt contracted of &#8364;5,102 million in the first half of&#160;2024)&#59; (iii) movements in Sanofi&#8217;s share capital, including purchases of treasury shares and the related tax effects (&#8364;4,003 million, versus &#8364;302 million in the first half of 2024)&#59; and (iv) share capital increases of &#8364;29 million (compared with &#8364;21 million in the first half of 2024).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> net change in cash and cash equivalents</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the first half of 2025 was an increase of &#8364;7,918&#160;million, compared with a decrease of &#8364;1,915&#160;million in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Free cash flow&#8221; is a non-IFRS financial measure which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), for debt repayment, and for payments to shareholders. &#8220;Free cash flow&#8221; is determined from business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> after adding back (in the case of expenses and losses) or deducting (in the case of income and gains) the following </font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Above a cap of &#8364;500 million per transaction.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure, as defined in &#8220;Business net income&#8221; above.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">54</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">items&#58; depreciation, amortization and impairment, share of undistributed earnings from investments accounted for using the equity method, gains &#38; losses on disposals of non-current assets, net change in provisions (including pensions and other post-employment benefits), deferred taxes, share-based payment expense and other non-cash items. It also includes net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and payments related to restructuring and similar items. &#8220;Free cash flow&#8221; is not defined by IFRS, and is not a substitute for Net cash provided by&#47;(used in) operating activities as reported under IFRS. Management recognizes that the term &#8220;Free cash flow&#8221; may be interpreted differently by other companies and under different circumstances. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth a reconciliation between</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash provided by&#47;(used in) operating activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and &#8220;Free cash flow&#8221;&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"><tr><td style="width:1.0%"></td><td style="width:69.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6&#160;months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6&#160;months)</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,555</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,422</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(188)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(184)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(911)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of intangible assets, equity interests and other non-current financial assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(986)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(506)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(124)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">640&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Free cash flow</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,458</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Most directly comparable IFRS measure to free cash flow.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Non-IFRS financial measure (see&#160;definition in section D.2. above).</font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_46"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="icb77f9f7cdad4af6bedea35567fd5987"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.7. Consolidated balance sheet</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets were &#8364;124,959&#160;million as of June&#160;30, 2025, versus &#8364;132,798 million as of December 31, 2024, representing a decrease of &#8364;7,839 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net debt</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;5,102 million as of June&#160;30, 2025, versus &#8364;8,772 million as of December&#160;31, 2024. We believe the presentation of this non-IFRS financial measure, which is reviewed by our management, provides useful information to measure our overall liquidity and capital resources. We define &#8220;net debt&#8221; as (i) the sum total of short-term debt, long-term debt, and interest rate derivatives and currency derivatives used to manage debt, minus (ii) the sum total of cash and cash equivalents and interest rate derivatives and currency derivatives used to manage cash and cash equivalents.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024 </font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,200&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,791&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,309&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,209&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt (IFRS)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,519</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,137</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</font></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)  </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(non-IFRS)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,102</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,772</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70,279&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77,857&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gearing ratio (non-IFRS)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024.</font></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To assess our financing risk, we use the &#8220;gearing ratio&#8221;, another non-IFRS financial measure. This ratio (which we define as the ratio of net debt to total equity) rose from 11.3% as of December&#160;31, 2024 to 7.3% as of June 30, 2025. Analyses of our debt as of June&#160;30, 2025 and December&#160;31,&#160;2024 are provided in Note B.9. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;net debt&#8221; and &#8220;gearing ratio&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-IFRS measures by management in setting goals and measuring performance, these measures have no standardized meaning prescribed by IFRS.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that the future cash flows generated by our operating activities will be sufficient to repay our debt. The financing arrangements in place as of June&#160;30, 2025 at the Sanofi parent company level are not subject to covenants regarding financial ratios and do not contain any clauses linking credit spreads or fees to Sanofi&#8217;s credit rating.</font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other key movements in the balance sheet are described below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity was &#8364;70,279&#160;million as of June&#160;30, 2025, versus &#8364;77,857 million as of December&#160;31,&#160;2024. The net change reflects the following principal factors&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an increase representing our net income for the first half of 2025 (&#8364;5,837 million)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an decrease of &#8364;5,203 million due to currency translation differences arising on the financial statements of foreign subsidiaries, mainly due to movements in the US dollar&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a decrease representing the dividend payout to our shareholders of &#8364;4,772 million&#59; and</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the repurchase by Sanofi of 39,344,633 of its own shares during the first half of 2025 for a total amount of &#8364;3,988&#160;million, plus &#8364;15 million of related tax payments.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025 we held 10.66&#160;million of our own shares, recorded as a deduction from equity and representing 0.868% of our share&#160;capital.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other intangible assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;60,714&#160;million in total) decreased by &#8364;5,299 million, due mainly to the impact of exchange rates and particularly to the fluctuation in the US dollar.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;3,563 million) increased by &#8364;3,247 million. This increase primarily results from Sanofi retaining a 48.2% equity interest in OPAL JV Co following the loss of control of Opella, with CD&#38;R holding 50% and Bpifrance holding 1.8%. For further details, please refer to Note B.1. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;4,109&#160;million) increased by &#8364;356&#160;million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net deferred tax assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were &#8364;6,293 million as of June 30, 2025, compared with &#8364;6,166 million as of December 31, 2024, an increase of &#8364;127 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;7,116&#160;million) fell by &#8364;980&#160;million relative to December&#160;31,&#160;2024. This reduction is mainly due to foreign exchange impacts (&#8364;522 million), and to the settlement reached on the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see Note B.14. to our condensed half-year consolidated financial statements). </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;564&#160;million) decreased by &#8364;77 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_49"></div><div style="margin-bottom:12pt;margin-top:9pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i8d9aa26ca019415ba2bce351212c354a"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">E&#47; Risk factors and related party transactions</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="id1574fefc7f84bc59aff538f06cd44e5"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.1. Risk factors</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main risk factors to which Sanofi is exposed are described in the 2024 Form 20-F for the year ended December&#160;31, 2024, filed with the US Securities and Exchange Commission on February 13, 2025</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The risk &#8220;Completion of the separation of Opella is subject to conditions that may not be satisfied and we may fail to realize any or all of the anticipated benefits of the separation and&#47;or face unintended adverse impacts on our business&#8221; is replaced by the risk &#8220;We </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">may fail to realize any or all of the anticipated benefits of the separation of Opella and&#47;or face unintended adverse impacts on our business&#8221;, and should be read as follows&#58;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;On April 30, 2025, we announced that the Opella transaction had been completed. Completion of the separation, for which we have incurred and are expected to incur significant costs, may not achieve the expected benefits in full or in part and there is no guarantee as to the timing of when or if any such benefits may be realized. The success of the transaction and its expected benefits will depend on several factors, including many factors outside of our control, and a number of assumptions that may prove incorrect.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Further to the separation, we may face a number of challenges relating to the implementation of the separation and to operating without the Opella business. There may be adverse financial, operational, regulatory, consumer, patient and reputational implications if we fail (either wholly or in part) to meet such challenges. Such adverse implications could impact our financial condition, results of operations and&#47;or prospects. For example, since the separation our business is smaller and less diversified than previously, and is more susceptible to adverse developments in the remaining business and markets in which we operate. Accordingly, should any part of our remaining business underperform, this could have a greater adverse impact on our results or financial condition following separation than would have been the case prior to the separation. In addition, post-separation we have greater relative exposure to the global pharmaceuticals and vaccines markets and the associated risks and will no longer benefit from exposure to the Consumer Healthcare market we had prior to separation from the Opella business&#59; this change makes us more reliant on R&#38;D processes (see &#34;&#8212;Several factors may hinder or delay Sanofi's research and development efforts to renew Sanofi's portfolio of medicines and vaccines&#34; in Item 3.D. of the 2024 Form 20-F). There is a risk that the anticipated benefits of the separation may not be realized as expected.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The process of separating Opella from our remaining operations may be complex, time-consuming, and resource-intensive, and will require the separation of previously shared systems, processes, and infrastructure, which could result in unanticipated costs, delays, or ongoing operational inefficiencies. In connection with the divestiture, we are required to provide transitional services to Opella, which will require further resources and could expose us to additional liabilities.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, as we retain a holding in Opella of 48.2% with veto rights only on certain matters, we will not control operational decisions and Opella's success will depend on its ability to retain talent and skilled professionals and take advantage of the opportunities that lie ahead in its segment. Therefore, our remaining holding in Opella may fall in value if Opella's strategy does not deliver the expected benefits.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The risk &#8220;Our largest shareholder owns a significant percentage of the share capital and voting rights of Sanofi&#8221; is modified and should now be read as follows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Following the buy-back we made of a block of shares from L'Or&#233;al in February 2025, and after cancellation on March 13, 2025 of said shares, as of June 30, 2025 L&#8217;Or&#233;al held 7.23% of Sanofi's share capital and 13.12% of Sanofi's effective voting rights (excluding treasury shares). Individuals linked to L'Or&#233;al currently serve on Sanofi's Board of Directors. For as long as L'Or&#233;al retains its interest in our share capital and voting rights, it will remain in a position to exert influence in the appointment of directors and officers of Sanofi and in other corporate actions that require shareholder approval.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any of those risks, and others that we may not yet have identified, could materialize during the second half of 2025 or during subsequent periods, and could cause actual results to differ materially from those described elsewhere in this report.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i2cc30fd1ddc24911be02409728d6fa67"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.2. Related party transactions</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our principal related parties are defined in Note D.33. to our consolidated financial statements included in the 2024 Form 20-F (page F-92)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.5. to our condensed half-year consolidated financial statements provides a description of the main transactions and balances for the six months ended June 30, 2025 with equity-accounted entities that qualify as related parties. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not enter into any transactions with key management personnel during the first half of 2025. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial relations with the Group&#8217;s principal shareholders fall within the ordinary course of business and were immaterial in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Available on our corporate website&#58; www.sanofi.com.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">57</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_52"></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i614aaf8b759a4182af7e9c5e8920184a"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">F&#47; Outlook</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2025, net sales are anticipated to grow by a high single-digit percentage at CER</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business earnings per share</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (business EPS) rebound with growth at a low double-digit percentage at CER (before share buybacks), and now including all expenses from newly acquired businesses. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi intends to complete its &#8364;5 billion share buyback program in 2025 of which 80.3% has been completed to date.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Applying average July 2025 exchange rates, the currency impact on 2025 business EPS is expected to be around -6%.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Full-year business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for 2024 was &#8364;8,912 million, resulting in business earnings per share of &#8364;7.12.</font></div><div style="margin-bottom:2pt;text-align:justify;text-indent:6.66pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This guidance was prepared on a basis comparable with that used to prepare our historical financial information, and in accordance with Sanofi accounting policies. It was also prepared on the basis of assumptions established by Sanofi and its subsidiaries, including but not limited to&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in the competitive environment, in terms of innovative products and launches of generics&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">respect for our intellectual property rights&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">progress on our research and development programs&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the impact of, and progress on, our operating cost containment policy&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in exchange rates and interest rates&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">integration of the contribution from acquisitions&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average number of shares outstanding.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some of the above information, estimates and assumptions are derived from or rely on, in full or in part, judgments and decisions made by Sanofi management which may change or be amended in future.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, see Section D.3., &#8220;Net Sales&#8221; above.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, see Section D.2., &#8220;Business net income&#8221; above.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">58</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_55"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ifbabe9fc3d2a497dbee531791f138717"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-looking statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This document contains forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;can&#8221;, &#8220;contemplate&#8221;, &#8220;could&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;is designed to&#8221;, &#8220;may&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221; &#8220;target&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;predict&#8221;, &#8220;forecast&#8221;, &#8220;ambition&#8221;, &#8220;guideline&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; or the negative of these and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;may&#8221;, &#8220;is considering&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;envisages&#8221;, &#8220;aims&#8221;, &#8220;plans&#8221;, &#8220;is designed to&#8221;, &#8220;could&#8221;, &#8220;forecasts&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;is programming&#8221;, &#8220;is likely to&#8221; and &#8220;wants&#8221; or the negative thereof, and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and&#47;or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crisis may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the U.S. Securities and Exchange Commission (SEC) and the French Autorit&#233; des march&#233;s financiers (AMF) made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024. For an update on litigation, refer to Note B.14. &#8220;Legal and arbitration proceedings&#8221; to our condensed half-year consolidated financial statements for the six months ended June 30, 2025, and to section &#8220;A.3.2. Legal and arbitration proceedings&#8221;, and section &#8220;E&#47; Risk factors and related party transactions&#8221;, of this half-year management report. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With respect to any sustainability or environmental, social and governance (ESG)-related information contained herein, in light of the significant uncertainties inherent in such statements and other related information contained herein, investors should not regard these statements as a representation or warranty by Sanofi or any other person that Sanofi will achieve its goals, objectives, aspirations, metrics, plans or targets in any specified time frame or at all, including with respect to ESG and sustainability matters, and such statements and other information are dependent on future market factors, such as customer demand, continued technological progress, policy support and timely rule-making or continuation of government incentives and funding, and are forward-looking statements. Sanofi&#8217;s ability to achieve goals, objectives, aspirations, metrics, plans or targets in any specified time frame or at all, including with respect to ESG and sustainability matters, is subject to other conditions and considerations, both within and outside Sanofi&#8217;s control, that may affect its ability to meet such goals, objectives, aspirations, metrics, plans or targets, and&#47;or put in place the initiatives required to meet them. Such conditions and considerations include but are not limited to the risk factors described above. In addition, historical, current, and forward-looking environmental and other ESG or sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future, including future laws and rulemaking. Sanofi plans to continue to evaluate its goals, objectives, aspirations, metrics, plans and targets and its approach to them and may make adjustments as it deems necessary in light of such considerations.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All trademarks mentioned in this document are protected and are either trademarks owned by Sanofi and&#47;or its subsidiaries, or trademarks licensed to Sanofi and&#47;or its subsidiaries, or trademarks owned by third parties (including Regeneron and Sobi).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">59</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_61"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.431%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="ifb57349444f24112a34d8c3272a137f0"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">G&#47; Appendix - research and development pipeline</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i486b48aa52c245cea135fda4c66a8f00"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">R&#38;D Pipeline</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Registration</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL4xIL13 mAb</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bullous pemphigoid (EU, JP, CN)</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chronic spontaneous urticaria (EU)</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Qfitlia </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RNAi targeting anti-thrombin</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hemophilia A and B (CN)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">rilzabrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BTK inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immune thrombocytopenia (US, EU, CN)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enzyme replacement therapy</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gaucher disease type 3 (US)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">tolebrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BTK inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-relapsing secondary progressive MS (US, EU)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD38 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NDMM, TE (HD7) (EU)</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 3</font></td><td colspan="3" rowspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="background-color:#7802e6;color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></div></td><td colspan="9" style="background-color:#0f7f40;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="background-color:#0f7f40;color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL4xIL13 mAb</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic pruritus of unknown origin</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Lichen simplex chronicus</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">tolebrutinib</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BTK inhibitor</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Primary progressive MS</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">itepekimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a) (2)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL33 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic obstructive pulmonary disease</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic rhinosinusitis with nasal polyps</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">frexalimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Relapsing MS</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Non-relapsing secondary progressive MS</font></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">amlitelimab</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OX40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atopic dermatitis</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">riliprubart</font></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C1s inhibitor</font></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">SOC-refractory CIDP</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">IVIg-treated CIDP</font></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ROCK2 inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chronic lung allograft dysfunction</font></div></td><td colspan="9" style="background-color:#200f45;border-top:0.5pt solid #200f45;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD3 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type 1 diabetes</font></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD38 mAb</font></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NDMM, TE (HD7) (US)<br>NDMM, TE (IsKia)<br>Smoldering MM (ITHACA)</font></td></tr><tr style="height:26pt"><td colspan="9" style="background-color:#929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD38 mAb subcutaneous</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Relapsed&#47;refractory MM (IRAKLIA)</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme</font></td><td colspan="3" style="border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enzyme replacement therapy</font></td><td colspan="3" style="border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infantile-onset Pompe disease</font></div></td><td colspan="9" style="background-color:#faac16;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></div></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">venglustat</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oral GCS inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Fabry disease</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Gaucher disease type 3</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fluzone HD</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multivalent inactivated vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu (50 years+)</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0087</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vero cell vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rabies</font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0125</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Live attenuated vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV (toddlers)</font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0202</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21-valent conjugate vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pneumococcal disease</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0218</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vero cell vaccine</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yellow fever</font></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1) Also known as fitusiran, currently in phase 3 in the EU</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(2) Subject to further analysis and regulatory discussions</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Collaborations (a) Regeneron - (b) ImmuNext - (c) SK bioscience</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Abbreviations</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">BTK&#58; Bruton&#8217;s tyrosine kinase - CD&#58; Cluster of differentiation - C1s&#58; Complement component 1s - CIDP&#58; Chronic inflammatory demyelinating polyneuropathy - CN&#58; China - EU&#58; Europe - GCS&#58; Glucosylceramide synthase - HD&#58; High dose - IL&#58; Interleukin - IVIg&#58; Intravenous immunoglobulin - JP&#58; Japan - mAb&#58; Monoclonal antibody - MM&#58; Multiple myeloma - MS&#58; Multiple sclerosis - NDMM&#58; Newly diagnosed multiple myeloma - RNAi&#58; RNA interference - ROCK2&#58; Rho Associated coiled-coil containing protein kinase 2 - RSV&#58; Respiratory syncytial virus - SOC&#58; Standard of care - TE&#58; Transplant eligible - US&#58; United States of America</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="height:39.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">60</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#929292;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL4xIL13 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ulcerative colitis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">rilzabrutinib</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">BTK inhibitor</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Warm autoimmune hemolytic anemia</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">itepekimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL33 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Bronchiectasis</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic rhinosinusitis without nasal polyps</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR447537</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">AAT fusion protein</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Alpha-1 antitrypsin deficiency</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">amlitelimab</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OX40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Alopecia areata</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Asthma</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Celiac disease</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Systemic sclerosis</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">frexalimab rilzabrutinib brivekimig</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD40L mAb </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">BTK inhibitor</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">TNFaxOX40L NANOBODY&#174; VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Focal segmental glomerulosclerosis&#47;</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">minimal change disease</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">rilzabrutinib</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BTK inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Asthma</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic spontaneous urticaria</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">IgG4-related disease</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#200f45;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td><td colspan="3" style="background-color:#200f45;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#200f45;border-top:0.25pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">frexalimab </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Systemic lupus erythematosus</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Type 1 diabetes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD38 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Relapsed&#47;refractory MM</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">balinatunfib</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oral TNFR1 signaling inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Rheumatoid arthritis</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Crohn&#8217;s disease</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Ulcerative colitis</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR447873</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSTR targeting alpha-emitter therapy</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gastroenteropancreatic neuroendocrine tumors</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">lunsekimig</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL13xTSLP NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Asthma</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">High-risk asthma</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Atopic dermatitis</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Chronic rhinosinusitis with nasal polyps</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR445877</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PD1xIL15 fusion protein</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solid tumors</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">eclitasertib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RIPK1 inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ulcerative colitis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">brivekimig</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TNFaxOX40L NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Hidradenitis suppurativa</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Type 1 diabetes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0230</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5-valent (ACWY+B) vaccine</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">duvakitug</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TL1A mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Crohn&#8217;s disease</font></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Ulcerative colitis</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0256 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV (older adults)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">riliprubart</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C1s inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antibody-mediated rejection</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0268</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acne</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0289</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu (H5 pandemic)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0335</font></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inactivated adjuvanted vaccine</font></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu (H5 pandemic)</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#200f45;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR444336</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-beta IL2 Synthorin</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">TM</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR445953 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CEACAM5-Topo1 ADC</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colorectal cancer</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR445399</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IL1R3 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446523</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">GPRC5D mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multiple myeloma</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR445514 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Trifunctional anti-BCMA NK cell engager</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;border-top:0.25pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446422</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD28xOX40 bispecific Ab</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #faac16;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0237</font></td><td colspan="3" style="border-top:0.5pt solid #faac16;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.5pt solid #faac16;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446959</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MMP13xADAMTS5xCAP NANOBODY</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Knee osteoarthritis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0287</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fluzone HD+Nuvaxovid</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu+COVID-19</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR448501</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD20 bispecific mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0287</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flublok+Nuvaxovid</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flu+COVID-19</font></td></tr><tr><td colspan="3" style="background-color:#0f7f40;border-top:0.5pt solid #0f7f40;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></div></td><td colspan="3" style="background-color:#0f7f40;border-top:0.5pt solid #0f7f40;padding:0 1pt"></td><td colspan="3" style="background-color:#0f7f40;border-top:0.5pt solid #0f7f40;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0256 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV+hMPV (older adults)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446159 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SynucleinxIGF1R mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Parkinson&#8217;s disease</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0291</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV+hMPV+PIV3 (older adults)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR402663</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AAV2-sFLT01 gene therapy</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wet age-related macular degeneration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0269</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chlamydia</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1) Also known as MAB212, in-licensed from MAB Discovery</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Collaborations (a) Regeneron - (b) ImmuNext - (c) Denali - (d) Teva Pharmaceuticals - (e) RadioMedix and Orano Med - (f) Innate Pharma - (g) ABL Bio - (h) Pfizer</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Abbreviations</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">AAT&#58; Alpha-1 antitrypsin - AAV2&#58; Adeno-associated virus type 2 - Ab&#58; Antibody - ADAMTS5&#58; A Disintegrin And Metalloproteinase with Thrombospondin Motifs 5 - ADC&#58; Antibody-drug conjugate - BCMA&#58; B-Cell maturation antigen - BTK&#58; Bruton&#8217;s tyrosine kinase - C1s&#58; Complement component 1s - CAP&#58; Cartilage anchoring protein - CD&#58; Cluster of differentiation - CEACAM5&#58; Carcinoembryonic antigen cell adhesion molecule 5 - GPRC5D&#58; G-protein coupled receptor family C group 5 member D - H5&#58; hemagglutinin 5 - hMPV&#58; human Metapneumovirus - IGF1R&#58; Insulin-like growth factor 1 receptor - IgG4&#58; Immunoglobulin G4 - IL&#58; Interleukin - IL1R3&#58; Interleukin-1 receptor 3 - mAb&#58; Monoclonal antibody - MM&#58; Multiple myeloma - MMP13&#58; Matrix metallopeptidase 13 - mRNA&#58; messenger RNA - NK&#58; Natural killer - PD1&#58; Programmed death protein 1 &#8211; PIV3&#58; Parainfluenza virus type 3 - RIPK1&#58; Receptor-interacting serine&#47;threonine protein kinase 1 - RSV&#58; Respiratory syncytial virus - SSTR&#58; Somatostatin receptor - TL1A&#58; Tumor necrosis factor-like cytokine 1A - TNFa&#58; Tumor necrosis factor alpha - TNFR1&#58; Tumor necrosis factor receptor 1 - Topo1&#58; Topoisomerase - TSLP&#58; Thymic stromal lymphopoietin</font></div><div style="height:39.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">61</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_64"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="ie292f622033442c2969a1679079d01cf"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">3. Statutory auditors&#8217; review report on the half-yearly financial information</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Period from January 1 to June 30, 2025</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Shareholders,</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the assignment entrusted to us by your Annual General Meetings and in accordance with the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Code mon&#233;taire et financier</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we hereby report to you on&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the review of the accompanying (condensed) half-yearly consolidated financial statements of Sanofi, for the period from January 1, 2025 to June 30, 2025&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the verification of the information presented in the half-yearly management report.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i6a353155dc924bd58d2ce41656e56192"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;Conclusion on the financial statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conducted our review in accordance with professional standards applicable in France. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 &#8211; standard of the IFRSs as adopted by the European Union applicable to interim financial information.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ic22a04860b52409f89d29969949ed04d"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;Specific verification</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have also verified the information presented in the half-yearly management report on the condensed half-yearly consolidated financial statements subject to our review.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial statements.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neuilly-sur-Seine and Levallois-Perret, July 31 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The statutory auditors<br>French original signed by</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit </font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forvis Mazars SA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Anne-Claire Ferri&#233;                Am&#233;lie Graffan </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lo&#239;c Wallaert               Ariane Mignon</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This is a free translation into English of the statutory auditors&#8217; review report on the half-yearly financial information issued in French and is provided solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the Group&#8217;s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">62</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_67"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="ie70311e4382e43369c27dcdcf4689f56"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">4. Responsibility statement of the certifying officer&#58; half-year financial report</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;I hereby certify that, to the best of my knowledge, the condensed half-year consolidated financial statements have been prepared in accordance with the applicable accounting standards and give a true and fair view of the assets and liabilities, financial position and net income of the Company and the entities included in the scope of consolidation, and that the half-year management report starting on page <a href="#i0f074ff5ccee4c41adecb7b0b757aded_4" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none">36</a> provides an accurate overview of the significant events of the first six months of the financial year with their impact on the half-year consolidated financial statements, together with the major transactions with related parties and a description of the main risks and uncertainties for the remaining six months of the financial year.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paris, July 31, 2025</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63</font></div></td></tr></table></div></div></div><div id="i0f074ff5ccee4c41adecb7b0b757aded_70"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><img alt="a2025half-yearfinancialrep.jpg" src="a2025half-yearfinancialrep.jpg" style="height:1121px;margin-bottom:5pt;vertical-align:text-bottom;width:793px"></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sny-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sny="http://www.sanofi.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sanofi.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.sanofi.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedIncomeStatements" roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements">
        <link:definition>9952152 - Statement - Consolidated Income Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedIncomeStatements_1" roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1">
        <link:definition>9952152 - Statement - Consolidated Income Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952153 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome_1" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1">
        <link:definition>9952153 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquity" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquityParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Introduction" roleURI="http://www.sanofi.com/role/Introduction">
        <link:definition>9952158 - Disclosure - Introduction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies">
        <link:definition>9952159 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements">
        <link:definition>9952160 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipment">
        <link:definition>9952161 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>9952162 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofIntangibleAssets" roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssets">
        <link:definition>9952163 - Disclosure - Impairment of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethod" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod">
        <link:definition>9952164 - Disclosure - Investments Accounted for Using the Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssets" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssets">
        <link:definition>9952165 - Disclosure - Other Non-Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivable" roleURI="http://www.sanofi.com/role/AccountsReceivable">
        <link:definition>9952166 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquity" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquity">
        <link:definition>9952167 - Disclosure - Consolidated Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalents" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalents">
        <link:definition>9952168 - Disclosure - Debt, Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstruments">
        <link:definition>9952169 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests">
        <link:definition>9952170 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilities" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities">
        <link:definition>9952171 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffBalanceSheetCommitments" roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitments">
        <link:definition>9952172 - Disclosure - Off Balance Sheet Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandArbitrationProceedings" roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedings">
        <link:definition>9952173 - Disclosure - Litigation and Arbitration Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpenses" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses">
        <link:definition>9952174 - Disclosure - Other Operating Income And Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItems" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItems">
        <link:definition>9952175 - Disclosure - Restructuring Costs and Similar Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherGainsandLossesandLitigation" roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigation">
        <link:definition>9952176 - Disclosure - Other Gains and Losses, and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncome" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncome">
        <link:definition>9952177 - Disclosure - Financial Expenses and Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpense" roleURI="http://www.sanofi.com/role/IncomeTaxExpense">
        <link:definition>9952178 - Disclosure - Income Tax Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.sanofi.com/role/SegmentInformation">
        <link:definition>9952179 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsSubsequenttoJune302023" roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023">
        <link:definition>9952180 - Disclosure - Events Subsequent to June 30, 2023</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuefromcontractswithcustomers" roleURI="http://www.sanofi.com/role/Revenuefromcontractswithcustomers">
        <link:definition>9952181 - Disclosure - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Noncurrentassetheldforsaleanddiscontinuedoperations" roleURI="http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations">
        <link:definition>9952182 - Disclosure - Non-current asset held for sale and discontinued operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9955513 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>9955514 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodTables" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables">
        <link:definition>9955515 - Disclosure - Investments Accounted for Using the Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssetsTables" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsTables">
        <link:definition>9955516 - Disclosure - Other Non-Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableTables" roleURI="http://www.sanofi.com/role/AccountsReceivableTables">
        <link:definition>9955517 - Disclosure - Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquityTables" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables">
        <link:definition>9955518 - Disclosure - Consolidated Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsTables" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables">
        <link:definition>9955519 - Disclosure - Debt, Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>9955520 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables">
        <link:definition>9955521 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables">
        <link:definition>9955522 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesTables" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables">
        <link:definition>9955523 - Disclosure - Other Operating Income And Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsTables" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables">
        <link:definition>9955524 - Disclosure - Restructuring Costs and Similar Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeTables" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeTables">
        <link:definition>9955525 - Disclosure - Financial Expenses and Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseTables" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseTables">
        <link:definition>9955526 - Disclosure - Income Tax Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.sanofi.com/role/SegmentInformationTables">
        <link:definition>9955527 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromcontractswithcustomersTables" roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables">
        <link:definition>9955528 - Disclosure - Revenue from contracts with customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentassetheldforsaleanddiscontinuedoperationsTables" roleURI="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsTables">
        <link:definition>9955529 - Disclosure - Non-current asset held for sale and discontinued operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails">
        <link:definition>9955530 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails">
        <link:definition>9955531 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails">
        <link:definition>9955532 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails">
        <link:definition>9955533 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails">
        <link:definition>9955535 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails">
        <link:definition>9955536 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails">
        <link:definition>9955537 - Disclosure - Impairment of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails">
        <link:definition>9955538 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>9955539 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails">
        <link:definition>9955540 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails">
        <link:definition>9955541 - Disclosure - Other Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableSummaryofAccountsReceivableDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails">
        <link:definition>9955542 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - Accounts Receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails">
        <link:definition>9955544 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquityAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails">
        <link:definition>9955545 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails">
        <link:definition>9955546 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails">
        <link:definition>9955547 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails">
        <link:definition>9955548 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails">
        <link:definition>9955549 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails">
        <link:definition>9955550 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails">
        <link:definition>9955551 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails">
        <link:definition>9955552 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails">
        <link:definition>9955553 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails">
        <link:definition>9955554 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails">
        <link:definition>9955555 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails">
        <link:definition>9955556 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails">
        <link:definition>9955557 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails">
        <link:definition>9955558 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails">
        <link:definition>9955559 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails">
        <link:definition>9955560 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails">
        <link:definition>9955561 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails">
        <link:definition>9955562 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails">
        <link:definition>9955563 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails">
        <link:definition>9955564 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffBalanceSheetCommitmentsDetails" roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails">
        <link:definition>9955565 - Disclosure - Off Balance Sheet Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandArbitrationProceedingsDetails" roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails">
        <link:definition>9955566 - Disclosure - Litigation and Arbitration Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails">
        <link:definition>9955567 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails">
        <link:definition>9955568 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails">
        <link:definition>9955569 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails">
        <link:definition>9955570 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherGainsandLossesandLitigationDetails" roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails">
        <link:definition>9955571 - Disclosure - Other Gains and Losses, and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeDetails" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails">
        <link:definition>9955572 - Disclosure - Financial Expenses and Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeDetails_1" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1">
        <link:definition>9955572 - Disclosure - Financial Expenses and Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails">
        <link:definition>9955573 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails">
        <link:definition>9955574 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical">
        <link:definition>9955575 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9955576 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails">
        <link:definition>9955577 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentResultsDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails">
        <link:definition>9955578 - Disclosure - Segment Information - Schedule of Segment Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails">
        <link:definition>9955579 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails">
        <link:definition>9955580 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails">
        <link:definition>9955581 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationPrincipalCustomersandCreditRiskDetails" roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails">
        <link:definition>9955582 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsSubsequenttoJune302023Details" roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details">
        <link:definition>9955583 - Disclosure - Events Subsequent to June 30, 2023 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromcontractswithcustomersDetails" roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails">
        <link:definition>9955584 - Disclosure - Revenue from contracts with customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentassetheldforsaleanddiscontinuedoperationsDetails" roleURI="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails">
        <link:definition>9955585 - Disclosure - Non-current asset held for sale and discontinued operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="NonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentProvisionsAndOtherCurrentLiabilities" abstract="false" name="CurrentProvisionsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherGainsLossesAndLitigation" abstract="false" name="OtherGainsLossesAndLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="BasicEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="DilutedEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" abstract="false" name="GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeFromContinuedOperations" abstract="false" name="OtherComprehensiveIncomeFromContinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeFromDiscontinuedOperations" abstract="false" name="OtherComprehensiveIncomeFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" abstract="false" name="ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" abstract="false" name="ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" abstract="false" name="ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShareBasedPaymentPlansAbstract" abstract="true" name="ShareBasedPaymentPlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" abstract="false" name="IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EuroapiMember" abstract="true" name="EuroapiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" abstract="false" name="ExceptionalSupplementaryDividendPercentageOfShareCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_TaxesOnShareCancellations" abstract="false" name="TaxesOnShareCancellations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForLossesGainsOnTransferOfBusiness" abstract="false" name="AdjustmentsForLossesGainsOnTransferOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" abstract="false" name="AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" abstract="false" name="ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" abstract="false" name="NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetChangeInOtherNonCurrentAssets" abstract="false" name="NetChangeInOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashProvidedByusedInContinuingInvestingActivities" abstract="false" name="NetCashProvidedByusedInContinuingInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" abstract="false" name="NetCashProvidedByusedInDiscontinuingInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashInflowFromDiscontinuedOperations" abstract="false" name="NetCashInflowFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DividendsPaidAbstract" abstract="true" name="DividendsPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" abstract="false" name="CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" abstract="false" name="CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashAndCashEquivalentsDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommercialPaperProgramInUSAMember" abstract="true" name="CommercialPaperProgramInUSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaMember" abstract="true" name="OpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" abstract="false" name="DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GeneralInformationAboutFinancialStatementsAbstract" abstract="true" name="GeneralInformationAboutFinancialStatementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" abstract="false" name="DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfTradeReceivablesTextBlock" abstract="false" name="DisclosureOfTradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" abstract="false" name="DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OffBalanceSheetCommitmentsAbstract" abstract="true" name="OffBalanceSheetCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" abstract="true" name="OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" abstract="false" name="DisclosureOfLegalAndArbitralProceedingsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" abstract="false" name="DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringTextBlock" abstract="false" name="DisclosureOfRestructuringTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" abstract="false" name="DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" abstract="false" name="DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOtherRevenueTextBlock" abstract="false" name="DisclosureOfOtherRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" abstract="true" name="SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" abstract="false" name="SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" abstract="false" name="AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" abstract="false" name="DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" abstract="false" name="DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" abstract="false" name="DisclosureOfCurrentTradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" abstract="false" name="DisclosureOfOverdueReceivablesGrossValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" abstract="false" name="DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" abstract="false" name="DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" abstract="false" name="DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfChangesInFinancialPositionTableTextBlock" abstract="false" name="DisclosureOfChangesInFinancialPositionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" abstract="false" name="DisclosureOfMarketValueOfNetDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" abstract="false" name="DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" abstract="false" name="DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTableTextBlock" abstract="false" name="DisclosureOfNonCurrentProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" abstract="false" name="DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherOperatingExpensesTableTextBlock" abstract="false" name="OtherOperatingExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" abstract="false" name="DisclosureOfRestructuringCostsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" abstract="false" name="DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" abstract="false" name="DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" abstract="false" name="DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_TypesOfAgreementAxis" abstract="true" name="TypesOfAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_TypesOfAgreementDomain" abstract="true" name="TypesOfAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementWithGSKMember" abstract="true" name="CollaborationAgreementWithGSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" abstract="false" name="CumulativeConsumerPriceInflationRateOverTheLastThreeYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" abstract="false" name="GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ProventionBioIncMember" abstract="true" name="ProventionBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InhibrxIncMember" abstract="true" name="InhibrxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AssetsAcquisitionAxis" abstract="true" name="AssetsAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AssetsAcquisitionDomain" abstract="true" name="AssetsAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AssetsAcquisitionMember" abstract="true" name="AssetsAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_VigilNeuroscienceIncMember" abstract="true" name="VigilNeuroscienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_BlueprintMedicinesCorporationMember" abstract="true" name="BlueprintMedicinesCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OpellaBusinessMember" abstract="true" name="OpellaBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" abstract="false" name="InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePricePerShare" abstract="false" name="BusinessCombinationPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_FutureRoyaltiesReceivableValue" abstract="false" name="FutureRoyaltiesReceivableValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationNominalValue" abstract="false" name="BusinessCombinationNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsAcquisitionNominalValue" abstract="false" name="AssetsAcquisitionNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsAcquisitionPurchasePricePerShare" abstract="false" name="AssetsAcquisitionPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_FairValueOfInvestmentsInEquityInstruments" abstract="false" name="FairValueOfInvestmentsInEquityInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TransactionCost" abstract="false" name="TransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PotentialFuturePayments" abstract="false" name="PotentialFuturePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityInterestsOfAcquirerPerShare" abstract="false" name="EquityInterestsOfAcquirerPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_DeferredCashPayments" abstract="false" name="DeferredCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashTransferredPerShare" abstract="false" name="CashTransferredPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAgreementsTable" abstract="true" name="DisclosureOfPrincipalAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_PrincipalAlliancesAxis" abstract="true" name="PrincipalAlliancesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_PrincipalAlliancesDomain" abstract="true" name="PrincipalAlliancesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntibodiesCollaborationAgreementMember" abstract="true" name="AntibodiesCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SwedishOrphanBiovitrumABMember" abstract="true" name="SwedishOrphanBiovitrumABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MajorTerritoriesMember" abstract="true" name="MajorTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherTerritoriesMember" abstract="true" name="OtherTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherIntangibleAssetsExcludingSoftwareMember" abstract="true" name="OtherIntangibleAssetsExcludingSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MajorFinancialLiabilityMember" abstract="true" name="MajorFinancialLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAgreementsLineItems" abstract="true" name="DisclosureOfPrincipalAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CollaborationAgreementsUpfrontPayment" abstract="false" name="CollaborationAgreementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CollaborationAgreementsDevelopmentMilestonePayment" abstract="false" name="CollaborationAgreementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CollaborationAgreementsRegulatoryMilestonePayment" abstract="false" name="CollaborationAgreementsRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" abstract="false" name="CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageOfProfitsArisingFromCommercialOperations" abstract="false" name="PercentageOfProfitsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_PercentageOfNetSalesArisingFromCommercialOperations" abstract="false" name="PercentageOfNetSalesArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" abstract="false" name="PercentageOfDevelopmentCostsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ConsumerHealthcareSegmentMember" abstract="true" name="ConsumerHealthcareSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ManufacturingAndSupplyMember" abstract="true" name="ManufacturingAndSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfOperatingSegments" abstract="false" name="NumberOfOperatingSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_FirmOrdersOfPropertyPlantAndEquipment" abstract="false" name="FirmOrdersOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MarketedProductsMember" abstract="true" name="MarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TechnologicalPlatformsMember" abstract="true" name="TechnologicalPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_VaccinesCoExclusiveLicensingAgreementMember" abstract="true" name="VaccinesCoExclusiveLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_NovavaxMember" abstract="true" name="NovavaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AcquiredResearchAndDevelopmentMember" abstract="true" name="AcquiredResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProductsTrademarksAndOtherRightsMember" abstract="true" name="ProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AltuviiioMember" abstract="true" name="AltuviiioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AcquiredRDMember" abstract="true" name="AcquiredRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_MarketedProductsTrademarksAndOtherRightsMember" abstract="true" name="MarketedProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" abstract="false" name="ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" abstract="false" name="ImpairmentLossOnIntangibleAssetOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InfraservGmbhAndCoHochstKGMember" abstract="true" name="InfraservGmbhAndCoHochstKGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MSPVaccineCompanyMember" abstract="true" name="MSPVaccineCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MCMVaccineBVMember" abstract="true" name="MCMVaccineBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AssociatesAndJointVenturesMember" abstract="true" name="AssociatesAndJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockPrice" abstract="false" name="StockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_LoansToAssociates" abstract="false" name="LoansToAssociates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" abstract="false" name="RoyaltiesAndOtherIncomeRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherAssetsRelatedPartyTransactions" abstract="false" name="OtherAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SubordinateHybridBondRelatedPartyTransactions" abstract="false" name="SubordinateHybridBondRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeRelatedPartyDisclosures" abstract="false" name="OtherComprehensiveIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ComprehensiveIncomeRelatedPartyDisclosures" abstract="false" name="ComprehensiveIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAndLiabilitiesRelatedPartyTransactions" abstract="false" name="EquityAndLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentAssetsRelatedPartyTransactions" abstract="false" name="CurrentAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsRelatedPartyTransactions" abstract="false" name="AssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" abstract="false" name="EquityAttributableToEquityHoldersRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" abstract="false" name="EquityAttributableToNonControllingInterestRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityRelatedPartyTransactions" abstract="false" name="EquityRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedPartyTransactions" abstract="false" name="NonCurrentLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedPartyTransactions" abstract="false" name="CurrentLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilitiesRelatedPartyTransactions" abstract="false" name="LiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentAssetsRelatedPartyTransactions" abstract="false" name="NonCurrentAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetIncomeRelatedPartyDisclosures" abstract="false" name="NetIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" abstract="false" name="NetSalesAndOtherRevenuesRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsTable" abstract="true" name="DisclosureOfOtherNonCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsLineItems" abstract="true" name="DisclosureOfOtherNonCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" abstract="false" name="OtherFinancialAssetsAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PreFundedPensionObligations" abstract="false" name="PreFundedPensionObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LongTermPrepaidExpenses" abstract="false" name="LongTermPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLoansAndReceivables" abstract="false" name="NonCurrentLoansAndReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableTable" abstract="true" name="DisclosureOfAccountsReceivableTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableLineItems" abstract="true" name="DisclosureOfAccountsReceivableLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DerecognizedReceivables" abstract="false" name="DerecognizedReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OverdueReceivablesGrossValue" abstract="false" name="OverdueReceivablesGrossValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareProgramAxis" abstract="true" name="ShareProgramAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ShareProgramDomain" abstract="true" name="ShareProgramDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2022ProgramMember" abstract="true" name="ShareRepurchase2022ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2023ProgramMember" abstract="true" name="ShareRepurchase2023ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2024ProgramMember" abstract="true" name="ShareRepurchase2024ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2025ProgramMember" abstract="true" name="ShareRepurchase2025ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_EmployeeShareOwnershipPlanMember" abstract="true" name="EmployeeShareOwnershipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentsMember" abstract="true" name="DebtInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashFlowAndFairValueHedgeMember" abstract="true" name="CashFlowAndFairValueHedgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForeignCurrencyTranslationMember" abstract="true" name="ForeignCurrencyTranslationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" abstract="false" name="NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesAlloted" abstract="false" name="NumberOfRestrictedSharesAlloted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PeriodOfShareRepurchaseProgram" abstract="false" name="PeriodOfShareRepurchaseProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_NumberOfSharesRepurchased" abstract="false" name="NumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_AmountOfSharesRepurchased" abstract="false" name="AmountOfSharesRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SubscriptionPricePerShare" abstract="false" name="SubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_NumberOfSharesSubscribed" abstract="false" name="NumberOfSharesSubscribed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_IssuanceOfFurtherSharesAsAnEmployersContribution" abstract="false" name="IssuanceOfFurtherSharesAsAnEmployersContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PerShareValueOfSharesRepurchased" abstract="false" name="PerShareValueOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_NumberOfSharesHeld" abstract="false" name="NumberOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PercentageOfShareCapitalForThePeriod" abstract="false" name="PercentageOfShareCapitalForThePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023Member" abstract="true" name="RestrictedSharePlan2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023AdditionalSharesMember" abstract="true" name="RestrictedSharePlan2023AdditionalSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2024Member" abstract="true" name="RestrictedSharePlan2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2024AdditionalSharesMember" abstract="true" name="RestrictedSharePlan2024AdditionalSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2025Member" abstract="true" name="RestrictedSharePlan2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_MarketConditionAxis" abstract="true" name="MarketConditionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_MarketConditionDomain" abstract="true" name="MarketConditionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithoutMarketConditionMember" abstract="true" name="WithoutMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithMarketConditionMember" abstract="true" name="WithMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExcludingChiefExecutiveOfficerMember" abstract="true" name="ExcludingChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriod" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_FairValueOfPlanAtDateOfGrant" abstract="false" name="FairValueOfPlanAtDateOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfYearsServicePeriod" abstract="false" name="NumberOfYearsServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_RestrictedSharesMember" abstract="true" name="RestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2022Member" abstract="true" name="RestrictedSharePlan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2021Member" abstract="true" name="RestrictedSharePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2020Member" abstract="true" name="RestrictedSharePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesNotYetFullyVested" abstract="false" name="NumberOfRestrictedSharesNotYetFullyVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockOptionPlanMember" abstract="true" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" abstract="false" name="DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsIncludedInFinancialAssetsMember" abstract="true" name="EquityInstrumentsIncludedInFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" abstract="true" name="FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" abstract="false" name="ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" abstract="false" name="EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" abstract="false" name="ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnTaxEffects" abstract="false" name="ChangeInCurrencyTranslationOnTaxEffects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DebtNetOfCashAndCashEquivalents" abstract="false" name="DebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmortizedCostNettingMember" abstract="true" name="AmortizedCostNettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdjustmentToDebtMeasuredAtFairValueMember" abstract="true" name="AdjustmentToDebtMeasuredAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOnRedemptionMember" abstract="true" name="ValueOnRedemptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_OtherBankBorrowings" abstract="false" name="OtherBankBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesMember" abstract="true" name="NonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercialPaperProgramInFranceMember" abstract="true" name="CommercialPaperProgramInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" abstract="true" name="OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OneBillionBondsMaturingJune2023Member" abstract="true" name="OneBillionBondsMaturingJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityOneMember" abstract="true" name="SyndicatedCreditFacilityOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityTwoMember" abstract="true" name="SyndicatedCreditFacilityTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityCanceledMember" abstract="true" name="SyndicatedCreditFacilityCanceledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingApril2024Redeemed2024Member" abstract="true" name="FixedRateBondMaturingApril2024Redeemed2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingDecember2027Member" abstract="true" name="FourBillionFacilityMaturingDecember2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingMarch2030Member" abstract="true" name="FourBillionFacilityMaturingMarch2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OneBillionFiftyMillionBondsMaturingApril2025Member" abstract="true" name="OneBillionFiftyMillionBondsMaturingApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondIssueFromApril2020Member" abstract="true" name="FixedRateBondIssueFromApril2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondIssueFromApril2022Member" abstract="true" name="FixedRateBondIssueFromApril2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" abstract="true" name="OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMarch2027Member" abstract="true" name="FixedRateBondMaturingMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMarch2031Member" abstract="true" name="FixedRateBondMaturingMarch2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingJune2029Member" abstract="true" name="FixedRateBondMaturingJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMarch2032Member" abstract="true" name="FixedRateBondMaturingMarch2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" abstract="true" name="OneBillionFiveHundredMillionBondsIssuedInJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DebtInstrumentAxis" abstract="true" name="DebtInstrumentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DebtInstrumentDomain" abstract="true" name="DebtInstrumentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiEuroMediumTermNotesMember" abstract="true" name="SanofiEuroMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MazeTherapeuticsMember" abstract="true" name="MazeTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfBondIssuesRedeemed" abstract="false" name="NumberOfBondIssuesRedeemed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionNumber" abstract="false" name="CreditFacilitiesExtensionOptionNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionPeriod" abstract="false" name="CreditFacilitiesExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_BorrowingAverageDrawdown" abstract="false" name="BorrowingAverageDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfTranches" abstract="false" name="NumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AtMarketValueMember" abstract="true" name="AtMarketValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RedemptionOfDebtInstrumentIssued" abstract="false" name="RedemptionOfDebtInstrumentIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AtNotionalAmountMember" abstract="true" name="AtNotionalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfHedgeRecognizedInEquityMember" abstract="true" name="ValueOfHedgeRecognizedInEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NotEligibleForHedgeAccountingMember" abstract="true" name="NotEligibleForHedgeAccountingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesMember" abstract="true" name="ForwardCurrencySalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInUSDollarMember" abstract="true" name="ForwardCurrencySalesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencySalesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInJapaneseYenMember" abstract="true" name="ForwardCurrencySalesInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInMexicanPesoMember" abstract="true" name="ForwardCurrencySalesInMexicanPesoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInSingaporeDollarMember" abstract="true" name="ForwardCurrencySalesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesMember" abstract="true" name="ForwardCurrencyPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInSingaporeDollarMember" abstract="true" name="ForwardCurrencyPurchasesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInCanadianDollarMember" abstract="true" name="ForwardCurrencyPurchasesInCanadianDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInKoreanWonMember" abstract="true" name="ForwardCurrencyPurchasesInKoreanWonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencyPurchasesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInRussianRoubleMember" abstract="true" name="ForwardCurrencySalesInRussianRoubleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInTurkishLiraMember" abstract="true" name="ForwardCurrencyPurchasesInTurkishLiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInRussianRoubleMember" abstract="true" name="ForwardCurrencyPurchasesInRussianRoubleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialInstruments" abstract="false" name="DerivativeFinancialInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInPoundSterlingMember" abstract="true" name="ForwardCurrencySalesInPoundSterlingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInJapaneseYenMember" abstract="true" name="ForwardCurrencyPurchasesInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarUSBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInCanadianDollarMember" abstract="true" name="ForwardCurrencySalesInCanadianDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInHungarianFlorintMember" abstract="true" name="ForwardCurrencyPurchasesInHungarianFlorintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapExpiring2029Member" abstract="true" name="CrossCurrencySwapExpiring2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapExpiring2032Member" abstract="true" name="CrossCurrencySwapExpiring2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapMember" abstract="true" name="CrossCurrencySwapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CrossCurrencySellerSwapsMember" abstract="true" name="CrossCurrencySellerSwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CrossCurrencySellerSwapsInUSDollarMember" abstract="true" name="CrossCurrencySellerSwapsInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialInstrumentsToManageFinancialExposure" abstract="false" name="DerivativeFinancialInstrumentsToManageFinancialExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive069Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive092Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive343Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive3.56Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsInterestRate" abstract="false" name="InterestRateSwapsInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" abstract="false" name="CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" abstract="false" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" abstract="true" name="BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" abstract="true" name="MSDContingentConsiderationEuropeanVaccinesBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" abstract="true" name="ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" abstract="true" name="ContingentConsiderationArisingFromAcquisitionOfAmunixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherLiabilities1Member" abstract="true" name="OtherLiabilities1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" abstract="true" name="ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" abstract="false" name="OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PotentialPaymentsRelatedToPercentageOfSales" abstract="false" name="PotentialPaymentsRelatedToPercentageOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PaymentToSaleOfBusinessPeriod" abstract="false" name="PaymentToSaleOfBusinessPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_PercentageIncreaseInFairValueLiabilities" abstract="false" name="PercentageIncreaseInFairValueLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTable" abstract="true" name="DisclosureOfNonCurrentProvisionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsLineItems" abstract="true" name="DisclosureOfNonCurrentProvisionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" abstract="true" name="ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsForOtherLongTermBenefitsMember" abstract="true" name="ProvisionsForOtherLongTermBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentRestructuringProvisionMember" abstract="true" name="NonCurrentRestructuringProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" abstract="false" name="IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" abstract="false" name="IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" abstract="false" name="IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PensionsAndOtherPostEmploymentBenefitsMember" abstract="true" name="PensionsAndOtherPostEmploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EUROZONEMember" abstract="true" name="EUROZONEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UKZONEMember" abstract="true" name="UKZONEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsTable" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ScribeTherapeuticsMember" abstract="true" name="ScribeTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FulcrumTherapeuticsMember" abstract="true" name="FulcrumTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_LeaseTerm" abstract="false" name="LeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_LeaseCost" abstract="false" name="LeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsNumber" abstract="false" name="LeaseExtensionOptionsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsTerm" abstract="false" name="LeaseExtensionOptionsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_TotalMilestonePayments" abstract="false" name="TotalMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DevelopmentRegulatoryAndLaunchMilestonePayments" abstract="false" name="DevelopmentRegulatoryAndLaunchMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdditionalLaunchAndSalesMilestonePayments" abstract="false" name="AdditionalLaunchAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ContingentMilestonePayments" abstract="false" name="ContingentMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTable" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsAxis" abstract="true" name="LegalAndArbitralProceedingsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsDomain" abstract="true" name="LegalAndArbitralProceedingsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlavixAttorneyGeneralActionInHawaiiMember" abstract="true" name="PlavixAttorneyGeneralActionInHawaiiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxotereProductLitigationInTheUSMember" abstract="true" name="TaxotereProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ZantacProductLitigationInTheUSMember" abstract="true" name="ZantacProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_GoldBondProductLitigationInTheUSMember" abstract="true" name="GoldBondProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DefendantAxis" abstract="true" name="DefendantAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DefendantDomain" abstract="true" name="DefendantDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActionForWhichWeAreDefendantMember" abstract="true" name="ActionForWhichWeAreDefendantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActionForWhichSanofiAreDefendantMember" abstract="true" name="ActionForWhichSanofiAreDefendantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ProductLiabilitiesMember" abstract="true" name="ProductLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsLineItems" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" abstract="false" name="GlobalPenaltyFeeIncurredByDefendantsAmountVacated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" abstract="false" name="PenaltyFeeIncurredByDefendantsInterestsAmountVacated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfPlaintiffs" abstract="false" name="NumberOfPlaintiffs" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfCases" abstract="false" name="NumberOfCases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfDismissals" abstract="false" name="NumberOfDismissals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_PenaltyFeeIncurred" abstract="false" name="PenaltyFeeIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PaymentOfDamagesClaimedByCounterparty" abstract="false" name="PaymentOfDamagesClaimedByCounterparty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesTable" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_RegeneronMember" abstract="true" name="RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherOperatingIncomeExpenseMember" abstract="true" name="OtherOperatingIncomeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GainsOnDivestmentOfProducts" abstract="false" name="GainsOnDivestmentOfProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AntibodiesAllianceMember" abstract="true" name="AntibodiesAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImmunoOncologyAllianceMember" abstract="true" name="ImmunoOncologyAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OthersCounterpartyMember" abstract="true" name="OthersCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfZaltrapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercializationRelatedExpensesMember" abstract="true" name="CommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MiscellaneousOtherOperatingIncomeExpenses" abstract="false" name="MiscellaneousOtherOperatingIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" abstract="false" name="ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" abstract="false" name="ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" abstract="false" name="ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" abstract="false" name="ExpenseOfRestructuringActivitiesTransformationProgramsCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherRestructuringCosts" abstract="false" name="OtherRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" abstract="false" name="IncreaseDecreaseInTotalExpenseOfRestructuringActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilityRecognisedForEstimatedFutureRoyalties" abstract="false" name="LiabilityRecognisedForEstimatedFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesMember" abstract="true" name="InterestRateAndCurrencyDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestIncome" abstract="false" name="InterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CostOfDebtNet" abstract="false" name="CostOfDebtNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonOperatingForeignExchangeGainsLosses" abstract="false" name="NonOperatingForeignExchangeGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetInterestCostRelatedToEmployeeBenefits" abstract="false" name="NetInterestCostRelatedToEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageDebt" abstract="false" name="GainLossOnDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" abstract="false" name="GainLossOnDerivativesUsedToManageCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" abstract="false" name="UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" abstract="false" name="RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" abstract="false" name="TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" abstract="false" name="TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_CurrentTaxExpenseRelatedToPillarTwo" abstract="false" name="CurrentTaxExpenseRelatedToPillarTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PharmaSegmentMember" abstract="true" name="PharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OtherProductsSegmentMember" abstract="true" name="OtherProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_SpecialtyCareMember" abstract="true" name="SpecialtyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DupixentMember" abstract="true" name="DupixentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AubagioMember" abstract="true" name="AubagioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CerezymeMember" abstract="true" name="CerezymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MyozymeLumizymeMember" abstract="true" name="MyozymeLumizymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FabrazymeMember" abstract="true" name="FabrazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_JevtanaMember" abstract="true" name="JevtanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AlprolixMember" abstract="true" name="AlprolixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EloctateMember" abstract="true" name="EloctateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GeneralMedicinesMember" abstract="true" name="GeneralMedicinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CoreAssetsMember" abstract="true" name="CoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LovenoxMember" abstract="true" name="LovenoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ToujeoMember" abstract="true" name="ToujeoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlavixMember" abstract="true" name="PlavixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCoreAssetsMember" abstract="true" name="NonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LantusMember" abstract="true" name="LantusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherNonCoreAssetsMember" abstract="true" name="OtherNonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IndustrialSalesMember" abstract="true" name="IndustrialSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_VaccinesMember" abstract="true" name="VaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PolioPertussisHibVaccinesMember" abstract="true" name="PolioPertussisHibVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InfluenzaVaccinesMember" abstract="true" name="InfluenzaVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AllergyMember" abstract="true" name="AllergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PainCareMember" abstract="true" name="PainCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DigestiveWellnessMember" abstract="true" name="DigestiveWellnessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NexviazymeMember" abstract="true" name="NexviazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_SarclisaMember" abstract="true" name="SarclisaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RezurockMember" abstract="true" name="RezurockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CabliviMember" abstract="true" name="CabliviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_XenpozymeMember" abstract="true" name="XenpozymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_EnjaymoMember" abstract="true" name="EnjaymoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_TzieldMember" abstract="true" name="TzieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RSVVaccinesMember" abstract="true" name="RSVVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_MeningitisTravelAndEndemicVaccinesMember" abstract="true" name="MeningitisTravelAndEndemicVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_SeasonalSymptomsAndPainReliefMember" abstract="true" name="SeasonalSymptomsAndPainReliefMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_WellnessBrandsMember" abstract="true" name="WellnessBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OthersMember" abstract="true" name="OthersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RareDiseasesMember" abstract="true" name="RareDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_PharmaLaunchesMember" abstract="true" name="PharmaLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_BusinessOperatingIncome" abstract="false" name="BusinessOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" abstract="true" name="ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ClinicalStudyMember" abstract="true" name="ClinicalStudyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_SAR44425Member" abstract="true" name="SAR44425Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImmunoOncologyCollaborationAgreementMember" abstract="true" name="ImmunoOncologyCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RegeneronPharmaceuticalsIncMember" abstract="true" name="RegeneronPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" abstract="false" name="AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" abstract="false" name="ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeResultingFromOutLicensing" abstract="false" name="IncomeResultingFromOutLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="UpfrontPaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetReversalOfImpairmentLoss" abstract="false" name="NetReversalOfImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" abstract="false" name="ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ReportableGeographicalZonesMember" abstract="true" name="ReportableGeographicalZonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" abstract="true" name="OtherCountriesExcludingEuropeAndNorthAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CertainWholesalersInTheUnitedStatesMember" abstract="true" name="CertainWholesalersInTheUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_RecludixPharmaMember" abstract="true" name="RecludixPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MajorCollaborationAgreementMember" abstract="true" name="MajorCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QRIBIntermediateHoldingsLLCMember" abstract="true" name="QRIBIntermediateHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_VicebioLtdMember" abstract="true" name="VicebioLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePrice" abstract="false" name="BusinessCombinationPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RevenueFromVaxServeSalesOfNonSanofiProducts" abstract="false" name="RevenueFromVaxServeSalesOfNonSanofiProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" abstract="false" name="RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MiscellaneousOtherRevenue" abstract="false" name="MiscellaneousOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" abstract="false" name="IrrevocablePurchaseCommitmentsDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" abstract="false" name="IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" abstract="false" name="IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" abstract="false" name="CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" abstract="false" name="TotalOffBalanceSheetCommitmentsDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangesInProfitLossFromDiscontinuedOperations" abstract="false" name="ChangesInProfitLossFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="GoodwillDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="InventoriesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="OtherAssetsDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="AssetsOfDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="AccountsPayableDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="RevenueFromDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>sny-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_f397ab80-9c36-401e-ba55-b4ed8c05030a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_f397ab80-9c36-401e-ba55-b4ed8c05030a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_926c29d5-5e99-4b3a-aff7-3744ad1031a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_RightofuseAssets_926c29d5-5e99-4b3a-aff7-3744ad1031a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_2d53c2da-dbda-4679-900d-a80b7bdbbb2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_Goodwill_2d53c2da-dbda-4679-900d-a80b7bdbbb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_c1f63ecf-d74b-4aed-b0b6-bb3027f19d3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_c1f63ecf-d74b-4aed-b0b6-bb3027f19d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_6d03d18a-0d97-4051-ad08-16cf62ae5bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_6d03d18a-0d97-4051-ad08-16cf62ae5bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_a826899a-ecc5-438e-86de-266fb952baac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_a826899a-ecc5-438e-86de-266fb952baac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_fa3f8582-1a13-4cd4-b9ae-24efe27fafd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_fa3f8582-1a13-4cd4-b9ae-24efe27fafd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_0f956887-34e5-4b43-92aa-ec40b8e8fb15" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_d674d6ac-081a-41b5-93fe-e85881f982be" xlink:to="loc_ifrs-full_DeferredTaxAssets_0f956887-34e5-4b43-92aa-ec40b8e8fb15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_1ddea468-0345-4248-b63d-310607176028" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_1ddea468-0345-4248-b63d-310607176028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_7cc2dfe1-3f05-4899-80f0-b7af378d3fff" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_7cc2dfe1-3f05-4899-80f0-b7af378d3fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_75f3ebee-81aa-4b2d-81d4-b60fa23e7a04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_75f3ebee-81aa-4b2d-81d4-b60fa23e7a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_2b778591-0ba4-4f7a-9e00-4444379bef5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_2b778591-0ba4-4f7a-9e00-4444379bef5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_96d9f4d6-5c03-4acb-87e0-63a40852f0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_96d9f4d6-5c03-4acb-87e0-63a40852f0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_7ba1a887-3d59-4751-ae83-2d116b53fe2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_796023f7-446a-45eb-9d13-c5042136bc10" xlink:to="loc_ifrs-full_LongtermBorrowings_7ba1a887-3d59-4751-ae83-2d116b53fe2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_23c2512e-5633-48d5-b43f-bfdea43b6b7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_da58cc9d-3456-492a-8f21-ba46b728ed76" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_23c2512e-5633-48d5-b43f-bfdea43b6b7f" xlink:to="loc_ifrs-full_Equity_da58cc9d-3456-492a-8f21-ba46b728ed76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_9dc34703-9bb1-409e-a652-1ca992a331bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_23c2512e-5633-48d5-b43f-bfdea43b6b7f" xlink:to="loc_ifrs-full_NoncurrentLiabilities_9dc34703-9bb1-409e-a652-1ca992a331bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_2029edf0-3733-46d5-b615-c381ae7f0c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_23c2512e-5633-48d5-b43f-bfdea43b6b7f" xlink:to="loc_ifrs-full_CurrentLiabilities_2029edf0-3733-46d5-b615-c381ae7f0c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_91ab969e-a0bd-4ea6-901c-55fab38be442" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_38d4454c-99f8-4abc-a7e8-9fd51b013a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_91ab969e-a0bd-4ea6-901c-55fab38be442" xlink:to="loc_ifrs-full_NoncontrollingInterests_38d4454c-99f8-4abc-a7e8-9fd51b013a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_563f0e0a-cb40-4f22-911c-cb012934420c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_91ab969e-a0bd-4ea6-901c-55fab38be442" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_563f0e0a-cb40-4f22-911c-cb012934420c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_225477eb-e29b-4baf-a4da-92967b429afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_225477eb-e29b-4baf-a4da-92967b429afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_8fa0f469-664a-41a4-8c41-859a7d483044" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_8fa0f469-664a-41a4-8c41-859a7d483044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6debaef4-fe08-4da9-8b79-af5440ed6aaa" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6debaef4-fe08-4da9-8b79-af5440ed6aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_0edb5ff2-91fa-42d5-bfb2-d5df2d424f21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_0edb5ff2-91fa-42d5-bfb2-d5df2d424f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6c3a76fe-d157-4d9a-82a2-ad1e569e18f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6c3a76fe-d157-4d9a-82a2-ad1e569e18f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2c5e9615-5fec-4117-bfa2-5c07070f5d73" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2c5e9615-5fec-4117-bfa2-5c07070f5d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_13a26529-7db2-4a5f-b735-dda7845953ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_474dcf94-e9a9-4bf2-856c-6a2a6ddca5fb" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_13a26529-7db2-4a5f-b735-dda7845953ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_95870871-4fec-4852-869e-d6ea43653f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_Inventories_95870871-4fec-4852-869e-d6ea43653f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_e62025a3-130b-4306-9abd-7ee92f7376e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_CurrentTradeReceivables_e62025a3-130b-4306-9abd-7ee92f7376e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_c77b5d42-414f-48b4-a77b-8c5120016f86" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_OtherCurrentAssets_c77b5d42-414f-48b4-a77b-8c5120016f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_e69389af-408c-4c0c-a169-cb1ba4683021" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_e69389af-408c-4c0c-a169-cb1ba4683021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_ec1cc148-6cfb-41da-a386-e8ad8982fb91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_ec1cc148-6cfb-41da-a386-e8ad8982fb91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_e68d3e0b-9a14-42e9-b508-d6e35c9ebf38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1b55ff24-38f5-441e-a989-3c366ab42adf" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_e68d3e0b-9a14-42e9-b508-d6e35c9ebf38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_71d79b5d-9ce9-4912-a19f-9571e4b578f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_bade2254-3655-45c6-8b05-22a46c6938ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_71d79b5d-9ce9-4912-a19f-9571e4b578f3" xlink:to="loc_ifrs-full_NoncurrentAssets_bade2254-3655-45c6-8b05-22a46c6938ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_f0ed26d6-a61b-4e29-9ba0-0c5bbe5cfa02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_71d79b5d-9ce9-4912-a19f-9571e4b578f3" xlink:to="loc_ifrs-full_CurrentAssets_f0ed26d6-a61b-4e29-9ba0-0c5bbe5cfa02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedIncomeStatements"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_301f0336-2418-4d60-bc21-7b331fa70c0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_eadf7680-2169-4c3c-b06d-88a878f00d20" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_301f0336-2418-4d60-bc21-7b331fa70c0c" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_eadf7680-2169-4c3c-b06d-88a878f00d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_fb2d2cf1-adda-4556-b51d-8269528e40fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_301f0336-2418-4d60-bc21-7b331fa70c0c" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_fb2d2cf1-adda-4556-b51d-8269528e40fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_659ae54d-a4b5-4154-91bf-19e59d06910a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_301f0336-2418-4d60-bc21-7b331fa70c0c" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_659ae54d-a4b5-4154-91bf-19e59d06910a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_ac193f71-41c3-4c40-9262-8b6e1a9b744e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_25253ece-d91f-4a98-b755-4a1500bacfc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_ac193f71-41c3-4c40-9262-8b6e1a9b744e" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_25253ece-d91f-4a98-b755-4a1500bacfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_42787e15-093b-42b1-b0dc-7e0f5593e6b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_ac193f71-41c3-4c40-9262-8b6e1a9b744e" xlink:to="loc_ifrs-full_OtherRevenue_42787e15-093b-42b1-b0dc-7e0f5593e6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_04374565-309f-4cca-b744-3df995b11e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_ac193f71-41c3-4c40-9262-8b6e1a9b744e" xlink:to="loc_ifrs-full_CostOfSales_04374565-309f-4cca-b744-3df995b11e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_aedcfd8b-1c91-4b66-a179-883aceb61abb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_3939fba9-aabd-4c9e-8211-7e6acf0d8b88" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_aedcfd8b-1c91-4b66-a179-883aceb61abb" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_3939fba9-aabd-4c9e-8211-7e6acf0d8b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_d9198849-8b18-4dd8-968e-fbfa78df0d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_aedcfd8b-1c91-4b66-a179-883aceb61abb" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_d9198849-8b18-4dd8-968e-fbfa78df0d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_d2b8b4a1-04ac-4b5f-85b3-eef110c8947a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_d2b8b4a1-04ac-4b5f-85b3-eef110c8947a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_551b829f-b83f-4048-8c37-820dcba0fe4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_551b829f-b83f-4048-8c37-820dcba0fe4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_88402712-29a3-4caf-91c9-46394fce3983" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_88402712-29a3-4caf-91c9-46394fce3983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_8801c7d1-e390-48ae-9b81-488a3e4e4d80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_8801c7d1-e390-48ae-9b81-488a3e4e4d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_8f77ee00-a23d-4323-8363-609fde215fe3" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_sny_OtherGainsLossesAndLitigation_8f77ee00-a23d-4323-8363-609fde215fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_f25ddab6-3153-4b89-936c-74c22df10c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_f25ddab6-3153-4b89-936c-74c22df10c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_7d0e8268-9a97-4d5b-bcd0-b9cb8d5ecac0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_7d0e8268-9a97-4d5b-bcd0-b9cb8d5ecac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_66506972-066d-4aae-97d9-5da385af912e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_GrossProfit_66506972-066d-4aae-97d9-5da385af912e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_beffc6bb-bdaf-478c-8ea5-84058afc4e30" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_beffc6bb-bdaf-478c-8ea5-84058afc4e30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3aa4c580-c1c1-4c86-9ba8-f4ec6fe9f73e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_bedf4f40-f664-4509-a6f2-d42947b13f07" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3aa4c580-c1c1-4c86-9ba8-f4ec6fe9f73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_f616fb18-f46c-4c0f-a01e-7e41018cdb42" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_1e400f04-5e81-48f3-a433-5232c0d1c50b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_f616fb18-f46c-4c0f-a01e-7e41018cdb42" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_1e400f04-5e81-48f3-a433-5232c0d1c50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a048714a-ed8d-408f-b66b-2ab45b446304" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_f616fb18-f46c-4c0f-a01e-7e41018cdb42" xlink:to="loc_ifrs-full_FinanceCosts_a048714a-ed8d-408f-b66b-2ab45b446304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_2565ec23-c526-42ee-ac42-c082cee294cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_f616fb18-f46c-4c0f-a01e-7e41018cdb42" xlink:to="loc_ifrs-full_FinanceIncome_2565ec23-c526-42ee-ac42-c082cee294cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedIncomeStatements_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_ba39c022-d88c-4c68-97b3-4f09b6589092" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_09a52e18-5c93-4187-85e3-9c8ec285d29e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_ba39c022-d88c-4c68-97b3-4f09b6589092" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_09a52e18-5c93-4187-85e3-9c8ec285d29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_78d8b704-aae1-4ae3-b485-36654f73ca17" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_ba39c022-d88c-4c68-97b3-4f09b6589092" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_78d8b704-aae1-4ae3-b485-36654f73ca17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_049ba16a-7661-45ec-848e-0f811bcd23de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_55bb2002-3d92-40cc-9b67-6cd1296d6668" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_049ba16a-7661-45ec-848e-0f811bcd23de" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_55bb2002-3d92-40cc-9b67-6cd1296d6668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_5ae537b9-e8e9-4e32-8c59-f8eff7f8fb29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_049ba16a-7661-45ec-848e-0f811bcd23de" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_5ae537b9-e8e9-4e32-8c59-f8eff7f8fb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_a85fbec2-26b2-4da5-948f-7d1819468aa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_471e72e8-5cee-490c-8e33-de917946c0c0" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_a85fbec2-26b2-4da5-948f-7d1819468aa4" xlink:to="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_471e72e8-5cee-490c-8e33-de917946c0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_c2c01f4b-d61b-4d18-b459-b4021e6518e5" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_a85fbec2-26b2-4da5-948f-7d1819468aa4" xlink:to="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_c2c01f4b-d61b-4d18-b459-b4021e6518e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_64973807-5c22-416e-ae0a-dfa3288f48c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_e98761b9-6f94-40ce-b7c5-ac6f373032d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_64973807-5c22-416e-ae0a-dfa3288f48c8" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_e98761b9-6f94-40ce-b7c5-ac6f373032d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_516b1aeb-4c83-4227-a5a6-5537cea7dc13" xlink:href="sny-20250630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_64973807-5c22-416e-ae0a-dfa3288f48c8" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_516b1aeb-4c83-4227-a5a6-5537cea7dc13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_589675f5-f38a-4e24-a14b-4848a39f1a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_64973807-5c22-416e-ae0a-dfa3288f48c8" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_589675f5-f38a-4e24-a14b-4848a39f1a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_37695692-53b2-4aa5-9573-04c2311a05bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_64973807-5c22-416e-ae0a-dfa3288f48c8" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_37695692-53b2-4aa5-9573-04c2311a05bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_5e0751ff-2a32-4102-9174-daa620a41c2e" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_85cef093-0117-4675-9cde-13ad8d5a5931" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_5e0751ff-2a32-4102-9174-daa620a41c2e" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_85cef093-0117-4675-9cde-13ad8d5a5931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_baeb02b5-0d5b-43e0-b4c0-4c7aae1efbbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_5e0751ff-2a32-4102-9174-daa620a41c2e" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_baeb02b5-0d5b-43e0-b4c0-4c7aae1efbbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_73d89e7c-be2d-4e03-a934-9bcd96210535" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_baa94501-f9af-4407-80bf-cf16c5435931" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_73d89e7c-be2d-4e03-a934-9bcd96210535" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_baa94501-f9af-4407-80bf-cf16c5435931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_710e84ed-d791-4f5e-8fb9-a1251a159366" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_73d89e7c-be2d-4e03-a934-9bcd96210535" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_710e84ed-d791-4f5e-8fb9-a1251a159366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_d5ae2927-01a0-4166-96c7-87f248c406af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_73d89e7c-be2d-4e03-a934-9bcd96210535" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_d5ae2927-01a0-4166-96c7-87f248c406af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_0c7788d2-be51-4b73-8d15-5da31d349cdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_6a6e54a0-c443-44ca-bc47-92d501201004" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0c7788d2-be51-4b73-8d15-5da31d349cdc" xlink:to="loc_ifrs-full_ProfitLoss_6a6e54a0-c443-44ca-bc47-92d501201004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_7813400d-137b-404c-97f7-bd80a2d9df54" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0c7788d2-be51-4b73-8d15-5da31d349cdc" xlink:to="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_7813400d-137b-404c-97f7-bd80a2d9df54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_c0fed3dc-7bec-45c4-a356-afc707f1d72d" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0c7788d2-be51-4b73-8d15-5da31d349cdc" xlink:to="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_c0fed3dc-7bec-45c4-a356-afc707f1d72d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_72f9c3b5-0a2f-4915-918d-37a1170a7e3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_72f9c3b5-0a2f-4915-918d-37a1170a7e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_98406292-786e-4099-9d2f-06caa91ebb61" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_98406292-786e-4099-9d2f-06caa91ebb61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_2fbdb18b-c573-4903-b645-651faf2ad611" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_2fbdb18b-c573-4903-b645-651faf2ad611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d95521af-2cc9-4561-972b-cc7dbb9dc87f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d95521af-2cc9-4561-972b-cc7dbb9dc87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_bd00070d-cec4-4a2d-812f-7fe4a16162e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_bd00070d-cec4-4a2d-812f-7fe4a16162e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_ee98f434-6740-4cbb-80b3-0ef8272432cf" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_a9d8100e-9572-410b-b308-8a9c911ad203" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_ee98f434-6740-4cbb-80b3-0ef8272432cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_69973b3a-420c-4905-8e1b-b94c0bee2dbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_8b5ad070-a04a-4710-9f92-f031edb150a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_69973b3a-420c-4905-8e1b-b94c0bee2dbf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_8b5ad070-a04a-4710-9f92-f031edb150a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_5d919ff4-f58f-44a7-ae93-a3c3c7383f2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_69973b3a-420c-4905-8e1b-b94c0bee2dbf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_5d919ff4-f58f-44a7-ae93-a3c3c7383f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_90e379b6-c629-400c-9aa8-57884d563a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_90e379b6-c629-400c-9aa8-57884d563a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_4799c244-084b-4a80-8f36-bf78cfa7b6d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_4799c244-084b-4a80-8f36-bf78cfa7b6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_cdb0dd18-2ee4-41d8-a6c2-88f4b4f7a4e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_cdb0dd18-2ee4-41d8-a6c2-88f4b4f7a4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_cf2548ba-5aac-4d3b-98f7-8f37edc0b85a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_cf2548ba-5aac-4d3b-98f7-8f37edc0b85a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_0f734802-b920-4a88-8993-0c9854e656be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_0f734802-b920-4a88-8993-0c9854e656be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_40ba537c-d521-4f8d-949d-f5afbf3d77ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_40ba537c-d521-4f8d-949d-f5afbf3d77ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_82de07ad-d8ae-4fb1-976d-a65f2c23d600" xlink:href="sny-20250630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_82de07ad-d8ae-4fb1-976d-a65f2c23d600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_33661404-5309-4ab5-9398-46b08055b6fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_270416ac-82df-4382-9f2a-8a74fc2ef875" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_33661404-5309-4ab5-9398-46b08055b6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0b4cbe79-d88a-4897-a2f4-ded5115097f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0b4cbe79-d88a-4897-a2f4-ded5115097f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b63e9d46-88f7-4df1-9b7b-3c7143036cf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b63e9d46-88f7-4df1-9b7b-3c7143036cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_eb21c798-03c3-4f37-8451-bfa5c9a1b52c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_eb21c798-03c3-4f37-8451-bfa5c9a1b52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_8dc7760c-eb96-4652-93e5-c9e0b5a549b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_8dc7760c-eb96-4652-93e5-c9e0b5a549b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_ebd97d72-33a8-4902-aed5-456d6d071e96" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_e8a478f1-da21-4694-8432-5abc300dab54" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_ebd97d72-33a8-4902-aed5-456d6d071e96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_10e8770e-95eb-46d6-b177-a497aba5d6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_34d5675c-b153-4aea-9fee-9b59f981747d" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_10e8770e-95eb-46d6-b177-a497aba5d6b8" xlink:to="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_34d5675c-b153-4aea-9fee-9b59f981747d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_f7322886-d249-4ad3-a404-818fcce713e7" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_10e8770e-95eb-46d6-b177-a497aba5d6b8" xlink:to="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_f7322886-d249-4ad3-a404-818fcce713e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_4c974e6b-7b3a-49a5-a874-3f237d08ed6a" xlink:href="sny-20250630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_10e8770e-95eb-46d6-b177-a497aba5d6b8" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_4c974e6b-7b3a-49a5-a874-3f237d08ed6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c8fc264f-690d-448c-9e87-a27e97cd82c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_6f34d251-028b-43c1-9a9b-a182a6fbefad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c8fc264f-690d-448c-9e87-a27e97cd82c0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_6f34d251-028b-43c1-9a9b-a182a6fbefad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_0ca8b727-8a32-4693-9b77-59c132b328a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c8fc264f-690d-448c-9e87-a27e97cd82c0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_0ca8b727-8a32-4693-9b77-59c132b328a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_18bd4adf-ab51-4617-af7b-324c05f45ca4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_18bd4adf-ab51-4617-af7b-324c05f45ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_74e2f615-b49a-485d-b2ab-680b0a8b8e4a" xlink:href="sny-20250630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_74e2f615-b49a-485d-b2ab-680b0a8b8e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d5f5609c-eb63-4494-9777-c35703d47574" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d5f5609c-eb63-4494-9777-c35703d47574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_5f3d4961-6304-4ab2-9c96-49b27bd86f08" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_5f3d4961-6304-4ab2-9c96-49b27bd86f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_87dc1f1a-6c53-4496-b8d6-4cb40e1be074" xlink:href="sny-20250630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_87dc1f1a-6c53-4496-b8d6-4cb40e1be074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_8d8553e0-dccd-4483-86dd-3aa0fd4e50e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_8d8553e0-dccd-4483-86dd-3aa0fd4e50e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_e0674996-a059-4d03-b0ae-8f316aed98dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_e0674996-a059-4d03-b0ae-8f316aed98dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_ea05d6e1-555d-46a3-98fe-1944228d7f06" xlink:href="sny-20250630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_ea05d6e1-555d-46a3-98fe-1944228d7f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_67c59553-c85a-4d73-9272-64e0f08d6f2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_67c59553-c85a-4d73-9272-64e0f08d6f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_7c6b8c1b-bdb3-4cd1-b957-a11d473ca6bb" xlink:href="sny-20250630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_7c6b8c1b-bdb3-4cd1-b957-a11d473ca6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_551e2464-2cca-402d-a403-70aa56da0ba3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_4f9c3a9d-4447-4952-9aec-214d22d0a883" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_551e2464-2cca-402d-a403-70aa56da0ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_fdee2c8c-7d3d-411c-a864-8383e4087fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_fdee2c8c-7d3d-411c-a864-8383e4087fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_97d4bffc-853b-4bc3-8af3-742a1515da8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_97d4bffc-853b-4bc3-8af3-742a1515da8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_724620a0-79c7-45a9-8849-a8fb1517f964" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_724620a0-79c7-45a9-8849-a8fb1517f964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0833f06c-78e2-4654-9d0b-6d3c870750d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0833f06c-78e2-4654-9d0b-6d3c870750d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_63519e03-1f6a-41ae-b6ad-9ff0d6a0822d" xlink:href="sny-20250630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1c74f21d-fa0e-4213-8b36-3036a0c17021" xlink:to="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_63519e03-1f6a-41ae-b6ad-9ff0d6a0822d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_5a17146e-5887-4d5e-a39f-53e6b243d977" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_5a17146e-5887-4d5e-a39f-53e6b243d977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_e9072b2f-31f2-4ddf-ae79-bfe1067c0152" xlink:href="sny-20250630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_e9072b2f-31f2-4ddf-ae79-bfe1067c0152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_0fea4cf6-6659-451a-a31e-7a12559d925c" xlink:href="sny-20250630.xsd#sny_PreFundedPensionObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:to="loc_sny_PreFundedPensionObligations_0fea4cf6-6659-451a-a31e-7a12559d925c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_0a08d297-8129-4cbe-b4f4-9efcfc1e3f3e" xlink:href="sny-20250630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:to="loc_sny_LongTermPrepaidExpenses_0a08d297-8129-4cbe-b4f4-9efcfc1e3f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_eaabba61-299a-478a-8b39-ed182da1cb4c" xlink:href="sny-20250630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_8d54dd8a-112a-421f-ac32-eba94104c4b7" xlink:to="loc_sny_NonCurrentLoansAndReceivables_eaabba61-299a-478a-8b39-ed182da1cb4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_380dee43-c060-4aec-a71e-5b2a8b7fb4f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_9008bded-be46-4eb8-9ed7-1223208d7202" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_380dee43-c060-4aec-a71e-5b2a8b7fb4f2" xlink:to="loc_ifrs-full_WeightedAverageShares_9008bded-be46-4eb8-9ed7-1223208d7202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_078d99bb-b7a7-4e29-87a1-2527ad19afcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_380dee43-c060-4aec-a71e-5b2a8b7fb4f2" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_078d99bb-b7a7-4e29-87a1-2527ad19afcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_e0494ee5-fec0-4a1f-a30a-3a8db7a09c07" xlink:href="sny-20250630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_380dee43-c060-4aec-a71e-5b2a8b7fb4f2" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_e0494ee5-fec0-4a1f-a30a-3a8db7a09c07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_2a4121e8-e1bd-4d7e-862c-800811dc812d" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_2a4121e8-e1bd-4d7e-862c-800811dc812d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_1ae02cb4-fa2f-490c-b90c-f68af98bbbf7" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_1ae02cb4-fa2f-490c-b90c-f68af98bbbf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_64218517-f847-479a-a140-a7a7fd97ec62" xlink:href="sny-20250630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_64218517-f847-479a-a140-a7a7fd97ec62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_575ea23f-87fe-47de-87c7-170cb4f9390b" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_575ea23f-87fe-47de-87c7-170cb4f9390b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_4dc19ffd-890b-4c89-9f0e-144090d07ef9" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_4dc19ffd-890b-4c89-9f0e-144090d07ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_2b4c23f2-aa71-4b42-b6dd-d40c5284bf59" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_2b4c23f2-aa71-4b42-b6dd-d40c5284bf59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_b4b3e5bf-e9c4-4e87-9866-ad7fc4583c99" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7eb11677-174d-4f15-917b-2e74f0e20440" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_b4b3e5bf-e9c4-4e87-9866-ad7fc4583c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_bdf4edd8-e4ac-432b-8fc7-e97f185ae692" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_bdf4edd8-e4ac-432b-8fc7-e97f185ae692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_fe309f89-b652-4ec9-97ed-2b82dbab249f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_fe309f89-b652-4ec9-97ed-2b82dbab249f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0d645758-5c0f-40a5-bba2-07118f89e9d1" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0d645758-5c0f-40a5-bba2-07118f89e9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_a4a60cff-bb8e-4e9f-8721-6b4ee4e7efed" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_a4a60cff-bb8e-4e9f-8721-6b4ee4e7efed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_abd05db6-9d63-44e7-9c95-ab3d1effe66d" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_abd05db6-9d63-44e7-9c95-ab3d1effe66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_7b4186f3-a43f-47ad-9f6a-8f866d4dfa9c" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_7b4186f3-a43f-47ad-9f6a-8f866d4dfa9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_dcbe731d-f62e-4dc0-abea-f1cfc283bab6" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_dcbe731d-f62e-4dc0-abea-f1cfc283bab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_db6ed328-9a76-40fb-893a-aa83debe6cab" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_db6ed328-9a76-40fb-893a-aa83debe6cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_3c4d0910-464d-423b-9cc5-cd9e60f13cd9" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_3c4d0910-464d-423b-9cc5-cd9e60f13cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_49e3335f-1713-460c-a312-ea70cdf2ac7f" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_135ce8ac-3f12-44a1-8f66-d55b938436f7" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_49e3335f-1713-460c-a312-ea70cdf2ac7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_594aebb6-153e-4689-855e-844aac9aec72" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_89d3aabf-acb2-4c19-93fd-2af75ea9571d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_594aebb6-153e-4689-855e-844aac9aec72" xlink:to="loc_ifrs-full_Borrowings_89d3aabf-acb2-4c19-93fd-2af75ea9571d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4b7ee5b5-bf39-4324-9ac7-c4b87268ab6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_594aebb6-153e-4689-855e-844aac9aec72" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4b7ee5b5-bf39-4324-9ac7-c4b87268ab6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_44bfd533-5449-4fb1-b1c0-6d33f1c553cc" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_594aebb6-153e-4689-855e-844aac9aec72" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_44bfd533-5449-4fb1-b1c0-6d33f1c553cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_704dacce-9d95-43cb-afd1-0deb4c98d14c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_173c7d27-328e-4524-8d69-985f3cd81560" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_704dacce-9d95-43cb-afd1-0deb4c98d14c" xlink:to="loc_ifrs-full_LongtermBorrowings_173c7d27-328e-4524-8d69-985f3cd81560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_cf682c27-1088-4563-9eb8-397776e955d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_704dacce-9d95-43cb-afd1-0deb4c98d14c" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_cf682c27-1088-4563-9eb8-397776e955d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_c2201036-740c-4895-b593-fad2a4099c8a" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_704dacce-9d95-43cb-afd1-0deb4c98d14c" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_c2201036-740c-4895-b593-fad2a4099c8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_4be70fc1-e2f6-4a6a-854e-5e025d3a9f91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:to="loc_ifrs-full_BondsIssued_4be70fc1-e2f6-4a6a-854e-5e025d3a9f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_18d0bcde-80b2-4646-a27a-b959ae524b22" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:to="loc_sny_OtherBankBorrowings_18d0bcde-80b2-4646-a27a-b959ae524b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_92d60d05-ab40-4856-a289-bebcfc0c414d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:to="loc_ifrs-full_OtherBorrowings_92d60d05-ab40-4856-a289-bebcfc0c414d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_25126a97-8cb7-45bd-b4d3-b97324f23410" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_25126a97-8cb7-45bd-b4d3-b97324f23410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_84699188-2a05-42aa-84de-b4eb11a23e5a" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4b83f881-a470-4fda-accb-ecc3ba7cc42e" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_84699188-2a05-42aa-84de-b4eb11a23e5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_77c1954a-2a8d-4a9c-9052-139c16a01f66" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_1bf609e0-7453-4c89-9536-5c6cff44b75f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_77c1954a-2a8d-4a9c-9052-139c16a01f66" xlink:to="loc_ifrs-full_NoncurrentProvisions_1bf609e0-7453-4c89-9536-5c6cff44b75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_3672804f-1cd4-4cf0-afef-6fe0e7c1877f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_77c1954a-2a8d-4a9c-9052-139c16a01f66" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_3672804f-1cd4-4cf0-afef-6fe0e7c1877f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_77e41dad-bc9d-4260-ad49-8535a5ad181d" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_77e41dad-bc9d-4260-ad49-8535a5ad181d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_38a1daa6-d2c4-48c9-b774-ec4f819f009f" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_38a1daa6-d2c4-48c9-b774-ec4f819f009f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_691c1e49-927d-488d-9099-6b49763c8e48" xlink:href="sny-20250630.xsd#sny_OtherRestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:to="loc_sny_OtherRestructuringCosts_691c1e49-927d-488d-9099-6b49763c8e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_87ab0e4c-c325-42a2-a077-e741cc3f09f9" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_87ab0e4c-c325-42a2-a077-e741cc3f09f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_bdf8dd33-2ec6-48a5-b6ef-ae732ced84d5" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_84aa9856-aeb4-41d0-911b-628580c89f21" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_bdf8dd33-2ec6-48a5-b6ef-ae732ced84d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_3f2b4660-3ba3-4f78-896c-d82b33cff0f1" xlink:href="sny-20250630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_3f2b4660-3ba3-4f78-896c-d82b33cff0f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_3cc6464a-0712-4385-977d-754afc6b5bfb" xlink:href="sny-20250630.xsd#sny_CostOfDebtNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_sny_CostOfDebtNet_3cc6464a-0712-4385-977d-754afc6b5bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_10f9a7ac-5d34-49c9-b6fc-1fd06c32a50e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_10f9a7ac-5d34-49c9-b6fc-1fd06c32a50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_f8ce590d-5e31-4a7d-978d-18a1e0c14390" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_f8ce590d-5e31-4a7d-978d-18a1e0c14390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_4aa78355-3293-4fc0-8a50-a70ee6b2bd27" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_4aa78355-3293-4fc0-8a50-a70ee6b2bd27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_3709d9d3-cc38-4ea6-b7ce-c3c4c5921f60" xlink:href="sny-20250630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_3709d9d3-cc38-4ea6-b7ce-c3c4c5921f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_b3cb3541-1e9f-4602-961f-e5b9864879f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_b7edf673-7e8d-41b4-9c1b-d9c219df4d7e" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_b3cb3541-1e9f-4602-961f-e5b9864879f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_5b4b06d6-b47b-4127-8839-53ec2ae0beea" xlink:href="sny-20250630.xsd#sny_CostOfDebtNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_f1da630d-ca21-403a-b312-9e6eb9950a33" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_5b4b06d6-b47b-4127-8839-53ec2ae0beea" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_f1da630d-ca21-403a-b312-9e6eb9950a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_9edc32dc-116c-48bf-985a-b897c8120785" xlink:href="sny-20250630.xsd#sny_InterestIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_5b4b06d6-b47b-4127-8839-53ec2ae0beea" xlink:to="loc_sny_InterestIncome_9edc32dc-116c-48bf-985a-b897c8120785" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncomeDetails_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_e02d9cb1-c31c-43cc-bde8-76b4bb9e34cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_2f28075d-bea1-4e8c-b125-c944df3b310d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_e02d9cb1-c31c-43cc-bde8-76b4bb9e34cd" xlink:to="loc_ifrs-full_FinanceCosts_2f28075d-bea1-4e8c-b125-c944df3b310d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_2f014231-0cad-4720-8fd2-52b68d059dd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_e02d9cb1-c31c-43cc-bde8-76b4bb9e34cd" xlink:to="loc_ifrs-full_FinanceIncome_2f014231-0cad-4720-8fd2-52b68d059dd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_a7abb82a-24f4-45a3-ab01-8e8ddb49b3ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_0ab3cd54-7b51-4298-a6cd-9460e6589cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_a7abb82a-24f4-45a3-ab01-8e8ddb49b3ff" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_0ab3cd54-7b51-4298-a6cd-9460e6589cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_9b852734-47f1-4f22-b90d-24e6f08e6180" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_a7abb82a-24f4-45a3-ab01-8e8ddb49b3ff" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_9b852734-47f1-4f22-b90d-24e6f08e6180" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_45832d40-559a-4a33-9210-1b2ce2b53bb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:to="loc_ifrs-full_ApplicableTaxRate_45832d40-559a-4a33-9210-1b2ce2b53bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_88e48dff-23b1-4b16-a957-55332a775744" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_88e48dff-23b1-4b16-a957-55332a775744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_52ff9dc0-38ac-4d30-a395-5d4338eab414" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_52ff9dc0-38ac-4d30-a395-5d4338eab414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_d49ededd-eb12-4d96-bf39-ce05d90d20cd" xlink:href="sny-20250630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_d49ededd-eb12-4d96-bf39-ce05d90d20cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_0d54b612-fbd8-41a8-82d6-090625e0afa0" xlink:href="sny-20250630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_5853c148-483c-4531-80d6-9f758e5db81a" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_0d54b612-fbd8-41a8-82d6-090625e0afa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_295dbb49-2376-49bf-96c5-2967c9346630" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_295dbb49-2376-49bf-96c5-2967c9346630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_a4262f99-121d-4f97-a934-c2d2d2b8a2ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_OtherRevenue_a4262f99-121d-4f97-a934-c2d2d2b8a2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_e3326d9a-76b4-4e66-b67b-85bb3ea75770" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_CostOfSales_e3326d9a-76b4-4e66-b67b-85bb3ea75770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_56b30864-a640-4c4e-aa1f-59f4e635b543" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_56b30864-a640-4c4e-aa1f-59f4e635b543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ccb0ac9e-c1b4-4e8a-b5c5-d3bde7d67feb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ccb0ac9e-c1b4-4e8a-b5c5-d3bde7d67feb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_7f3584cd-b1c3-4b00-b051-9c2394552935" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_7f3584cd-b1c3-4b00-b051-9c2394552935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_f091179c-b79e-416d-8b02-0ebf941aa8fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_f091179c-b79e-416d-8b02-0ebf941aa8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_369f3a76-e16b-415e-bf9a-be7307552859" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_503db4ba-9bcd-42fc-8272-083edf8b4d83" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_369f3a76-e16b-415e-bf9a-be7307552859" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_44ba529f-1204-481a-87e1-3a1faaa00d0e" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_sny_BusinessOperatingIncome_44ba529f-1204-481a-87e1-3a1faaa00d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6650671f-3703-4d57-8be4-b65ad16e028a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6650671f-3703-4d57-8be4-b65ad16e028a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d3cefe3c-526c-486e-86a5-984ab9ee91ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d3cefe3c-526c-486e-86a5-984ab9ee91ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_f3be769b-8311-430b-9dcf-7ca3e2cca167" xlink:href="sny-20250630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_f3be769b-8311-430b-9dcf-7ca3e2cca167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_9f5c701e-49f1-4a63-82ed-533aee538579" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_9f5c701e-49f1-4a63-82ed-533aee538579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_cb67dce5-778d-42e6-98ed-338eaf5fc3ce" xlink:href="sny-20250630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_cb67dce5-778d-42e6-98ed-338eaf5fc3ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_3ee35030-313d-463c-8d40-f051ac97db9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_3ee35030-313d-463c-8d40-f051ac97db9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_56e7a3ae-c462-47f5-892b-d485201ccd40" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_b2509815-9bb9-4eda-925a-16aeff4732d8" xlink:to="loc_sny_OtherGainsLossesAndLitigation_56e7a3ae-c462-47f5-892b-d485201ccd40" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>sny-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20250630.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_0672e624-0f2e-450d-8a4f-9ee6db672e41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_EntitiesTable_0672e624-0f2e-450d-8a4f-9ee6db672e41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_168a4601-7365-4fab-aa43-6fd251be491c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentType_168a4601-7365-4fab-aa43-6fd251be491c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e5a6f666-4e70-4ac8-82dd-a995a8639524" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_EntityRegistrantName_e5a6f666-4e70-4ac8-82dd-a995a8639524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_14fc3f04-3e95-48ba-8989-6c2df7a7038d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_AmendmentFlag_14fc3f04-3e95-48ba-8989-6c2df7a7038d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3fed6721-bb75-4e97-9ce7-4dd69f18f9b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_EntityCentralIndexKey_3fed6721-bb75-4e97-9ce7-4dd69f18f9b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5a7b1a30-b2cb-4641-9382-f379ee1ac2d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5a7b1a30-b2cb-4641-9382-f379ee1ac2d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8a11ce83-d5b9-4886-b179-ee176a760a47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentPeriodEndDate_8a11ce83-d5b9-4886-b179-ee176a760a47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33315dba-9d34-47fb-8197-3e7930a0d619" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentFiscalYearFocus_33315dba-9d34-47fb-8197-3e7930a0d619" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9406e32c-c4ec-41a1-acac-3d3e7355cc01" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9406e32c-c4ec-41a1-acac-3d3e7355cc01" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_214fc50f-3b85-482e-8b50-8c8af8db3ecd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_214fc50f-3b85-482e-8b50-8c8af8db3ecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_01500599-9dab-42e0-9fb9-5eec0394e584" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_IssuedCapitalMember_01500599-9dab-42e0-9fb9-5eec0394e584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_63c9faf0-8bda-4b4a-8d03-12a8ffbbac01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_63c9faf0-8bda-4b4a-8d03-12a8ffbbac01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_5e686308-b618-474c-b01d-017ea03cd6a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_TreasurySharesMember_5e686308-b618-474c-b01d-017ea03cd6a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_7a9c5ee3-d29a-45f8-90e1-1f5546b22d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_RetainedEarningsMember_7a9c5ee3-d29a-45f8-90e1-1f5546b22d3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_29ecc91d-4167-4a50-b9ae-13376bcd07c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_29ecc91d-4167-4a50-b9ae-13376bcd07c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4fc091e-ad8d-4fb1-b93c-d8891c4119f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4fc091e-ad8d-4fb1-b93c-d8891c4119f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_e18d3b72-2a3c-4d80-92b1-fb68b29617a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_e18d3b72-2a3c-4d80-92b1-fb68b29617a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_fb915436-1f9e-4e2e-b1ae-09a74a97275c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_Equity_fb915436-1f9e-4e2e-b1ae-09a74a97275c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_fdcff009-e88a-4eb7-a3f2-988361a69738" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_fdcff009-e88a-4eb7-a3f2-988361a69738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_11db47b9-20b3-456e-8b9e-2b90c8f3d1a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ProfitLoss_11db47b9-20b3-456e-8b9e-2b90c8f3d1a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_2b2f463a-6057-4cb5-b010-32360369a645" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ComprehensiveIncome_2b2f463a-6057-4cb5-b010-32360369a645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_35781e23-620d-4e47-b00f-81f2b1ee691c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_35781e23-620d-4e47-b00f-81f2b1ee691c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_729ef720-64cb-4566-bb16-d4d9c44bb5ba" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_729ef720-64cb-4566-bb16-d4d9c44bb5ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_f7796c77-b427-4ad7-b7a5-82176fd7496a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_f7796c77-b427-4ad7-b7a5-82176fd7496a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_3056ef6e-42bb-4d59-9ec3-1f42eef1802b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_3056ef6e-42bb-4d59-9ec3-1f42eef1802b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_34a6947d-07a9-49c1-8839-d28a2b8a52dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_34a6947d-07a9-49c1-8839-d28a2b8a52dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:href="sny-20250630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1a5562d0-49c7-42a6-acea-c00c670330f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1a5562d0-49c7-42a6-acea-c00c670330f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1fe26c94-22eb-4347-91a7-c300a682f00e" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1fe26c94-22eb-4347-91a7-c300a682f00e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_a24f3dd8-a172-43c9-a9ff-272b2f37714f" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_a24f3dd8-a172-43c9-a9ff-272b2f37714f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_38aba715-3e0e-468f-9751-a241ec86c156" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_38aba715-3e0e-468f-9751-a241ec86c156" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_9029f5df-1ecf-4359-af76-ef827babe534" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_9029f5df-1ecf-4359-af76-ef827babe534" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_142885f0-305a-4fe6-9090-5d5fca8da0d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_142885f0-305a-4fe6-9090-5d5fca8da0d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_625cd880-8297-43f3-8ff9-0c3d83fa7981" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_625cd880-8297-43f3-8ff9-0c3d83fa7981" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_9115cf4b-0dd2-4e7e-a6c6-b0601b608670" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_9115cf4b-0dd2-4e7e-a6c6-b0601b608670" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_16b768aa-a02c-4437-8b35-71da9cf50f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_53a6f157-095d-4b8d-ae44-1dcbc03f1835" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_53a6f157-095d-4b8d-ae44-1dcbc03f1835" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofChangesinEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e718814e-99ec-4fab-8974-9e3ec90e7221_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e718814e-99ec-4fab-8974-9e3ec90e7221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_6959c97b-a826-4f75-a07b-d8ec216c370b" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:to="loc_sny_EuroapiMember_6959c97b-a826-4f75-a07b-d8ec216c370b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_a2507fbc-313f-4451-a4b1-ff6d159da920_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_a2507fbc-313f-4451-a4b1-ff6d159da920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_bdf78535-f69c-4904-abf8-c82048735141" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_bdf78535-f69c-4904-abf8-c82048735141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_8ccc7149-1aea-47c1-88ad-739f5092cafa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_IssuedCapitalMember_8ccc7149-1aea-47c1-88ad-739f5092cafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_a14a434b-82db-47ec-b916-319cfdc2ebc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_RetainedEarningsMember_a14a434b-82db-47ec-b916-319cfdc2ebc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_43a2481e-dcb1-4db6-bcf1-d1129d1dec4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_TreasurySharesMember_43a2481e-dcb1-4db6-bcf1-d1129d1dec4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_7d8fe56c-064d-416f-8759-412851b8e1b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_7d8fe56c-064d-416f-8759-412851b8e1b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_2c2d8e69-a13c-4a88-a684-9d38f42fa912" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_2c2d8e69-a13c-4a88-a684-9d38f42fa912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_05a862cc-1e66-4d61-8a75-c82e5b90f54d" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_05a862cc-1e66-4d61-8a75-c82e5b90f54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_ac64832b-cae0-492b-afca-05d9caaff597" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_ac64832b-cae0-492b-afca-05d9caaff597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_0920935e-63a6-4292-9b0f-ffd47ad87185" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_0920935e-63a6-4292-9b0f-ffd47ad87185" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations_7b2dde19-966a-4842-927f-9deab3a09a4b" xlink:href="sny-20250630.xsd#sny_TaxesOnShareCancellations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_sny_TaxesOnShareCancellations_7b2dde19-966a-4842-927f-9deab3a09a4b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_befc1c5c-693e-4917-9282-1a742578fe1a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_befc1c5c-693e-4917-9282-1a742578fe1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_79d8fd7d-4922-4f52-9a0e-9e1d191a1c66" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_79d8fd7d-4922-4f52-9a0e-9e1d191a1c66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_665a8432-2202-4812-bd7d-7fe52b123a8e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_665a8432-2202-4812-bd7d-7fe52b123a8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_da1bb191-3e37-45d7-b21c-1bc5b0bb9f13" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:to="loc_sny_OpellaMember_da1bb191-3e37-45d7-b21c-1bc5b0bb9f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_34cb1e33-afab-4247-9962-8dfbb64f277f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_34cb1e33-afab-4247-9962-8dfbb64f277f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_32ca314a-9d2f-4ae8-bfde-aad42f69d9c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_32ca314a-9d2f-4ae8-bfde-aad42f69d9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_473adec6-2c31-4bbc-893e-53b5aa5499be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_473adec6-2c31-4bbc-893e-53b5aa5499be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_aca9fa52-ee87-4345-ada7-361c2fb73bd4" xlink:href="sny-20250630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_aca9fa52-ee87-4345-ada7-361c2fb73bd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_4e43992b-7a05-4d4b-a4b6-8d4995ae4c04" xlink:href="sny-20250630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_4e43992b-7a05-4d4b-a4b6-8d4995ae4c04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_08f42e9a-8e47-4eba-9655-77a765c23e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_08f42e9a-8e47-4eba-9655-77a765c23e4d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:to="loc_ifrs-full_GeographicalAreasDomain_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:to="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_f79480a8-da7a-49d9-9c18-3ffeaa0cf27e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:to="loc_country_AR_f79480a8-da7a-49d9-9c18-3ffeaa0cf27e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_03073710-8cd8-4179-941b-6b1a7852930e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:to="loc_country_TR_03073710-8cd8-4179-941b-6b1a7852930e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_c4f1b048-ef40-4fec-a8fc-709e701b454d_default" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:to="loc_sny_TypesOfAgreementDomain_c4f1b048-ef40-4fec-a8fc-709e701b454d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:to="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_49c6cc2c-428a-4884-89cd-b609bfd429de" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_49c6cc2c-428a-4884-89cd-b609bfd429de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:to="loc_ifrs-full_CounterpartiesDomain_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:to="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_d9d54a84-246c-46d3-9739-4054da0f49b8" xlink:href="sny-20250630.xsd#sny_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:to="loc_sny_USGovernmentMember_d9d54a84-246c-46d3-9739-4054da0f49b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_840ad324-cece-40c3-bcc0-5a8a2c7ad18f" xlink:href="sny-20250630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_840ad324-cece-40c3-bcc0-5a8a2c7ad18f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_ff9b4264-fcda-4831-bb0c-899475b21fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_ifrs-full_CurrentContractLiabilities_ff9b4264-fcda-4831-bb0c-899475b21fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_5f55c610-fc6f-46ab-860b-d4e280e09f7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_ifrs-full_OtherRevenue_5f55c610-fc6f-46ab-860b-d4e280e09f7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_f653c7de-7661-4bfa-8799-2c0669cac1dc" xlink:href="sny-20250630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_f653c7de-7661-4bfa-8799-2c0669cac1dc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_0035ebab-9864-4864-9299-4f8b83c7494d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_0035ebab-9864-4864-9299-4f8b83c7494d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_fdd8d4e4-7126-4a36-bcfb-2cc953f85518" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:to="loc_sny_ProventionBioIncMember_fdd8d4e4-7126-4a36-bcfb-2cc953f85518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_a629f655-5483-4557-a642-e57f1f28dfae" xlink:href="sny-20250630.xsd#sny_InhibrxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:to="loc_sny_InhibrxIncMember_a629f655-5483-4557-a642-e57f1f28dfae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_83e90329-cac4-4c0b-8b36-c106f37c3917_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_83e90329-cac4-4c0b-8b36-c106f37c3917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_c07938d4-b106-43a3-b0cb-6ea7a6e12ab2" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:to="loc_sny_ProventionBioIncMember_c07938d4-b106-43a3-b0cb-6ea7a6e12ab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_878f4354-382e-442c-8c8c-7a9295701ccb_default" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:to="loc_sny_AssetsAcquisitionDomain_878f4354-382e-442c-8c8c-7a9295701ccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:to="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_fb5e9b74-501f-4ef5-a7ca-6346cb88c2d8" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_AssetsAcquisitionMember_fb5e9b74-501f-4ef5-a7ca-6346cb88c2d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VigilNeuroscienceIncMember_0407a594-42a7-4eac-b122-0b27cb34a123" xlink:href="sny-20250630.xsd#sny_VigilNeuroscienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_VigilNeuroscienceIncMember_0407a594-42a7-4eac-b122-0b27cb34a123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlueprintMedicinesCorporationMember_f8c0b090-cf25-4739-b75e-c73aa091c675" xlink:href="sny-20250630.xsd#sny_BlueprintMedicinesCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_BlueprintMedicinesCorporationMember_f8c0b090-cf25-4739-b75e-c73aa091c675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_ca43f5d7-2b88-4a92-be05-922d556425d8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_ca43f5d7-2b88-4a92-be05-922d556425d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_03f93175-0efb-47d2-9b40-bb7dad8583f7" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:to="loc_sny_OpellaMember_03f93175-0efb-47d2-9b40-bb7dad8583f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_2e376553-cd07-4d46-a480-5c7132d9bff9" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:to="loc_sny_OpellaBusinessMember_2e376553-cd07-4d46-a480-5c7132d9bff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_acb07682-5eb8-4113-a81d-b40a04083b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_CashTransferred_acb07682-5eb8-4113-a81d-b40a04083b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_120786e6-8378-460c-9c65-8e3172ec8a85" xlink:href="sny-20250630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_120786e6-8378-460c-9c65-8e3172ec8a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_49e2bcff-6599-4348-8b3f-72a5288c3f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_49e2bcff-6599-4348-8b3f-72a5288c3f0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_a6d6761c-b877-4537-9dc0-a8dcb2e13499" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_a6d6761c-b877-4537-9dc0-a8dcb2e13499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_8e0654c8-47f6-4393-9104-c55c7cffc9ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_8e0654c8-47f6-4393-9104-c55c7cffc9ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_e50224a6-c025-4df7-9d26-ec3d831be472" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_e50224a6-c025-4df7-9d26-ec3d831be472" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue_0d8d5a97-be55-43eb-907b-03b32c836a9e" xlink:href="sny-20250630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_FutureRoyaltiesReceivableValue_0d8d5a97-be55-43eb-907b-03b32c836a9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d5aa5848-d8e1-4815-93ce-9d429f9fc53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d5aa5848-d8e1-4815-93ce-9d429f9fc53a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree_4c232715-2334-4862-8e30-53310c4ffe9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NameOfAcquiree_4c232715-2334-4862-8e30-53310c4ffe9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue_99faf94d-2661-4bf3-b8ae-c2215a79efff" xlink:href="sny-20250630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_BusinessCombinationNominalValue_99faf94d-2661-4bf3-b8ae-c2215a79efff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue_9d2d36e8-9465-438c-8739-bbd6e6b90ad8" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_AssetsAcquisitionNominalValue_9d2d36e8-9465-438c-8739-bbd6e6b90ad8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare_7fd749fb-df5c-4516-962a-89248c15e20a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_AssetsAcquisitionPurchasePricePerShare_7fd749fb-df5c-4516-962a-89248c15e20a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_2722b9b6-3c09-4708-b752-e65a87537004" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_2722b9b6-3c09-4708-b752-e65a87537004" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_c59d9526-6983-4070-93f0-5129d98be9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_c59d9526-6983-4070-93f0-5129d98be9cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_6ac111fc-348b-4127-a7c7-245956960751" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_6ac111fc-348b-4127-a7c7-245956960751" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfInvestmentsInEquityInstruments_99a8e02d-471e-414c-b7fc-d7604fb07fe0" xlink:href="sny-20250630.xsd#sny_FairValueOfInvestmentsInEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_FairValueOfInvestmentsInEquityInstruments_99a8e02d-471e-414c-b7fc-d7604fb07fe0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransactionCost_523bd537-9905-4fc5-a5d8-defc6b993744" xlink:href="sny-20250630.xsd#sny_TransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_TransactionCost_523bd537-9905-4fc5-a5d8-defc6b993744" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialFuturePayments_9c1abbc2-90f0-4c8d-9e89-86e4a960657c" xlink:href="sny-20250630.xsd#sny_PotentialFuturePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_PotentialFuturePayments_9c1abbc2-90f0-4c8d-9e89-86e4a960657c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_4464051f-ccd3-47f4-a5f8-25226f9436d7" xlink:href="sny-20250630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_4464051f-ccd3-47f4-a5f8-25226f9436d7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_84b31aba-eae6-44b8-a1dc-19e616530202" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_84b31aba-eae6-44b8-a1dc-19e616530202" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_5ff5d795-b4d2-4488-9abc-cf6131ccbad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_5ff5d795-b4d2-4488-9abc-cf6131ccbad9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsOfAcquirerPerShare_8c799562-9955-4766-a813-8748a437f459" xlink:href="sny-20250630.xsd#sny_EquityInterestsOfAcquirerPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_EquityInterestsOfAcquirerPerShare_8c799562-9955-4766-a813-8748a437f459" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredCashPayments_d489ba68-4cf8-4bec-9520-2f4f321617a6" xlink:href="sny-20250630.xsd#sny_DeferredCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_DeferredCashPayments_d489ba68-4cf8-4bec-9520-2f4f321617a6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_ed252044-4a1d-468d-83c5-e6b39fe4391c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_ed252044-4a1d-468d-83c5-e6b39fe4391c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashTransferredPerShare_84f2bd1b-7ac3-4b2b-a834-b8f3822559e9" xlink:href="sny-20250630.xsd#sny_CashTransferredPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_CashTransferredPerShare_84f2bd1b-7ac3-4b2b-a834-b8f3822559e9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_52c34ee9-f3c2-4285-9d12-7e11c32941a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_52c34ee9-f3c2-4285-9d12-7e11c32941a5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_0dbd7e86-60f6-4ac5-ac98-5340b87ea3b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NetAssetsLiabilities_0dbd7e86-60f6-4ac5-ac98-5340b87ea3b8" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6_default" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:to="loc_sny_PrincipalAlliancesDomain_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:to="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_1984029c-a8f8-4a06-9634-e838591ac256" xlink:href="sny-20250630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_1984029c-a8f8-4a06-9634-e838591ac256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_a5cd6eab-5405-4e60-ad91-36b9b266e785_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:to="loc_ifrs-full_CounterpartiesDomain_a5cd6eab-5405-4e60-ad91-36b9b266e785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:to="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_ef452047-61a8-4148-a708-128b72c2dbef" xlink:href="sny-20250630.xsd#sny_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:to="loc_sny_AstraZenecaMember_ef452047-61a8-4148-a708-128b72c2dbef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_6b5a5aaa-198d-45fb-9546-77ea24660269" xlink:href="sny-20250630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_6b5a5aaa-198d-45fb-9546-77ea24660269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_84ce19a6-098a-4b15-aa6f-3ba74484ad49_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:to="loc_ifrs-full_GeographicalAreasDomain_84ce19a6-098a-4b15-aa6f-3ba74484ad49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:to="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_92af1206-3901-4400-89ab-df436218e148" xlink:href="sny-20250630.xsd#sny_MajorTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:to="loc_sny_MajorTerritoriesMember_92af1206-3901-4400-89ab-df436218e148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_2ec4389f-5b9d-4cb7-b6b3-03cbf110b97d" xlink:href="sny-20250630.xsd#sny_OtherTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:to="loc_sny_OtherTerritoriesMember_2ec4389f-5b9d-4cb7-b6b3-03cbf110b97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_79158748-206a-451d-bcf9-32bc45013b0a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_79158748-206a-451d-bcf9-32bc45013b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_e286bdbb-7918-45e2-a3d0-832fd78e8836" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_e286bdbb-7918-45e2-a3d0-832fd78e8836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_41a9a0b4-c742-4e6a-854a-963519c61e49_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_41a9a0b4-c742-4e6a-854a-963519c61e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember_ad8f1a28-5233-4817-8cdc-2d027c5ea6d6" xlink:href="sny-20250630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:to="loc_sny_MajorFinancialLiabilityMember_ad8f1a28-5233-4817-8cdc-2d027c5ea6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_e6b1d536-3dd1-4ad3-82fd-9d27679b0ff1" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:to="loc_sny_OpellaBusinessMember_e6b1d536-3dd1-4ad3-82fd-9d27679b0ff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_67d3ab25-71a9-42bf-ac3d-7f068c8503b0" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_67d3ab25-71a9-42bf-ac3d-7f068c8503b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_6440ede8-92b3-4645-867b-5f02aa447584" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_6440ede8-92b3-4645-867b-5f02aa447584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_81e221cc-05f6-4070-a6f4-87a4023a9600" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_81e221cc-05f6-4070-a6f4-87a4023a9600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9c596413-1116-409e-ae2c-fc3ab608e5bb" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9c596413-1116-409e-ae2c-fc3ab608e5bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_be3fabf1-6502-41fd-8ed0-8a946901c13b" xlink:href="sny-20250630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_be3fabf1-6502-41fd-8ed0-8a946901c13b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_5b7a8117-8a9d-4573-87c6-1b5169e5a51e" xlink:href="sny-20250630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_5b7a8117-8a9d-4573-87c6-1b5169e5a51e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_3af9c329-3633-42e3-80af-af27445ca2d8" xlink:href="sny-20250630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_3af9c329-3633-42e3-80af-af27445ca2d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_eec6c616-f304-42fd-81b8-9c4e653a66c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_eec6c616-f304-42fd-81b8-9c4e653a66c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_d9d12d65-d017-4529-97db-fde8530d42bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_d9d12d65-d017-4529-97db-fde8530d42bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_b2e7dbc6-5882-4d5c-8e60-3b7d61dc8835" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_b2e7dbc6-5882-4d5c-8e60-3b7d61dc8835" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_6d52f6bc-d29b-4115-8b88-80d09aee6da0" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_6d52f6bc-d29b-4115-8b88-80d09aee6da0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_f527d166-b198-4c9a-8c67-516efe482d23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_f527d166-b198-4c9a-8c67-516efe482d23" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:to="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_665a0648-b8d7-48d3-9da8-d508e8430aa1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:to="loc_ifrs-full_SegmentsDomain_665a0648-b8d7-48d3-9da8-d508e8430aa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:to="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_4e1ab1c6-1ae8-4803-8319-cf08ce9ffbb0" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_BiopharmaSegmentMember_4e1ab1c6-1ae8-4803-8319-cf08ce9ffbb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_7c2c2737-da01-40ba-b4ce-ec4ca2ec9a09" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_7c2c2737-da01-40ba-b4ce-ec4ca2ec9a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_8b8e6e20-6125-43c5-8505-f9968d13907b" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_OpellaMember_8b8e6e20-6125-43c5-8505-f9968d13907b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_eaad79f2-b1a2-449a-a42c-92f1d4c43731_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_eaad79f2-b1a2-449a-a42c-92f1d4c43731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_53d46d88-df25-4edb-ab2c-d6e0356ef6a2" xlink:href="sny-20250630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:to="loc_sny_ManufacturingAndSupplyMember_53d46d88-df25-4edb-ab2c-d6e0356ef6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0d5e7cf9-f404-40d3-aeb2-ace2cdb612ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0d5e7cf9-f404-40d3-aeb2-ace2cdb612ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_bd20e792-af22-4cc9-93dc-d10f7ba3ccdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_bd20e792-af22-4cc9-93dc-d10f7ba3ccdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_e985553e-f24f-4272-a50c-0a7aa5b66eb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_ifrs-full_InterestCostsCapitalised_e985553e-f24f-4272-a50c-0a7aa5b66eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_7b631e3b-6f8c-4cb1-acd8-c693cf876855" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_sny_NumberOfOperatingSegments_7b631e3b-6f8c-4cb1-acd8-c693cf876855" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_db7cc7dd-e67e-4172-8a87-4a39121db564_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_db7cc7dd-e67e-4172-8a87-4a39121db564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_eb228925-d71b-4c50-ac56-5595fd130e82" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_eb228925-d71b-4c50-ac56-5595fd130e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_3290e0b1-e176-4fd9-90de-f93eb2bc1379" xlink:href="sny-20250630.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_MarketedProductsMember_3290e0b1-e176-4fd9-90de-f93eb2bc1379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_6aeb3fc5-2814-494e-9d62-2cf375826b74" xlink:href="sny-20250630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_TechnologicalPlatformsMember_6aeb3fc5-2814-494e-9d62-2cf375826b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_8bc05fa7-4231-4472-abc0-fadc41301692_default" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:to="loc_sny_PrincipalAlliancesDomain_8bc05fa7-4231-4472-abc0-fadc41301692_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:to="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_34476389-c066-49ea-9557-fb5fc5c33c9f" xlink:href="sny-20250630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:to="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_34476389-c066-49ea-9557-fb5fc5c33c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_174aa02f-72ff-403d-8d0c-10c1d73bfa5b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:to="loc_ifrs-full_CounterpartiesDomain_174aa02f-72ff-403d-8d0c-10c1d73bfa5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:to="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_f0c24697-d9f0-401e-962e-59fd576ef373" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:to="loc_sny_NovavaxMember_f0c24697-d9f0-401e-962e-59fd576ef373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7a32c5dd-5a6a-440f-8a1e-9bcd49d84fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_Goodwill_7a32c5dd-5a6a-440f-8a1e-9bcd49d84fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_436f7533-d7c7-4423-98c4-5826d65a2273" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_436f7533-d7c7-4423-98c4-5826d65a2273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec5d48d9-58f8-4583-b083-4bddcb700350" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec5d48d9-58f8-4583-b083-4bddcb700350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a411ced7-9b98-4c8a-9105-409c0f006515" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a411ced7-9b98-4c8a-9105-409c0f006515" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2f6376a3-566b-4071-8c97-fd51eb86aeef_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_2f6376a3-566b-4071-8c97-fd51eb86aeef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_8f8497e1-570a-4d4d-b09e-95dac947505b" xlink:href="sny-20250630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_8f8497e1-570a-4d4d-b09e-95dac947505b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:href="sny-20250630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_29afe0e4-f0a8-42ce-bb25-2b6f9624531c" xlink:href="sny-20250630.xsd#sny_AltuviiioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:to="loc_sny_AltuviiioMember_29afe0e4-f0a8-42ce-bb25-2b6f9624531c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_f966b258-4f2a-4a4a-8294-511abd8c8800" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_ifrs-full_ComputerSoftwareMember_f966b258-4f2a-4a4a-8294-511abd8c8800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_fbf50114-3879-437b-9d8f-b4bb83e62c87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_fbf50114-3879-437b-9d8f-b4bb83e62c87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_85aba08c-f414-4b37-91fd-e5c6a6e40aeb" xlink:href="sny-20250630.xsd#sny_AcquiredRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_AcquiredRDMember_85aba08c-f414-4b37-91fd-e5c6a6e40aeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_d3984450-422a-426a-b2f5-09b4c51d92be" xlink:href="sny-20250630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_d3984450-422a-426a-b2f5-09b4c51d92be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_efd69652-a4ab-41b6-88cc-696710db3b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_efd69652-a4ab-41b6-88cc-696710db3b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_80224f50-61f7-4544-baaf-8b8a2b1dd378_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:to="loc_ifrs-full_CarryingAmountMember_80224f50-61f7-4544-baaf-8b8a2b1dd378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:to="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d4a569e2-6dea-4343-b683-6ca37e3d83c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d4a569e2-6dea-4343-b683-6ca37e3d83c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_48061d55-06bb-4aaf-b581-b2040a630989" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_48061d55-06bb-4aaf-b581-b2040a630989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_e3a9727c-00c6-49a8-b218-df50b72e26c2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_e3a9727c-00c6-49a8-b218-df50b72e26c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_e79c6569-37f5-4c47-974a-dc4d5f2ca559" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:to="loc_sny_ProventionBioIncMember_e79c6569-37f5-4c47-974a-dc4d5f2ca559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_de39c171-d911-4549-a96a-dcee5d7ebe1e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:to="loc_ifrs-full_CounterpartiesDomain_de39c171-d911-4549-a96a-dcee5d7ebe1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:to="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_d1f8fa10-bbd8-4c91-88ed-e27ca64547e9" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:to="loc_sny_NovavaxMember_d1f8fa10-bbd8-4c91-88ed-e27ca64547e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_a69c79dc-927d-4e89-a837-6ee5d986b171" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_OtherIntangibleAssets_a69c79dc-927d-4e89-a837-6ee5d986b171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c36d3f2b-b2d4-459d-8420-f667418d7a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c36d3f2b-b2d4-459d-8420-f667418d7a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_6ec2cd19-4989-4c9d-b5c1-b3712d5cc5b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_6ec2cd19-4989-4c9d-b5c1-b3712d5cc5b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_d379f934-d6ff-4829-9eb4-477db070baca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_d379f934-d6ff-4829-9eb4-477db070baca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_133652e6-19bf-4a95-95c1-7ab2aed28f32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_133652e6-19bf-4a95-95c1-7ab2aed28f32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4dc78734-ed6e-4b1a-bef0-a7bec1008f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4dc78734-ed6e-4b1a-bef0-a7bec1008f83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b57ece84-4e5e-4fb4-bea5-b5fd442d0279" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b57ece84-4e5e-4fb4-bea5-b5fd442d0279" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_5790f65d-19b5-4c2b-8ef7-8a9177d702f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_5790f65d-19b5-4c2b-8ef7-8a9177d702f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_529ba38e-5321-4372-9fe7-41bc22ae073e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_529ba38e-5321-4372-9fe7-41bc22ae073e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_a3545238-986d-4f6e-9d07-2e5da1c867bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_a3545238-986d-4f6e-9d07-2e5da1c867bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_a483d6d5-0cd1-4cf6-90bd-1dc3cb96d0e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_a483d6d5-0cd1-4cf6-90bd-1dc3cb96d0e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_97561d0c-9b6d-4662-ab1c-65bb79449471" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_cc870c3c-ae3e-4ac7-9168-bc5fcf7ded4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_cc870c3c-ae3e-4ac7-9168-bc5fcf7ded4c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_1f0ad5e3-1817-4310-a99c-667cf0fce2c1" xlink:href="sny-20250630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_1f0ad5e3-1817-4310-a99c-667cf0fce2c1" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_97bf2e23-6ed6-49dd-94a9-3a7300557dc1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:to="loc_ifrs-full_JointVenturesDomain_97bf2e23-6ed6-49dd-94a9-3a7300557dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:to="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_89979bf0-a722-4800-a72a-7e347e1f2a2a" xlink:href="sny-20250630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_89979bf0-a722-4800-a72a-7e347e1f2a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_095bad19-9c88-4586-ad89-aa98c1cd2aa7" xlink:href="sny-20250630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_sny_MSPVaccineCompanyMember_095bad19-9c88-4586-ad89-aa98c1cd2aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_af33e7fc-6fd0-49d6-93ea-e270ddfe2926" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_af33e7fc-6fd0-49d6-93ea-e270ddfe2926" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f37157f2-0755-4cdc-af9a-4558b9c42acf_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:to="loc_dei_EntityDomain_f37157f2-0755-4cdc-af9a-4558b9c42acf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:to="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_588ac4b4-24f3-41bf-a302-899cdc16c549" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:to="loc_sny_EuroapiMember_588ac4b4-24f3-41bf-a302-899cdc16c549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_68ac8f98-bdc6-4221-964d-d9a155fd80fb" xlink:href="sny-20250630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:to="loc_sny_MSPVaccineCompanyMember_68ac8f98-bdc6-4221-964d-d9a155fd80fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_cf6972b7-4119-4d43-a774-2fc3f78ea84b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_cf6972b7-4119-4d43-a774-2fc3f78ea84b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f3a3072f-6992-4fd8-a8f4-fe389dcc2577" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:to="loc_sny_EuroapiMember_f3a3072f-6992-4fd8-a8f4-fe389dcc2577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_5250d236-9ded-4cdb-b2fe-e5898ed1cded" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:to="loc_sny_OpellaMember_5250d236-9ded-4cdb-b2fe-e5898ed1cded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f49c5b90-2248-424f-b86e-1b5fa097c326_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f49c5b90-2248-424f-b86e-1b5fa097c326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_96ac147d-7793-4bd4-9cce-61cc14d2ed40" xlink:href="sny-20250630.xsd#sny_MCMVaccineBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:to="loc_sny_MCMVaccineBVMember_96ac147d-7793-4bd4-9cce-61cc14d2ed40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_e4bb5412-df8a-47e2-98fb-74b38750672f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_e4bb5412-df8a-47e2-98fb-74b38750672f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_e484b457-c96a-42d3-8400-917a0dc0b5b2" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:to="loc_sny_AssociatesAndJointVenturesMember_e484b457-c96a-42d3-8400-917a0dc0b5b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_46b3261c-188f-46eb-a20d-9324a85dff9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_46b3261c-188f-46eb-a20d-9324a85dff9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_ced21079-f409-4e25-9ed8-7cd635329a58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_ced21079-f409-4e25-9ed8-7cd635329a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_44c48aa4-992f-4a99-a6f5-3362ef6ae83c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_44c48aa4-992f-4a99-a6f5-3362ef6ae83c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_b3c48cac-8243-486b-9375-f1d9ce2d881d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_b3c48cac-8243-486b-9375-f1d9ce2d881d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_1bd1aef0-6e04-48c5-8b16-457d916612c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_1bd1aef0-6e04-48c5-8b16-457d916612c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_9e2a79fb-8741-4a88-95ad-124beadab2c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_9e2a79fb-8741-4a88-95ad-124beadab2c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_6d6d709f-4ba2-4255-bde1-a8ae5361f46e" xlink:href="sny-20250630.xsd#sny_StockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_sny_StockPrice_6d6d709f-4ba2-4255-bde1-a8ae5361f46e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_fb130eed-dc58-491f-8c61-59ac37d05025" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_fb130eed-dc58-491f-8c61-59ac37d05025" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_c544403f-48d0-4cd1-bf5d-f52fe56ade89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_SubordinatedLiabilities_c544403f-48d0-4cd1-bf5d-f52fe56ade89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_afdb8651-2e5d-4829-a591-8eda5037062c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_afdb8651-2e5d-4829-a591-8eda5037062c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates_d09c8e33-2b9a-44a4-b20d-6fb0c7b2525e" xlink:href="sny-20250630.xsd#sny_LoansToAssociates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_sny_LoansToAssociates_d09c8e33-2b9a-44a4-b20d-6fb0c7b2525e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_1212d925-7548-4c2f-b65c-b9ee98391f70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_1212d925-7548-4c2f-b65c-b9ee98391f70" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_32b05a9a-ead2-44f8-9d0c-44efbce937ae_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_32b05a9a-ead2-44f8-9d0c-44efbce937ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_7da2e7ef-fd9f-4209-a968-6065fc39b407" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:to="loc_sny_AssociatesAndJointVenturesMember_7da2e7ef-fd9f-4209-a968-6065fc39b407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_757804d5-3119-4678-93ea-cba6aa3508c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_757804d5-3119-4678-93ea-cba6aa3508c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_f37113d6-a5a8-4769-bf8a-9a67bee98aaa" xlink:href="sny-20250630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_f37113d6-a5a8-4769-bf8a-9a67bee98aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_b166cc61-2d5b-4e09-bdaa-38ed766cb1bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_b166cc61-2d5b-4e09-bdaa-38ed766cb1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions_39158c7a-c717-43ae-b516-93f516286a27" xlink:href="sny-20250630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_OtherAssetsRelatedPartyTransactions_39158c7a-c717-43ae-b516-93f516286a27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_68d3af72-5327-4383-8206-9d7c64779800" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_68d3af72-5327-4383-8206-9d7c64779800" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_c84e1b81-7a9b-4015-b8db-5a4dd743c149" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_c84e1b81-7a9b-4015-b8db-5a4dd743c149" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_8ebca5c2-a203-4fa9-a575-b7efcf4e846e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_SubordinatedLiabilities_8ebca5c2-a203-4fa9-a575-b7efcf4e846e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions_659b2d72-690e-4528-9f2e-f45f48f97c59" xlink:href="sny-20250630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_SubordinateHybridBondRelatedPartyTransactions_659b2d72-690e-4528-9f2e-f45f48f97c59" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_f298b39b-47e1-4346-a08e-226bb059e714_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_f298b39b-47e1-4346-a08e-226bb059e714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_f43b0ff4-980b-4597-b154-2b7ed88b7fb8" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:to="loc_sny_AssociatesAndJointVenturesMember_f43b0ff4-980b-4597-b154-2b7ed88b7fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_2ec913b4-77ed-4739-9bf0-b3f759d9e4f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_2ec913b4-77ed-4739-9bf0-b3f759d9e4f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_94314bf3-4014-4e16-a601-6dd475722ed3" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_94314bf3-4014-4e16-a601-6dd475722ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_0a19088f-ac39-4a65-a161-88860ae4f8a3" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_0a19088f-ac39-4a65-a161-88860ae4f8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_e800e3af-4e43-449f-ba7e-303e369b5548" xlink:href="sny-20250630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_e800e3af-4e43-449f-ba7e-303e369b5548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions_6c6b20f3-3146-49fb-b2a9-f6f829c94b93" xlink:href="sny-20250630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_CurrentAssetsRelatedPartyTransactions_6c6b20f3-3146-49fb-b2a9-f6f829c94b93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions_7acdbe56-9ca2-4629-ae78-3deacd568da1" xlink:href="sny-20250630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_AssetsRelatedPartyTransactions_7acdbe56-9ca2-4629-ae78-3deacd568da1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_3635cc1f-ff34-4cb3-befc-a89164e0dd9d" xlink:href="sny-20250630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_3635cc1f-ff34-4cb3-befc-a89164e0dd9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_0ab0b139-35d5-446c-8279-32e13b159397" xlink:href="sny-20250630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_0ab0b139-35d5-446c-8279-32e13b159397" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_84046a15-17cd-4aa4-b2f8-d49dec5a87c4" xlink:href="sny-20250630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityRelatedPartyTransactions_84046a15-17cd-4aa4-b2f8-d49dec5a87c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_4ce8e03b-38bd-47f7-9645-8f307e25ae36" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_4ce8e03b-38bd-47f7-9645-8f307e25ae36" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_372734bf-f125-48e9-92f1-959df46faf3d" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_372734bf-f125-48e9-92f1-959df46faf3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_bc5d79bc-0bca-4646-b789-17438c1c08fd" xlink:href="sny-20250630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_LiabilitiesRelatedPartyTransactions_bc5d79bc-0bca-4646-b789-17438c1c08fd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions_77a92741-53f2-49ed-8684-c125058a40a7" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NonCurrentAssetsRelatedPartyTransactions_77a92741-53f2-49ed-8684-c125058a40a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures_567944cd-bf00-45a1-bff0-d290caf0a45d" xlink:href="sny-20250630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NetIncomeRelatedPartyDisclosures_567944cd-bf00-45a1-bff0-d290caf0a45d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_484a48ce-a831-4cbf-bb57-cfcae83fbbab" xlink:href="sny-20250630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_484a48ce-a831-4cbf-bb57-cfcae83fbbab" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_3ab2b13b-153b-4db3-947d-2c618dd2e15d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_3ab2b13b-153b-4db3-947d-2c618dd2e15d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_6ae738c8-608e-4f9e-b9c3-19f2d543528e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_6ae738c8-608e-4f9e-b9c3-19f2d543528e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_08c4d905-8f38-450d-a925-e22abb4f3a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:to="loc_ifrs-full_DebtSecuritiesMember_08c4d905-8f38-450d-a925-e22abb4f3a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_42925cde-3bca-4c3b-97e8-559c995e361d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_42925cde-3bca-4c3b-97e8-559c995e361d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_2a788830-d8c4-4167-847c-22937520f393" xlink:href="sny-20250630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_2a788830-d8c4-4167-847c-22937520f393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_13860fff-c3a5-4dc0-b7b2-8160355576c7" xlink:href="sny-20250630.xsd#sny_PreFundedPensionObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_PreFundedPensionObligations_13860fff-c3a5-4dc0-b7b2-8160355576c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_990fa71d-785a-4454-94a1-9d07ddafeca1" xlink:href="sny-20250630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_LongTermPrepaidExpenses_990fa71d-785a-4454-94a1-9d07ddafeca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_5ad51722-69fb-4688-8ca5-df9f402fb988" xlink:href="sny-20250630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_NonCurrentLoansAndReceivables_5ad51722-69fb-4688-8ca5-df9f402fb988" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_658c9ca3-472d-40eb-b029-ad91999a06e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_658c9ca3-472d-40eb-b029-ad91999a06e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_752e0374-91df-413b-ba9d-3525b1b1d744" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_752e0374-91df-413b-ba9d-3525b1b1d744" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableSummaryofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:to="loc_ifrs-full_CarryingAmountMember_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:to="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_06498d61-5d37-44a3-9235-441d39ed2706" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_06498d61-5d37-44a3-9235-441d39ed2706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_22fa774c-9ba3-48bf-88df-f5cbbdb372a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_22fa774c-9ba3-48bf-88df-f5cbbdb372a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_0acf06f2-0abf-49b1-853b-71487a244df3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:to="loc_ifrs-full_CurrentTradeReceivables_0acf06f2-0abf-49b1-853b-71487a244df3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:to="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_3c26fdf9-3dd6-445a-9845-a130c7d6689e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:to="loc_ifrs-full_MaturityDomain_3c26fdf9-3dd6-445a-9845-a130c7d6689e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:to="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_12b84da8-793d-447e-a6ad-9b1f68c15638" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_12b84da8-793d-447e-a6ad-9b1f68c15638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_c72393b4-a39f-493d-bfe1-938ef1219b1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_c72393b4-a39f-493d-bfe1-938ef1219b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a21f4c88-3540-4a5e-b1b4-39f0f59f7ae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a21f4c88-3540-4a5e-b1b4-39f0f59f7ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_bf2b767d-c7ac-4bc8-87a4-ea11f437909c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_bf2b767d-c7ac-4bc8-87a4-ea11f437909c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_59d173cf-dd44-44fb-9125-9709dea71b48" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanOneYearMember_59d173cf-dd44-44fb-9125-9709dea71b48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_6c583a1f-6312-411c-9f50-96a5f3498dba" xlink:href="sny-20250630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:to="loc_sny_OverdueReceivablesGrossValue_6c583a1f-6312-411c-9f50-96a5f3498dba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_94505854-c113-43e1-b3f9-fc931f5d7168_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_94505854-c113-43e1-b3f9-fc931f5d7168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4995c15c-c98f-44f6-91a3-3b65d3e8bba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:to="loc_ifrs-full_IssuedCapitalMember_4995c15c-c98f-44f6-91a3-3b65d3e8bba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_fbc7109f-683e-4ccc-8229-2940cf331d5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_fbc7109f-683e-4ccc-8229-2940cf331d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99f3f145-7943-4b27-be9d-19c469ad9624_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:to="loc_dei_EntityDomain_99f3f145-7943-4b27-be9d-19c469ad9624_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:to="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_71087e4f-ec90-437e-bcd4-d7acc2818f74" xlink:href="sny-20250630.xsd#sny_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:to="loc_sny_SanofiMember_71087e4f-ec90-437e-bcd4-d7acc2818f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:href="sny-20250630.xsd#sny_ShareProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_0b520109-5430-4105-8f0e-0a8ffd746cc4_default" xlink:href="sny-20250630.xsd#sny_ShareProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:to="loc_sny_ShareProgramDomain_0b520109-5430-4105-8f0e-0a8ffd746cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:href="sny-20250630.xsd#sny_ShareProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:to="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_99671434-ac8b-4d0f-8114-62d47f80be8b" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_99671434-ac8b-4d0f-8114-62d47f80be8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_28815b68-aad1-484e-8d28-284aa4f16a30" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_28815b68-aad1-484e-8d28-284aa4f16a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember_86297874-a2c9-49f6-b6a2-6978de8929cd" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2024ProgramMember_86297874-a2c9-49f6-b6a2-6978de8929cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember_bd319370-361e-4756-a167-ac76f1318fdf" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2025ProgramMember_bd319370-361e-4756-a167-ac76f1318fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ce065e23-ded7-4791-837e-15c1fac27387_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ce065e23-ded7-4791-837e-15c1fac27387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_ff59e156-4127-4432-9832-a4c1dd06cfe7" xlink:href="sny-20250630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_ff59e156-4127-4432-9832-a4c1dd06cfe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_7bb93a28-1fa5-4f38-97db-92ad19e34e60_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_7bb93a28-1fa5-4f38-97db-92ad19e34e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_15b78d2a-b136-4964-b491-76c6582e8ce1" xlink:href="sny-20250630.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_DebtInstrumentsMember_15b78d2a-b136-4964-b491-76c6582e8ce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_68106fd7-a902-4a6b-9f33-8e8b538b31ff" xlink:href="sny-20250630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_68106fd7-a902-4a6b-9f33-8e8b538b31ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_68cda4d2-15b7-42b7-af32-9cfb0ea8783b" xlink:href="sny-20250630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_ForeignCurrencyTranslationMember_68cda4d2-15b7-42b7-af32-9cfb0ea8783b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_fa742464-642b-4761-b741-92838b20d700_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_fa742464-642b-4761-b741-92838b20d700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_4447e423-7c9d-410f-83aa-efa1de22ff9e" xlink:href="sny-20250630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_4447e423-7c9d-410f-83aa-efa1de22ff9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_0c50fcab-ee47-4706-ba79-ca6a4c9c48c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_IssuedCapital_0c50fcab-ee47-4706-ba79-ca6a4c9c48c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_809826ae-375e-4ce3-94c7-a299bd33cded" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_NumberOfSharesIssued_809826ae-375e-4ce3-94c7-a299bd33cded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_55996101-ee83-463a-aaf1-618f27c1f437" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_ParValuePerShare_55996101-ee83-463a-aaf1-618f27c1f437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_442455b8-ff1a-49a0-afdb-e118c10ded78" xlink:href="sny-20250630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_442455b8-ff1a-49a0-afdb-e118c10ded78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_ea17a64b-a2f6-49e0-a77a-5943440021d8" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_ea17a64b-a2f6-49e0-a77a-5943440021d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_1ddf5c70-76e6-401e-8cdb-d2a870d3cffb" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_1ddf5c70-76e6-401e-8cdb-d2a870d3cffb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted_b380a361-9b18-4840-a0a7-9f6e2e669d96" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesAlloted_b380a361-9b18-4840-a0a7-9f6e2e669d96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_0e6e65f6-d435-4eca-93b9-46d3e5cfa533" xlink:href="sny-20250630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_0e6e65f6-d435-4eca-93b9-46d3e5cfa533" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_92c69232-38eb-4d69-8276-4cd4bf14908e" xlink:href="sny-20250630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesRepurchased_92c69232-38eb-4d69-8276-4cd4bf14908e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_abac8f13-b579-4097-a3ff-e04501da2df0" xlink:href="sny-20250630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_AmountOfSharesRepurchased_abac8f13-b579-4097-a3ff-e04501da2df0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_f346b843-549e-4192-990b-863c8d06780a" xlink:href="sny-20250630.xsd#sny_SubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_SubscriptionPricePerShare_f346b843-549e-4192-990b-863c8d06780a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_dac74e75-7a25-493e-a611-fb97f697a660" xlink:href="sny-20250630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesSubscribed_dac74e75-7a25-493e-a611-fb97f697a660" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_e5b5d1d0-7694-45b7-9ced-2cb643c500a7" xlink:href="sny-20250630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_e5b5d1d0-7694-45b7-9ced-2cb643c500a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a3a216ae-3581-470f-9c3e-7b57b10d8bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a3a216ae-3581-470f-9c3e-7b57b10d8bbb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_7ac0486d-7e03-481c-acc6-9a5149ae43e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_7ac0486d-7e03-481c-acc6-9a5149ae43e4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_3bc3f658-7452-46d7-9e01-cfd6f7260848" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_3bc3f658-7452-46d7-9e01-cfd6f7260848" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b706207f-752d-4077-a255-d02127178ef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b706207f-752d-4077-a255-d02127178ef4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares_2e0e9c8f-7b7c-4a5f-975d-d3053c7aefb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_CancellationOfTreasuryShares_2e0e9c8f-7b7c-4a5f-975d-d3053c7aefb0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased_bf34e252-1325-463b-87a4-b04942b2dab9" xlink:href="sny-20250630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_PerShareValueOfSharesRepurchased_bf34e252-1325-463b-87a4-b04942b2dab9" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_65c3f1ab-e179-4bdb-9ed8-5b357259ce17_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_65c3f1ab-e179-4bdb-9ed8-5b357259ce17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_5aef147f-31e4-41bd-acaa-d975c6435728" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2023Member_5aef147f-31e4-41bd-acaa-d975c6435728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_d88d92c3-71ef-4830-9cf2-362d7b798b0a" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_d88d92c3-71ef-4830-9cf2-362d7b798b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_bbe4f0e9-c08f-4ff6-827c-ec30fdc755fa" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2024Member_bbe4f0e9-c08f-4ff6-827c-ec30fdc755fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_01559c81-f009-4136-a591-740eee5fbcb6" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_01559c81-f009-4136-a591-740eee5fbcb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_ae4a87e2-b376-4fc5-85b5-16ae4645cf79" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2025Member_ae4a87e2-b376-4fc5-85b5-16ae4645cf79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:href="sny-20250630.xsd#sny_MarketConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_8e2e7948-b17a-4992-b7ce-4d2781594d91_default" xlink:href="sny-20250630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:to="loc_sny_MarketConditionDomain_8e2e7948-b17a-4992-b7ce-4d2781594d91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:href="sny-20250630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:to="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_83dd5722-9b14-49f4-945f-886a3021e34b" xlink:href="sny-20250630.xsd#sny_WithoutMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:to="loc_sny_WithoutMarketConditionMember_83dd5722-9b14-49f4-945f-886a3021e34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_3de71f98-14e7-476b-a148-050fbc871935" xlink:href="sny-20250630.xsd#sny_WithMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:to="loc_sny_WithMarketConditionMember_3de71f98-14e7-476b-a148-050fbc871935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_85e2ddb8-9d0d-49e5-872b-d5c90b524219" xlink:href="sny-20250630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_85e2ddb8-9d0d-49e5-872b-d5c90b524219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_2cfdc032-1914-4baf-8971-31d9a7ccd6cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:to="loc_srt_ChiefExecutiveOfficerMember_2cfdc032-1914-4baf-8971-31d9a7ccd6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_32575934-5d97-4dcf-b6b8-6b76d30975e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_32575934-5d97-4dcf-b6b8-6b76d30975e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_2a1ec2f3-f0ed-4763-95f9-83e01f7c9cb6" xlink:href="sny-20250630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_2a1ec2f3-f0ed-4763-95f9-83e01f7c9cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_65dcc024-99a3-4068-a5fd-3cf1978871f3" xlink:href="sny-20250630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_65dcc024-99a3-4068-a5fd-3cf1978871f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_4d47661b-33a7-4ef2-86f4-d056c8f0edb9" xlink:href="sny-20250630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_NumberOfYearsServicePeriod_4d47661b-33a7-4ef2-86f4-d056c8f0edb9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5badf5f3-42a3-4a03-af90-49b99e174aa3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5badf5f3-42a3-4a03-af90-49b99e174aa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:href="sny-20250630.xsd#sny_RestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_646610e1-5fa0-4bfe-ad2e-0e98313f0c28" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2023Member_646610e1-5fa0-4bfe-ad2e-0e98313f0c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_b80e985b-7c99-4485-8199-7a2f0a1b601e" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2022Member_b80e985b-7c99-4485-8199-7a2f0a1b601e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_f0e97d48-8cad-47fa-ba1d-070606cad99c" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2021Member_f0e97d48-8cad-47fa-ba1d-070606cad99c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_8aad7fe1-16f6-4a65-9ff2-40099dc5e8ac" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2020Member_8aad7fe1-16f6-4a65-9ff2-40099dc5e8ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_c9d4c47b-647a-4075-9f7f-edf8053f0ddb" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharePlan2024Member_c9d4c47b-647a-4075-9f7f-edf8053f0ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_ab56dabc-3a14-4650-8416-922fedfbb851" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharePlan2025Member_ab56dabc-3a14-4650-8416-922fedfbb851" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e012fbf2-72ec-42fc-b3e8-e8f5f572ba95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e012fbf2-72ec-42fc-b3e8-e8f5f572ba95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_74788917-730a-4c92-b6cb-ab956f3a501d" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_74788917-730a-4c92-b6cb-ab956f3a501d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_08586a36-d0fa-46f9-8af9-ccb1cb23ff75_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:to="loc_ifrs-full_RangeDomain_08586a36-d0fa-46f9-8af9-ccb1cb23ff75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:to="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_a1a294a4-9cf2-4958-9dd6-5cf7c020085d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:to="loc_ifrs-full_BottomOfRangeMember_a1a294a4-9cf2-4958-9dd6-5cf7c020085d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_06b6a693-0ab8-49ed-a6a6-b93f88c477ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:to="loc_ifrs-full_TopOfRangeMember_06b6a693-0ab8-49ed-a6a6-b93f88c477ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_b03720fb-2471-4e44-bbfb-92879394b188_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_b03720fb-2471-4e44-bbfb-92879394b188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_fbf4924e-708e-467c-be1f-84a0905c5a95" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeTwoMember_fbf4924e-708e-467c-be1f-84a0905c5a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_26cfa74d-6ee1-43f6-9ef4-fea9a04dded2" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeThreeMember_26cfa74d-6ee1-43f6-9ef4-fea9a04dded2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_aba1a7f5-1b1a-4264-be45-777b9a5c99f1" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeFourMember_aba1a7f5-1b1a-4264-be45-777b9a5c99f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_402dab1d-af3e-4429-9462-87d2554e093a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_402dab1d-af3e-4429-9462-87d2554e093a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_92756174-2bae-4c52-b4bd-4c3f8536ea0b" xlink:href="sny-20250630.xsd#sny_StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:to="loc_sny_StockOptionPlanMember_92756174-2bae-4c52-b4bd-4c3f8536ea0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35504ab8-862d-4c80-b007-afc7341a1a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35504ab8-862d-4c80-b007-afc7341a1a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_947d6c19-9715-4222-adc0-e1100735ee5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_947d6c19-9715-4222-adc0-e1100735ee5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1079ab00-c246-4743-9738-c1062faaa7f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1079ab00-c246-4743-9738-c1062faaa7f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_382538af-8c47-437d-b1cf-e0dccc400dd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_382538af-8c47-437d-b1cf-e0dccc400dd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3504c941-9dc1-4c19-92a0-571e6b72efc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3504c941-9dc1-4c19-92a0-571e6b72efc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_65d79443-0d75-4f9a-a4e9-5cafea409f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_65d79443-0d75-4f9a-a4e9-5cafea409f1d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_81d1493c-5d68-43a8-8347-b9b222137563_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_81d1493c-5d68-43a8-8347-b9b222137563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_9c5aab01-946b-4ec8-8c43-ae6e697f4853" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_9c5aab01-946b-4ec8-8c43-ae6e697f4853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_4826e588-a4f5-4747-87f4-834a21fafe4f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_4826e588-a4f5-4747-87f4-834a21fafe4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_5ade3b70-ae71-4910-a0bf-718b3c0b3006" xlink:href="sny-20250630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_5ade3b70-ae71-4910-a0bf-718b3c0b3006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_9efb883f-d28a-4e12-a96f-b8389fd7270d" xlink:href="sny-20250630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_9efb883f-d28a-4e12-a96f-b8389fd7270d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_9dcde02b-7732-4b06-b1dc-28309c42f6e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_9dcde02b-7732-4b06-b1dc-28309c42f6e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_20af1b5b-6b8e-4551-96c1-d1ea2b968f03" xlink:href="sny-20250630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_20af1b5b-6b8e-4551-96c1-d1ea2b968f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_67c9dc74-c63e-4615-8288-2da6b7fdca18" xlink:href="sny-20250630.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_DebtInstrumentsMember_67c9dc74-c63e-4615-8288-2da6b7fdca18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_27825a35-a0de-4451-b9d9-348810c5c72d" xlink:href="sny-20250630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_27825a35-a0de-4451-b9d9-348810c5c72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_0586bc6d-f596-4de1-befb-c274397d7312" xlink:href="sny-20250630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_ForeignCurrencyTranslationMember_0586bc6d-f596-4de1-befb-c274397d7312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_c24e375c-167b-42ed-a105-44a92a9246c7" xlink:href="sny-20250630.xsd#sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_c24e375c-167b-42ed-a105-44a92a9246c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c8497b9-1df1-4ef2-b217-70408d0daba6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c8497b9-1df1-4ef2-b217-70408d0daba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_b9d6ad81-3dcc-4a7e-a02b-5209b42befdf" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:to="loc_sny_EuroapiMember_b9d6ad81-3dcc-4a7e-a02b-5209b42befdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f5b0768f-5793-48d7-8725-e086422dcd3d" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f5b0768f-5793-48d7-8725-e086422dcd3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e3a59fdd-4313-4f55-8eca-6ccd63ebcc62" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e3a59fdd-4313-4f55-8eca-6ccd63ebcc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_679e90cf-23c1-4dfc-bf35-cd61b0db0922" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_679e90cf-23c1-4dfc-bf35-cd61b0db0922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9e1754ec-74d3-45b8-b624-fdd0ac5b5a3a" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9e1754ec-74d3-45b8-b624-fdd0ac5b5a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_a62cfb4a-04ba-49d7-8355-fcc15ed28e49" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_a62cfb4a-04ba-49d7-8355-fcc15ed28e49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_8f7060c0-599f-458f-9939-6bbe01acce19" xlink:href="sny-20250630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_8f7060c0-599f-458f-9939-6bbe01acce19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_32918977-084c-4cf3-8b96-a612dd8fea08" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_32918977-084c-4cf3-8b96-a612dd8fea08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_49af6090-ecc8-469b-8c40-d9066e0a9f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_49af6090-ecc8-469b-8c40-d9066e0a9f7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_ba9ec75a-5670-4420-a198-12e51943c5e8" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_ba9ec75a-5670-4420-a198-12e51943c5e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_c6c01722-0a21-400b-8c61-b35656440c4e" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_c6c01722-0a21-400b-8c61-b35656440c4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_d6a248ee-e2e5-4a6c-b027-b3afee192931" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_d6a248ee-e2e5-4a6c-b027-b3afee192931" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_83804225-e36a-4352-bb73-870af59bf3e7" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_83804225-e36a-4352-bb73-870af59bf3e7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_2a296562-08bb-44c0-90c0-df34400d0287" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_2a296562-08bb-44c0-90c0-df34400d0287" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_f9812e2d-5843-47cb-8115-2bd741ea6556" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_f9812e2d-5843-47cb-8115-2bd741ea6556" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_dbd1975c-99d4-40d5-95a8-f553ac330f89" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_dbd1975c-99d4-40d5-95a8-f553ac330f89" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_bdb903e9-49d1-4349-b4bb-fa0e7ca0d466" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_bdb903e9-49d1-4349-b4bb-fa0e7ca0d466" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_59c38f13-107c-408b-a706-6b8b14ec4507" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_59c38f13-107c-408b-a706-6b8b14ec4507" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_23de71d7-da30-48e7-a3d4-fb16a53e0bf6" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_23de71d7-da30-48e7-a3d4-fb16a53e0bf6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_01fc3057-0eab-489d-a97d-3508ca9af7cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_01fc3057-0eab-489d-a97d-3508ca9af7cc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ef367ef1-4c55-44d1-9679-d12d1505efe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ef367ef1-4c55-44d1-9679-d12d1505efe9" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:to="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_0ecdf79c-c109-47ce-aa31-9585ab026d66_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:to="loc_ifrs-full_MeasurementDomain_0ecdf79c-c109-47ce-aa31-9585ab026d66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:to="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_ed782704-1def-42fc-95c7-2a8c91c3fa9a" xlink:href="sny-20250630.xsd#sny_AmortizedCostNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_AmortizedCostNettingMember_ed782704-1def-42fc-95c7-2a8c91c3fa9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_894dd5a9-4d9d-419e-8981-fa35b62f625b" xlink:href="sny-20250630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_894dd5a9-4d9d-419e-8981-fa35b62f625b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_840d47d9-5d57-407f-afc4-122d2100af18" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_ValueOnRedemptionMember_840d47d9-5d57-407f-afc4-122d2100af18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_bba8557d-1dd0-4452-9b66-39c6bfdbb51f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_LongtermBorrowings_bba8557d-1dd0-4452-9b66-39c6bfdbb51f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0796443b-f3b7-4f0c-b98d-4af0fa3d80cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0796443b-f3b7-4f0c-b98d-4af0fa3d80cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_411815ae-3c7c-437c-995d-7902bda941c5" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_411815ae-3c7c-437c-995d-7902bda941c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_309dc37f-7b30-4ac3-8498-182ff68c555b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_Borrowings_309dc37f-7b30-4ac3-8498-182ff68c555b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_82b9268a-3013-43af-a1c8-c75b58771f38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_CashAndCashEquivalents_82b9268a-3013-43af-a1c8-c75b58771f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_baf12963-44fc-4ff4-a290-c7d981178e79" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_baf12963-44fc-4ff4-a290-c7d981178e79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_b7c30ffd-45f8-44ee-9b18-8d47ef3759d4" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_b7c30ffd-45f8-44ee-9b18-8d47ef3759d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_9c3c03d5-d9fd-413c-94e9-b4cd0a54792e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_LeaseLiabilities_9c3c03d5-d9fd-413c-94e9-b4cd0a54792e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_749dc644-8f87-4e83-8d9f-8c70fc24134e" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_OtherBankBorrowings_749dc644-8f87-4e83-8d9f-8c70fc24134e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_d2c05789-87a3-4f41-9554-ac9ab0a71d6f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:to="loc_ifrs-full_MeasurementDomain_d2c05789-87a3-4f41-9554-ac9ab0a71d6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:to="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_ce85de2e-b4d4-4d3b-86e0-f28620e12990" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:to="loc_sny_ValueOnRedemptionMember_ce85de2e-b4d4-4d3b-86e0-f28620e12990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesDomain_3ab1dfe3-1855-4958-8d12-f1c9462e6444_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesDomain_3ab1dfe3-1855-4958-8d12-f1c9462e6444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_4045995c-00a6-4de1-bcd7-9a7f334ac036" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:to="loc_sny_NonCurrentLiabilitiesMember_4045995c-00a6-4de1-bcd7-9a7f334ac036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_74d00630-fbda-4800-be06-b8f420a47a98" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:to="loc_sny_CurrentLiabilitiesMember_74d00630-fbda-4800-be06-b8f420a47a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_dca0a280-c1a3-47cc-ba0b-cd61420bf519_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_dca0a280-c1a3-47cc-ba0b-cd61420bf519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_71549695-4b5e-4048-b6ed-c147eed33062" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:to="loc_sny_NonCurrentAssetsMember_71549695-4b5e-4048-b6ed-c147eed33062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_c6ec32db-7b65-41ae-a03f-79582a2f675d" xlink:href="sny-20250630.xsd#sny_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:to="loc_sny_CurrentAssetsMember_c6ec32db-7b65-41ae-a03f-79582a2f675d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_e7797a3a-8fc4-4b72-884a-6254a02cae57" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_e7797a3a-8fc4-4b72-884a-6254a02cae57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_5c36713e-8b57-4adf-8b71-b1a342000661" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_5c36713e-8b57-4adf-8b71-b1a342000661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_7d556d68-4a4e-4367-8d43-8369b6537f98" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_BondsIssued_7d556d68-4a4e-4367-8d43-8369b6537f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_c414c80a-5aaf-4718-b9bb-c40b2d8faa5b" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_OtherBankBorrowings_c414c80a-5aaf-4718-b9bb-c40b2d8faa5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_23f5c6b8-3ab3-4776-b32a-81cc55739fbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_OtherBorrowings_23f5c6b8-3ab3-4776-b32a-81cc55739fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_3e69febc-d9ed-4a50-bfe4-66e8cbadb9d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_3e69febc-d9ed-4a50-bfe4-66e8cbadb9d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_e5666fdc-ef92-486d-ae45-ee00424a58e5" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_e5666fdc-ef92-486d-ae45-ee00424a58e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b9f4c34c-52a9-41b0-ba37-cd2ce10d6757" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_Borrowings_b9f4c34c-52a9-41b0-ba37-cd2ce10d6757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3631539d-c18b-414f-a369-9ea549bfc7c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3631539d-c18b-414f-a369-9ea549bfc7c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_4f11bed2-f943-43a3-b789-c5a2ecb22a53" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_4f11bed2-f943-43a3-b789-c5a2ecb22a53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_68463865-5870-4594-9c76-b39294891f4b" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_68463865-5870-4594-9c76-b39294891f4b" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_b5227ed4-6246-4449-8001-90de62f43851_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_b5227ed4-6246-4449-8001-90de62f43851_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_53ddde17-9e83-45b3-8cc5-25403248c414" xlink:href="sny-20250630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_53ddde17-9e83-45b3-8cc5-25403248c414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_434bc50a-daa7-48e6-a2d8-9de4a0e17577" xlink:href="sny-20250630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_434bc50a-daa7-48e6-a2d8-9de4a0e17577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember_6a7e7452-9aed-4316-98fc-c5a689fafda6" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityOneMember_6a7e7452-9aed-4316-98fc-c5a689fafda6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember_50c13ef4-4c75-43d9-9181-6ad43435e5c3" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityTwoMember_50c13ef4-4c75-43d9-9181-6ad43435e5c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_f2b35c8b-fd61-48e4-bb9a-a6d10ad12f66" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_f2b35c8b-fd61-48e4-bb9a-a6d10ad12f66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_7d4c11c4-68c5-4d4b-a174-3f27eb724ad5" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_7d4c11c4-68c5-4d4b-a174-3f27eb724ad5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_507721c5-6583-42d9-a1ce-588d24cab615" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_507721c5-6583-42d9-a1ce-588d24cab615" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6548412b-5e9c-4ffc-8b7f-5c03b29001c1" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6548412b-5e9c-4ffc-8b7f-5c03b29001c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member_dc1ce9fc-d602-4835-b572-14fecf1d3ad7" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FourBillionFacilityMaturingDecember2027Member_dc1ce9fc-d602-4835-b572-14fecf1d3ad7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2030Member_c95d6cbe-9113-4f87-831a-6fe689460c37" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingMarch2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FourBillionFacilityMaturingMarch2030Member_c95d6cbe-9113-4f87-831a-6fe689460c37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_a3694985-895c-4a23-9826-ffbda61f29e1" xlink:href="sny-20250630.xsd#sny_OneBillionFiftyMillionBondsMaturingApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_a3694985-895c-4a23-9826-ffbda61f29e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2020Member_200d17c5-403f-4b00-9205-13083ff04e49" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondIssueFromApril2020Member_200d17c5-403f-4b00-9205-13083ff04e49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2022Member_d3edc99d-acf6-4a45-90d2-0e5cf031f6d5" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondIssueFromApril2022Member_d3edc99d-acf6-4a45-90d2-0e5cf031f6d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_f004a20b-3f9b-41d6-9cbe-03c8e73aec89" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_f004a20b-3f9b-41d6-9cbe-03c8e73aec89" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2027Member_0a208447-1583-4b9d-91f9-7aba12769893" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2027Member_0a208447-1583-4b9d-91f9-7aba12769893" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2031Member_ca4c2a84-2e06-4e80-a242-12ab997e6f53" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2031Member_ca4c2a84-2e06-4e80-a242-12ab997e6f53" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingJune2029Member_1e720096-345f-4ef0-9f9e-76c0e0c96efe" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingJune2029Member_1e720096-345f-4ef0-9f9e-76c0e0c96efe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2032Member_e802388e-b275-4928-80be-8ab00a861c19" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2032Member_e802388e-b275-4928-80be-8ab00a861c19" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_c98faf60-3329-469f-a3fa-e8bf3bf8378c" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_c98faf60-3329-469f-a3fa-e8bf3bf8378c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:href="sny-20250630.xsd#sny_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_a2fa8c36-78a4-42f2-9312-8e8502d41828_default" xlink:href="sny-20250630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:to="loc_sny_DebtInstrumentDomain_a2fa8c36-78a4-42f2-9312-8e8502d41828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:href="sny-20250630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:to="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_28484c9e-7881-43b1-868d-bd5fd199d222" xlink:href="sny-20250630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_28484c9e-7881-43b1-868d-bd5fd199d222" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_43efe2fa-c394-4e9d-9535-34dd9eb577a2" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_43efe2fa-c394-4e9d-9535-34dd9eb577a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_891017a0-6cbf-460e-b3f3-5c7e90c0693e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:to="loc_ifrs-full_CounterpartiesDomain_891017a0-6cbf-460e-b3f3-5c7e90c0693e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:to="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_ee662c0e-d871-41cf-ba95-d2b44d12928a" xlink:href="sny-20250630.xsd#sny_MazeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:to="loc_sny_MazeTherapeuticsMember_ee662c0e-d871-41cf-ba95-d2b44d12928a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_5bfa6eea-8da7-4e92-8e93-c8292d4d329e" xlink:href="sny-20250630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_5bfa6eea-8da7-4e92-8e93-c8292d4d329e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_2aca6840-acfe-4796-bd1e-d4e0e896b98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_ifrs-full_NotionalAmount_2aca6840-acfe-4796-bd1e-d4e0e896b98a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_e6b9980a-ed39-4de5-bf34-947158268839" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_e6b9980a-ed39-4de5-bf34-947158268839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_76ea91ad-da40-41ce-b937-79efdcf62e36" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_76ea91ad-da40-41ce-b937-79efdcf62e36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_a9fe7f06-987c-4e34-8e55-13200d7ba589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_ifrs-full_CommercialPapersIssued_a9fe7f06-987c-4e34-8e55-13200d7ba589" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_bb8c24ca-8634-428f-b28f-fd755da07bd2" xlink:href="sny-20250630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_BorrowingAverageDrawdown_bb8c24ca-8634-428f-b28f-fd755da07bd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_ebe765e3-52f0-452b-857e-359c2efc0c1a" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_UpfrontPayments_ebe765e3-52f0-452b-857e-359c2efc0c1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches_07fcc45a-9440-416b-aeff-911d7dc80044" xlink:href="sny-20250630.xsd#sny_NumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_NumberOfTranches_07fcc45a-9440-416b-aeff-911d7dc80044" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:to="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_e0b5fe52-8bfb-4186-98ff-2e5de19f156a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:to="loc_ifrs-full_MeasurementDomain_e0b5fe52-8bfb-4186-98ff-2e5de19f156a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:to="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_1babb1bb-800c-4f2f-9fec-2e8b59e8c0e1" xlink:href="sny-20250630.xsd#sny_AtMarketValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:to="loc_sny_AtMarketValueMember_1babb1bb-800c-4f2f-9fec-2e8b59e8c0e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_090e5745-9337-4e3b-9def-9cafa579f163" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:to="loc_sny_ValueOnRedemptionMember_090e5745-9337-4e3b-9def-9cafa579f163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_cc053098-00af-4e83-9af2-9bbac87c4ccd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:to="loc_ifrs-full_Borrowings_cc053098-00af-4e83-9af2-9bbac87c4ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_9ee8cd34-c7f0-4d17-9a5f-0f2e33a4642e" xlink:href="sny-20250630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_9ee8cd34-c7f0-4d17-9a5f-0f2e33a4642e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_214df008-4ef9-4733-a20a-66a38969b4eb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:to="loc_ifrs-full_MeasurementDomain_214df008-4ef9-4733-a20a-66a38969b4eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:to="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_484f080b-161d-4f50-af32-425cf73eb184" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:to="loc_sny_AtNotionalAmountMember_484f080b-161d-4f50-af32-425cf73eb184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:to="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_5c8386a1-c531-4387-8aa4-597daac581af" xlink:href="sny-20250630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_5c8386a1-c531-4387-8aa4-597daac581af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_0f756767-f2d1-4127-954b-f3c8276befc4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_0f756767-f2d1-4127-954b-f3c8276befc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_9bd8dccb-1e0c-4174-8a45-46b629563cc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:to="loc_ifrs-full_CashFlowHedgesMember_9bd8dccb-1e0c-4174-8a45-46b629563cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_7f852eba-95bb-4b6a-9517-da45f9e3be57" xlink:href="sny-20250630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_7f852eba-95bb-4b6a-9517-da45f9e3be57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_febfedd4-06fb-450a-b268-e08bb524f496_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_febfedd4-06fb-450a-b268-e08bb524f496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_023ca5d7-73b1-4214-81fe-e1d3d43fbe20" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_023ca5d7-73b1-4214-81fe-e1d3d43fbe20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_58fd2c49-6962-4422-9183-2b4723816815" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_58fd2c49-6962-4422-9183-2b4723816815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_60918041-a9ab-49e8-8fec-3107b2c4391d" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_60918041-a9ab-49e8-8fec-3107b2c4391d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember_5057955b-cbb6-4088-a98b-666cde0e294e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInMexicanPesoMember_5057955b-cbb6-4088-a98b-666cde0e294e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_d8b3a41e-003f-46ef-ac04-af4b72e2dfb5" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_d8b3a41e-003f-46ef-ac04-af4b72e2dfb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_9510e440-cef8-496a-92a5-e1280499b6d9" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_9510e440-cef8-496a-92a5-e1280499b6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_a5337bb2-9024-43ea-8bf8-7d1c048ad853" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_a5337bb2-9024-43ea-8bf8-7d1c048ad853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_30a6503f-fb37-4ae7-8cc6-287f17c2f8ae" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_30a6503f-fb37-4ae7-8cc6-287f17c2f8ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_dbbf88ab-e34c-499a-8a0e-8342aa200731" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_dbbf88ab-e34c-499a-8a0e-8342aa200731" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_64bdfd13-236b-414e-8232-6cacff03ab1e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_64bdfd13-236b-414e-8232-6cacff03ab1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember_9ef2566c-5733-4b6d-ad69-e3d26238b69c" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencySalesInRussianRoubleMember_9ef2566c-5733-4b6d-ad69-e3d26238b69c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_ae0e6b0e-83fb-48bf-bf6c-b38722653cf3" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_ae0e6b0e-83fb-48bf-bf6c-b38722653cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_3dd79546-7174-41a5-9e71-e6628f8a1323" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_3dd79546-7174-41a5-9e71-e6628f8a1323" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_fff56ba7-f99f-43c8-9862-b24144d17a16" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:to="loc_sny_DerivativeFinancialInstruments_fff56ba7-f99f-43c8-9862-b24144d17a16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_8c28bddd-98d7-4f90-bc37-ed23300f6a6f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:to="loc_ifrs-full_MeasurementDomain_8c28bddd-98d7-4f90-bc37-ed23300f6a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:to="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_e14f90f7-f5ad-46f6-bb3f-454089bf4a9c" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:to="loc_sny_AtNotionalAmountMember_e14f90f7-f5ad-46f6-bb3f-454089bf4a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_94f5f959-6e94-46fd-b2df-609991e84934" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:to="loc_ifrs-full_AtFairValueMember_94f5f959-6e94-46fd-b2df-609991e84934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_9ab2c2b4-b0bb-4292-85cc-93a8089bce41" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_9ab2c2b4-b0bb-4292-85cc-93a8089bce41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_bff6c37a-e8a6-4ce7-bcc9-1010e94de0cb" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_bff6c37a-e8a6-4ce7-bcc9-1010e94de0cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_3f6529c4-4a2c-40d2-8836-cca27d665e99" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_3f6529c4-4a2c-40d2-8836-cca27d665e99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_034d6efd-ba97-4834-adbd-bfede0fe4a37" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_034d6efd-ba97-4834-adbd-bfede0fe4a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_599ade74-253d-43b9-956e-a284e2ffc980" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_599ade74-253d-43b9-956e-a284e2ffc980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_17b77dab-804b-4eda-9764-7cb51d97d73c" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_17b77dab-804b-4eda-9764-7cb51d97d73c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_9d23f159-e7f6-4731-92b1-c083a0668f55" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_9d23f159-e7f6-4731-92b1-c083a0668f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_111e08b9-ceb7-4776-909f-b3b5a364673e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_111e08b9-ceb7-4776-909f-b3b5a364673e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_c1a7567a-67ed-4582-ae8a-6a193b55f292" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_c1a7567a-67ed-4582-ae8a-6a193b55f292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember_47f1f6ad-370c-4a62-89a1-e64b55a17865" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesInCanadianDollarMember_47f1f6ad-370c-4a62-89a1-e64b55a17865" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_4dee6dcf-4668-448f-a2d7-f30ca3ddf36a" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_4dee6dcf-4668-448f-a2d7-f30ca3ddf36a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member_bd59540b-52fa-4d14-9dc6-91b1857e5a71" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapExpiring2029Member_bd59540b-52fa-4d14-9dc6-91b1857e5a71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member_b8fb727d-0507-4041-941f-37d36080c409" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapExpiring2032Member_b8fb727d-0507-4041-941f-37d36080c409" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember_d389f0f6-2cf3-4489-89e7-f770db28630a" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapMember_d389f0f6-2cf3-4489-89e7-f770db28630a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember_689878e9-e7a4-4bb0-b6f2-bedfbbbe8b9f" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySellerSwapsMember_689878e9-e7a4-4bb0-b6f2-bedfbbbe8b9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_590e70ae-db95-4593-b32b-5286b20cfd9a" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_590e70ae-db95-4593-b32b-5286b20cfd9a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_64f35b6b-fed7-4105-b5ef-19c2995a5447_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:to="loc_ifrs-full_MaturityDomain_64f35b6b-fed7-4105-b5ef-19c2995a5447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:to="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_d75c1928-dfa5-4f50-90e2-976aa692583a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_d75c1928-dfa5-4f50-90e2-976aa692583a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_a0e264f9-0bd9-4605-b465-756a7a583a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_a0e264f9-0bd9-4605-b465-756a7a583a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_1059c4e9-4956-4bba-aeeb-77cc7807e6d3" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_1059c4e9-4956-4bba-aeeb-77cc7807e6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_e6f6ed5d-36c1-467c-861c-90ec8a3e50ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_NotionalAmount_e6f6ed5d-36c1-467c-861c-90ec8a3e50ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_28d93c16-4109-4e83-898c-3787338b312b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_28d93c16-4109-4e83-898c-3787338b312b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_72963578-f4ba-4795-a4af-fc282bf6570a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_72963578-f4ba-4795-a4af-fc282bf6570a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_988f1b50-7f50-4324-8795-60b2a72b7abf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_988f1b50-7f50-4324-8795-60b2a72b7abf" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_b4c61c97-9e61-4b62-af8d-b4fccf2e7435_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_b4c61c97-9e61-4b62-af8d-b4fccf2e7435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_9c1b0308-7c6e-4970-8dc6-3439453aeb9d" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_9c1b0308-7c6e-4970-8dc6-3439453aeb9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_73f5cc7a-72fe-4404-8431-c2b8254d79eb" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_73f5cc7a-72fe-4404-8431-c2b8254d79eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_13065544-d52e-4b5a-9d14-98a09242d5fd" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_13065544-d52e-4b5a-9d14-98a09242d5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_8dceac37-3865-44d9-87cd-29dbd814426c" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_8dceac37-3865-44d9-87cd-29dbd814426c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_5c2b80b2-a784-4c62-9898-2114d7d75ab7" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_5c2b80b2-a784-4c62-9898-2114d7d75ab7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_38d0706d-2652-45db-84ab-4ff7715688a3" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_38d0706d-2652-45db-84ab-4ff7715688a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_f5e24659-8d61-4685-8fce-8d76081f3b70" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_f5e24659-8d61-4685-8fce-8d76081f3b70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_a578eb55-c556-4168-95c4-4d5f34021648_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:to="loc_ifrs-full_MeasurementDomain_a578eb55-c556-4168-95c4-4d5f34021648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:to="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_b1526ae3-1b76-4254-9bb5-36d773356e16" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_sny_AtNotionalAmountMember_b1526ae3-1b76-4254-9bb5-36d773356e16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_79fb455d-7d14-48de-a40e-6085076b0b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_ifrs-full_AtFairValueMember_79fb455d-7d14-48de-a40e-6085076b0b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_4db210ba-69a5-42d5-b442-de2dffbc8c4a" xlink:href="sny-20250630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_4db210ba-69a5-42d5-b442-de2dffbc8c4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_bb295a22-7d71-4764-aa8b-f59effa6ea18_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:to="loc_ifrs-full_MaturityDomain_bb295a22-7d71-4764-aa8b-f59effa6ea18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:to="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_e542c8e4-d6be-4847-8437-a681bd42d877" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_e542c8e4-d6be-4847-8437-a681bd42d877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c02f4219-ec6a-4a30-8a59-d2a60a42d904" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c02f4219-ec6a-4a30-8a59-d2a60a42d904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e028b3fe-5a7a-4fdf-97a9-0e68c980728b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e028b3fe-5a7a-4fdf-97a9-0e68c980728b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cc197fd-2d19-425d-b28e-05eb185ccb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cc197fd-2d19-425d-b28e-05eb185ccb96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_f96f6e54-e44c-495b-bc1a-1811c26ca0cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_f96f6e54-e44c-495b-bc1a-1811c26ca0cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_170c1ded-1360-48df-b025-b71de8aa4b2c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_170c1ded-1360-48df-b025-b71de8aa4b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_8403360a-d965-4bfa-b870-83039a289739" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:to="loc_ifrs-full_FairValueHedgesMember_8403360a-d965-4bfa-b870-83039a289739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_1e7c977d-6e5e-40a4-b7b8-21bebb2e74a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:to="loc_ifrs-full_CashFlowHedgesMember_1e7c977d-6e5e-40a4-b7b8-21bebb2e74a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_e1bee4f2-5b28-4bc9-a4a7-a0e5a2f33d32" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:to="loc_sny_InterestRateSwapsInterestRate_e1bee4f2-5b28-4bc9-a4a7-a0e5a2f33d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_2301c171-f354-4fd4-973d-9afc869c99b1" xlink:href="sny-20250630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_2301c171-f354-4fd4-973d-9afc869c99b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_cbd07fdd-dbc6-437c-b792-51c7d9f008e7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_cbd07fdd-dbc6-437c-b792-51c7d9f008e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_afe8db8c-2fe6-46c9-b51b-5c9eddcc9ced" xlink:href="sny-20250630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_afe8db8c-2fe6-46c9-b51b-5c9eddcc9ced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_d4a6e036-8093-4a5c-8394-fe28dae86ad0" xlink:href="sny-20250630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_d4a6e036-8093-4a5c-8394-fe28dae86ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_cd36f096-aa08-46ac-bce5-e1f3e3f9795a" xlink:href="sny-20250630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_cd36f096-aa08-46ac-bce5-e1f3e3f9795a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2ec74a3d-0c8e-43fa-a8fc-ffaa0df7b636" xlink:href="sny-20250630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2ec74a3d-0c8e-43fa-a8fc-ffaa0df7b636" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_d0c789a0-f852-4837-874a-d4508c92c484" xlink:href="sny-20250630.xsd#sny_OtherLiabilities1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_OtherLiabilities1Member_d0c789a0-f852-4837-874a-d4508c92c484" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:href="sny-20250630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_9583e5ee-95f7-417a-a561-fad1a9834463" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_9583e5ee-95f7-417a-a561-fad1a9834463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_4d155d7e-5e8b-4774-9500-68d29a679a85" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_4d155d7e-5e8b-4774-9500-68d29a679a85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_9213eafe-7d01-4da8-9d27-714f90cee3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_9213eafe-7d01-4da8-9d27-714f90cee3df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_9b6a3a63-2089-4205-963c-eb139a6d8af3" xlink:href="sny-20250630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_9b6a3a63-2089-4205-963c-eb139a6d8af3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_0905cc08-3764-45b4-94d4-c7c15ed4ca0b" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_0905cc08-3764-45b4-94d4-c7c15ed4ca0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_f7730561-b59b-4e7f-9cae-8381f4a30c2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_0deed43d-dfb7-4382-b053-e2742fd79bc0" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_0deed43d-dfb7-4382-b053-e2742fd79bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3ddd0de1-5197-44fa-ac3f-a9f032a680e0" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3ddd0de1-5197-44fa-ac3f-a9f032a680e0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_1f85af32-0e6b-4772-95ae-a5fcf791040e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_1f85af32-0e6b-4772-95ae-a5fcf791040e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_647af1e0-e4c3-4135-ac66-5cecc6364b9a" xlink:href="sny-20250630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_647af1e0-e4c3-4135-ac66-5cecc6364b9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_f44da72e-8604-4d07-b3ed-a11863d198d9" xlink:href="sny-20250630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_f44da72e-8604-4d07-b3ed-a11863d198d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_67ad9eaa-b3a9-4262-92d4-5123f413b356" xlink:href="sny-20250630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_67ad9eaa-b3a9-4262-92d4-5123f413b356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2b6f04f6-2cd3-4040-aaef-88a1d0e15e68" xlink:href="sny-20250630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2b6f04f6-2cd3-4040-aaef-88a1d0e15e68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:to="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_a651d61d-88bd-4979-90f0-63d2e2a84620_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:to="loc_ifrs-full_RangeDomain_a651d61d-88bd-4979-90f0-63d2e2a84620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:to="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2a4600d3-6e9e-44a1-8012-221b1b444296" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:to="loc_ifrs-full_TopOfRangeMember_2a4600d3-6e9e-44a1-8012-221b1b444296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_4881dd78-e39d-46e7-8345-01ed56294eee" xlink:href="sny-20250630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_4881dd78-e39d-46e7-8345-01ed56294eee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod_e331b9e7-8640-452c-b134-1f4f90ee63bc" xlink:href="sny-20250630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PaymentToSaleOfBusinessPeriod_e331b9e7-8640-452c-b134-1f4f90ee63bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_8f84e2a6-0560-4605-badb-068db5657082" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_8f84e2a6-0560-4605-badb-068db5657082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_5b1fcfff-325e-4ac6-b553-b9d4f93d5f43" xlink:href="sny-20250630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_5b1fcfff-325e-4ac6-b553-b9d4f93d5f43" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_c02f721a-e795-4057-a294-b5382bf6d9b5_default" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:to="loc_sny_PrincipalAlliancesDomain_c02f721a-e795-4057-a294-b5382bf6d9b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:to="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_e5425e42-6ae9-4b49-97c7-b7b5fbcd0ba5" xlink:href="sny-20250630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_e5425e42-6ae9-4b49-97c7-b7b5fbcd0ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_e262ecdd-25b3-4d1a-8952-71d3001b21b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:to="loc_ifrs-full_CounterpartiesDomain_e262ecdd-25b3-4d1a-8952-71d3001b21b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:to="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_c8d75df2-6054-4b88-b311-95d87ac1c389" xlink:href="sny-20250630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_c8d75df2-6054-4b88-b311-95d87ac1c389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_27b4be91-eafb-4b03-bf42-0f38b8ee4484_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:to="loc_ifrs-full_MaturityDomain_27b4be91-eafb-4b03-bf42-0f38b8ee4484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:to="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_270a7edd-e9ed-4d43-8868-febe9e33f330" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_270a7edd-e9ed-4d43-8868-febe9e33f330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_ae274a5f-0261-40a9-882f-fd110ac1145a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_ae274a5f-0261-40a9-882f-fd110ac1145a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_ffa2bb75-21bd-40d2-93ec-d7b4b5647c28" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_ifrs-full_NoncurrentProvisions_ffa2bb75-21bd-40d2-93ec-d7b4b5647c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_be484fd3-25da-43b1-b293-11ef12fa601e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_be484fd3-25da-43b1-b293-11ef12fa601e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_cb34c28c-b05f-468c-bd52-5a842f3a5f5f" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_cb34c28c-b05f-468c-bd52-5a842f3a5f5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_a4739329-c537-4aef-8be8-ebe235dce064" xlink:href="sny-20250630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_a4739329-c537-4aef-8be8-ebe235dce064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_dc8f99ed-87d0-4d42-9665-9ea6545389e7" xlink:href="sny-20250630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_dc8f99ed-87d0-4d42-9665-9ea6545389e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_5544ba06-d98a-436d-b5e0-c7dc84f03c14" xlink:href="sny-20250630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_5544ba06-d98a-436d-b5e0-c7dc84f03c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_aa9e6953-f209-4dc7-9312-c7c05b227401" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_aa9e6953-f209-4dc7-9312-c7c05b227401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ae4bb713-d935-42bf-89f2-53889f1db1c7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ae4bb713-d935-42bf-89f2-53889f1db1c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:to="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_d00fc237-fd06-42a2-8aa3-80e2d75b245f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:to="loc_country_GB_d00fc237-fd06-42a2-8aa3-80e2d75b245f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_85d677da-4815-409e-acfc-3ce682d539dd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_85d677da-4815-409e-acfc-3ce682d539dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_257c66a2-95fa-4074-8630-1a48a2d24f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:to="loc_ifrs-full_PlanAssetsMember_257c66a2-95fa-4074-8630-1a48a2d24f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_7a08e355-1127-4498-96cd-207d0815f5ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_NoncurrentProvisions_7a08e355-1127-4498-96cd-207d0815f5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_fdd7de98-7eef-447a-92fa-0bf375010e95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_fdd7de98-7eef-447a-92fa-0bf375010e95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_2b9f8e28-d6dd-413f-bb1a-d0f234ff261f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_2b9f8e28-d6dd-413f-bb1a-d0f234ff261f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_f18bda18-1a14-460c-a0d6-319ab9d18d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_f18bda18-1a14-460c-a0d6-319ab9d18d09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_a276bef8-cce3-4c0a-9713-53bb3c66050b" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_a276bef8-cce3-4c0a-9713-53bb3c66050b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c3aac57e-d0d8-4eff-a546-0ca21d6ea547" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c3aac57e-d0d8-4eff-a546-0ca21d6ea547" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_8e89532b-5bc4-482a-a86b-6dc10db93802" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_8e89532b-5bc4-482a-a86b-6dc10db93802" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_f22bb33a-cb79-4f91-9aa1-b4a78667d71e" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_f22bb33a-cb79-4f91-9aa1-b4a78667d71e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_d6d16e13-c6c2-446d-a1b6-d625bacb67c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a2625f91-895a-4843-8b0e-bb3a0c00dec4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a2625f91-895a-4843-8b0e-bb3a0c00dec4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_6dc16b6d-887c-4123-b170-79b7336f213e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_6dc16b6d-887c-4123-b170-79b7336f213e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_c58fdeab-be91-4a72-a298-1cdc02a1e497" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:to="loc_ifrs-full_PlanAssetsMember_c58fdeab-be91-4a72-a298-1cdc02a1e497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_b70cb389-984f-4c5b-9735-c89d836047f2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_b70cb389-984f-4c5b-9735-c89d836047f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1f4236b5-e353-4c1e-b42c-67ce96b49b6e" xlink:href="sny-20250630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1f4236b5-e353-4c1e-b42c-67ce96b49b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_e6681574-2d82-4f27-90f0-ff1267a7f206_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:to="loc_ifrs-full_GeographicalAreasDomain_e6681574-2d82-4f27-90f0-ff1267a7f206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:to="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_a3e98b5f-ee34-4933-a2cb-13dcdd1e3cab" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_country_GB_a3e98b5f-ee34-4933-a2cb-13dcdd1e3cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember_2feb9a02-9038-48fa-9bc9-ba9373bcdc89" xlink:href="sny-20250630.xsd#sny_EUROZONEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_sny_EUROZONEMember_2feb9a02-9038-48fa-9bc9-ba9373bcdc89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember_defd8801-2b4c-451b-93ed-7761576a711b" xlink:href="sny-20250630.xsd#sny_UKZONEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_sny_UKZONEMember_defd8801-2b4c-451b-93ed-7761576a711b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_aa3f26bf-64b1-4df1-8648-88e7d9e6c224_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_aa3f26bf-64b1-4df1-8648-88e7d9e6c224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_98240db7-cd87-4c7e-a0e9-bffd61f31cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_98240db7-cd87-4c7e-a0e9-bffd61f31cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_52721bab-68e6-4bf0-b5de-a492d15738b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_52721bab-68e6-4bf0-b5de-a492d15738b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d99427f6-93d9-4e8a-9b79-cc700ae6162e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:to="loc_srt_RangeMember_d99427f6-93d9-4e8a-9b79-cc700ae6162e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:to="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19e2e3d7-3f6c-407d-b580-b14580502be3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:to="loc_srt_MinimumMember_19e2e3d7-3f6c-407d-b580-b14580502be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f53ce24-2348-4330-80eb-6cba30fedd2c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:to="loc_srt_MaximumMember_9f53ce24-2348-4330-80eb-6cba30fedd2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_869f8942-418e-457e-b77b-1ff3bc2e3b2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_869f8942-418e-457e-b77b-1ff3bc2e3b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_2b687137-fcbc-4e4f-ae8a-ef85a9005163" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:to="loc_sny_OpellaBusinessMember_2b687137-fcbc-4e4f-ae8a-ef85a9005163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_55f1faab-1d59-4c00-ab0b-e16d2738c108" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_55f1faab-1d59-4c00-ab0b-e16d2738c108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_412b89bd-66fa-473c-baa9-62a7e507106d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_412b89bd-66fa-473c-baa9-62a7e507106d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_838333fb-2be2-4257-8899-6fd9b25767bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_838333fb-2be2-4257-8899-6fd9b25767bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cf28d978-e9a4-41ad-ae56-ff7b8c5fb2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cf28d978-e9a4-41ad-ae56-ff7b8c5fb2df" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OffBalanceSheetCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_ffb2341f-8a5d-46f2-aae1-7d41e779d758_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:to="loc_ifrs-full_CounterpartiesDomain_ffb2341f-8a5d-46f2-aae1-7d41e779d758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:to="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_1fed95a8-207b-46b6-a2e4-57379d5450bc" xlink:href="sny-20250630.xsd#sny_MazeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_MazeTherapeuticsMember_1fed95a8-207b-46b6-a2e4-57379d5450bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_b7433fb3-f22c-4a73-bfa3-166eff1afc3e" xlink:href="sny-20250630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_ScribeTherapeuticsMember_b7433fb3-f22c-4a73-bfa3-166eff1afc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_9113c24d-0228-4de2-b113-8185cfccbf17" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_NovavaxMember_9113c24d-0228-4de2-b113-8185cfccbf17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember_bf534ef9-64cf-467c-aed2-1471eb64e63a" xlink:href="sny-20250630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_FulcrumTherapeuticsMember_bf534ef9-64cf-467c-aed2-1471eb64e63a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:to="loc_ifrs-full_RangeDomain_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:to="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5c70eef-e372-486c-8f1a-3245eb59b6a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:to="loc_srt_MaximumMember_a5c70eef-e372-486c-8f1a-3245eb59b6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_22e84024-95e5-4fa1-8221-6ba67452134d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:to="loc_srt_RangeMember_22e84024-95e5-4fa1-8221-6ba67452134d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:to="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88cf7844-5712-4055-99ce-c1d0d73851d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:to="loc_srt_MinimumMember_88cf7844-5712-4055-99ce-c1d0d73851d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_7ad703c9-db7c-4a6e-b4e7-d7d983c1954a" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_UpfrontPayments_7ad703c9-db7c-4a6e-b4e7-d7d983c1954a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_aaf237e8-b994-4675-9e8e-46aa2ba56896" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_aaf237e8-b994-4675-9e8e-46aa2ba56896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_ed138965-e556-4e4c-bb71-ebd2676dc39f" xlink:href="sny-20250630.xsd#sny_LeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseTerm_ed138965-e556-4e4c-bb71-ebd2676dc39f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost_6903f1a4-2fc0-4c48-a17e-d800a8084832" xlink:href="sny-20250630.xsd#sny_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseCost_6903f1a4-2fc0-4c48-a17e-d800a8084832" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_0778c731-6bbe-4160-80f3-1ad130c38a42" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseExtensionOptionsNumber_0778c731-6bbe-4160-80f3-1ad130c38a42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_66d9aa6b-482e-44bf-9330-8e441437b2a8" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseExtensionOptionsTerm_66d9aa6b-482e-44bf-9330-8e441437b2a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_56b0d610-f5cc-4232-a8a6-1823e6bb330b" xlink:href="sny-20250630.xsd#sny_TotalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_TotalMilestonePayments_56b0d610-f5cc-4232-a8a6-1823e6bb330b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_7c65632e-bbfc-4080-884c-205f719f4f03" xlink:href="sny-20250630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_7c65632e-bbfc-4080-884c-205f719f4f03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments_36081b8a-b162-4562-ac84-a33bdc4f6993" xlink:href="sny-20250630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_AdditionalLaunchAndSalesMilestonePayments_36081b8a-b162-4562-ac84-a33bdc4f6993" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments_20562a64-be0c-4701-8f66-0c9783f7e27b" xlink:href="sny-20250630.xsd#sny_ContingentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_ContingentMilestonePayments_20562a64-be0c-4701-8f66-0c9783f7e27b" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LitigationandArbitrationProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67_default" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_5eb8eace-65fc-4a0f-b889-93dad9c35e4f" xlink:href="sny-20250630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_5eb8eace-65fc-4a0f-b889-93dad9c35e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_a406d85c-2f51-423e-94aa-84a6247980a9" xlink:href="sny-20250630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_a406d85c-2f51-423e-94aa-84a6247980a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember_df493d8a-5be7-4141-8b33-4a41f5029a24" xlink:href="sny-20250630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_ZantacProductLitigationInTheUSMember_df493d8a-5be7-4141-8b33-4a41f5029a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_0e044a07-519f-4bae-88c2-625354d2f563" xlink:href="sny-20250630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_0e044a07-519f-4bae-88c2-625354d2f563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:href="sny-20250630.xsd#sny_DefendantAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_9b2854e6-5d3d-4e0b-a75a-ad2414f76843_default" xlink:href="sny-20250630.xsd#sny_DefendantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:to="loc_sny_DefendantDomain_9b2854e6-5d3d-4e0b-a75a-ad2414f76843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:href="sny-20250630.xsd#sny_DefendantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:to="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_e90344f9-83c1-4039-bdd4-47363317b6dd" xlink:href="sny-20250630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_e90344f9-83c1-4039-bdd4-47363317b6dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichSanofiAreDefendantMember_d210fb02-f7c6-4215-92cb-c118c534bbf2" xlink:href="sny-20250630.xsd#sny_ActionForWhichSanofiAreDefendantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:to="loc_sny_ActionForWhichSanofiAreDefendantMember_d210fb02-f7c6-4215-92cb-c118c534bbf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_2c5a1199-0771-40d4-a8a9-898b058d5975_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_2c5a1199-0771-40d4-a8a9-898b058d5975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_3eb5258f-60be-4ac8-a311-830e40664fd4" xlink:href="sny-20250630.xsd#sny_ProductLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:to="loc_sny_ProductLiabilitiesMember_3eb5258f-60be-4ac8-a311-830e40664fd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_baf0f865-ea20-41b7-9d98-f5d73ebf1726" xlink:href="sny-20250630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_baf0f865-ea20-41b7-9d98-f5d73ebf1726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_d052ba6d-db7b-471e-93e1-8b47c0629267" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_d052ba6d-db7b-471e-93e1-8b47c0629267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_5d402078-8d55-4333-baac-725255b2a5bf" xlink:href="sny-20250630.xsd#sny_NumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfPlaintiffs_5d402078-8d55-4333-baac-725255b2a5bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_69797165-2ef2-43d3-b36d-b3ddf9257ffb" xlink:href="sny-20250630.xsd#sny_NumberOfCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfCases_69797165-2ef2-43d3-b36d-b3ddf9257ffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_fee46e64-c7f0-4ec2-80d6-2185d61b6454" xlink:href="sny-20250630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfClassActionLawsuits_fee46e64-c7f0-4ec2-80d6-2185d61b6454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals_528735e6-1d9b-49bc-afcf-05aad15e6f1e" xlink:href="sny-20250630.xsd#sny_NumberOfDismissals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfDismissals_528735e6-1d9b-49bc-afcf-05aad15e6f1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_e842b336-5a93-4936-ba2f-c20d46a03f70" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PenaltyFeeIncurred_e842b336-5a93-4936-ba2f-c20d46a03f70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty_ed2c9a9a-d6ca-44d0-8b45-abded422c4ad" xlink:href="sny-20250630.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PaymentOfDamagesClaimedByCounterparty_ed2c9a9a-d6ca-44d0-8b45-abded422c4ad" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpensesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_9cc5a52d-d173-4251-bc21-04fc54c66984" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_9cc5a52d-d173-4251-bc21-04fc54c66984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_edd4c259-4f02-4537-a9ca-84536d56a915_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_edd4c259-4f02-4537-a9ca-84536d56a915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_70883ea3-00ca-41ee-985c-d670388c1e15" xlink:href="sny-20250630.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:to="loc_sny_RegeneronMember_70883ea3-00ca-41ee-985c-d670388c1e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_62861c98-4c62-4476-9e0c-6a75c8901138_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_62861c98-4c62-4476-9e0c-6a75c8901138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_424ca006-97e1-4751-ab5c-6ce938eca652" xlink:href="sny-20250630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_424ca006-97e1-4751-ab5c-6ce938eca652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6dcb766a-660e-471d-8813-86832133beb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6dcb766a-660e-471d-8813-86832133beb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_4084d8dc-643a-4686-b17a-44e5ef66f2f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_4084d8dc-643a-4686-b17a-44e5ef66f2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_2c571ee5-5d47-43c1-9155-c6303344fb24" xlink:href="sny-20250630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_sny_GainsOnDivestmentOfProducts_2c571ee5-5d47-43c1-9155-c6303344fb24" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_a6d7b5d9-2ce8-428c-8072-b36eba79d68f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_a6d7b5d9-2ce8-428c-8072-b36eba79d68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_a97f6bd5-34f7-4b34-a875-8d6d737d7510" xlink:href="sny-20250630.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:to="loc_sny_RegeneronMember_a97f6bd5-34f7-4b34-a875-8d6d737d7510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5852610f-154f-48fe-8d37-b8a067d9fa64_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5852610f-154f-48fe-8d37-b8a067d9fa64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_cbe4f08c-ac37-4489-a7ab-461c9cda0fce" xlink:href="sny-20250630.xsd#sny_AntibodiesAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_AntibodiesAllianceMember_cbe4f08c-ac37-4489-a7ab-461c9cda0fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember_40e5727a-f956-4d41-9099-434c19af303f" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_ImmunoOncologyAllianceMember_40e5727a-f956-4d41-9099-434c19af303f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_a9aaa410-da32-4238-af09-6304d3b8bd5d" xlink:href="sny-20250630.xsd#sny_OthersCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_OthersCounterpartyMember_a9aaa410-da32-4238-af09-6304d3b8bd5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_063ead51-014f-45c0-bb46-bed206a908db_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_063ead51-014f-45c0-bb46-bed206a908db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_4464bd8c-fb3f-4bb1-a2d5-259f71e9464e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_4464bd8c-fb3f-4bb1-a2d5-259f71e9464e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_89845904-a270-43fe-bd7a-d61c62b2a265_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_89845904-a270-43fe-bd7a-d61c62b2a265_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_da902c6b-2b46-46a2-8599-cd4cb7d35e09" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_da902c6b-2b46-46a2-8599-cd4cb7d35e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_e5953076-28d9-4082-b43e-c9bbe1ac0f86" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_e5953076-28d9-4082-b43e-c9bbe1ac0f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_b73ec575-2bcc-4b00-9b20-242d3271273b" xlink:href="sny-20250630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_CommercializationRelatedExpensesMember_b73ec575-2bcc-4b00-9b20-242d3271273b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_5b96da9f-0838-4c0b-afec-fb8c5998698e" xlink:href="sny-20250630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_5b96da9f-0838-4c0b-afec-fb8c5998698e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bc4ab099-f5da-4a8f-9f5a-094a6148aaa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bc4ab099-f5da-4a8f-9f5a-094a6148aaa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_2c02c52f-ab70-44dc-a78c-f44199f92cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_2c02c52f-ab70-44dc-a78c-f44199f92cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_34da184e-d87b-49bd-9027-6f7c3e3dd4f1" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_34da184e-d87b-49bd-9027-6f7c3e3dd4f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_f26d6db6-5d87-41b4-8004-dfe52c6b3952" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_f26d6db6-5d87-41b4-8004-dfe52c6b3952" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:to="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:to="loc_ifrs-full_HedgedItemsDomain_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:to="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_0e62f000-5ead-4756-b518-4ae96b089c8b" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_0e62f000-5ead-4756-b518-4ae96b089c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_25e7c975-db1f-4487-82bd-258e02af560f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_25e7c975-db1f-4487-82bd-258e02af560f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_f8315d93-0c73-4683-88a8-67237bd8c823" xlink:href="sny-20250630.xsd#sny_InterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_InterestIncome_f8315d93-0c73-4683-88a8-67237bd8c823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_9b7e4dc6-597d-4b25-aa69-ba21ead03386" xlink:href="sny-20250630.xsd#sny_CostOfDebtNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_CostOfDebtNet_9b7e4dc6-597d-4b25-aa69-ba21ead03386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_4c2af26e-8696-4cb3-91b6-bfb23642c666" xlink:href="sny-20250630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_4c2af26e-8696-4cb3-91b6-bfb23642c666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_75cc6624-63ef-4999-b37d-a7e07146cab2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_75cc6624-63ef-4999-b37d-a7e07146cab2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_ddf494e1-d33b-4092-9ab8-061b79c6d0d6" xlink:href="sny-20250630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_ddf494e1-d33b-4092-9ab8-061b79c6d0d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_ad237eec-1052-43eb-b4e3-0edfbb16f2f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_ad237eec-1052-43eb-b4e3-0edfbb16f2f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_1ed3d481-f004-4521-928d-2c5f088d79f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_1ed3d481-f004-4521-928d-2c5f088d79f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_eafbf6ed-57bb-41a5-8043-ba9b7ab0ba3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_eafbf6ed-57bb-41a5-8043-ba9b7ab0ba3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_57f58fdb-3165-49d8-a30b-da6b3245002e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceIncomeCost_57f58fdb-3165-49d8-a30b-da6b3245002e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_7dfe43b0-199c-4f06-960b-ee8366e503e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceCosts_7dfe43b0-199c-4f06-960b-ee8366e503e6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_2bb0aabf-ce0d-4415-908b-ee1625d2f0e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceIncome_2bb0aabf-ce0d-4415-908b-ee1625d2f0e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_f47cd94b-5f0c-42e1-8f1e-7164e49ef5aa" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_f47cd94b-5f0c-42e1-8f1e-7164e49ef5aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_14c90498-ac85-480c-9d66-dc1c84f2ceb8" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_14c90498-ac85-480c-9d66-dc1c84f2ceb8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_614116c7-2f09-4a27-b3c4-d66c30626c3c" xlink:href="sny-20250630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_614116c7-2f09-4a27-b3c4-d66c30626c3c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_2e271ec7-2678-4bed-a0bb-03ba5be67c90" xlink:href="sny-20250630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_2e271ec7-2678-4bed-a0bb-03ba5be67c90" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_22f57f4c-cc86-465d-a835-c35768e32915_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_22f57f4c-cc86-465d-a835-c35768e32915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_82e467aa-53bd-4f7a-985a-a9134a6f45a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_82e467aa-53bd-4f7a-985a-a9134a6f45a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_7958620f-26ec-4c63-b8c2-64a8e5df6f99" xlink:href="sny-20250630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_7958620f-26ec-4c63-b8c2-64a8e5df6f99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:to="loc_ifrs-full_GeographicalAreasDomain_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:to="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5a5ace78-160d-4c9c-b653-fec43a2a2a4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_srt_EuropeMember_5a5ace78-160d-4c9c-b653-fec43a2a2a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b5d65ff-a8a7-4c9c-8542-a664474f6a46" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_country_US_2b5d65ff-a8a7-4c9c-8542-a664474f6a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_1a6804fa-aa65-4d94-9dfb-c0483fd979f2" xlink:href="sny-20250630.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_sny_OtherCountriesMember_1a6804fa-aa65-4d94-9dfb-c0483fd979f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_21168bad-03e9-471e-9f0b-14a693e20ce2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:to="loc_ifrs-full_SegmentsDomain_21168bad-03e9-471e-9f0b-14a693e20ce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:to="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_07f83897-d4f0-4256-a915-c2675ed2981f" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_BiopharmaSegmentMember_07f83897-d4f0-4256-a915-c2675ed2981f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_9db28d1c-32c9-4d9f-b821-4cab471734cf" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_9db28d1c-32c9-4d9f-b821-4cab471734cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_55c99cf7-b298-4163-baf0-60e1db35a2c6" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_OpellaMember_55c99cf7-b298-4163-baf0-60e1db35a2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_0a7c5e17-42f0-4f4f-9c85-db2f9b2b5851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_0a7c5e17-42f0-4f4f-9c85-db2f9b2b5851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_41aff729-dfda-479a-86fd-6a9fd36c5e69" xlink:href="sny-20250630.xsd#sny_PharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_PharmaSegmentMember_41aff729-dfda-479a-86fd-6a9fd36c5e69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_040da8d5-cfa4-425c-86d6-28e9f95f069e" xlink:href="sny-20250630.xsd#sny_OtherProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_OtherProductsSegmentMember_040da8d5-cfa4-425c-86d6-28e9f95f069e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:href="sny-20250630.xsd#sny_SpecialtyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_1162e6c6-64c4-4180-93a1-36bba7d6bb75" xlink:href="sny-20250630.xsd#sny_DupixentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_DupixentMember_1162e6c6-64c4-4180-93a1-36bba7d6bb75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_79539d5c-4797-431e-adc4-23c960051b05" xlink:href="sny-20250630.xsd#sny_AubagioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_AubagioMember_79539d5c-4797-431e-adc4-23c960051b05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_9379b038-f6ae-4592-aa90-2c9ae8cca51e" xlink:href="sny-20250630.xsd#sny_CerezymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_CerezymeMember_9379b038-f6ae-4592-aa90-2c9ae8cca51e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember_a4db36d3-305f-41c5-8dac-3c3c555efe5f" xlink:href="sny-20250630.xsd#sny_MyozymeLumizymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_MyozymeLumizymeMember_a4db36d3-305f-41c5-8dac-3c3c555efe5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_23f98185-ec28-4d52-905f-66628fd7cc37" xlink:href="sny-20250630.xsd#sny_FabrazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_FabrazymeMember_23f98185-ec28-4d52-905f-66628fd7cc37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_816b6f55-ad9b-41b6-bdf7-bac957530537" xlink:href="sny-20250630.xsd#sny_JevtanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_JevtanaMember_816b6f55-ad9b-41b6-bdf7-bac957530537" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_5ba09927-6a3e-409d-898f-ddf02730e13b" xlink:href="sny-20250630.xsd#sny_AlprolixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_AlprolixMember_5ba09927-6a3e-409d-898f-ddf02730e13b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_53205611-7802-4681-a47d-3bcbdb435a44" xlink:href="sny-20250630.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_EloctateMember_53205611-7802-4681-a47d-3bcbdb435a44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:href="sny-20250630.xsd#sny_GeneralMedicinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:href="sny-20250630.xsd#sny_CoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_87f23119-aa15-4e4a-a1ba-b4ac7dc4e415" xlink:href="sny-20250630.xsd#sny_LovenoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_LovenoxMember_87f23119-aa15-4e4a-a1ba-b4ac7dc4e415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_e9656ae7-ccaa-4566-9717-7eb35cb7dff9" xlink:href="sny-20250630.xsd#sny_ToujeoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_ToujeoMember_e9656ae7-ccaa-4566-9717-7eb35cb7dff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_6d016c99-51d2-443e-84d0-c5a32fb238d7" xlink:href="sny-20250630.xsd#sny_PlavixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_PlavixMember_6d016c99-51d2-443e-84d0-c5a32fb238d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:href="sny-20250630.xsd#sny_NonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_52e2e985-c102-444d-a80c-e2929f3d5287" xlink:href="sny-20250630.xsd#sny_LantusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:to="loc_sny_LantusMember_52e2e985-c102-444d-a80c-e2929f3d5287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_2955c8d2-8672-4d07-bb74-ea81d9f34a9f" xlink:href="sny-20250630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:to="loc_sny_OtherNonCoreAssetsMember_2955c8d2-8672-4d07-bb74-ea81d9f34a9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_46c738d0-030e-421c-938b-cb1f5a271e9c" xlink:href="sny-20250630.xsd#sny_IndustrialSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_IndustrialSalesMember_46c738d0-030e-421c-938b-cb1f5a271e9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:href="sny-20250630.xsd#sny_VaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_27ed296b-1166-4776-a8f6-5d5bd71772e8" xlink:href="sny-20250630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_27ed296b-1166-4776-a8f6-5d5bd71772e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_8b742c9e-2cec-4f9a-86ad-34fe5a01e7e6" xlink:href="sny-20250630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:to="loc_sny_InfluenzaVaccinesMember_8b742c9e-2cec-4f9a-86ad-34fe5a01e7e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_87b1ac2a-1cbb-4d8d-8867-238147e2163b" xlink:href="sny-20250630.xsd#sny_AllergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_AllergyMember_87b1ac2a-1cbb-4d8d-8867-238147e2163b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_716c68cd-c954-4af9-9c97-72ff081442a8" xlink:href="sny-20250630.xsd#sny_PainCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_PainCareMember_716c68cd-c954-4af9-9c97-72ff081442a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_3656177f-c501-4430-9f51-d1d6d08f3629" xlink:href="sny-20250630.xsd#sny_DigestiveWellnessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_DigestiveWellnessMember_3656177f-c501-4430-9f51-d1d6d08f3629" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember_3711a0e5-efdc-492e-a0ac-bc22343f70c1" xlink:href="sny-20250630.xsd#sny_NexviazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_NexviazymeMember_3711a0e5-efdc-492e-a0ac-bc22343f70c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_79375ef8-268c-4d3e-9217-3b62044c9ab0" xlink:href="sny-20250630.xsd#sny_SarclisaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SarclisaMember_79375ef8-268c-4d3e-9217-3b62044c9ab0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_fc5a0fc8-64f4-489c-aa74-ea5187eef694" xlink:href="sny-20250630.xsd#sny_AltuviiioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_AltuviiioMember_fc5a0fc8-64f4-489c-aa74-ea5187eef694" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_3a3f5ded-6d04-4a23-8e76-28e75a0526f0" xlink:href="sny-20250630.xsd#sny_RezurockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RezurockMember_3a3f5ded-6d04-4a23-8e76-28e75a0526f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember_c241358e-a39b-4ff0-bb05-325450de7005" xlink:href="sny-20250630.xsd#sny_CabliviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_CabliviMember_c241358e-a39b-4ff0-bb05-325450de7005" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember_8e5cbe43-4370-4efc-bfe5-71c78c337124" xlink:href="sny-20250630.xsd#sny_XenpozymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_XenpozymeMember_8e5cbe43-4370-4efc-bfe5-71c78c337124" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember_198aa125-879b-4b12-a9cb-a68a930d922e" xlink:href="sny-20250630.xsd#sny_EnjaymoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_EnjaymoMember_198aa125-879b-4b12-a9cb-a68a930d922e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember_84035323-a9fb-4ffe-992d-54939cc72041" xlink:href="sny-20250630.xsd#sny_TzieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_TzieldMember_84035323-a9fb-4ffe-992d-54939cc72041" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember_3adde4bc-915f-4bc7-b0f5-0b01be6d2b85" xlink:href="sny-20250630.xsd#sny_RSVVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RSVVaccinesMember_3adde4bc-915f-4bc7-b0f5-0b01be6d2b85" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember_a92b7636-9034-45ff-a9a1-3ede8221f610" xlink:href="sny-20250630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_MeningitisTravelAndEndemicVaccinesMember_a92b7636-9034-45ff-a9a1-3ede8221f610" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember_51d27e27-f275-4f07-aec8-ef44d2d953e4" xlink:href="sny-20250630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SeasonalSymptomsAndPainReliefMember_51d27e27-f275-4f07-aec8-ef44d2d953e4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember_f53f1dd2-0b1c-4987-b600-2e6f4c4379d0" xlink:href="sny-20250630.xsd#sny_WellnessBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_WellnessBrandsMember_f53f1dd2-0b1c-4987-b600-2e6f4c4379d0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember_7be451eb-1c77-41c8-816c-881f85109eb7" xlink:href="sny-20250630.xsd#sny_OthersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_OthersMember_7be451eb-1c77-41c8-816c-881f85109eb7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RareDiseasesMember_c833114a-a226-460c-bfb2-51c9c3692a75" xlink:href="sny-20250630.xsd#sny_RareDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RareDiseasesMember_c833114a-a226-460c-bfb2-51c9c3692a75" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50587ddd-95a6-49f5-a2ad-a23ccf55790e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:to="loc_srt_ProductsAndServicesDomain_50587ddd-95a6-49f5-a2ad-a23ccf55790e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:to="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_3228186f-f05e-4e8d-a445-fd1ba38de43e" xlink:href="sny-20250630.xsd#sny_PharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_PharmaSegmentMember_3228186f-f05e-4e8d-a445-fd1ba38de43e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember_d440d021-c5a8-4098-ab75-71e7f132487d" xlink:href="sny-20250630.xsd#sny_PharmaLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_PharmaLaunchesMember_d440d021-c5a8-4098-ab75-71e7f132487d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_b761ea7a-c248-4c7e-9613-35ea42dbf3a8" xlink:href="sny-20250630.xsd#sny_OtherProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_OtherProductsSegmentMember_b761ea7a-c248-4c7e-9613-35ea42dbf3a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_bc134f42-7a9c-40e4-b823-af66d95b1a9d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_bc134f42-7a9c-40e4-b823-af66d95b1a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_fe8dae06-eb58-4659-818d-81bbc717956d" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:to="loc_sny_OpellaBusinessMember_fe8dae06-eb58-4659-818d-81bbc717956d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_854c42fb-b4b1-43f3-8a56-3dc7919fb44b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_854c42fb-b4b1-43f3-8a56-3dc7919fb44b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_d3573e56-ce61-413d-8e67-640e9f46210f" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_NumberOfOperatingSegments_d3573e56-ce61-413d-8e67-640e9f46210f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_272d524d-664c-4fd6-b4ff-e0647f10d7c3" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_BusinessOperatingIncome_272d524d-664c-4fd6-b4ff-e0647f10d7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_0f05b683-d43d-4f1a-9923-75283db5b6f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_OtherRevenue_0f05b683-d43d-4f1a-9923-75283db5b6f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_32f07cdf-0e22-4c85-935b-124b39768152" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_CostOfSales_32f07cdf-0e22-4c85-935b-124b39768152" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_3d426484-deee-402a-a745-c17f6f4faaf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_3d426484-deee-402a-a745-c17f6f4faaf5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18df7870-bb06-4d2a-ad15-9d505cd04dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18df7870-bb06-4d2a-ad15-9d505cd04dfe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_d41d74fb-4b37-4155-b255-a368a24f35aa" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_d41d74fb-4b37-4155-b255-a368a24f35aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_0d81a579-0bfb-4293-9840-fb623a06d2d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_0d81a579-0bfb-4293-9840-fb623a06d2d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_70d61ee3-ccb3-486d-bebe-d0e8985d7599" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_70d61ee3-ccb3-486d-bebe-d0e8985d7599" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_58918bfb-47f8-4f80-955a-e0c66fe726f4" xlink:href="sny-20250630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_58918bfb-47f8-4f80-955a-e0c66fe726f4" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:to="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_d22b479d-0dd6-4d6c-84c3-a466e704b35a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:to="loc_ifrs-full_SegmentsDomain_d22b479d-0dd6-4d6c-84c3-a466e704b35a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:to="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:to="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_62c03c0e-9b25-460f-bea5-2bd4625fe400" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_sny_BiopharmaSegmentMember_62c03c0e-9b25-460f-bea5-2bd4625fe400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_77526cba-0042-4fe5-9927-5629e2db8be7" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_77526cba-0042-4fe5-9927-5629e2db8be7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_be879115-904b-46da-acd1-dd54ac1cc48f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_be879115-904b-46da-acd1-dd54ac1cc48f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_647613d2-e499-46d6-896b-da7894c02c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_647613d2-e499-46d6-896b-da7894c02c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_fa93ef87-dcc8-49a6-bd54-f7622f9d0a67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_OtherRevenue_fa93ef87-dcc8-49a6-bd54-f7622f9d0a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_bbd65ccd-ae7c-4528-8036-aabd2cffca08" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_CostOfSales_bbd65ccd-ae7c-4528-8036-aabd2cffca08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_49766e3b-b065-469e-994b-1736f265a090" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_49766e3b-b065-469e-994b-1736f265a090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_afa80cc8-e638-45ee-9902-08a7db8da7c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_afa80cc8-e638-45ee-9902-08a7db8da7c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_545c7e69-6215-4ce5-a566-a5783a96e221" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_545c7e69-6215-4ce5-a566-a5783a96e221" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d2dca40e-8ccc-47e5-b213-5ba0f455c353" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d2dca40e-8ccc-47e5-b213-5ba0f455c353" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_7c88e9b6-9590-42c6-b793-dcfc651b9aec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_7c88e9b6-9590-42c6-b793-dcfc651b9aec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_822ffc56-1b60-4b96-85a5-c6e26665665a" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_BusinessOperatingIncome_822ffc56-1b60-4b96-85a5-c6e26665665a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_cc720e3f-65b6-41b7-b4b7-4451d0735928" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_NumberOfOperatingSegments_cc720e3f-65b6-41b7-b4b7-4451d0735928" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_bad9feb2-bf9a-4fd5-be5b-db923dc64c62_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_bad9feb2-bf9a-4fd5-be5b-db923dc64c62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_db2f4225-705c-4901-8430-34e2762f640b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:to="loc_ifrs-full_OperatingSegmentsMember_db2f4225-705c-4901-8430-34e2762f640b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_d7c63ec0-02c9-4c0f-803b-deda96580bad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_d7c63ec0-02c9-4c0f-803b-deda96580bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_67ea1185-e2bb-4c60-b372-106280f366bf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_67ea1185-e2bb-4c60-b372-106280f366bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_6cf59390-5ea3-4658-966f-ac6ca6beca9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_6cf59390-5ea3-4658-966f-ac6ca6beca9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_695070fe-4fd6-4169-ad50-65874de39364" xlink:href="sny-20250630.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:to="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_695070fe-4fd6-4169-ad50-65874de39364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ClinicalStudyMember_1b5c116b-2308-46a8-ac98-656873e7504c" xlink:href="sny-20250630.xsd#sny_ClinicalStudyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:to="loc_sny_ClinicalStudyMember_1b5c116b-2308-46a8-ac98-656873e7504c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_fa2ba5b6-3d81-4277-b17d-6496d4691b95_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_fa2ba5b6-3d81-4277-b17d-6496d4691b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_145a28a9-2fc0-40bb-bb5c-4803a3f28330" xlink:href="sny-20250630.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:to="loc_sny_EloctateMember_145a28a9-2fc0-40bb-bb5c-4803a3f28330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member_4cee04ec-39e5-4bb2-903c-e099bc73b5c4" xlink:href="sny-20250630.xsd#sny_SAR44425Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:to="loc_sny_SAR44425Member_4cee04ec-39e5-4bb2-903c-e099bc73b5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228_default" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:to="loc_sny_PrincipalAlliancesDomain_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:to="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_9fc2d2f4-8118-4c4c-a619-479946e55817" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_9fc2d2f4-8118-4c4c-a619-479946e55817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_4bfdee8d-08d7-4b94-a5df-15672a904f11_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:to="loc_ifrs-full_CounterpartiesDomain_4bfdee8d-08d7-4b94-a5df-15672a904f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:to="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_8fae4827-66d7-4011-a06c-66ea1ab439e1" xlink:href="sny-20250630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_8fae4827-66d7-4011-a06c-66ea1ab439e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_266f636a-315e-4d5f-a52a-15889d23e372_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:to="loc_srt_ProductsAndServicesDomain_266f636a-315e-4d5f-a52a-15889d23e372_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:to="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_f33cbed1-ad5d-4d9b-a63f-d3c88d8fd594" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:to="loc_sny_BiopharmaSegmentMember_f33cbed1-ad5d-4d9b-a63f-d3c88d8fd594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_67131942-e1fa-440f-99c3-61683d504539" xlink:href="sny-20250630.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:to="loc_sny_MarketedProductsMember_67131942-e1fa-440f-99c3-61683d504539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_58430b16-948c-4f37-9c85-615654ff9ff7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:to="loc_ifrs-full_SegmentsDomain_58430b16-948c-4f37-9c85-615654ff9ff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:to="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_eb71c8f2-e244-4be3-bef4-04361aeaf7ba" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:to="loc_sny_BiopharmaSegmentMember_eb71c8f2-e244-4be3-bef4-04361aeaf7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_46f7d420-b61b-44f4-918c-f6bfac9b808f" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_BusinessOperatingIncome_46f7d420-b61b-44f4-918c-f6bfac9b808f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_e3d48deb-98fb-4952-a17f-fa7af4b9c491" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_e3d48deb-98fb-4952-a17f-fa7af4b9c491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f72380d2-3169-4b60-b04b-19bc1b40e074" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f72380d2-3169-4b60-b04b-19bc1b40e074" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b16d569d-e13f-48cb-8c95-3b2e53f18fb2" xlink:href="sny-20250630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b16d569d-e13f-48cb-8c95-3b2e53f18fb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_6795c7b0-80f8-4ff8-bde0-b8ef77c51ec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_6795c7b0-80f8-4ff8-bde0-b8ef77c51ec2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_8b8c4b19-aa6e-45ef-92da-9f1ca94a2d66" xlink:href="sny-20250630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_8b8c4b19-aa6e-45ef-92da-9f1ca94a2d66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_1881d459-0fb5-4b38-90ef-c2bebd837505" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_1881d459-0fb5-4b38-90ef-c2bebd837505" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_8a942302-2c99-4d12-8479-5d0a8a2de094" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_OtherGainsLossesAndLitigation_8a942302-2c99-4d12-8479-5d0a8a2de094" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_b15fca1d-510e-4cc9-85e9-6009719f3c53" xlink:href="sny-20250630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_IncomeResultingFromOutLicensing_b15fca1d-510e-4cc9-85e9-6009719f3c53" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7cbd38a6-d1b1-43c2-a0ad-b1bd8aec90f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_7cbd38a6-d1b1-43c2-a0ad-b1bd8aec90f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_4c494e03-d413-499c-a562-12e0353a370a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_FinanceCosts_4c494e03-d413-499c-a562-12e0353a370a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_4a4feec4-275b-4b3e-84cb-919619e2ab7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_FinanceIncome_4a4feec4-275b-4b3e-84cb-919619e2ab7e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_89459853-5125-4ebd-b73c-557c2c7a75e6" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_89459853-5125-4ebd-b73c-557c2c7a75e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_56204cf5-3345-4ba1-a730-1e10ac2a60eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_56204cf5-3345-4ba1-a730-1e10ac2a60eb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_695b26ad-29f9-49f0-be5a-8bfe154f2e9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_695b26ad-29f9-49f0-be5a-8bfe154f2e9c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e87eba1-3478-4574-8cec-d8d740786c7c" xlink:href="sny-20250630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e87eba1-3478-4574-8cec-d8d740786c7c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3e9b6586-a871-4fa2-a7e0-4afdca04d988" xlink:href="sny-20250630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3e9b6586-a871-4fa2-a7e0-4afdca04d988" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss_be8db8fb-3445-4360-bd3d-821dd8aa8b39" xlink:href="sny-20250630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_NetReversalOfImpairmentLoss_be8db8fb-3445-4360-bd3d-821dd8aa8b39" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_a343a840-f645-4e65-bde9-4c7ded505769" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_a343a840-f645-4e65-bde9-4c7ded505769" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_7e331701-4e59-4a1f-9b58-8d9753e286a9" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_7e331701-4e59-4a1f-9b58-8d9753e286a9" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:to="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_15d6dbae-d112-48e4-b5dc-62da5ac36bf1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:to="loc_ifrs-full_SegmentsDomain_15d6dbae-d112-48e4-b5dc-62da5ac36bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:to="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:to="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_aea8b6a4-4d15-4b3c-bbcf-0cc9c3f4f836" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:to="loc_sny_BiopharmaSegmentMember_aea8b6a4-4d15-4b3c-bbcf-0cc9c3f4f836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_29f8fd13-2202-488c-a624-30aa34eb2225" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_29f8fd13-2202-488c-a624-30aa34eb2225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_a71b4246-7d56-4c44-9265-731e4d0c2fe4" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:to="loc_sny_OpellaMember_a71b4246-7d56-4c44-9265-731e4d0c2fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_677014ac-3e57-46f7-beb5-f2f506c9e3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_677014ac-3e57-46f7-beb5-f2f506c9e3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2db79bf2-cd3d-4236-a35e-bef58b19f91b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2db79bf2-cd3d-4236-a35e-bef58b19f91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_a61f313e-3251-4a43-a523-eea8fe989380" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_a61f313e-3251-4a43-a523-eea8fe989380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_9c366240-857b-4f4f-b69a-92f3f259ba3a" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_sny_NumberOfOperatingSegments_9c366240-857b-4f4f-b69a-92f3f259ba3a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_f950688d-06f3-46b8-b483-af4999cfa23e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_f950688d-06f3-46b8-b483-af4999cfa23e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:href="sny-20250630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:to="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5a077d53-cbd3-4b82-ab26-c0f9738cec18" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:to="loc_country_FR_5a077d53-cbd3-4b82-ab26-c0f9738cec18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1d090074-94a7-4a9b-8262-0cadb00b2a42" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_country_US_1d090074-94a7-4a9b-8262-0cadb00b2a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_07c9d782-899b-46c9-961b-54d71dce08f0" xlink:href="sny-20250630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_07c9d782-899b-46c9-961b-54d71dce08f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_cae81c9c-5683-417b-a5a6-281398b37649" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_country_CN_cae81c9c-5683-417b-a5a6-281398b37649" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_89086b36-8226-4c2f-8cd9-963b265c6401" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_89086b36-8226-4c2f-8cd9-963b265c6401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_f24af244-df00-4006-9b12-d3758c65e0b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_f24af244-df00-4006-9b12-d3758c65e0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_2f2b63a2-c71a-4564-a600-366d21fdd701" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_Goodwill_2f2b63a2-c71a-4564-a600-366d21fdd701" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a9ffdb81-b5fe-499c-b1bd-15a53cc9af39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a9ffdb81-b5fe-499c-b1bd-15a53cc9af39" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationPrincipalCustomersandCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:to="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_a3109e2e-5ddb-4bdb-8287-a680bad6c731_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:to="loc_ifrs-full_MajorCustomersDomain_a3109e2e-5ddb-4bdb-8287-a680bad6c731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:to="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_a1c05f89-74b6-4cdc-8978-7c7bdeb309cf" xlink:href="sny-20250630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_a1c05f89-74b6-4cdc-8978-7c7bdeb309cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_7ce80c21-594f-4695-ba2a-a97bfd09dabf" xlink:href="sny-20250630.xsd#sny_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerOneMember_7ce80c21-594f-4695-ba2a-a97bfd09dabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_8e894250-20e8-439d-abf4-515de4a722dd" xlink:href="sny-20250630.xsd#sny_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerTwoMember_8e894250-20e8-439d-abf4-515de4a722dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_d7ac1dc2-7879-434a-ace1-651ab881e935" xlink:href="sny-20250630.xsd#sny_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerThreeMember_d7ac1dc2-7879-434a-ace1-651ab881e935" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_5e365db9-3fee-44ba-b127-18c16556f6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_5e365db9-3fee-44ba-b127-18c16556f6c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="simple" xlink:href="sny-20250630.xsd#EventsSubsequenttoJune302023Details"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_028df542-208e-4221-a39a-5eae89c13bb3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:to="loc_ifrs-full_CounterpartiesDomain_028df542-208e-4221-a39a-5eae89c13bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:to="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember_fd19df45-7352-491e-9edc-2944b28a2b23" xlink:href="sny-20250630.xsd#sny_RecludixPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:to="loc_sny_RecludixPharmaMember_fd19df45-7352-491e-9edc-2944b28a2b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_48c0e34c-0acd-4659-9e70-1047fa2e808d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_48c0e34c-0acd-4659-9e70-1047fa2e808d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_63314d9f-a4b0-42c5-97a3-0d4a16f86a4a" xlink:href="sny-20250630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:to="loc_sny_MajorCollaborationAgreementMember_63314d9f-a4b0-42c5-97a3-0d4a16f86a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_54aa9325-a62f-42a0-8c6d-bb854a818d34" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_54aa9325-a62f-42a0-8c6d-bb854a818d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_bb894689-c058-46eb-8279-7e8a5b4f809e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:to="loc_ifrs-full_RangeDomain_bb894689-c058-46eb-8279-7e8a5b4f809e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:to="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa33ec38-9217-48dc-9bf1-3cb2c4cd30cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:to="loc_srt_MaximumMember_fa33ec38-9217-48dc-9bf1-3cb2c4cd30cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_827e13f2-2ccd-4b54-be55-6d200fbc9b68_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_827e13f2-2ccd-4b54-be55-6d200fbc9b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_2058529f-8b44-488d-809e-6c19104a0c30" xlink:href="sny-20250630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_2058529f-8b44-488d-809e-6c19104a0c30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a_default" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:to="loc_sny_AssetsAcquisitionDomain_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:to="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_ec6bd059-96a4-42c4-b77f-0ce681ffc09c" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:to="loc_sny_AssetsAcquisitionMember_ec6bd059-96a4-42c4-b77f-0ce681ffc09c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VicebioLtdMember_7e124efa-e319-4a28-90ae-352048a69afa" xlink:href="sny-20250630.xsd#sny_VicebioLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:to="loc_sny_VicebioLtdMember_7e124efa-e319-4a28-90ae-352048a69afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_48df1bcb-fa41-4a4c-97aa-8a074e0dae42" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_UpfrontPayments_48df1bcb-fa41-4a4c-97aa-8a074e0dae42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_8e9bb0e9-2322-4923-ac95-84752a6d8754" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_8e9bb0e9-2322-4923-ac95-84752a6d8754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_e2ffd877-9b6e-4a9d-99fd-612382ab0fda" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_BusinessCombinationPurchasePrice_e2ffd877-9b6e-4a9d-99fd-612382ab0fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialFuturePayments_9630a929-f0bb-4222-9e9e-2965c3d064e0" xlink:href="sny-20250630.xsd#sny_PotentialFuturePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_PotentialFuturePayments_9630a929-f0bb-4222-9e9e-2965c3d064e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_89b77b6d-265d-49a6-825f-d3e8507a15a8" xlink:href="sny-20250630.xsd#sny_TotalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_TotalMilestonePayments_89b77b6d-265d-49a6-825f-d3e8507a15a8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#RevenuefromcontractswithcustomersDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_5b36a411-c864-49f7-8ec2-07828ac5283e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_5b36a411-c864-49f7-8ec2-07828ac5283e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_e27986b7-9437-412e-9537-b5a1bd08c3b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_e27986b7-9437-412e-9537-b5a1bd08c3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_ed409700-baec-4e46-b4f5-b300f4eb59fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:to="loc_ifrs-full_GeographicalAreasDomain_ed409700-baec-4e46-b4f5-b300f4eb59fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_40bad8ed-27b7-474c-8af2-8f32fc10c645" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:to="loc_ifrs-full_GeographicalAreasDomain_40bad8ed-27b7-474c-8af2-8f32fc10c645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersDomain_66436ff1-8138-459c-ae69-d487b04bce5d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:to="loc_ifrs-full_MarketsOfCustomersDomain_66436ff1-8138-459c-ae69-d487b04bce5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersDomain_94fee2c8-000b-4f8c-a000-b4201f4943e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:to="loc_ifrs-full_MarketsOfCustomersDomain_94fee2c8-000b-4f8c-a000-b4201f4943e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersDomain_d381b48d-f9cf-408d-9606-1dbc5bb62d3c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:to="loc_ifrs-full_TypesOfCustomersDomain_d381b48d-f9cf-408d-9606-1dbc5bb62d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersDomain_2cc7f093-24e5-4fcc-a3d8-2540b67bf8f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:to="loc_ifrs-full_TypesOfCustomersDomain_2cc7f093-24e5-4fcc-a3d8-2540b67bf8f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_b2b4cac2-e3d4-4456-962d-417f6f0d7085_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:to="loc_ifrs-full_TypesOfContractsDomain_b2b4cac2-e3d4-4456-962d-417f6f0d7085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2c643182-57d7-4c11-97f9-32870ba5767d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2c643182-57d7-4c11-97f9-32870ba5767d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationDomain_b81ce89e-7a52-4bf8-8449-78c377bec07e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:to="loc_ifrs-full_ContractDurationDomain_b81ce89e-7a52-4bf8-8449-78c377bec07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationDomain_fbba6025-da68-46cc-8ba8-bfdc321018f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:to="loc_ifrs-full_ContractDurationDomain_fbba6025-da68-46cc-8ba8-bfdc321018f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_898551b8-0ceb-49e6-a260-30f2a56b3406_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_898551b8-0ceb-49e6-a260-30f2a56b3406_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8780de7d-3b6c-417e-a7a4-71c87aa05059" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8780de7d-3b6c-417e-a7a4-71c87aa05059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsDomain_400f7718-6215-42bc-92c5-4b399b1bdaf7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:to="loc_ifrs-full_SalesChannelsDomain_400f7718-6215-42bc-92c5-4b399b1bdaf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsDomain_caf245f6-9c44-460c-960e-36690935a03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:to="loc_ifrs-full_SalesChannelsDomain_caf245f6-9c44-460c-960e-36690935a03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_063387e1-3ba3-40f9-bd1c-7909554ee431_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:to="loc_ifrs-full_SegmentsDomain_063387e1-3ba3-40f9-bd1c-7909554ee431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:to="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_485c5b24-c9a6-4051-927d-8e53df69dcc5" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:to="loc_sny_BiopharmaSegmentMember_485c5b24-c9a6-4051-927d-8e53df69dcc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_c185f884-824e-4cc6-b2ed-fa8802082110" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:to="loc_sny_OpellaBusinessMember_c185f884-824e-4cc6-b2ed-fa8802082110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_8289540a-d7c1-4bf4-83ec-8f04944989f9" xlink:href="sny-20250630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_8289540a-d7c1-4bf4-83ec-8f04944989f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_3e7386a0-1375-4f39-8a91-19e63e0f5228" xlink:href="sny-20250630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_3e7386a0-1375-4f39-8a91-19e63e0f5228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_cf344889-3bbc-460e-b4dc-b5535358b8eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_ifrs-full_RevenueFromRoyalties_cf344889-3bbc-460e-b4dc-b5535358b8eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue_dc4c73f3-ef17-4f7b-9d3e-d737728bf188" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_MiscellaneousOtherRevenue_dc4c73f3-ef17-4f7b-9d3e-d737728bf188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_e32123dd-2f1e-472a-8565-3722d1eeb49f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_ifrs-full_OtherRevenue_e32123dd-2f1e-472a-8565-3722d1eeb49f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:to="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_ed386d24-b750-473d-93ea-4ffa963a6597_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:to="loc_ifrs-full_MaturityDomain_ed386d24-b750-473d-93ea-4ffa963a6597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:to="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_11296a96-f371-4180-a4df-5f0c6faac10c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_11296a96-f371-4180-a4df-5f0c6faac10c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4ddd946d-53de-48f1-8de2-ac2dd8db649f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4ddd946d-53de-48f1-8de2-ac2dd8db649f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_4135fb10-ba6b-42ee-8bb7-86bc12c6e86a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_4135fb10-ba6b-42ee-8bb7-86bc12c6e86a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_81a5f73d-d98f-464d-9941-3f7c8f8cd8c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_81a5f73d-d98f-464d-9941-3f7c8f8cd8c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_b4543bb6-9f51-4769-9c7b-0d020a9a18ce" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_b4543bb6-9f51-4769-9c7b-0d020a9a18ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_8c13bf6f-2e77-4cf1-8417-e776b03229ac" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_8c13bf6f-2e77-4cf1-8417-e776b03229ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_1f1605a9-d4ca-4058-a4d7-75c036f565f7" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_1f1605a9-d4ca-4058-a4d7-75c036f565f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_8b305837-f248-4415-94ce-417ddf0b767b" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_8b305837-f248-4415-94ce-417ddf0b767b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_39d28ab2-6490-4998-b114-e9e8864e5239" xlink:href="sny-20250630.xsd#sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_39d28ab2-6490-4998-b114-e9e8864e5239" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_fa2a86bc-39e9-4dc4-929d-471c8de1a644_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_fa2a86bc-39e9-4dc4-929d-471c8de1a644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_5b5bfbae-4d5a-4135-a9de-1a03e7b8e151" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:to="loc_sny_OpellaBusinessMember_5b5bfbae-4d5a-4135-a9de-1a03e7b8e151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c3078b46-35b7-493e-8e4e-323e0ce10a00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c3078b46-35b7-493e-8e4e-323e0ce10a00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_53c9ccc8-9f51-4b1d-8769-28cd82946f3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_53c9ccc8-9f51-4b1d-8769-28cd82946f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInProfitLossFromDiscontinuedOperations_226d7eb7-adbf-4267-a1a4-9dc0ff1bded5" xlink:href="sny-20250630.xsd#sny_ChangesInProfitLossFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_ChangesInProfitLossFromDiscontinuedOperations_226d7eb7-adbf-4267-a1a4-9dc0ff1bded5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_039b0a0b-c4db-495d-979e-841f76c13efe" xlink:href="sny-20250630.xsd#sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_039b0a0b-c4db-495d-979e-841f76c13efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_803787eb-29ab-4339-82db-c743ecc9484c" xlink:href="sny-20250630.xsd#sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_803787eb-29ab-4339-82db-c743ecc9484c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_d25d0cc6-bb15-4f9f-9c63-1a26849eebd3" xlink:href="sny-20250630.xsd#sny_GoodwillDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_d25d0cc6-bb15-4f9f-9c63-1a26849eebd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_d531969c-b2b6-46eb-92d8-463628e10a62" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_d531969c-b2b6-46eb-92d8-463628e10a62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_ff842c3c-9372-40a3-8eab-85042bbd6de6" xlink:href="sny-20250630.xsd#sny_InventoriesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_ff842c3c-9372-40a3-8eab-85042bbd6de6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_cae14581-13df-44d7-8d26-515d8a33c251" xlink:href="sny-20250630.xsd#sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_cae14581-13df-44d7-8d26-515d8a33c251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_61b833c5-6547-4ae6-b7b3-8192c21b8a64" xlink:href="sny-20250630.xsd#sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_61b833c5-6547-4ae6-b7b3-8192c21b8a64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_13590751-dfc2-4d1c-b7f5-a067b2a603ab" xlink:href="sny-20250630.xsd#sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_13590751-dfc2-4d1c-b7f5-a067b2a603ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_98fd0c10-4251-4532-8797-5c69734ee84b" xlink:href="sny-20250630.xsd#sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_98fd0c10-4251-4532-8797-5c69734ee84b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_dd163462-bada-479f-b9cd-187bed4fcbfb" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_dd163462-bada-479f-b9cd-187bed4fcbfb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_996fc23f-4c9b-4019-8e61-aa62f448112a" xlink:href="sny-20250630.xsd#sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_996fc23f-4c9b-4019-8e61-aa62f448112a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_9f7f224b-9f7c-43fc-834f-ff9d241f5b5d" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_9f7f224b-9f7c-43fc-834f-ff9d241f5b5d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_43eb9a6a-03d6-48c2-831c-4f6196ec8c86" xlink:href="sny-20250630.xsd#sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_43eb9a6a-03d6-48c2-831c-4f6196ec8c86" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_d87fcb1f-37fb-4cb4-b92d-f943bf5db6b2" xlink:href="sny-20250630.xsd#sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_d87fcb1f-37fb-4cb4-b92d-f943bf5db6b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_2caa7c02-267c-4df7-ab64-4ec6f105c2fa" xlink:href="sny-20250630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_2caa7c02-267c-4df7-ab64-4ec6f105c2fa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_80ab4b3a-1f58-4808-9271-b2f74e9ef1bd" xlink:href="sny-20250630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_80ab4b3a-1f58-4808-9271-b2f74e9ef1bd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_9f65f664-27fd-4281-942b-81d1d94d10ae" xlink:href="sny-20250630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_9f65f664-27fd-4281-942b-81d1d94d10ae" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_12d24a7e-51f6-4ecb-a60b-cd0c998fe4d0" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_12d24a7e-51f6-4ecb-a60b-cd0c998fe4d0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_897b7636-5548-433c-bcc5-eaf3b1d04e15" xlink:href="sny-20250630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_897b7636-5548-433c-bcc5-eaf3b1d04e15" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_3eb7838e-5f2d-4127-8073-11525ebcbd7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_3eb7838e-5f2d-4127-8073-11525ebcbd7d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_619fa632-d6f4-47ed-906f-de17b2dc9619" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_WeightedAverageShares_619fa632-d6f4-47ed-906f-de17b2dc9619" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_2de339aa-70b2-41ea-97d6-9fa0769dc589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_2de339aa-70b2-41ea-97d6-9fa0769dc589" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_6d6c39e6-82a9-47b1-9902-6767fcd85d94" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_6d6c39e6-82a9-47b1-9902-6767fcd85d94" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_d8810a8e-d181-43e4-9fd1-19e78d1b99c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_d8810a8e-d181-43e4-9fd1-19e78d1b99c2" xlink:type="arc" order="26"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sny-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_429f9ac5-888e-4efd-96ef-26710fd6769b_terseLabel_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Received From Nonconsolidated Entities Classified As Operating Activities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:href="sny-20250630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:to="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_c35b32ae-1b52-432d-a000-6bf3fbf97442_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates [Axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ScribeTherapeuticsMember_9470b2e4-bab3-457d-addb-9a07ead71fd0_terseLabel_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_label_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics [Member]</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember" xlink:href="sny-20250630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ScribeTherapeuticsMember" xlink:to="lab_sny_ScribeTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_4d712603-9aee-4da3-aac1-dce3382bf8b8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income/(expenses), net related to Regeneron</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b199c8ff-cc5b-433c-bae8-85173b7b16ed_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_4210fad6-4dcf-4045-b39c-f15e922be345_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes arising from issuance of restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Issuance Of Restricted Shares, Equity</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through issuance of restricted shares, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:to="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentAxis_1ab44374-1149-470d-ae90-3354a169ea4c_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_label_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_documentation_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis" xlink:href="sny-20250630.xsd#sny_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentAxis" xlink:to="lab_sny_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_a0d8a960-8dad-446f-92d0-bb17dae4bd57_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Singapore Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c5bf5f76-ca52-4da6-965f-e901b9b41e74_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0fea0d06-2cb4-415d-bf28-3f23d12aed53_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_5a490ba1-5e13-4a9d-b22e-49414d51e520_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_67ad3781-c607-4177-9c76-d8cafcc99daa_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 0.92%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_5adc67fb-54f8-44a1-a58d-3dd889352a11_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility, expires in 2027</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility One [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated credit facility one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityOneMember" xlink:to="lab_sny_SyndicatedCreditFacilityOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_d63267e5-1e1f-4d38-9a2b-8a0fbac7f7ce_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_20400624-fc59-4435-90e7-50fa45c03e26_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfInvestmentsInEquityInstruments_06a5672c-a1a7-4c2f-9e0f-ad90d7252a5f_terseLabel_en-US" xlink:label="lab_sny_FairValueOfInvestmentsInEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Investments in Equity Instruments</link:label>
    <link:label id="lab_sny_FairValueOfInvestmentsInEquityInstruments_label_en-US" xlink:label="lab_sny_FairValueOfInvestmentsInEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Investments in Equity Instruments</link:label>
    <link:label id="lab_sny_FairValueOfInvestmentsInEquityInstruments_documentation_en-US" xlink:label="lab_sny_FairValueOfInvestmentsInEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Investments in Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfInvestmentsInEquityInstruments" xlink:href="sny-20250630.xsd#sny_FairValueOfInvestmentsInEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfInvestmentsInEquityInstruments" xlink:to="lab_sny_FairValueOfInvestmentsInEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1bc1b158-0ebb-459f-a9c4-222dfa8394bf_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_2e2aa1e1-552d-42e6-b0ab-4314699bf057_terseLabel_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of share repurchase program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_label_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Share Repurchase Program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_documentation_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of share repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram" xlink:href="sny-20250630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PeriodOfShareRepurchaseProgram" xlink:to="lab_sny_PeriodOfShareRepurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_233b19f9-235d-42fb-a69b-b54ffedf8c00_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain" xlink:to="lab_ifrs-full_GeographicalAreasDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_2de1fbf1-ad9c-4dbb-a867-e7fa116bca24_terseLabel_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow and fair value hedge</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_label_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge [Member]</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_documentation_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember" xlink:href="sny-20250630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowAndFairValueHedgeMember" xlink:to="lab_sny_CashFlowAndFairValueHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_8665bd52-bd48-44e5-a885-08d3e866f629_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_bd214a12-306d-44b7-aa98-1573a4dc02e6_negatedLabel_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_label_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Interest Cost Related To Employee Benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_documentation_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:href="sny-20250630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:to="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingAverageDrawdown_82b5d076-7bb2-497c-a4d4-1ab8603d4659_terseLabel_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, average drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_label_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown" xlink:href="sny-20250630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingAverageDrawdown" xlink:to="lab_sny_BorrowingAverageDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_bc57f624-08d1-455b-b682-79745ea82094_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis of Financial Income and Expenses</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for financial income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_df2f78f5-d0f0-4b69-b7e1-d5077e418f0d_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7d91eaf0-97d3-4afd-85e9-e6e9f47f24dc_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_3125a0de-4df9-4e07-87af-bc5a243650ad_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of dividends to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PenaltyFeeIncurred_6a05b628-0e53-427e-9021-2b7c857efd1a_terseLabel_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_label_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_documentation_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PenaltyFeeIncurred" xlink:to="lab_sny_PenaltyFeeIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersDomain_4c4e6e79-4eca-4f3f-8c61-de5935dac8e9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers [Member]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersDomain_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersDomain" xlink:to="lab_ifrs-full_MajorCustomersDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_4c31745d-e16c-4fbc-8e87-42f8e8d8dda9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OthersMember_12ddf81e-c08d-4dd3-bda1-785bd14e8da0_terseLabel_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_OthersMember_label_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others [Member]</link:label>
    <link:label id="lab_sny_OthersMember_documentation_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember" xlink:href="sny-20250630.xsd#sny_OthersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OthersMember" xlink:to="lab_sny_OthersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_8953cebc-9493-48f8-aa6c-bd5ed3747112_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_23898bb1-cc0e-417c-b386-5c347543a2e1_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_label_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:href="sny-20250630.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:to="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilities1Member_0039637d-bda1-456f-ac54-546a8c9ca5cd_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_label_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities1 [member]</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_documentation_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member" xlink:href="sny-20250630.xsd#sny_OtherLiabilities1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilities1Member" xlink:to="lab_sny_OtherLiabilities1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_85659099-e618-481f-8b98-ea1c9746b80d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue</link:label>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherRevenueTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherRevenueTextBlock" xlink:to="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_541d5f6f-4ee5-4191-b622-ccdf58443ef1_terseLabel_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on divestment of some mature products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_label_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains On Divestment Of Products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_documentation_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains on divestment of products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts" xlink:href="sny-20250630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsOnDivestmentOfProducts" xlink:to="lab_sny_GainsOnDivestmentOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ea9abb3f-ea5d-449c-897c-88237142704f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_e64a5073-2da5-41e1-a15b-73fe65ac4b8b_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_b296ce8e-181c-4e5b-8032-9bd6b30eda9f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IndustrialSalesMember_8a12d8d5-f522-4154-86ac-b8711fce60c9_terseLabel_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industrial Sales [Member]</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_label_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industrial Sales [Member]</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_documentation_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Industrial Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember" xlink:href="sny-20250630.xsd#sny_IndustrialSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IndustrialSalesMember" xlink:to="lab_sny_IndustrialSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsDomain_17bf8855-01d3-4ada-8483-03d3d888ec76_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [domain]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsDomain_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain" xlink:to="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_6ef73c0a-3c79-45e7-85ea-71604ee3dbe5_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, development milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredRDMember_248ce059-89f8-44e8-9150-e0b17866dea8_terseLabel_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired R D</link:label>
    <link:label id="lab_sny_AcquiredRDMember_label_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired R D [Member]</link:label>
    <link:label id="lab_sny_AcquiredRDMember_documentation_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired R D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember" xlink:href="sny-20250630.xsd#sny_AcquiredRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredRDMember" xlink:to="lab_sny_AcquiredRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_75695b75-3adc-4798-8c68-92101d9b2b26_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_25ae85c4-6198-4b22-878c-6eeba0febd42_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DeferredCashPayments_d06b081f-765a-4f8e-b039-a7e2a0e0ee06_terseLabel_en-US" xlink:label="lab_sny_DeferredCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Cash Payments</link:label>
    <link:label id="lab_sny_DeferredCashPayments_label_en-US" xlink:label="lab_sny_DeferredCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Cash Payments</link:label>
    <link:label id="lab_sny_DeferredCashPayments_documentation_en-US" xlink:label="lab_sny_DeferredCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredCashPayments" xlink:href="sny-20250630.xsd#sny_DeferredCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DeferredCashPayments" xlink:to="lab_sny_DeferredCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_34e9a6f0-24b6-4b17-aaf1-9c108b538fe6_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_6559e48c-db26-402b-830d-5a002f0562a3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsDomain_0b98bc1f-33c2-42de-aa2b-323bce5828bb_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsDomain_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsDomain" xlink:to="lab_ifrs-full_HedgedItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_597eb854-1cf2-4a77-bccb-496f39c0e183_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsAxis" xlink:to="lab_ifrs-full_HedgedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_3aaf0285-1f21-4833-969d-0fb980c3298f_negatedLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_7e813cd5-4d8f-4a42-964c-8c9374432232_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_d850bd25-398a-4674-9da5-bdd28891b7c4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareProgramDomain_b13a47aa-f5e7-4269-a3e6-eeb3fa9cc636_terseLabel_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:label id="lab_sny_ShareProgramDomain_label_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:label id="lab_sny_ShareProgramDomain_documentation_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain" xlink:href="sny-20250630.xsd#sny_ShareProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareProgramDomain" xlink:to="lab_sny_ShareProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_5232942d-b6c6-48ff-8f16-5694db96e376_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity instruments included in financial assets and financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_efdd1326-b1e1-4bac-9483-76090fe751ed_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Turkey</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">T&#220;RKIYE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_dedebea4-4bc6-4320-bd99-ee6ee0e47a58_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated individually immaterial associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:to="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PharmaSegmentMember_dd34ddcb-97d8-4d80-8aee-a728858fd465_terseLabel_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharma Segment</link:label>
    <link:label id="lab_sny_PharmaSegmentMember_label_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharma Segment [Member]</link:label>
    <link:label id="lab_sny_PharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharma Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember" xlink:href="sny-20250630.xsd#sny_PharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PharmaSegmentMember" xlink:to="lab_sny_PharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_118d8635-22e1-4fe3-b1e0-ca4a77128269_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_8947ec95-1679-467a-8d4a-c35cd44f2596_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_a686238e-5242-4526-a22d-97d0c7f7bb61_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average residual life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_c24f4fc4-f2d8-44e2-9033-de98986c947d_terseLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives [Member]</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_9dc82712-66d5-4c4a-868d-3757834e0822_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_d6351454-4621-4e49-938a-c3914debdfd7_terseLabel_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees share ownership plan</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_label_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan [Member]</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_documentation_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees share ownership plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember" xlink:href="sny-20250630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeeShareOwnershipPlanMember" xlink:to="lab_sny_EmployeeShareOwnershipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_0e81d429-7636-4d64-b9c9-74c13301c9c6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherTerritoriesMember_4aefe77c-b137-4a9c-9592-c4fe38ff88ac_terseLabel_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other territories</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_label_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Territories [Member]</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_documentation_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember" xlink:href="sny-20250630.xsd#sny_OtherTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherTerritoriesMember" xlink:to="lab_sny_OtherTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_738387e7-0785-41d5-aa51-a1e05395339e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_118784e2-28cc-4937-b56f-5c6e15fb1272_negatedLabel_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of intangible assets</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization And Impairment Of Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and impairment of intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20250630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_7b914a6b-3141-463c-890f-c8fc3f249ec3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MarketsOfCustomersDomain_4c790dc0-fd09-4083-9e1c-34a1f857b85d_terseLabel_en-US" xlink:label="lab_ifrs-full_MarketsOfCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Markets of customers [domain]</link:label>
    <link:label id="lab_ifrs-full_MarketsOfCustomersDomain_label_en-US" xlink:label="lab_ifrs-full_MarketsOfCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Markets of customers [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MarketsOfCustomersDomain" xlink:to="lab_ifrs-full_MarketsOfCustomersDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProductsSegmentMember_d681d7da-032d-4c2a-a0e0-ef8c26421a73_terseLabel_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Products Segment</link:label>
    <link:label id="lab_sny_OtherProductsSegmentMember_label_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products Segment [Member]</link:label>
    <link:label id="lab_sny_OtherProductsSegmentMember_documentation_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember" xlink:href="sny-20250630.xsd#sny_OtherProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProductsSegmentMember" xlink:to="lab_sny_OtherProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_c27b1b4d-038b-496e-a620-dbaf2ee1c68f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_5cbd2532-b51d-47f8-92f1-ca27c15b591d_terseLabel_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_cedc28c4-7b0f-45fe-9d3b-f72e47e05b62_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase through remeasurement of financial liability</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Current Liabilities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:to="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_6b16a3d2-91ee-45d6-8b27-ae443cdde0b3_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingSegmentsMember" xlink:to="lab_ifrs-full_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_48ec07d6-2255-48c9-94f5-56f847185777_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_299eb266-939f-4b62-9dfe-549ba166d476_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation and Arbitration Proceedings</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_41fb2a77-e595-4b84-99ad-e5d186a0bbcc_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_5675d26d-214e-426a-a6cd-ecfe308f3012_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionDomain_c82d6b8d-8ecf-4501-b352-444934c3946c_terseLabel_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_label_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_documentation_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain" xlink:href="sny-20250630.xsd#sny_MarketConditionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionDomain" xlink:to="lab_sny_MarketConditionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementAxis_7cc039e0-fb77-411e-bf7d-045dbe9192a5_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_label_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementAxis" xlink:to="lab_sny_TypesOfAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_1847c60d-de04-4f30-bcc3-cd9501f20f1e_terseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exceptional supplementary dividend, in percentage</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:to="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AllergyMember_28aeff78-1558-4400-8ed2-c209ec8facee_terseLabel_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allergy [Member]</link:label>
    <link:label id="lab_sny_AllergyMember_label_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allergy [Member]</link:label>
    <link:label id="lab_sny_AllergyMember_documentation_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allergy, Cough And Cold [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember" xlink:href="sny-20250630.xsd#sny_AllergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AllergyMember" xlink:to="lab_sny_AllergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_999f5531-cf43-4882-9c58-31edc26764c4_terseLabel_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, discontinued operations</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_label_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, discontinued operations</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:to="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherBankBorrowings_a1c33741-d7e2-4761-b9e0-3a364d84e43c_terseLabel_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other bank borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_label_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Bank Borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_documentation_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other bank borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherBankBorrowings" xlink:to="lab_sny_OtherBankBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_53e4067e-6a97-40dc-9a33-a2e3b36bda43_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about hyperinflationary reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:to="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_2e7a6915-646f-4fa8-b96b-7c043a91e7c6_terseLabel_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major financial liability</link:label>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_label_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Financial Liability [Member]</link:label>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_documentation_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Financial Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember" xlink:href="sny-20250630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorFinancialLiabilityMember" xlink:to="lab_sny_MajorFinancialLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_c446f152-077b-4653-9710-de86d6c05b8e_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities related to assets held for sale</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_2fadb0e4-1b0e-477b-a7d0-27eee26fe9f9_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_357eb246-3348-4380-8a5b-0844d0a12043_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of Hedges [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of hedges [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesAxis" xlink:to="lab_ifrs-full_TypesOfHedgesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_4e53877b-addc-4b99-bcc9-230260a4c1e4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_b69e61f1-c3d4-4bf4-be0c-de0b44409707_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) excluding investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BiopharmaSegmentMember_9ce76651-6473-41c6-9f13-1997aba1cba8_terseLabel_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_label_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceuticals segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BiopharmaSegmentMember" xlink:to="lab_sny_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestIncome_4c69bbd6-31a4-49d9-ad74-3376f592de9a_terseLabel_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_sny_InterestIncome_label_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_sny_InterestIncome_documentation_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome" xlink:href="sny-20250630.xsd#sny_InterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestIncome" xlink:to="lab_sny_InterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VicebioLtdMember_baea28dd-0aba-4f60-ae95-b867872ddecd_terseLabel_en-US" xlink:label="lab_sny_VicebioLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vicebio Ltd</link:label>
    <link:label id="lab_sny_VicebioLtdMember_label_en-US" xlink:label="lab_sny_VicebioLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vicebio Ltd [Member]</link:label>
    <link:label id="lab_sny_VicebioLtdMember_documentation_en-US" xlink:label="lab_sny_VicebioLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vicebio Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VicebioLtdMember" xlink:href="sny-20250630.xsd#sny_VicebioLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VicebioLtdMember" xlink:to="lab_sny_VicebioLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_d55ac673-a61c-468c-bbaa-a93e13c4b4a3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about finance income expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent detailed information about finance income expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_70d7a55f-db83-4b35-a337-866167b82c3d_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesChannelsDomain_14b043a7-9598-4e5b-908e-a8b4da0f7610_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesChannelsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales channels [domain]</link:label>
    <link:label id="lab_ifrs-full_SalesChannelsDomain_label_en-US" xlink:label="lab_ifrs-full_SalesChannelsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales channels [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesChannelsDomain" xlink:to="lab_ifrs-full_SalesChannelsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_40d75d0b-074a-4e03-8514-de85a5da5226_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_3ed82b3e-cba4-4264-821a-d3797977b253_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_07f29682-9868-46e1-92e2-5dd32a823397_terseLabel_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;1 billion bonds maturing June 2023</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_label_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Bonds Maturing June 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Bonds Maturing June 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:href="sny-20250630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:to="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_27042cdf-8590-430d-93ff-19c49eaf4d88_terseLabel_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_label_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revisions To Tax Exposures And Settlements Of Tax Disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_documentation_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:href="sny-20250630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:to="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_ff537d2c-8d9d-4618-b4dd-80f3e820a5af_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_43818368-dc5a-4093-be51-e8ad82361f33_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_90e7b897-0fdd-4c55-9e63-6ea8b20d5718_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other current assets and other current liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Current Assets And Other Current Liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:to="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxesOnShareCancellations_b07f1968-0d37-43af-847c-6ddc844d2d69_terseLabel_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes on Share Cancellations</link:label>
    <link:label id="lab_sny_TaxesOnShareCancellations_label_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Share Cancellations</link:label>
    <link:label id="lab_sny_TaxesOnShareCancellations_documentation_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxes on Share Cancellations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations" xlink:href="sny-20250630.xsd#sny_TaxesOnShareCancellations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxesOnShareCancellations" xlink:to="lab_sny_TaxesOnShareCancellations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_c47347f1-eb5f-4f13-94e2-72ae64e9bac9_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DupixentMember_bf850c51-7dcc-442f-b8ba-9269c43c423e_terseLabel_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dupixent</link:label>
    <link:label id="lab_sny_DupixentMember_label_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dupixent [Member]</link:label>
    <link:label id="lab_sny_DupixentMember_documentation_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dupixent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember" xlink:href="sny-20250630.xsd#sny_DupixentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DupixentMember" xlink:to="lab_sny_DupixentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_14d443aa-27a9-4978-adb3-38f55f8a52ae_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:href="sny-20250630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherBorrowings_ee23321c-5cd2-40fc-a278-569a84c83705_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherBorrowings" xlink:to="lab_ifrs-full_OtherBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_7a2ad245-94f2-488b-b373-e2af9262602f_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_label_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestCostsCapitalised" xlink:to="lab_ifrs-full_InterestCostsCapitalised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_b5660553-3e14-479a-adbb-a9d235e02d75_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_646f1f50-cfdd-4dcb-b53a-d0df1ec646e2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expenses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_3a43f884-444c-40c2-b1a1-b1a2fa73faf4_terseLabel_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per Share Value of Shares Repurchased</link:label>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_label_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per Share Value of Shares Repurchased</link:label>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per Share Value of Shares Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased" xlink:href="sny-20250630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PerShareValueOfSharesRepurchased" xlink:to="lab_sny_PerShareValueOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_5a3bafe3-da46-4b4c-a08e-b066b18dfbdc_terseLabel_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regular milestone payments</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20250630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralMedicinesMember_787d67f9-c1f6-4d70-b851-4555826aac88_terseLabel_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Medicines [Member]</link:label>
    <link:label id="lab_sny_GeneralMedicinesMember_label_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Medicines [Member]</link:label>
    <link:label id="lab_sny_GeneralMedicinesMember_documentation_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Medicines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember" xlink:href="sny-20250630.xsd#sny_GeneralMedicinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralMedicinesMember" xlink:to="lab_sny_GeneralMedicinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesSubscribed_5f746842-de21-45c0-a2af-feed6a67cf81_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_label_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Subscribed</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_documentation_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares subscribed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed" xlink:href="sny-20250630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesSubscribed" xlink:to="lab_sny_NumberOfSharesSubscribed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_ff15e7e8-0961-4154-a4a7-8856f8727609_terseLabel_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;1.75 billion bonds maturing March 2023</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_label_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:href="sny-20250630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:to="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_84f17df5-c258-4380-a0b7-3c072a1ae5eb_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ToujeoMember_4d48fc33-8a1c-403d-b062-e827f37be29a_terseLabel_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toujeo</link:label>
    <link:label id="lab_sny_ToujeoMember_label_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toujeo [Member]</link:label>
    <link:label id="lab_sny_ToujeoMember_documentation_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toujeo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember" xlink:href="sny-20250630.xsd#sny_ToujeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ToujeoMember" xlink:to="lab_sny_ToujeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_9cb8850e-1f50-4817-9eef-2b524ebda46e_negatedLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_6bb82b72-efbd-4be6-aa83-a52f0167461a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_a2d3c10f-1977-49a0-8c9f-e87ccdd40dd0_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithoutMarketConditionMember_df6121f4-fd8b-419c-886c-2b7748a43eba_terseLabel_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Without market condition</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_label_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Without Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Without Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember" xlink:href="sny-20250630.xsd#sny_WithoutMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithoutMarketConditionMember" xlink:to="lab_sny_WithoutMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_05cde550-8a24-43b0-9807-fb8ea7fcdb4d_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [Axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashTransferredPerShare_3cb96770-75d8-4c1f-8644-7cf7361bc983_terseLabel_en-US" xlink:label="lab_sny_CashTransferredPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Transferred, Per Share</link:label>
    <link:label id="lab_sny_CashTransferredPerShare_label_en-US" xlink:label="lab_sny_CashTransferredPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Transferred, Per Share</link:label>
    <link:label id="lab_sny_CashTransferredPerShare_documentation_en-US" xlink:label="lab_sny_CashTransferredPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Transferred, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashTransferredPerShare" xlink:href="sny-20250630.xsd#sny_CashTransferredPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashTransferredPerShare" xlink:to="lab_sny_CashTransferredPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_bb77210d-f851-4dc9-bd92-ebe57bb17472_terseLabel_en-US" xlink:label="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_43894e3d-7282-42e0-a4c2-d336dc343036_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_88dc3daf-48f8-4214-8a00-1f3338b86594_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2027Member_c97e8fa3-cdd9-4323-a321-8f43996fea45_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2027</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2027Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2027 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2027Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2027Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMarch2027Member" xlink:to="lab_sny_FixedRateBondMaturingMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a13b231e-6ebb-4d54-9d3e-d6b48c9d1c45_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_b792fae5-23ce-459f-bf48-0fcdfb7e2049_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_93a20fbe-fa72-46bf-bb7b-160a35ba0ec7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_JevtanaMember_263674ec-dfa8-437e-a16e-0b10536b6d4c_terseLabel_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jevtana</link:label>
    <link:label id="lab_sny_JevtanaMember_label_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jevtana [Member]</link:label>
    <link:label id="lab_sny_JevtanaMember_documentation_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jevtana.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember" xlink:href="sny-20250630.xsd#sny_JevtanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_JevtanaMember" xlink:to="lab_sny_JevtanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_d9c2c226-55c8-476e-afeb-1ff2ed027d6c_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaBusinessMember_5b5bca27-89a2-44fd-a2bf-ed00a909a89a_terseLabel_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opella Business</link:label>
    <link:label id="lab_sny_OpellaBusinessMember_label_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opella Business [Member]</link:label>
    <link:label id="lab_sny_OpellaBusinessMember_documentation_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opella Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaBusinessMember" xlink:to="lab_sny_OpellaBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_d170bb63-7aab-4453-896b-fa3ff09f285a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_a56ff0db-4b30-4179-b9a7-46f6b0f4735a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssets" xlink:to="lab_ifrs-full_OtherIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_c2e5b57b-6db8-4c11-aada-57abf58fdf1f_terseLabel_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets at fair value through profit or loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sny-20250630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_07809bfa-0ed6-49de-9073-8db6f0df4741_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_0a25b48c-ccd0-4021-b0af-285fce219d87_terseLabel_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_label_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember" xlink:href="sny-20250630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherNonCoreAssetsMember" xlink:to="lab_sny_OtherNonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_e0651d3e-0e89-4cb8-be1d-e14c56e32a8f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_34cabb5c-e947-4631-9d3d-6b279c9d46df_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_809073a7-fe8a-4546-8b47-caecf18cf70d_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesChannelsAxis_b72ab2c4-efa3-46a4-83a5-bbbb43b6967d_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesChannelsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales channels [axis]</link:label>
    <link:label id="lab_ifrs-full_SalesChannelsAxis_label_en-US" xlink:label="lab_ifrs-full_SalesChannelsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales channels [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesChannelsAxis" xlink:to="lab_ifrs-full_SalesChannelsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_37f1b9a9-8185-4d0b-81de-48b914be7c3b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_4832aedc-1b2a-4040-8d44-4c538cf316ed_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Income and Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProventionBioIncMember_36249cee-f67c-4ff0-b8b4-4a6342b51cb3_terseLabel_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention Bio</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_label_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc [Member]</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_documentation_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProventionBioIncMember" xlink:to="lab_sny_ProventionBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1cbff931-3cb1-40d2-be2c-71dc832bc84d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_65941212-29db-4aa8-9282-fa2b2ebb5226_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2022</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2022Member" xlink:to="lab_sny_RestrictedSharePlan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OthersCounterpartyMember_9c3a07df-e8bb-4dfb-b4a2-42dc5c081a95_terseLabel_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (mainly Zaltrap and Libtayo)</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_label_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_documentation_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember" xlink:href="sny-20250630.xsd#sny_OthersCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OthersCounterpartyMember" xlink:to="lab_sny_OthersCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_22759f9a-c31d-4c73-b419-80cfb0edf537_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesMember_11774188-235c-49e6-9b84-34e5d364ae42_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesMember" xlink:to="lab_sny_ForwardCurrencySalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesHeld_811eb30b-3bb5-4c3f-92ca-6641d9685aa1_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_label_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Held</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_documentation_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld" xlink:href="sny-20250630.xsd#sny_NumberOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesHeld" xlink:to="lab_sny_NumberOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtNotionalAmountMember_2e296841-d994-40e3-be98-ab45579c2ea1_terseLabel_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_label_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Notional Amount [member]</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_documentation_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At notional amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtNotionalAmountMember" xlink:to="lab_sny_AtNotionalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_c8eadb65-fb4d-4ff8-b008-db0b0ec93dfa_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_41ced76a-bd7a-4dfc-8a82-a5f115eeef66_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of interest rates hedging instruments with notional amount by expiry date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_0385a81e-97e2-44bf-acc0-16f30f7ab182_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Shareholders' Equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bce8f906-dfff-4e1d-8817-937a6dd382d0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_105b542d-f4b4-43ef-8e36-70258cd76610_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Member]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_f894505c-40de-4ced-81a7-a5868898bce8_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActionForWhichSanofiAreDefendantMember_ae8732b0-9ad7-4333-8773-18fce19275bd_terseLabel_en-US" xlink:label="lab_sny_ActionForWhichSanofiAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Action For Which Sanofi Are Defendant</link:label>
    <link:label id="lab_sny_ActionForWhichSanofiAreDefendantMember_label_en-US" xlink:label="lab_sny_ActionForWhichSanofiAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Action For Which Sanofi Are Defendant [Member]</link:label>
    <link:label id="lab_sny_ActionForWhichSanofiAreDefendantMember_documentation_en-US" xlink:label="lab_sny_ActionForWhichSanofiAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Action For Which Sanofi Are Defendant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichSanofiAreDefendantMember" xlink:href="sny-20250630.xsd#sny_ActionForWhichSanofiAreDefendantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActionForWhichSanofiAreDefendantMember" xlink:to="lab_sny_ActionForWhichSanofiAreDefendantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_473a874e-cdab-44db-ad25-9a38089449a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FabrazymeMember_9670eb53-5a06-439f-bc5a-1911ccae9a63_terseLabel_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fabrazyme</link:label>
    <link:label id="lab_sny_FabrazymeMember_label_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:label id="lab_sny_FabrazymeMember_documentation_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember" xlink:href="sny-20250630.xsd#sny_FabrazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FabrazymeMember" xlink:to="lab_sny_FabrazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_91d38e43-992b-4d17-be3d-b439eb0a41a6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Current Trade Receivables [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of current trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:to="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_2d0ae984-8a73-4e3d-9f77-8630b18a731c_terseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on benefit obligations</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8dbd4274-b02e-4172-80db-5d6b25e19606_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_8768e1ee-cebe-42b3-b5fc-08b30369b744_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_1a93982a-175d-4f44-b67d-3330570a3f66_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by less than 1 month</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:to="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_25705ceb-1c2e-46fa-bef0-2c5e90e1c97f_terseLabel_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Given, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Given, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Given, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:to="lab_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d666f704-cf85-42da-a47a-08565f0c564a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_a97c31ae-f6c0-4617-bfd8-777edbaa3457_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility canceled</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Canceled [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:to="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_e40efdf1-6164-4e77-8523-69fe6b13596d_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseCost_78717788-3e97-41d6-843e-a4bffb74468a_terseLabel_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_sny_LeaseCost_label_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_sny_LeaseCost_documentation_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost" xlink:href="sny-20250630.xsd#sny_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseCost" xlink:to="lab_sny_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_09fb4ae2-b2fa-464f-bcc3-792e54d9f421_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_f12feb15-00c5-46c2-b796-3b8514b65f08_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Singapore Dollar [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_35a0fa12-e245-41f7-85af-de980948c2af_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;60.00 to &#8364;70.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeTwoMember" xlink:to="lab_sny_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_fa07f1ea-4179-4999-88cf-896097244b2d_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_9c2eff2f-ae5f-4b78-bd87-3d4c36fe751a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_ce29a3bf-28a3-412b-8674-c8f9286ddf60_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_ade87e95-9507-460e-b620-b4a2201712d2_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_fba66019-ee4b-4f18-ae81-f48c1091ab82_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_8c6600e4-2950-4c00-93f2-9c3b1f337623_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD / receive 1.17%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_90c38c3c-88e6-40d3-b0a8-f60b26f6e70f_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_7946d0e1-1e8d-4672-a6c0-1a95b0c9fa95_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_label_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:href="sny-20250630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:to="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_7daac6cc-2bed-4f9e-b542-9151d0e4d9a3_totalLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income from continued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income from continued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other comprehensive income from continued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:to="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MCMVaccineBVMember_f3d0c991-3583-45f9-8868-75bc48c9bb77_terseLabel_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_label_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV [Member]</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_documentation_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember" xlink:href="sny-20250630.xsd#sny_MCMVaccineBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MCMVaccineBVMember" xlink:to="lab_sny_MCMVaccineBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ca855919-0c3d-4f5a-ae5f-6cd4a91b5a4c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_373ab01a-5bc0-4a3e-b58a-abc4a5720b77_terseLabel_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment Loss On Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Loss On Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Loss On Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_e75ae4fb-ccbb-4b6d-baf0-46132e53c3d9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_b9346e5d-a4b1-4bfc-a583-740263bcbeec_terseLabel_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to sale of business period</link:label>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_label_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment To Sale Of Business Period</link:label>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_documentation_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment to sale of business period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod" xlink:href="sny-20250630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PaymentToSaleOfBusinessPeriod" xlink:to="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_5fece905-fc23-47a5-81c6-0a046b6aad0c_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionMember_21052bd4-b53d-4b02-b5bd-89f6dcba6519_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:label id="lab_sny_AssetsAcquisitionMember_label_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Member]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionMember_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionMember" xlink:to="lab_sny_AssetsAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_c59045f3-70d1-4f01-8d30-31e0daf74e93_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_label_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_documentation_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:href="sny-20250630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:to="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6d7be808-5e15-43f2-9a55-8b1fa471aa2c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2fd3cf9d-cf16-4e14-97f9-b9edc81a9a60_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_6fddcae1-451c-4c21-94b2-e3cebfbce5a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend paid per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid, ordinary shares per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_df0533a5-f44c-4b6c-ba64-39db35a364e9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customers [Axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BondsIssued_094aecd1-4881-4570-8c0e-7cda975cea18_terseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bond issues</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_label_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BondsIssued" xlink:to="lab_ifrs-full_BondsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_dc57a2ad-f771-4cd6-a110-4af9f769ea78_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessOperatingIncome_e20f5a9a-5ec5-4da0-8fec-816f303b4658_terseLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_ebb9afcd-f7c7-41b1-9c3e-133363020fe8_totalLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Business Operating Income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_label_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Operating Income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_documentation_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessOperatingIncome" xlink:to="lab_sny_BusinessOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_11825d35-334a-438c-b14a-c6e176883f2c_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [Member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_751eea08-8091-46f4-8b0e-6fc03b5071ef_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest related to employees benefits and unwinding of discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_cf1c3f59-358e-4510-9740-10886cd4d392_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2021</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2021 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2021Member" xlink:to="lab_sny_RestrictedSharePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_8602b7ba-5f82-4e42-b2f9-9a6fc48e240c_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on transfer of business</link:label>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_label_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on transfer of business</link:label>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_documentation_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on transfer of business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:href="sny-20250630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:to="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_415a06fe-f72a-4d6d-8016-41a36fc44422_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_61dba224-c701-46e0-966f-ded16ad7ed0d_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans (B.12.1.)</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_aaefdcf7-1629-4917-ab00-abf0eddce585_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossProfit_d8422850-c672-468e-b4bf-2afc90568385_totalLabel_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_ifrs-full_GrossProfit_label_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="lab_ifrs-full_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_01d5848b-1354-4141-961d-9b4148aca9bb_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_9781ac08-343b-4f0d-ba38-2e1774ac7fc6_terseLabel_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets (liabilities)</link:label>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets (liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ClinicalStudyMember_b8da095b-2d93-4dab-804f-b351ae34e7e6_terseLabel_en-US" xlink:label="lab_sny_ClinicalStudyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Study</link:label>
    <link:label id="lab_sny_ClinicalStudyMember_label_en-US" xlink:label="lab_sny_ClinicalStudyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Study [Member]</link:label>
    <link:label id="lab_sny_ClinicalStudyMember_documentation_en-US" xlink:label="lab_sny_ClinicalStudyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Study [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ClinicalStudyMember" xlink:href="sny-20250630.xsd#sny_ClinicalStudyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ClinicalStudyMember" xlink:to="lab_sny_ClinicalStudyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_f7ac1c22-98f2-4560-8f99-64df724020b6_terseLabel_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_label_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Eligible For Hedge Accounting [Member]</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_documentation_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember" xlink:href="sny-20250630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NotEligibleForHedgeAccountingMember" xlink:to="lab_sny_NotEligibleForHedgeAccountingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8dc39d46-96f7-41ce-ac98-12f4fcbbb931_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareProgramAxis_f7c62c66-a671-4644-b518-ebc554142245_terseLabel_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:label id="lab_sny_ShareProgramAxis_label_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:label id="lab_sny_ShareProgramAxis_documentation_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis" xlink:href="sny-20250630.xsd#sny_ShareProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareProgramAxis" xlink:to="lab_sny_ShareProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_b60af6be-c70d-4994-a0e1-dae672fa91ec_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_090484a2-201a-4adb-9aee-7825899e0f50_terseLabel_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentMilestonePayments_0d640a7b-b5a2-48f7-8dca-01e194d761f2_terseLabel_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:label id="lab_sny_ContingentMilestonePayments_label_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:label id="lab_sny_ContingentMilestonePayments_documentation_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments" xlink:href="sny-20250630.xsd#sny_ContingentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentMilestonePayments" xlink:to="lab_sny_ContingentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_fd8cb366-f194-42b7-bf89-7c23ac43b762_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_0f7f85df-4359-463d-83e8-3e6b60b41e09_terseLabel_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank credit balances</link:label>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_5ed25634-3235-40fb-ab9c-7ef7c31d9caa_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_96409984-71e5-46c6-8fa3-097c0fecd16e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_3302542c-a319-46d3-ae44-b0a7dfd63806_terseLabel_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excluding General Director</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer [Member]</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:href="sny-20250630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:to="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_d63f8351-22e8-46bd-83a4-426544ebf8e1_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronMember_73d0b582-0adb-4c9a-b7ea-fdac8e6b58bf_terseLabel_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:label id="lab_sny_RegeneronMember_label_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron [Member]</link:label>
    <link:label id="lab_sny_RegeneronMember_documentation_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember" xlink:href="sny-20250630.xsd#sny_RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronMember" xlink:to="lab_sny_RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1e25c616-9360-4d95-b472-4deaf14f8c76_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payment [Member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_c5f1f917-79c2-4f36-8f59-710213e2dc79_terseLabel_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:to="lab_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_bc66ebb4-4c1d-449f-a82e-7bcee2d60885_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of allocation of income tax between current and deferred taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:to="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_fea02614-c2c0-489e-a3f0-30e51c2db5d6_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International Financial Reporting Standards (IFRS)</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_9126fe46-64ba-40a9-9d23-8f0f5c5c9662_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_98e5444b-6b7d-4971-a351-6ec3150d51a3_terseLabel_en-US" xlink:label="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Billion Fifty Million Bonds Maturing April 2025</link:label>
    <link:label id="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_label_en-US" xlink:label="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Fifty Million Bonds Maturing April 2025 [Member]</link:label>
    <link:label id="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_documentation_en-US" xlink:label="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Fifty Million Bonds Maturing April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:href="sny-20250630.xsd#sny_OneBillionFiftyMillionBondsMaturingApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:to="lab_sny_OneBillionFiftyMillionBondsMaturingApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_aa7fea20-62f6-43cb-8e71-4c42777300b7_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain" xlink:to="lab_sny_LegalAndArbitralProceedingsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_66b2aab7-f027-4cf2-9f6e-0add2db6b651_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_d1047dff-0a17-4eda-a7f6-63f8b3e49d3c_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the&#160;equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_37ea5b46-a4e5-4e1c-a5c4-8365b6b84400_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In USA [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInUSAMember" xlink:to="lab_sny_CommercialPaperProgramInUSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_d4f4b1aa-e1da-4930-b2a2-c8241fe99475_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for liabilities related to business combination and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_c867b97a-cdc3-4115-ae51-24f0d42468dd_terseLabel_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_label_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB [Member]</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_documentation_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember" xlink:href="sny-20250630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SwedishOrphanBiovitrumABMember" xlink:to="lab_sny_SwedishOrphanBiovitrumABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_89b53a8a-7397-4d70-8170-9049f96c1393_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_f9054760-4697-44bb-9cfa-26ffd397abdb_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_b02afe2c-981b-4a08-855d-f218140e538c_terseLabel_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_label_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:href="sny-20250630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:to="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_6ef7ddfd-59bd-41be-b121-34eed6402630_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted shares and vesting of existing restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CerezymeMember_c8563246-dccf-4421-9768-6a073d8df670_terseLabel_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cerezyme</link:label>
    <link:label id="lab_sny_CerezymeMember_label_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cerezyme [Member]</link:label>
    <link:label id="lab_sny_CerezymeMember_documentation_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cerezyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember" xlink:href="sny-20250630.xsd#sny_CerezymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CerezymeMember" xlink:to="lab_sny_CerezymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_8097bb5f-eb1d-4898-9c6c-ca905879307c_terseLabel_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialInstrumentsAbstract" xlink:to="lab_sny_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_189569cb-f2af-40ed-8d4f-251e1381e293_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Axis]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_bd587336-191b-4071-9831-e1f3f8930dd3_terseLabel_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Of Damages Claimed By Counterparty</link:label>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_label_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Damages Claimed By Counterparty</link:label>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_documentation_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Damages Claimed By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty" xlink:href="sny-20250630.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PaymentOfDamagesClaimedByCounterparty" xlink:to="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_5abf2bb7-5e35-434c-8ea4-8a15bc463f32_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:to="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_ba05af08-8134-427a-851c-03a58c109efa_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_16ebf1db-848c-4ced-9e6c-1867e5ce23a9_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_de144b7d-1590-47fc-9fb7-f1dc9c4b0faf_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Segments Reconciling Items [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating segments reconciling items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CostOfDebtNet_29340d9f-11b8-407d-8836-e78f21a72c49_negatedTotalLabel_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_sny_CostOfDebtNet_label_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Debt Net</link:label>
    <link:label id="lab_sny_CostOfDebtNet_documentation_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of debt net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet" xlink:href="sny-20250630.xsd#sny_CostOfDebtNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CostOfDebtNet" xlink:to="lab_sny_CostOfDebtNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d2c66fee-9e58-47d9-9774-5013d071f0c9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_61da5a0b-c467-4c5f-8498-603a6fee181d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_4f58c2f3-381b-4562-ab52-1baaff9d263a_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GSK</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_label_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With GSK [Member]</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementWithGSKMember" xlink:to="lab_sny_CollaborationAgreementWithGSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_0ba2df7a-4503-4398-a0b7-5e605d09b021_terseLabel_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_label_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Debt Instrument Issued</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_documentation_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption of debt instrument issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:href="sny-20250630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:to="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixMember_f70aa2a2-60a0-4ef8-adbb-01ee37511838_terseLabel_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plavix</link:label>
    <link:label id="lab_sny_PlavixMember_label_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:label id="lab_sny_PlavixMember_documentation_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember" xlink:href="sny-20250630.xsd#sny_PlavixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixMember" xlink:to="lab_sny_PlavixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_522225b4-a620-4a01-a2af-867875445fa0_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis" xlink:to="lab_sny_LegalAndArbitralProceedingsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_1a16a579-9b3d-4ee4-9c52-8bb933f4addd_terseLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions and other current liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:to="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_ca258b9e-2418-4816-9f91-64da3993cc90_terseLabel_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US</link:label>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US [Member]</link:label>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember" xlink:href="sny-20250630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ZantacProductLitigationInTheUSMember" xlink:to="lab_sny_ZantacProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_1f44f9c3-2ba5-4c79-a605-5304ef9356f0_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, purchase price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePrice" xlink:to="lab_sny_BusinessCombinationPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_4934af0f-e8c3-4802-9b04-b453a2622efc_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_263067dc-a944-4b79-8994-4a3cad6b4ec7_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per share awarded (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value per share awarded to a three year service period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:href="sny-20250630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractDurationAxis_914b98b2-7286-4cb7-8533-d9a938b44fba_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractDurationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract duration [axis]</link:label>
    <link:label id="lab_ifrs-full_ContractDurationAxis_label_en-US" xlink:label="lab_ifrs-full_ContractDurationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract duration [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractDurationAxis" xlink:to="lab_ifrs-full_ContractDurationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_885c97f7-0f5a-4fd9-a787-cf49d84ce213_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_009a4a77-fc00-4945-a8d7-11260ca7e5be_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on plan assets</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_cf0a8527-c443-4cef-b86c-0fec0393e679_terseLabel_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_label_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes [Member]</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_documentation_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember" xlink:href="sny-20250630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiEuroMediumTermNotesMember" xlink:to="lab_sny_SanofiEuroMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_2ab4486a-4689-4615-a362-88baa59cc289_terseLabel_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:href="sny-20250630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:to="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_12f3080e-3af7-486c-809a-7a529fba5049_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2025</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2025 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2025Member" xlink:to="lab_sny_RestrictedSharePlan2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_bdb84d59-1cdb-48f0-8132-948533bead76_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Introduction</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_cf13ee04-0574-4bf8-b286-6477234d6904_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_18ce5da9-0b4d-43b8-8ba4-46c97ee534c5_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_4cce2887-83c3-4581-931f-7d1a0f48686e_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_5ac811cb-4bcd-404c-bb61-3f8b762084d0_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_f488fa54-340e-44b4-9255-898939999229_terseLabel_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sales arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:href="sny-20250630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_4cee25ad-c002-443b-90e3-37a4bde63946_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_10ce88f0-4318-45f4-8524-51bfcbe0c329_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_bd9807bf-8bf1-4b3a-84a8-ab2281eb3b85_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of goods and services (including research expenses) (c) (d)</link:label>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_f592aa43-cfac-4937-b2be-603469af121f_terseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_14f8957e-70b0-4374-a26e-35068e0d7cbe_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:to="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_93f75b08-47a9-4aee-bd8e-3973e8695763_terseLabel_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsRelatedPartyTransactions" xlink:to="lab_sny_AssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_ff6f64f2-cf3a-42a9-8e4e-3fa6b3559233_terseLabel_en-US" xlink:label="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Of Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Of Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Of Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_459c74c6-12a7-4f87-9d80-9d8905db439b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Principal Characteristics of Restricted Share Plans</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_0f0ff46b-cf8a-4a7f-984a-fd6f043e56fe_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_4dcc122a-9574-473f-b449-a59854b38f82_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_210542a3-0b50-473f-9322-6301d900adf8_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable" xlink:to="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_f9a96c79-3020-4376-8eec-7d0d62d3315c_terseLabel_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, ownership percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_label_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_documentation_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:href="sny-20250630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:to="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionMember_4f0a4f71-5b5d-4027-9d34-326cfb4dd136_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value On Redemption [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionMember" xlink:to="lab_sny_ValueOnRedemptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain_1ae0940c-c80d-4f24-a9b2-b21f9d870a83_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for associates [Member]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_0bd870bb-53ee-418d-afc2-37a5cd94d65b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_e752b64d-e322-43cf-9524-fc9c55338613_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductLiabilitiesMember_d0bbc6c5-0670-4b36-aa62-61b60b86b1a6_terseLabel_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liabilities</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_label_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liabilities [Member]</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember" xlink:href="sny-20250630.xsd#sny_ProductLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductLiabilitiesMember" xlink:to="lab_sny_ProductLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_93372581-197c-487e-aaac-252167d99e17_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, number of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_label_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments [Abstract]</link:label>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_documentation_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:href="sny-20250630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:to="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_a9b38a5f-dfae-46f1-8755-081475c901d7_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialAssets" xlink:to="lab_ifrs-full_DerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_e066aa5d-8d0d-43cb-8446-b333d12c2370_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off Balance Sheet Commitments</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of off-balance sheet commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities in business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_1830609d-fb22-4374-ae52-c9ae05467440_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_31582013-93ae-4412-8b5b-b96599c54343_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_ba9f0092-16f7-41d3-9f91-b25c98f14f67_terseLabel_en-US" xlink:label="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivables, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivables, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivables, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_ceb35911-1ad8-470d-9c23-6d24a0192e49_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar, commercial paper</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, Commercial Paper [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_efefc2b5-93b8-4d62-9949-8ea3a4027742_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TechnologicalPlatformsMember_6d573dd3-388c-4da9-b792-64676546941c_terseLabel_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technological platforms</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_label_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technological Platforms [Member]</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_documentation_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technological Platforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember" xlink:href="sny-20250630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TechnologicalPlatformsMember" xlink:to="lab_sny_TechnologicalPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsMember_18649441-a7cb-4663-9b6a-cd810dc3161d_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_label_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember" xlink:href="sny-20250630.xsd#sny_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsMember" xlink:to="lab_sny_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_8b6796dd-680f-49bf-9c2a-2eb136bc5e6a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_f7a4a0a0-823b-432a-ae94-eab7368f6b8a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_dceb9d03-fcb4-4236-883a-91ca158f99d2_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_daa421d1-1a78-480f-b522-515d356a2127_terseLabel_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Not Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20250630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_06812ecf-7ab1-43cd-bf2b-3d6abab63c5d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_94f76a9a-1102-436f-82ff-edf465530be8_terseLabel_en-US" xlink:label="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Of Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Of Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Of Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_c456c582-0a6c-41eb-9a9e-ab82d989e0c3_terseLabel_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_label_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_documentation_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss" xlink:href="sny-20250630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetReversalOfImpairmentLoss" xlink:to="lab_sny_NetReversalOfImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_6dbf20ed-9bfc-4576-b71b-83257e88e75c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionPlanMember_bbc2c584-e9a8-4e2e-a5c2-2364fb4a3fba_terseLabel_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_label_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_documentation_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember" xlink:href="sny-20250630.xsd#sny_StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionPlanMember" xlink:to="lab_sny_StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_a464d082-336b-4dc4-bfbd-a07521ee03c4_terseLabel_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_label_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:href="sny-20250630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:to="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UKZONEMember_ed25a1da-f813-439a-984a-cdda48026282_terseLabel_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UKZONE</link:label>
    <link:label id="lab_sny_UKZONEMember_label_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UKZONE [Member]</link:label>
    <link:label id="lab_sny_UKZONEMember_documentation_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UKZONE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember" xlink:href="sny-20250630.xsd#sny_UKZONEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UKZONEMember" xlink:to="lab_sny_UKZONEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_84a8b92a-58e4-426b-b03b-54b8658716f2_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_153efb50-2a12-4a2d-a9d8-be93abf5321e_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_28b830d8-2b0e-4783-85f1-2688c35701df_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [Member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_c3db8688-6c4c-46f9-b831-43434a6c4c22_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Discontinued Operations</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Discontinued Operations</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:to="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_86f7b956-9f86-494c-978c-ca1f682bd069_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences business combinations and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_5e56c35d-31fa-4812-8881-17d97450e3df_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay 2.08% / receive Euribor 3m</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_66ebca18-48ea-4f67-84bf-888d9ca07a3d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Principal Transactions and Balances with Related Parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_4c79d885-54bc-42ab-954e-4007fe78706c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingJune2029Member_bb3cc7ab-97c6-48b4-8bb0-67e38a777d34_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing June 2029</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingJune2029Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing June 2029 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingJune2029Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing June 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingJune2029Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingJune2029Member" xlink:to="lab_sny_FixedRateBondMaturingJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VigilNeuroscienceIncMember_e94a2b6f-3922-4f44-883c-baf8ccacfd39_terseLabel_en-US" xlink:label="lab_sny_VigilNeuroscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vigil Neuroscience, Inc</link:label>
    <link:label id="lab_sny_VigilNeuroscienceIncMember_label_en-US" xlink:label="lab_sny_VigilNeuroscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vigil Neuroscience, Inc [Member]</link:label>
    <link:label id="lab_sny_VigilNeuroscienceIncMember_documentation_en-US" xlink:label="lab_sny_VigilNeuroscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vigil Neuroscience, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VigilNeuroscienceIncMember" xlink:href="sny-20250630.xsd#sny_VigilNeuroscienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VigilNeuroscienceIncMember" xlink:to="lab_sny_VigilNeuroscienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_f8f7413e-4079-40f5-9d3a-fa0b9999d511_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_XenpozymeMember_ce7ffb27-72c6-42df-8621-1587e748eb79_terseLabel_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xenpozyme</link:label>
    <link:label id="lab_sny_XenpozymeMember_label_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xenpozyme [Member]</link:label>
    <link:label id="lab_sny_XenpozymeMember_documentation_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xenpozyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember" xlink:href="sny-20250630.xsd#sny_XenpozymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_XenpozymeMember" xlink:to="lab_sny_XenpozymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_24cba019-c232-43e2-ba52-f36a5e7d23f3_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges of net investments in foreign operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Hedges Of Net Investments In Foreign Operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on hedges of net investments in foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:to="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_825fa10f-3889-475d-a1bb-3cbbf9325313_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Market Value of Net Debt</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Market Value Of Net Debt [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of market value of net debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:to="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_ee43f9a5-a6a9-4267-bf7b-856cd68ae7dd_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD / receive 1.32%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RezurockMember_30dfdcbc-02a4-4e75-a072-be96d53e54a2_terseLabel_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:label id="lab_sny_RezurockMember_label_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rezurock [Member]</link:label>
    <link:label id="lab_sny_RezurockMember_documentation_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember" xlink:href="sny-20250630.xsd#sny_RezurockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RezurockMember" xlink:to="lab_sny_RezurockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_da3aea1f-73b7-4c90-9b6f-2541f576cea4_terseLabel_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penalty fee incurred by defendants, interests, amount vacated</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_label_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred By Defendants, Interests, Amount Vacated</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_documentation_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred By Defendants, Interests, Amount Vacated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:to="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_18723798-9498-4b55-9cdb-b368934f40a6_terseLabel_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Vaccines [Member]</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_label_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Vaccines [Member]</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_documentation_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember" xlink:href="sny-20250630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PolioPertussisHibVaccinesMember" xlink:to="lab_sny_PolioPertussisHibVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LovenoxMember_cda3d962-ab5c-4819-919e-b5242965360b_terseLabel_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lovenox</link:label>
    <link:label id="lab_sny_LovenoxMember_label_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lovenox [Member]</link:label>
    <link:label id="lab_sny_LovenoxMember_documentation_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lovenox.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember" xlink:href="sny-20250630.xsd#sny_LovenoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LovenoxMember" xlink:to="lab_sny_LovenoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_d15c472d-8b3d-465a-a80d-a190f46931f2_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility, expires in 2028</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Two [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated credit facility two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityTwoMember" xlink:to="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_acfd02c4-860b-44bb-b0b9-8028a27f4a6f_verboseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_c87ef110-255d-4f5f-ae3d-20df61da85ae_negatedNetLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Other gains and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_label_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Gains, (Losses) And Litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_documentation_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherGainsLossesAndLitigation" xlink:to="lab_sny_OtherGainsLossesAndLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_01fbd4d8-527f-4909-864b-3ae5cb0a69c5_terseLabel_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Attributable to Equity Holders, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Attributable to Equity Holders, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Attributable to Equity Holders, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:to="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_c926635e-5395-46e6-8761-1b4affda2293_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AlprolixMember_8b40df5c-8ec6-4879-9bec-9730220fef32_terseLabel_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alprolix</link:label>
    <link:label id="lab_sny_AlprolixMember_label_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alprolix [Member]</link:label>
    <link:label id="lab_sny_AlprolixMember_documentation_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alprolix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember" xlink:href="sny-20250630.xsd#sny_AlprolixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AlprolixMember" xlink:to="lab_sny_AlprolixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_49801d83-aacb-40bc-b065-83d51b4b2195_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_9045ecf5-36d2-4d95-b295-7b1721ff4a09_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Treasury Shares Held</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_14fccc00-5f7f-4c27-934f-989bee5464d1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_52c38c08-83eb-4b04-853f-955db6a72df0_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsAxis" xlink:to="lab_ifrs-full_TypesOfContractsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_8297d0fc-d4bd-47c3-bfab-d0b45b192d13_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_73ffe4bf-2c54-46cc-b674-d8fdeab46628_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TransactionCost_675e70a9-71a3-421f-bc5e-f51ee67942aa_terseLabel_en-US" xlink:label="lab_sny_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Cost</link:label>
    <link:label id="lab_sny_TransactionCost_label_en-US" xlink:label="lab_sny_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Cost</link:label>
    <link:label id="lab_sny_TransactionCost_documentation_en-US" xlink:label="lab_sny_TransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransactionCost" xlink:href="sny-20250630.xsd#sny_TransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TransactionCost" xlink:to="lab_sny_TransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesDomain_356142f3-a2d5-4b23-b081-72eda94bdc94_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [Member]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesDomain" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_4854c754-4a24-4a3c-9ceb-01db3556b21a_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total number of shares awarded (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_bcedcd61-9df9-49fd-9296-695d42e404ed_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events Subsequent to June 30, 2023</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_0d97fab6-8957-4778-b615-2c54e2a1e3a3_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_label_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_documentation_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:href="sny-20250630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:to="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperations_8eb4eaad-aaa3-4e3a-b089-e3bf84a7ed5c_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_db8c4734-62a3-4027-b52f-1fa6b9a5cf38_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b101402d-5ae2-47a1-8814-9a8ff9063cb5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_6ecce4c9-157d-4163-8690-dee770a938eb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_82eafc53-c372-4c07-bee4-e3b5eaa2f10f_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_ffaacd03-0246-4e17-9fe0-04b4277fe7ef_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2032</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_label_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2032 [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2032 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapExpiring2032Member" xlink:to="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsAxis_083663e6-4441-416c-81dd-d72420a6c52b_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_0e1938b8-c187-4f0a-94ff-aa7de230019a_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_88cce19d-4dee-4416-b662-fb87ba2bc02d_terseLabel_en-US" xlink:label="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_9bad6fe3-33f3-4d0a-a380-0d746fc49cf8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_4c53dd83-b54b-4fc5-8e8b-af2e8ab40598_terseLabel_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for restricted shares (in shares)</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_label_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Effect Of Share Options On Number Of Restricted Shares</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_documentation_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:href="sny-20250630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:to="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_83c93a4a-2a07-4683-828f-26a3498c4e46_terseLabel_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:href="sny-20250630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_395f079d-9e87-4e48-99f0-821cb6d9eb5f_terseLabel_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development costs arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:href="sny-20250630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_b9e76e0c-2c8a-4931-9599-415ad247a1f5_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price per share (in USD per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:to="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9c82723c-2bf3-4f67-a830-9eb9d25899af_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment owned</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_4ff3e806-6d1a-47da-9e64-83ed2557665c_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringTextBlock_8f9c4fae-1586-4f95-b781-2e609433d62e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_3adb9990-e42c-4385-97fb-e0de8ce1f59e_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [Axis]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MazeTherapeuticsMember_64635338-785e-4cbf-ae5c-4ab0234f902d_terseLabel_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maze Therapeutics</link:label>
    <link:label id="lab_sny_MazeTherapeuticsMember_label_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maze Therapeutics [Member]</link:label>
    <link:label id="lab_sny_MazeTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maze Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember" xlink:href="sny-20250630.xsd#sny_MazeTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MazeTherapeuticsMember" xlink:to="lab_sny_MazeTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_ab194adb-05ac-496c-b72a-45e88bc1ae40_terseLabel_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_63b0bd50-59eb-4653-a850-66f5b0406b1e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_9694575a-d9e3-4eaf-ba65-bd7701dd9d44_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncomeCost" xlink:to="lab_ifrs-full_OtherFinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_560d510e-bbd2-490f-b4f8-abec53dedcfd_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [Member]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapMember_b3fde738-2c32-474d-9b9d-84a72ef2a840_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross Currency Swap</link:label>
    <link:label id="lab_sny_CrossCurrencySwapMember_label_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapMember" xlink:to="lab_sny_CrossCurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_9c65524f-bbc8-43ed-a24b-02e62b5b5389_terseLabel_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherAssetsRelatedPartyTransactions" xlink:to="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_b5635d1e-4d7b-471d-8656-afae41873765_terseLabel_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_label_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_documentation_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:href="sny-20250630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:to="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_87f1e351-dca8-4e48-b775-ec1935b4f223_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_023f5973-4fc5-4ea2-a52d-927c22915c1a_verboseLabel_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Segment [Member]</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_0bc484fe-dbc6-476d-9745-e8830fd1d289_terseLabel_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Segment [Member]</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_label_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Segment [Member]</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_documentation_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsumerHealthcareSegmentMember" xlink:to="lab_sny_ConsumerHealthcareSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_b21a4957-85c8-48b4-8d41-66594057b0e7_terseLabel_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20250630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_9c2b710b-9919-4d39-8f9e-5ae0de70405c_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecuritiesMember" xlink:to="lab_ifrs-full_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_bc370e8a-4d91-4b4a-9b14-95130fe9fc76_negatedLabel_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled liabilities, contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_8d289651-6767-4060-8f3e-5522b0048cf2_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 3.56%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_9d5d1682-636a-4c82-87d9-f9e49b8902ee_terseLabel_en-US" xlink:label="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventories, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_InventoriesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_77699f90-9189-475b-9a01-43ccc6fb8929_verboseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_5b3dc3ed-8205-42c5-ab44-c0e630b77096_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facilities, number of extension options</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:to="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_c8834909-188b-414d-89f0-b22af0c72f80_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_4b53def7-7367-4e76-a35d-d8ba2ccd9fc2_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_1699718c-ce0c-4ad3-9e65-a99903938c9c_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_1cd02e8a-64fd-4429-baf1-f0f381aac84c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesMember_163894fb-9419-4d8f-9cba-6544cce72c5f_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Countries [member]</link:label>
    <link:label id="lab_sny_OtherCountriesMember_label_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries [member]</link:label>
    <link:label id="lab_sny_OtherCountriesMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other countries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember" xlink:href="sny-20250630.xsd#sny_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesMember" xlink:to="lab_sny_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_91548fdf-075b-4e0f-ba43-ff40b74931fa_terseLabel_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_label_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_documentation_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:href="sny-20250630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:to="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashAndCashEquivalentsDiscontinuedOperations_97604fc9-5a6f-41ba-b1d4-8180e3179359_terseLabel_en-US" xlink:label="lab_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, discontinued operations</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsDiscontinuedOperations_label_en-US" xlink:label="lab_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, discontinued operations</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_CashAndCashEquivalentsDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:to="lab_sny_CashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_c867ce00-a7ba-4a35-b9c9-53134b267b31_terseLabel_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, continuing operations</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_label_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, continuing operations</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_documentation_en-US" xlink:label="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:to="lab_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_d4ea5de2-33b1-4c4f-a9f0-6eac00cf87ac_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CoreAssetsMember_76721726-6447-44a5-80f4-fa518980a9a1_terseLabel_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Core Assets [Member]</link:label>
    <link:label id="lab_sny_CoreAssetsMember_label_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core Assets [Member]</link:label>
    <link:label id="lab_sny_CoreAssetsMember_documentation_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember" xlink:href="sny-20250630.xsd#sny_CoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CoreAssetsMember" xlink:to="lab_sny_CoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_f9e7b752-f894-4fcf-9d5d-47d0a6402270_terseLabel_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill, reversal amount</link:label>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SAR44425Member_9fc1c28c-7fca-4edc-aa51-dac8479b485f_terseLabel_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAR44425</link:label>
    <link:label id="lab_sny_SAR44425Member_label_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAR44425 [Member]</link:label>
    <link:label id="lab_sny_SAR44425Member_documentation_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAR44425</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member" xlink:href="sny-20250630.xsd#sny_SAR44425Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SAR44425Member" xlink:to="lab_sny_SAR44425Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_a0e8d9c8-0e84-44ac-852d-6ab052ec4e8e_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, extension options, term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsTerm" xlink:to="lab_sny_LeaseExtensionOptionsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_d9f95ac2-d1cf-41ec-ba06-7816fa6ab956_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other profit or loss items with no cash effect on cash flows generated by operating activities</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_6d236dc3-f1c5-49f0-b850-27279a6915b3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information About Major Customers and Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RSVVaccinesMember_47168a0e-6323-4242-9be3-a7355c673227_terseLabel_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSV Vaccines</link:label>
    <link:label id="lab_sny_RSVVaccinesMember_label_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSV Vaccines [Member]</link:label>
    <link:label id="lab_sny_RSVVaccinesMember_documentation_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSV Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember" xlink:href="sny-20250630.xsd#sny_RSVVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RSVVaccinesMember" xlink:to="lab_sny_RSVVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_f8215b8e-a79a-4d8f-81b4-214821841fe2_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing December 2027</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing December 2027 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing December 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingDecember2027Member" xlink:to="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_686a614c-0692-420c-8aca-1fe81728f4ee_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_label_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueHedgesMember" xlink:to="lab_ifrs-full_FairValueHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NexviazymeMember_bc3f2dbe-4c7c-4314-b815-24b2e3978ca0_terseLabel_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nexviazyme</link:label>
    <link:label id="lab_sny_NexviazymeMember_label_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nexviazyme [Member]</link:label>
    <link:label id="lab_sny_NexviazymeMember_documentation_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nexviazyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember" xlink:href="sny-20250630.xsd#sny_NexviazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NexviazymeMember" xlink:to="lab_sny_NexviazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialtyCareMember_d1a2c805-c567-42f8-b191-d597e56dd9e4_terseLabel_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_label_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_documentation_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember" xlink:href="sny-20250630.xsd#sny_SpecialtyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialtyCareMember" xlink:to="lab_sny_SpecialtyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_773c0378-16ac-4335-9606-2390e0b372e0_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_4d5a6154-a9b7-40f2-b93c-156a34827690_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c178d966-4919-4791-8eb7-a779a4031654_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_4034990e-8429-4f29-8bad-cc35ffb0d21b_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_b0151b18-8527-4028-8ae5-e17edc9481b3_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional share of profit paid by Regeneron towards development costs</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of Zaltrap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LongTermPrepaidExpenses_17b56b15-79e6-4f85-8e71-9dee2dd8a502_terseLabel_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term prepaid expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_label_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Prepaid Expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_documentation_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long term prepaid expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses" xlink:href="sny-20250630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LongTermPrepaidExpenses" xlink:to="lab_sny_LongTermPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_155b5679-61a9-4861-ba7a-c7aad4621302_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net financial income/(expenses)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_02fa14ec-dfb9-4e0d-8d8b-14431096dc29_terseLabel_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_label_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy [Policy Text Block]</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:href="sny-20250630.xsd#sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:to="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_589c0b78-3ba0-4376-bc60-46dde1f33e19_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Operating Income (Expenses)</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_label_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Operating Income (Expenses)</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other operating income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:to="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockPrice_f89fdc43-c784-48db-92c3-f81b47bdfb39_terseLabel_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in euro per share)</link:label>
    <link:label id="lab_sny_StockPrice_label_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_sny_StockPrice_documentation_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice" xlink:href="sny-20250630.xsd#sny_StockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockPrice" xlink:to="lab_sny_StockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_fc257280-0b28-427b-b7b3-b14a11b2fe76_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_26f8977d-d46a-4a1d-a605-6c4f1a2f2afe_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1ed2acd9-bbc0-42f4-9cc1-d0ae4e137e7c_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_33bfb250-9592-451c-aa80-9e2ddd6abfe3_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_f1c178a8-1999-42f6-aff4-2162e9b3000b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_13533f4b-7d4d-4467-8907-600f3f29102d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other equity investments</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EloctateMember_136e91e6-cdb7-4ab4-9c2b-510d8e89446d_terseLabel_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eloctate</link:label>
    <link:label id="lab_sny_EloctateMember_label_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:label id="lab_sny_EloctateMember_documentation_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember" xlink:href="sny-20250630.xsd#sny_EloctateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EloctateMember" xlink:to="lab_sny_EloctateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesAbstract_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CancellationOfTreasuryShares_b79bf1e6-1f43-4165-9c2a-336e4d3c2cb7_terseLabel_en-US" xlink:label="lab_ifrs-full_CancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of treasury shares</link:label>
    <link:label id="lab_ifrs-full_CancellationOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_CancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancellation of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CancellationOfTreasuryShares" xlink:to="lab_ifrs-full_CancellationOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_71ff9944-3b25-40b6-b76f-a399446bca1a_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_0fb33b40-cbc2-4333-acb9-2ce208392f3d_verboseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_0e2e945d-c3e8-49c4-9363-0a8331cb615c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements (b)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_756b8f11-2237-4fdd-af43-a8c06ff86450_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment and intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_5059fb82-cfe6-4a30-a0d6-ebd4ef1b11ed_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares and related tax effect</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_label_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_d472be5e-625d-41ce-b1f6-d7ea8c95daad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of single amount of discontinued operations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_7226704d-61f7-4f24-acf2-4a0179b52f69_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_630be39c-7419-4734-9a6a-6ca1c0c4f793_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesAlloted" xlink:to="lab_sny_NumberOfRestrictedSharesAlloted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NameOfAcquiree_ede93177-9975-450a-bf34-c30817dbc483_terseLabel_en-US" xlink:label="lab_ifrs-full_NameOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of acquiree</link:label>
    <link:label id="lab_ifrs-full_NameOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_NameOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of acquiree</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NameOfAcquiree" xlink:to="lab_ifrs-full_NameOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_7ab419e2-7f77-425d-8465-993ff6d8c074_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_1b251ea8-87a1-4aa6-a1b0-53f4d9a7fb87_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, regulatory milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_b8fd26f3-c48b-488f-8749-df2c50f9d876_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_d65cff64-a657-4315-a698-0ff0a1f18dca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_942ee917-243c-4e59-898e-1a713b4dc34c_terseLabel_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_03bed411-8e59-44bd-8264-ae8b926406d8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_92035619-3d99-492d-add5-e61ae7a4087b_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_c137d31a-c97c-4e3a-b9c1-941f8a0dba8d_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_2244bcfe-d851-41af-938d-438fa0517798_verboseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_f05e8ee4-0d37-4399-8478-f14c28e47f87_terseLabel_en-US" xlink:label="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right Of Use Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Use Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right Of Use Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_0f14cc46-73db-445e-8f49-221bcace5d45_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans and advances and other non-current receivables</link:label>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_label_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non current loans and receivables</link:label>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_documentation_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non current loans and receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables" xlink:href="sny-20250630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLoansAndReceivables" xlink:to="lab_sny_NonCurrentLoansAndReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_097ef07b-2fdf-4e8f-be52-b9c189596a83_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_6c0b79c8-fac9-49aa-a3b5-bfecb2592306_terseLabel_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Received, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Received, Discontinued Operations</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Irrevocable Purchase Commitments Received, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:to="lab_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_45d62bd9-3ea7-4257-ac7f-50f66ebf7f75_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_261ab89d-521f-460f-b37a-bd30556fc3d9_terseLabel_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity and Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_d6795810-9310-40b7-8424-ae2291eac59d_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_97793890-466f-40fc-b72e-681c8d6189ae_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsRelatedPartyTransactions" xlink:to="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_8778c236-b0ad-4f31-b2d5-d7abee569c1e_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share ownership plan</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee share ownership plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_5b562962-5dde-4454-8079-e9b823af0668_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_d665ee17-5b6a-4033-aa5e-b12ceff89d60_terseLabel_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from out-licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_label_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_documentation_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing" xlink:href="sny-20250630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeResultingFromOutLicensing" xlink:to="lab_sny_IncomeResultingFromOutLicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_7d390716-c830-4d0b-83dc-898bee00a517_totalLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_399230e6-a9c9-4cc2-8430-1e7ff90253aa_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Equity Method Investments</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for equity method investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_6f40ef41-23e9-4828-ae4a-cbea0243fe75_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program</link:label>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2025ProgramMember" xlink:to="lab_sny_ShareRepurchase2025ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_c56db796-0e2b-47de-bda8-8662795d1308_terseLabel_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_label_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_documentation_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:href="sny-20250630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:to="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_5121e0e8-b4d3-4575-b0ff-65d81c5e2cd7_terseLabel_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In March 2025</link:label>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_label_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In March 2025 [Member]</link:label>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_documentation_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In March 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:to="lab_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_4f7ec3a8-0110-4b26-b901-bbc9530858f5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_79a0f65b-1925-4a9e-85d1-dc5bf9d32934_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_ae900b06-75ae-426b-94c4-ede9ffebb20d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_c1b31126-5799-43dc-aad8-54b6db88246b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_b179605f-5be7-46ce-8e04-f07e184bb114_terseLabel_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:to="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_b24b6584-9e63-4dd0-be22-64daa74063aa_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividend paid out of earnings</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_90e82ee6-9a6a-453b-85f8-b56448ae5876_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:to="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_72b90f4b-807e-43b1-bfa3-b1226a16410f_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EUROZONEMember_59c23a1f-9c7d-4fab-8a0c-ee4057cc9481_terseLabel_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eurozone</link:label>
    <link:label id="lab_sny_EUROZONEMember_label_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EUROZONE [Member]</link:label>
    <link:label id="lab_sny_EUROZONEMember_documentation_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EUROZONE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember" xlink:href="sny-20250630.xsd#sny_EUROZONEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EUROZONEMember" xlink:to="lab_sny_EUROZONEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_a0ad8735-c625-441d-926d-dc7bf02ab8a2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investments in Associates and Joint Ventures</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of investments in associates and joint ventures explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:to="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_6a72f250-72e3-4d15-b85e-ae30f804a1da_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_label_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionNominalValue" xlink:to="lab_sny_AssetsAcquisitionNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubordinatedLiabilities_7e24676c-e91b-458c-ab81-4d209474dc67_terseLabel_en-US" xlink:label="lab_ifrs-full_SubordinatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinated liabilities</link:label>
    <link:label id="lab_ifrs-full_SubordinatedLiabilities_label_en-US" xlink:label="lab_ifrs-full_SubordinatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinated liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubordinatedLiabilities" xlink:to="lab_ifrs-full_SubordinatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_54960eb8-b2a2-43f7-92f3-5f4b97ab2984_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard tax rate applicable in France</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_ad95ecd5-182c-457d-b53f-c3bd6ed4b6a2_terseLabel_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales and Other Revenues</link:label>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Sales and Other Revenues, Related Party Disclosures</link:label>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Sales and Other Revenues, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:href="sny-20250630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:to="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_7f0ba060-c33e-42bf-9d6d-82a38b37cc5a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_022fdce3-4edb-450d-af0f-929b9d978fa5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_99787d24-c806-42fb-845e-19b1c8285cf8_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Options Outstanding and Exercisable</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashTransferred_569657f8-40df-407b-9ade-86dda0defb6d_terseLabel_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
    <link:label id="lab_ifrs-full_CashTransferred_label_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_25e5650d-c9bc-47c7-9d47-43f6d41a314d_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding options (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_88c4ca25-2fe6-4207-8915-8e83059495c2_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_c10467a3-11b9-400d-bc27-86dac7f7e9e8_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Non-Current Provisions</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of noncurrent provisions explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_243d435e-acca-4cda-99d2-6270eadfc7d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_f9c4c35c-c514-484c-9d2c-b11cb01b6eed_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves and retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_102197ff-d42b-4710-9ac0-2e52e48719f1_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Gross Value of Overdue Receivables</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Overdue Receivables Gross Value [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:to="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_f7add816-2f6e-42c2-bc33-05ab958fff20_negatedLabel_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expense arising from the impact of acquisitions on inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_label_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Arising From The Impact Of Acquisitions On Inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_documentation_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses arising from the impact of acquisitions on inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:href="sny-20250630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:to="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_2b522488-5ff8-4154-8d44-dfba40c35db8_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ade85a18-bd6f-45ad-9fa2-7e6044e05c80_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_712a24f3-ccdc-444b-afb5-c3bc19d14a2b_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number&#160;of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_c780374d-05ec-4ba9-b278-da79ca9b5e70_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_6e008e32-18e1-4bd5-bc59-acea13bd0b8a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_df168c2e-faf9-4134-a211-52d680a0815a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_5e64c808-14f3-4ef0-b9a3-e27717708a0b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in accounts receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_2221595e-3ebd-421d-a022-0f93c53c49e3_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_label_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_documentation_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued in regards of capital increase by exercise of stock subscription options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:href="sny-20250630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:to="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_4710c283-660c-4746-96eb-2794b5195094_terseLabel_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_label_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_documentation_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:href="sny-20250630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:to="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_f9b33060-9310-407c-92b2-1f5a7be941d7_terseLabel_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal Trends</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_label_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:href="sny-20250630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:to="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TzieldMember_a8c885ef-5346-48c9-afdf-cc65355ad040_terseLabel_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tzield</link:label>
    <link:label id="lab_sny_TzieldMember_label_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tzield [Member]</link:label>
    <link:label id="lab_sny_TzieldMember_documentation_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tzield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember" xlink:href="sny-20250630.xsd#sny_TzieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TzieldMember" xlink:to="lab_sny_TzieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_8bb494ea-6437-4540-a04c-bda3a2f03e61_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional long-term debt contracted</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_9dd94b8a-2437-4c4b-9cdf-42f9eaa3870e_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other revenue</link:label>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_label_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other revenue</link:label>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherRevenue" xlink:to="lab_sny_MiscellaneousOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CabliviMember_52fc2313-c783-4eaa-977b-a0b1a75e8bd1_terseLabel_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cablivi</link:label>
    <link:label id="lab_sny_CabliviMember_label_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cablivi [Member]</link:label>
    <link:label id="lab_sny_CabliviMember_documentation_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cablivi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember" xlink:href="sny-20250630.xsd#sny_CabliviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CabliviMember" xlink:to="lab_sny_CabliviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_127c2874-327d-4f21-a549-7c7f0cc00c4f_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:to="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_c5ed08fc-d0d9-4736-bf10-8e45df04705d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EnjaymoMember_2e409bd0-de6c-4bba-a6d5-195c2d5f0b61_terseLabel_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enjaymo</link:label>
    <link:label id="lab_sny_EnjaymoMember_label_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enjaymo [Member]</link:label>
    <link:label id="lab_sny_EnjaymoMember_documentation_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enjaymo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember" xlink:href="sny-20250630.xsd#sny_EnjaymoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EnjaymoMember" xlink:to="lab_sny_EnjaymoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_5d6931dd-8cdd-4d4a-9dd5-6f46a8870792_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_label_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionPurchasePricePerShare" xlink:to="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOperatingSegments_ae913f66-4f86-401a-bb7b-3bae6571370c_terseLabel_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_label_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_documentation_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOperatingSegments" xlink:to="lab_sny_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fc40d58c-c957-47c6-bae2-75a20b7dea5d_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RecludixPharmaMember_7091e86f-9603-4b91-a010-f41518d8d6c4_terseLabel_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recludix Pharma</link:label>
    <link:label id="lab_sny_RecludixPharmaMember_label_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recludix Pharma [Member]</link:label>
    <link:label id="lab_sny_RecludixPharmaMember_documentation_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recludix Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember" xlink:href="sny-20250630.xsd#sny_RecludixPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RecludixPharmaMember" xlink:to="lab_sny_RecludixPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_b09f0175-b309-4485-b72a-cf51d582c99d_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_4e77419c-c0d4-4278-99f1-ae50b042c8d6_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMember_2067652a-3f2b-4f17-9415-1cf532bd8f1c_terseLabel_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiMember_label_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi [member]</link:label>
    <link:label id="lab_sny_SanofiMember_documentation_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember" xlink:href="sny-20250630.xsd#sny_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMember" xlink:to="lab_sny_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_07ee3b5b-b2c6-4772-900c-608dcf4ccd17_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Expenses</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_label_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_documentation_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:href="sny-20250630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:to="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ce5c6304-26ee-4ecb-b8d7-0d3b741b529c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherRestructuringCosts_a53dca42-2be5-4e5c-afd1-7d31e5821c59_terseLabel_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other restructuring costs</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_label_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_documentation_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other restructuring costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts" xlink:href="sny-20250630.xsd#sny_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherRestructuringCosts" xlink:to="lab_sny_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_3326d3be-1461-4ac7-93eb-684d00ee09f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_c1daa2f0-5ddd-48f6-bb3b-b0207c485901_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_eb2427e1-5176-4e8b-9700-9646099519b0_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for pensions &amp; other post-employment benefits</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Pensions And Other Postemployment Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:href="sny-20250630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:to="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_449d4402-fcfa-484e-bf15-6116db8c0981_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_8aade469-7277-4e99-adea-b24da6da136c_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurement of contingent consideration liabilities</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_label_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:href="sny-20250630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:to="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_915cc91e-e492-4de1-a9eb-0d100bcad23b_terseLabel_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_label_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_documentation_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod" xlink:href="sny-20250630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfYearsServicePeriod" xlink:to="lab_sny_NumberOfYearsServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_58b6a315-2dcf-4377-8711-a1b7f0e29370_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of Contingent Liabilities [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_c5ec17d3-e116-46ce-9aa3-3fb3eb52bc3f_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments included in financial assets</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_label_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets [Member]</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets[member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:href="sny-20250630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:to="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_b6306dbb-96d2-4681-b33d-a802fb439beb_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares not yet fully vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:to="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_75c517d8-49fd-4b1f-82e4-347a749e34d8_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_58259328-294a-43b1-85b9-d8790574290e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_dff7974d-0eec-4ca6-8094-1b0258a849bf_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on other intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesAllianceMember_7fcf7813-5000-4002-afc2-7dbcb933f635_terseLabel_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monoclonal Antibodies Alliance</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_label_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_documentation_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember" xlink:href="sny-20250630.xsd#sny_AntibodiesAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesAllianceMember" xlink:to="lab_sny_AntibodiesAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_94599f4d-22ed-4e45-8a60-0b3fcac849ee_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Instruments [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_d7249ad4-75d3-4eda-ae62-5fc82d0108a0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PainCareMember_adedb77f-240b-4e7a-b8dc-a022a362e31e_terseLabel_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pain Care [Member]</link:label>
    <link:label id="lab_sny_PainCareMember_label_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pain Care [Member]</link:label>
    <link:label id="lab_sny_PainCareMember_documentation_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pain [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember" xlink:href="sny-20250630.xsd#sny_PainCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PainCareMember" xlink:to="lab_sny_PainCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MyozymeLumizymeMember_4dfdd2a1-b662-44da-abcf-45722d888795_terseLabel_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme</link:label>
    <link:label id="lab_sny_MyozymeLumizymeMember_label_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme [Member]</link:label>
    <link:label id="lab_sny_MyozymeLumizymeMember_documentation_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember" xlink:href="sny-20250630.xsd#sny_MyozymeLumizymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MyozymeLumizymeMember" xlink:to="lab_sny_MyozymeLumizymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_280a027d-077d-4427-b6db-9f38ca670a7d_terseLabel_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In June 2025</link:label>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_label_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In June 2025 [Member]</link:label>
    <link:label id="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_documentation_en-US" xlink:label="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Five Hundred Million Bonds, Issued In June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:to="lab_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_bf260dc4-27f3-4b67-a159-a09a67790834_terseLabel_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of hedge recognized in equity</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_label_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_documentation_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:href="sny-20250630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:to="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_403cca39-39f2-44e9-b8be-92a72523ee7b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_fae0302f-8999-4a6e-98fb-f387af446a77_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration arising from acquisition of Amunix</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_label_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Arising From Acquisition Of Amunix [Member]</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Arising From Acquisition Of Amunix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:href="sny-20250630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:to="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsDomain_c9744ce5-c38d-46b6-9840-a1c4913382e7_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging instruments [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain" xlink:to="lab_ifrs-full_HedgingInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_8da612f6-3a16-493b-85f8-05346e1af852_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-current assets held for sale and discontinued operations [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current assets held for sale and discontinued operations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_8f3196d3-dcad-40e7-9157-5eaf543dd3db_verboseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReportableSegmentsMember" xlink:to="lab_ifrs-full_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_3d137680-d6c2-4787-8741-c925b9948895_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_label_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties" xlink:to="lab_ifrs-full_RevenueFromRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_fcb97fa9-390c-4b0e-b32c-59affab821d2_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discounting of provisions</link:label>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_label_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense arising from passage of time on other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_7b296d62-09c5-4634-8711-c9519eb0b9fa_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_efe50df2-7ebf-444e-9714-826d3dd138fc_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Before Tax Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation before tax excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InhibrxIncMember_1a03d09e-cc76-4b0e-92bc-37ab498198bc_terseLabel_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:label id="lab_sny_InhibrxIncMember_label_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc [Member]</link:label>
    <link:label id="lab_sny_InhibrxIncMember_documentation_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember" xlink:href="sny-20250630.xsd#sny_InhibrxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InhibrxIncMember" xlink:to="lab_sny_InhibrxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_f89ae8c1-197f-4929-9548-95fa228e3266_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impairment of intangible assets and property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_a6db9628-f662-4bb9-9c21-5780e31455d9_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_4c6cd33f-7607-4716-97e6-a2d4773e17a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_0f01f9ad-4039-4741-a722-3c6c37d43642_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_105747b7-4e81-4c64-82a6-fe5a730da44f_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesMember" xlink:to="lab_sny_ForwardCurrencyPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_355be609-1371-41bd-8b81-639021cd2af2_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, extension options, number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsNumber" xlink:to="lab_sny_LeaseExtensionOptionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_3c5ccf10-bd36-4d44-ad4a-8bd0d1d5ad8d_terseLabel_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets excluding software</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_label_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets Excluding Software [Member]</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_documentation_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:to="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsDomain_1fa07a5f-1c03-4695-8fba-413021a178ad_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Member]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsDomain_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain" xlink:to="lab_ifrs-full_ReclassifiedItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_cd9a602f-e722-4a66-9e9e-e43101c040e1_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;80.00 to &#8364;90.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeFourMember" xlink:to="lab_sny_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_f613456d-205f-4303-89de-a34b019cb1b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_ee09a675-10f5-41db-8320-d12d7253a232_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_17a6641b-1d8f-4426-9d46-f5eb535babe8_terseLabel_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper programs</link:label>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_label_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommercialPapersIssued" xlink:to="lab_ifrs-full_CommercialPapersIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2032Member_f3295565-f1db-4bb2-a1d4-6e4054d3f72f_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2032</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2032Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2032 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2032Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2032 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2032Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMarch2032Member" xlink:to="lab_sny_FixedRateBondMaturingMarch2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsMember_ee87b2f5-3a7e-43f8-b42e-ce70694f75f4_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_sny_MarketedProductsMember_label_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember" xlink:href="sny-20250630.xsd#sny_MarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsMember" xlink:to="lab_sny_MarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_4bad9c79-cead-4d27-a97f-dfb37d4bb682_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_f5922d7c-c7a9-4e90-b3c4-724e896efdf7_terseLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income from discontinued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income from discontinued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other comprehensive income from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:to="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_b1d99d2a-7fec-4324-9dcb-929427bf64ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_3607de58-21ff-4d9a-b6b1-cfb3ba9bfab0_terseLabel_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_label_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Debt Measured At Fair Value [Member]</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_documentation_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:href="sny-20250630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:to="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LantusMember_41bd3942-448f-437b-b4f4-58fe872e9414_terseLabel_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lantus</link:label>
    <link:label id="lab_sny_LantusMember_label_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lantus [Member]</link:label>
    <link:label id="lab_sny_LantusMember_documentation_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lantus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember" xlink:href="sny-20250630.xsd#sny_LantusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LantusMember" xlink:to="lab_sny_LantusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_42677fa7-6cd9-40dd-a404-c4310ba7a77d_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 and beyond</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_a251a4b4-29ee-42e8-8345-58a21f193ed4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs And Similar Items [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of restructuring costs and similar items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_ab35baca-f301-4653-b111-781032c937f9_verboseLabel_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20250630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_4f198603-c077-49c3-9559-dd2c7ddd6c60_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Mexican peso</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Mexican Peso [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Mexican Peso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:to="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_25bc53b5-921e-4c39-9555-d89d0aa4969e_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2024Member" xlink:to="lab_sny_RestrictedSharePlan2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_e5a0f4aa-693f-42ee-82c1-ffe548d0ad67_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_19ceb0f0-99cd-409b-886e-9b07f6f54b5c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income for the period</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_077d023c-a5ae-4673-8838-7775ccd9e4d9_terseLabel_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_label_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:href="sny-20250630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:to="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfDismissals_d350bcb8-ee6c-4d95-88b4-59b3ff19dc33_terseLabel_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:label id="lab_sny_NumberOfDismissals_label_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:label id="lab_sny_NumberOfDismissals_documentation_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals" xlink:href="sny-20250630.xsd#sny_NumberOfDismissals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfDismissals" xlink:to="lab_sny_NumberOfDismissals" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInterestsOfAcquirerPerShare_c952547b-f121-4be0-b3d1-131225725a9c_terseLabel_en-US" xlink:label="lab_sny_EquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interests Of Acquirer, Per Share</link:label>
    <link:label id="lab_sny_EquityInterestsOfAcquirerPerShare_label_en-US" xlink:label="lab_sny_EquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interests Of Acquirer, Per Share</link:label>
    <link:label id="lab_sny_EquityInterestsOfAcquirerPerShare_documentation_en-US" xlink:label="lab_sny_EquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Interests Of Acquirer, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsOfAcquirerPerShare" xlink:href="sny-20250630.xsd#sny_EquityInterestsOfAcquirerPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInterestsOfAcquirerPerShare" xlink:to="lab_sny_EquityInterestsOfAcquirerPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_08a32e07-2095-4e85-8dd4-21b4aee738f0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsPaidAbstract_1314c9b5-6745-41eb-9616-3907a963fd80_terseLabel_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid:</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_label_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Paid [Abstract]</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_documentation_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract" xlink:href="sny-20250630.xsd#sny_DividendsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsPaidAbstract" xlink:to="lab_sny_DividendsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_7aa3b9b0-cb8c-4f1f-87d3-75c753652e79_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 program</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2023ProgramMember" xlink:to="lab_sny_ShareRepurchase2023ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfCustomersDomain_d8c44a6c-90a0-41e5-92d9-5c881bdab449_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of customers [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfCustomersDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of customers [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfCustomersDomain" xlink:to="lab_ifrs-full_TypesOfCustomersDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_c260ecc5-acad-43a8-8f26-572517ae85f0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to cash flow hedges included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_af086252-69a7-4d7c-a05c-21b54465520c_terseLabel_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired R&amp;D</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_label_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Research And Development [Member]</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:href="sny-20250630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:to="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_cbf4697d-7dad-461d-99cb-4692982e23d9_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests" xlink:to="lab_ifrs-full_NoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesMember_4ac9c3e1-6c30-46c6-8a40-1a75d0835b14_terseLabel_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_sny_VaccinesMember_label_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_sny_VaccinesMember_documentation_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember" xlink:href="sny-20250630.xsd#sny_VaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesMember" xlink:to="lab_sny_VaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_99c72553-5ecd-49d4-a392-162a6911d37b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_4775235d-55f6-4fdd-8ee3-60a748466280_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_29a12fe4-e401-42aa-ab87-cea45bdd91d5_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesDomain_6ac5e316-15d2-4046-bc33-b2ae4cd1f116_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges [Member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of hedges [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesDomain" xlink:to="lab_ifrs-full_TypesOfHedgesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2030Member_a2c209ee-e204-462f-85f5-f8b762d1b17e_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing March 2030</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2030Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing March 2030 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2030Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing March 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2030Member" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingMarch2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingMarch2030Member" xlink:to="lab_sny_FourBillionFacilityMaturingMarch2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_2eda0bf9-f7e5-432f-abba-895e631b5e3d_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_label_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesAxis_3f7a4f92-854f-4056-a173-f47beef5be20_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_label_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesAxis" xlink:to="lab_sny_PrincipalAlliancesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_59432fae-b768-4629-970d-538cfe5309e4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_b8580015-53e3-4434-83d6-6fef77cc9fa0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_2db4dce1-89ec-4343-b1ee-4d83fa3db0e5_terseLabel_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Action for which we are defendant</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_label_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Action For Which We Are Defendant [member]</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_documentation_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Action for which we are defendant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember" xlink:href="sny-20250630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActionForWhichWeAreDefendantMember" xlink:to="lab_sny_ActionForWhichWeAreDefendantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaMember_85829b16-b35b-4141-a19c-581fb9fe2e01_terseLabel_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opella</link:label>
    <link:label id="lab_sny_OpellaMember_label_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opella [Member]</link:label>
    <link:label id="lab_sny_OpellaMember_documentation_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaMember" xlink:to="lab_sny_OpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementDomain_593e8242-4b0e-40c7-8580-8c7d778ce0ae_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [Member]</link:label>
    <link:label id="lab_ifrs-full_MeasurementDomain_label_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementDomain" xlink:to="lab_ifrs-full_MeasurementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_54d485cb-07cc-4507-a862-32688eb988fc_terseLabel_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in short-term debt and other financial instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_label_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_documentation_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:href="sny-20250630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:to="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_fbd85363-1642-407d-ab84-53fbc9b632ce_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to details of finance income (expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_80662ef8-1cba-4099-b0e4-91a59ec6c7f7_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization and impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_02818e5a-4623-4c3d-8a93-7a94f56fd10e_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_2fa30780-a7f8-46ff-ac29-7d30741f3d17_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerTwoMember_b6549c11-a567-4024-87cc-2527d8c2cc97_terseLabel_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer two</link:label>
    <link:label id="lab_sny_CustomerTwoMember_label_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [member]</link:label>
    <link:label id="lab_sny_CustomerTwoMember_documentation_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember" xlink:href="sny-20250630.xsd#sny_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerTwoMember" xlink:to="lab_sny_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorTerritoriesMember_3242740b-83bc-465f-802f-f328762d8bed_terseLabel_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major territories</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_label_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Territories [Member]</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_documentation_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember" xlink:href="sny-20250630.xsd#sny_MajorTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorTerritoriesMember" xlink:to="lab_sny_MajorTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_2f4062f7-decb-4835-8d97-a6e4ff37e3d3_terseLabel_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_ac9a3894-8b1c-42f9-b282-8c2aa0693f88_terseLabel_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity risk hedging instruments designated as fair value hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_label_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_documentation_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:href="sny-20250630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:to="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithMarketConditionMember_51ca01f1-e4af-4434-a31d-dc9f0d97139f_terseLabel_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">With market condition</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_label_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">With Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">With Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember" xlink:href="sny-20250630.xsd#sny_WithMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithMarketConditionMember" xlink:to="lab_sny_WithMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_db57c437-e2a4-4eb1-824f-6c94d5c7997c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansDomain_da2f5235-7538-4979-987d-0126138283e3_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Member]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansDomain_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain" xlink:to="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c2c2eaf9-3f62-4ade-bf9a-f33faedc8990_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_8438c333-f563-4fa0-beb3-fc769d5cafa8_terseLabel_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_label_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_documentation_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:href="sny-20250630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:to="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_decd5424-d057-43af-b805-9c9c3fa49fb7_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_7141cab2-b450-449e-af03-dd2ab58a57c0_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_9ba68f0a-1e8b-4344-a1d8-77ddaa0ed546_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_fdb50148-ae66-4cc7-b785-cdebc024acdd_terseLabel_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20250630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_4379644f-8915-441c-a389-50a71b44970a_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_b14c40e3-151c-48de-badd-b8cad9b2c8aa_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_78d763d5-911b-4956-b909-a48fcb269d7d_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [domain]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_61904c5c-b45e-45c1-87d5-38dfb53f01b0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Financial Position</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Financial Position [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of changes in financial position [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_0ecf2080-0448-4b85-acb9-9250a8b9c17f_terseLabel_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and other income (c) (d)</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties And Other Income, Related Party Transactions</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties and other income, related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:to="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_78d3d05b-a42f-40c4-9169-dda28aac773d_terseLabel_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% of share capital for the period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_label_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Share Capital For The Period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_documentation_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of share capital for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:href="sny-20250630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:to="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionAxis_e1be9c4c-1ce2-4b5f-a867-a9b571e2e9b6_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Axis]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionAxis_label_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Axis]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionAxis_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionAxis" xlink:to="lab_sny_AssetsAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfluenzaVaccinesMember_44b54e36-ef39-4e3b-ba29-5031b2e917f8_terseLabel_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Influenza Vaccines [Member]</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_label_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Influenza Vaccines [Member]</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_documentation_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Influenza Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember" xlink:href="sny-20250630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfluenzaVaccinesMember" xlink:to="lab_sny_InfluenzaVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_4b9b431c-59b0-4cce-943a-0371dc9ef431_terseLabel_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Off-Balance Sheet Commitments, Discontinued Operations</link:label>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_label_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Off-Balance Sheet Commitments, Discontinued Operations</link:label>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Off-Balance Sheet Commitments, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:to="lab_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_f7694dd5-d12f-4096-80cc-0389f2563d58_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_079d4754-a65f-4164-80e4-cd00d3b1a77a_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for noncurrent provisions and other noncurrent liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20250630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2bebd89b-b8bb-4a9c-b455-dca9944c52e8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsDomain_a7c8070a-2355-456c-b4d6-deba6d50454d_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Member]</link:label>
    <link:label id="lab_ifrs-full_SegmentsDomain_label_en-US" xlink:label="lab_ifrs-full_SegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsDomain" xlink:to="lab_ifrs-full_SegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_58792a52-009d-4d73-867e-5d50ed93f3d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_aaa7e812-2296-4f15-ac32-7783c2773ab4_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_68ae94fe-1e78-4b93-b97f-d66237801236_terseLabel_en-US" xlink:label="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_GoodwillDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_b34bf13a-fd1c-4271-9823-0d91862b1369_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_97210135-a2e2-4d6c-ac0c-8ce39ff8f93f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DigestiveWellnessMember_8eac631a-6bdd-4558-af7e-d72011a0d406_terseLabel_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_label_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_documentation_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember" xlink:href="sny-20250630.xsd#sny_DigestiveWellnessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DigestiveWellnessMember" xlink:to="lab_sny_DigestiveWellnessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_34095969-4411-4816-be21-0f31f8249737_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_d5fe3c1b-48d4-44f0-9094-d03abc26ab6a_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_01503877-cbae-45fa-9bde-b8644035b1db_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_3ee851a1-62e6-4b85-8bd0-c92c36bfd4d9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major business combination</link:label>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_label_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major business combination [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorBusinessCombinationMember" xlink:to="lab_ifrs-full_MajorBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_365bfb7e-6b05-4b84-a9d1-9bbeefa29daa_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Axis]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis" xlink:to="lab_ifrs-full_ReclassifiedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_55da88fc-144c-4872-9016-d925e0ca2638_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar, US bond</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_118dc423-8441-4fb8-b477-931e95c8457e_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesMember" xlink:to="lab_sny_NonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesMember_455c7724-4cbb-4f98-b249-174d8432d6fe_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesMember" xlink:to="lab_sny_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityInterestsOfAcquirer_37ad9a8b-38ba-49ee-940f-0441378052e3_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interests of acquirer</link:label>
    <link:label id="lab_ifrs-full_EquityInterestsOfAcquirer_label_en-US" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity interests of acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_f8cfd8f0-9fc5-449d-8044-fe9e0a6d55b0_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerecognizedReceivables_75594567-0d93-4523-aab3-2c60f6c308fc_terseLabel_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognized receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_label_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognized Receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_documentation_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognized receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables" xlink:href="sny-20250630.xsd#sny_DerecognizedReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerecognizedReceivables" xlink:to="lab_sny_DerecognizedReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_f68911c7-a788-4a42-8fbe-47031d840245_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program</link:label>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2024ProgramMember" xlink:to="lab_sny_ShareRepurchase2024ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_fadc681c-43ba-419e-bb2d-8ec706e2482b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of number of restricted share plans Not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:to="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCoreAssetsMember_9867f12a-a9b2-4089-8f20-15eb454666cb_terseLabel_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_label_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember" xlink:href="sny-20250630.xsd#sny_NonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCoreAssetsMember" xlink:to="lab_sny_NonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_7c0bd9e3-a31b-4bab-ad65-6c7d79d61680_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPayments_e0f91942-d2e4-49e5-b5bd-34282c98791c_terseLabel_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_sny_UpfrontPayments_label_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments</link:label>
    <link:label id="lab_sny_UpfrontPayments_documentation_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPayments" xlink:to="lab_sny_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_31ea3c0d-7a89-4efb-a750-1a37a89f4f86_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements within Other Comprehensive Income</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information of accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MarketsOfCustomersAxis_a5492e92-43d4-4438-92df-0b221e5416ed_terseLabel_en-US" xlink:label="lab_ifrs-full_MarketsOfCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Markets of customers [axis]</link:label>
    <link:label id="lab_ifrs-full_MarketsOfCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MarketsOfCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Markets of customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MarketsOfCustomersAxis" xlink:to="lab_ifrs-full_MarketsOfCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_76f44885-506c-4137-b0f1-a6b0783c6637_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_1f602c9d-f52e-47a4-9eff-ce3da10b08d2_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in associates</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_a4702a98-1497-4e8a-b155-10347325315a_terseLabel_en-US" xlink:label="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_5b341e57-3645-4a24-9148-4832c36bdec8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_32fe4063-fa5d-4341-a777-b9f570f856a8_terseLabel_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Continuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_label_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Continuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_documentation_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Continuing Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:to="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesDomain_b3576802-4047-46f0-8acb-7bbb8218627a_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_label_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesDomain" xlink:to="lab_sny_PrincipalAlliancesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_1fc55f34-1b27-4945-9be1-c24e4e5e5ec6_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_label_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsInterestRate" xlink:to="lab_sny_InterestRateSwapsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_ef85a159-18a2-4669-a844-6dd48c8ef314_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in France</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In France [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program In France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInFranceMember" xlink:to="lab_sny_CommercialPaperProgramInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_bf5b4599-de47-468a-8667-55f3ee70404e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Pronouncements Issued by the IASB and Applicable from 2024</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_79c4455b-87f2-4a49-8ed5-9ebdd5bfa0d2_terseLabel_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_label_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Plan At Date Of Grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_documentation_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:href="sny-20250630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:to="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerThreeMember_189adaa0-b938-444a-9088-d988750add30_terseLabel_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer three</link:label>
    <link:label id="lab_sny_CustomerThreeMember_label_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [member]</link:label>
    <link:label id="lab_sny_CustomerThreeMember_documentation_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember" xlink:href="sny-20250630.xsd#sny_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerThreeMember" xlink:to="lab_sny_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_153123cb-b72c-4db9-a8d9-ce30d7222fea_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_0b293ced-9eba-4542-b572-67bffcc33666_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_82bfac45-f5df-4f12-a3ff-ab0c4784bd94_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_43a2cd38-d659-45f1-87af-509643124070_terseLabel_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_label_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:to="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_6440d236-1a7c-46fc-827f-771841d1212b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Non-Current Assets</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Components Of Other Non-Current Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of components of other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_b730fd7d-1c3c-476f-bc4e-d971303c5c68_terseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_d2608937-6950-407c-957b-f487748be98b_verboseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All other segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllOtherSegmentsMember" xlink:to="lab_ifrs-full_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_69927601-69c6-49a0-ac7c-2bb411fbc1ba_terseLabel_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:href="sny-20250630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:to="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_f9935b07-1f65-495c-95ee-1228db714346_terseLabel_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of bond issues redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_label_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_documentation_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed" xlink:href="sny-20250630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfBondIssuesRedeemed" xlink:to="lab_sny_NumberOfBondIssuesRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_5a01fd70-cb89-4b31-996c-7196e2473acd_terseLabel_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain wholesalers in the United States</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_label_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States [Member]</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_documentation_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:href="sny-20250630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:to="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_5bcd4e78-285f-45ff-9eab-3923b7e1674f_terseLabel_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRelatedPartyTransactions" xlink:to="lab_sny_EquityRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3951b291-4af5-42e8-8c0c-29e511ebec0d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_f8807361-0865-44a9-9c68-ba34e65eb23d_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in non-controlling interests without loss of control</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_3e6e3f64-70bd-4938-98d6-ced7482d130c_terseLabel_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Discontinuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_label_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Discontinuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_documentation_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Discontinuing Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:to="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_3c73ab94-4d00-45e1-b89f-e3d90712ca8f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in deferred taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for deferred tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_4e58ad3f-eb38-4628-8ba7-3ea3d0a03bc6_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for other long-term benefits</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Other Long Term Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for other long term benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:href="sny-20250630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:to="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_dfd834fe-1134-4571-8e80-f000e0eb900e_terseLabel_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement to Regeneron of selling expenses incurred</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Related Expenses [Member]</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember" xlink:href="sny-20250630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercializationRelatedExpensesMember" xlink:to="lab_sny_CommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_2c974e4e-e192-4804-870e-43b951bf4699_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2023</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023Member" xlink:to="lab_sny_RestrictedSharePlan2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_be62316d-9cf0-48e8-a423-d33f382b3f09_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_88beae4f-7c9a-4e63-805d-676e5472fcf8_totalLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_4d428767-cffa-4839-9531-21fa9c95284b_negatedTerseLabel_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Movements, Contingent Liabilities Recognised In Business Combination</link:label>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_documentation_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other movements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="sny-20250630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfTranches_00bb5c2d-88a6-4a6f-abdd-912f6ff6ebf6_terseLabel_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_sny_NumberOfTranches_label_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_sny_NumberOfTranches_documentation_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches" xlink:href="sny-20250630.xsd#sny_NumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfTranches" xlink:to="lab_sny_NumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_9e593479-28e8-4f45-bbcd-2dec02580d16_terseLabel_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinate Hybrid Bond, Related Party Transactions</link:label>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinate Hybrid Bond, Related Party Transactions</link:label>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subordinate Hybrid Bond, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:to="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_8109c5ea-a01f-468b-b6c2-14b6bfbb53e6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsMember_2abcc779-9b90-48a9-972b-4a1ddd7f7e99_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsMember_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_a845cc3d-3d6b-4145-8597-5f28bf262fc0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_3ef97591-312b-489a-bbc5-a0313783f82f_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment consolidation items [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:to="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LoansToAssociates_e13c149b-4112-4f0a-96a4-c96c6c35a085_terseLabel_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:label id="lab_sny_LoansToAssociates_label_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:label id="lab_sny_LoansToAssociates_documentation_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates" xlink:href="sny-20250630.xsd#sny_LoansToAssociates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LoansToAssociates" xlink:to="lab_sny_LoansToAssociates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_cd87c9bf-f83d-4928-b3af-e3c30f029cb8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractDurationDomain_c03e6bb5-e50b-4049-9f86-ad97dbb19d11_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractDurationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract duration [domain]</link:label>
    <link:label id="lab_ifrs-full_ContractDurationDomain_label_en-US" xlink:label="lab_ifrs-full_ContractDurationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract duration [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractDurationDomain" xlink:to="lab_ifrs-full_ContractDurationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesRepurchased_582e85e0-5277-42bf-be40-bbb689561f7b_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_label_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Repurchased</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased" xlink:href="sny-20250630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesRepurchased" xlink:to="lab_sny_NumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_595e4252-bbc0-4cff-a6bb-387ba1b2135e_terseLabel_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grant recognised as deduction from development expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_label_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_documentation_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:href="sny-20250630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:to="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentsMember_1c7b2f2c-4fce-4ee5-89b4-217a917055fa_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_label_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments [Member]</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_documentation_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember" xlink:href="sny-20250630.xsd#sny_DebtInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentsMember" xlink:to="lab_sny_DebtInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_52e6c2bf-cad6-4691-a34b-ffecae12b4cc_terseLabel_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates and joint ventures</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_label_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates And Joint Ventures [Member]</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_documentation_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Associates and Joint Ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssociatesAndJointVenturesMember" xlink:to="lab_sny_AssociatesAndJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_23aebc83-4e08-4269-b23f-5948217eac97_terseLabel_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Alliance</link:label>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_label_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Alliance [Member]</link:label>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_documentation_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno-oncology Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunoOncologyAllianceMember" xlink:to="lab_sny_ImmunoOncologyAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b3ff544d-ada9-4a62-a09f-06e91656d442_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPlaintiffs_14863a04-892d-4f99-9f68-16541f19562b_terseLabel_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_label_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_documentation_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs" xlink:href="sny-20250630.xsd#sny_NumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPlaintiffs" xlink:to="lab_sny_NumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_2783ddbf-23a0-45aa-b820-03762f437390_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_bab1ab8d-7e15-4c85-9146-0952fd773fcb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_2b4cb6da-b007-46e1-b77d-fe32d9047517_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_24065ea2-b1e0-4357-bb5e-98377447cc7f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_13673056-d9fe-4166-8f22-7385a657aab5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 6-12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_d5159455-4030-4e33-b2c7-cfe09e6b3339_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_db34ce03-a6ff-4c40-abb9-4291e09095c3_terseLabel_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_label_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Restructuring Provision [Member]</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_documentation_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember" xlink:href="sny-20250630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentRestructuringProvisionMember" xlink:to="lab_sny_NonCurrentRestructuringProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_9039f0f2-734e-4869-9fe0-f11a77276361_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Operating Currency Hedging Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fe2dd31d-b5ae-4ce7-bd66-548bf2cba9d1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RareDiseasesMember_e214a126-39e8-46df-90d4-fe7aa23e643d_terseLabel_en-US" xlink:label="lab_sny_RareDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Diseases</link:label>
    <link:label id="lab_sny_RareDiseasesMember_label_en-US" xlink:label="lab_sny_RareDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Diseases [Member]</link:label>
    <link:label id="lab_sny_RareDiseasesMember_documentation_en-US" xlink:label="lab_sny_RareDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RareDiseasesMember" xlink:href="sny-20250630.xsd#sny_RareDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RareDiseasesMember" xlink:to="lab_sny_RareDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_8bf43785-6810-4464-a8f7-58746aa2410a_terseLabel_en-US" xlink:label="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2020Member_a97b1602-5921-45ac-9540-c78a058a4bae_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2020</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2020Member_label_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2020 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2020Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2020Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondIssueFromApril2020Member" xlink:to="lab_sny_FixedRateBondIssueFromApril2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_93d83893-0a3d-41d8-925d-6450ae0b75a4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_7fd9ad65-5785-4b39-a78b-38da02037cdb_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_71088eda-0d1d-401e-93d9-b24809c3b069_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 3-6 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_4c3449fe-62eb-476f-a7b6-f6fddf9846cc_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue by &gt; 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_efffc5fb-20a7-4f8d-8093-2df392437638_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_b1ef7a68-ee34-4438-864c-93022b8117aa_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_a1cba115-30af-4988-b685-e29297cd429f_terseLabel_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material reconciling items</link:label>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:to="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_20fe997e-240a-4a6f-a09c-0df717d4d0df_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of shares used to compute diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:to="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_2047c27f-858e-44d0-a3ea-cd3777134ca7_terseLabel_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_label_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC [Member]</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_documentation_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:href="sny-20250630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:to="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_f3a73e39-5014-443c-a14f-e6bfd099b086_terseLabel_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discount and gains (losses) arising from revisions of expected cash flows</link:label>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_label_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost</link:label>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_documentation_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:href="sny-20250630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:to="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_e1e824f3-40c7-4d59-85ae-a654af188dbe_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionDomain_895fad94-0aec-48bb-87a5-de49a585009c_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionDomain_label_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionDomain_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionDomain" xlink:to="lab_sny_AssetsAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_479ef75f-86ea-4ebb-9ffb-cbdca1bbf367_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_89a363d2-9566-4b13-9f7c-51a499aa0ca4_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_documentation_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember" xlink:href="sny-20250630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingIncomeExpenseMember" xlink:to="lab_sny_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6984ac0c-4cbc-4a74-9e48-28a96f5405e7_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_ab8aa38c-192c-4302-a7d2-9fce7b79fb63_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_f42be004-a943-4358-851a-ea582c748afb_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3924b2b5-83a5-416a-becb-81ab92034829_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_cd721ecc-7379-4710-b4dc-c96e0711521e_terseLabel_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infraserv GmbH &amp; Co. H&#246;chst KG</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_label_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infraserv Gmbh And Co Hochst KG [member]</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_documentation_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infraserv GmbH and Co. Hochst KG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:href="sny-20250630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:to="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfCustomersAxis_681fca4f-4d19-4049-87ba-89d6ee4e4cb4_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of customers [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfCustomersAxis" xlink:to="lab_ifrs-full_TypesOfCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_24eaeab0-f72b-45fb-ba3c-1fd0cd59b0d2_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_5c1bbff1-bb9e-4618-a2d3-a274ab2a59a8_terseLabel_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances</link:label>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_label_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for credit losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:to="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f7e44005-da08-4665-a495-71f1eedd5dd1_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AR_5894938c-38f3-496b-898f-f9a1bcbfa5ac_terseLabel_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Argentina</link:label>
    <link:label id="lab_country_AR_label_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARGENTINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AR" xlink:to="lab_country_AR" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_5a17d0db-2f81-4c61-9138-4a60a1e97a67_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, upfront payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:to="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsMember_ec5181ad-35fc-4724-ac2a-5b40bf7d2992_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_label_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Assets [Member]</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsMember" xlink:to="lab_sny_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_15ff59b5-093e-4b60-9494-6ab8dd276903_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantDomain_3f863125-ffd2-4324-9eed-e6c31d68021b_terseLabel_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_label_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_documentation_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain" xlink:href="sny-20250630.xsd#sny_DefendantDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantDomain" xlink:to="lab_sny_DefendantDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SarclisaMember_08306f6d-638e-478d-ac06-af7476c7aaf1_terseLabel_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:label id="lab_sny_SarclisaMember_label_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarclisa [Member]</link:label>
    <link:label id="lab_sny_SarclisaMember_documentation_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember" xlink:href="sny-20250630.xsd#sny_SarclisaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SarclisaMember" xlink:to="lab_sny_SarclisaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_606a0990-d2f4-480d-95f4-f4f408feeae6_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_1e444867-3476-408a-86d1-793593d90a9c_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationNominalValue_f10b0703-0a6b-441f-9854-d0f53e4a6c75_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:label id="lab_sny_BusinessCombinationNominalValue_label_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:label id="lab_sny_BusinessCombinationNominalValue_documentation_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue" xlink:href="sny-20250630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationNominalValue" xlink:to="lab_sny_BusinessCombinationNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharesMember_44fca7a6-4b7d-43ff-b76e-f8715b154ac9_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember" xlink:href="sny-20250630.xsd#sny_RestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharesMember" xlink:to="lab_sny_RestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_adc52af3-5881-4304-8008-737be305d335_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_eabb514f-918b-48bf-bd9a-ec12af0e33bb_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares after dilution (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_2b96fb0c-e15d-429c-a157-5cc430e1554a_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Average number of shares used to compute diluted earnings per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_af9f479b-5ede-46da-ba1d-80b53e7b208c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_ad340e84-5247-42bd-9c59-33f19314639c_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_559901c7-9a1e-4c0e-9329-b73162583264_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_5c1e7bf5-8659-4705-ae60-cc2343a69c4d_terseLabel_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Inflow from Discontinued Operations</link:label>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_label_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Inflow from Discontinued Operations</link:label>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Inflow from Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashInflowFromDiscontinuedOperations" xlink:to="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_e7c169ff-de32-404e-8a28-b9d1bf9e081b_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2020</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2020 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2020Member" xlink:to="lab_sny_RestrictedSharePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_187e4d00-8d56-47c6-a873-bba804400500_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a2802c46-66b4-4e8f-821c-7589147ba44e_netLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total expense for restricted share plans</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_4a18d048-c17c-4da4-9ec7-e557cb11e78c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Sanofi shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_d66ccd44-2da8-430c-91f1-308bd8de2773_terseLabel_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Firm orders of property, plant and equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Firm Orders Of Property Plant And Equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Firm orders of property plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:href="sny-20250630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:to="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_4cb6661e-1f82-4237-affb-a8ae20f8d554_terseLabel_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics</link:label>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_label_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics [Member]</link:label>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember" xlink:href="sny-20250630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FulcrumTherapeuticsMember" xlink:to="lab_sny_FulcrumTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_4655f032-eaa7-44b7-8eb9-bed0d750f64e_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_5ff1e078-4f04-4421-b8cc-0a2d2190ed88_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_cd9d6f8d-95e3-4e54-b98b-ee6816dfcba6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts receivable Table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable" xlink:to="lab_sny_DisclosureOfAccountsReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_9bd9d815-6caa-4f25-84f8-81c0b49b0048_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in contingent consideration asset (liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_6537ad9a-0a66-4484-bdc4-925848b2f127_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_289a6762-2719-4328-8d5b-5d8d950abca3_terseLabel_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_label_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_documentation_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:href="sny-20250630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:to="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_dc94013c-31c5-4a25-8891-3a4d9aa2d09a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of average effective tax rate and applicable tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_e927a5a9-8c64-4de9-b944-2ecccc2c6205_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_9b26cb5b-1399-402f-bbe3-4948548526fb_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_fc56e3f0-64ec-4d78-aba7-6e3cad7621a3_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facilities, extension option period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:to="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_592e285a-e388-4809-983e-ed58e60e803f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_f9777546-bc4e-4e2b-a3e8-1c473f0ed5f9_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in currency translation differences</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_6a498f05-f53e-4e8f-8e99-5ecf8fc5a723_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_fb26887b-215d-4d42-b6f8-f642eb0901dd_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_f97797c9-af2c-439c-b236-c6f582f074ce_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_b96a65ff-4764-44a6-9a06-7ea7aab97bae_negatedTerseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_aa2c75bb-36cb-4921-9176-adbf398bb756_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_7e565caf-b611-4b6e-bcc9-20b98e0f687c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_3d08eed5-11af-48a7-a01c-46f7b0412b24_netLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d531c8b3-f403-4de6-948a-476e6b53c424_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_4e6f7c05-6f2d-4d7c-a701-9c2280bc7c38_terseLabel_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_label_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Operating Foreign Exchange Gains/(Losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_documentation_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:href="sny-20250630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:to="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_de640350-bca9-4969-9ba8-dbd170adcf61_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Acquisitions and Capitalized Interest by Operating Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_0b99d7ff-4005-46d3-a18c-f1f8cc53a8cb_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_7dee5bf6-611f-43f4-9290-9f0958f06775_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [Member]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_893bb375-613d-4b56-a631-fd0b0fe0b52f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_9fc3bb30-54b8-4301-9c97-83eae5a2292a_negatedLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in total expense of restructuring activities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Total Expense Of Restructuring Activities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Total Expense Of Restructuring Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:to="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseTerm_664eef0d-f5cb-4d95-b326-1275d2334593_terseLabel_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, term</link:label>
    <link:label id="lab_sny_LeaseTerm_label_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Term</link:label>
    <link:label id="lab_sny_LeaseTerm_documentation_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm" xlink:href="sny-20250630.xsd#sny_LeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseTerm" xlink:to="lab_sny_LeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_68043509-3413-4183-a6c6-74c16ca30c43_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_549ccfb5-21c2-4caf-90c8-c0191f020a1b_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 program</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2022ProgramMember" xlink:to="lab_sny_ShareRepurchase2022ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_bac13813-6038-4100-87ab-dbdce2c01882_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains/(losses) on disposals of financial assets</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:to="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_337259f8-d01f-40a5-bf94-53ea87acbbbf_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses)</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_34ec1925-a8b1-479a-bcf5-225194813c70_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsDomain" xlink:to="lab_ifrs-full_TypesOfContractsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_dc3d811b-8a99-49d0-9462-144a98d3b82a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_12d1bb13-3888-4fda-b30b-7228d341b598_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_0290cec6-bc20-4ad3-b053-7687b06024ce_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_9214d547-aca6-4577-b211-7a1d2c3b1073_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share of undistributed earnings from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for undistributed profits of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_ddadd285-efae-41d1-ac26-800f5ac459bf_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_78d9e48d-df95-4224-af16-bf0fca05f9cc_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_06c4d884-ae95-40ba-84b9-0eaa5308978a_terseLabel_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment plans:</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_label_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Payment Plans [abstract]</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_documentation_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based payment plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract" xlink:href="sny-20250630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract" xlink:to="lab_sny_ShareBasedPaymentPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_4f49919a-0f14-40e8-ba88-a8696f3568c5_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_66b96029-bad4-44bb-90b8-8c62381b445c_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences (investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_8fd2e626-1235-4f2b-a05b-b52179ad07eb_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_c4f91b50-063a-4c4c-a416-ee3294b5fa37_terseLabel_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue From Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_e4ff4bb7-0735-4cd1-8a38-9063fe0c5d8d_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_label_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySellerSwapsMember" xlink:to="lab_sny_CrossCurrencySellerSwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_5d504b53-0691-4888-bcd2-0cb4ca2382c5_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_8c59a6e1-42c6-4354-8286-b89776822433_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Movements in Other Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in other intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_332590d4-bc0e-4b4b-aa9f-f7b171936a7d_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_8dae00e9-8d85-410f-a175-734d326a46dc_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Debt by Type Valuation of Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of debt net of cash and cash equivalents by type at value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_ee233c15-36a2-42b9-ba36-8535a86f3e10_terseLabel_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued immediately for employer's contribution (in shares)</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_label_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Further Shares As An Employers Contribution</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_documentation_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Further shares as an employers contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:href="sny-20250630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:to="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_7d0b8515-a44f-47ed-855d-b9f4e067b1ca_terseLabel_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from VaxServe sales of non-Sanofi products</link:label>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_label_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from VaxServe sales of non-Sanofi products</link:label>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_documentation_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from VaxServe sales of non-Sanofi products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:href="sny-20250630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:to="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_3e0525a4-9b2c-4167-ab9d-dacb75d98a97_terseLabel_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Attributable to Non Controlling Interest, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Attributable to Non Controlling Interest, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Attributable to Non Controlling Interest, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:to="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_85d401bf-77a4-45e0-adea-7419b558fdf7_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Pound sterling</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:to="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_07c893f8-bff5-4037-9ce3-09b90ebf9dc2_terseLabel_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures" xlink:href="sny-20250630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetIncomeRelatedPartyDisclosures" xlink:to="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_label_en-US" xlink:label="lab_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]</link:label>
    <link:label id="lab_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_documentation_en-US" xlink:label="lab_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" xlink:href="sny-20250630.xsd#sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" xlink:to="lab_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_1807353c-1a84-4bbb-ba5e-f66d84a2e0cb_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation for early termination of contracts (other than contracts of employment)</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Compensation For Early Termination Of Contracts</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation for early termination of contracts (other than contracts of employment).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_5114fe90-cf9a-464b-93b4-c008e80dace9_totalLabel_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubscriptionPricePerShare_c9f435f0-5ab9-4431-82fd-e8b2476fda5a_terseLabel_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription price (in euros per share)</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_label_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Price Per Share</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_documentation_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare" xlink:href="sny-20250630.xsd#sny_SubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubscriptionPricePerShare" xlink:to="lab_sny_SubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_1fb64b2f-a312-4e99-95d1-9ff3ca706355_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_4b6e390d-7e4e-4641-9db0-80537e1c5f92_terseLabel_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of profits arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:href="sny-20250630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_db33865c-2b25-4874-9440-a77b921b2f10_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_c1e5650f-32ba-4780-8de2-37471388c649_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_6b10e07f-a564-459d-a0f7-8f7fc1572443_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_95cd059f-1dd1-406c-841f-ed4db5f24def_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_da18591e-0704-4cba-afd1-53eb0f88bfc0_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_e0b7b6aa-aca2-45d3-843a-64888ee4caed_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_3bc7dc5d-317f-471c-b4b2-a28d056ef172_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_63e14522-6fd7-4767-87a1-46794202f33d_totalLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_45583040-6493-4dcc-915d-f816d510daa3_terseLabel_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalties receivable, value</link:label>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_label_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Receivable, Value</link:label>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_documentation_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Royalties Receivable, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue" xlink:href="sny-20250630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FutureRoyaltiesReceivableValue" xlink:to="lab_sny_FutureRoyaltiesReceivableValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PreFundedPensionObligations_1a793c11-239e-47ad-b699-94ca23a00c5a_terseLabel_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_label_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Pension Obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_documentation_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations" xlink:href="sny-20250630.xsd#sny_PreFundedPensionObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PreFundedPensionObligations" xlink:to="lab_sny_PreFundedPensionObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AltuviiioMember_60d23830-9a35-4670-81ea-18744912a44e_terseLabel_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Altuviiio</link:label>
    <link:label id="lab_sny_AltuviiioMember_label_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altuviiio [Member]</link:label>
    <link:label id="lab_sny_AltuviiioMember_documentation_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altuviiio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember" xlink:href="sny-20250630.xsd#sny_AltuviiioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AltuviiioMember" xlink:to="lab_sny_AltuviiioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_f13370ae-97b1-4cbd-b7f4-38cbc20b67c0_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_be00cb32-ea2f-4b06-b8ba-9499f65725da_negatedTerseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Of Unused Provision Reversed, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Decrease Of Unused Provision Reversed, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementDomain_d3fb1c1e-cd21-48f8-8429-48f40af6d9b6_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_label_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementDomain" xlink:to="lab_sny_TypesOfAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a9ab6d6e-d08e-481f-b11f-cd9bc06e90fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_6fca632a-3ecd-455d-8c2f-17886a24b5a7_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:to="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_715d784c-1c00-446e-91ee-6546002e5f86_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_b479cba3-549e-4fdc-abd3-b310f6b23f8b_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2023, additional shares</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023, Additional Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:to="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerOneMember_b6299b34-46f7-4fd9-9e42-7ab4f0d030d9_terseLabel_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer one</link:label>
    <link:label id="lab_sny_CustomerOneMember_label_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [member]</link:label>
    <link:label id="lab_sny_CustomerOneMember_documentation_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember" xlink:href="sny-20250630.xsd#sny_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerOneMember" xlink:to="lab_sny_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_60a46b1d-66a3-4665-b6d7-44f43964eca2_terseLabel_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products, Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:href="sny-20250630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_a3e5adeb-648a-4c8a-bc3a-c5c0a6966fab_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:to="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_e8fb3214-dc62-4f09-866b-fb51d540e10e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_96d83711-6cbb-4681-94f3-48dde60fe324_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of restructuring costs details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_e46641c9-7545-41cd-bff3-98db13026643_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Cash and Cash Equivalents</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Instruments Issued Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of debt instruments issued explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_d04ffdd0-580e-44e7-95a4-5f3ffde4b173_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WellnessBrandsMember_ad151086-138f-4c82-9116-f961d668997b_terseLabel_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wellness Brands</link:label>
    <link:label id="lab_sny_WellnessBrandsMember_label_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wellness Brands [Member]</link:label>
    <link:label id="lab_sny_WellnessBrandsMember_documentation_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wellness Brands</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember" xlink:href="sny-20250630.xsd#sny_WellnessBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WellnessBrandsMember" xlink:to="lab_sny_WellnessBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_56db58a5-8d48-4764-803d-fe3a0ff5b5ed_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalMilestonePayments_e221415c-805c-4ae1-9622-4407782ef1b3_terseLabel_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:label id="lab_sny_TotalMilestonePayments_label_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:label id="lab_sny_TotalMilestonePayments_documentation_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments" xlink:href="sny-20250630.xsd#sny_TotalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalMilestonePayments" xlink:to="lab_sny_TotalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_50e3b5f1-9d45-4645-bc60-71ff98a3c852_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_3b52b0d5-c478-4bb4-9b0f-120addf5a8d7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_812a6fd0-563f-487a-a064-00cfdda5f9ab_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_4b2ce92b-01fd-47ff-86f4-c156998132c3_negatedTerseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Tax Effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on tax effects.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:to="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_ce35be68-de26-49ab-99a4-eaa08a822dd3_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_8271754b-6c96-479c-a9ef-c68f4717bccf_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_d3132299-2275-4c6c-8f12-e79ac9ea43a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_8d704987-5ff7-4832-ab18-7f6445c46761_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_8b9e8f93-92ee-4b2e-95d1-725682335a37_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_a5ad62cf-a1e5-47c4-9553-d2e0825d9ee7_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_6ae25741-d8d2-4cf2-8da7-4f7a4112767b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_26f8cc30-701e-4c5b-a979-5291310cd98e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_57bc5d61-3401-4f0e-9e94-f0362326ab37_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstruments_65b17f90-e4d9-4a4a-aaf1-8068d24261dc_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstruments" xlink:to="lab_sny_DerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_USGovernmentMember_982076a1-bc1b-46c5-b488-a473472c1a45_terseLabel_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Government</link:label>
    <link:label id="lab_sny_USGovernmentMember_label_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_sny_USGovernmentMember_documentation_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember" xlink:href="sny-20250630.xsd#sny_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_USGovernmentMember" xlink:to="lab_sny_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2031Member_b8667501-c1c6-491f-a6c0-9888a38c6495_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2031</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2031Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2031 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2031Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2031Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMarch2031Member" xlink:to="lab_sny_FixedRateBondMaturingMarch2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_dd7e7199-3f7c-4524-a474-6348a7cb2aab_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_c8ffc135-436a-4c09-b069-b4f55824dd89_terseLabel_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember" xlink:href="sny-20250630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesCollaborationAgreementMember" xlink:to="lab_sny_AntibodiesCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_06603320-0703-4c2f-b1d9-b247ea6d1031_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_e442522f-4483-4129-b073-ee29acaec423_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments To Manage Financial Exposure</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instruments to manage financial exposure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:to="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCases_c4906f09-430d-46e8-93a8-0088f5d819bc_terseLabel_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:label id="lab_sny_NumberOfCases_label_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:label id="lab_sny_NumberOfCases_documentation_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases" xlink:href="sny-20250630.xsd#sny_NumberOfCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCases" xlink:to="lab_sny_NumberOfCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_97a7ecbb-e04f-46d8-8941-847eb4adc160_terseLabel_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major collaboration agreement</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember" xlink:href="sny-20250630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorCollaborationAgreementMember" xlink:to="lab_sny_MajorCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_99b7ce03-20e2-49a9-919c-634f4c670fed_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_63a46cc8-8fa0-4699-b3a4-55ad847c2771_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_5b9eaba2-1724-4d94-8520-982912ffa41d_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [Member]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsDomain" xlink:to="lab_ifrs-full_BusinessCombinationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_8776b7e1-3235-471b-bba6-e9ef3f38480c_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest in acquiree held before acquisition date</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_32be986f-2ca4-433f-9aa6-e00e9e1176a5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_3eec7405-afa7-494a-8fd6-319dff2be9b2_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesDomain" xlink:to="lab_ifrs-full_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_92d2c525-ad69-41ed-9e0a-0ee9eff3461e_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_label_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Non-Current Assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:to="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e201d62e-f8c9-4484-9971-d182a582d574_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_26f4b712-cfd4-4870-821c-6b20eda802ff_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_6785ed5b-f0b2-4774-932e-5f756a0eba5b_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_4adb1845-5483-4c88-b89d-9451e09d7bbd_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_bdc021d3-99c9-4ed1-bc15-53d9f666d672_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_e134d725-7ae2-4d1d-8c27-c5ef4241bfd5_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration payable</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_e33e2398-45c2-4319-99d5-228b6af9472c_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Korean won</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Korean Won [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Korean Won</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_7f012929-2716-476a-9400-1bca4b402357_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Expenses and Income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PharmaLaunchesMember_1f1c5195-8338-4db9-ab8c-7e594efc6137_terseLabel_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharma Launches</link:label>
    <link:label id="lab_sny_PharmaLaunchesMember_label_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharma Launches [Member]</link:label>
    <link:label id="lab_sny_PharmaLaunchesMember_documentation_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharma Launches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember" xlink:href="sny-20250630.xsd#sny_PharmaLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PharmaLaunchesMember" xlink:to="lab_sny_PharmaLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_24ecb861-7da0-4510-a411-59795c256a5a_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Employee Related Expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_659071ef-20a9-4ff8-ad4b-f5ef428a6cf2_terseLabel_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno Oncology Collaboration Agreement</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno Oncology Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno oncology collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:to="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2022Member_2623a53c-a3fb-40ab-a502-55c288ae016f_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2022</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2022Member_label_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2022 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromApril2022Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondIssueFromApril2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from April 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2022Member" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondIssueFromApril2022Member" xlink:to="lab_sny_FixedRateBondIssueFromApril2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_0819ee0c-a4ba-448f-80a8-7b37155a966d_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Japanese yen</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Japanese Yen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_48eaa04e-cbb8-4cad-b0c2-c12d26706090_terseLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_55ceaa5b-308a-4434-93d3-2639c846d8c8_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases in provisions and other liabilities</link:label>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInOtherProvisions" xlink:to="lab_ifrs-full_ChangesInOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsDomain_eabade04-6f37-4e76-a8a4-d2a0f5cb8c18_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [Member]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsDomain_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain" xlink:to="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_9cce61c6-fd1d-40cd-869a-f4cc92b7bc94_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [Member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_b6667550-faf5-4da4-a2b1-1e02f680a1b6_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_dc1a8f74-6fdc-42be-a287-5687dd8de632_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_f7dfbcee-bb4e-448c-a433-659e2a15ec65_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to&#160;non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_5e70c9e4-cb76-40c4-b972-09aa48b095f7_negatedLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_d0256243-452d-4d24-a6f6-1fb4ec23d4c9_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expense</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_d726a388-2c3d-41a3-8268-0a7f7a0c299c_terseLabel_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global penalty fee incurred by defendants, amount vacated</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_label_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Penalty Fee Incurred By Defendants, Amount Vacated</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_documentation_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Penalty Fee Incurred By Defendants, Amount Vacated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:href="sny-20250630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:to="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_2eb05e16-8813-48fd-a97d-312af638c9b0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (d)</link:label>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0c96c482-d306-43d6-8486-f380b83173f8_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_51d4a6a8-7f65-4274-860a-b90a6fa415d1_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesDomain" xlink:to="lab_ifrs-full_CounterpartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_c223b696-6d35-48c2-98b5-762d5f69c85e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduction in share capital</link:label>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_17b015b0-8f64-4d86-948a-b335aa5de063_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in share capital</link:label>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_label_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_2eb9c904-3de8-4e43-a227-e5cae8d22d8a_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_fce0b757-740c-4b4d-949e-58e3e82b14c5_terseLabel_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading equity securities</link:label>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading equity securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:to="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_1f3ef7e2-5880-41f9-ac80-5c0a58367d39_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:to="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_5f3eb031-03ed-42d0-b0dc-5ae033144716_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2029</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_label_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2029 [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapExpiring2029Member" xlink:to="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7512f138-e3d9-4eda-b611-d0779843a784_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_53c6c0ef-45c4-43d0-a7a9-c03c68c01f83_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_2e27fe2e-deec-47c8-b40f-a0895d6da25c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_ae55fa2e-52f6-45b6-8699-4b4c8b1d89b5_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_d147064f-8ecf-45e0-aa79-aff545c77814_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizedCostNettingMember_b18cd235-8762-4c16-bd3f-aaeca341bfe5_terseLabel_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_label_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost, Netting [Member]</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_documentation_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember" xlink:href="sny-20250630.xsd#sny_AmortizedCostNettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizedCostNettingMember" xlink:to="lab_sny_AmortizedCostNettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_bef94339-bf5b-465d-b36a-dbb57129ae45_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_11286916-a231-4106-a455-d9d4260063e4_terseLabel_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Reclassified to Assets Held for Sale</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_label_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Reclassified to Assets Held for Sale</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_documentation_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Reclassified to Assets Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:href="sny-20250630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:to="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_e241a5f6-e21a-41e6-bf9a-c97f56bd3345_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Japanese Yen</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchased In Japanese yen [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BlueprintMedicinesCorporationMember_c5809da8-64fa-4129-83ff-3104b2fb3c85_terseLabel_en-US" xlink:label="lab_sny_BlueprintMedicinesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blueprint Medicines Corporation</link:label>
    <link:label id="lab_sny_BlueprintMedicinesCorporationMember_label_en-US" xlink:label="lab_sny_BlueprintMedicinesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blueprint Medicines Corporation [Member]</link:label>
    <link:label id="lab_sny_BlueprintMedicinesCorporationMember_documentation_en-US" xlink:label="lab_sny_BlueprintMedicinesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blueprint Medicines Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlueprintMedicinesCorporationMember" xlink:href="sny-20250630.xsd#sny_BlueprintMedicinesCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BlueprintMedicinesCorporationMember" xlink:to="lab_sny_BlueprintMedicinesCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_f0584ac5-8148-4cac-9c93-35437a864211_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_32fad2f3-cfd6-40e1-a998-821dbd65bff6_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_b230b1cf-77eb-489e-a170-0c677f40827f_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [Axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_ddd09014-1749-4929-abd5-ffc6a0289e21_terseLabel_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plavix Attorney General action in Hawaii</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_label_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plavix Attorney General Action In Hawaii [Member]</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_documentation_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plavix Attorney General Action In Hawaii</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:href="sny-20250630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:to="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_fae884a3-f6f7-4015-bf63-d1e072de69ce_terseLabel_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shire contingent consideration arising from acquisition of Translate Bio</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_label_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_documentation_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:href="sny-20250630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:to="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_8b53fc6c-8f4a-46aa-a1a2-ec7b1a26b238_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase by issuance of restricted shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Issued In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares issued in regards of capital increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_93c8cf3b-7455-4335-8b22-fb259516294d_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_e55015e5-7e76-47d8-97ec-276e3c4a3477_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:to="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_ad2f1675-e2b0-4392-99af-4a76b7328984_terseLabel_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_d8184b2d-796c-4a88-a457-948fd99fabe2_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_label_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:to="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_bc527bbc-797f-4254-bb21-c19c8f82b255_terseLabel_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract" xlink:href="sny-20250630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract" xlink:to="lab_sny_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_2c243cbd-29f8-48fb-8a86-2aad60dbb44b_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_62e7d73b-e6b8-4142-8e2a-90f946a717a8_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EuroapiMember_989b9137-5f83-4f2b-afbb-b138ae71d137_terseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euroapi</link:label>
    <link:label id="lab_sny_EuroapiMember_75dd3e26-45dd-4e40-b60c-e588bfd3de3a_verboseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EUROAPI</link:label>
    <link:label id="lab_sny_EuroapiMember_label_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euroapi [Member]</link:label>
    <link:label id="lab_sny_EuroapiMember_documentation_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Euroapi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EuroapiMember" xlink:to="lab_sny_EuroapiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_37273867-e5bd-4e1c-9597-430f8771c928_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Sales by Segment and Geographical Area</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of net sales by segment and geographical area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:to="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_d0bf1ded-e57b-46d3-be7d-fe3fcf6def4d_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_414689cf-20f8-40c6-bb2d-8fbd491e89bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_444ed877-5538-494c-a2d5-c2478d6c6a04_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps In US Dollar</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_label_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps In US Dollar [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps In US Dollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:to="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_f87c7c2c-fc1d-4887-b38d-b77fff02468d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Measurement Principles Applied to Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_0b0efefe-76ff-4299-a7ee-9a83fcef14c9_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4e6989cb-709a-4b74-86ab-e68b5d39a3f9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_6368021a-e3b4-4bc3-bb07-e0ea2d2c08c1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_59dc7529-6427-4840-bac4-591f78a16de7_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_5f2e9694-8d75-4382-b82a-34e57eb4d056_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:to="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_37003fa2-2c2e-4dbf-ae86-c944e3e41d55_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_131ca458-1d71-4910-b42b-9f55b0e4386f_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in joint ventures</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesDomain_f6010b23-acf5-41fb-897d-ec03a2775b31_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for joint ventures [Member]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesDomain_label_en-US" xlink:label="lab_ifrs-full_JointVenturesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesDomain" xlink:to="lab_ifrs-full_JointVenturesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_fdc24fe9-ff3b-4758-a02d-a750c6a62fbf_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [Member]</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtMarketValueMember_aab162b4-f60d-4bda-9b0d-4cb9f629117a_terseLabel_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_sny_AtMarketValueMember_label_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Value [member]</link:label>
    <link:label id="lab_sny_AtMarketValueMember_documentation_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember" xlink:href="sny-20250630.xsd#sny_AtMarketValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtMarketValueMember" xlink:to="lab_sny_AtMarketValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_17ca523e-9fc8-4798-b418-b9e552992caa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Results</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_cdb96f4a-fcc1-4612-b40a-be60be5386dd_terseLabel_en-US" xlink:label="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_label_en-US" xlink:label="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures [Member]</link:label>
    <link:label id="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_documentation_en-US" xlink:label="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:href="sny-20250630.xsd#sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:to="lab_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ab0c42df-f238-4554-b885-77007697852c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_75ee81d6-39a3-4299-8cbf-c48601e3952a_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_e131f2a7-2447-46fc-b976-10a33211221f_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_80425190-f5a0-415f-949e-83d9dc838233_terseLabel_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative consumer price inflation rate</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_label_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_documentation_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:href="sny-20250630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:to="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_8dc934ed-d161-421c-8260-ec6b445ce365_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provisions utilized</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_a5e4f319-d1dd-47a9-aa7a-b175400bd4a7_terseLabel_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_label_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions And Other Post-Employment Benefits [Member]</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:href="sny-20250630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:to="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_fb3c9e9a-173f-49f7-8be5-64ffe636d79a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-Current Provisions and Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_2f65af70-64ec-425c-a06e-71f24007dee0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_4678c961-af50-41d4-bb59-92adbf862f92_terseLabel_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of liability</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_label_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Fair Value Liabilities</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_documentation_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage increase in fair value liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:href="sny-20250630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:to="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_c4e4b8da-1107-4c5e-90ab-8ca4a5692720_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Chinese Yuan Renminbi [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Chinese Yuan Renminbi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangesInProfitLossFromDiscontinuedOperations_fc3e2849-dfde-4643-bc1d-22741b633d07_terseLabel_en-US" xlink:label="lab_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Profit Loss from Discontinued Operations</link:label>
    <link:label id="lab_sny_ChangesInProfitLossFromDiscontinuedOperations_label_en-US" xlink:label="lab_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Profit Loss from Discontinued Operations</link:label>
    <link:label id="lab_sny_ChangesInProfitLossFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in Profit Loss from Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_ChangesInProfitLossFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:to="lab_sny_ChangesInProfitLossFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PotentialFuturePayments_416b621b-7b9d-4347-b578-b057ab14e4af_terseLabel_en-US" xlink:label="lab_sny_PotentialFuturePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Future Payments</link:label>
    <link:label id="lab_sny_PotentialFuturePayments_label_en-US" xlink:label="lab_sny_PotentialFuturePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Payments</link:label>
    <link:label id="lab_sny_PotentialFuturePayments_documentation_en-US" xlink:label="lab_sny_PotentialFuturePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Future Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialFuturePayments" xlink:href="sny-20250630.xsd#sny_PotentialFuturePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PotentialFuturePayments" xlink:to="lab_sny_PotentialFuturePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AstraZenecaMember_5e7827ed-a1ac-43f3-ab28-5518e808a7cc_terseLabel_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_sny_AstraZenecaMember_label_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_sny_AstraZenecaMember_documentation_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember" xlink:href="sny-20250630.xsd#sny_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AstraZenecaMember" xlink:to="lab_sny_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_1d4f194b-7e4e-4fb6-b5dd-5abf75e115c5_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales (c) (d)</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AubagioMember_8a9ab113-df58-4a13-9869-c25dfe07d96d_terseLabel_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aubagio</link:label>
    <link:label id="lab_sny_AubagioMember_label_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aubagio [Member]</link:label>
    <link:label id="lab_sny_AubagioMember_documentation_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aubagio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember" xlink:href="sny-20250630.xsd#sny_AubagioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AubagioMember" xlink:to="lab_sny_AubagioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantAxis_bc85234f-5726-40c9-92bc-eea3e30ec283_terseLabel_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_label_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_documentation_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis" xlink:href="sny-20250630.xsd#sny_DefendantAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantAxis" xlink:to="lab_sny_DefendantAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmountOfSharesRepurchased_562badca-0ab0-4767-b19c-87185789ffe6_terseLabel_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of shares repurchased</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_label_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Of Shares Repurchased</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased" xlink:href="sny-20250630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmountOfSharesRepurchased" xlink:to="lab_sny_AmountOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_27eb99a6-6d79-400c-bb1e-77fa28d592eb_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_d11bdfb5-1bf5-4847-9df9-ab5afad3fd0c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_label_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flow hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowHedgesMember" xlink:to="lab_ifrs-full_CashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_cb395f48-df91-4c51-9d59-fcf5aa886342_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_8666570e-0c60-4553-9adc-3e2af42f5178_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flow on acquisition</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_cc290e54-d13a-4286-9736-bac2b092600c_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NovavaxMember_65118f61-832a-4077-b0dd-6c3edf579ad3_terseLabel_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novavax</link:label>
    <link:label id="lab_sny_NovavaxMember_label_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novavax [Member]</link:label>
    <link:label id="lab_sny_NovavaxMember_documentation_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novavax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NovavaxMember" xlink:to="lab_sny_NovavaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSPVaccineCompanyMember_cb162e49-4dc0-4066-8e9a-9fee0adf6f6f_terseLabel_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_label_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company [Member]</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_documentation_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember" xlink:href="sny-20250630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSPVaccineCompanyMember" xlink:to="lab_sny_MSPVaccineCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_b5d6a5ef-cc7a-49dc-963d-3c1e313cbd98_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_3ab10d0a-30bd-42a7-bc70-0d3b2e9633c5_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:to="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_acb880ea-0c24-445b-ab5c-4e7e15d47453_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges, gains or losses on assets</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities related to property plant and equipment to inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_fe7201c2-136e-477e-9283-e7d68c43a194_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_0140e581-03bc-4dd4-b62f-1eca458e2cd0_terseLabel_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from intragroup sales from continuing to discontinued operations</link:label>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_label_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from intragroup sales from continuing to discontinued operations</link:label>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from intragroup sales from continuing to discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:to="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_451e8149-71d8-41e7-aec9-c1bfe11cae8b_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Canadian dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Canadian Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Canadian Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_29f4929d-59dc-440f-9177-1aec8440f558_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses, net of reversals</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in other comprehensive income, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_f5024e50-afdb-45b2-b913-fc1f73eab6d7_terseLabel_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing &amp; Supply</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_label_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing And Supply [Member]</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_documentation_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember" xlink:href="sny-20250630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManufacturingAndSupplyMember" xlink:to="lab_sny_ManufacturingAndSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_7b72d846-0cc0-4cb4-8c7b-83b7604ea748_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_d42afbae-e17e-452d-b164-9f6292d97fd5_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition</link:label>
    <link:label id="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_label_en-US" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:to="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_dc7cacbe-9288-4d2c-adb2-b5291fea1f4f_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments related to potential milestone payments for projects under collaboration agreements</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:to="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_f944c0e8-5b23-4ab8-8de7-0843690d5f63_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:to="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_18c5b75d-32a0-4c5f-93eb-35d322fff25d_terseLabel_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief</link:label>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_label_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief [Member]</link:label>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_documentation_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember" xlink:href="sny-20250630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeasonalSymptomsAndPainReliefMember" xlink:to="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_88fb54b3-38e6-4609-9224-a0814a4c63fc_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of transformation programs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_7fc038d5-e012-4e49-8bbb-ab50aa8f8b73_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_1897e837-5054-4c03-a6b0-eed34b64c1c5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_a9f5a69d-e8dd-4e08-98a9-596473159efd_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [Axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_b1742df9-426d-4151-b70a-4410847ee960_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_47480b7e-aa84-445a-8c5b-298afc2869d3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_5b8ce82d-ae33-4367-8073-e2387b31ef89_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_0fbde8a5-e57c-4475-8d5d-4048d6d53a74_terseLabel_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Projects And Technology Platforms</link:label>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_label_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Projects And Technology Platforms [Member]</link:label>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_documentation_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Projects And Technology Platforms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:href="sny-20250630.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:to="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_eca43ff7-3b68-422d-886f-673c728c3f28_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4160ac81-2063-4b17-b941-bb751138a857_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentDomain_20594d9c-71a6-4e98-9204-ce4ad83e65e0_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_label_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_documentation_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain" xlink:href="sny-20250630.xsd#sny_DebtInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentDomain" xlink:to="lab_sny_DebtInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_16bcc708-5d88-4597-a58f-4452cfd63263_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_eb2b9e0a-54fa-49a8-843f-004d284e1a24_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 1-3 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_510c36d2-c415-4a44-b8ee-d5da31a8ce08_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax effects of share-based payments</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax effects of the exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_15f51778-ff8a-4465-88eb-6020c695e58d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_be69ddc0-f10e-4616-b016-ecc5f3b33808_terseLabel_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits" xlink:href="sny-20250630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClassActionLawsuits" xlink:to="lab_sny_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_3764d7f2-8c67-4450-bca1-0177d30f38dc_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for stock options with dilutive effect (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_adcc5a34-1e1a-4cb4-bbb5-b65ccee6790a_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;70.00 to &#8364;80.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeThreeMember" xlink:to="lab_sny_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_7f066596-1ee6-431d-a81f-37708a95b930_terseLabel_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20250630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_6658dc58-8e4b-4c0d-a42c-4b52b05df2cb_terseLabel_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_label_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines [Member]</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_documentation_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:href="sny-20250630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:to="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_913aa8db-a67a-4658-85d6-8ffa1294b398_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint ventures [Axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_f8baca9f-10b3-4fb0-bd1e-793217759daa_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of employee benefits (stock options and other share-based payments)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_aee5689b-726e-4d5b-ad58-8945a523f1cb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_3f6cfa82-a1f9-40ca-8aac-ee111a94ce46_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_d356d9c6-4591-47f5-a9e9-ebbccf315b1b_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_edbd5784-2b45-4bb2-a37e-1c17e03378ee_terseLabel_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Geographical Zones [Member]</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_label_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Geographical Zones [Member]</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_documentation_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable geographical zones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember" xlink:href="sny-20250630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReportableGeographicalZonesMember" xlink:to="lab_sny_ReportableGeographicalZonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_28fc18ea-d4ab-4a80-98e5-73d5db4d2d5c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains and losses on disposals of non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_a2e53b01-1e6d-472f-bb30-c07474326994_terseLabel_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer contingent consideration arising from acquisition of Genzyme</link:label>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_label_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer Contingent Purchase Consideration Arising From Acquisition Of Genzyme [Member]</link:label>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_documentation_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer contingent purchase consideration arising from the acquisition of Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:href="sny-20250630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:to="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_9074e03a-6511-43dd-9af6-fd125638ef68_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_babb44ea-dfc8-4fce-b530-fd8ff186d5e4_terseLabel_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentiel payments related to percentage of sales of alemtuzumab</link:label>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_label_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Payments Related To Percentage Of Sales</link:label>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_documentation_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential payments related to percentage of sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:href="sny-20250630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:to="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_dc59d059-35be-4eb9-9f6f-9a6c5d2298dd_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt and current portion of long-term debt</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_f9f8197a-ec7c-4cf9-ae85-3cd1a97875e1_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_5fb7cda5-2053-47d1-b25c-59e6830d856e_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_90657572-1d25-4b83-8bfe-4012c41a1e09_terseLabel_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MSD contingent consideration (European Vaccines business)</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_label_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MSD Contingent Consideration European Vaccines Business [Member]</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_documentation_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MSD contingent consideration European vaccines business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:href="sny-20250630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:to="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_5ab96485-abb9-48e1-b2d3-dafeec8e08a4_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_3e03513a-76b5-44e1-ba66-f18aaa062b04_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d2282460-1804-4965-8026-41b3cdf6ee89_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_6acfa04f-a4f1-4b64-9fa1-5c5c97387594_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_4214a042-15d7-4e25-b32f-785574afdf3a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block</link:label>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:to="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_7b9006cb-4e2a-467b-b97f-ac99c1e53b9f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Geographical Information on Net Sales and Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_30000e1b-214b-432f-b2ec-0510ca95880d_terseLabel_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_label_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_documentation_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:href="sny-20250630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:to="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_39512637-6232-4208-a4ba-080a5c38afb8_terseLabel_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement</link:label>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_label_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement [Member]</link:label>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_documentation_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:href="sny-20250630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:to="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_cc4c3c7f-78f9-47f8-94b5-2db77e98da8b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_7b74bca7-b541-4733-8fa5-abb4e3238a88_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperations_a060e1da-0a07-4300-ae95-731ea181ffef_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_b25d890a-ea95-475e-8f89-61006a44b292_terseLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:to="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_c3226cee-d82c-4b52-93ad-cfaccb3dc55a_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_a25bd5aa-005f-473b-9e69-9653234cceef_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_637a15d7-6b82-4adb-b408-de8063837e7e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of Carrying Amount to Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_5e0636e8-9a7a-43d0-bf41-d2d1694dd305_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between the standard French tax rate and the rates applicable to Sanofi</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionAxis_99af320c-3a5d-4e5b-b495-888f6c2a05ab_terseLabel_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_label_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_documentation_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis" xlink:href="sny-20250630.xsd#sny_MarketConditionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionAxis" xlink:to="lab_sny_MarketConditionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_40e575f2-a935-4807-9149-beed19ec0284_verboseLabel_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_label_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue Receivables Gross Value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_documentation_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue" xlink:href="sny-20250630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OverdueReceivablesGrossValue" xlink:to="lab_sny_OverdueReceivablesGrossValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_db194608-a668-4cc4-9d58-77b7a55564c2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Gains and Losses, and Litigation</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Gains And Losses, And Litigation [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of other gains and losses, and litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:to="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_2e2b564d-1c1b-4e49-acd8-163fe9aff314_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than three years and not later than five years [member]</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_121454cf-c0f6-4aae-96f4-b6fa3cf8a0ac_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_8e371783-8a8e-4d7a-9c67-cdbeff9b51bb_terseLabel_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_label_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation [Member]</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_documentation_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember" xlink:href="sny-20250630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForeignCurrencyTranslationMember" xlink:to="lab_sny_ForeignCurrencyTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_b1c4d0fe-bf51-479c-8837-5d7204966694_terseLabel_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Revenue, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Revenue, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Revenue, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20250630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_de52990c-dd1c-4486-a2c2-626f2f38b464_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sny-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:07db7c94-91f4-4fd2-95fe-08ff63940db0,g:3f324309-e50f-453d-bcd2-39879099f161-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20250630.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b47a81bf-9ab4-4589-bfd0-2b6c35871610" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_0672e624-0f2e-450d-8a4f-9ee6db672e41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b47a81bf-9ab4-4589-bfd0-2b6c35871610" xlink:to="loc_dei_EntitiesTable_0672e624-0f2e-450d-8a4f-9ee6db672e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_0672e624-0f2e-450d-8a4f-9ee6db672e41" xlink:to="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_168a4601-7365-4fab-aa43-6fd251be491c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentType_168a4601-7365-4fab-aa43-6fd251be491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e5a6f666-4e70-4ac8-82dd-a995a8639524" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_EntityRegistrantName_e5a6f666-4e70-4ac8-82dd-a995a8639524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_14fc3f04-3e95-48ba-8989-6c2df7a7038d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_AmendmentFlag_14fc3f04-3e95-48ba-8989-6c2df7a7038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3fed6721-bb75-4e97-9ce7-4dd69f18f9b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_EntityCentralIndexKey_3fed6721-bb75-4e97-9ce7-4dd69f18f9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5a7b1a30-b2cb-4641-9382-f379ee1ac2d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5a7b1a30-b2cb-4641-9382-f379ee1ac2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8a11ce83-d5b9-4886-b179-ee176a760a47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentPeriodEndDate_8a11ce83-d5b9-4886-b179-ee176a760a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33315dba-9d34-47fb-8197-3e7930a0d619" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentFiscalYearFocus_33315dba-9d34-47fb-8197-3e7930a0d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9406e32c-c4ec-41a1-acac-3d3e7355cc01" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e28eb616-71c6-41bb-bff1-d817408928e2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9406e32c-c4ec-41a1-acac-3d3e7355cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_fd35b63c-c033-4a67-bf13-7856b2678672" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_fd35b63c-c033-4a67-bf13-7856b2678672" xlink:to="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7e26d3c4-05e7-4ced-b2fe-a44d7ab040e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7e26d3c4-05e7-4ced-b2fe-a44d7ab040e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_164d86e8-043f-453c-88cc-c8760db5725d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_RightofuseAssets_164d86e8-043f-453c-88cc-c8760db5725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_3b0fe149-9520-41ef-a192-e7397e1e54f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_Goodwill_3b0fe149-9520-41ef-a192-e7397e1e54f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e4d63920-a394-40f7-b850-43b1bc421a3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_e4d63920-a394-40f7-b850-43b1bc421a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_fed49fdb-c2e8-422c-9363-79ff477cbce3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_fed49fdb-c2e8-422c-9363-79ff477cbce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_22717768-02bc-450c-8017-5c9220cd2da2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_22717768-02bc-450c-8017-5c9220cd2da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_b73f0e26-ec92-4855-9216-d5c46f843de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_b73f0e26-ec92-4855-9216-d5c46f843de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_27b8e03c-ef1c-4f66-aa57-05d8ea0da209" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_DeferredTaxAssets_27b8e03c-ef1c-4f66-aa57-05d8ea0da209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_dc7f0266-c56a-46b6-b967-745a46137bd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_NoncurrentAssets_dc7f0266-c56a-46b6-b967-745a46137bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_63ee706b-37ec-49ae-9757-98b84fa97fb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_CurrentAssets_63ee706b-37ec-49ae-9757-98b84fa97fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_df934eb5-ce42-43a6-96f7-47c54fe8ee04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_Inventories_df934eb5-ce42-43a6-96f7-47c54fe8ee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_795112b1-c72a-4a1f-bf50-df7c28fc6b7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_CurrentTradeReceivables_795112b1-c72a-4a1f-bf50-df7c28fc6b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_d66a1db6-2f5e-4a6d-b0d6-1eb44d0627d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_OtherCurrentAssets_d66a1db6-2f5e-4a6d-b0d6-1eb44d0627d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_13ad7011-14b0-4cb1-b5b0-d7cea5a4cfc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_13ad7011-14b0-4cb1-b5b0-d7cea5a4cfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_77d042bd-4a00-4cc5-b4b3-86b5d9f620ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_CashAndCashEquivalents_77d042bd-4a00-4cc5-b4b3-86b5d9f620ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_bb27c9a8-9b44-4635-87b0-28a9528c9789" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_bb27c9a8-9b44-4635-87b0-28a9528c9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_e8f0cc0e-edfc-451a-8e1c-e13c99dc89f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_699018c4-677b-4bb2-bb2c-0724e4c900d2" xlink:to="loc_ifrs-full_Assets_e8f0cc0e-edfc-451a-8e1c-e13c99dc89f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_fd35b63c-c033-4a67-bf13-7856b2678672" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_a0f807f3-5d1f-42a3-845e-c7a05f1fc3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_a0f807f3-5d1f-42a3-845e-c7a05f1fc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_df2ade66-eccb-442c-aa8f-ab7115842627" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_NoncontrollingInterests_df2ade66-eccb-442c-aa8f-ab7115842627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0431661c-7336-4b14-822f-0feba50a1f53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_Equity_0431661c-7336-4b14-822f-0feba50a1f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_d3628beb-8904-4857-9ea3-7147271aa03d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_LongtermBorrowings_d3628beb-8904-4857-9ea3-7147271aa03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_5cfcafb0-59be-4cf1-ac0f-037698dece2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_5cfcafb0-59be-4cf1-ac0f-037698dece2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_abc32ca7-835f-4cda-84eb-14b4d3449d33" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_abc32ca7-835f-4cda-84eb-14b4d3449d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_fa3a3bf9-5356-4881-93bb-764b983e8f8b" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_fa3a3bf9-5356-4881-93bb-764b983e8f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_8335b2f0-8e8b-43e9-b778-dbb7fa2a6df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_8335b2f0-8e8b-43e9-b778-dbb7fa2a6df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_12323c6c-d00f-45b4-8ae1-a900ca95a47e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_12323c6c-d00f-45b4-8ae1-a900ca95a47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_cb00e9c9-91ed-4dfa-86a0-43d5aa2ece91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_NoncurrentLiabilities_cb00e9c9-91ed-4dfa-86a0-43d5aa2ece91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_47d63f32-d00b-4ef4-82f2-1f6081af9853" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_47d63f32-d00b-4ef4-82f2-1f6081af9853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_5544d1d1-e214-44d0-bf45-9b1c37ebc113" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_5544d1d1-e214-44d0-bf45-9b1c37ebc113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_dc72ac48-01cf-4003-a494-ee23d8643a79" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_dc72ac48-01cf-4003-a494-ee23d8643a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_48ee6e21-c88c-49be-9c20-54712b05be03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_48ee6e21-c88c-49be-9c20-54712b05be03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_ddc4f7e6-f5e6-4587-b160-f378db05155b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_ddc4f7e6-f5e6-4587-b160-f378db05155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1b87d5bc-b52c-494b-9a47-35b1fa0d0051" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1b87d5bc-b52c-494b-9a47-35b1fa0d0051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_4a61f3c3-32e0-4687-836d-a058d5a0411a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_CurrentLiabilities_4a61f3c3-32e0-4687-836d-a058d5a0411a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_b0f2d561-d9d2-41a0-8e86-1cf287150461" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_b0f2d561-d9d2-41a0-8e86-1cf287150461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_cd340271-af42-47eb-9e58-4785e0a84ba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_178bf059-fc3d-4c0a-a5c6-2c06b70ec0df" xlink:to="loc_ifrs-full_EquityAndLiabilities_cd340271-af42-47eb-9e58-4785e0a84ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedIncomeStatements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_baabf544-41d1-447e-9d2c-91663175c960" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_baabf544-41d1-447e-9d2c-91663175c960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_2baf6f17-2a34-4a42-88f3-e9000e11f1ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_OtherRevenue_2baf6f17-2a34-4a42-88f3-e9000e11f1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_ac5bfda0-94c0-480a-bc32-146ac1d30356" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_CostOfSales_ac5bfda0-94c0-480a-bc32-146ac1d30356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_87cf35b1-85bc-4caa-91c6-11673a29eaaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_GrossProfit_87cf35b1-85bc-4caa-91c6-11673a29eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_648a184e-e90c-485d-aacf-9e4604b8b44e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_648a184e-e90c-485d-aacf-9e4604b8b44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6149ee77-b17a-4e50-afec-0f088ab4430f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6149ee77-b17a-4e50-afec-0f088ab4430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7808d898-ed1b-4a09-9c73-94e86d55ae6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7808d898-ed1b-4a09-9c73-94e86d55ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_b6f75c51-0789-4ba9-8b8c-8726bb0d750f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_b6f75c51-0789-4ba9-8b8c-8726bb0d750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_43aee99a-4596-433f-aa9e-c8cc26fd4728" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_43aee99a-4596-433f-aa9e-c8cc26fd4728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c5358c20-e67c-4789-a934-af8804d98f10" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c5358c20-e67c-4789-a934-af8804d98f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_8159d938-7795-4429-a77c-c4a60fe7c2a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_8159d938-7795-4429-a77c-c4a60fe7c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_6afd68c5-4d7d-4ba9-b52b-444f4cda8b7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_6afd68c5-4d7d-4ba9-b52b-444f4cda8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_794674cb-9caf-4656-8e42-906bbac23178" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_sny_OtherGainsLossesAndLitigation_794674cb-9caf-4656-8e42-906bbac23178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_65f0ef77-c929-4c89-8234-1adbc0c34a1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_65f0ef77-c929-4c89-8234-1adbc0c34a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_9862898d-1cc5-4408-850e-c476c56e0263" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_FinanceCosts_9862898d-1cc5-4408-850e-c476c56e0263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_395ae5bc-591b-4610-b239-8f64f3ac2e39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_FinanceIncome_395ae5bc-591b-4610-b239-8f64f3ac2e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_1f7a0849-c5a3-4eed-868e-140c1668112b" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_1f7a0849-c5a3-4eed-868e-140c1668112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_72490c85-15c5-4579-a3a3-06b47c835bc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_72490c85-15c5-4579-a3a3-06b47c835bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_5c63d1eb-2888-479e-b15d-6ed1a661257f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_5c63d1eb-2888-479e-b15d-6ed1a661257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_40531e9e-1ff5-4e47-b227-5d3f46c1743c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_40531e9e-1ff5-4e47-b227-5d3f46c1743c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_89800caf-c34d-46b3-958b-e5baeef88502" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_89800caf-c34d-46b3-958b-e5baeef88502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_c60ee39d-165b-4308-ac76-b2fff77d6fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_ProfitLoss_c60ee39d-165b-4308-ac76-b2fff77d6fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_dd99e573-c20a-42d7-b1a3-92bb00f8d887" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLoss_c60ee39d-165b-4308-ac76-b2fff77d6fa2" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_dd99e573-c20a-42d7-b1a3-92bb00f8d887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_a96f6818-781d-410c-9ce5-19eab377c848" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLoss_c60ee39d-165b-4308-ac76-b2fff77d6fa2" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_a96f6818-781d-410c-9ce5-19eab377c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_8195b0b8-90ed-4e3e-b1bd-59ceb3f9a210" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_WeightedAverageShares_8195b0b8-90ed-4e3e-b1bd-59ceb3f9a210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_b1977e34-bcd2-49b6-a610-a442553556ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_b1977e34-bcd2-49b6-a610-a442553556ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_0aa741f6-5d8d-4e7c-bff2-5caa8496c31f" xlink:href="sny-20250630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_0aa741f6-5d8d-4e7c-bff2-5caa8496c31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_77c96f7c-066f-4d16-ab68-c319ee2bb531" xlink:href="sny-20250630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_77c96f7c-066f-4d16-ab68-c319ee2bb531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2e76723c-17a7-46dd-aa57-77f54c0aecb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_2e76723c-17a7-46dd-aa57-77f54c0aecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1f76fffc-65c5-4249-ad23-6f7e096c6192" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_1f76fffc-65c5-4249-ad23-6f7e096c6192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_f7fe6562-528a-4825-ab06-644b251b891d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_f7fe6562-528a-4825-ab06-644b251b891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_ed75c29c-e4f6-465a-b346-7dfd4f58f8f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_17c2e624-2576-47f8-b19e-2b81227aeec4" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_ed75c29c-e4f6-465a-b346-7dfd4f58f8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_dbe9373a-85b8-4862-ab89-8464704413ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ProfitLoss_dbe9373a-85b8-4862-ab89-8464704413ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_0af318c6-b1dc-41fd-a982-0c1bca8fee04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_0af318c6-b1dc-41fd-a982-0c1bca8fee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1ac83eb8-964e-42d3-a066-aceab5cdda53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1ac83eb8-964e-42d3-a066-aceab5cdda53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_315665bc-921e-4c23-a5a4-6e6219c0122a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_315665bc-921e-4c23-a5a4-6e6219c0122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_2e44d897-3fcc-4663-a0a9-7d48aba33e2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_2e44d897-3fcc-4663-a0a9-7d48aba33e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_276d8f31-097b-4290-a6e5-db667357519e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_276d8f31-097b-4290-a6e5-db667357519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_659cfc58-2cbc-43bf-9c6d-7b19df586cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_659cfc58-2cbc-43bf-9c6d-7b19df586cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_1df5eab9-7829-4e6b-a72f-4e85920beeff" xlink:href="sny-20250630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_1df5eab9-7829-4e6b-a72f-4e85920beeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_ef879101-cc32-4ec7-a99d-389193831b53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_ef879101-cc32-4ec7-a99d-389193831b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_99fc95bb-30dd-4347-a593-9f821572a5b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_99fc95bb-30dd-4347-a593-9f821572a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_c9d81ce9-216b-47ef-9057-248422175280" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_c9d81ce9-216b-47ef-9057-248422175280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d6a1ffe9-ee46-4742-bbf8-f45f3f01cd46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d6a1ffe9-ee46-4742-bbf8-f45f3f01cd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_88c8c620-3cc1-48f6-8a39-b325e9167791" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_88c8c620-3cc1-48f6-8a39-b325e9167791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_b88b23f1-d0c3-4e68-9d70-33d0a1f43829" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_3fbcf09e-bd0c-4bc0-8611-972842316fdc" xlink:to="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_b88b23f1-d0c3-4e68-9d70-33d0a1f43829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_db15240b-ed56-40b5-aaba-6ea5e33a29d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ComprehensiveIncome_db15240b-ed56-40b5-aaba-6ea5e33a29d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_a3288d2c-1845-49a1-860b-a603ee0db29b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_a3288d2c-1845-49a1-860b-a603ee0db29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_8847b121-d3c9-4127-9e5a-31e1fa4e13af" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations_8847b121-d3c9-4127-9e5a-31e1fa4e13af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_4afbd6c3-cf6b-4c0f-ae67-e825ee1db2af" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations_4afbd6c3-cf6b-4c0f-ae67-e825ee1db2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_91f6acec-e8c5-4955-9a90-f788e8d705fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_512a3af2-d25d-4fba-9a78-8cd130587615" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_91f6acec-e8c5-4955-9a90-f788e8d705fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_b1a74a23-331f-4b5b-8836-08b976a08d9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_b1a74a23-331f-4b5b-8836-08b976a08d9c" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_214fc50f-3b85-482e-8b50-8c8af8db3ecd" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_01500599-9dab-42e0-9fb9-5eec0394e584" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_IssuedCapitalMember_01500599-9dab-42e0-9fb9-5eec0394e584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_63c9faf0-8bda-4b4a-8d03-12a8ffbbac01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_63c9faf0-8bda-4b4a-8d03-12a8ffbbac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_5e686308-b618-474c-b01d-017ea03cd6a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_TreasurySharesMember_5e686308-b618-474c-b01d-017ea03cd6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_7a9c5ee3-d29a-45f8-90e1-1f5546b22d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_RetainedEarningsMember_7a9c5ee3-d29a-45f8-90e1-1f5546b22d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_29ecc91d-4167-4a50-b9ae-13376bcd07c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_29ecc91d-4167-4a50-b9ae-13376bcd07c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4fc091e-ad8d-4fb1-b93c-d8891c4119f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_93b417aa-635d-4c8d-b433-10ed90421062" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4fc091e-ad8d-4fb1-b93c-d8891c4119f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_e18d3b72-2a3c-4d80-92b1-fb68b29617a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_7af06a46-4a79-4dc4-b715-3643954c93a1" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_e18d3b72-2a3c-4d80-92b1-fb68b29617a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_6e129974-fd1b-4754-8fc2-e800df802d9e" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_fb915436-1f9e-4e2e-b1ae-09a74a97275c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_Equity_fb915436-1f9e-4e2e-b1ae-09a74a97275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_fdcff009-e88a-4eb7-a3f2-988361a69738" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_fdcff009-e88a-4eb7-a3f2-988361a69738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_11db47b9-20b3-456e-8b9e-2b90c8f3d1a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ProfitLoss_11db47b9-20b3-456e-8b9e-2b90c8f3d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_2b2f463a-6057-4cb5-b010-32360369a645" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ComprehensiveIncome_2b2f463a-6057-4cb5-b010-32360369a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_35781e23-620d-4e47-b00f-81f2b1ee691c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_35781e23-620d-4e47-b00f-81f2b1ee691c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_729ef720-64cb-4566-bb16-d4d9c44bb5ba" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_729ef720-64cb-4566-bb16-d4d9c44bb5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_f7796c77-b427-4ad7-b7a5-82176fd7496a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_f7796c77-b427-4ad7-b7a5-82176fd7496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_3056ef6e-42bb-4d59-9ec3-1f42eef1802b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_3056ef6e-42bb-4d59-9ec3-1f42eef1802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_34a6947d-07a9-49c1-8839-d28a2b8a52dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_34a6947d-07a9-49c1-8839-d28a2b8a52dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:href="sny-20250630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1a5562d0-49c7-42a6-acea-c00c670330f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1a5562d0-49c7-42a6-acea-c00c670330f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1fe26c94-22eb-4347-91a7-c300a682f00e" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1fe26c94-22eb-4347-91a7-c300a682f00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_a24f3dd8-a172-43c9-a9ff-272b2f37714f" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_a24f3dd8-a172-43c9-a9ff-272b2f37714f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_38aba715-3e0e-468f-9751-a241ec86c156" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_38aba715-3e0e-468f-9751-a241ec86c156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_9029f5df-1ecf-4359-af76-ef827babe534" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_9029f5df-1ecf-4359-af76-ef827babe534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_142885f0-305a-4fe6-9090-5d5fca8da0d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_9f740995-77ba-44e8-96e9-2f3d8863a265" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_142885f0-305a-4fe6-9090-5d5fca8da0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_625cd880-8297-43f3-8ff9-0c3d83fa7981" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_625cd880-8297-43f3-8ff9-0c3d83fa7981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_9115cf4b-0dd2-4e7e-a6c6-b0601b608670" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_9115cf4b-0dd2-4e7e-a6c6-b0601b608670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_16b768aa-a02c-4437-8b35-71da9cf50f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_Equity_16b768aa-a02c-4437-8b35-71da9cf50f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_53a6f157-095d-4b8d-ae44-1dcbc03f1835" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_37f4b70b-ff16-4a27-b1f7-db96cbaa9918" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_53a6f157-095d-4b8d-ae44-1dcbc03f1835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofChangesinEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_fdafeac4-8aca-4845-8c52-ecf3eb6727a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fdafeac4-8aca-4845-8c52-ecf3eb6727a8" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e718814e-99ec-4fab-8974-9e3ec90e7221" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_6959c97b-a826-4f75-a07b-d8ec216c370b" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_f6fa6790-5438-4a39-8489-ef2bcf491583" xlink:to="loc_sny_EuroapiMember_6959c97b-a826-4f75-a07b-d8ec216c370b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2507fbc-313f-4451-a4b1-ff6d159da920" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_bdf78535-f69c-4904-abf8-c82048735141" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_bdf78535-f69c-4904-abf8-c82048735141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_8ccc7149-1aea-47c1-88ad-739f5092cafa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_IssuedCapitalMember_8ccc7149-1aea-47c1-88ad-739f5092cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_a14a434b-82db-47ec-b916-319cfdc2ebc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_RetainedEarningsMember_a14a434b-82db-47ec-b916-319cfdc2ebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_43a2481e-dcb1-4db6-bcf1-d1129d1dec4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_TreasurySharesMember_43a2481e-dcb1-4db6-bcf1-d1129d1dec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_7d8fe56c-064d-416f-8759-412851b8e1b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_de947497-0994-48ae-a090-03e5ebd33eed" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_7d8fe56c-064d-416f-8759-412851b8e1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_076829e0-1380-4804-aa76-2c3f0808be4c" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_2c2d8e69-a13c-4a88-a684-9d38f42fa912" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_2c2d8e69-a13c-4a88-a684-9d38f42fa912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_05a862cc-1e66-4d61-8a75-c82e5b90f54d" xlink:href="sny-20250630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_05a862cc-1e66-4d61-8a75-c82e5b90f54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_ac64832b-cae0-492b-afca-05d9caaff597" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_ac64832b-cae0-492b-afca-05d9caaff597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_0920935e-63a6-4292-9b0f-ffd47ad87185" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_0920935e-63a6-4292-9b0f-ffd47ad87185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations_7b2dde19-966a-4842-927f-9deab3a09a4b" xlink:href="sny-20250630.xsd#sny_TaxesOnShareCancellations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_5beec586-cc79-4d96-abb0-256755675c39" xlink:to="loc_sny_TaxesOnShareCancellations_7b2dde19-966a-4842-927f-9deab3a09a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_01f3037c-8bbb-420d-8764-c212c11e10c5" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fdafeac4-8aca-4845-8c52-ecf3eb6727a8" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_01f3037c-8bbb-420d-8764-c212c11e10c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_36d9899b-0722-4a19-a639-c719a502bcf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fdafeac4-8aca-4845-8c52-ecf3eb6727a8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_36d9899b-0722-4a19-a639-c719a502bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_d0209568-34ba-4c90-9835-2833dc1fa446" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fdafeac4-8aca-4845-8c52-ecf3eb6727a8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_d0209568-34ba-4c90-9835-2833dc1fa446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_beb056fb-82f4-43e1-885d-fe6b598bba16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_beb056fb-82f4-43e1-885d-fe6b598bba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_13a884af-7d5c-4f88-81b9-93b66c44da40" xlink:href="sny-20250630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_13a884af-7d5c-4f88-81b9-93b66c44da40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8de280c7-c244-46d3-9d12-a1dfe0bf9651" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8de280c7-c244-46d3-9d12-a1dfe0bf9651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_842d0e68-f37d-467d-9fa6-2cd919218496" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_842d0e68-f37d-467d-9fa6-2cd919218496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_41a8a779-3c5b-4192-8832-7cd9f3ee4d89" xlink:href="sny-20250630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_41a8a779-3c5b-4192-8832-7cd9f3ee4d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_e6457bff-83cc-475d-a0df-be19c24aeff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_e6457bff-83cc-475d-a0df-be19c24aeff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_2db810b7-c74e-481a-8ba6-9fba5d18389b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_2db810b7-c74e-481a-8ba6-9fba5d18389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_8ee24588-ac26-4bc1-9972-c0ad7f88d078" xlink:href="sny-20250630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_8ee24588-ac26-4bc1-9972-c0ad7f88d078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_e55b55eb-cfa1-4aae-b9e6-94320845ad31" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_e55b55eb-cfa1-4aae-b9e6-94320845ad31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_71606896-4de8-4ab4-9a47-18a63f07d8ad" xlink:href="sny-20250630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_71606896-4de8-4ab4-9a47-18a63f07d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_8597ea03-a008-44aa-a7fe-3e8f614d1dde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_8597ea03-a008-44aa-a7fe-3e8f614d1dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0f953e94-9b49-43f0-8411-08a3906339e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0f953e94-9b49-43f0-8411-08a3906339e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_5b689e8d-03db-478a-b851-b0084087e96c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_5b689e8d-03db-478a-b851-b0084087e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_29cb2220-f890-4c37-b32d-5b2844a011ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_29cb2220-f890-4c37-b32d-5b2844a011ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_e3913c9d-e820-4282-987c-e12a96d979ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_e3913c9d-e820-4282-987c-e12a96d979ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_09084cc9-4974-48ef-95be-ce2f3f2a111b" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_09084cc9-4974-48ef-95be-ce2f3f2a111b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_c551ff06-4599-4725-aa15-24db8d396089" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_c551ff06-4599-4725-aa15-24db8d396089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_4e7f520c-4df2-4934-a482-5f12ea57fe56" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_59866508-5f9b-4bad-8b33-6519a7604f8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_4e7f520c-4df2-4934-a482-5f12ea57fe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6d36db19-bda5-4659-9e8a-0c2ee4d9db54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_399a7b17-2c83-4b2b-a038-bc70096013ea" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6d36db19-bda5-4659-9e8a-0c2ee4d9db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d2e17f6b-7670-41fb-a249-3075dc6f5bd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d2e17f6b-7670-41fb-a249-3075dc6f5bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_83cc19d4-fff5-4b10-b5a2-e8309b3e1da2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_83cc19d4-fff5-4b10-b5a2-e8309b3e1da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_6fb05783-f264-4eac-94d5-6865ec1f368b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_6fb05783-f264-4eac-94d5-6865ec1f368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_40d6b90e-91b4-49a6-81d0-9e39dca692a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_40d6b90e-91b4-49a6-81d0-9e39dca692a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d7c2e663-1001-447d-81fe-4107065a47d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d7c2e663-1001-447d-81fe-4107065a47d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_b35d1941-fe96-488d-940f-4cae6eec9d41" xlink:href="sny-20250630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_b35d1941-fe96-488d-940f-4cae6eec9d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_a925f5e6-0e0e-4636-bfdb-d78154c161c9" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_a925f5e6-0e0e-4636-bfdb-d78154c161c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_8f5efa18-2b8e-412a-8f87-b7147a1e03b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_8f5efa18-2b8e-412a-8f87-b7147a1e03b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_037a9762-1ff7-4a56-b249-d23dab861095" xlink:href="sny-20250630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_037a9762-1ff7-4a56-b249-d23dab861095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f958e217-61ac-4703-a497-0eff154ed63b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f958e217-61ac-4703-a497-0eff154ed63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_a2973a40-0258-4661-9741-b42423c0ead4" xlink:href="sny-20250630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_222f15c4-4faa-47ae-8321-ab913bea9aaa" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_a2973a40-0258-4661-9741-b42423c0ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_91b3d341-1b5a-4e28-80d1-f514b1d96779" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_91b3d341-1b5a-4e28-80d1-f514b1d96779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract_453d8c79-5824-455e-b10a-c7548e0c3a96" xlink:href="sny-20250630.xsd#sny_DividendsPaidAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_sny_DividendsPaidAbstract_453d8c79-5824-455e-b10a-c7548e0c3a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_b07b9ba5-886a-4a7a-844f-c70160fc2e69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_453d8c79-5824-455e-b10a-c7548e0c3a96" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_b07b9ba5-886a-4a7a-844f-c70160fc2e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_6687b4bd-799f-47a6-a846-74b2a7ce59fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_453d8c79-5824-455e-b10a-c7548e0c3a96" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_6687b4bd-799f-47a6-a846-74b2a7ce59fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_3a190e1a-4c97-4b56-ba72-23b0c12e0dfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_3a190e1a-4c97-4b56-ba72-23b0c12e0dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_934660c2-ff97-4033-9854-6a340884cff9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_934660c2-ff97-4033-9854-6a340884cff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_f3586f4f-29ab-4412-8734-a763871555ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_f3586f4f-29ab-4412-8734-a763871555ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_02c7151e-11ae-4193-a038-30e57075938f" xlink:href="sny-20250630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_02c7151e-11ae-4193-a038-30e57075938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_08933abf-ff1d-4cf4-b4d0-c4d9a7686757" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_08933abf-ff1d-4cf4-b4d0-c4d9a7686757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_f9ed8dec-3ad6-408c-92e5-3166833c848e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_f9ed8dec-3ad6-408c-92e5-3166833c848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_610dbca2-b4bb-417e-8ab4-5178b06432da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9de9b77-79b3-4ae3-9544-1ea706b8a6b1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_610dbca2-b4bb-417e-8ab4-5178b06432da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_42ede40e-2289-49f8-b144-ea3588f9c327" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_42ede40e-2289-49f8-b144-ea3588f9c327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_e956c471-34e2-4d56-8071-a8849c043541" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_e956c471-34e2-4d56-8071-a8849c043541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_68282aba-a039-4845-a856-fb03d396f5e9" xlink:href="sny-20250630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_68282aba-a039-4845-a856-fb03d396f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1d0ad31e-c63e-4c77-831c-57aa2d4498a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1d0ad31e-c63e-4c77-831c-57aa2d4498a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a5152cb1-b24f-4043-920e-c1893e4fa798" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a5152cb1-b24f-4043-920e-c1893e4fa798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2eae5dcb-b619-4a2d-a870-ae8783191fd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2eae5dcb-b619-4a2d-a870-ae8783191fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsDiscontinuedOperations_85994a9f-2a2b-416a-8f2a-bccabf75a734" xlink:href="sny-20250630.xsd#sny_CashAndCashEquivalentsDiscontinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_c3f246c0-cefe-4102-87d3-2b58c61d15fe" xlink:to="loc_sny_CashAndCashEquivalentsDiscontinuedOperations_85994a9f-2a2b-416a-8f2a-bccabf75a734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_8cbf927a-c15f-481b-9d1a-3285037e12ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_8cbf927a-c15f-481b-9d1a-3285037e12ee" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_befc1c5c-693e-4917-9282-1a742578fe1a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_79d8fd7d-4922-4f52-9a0e-9e1d191a1c66" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d8adb4f1-7bb9-4c03-872c-5a4d75528277" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_79d8fd7d-4922-4f52-9a0e-9e1d191a1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_665a8432-2202-4812-bd7d-7fe52b123a8e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_da1bb191-3e37-45d7-b21c-1bc5b0bb9f13" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_88672f47-2846-45e1-b495-9766b594819d" xlink:to="loc_sny_OpellaMember_da1bb191-3e37-45d7-b21c-1bc5b0bb9f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_97103ec1-3ddb-4ac7-8aa2-af5a2ca829bc" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_34cb1e33-afab-4247-9962-8dfbb64f277f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_34cb1e33-afab-4247-9962-8dfbb64f277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_32ca314a-9d2f-4ae8-bfde-aad42f69d9c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_32ca314a-9d2f-4ae8-bfde-aad42f69d9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_473adec6-2c31-4bbc-893e-53b5aa5499be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_473adec6-2c31-4bbc-893e-53b5aa5499be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_aca9fa52-ee87-4345-ada7-361c2fb73bd4" xlink:href="sny-20250630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_aca9fa52-ee87-4345-ada7-361c2fb73bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_4e43992b-7a05-4d4b-a4b6-8d4995ae4c04" xlink:href="sny-20250630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_4e43992b-7a05-4d4b-a4b6-8d4995ae4c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_08f42e9a-8e47-4eba-9655-77a765c23e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fb823779-2f4f-426e-ab95-c02554e2c52f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_08f42e9a-8e47-4eba-9655-77a765c23e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Introduction" xlink:type="simple" xlink:href="sny-20250630.xsd#Introduction"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Introduction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_67c12113-9c90-4062-96f6-fa3627277721" xlink:href="sny-20250630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_ea94361f-54ed-47cc-bda1-5a3935ef603d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_67c12113-9c90-4062-96f6-fa3627277721" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_ea94361f-54ed-47cc-bda1-5a3935ef603d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" xlink:type="simple" xlink:href="sny-20250630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1af4e173-8a3d-4a02-a5ec-5c3ed8c5d137" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_a8716869-b985-459a-8eb9-64c53d3ca9f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1af4e173-8a3d-4a02-a5ec-5c3ed8c5d137" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_a8716869-b985-459a-8eb9-64c53d3ca9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" xlink:type="simple" xlink:href="sny-20250630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_2650e474-2c5a-4d94-9d53-453fdaa4bf7c" xlink:href="sny-20250630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_4db01347-163f-436b-aa61-6bafcb565f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_209deb6e-ad86-4873-91cc-6d046545fbfd" xlink:href="sny-20250630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_4db01347-163f-436b-aa61-6bafcb565f7a" xlink:to="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_209deb6e-ad86-4873-91cc-6d046545fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="sny-20250630.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_b47f4447-2a5d-44ae-a0dc-c1fa504f9b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_8329a3ce-4b07-4d08-81d6-327c2614ce3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_b47f4447-2a5d-44ae-a0dc-c1fa504f9b2d" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_8329a3ce-4b07-4d08-81d6-327c2614ce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_e3cb37b9-485e-43fc-9258-cad407a6550e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_afceec4e-e457-43c3-ac88-f8a5d07f261f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_e3cb37b9-485e-43fc-9258-cad407a6550e" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_afceec4e-e457-43c3-ac88-f8a5d07f261f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssets" xlink:type="simple" xlink:href="sny-20250630.xsd#ImpairmentofIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_870dd4b0-4c09-4cba-9e57-77344a8d891f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_6a0b3820-52f5-4579-8d2d-8e46263fcefa" xlink:href="sny-20250630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_870dd4b0-4c09-4cba-9e57-77344a8d891f" xlink:to="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_6a0b3820-52f5-4579-8d2d-8e46263fcefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethod"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_55ff1973-fe81-4732-88d1-ff39c76b98fc" xlink:href="sny-20250630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_ab23f625-dd70-41b4-9a06-6bc6708ea5dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_55ff1973-fe81-4732-88d1-ff39c76b98fc" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_ab23f625-dd70-41b4-9a06-6bc6708ea5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssets" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherNonCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bf91154a-11d9-4bff-b4d2-7dc8cd38b658" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_8903a979-5934-49ee-8faf-c02267f0397c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bf91154a-11d9-4bff-b4d2-7dc8cd38b658" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_8903a979-5934-49ee-8faf-c02267f0397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivable" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivable"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_7c53c397-f3e8-4e7b-b73a-c90cc73d6c81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock_6a08e583-6207-4eab-ae7b-044e0ddd3069" xlink:href="sny-20250630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_7c53c397-f3e8-4e7b-b73a-c90cc73d6c81" xlink:to="loc_sny_DisclosureOfTradeReceivablesTextBlock_6a08e583-6207-4eab-ae7b-044e0ddd3069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquity" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_398a2777-10b4-40e2-b838-7318eb203bba" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_b3331ec1-d1e1-4a5b-a725-ad940cbb9ed0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_398a2777-10b4-40e2-b838-7318eb203bba" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_b3331ec1-d1e1-4a5b-a725-ad940cbb9ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_ef5af730-f1fe-4b66-98ea-312e35cc2197" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_398a2777-10b4-40e2-b838-7318eb203bba" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_ef5af730-f1fe-4b66-98ea-312e35cc2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalents" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalents"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_b66363c7-ca5e-4655-9b1a-912bc73025cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_a5b50c4d-bd4f-471d-ad6c-8e2ad4f3e2d9" xlink:href="sny-20250630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_b66363c7-ca5e-4655-9b1a-912bc73025cf" xlink:to="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_a5b50c4d-bd4f-471d-ad6c-8e2ad4f3e2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_d83b7039-a1a9-48f4-9b0e-9f775c4a6dde" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_50dd276f-0ffb-4b12-9800-a6d290c13035" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_d83b7039-a1a9-48f4-9b0e-9f775c4a6dde" xlink:to="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_50dd276f-0ffb-4b12-9800-a6d290c13035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_ea0ef987-148d-4208-973a-120b08ca734d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_755f7280-3904-431c-b160-34c4cd44fea2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_3bdfeb47-3716-45e1-bebb-aa75b28beb8d" xlink:href="sny-20250630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_755f7280-3904-431c-b160-34c4cd44fea2" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_3bdfeb47-3716-45e1-bebb-aa75b28beb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitments" xlink:type="simple" xlink:href="sny-20250630.xsd#OffBalanceSheetCommitments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_4eb03af6-ce94-439f-93b6-52f898007089" xlink:href="sny-20250630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_d8a74a9c-21b3-4071-ad06-b11f5e532522" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_4eb03af6-ce94-439f-93b6-52f898007089" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_d8a74a9c-21b3-4071-ad06-b11f5e532522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedings" xlink:type="simple" xlink:href="sny-20250630.xsd#LitigationandArbitrationProceedings"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_ab474696-19a3-437d-84cd-f77b4441ef87" xlink:href="sny-20250630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_a56b6d7c-bc67-4b0b-ab68-64df928e9233" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_ab474696-19a3-437d-84cd-f77b4441ef87" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_a56b6d7c-bc67-4b0b-ab68-64df928e9233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpenses"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b5675a60-bead-4dec-b3ea-4c1a9027294a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_7dbc887d-4f62-4c81-950c-a47609d6544a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b5675a60-bead-4dec-b3ea-4c1a9027294a" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_7dbc887d-4f62-4c81-950c-a47609d6544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItems" xlink:type="simple" xlink:href="sny-20250630.xsd#RestructuringCostsandSimilarItems"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8c86c0f8-9722-44cd-8d6d-69ac7ac199fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_0d74ec27-28bb-453a-831a-780cf5386316" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8c86c0f8-9722-44cd-8d6d-69ac7ac199fe" xlink:to="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_0d74ec27-28bb-453a-831a-780cf5386316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringTextBlock_78ab34b4-e828-4523-afb6-f1cf08f47131" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_8c86c0f8-9722-44cd-8d6d-69ac7ac199fe" xlink:to="loc_sny_DisclosureOfRestructuringTextBlock_78ab34b4-e828-4523-afb6-f1cf08f47131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigation" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherGainsandLossesandLitigation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherGainsandLossesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e1ce1283-8834-444e-aaec-85db873b38bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_b335b3d3-f6a3-470d-859f-3348f77811cd" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e1ce1283-8834-444e-aaec-85db873b38bd" xlink:to="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_b335b3d3-f6a3-470d-859f-3348f77811cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_92bda167-5c7d-4186-9230-796bcb459139" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncome" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9c9c209b-30bf-40d1-a9c7-0bea1e25cfbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_5c07d9fa-cd42-40c3-8912-1378afbdfd8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9c9c209b-30bf-40d1-a9c7-0bea1e25cfbc" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_5c07d9fa-cd42-40c3-8912-1378afbdfd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpense" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpense"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_53f4b324-3adb-4bda-9b90-8171a13f75a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_f25b7cbd-bf76-4cc7-ae56-5976de979a45" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_53f4b324-3adb-4bda-9b90-8171a13f75a6" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_f25b7cbd-bf76-4cc7-ae56-5976de979a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformation" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_e330c7ed-a70a-4a8f-9e94-c1b20b8fbfcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_619a6c39-b295-4c6a-8db8-e3b380886e1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_e330c7ed-a70a-4a8f-9e94-c1b20b8fbfcb" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_619a6c39-b295-4c6a-8db8-e3b380886e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_6568528d-ba26-4e1b-ab9c-478611fc5cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_7e21d227-ff1b-4bf1-bb81-b915985d73d0" xlink:href="sny-20250630.xsd#sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_b270f8ca-4cff-4530-a809-a2c521d858e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023" xlink:type="simple" xlink:href="sny-20250630.xsd#EventsSubsequenttoJune302023"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_168bdc9f-17e9-4a23-85bf-7737bba802cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_976d5811-9a10-42f8-9b30-d497e1799703" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_168bdc9f-17e9-4a23-85bf-7737bba802cf" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_976d5811-9a10-42f8-9b30-d497e1799703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_67f56d3f-22b7-4ce6-a8fd-016a7d691416" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Revenuefromcontractswithcustomers" xlink:type="simple" xlink:href="sny-20250630.xsd#Revenuefromcontractswithcustomers"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Revenuefromcontractswithcustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_973b9758-12ad-4305-a877-0a0456498e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_8ecfb038-27f5-4ff7-ba3f-d4beb079b4bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_973b9758-12ad-4305-a877-0a0456498e62" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_8ecfb038-27f5-4ff7-ba3f-d4beb079b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherRevenueTextBlock_4ec91d91-80e7-4124-a398-d879600c75da" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherRevenueTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations" xlink:type="simple" xlink:href="sny-20250630.xsd#Noncurrentassetheldforsaleanddiscontinuedoperations"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_da6e0cf1-0603-4db9-b7d9-e169c66e0cbd" xlink:href="sny-20250630.xsd#sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_e17c0fdf-11c2-4d5c-83d9-eb6cc56c4032" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_da6e0cf1-0603-4db9-b7d9-e169c66e0cbd" xlink:to="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_e17c0fdf-11c2-4d5c-83d9-eb6cc56c4032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_4dd8a9e6-87e1-411f-b9ab-a156f4b7c05d" xlink:href="sny-20250630.xsd#sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_da6e0cf1-0603-4db9-b7d9-e169c66e0cbd" xlink:to="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_4dd8a9e6-87e1-411f-b9ab-a156f4b7c05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_eba87433-7904-4e4d-8873-eaffceb3bd38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sny-20250630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_1620fe06-92c6-4c14-99e9-eedbc7192dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_1620fe06-92c6-4c14-99e9-eedbc7192dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_af8fc806-feec-4dcc-b92c-9c1cc2932545" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_af8fc806-feec-4dcc-b92c-9c1cc2932545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_27be89bb-5c89-42e7-a853-193b38e650ed" xlink:href="sny-20250630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_27be89bb-5c89-42e7-a853-193b38e650ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_c69f8615-b706-4c2a-a264-6522d182cd24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_c69f8615-b706-4c2a-a264-6522d182cd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_5c1e3d74-d44a-43cc-a656-0021f0fab275" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_5c1e3d74-d44a-43cc-a656-0021f0fab275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_fb545507-f79a-436b-9952-b7de67ff303c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_fb545507-f79a-436b-9952-b7de67ff303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_5a2b0735-e40f-420c-ba0a-fc64ff83ae11" xlink:href="sny-20250630.xsd#sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_ff016bbc-23c7-4f43-b74d-a50d93a3fcc3" xlink:to="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_5a2b0735-e40f-420c-ba0a-fc64ff83ae11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" xlink:type="simple" xlink:href="sny-20250630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1d3497f6-5588-430a-9a07-592fbe2d05f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_e19a361d-252f-47ef-89bf-f98f075efdb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1d3497f6-5588-430a-9a07-592fbe2d05f3" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_e19a361d-252f-47ef-89bf-f98f075efdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="sny-20250630.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_b6f064ed-917d-4ca7-879b-5f6028ed8d39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_6e8f64fa-ea77-44c6-ba16-5d844502c9b1" xlink:href="sny-20250630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_b6f064ed-917d-4ca7-879b-5f6028ed8d39" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_6e8f64fa-ea77-44c6-ba16-5d844502c9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_f90a11ef-1ead-448a-9274-5e3659d271d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_6c856d2d-1d37-4b1d-8d43-c467e5ab4e6c" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_f90a11ef-1ead-448a-9274-5e3659d271d5" xlink:to="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_6c856d2d-1d37-4b1d-8d43-c467e5ab4e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_ae999fa9-d1c5-48be-8609-896d8ac87dd3" xlink:href="sny-20250630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_16724dfd-0e69-4901-a37f-b1e1c65e13f8" xlink:href="sny-20250630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_ae999fa9-d1c5-48be-8609-896d8ac87dd3" xlink:to="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_16724dfd-0e69-4901-a37f-b1e1c65e13f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_fce720fd-35c4-4b48-aa5e-3e7122a60d45" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_ae999fa9-d1c5-48be-8609-896d8ac87dd3" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_fce720fd-35c4-4b48-aa5e-3e7122a60d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherNonCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387d61cc-9f16-4cb3-9aac-603801e2275d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_5dbdef6f-84bd-44e1-a423-0b222599b3c2" xlink:href="sny-20250630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387d61cc-9f16-4cb3-9aac-603801e2275d" xlink:to="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_5dbdef6f-84bd-44e1-a423-0b222599b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableTables" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_bb3e83d9-f911-4e0a-a1f5-85f563d333bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_c0243126-9dfd-4a5d-864b-5f7d72335e04" xlink:href="sny-20250630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_bb3e83d9-f911-4e0a-a1f5-85f563d333bd" xlink:to="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_c0243126-9dfd-4a5d-864b-5f7d72335e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_2d9222e3-727a-4858-a85a-87c3b5ab9a5c" xlink:href="sny-20250630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_bb3e83d9-f911-4e0a-a1f5-85f563d333bd" xlink:to="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_2d9222e3-727a-4858-a85a-87c3b5ab9a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_d59f89b2-28e8-41bb-b07a-f7dca0f2fb84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_d59f89b2-28e8-41bb-b07a-f7dca0f2fb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_afc4cf15-f3a8-4596-bbf2-06d7432eedc8" xlink:href="sny-20250630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_afc4cf15-f3a8-4596-bbf2-06d7432eedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_9d21c067-9cdb-45ab-8976-b6d056edccaa" xlink:href="sny-20250630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_9d21c067-9cdb-45ab-8976-b6d056edccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_ec551277-337a-48f4-b69c-5fdad957e6be" xlink:href="sny-20250630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_ec551277-337a-48f4-b69c-5fdad957e6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_f95d624d-cee3-4f43-a84c-33b488dd9a08" xlink:href="sny-20250630.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_f95d624d-cee3-4f43-a84c-33b488dd9a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_b850e513-7059-4e01-a589-c4a4bafd233e" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c2b7bd90-4dfe-472c-8762-eeb99a7242e8" xlink:to="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_b850e513-7059-4e01-a589-c4a4bafd233e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_7600224b-6309-4802-a4b3-674b070ddb93" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_c2794caf-ec7c-4bcb-a939-6bdd4008f727" xlink:href="sny-20250630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_7600224b-6309-4802-a4b3-674b070ddb93" xlink:to="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_c2794caf-ec7c-4bcb-a939-6bdd4008f727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_856cc279-d600-45b6-a89a-c67a3c4568b8" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_7600224b-6309-4802-a4b3-674b070ddb93" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_856cc279-d600-45b6-a89a-c67a3c4568b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_99945f5f-c636-4057-903d-541cff864028" xlink:href="sny-20250630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_7600224b-6309-4802-a4b3-674b070ddb93" xlink:to="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_99945f5f-c636-4057-903d-541cff864028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_8fb5373a-a9a5-4d6e-8d29-c6a7041d3a16" xlink:href="sny-20250630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_7600224b-6309-4802-a4b3-674b070ddb93" xlink:to="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_8fb5373a-a9a5-4d6e-8d29-c6a7041d3a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_f43c113f-c23e-40fc-92c5-262e0b09b395" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_9c58b3c7-e433-48b5-9b20-f96ad8b61710" xlink:href="sny-20250630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_f43c113f-c23e-40fc-92c5-262e0b09b395" xlink:to="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_9c58b3c7-e433-48b5-9b20-f96ad8b61710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_4f688032-92db-4537-bab8-e5cef1f8bded" xlink:href="sny-20250630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_f43c113f-c23e-40fc-92c5-262e0b09b395" xlink:to="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_4f688032-92db-4537-bab8-e5cef1f8bded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_ba1afcdd-33ba-4a4d-9f18-89701c16c896" xlink:href="sny-20250630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_f43c113f-c23e-40fc-92c5-262e0b09b395" xlink:to="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_ba1afcdd-33ba-4a4d-9f18-89701c16c896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_63678a63-9820-48ec-9aba-b6c627ac6d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_8b1a65d1-307e-4128-9832-9ae1dbdcf553" xlink:href="sny-20250630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_63678a63-9820-48ec-9aba-b6c627ac6d0c" xlink:to="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_8b1a65d1-307e-4128-9832-9ae1dbdcf553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387621a3-480f-40d0-93ca-4e60afb36574" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_ace70969-037e-49fa-b1af-b5ce130b7b3b" xlink:href="sny-20250630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387621a3-480f-40d0-93ca-4e60afb36574" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_ace70969-037e-49fa-b1af-b5ce130b7b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_9d365567-b37c-4334-b4db-a500b20525ad" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387621a3-480f-40d0-93ca-4e60afb36574" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_9d365567-b37c-4334-b4db-a500b20525ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_2f01a679-ccbd-4549-bad0-dfa13254f6e7" xlink:href="sny-20250630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_387621a3-480f-40d0-93ca-4e60afb36574" xlink:to="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_2f01a679-ccbd-4549-bad0-dfa13254f6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpensesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9c937f28-7e7b-49ea-9c2d-11033b3032be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock_c28afb85-c276-4b43-ba0f-5d5e4c1c3b1b" xlink:href="sny-20250630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9c937f28-7e7b-49ea-9c2d-11033b3032be" xlink:to="loc_sny_OtherOperatingExpensesTableTextBlock_c28afb85-c276-4b43-ba0f-5d5e4c1c3b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#RestructuringCostsandSimilarItemsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_293dd923-a050-460e-9653-2f12ebcd2c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_4addbe4b-42cb-4ae1-b23f-509e97d61606" xlink:href="sny-20250630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_293dd923-a050-460e-9653-2f12ebcd2c54" xlink:to="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_4addbe4b-42cb-4ae1-b23f-509e97d61606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeTables" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncomeTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6890442f-40fa-4601-b406-ec2b45f6ec29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_dc9c0c9c-823c-4e30-81aa-1305f727e590" xlink:href="sny-20250630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6890442f-40fa-4601-b406-ec2b45f6ec29" xlink:to="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_dc9c0c9c-823c-4e30-81aa-1305f727e590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseTables" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_56e78cef-fe2b-408e-8da8-1b9f9c0dcd9b" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_b2c07630-402e-4d27-86ec-448cf93ba1a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_5fb3a415-3bdd-45d1-98d8-27b94d0a965a" xlink:href="sny-20250630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_b2c07630-402e-4d27-86ec-448cf93ba1a2" xlink:to="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_5fb3a415-3bdd-45d1-98d8-27b94d0a965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_41220edc-1fe3-45cb-8ac9-893c41be3c17" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_b2c07630-402e-4d27-86ec-448cf93ba1a2" xlink:to="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_41220edc-1fe3-45cb-8ac9-893c41be3c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_7c250c04-a031-4158-b3ed-6b96e482fc59" xlink:href="sny-20250630.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:to="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_7c250c04-a031-4158-b3ed-6b96e482fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_743e5639-9d29-48c5-bb6d-c0919b338685" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_743e5639-9d29-48c5-bb6d-c0919b338685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_68c7034c-7452-4a83-a4f4-3f47c50b81d2" xlink:href="sny-20250630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:to="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_68c7034c-7452-4a83-a4f4-3f47c50b81d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_59a565d9-c6b5-4f86-8fab-3eedc3d5a9b2" xlink:href="sny-20250630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_59a565d9-c6b5-4f86-8fab-3eedc3d5a9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_6831a796-0af5-4658-8c40-cc5cde5c8f95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_670171ab-47cc-4072-a1a9-6ce9e8f9cdee" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_6831a796-0af5-4658-8c40-cc5cde5c8f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables" xlink:type="simple" xlink:href="sny-20250630.xsd#RevenuefromcontractswithcustomersTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_5e8743b8-ff1c-4a98-a58f-45f79db608d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_8a41d16e-2b0d-4b1e-9fd2-9888bc46c9fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_5e8743b8-ff1c-4a98-a58f-45f79db608d2" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_8a41d16e-2b0d-4b1e-9fd2-9888bc46c9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherRevenueTextBlock_241e1082-e4af-4f9f-8e25-b8792792843f" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherRevenueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_5e8743b8-ff1c-4a98-a58f-45f79db608d2" xlink:to="loc_sny_DisclosureOfOtherRevenueTextBlock_241e1082-e4af-4f9f-8e25-b8792792843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsTables" xlink:type="simple" xlink:href="sny-20250630.xsd#NoncurrentassetheldforsaleanddiscontinuedoperationsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_da702089-4a57-49f2-9dc9-e2d73e72f9f9" xlink:href="sny-20250630.xsd#sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_7c8e91df-1ea8-48c7-aac6-ef5748cb9fb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_7c8e91df-1ea8-48c7-aac6-ef5748cb9fb0" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b72c1ff7-b5d2-4123-a5a3-40cb74f71aef" xlink:to="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_f79480a8-da7a-49d9-9c18-3ffeaa0cf27e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:to="loc_country_AR_f79480a8-da7a-49d9-9c18-3ffeaa0cf27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_03073710-8cd8-4179-941b-6b1a7852930e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_44d72c82-caa7-4cf8-9a33-3cf3315c8588" xlink:to="loc_country_TR_03073710-8cd8-4179-941b-6b1a7852930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:href="sny-20250630.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_c4f1b048-ef40-4fec-a8fc-709e701b454d" xlink:to="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_49c6cc2c-428a-4884-89cd-b609bfd429de" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_53103d88-d083-4470-8666-5e1d8368a74f" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_49c6cc2c-428a-4884-89cd-b609bfd429de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_d5bfcbd8-4f3e-4a25-a9ac-dc4bd20c0f04" xlink:to="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_d9d54a84-246c-46d3-9739-4054da0f49b8" xlink:href="sny-20250630.xsd#sny_USGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_2e3edf1c-f419-4a30-8880-f62e5a447ee7" xlink:to="loc_sny_USGovernmentMember_d9d54a84-246c-46d3-9739-4054da0f49b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ace27a2-428a-4ab7-9fbf-d0f02381c25f" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_840ad324-cece-40c3-bcc0-5a8a2c7ad18f" xlink:href="sny-20250630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_840ad324-cece-40c3-bcc0-5a8a2c7ad18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_ff9b4264-fcda-4831-bb0c-899475b21fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_ifrs-full_CurrentContractLiabilities_ff9b4264-fcda-4831-bb0c-899475b21fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_5f55c610-fc6f-46ab-860b-d4e280e09f7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_ifrs-full_OtherRevenue_5f55c610-fc6f-46ab-860b-d4e280e09f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_f653c7de-7661-4bfa-8799-2c0669cac1dc" xlink:href="sny-20250630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_6e9afce6-b507-45ba-84ae-4bf9a97a3603" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_f653c7de-7661-4bfa-8799-2c0669cac1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_650a3f18-f0e7-467d-8322-32278cb4c921" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_650a3f18-f0e7-467d-8322-32278cb4c921" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_0035ebab-9864-4864-9299-4f8b83c7494d" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_fdd8d4e4-7126-4a36-bcfb-2cc953f85518" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:to="loc_sny_ProventionBioIncMember_fdd8d4e4-7126-4a36-bcfb-2cc953f85518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_a629f655-5483-4557-a642-e57f1f28dfae" xlink:href="sny-20250630.xsd#sny_InhibrxIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_029bcb14-e39f-4851-ad8f-2791d86ee08d" xlink:to="loc_sny_InhibrxIncMember_a629f655-5483-4557-a642-e57f1f28dfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_83e90329-cac4-4c0b-8b36-c106f37c3917" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_c07938d4-b106-43a3-b0cb-6ea7a6e12ab2" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c755a62-fc0d-4ab5-8f03-25dee15a6cbe" xlink:to="loc_sny_ProventionBioIncMember_c07938d4-b106-43a3-b0cb-6ea7a6e12ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionAxis_878f4354-382e-442c-8c8c-7a9295701ccb" xlink:to="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_fb5e9b74-501f-4ef5-a7ca-6346cb88c2d8" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_AssetsAcquisitionMember_fb5e9b74-501f-4ef5-a7ca-6346cb88c2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VigilNeuroscienceIncMember_0407a594-42a7-4eac-b122-0b27cb34a123" xlink:href="sny-20250630.xsd#sny_VigilNeuroscienceIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_VigilNeuroscienceIncMember_0407a594-42a7-4eac-b122-0b27cb34a123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlueprintMedicinesCorporationMember_f8c0b090-cf25-4739-b75e-c73aa091c675" xlink:href="sny-20250630.xsd#sny_BlueprintMedicinesCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_26b25d2f-6328-4112-a71e-ea3e2106ef64" xlink:to="loc_sny_BlueprintMedicinesCorporationMember_f8c0b090-cf25-4739-b75e-c73aa091c675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_ca43f5d7-2b88-4a92-be05-922d556425d8" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_03f93175-0efb-47d2-9b40-bb7dad8583f7" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:to="loc_sny_OpellaMember_03f93175-0efb-47d2-9b40-bb7dad8583f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_2e376553-cd07-4d46-a480-5c7132d9bff9" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_1c5c3fff-0a52-4b7e-b757-d3f91f830697" xlink:to="loc_sny_OpellaBusinessMember_2e376553-cd07-4d46-a480-5c7132d9bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_836fd624-3fd2-44fe-8634-423ece0fa508" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_acb07682-5eb8-4113-a81d-b40a04083b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_CashTransferred_acb07682-5eb8-4113-a81d-b40a04083b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_120786e6-8378-460c-9c65-8e3172ec8a85" xlink:href="sny-20250630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_120786e6-8378-460c-9c65-8e3172ec8a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_49e2bcff-6599-4348-8b3f-72a5288c3f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_49e2bcff-6599-4348-8b3f-72a5288c3f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_a6d6761c-b877-4537-9dc0-a8dcb2e13499" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_a6d6761c-b877-4537-9dc0-a8dcb2e13499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_8e0654c8-47f6-4393-9104-c55c7cffc9ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_8e0654c8-47f6-4393-9104-c55c7cffc9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_e50224a6-c025-4df7-9d26-ec3d831be472" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_e50224a6-c025-4df7-9d26-ec3d831be472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue_0d8d5a97-be55-43eb-907b-03b32c836a9e" xlink:href="sny-20250630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_FutureRoyaltiesReceivableValue_0d8d5a97-be55-43eb-907b-03b32c836a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d5aa5848-d8e1-4815-93ce-9d429f9fc53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_d5aa5848-d8e1-4815-93ce-9d429f9fc53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree_4c232715-2334-4862-8e30-53310c4ffe9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfAcquiree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NameOfAcquiree_4c232715-2334-4862-8e30-53310c4ffe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue_99faf94d-2661-4bf3-b8ae-c2215a79efff" xlink:href="sny-20250630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_BusinessCombinationNominalValue_99faf94d-2661-4bf3-b8ae-c2215a79efff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue_9d2d36e8-9465-438c-8739-bbd6e6b90ad8" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_AssetsAcquisitionNominalValue_9d2d36e8-9465-438c-8739-bbd6e6b90ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare_7fd749fb-df5c-4516-962a-89248c15e20a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_AssetsAcquisitionPurchasePricePerShare_7fd749fb-df5c-4516-962a-89248c15e20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_2722b9b6-3c09-4708-b752-e65a87537004" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_2722b9b6-3c09-4708-b752-e65a87537004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_c59d9526-6983-4070-93f0-5129d98be9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_c59d9526-6983-4070-93f0-5129d98be9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_6ac111fc-348b-4127-a7c7-245956960751" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition_6ac111fc-348b-4127-a7c7-245956960751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfInvestmentsInEquityInstruments_99a8e02d-471e-414c-b7fc-d7604fb07fe0" xlink:href="sny-20250630.xsd#sny_FairValueOfInvestmentsInEquityInstruments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_FairValueOfInvestmentsInEquityInstruments_99a8e02d-471e-414c-b7fc-d7604fb07fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransactionCost_523bd537-9905-4fc5-a5d8-defc6b993744" xlink:href="sny-20250630.xsd#sny_TransactionCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_TransactionCost_523bd537-9905-4fc5-a5d8-defc6b993744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialFuturePayments_9c1abbc2-90f0-4c8d-9e89-86e4a960657c" xlink:href="sny-20250630.xsd#sny_PotentialFuturePayments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_PotentialFuturePayments_9c1abbc2-90f0-4c8d-9e89-86e4a960657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_4464051f-ccd3-47f4-a5f8-25226f9436d7" xlink:href="sny-20250630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_4464051f-ccd3-47f4-a5f8-25226f9436d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_84b31aba-eae6-44b8-a1dc-19e616530202" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_84b31aba-eae6-44b8-a1dc-19e616530202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_5ff5d795-b4d2-4488-9abc-cf6131ccbad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_5ff5d795-b4d2-4488-9abc-cf6131ccbad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsOfAcquirerPerShare_8c799562-9955-4766-a813-8748a437f459" xlink:href="sny-20250630.xsd#sny_EquityInterestsOfAcquirerPerShare"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_EquityInterestsOfAcquirerPerShare_8c799562-9955-4766-a813-8748a437f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredCashPayments_d489ba68-4cf8-4bec-9520-2f4f321617a6" xlink:href="sny-20250630.xsd#sny_DeferredCashPayments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_DeferredCashPayments_d489ba68-4cf8-4bec-9520-2f4f321617a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_ed252044-4a1d-468d-83c5-e6b39fe4391c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_ed252044-4a1d-468d-83c5-e6b39fe4391c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashTransferredPerShare_84f2bd1b-7ac3-4b2b-a834-b8f3822559e9" xlink:href="sny-20250630.xsd#sny_CashTransferredPerShare"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_sny_CashTransferredPerShare_84f2bd1b-7ac3-4b2b-a834-b8f3822559e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_52c34ee9-f3c2-4285-9d12-7e11c32941a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_52c34ee9-f3c2-4285-9d12-7e11c32941a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_0dbd7e86-60f6-4ac5-ac98-5340b87ea3b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c3a0939d-01ab-427d-827e-2c2215bf8e4c" xlink:to="loc_ifrs-full_NetAssetsLiabilities_0dbd7e86-60f6-4ac5-ac98-5340b87ea3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_13d425c7-9f10-48a1-bb4c-aad7d9084ea9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_13d425c7-9f10-48a1-bb4c-aad7d9084ea9" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_b8ce2528-8f24-42a0-8fcd-3ba0117ec6d6" xlink:to="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_1984029c-a8f8-4a06-9634-e838591ac256" xlink:href="sny-20250630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_eb88a9bf-2e50-4300-9a36-2cccdac566e3" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_1984029c-a8f8-4a06-9634-e838591ac256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_a5cd6eab-5405-4e60-ad91-36b9b266e785" xlink:to="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_ef452047-61a8-4148-a708-128b72c2dbef" xlink:href="sny-20250630.xsd#sny_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:to="loc_sny_AstraZenecaMember_ef452047-61a8-4148-a708-128b72c2dbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_6b5a5aaa-198d-45fb-9546-77ea24660269" xlink:href="sny-20250630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_864f400a-d1f9-4a59-8d7f-a9d7f8e0cef6" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_6b5a5aaa-198d-45fb-9546-77ea24660269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_84ce19a6-098a-4b15-aa6f-3ba74484ad49" xlink:to="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_92af1206-3901-4400-89ab-df436218e148" xlink:href="sny-20250630.xsd#sny_MajorTerritoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:to="loc_sny_MajorTerritoriesMember_92af1206-3901-4400-89ab-df436218e148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_2ec4389f-5b9d-4cb7-b6b3-03cbf110b97d" xlink:href="sny-20250630.xsd#sny_OtherTerritoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_2adbdc54-7e29-4329-a8be-301705a82299" xlink:to="loc_sny_OtherTerritoriesMember_2ec4389f-5b9d-4cb7-b6b3-03cbf110b97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_79158748-206a-451d-bcf9-32bc45013b0a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_e286bdbb-7918-45e2-a3d0-832fd78e8836" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_734103a4-e173-4f90-aada-0b7414cfd0d3" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_e286bdbb-7918-45e2-a3d0-832fd78e8836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_41a9a0b4-c742-4e6a-854a-963519c61e49" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember_ad8f1a28-5233-4817-8cdc-2d027c5ea6d6" xlink:href="sny-20250630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_60279509-9771-4a5d-bd00-9127d947a861" xlink:to="loc_sny_MajorFinancialLiabilityMember_ad8f1a28-5233-4817-8cdc-2d027c5ea6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e20358f7-9a06-4ffd-8e30-4836dd5a5c6a" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_e6b1d536-3dd1-4ad3-82fd-9d27679b0ff1" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_7a48e285-235c-4c91-be8c-9b43e9cc2cd1" xlink:to="loc_sny_OpellaBusinessMember_e6b1d536-3dd1-4ad3-82fd-9d27679b0ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:href="sny-20250630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_33ad9354-3c3d-4e98-b8e2-41b21c156751" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_67d3ab25-71a9-42bf-ac3d-7f068c8503b0" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_67d3ab25-71a9-42bf-ac3d-7f068c8503b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_6440ede8-92b3-4645-867b-5f02aa447584" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_6440ede8-92b3-4645-867b-5f02aa447584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_81e221cc-05f6-4070-a6f4-87a4023a9600" xlink:href="sny-20250630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_81e221cc-05f6-4070-a6f4-87a4023a9600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9c596413-1116-409e-ae2c-fc3ab608e5bb" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9c596413-1116-409e-ae2c-fc3ab608e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_be3fabf1-6502-41fd-8ed0-8a946901c13b" xlink:href="sny-20250630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_be3fabf1-6502-41fd-8ed0-8a946901c13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_5b7a8117-8a9d-4573-87c6-1b5169e5a51e" xlink:href="sny-20250630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_5b7a8117-8a9d-4573-87c6-1b5169e5a51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_3af9c329-3633-42e3-80af-af27445ca2d8" xlink:href="sny-20250630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_3af9c329-3633-42e3-80af-af27445ca2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_eec6c616-f304-42fd-81b8-9c4e653a66c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_eec6c616-f304-42fd-81b8-9c4e653a66c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_d9d12d65-d017-4529-97db-fde8530d42bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_d9d12d65-d017-4529-97db-fde8530d42bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_b2e7dbc6-5882-4d5c-8e60-3b7d61dc8835" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_b2e7dbc6-5882-4d5c-8e60-3b7d61dc8835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_6d52f6bc-d29b-4115-8b88-80d09aee6da0" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_6d52f6bc-d29b-4115-8b88-80d09aee6da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_f527d166-b198-4c9a-8c67-516efe482d23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_d0b506b2-539d-4806-a4c0-2b4e760ab440" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_f527d166-b198-4c9a-8c67-516efe482d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_3e1bb069-e65b-4c02-a19e-629ba875f83d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_3e1bb069-e65b-4c02-a19e-629ba875f83d" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:to="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_665a0648-b8d7-48d3-9da8-d508e8430aa1" xlink:to="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_4e1ab1c6-1ae8-4803-8319-cf08ce9ffbb0" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_BiopharmaSegmentMember_4e1ab1c6-1ae8-4803-8319-cf08ce9ffbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_7c2c2737-da01-40ba-b4ce-ec4ca2ec9a09" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_7c2c2737-da01-40ba-b4ce-ec4ca2ec9a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_8b8e6e20-6125-43c5-8505-f9968d13907b" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_7e1e34ef-b9a1-4d50-b005-0c6ecaf8dbad" xlink:to="loc_sny_OpellaMember_8b8e6e20-6125-43c5-8505-f9968d13907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_53d46d88-df25-4edb-ab2c-d6e0356ef6a2" xlink:href="sny-20250630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb1d0cc8-9ad0-458c-9ce1-ec37124c8b2e" xlink:to="loc_sny_ManufacturingAndSupplyMember_53d46d88-df25-4edb-ab2c-d6e0356ef6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0d5e7cf9-f404-40d3-aeb2-ace2cdb612ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eaad79f2-b1a2-449a-a42c-92f1d4c43731" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0d5e7cf9-f404-40d3-aeb2-ace2cdb612ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_c121c32e-7e09-4efc-ba9f-94807323df05" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_bd20e792-af22-4cc9-93dc-d10f7ba3ccdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_bd20e792-af22-4cc9-93dc-d10f7ba3ccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_e985553e-f24f-4272-a50c-0a7aa5b66eb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_ifrs-full_InterestCostsCapitalised_e985553e-f24f-4272-a50c-0a7aa5b66eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_7b631e3b-6f8c-4cb1-acd8-c693cf876855" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b14b0a56-ad8d-4198-b0a0-8161b1e1eb3a" xlink:to="loc_sny_NumberOfOperatingSegments_7b631e3b-6f8c-4cb1-acd8-c693cf876855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_1d883140-4721-47e6-8715-07ac6c9c6354" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_2d7d5dc1-a087-43f1-9d49-63fc480fa32c" xlink:href="sny-20250630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_1d883140-4721-47e6-8715-07ac6c9c6354" xlink:to="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_2d7d5dc1-a087-43f1-9d49-63fc480fa32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_90314bac-cc4d-497d-9b23-de9adb731866" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_90314bac-cc4d-497d-9b23-de9adb731866" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_db7cc7dd-e67e-4172-8a87-4a39121db564" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_eb228925-d71b-4c50-ac56-5595fd130e82" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_eb228925-d71b-4c50-ac56-5595fd130e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_3290e0b1-e176-4fd9-90de-f93eb2bc1379" xlink:href="sny-20250630.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_MarketedProductsMember_3290e0b1-e176-4fd9-90de-f93eb2bc1379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_6aeb3fc5-2814-494e-9d62-2cf375826b74" xlink:href="sny-20250630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ffa5376-03e5-494c-915d-508eaafa0c05" xlink:to="loc_sny_TechnologicalPlatformsMember_6aeb3fc5-2814-494e-9d62-2cf375826b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_8bc05fa7-4231-4472-abc0-fadc41301692" xlink:to="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_34476389-c066-49ea-9557-fb5fc5c33c9f" xlink:href="sny-20250630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_37042db2-f78a-424d-b8e1-4477eec4dfc4" xlink:to="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_34476389-c066-49ea-9557-fb5fc5c33c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_174aa02f-72ff-403d-8d0c-10c1d73bfa5b" xlink:to="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_f0c24697-d9f0-401e-962e-59fd576ef373" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_091f3946-a2c2-4ff6-86d4-65b7200e366d" xlink:to="loc_sny_NovavaxMember_f0c24697-d9f0-401e-962e-59fd576ef373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_f07e1919-f7cf-49d9-9345-7a178084e8a9" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7a32c5dd-5a6a-440f-8a1e-9bcd49d84fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_Goodwill_7a32c5dd-5a6a-440f-8a1e-9bcd49d84fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_436f7533-d7c7-4423-98c4-5826d65a2273" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_436f7533-d7c7-4423-98c4-5826d65a2273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec5d48d9-58f8-4583-b083-4bddcb700350" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec5d48d9-58f8-4583-b083-4bddcb700350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a411ced7-9b98-4c8a-9105-409c0f006515" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_010da747-1102-4170-afd4-c8f3364139b5" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a411ced7-9b98-4c8a-9105-409c0f006515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_d76cece2-8f2d-4613-8eee-ef157ccce87f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_d76cece2-8f2d-4613-8eee-ef157ccce87f" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_8f8497e1-570a-4d4d-b09e-95dac947505b" xlink:href="sny-20250630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_8f8497e1-570a-4d4d-b09e-95dac947505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:href="sny-20250630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_29afe0e4-f0a8-42ce-bb25-2b6f9624531c" xlink:href="sny-20250630.xsd#sny_AltuviiioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember_caa6131d-b891-4600-8083-048aa38fd7a3" xlink:to="loc_sny_AltuviiioMember_29afe0e4-f0a8-42ce-bb25-2b6f9624531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_f966b258-4f2a-4a4a-8294-511abd8c8800" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_ifrs-full_ComputerSoftwareMember_f966b258-4f2a-4a4a-8294-511abd8c8800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_fbf50114-3879-437b-9d8f-b4bb83e62c87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_fbf50114-3879-437b-9d8f-b4bb83e62c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_85aba08c-f414-4b37-91fd-e5c6a6e40aeb" xlink:href="sny-20250630.xsd#sny_AcquiredRDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_AcquiredRDMember_85aba08c-f414-4b37-91fd-e5c6a6e40aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_d3984450-422a-426a-b2f5-09b4c51d92be" xlink:href="sny-20250630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3ea998f2-0814-4ea5-9797-8ab4d3cb6dc5" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_d3984450-422a-426a-b2f5-09b4c51d92be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_efd69652-a4ab-41b6-88cc-696710db3b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_2f6376a3-566b-4071-8c97-fd51eb86aeef" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_efd69652-a4ab-41b6-88cc-696710db3b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_80224f50-61f7-4544-baaf-8b8a2b1dd378" xlink:to="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d4a569e2-6dea-4343-b683-6ca37e3d83c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d4a569e2-6dea-4343-b683-6ca37e3d83c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_48061d55-06bb-4aaf-b581-b2040a630989" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_b373806c-2227-4972-bea9-cba8063afc82" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_48061d55-06bb-4aaf-b581-b2040a630989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_e3a9727c-00c6-49a8-b218-df50b72e26c2" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_e79c6569-37f5-4c47-974a-dc4d5f2ca559" xlink:href="sny-20250630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_108a851b-c209-462f-bb4b-b2a28bcd8af6" xlink:to="loc_sny_ProventionBioIncMember_e79c6569-37f5-4c47-974a-dc4d5f2ca559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_de39c171-d911-4549-a96a-dcee5d7ebe1e" xlink:to="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_d1f8fa10-bbd8-4c91-88ed-e27ca64547e9" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_12ffd6f1-b40c-41ca-bba1-10f4b907d758" xlink:to="loc_sny_NovavaxMember_d1f8fa10-bbd8-4c91-88ed-e27ca64547e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_8f05f19f-38cc-4a1c-af5d-3e51d501fa38" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_a69c79dc-927d-4e89-a837-6ee5d986b171" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_OtherIntangibleAssets_a69c79dc-927d-4e89-a837-6ee5d986b171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c36d3f2b-b2d4-459d-8420-f667418d7a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c36d3f2b-b2d4-459d-8420-f667418d7a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_6ec2cd19-4989-4c9d-b5c1-b3712d5cc5b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_6ec2cd19-4989-4c9d-b5c1-b3712d5cc5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_d379f934-d6ff-4829-9eb4-477db070baca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_d379f934-d6ff-4829-9eb4-477db070baca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_133652e6-19bf-4a95-95c1-7ab2aed28f32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_133652e6-19bf-4a95-95c1-7ab2aed28f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4dc78734-ed6e-4b1a-bef0-a7bec1008f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4dc78734-ed6e-4b1a-bef0-a7bec1008f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b57ece84-4e5e-4fb4-bea5-b5fd442d0279" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b57ece84-4e5e-4fb4-bea5-b5fd442d0279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_5790f65d-19b5-4c2b-8ef7-8a9177d702f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_5790f65d-19b5-4c2b-8ef7-8a9177d702f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_529ba38e-5321-4372-9fe7-41bc22ae073e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_529ba38e-5321-4372-9fe7-41bc22ae073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_a3545238-986d-4f6e-9d07-2e5da1c867bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_a3545238-986d-4f6e-9d07-2e5da1c867bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_a483d6d5-0cd1-4cf6-90bd-1dc3cb96d0e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_a483d6d5-0cd1-4cf6-90bd-1dc3cb96d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_97561d0c-9b6d-4662-ab1c-65bb79449471" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_OtherIntangibleAssets_97561d0c-9b6d-4662-ab1c-65bb79449471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_cc870c3c-ae3e-4ac7-9168-bc5fcf7ded4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_cc870c3c-ae3e-4ac7-9168-bc5fcf7ded4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_1f0ad5e3-1817-4310-a99c-667cf0fce2c1" xlink:href="sny-20250630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b76e14a3-20d3-4ede-9380-4ef7cb32f485" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_1f0ad5e3-1817-4310-a99c-667cf0fce2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ImpairmentofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_0a54aff8-9ecb-47a1-b0b0-3877f520c2c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e5e3672c-9209-4315-83ff-d56840fd36b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_0a54aff8-9ecb-47a1-b0b0-3877f520c2c5" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e5e3672c-9209-4315-83ff-d56840fd36b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_38d89898-b992-4b98-b60c-317f2111313f" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_0a54aff8-9ecb-47a1-b0b0-3877f520c2c5" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_38d89898-b992-4b98-b60c-317f2111313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_df13fed1-287b-4120-988f-a4641a412889" xlink:href="sny-20250630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_df13fed1-287b-4120-988f-a4641a412889" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_97bf2e23-6ed6-49dd-94a9-3a7300557dc1" xlink:to="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_89979bf0-a722-4800-a72a-7e347e1f2a2a" xlink:href="sny-20250630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_89979bf0-a722-4800-a72a-7e347e1f2a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_095bad19-9c88-4586-ad89-aa98c1cd2aa7" xlink:href="sny-20250630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_sny_MSPVaccineCompanyMember_095bad19-9c88-4586-ad89-aa98c1cd2aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_af33e7fc-6fd0-49d6-93ea-e270ddfe2926" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesDomain_c66da4da-5716-4aa4-af1e-6aad9c1e26a7" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_af33e7fc-6fd0-49d6-93ea-e270ddfe2926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f37157f2-0755-4cdc-af9a-4558b9c42acf" xlink:to="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_588ac4b4-24f3-41bf-a302-899cdc16c549" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:to="loc_sny_EuroapiMember_588ac4b4-24f3-41bf-a302-899cdc16c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_68ac8f98-bdc6-4221-964d-d9a155fd80fb" xlink:href="sny-20250630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ade69121-53e3-4283-9428-323b495bf77b" xlink:to="loc_sny_MSPVaccineCompanyMember_68ac8f98-bdc6-4221-964d-d9a155fd80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cf6972b7-4119-4d43-a774-2fc3f78ea84b" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f3a3072f-6992-4fd8-a8f4-fe389dcc2577" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:to="loc_sny_EuroapiMember_f3a3072f-6992-4fd8-a8f4-fe389dcc2577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_5250d236-9ded-4cdb-b2fe-e5898ed1cded" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c872fd9f-cd59-44af-ab06-edc1b691109a" xlink:to="loc_sny_OpellaMember_5250d236-9ded-4cdb-b2fe-e5898ed1cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_f49c5b90-2248-424f-b86e-1b5fa097c326" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_96ac147d-7793-4bd4-9cce-61cc14d2ed40" xlink:href="sny-20250630.xsd#sny_MCMVaccineBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_d06037f8-cf4f-4ca7-937f-7cb8a6ad9532" xlink:to="loc_sny_MCMVaccineBVMember_96ac147d-7793-4bd4-9cce-61cc14d2ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e4bb5412-df8a-47e2-98fb-74b38750672f" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_e484b457-c96a-42d3-8400-917a0dc0b5b2" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_466ad6ff-5d95-4843-ac87-5cc73468e498" xlink:to="loc_sny_AssociatesAndJointVenturesMember_e484b457-c96a-42d3-8400-917a0dc0b5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_bc24740a-983c-45ad-84ab-0154bd5688aa" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_46b3261c-188f-46eb-a20d-9324a85dff9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_46b3261c-188f-46eb-a20d-9324a85dff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_ced21079-f409-4e25-9ed8-7cd635329a58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_ced21079-f409-4e25-9ed8-7cd635329a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_44c48aa4-992f-4a99-a6f5-3362ef6ae83c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_44c48aa4-992f-4a99-a6f5-3362ef6ae83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_b3c48cac-8243-486b-9375-f1d9ce2d881d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_b3c48cac-8243-486b-9375-f1d9ce2d881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_1bd1aef0-6e04-48c5-8b16-457d916612c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_1bd1aef0-6e04-48c5-8b16-457d916612c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_9e2a79fb-8741-4a88-95ad-124beadab2c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_9e2a79fb-8741-4a88-95ad-124beadab2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_6d6d709f-4ba2-4255-bde1-a8ae5361f46e" xlink:href="sny-20250630.xsd#sny_StockPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_sny_StockPrice_6d6d709f-4ba2-4255-bde1-a8ae5361f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_fb130eed-dc58-491f-8c61-59ac37d05025" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_fb130eed-dc58-491f-8c61-59ac37d05025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_c544403f-48d0-4cd1-bf5d-f52fe56ade89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_SubordinatedLiabilities_c544403f-48d0-4cd1-bf5d-f52fe56ade89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_afdb8651-2e5d-4829-a591-8eda5037062c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_afdb8651-2e5d-4829-a591-8eda5037062c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates_d09c8e33-2b9a-44a4-b20d-6fb0c7b2525e" xlink:href="sny-20250630.xsd#sny_LoansToAssociates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_sny_LoansToAssociates_d09c8e33-2b9a-44a4-b20d-6fb0c7b2525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_1212d925-7548-4c2f-b65c-b9ee98391f70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_613ab2d1-9f1d-41e5-9a67-a8610fbf55a9" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_1212d925-7548-4c2f-b65c-b9ee98391f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_fd15ddc5-df65-4e90-9568-241e8596387e" xlink:href="sny-20250630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_fd15ddc5-df65-4e90-9568-241e8596387e" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_32b05a9a-ead2-44f8-9d0c-44efbce937ae" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_7da2e7ef-fd9f-4209-a968-6065fc39b407" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_b5dd0e08-355f-473c-8e9e-f01b54d152cf" xlink:to="loc_sny_AssociatesAndJointVenturesMember_7da2e7ef-fd9f-4209-a968-6065fc39b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_e47a1eff-a228-4854-adc3-622806b3e396" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_757804d5-3119-4678-93ea-cba6aa3508c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_757804d5-3119-4678-93ea-cba6aa3508c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_f37113d6-a5a8-4769-bf8a-9a67bee98aaa" xlink:href="sny-20250630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_f37113d6-a5a8-4769-bf8a-9a67bee98aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_b166cc61-2d5b-4e09-bdaa-38ed766cb1bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_b166cc61-2d5b-4e09-bdaa-38ed766cb1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions_39158c7a-c717-43ae-b516-93f516286a27" xlink:href="sny-20250630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_OtherAssetsRelatedPartyTransactions_39158c7a-c717-43ae-b516-93f516286a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_68d3af72-5327-4383-8206-9d7c64779800" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_68d3af72-5327-4383-8206-9d7c64779800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_c84e1b81-7a9b-4015-b8db-5a4dd743c149" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_c84e1b81-7a9b-4015-b8db-5a4dd743c149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_8ebca5c2-a203-4fa9-a575-b7efcf4e846e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_ifrs-full_SubordinatedLiabilities_8ebca5c2-a203-4fa9-a575-b7efcf4e846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions_659b2d72-690e-4528-9f2e-f45f48f97c59" xlink:href="sny-20250630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98bd5730-10ef-4aee-b2db-81938c8d3ab8" xlink:to="loc_sny_SubordinateHybridBondRelatedPartyTransactions_659b2d72-690e-4528-9f2e-f45f48f97c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f9b1ae72-e560-4a53-9961-509e94d0f213" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f9b1ae72-e560-4a53-9961-509e94d0f213" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f298b39b-47e1-4346-a08e-226bb059e714" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_f43b0ff4-980b-4597-b154-2b7ed88b7fb8" xlink:href="sny-20250630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_26ddf049-deb7-425e-bca7-c8c3573ced1a" xlink:to="loc_sny_AssociatesAndJointVenturesMember_f43b0ff4-980b-4597-b154-2b7ed88b7fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_b5960700-0b26-4d16-8d0e-ea400bdb6736" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_2ec913b4-77ed-4739-9bf0-b3f759d9e4f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_2ec913b4-77ed-4739-9bf0-b3f759d9e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_94314bf3-4014-4e16-a601-6dd475722ed3" xlink:href="sny-20250630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_94314bf3-4014-4e16-a601-6dd475722ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_0a19088f-ac39-4a65-a161-88860ae4f8a3" xlink:href="sny-20250630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_0a19088f-ac39-4a65-a161-88860ae4f8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_e800e3af-4e43-449f-ba7e-303e369b5548" xlink:href="sny-20250630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_e800e3af-4e43-449f-ba7e-303e369b5548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions_6c6b20f3-3146-49fb-b2a9-f6f829c94b93" xlink:href="sny-20250630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_CurrentAssetsRelatedPartyTransactions_6c6b20f3-3146-49fb-b2a9-f6f829c94b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions_7acdbe56-9ca2-4629-ae78-3deacd568da1" xlink:href="sny-20250630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_AssetsRelatedPartyTransactions_7acdbe56-9ca2-4629-ae78-3deacd568da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_3635cc1f-ff34-4cb3-befc-a89164e0dd9d" xlink:href="sny-20250630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_3635cc1f-ff34-4cb3-befc-a89164e0dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_0ab0b139-35d5-446c-8279-32e13b159397" xlink:href="sny-20250630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_0ab0b139-35d5-446c-8279-32e13b159397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_84046a15-17cd-4aa4-b2f8-d49dec5a87c4" xlink:href="sny-20250630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_EquityRelatedPartyTransactions_84046a15-17cd-4aa4-b2f8-d49dec5a87c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_4ce8e03b-38bd-47f7-9645-8f307e25ae36" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_4ce8e03b-38bd-47f7-9645-8f307e25ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_372734bf-f125-48e9-92f1-959df46faf3d" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_372734bf-f125-48e9-92f1-959df46faf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_bc5d79bc-0bca-4646-b789-17438c1c08fd" xlink:href="sny-20250630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_LiabilitiesRelatedPartyTransactions_bc5d79bc-0bca-4646-b789-17438c1c08fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions_77a92741-53f2-49ed-8684-c125058a40a7" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NonCurrentAssetsRelatedPartyTransactions_77a92741-53f2-49ed-8684-c125058a40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures_567944cd-bf00-45a1-bff0-d290caf0a45d" xlink:href="sny-20250630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NetIncomeRelatedPartyDisclosures_567944cd-bf00-45a1-bff0-d290caf0a45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_484a48ce-a831-4cbf-bb57-cfcae83fbbab" xlink:href="sny-20250630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_37426009-6477-47fe-89dc-83e735d4e95f" xlink:to="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_484a48ce-a831-4cbf-bb57-cfcae83fbbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_23901de8-00e5-44c7-8acd-4c33189a1bc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_23901de8-00e5-44c7-8acd-4c33189a1bc7" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3ab2b13b-153b-4db3-947d-2c618dd2e15d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_6ae738c8-608e-4f9e-b9c3-19f2d543528e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_6ae738c8-608e-4f9e-b9c3-19f2d543528e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_08c4d905-8f38-450d-a925-e22abb4f3a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_ca2df93e-c0ca-4b88-b4f5-eb0f265807cd" xlink:to="loc_ifrs-full_DebtSecuritiesMember_08c4d905-8f38-450d-a925-e22abb4f3a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_d90a25cf-63a0-46ff-8ccc-ab37e815ee50" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_42925cde-3bca-4c3b-97e8-559c995e361d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_42925cde-3bca-4c3b-97e8-559c995e361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_2a788830-d8c4-4167-847c-22937520f393" xlink:href="sny-20250630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_2a788830-d8c4-4167-847c-22937520f393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_13860fff-c3a5-4dc0-b7b2-8160355576c7" xlink:href="sny-20250630.xsd#sny_PreFundedPensionObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_PreFundedPensionObligations_13860fff-c3a5-4dc0-b7b2-8160355576c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_990fa71d-785a-4454-94a1-9d07ddafeca1" xlink:href="sny-20250630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_LongTermPrepaidExpenses_990fa71d-785a-4454-94a1-9d07ddafeca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_5ad51722-69fb-4688-8ca5-df9f402fb988" xlink:href="sny-20250630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_sny_NonCurrentLoansAndReceivables_5ad51722-69fb-4688-8ca5-df9f402fb988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_658c9ca3-472d-40eb-b029-ad91999a06e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_658c9ca3-472d-40eb-b029-ad91999a06e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_752e0374-91df-413b-ba9d-3525b1b1d744" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_3caf76bb-e259-446c-9624-14085a9c3763" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_752e0374-91df-413b-ba9d-3525b1b1d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableSummaryofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_9d0b5cf2-cb66-422d-8b0f-c42c47d086f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_9d0b5cf2-cb66-422d-8b0f-c42c47d086f8" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_8a1ed401-e667-4bc6-a61a-ccf8df4e6b18" xlink:to="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_06498d61-5d37-44a3-9235-441d39ed2706" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_06498d61-5d37-44a3-9235-441d39ed2706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_22fa774c-9ba3-48bf-88df-f5cbbdb372a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_570e03d4-3c62-490c-8014-e298dafb0422" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_22fa774c-9ba3-48bf-88df-f5cbbdb372a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:href="sny-20250630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_0a1e159c-d55c-4b28-a425-0b4286fd29c0" xlink:to="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_0acf06f2-0abf-49b1-853b-71487a244df3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_acc9a0c9-fa17-4882-94ce-dedaf2bc8677" xlink:to="loc_ifrs-full_CurrentTradeReceivables_0acf06f2-0abf-49b1-853b-71487a244df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f65e3d1c-7714-4ab2-a4d9-a7fd12ca99f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_7a374f47-1a3c-405c-b5ce-0456f98240c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f65e3d1c-7714-4ab2-a4d9-a7fd12ca99f0" xlink:to="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_7a374f47-1a3c-405c-b5ce-0456f98240c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables_0823a854-ec1e-435f-94eb-2c1ea3152fad" xlink:href="sny-20250630.xsd#sny_DerecognizedReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f65e3d1c-7714-4ab2-a4d9-a7fd12ca99f0" xlink:to="loc_sny_DerecognizedReceivables_0823a854-ec1e-435f-94eb-2c1ea3152fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_33d34e7c-0e58-4638-a2a1-4ccce3fbff28" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_33d34e7c-0e58-4638-a2a1-4ccce3fbff28" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:to="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_3c26fdf9-3dd6-445a-9845-a130c7d6689e" xlink:to="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_12b84da8-793d-447e-a6ad-9b1f68c15638" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_12b84da8-793d-447e-a6ad-9b1f68c15638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_c72393b4-a39f-493d-bfe1-938ef1219b1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_c72393b4-a39f-493d-bfe1-938ef1219b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a21f4c88-3540-4a5e-b1b4-39f0f59f7ae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a21f4c88-3540-4a5e-b1b4-39f0f59f7ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_bf2b767d-c7ac-4bc8-87a4-ea11f437909c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_bf2b767d-c7ac-4bc8-87a4-ea11f437909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_59d173cf-dd44-44fb-9125-9709dea71b48" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_697dab55-8e2b-4e26-bf84-0aeef2393cf6" xlink:to="loc_ifrs-full_LaterThanOneYearMember_59d173cf-dd44-44fb-9125-9709dea71b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_6d94fddd-d181-4073-af25-c1f4841e2a9e" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_6c583a1f-6312-411c-9f50-96a5f3498dba" xlink:href="sny-20250630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_197f50a2-4891-49a6-a2c3-e7ad46ec4548" xlink:to="loc_sny_OverdueReceivablesGrossValue_6c583a1f-6312-411c-9f50-96a5f3498dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_ed62dd24-5867-4b9f-b4bb-0c247dfc0aef" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_ed62dd24-5867-4b9f-b4bb-0c247dfc0aef" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_94505854-c113-43e1-b3f9-fc931f5d7168" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4995c15c-c98f-44f6-91a3-3b65d3e8bba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:to="loc_ifrs-full_IssuedCapitalMember_4995c15c-c98f-44f6-91a3-3b65d3e8bba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_fbc7109f-683e-4ccc-8229-2940cf331d5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_af7bfa95-4428-4037-b585-49c5d2a946d1" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_fbc7109f-683e-4ccc-8229-2940cf331d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_99f3f145-7943-4b27-be9d-19c469ad9624" xlink:to="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_71087e4f-ec90-437e-bcd4-d7acc2818f74" xlink:href="sny-20250630.xsd#sny_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_255a9c18-2077-4b7a-87b0-1744c7909e08" xlink:to="loc_sny_SanofiMember_71087e4f-ec90-437e-bcd4-d7acc2818f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:href="sny-20250630.xsd#sny_ShareProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:href="sny-20250630.xsd#sny_ShareProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramAxis_0b520109-5430-4105-8f0e-0a8ffd746cc4" xlink:to="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_99671434-ac8b-4d0f-8114-62d47f80be8b" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_99671434-ac8b-4d0f-8114-62d47f80be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_28815b68-aad1-484e-8d28-284aa4f16a30" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_28815b68-aad1-484e-8d28-284aa4f16a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember_86297874-a2c9-49f6-b6a2-6978de8929cd" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2024ProgramMember_86297874-a2c9-49f6-b6a2-6978de8929cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember_bd319370-361e-4756-a167-ac76f1318fdf" xlink:href="sny-20250630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_a3c432fe-5aff-4626-8ba4-173ffd7ab2c5" xlink:to="loc_sny_ShareRepurchase2025ProgramMember_bd319370-361e-4756-a167-ac76f1318fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ce065e23-ded7-4791-837e-15c1fac27387" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_ff59e156-4127-4432-9832-a4c1dd06cfe7" xlink:href="sny-20250630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6a63ebde-1daa-499b-9ec3-34881ef4d307" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_ff59e156-4127-4432-9832-a4c1dd06cfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_7bb93a28-1fa5-4f38-97db-92ad19e34e60" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_15b78d2a-b136-4964-b491-76c6582e8ce1" xlink:href="sny-20250630.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_DebtInstrumentsMember_15b78d2a-b136-4964-b491-76c6582e8ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_68106fd7-a902-4a6b-9f33-8e8b538b31ff" xlink:href="sny-20250630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_68106fd7-a902-4a6b-9f33-8e8b538b31ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_68cda4d2-15b7-42b7-af32-9cfb0ea8783b" xlink:href="sny-20250630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_aefedf83-c86b-4b96-9bf8-36091db0c160" xlink:to="loc_sny_ForeignCurrencyTranslationMember_68cda4d2-15b7-42b7-af32-9cfb0ea8783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_fa742464-642b-4761-b741-92838b20d700" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_4447e423-7c9d-410f-83aa-efa1de22ff9e" xlink:href="sny-20250630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_8a47d1bc-a33d-4d1f-8d9e-9aaee7c031c3" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_4447e423-7c9d-410f-83aa-efa1de22ff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_bd72830d-c99c-4e4e-a0a9-f6b17d7139dc" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_0c50fcab-ee47-4706-ba79-ca6a4c9c48c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_IssuedCapital_0c50fcab-ee47-4706-ba79-ca6a4c9c48c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_809826ae-375e-4ce3-94c7-a299bd33cded" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_NumberOfSharesIssued_809826ae-375e-4ce3-94c7-a299bd33cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_55996101-ee83-463a-aaf1-618f27c1f437" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_ParValuePerShare_55996101-ee83-463a-aaf1-618f27c1f437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_442455b8-ff1a-49a0-afdb-e118c10ded78" xlink:href="sny-20250630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_442455b8-ff1a-49a0-afdb-e118c10ded78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_ea17a64b-a2f6-49e0-a77a-5943440021d8" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_ea17a64b-a2f6-49e0-a77a-5943440021d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_1ddf5c70-76e6-401e-8cdb-d2a870d3cffb" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_1ddf5c70-76e6-401e-8cdb-d2a870d3cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted_b380a361-9b18-4840-a0a7-9f6e2e669d96" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesAlloted_b380a361-9b18-4840-a0a7-9f6e2e669d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_0e6e65f6-d435-4eca-93b9-46d3e5cfa533" xlink:href="sny-20250630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_0e6e65f6-d435-4eca-93b9-46d3e5cfa533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_92c69232-38eb-4d69-8276-4cd4bf14908e" xlink:href="sny-20250630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesRepurchased_92c69232-38eb-4d69-8276-4cd4bf14908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_abac8f13-b579-4097-a3ff-e04501da2df0" xlink:href="sny-20250630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_AmountOfSharesRepurchased_abac8f13-b579-4097-a3ff-e04501da2df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_f346b843-549e-4192-990b-863c8d06780a" xlink:href="sny-20250630.xsd#sny_SubscriptionPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_SubscriptionPricePerShare_f346b843-549e-4192-990b-863c8d06780a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_dac74e75-7a25-493e-a611-fb97f697a660" xlink:href="sny-20250630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfSharesSubscribed_dac74e75-7a25-493e-a611-fb97f697a660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_e5b5d1d0-7694-45b7-9ced-2cb643c500a7" xlink:href="sny-20250630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_e5b5d1d0-7694-45b7-9ced-2cb643c500a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a3a216ae-3581-470f-9c3e-7b57b10d8bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a3a216ae-3581-470f-9c3e-7b57b10d8bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_7ac0486d-7e03-481c-acc6-9a5149ae43e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_7ac0486d-7e03-481c-acc6-9a5149ae43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_3bc3f658-7452-46d7-9e01-cfd6f7260848" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_3bc3f658-7452-46d7-9e01-cfd6f7260848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b706207f-752d-4077-a255-d02127178ef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b706207f-752d-4077-a255-d02127178ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares_2e0e9c8f-7b7c-4a5f-975d-d3053c7aefb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_ifrs-full_CancellationOfTreasuryShares_2e0e9c8f-7b7c-4a5f-975d-d3053c7aefb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased_bf34e252-1325-463b-87a4-b04942b2dab9" xlink:href="sny-20250630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4831efbd-adab-44c4-838a-6a2c77e40b5b" xlink:to="loc_sny_PerShareValueOfSharesRepurchased_bf34e252-1325-463b-87a4-b04942b2dab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b15d2d2c-518b-42c2-b6f3-a6643bac0334" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld_83f24a08-7d75-449e-83f3-cc7721dd661a" xlink:href="sny-20250630.xsd#sny_NumberOfSharesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b15d2d2c-518b-42c2-b6f3-a6643bac0334" xlink:to="loc_sny_NumberOfSharesHeld_83f24a08-7d75-449e-83f3-cc7721dd661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod_1c0b5219-0221-49c9-9d3a-511048d46fb9" xlink:href="sny-20250630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b15d2d2c-518b-42c2-b6f3-a6643bac0334" xlink:to="loc_sny_PercentageOfShareCapitalForThePeriod_1c0b5219-0221-49c9-9d3a-511048d46fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_5cb36fa5-833f-46e1-b40a-5c5e63863d1c" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_5cb36fa5-833f-46e1-b40a-5c5e63863d1c" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_65c3f1ab-e179-4bdb-9ed8-5b357259ce17" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_5aef147f-31e4-41bd-acaa-d975c6435728" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2023Member_5aef147f-31e4-41bd-acaa-d975c6435728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_d88d92c3-71ef-4830-9cf2-362d7b798b0a" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_d88d92c3-71ef-4830-9cf2-362d7b798b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_bbe4f0e9-c08f-4ff6-827c-ec30fdc755fa" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2024Member_bbe4f0e9-c08f-4ff6-827c-ec30fdc755fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_01559c81-f009-4136-a591-740eee5fbcb6" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_01559c81-f009-4136-a591-740eee5fbcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_ae4a87e2-b376-4fc5-85b5-16ae4645cf79" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f8ef81cb-2552-4615-8197-08cbe0fbddb4" xlink:to="loc_sny_RestrictedSharePlan2025Member_ae4a87e2-b376-4fc5-85b5-16ae4645cf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:href="sny-20250630.xsd#sny_MarketConditionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:href="sny-20250630.xsd#sny_MarketConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionAxis_8e2e7948-b17a-4992-b7ce-4d2781594d91" xlink:to="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_83dd5722-9b14-49f4-945f-886a3021e34b" xlink:href="sny-20250630.xsd#sny_WithoutMarketConditionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:to="loc_sny_WithoutMarketConditionMember_83dd5722-9b14-49f4-945f-886a3021e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_3de71f98-14e7-476b-a148-050fbc871935" xlink:href="sny-20250630.xsd#sny_WithMarketConditionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_e5fce2af-2e0e-499d-aa3e-49173c7dd661" xlink:to="loc_sny_WithMarketConditionMember_3de71f98-14e7-476b-a148-050fbc871935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7c9dec0e-7c73-4e2e-bf87-e0d59ed0c24a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_85e2ddb8-9d0d-49e5-872b-d5c90b524219" xlink:href="sny-20250630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_85e2ddb8-9d0d-49e5-872b-d5c90b524219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_2cfdc032-1914-4baf-8971-31d9a7ccd6cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81b2ac3e-f24d-42a3-998d-d716e65c9dfd" xlink:to="loc_srt_ChiefExecutiveOfficerMember_2cfdc032-1914-4baf-8971-31d9a7ccd6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_13f65d30-1a0e-4461-9fae-5f53f0196de1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_32575934-5d97-4dcf-b6b8-6b76d30975e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_32575934-5d97-4dcf-b6b8-6b76d30975e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_2a1ec2f3-f0ed-4763-95f9-83e01f7c9cb6" xlink:href="sny-20250630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_2a1ec2f3-f0ed-4763-95f9-83e01f7c9cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_65dcc024-99a3-4068-a5fd-3cf1978871f3" xlink:href="sny-20250630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_65dcc024-99a3-4068-a5fd-3cf1978871f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_4d47661b-33a7-4ef2-86f4-d056c8f0edb9" xlink:href="sny-20250630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6986bf13-8b33-4aa2-993b-c450304bd8fb" xlink:to="loc_sny_NumberOfYearsServicePeriod_4d47661b-33a7-4ef2-86f4-d056c8f0edb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d1a3bb50-9624-4b50-aaa7-bb01a38cff4a" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d1a3bb50-9624-4b50-aaa7-bb01a38cff4a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5badf5f3-42a3-4a03-af90-49b99e174aa3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:href="sny-20250630.xsd#sny_RestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_646610e1-5fa0-4bfe-ad2e-0e98313f0c28" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2023Member_646610e1-5fa0-4bfe-ad2e-0e98313f0c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_b80e985b-7c99-4485-8199-7a2f0a1b601e" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2022Member_b80e985b-7c99-4485-8199-7a2f0a1b601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_f0e97d48-8cad-47fa-ba1d-070606cad99c" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2021Member_f0e97d48-8cad-47fa-ba1d-070606cad99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_8aad7fe1-16f6-4a65-9ff2-40099dc5e8ac" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_28352a8f-c1b5-402b-9684-38c8d337ac15" xlink:to="loc_sny_RestrictedSharePlan2020Member_8aad7fe1-16f6-4a65-9ff2-40099dc5e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_c9d4c47b-647a-4075-9f7f-edf8053f0ddb" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharePlan2024Member_c9d4c47b-647a-4075-9f7f-edf8053f0ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_ab56dabc-3a14-4650-8416-922fedfbb851" xlink:href="sny-20250630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4323ca75-9c8f-4603-adc3-b74cb87bdd5e" xlink:to="loc_sny_RestrictedSharePlan2025Member_ab56dabc-3a14-4650-8416-922fedfbb851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_5e0f6e5d-e7bf-4d39-89f2-f1e06cd398a4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e012fbf2-72ec-42fc-b3e8-e8f5f572ba95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e012fbf2-72ec-42fc-b3e8-e8f5f572ba95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_74788917-730a-4c92-b6cb-ab956f3a501d" xlink:href="sny-20250630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d443d616-87e6-4313-87db-2736f6973133" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_74788917-730a-4c92-b6cb-ab956f3a501d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b3cef88a-a147-4b4a-a1bb-575ad108bd94" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b3cef88a-a147-4b4a-a1bb-575ad108bd94" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_08586a36-d0fa-46f9-8af9-ccb1cb23ff75" xlink:to="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_a1a294a4-9cf2-4958-9dd6-5cf7c020085d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:to="loc_ifrs-full_BottomOfRangeMember_a1a294a4-9cf2-4958-9dd6-5cf7c020085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_06b6a693-0ab8-49ed-a6a6-b93f88c477ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_f5aca447-5c7d-48f5-b207-3594c69a734f" xlink:to="loc_ifrs-full_TopOfRangeMember_06b6a693-0ab8-49ed-a6a6-b93f88c477ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b03720fb-2471-4e44-bbfb-92879394b188" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_fbf4924e-708e-467c-be1f-84a0905c5a95" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeTwoMember_fbf4924e-708e-467c-be1f-84a0905c5a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_26cfa74d-6ee1-43f6-9ef4-fea9a04dded2" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeThreeMember_26cfa74d-6ee1-43f6-9ef4-fea9a04dded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_aba1a7f5-1b1a-4264-be45-777b9a5c99f1" xlink:href="sny-20250630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_958651b5-2728-4105-8b33-47c49bd8c5ed" xlink:to="loc_sny_ExercisePriceRangeFourMember_aba1a7f5-1b1a-4264-be45-777b9a5c99f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_402dab1d-af3e-4429-9462-87d2554e093a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_92756174-2bae-4c52-b4bd-4c3f8536ea0b" xlink:href="sny-20250630.xsd#sny_StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_cb8f1695-81a7-4df0-83e0-e3428dec4bd0" xlink:to="loc_sny_StockOptionPlanMember_92756174-2bae-4c52-b4bd-4c3f8536ea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8513a721-e1e4-49e3-86b4-e1e59ead3173" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35504ab8-862d-4c80-b007-afc7341a1a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35504ab8-862d-4c80-b007-afc7341a1a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_947d6c19-9715-4222-adc0-e1100735ee5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_947d6c19-9715-4222-adc0-e1100735ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1079ab00-c246-4743-9738-c1062faaa7f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1079ab00-c246-4743-9738-c1062faaa7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_382538af-8c47-437d-b1cf-e0dccc400dd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_382538af-8c47-437d-b1cf-e0dccc400dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3504c941-9dc1-4c19-92a0-571e6b72efc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3504c941-9dc1-4c19-92a0-571e6b72efc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_65d79443-0d75-4f9a-a4e9-5cafea409f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7290c07-8d59-48db-a476-d0e23e3626f4" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_65d79443-0d75-4f9a-a4e9-5cafea409f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_13959dd7-948d-4dfa-a9b0-083f304ce395" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_73f98510-314e-490c-9f11-494598ef86de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_13959dd7-948d-4dfa-a9b0-083f304ce395" xlink:to="loc_ifrs-full_WeightedAverageShares_73f98510-314e-490c-9f11-494598ef86de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_e556ec5f-0dd5-4357-90b0-b47ce9495d2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_13959dd7-948d-4dfa-a9b0-083f304ce395" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_e556ec5f-0dd5-4357-90b0-b47ce9495d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_8a01dfc2-0d11-426e-b48c-1922f852a81a" xlink:href="sny-20250630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_13959dd7-948d-4dfa-a9b0-083f304ce395" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_8a01dfc2-0d11-426e-b48c-1922f852a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_e1f8f2f5-3da5-4218-9398-9e5fa5066a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_13959dd7-948d-4dfa-a9b0-083f304ce395" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_e1f8f2f5-3da5-4218-9398-9e5fa5066a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a7203a9b-e499-4f11-a778-0f7e47599277" xlink:href="sny-20250630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a7203a9b-e499-4f11-a778-0f7e47599277" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_81d1493c-5d68-43a8-8347-b9b222137563" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_9c5aab01-946b-4ec8-8c43-ae6e697f4853" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_ddcb7689-0fc1-4f77-9ae2-33ef8990f70d" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_9c5aab01-946b-4ec8-8c43-ae6e697f4853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4826e588-a4f5-4747-87f4-834a21fafe4f" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_5ade3b70-ae71-4910-a0bf-718b3c0b3006" xlink:href="sny-20250630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_5ade3b70-ae71-4910-a0bf-718b3c0b3006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_9efb883f-d28a-4e12-a96f-b8389fd7270d" xlink:href="sny-20250630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_7d7275b6-bb17-42c2-a79e-740f320b9752" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_9efb883f-d28a-4e12-a96f-b8389fd7270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_9dcde02b-7732-4b06-b1dc-28309c42f6e9" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_20af1b5b-6b8e-4551-96c1-d1ea2b968f03" xlink:href="sny-20250630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_20af1b5b-6b8e-4551-96c1-d1ea2b968f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_67c9dc74-c63e-4615-8288-2da6b7fdca18" xlink:href="sny-20250630.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_DebtInstrumentsMember_67c9dc74-c63e-4615-8288-2da6b7fdca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_27825a35-a0de-4451-b9d9-348810c5c72d" xlink:href="sny-20250630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_27825a35-a0de-4451-b9d9-348810c5c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_0586bc6d-f596-4de1-befb-c274397d7312" xlink:href="sny-20250630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_ForeignCurrencyTranslationMember_0586bc6d-f596-4de1-befb-c274397d7312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_c24e375c-167b-42ed-a105-44a92a9246c7" xlink:href="sny-20250630.xsd#sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_6c4ae7bf-cb62-4ee6-af01-9eb4de39f5e2" xlink:to="loc_sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember_c24e375c-167b-42ed-a105-44a92a9246c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c8497b9-1df1-4ef2-b217-70408d0daba6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_b9d6ad81-3dcc-4a7e-a02b-5209b42befdf" xlink:href="sny-20250630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_2b21a7e5-b2cf-4b57-b586-6c3956feabae" xlink:to="loc_sny_EuroapiMember_b9d6ad81-3dcc-4a7e-a02b-5209b42befdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_f67213da-1446-43fb-832b-69d42b59ef69" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f5b0768f-5793-48d7-8725-e086422dcd3d" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f5b0768f-5793-48d7-8725-e086422dcd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e3a59fdd-4313-4f55-8eca-6ccd63ebcc62" xlink:href="sny-20250630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e3a59fdd-4313-4f55-8eca-6ccd63ebcc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_679e90cf-23c1-4dfc-bf35-cd61b0db0922" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_679e90cf-23c1-4dfc-bf35-cd61b0db0922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9e1754ec-74d3-45b8-b624-fdd0ac5b5a3a" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9e1754ec-74d3-45b8-b624-fdd0ac5b5a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_a62cfb4a-04ba-49d7-8355-fcc15ed28e49" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_a62cfb4a-04ba-49d7-8355-fcc15ed28e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_8f7060c0-599f-458f-9939-6bbe01acce19" xlink:href="sny-20250630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_8f7060c0-599f-458f-9939-6bbe01acce19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_32918977-084c-4cf3-8b96-a612dd8fea08" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_32918977-084c-4cf3-8b96-a612dd8fea08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_49af6090-ecc8-469b-8c40-d9066e0a9f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_49af6090-ecc8-469b-8c40-d9066e0a9f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_ba9ec75a-5670-4420-a198-12e51943c5e8" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_ba9ec75a-5670-4420-a198-12e51943c5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_c6c01722-0a21-400b-8c61-b35656440c4e" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_c6c01722-0a21-400b-8c61-b35656440c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_d6a248ee-e2e5-4a6c-b027-b3afee192931" xlink:href="sny-20250630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_d6a248ee-e2e5-4a6c-b027-b3afee192931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_83804225-e36a-4352-bb73-870af59bf3e7" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_83804225-e36a-4352-bb73-870af59bf3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_2a296562-08bb-44c0-90c0-df34400d0287" xlink:href="sny-20250630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_2a296562-08bb-44c0-90c0-df34400d0287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_f9812e2d-5843-47cb-8115-2bd741ea6556" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_f9812e2d-5843-47cb-8115-2bd741ea6556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_dbd1975c-99d4-40d5-95a8-f553ac330f89" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_dbd1975c-99d4-40d5-95a8-f553ac330f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_bdb903e9-49d1-4349-b4bb-fa0e7ca0d466" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_bdb903e9-49d1-4349-b4bb-fa0e7ca0d466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_59c38f13-107c-408b-a706-6b8b14ec4507" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_59c38f13-107c-408b-a706-6b8b14ec4507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_23de71d7-da30-48e7-a3d4-fb16a53e0bf6" xlink:href="sny-20250630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_23de71d7-da30-48e7-a3d4-fb16a53e0bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_01fc3057-0eab-489d-a97d-3508ca9af7cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_01fc3057-0eab-489d-a97d-3508ca9af7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ef367ef1-4c55-44d1-9679-d12d1505efe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2fa3ddf-c3e9-4761-a25e-7bb29227a651" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ef367ef1-4c55-44d1-9679-d12d1505efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_cb64be8c-ae5e-401e-b32e-19f7c2e95ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_ifrs-full_LongtermBorrowings_cb64be8c-ae5e-401e-b32e-19f7c2e95ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2fce01d1-3971-47ee-8066-455809adbed0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2fce01d1-3971-47ee-8066-455809adbed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd94023d-5d5c-4f39-8353-50685ea4c129" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd94023d-5d5c-4f39-8353-50685ea4c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_61762456-bc46-430e-a7a5-9a496fe2f1b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_ifrs-full_Borrowings_61762456-bc46-430e-a7a5-9a496fe2f1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fb1dbd02-da70-46a9-b163-65ac9265bf78" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fb1dbd02-da70-46a9-b163-65ac9265bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_170beeee-e30a-44a4-9eeb-448e38a23fd0" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_170beeee-e30a-44a4-9eeb-448e38a23fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_f1b31a6f-9be0-4de4-af64-f72c7c48a453" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_f1b31a6f-9be0-4de4-af64-f72c7c48a453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_090c1979-2680-43a2-a757-7706314b3142" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_cde0ec32-3b69-4fa8-8cc9-8ffee0612dde" xlink:to="loc_ifrs-full_LeaseLiabilities_090c1979-2680-43a2-a757-7706314b3142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_fdc83587-3a91-4578-9112-e7fdef26346d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_fdc83587-3a91-4578-9112-e7fdef26346d" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:to="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_0ecdf79c-c109-47ce-aa31-9585ab026d66" xlink:to="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_ed782704-1def-42fc-95c7-2a8c91c3fa9a" xlink:href="sny-20250630.xsd#sny_AmortizedCostNettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_AmortizedCostNettingMember_ed782704-1def-42fc-95c7-2a8c91c3fa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_894dd5a9-4d9d-419e-8981-fa35b62f625b" xlink:href="sny-20250630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_894dd5a9-4d9d-419e-8981-fa35b62f625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_840d47d9-5d57-407f-afc4-122d2100af18" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_4e62ab28-7dc4-4169-a127-fc3a11409d77" xlink:to="loc_sny_ValueOnRedemptionMember_840d47d9-5d57-407f-afc4-122d2100af18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_d8c5cab6-bcc6-449e-b9bd-0186db2ca36e" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_bba8557d-1dd0-4452-9b66-39c6bfdbb51f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_LongtermBorrowings_bba8557d-1dd0-4452-9b66-39c6bfdbb51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0796443b-f3b7-4f0c-b98d-4af0fa3d80cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0796443b-f3b7-4f0c-b98d-4af0fa3d80cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_411815ae-3c7c-437c-995d-7902bda941c5" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_411815ae-3c7c-437c-995d-7902bda941c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_309dc37f-7b30-4ac3-8498-182ff68c555b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_Borrowings_309dc37f-7b30-4ac3-8498-182ff68c555b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_82b9268a-3013-43af-a1c8-c75b58771f38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_CashAndCashEquivalents_82b9268a-3013-43af-a1c8-c75b58771f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_baf12963-44fc-4ff4-a290-c7d981178e79" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_baf12963-44fc-4ff4-a290-c7d981178e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_b7c30ffd-45f8-44ee-9b18-8d47ef3759d4" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_b7c30ffd-45f8-44ee-9b18-8d47ef3759d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_9c3c03d5-d9fd-413c-94e9-b4cd0a54792e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_ifrs-full_LeaseLiabilities_9c3c03d5-d9fd-413c-94e9-b4cd0a54792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_749dc644-8f87-4e83-8d9f-8c70fc24134e" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_3e25a7c9-41bc-492d-bc6e-ec7a330dea33" xlink:to="loc_sny_OtherBankBorrowings_749dc644-8f87-4e83-8d9f-8c70fc24134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_488bac72-bfdf-4c5d-a946-5fc7941c9363" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_488bac72-bfdf-4c5d-a946-5fc7941c9363" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_d2c05789-87a3-4f41-9554-ac9ab0a71d6f" xlink:to="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_ce85de2e-b4d4-4d3b-86e0-f28620e12990" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_6f9db841-13f8-4839-b3fb-ba8a780a23da" xlink:to="loc_sny_ValueOnRedemptionMember_ce85de2e-b4d4-4d3b-86e0-f28620e12990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAndLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_3ab1dfe3-1855-4958-8d12-f1c9462e6444" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_4045995c-00a6-4de1-bcd7-9a7f334ac036" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:to="loc_sny_NonCurrentLiabilitiesMember_4045995c-00a6-4de1-bcd7-9a7f334ac036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_74d00630-fbda-4800-be06-b8f420a47a98" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesDomain_7ad116e9-d30a-49b7-b1b2-2db3f705b3b7" xlink:to="loc_sny_CurrentLiabilitiesMember_74d00630-fbda-4800-be06-b8f420a47a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_dca0a280-c1a3-47cc-ba0b-cd61420bf519" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_71549695-4b5e-4048-b6ed-c147eed33062" xlink:href="sny-20250630.xsd#sny_NonCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:to="loc_sny_NonCurrentAssetsMember_71549695-4b5e-4048-b6ed-c147eed33062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_c6ec32db-7b65-41ae-a03f-79582a2f675d" xlink:href="sny-20250630.xsd#sny_CurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_a3b7a64f-4ae6-4e1a-8805-b956cacc9019" xlink:to="loc_sny_CurrentAssetsMember_c6ec32db-7b65-41ae-a03f-79582a2f675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_0e1ef0f3-2812-44fc-9b00-d41c887e6a9c" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_e7797a3a-8fc4-4b72-884a-6254a02cae57" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_e7797a3a-8fc4-4b72-884a-6254a02cae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_5c36713e-8b57-4adf-8b71-b1a342000661" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_75d57e8c-8761-4a06-9813-2fdc4a2918ea" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_5c36713e-8b57-4adf-8b71-b1a342000661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:href="sny-20250630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_a07af597-85ac-4532-81ac-f27867e854ee" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_7d556d68-4a4e-4367-8d43-8369b6537f98" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_BondsIssued_7d556d68-4a4e-4367-8d43-8369b6537f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_c414c80a-5aaf-4718-b9bb-c40b2d8faa5b" xlink:href="sny-20250630.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_OtherBankBorrowings_c414c80a-5aaf-4718-b9bb-c40b2d8faa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_23f5c6b8-3ab3-4776-b32a-81cc55739fbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_OtherBorrowings_23f5c6b8-3ab3-4776-b32a-81cc55739fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_3e69febc-d9ed-4a50-bfe4-66e8cbadb9d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_3e69febc-d9ed-4a50-bfe4-66e8cbadb9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_e5666fdc-ef92-486d-ae45-ee00424a58e5" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_e5666fdc-ef92-486d-ae45-ee00424a58e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b9f4c34c-52a9-41b0-ba37-cd2ce10d6757" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_Borrowings_b9f4c34c-52a9-41b0-ba37-cd2ce10d6757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3631539d-c18b-414f-a369-9ea549bfc7c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3631539d-c18b-414f-a369-9ea549bfc7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_4f11bed2-f943-43a3-b789-c5a2ecb22a53" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_4f11bed2-f943-43a3-b789-c5a2ecb22a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_68463865-5870-4594-9c76-b39294891f4b" xlink:href="sny-20250630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_5cf24e99-f8b6-479a-b4c2-5fb7e07e98d1" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_68463865-5870-4594-9c76-b39294891f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_2634598e-cee4-4d35-9862-d67c21f5b568" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_2634598e-cee4-4d35-9862-d67c21f5b568" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_b5227ed4-6246-4449-8001-90de62f43851" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_53ddde17-9e83-45b3-8cc5-25403248c414" xlink:href="sny-20250630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_53ddde17-9e83-45b3-8cc5-25403248c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_434bc50a-daa7-48e6-a2d8-9de4a0e17577" xlink:href="sny-20250630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_434bc50a-daa7-48e6-a2d8-9de4a0e17577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember_6a7e7452-9aed-4316-98fc-c5a689fafda6" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityOneMember_6a7e7452-9aed-4316-98fc-c5a689fafda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember_50c13ef4-4c75-43d9-9181-6ad43435e5c3" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityTwoMember_50c13ef4-4c75-43d9-9181-6ad43435e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_f2b35c8b-fd61-48e4-bb9a-a6d10ad12f66" xlink:href="sny-20250630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_f2b35c8b-fd61-48e4-bb9a-a6d10ad12f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_7d4c11c4-68c5-4d4b-a174-3f27eb724ad5" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_7d4c11c4-68c5-4d4b-a174-3f27eb724ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_507721c5-6583-42d9-a1ce-588d24cab615" xlink:href="sny-20250630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_507721c5-6583-42d9-a1ce-588d24cab615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6548412b-5e9c-4ffc-8b7f-5c03b29001c1" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6548412b-5e9c-4ffc-8b7f-5c03b29001c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member_dc1ce9fc-d602-4835-b572-14fecf1d3ad7" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FourBillionFacilityMaturingDecember2027Member_dc1ce9fc-d602-4835-b572-14fecf1d3ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2030Member_c95d6cbe-9113-4f87-831a-6fe689460c37" xlink:href="sny-20250630.xsd#sny_FourBillionFacilityMaturingMarch2030Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FourBillionFacilityMaturingMarch2030Member_c95d6cbe-9113-4f87-831a-6fe689460c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_a3694985-895c-4a23-9826-ffbda61f29e1" xlink:href="sny-20250630.xsd#sny_OneBillionFiftyMillionBondsMaturingApril2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiftyMillionBondsMaturingApril2025Member_a3694985-895c-4a23-9826-ffbda61f29e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2020Member_200d17c5-403f-4b00-9205-13083ff04e49" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2020Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondIssueFromApril2020Member_200d17c5-403f-4b00-9205-13083ff04e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromApril2022Member_d3edc99d-acf6-4a45-90d2-0e5cf031f6d5" xlink:href="sny-20250630.xsd#sny_FixedRateBondIssueFromApril2022Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondIssueFromApril2022Member_d3edc99d-acf6-4a45-90d2-0e5cf031f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_f004a20b-3f9b-41d6-9cbe-03c8e73aec89" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member_f004a20b-3f9b-41d6-9cbe-03c8e73aec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2027Member_0a208447-1583-4b9d-91f9-7aba12769893" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2027Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2027Member_0a208447-1583-4b9d-91f9-7aba12769893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2031Member_ca4c2a84-2e06-4e80-a242-12ab997e6f53" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2031Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2031Member_ca4c2a84-2e06-4e80-a242-12ab997e6f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingJune2029Member_1e720096-345f-4ef0-9f9e-76c0e0c96efe" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingJune2029Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingJune2029Member_1e720096-345f-4ef0-9f9e-76c0e0c96efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2032Member_e802388e-b275-4928-80be-8ab00a861c19" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingMarch2032Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_FixedRateBondMaturingMarch2032Member_e802388e-b275-4928-80be-8ab00a861c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_c98faf60-3329-469f-a3fa-e8bf3bf8378c" xlink:href="sny-20250630.xsd#sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_d37fb394-5a2c-4c6b-a355-bd5f0128b058" xlink:to="loc_sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member_c98faf60-3329-469f-a3fa-e8bf3bf8378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:href="sny-20250630.xsd#sny_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:href="sny-20250630.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentAxis_a2fa8c36-78a4-42f2-9312-8e8502d41828" xlink:to="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_28484c9e-7881-43b1-868d-bd5fd199d222" xlink:href="sny-20250630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_28484c9e-7881-43b1-868d-bd5fd199d222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_43efe2fa-c394-4e9d-9535-34dd9eb577a2" xlink:href="sny-20250630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_bce8ad89-5dc1-4b90-a4fd-24e30c2af938" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_43efe2fa-c394-4e9d-9535-34dd9eb577a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_891017a0-6cbf-460e-b3f3-5c7e90c0693e" xlink:to="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_ee662c0e-d871-41cf-ba95-d2b44d12928a" xlink:href="sny-20250630.xsd#sny_MazeTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_7c7736dd-5823-4e86-9852-eb5ee172a9ab" xlink:to="loc_sny_MazeTherapeuticsMember_ee662c0e-d871-41cf-ba95-d2b44d12928a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_3df26285-5e97-4c08-ae5a-f66e0b776ac7" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_5bfa6eea-8da7-4e92-8e93-c8292d4d329e" xlink:href="sny-20250630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_5bfa6eea-8da7-4e92-8e93-c8292d4d329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_2aca6840-acfe-4796-bd1e-d4e0e896b98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_ifrs-full_NotionalAmount_2aca6840-acfe-4796-bd1e-d4e0e896b98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_e6b9980a-ed39-4de5-bf34-947158268839" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_e6b9980a-ed39-4de5-bf34-947158268839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_76ea91ad-da40-41ce-b937-79efdcf62e36" xlink:href="sny-20250630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_76ea91ad-da40-41ce-b937-79efdcf62e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_a9fe7f06-987c-4e34-8e55-13200d7ba589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_ifrs-full_CommercialPapersIssued_a9fe7f06-987c-4e34-8e55-13200d7ba589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_bb8c24ca-8634-428f-b28f-fd755da07bd2" xlink:href="sny-20250630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_BorrowingAverageDrawdown_bb8c24ca-8634-428f-b28f-fd755da07bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_ebe765e3-52f0-452b-857e-359c2efc0c1a" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_UpfrontPayments_ebe765e3-52f0-452b-857e-359c2efc0c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches_07fcc45a-9440-416b-aeff-911d7dc80044" xlink:href="sny-20250630.xsd#sny_NumberOfTranches"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_3e8abe83-40a9-469c-8e71-127e51b36da6" xlink:to="loc_sny_NumberOfTranches_07fcc45a-9440-416b-aeff-911d7dc80044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_109b3316-8f3a-4780-bbc8-73744322fb67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_109b3316-8f3a-4780-bbc8-73744322fb67" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:to="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_e0b5fe52-8bfb-4186-98ff-2e5de19f156a" xlink:to="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_1babb1bb-800c-4f2f-9fec-2e8b59e8c0e1" xlink:href="sny-20250630.xsd#sny_AtMarketValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:to="loc_sny_AtMarketValueMember_1babb1bb-800c-4f2f-9fec-2e8b59e8c0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_090e5745-9337-4e3b-9def-9cafa579f163" xlink:href="sny-20250630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_26117994-549b-45f5-bbee-cbab8331858c" xlink:to="loc_sny_ValueOnRedemptionMember_090e5745-9337-4e3b-9def-9cafa579f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5d9676b7-28d2-4b7c-84fa-2a79ca6f2ea2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_cc053098-00af-4e83-9af2-9bbac87c4ccd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:to="loc_ifrs-full_Borrowings_cc053098-00af-4e83-9af2-9bbac87c4ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_9ee8cd34-c7f0-4d17-9a5f-0f2e33a4642e" xlink:href="sny-20250630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_2d0f4a3f-1ec3-4408-b095-ef73c4aa40e3" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_9ee8cd34-c7f0-4d17-9a5f-0f2e33a4642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_be1fbcbb-aca9-4f6b-999d-7421f82468da" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_be1fbcbb-aca9-4f6b-999d-7421f82468da" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_214df008-4ef9-4733-a20a-66a38969b4eb" xlink:to="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_484f080b-161d-4f50-af32-425cf73eb184" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:to="loc_sny_AtNotionalAmountMember_484f080b-161d-4f50-af32-425cf73eb184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_c592455a-0fb6-4abc-8992-ee870f07f720" xlink:to="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_5c8386a1-c531-4387-8aa4-597daac581af" xlink:href="sny-20250630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AtFairValueMember_1726edfd-8b26-4c1b-a92f-9e93b3f101e8" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_5c8386a1-c531-4387-8aa4-597daac581af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0f756767-f2d1-4127-954b-f3c8276befc4" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_9bd8dccb-1e0c-4174-8a45-46b629563cc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:to="loc_ifrs-full_CashFlowHedgesMember_9bd8dccb-1e0c-4174-8a45-46b629563cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_7f852eba-95bb-4b6a-9517-da45f9e3be57" xlink:href="sny-20250630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_dd93c067-ad7d-47db-af67-24fd9ba293b5" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_7f852eba-95bb-4b6a-9517-da45f9e3be57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_febfedd4-06fb-450a-b268-e08bb524f496" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_023ca5d7-73b1-4214-81fe-e1d3d43fbe20" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_023ca5d7-73b1-4214-81fe-e1d3d43fbe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_58fd2c49-6962-4422-9183-2b4723816815" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_58fd2c49-6962-4422-9183-2b4723816815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_60918041-a9ab-49e8-8fec-3107b2c4391d" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_60918041-a9ab-49e8-8fec-3107b2c4391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember_5057955b-cbb6-4088-a98b-666cde0e294e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInMexicanPesoMember_5057955b-cbb6-4088-a98b-666cde0e294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_d8b3a41e-003f-46ef-ac04-af4b72e2dfb5" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_c587da3a-91dd-4293-b0b8-b6ffca75ed79" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_d8b3a41e-003f-46ef-ac04-af4b72e2dfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_9510e440-cef8-496a-92a5-e1280499b6d9" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_9510e440-cef8-496a-92a5-e1280499b6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_a5337bb2-9024-43ea-8bf8-7d1c048ad853" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_a5337bb2-9024-43ea-8bf8-7d1c048ad853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_30a6503f-fb37-4ae7-8cc6-287f17c2f8ae" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_30a6503f-fb37-4ae7-8cc6-287f17c2f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_dbbf88ab-e34c-499a-8a0e-8342aa200731" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_dbbf88ab-e34c-499a-8a0e-8342aa200731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_64bdfd13-236b-414e-8232-6cacff03ab1e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_659bde53-8b4c-42aa-b8d1-0986d0daca90" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_64bdfd13-236b-414e-8232-6cacff03ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember_9ef2566c-5733-4b6d-ad69-e3d26238b69c" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencySalesInRussianRoubleMember_9ef2566c-5733-4b6d-ad69-e3d26238b69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_ae0e6b0e-83fb-48bf-bf6c-b38722653cf3" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_ae0e6b0e-83fb-48bf-bf6c-b38722653cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_3dd79546-7174-41a5-9e71-e6628f8a1323" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_17a82991-e68f-4459-94e5-69dc43978bfc" xlink:to="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_3dd79546-7174-41a5-9e71-e6628f8a1323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b4ff2227-2015-465a-b218-6e6cf753e673" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_fff56ba7-f99f-43c8-9862-b24144d17a16" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_0fc80070-13d1-48eb-bbd7-ce91cadbb9f2" xlink:to="loc_sny_DerivativeFinancialInstruments_fff56ba7-f99f-43c8-9862-b24144d17a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_7e79941f-d4a6-4b3e-882a-ea00a60071f8" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_7e79941f-d4a6-4b3e-882a-ea00a60071f8" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_8c28bddd-98d7-4f90-bc37-ed23300f6a6f" xlink:to="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_e14f90f7-f5ad-46f6-bb3f-454089bf4a9c" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:to="loc_sny_AtNotionalAmountMember_e14f90f7-f5ad-46f6-bb3f-454089bf4a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_94f5f959-6e94-46fd-b2df-609991e84934" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_927470ae-65ec-45b5-a5c4-0dee67b03287" xlink:to="loc_ifrs-full_AtFairValueMember_94f5f959-6e94-46fd-b2df-609991e84934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_9eb2faaa-488d-46fc-9e78-8f1696cbfe2e" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_9ab2c2b4-b0bb-4292-85cc-93a8089bce41" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_9ab2c2b4-b0bb-4292-85cc-93a8089bce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_bff6c37a-e8a6-4ce7-bcc9-1010e94de0cb" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_bff6c37a-e8a6-4ce7-bcc9-1010e94de0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_3f6529c4-4a2c-40d2-8836-cca27d665e99" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_b43fc7f0-a59c-465a-8074-c42ee6efeb12" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_3f6529c4-4a2c-40d2-8836-cca27d665e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_034d6efd-ba97-4834-adbd-bfede0fe4a37" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_034d6efd-ba97-4834-adbd-bfede0fe4a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_599ade74-253d-43b9-956e-a284e2ffc980" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_599ade74-253d-43b9-956e-a284e2ffc980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_17b77dab-804b-4eda-9764-7cb51d97d73c" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_0869d138-570b-4b7f-8abb-5dd743e02dc8" xlink:to="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_17b77dab-804b-4eda-9764-7cb51d97d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_9d23f159-e7f6-4731-92b1-c083a0668f55" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_9d23f159-e7f6-4731-92b1-c083a0668f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_111e08b9-ceb7-4776-909f-b3b5a364673e" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_111e08b9-ceb7-4776-909f-b3b5a364673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_c1a7567a-67ed-4582-ae8a-6a193b55f292" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_c1a7567a-67ed-4582-ae8a-6a193b55f292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember_47f1f6ad-370c-4a62-89a1-e64b55a17865" xlink:href="sny-20250630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencySalesInCanadianDollarMember_47f1f6ad-370c-4a62-89a1-e64b55a17865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_4dee6dcf-4668-448f-a2d7-f30ca3ddf36a" xlink:href="sny-20250630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_4dee6dcf-4668-448f-a2d7-f30ca3ddf36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member_bd59540b-52fa-4d14-9dc6-91b1857e5a71" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapExpiring2029Member_bd59540b-52fa-4d14-9dc6-91b1857e5a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member_b8fb727d-0507-4041-941f-37d36080c409" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapExpiring2032Member_b8fb727d-0507-4041-941f-37d36080c409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember_d389f0f6-2cf3-4489-89e7-f770db28630a" xlink:href="sny-20250630.xsd#sny_CrossCurrencySwapMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySwapMember_d389f0f6-2cf3-4489-89e7-f770db28630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember_689878e9-e7a4-4bb0-b6f2-bedfbbbe8b9f" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySellerSwapsMember_689878e9-e7a4-4bb0-b6f2-bedfbbbe8b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_590e70ae-db95-4593-b32b-5286b20cfd9a" xlink:href="sny-20250630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_3d52f8a7-b42d-449d-9380-e8e179a731bf" xlink:to="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_590e70ae-db95-4593-b32b-5286b20cfd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_64f35b6b-fed7-4105-b5ef-19c2995a5447" xlink:to="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_d75c1928-dfa5-4f50-90e2-976aa692583a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_d75c1928-dfa5-4f50-90e2-976aa692583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_a0e264f9-0bd9-4605-b465-756a7a583a41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_e8c43224-568b-4780-abc8-b42ac7b611b5" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_a0e264f9-0bd9-4605-b465-756a7a583a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_dd72514f-efe9-46aa-805c-a3ca020a3820" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_1059c4e9-4956-4bba-aeeb-77cc7807e6d3" xlink:href="sny-20250630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_1059c4e9-4956-4bba-aeeb-77cc7807e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_e6f6ed5d-36c1-467c-861c-90ec8a3e50ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_NotionalAmount_e6f6ed5d-36c1-467c-861c-90ec8a3e50ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_28d93c16-4109-4e83-898c-3787338b312b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_28d93c16-4109-4e83-898c-3787338b312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_72963578-f4ba-4795-a4af-fc282bf6570a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_72963578-f4ba-4795-a4af-fc282bf6570a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_988f1b50-7f50-4324-8795-60b2a72b7abf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_6a3acc28-1bd1-4040-b660-fbbfc1caab8e" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_988f1b50-7f50-4324-8795-60b2a72b7abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_f85da6ff-45de-4b94-a727-a7bc19cfe07a" xlink:href="sny-20250630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_f85da6ff-45de-4b94-a727-a7bc19cfe07a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_b4c61c97-9e61-4b62-af8d-b4fccf2e7435" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_9c1b0308-7c6e-4970-8dc6-3439453aeb9d" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_9c1b0308-7c6e-4970-8dc6-3439453aeb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_73f5cc7a-72fe-4404-8431-c2b8254d79eb" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_73f5cc7a-72fe-4404-8431-c2b8254d79eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_13065544-d52e-4b5a-9d14-98a09242d5fd" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_13065544-d52e-4b5a-9d14-98a09242d5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_8dceac37-3865-44d9-87cd-29dbd814426c" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_8dceac37-3865-44d9-87cd-29dbd814426c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_5c2b80b2-a784-4c62-9898-2114d7d75ab7" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_5c2b80b2-a784-4c62-9898-2114d7d75ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_38d0706d-2652-45db-84ab-4ff7715688a3" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_38d0706d-2652-45db-84ab-4ff7715688a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_f5e24659-8d61-4685-8fce-8d76081f3b70" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_fd926ebb-3879-4d1f-9929-b28356928c21" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_f5e24659-8d61-4685-8fce-8d76081f3b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_a578eb55-c556-4168-95c4-4d5f34021648" xlink:to="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_b1526ae3-1b76-4254-9bb5-36d773356e16" xlink:href="sny-20250630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_sny_AtNotionalAmountMember_b1526ae3-1b76-4254-9bb5-36d773356e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_79fb455d-7d14-48de-a40e-6085076b0b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_ifrs-full_AtFairValueMember_79fb455d-7d14-48de-a40e-6085076b0b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_4db210ba-69a5-42d5-b442-de2dffbc8c4a" xlink:href="sny-20250630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_5e6de260-c976-4631-aeda-4074ae430506" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_4db210ba-69a5-42d5-b442-de2dffbc8c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_bb295a22-7d71-4764-aa8b-f59effa6ea18" xlink:to="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_e542c8e4-d6be-4847-8437-a681bd42d877" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_e542c8e4-d6be-4847-8437-a681bd42d877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c02f4219-ec6a-4a30-8a59-d2a60a42d904" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c02f4219-ec6a-4a30-8a59-d2a60a42d904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e028b3fe-5a7a-4fdf-97a9-0e68c980728b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e028b3fe-5a7a-4fdf-97a9-0e68c980728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cc197fd-2d19-425d-b28e-05eb185ccb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cc197fd-2d19-425d-b28e-05eb185ccb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_f96f6e54-e44c-495b-bc1a-1811c26ca0cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_cacfed89-556f-4b77-af72-07e2e8bac1fd" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_f96f6e54-e44c-495b-bc1a-1811c26ca0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_170c1ded-1360-48df-b025-b71de8aa4b2c" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_8403360a-d965-4bfa-b870-83039a289739" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:to="loc_ifrs-full_FairValueHedgesMember_8403360a-d965-4bfa-b870-83039a289739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_1e7c977d-6e5e-40a4-b7b8-21bebb2e74a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_d1d957ab-0018-45d0-b05f-1487ef878c92" xlink:to="loc_ifrs-full_CashFlowHedgesMember_1e7c977d-6e5e-40a4-b7b8-21bebb2e74a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_23d4c522-a09d-4eac-84c1-816c72b57e6b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_e1bee4f2-5b28-4bc9-a4a7-a0e5a2f33d32" xlink:href="sny-20250630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:to="loc_sny_InterestRateSwapsInterestRate_e1bee4f2-5b28-4bc9-a4a7-a0e5a2f33d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_2301c171-f354-4fd4-973d-9afc869c99b1" xlink:href="sny-20250630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d37e70ee-22ec-408e-9332-7adae161003d" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_2301c171-f354-4fd4-973d-9afc869c99b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_2b93a500-03e6-4ce1-80f7-3432e739b083" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_160e7e49-95fa-4bfd-bc7a-d6681a0046a8" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_2b93a500-03e6-4ce1-80f7-3432e739b083" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_160e7e49-95fa-4bfd-bc7a-d6681a0046a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_2b93a500-03e6-4ce1-80f7-3432e739b083" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cbd07fdd-dbc6-437c-b792-51c7d9f008e7" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_afe8db8c-2fe6-46c9-b51b-5c9eddcc9ced" xlink:href="sny-20250630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_afe8db8c-2fe6-46c9-b51b-5c9eddcc9ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_d4a6e036-8093-4a5c-8394-fe28dae86ad0" xlink:href="sny-20250630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_d4a6e036-8093-4a5c-8394-fe28dae86ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_cd36f096-aa08-46ac-bce5-e1f3e3f9795a" xlink:href="sny-20250630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_cd36f096-aa08-46ac-bce5-e1f3e3f9795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2ec74a3d-0c8e-43fa-a8fc-ffaa0df7b636" xlink:href="sny-20250630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2ec74a3d-0c8e-43fa-a8fc-ffaa0df7b636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_d0c789a0-f852-4837-874a-d4508c92c484" xlink:href="sny-20250630.xsd#sny_OtherLiabilities1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_deea234f-7bb6-4f68-8bf6-4e18913c237c" xlink:to="loc_sny_OtherLiabilities1Member_d0c789a0-f852-4837-874a-d4508c92c484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_fe0f4835-f722-4cab-a892-52a340765f7c" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:href="sny-20250630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_9583e5ee-95f7-417a-a561-fad1a9834463" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_9583e5ee-95f7-417a-a561-fad1a9834463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_4d155d7e-5e8b-4774-9500-68d29a679a85" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_4d155d7e-5e8b-4774-9500-68d29a679a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_9213eafe-7d01-4da8-9d27-714f90cee3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_9213eafe-7d01-4da8-9d27-714f90cee3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_9b6a3a63-2089-4205-963c-eb139a6d8af3" xlink:href="sny-20250630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_9b6a3a63-2089-4205-963c-eb139a6d8af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_0905cc08-3764-45b4-94d4-c7c15ed4ca0b" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_0905cc08-3764-45b4-94d4-c7c15ed4ca0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_f7730561-b59b-4e7f-9cae-8381f4a30c2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_ad17fd87-b275-4fab-8f13-02880a17ae62" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_f7730561-b59b-4e7f-9cae-8381f4a30c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_0deed43d-dfb7-4382-b053-e2742fd79bc0" xlink:href="sny-20250630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_0deed43d-dfb7-4382-b053-e2742fd79bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3ddd0de1-5197-44fa-ac3f-a9f032a680e0" xlink:href="sny-20250630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_4d3e41f6-56c1-48c7-bea5-d13abc805cb9" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3ddd0de1-5197-44fa-ac3f-a9f032a680e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_2b6456f8-74a6-4703-8bb0-d0640998a9a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_2b6456f8-74a6-4703-8bb0-d0640998a9a8" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1f85af32-0e6b-4772-95ae-a5fcf791040e" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_647af1e0-e4c3-4135-ac66-5cecc6364b9a" xlink:href="sny-20250630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_647af1e0-e4c3-4135-ac66-5cecc6364b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_f44da72e-8604-4d07-b3ed-a11863d198d9" xlink:href="sny-20250630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_f44da72e-8604-4d07-b3ed-a11863d198d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_67ad9eaa-b3a9-4262-92d4-5123f413b356" xlink:href="sny-20250630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_67ad9eaa-b3a9-4262-92d4-5123f413b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2b6f04f6-2cd3-4040-aaef-88a1d0e15e68" xlink:href="sny-20250630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_054b2f12-1e3a-4453-bb69-d0d36bd0d0c9" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_2b6f04f6-2cd3-4040-aaef-88a1d0e15e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:to="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_a651d61d-88bd-4979-90f0-63d2e2a84620" xlink:to="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2a4600d3-6e9e-44a1-8012-221b1b444296" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_d06b6a87-70a6-46a7-b9f5-799ce6787e2c" xlink:to="loc_ifrs-full_TopOfRangeMember_2a4600d3-6e9e-44a1-8012-221b1b444296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:href="sny-20250630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_33cdba0a-7462-4e40-ac67-54e243221c8b" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_4881dd78-e39d-46e7-8345-01ed56294eee" xlink:href="sny-20250630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_4881dd78-e39d-46e7-8345-01ed56294eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod_e331b9e7-8640-452c-b134-1f4f90ee63bc" xlink:href="sny-20250630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PaymentToSaleOfBusinessPeriod_e331b9e7-8640-452c-b134-1f4f90ee63bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_8f84e2a6-0560-4605-badb-068db5657082" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_8f84e2a6-0560-4605-badb-068db5657082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_5b1fcfff-325e-4ac6-b553-b9d4f93d5f43" xlink:href="sny-20250630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_8a786fc7-bfca-4a7c-aa9d-206641c32754" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_5b1fcfff-325e-4ac6-b553-b9d4f93d5f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8ffbc847-b818-48e9-9968-bfa28b239db4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8ffbc847-b818-48e9-9968-bfa28b239db4" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_c02f721a-e795-4057-a294-b5382bf6d9b5" xlink:to="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_e5425e42-6ae9-4b49-97c7-b7b5fbcd0ba5" xlink:href="sny-20250630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_2a5a3460-9347-460d-82be-11e0cb151516" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_e5425e42-6ae9-4b49-97c7-b7b5fbcd0ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_e262ecdd-25b3-4d1a-8952-71d3001b21b3" xlink:to="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_c8d75df2-6054-4b88-b311-95d87ac1c389" xlink:href="sny-20250630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_9f740dc9-4c38-4fee-a644-adf2064282b2" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_c8d75df2-6054-4b88-b311-95d87ac1c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_27b4be91-eafb-4b03-bf42-0f38b8ee4484" xlink:to="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_270a7edd-e9ed-4d43-8868-febe9e33f330" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_270a7edd-e9ed-4d43-8868-febe9e33f330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_ae274a5f-0261-40a9-882f-fd110ac1145a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_08fa631f-77a4-4ba4-8dd0-4d55f7becabc" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_ae274a5f-0261-40a9-882f-fd110ac1145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_82a553b4-d260-477d-832d-97eff1031574" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_ffa2bb75-21bd-40d2-93ec-d7b4b5647c28" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_ifrs-full_NoncurrentProvisions_ffa2bb75-21bd-40d2-93ec-d7b4b5647c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_be484fd3-25da-43b1-b293-11ef12fa601e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_be484fd3-25da-43b1-b293-11ef12fa601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_cb34c28c-b05f-468c-bd52-5a842f3a5f5f" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_2a88d7bd-8ab0-4eec-954b-6f2d52dec565" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_cb34c28c-b05f-468c-bd52-5a842f3a5f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_baf71ed9-94c5-47cf-941e-4e058663bbf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_baf71ed9-94c5-47cf-941e-4e058663bbf2" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c5c3c6fa-3ca3-4d3f-97c4-cc4097eff855" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_a4739329-c537-4aef-8be8-ebe235dce064" xlink:href="sny-20250630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_a4739329-c537-4aef-8be8-ebe235dce064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_dc8f99ed-87d0-4d42-9665-9ea6545389e7" xlink:href="sny-20250630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_dc8f99ed-87d0-4d42-9665-9ea6545389e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_5544ba06-d98a-436d-b5e0-c7dc84f03c14" xlink:href="sny-20250630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_5544ba06-d98a-436d-b5e0-c7dc84f03c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_aa9e6953-f209-4dc7-9312-c7c05b227401" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_70ec542d-c911-45a0-bca3-4d34555935e1" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_aa9e6953-f209-4dc7-9312-c7c05b227401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ae4bb713-d935-42bf-89f2-53889f1db1c7" xlink:to="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_d00fc237-fd06-42a2-8aa3-80e2d75b245f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_9c811c83-e462-495b-9af5-94d22aa32608" xlink:to="loc_country_GB_d00fc237-fd06-42a2-8aa3-80e2d75b245f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_85d677da-4815-409e-acfc-3ce682d539dd" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_257c66a2-95fa-4074-8630-1a48a2d24f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_5f05b483-ba4e-420c-a971-638356ae262d" xlink:to="loc_ifrs-full_PlanAssetsMember_257c66a2-95fa-4074-8630-1a48a2d24f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:href="sny-20250630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_8fc0d09d-47c0-4f89-b4ae-a44c3214f0b8" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_7a08e355-1127-4498-96cd-207d0815f5ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_NoncurrentProvisions_7a08e355-1127-4498-96cd-207d0815f5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_fdd7de98-7eef-447a-92fa-0bf375010e95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_fdd7de98-7eef-447a-92fa-0bf375010e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_2b9f8e28-d6dd-413f-bb1a-d0f234ff261f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_2b9f8e28-d6dd-413f-bb1a-d0f234ff261f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_f18bda18-1a14-460c-a0d6-319ab9d18d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_f18bda18-1a14-460c-a0d6-319ab9d18d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_a276bef8-cce3-4c0a-9713-53bb3c66050b" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_a276bef8-cce3-4c0a-9713-53bb3c66050b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c3aac57e-d0d8-4eff-a546-0ca21d6ea547" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c3aac57e-d0d8-4eff-a546-0ca21d6ea547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_8e89532b-5bc4-482a-a86b-6dc10db93802" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_8e89532b-5bc4-482a-a86b-6dc10db93802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_f22bb33a-cb79-4f91-9aa1-b4a78667d71e" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_f22bb33a-cb79-4f91-9aa1-b4a78667d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_d6d16e13-c6c2-446d-a1b6-d625bacb67c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_27f509e5-64e6-4181-a046-a2da009b937d" xlink:to="loc_ifrs-full_NoncurrentProvisions_d6d16e13-c6c2-446d-a1b6-d625bacb67c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a2625f91-895a-4843-8b0e-bb3a0c00dec4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_6d8baf3d-f630-4ab0-93ea-9d73efff3725" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_a2625f91-895a-4843-8b0e-bb3a0c00dec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9628237d-3904-4b3f-8db6-778116eab7a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9628237d-3904-4b3f-8db6-778116eab7a7" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6dc16b6d-887c-4123-b170-79b7336f213e" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_c58fdeab-be91-4a72-a298-1cdc02a1e497" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_d026c44c-41af-431a-85c2-536df745917d" xlink:to="loc_ifrs-full_PlanAssetsMember_c58fdeab-be91-4a72-a298-1cdc02a1e497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b70cb389-984f-4c5b-9735-c89d836047f2" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1f4236b5-e353-4c1e-b42c-67ce96b49b6e" xlink:href="sny-20250630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain_a3b64d9e-9683-4d46-a554-8e534db84618" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1f4236b5-e353-4c1e-b42c-67ce96b49b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e6681574-2d82-4f27-90f0-ff1267a7f206" xlink:to="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_a3e98b5f-ee34-4933-a2cb-13dcdd1e3cab" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_country_GB_a3e98b5f-ee34-4933-a2cb-13dcdd1e3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember_2feb9a02-9038-48fa-9bc9-ba9373bcdc89" xlink:href="sny-20250630.xsd#sny_EUROZONEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_sny_EUROZONEMember_2feb9a02-9038-48fa-9bc9-ba9373bcdc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember_defd8801-2b4c-451b-93ed-7761576a711b" xlink:href="sny-20250630.xsd#sny_UKZONEMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_d80263bd-8130-45cf-aa1f-38835f775c24" xlink:to="loc_sny_UKZONEMember_defd8801-2b4c-451b-93ed-7761576a711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_aa3f26bf-64b1-4df1-8648-88e7d9e6c224" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_98240db7-cd87-4c7e-a0e9-bffd61f31cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_98240db7-cd87-4c7e-a0e9-bffd61f31cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_52721bab-68e6-4bf0-b5de-a492d15738b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_516c6196-944d-4a50-a325-8ce04a838b99" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_52721bab-68e6-4bf0-b5de-a492d15738b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d99427f6-93d9-4e8a-9b79-cc700ae6162e" xlink:to="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19e2e3d7-3f6c-407d-b580-b14580502be3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:to="loc_srt_MinimumMember_19e2e3d7-3f6c-407d-b580-b14580502be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f53ce24-2348-4330-80eb-6cba30fedd2c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4d4e83b-7366-468a-b268-5e5e18625bbc" xlink:to="loc_srt_MaximumMember_9f53ce24-2348-4330-80eb-6cba30fedd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_869f8942-418e-457e-b77b-1ff3bc2e3b2e" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_2b687137-fcbc-4e4f-ae8a-ef85a9005163" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_0aafef22-fba4-4fa0-b93e-45fc3ae43bf0" xlink:to="loc_sny_OpellaBusinessMember_2b687137-fcbc-4e4f-ae8a-ef85a9005163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_cd8e3a46-04bc-4b3d-af90-98a8795f79c6" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_55f1faab-1d59-4c00-ab0b-e16d2738c108" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_55f1faab-1d59-4c00-ab0b-e16d2738c108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_412b89bd-66fa-473c-baa9-62a7e507106d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_412b89bd-66fa-473c-baa9-62a7e507106d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_838333fb-2be2-4257-8899-6fd9b25767bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_838333fb-2be2-4257-8899-6fd9b25767bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cf28d978-e9a4-41ad-ae56-ff7b8c5fb2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_43337d1d-66b7-4d10-82aa-6f8321182084" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_cf28d978-e9a4-41ad-ae56-ff7b8c5fb2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OffBalanceSheetCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_3ad7bb28-36a8-4333-be2d-0b7b13d3181f" xlink:href="sny-20250630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_3ad7bb28-36a8-4333-be2d-0b7b13d3181f" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_ffb2341f-8a5d-46f2-aae1-7d41e779d758" xlink:to="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_1fed95a8-207b-46b6-a2e4-57379d5450bc" xlink:href="sny-20250630.xsd#sny_MazeTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_MazeTherapeuticsMember_1fed95a8-207b-46b6-a2e4-57379d5450bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_b7433fb3-f22c-4a73-bfa3-166eff1afc3e" xlink:href="sny-20250630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_ScribeTherapeuticsMember_b7433fb3-f22c-4a73-bfa3-166eff1afc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_9113c24d-0228-4de2-b113-8185cfccbf17" xlink:href="sny-20250630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_NovavaxMember_9113c24d-0228-4de2-b113-8185cfccbf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember_bf534ef9-64cf-467c-aed2-1471eb64e63a" xlink:href="sny-20250630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_42081e1f-7bf5-4e0a-b3b6-b020b6acce07" xlink:to="loc_sny_FulcrumTherapeuticsMember_bf534ef9-64cf-467c-aed2-1471eb64e63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_0fbdb542-fc39-4b44-8caa-64c34d8cfd5f" xlink:to="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5c70eef-e372-486c-8f1a-3245eb59b6a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_eb767c12-5f75-4bf6-88db-de6779caadba" xlink:to="loc_srt_MaximumMember_a5c70eef-e372-486c-8f1a-3245eb59b6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_22e84024-95e5-4fa1-8221-6ba67452134d" xlink:to="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88cf7844-5712-4055-99ce-c1d0d73851d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ffe113e9-2f8e-4d66-a93f-4380ee03c6ad" xlink:to="loc_srt_MinimumMember_88cf7844-5712-4055-99ce-c1d0d73851d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_383c98fb-835d-4502-ad29-87a2f78ce4e6" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_7ad703c9-db7c-4a6e-b4e7-d7d983c1954a" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_UpfrontPayments_7ad703c9-db7c-4a6e-b4e7-d7d983c1954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_aaf237e8-b994-4675-9e8e-46aa2ba56896" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_aaf237e8-b994-4675-9e8e-46aa2ba56896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_ed138965-e556-4e4c-bb71-ebd2676dc39f" xlink:href="sny-20250630.xsd#sny_LeaseTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseTerm_ed138965-e556-4e4c-bb71-ebd2676dc39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost_6903f1a4-2fc0-4c48-a17e-d800a8084832" xlink:href="sny-20250630.xsd#sny_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseCost_6903f1a4-2fc0-4c48-a17e-d800a8084832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_0778c731-6bbe-4160-80f3-1ad130c38a42" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseExtensionOptionsNumber_0778c731-6bbe-4160-80f3-1ad130c38a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_66d9aa6b-482e-44bf-9330-8e441437b2a8" xlink:href="sny-20250630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_LeaseExtensionOptionsTerm_66d9aa6b-482e-44bf-9330-8e441437b2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_56b0d610-f5cc-4232-a8a6-1823e6bb330b" xlink:href="sny-20250630.xsd#sny_TotalMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_TotalMilestonePayments_56b0d610-f5cc-4232-a8a6-1823e6bb330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_7c65632e-bbfc-4080-884c-205f719f4f03" xlink:href="sny-20250630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_7c65632e-bbfc-4080-884c-205f719f4f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments_36081b8a-b162-4562-ac84-a33bdc4f6993" xlink:href="sny-20250630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_AdditionalLaunchAndSalesMilestonePayments_36081b8a-b162-4562-ac84-a33bdc4f6993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments_20562a64-be0c-4701-8f66-0c9783f7e27b" xlink:href="sny-20250630.xsd#sny_ContingentMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_b58daa0c-8561-40ac-a780-4eae91bdd38d" xlink:to="loc_sny_ContingentMilestonePayments_20562a64-be0c-4701-8f66-0c9783f7e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#LitigationandArbitrationProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_7ef3c069-8325-4276-b18b-285454589266" xlink:href="sny-20250630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_7ef3c069-8325-4276-b18b-285454589266" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:href="sny-20250630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_a5eb8abf-fe82-4a1f-8fc5-5acd68ec3b67" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_5eb8eace-65fc-4a0f-b889-93dad9c35e4f" xlink:href="sny-20250630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_5eb8eace-65fc-4a0f-b889-93dad9c35e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_a406d85c-2f51-423e-94aa-84a6247980a9" xlink:href="sny-20250630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_a406d85c-2f51-423e-94aa-84a6247980a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember_df493d8a-5be7-4141-8b33-4a41f5029a24" xlink:href="sny-20250630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_ZantacProductLitigationInTheUSMember_df493d8a-5be7-4141-8b33-4a41f5029a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_0e044a07-519f-4bae-88c2-625354d2f563" xlink:href="sny-20250630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_bc8a52b9-de34-4f1d-9d4e-1b9715380a2d" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_0e044a07-519f-4bae-88c2-625354d2f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:href="sny-20250630.xsd#sny_DefendantAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:href="sny-20250630.xsd#sny_DefendantDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantAxis_9b2854e6-5d3d-4e0b-a75a-ad2414f76843" xlink:to="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_e90344f9-83c1-4039-bdd4-47363317b6dd" xlink:href="sny-20250630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_e90344f9-83c1-4039-bdd4-47363317b6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichSanofiAreDefendantMember_d210fb02-f7c6-4215-92cb-c118c534bbf2" xlink:href="sny-20250630.xsd#sny_ActionForWhichSanofiAreDefendantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantDomain_d257be04-6f08-4592-b299-4cf323c74c5d" xlink:to="loc_sny_ActionForWhichSanofiAreDefendantMember_d210fb02-f7c6-4215-92cb-c118c534bbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_2c5a1199-0771-40d4-a8a9-898b058d5975" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_3eb5258f-60be-4ac8-a311-830e40664fd4" xlink:href="sny-20250630.xsd#sny_ProductLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_7242db0f-0cee-4183-b910-1340baecfb24" xlink:to="loc_sny_ProductLiabilitiesMember_3eb5258f-60be-4ac8-a311-830e40664fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:href="sny-20250630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_101a1b68-cfe3-487e-81d5-3dece49c1852" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_baf0f865-ea20-41b7-9d98-f5d73ebf1726" xlink:href="sny-20250630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_baf0f865-ea20-41b7-9d98-f5d73ebf1726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_d052ba6d-db7b-471e-93e1-8b47c0629267" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_d052ba6d-db7b-471e-93e1-8b47c0629267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_5d402078-8d55-4333-baac-725255b2a5bf" xlink:href="sny-20250630.xsd#sny_NumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfPlaintiffs_5d402078-8d55-4333-baac-725255b2a5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_69797165-2ef2-43d3-b36d-b3ddf9257ffb" xlink:href="sny-20250630.xsd#sny_NumberOfCases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfCases_69797165-2ef2-43d3-b36d-b3ddf9257ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_fee46e64-c7f0-4ec2-80d6-2185d61b6454" xlink:href="sny-20250630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfClassActionLawsuits_fee46e64-c7f0-4ec2-80d6-2185d61b6454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals_528735e6-1d9b-49bc-afcf-05aad15e6f1e" xlink:href="sny-20250630.xsd#sny_NumberOfDismissals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_NumberOfDismissals_528735e6-1d9b-49bc-afcf-05aad15e6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_e842b336-5a93-4936-ba2f-c20d46a03f70" xlink:href="sny-20250630.xsd#sny_PenaltyFeeIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PenaltyFeeIncurred_e842b336-5a93-4936-ba2f-c20d46a03f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty_ed2c9a9a-d6ca-44d0-8b45-abded422c4ad" xlink:href="sny-20250630.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_ecfa1ed5-a7c8-478f-89d2-ea9774d6057b" xlink:to="loc_sny_PaymentOfDamagesClaimedByCounterparty_ed2c9a9a-d6ca-44d0-8b45-abded422c4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e4c92934-3855-4518-998f-0714d3a460d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e4c92934-3855-4518-998f-0714d3a460d8" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7a7ea5a3-91af-44c5-8d5a-82c7d3b77e91" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_9cc5a52d-d173-4251-bc21-04fc54c66984" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_2a0b0913-b0e7-4a8f-bc63-a72ea3302b89" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_9cc5a52d-d173-4251-bc21-04fc54c66984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_edd4c259-4f02-4537-a9ca-84536d56a915" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_70883ea3-00ca-41ee-985c-d670388c1e15" xlink:href="sny-20250630.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_3b289657-ab88-4e3a-9808-d9a021ff5baa" xlink:to="loc_sny_RegeneronMember_70883ea3-00ca-41ee-985c-d670388c1e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_62861c98-4c62-4476-9e0c-6a75c8901138" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_424ca006-97e1-4751-ab5c-6ce938eca652" xlink:href="sny-20250630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_b1c39103-5cd4-4f50-9b8c-3bcca8c41639" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_424ca006-97e1-4751-ab5c-6ce938eca652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_14786044-a477-4e1f-9e72-6d9f8bc11ac9" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6dcb766a-660e-471d-8813-86832133beb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6dcb766a-660e-471d-8813-86832133beb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_4084d8dc-643a-4686-b17a-44e5ef66f2f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_4084d8dc-643a-4686-b17a-44e5ef66f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_2c571ee5-5d47-43c1-9155-c6303344fb24" xlink:href="sny-20250630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_0d72d395-3b52-437f-b55a-9e7e0fd16553" xlink:to="loc_sny_GainsOnDivestmentOfProducts_2c571ee5-5d47-43c1-9155-c6303344fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fa97d4a6-3fc0-4ed6-8b23-ad4b75913b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fa97d4a6-3fc0-4ed6-8b23-ad4b75913b2c" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_a6d7b5d9-2ce8-428c-8072-b36eba79d68f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_a97f6bd5-34f7-4b34-a875-8d6d737d7510" xlink:href="sny-20250630.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_c6dbc081-80a0-4a4c-a7bb-5c41808ac68f" xlink:to="loc_sny_RegeneronMember_a97f6bd5-34f7-4b34-a875-8d6d737d7510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5852610f-154f-48fe-8d37-b8a067d9fa64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_cbe4f08c-ac37-4489-a7ab-461c9cda0fce" xlink:href="sny-20250630.xsd#sny_AntibodiesAllianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_AntibodiesAllianceMember_cbe4f08c-ac37-4489-a7ab-461c9cda0fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember_40e5727a-f956-4d41-9099-434c19af303f" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_ImmunoOncologyAllianceMember_40e5727a-f956-4d41-9099-434c19af303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_a9aaa410-da32-4238-af09-6304d3b8bd5d" xlink:href="sny-20250630.xsd#sny_OthersCounterpartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07adb79b-7549-44e7-9c10-ef8ff73f48a7" xlink:to="loc_sny_OthersCounterpartyMember_a9aaa410-da32-4238-af09-6304d3b8bd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_063ead51-014f-45c0-bb46-bed206a908db" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_4464bd8c-fb3f-4bb1-a2d5-259f71e9464e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7d87596c-b480-4694-9691-7abeb1005ac2" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_4464bd8c-fb3f-4bb1-a2d5-259f71e9464e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_89845904-a270-43fe-bd7a-d61c62b2a265" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_da902c6b-2b46-46a2-8599-cd4cb7d35e09" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_da902c6b-2b46-46a2-8599-cd4cb7d35e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_e5953076-28d9-4082-b43e-c9bbe1ac0f86" xlink:href="sny-20250630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_e5953076-28d9-4082-b43e-c9bbe1ac0f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_b73ec575-2bcc-4b00-9b20-242d3271273b" xlink:href="sny-20250630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_CommercializationRelatedExpensesMember_b73ec575-2bcc-4b00-9b20-242d3271273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_5b96da9f-0838-4c0b-afec-fb8c5998698e" xlink:href="sny-20250630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0e38736f-f26c-4f8b-add4-385cffbe0c81" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_5b96da9f-0838-4c0b-afec-fb8c5998698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:href="sny-20250630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_b9b5c6a1-dd3c-4453-b497-913692c1943a" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bc4ab099-f5da-4a8f-9f5a-094a6148aaa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bc4ab099-f5da-4a8f-9f5a-094a6148aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_2c02c52f-ab70-44dc-a78c-f44199f92cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_2c02c52f-ab70-44dc-a78c-f44199f92cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_34da184e-d87b-49bd-9027-6f7c3e3dd4f1" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_34da184e-d87b-49bd-9027-6f7c3e3dd4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_f26d6db6-5d87-41b4-8004-dfe52c6b3952" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1d640c48-f7d1-4a58-908a-5781e457784f" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_f26d6db6-5d87-41b4-8004-dfe52c6b3952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_dc7938ad-1424-4a69-bf24-17f484a91a26" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_dc7938ad-1424-4a69-bf24-17f484a91a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_3758f98a-166d-41be-947a-127128f33460" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_3758f98a-166d-41be-947a-127128f33460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_54c4a67e-0ec0-450f-9ea3-e079edb377a4" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_54c4a67e-0ec0-450f-9ea3-e079edb377a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_01e67f65-47b5-48f9-9720-4975a0f8fa51" xlink:href="sny-20250630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_01e67f65-47b5-48f9-9720-4975a0f8fa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_136c6d73-dc75-443d-8e71-fa21ac002ea1" xlink:href="sny-20250630.xsd#sny_OtherRestructuringCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_sny_OtherRestructuringCosts_136c6d73-dc75-443d-8e71-fa21ac002ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_1a869a65-bd49-41da-8e02-1f40d66f30c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b99a1da1-5fdc-4f89-b1dc-b344e61df8ee" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_1a869a65-bd49-41da-8e02-1f40d66f30c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#RestructuringCostsandSimilarItemsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4c21f321-4fba-4547-b4e8-82c1d8fcb978" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_8363062e-a2ec-4f92-82f5-da7bbfce54d3" xlink:href="sny-20250630.xsd#sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4c21f321-4fba-4547-b4e8-82c1d8fcb978" xlink:to="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_8363062e-a2ec-4f92-82f5-da7bbfce54d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#OtherGainsandLossesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fb9efa4e-50e8-439c-90fe-2d3d7dae61cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_cdddc8ac-c0bf-495e-af7b-b7603b1b6fef" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fb9efa4e-50e8-439c-90fe-2d3d7dae61cc" xlink:to="loc_sny_OtherGainsLossesAndLitigation_cdddc8ac-c0bf-495e-af7b-b7603b1b6fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_1bfad879-408f-4580-bb68-924b27ca3cc3" xlink:href="sny-20250630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fb9efa4e-50e8-439c-90fe-2d3d7dae61cc" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_1bfad879-408f-4580-bb68-924b27ca3cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1fa2199b-dce5-489a-9e00-935806de46b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1fa2199b-dce5-489a-9e00-935806de46b0" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:to="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_86f4db5a-32be-49f2-8982-9f5e7a9a5b5c" xlink:to="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_0e62f000-5ead-4756-b518-4ae96b089c8b" xlink:href="sny-20250630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsDomain_5d4363cb-8497-4b7d-9d54-941ae0743589" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_0e62f000-5ead-4756-b518-4ae96b089c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:href="sny-20250630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_f7da89b3-d199-4269-9cc5-63cdd1821de1" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_25e7c975-db1f-4487-82bd-258e02af560f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_25e7c975-db1f-4487-82bd-258e02af560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_f8315d93-0c73-4683-88a8-67237bd8c823" xlink:href="sny-20250630.xsd#sny_InterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_InterestIncome_f8315d93-0c73-4683-88a8-67237bd8c823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_9b7e4dc6-597d-4b25-aa69-ba21ead03386" xlink:href="sny-20250630.xsd#sny_CostOfDebtNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_CostOfDebtNet_9b7e4dc6-597d-4b25-aa69-ba21ead03386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_4c2af26e-8696-4cb3-91b6-bfb23642c666" xlink:href="sny-20250630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_4c2af26e-8696-4cb3-91b6-bfb23642c666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_75cc6624-63ef-4999-b37d-a7e07146cab2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_75cc6624-63ef-4999-b37d-a7e07146cab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_ddf494e1-d33b-4092-9ab8-061b79c6d0d6" xlink:href="sny-20250630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_ddf494e1-d33b-4092-9ab8-061b79c6d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_ad237eec-1052-43eb-b4e3-0edfbb16f2f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_ad237eec-1052-43eb-b4e3-0edfbb16f2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_1ed3d481-f004-4521-928d-2c5f088d79f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_1ed3d481-f004-4521-928d-2c5f088d79f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_eafbf6ed-57bb-41a5-8043-ba9b7ab0ba3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_eafbf6ed-57bb-41a5-8043-ba9b7ab0ba3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_57f58fdb-3165-49d8-a30b-da6b3245002e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceIncomeCost_57f58fdb-3165-49d8-a30b-da6b3245002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_7dfe43b0-199c-4f06-960b-ee8366e503e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceCosts_7dfe43b0-199c-4f06-960b-ee8366e503e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_2bb0aabf-ce0d-4415-908b-ee1625d2f0e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_ifrs-full_FinanceIncome_2bb0aabf-ce0d-4415-908b-ee1625d2f0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_f47cd94b-5f0c-42e1-8f1e-7164e49ef5aa" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_f47cd94b-5f0c-42e1-8f1e-7164e49ef5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_14c90498-ac85-480c-9d66-dc1c84f2ceb8" xlink:href="sny-20250630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_14c90498-ac85-480c-9d66-dc1c84f2ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_614116c7-2f09-4a27-b3c4-d66c30626c3c" xlink:href="sny-20250630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_614116c7-2f09-4a27-b3c4-d66c30626c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_2e271ec7-2678-4bed-a0bb-03ba5be67c90" xlink:href="sny-20250630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_e367829c-46bb-48c0-9be2-71a951d353a3" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_2e271ec7-2678-4bed-a0bb-03ba5be67c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0c3dc2d7-e2bf-4e78-97e2-423116b8daac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_5fd08df8-e7dd-45a9-8d97-77c367602a72" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0c3dc2d7-e2bf-4e78-97e2-423116b8daac" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_5fd08df8-e7dd-45a9-8d97-77c367602a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_2298b3ee-596e-4d31-a22f-d26ccb75f7ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0c3dc2d7-e2bf-4e78-97e2-423116b8daac" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_2298b3ee-596e-4d31-a22f-d26ccb75f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c294b174-5533-4ca0-a854-a2593391644d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0c3dc2d7-e2bf-4e78-97e2-423116b8daac" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c294b174-5533-4ca0-a854-a2593391644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_227c7396-d51f-43af-ae67-0b7cb0d2b302" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0c3dc2d7-e2bf-4e78-97e2-423116b8daac" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_227c7396-d51f-43af-ae67-0b7cb0d2b302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_1a6aa813-1a8f-4121-a0bc-f656b9b935c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_ifrs-full_ApplicableTaxRate_1a6aa813-1a8f-4121-a0bc-f656b9b935c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_adf255f9-0dbc-4659-bad0-a82ad53ece05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_adf255f9-0dbc-4659-bad0-a82ad53ece05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_6f015fff-0171-4476-8ea5-4f3c30edf6b6" xlink:href="sny-20250630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_6f015fff-0171-4476-8ea5-4f3c30edf6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_aa7d6202-6d2a-4b29-af05-b99d66b9087e" xlink:href="sny-20250630.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_aa7d6202-6d2a-4b29-af05-b99d66b9087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_f023f135-a9fd-4965-bd19-3a39064e20d6" xlink:href="sny-20250630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_f023f135-a9fd-4965-bd19-3a39064e20d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_f2143728-344e-4c9d-a3a9-7dc8ccb62808" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_f2143728-344e-4c9d-a3a9-7dc8ccb62808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_b9401906-fd64-492f-a6b9-fc83be46ed6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_b9401906-fd64-492f-a6b9-fc83be46ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_7aa699d7-0bbd-41e2-88a6-fbf7cb62b50c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_7aa699d7-0bbd-41e2-88a6-fbf7cb62b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_282b34c0-a59b-4465-bb84-096f408ed57c" xlink:href="sny-20250630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_79195715-a917-44bd-9376-e1106e4a066b" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_282b34c0-a59b-4465-bb84-096f408ed57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="simple" xlink:href="sny-20250630.xsd#IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_82e467aa-53bd-4f7a-985a-a9134a6f45a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_22f57f4c-cc86-465d-a835-c35768e32915" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_82e467aa-53bd-4f7a-985a-a9134a6f45a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_29d7731c-f435-4ccc-ad18-b9fda052b6c3" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_7958620f-26ec-4c63-b8c2-64a8e5df6f99" xlink:href="sny-20250630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bbc19059-2b7b-4676-91b2-f2bb222df79f" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_7958620f-26ec-4c63-b8c2-64a8e5df6f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_bece7f55-b58f-4190-9fd4-d23f8a9288c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_12e2af65-8ae3-43c9-b2f4-15e4eec111c3" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_bece7f55-b58f-4190-9fd4-d23f8a9288c2" xlink:to="loc_sny_NumberOfOperatingSegments_12e2af65-8ae3-43c9-b2f4-15e4eec111c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_607f0d8c-3fce-4a48-9f5c-de3e442e537b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_607f0d8c-3fce-4a48-9f5c-de3e442e537b" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c72cd64f-1d42-4a68-a0a7-bd7d5e1de795" xlink:to="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5a5ace78-160d-4c9c-b653-fec43a2a2a4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_srt_EuropeMember_5a5ace78-160d-4c9c-b653-fec43a2a2a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b5d65ff-a8a7-4c9c-8542-a664474f6a46" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_country_US_2b5d65ff-a8a7-4c9c-8542-a664474f6a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_1a6804fa-aa65-4d94-9dfb-c0483fd979f2" xlink:href="sny-20250630.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_e7ee42de-f215-4675-9f8a-6919869c99bb" xlink:to="loc_sny_OtherCountriesMember_1a6804fa-aa65-4d94-9dfb-c0483fd979f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_21168bad-03e9-471e-9f0b-14a693e20ce2" xlink:to="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_07f83897-d4f0-4256-a915-c2675ed2981f" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_BiopharmaSegmentMember_07f83897-d4f0-4256-a915-c2675ed2981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_9db28d1c-32c9-4d9f-b821-4cab471734cf" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_9db28d1c-32c9-4d9f-b821-4cab471734cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_55c99cf7-b298-4163-baf0-60e1db35a2c6" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_OpellaMember_55c99cf7-b298-4163-baf0-60e1db35a2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_0a7c5e17-42f0-4f4f-9c85-db2f9b2b5851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_0a7c5e17-42f0-4f4f-9c85-db2f9b2b5851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_41aff729-dfda-479a-86fd-6a9fd36c5e69" xlink:href="sny-20250630.xsd#sny_PharmaSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_PharmaSegmentMember_41aff729-dfda-479a-86fd-6a9fd36c5e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_040da8d5-cfa4-425c-86d6-28e9f95f069e" xlink:href="sny-20250630.xsd#sny_OtherProductsSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_06ee7efe-45f9-443f-8217-84561834225a" xlink:to="loc_sny_OtherProductsSegmentMember_040da8d5-cfa4-425c-86d6-28e9f95f069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_41618d0a-0a68-43a0-b4fa-2ef97eac8c5b" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:href="sny-20250630.xsd#sny_SpecialtyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_1162e6c6-64c4-4180-93a1-36bba7d6bb75" xlink:href="sny-20250630.xsd#sny_DupixentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_DupixentMember_1162e6c6-64c4-4180-93a1-36bba7d6bb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_79539d5c-4797-431e-adc4-23c960051b05" xlink:href="sny-20250630.xsd#sny_AubagioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_AubagioMember_79539d5c-4797-431e-adc4-23c960051b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_9379b038-f6ae-4592-aa90-2c9ae8cca51e" xlink:href="sny-20250630.xsd#sny_CerezymeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_CerezymeMember_9379b038-f6ae-4592-aa90-2c9ae8cca51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember_a4db36d3-305f-41c5-8dac-3c3c555efe5f" xlink:href="sny-20250630.xsd#sny_MyozymeLumizymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_MyozymeLumizymeMember_a4db36d3-305f-41c5-8dac-3c3c555efe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_23f98185-ec28-4d52-905f-66628fd7cc37" xlink:href="sny-20250630.xsd#sny_FabrazymeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_FabrazymeMember_23f98185-ec28-4d52-905f-66628fd7cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_816b6f55-ad9b-41b6-bdf7-bac957530537" xlink:href="sny-20250630.xsd#sny_JevtanaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_JevtanaMember_816b6f55-ad9b-41b6-bdf7-bac957530537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_5ba09927-6a3e-409d-898f-ddf02730e13b" xlink:href="sny-20250630.xsd#sny_AlprolixMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_AlprolixMember_5ba09927-6a3e-409d-898f-ddf02730e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_53205611-7802-4681-a47d-3bcbdb435a44" xlink:href="sny-20250630.xsd#sny_EloctateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_9c324eb2-2a7e-4aa2-8787-1c780cdc84b8" xlink:to="loc_sny_EloctateMember_53205611-7802-4681-a47d-3bcbdb435a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:href="sny-20250630.xsd#sny_GeneralMedicinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:href="sny-20250630.xsd#sny_CoreAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_87f23119-aa15-4e4a-a1ba-b4ac7dc4e415" xlink:href="sny-20250630.xsd#sny_LovenoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_LovenoxMember_87f23119-aa15-4e4a-a1ba-b4ac7dc4e415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_e9656ae7-ccaa-4566-9717-7eb35cb7dff9" xlink:href="sny-20250630.xsd#sny_ToujeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_ToujeoMember_e9656ae7-ccaa-4566-9717-7eb35cb7dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_6d016c99-51d2-443e-84d0-c5a32fb238d7" xlink:href="sny-20250630.xsd#sny_PlavixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_e2e4e485-ccbc-4097-9276-405ebf145783" xlink:to="loc_sny_PlavixMember_6d016c99-51d2-443e-84d0-c5a32fb238d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:href="sny-20250630.xsd#sny_NonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_52e2e985-c102-444d-a80c-e2929f3d5287" xlink:href="sny-20250630.xsd#sny_LantusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:to="loc_sny_LantusMember_52e2e985-c102-444d-a80c-e2929f3d5287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_2955c8d2-8672-4d07-bb74-ea81d9f34a9f" xlink:href="sny-20250630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_8759ef0c-3657-4656-8ca4-028ba8850bdc" xlink:to="loc_sny_OtherNonCoreAssetsMember_2955c8d2-8672-4d07-bb74-ea81d9f34a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_46c738d0-030e-421c-938b-cb1f5a271e9c" xlink:href="sny-20250630.xsd#sny_IndustrialSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_b4c57266-1dce-4d9a-af93-c8f52f4bc403" xlink:to="loc_sny_IndustrialSalesMember_46c738d0-030e-421c-938b-cb1f5a271e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:href="sny-20250630.xsd#sny_VaccinesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_27ed296b-1166-4776-a8f6-5d5bd71772e8" xlink:href="sny-20250630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_27ed296b-1166-4776-a8f6-5d5bd71772e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_8b742c9e-2cec-4f9a-86ad-34fe5a01e7e6" xlink:href="sny-20250630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_eac974ed-2d2f-4250-af65-01d1b165bb82" xlink:to="loc_sny_InfluenzaVaccinesMember_8b742c9e-2cec-4f9a-86ad-34fe5a01e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_87b1ac2a-1cbb-4d8d-8867-238147e2163b" xlink:href="sny-20250630.xsd#sny_AllergyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_AllergyMember_87b1ac2a-1cbb-4d8d-8867-238147e2163b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_716c68cd-c954-4af9-9c97-72ff081442a8" xlink:href="sny-20250630.xsd#sny_PainCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_PainCareMember_716c68cd-c954-4af9-9c97-72ff081442a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_3656177f-c501-4430-9f51-d1d6d08f3629" xlink:href="sny-20250630.xsd#sny_DigestiveWellnessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_DigestiveWellnessMember_3656177f-c501-4430-9f51-d1d6d08f3629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember_3711a0e5-efdc-492e-a0ac-bc22343f70c1" xlink:href="sny-20250630.xsd#sny_NexviazymeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_NexviazymeMember_3711a0e5-efdc-492e-a0ac-bc22343f70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_79375ef8-268c-4d3e-9217-3b62044c9ab0" xlink:href="sny-20250630.xsd#sny_SarclisaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SarclisaMember_79375ef8-268c-4d3e-9217-3b62044c9ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_fc5a0fc8-64f4-489c-aa74-ea5187eef694" xlink:href="sny-20250630.xsd#sny_AltuviiioMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_AltuviiioMember_fc5a0fc8-64f4-489c-aa74-ea5187eef694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_3a3f5ded-6d04-4a23-8e76-28e75a0526f0" xlink:href="sny-20250630.xsd#sny_RezurockMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RezurockMember_3a3f5ded-6d04-4a23-8e76-28e75a0526f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember_c241358e-a39b-4ff0-bb05-325450de7005" xlink:href="sny-20250630.xsd#sny_CabliviMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_CabliviMember_c241358e-a39b-4ff0-bb05-325450de7005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember_8e5cbe43-4370-4efc-bfe5-71c78c337124" xlink:href="sny-20250630.xsd#sny_XenpozymeMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_XenpozymeMember_8e5cbe43-4370-4efc-bfe5-71c78c337124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember_198aa125-879b-4b12-a9cb-a68a930d922e" xlink:href="sny-20250630.xsd#sny_EnjaymoMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_EnjaymoMember_198aa125-879b-4b12-a9cb-a68a930d922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember_84035323-a9fb-4ffe-992d-54939cc72041" xlink:href="sny-20250630.xsd#sny_TzieldMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_TzieldMember_84035323-a9fb-4ffe-992d-54939cc72041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember_3adde4bc-915f-4bc7-b0f5-0b01be6d2b85" xlink:href="sny-20250630.xsd#sny_RSVVaccinesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RSVVaccinesMember_3adde4bc-915f-4bc7-b0f5-0b01be6d2b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember_a92b7636-9034-45ff-a9a1-3ede8221f610" xlink:href="sny-20250630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_MeningitisTravelAndEndemicVaccinesMember_a92b7636-9034-45ff-a9a1-3ede8221f610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember_51d27e27-f275-4f07-aec8-ef44d2d953e4" xlink:href="sny-20250630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_SeasonalSymptomsAndPainReliefMember_51d27e27-f275-4f07-aec8-ef44d2d953e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember_f53f1dd2-0b1c-4987-b600-2e6f4c4379d0" xlink:href="sny-20250630.xsd#sny_WellnessBrandsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_WellnessBrandsMember_f53f1dd2-0b1c-4987-b600-2e6f4c4379d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember_7be451eb-1c77-41c8-816c-881f85109eb7" xlink:href="sny-20250630.xsd#sny_OthersMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_OthersMember_7be451eb-1c77-41c8-816c-881f85109eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RareDiseasesMember_c833114a-a226-460c-bfb2-51c9c3692a75" xlink:href="sny-20250630.xsd#sny_RareDiseasesMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_42f4b042-4968-4ac8-ad5b-3b375ad7b904" xlink:to="loc_sny_RareDiseasesMember_c833114a-a226-460c-bfb2-51c9c3692a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50587ddd-95a6-49f5-a2ad-a23ccf55790e" xlink:to="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_3228186f-f05e-4e8d-a445-fd1ba38de43e" xlink:href="sny-20250630.xsd#sny_PharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_PharmaSegmentMember_3228186f-f05e-4e8d-a445-fd1ba38de43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember_d440d021-c5a8-4098-ab75-71e7f132487d" xlink:href="sny-20250630.xsd#sny_PharmaLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_PharmaLaunchesMember_d440d021-c5a8-4098-ab75-71e7f132487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_b761ea7a-c248-4c7e-9613-35ea42dbf3a8" xlink:href="sny-20250630.xsd#sny_OtherProductsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6263b60d-7f2f-41da-a05a-dfef21abf3a6" xlink:to="loc_sny_OtherProductsSegmentMember_b761ea7a-c248-4c7e-9613-35ea42dbf3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_bc134f42-7a9c-40e4-b823-af66d95b1a9d" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_fe8dae06-eb58-4659-818d-81bbc717956d" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_e4b156eb-8338-47c2-b3c0-36ed109837ae" xlink:to="loc_sny_OpellaBusinessMember_fe8dae06-eb58-4659-818d-81bbc717956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_60375667-402d-4388-8c6e-0b4a19ac2f4d" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_854c42fb-b4b1-43f3-8a56-3dc7919fb44b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_854c42fb-b4b1-43f3-8a56-3dc7919fb44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_d3573e56-ce61-413d-8e67-640e9f46210f" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_NumberOfOperatingSegments_d3573e56-ce61-413d-8e67-640e9f46210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_272d524d-664c-4fd6-b4ff-e0647f10d7c3" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_BusinessOperatingIncome_272d524d-664c-4fd6-b4ff-e0647f10d7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_0f05b683-d43d-4f1a-9923-75283db5b6f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_OtherRevenue_0f05b683-d43d-4f1a-9923-75283db5b6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_32f07cdf-0e22-4c85-935b-124b39768152" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_CostOfSales_32f07cdf-0e22-4c85-935b-124b39768152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_3d426484-deee-402a-a745-c17f6f4faaf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_3d426484-deee-402a-a745-c17f6f4faaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18df7870-bb06-4d2a-ad15-9d505cd04dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_18df7870-bb06-4d2a-ad15-9d505cd04dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_d41d74fb-4b37-4155-b255-a368a24f35aa" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_d41d74fb-4b37-4155-b255-a368a24f35aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_0d81a579-0bfb-4293-9840-fb623a06d2d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_0d81a579-0bfb-4293-9840-fb623a06d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_70d61ee3-ccb3-486d-bebe-d0e8985d7599" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_70d61ee3-ccb3-486d-bebe-d0e8985d7599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_58918bfb-47f8-4f80-955a-e0c66fe726f4" xlink:href="sny-20250630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_e2b5b0e1-e5ec-4ca4-a4dd-4a33d88b35e5" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_58918bfb-47f8-4f80-955a-e0c66fe726f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_a6bf3e3c-f108-4fe5-a4f1-24d4e75bdace" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_a6bf3e3c-f108-4fe5-a4f1-24d4e75bdace" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:to="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_d22b479d-0dd6-4d6c-84c3-a466e704b35a" xlink:to="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_b7f170e8-96f3-4092-8b7c-79502297d406" xlink:to="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_62c03c0e-9b25-460f-bea5-2bd4625fe400" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_sny_BiopharmaSegmentMember_62c03c0e-9b25-460f-bea5-2bd4625fe400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_77526cba-0042-4fe5-9927-5629e2db8be7" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_77526cba-0042-4fe5-9927-5629e2db8be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_be879115-904b-46da-acd1-dd54ac1cc48f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_425a451c-40f4-4b97-825d-c30c3ff1072f" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_be879115-904b-46da-acd1-dd54ac1cc48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_e5f47608-a8d5-423b-9e5a-f82fe3a482a8" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_647613d2-e499-46d6-896b-da7894c02c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_647613d2-e499-46d6-896b-da7894c02c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_fa93ef87-dcc8-49a6-bd54-f7622f9d0a67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_OtherRevenue_fa93ef87-dcc8-49a6-bd54-f7622f9d0a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_bbd65ccd-ae7c-4528-8036-aabd2cffca08" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_CostOfSales_bbd65ccd-ae7c-4528-8036-aabd2cffca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_49766e3b-b065-469e-994b-1736f265a090" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_49766e3b-b065-469e-994b-1736f265a090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_afa80cc8-e638-45ee-9902-08a7db8da7c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_afa80cc8-e638-45ee-9902-08a7db8da7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_545c7e69-6215-4ce5-a566-a5783a96e221" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_545c7e69-6215-4ce5-a566-a5783a96e221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d2dca40e-8ccc-47e5-b213-5ba0f455c353" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d2dca40e-8ccc-47e5-b213-5ba0f455c353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_7c88e9b6-9590-42c6-b793-dcfc651b9aec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_7c88e9b6-9590-42c6-b793-dcfc651b9aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_822ffc56-1b60-4b96-85a5-c6e26665665a" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_BusinessOperatingIncome_822ffc56-1b60-4b96-85a5-c6e26665665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_cc720e3f-65b6-41b7-b4b7-4451d0735928" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c3403c75-94f7-4fe6-a6f4-176b815b80d0" xlink:to="loc_sny_NumberOfOperatingSegments_cc720e3f-65b6-41b7-b4b7-4451d0735928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_afef0b67-db97-4499-9584-ccdd9e756a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_afef0b67-db97-4499-9584-ccdd9e756a38" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_bad9feb2-bf9a-4fd5-be5b-db923dc64c62" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_db2f4225-705c-4901-8430-34e2762f640b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:to="loc_ifrs-full_OperatingSegmentsMember_db2f4225-705c-4901-8430-34e2762f640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_d7c63ec0-02c9-4c0f-803b-deda96580bad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_e51e2f4c-f01b-46e4-8e23-461fbf117b22" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_d7c63ec0-02c9-4c0f-803b-deda96580bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_6cf59390-5ea3-4658-966f-ac6ca6beca9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_65510751-3108-49be-aa08-043fa8d9340e" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_6cf59390-5ea3-4658-966f-ac6ca6beca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_67ea1185-e2bb-4c60-b372-106280f366bf" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_695070fe-4fd6-4169-ad50-65874de39364" xlink:href="sny-20250630.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:to="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_695070fe-4fd6-4169-ad50-65874de39364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ClinicalStudyMember_1b5c116b-2308-46a8-ac98-656873e7504c" xlink:href="sny-20250630.xsd#sny_ClinicalStudyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_8c1661c9-8a32-4606-9634-3e49e5b0e301" xlink:to="loc_sny_ClinicalStudyMember_1b5c116b-2308-46a8-ac98-656873e7504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_fa2ba5b6-3d81-4277-b17d-6496d4691b95" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_145a28a9-2fc0-40bb-bb5c-4803a3f28330" xlink:href="sny-20250630.xsd#sny_EloctateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:to="loc_sny_EloctateMember_145a28a9-2fc0-40bb-bb5c-4803a3f28330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member_4cee04ec-39e5-4bb2-903c-e099bc73b5c4" xlink:href="sny-20250630.xsd#sny_SAR44425Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_e40718d8-7d47-4c1c-b421-7c1e6b7e6de3" xlink:to="loc_sny_SAR44425Member_4cee04ec-39e5-4bb2-903c-e099bc73b5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:href="sny-20250630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_cfdcc1e1-5a5a-40d9-a0da-cbd25a1e2228" xlink:to="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_9fc2d2f4-8118-4c4c-a619-479946e55817" xlink:href="sny-20250630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_48328cf6-7263-4cee-84a0-71669e1a6628" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_9fc2d2f4-8118-4c4c-a619-479946e55817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_4bfdee8d-08d7-4b94-a5df-15672a904f11" xlink:to="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_8fae4827-66d7-4011-a06c-66ea1ab439e1" xlink:href="sny-20250630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_b9dfc9b1-6cc4-40fa-8612-0f40b6975d4f" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_8fae4827-66d7-4011-a06c-66ea1ab439e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_266f636a-315e-4d5f-a52a-15889d23e372" xlink:to="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_f33cbed1-ad5d-4d9b-a63f-d3c88d8fd594" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:to="loc_sny_BiopharmaSegmentMember_f33cbed1-ad5d-4d9b-a63f-d3c88d8fd594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_67131942-e1fa-440f-99c3-61683d504539" xlink:href="sny-20250630.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691ca295-73cb-4f91-b4f9-460ff5f419e9" xlink:to="loc_sny_MarketedProductsMember_67131942-e1fa-440f-99c3-61683d504539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_58430b16-948c-4f37-9c85-615654ff9ff7" xlink:to="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_eb71c8f2-e244-4be3-bef4-04361aeaf7ba" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_8aa0bdba-6a14-485f-8f31-a331eb3770cc" xlink:to="loc_sny_BiopharmaSegmentMember_eb71c8f2-e244-4be3-bef4-04361aeaf7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_31baca04-3128-42bf-bf4f-8b26d5ee8dfe" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_46f7d420-b61b-44f4-918c-f6bfac9b808f" xlink:href="sny-20250630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_BusinessOperatingIncome_46f7d420-b61b-44f4-918c-f6bfac9b808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_e3d48deb-98fb-4952-a17f-fa7af4b9c491" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_e3d48deb-98fb-4952-a17f-fa7af4b9c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f72380d2-3169-4b60-b04b-19bc1b40e074" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f72380d2-3169-4b60-b04b-19bc1b40e074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b16d569d-e13f-48cb-8c95-3b2e53f18fb2" xlink:href="sny-20250630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b16d569d-e13f-48cb-8c95-3b2e53f18fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_6795c7b0-80f8-4ff8-bde0-b8ef77c51ec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_6795c7b0-80f8-4ff8-bde0-b8ef77c51ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_8b8c4b19-aa6e-45ef-92da-9f1ca94a2d66" xlink:href="sny-20250630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_8b8c4b19-aa6e-45ef-92da-9f1ca94a2d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_1881d459-0fb5-4b38-90ef-c2bebd837505" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_1881d459-0fb5-4b38-90ef-c2bebd837505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_8a942302-2c99-4d12-8479-5d0a8a2de094" xlink:href="sny-20250630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_OtherGainsLossesAndLitigation_8a942302-2c99-4d12-8479-5d0a8a2de094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_b15fca1d-510e-4cc9-85e9-6009719f3c53" xlink:href="sny-20250630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_IncomeResultingFromOutLicensing_b15fca1d-510e-4cc9-85e9-6009719f3c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7cbd38a6-d1b1-43c2-a0ad-b1bd8aec90f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_7cbd38a6-d1b1-43c2-a0ad-b1bd8aec90f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_4c494e03-d413-499c-a562-12e0353a370a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_FinanceCosts_4c494e03-d413-499c-a562-12e0353a370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_4a4feec4-275b-4b3e-84cb-919619e2ab7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_FinanceIncome_4a4feec4-275b-4b3e-84cb-919619e2ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_89459853-5125-4ebd-b73c-557c2c7a75e6" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_89459853-5125-4ebd-b73c-557c2c7a75e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_56204cf5-3345-4ba1-a730-1e10ac2a60eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_56204cf5-3345-4ba1-a730-1e10ac2a60eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_695b26ad-29f9-49f0-be5a-8bfe154f2e9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_695b26ad-29f9-49f0-be5a-8bfe154f2e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e87eba1-3478-4574-8cec-d8d740786c7c" xlink:href="sny-20250630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e87eba1-3478-4574-8cec-d8d740786c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3e9b6586-a871-4fa2-a7e0-4afdca04d988" xlink:href="sny-20250630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3e9b6586-a871-4fa2-a7e0-4afdca04d988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss_be8db8fb-3445-4360-bd3d-821dd8aa8b39" xlink:href="sny-20250630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_NetReversalOfImpairmentLoss_be8db8fb-3445-4360-bd3d-821dd8aa8b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_a343a840-f645-4e65-bde9-4c7ded505769" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_a343a840-f645-4e65-bde9-4c7ded505769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_7e331701-4e59-4a1f-9b58-8d9753e286a9" xlink:href="sny-20250630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_af05f0df-eee6-4cb8-a27b-fb4fa36ba40e" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_7e331701-4e59-4a1f-9b58-8d9753e286a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_38cf8aee-1d78-4a1f-842f-5a177b560fb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_38cf8aee-1d78-4a1f-842f-5a177b560fb3" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:to="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_15d6dbae-d112-48e4-b5dc-62da5ac36bf1" xlink:to="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:to="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_aea8b6a4-4d15-4b3c-bbcf-0cc9c3f4f836" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:to="loc_sny_BiopharmaSegmentMember_aea8b6a4-4d15-4b3c-bbcf-0cc9c3f4f836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_29f8fd13-2202-488c-a624-30aa34eb2225" xlink:href="sny-20250630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_2402da22-cd3c-420e-b44f-49fe95e1c0ec" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_29f8fd13-2202-488c-a624-30aa34eb2225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_a71b4246-7d56-4c44-9265-731e4d0c2fe4" xlink:href="sny-20250630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_b960f6f1-dd13-4bdd-a2d3-f4c35a8c6c73" xlink:to="loc_sny_OpellaMember_a71b4246-7d56-4c44-9265-731e4d0c2fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_95396dcf-850e-46b6-8191-6a9a2c330de7" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_677014ac-3e57-46f7-beb5-f2f506c9e3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_677014ac-3e57-46f7-beb5-f2f506c9e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2db79bf2-cd3d-4236-a35e-bef58b19f91b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2db79bf2-cd3d-4236-a35e-bef58b19f91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_a61f313e-3251-4a43-a523-eea8fe989380" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_a61f313e-3251-4a43-a523-eea8fe989380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_9c366240-857b-4f4f-b69a-92f3f259ba3a" xlink:href="sny-20250630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_ed3580c0-5e9a-455d-8425-d7c048b5116f" xlink:to="loc_sny_NumberOfOperatingSegments_9c366240-857b-4f4f-b69a-92f3f259ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0c8394af-61df-4ca8-abd4-571323e4664c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0c8394af-61df-4ca8-abd4-571323e4664c" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:to="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_f950688d-06f3-46b8-b483-af4999cfa23e" xlink:to="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:href="sny-20250630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_3db07605-4e29-4a98-9707-a3d6201e9188" xlink:to="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5a077d53-cbd3-4b82-ab26-c0f9738cec18" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EuropeMember_7315ff03-7a99-4bc9-92a8-28a0046af1f4" xlink:to="loc_country_FR_5a077d53-cbd3-4b82-ab26-c0f9738cec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1d090074-94a7-4a9b-8262-0cadb00b2a42" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_country_US_1d090074-94a7-4a9b-8262-0cadb00b2a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_07c9d782-899b-46c9-961b-54d71dce08f0" xlink:href="sny-20250630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_07c9d782-899b-46c9-961b-54d71dce08f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_cae81c9c-5683-417b-a5a6-281398b37649" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_61cc37af-011d-4f13-b7eb-b097233fbcee" xlink:to="loc_country_CN_cae81c9c-5683-417b-a5a6-281398b37649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_86db7099-4a3f-4a5b-9938-b2f2c083d90e" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_89086b36-8226-4c2f-8cd9-963b265c6401" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_89086b36-8226-4c2f-8cd9-963b265c6401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_7c61867c-caea-4133-8ccf-42ad0f4988d9" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_f24af244-df00-4006-9b12-d3758c65e0b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_f24af244-df00-4006-9b12-d3758c65e0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_2f2b63a2-c71a-4564-a600-366d21fdd701" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_Goodwill_2f2b63a2-c71a-4564-a600-366d21fdd701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a9ffdb81-b5fe-499c-b1bd-15a53cc9af39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_89801a82-6372-4ead-ab87-1f6110d04474" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a9ffdb81-b5fe-499c-b1bd-15a53cc9af39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#SegmentInformationPrincipalCustomersandCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_5220f5b5-5fe0-4a89-935a-7e59db4b28ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_5220f5b5-5fe0-4a89-935a-7e59db4b28ad" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:to="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_a3109e2e-5ddb-4bdb-8287-a680bad6c731" xlink:to="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_a1c05f89-74b6-4cdc-8978-7c7bdeb309cf" xlink:href="sny-20250630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_a1c05f89-74b6-4cdc-8978-7c7bdeb309cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_7ce80c21-594f-4695-ba2a-a97bfd09dabf" xlink:href="sny-20250630.xsd#sny_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerOneMember_7ce80c21-594f-4695-ba2a-a97bfd09dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_8e894250-20e8-439d-abf4-515de4a722dd" xlink:href="sny-20250630.xsd#sny_CustomerTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerTwoMember_8e894250-20e8-439d-abf4-515de4a722dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_d7ac1dc2-7879-434a-ace1-651ab881e935" xlink:href="sny-20250630.xsd#sny_CustomerThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_1e67f160-5826-4a40-ba9f-9f039cbcaace" xlink:to="loc_sny_CustomerThreeMember_d7ac1dc2-7879-434a-ace1-651ab881e935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:href="sny-20250630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_87913463-a8d7-47c8-9a10-63b80c87f8d3" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_5e365db9-3fee-44ba-b127-18c16556f6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_2dd3648c-ada9-4512-8788-abfabe39726a" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_5e365db9-3fee-44ba-b127-18c16556f6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="simple" xlink:href="sny-20250630.xsd#EventsSubsequenttoJune302023Details"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_e334a9df-7ae2-439d-8582-af636502e900" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_e334a9df-7ae2-439d-8582-af636502e900" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_028df542-208e-4221-a39a-5eae89c13bb3" xlink:to="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember_fd19df45-7352-491e-9edc-2944b28a2b23" xlink:href="sny-20250630.xsd#sny_RecludixPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_938614d1-7dc9-4f97-bc44-2b20dcc5a2d7" xlink:to="loc_sny_RecludixPharmaMember_fd19df45-7352-491e-9edc-2944b28a2b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_48c0e34c-0acd-4659-9e70-1047fa2e808d" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_63314d9f-a4b0-42c5-97a3-0d4a16f86a4a" xlink:href="sny-20250630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:to="loc_sny_MajorCollaborationAgreementMember_63314d9f-a4b0-42c5-97a3-0d4a16f86a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_54aa9325-a62f-42a0-8c6d-bb854a818d34" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_01a62d1c-b566-441a-a838-4e7da3595e39" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_54aa9325-a62f-42a0-8c6d-bb854a818d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_bb894689-c058-46eb-8279-7e8a5b4f809e" xlink:to="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa33ec38-9217-48dc-9bf1-3cb2c4cd30cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_6e861398-cf48-4f01-9a9d-d56ce30b3de7" xlink:to="loc_srt_MaximumMember_fa33ec38-9217-48dc-9bf1-3cb2c4cd30cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_827e13f2-2ccd-4b54-be55-6d200fbc9b68" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_2058529f-8b44-488d-809e-6c19104a0c30" xlink:href="sny-20250630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_c1b0f13d-d42b-4ab8-b86e-e3828c9810e4" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_2058529f-8b44-488d-809e-6c19104a0c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionAxis_88981cf1-cf11-4eb8-98d1-2c75fcd34e1a" xlink:to="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_ec6bd059-96a4-42c4-b77f-0ce681ffc09c" xlink:href="sny-20250630.xsd#sny_AssetsAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:to="loc_sny_AssetsAcquisitionMember_ec6bd059-96a4-42c4-b77f-0ce681ffc09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VicebioLtdMember_7e124efa-e319-4a28-90ae-352048a69afa" xlink:href="sny-20250630.xsd#sny_VicebioLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_461c8adb-3395-463b-b827-45a7188e123a" xlink:to="loc_sny_VicebioLtdMember_7e124efa-e319-4a28-90ae-352048a69afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_92270b6e-06a3-41e1-ac4e-ad23d3fb7eea" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_48df1bcb-fa41-4a4c-97aa-8a074e0dae42" xlink:href="sny-20250630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_UpfrontPayments_48df1bcb-fa41-4a4c-97aa-8a074e0dae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_8e9bb0e9-2322-4923-ac95-84752a6d8754" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_8e9bb0e9-2322-4923-ac95-84752a6d8754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_e2ffd877-9b6e-4a9d-99fd-612382ab0fda" xlink:href="sny-20250630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_BusinessCombinationPurchasePrice_e2ffd877-9b6e-4a9d-99fd-612382ab0fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialFuturePayments_9630a929-f0bb-4222-9e9e-2965c3d064e0" xlink:href="sny-20250630.xsd#sny_PotentialFuturePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_PotentialFuturePayments_9630a929-f0bb-4222-9e9e-2965c3d064e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_89b77b6d-265d-49a6-825f-d3e8507a15a8" xlink:href="sny-20250630.xsd#sny_TotalMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3669c742-2d06-445b-ae03-1755927672a9" xlink:to="loc_sny_TotalMilestonePayments_89b77b6d-265d-49a6-825f-d3e8507a15a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#RevenuefromcontractswithcustomersDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_da3e5d1e-cc1d-4302-a3c4-d6a48f412840" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_da3e5d1e-cc1d-4302-a3c4-d6a48f412840" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_e27986b7-9437-412e-9537-b5a1bd08c3b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_5b36a411-c864-49f7-8ec2-07828ac5283e" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_e27986b7-9437-412e-9537-b5a1bd08c3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_40bad8ed-27b7-474c-8af2-8f32fc10c645" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ed409700-baec-4e46-b4f5-b300f4eb59fd" xlink:to="loc_ifrs-full_GeographicalAreasDomain_40bad8ed-27b7-474c-8af2-8f32fc10c645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MarketsOfCustomersDomain_94fee2c8-000b-4f8c-a000-b4201f4943e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MarketsOfCustomersDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MarketsOfCustomersAxis_66436ff1-8138-459c-ae69-d487b04bce5d" xlink:to="loc_ifrs-full_MarketsOfCustomersDomain_94fee2c8-000b-4f8c-a000-b4201f4943e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfCustomersDomain_2cc7f093-24e5-4fcc-a3d8-2540b67bf8f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfCustomersDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfCustomersAxis_d381b48d-f9cf-408d-9606-1dbc5bb62d3c" xlink:to="loc_ifrs-full_TypesOfCustomersDomain_2cc7f093-24e5-4fcc-a3d8-2540b67bf8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2c643182-57d7-4c11-97f9-32870ba5767d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_b2b4cac2-e3d4-4456-962d-417f6f0d7085" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2c643182-57d7-4c11-97f9-32870ba5767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractDurationDomain_fbba6025-da68-46cc-8ba8-bfdc321018f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractDurationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContractDurationAxis_b81ce89e-7a52-4bf8-8449-78c377bec07e" xlink:to="loc_ifrs-full_ContractDurationDomain_fbba6025-da68-46cc-8ba8-bfdc321018f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8780de7d-3b6c-417e-a7a4-71c87aa05059" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_898551b8-0ceb-49e6-a260-30f2a56b3406" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8780de7d-3b6c-417e-a7a4-71c87aa05059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsDomain_caf245f6-9c44-460c-960e-36690935a03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesChannelsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SalesChannelsAxis_400f7718-6215-42bc-92c5-4b399b1bdaf7" xlink:to="loc_ifrs-full_SalesChannelsDomain_caf245f6-9c44-460c-960e-36690935a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_063387e1-3ba3-40f9-bd1c-7909554ee431" xlink:to="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_485c5b24-c9a6-4051-927d-8e53df69dcc5" xlink:href="sny-20250630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:to="loc_sny_BiopharmaSegmentMember_485c5b24-c9a6-4051-927d-8e53df69dcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_c185f884-824e-4cc6-b2ed-fa8802082110" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_e6fb03ab-5d79-4ec6-b9b7-147da60fa6a3" xlink:to="loc_sny_OpellaBusinessMember_c185f884-824e-4cc6-b2ed-fa8802082110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_d95da1dc-74d2-4732-ac65-c96553ea51f7" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_8289540a-d7c1-4bf4-83ec-8f04944989f9" xlink:href="sny-20250630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_8289540a-d7c1-4bf4-83ec-8f04944989f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_3e7386a0-1375-4f39-8a91-19e63e0f5228" xlink:href="sny-20250630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_3e7386a0-1375-4f39-8a91-19e63e0f5228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_cf344889-3bbc-460e-b4dc-b5535358b8eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_ifrs-full_RevenueFromRoyalties_cf344889-3bbc-460e-b4dc-b5535358b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue_dc4c73f3-ef17-4f7b-9d3e-d737728bf188" xlink:href="sny-20250630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_sny_MiscellaneousOtherRevenue_dc4c73f3-ef17-4f7b-9d3e-d737728bf188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_e32123dd-2f1e-472a-8565-3722d1eeb49f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e00370c5-3515-4408-852d-2582e0e62c4e" xlink:to="loc_ifrs-full_OtherRevenue_e32123dd-2f1e-472a-8565-3722d1eeb49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails" xlink:type="simple" xlink:href="sny-20250630.xsd#NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_f5e0dc7c-d905-4faa-9340-c6230b0e157d" xlink:href="sny-20250630.xsd#sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_f5e0dc7c-d905-4faa-9340-c6230b0e157d" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:to="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_ed386d24-b750-473d-93ea-4ffa963a6597" xlink:to="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_11296a96-f371-4180-a4df-5f0c6faac10c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_11296a96-f371-4180-a4df-5f0c6faac10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4ddd946d-53de-48f1-8de2-ac2dd8db649f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_4ddd946d-53de-48f1-8de2-ac2dd8db649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_4135fb10-ba6b-42ee-8bb7-86bc12c6e86a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_4135fb10-ba6b-42ee-8bb7-86bc12c6e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_81a5f73d-d98f-464d-9941-3f7c8f8cd8c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_d7d8ff0f-c524-4439-9a3e-b5d5511065f6" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_81a5f73d-d98f-464d-9941-3f7c8f8cd8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:href="sny-20250630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eb0b0e9a-5443-47c8-94ef-b099806372de" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_b4543bb6-9f51-4769-9c7b-0d020a9a18ce" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations_b4543bb6-9f51-4769-9c7b-0d020a9a18ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_8c13bf6f-2e77-4cf1-8417-e776b03229ac" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations_8c13bf6f-2e77-4cf1-8417-e776b03229ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_1f1605a9-d4ca-4058-a4d7-75c036f565f7" xlink:href="sny-20250630.xsd#sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations_1f1605a9-d4ca-4058-a4d7-75c036f565f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_8b305837-f248-4415-94ce-417ddf0b767b" xlink:href="sny-20250630.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations_8b305837-f248-4415-94ce-417ddf0b767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_39d28ab2-6490-4998-b114-e9e8864e5239" xlink:href="sny-20250630.xsd#sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_c00edd1f-5f49-4036-9fce-24238a7e1014" xlink:to="loc_sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations_39d28ab2-6490-4998-b114-e9e8864e5239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_f5e0dc7c-d905-4faa-9340-c6230b0e157d" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_fa2a86bc-39e9-4dc4-929d-471c8de1a644" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_5b5bfbae-4d5a-4135-a9de-1a03e7b8e151" xlink:href="sny-20250630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_dc906cf9-dae9-4061-b16e-1d2af0a96851" xlink:to="loc_sny_OpellaBusinessMember_5b5bfbae-4d5a-4135-a9de-1a03e7b8e151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable_48fc25fb-65f9-4ad7-bf33-a7f6490cfde7" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c3078b46-35b7-493e-8e4e-323e0ce10a00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_c3078b46-35b7-493e-8e4e-323e0ce10a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_53c9ccc8-9f51-4b1d-8769-28cd82946f3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_53c9ccc8-9f51-4b1d-8769-28cd82946f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInProfitLossFromDiscontinuedOperations_226d7eb7-adbf-4267-a1a4-9dc0ff1bded5" xlink:href="sny-20250630.xsd#sny_ChangesInProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_ChangesInProfitLossFromDiscontinuedOperations_226d7eb7-adbf-4267-a1a4-9dc0ff1bded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_039b0a0b-c4db-495d-979e-841f76c13efe" xlink:href="sny-20250630.xsd#sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations_039b0a0b-c4db-495d-979e-841f76c13efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_803787eb-29ab-4339-82db-c743ecc9484c" xlink:href="sny-20250630.xsd#sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations_803787eb-29ab-4339-82db-c743ecc9484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_d25d0cc6-bb15-4f9f-9c63-1a26849eebd3" xlink:href="sny-20250630.xsd#sny_GoodwillDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations_d25d0cc6-bb15-4f9f-9c63-1a26849eebd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_d531969c-b2b6-46eb-92d8-463628e10a62" xlink:href="sny-20250630.xsd#sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations_d531969c-b2b6-46eb-92d8-463628e10a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_ff842c3c-9372-40a3-8eab-85042bbd6de6" xlink:href="sny-20250630.xsd#sny_InventoriesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations_ff842c3c-9372-40a3-8eab-85042bbd6de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_cae14581-13df-44d7-8d26-515d8a33c251" xlink:href="sny-20250630.xsd#sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations_cae14581-13df-44d7-8d26-515d8a33c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_61b833c5-6547-4ae6-b7b3-8192c21b8a64" xlink:href="sny-20250630.xsd#sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations_61b833c5-6547-4ae6-b7b3-8192c21b8a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_13590751-dfc2-4d1c-b7f5-a067b2a603ab" xlink:href="sny-20250630.xsd#sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations_13590751-dfc2-4d1c-b7f5-a067b2a603ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_98fd0c10-4251-4532-8797-5c69734ee84b" xlink:href="sny-20250630.xsd#sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations_98fd0c10-4251-4532-8797-5c69734ee84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_dd163462-bada-479f-b9cd-187bed4fcbfb" xlink:href="sny-20250630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_dd163462-bada-479f-b9cd-187bed4fcbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_996fc23f-4c9b-4019-8e61-aa62f448112a" xlink:href="sny-20250630.xsd#sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations_996fc23f-4c9b-4019-8e61-aa62f448112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_9f7f224b-9f7c-43fc-834f-ff9d241f5b5d" xlink:href="sny-20250630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations_9f7f224b-9f7c-43fc-834f-ff9d241f5b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_43eb9a6a-03d6-48c2-831c-4f6196ec8c86" xlink:href="sny-20250630.xsd#sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations_43eb9a6a-03d6-48c2-831c-4f6196ec8c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_d87fcb1f-37fb-4cb4-b92d-f943bf5db6b2" xlink:href="sny-20250630.xsd#sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations_d87fcb1f-37fb-4cb4-b92d-f943bf5db6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_2caa7c02-267c-4df7-ab64-4ec6f105c2fa" xlink:href="sny-20250630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_2caa7c02-267c-4df7-ab64-4ec6f105c2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_80ab4b3a-1f58-4808-9271-b2f74e9ef1bd" xlink:href="sny-20250630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_80ab4b3a-1f58-4808-9271-b2f74e9ef1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_9f65f664-27fd-4281-942b-81d1d94d10ae" xlink:href="sny-20250630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_9f65f664-27fd-4281-942b-81d1d94d10ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_12d24a7e-51f6-4ecb-a60b-cd0c998fe4d0" xlink:href="sny-20250630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_12d24a7e-51f6-4ecb-a60b-cd0c998fe4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_897b7636-5548-433c-bcc5-eaf3b1d04e15" xlink:href="sny-20250630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_897b7636-5548-433c-bcc5-eaf3b1d04e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_3eb7838e-5f2d-4127-8073-11525ebcbd7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_3eb7838e-5f2d-4127-8073-11525ebcbd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_619fa632-d6f4-47ed-906f-de17b2dc9619" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_WeightedAverageShares_619fa632-d6f4-47ed-906f-de17b2dc9619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_2de339aa-70b2-41ea-97d6-9fa0769dc589" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_2de339aa-70b2-41ea-97d6-9fa0769dc589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_6d6c39e6-82a9-47b1-9902-6767fcd85d94" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_6d6c39e6-82a9-47b1-9902-6767fcd85d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_d8810a8e-d181-43e4-9fd1-19e78d1b99c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems_204b8b67-cda4-4d12-96de-66cc7b281e6a" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_d8810a8e-d181-43e4-9fd1-19e78d1b99c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_c8d0e201-abaa-4a36-a695-aea724201420" xlink:href="sny-20250630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract_f5e0dc7c-d905-4faa-9340-c6230b0e157d" xlink:to="loc_sny_AmountOfSharesRepurchased_c8d0e201-abaa-4a36-a695-aea724201420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a2025half-yearfinancialrep.jpg
<TEXT>
begin 644 a2025half-yearfinancialrep.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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MI  YI@&*  T *10 4 )C- "@4 )UH ,4@%QB@!,T +3 ,4 *!0 4 .%( Q3
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MT .V9H 01]Z '!<4 6T7% &C$* -.$YQ0,UHCNH O*.U,186@"13WI@2]NU
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MZ4@%'%,!W2@ QF@!P% "]*0"XH 44P#WH 6@ I /H "*8"4 % !B@ I *!3
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MM:'!H Z6#I^%,1?/'2@"I+T^E S%N>E CC-0%,#BK@;NO^?\^E %8"D,1N:
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MM #O,S0 X/3 3S: '^94@+YE "[Z 'B2F OF47 7?0 OF4 .#TP%WYI &^@
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ME_*@#0C3=S_G\*:$7EBI@6$3O^E2!KV\77IF@9JQKF@"V*!%A!B@"RO6@98
MS2&AHZ_Y_.@9*#B@"&3BD!FSC_/K02RCU]J )@M R5#DTP-6U;- CI+?_P#7
M3$7-V.:8$$G'Y4@,2Y.,T <;J)IH#CY^.E %,'%(!?PH 3.: (GH ?&<4#-6
MVZTQ&O ?0U1)HQ].* +8_P XI@1N/6@"I*M %!^32 J&@!!S0 O7B@!O6@!I
MH B<4 5GH K/B@"%AZ4 .7CZT 7[?CF@#8M&H ZBS>@#I;1Z -N%J -6.3-
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MK0(G2@"U'S0,M)@T 6%.>U %I<"@"P..: )UH G3B@"0-B@!Y'X4 . H <*
M&@=* %/^?6@!210!\WO'CG],T%&<\>/\_P"<TAE)UQQQ2 KXI@31B@1H0+0!
MK11T"N7(^?>F(NQQB@#1BCQ0!<"<?3TH D\G':@ ,6* (GBH B,6* *LL0H
MSIH\?@,4 49(N^* *;1T ,V<4 -V4 2(G:@"4)CB@!PCS0!$4XH B*9H KN.
M,TF,IRC% S-F3/-(#-D&VD!#B@!BMS0!I1'I_2@#8A[?Y]__ *U,#0B7 IB+
M\<>.*+ 7X$_"I&:B)TH L4 .''6@"U'0,L_>%(:&=.M R53F@"&3D4@,V89I
M"*U #E;_  IV&2H,_P"?Y4Q&I:T".EMCFF!;S3$5I>:0&+=MF@#C=0^;\/\
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M+-F@"C++]*8&1-+FD!BW$M SG+N7- '+WK[J .6NVP<4 8CG'% #>^?_ *]
M"$YYQ0 SWH #_G% !G'I0 W<: ' X'N*!H>C9_G4C%"TP'8XI,!1Q2&.VY-
M@H M0IGGO3 V+1<$'T_S_GI5"9Z+H6I"+%5<D]ATG6QQ_C57$=_8ZXI'7]:
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M_/- "<B@!V/6@! ,T !_/% %=Z (& ZT 5WYH K-Q^- !TH M1'% &O W.:
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M8!]I[YH 7[3B@!?M6?6@!1=T !N\4 2?:O?- #A=4 .^U4 .6[QWH >;K(H
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M,@$&*0$\<1S0!;6+% B4)FD!9C&*!EM!QCM0!<3CB@"4$B@ _/ H :QH @-
M%68Y&* ,F4YH HR^E %)QCB@",C H <!F@"51BF!.M "GZ4 0.>10!6(!XH
MK2\T@*SC'^>:!E?RZ0$?E9_2@ 6WQ_G\* +L%KGTH$;EK:8Q3$;UO9?C5 :T
M&G\4#+YM.^* $-KCBD!$\..E(92F2I&5",=1^=(8].U $ZM_*D-#%.328R=:
M!#9>:0S,D&!3$5\\T *HQ0(E09I@:ML,=:8CH+:@"[C% %5^/RH QKKGZ4 <
MCJ*_G5 <E.,FI H]*!AUH 7H*!%<G./:@8^(\U0C2AH V(!GZTR330>] %Q%
MP/\ &@"-UW4 4Y* ,R7&.* *Q.* %+#W_P F@!4;'_UZ '*V: &$XH @D.*
M("<T 5WH AH CW#\*!$ZL&H&7HC0!HPG% &E'+0!=AFQUH N+-0!,MSC_/\
MG\* $^U4 *+O(YH 7[5_G- "FZ_SF@8PW>1[T"%%Y^5 #A=T "WA_&@ %UB@
M!?M5 "_:L]>: %%W^7O0 HNL4 !NL\]OK0 BW?O_ $H =]KW4 .^U4 'VG/<
M_G0 &YH <;OM2 !=9I@+]K(H /M>* '_ &LT *+N@!ZW6:0#UNL4 *MU^M #
M_MA-  ;KZ=O_ -5 #3>4@'?;,U0#A=Y[^WUH /M?OZ4 *+O)XH D^UYH ?\
M:_\ /^?Y4 'VK- #Q=4 +]KVT 'VN@!WVOTH 7[41TS0 [[7]: '"Z/2@!PN
MJ %^V;.] #_M>*  7>>M "?:<_\ U^E("H]SG_Z] &?+<9I@9TL_- &9-)_G
M_/\ GF@#)F.XT 9[@F@"-DH 3RZ0"!.M "F.@!I3 QVH 84^E,!NW=0 X*10
M %/SI%#"*0"$4 -"@T@"@"Q",$4 :D2[OYU2$S1C04Q%A8LT 6DBVT 3B*@
M\GTH 9Y6* &[-M "&.@!=G>@!OET ,\N@!NS:,T ($STH -M "!2: #;2 9@
M@XH #D?C0 FZD,59#Z_K3 ?YS9ZG\R:07'?:#ZT6 5;EAW- [CA=-ZGZ46"X
M_P"WN.02/SHL%QW]I2'C<?SQ2L%R9-7E0<.?S-.P7#^UI4Y#'/UI6"Y>B\57
M,?1S^O\ C1RE<Y5N/$$UR?F8_F:?*)RN4'NVFZFG8EL8IS3$2+3 G3F@"7.*
M0#EYH M1G=B@"TAZT 6U'/:@"RIH LI[4 65YH F7F@"9?2@"93F@!X[4 .Z
MT  - "]*!!TH& R#VH \_:+_ #_G_.*T$0F#)_QH BEAQ0!FO#FI&0&#F@!W
MDXH$2^7_ )Z4@%"4#'XQ2 F7K0!=CH >"2* '4 1'@4 1,,T 4Y!F@#-G&*
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M$;>@!A@S[_K0 >30 TVU ""VH :;?% #?LYSZ\4 -\C'Y4 (8=M #&B(/XT
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M<<4@#IQ3 :,]:0#^M "<TP%H 5:8 2: %)H 3S,TK *)-M "!\_I0 HD([4
M'F&F TR$<T +YI/^?_U4 .$V: &^=WH //V]: &F3=Q0!%G/O]:0#2,\4@(]
MN.?YTP#;0 FW'- #63'I0 ;*0#66F S;3 :5QUH ;L ]Z  K^5("-A0,K[?\
MF@9 PQ28$9%("/.#0!>B:@#2B:J0F:*'%,1?C;/:@#05J +0<4 .+;O_ *]
M"X_SS0 C<T * /\ ZU #U _S_G_]5 #PM  %!ZT ."4 ."9[?X4 -\N@ \J@
M!#%B@ $6>: (O)S0 C04  MP.*  V^?\XH /(SC_ #TH 8UOF@!OV8?_ *Z
M$%MF@",VV,_X4 1FWQ0!$;<X[T 5C%B@" Q^E #=GT^M,!P-,"=#F@"0&@"9
M>.: )!]*0%A.*0%A10!=#4"+*T 6$XH&6%'Z4 6%.* )E..* )EXH 4<4 .Q
M0 H- ![T !- "F@#@BU:")5.3B@!)CNH SV'TJ0*YYXH 8#0 A;WI 1%P?7-
M R(ODT@%#[>M %E),]Z '^;0 %\T ,9\\F@")I* ('EW=* *$K8YH I.=W-
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MF@"@Y(H C#4 /4_TH <5H 1L^] $#MB@!C'% $= A#0 A/M_GI0 HXH G7-
M%E&YX'- RXDO^<T 61-TQ0 [SR>] #A,3TH ;]H(XH 038'_ ->@!?/H <+C
M/'% "BXP: %^U9H >;C:<9YH 43_ .>M "_:-O!H <+BD \SX].*8#_M'M0!
M)Y_/3-(=A1/3$+YX% #Q,#Z9H 4RAJ %\T4 .\S'I0 OFY_QH !(!0 OF8H
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M "[Z &[P* ';J0!TZ4P'<#Z4 %  J@^E  0![T -(% #&0"@!C)0(C>,'/%
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MG^30(V8930!JQ3C_ #S0!>\T$4 0/+@\?_6H KO-]: *,LV<_P!*11F3RYH
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M &;/_P!:@ $^: %$V[K0 OG4 +YV: &K-^F* '>;0 T3D?YXH 4R 4  F!H
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M8BX&&* $9LT@,Z<8'^?\_P#UJ0S$N./>@#.V\YH =L_S_G\* )$CH FV9'-
M"-%NH JRQ[N: (&&/\_C0(K,,4 1&@8P\4 )R*!#A0!(IVT#)5;% $H?)H D
M!SC_ #WH =OQ0 ;_ $H 3S-O^?\ /I0 !^_?_)H -^/;\J  /G\Z $W4 .W9
M/?- ">9W'- #_-Q2L %Z8#A)F@!1)@T .66@!_F8H 0OB@!QEH 4OGF@!RN*
M '%QZT  F- "^;GF@!WFX_\ U?C0 [S* #S* #S,T .\SZT 'G9Y_KS0 &7%
M "B?/^?\_P!: '>=CWH =YN?YT@%,N?Y_P"?>@!!-GI0 TSY].*8#O/QP.:
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MH$3KQ0!:BH M1\4 6%XYH&6QSZ4 3K0!,O/6@"<'- $O6@"04 .Q_GM0 =:
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MUI@ H "<T$B+\QH G04 3*O2@1*E %Q.: +*'N* +2G;0,L+_*@"PO% %A*
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MYH /-)H <),4 'FYZ]J '"2@!?,)H >)/?\ 6@ W4 .WXH 7?Q0 %Z #S,4
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M&/\ Z] "4 )G% "YS0 AH .M "$XH 7.Z@ /- "4 '!H ,YH ": $!!_^M0
MN,\T@'=>] "$YI%"=*8A.M,09H #QS0 X<4 +G- "GF@!<T !^:@!!\M #2<
M4 )TH :!CF@!=_TH 4-0 N: $#4 (30 IH 3)/6@ Z4 ,)H 0&@!>M "]: $
MS0 N<4 &<4 )NH 5CF@!=V: !3Q0 N[% #\Y% "[LB@!X/YT .SB@!!0 N:
M%W9H =BD 9Q2*$+Y-,!12 4G% "J>:8%M/6D!9BS3 OQ\4@+BMN[TR2=<XH
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M&W?%6(O(<T@+*"@!2:8%"<XI,9D3=:0$*\&@"Y$>U %Q&[T 6U- "4 59^:
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M"96Q0(D7FF(>*8$J\X]Z0#AS2$6%Z?2@"XC=* +*#% RR@H LJ* +"4 3H:
M)UYH E'% $HH .] #L9H ,@]J #- "$8]: /D;&#0 NS-(!=F<8H*#90 8]?
MY4@(RI'-,!^*"1A79P?>F F,>O\ G_/Y4 .VT (!F@!^S'>@!ZK0!*%QQQ0
M^@"=10 ,N* $VYH 8U "'U-(!IXH ,4 (!0 X-M/:F S'_UJ10$#VI 1%*8
M4R* (F7\Z $8>M $/6@!NWM0 A3- $3>E #2,9I !':@"/% "8Q0 Y: +4?^
M13 U[;CG_P#52 W87I#->$X_"D,T$D_'FI&.9\4P*<C_ ,J0BMFF#!3B@191
ML4P-.TY[4P.AA_S_ )_*@19% RM+0(P[LT <C?'.3[4#.4E;/?U[T"&9_P B
M@8]3S0 Y6_"@!']J!#EX-,"W&<FF2S5B(-4(OQTT!:''>@!V_'X=* ,Z?VI,
M9ES\]*0%51G/I0!>CY[9H O+R.:0%A.<>](!6.>:H"G<<\4 9\PH$47'7VH
MJX]_UH 8W- %4C=^- #'!% "!: %"8H 9LH&(5XS0 TQT -\OIQ0 !* #R\=
M: '%.* &>4!0 >50 >70 OE9_P ]* &F/K0 AC/6@ \O=Q0 >50 OEY- "[,
M4 .,7/- #1%0 ;,T -"8^M #O+]: $,?I0 ICP: &[: %V;J0";,\4P&JM #
MMFZ@! E #U7/:@!PCH 7R_K0 OET !3M0 ACQ0!$4S^% #?+H 0)0 F* $(^
MM !M_P#K4 &WF@!H6@ VXZ4 )MH 1ES_ )_&@",\\4 (O% !B@!/UH 0CO0
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MXH 5N* &L: (NG/6@!M "T )WH 3% #0>U #AS0 TT +CM0 E "F@ % "^U
M!TH #0 BT (3B@ W?E2 3=B@!X>@9,#D4#+"B@"8)FD!,JX%,!X2D!91,"F!
M.HH N1GZ8I 7DXI@6EH L#C\J0$B2<\T 64?- R8-2$/ZT &<T#% QQ0 P(!
M0(4IDT !2@!@C &: '^5F@ V;NM QOE<T -\F@!/('>@ :W#8H 8UO\ _KH
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MBC'N* +<8ST]JHEFK"/\]JH1H*U6!: SQVI, ?I2 I2\4 8TPQ4C(4.>OZT
M78Q0!=CH M(/K2'<<1Q0!0FIB*#\T 4Y#B@15(QQ0! ?\^E $- #&/K0 U?\
M\4#+76@0*N:!DHC[T /$?Z?E0 ;* $\N@ "9Z>E "B//:@ $?YYH 54Q0 AC
MH ;Y>: ';/3I0 %-O- "%,4 !3/M0 T+F@!#'GB@ *T &W/- ";* $V8H :%
MH 7H: &;,4 (%H 0KNYQ0 OEY]* &[<T &R@!P7% ";2: 'J-M $@6@ QF@
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M* &$TQ#<C^E A^1[4 #4 ,*@]*!$;+0,B QS[4P+24Q !@TP+"B@1,IS3$3
M_6F!*O- $B#/M^E(1)[FD!95?I0!.O% RZO- $Z<]: +*4 3J<T 3K0!944
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MF(N1C--"-:$X[U0B\I^M6!92@!S"I HRD4 9,XQ4C*Z'_/\ G_.* +T8S^-
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M0 9'7]/I0 O(I @I%!MY&?\ /^?RH '7F@!C#)H :W%4(@.%Q0 QO2@0UTH
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M;K0 WR\^M #BOTH ;MQ0 ;<T -V9Y_S_ )XH$+Y?>@",IB@!=FZ@!,4 ,\O
MH&.V]N_O0!%MW?C0 @3/^?Z4 )L[B@!Y7VH 81]>*  1YS0 NS_/UH 3;0 H
M&#0 NWH:0#B : #;QSB@:$(_QH$,*TBAK#'% $+TQ$#B@1&^!3 C/!H C*T
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MLK3 FS0!,HQZTQ$@H G48%2!:'OQ0!96@99'% %E1CF@"PM $ZD]* +"C(H
MD'% $H;;0 X"@ '% "B@!* '9H ^;MN* &E=W^>: #&/\\4 *PW>W^?\_G0
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M'H IN* (#QS0(JR#'O0!7[T )0!.G% %Z,$T#+<:4 6PF: ';<4 *PH -M
M%H "O^>]  %_G0 A7/KF@ (ZT #+F@!NV@ (S0   T 1E-M "GG_ #_*@!A2
M@!=N: %4[:!$>W% Q,9XYH -O^30 FWKZ4 ($[4 -V=Z !EQS0 @&: $VXH
M;M_S_DT .V@4 )Q0 T\T &<]10 X''% ";J0#2VW-(:(CQ0,B)QUH)(#T[4P
M(6_6F!&2#P: &$T 1DYH :U  #0 P')H  ,<B@"+.Z@!2M "+0 $ \4 *W2@
M!.M ",,4 'WOI]* $(S2 5J8"=* $!SQB@ SCM0 W[U #,&@!"N><T 1$8H
M:1Z4 1YQ0!9CYH OQ<TBC0C- %Q:0%I!0 X#% #Q2 </Z4 2$4 -84 1L:!D
M!;92&6$GS]: )]_J: $W4Q#L4AAY>[KCWH B>WR*8BI);XZ<47 J.I% $3-0
M(3SL4 .$WX4# 34 *)L=Z!#O.H&.\_/X4"'?:,<?RH&!N,T@#S\4 .%Q_A0
MX3FF X39XH$/$U #?-H >LV/Y?YYI@74DS3$:4+_ *T :4+4P-",Y]:!%U*8
M$R\4P)EXH$2@8I 3H/2@"S'T]/K2 LH<T#+2<T 64% $ZF@"=!0!,* )AQ0!
M** % Q0 O>@ S0 =Z %QF@#YQ)Q0 W.T4 .H 3@T (#V]* $/&?YT (PW<T
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M "%\=* &$XH :30 SK0 WC]/6@!A.: &$>_% ";<<]* &<T )C- "8Q0 8H
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M?Y_S[4 (>.: #_/^10 T"@!>@[4 -_S_ /JH ,YH 0)^0H ;C]* %VXH 3%
M#1QTH ,&@ "C_P#6* $*T &V@  S0!'U_P _TH :1C_.* %P/R_&@!I&>W3^
ME "&@!I_#/\ G_"@"/.#G_/^?6@!IX]* (R<4 -_I0!'F@!FZ@!A?'% QA.:
M!$1:D!&6S0!$QH @+TP$)W9_I0 T\T ,SF@!* $SF@!"<?G0 E !G%  * #/
MY4 !.* %8T ,% "EL4 )0 IXH 0G- "$[J #H:  G% #2,B@!I; H @)H CS
M0 9Q0!*M %R-J11?C:@"W&V* )PV:0#U;!I@2!NM("0'(_SZT /4XI#%:@"(
M]*0$#=Z (&]>U #<?G0 U3Y= $Z7!7K0.Y=2Z!QF@+EI9@^.10,1I10!6FE!
MH$9TDGT_S]: *3RYH$0-)3 C9^V* (]W/O0 W?UIB M3 7?0 X/F@8X-]*0"
M!Z  N!3 ?N_"D H- A0U %B(\B@#11N*H1JP<4"-N#G\:: V(C3 OQY/6@"9
M6I")A_G H D6F!,M("W'VI 6E:@"ROR\T#+$;9- %A?6@"=1B@"=2!0!,#F@
M!XYH <* %Z4 +UH ;G- !F@#YK\W'X=: $W[?I0 WS,&@! P44 (SYS_ )[_
M .?\\T -W8H  VZ@!-^* &E\\>WZ>M  6XS0!&ST )NH 86_S^E "%L4 )NQ
MUH * $SC^5 "[OUH "W>@!,YZT *?\* (SC/X4 +G_\ 52&!_P *!@>*  <_
MA0 @;=UH :3Q[T@&YV\?K3 86W?C_G^M #<XH C/Z4 -))I 1;OUI@,SNH 8
M* &\&F P\T"+ H G09],4AFK;\'\:0&S'\O'6I*1I1TF!;1<\<T /S0,K/Z_
MC2 1:!$F,4P%6F!I67S4 =)$,@9Q0#)L[10!3D.!S0!BW/M0,XO4J9)R<G&1
M2 :.>: )%'- $P(H >1DTQ"+3 OIQ_A3)-B#IGC%,#03"_K3 LJ.U A67_\
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M_P YH  : !CB@ S0 G6@ SB@ Z4 )F@ S0 V@ )'>@!"<T 1%Z &$YH 8QH
M:30!(IS0!<B?M2&74?:,4AEB,]Z8%@-WH <K9]:0$R/Q3 F#?E2 F'04@%+9
M_&@"-VH&5V_&D!"S9Y]: (MPZ<4 (3F@!",]J8AO'6@8PR[3Q0 &\*=\T@(F
MOL^M.P7(&N<T6 JO<#UHL! 9<T[ ,:6@0IEQ0 ADI@)YE( $N* %$U #O-H
M=YM #A-3 D$G%("0-FF!)2 L14 :<7U]*HDU8%Z4 ;L J@->$T@+T:YI@3J<
M^E("?J*!$N* )E'Z4@+*4 7%&: +"F@987VH L(>U $ZG- $P_*@"=3F@"3;
M0 Z@!0<4 +TYH 2@ - 'RR7STH !+_\ JH 0RXH 0/CWH ;YE  )/\_Y_P B
M@ #^AH 0-B@!-^* $9^M  '_ ,_CFD,3?VH 0OGBF(0R9^M "[A0 !Z #=0
M;LT &Z@ W<8[4  ;(H 9G\Z #-(H6@ !QWZT !;/- " X_\ KT@&@@"@!"<4
MP$8Y'''\Z0$3&@!AX_#O0 QCF@"$O3 1SCFD P&F A.* &YS]* )@V: +,-
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M9Z &&2@"$R9H 1C0 W=F@9$SYI#&;\<T@&,:8F,8TQ#2V,T )G-  #0 F:
M&@!-U  #0 ;J $S0 IYH ">U ">M "[LT &XT &Z@!-U #<T &<4 &: &D]J
M (\XH C)S0 PF@!I- #E;M0!;1L4 78V^E(9:1LT#)%;)_\ KT@)$.: +"MB
MF!,OZT 3*:D"0\T#(F- %4G_ /52 C/% $3-0 A>@!N<TQ$?3_/- QC4"*[T
M 5':F!39J8$).*8ANZ@!@.: ';L4#$:3TI"&&3% AOF9IC%,U(=Q!-0(42T
M2+)0,G23-("VC9I@6D.: +L0_P ^M C4B&.M,1JQ+B@#>@7%,#3B^6@"_&/I
M3 G7- %@'-(0X#-("RIS0!83TH LH0: +2F@9.O- %I?I0!8 Z4 3 4 3#TH
M D&* '#F@!>M "YQ0 TG/UH ",]* /DXOGM2&(9*8AIER/\ /^?I0 PR;P0:
M %+@\4 &_-  9-U "%Z $WYH  U "A^E24 ;/I0 N_FJ$-+#Z4"' YH "V*
M'*Q'K0 F[O0 H;_/I0 #TH :.: %Z>U Q?,J1@#FF F: %SBD @XI@(N10 !
MN*0##_G_ .M0!%NR*8$9&* &DT@(NE,!A;- #,YI (3B@ SS3 D0T 7(N?\
M.: ->W'/^3WJ0-F*D4C3BY%(9;1J!"YQTI#(7YI@)0(4<_2@9*JTP-&U7F@1
MTD60*!$E [%9^: ,2ZYH&<9J7H*9)R,O!H$,%(9-F@"8GB@ 89_.F(5.OI_G
MM3$7HSWQ^5,1LVK;?>F!JIQ0!8!H "WY]* *$IR* ,2Y&: *\;9H OQ-B@"]
M'2&BZ,_2D,<0*8BA< XX[T(1ENU,"HY[Y]* *LASSWH K.?\?TH JL* (J )
M5;M0!<CXZ4 6D>@"8/@>] #Q+M_PH 4RYXH =YU "^9G% #6DH 7S*  29H
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M&W;FI V(S2*1IQ4F,N4"'.<TAD#'-,0T+NI#' 4P'XS[4Q&G:-CWXH&='#3
ME)H J2\4@,6Y;_/^?YT".+U-NO:F(Y)ADT" #-(9(H_*@";'7N:8 W'>@!8U
MP:!&A#\M62;%M3 TXR*!%@&@!I&.G:@#/G[TAF)<GG'O0!%$* +\9QQ0!HQC
M;28RR#FD,<:8BA<+V%,1G.V.N* *3T 5R<\4 5&&Z@")AGW]Z *SM0!'G% "
MEZ $WYZ4 .WYZ_SH 3S<<4 'FT +YV#[4 .\SI0 [S/QH -_7&* $63- #O-
M_K0 >?F@8@DW<]J0"ES_ )- P\S=0 &;''\J8AIEYYH$!ESW- ">;F@!3)B@
M 6;:.] P$E !YN/_ *U !YF/TI6 C,F>>:!#?,HL "2@!GF=:8 7S0 TM0 Q
MFR: $+[>: &[LT )NW4 -WXH 7=^5 "9R* $)Q]/\\4 )NQU]* #- #=^:
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M9 H G'S<4A$JG/3\13&28Q@T@+"G!I 7(QB@"TG% BVN?2@"<8- R9!0!.M
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M13 S'- %5Z (&PP]: *Q7\Z *[X^M $#=* *Q- $;'% "%Z #=CZ=Z (]^*
M$#4 (&],T 2;Z  O0 N_F@ W4 )YF.U "[\\4 *9"* $$F:  /0,<LF?2@0T
M-C.: %+4 (&H 5F[T (&Q0 %\4 )NQ0 ;Z  T ('H 9NQ0 9ZT )NH "QH 1
MCF@!N[% !U[T  - #10 [J: #=0 V@!3S0 W- "9H 6@ QF@! * $(H 7[U
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M@(6I (#0 F[%, +T@&-S^%,!I- $9:D A-,!I'K0!&6H 830 UCF@!": %!
MH M1T6 T(.* -RV6I VHN?P-(9JQG^5246U/^%,0-]?RH&1L>](!@'T]: %Z
M9^E4(5: -.T'/Y4".EM\TRB8C- %.7I0!B73=Z0F<3J2_P"?K0(YB4\_YZT
M,6@"4?Y__70!*#CB@!Q.?\_3_&F(D7G]:!EV+_.:HDUH3GBK)-"/FD!:!I@1
MNV0:0&?.V?PH8S'F&12 9&,]Q0!H1$=>U &@OK0-%CI4B&L*8%&<YXI@9C-F
M@"HW/UH C8&F!784,"NX[_Y]:0%>0TP*S#O0!$QI 1-S0!'NQ0 TGWH 3=0
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MD A;/% "[L?2@ SCB@!"?K3 -W^<T@#./YT *&Q3 -V* &;LT )G'6D!&7H
M;OH 0FF TMCWIB(MWK0%QI;% 7&[L<4"$)Q0 %MW- "=* +<1H&:MOZ=:0S:
MMN14@;L7Z9I%(TXQC_/\JD"TM,8YCBD!"PH 8"?RH$/4YJ@'#CO0(T[/GTH
MZ.%:8[D^STH"Y4DZ4 8%X-WK2$<9J8_R* .4DZ_RH 0&@"=5S0!-MXY_S_GO
M0 O3\:8AZ&@9=0\_Y_S[51)L150BZE B<'%,!KGCZT 9TQI,9DRY7^E( BQV
M_*@#0B&?QH&7QS2&2KQ0 Y^?\^] C-N#V[TQ&<_RF@"I)Q_G\* &$"F! XH
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M ";C0(7?_G_/ZT#&DYYH&1ELT@ '- #-V/2@0A?'2F!&*!#,YH 4^M #2?\
M(H .G%  #B@"Y"<],4#1JV_RGK^=(9N6]2QFW"<_SI#-6.I&6@:8!C'I0!$1
MG_/ZT ,H$*![_G3$.]^: -6R..V#3 Z:(<"@"8\4 4I!VI 8MX.M '%:F0*8
MCDY!N/-(8BT 3(* )J8@QF@9(AP0:8B['Q30C7CJA%Q#MYIB+.WB@"-B!WH
MHS'-)C,B3J/Z4@"(\4 :2+B@"XH_*D46!STI (WKQ3$9EP#Z4Q&<YH J$YH
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MMIB'A?RH L1KB@"VOMQ0 TC'XT 0L<C_ #Z4 5Y%H HR#- %"44 5B* &8H
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MB@0$8Z4  &* '*,__7H #0,%H !S0 [&: %Q0 =* % H =C':@! ,4 ._K0
M8H =B@!V * %Q0 F* ';<#\*!#BO>@!0E  !MXH&.VYH 4#V_P _X4 .";?_
M *U  !0 H7% "E: % H =B@ *_A0 !: '=>30 T#UH <%% #0,4 .VT  7-
M!CVH "M "XI@*!0 C+0 FW;[4 *?2D G6@ QF@!W2F XKF@!,<9H  .* $*T
M )P* %7F@!N*  "D W&/_P!5 "&@!M "4 *.M !U-  .:!CU'_UJ0R5<BD!*
M,4P).G- #7&/>I JR4 4WZT#(2<T"&GI0,:OI0(4<<"J *0#1Q0 _&,&@!F:
M8F2#(IB)* +"4 6%':@!#SUH A;_ #S0!4D.: *$IX[4 4&YH CVX- #2N>*
M $ Q0!844 6T% %^+B@#4AYZ4@-2,?Y]/K3 U81BF!L1CIQ3 OP\4@+J?YQ3
M LJ<<TA$XXI@24@)AQ0P)T//%(9:3@"@"RA% %H#;0!90\YH L 8H G48H E
M'% #Q0!(!0 8S0 8S0 ?2@!VW%,#XH6D,"/I]*!C>M(!<4 (#F@!P6BP!G-,
MD3.: &'B@ Q0!(3F@! <]: $Q0 N<4K#N+NS3"XW=0%Q"VV@+@#NH$)C- "[
MJ5AW$S0(;GFF IYH 3I0  T -- #/O?A0 [.<T -'% #A0,:10(90 N: $]N
MU #<9H !SUH !0 4 6H#0-&O;M2&;=O\M2QFS",8S^E(9K1G-("PM PSBD!"
M_- #2/PIH3$'^?\ /YTQ$H.3Z8H UK3CGZ4P.EC&:0$Q/\J *<@^M &+>#CZ
MYH&<1JG^>],1RK\<T (BYI 2J,\4Q$R\<T##!IB)5XI@7XQB@1IQ"J$7HSGV
MH$3AME,"-Z ,^3(]_P *3&9DV32 >GS?Y_\ UT :*9..U)C+*\TADIY_^O0
MCG IB,Z<XIB,U^30!$_6@!F/QH 0#/\ A3 85]:8$,B_6@"JZX.* *SIC(I
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M>GO0!:&#0(G Q2 >!B@"530!90?G2&65/^?\* +2<4 6EYH L+Q0!92@"5:
M)EYH DS0 \4 .ZT (!F@! : %(S[4P/B9?FI . H &&:!C2:!!T% " T .SC
MI0 @X_PH 510 -Q0  T !&XT +G- "9H 3K0 H.* $84 -H #C% !G- "4 *
M>!0 @H 3%  .?PH 3&10 S..M !G%  : %- "9S0 A% !G/- #=N* "@!I&*
M $/I0 HXH NP+0-&K;\&D,V[=?\ /_UJD9L0_P"<TAHU$;-2,L(,T !_S_\
MJIB(VQUI#&8S30"D=/Z4R24#F@#4LR![TP.DBH$3GOZ4#*<O^?\ />D!A734
M SB=3.:8'+OQ0 J\T@)5&:8%C'^?\_\ UJ (U'>F(D5<TP+\0W=*8C5B'%,D
MOIS_ )]Z )>OI3 C;K[4 9\W/^?6DQF<W)I +&V>* -"+U% T7$J1C^O\Z8$
M;_6F29\XQ_G_ .M0!GM0(C[T !7)H&*5S3 0KC_/>@"-ER/\_P"?_K4P(&3^
M= %61,T 9DB8-2!$4S0(:$YH& !-  4_I3 -AI &V@ VYH$+LIC IQ0 %#0
MH6D ICZ\4 (J;: %*4 .$>*  1D<?E0 [8?>@!%0XZ&F(D$.?_KTABB(],4
M*(B:8"^22?2@ $!':@!?)/;^5 #Q"30 OE-Z46 <(2/I18!XMV'2D HMSZ4P
M 0&@!PA+?A3 46[4@'K;-Z?Y]*  6Q]*  VQ_"@!XLV- #EM&/UYI@!MBO\
M^J@!5M6;\* #[&P_^M0 \V3&@!!9,?J?Z46 5;)C0 HLS^ H%<!9D 4!<<+
M_C]* N-%B5_"BP7'&P-%@N*M@2?RHL,3^SB/KZ46 ?\ V<1UHL S[ 10!";+
M'%*P$)@*T ,,>,_Y_3UI@-*Y/O0 TYH 3% !C'^%  .>/\_Y_P#KT -S0 M
M"'YJ %''^>: $Z9J0&CUH ,9H -F#_6@ VT *!D^U T2J,&D,E5?3I0 \#;^
M% #NU(")C2&5)./K0(IN<"@"!NM $1.: %ZTT "F O4?X4@ &@"1.: )0,TP
M'@<TR215SS0!)MS0 FWKVH :QH B>@"NXZ^U %<CN* &^50 IBYH ##B@!3'
M0 X)0!((S0!.G- &C .,T :T0QB@#2AH V8ZH#0A;CM^- %M: )U&?\ 'O0(
ML T@)*8$J\T@+"C%(993F@"TBYH LJ: +*/MH L@8H G0YH E H D!Q0 \<T
M +WH 0\T '>@ Z4 ?$^* %P<4 (10 $X&?UH 4C'2@ ZT &,T !&* &\T .S
M0 G>@ VYH <>*  C% ##S0 M ![T &,T )C\*  B@!0N?TH 0*10 I7/- #-
MF?>@!Q4]* &'B@ - "8H -M ";: #&<T +L_"@!-O^30 *A- #O+H !"2.GZ
M4 !@(XH :8R.HH L1+0!K0#%(HVK<YJ6,UHOEI#-2(<9Z_K2&3 ^W:D K?UH
M 83^-,!HX_*@0+Z4P)%^E C4M>33 Z* \4")S_2@"E-0-&)=G^M(;.)U'_/X
M4R3F7'- QRC% $PYH$3=:!D9XZTP)DYIB+\28STIDFG$N>_:F(T$YI@2CF@"
M%SBD!GSM_P#7_P _YYH&9SFD ^/_ !H OQ#UI#+:_-[?Y_\ UTQC\XH BD/X
MT$F?*>30!2;OZT"(CQ0 H_G_ )YH >%H&/5<U0!Y?TI ,\FF GV;=VS2 JR6
M&Z@!PTO/'^?\]J )UT;)_P#K4[ 2?V-CC^GX4[ *-%V]CCZ46$)_88;_ #VQ
M188'1?;]*+ ']B9/3\Q^%%A"_P!C=L?Y_P *+#'#1L=OIQ0(!HV/I0 ?V/[9
MHL ?V'M[4K#'C1MO..?IQ18!W]B]L?I_7I18!1HP'3_/Z46 ?_9 &<T["'+I
M&..: '#20.E,!W]CXI +_95 #ETC'0>_2@!QTK=UZ?Y_^O0 HTD''% "KH_L
M/Y>] QW]D^W;K0(<-)Y_S_A0%P_LG':@"3^RO84"'#1Z '#2: #^R?7GIVH
M?_96Z@!W]EX__50 HTOV_,4 ._LH#D#W_P _X9I@!TD"@!W]E8[4 .72L=NM
M #AI>>PYH !I7M0 HTSV_P _E0 '2QUQD_2@!W]E>V1]* '?V7QT_2@ _LKO
MB@!W]EXH #I/'% #_P"RP>F* %.F9ZC]* %72]O8T 0R:?CC'Y"D!2>PV]OQ
MH&9\MGNI@9TMG4@9\UOCZ4 49(]O^?\ ZU RL10 A%(!",T &: $Z4 !/84
M(:  C% #<4@'"@ "4 &V@!P0]/UH ?M]:!DBKWJ1C\4 2$4 - S[4 1,*0%!
MJ!E5J (&&?:@"!NM A]- (?TI@//%(!P^;GI0!*,4 /VYIB)@*8B3&: 'D8/
M:@!FWO0 W% $;4 1,F: (F0T .6*@"014 2"+- #BF* &>7F@!QCW4 .5,4
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M_P!E[<\?Y]: %&F;:0$ATV@0@TWMB@!PTWVH %T[_.* %&F^WYT .&F?A^%
MQ?[-]OTH$._LWVZ>W^?_ *] "#3=O\J '?V=GK0 X::!V_2F '3_ -:0!_9M
M,!PL!_D4 ']F[:0#_P"S?_UT  T[/:@!?[.H <--!/\ D4P%&F[NWZ?_ %J0
M#QI^: '"PS0 PV&W_P"O2 HO84#*$M@/_P!= &7/8>V:8&7<66!0!AW%GU J
M0,.>''-,9FRQXZT 5"M2 @&.* &T &V@!!S0 %10 JK_ )Z4 +MQS0 ;:  C
M'6@!ZKF@"0)]/RH&AVS'TS2&/"4 /Q^-(!/H*8#6YI 0./2D,HR<T 56% B
M\4 1'_.*!A0(6F F.* 'J,4 3(* )P*H1(@Q0(G QUH  "* %V8H 9MR,F@"
M-AB@!FTT -5: )57% $RQ?Y% %E8N*  Q4 ,\O- #2F?_KT )M _.@"6$4 :
MD2[: -"'/XT ;">GX50&A$: +*XH F4?C2 G'ISD4@) V* )EH$65YH M*,<
M4 6EYH&60,T 65Z_6@"PHH G2@"=: 'YQ0 [K0 I.: %_E0 P>E !0!\R?8O
M_P!=4 XV1/XT) .-D6ZT["(GM,=J0$+66>/Z4@(9+3/;\A0,A:VS2 B-O]<T
M"(_(QQ0,=]G_ ,XH /L^: %^ST -,./_ -5 "&+- !Y- $9B^M $9CH !%F@
M"18<4 .\J@!PBS0!,EOO]O\ /2@"8PT !MJ (_(Q0 W[-CK0 S[/F@!?LV<T
M *MMB@"98,T 65M,T :5OI^[M^- &[;Z5N.<'C_/2@#H;?2!Q5"-V'2=O;%
M#Y-+ZXH S9]+Q]/\_P"30,Y^ZT[V_P _E3N(YZ\L^I_S^50QF+);[:11+"/;
M]*D9H*N3_P#7I#+R#WI#)L[12 4F@0WI3&-[_P"%(!Q&:8#U-,1J6O6@1T$1
MR/\ /^?\*8B1S0,JRG_/YT 85W]?UI SB]0/7VIB.8:@9*H_STH E H$3 9H
M&,;GK0!93T[U1++L7'%,1JQCCM5"+L0_"D!)C-,"%N!Z?6D!G3?I2&9TG/\
M6@!R4 7(QQCZ4F-%Q#0,,TR0;% %.?F@#/<T 1GB@!4YH LQK]?UZ4 78DXS
M0!H1Q9YQ3 U[>V#?Y_E3 V(+//O2$:,5CG_Z] &G%89[4#-*&P Z@4Q%Z.PS
M0!9%AM[4T '3L]OTI@)_9_M^E(!!88__ %4 -^P?ABF [^SZ0"?V>*5P Z<!
M_P#JHN ?V=]*H!3IU  ;"@ ^P4 .%D:0!]A_/_/-, ^P_C0 JV -*X"BQS0
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MH$6TX- %F,8_SZ4 61VZ9H&6<9'^% %J,4 3)0!:'Y4 2 4 2 T 2 8H .:
M$(Q0  YH ,8H \3%F%./\_Y_^M6@B6/3\=J )38[!C^= %*2TQSTI 5'LJ+
M5WM=PQ2&5WM-M("L;?!_&D! UOG.10 SR : '?9_\_Y__70 K09_S_GB@!K0
M9H @-N5H /)S0!$8L"@"/R\8],_Y_P _I0 BQ9H >L>30!(L.: )5ASQ0!9$
M/'Y4 6!;9_E0 GV?;S[4 (;?=S_GF@"-H<=: &_9Z %%N* )1;[J )%M<=*
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M3 /LV: %^S8YIW 46_M1<!WV:D!"]OF@"E+;9I 9TT% &5-:@C^E &'<V^*
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MF8\?/_UZ8%.1<'- $ 3/>I 78!0 ,H/^>* *[C- %=EQ0!$RT 5I5[?_ %J
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M '8:>_3B@#J[0]* .DM^.*H1LP\8I :L-,#2C% %E:0"FF A% "4@$H 0BF
MVD 4 &*8"4 !H 2@!!0 F*0"8I@% "F@!O2@ Q0 M(!IYI@+TH *0"'BF N*
M0!0 4P$H ,4 '2@ -( (Q0 =*8 :0"T )TI@ &:  \4 %(!<TP#K2 *8"B@
MS0 O6D II@1/0!3EYI 9<] &/<"A@8%V>O\ G\Z .6OL,*0''ZASF@#CKX=2
M:8&*>/7\:0QH.>: %QB@ ''O]: &$8H 7&: '+Q0 T+V_6@"1>*11+C_ #G^
M7O[4@'J*8#Q_G_.:0"\CI^5 #3EO:@!OO_G_ #_C0!$XH K-2 HN: *[9_R:
M0R!AB@"(C'- "%0* $Z"@!K4 ,Q3 5*!$J#'%4!:7VI 3H/3M5$EE3Q@T ./
M- #&X% "=>O6@!F/Q_S_ "H &&:  4 2J>XH L1\_I0!IJ,4 2$=O\__ *J
M G)_"@",C% %:0Y_S_GB@"O&.>] %LF@"U#Q0!L1G%4!?AI@6@,\Y_6D!87F
M@1*!FD \<4@)5':@994;J +4?% %E3B@"TOYT 64&.: +"GCF@"RE $JT 2#
MB@!00* %%  >* &]* #&: $ K019@ZT 3S\B@#(FH SWI-@4G(I 9\E S.ER
M* ,^2I B)Q0  T !.>* (3Q0! _% $#4 57XXH J/WH %_R: ' 4 3 YX]*
M+"'/^?QH T(^U %Q./\ Z] $F<4 1-[^E #&XH ;WH F4;: )0?\_P"?\]*
M+2+0-&O9CD=CQ4C.QT__ "*HD[*R%,#IK44P-=1Q0!%(.*0&7<&D!S-\: .%
MU3H>M(:/,M8QS2&<RHXI#)&PU(!5'\J!CP,#\<TAB]32$,;V]*8"CBD!(>:8
M HIB-6U(.,^U,#?B- #V'':D!3E7- S"N1@<^E SB]1X^E!)S3]J '+GI0!,
M#[T 3*,^E,0G^>* +D2YI@7HN,4Q&E#WJA%P4"%=LBF!7D.>!F@#+FXJ1F5,
M,=J ",YH T8Q_G-(:+XYI#+*TP' 8I 4[D\?2FA&:QS3$0L/RH 3H* +4!H
MU[8<T ;MF><_I0!UE@_(]<4 =C9-TH Z6V[4Q&U!UH UX:8&A'2 MJ,TP%Q0
M F*0"$4P$Q2 2@!,4P#% "4 )BD &@!*8"4 % "$9I &*8#:0!3 .E "4@#&
M* %H ,TP$Q2 ,4P"@!30 G2@!!2 7%, H 7- "4  %(!*8"]*  T )TH #0
MM !0 8S0 4 .H * %Z4 ,>D!0E% &;<?+Z4 8USQ0!@W- '*7O-(#D+U=W'_
M .N@#C]0&/6F!B'TI#"@!3S0 P\__6H 3'TH ,]J &*,T 2\4 /Z\TBAZC%(
M"8<4P'B@ ZT -(Q^= $>>W-(")EQ2 KO0,JN,T@*I% %=A0 SI0 P"@  Q0
MU@: &,?K3$(!MI@3+D4P+*_-2 LCTJA$PXH$/Q0 A[T -ZGI0 S.: $''XT
M _.@!X% %E!GB@#47D4 29% #2/UH ;C^= $4G2D!53C&.F*8%GJ,4 6K?\
M"@#7A&*I :$8IB+:\4@)AR>] $W6D!(&QGWI /4YH&6@U %E/FH MK0!93F@
M"VE $RC/I0!84]: )1S0!** %%  3CWH !Q0 I.: &9H  :T$6;=LG\* +,Q
MXH Q9OQI,#/D.<T@*KC- &?(:0&5(<Y[4QE&3TI 0CFD _K0 PG_ #[T 0F@
M"NQ&: (F!H K/^7M0!2:@!%^:@!PXH F7F@"Q'S_ )]* -!/I0!<3B@"48-
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M/Q[T@%'TH E6D,L*<?6@"TG% %J/GM0!;1L4 3K0!83 H M*: )AQ0 \?**
M'8H ,=Z %H 0=* &L?K0!4$GK6@BY;O@T 7)GXH Q97S28%!WQZT@*<CT@*,
MIX/_ .NF,SI: ,V6I C'- #AQ0 C>U $#B@"NPH C.: *LOZ4 4G.* #_/\
MGWH <#G^5 $JD4 6$H OQ?-0!<7I0!(2<4 ,8Y- #2: &YR>E %E>3_G_/\
M*@!XH LQ#- T;-EU%2,[2Q7 IB.PLO7BJ0CI[?FF!K#I0!#)T-(#+N/6D!S5
M[S0!PFJ="/:DQH\PUC'/TI,9S><U(Q[_ ,J!@"&/>DP)*!B'WZYH 3_/_P!>
MD(4#- QQ8@4"'"J$:EIS3 Z&(<?2@!S''- %.7I0,P+O^5(#C=3.#0(YIC3
M<!C_ #^E $RG- $H]J #I3$3Q''% &A&V*H1I0D?Y_R*!%M1FF(5C^% %:1L
MB@9ERD'M2 S): &P\T :41I#-!#CZT#+2?6D Z@"I/S]:8&8Y[&F20R<4 -S
M@=* +4!P!V_&@#8MS^E &E$.: .GTL\T =W9L!B@#I;>3_)IB-J&6F!K02YI
M :L4M %M)* )/,!H 7=3 ,T@"F E(!*8"4@$- "&@!,4P%-(!A&:8#C0 E
M: &&@!>M !TH 3% !2 !3 3K0 HYH 2D =* $% !0 N*8""@ I )BF 8H 6D
M 4 '2F $4@"F 4@ 4P%I %, H  : '=*0!G% $3TP*<E(#-FX%,#%N#UH P+
MKO4@<O>TP./O<<TP./O!G/KS2&8K4@$(Q0 H./I2&A.#0#$^[]*8@QB@!Q.*
M $6@:'CBI&/ H </\YH ?G'^ H "<TP$-(!AH B/UI 5W&:!D#T@*Y% %=Z
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M"!B: (6- $$E %)QMH 8/;\J %)S0 ]/;_/X4 6(VQQ0!H1G'IQ0!;0\4 3
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M: '"2@!?-H <)* %\S- "[Z %W4 % !FD G6@!,4 +0 F* $I@*: $H 3K2
M,4P"D 4P$Z4 % "8H 7% "XH ;0 M(!IH 6@!,9I@** #I2 2F 4@#K3 ":
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M 3- '*I+FJ3$7[67FJ LW$N1[4K 9$LN<T@*;ON.*0%9F_*F!6+9I#*DA[4
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MYS0 N: $S0 M "4 %  : #I2 .AH ,4P#&* "@!!Q2 ,4P B@!#0 M !C-
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MT 7(]7P<9_6@"VNK!LG/2@"R-6R>/6@"U'J8]?ZT 7$U'/\ ^N@"TNHYZ=*
M+2:AGOS[4 6TO0>G\Z8BPM[[T 64O: )TO>E $ZWF:0$XO,T 3BZ_P F@"47
M6:=P)A< 4 2BXS0!*)J )!/0 \347 >)* 'AZ %WYH =UI@%( I@% "8S0 E
M "YH !0 8H 4"D N,TP"D &@".09I@49<T 9<U &/<4 8%V<4@.6O.:0'(7W
M (].],9R%\-O6D!DMUH /YT )CB@!5/^>]  %QZYH !S0 $8.* %)S2*$#=J
M #;^II .QCK0 A_R*!B,012 :1B@0W- #: (6:D,B8"@!AH&1'F@9$WM0!&!
MC_$T"&-S_C0(KL* (FIB!?6@"PG-,"RAW4P+2J* )U&.M,D,8H 4#OTH 3DT
M -)SSVH 83GF@!PXH E0[: +<.210!?04 .8[J (<?A0!#)Q0!1FH K+R: )
MLY- %^UX_P _I3 V8#CWJD(V(_\ .*3 MK0!84YI 2C+4P'Y'X4 .QBI&3)0
M!<09H M** +*\T 64^6@"S'Q0!../_KT 3B@!XXH ?\ RH * $.30 AH /UH
M ^:TGR: +*7.* +*7- $OGY]* '++TH D1\_7_/^'% $ZM0 N[_/:@!RG/'\
MZ )DX- %A* #;_A0!&?Z?Y_&@"(T 1$T 5VH J2''2@"L1F@"(T +B@"6,XH
M N(,]Z +<8Q0!/UH 530 N[ _P YH >6% $BGM0 _P SM291('Q2 UK.3D4
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M:8AW6@0G2@!O?^O^- "8S0 @H 4&@"9: +4'- %T#% #F8F@"/\ *@""0;:
M,Z?B@"J#CB@"0M0!HVYI@;D)_&J0C7BYHL!<7YJD"SUI@2CF@!5]J ' 5(RP
MIH M(30!;3UH M(,&@"=.M %E>: )UH F% $M #UZT ** &DYXH 3K0 'D4
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MM_*@17>F @.>U #T;%4(LKSWH$2AOI0 [=CJ: (I'R* *<IH I.<_2@"J30
MTKC_ /50 8S0!** '8R<]Z0Q"VV@8F:0"#BF!&QP* *S4 0,N:9(1C% %R%B
M: -.WEQ0!I0S[: +'VGCG_/^?_K4 ->;=0!0E8^M(9GN2>*!D3#'2D U3S3
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M;0T@+"C_ #_]>F(<1ZTQ# ,=Z !AB@!A&* &GCF@!X&: )%Z?6@"Y!0!=^E
M"$[>.E $?7O0!$YW<T 9T[9_E0!40^F* )!S0!HVY_R: -NWXXJT(VHN13 N
MK@TF!8'2D!*!2 <#BF \#UQ2 E09I#+49VT 6%]: +B\4 65H L** +"T 3
M_G_GI0 _[QH FSGK0 S-  >* $P#0 A- 'RD(J ) M $@7% #AE<&@"S&U %
MV-L4 78SMH LJV* )E]: )T.>E %@4 .Q[T ,:@",CM0!$?2@"&3YA0!2<8-
M %9U]Z (L9H  .* 'H?>@"ZG- %E/F% %A1QFF T_E0 !N.:0#6./<4 -,N2
M: &B3'2@!1(1CK2*+4$N.: -VUN0IZ_CFA =-:W6 ?\ '^5,1T5K>8QF@1LK
M=>M #7NLT 9\UUD4#,"[N.M(9R5[-@'I4C.3N)-U BC2*!N:!@.M $RBD!(
M: '*.#_*D!(!BJ$/'/\ C_C0(D5<T :,"8IB-J$4 2'([T 59. ?RH&8MSS_
M )_S_6@#F+LYSWH YZ7KTH K8_E0 \?+0(#0,K.:8B+.ZF!,/TIH3)5- B0-
M0!(30 U^!0!3D.<_Y_PH JOW^M $!% !L H  G/I0 X+B@8IYJ1C<9I@)BD
MII@,VYH A*T 1.E,0BIBD(G3DYH N1_+0,M1MG^M,"93F@ <T@*[\^G'% RL
MPI 1M_G_  H :#0 ^@!.M(!I% $)&X4P(G6@"/9BF !*0"GBF(>!@TP)U./_
M *U("49QBD,D!P#3 G!(H D$F* 'K*1U/XT@)Q<GU/6@"PM\P_\ U4 64U)C
MC/\ /\* +L>KENY_.@"_'K-,"[%J^>!GW_\ KT@+Z:OCO0(NIJOO3 O)JN.]
M%QV+T>J9XS_GWI7%8M1ZKU[T#+B:KGOC\:8BXNI <_UH$6DU,"@"Y%J.[_\
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M*+@+B@!,?E1<!,4 ,:.@!C)0!(BXI@3JM("P*8$FX"@!K-0!$6R/Z4@(6&:
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M0$4G% &#=-GZ&@#D[\=:0'/R$\T 4Y!GGO0!#@F@!<$<]* (*8"9Q3 ?UI
M/>@"-A@T *$QS0 ;,=: $*8ZT 'EY]O>@ * TP)%BVT@&E,T 5VCW=/PH&0/
M\M(1 :0Q10!..10!.%P.* )"* (S0 PK^'UI@,(_I0(3.:8!YF/I3 -_/TI
M-+YH "] #?,[4P$WXZ4 .\S-(!!)@?YS0 H;O0 T/BD ;^U, WXI .#Y]/\
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MS-8LU8%F.$$YZT 6'MLCVI 9\T)6D(HR14P*;PD4#*KQGZT@*CKFD! 3@\T
M3(U("VK9H GS0 #_ #_G_/%, ''/% "$XZ4 1L/\B@"HXQ_A0! P_*@!A&*
M'4 . _S_ (T 6$'KB@"T@Q0!/B@")^: (6/^10!79J *D@S0!1E&* ,Z04 4
MW_SF@!F 3_6@ (S^M "Y_P _Y- "C/>@!RG&?6@"U&W;O0!80YI%&C",#\:
M-2!>F<'ZT 74YJ1EG:#0!-MH :ZT"&8QQ0 @7;0 [9G_ /50!(JXY[_Y_6F(
MF0 4Q&I U,"]OS_]>@"!I/TH JS2?Y_E0,R+F3?2&<O>MFI PI#FF! YX_S_
M )__ %T 5"V:  ?A0 4P(U&*0#T./\\4P#&: $(ST_*@!A]N/I0!(V#2 85W
M4P)!\U("110 K)GI0!&W&?2AC*[>]("K)^=("HYI#%7@T#+2'- B8<<4")5/
MTI@-ZT 1M3 B:@1&W(H C)I@)[4 (10 @H 3I0 N?\B@ S3 7FD E(!,X-
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M! Q[4 5F^M %4G/'% %24YH IR+S0!5V?Y_K_C0 FS=CWH 3R<\__J_S_A0
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M $Z4"%!H 0';UH 7K0 ,:  <4#%W8IB%SU-,!HR:0#J!CN](!X^;\* '#DT
M/7B@"8#F@0Y30!,O-(H<K9[4#)"W% "CYA0(=UH&.Z4  /OQ0 [.?Q]Z"1=F
M*8BU:@EAQG\* /2-)BQ@?2K)/3],C- '<62TQ'2VXXH T5I@.ZT '2@ H 4"
M@!#2 6@!!^E "T 1/3 H2"@#+FI 8US3 YV[S2 Y2_&::0'&WO&:; X^\';T
MJ1F4W%(!,T  ;T_6@"3D\YH 7% #@:D8M, -(9$: %SFF QO>D W@_3_ .O2
M 'YH&-;CG_/2@!!QT_6@"(F@"-N*0$1>@9"U R%N: (R<T"&'B@0QJ (6YH
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M7^54@-VWXQS5"-F/B@"THH G Q0!-G%(!!Q2 D4Y[XI 3KQ2&6$/X4 6E)H
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MH&6$XQ3$78QCFF@+2>E,DL(0HH >1B@!M  .: &]*  "@!ZY&: )5YH NH*
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M,F4YI 3(<&@"7?B@ +YIB(FDH CWXI@-ZT (* '9S0 A%,"%J (NM #U..E
M$R_K0!8"YI 2#FF,"NVDP%\O%(!I7% "B/% @V4 (!F@!XCH&2^6!0(MQ1Y]
M?Y_G0!HI#CK3&7$BS31!>CBQR*8%Q+;% $PML=*8!]GW<?G^% #5M^G\J !H
M,T --IB@!QM<9_P_SQ0!)]DQS0 HL<T 6%L=M%@+"6&*+ 64T_\ '_Z]%@+2
MV('446 M+98_SQ0(M+:?X4 7H;?%,#>MHPO2@#H;<8Q2 WX&QWIC-2.6E81:
M$],!_GYI .\W- #A/^=(!_G 4 /$E,!_FXH <):8"^;2 8TN: *4LN* ,R:2
MBXS(N):!&!=/0!R]X<@T <A?+NSS3 XS4/ZTF!D-S2&(.M #L_Y[4 .'J* '
MKZT .&3Q2&.ZT#&'_/\ *@!.O% #6.* $)I ,-(8E AO7ZT# ^O^?\_Y]J (
M"/2@"$T 0,*0RNQH B8[>*!$;<T )]* $!Q3$,_^O0,8>M #D&*8BU%S0!:3
MC\*H1;0T"+*\T *?_P!8H 0\>M #@!ZT 1YQ_A0 M #Q0!(AQUH MH,#B@"3
M.: (2<4 )B@"N>* *KK0 S&: )U&.?RH T;<9JD!N6ZXZU0C9CZ4 65_.@"<
M<4 /!H =C%2 H6D!*G-(9:4^E %M>* )E6@"XGI0!,HQ0!8 H E44 2J: 'Y
MQ0 &@!WUH 8>: !N: /&(I\>M &S:3X_PI@7Y+C/^>*8&//+WS0!G2S9H I/
M-GUI7 IR39YZ4 4))-_^?Z4@*;-GC_/^>] #4H OQG:: +J'%("Y&<4 29X_
M"F!)G'2@!C'- $'7F@!V: %]Z '*<8H EQ0,D4$<T")0,<B@!VW/^<4 5V7M
M3 ASWI@(%YI 3!,^U(!ZICUH M1QY_S_ $J0->TCS[U0'86=O@=_ZT#.GMK>
MF(W;>VR*8%_[/0!7DM]M(#&N8./PI <_>P=: ./OX\9_&@9Q.I+CK2$8/3K2
M*';\47 LH_M2 M(U %U9,4#) ] #PU A6.* !<DTP+2(&^E,DG\G(_.BX%66
MWHN!0DMJ!V,.YM>.:06.=N(,&@9DNG^1_G_.:8!LS2 <%S0@';,4 &".E $J
MKGWH T(%S_G^=,#15./6F(>T?I^7XT"(MOI0!'(@- [F9=)C\: ,*=,'\:5@
MN9[+DT!<@"YXI#$YH <O% #LXH <* '9HL X-2 57H >'H 8TE $!EQS3 <K
MYI@/SD4A7%6F,?TI *3F@"NU #.M #TH LHN?\^U,"PJYXI 6UCW4#) GI0
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MZ!B YZ4 -;Y?\B@1$U R!J *STAD)Z4#(C_D4"(]N/6@0F<XH .O I@1_>H
M8>:!#DXI@6X^* +"<U0BXGTH$3*._P#^N@!YH ,YH &.>* &@4  ;/\ ]:@"
M3KUXH D'- %M.10 H- #"<4 1\$_YS0 PT 0%?Y>M $6..WK0!,@VT :%OSQ
MZTT!NP9/_P"JK$;,2\?A0(N!=M #AQ0,=TH ,8Z5($BC%("=:0%A?EH&6D%
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MI 9LTN<T",*ZE(Z4QG/7,F/_ *] '-7#Y_SQ0(YVZYH S2N*0QNWM^- "XH
M7'^?\YH 4G'TH 7% "_Y]Z  MBI*$Z&@!AXXI@,QGI2 CSWI# &@0IH 0T 1
M,<T#*[4 0/S_ /KI 5S0,B/'6@9'UYXH)$QNYH ;UH 0BF PT"'+3 L)B@"T
MIY[_ (51);2@"RM #B<4 -'-  ?K0 W)% "KZF@"0#% $R\^U %D4 +NS0 S
M% $1)- " 8[T 0DY[#I0!&%Q0!** -&+YCTJD!OVT>:H1MQ1^] %D+B@!#Q0
M 9VT ./6I >G% $ZFI L*/\ /^10,MIQUS0!844 60<4 3 T 3J?_P!= %A1
MB@"04 .H 7% "$X_"@!Q% "9Q0!\YJ2:DHL1R>M,1<67 S3$1,^30!2+9X/2
M@"H\F/6@"H[D?_6H KN: (=^XT 6(^.1TH O1M0!>C)':@"XA_S^M %H'\*
M'8S0 T\?A0!#F@!^WB@!^W% R8>G:@"1%_S_ )_SB@"TH]J!DRKTH)#;F@"%
MQS0! R_E0 Y4% %M1GM0!,@H&7(A4C-^Q6@#L;!1BFA'5VBTQ'06\>: - QT
M 598Z ,>>+-,#GKM*0SBM3CVY'M2 \NUOO[TF(Y-O7_)[_\ UJ10,,_Y_G[4
M 2QG/K^- %Q!WH&7HA2 E'- #P* 'GU_STH F7UIB-BT7'UI@;<<(_S_ "H
M5H>M %26'-,#$NHRM '%Z@E '.N.:D9&J9]* %V@4 /(#]:!#"-W6F  #TH
MT8<T :<8!XIH3+2)3$*P':@"M(-M &5<#% &'/0!1=<?K0!79.>* (]N* $*
M9H 0K0!'MH ;C-(H3;0 PBD! PS3 K2?6F20GF@"6-N: +\>#0!>BA/K0!8,
M?%(9$XV4AE.6F!7Z4@+*<TP+T:]J0&A$,8Z?4TQEY%S_ )]:0%@ICI2 ,>M
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M:!#QS0!:2J LJ.]")+2\?_KI@3@YH 7I0 Z@!M "4 *>?YT 2#GVH E4@>E
M%E< 4 (.OK^M ##Q0 S(H 3DT 1$4 ,VXZ4 3 8- &Q:IBJ0'06PS5"-=%H
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M4@.<O!0-'!ZKSZ4@/*]=.<GI2$CD<<4B@R* +$5 %Z+CK0,O)R/\_P"?Y9I
M3#D4 *M $BC- $JDC_\ 7_\ JI@;5IQ0(Z.%>*8B<K0(IRKCM048-THI@<3J
M"YYI <LZ\XH 9G/2D,7&[VH$)B@"+-,!8\J:8&E#P/:D!JI\OXU0BT..*!!B
M@"K(-N?P_&@#*N1F@#&F'_UZ *++B@")EH CQF@!I7B@!I&: &$4 1LM #,4
M ,/-2,@8$4PN5'7-,1"HH FB3- &M!!0!IJH':@!Y3BD,K2\4#*#_K2 K]?\
M:8%A!C^5(#0BZ8I@7XEY_P ^M S0C_R:D"< =A0(%&[_ #_G\:!@5Q0(3I0
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M#<TAB?SI +]?2@0TY/\ ^N@"-N*!E=Z!$+4AD)H&B-C0,CX;K0(8.:!"G)H
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MI_G%(9H(<4 2J.HH ?0 [.10!,O:F!K6C<TT(Z>$<?Y_S_C3$R<C- RK+TI
M85X,?K3 XW4%Y_.@#CYA@_4_Y_S]:0$8.?QI#"@!!\WUH AR!S0(D%4!I1#'
M)H$:,1./_K4Q%E<B@!6<T 596Q0!F3*,F@#(E&,T 5'% $+#- #=M $>,XH
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M_P OO2&14"%Z4 -SG\Z (6.*!D+GUH$5V.:11$>?_KT#(R.* $Q0 A!]302
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MV*/=5$FA'%G'2@"00$?6@!I@(ZT -,1H ;Y9% #"O^?\_P Z $"8H =MQ^-
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MA@<3J34(#E9OZT (2!^E(!I.>M #3S0!#C''6F!-'R,4P+D;9H)+X?\ _73
MG$O7- #&EQ0!4EER* *$KT 47.?\_P"<T ,SF@!O2@!_7K0 G6@"(^HH ;R>
M* $!_.D F: %SD4@(FH**3FF!9L1D_C0A,[RP3-,1<DA_.@"I(F,_2@#)N.*
MDHQ[CD4AF//S0(J9H FC-,"_$,=N3VH T8N!2 NQCB@"<&@8A;'>@ #8Z4 .
M3@_UI 2]:"B0&@"7- $GTX% %N!*8&];6^>U,DWK>SQ5"-.&S[TR2\-.SV_2
MF(C.G9]OTH0%5].Q5 5FT[-*P%=M/P:0%5M.S0,KOIPI 026&3TH IG3L]*
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M ,_G0)G5V=OFK1)TMK;9Z"F)FY#:]_QH)-2.S'I3 <;'%,97>RQ0(KO89_\
MU4[@5FT_'I1<"!M/Q2 K-88_S^E %=M/!_/_ #Z4@*C:=3 @;3@: *SZ?]/R
MH KM88';\NE("LVGXI@5GT_/2D!7DL#Z<4 0/I^/;% $+V!;H/TH KM84 56
ML,\G^5%AD3697WHL!$UL12 C,16@!N&^O\Z  9% #A(<X]*8#Q/0 \39- $@
MN=O)I .%SB@!ZW&.XH ?]HQS0!+YW;B@!?.S0 \2XH F\V@!XES0 [S/\_2@
M"19,4P)/,HN!)YN>!0 X29X[T .#4@) :  MB@"%S0-%.5J0S/DP:0&?+Q2&
M4)2*!%9^: $Q@4#(LX'X4 -8\4"(&- R$\TAD1X%(8W&*0$?2F(3I3 0G?0(
MB;F@"/I3 N0\XH U81BJ$:UNGI3)-:%,T :$29H D9,B@!AB^M #7B[X% $?
MDG_/]* &&'%,!C0@T@$,5 #6AH IO#C\Z *31XH @9: )DXH EQ0 G7]: (I
M* 'VW-- ;]OS5DFQ&<_E3!ER,4,+DXI .'_UZ  \TF,44@)T..E R=6Q4@65
MYH MKS0!90=Z + YH F6@"4<4 3#F@!V* '8H ,T *10 W.* /EB2/8<5)1$
M!@>PI@2XQ2 D#9H L*<4P)3S0!*.?PH 7;FD!"1[TQ#,9-,0]<"@"PAH O1?
M+28RXM(8_K0 QOFI@1GF@!ZCI2 ?G%,"13CFD!.A_P _Y_&F!?BY% %U#^M,
M"4GB@1#UH$,)H 4#;0!87IQTH&+WI#+$0XH W;(9(J1G96/.*L1T]KC\:!'0
MVYH$: .: (9: ,BYH YF]I,9P>J+P: 9Y/KO.:3 Y%CCK2&(: )DH&:<3 4
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M&?\ /O0 WI0,B?G\Z!$+&@9 ?SI 1'YJ3*$;Y>U B,_I2 .H]ZH1'0!&QQ0
MS&/7- %Z >XI@:\'Z50C8MQ3)->!>?7W]* -.-<=>M $VWM0 C+0 PIGK0 G
ME]Z &E,T 1-'0 UES0 QTS_^N@"I(M %%T[4 5'6@!0F.* )0,4#!NM $$W
M_*@0MN.<TP-RWYJT(V83[9ID%I!^%,:+@^:I&)C'- "%:3&/ZU($R\C/2@99
M3\J0%E/EH L(<4 65X% %A30!8% $RG;0!)G% #QSQUH .E "T  XH &SVH
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M:T@(3:TP(VM:0$)M:8$#6M $;6E R)K2@1$;2@"NUG_G% $)M/8_C0,A:RH
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M!?@.?H:8&U;\U0C9@_.F(V8 #0!HQ#_]5 B?.: %8?Y_S^M #"O/^<4 (10
MG2@!I6@",J!0!$X]: *;I0!1DX_6@"@XH >!MZ4 /Q2*'8W>OX4 59\&F2);
M?Y]Z8&];YJT(UHCFJ(+J&@"RO/\ ^JI*'$T@&=.M#&2"D!,C>M(982D!93-
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M ,M #Q,1S]:0"K)FF [SC2 ;YG?O0 QI,BD!$6[4##I0 W[W^?PH 2@!C>E
M$3T"(6.:0R%FS0!$30-##S2 C- A,Y[?X4P$S0!'VH BZTP+L1*\4"-NW:F!
MN6S9Z?K^5,#9A;'X4P-*/Y/\^E!)-GZT )N]* $#4 +UH 0T -;B@!#_ #H
MKM0!3DH HRG;0!3<4 ./%(H0<4@' 9ZTT!6N#@8/_P"JF2-MQC_/Y4P-ZW'Z
M5:)->.K)+J#%("RO%(H7';BD U:3&/4 4@)ABD!:C&/\\\>M(983@>E %H?Y
M]Z )DX_^M0!80Y/^% %E: )10!, 10 H.* '"@!* "@ )Q[T ?+[G-9W-BN>
M: '(<?Y]:8%R.A$,T8UJA%A8^* ) F?_ *_6D K#BJ$4G&>:!$1Y/I0 #_\
M70!(!GZT 7(S@?Y_S_\ 6I#+BX/2@!V>*0R(\4P(R<4@!:8#^O%(";?GM^1-
M $T34 :$?/M^-,"X@_GZT 3GTI@1LW.* (QTH$*GI0!8[4ACE% %B.D,W;"@
M1V5CT]Z8'4V9IB-ZW.:!&CT% %>6@#)N* .9OS04<%JIZTF!Y3K9SD^M(#DG
M;!I 1G^5 $L><T :,0^M S3C_#I2 MKS0!)N]: ' XH DC.#0!OVG3\*H1M1
M\4P)2>*0%&?H>@I@<W?' /TH X.^')H P7&:D!H.[\* &G@?Y% P)XH C/!^
ME "CGU%,0]2!0!8W4 ,+9YJA$)DS0(C9J!E=FZU(R!SF@!N_;TIB)0^*!#DD
M%,"3?@>U(!'.:0##04&>*"1"?ZU0";<C\: (Y!C- %1N*!ERQ&6% 'H^EG*C
M]*!&DS8H H7'([4AHY6\;)-2,QISW[T#,6=J!%$FF@)8C0!IP#(I#-.,9H M
MIT_"D46,9H$)GUH&(: 'CC_Z] B1,&D!+G:,4#) <_7Z4@+40P?Q%,9Z#H_0
M>E4B6>F:< ?I5D':68R*H1TUL,4 :T2T 3E:!#-E #=E(!ACIC$,= AA2@!O
ME8H 88Z &F*D PQ4 ,,.*8$9AH 88 :0#/L^:8##!2 C:VI@1FWS0!$UOGTH
M C:#-(",VN: (OLN?QI@1-:T@(S:YH B:U]J8$1M*0$;6F:+@0FSS0!$UE18
M95DL_P#.* *$MGMH R)[*D!BW-EG/^% &#<6AH P[BUYH PYX2.M S-D&*0R
M(4@%S0 *:8!F@ SBD FZ@!3(:8#]WM0 H;/]:0Q<FD(;U.3_ /6H $.,9H&.
M(H C- B,_-]* &-0!"W]*!D#?C2 B/\ G_\ 50,:>:0R(\T$B]:8$3'% ##S
M0 P\]:8%B-L'- C6@EZ4P-VV?\: -F&3H.O^?K3 TDDS[47$2^9ZTPL+YN>]
M(+ KX_S_ "H"P>;CO0%@W\47$+O_ #I@(6S0!%(: *CF@"E)]: *+=: ''FD
M4.6D M- 59\$4R1+8YI@;EL*M$FQ%Q5$EM?YT 6X^*10X@5($;'%#&2#BD!,
MIQ4@6%/I0,M*<_A0!8C- %A1P* )TYH L"@"<#.* )@.,4 .H 3I0 N,T  X
MH :3DT ?++-Z'_"LCH&YW'% AZ=J!&C!]*I$,TXQCK3$6@NVF _92 ' (S_G
M_/\ GFJ$4) !_G_/UH$5MN>* ';<4 2*,4 6X@5Y]Z0T6EZ4ACV.:8$;]Z (
M,8.* %4]Z0#N#SWI@2 YI@6H^>OXT 7HQC\*D"ZM,"QU']: (:8#6YH$.3B@
M98Z4@%7]:0%J,8- S=LAC'M0A'8V(QBF!T]H,4Q&_;<8H$7RV* *<LE &/<2
MXH&<U>2X_P#KTAG!ZE(.E(#RW6SFA@<DQI ,)Q_.@"1!B@#2AXH THCG%(9;
M% $X- #L[J 'JW/^>E &_9-C^5,1LQBF!*5H H3]* .=O1N%(#@K\Y-,##?O
M_P#JI 0DXZ4 !'O0,2@!GM0(7I3 0'I0!-NQUI@1LV:!%9WIB(]_>@9$7I#(
M-_K2 :6^M #@^*9(Y9* )0^:0";L]J8#@U(H<"#02/'%,!I6F!#(U %1^: +
M5@<M0!Z3I?W1]/\ /^?6@#1D)Z4 9=T>:0T<S=L":D9CRMB@9BS\F@12/!IC
M)HOEH TX<T@-.-LX%("Z#F@HGH :QQS0 HY^E B0#- QXI /P1Q2 FP30!:A
M.XCZTP/0-)XQ_.J1+/2M.( ]*M$L[>Q%,1T]O0!K1T 39Q0(*8 : $-(!N*8
M"XH ;B@!-N: $*4@&[*8#/+I !BH :8J8#/+S0 GE4@(S'3 ;Y6: &&+-("/
MRJ &&&F SR: (S!F@!IMZ0$36^: &-!0 PVP)H C^S9I@1-;4@*SVU S.FM:
M ,N:V]J ,6YMN,T <_<V_P#G_(I <Y=6^?\ /_UJ .=NHLT#.>NEQ2&4NM(!
MF<4 &: %S_GM5 &* &]:0"@8'^<^E #^G% "YP:0QW6D N<=* #%(+!G%  3
MFF(A(S0!&3]* (''_P!:@9 3[4AD;"@9%D4A#.E, ;)H$,8XH C)P* (\Y]J
M8B13F@"]"^VF@->"7;_]>F!J177% %R.[_.@"P+KTH D6Y]Z0#UN0>* '"ZS
MQF@!1<9I@/\ .SUH D\X-B@0CR?AF@"K(V?;VH$4I)*8%4-N/^?TH F5LB@8
MJ''6D,=G=0@*MP.*9(V#DTP-R 8ZU:)-B/C%6278J0%@>M)C0\]:0QG6DQCQ
MQ2 F J0)DYH&6UH LKQ0!848H M+0!+'Z4 3]J )0: 'T !&: $ZT +0 W&Z
M@#Y0,M9'0*I[YH$6(CSF@3->WX_"K(-:-<"F(FQD4 .!R?6D 'FF!1FY]*8B
MH?\ /- #UI"'@4P+2+4C+0&*!BF@"-SB@"N3GF@!V<T +[4 2!L4P+4./2@#
M03CK2 N(<D=J ).E,!": &[O2F Y?3I0!,!Q[T /&#2 LQ<4AF]8FF([&QXQ
M0!U%L:8C8CEVT")7EH I2S4#,.ZGI,9S%_<9'X>M(9PVHS=: /.M7?=0(Y7&
M.* $-("6(?TH T83]* -2,9ZTAEY30!*.: %H D3K0!NVIP*8C:C.>W:F!)_
M7I0!0GXH YR^.12 X2_^4TP,)^*0R+/O0 N2>G^- $76@0S!H&.)Q3$)C- #
MP,4P(FH K.: (&;%,1"[]O2D!$Y- R)FQ2!ANIDBALT 2AZ )!)D4 29I#)D
M- AY;-, !S3 @8[J *LAQ0!8T_EJ /2=-/R4 7Y&R* ,RX>DQHY>Y;DTBC+F
M; I",:?O0,I$YXH FBY- &I#Q0!?B..: -!<FD,F5L4#% QSTH 0>W2@!R<^
M] $R83_Z] $J_A2 >IQ2 L6_4?6F@/1M(&1QU_S_ )_&J1+/1]-.<=JM$';V
M7:J Z>WI :\-,"6@0=: $H ,T@$I@'6@ S0 F: '9I )BF 8I (10 F,TP#%
M(!I7- ";* $V4P$*4@&>73 :8\T@&&*F TQT !CI ,,5,!AAH :8: (_(Q0
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M =TH >O% $X.* )0V* #?0 %J (RVV@""1Z +6GO\PH ]-TYLI^5 %AVSTH
MS+J3'/7I4E'.3-R:!F?,>*0&+.: *E BQ$: -&%J -!&Q0,NQF@"?.: 'YS2
M'<3.: '*U QV<4 /''O0!.K9I6 M6Y^8=*8'I.CC&/TIDGH^G<8JR#M['I3
MZ>W% &O'S3$2FD E "9I@)UH 6@ -( S0 AI@ XI &:8"9H 6D E,!P% !UI
M )3 2@ I %,!1Q0 E(!>M, S0 =: $ZT &*0"T %,""1: *$J9I 9DZ4P,*X
M6D!@W2XH Y6]7@TP..OACZ9H XN\.!VI,9CL<T@&%=M "K_DT *%P.: %VXY
MH'<4KD4 ($Q2&-QGM0 X#% Q0N#VJ6 F,T 1$4A@30,B;F@1 3B@1"S4P*SM
MCG_Z] %<G%(",G/6DQHC=J!D><TP#-!(TMB@!F: (R<4 *.*8BU'30%Q!@TP
M+J<T 2K\WK2 7'ZTP#!']:0"8]*  C/U]Z $[]: &YH D0X-,"VIX_"F(7.*
M!#\XH D0]J + /'>@"4'B@!": *\O% $EL,XIH#=MSG\.E:(S-B/-4!<2D!.
MIVTAH4C'7O2&-)H&/'/;BI G2D,E'/Y4@+<;%.E %I#B@"PC4 6%XH L+S0!
M*#0!** 'B@ QGI0 ?=H ,9XH ,T ?'8YJ"RP/K0!J6Z_C3$:L7 'O3 M[J!D
MBM[]* ',VWJ: *;R[* *SOG\Z0A5.: +*>N?\]:8%A!G'K2 N1TP)>GK_.D
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M,T 1=#0!)$* +L8YYIH1;4;N* $:/CV_2F!&Z4 4YH\].M C.9/\FF(J&/%
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M^;'2@1=B7!IH"ZG'- $AR<G_ #_6@"*3Z4 5)%IDF:Z^U,"LZ4 1E: &F/\
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MP#3$4)&H&4W..*0$!8M0 T'- "Y_.@ W4 .(S0 A.[_]=,0E %R,4P-:!<T
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MR\4"(U&?\: ),T -)Q_]>@"(L:!D>[-2,EC.!_A0"-*'_"D,UH#D>U(#20T
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M2&-SB@#2TW[PIB/7]&.['?/]*9)Z=IG2J [JPH ZBW- C6CH D-(!O6F =*
M$% "GB@!*0 : $I@%( I@*30 F:0!3 ,T@"@ H 2@!: "F E !2 ,T % "T
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M0!;MSFF@-N!<8K1&9L0TP+J\C_&F!(%^M("3FI&-VXH*) 1T%2!(*0R9#VI
M7$&: +*C% $\?- %D4 6$H E!H FZ?Y]: 'J: %H 3/UH 4F@!!Z4 ?'<8H&
M:$$/K0!HK'BD,L(OI0 XC.10!&X+=: *KI_G% $03/!IB)D6@"Y&*0RXB]*0
M%M!3 L+TXI /!Q_C0 UUS0!6:@"NQ[T *#F@"4'TH D7 YH NQ<T :<8]:8%
MR/\ S_*D!/D]*8#6&#3 5OFH DBI 6%.:0#LTQC68F@"+=N[\U($<C4 9,O/
M-,"@XI@563%(11F3 Z8JA&4_!H$1F@!V* &DGM^= $4G)X_S^= #=V:DHFB'
M]*8%^(E:D9K0-BD!HJ/RH L+S0!..* )0:8C9M..U,#HHJ +&: *DQQ_6F!S
M]Y^E(#@=4S_G_/\ A2 Y.48H CQ0 $9H 9B@9'0 J 4 6XSFF(LJ><^M #RV
M>M,1"S8IB(L[NM $3'\: 'JM "L/2@!C&@"NXX.* *[-0!6<!J!%9J &=: (
MG/&* ('XH&52N30!:BBH Z/38^12&>C62$K_ )_G2&32*<4 8MU'FI*1ES @
M4 8MT.*!&#<+DTP*P6J$2** )%&.E $RC!H LJ: #\*0#B<<4 +0 F30 9_*
MF X@4 1XS2 U=.^9AF@#U[0_GVYJR3T[33N&:8'>V7- '3VQ- C5CXH ?2 .
MM "8I@ H !0 =*0"=: $I@+0  T@$S3 *0!3 !0 4@$H <#0 V@!:8!0 8H
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MR//7CU-,#H81VH MYVT 49J8&#>&D!PNHCG\Z0'*.,GO0!%M]10 $4 -./\
MZ] $1I@,R: )4)%,"96QT_&D!&S4Q,B+;N*8A,T .!)H E''^% #LB@!N<T
M5Y&P/:@"H_3C\J *;')H 9N_S^% AF[- %=CB@"!CNXH&3PH* -BVCI,:.FT
M] K>M(9WUHN%I@$@R/\ /^?YT@,:X-2,PY^,T 8-T.M &+.-M,17 [U0#L9H
M <!S2 D'-4(E4\4 -;KBD,%.VD [=0 I]Z8#=VVD @^M #,YH V-*Y?/N* /
M8=#X Q5DGJ.FC(S3 [JP'%(#IK<4"-9* 'FF E( H ;3 =FD W%, Z4 &:
M<T )2 *8"T !- !0 G6@ I %, I )0 9H * %H 2@ H 6F E( H 6@""0TP*
M4M &7/\ -0!B7 Q0!SEWQ0!R=^<9I <;?\9^M '&7H!IW QB:D8O2@!P XH
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M ]ET8;<"J)/3],YQ]:8'<V(QBF!T]MTI"-1* 'TP"D VF 4 % "4@%I@)B@
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M  :8!0 &@!#Q0 9H *0!F@ ZTP$I !I@+F@ I )0 4 &*8"8S2 6F N*0"4
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MRI-?$\YI#,*XGW]: ,2=P?\ .: ,]FR:HD4,!Q0!*CXH LH] %I9-U $V_-
M#]_(H B>3- %"5Z11G,^/I0!3ED.:+@ D[9H 57R/Z4 3A_2@"W#(,BD!H)+
M3 MK+TQ2 =YO% #3-3 #/F@!ZW&*0$OGX- %22XS3 HRW ]J0RDUQ@_Y_P ^
MM%A#DN!C_.*+ !GS2&0F;OU]*!$334 4I)O2F!FRR\]N?Z4Q#2^?\_Y_S^H!
M,LF:!AG/%  QW9[T -&?SI 3QFD!J0\"@9JQ?K2 TDXY_P YH L(,4 *0 *
M'@4P-:S_  IH1T4!X_S_ )]:8%H#% %:4"D!@70QSSD<?EFAC.'U112$<K-U
M.: (Q[4 !X[4#(W/6@"!QNZT -89H C!QUIH0[=Q0!&ZY'%,3*K>U,0BG!H
M53[T 3))B@ W4 -9^U %<G/^<T 0MS0 P_-0 QFH KO@T -4;C0!H1(3_G_/
M_P!:@#8M8\<]Z -^W3-(HZ"P4[A]>* .OB^[0!1O,<\]J0SF;D[CUS4@8T_&
M?TH Q;C_ ":8&3*/\*!$.:: =]: $-  :8#@>*"0(H 04#N.QGI2& YH 7&:
M & >M ##P:8&[H_#8'>@#V;1>/\ &A"/3]-'2J$=Q8\@4".F@H U$'%,!QH
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M AWFT !E%,!OF9H /,H 024 'FT 'FT -\[% "^=0 GG8H&'FB@0AEH #-0
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M=9%,0OVN@ -V* &M=9I#&_:J &FZH !=XH 07= "_:Z &F[H 476: &FZ]:
M%^UB@!/M8- ""\SWH 7[7[T )]JS0 @NZ  W= "?:\4 !NZ #[50 GVP4 )]
MKS_^N@!WVO-,!OVS%(!?M= !]LQ0 C7GO0!6DN\]Z *$EWB@#,FNZ ,>XNJ8
M&!=70Y%(#F+N[]Z .4O;G -,#E;R7)H SR_>D >9GK0 \RX[]J #S* %$FWT
MH /-STH =OS0,3S,4AB&09H :9!4C%$NV@1$9:!D;24@*\CB@"F[]:8%!V I
MB*,K9H JM2 C-  #F@ - !0 Z@!U $T=,"]"V/:@#1ADH THI,>U,"\DN.]
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MAR:0&1-)MH S7EZ?Y_S_ )- S/E?=0(I.:8$>>/Z4 -!H "<?2@!HYI@.S2
M;3 7.WZT +G/6D H/I0  \4P%!H &)S2 T]/D\LCZTP/0=-NRN,<TR3T"PON
M/?/2D!V5G>XIC1T$%Z!WH$:"ZACOS0 '4,T ,_M #O0 AU >M "?VAF@ _M
M>M "?VCVR*  ZA[B@!O]H_2@ _M#T- #3J-  =1![T -.H^] #_[0 YS0 G]
MHY]Z &G4* #[<* %_M#'?M0(3[>#W_S^% #?[0SU(H&!U #O0 AU+'<4  U$
M'N,T (-0&.M #?[1]Z  ZA[T *=2'K0 @U,>HH 4ZCD=: ()-1&>* *$FHX^
MM(#-EU$#OTHN!B7&H@4[@85QJ&X<T <[=7__ ->@#G+J[_\ U4","><OZ?Y_
M+_ZU ROYF/\ /^?\:0#A(#0 HD -!0&3_P"M0 >8!0(7S<]_\]J $$V?\_\
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MY]Z (R^?\_X4P#=2 8&H 0F@!0WKTI@31M0!=23UH$7XGQ3 NI/FD,LI.?\
M/_ZJ0%U;K(Q3 @EG)Y/%(#.DFR<TAE-Y<4 5)'S0(KEJ $5J8#3Q0 "F AZ8
MH .!2 .M "@@T  /<=:8"BD HY_"@!=WKTH 4&@":*39B@#J[*\(XI@==8ZE
MM&.,?Y_"@1U]MJGOD47"YKQZMCN*8BV-:XSD4  UGM0 AU@'N*!V$.K>] 6$
M.K?G0 P:UZ'\J!"?VSQUH ;_ &P!D9H 3^V0.] !_:^.,B@ .L>_^?\ /K0
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M*(?LHI .,&>* $6W'2@ \C'TH ;]GY]Z &^1BF(0PXI#&^3@4 -:WI@)]F%
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M2 9G-  30 H- !P: )%/>F!<5Z +22;: )UFSU]:8#Q)B@"=;K%("-[@?X4
M5GDW<]Z0$1DQ0,@8YH$-//T% P H$*1F@!M,!!BBX!1<!#Z&D 8H 7I3 =G-
M "]:8"@$=* &4@)EZ4@+4=P8S3 U[;4=E(#:BUG/<4T!>3Q %YR*8@_X23/\
M0XH 0^(QZC\Z0Q&\1YSSUHN A\2 \Y%*X!_PDON/6BX6&GQ(#W'YX_&G<+"'
MQ(!U-*X6$'B,#N/S_P _UHN%A?\ A(_<?G1<!I\0CN1_GO1<!G_"1#ID4"L'
M_"0YYR.M,+ ?$F.XHN P^)/<?G1<!Q\1@]P:+C$'B''4]N>:+A8:OB,#^*@
M/B+'<4 )_P )%CO_ )_2@!O_  DN.XH 3_A(0._2@0G_  D87N*=PL \2!3]
MX?Y^M*X["#Q)_M?UHN P^(P.]%P >).>M*X"#Q)[C\J=P&#Q%[TK@!\1Y[C]
M*+@-/B0#N*=P&/XB&.U%P*S:\.N<&D!3DU?KT- RE)J+<T7$5/M1-("'SLT
M)YE !YM "^8:8"^:30,7S,4 )YF* &^90!'YM #?.Q0 >=2 0RDT ('S0 AD
MH 3S: &F3=S0(:7)^E $9;- !GFF @XH ,^M( H$ .:!@1F@!#3 4\T '6@!
M* ' T +YN.E #Q/B@!?.[4 'G&@8WSROM0(!+F@!3<$T -$QH 4RD4@$\XT
M*)<4 )YIZ4 (9*8"B7% #O-H /-H&-,V: )HGYH$=#8/Z^E:(DZ>T.?2M40S
MI+8YQCVJB6;<#4F)&@!FD42*V*0#<?E2*%'RTF,D'-2!/'Q2&60<4 6EH LJ
M?6@"=* +*^GK0!,.: )!0!*.: #K0 4  - #3TH \)C.: +JMN_SZT"';<4
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MF@8]3F@!V?6F(7K0 N<4@&[LT -84 -H&!% "[* &@T"#;B@!<#\:!B!2<4
M*%Q0 $ <]*!"D4 +MH 0BF 8S2 ",F@!PH  =OL* &EO7_.: &M(3UYH C:4
MCWH&1^<1W_\ KT "R\4A!YA?G- ""0T#'>8: $\W'>@!/--  )* '[\_Y_2@
M :7-  )#B@!"V* #S-M "F0XH :KT )NW4 *TF: &[Z $R!TI@.,GI0(:9,F
M@ 9Z0Q-^V@ \PT 'F9H ;YI'M0 P2=J 'B4T -+F@!/,/>@!0] #-Y[4 'F8
MH :7Q0 A?% AV^@0!Z!CM^:!@&S_ (T /W9H -U #6.: &$T -R: $9B: &
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MH K.: (RV: &=13 MQ/0!H0\TP-2+F@1HQ<&@#1AY'/M0,U(QCI2 T(^<<T
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M7-2!.AVTAEI* +*\T 64% %D<=#0!,M $R8'TH E R* ' 4 /Z4 )UH .E
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M^?TH  N: #9B@8GE8I ((\T !C]!0 FR@!"E @$=,8FRD("AQ3&((Z $V8I
M((Z %V8% @$= #?+Q0 _RZ %$5 #A'NXH D\B@8ODYH$-\N@!OETP!H_6@"/
M9F@!?+H #%0 HBS0,/*I .$1)H /(_"F(/)Q0 WRJ %,1H 3RC0 WR<T 'E4
M ($]J #RLT 'D^U ">6>E(!OE9_I0 W;_GZ4 'ET -V8H =LW4" 1T##9FF
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M7TH$-\W'YT 1M)CO3$1-+0!7,NR@"!IST'K_ /6H JM/2&0M<8X_"@!GVJ@
M:Y_S_G_Z] $7VF@!OVBD UKD<\T 1&YH C:XX]J (VN:!E9IZ8$#2F@1&9:
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M +"GB@"930!,.* ']* 'XH =TYH 9B@!>E 'Q\)O_P!59ECQ/C&* +,5V<4
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M* 'BR&>E $GV$#@B@!PT\4 /%D%H <+'/:@!PLAUQ].U "_8_:@!39T -^R
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M-2(9K1$LUH!CI5DFQ'S3)+R\4B@YI,!#Q4%"&AC)$I 39I#+2MBD!80YH G
MH LIQTH LQC% $PYH ES0 \<4 2#I0 G3F@ Z\T &<?_ *Z /C+-9ECAT% "
MXQ[4 2J=M S3@G/Z4T(W;>;<?K5DFW$^><\TR2V!C'O3 4B@""1,T@,N>':>
M.N,4AF)/'Q4V*1F/P:DH87H :SXI#*[/Q3$0--F@17:3F@"%Y* *S2>E $9E
MS0 PR9H 9OS0 W- #<TP&;J!"9Q0,0FD 9S0 4 +B@"-A0 FV@!-N: &;<T
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M*8$+3 TAD3S ?A2 @>4"@14:3.:!D)F'ZT#L+G'7% 6#?0 QI<T#&^8* $#
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MY'V84AB'6HS_ !"D(B;64'\0H&5SJB=,T#(SJ /?]: '_:QGK0,%NQZ__JH
M/M@/<4 1F\'J/PI )]MP.M #1? \9% @-Z.?K3"XOVT+QG_Z] A#?!NA% #?
MMH'.1TH$,%X&]*!C6OP>I% #/M@/>@!IOAW(H 3^T!ZB@!OVW/?ZT (U\* $
M.H ]3^M(!#?*>XIB%74AZC_/^30 UM27U% $9U%>>:!C6U%2/O"@1'_:2>M
MP_M-?44 ,.HKUR*!$;:FG3(S_GF@!/[20?Q#WH ;_:"MP"*!D?\ :2]R/QH
M:=24?A0 TZD!SG\:!#O[34GJ/SH&(-5 [T"%_M=5[_Y__50 '5P#U'YT )_:
MZX[4#$_MA?4?Y_SUH$+_ &P/\_XT ,;5A3 B.K*W<?KS2 B.J#..GX]: &?V
MF!S0 W^U!GU.<46&-.J@'Z?Y]* #^V,\4"(_[5H&!U7=]*!##J6#0 S^TNG:
M@8PZA0!&=3Q^- "?VCCT% "'4.: (_[1(]O:@!O]I$\_Y_S]* &&_([_ .?Q
MH$--[FF OV[% #&OO3'^?3]: %-]CITH 8;_ /\ K4@%%X6YH 5;O%  +W/I
M0 HO3TZ4 ,^V$\4 )]K)JAD1NC0 QKGBI :;OU- AANJ!C1<X]J!"?:]_P#G
M_"@8IN:!##<DT# W)H$/6<T 78I3GFK)-NW<-Z5HB3;@YZ59)K1<TR314]^M
M(8IJ1C"3C_/^?2I&(.*&42CCW-2!+0QEE*0%E./Z4 65YH G7@4 65% %A,F
M@"4<4 2 X^M "CB@ S0 N:   F@#YL:*LRS.EAI@1B+.#3 FBB'_ -84"-""
M$GVI@7H8"!Z>E(#6@AVU1)MV\>W!H T5AW#\!_G_ #VJA#'@.*H"A+"12$9%
MQ;8]10!SUW;9R3GV_*DT,Y^:VV_I4-%)F<T6*DH:(:  VW_ZZ!$1@SUH J20
M8Z>M(97\@F@!RV^#3$68H,50%E(<]:8BTL7I0(G2"@">.WSUH M1V^[K_P#J
MH&BU]FQ4C#[/N_6@!'AR<XZTP$\K-(!CV] &<8*0R(P8Z_E0!((<\'FF GDD
MT 'DY_&F(=]G]*0#A#@_Y% %F..@9;2.D(NQCM0,M1#'% %T#'^>] $X'I_G
MVI 3@4 2J,T *210 QE_SZTP)8ER?QH$=-:)GZ4P.GM8O2@9T,$6./\ .*0&
MC'#[4 6#$*0%22*@"F\>*8$!.T4 5);K90!ESZOY5 C,?Q"*!C%\0J>^* $_
MMN-^XHL!*-70\;A]*!DRZPI[CI2 M+JBCO0!934U'5A0,5M84#J*!$;:NG<@
M4 0'5DSPP_.@96.LJ.XQ0!5;6%/4C\Z (SJR>HH"Y'_:Z>HH /[70<Y_(T"$
M_MQ.N1[T -/B",'K0!$WB1%__70!"?$JMT%,!#XE0>E AO\ PDX/84!<4^*
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MKT_PH !<$=^:!"?:30,!=$=Z $^UE?>@ \[/ .* $^T%1]/TH$'GF@8IN"U
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M@ %  >E 'SVRX[_2H-"C(@- B 1[>E,18CC_  H T(H=U,#7CCS2 TH( /\
M/I5"L7HDV4"-:)<\]Z8B5HP:8%*:&D!CW$.<FF(PYX#GO^5,9A75OFI8S)FM
M@#G^E24B-(<G-2,>;?'^?\_Y- $1BQ2 HR09H B:# IB%$..G^>U,!XAQVXI
MB+*0XIB+<49/TH M+![4#L3K#F@1>B@QS2&6/)![4AB>5ZT -:+B@!!$&.:
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M#)GK0(7S3G/2@!1)[T#&^=0 ADX]:0#]],0*Y% Q?,Q0 !^?YT"'AJ!CC)0
M&3- #=] @+C\J!C=] AOF4#'>;GJ: &!_P J!!NH 7S* #?@YH&.+B@!H?-
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MB@9D7#YXZTP,>=\T@*1EVGMB@"$O0 GFYH /-H /,R,=J!"F3:/Z4 #-GZ4
M*'SR3B@8@DZ].OYT !DH$,W^E "F6@8GF$YH  ^/IB@!?,H$(): #S>G^?\
M/ZT )YOY?Y- #O-_SZG\O\]* $W[N/\ .: '"3(H&,,E !YN1Q0(1I.*!D?F
M8H -] !YE ">9CF@0C2;OPH&(9./I0 OG[3F@0AD!]_\: $\W%(8WSJ8#3)T
MI 1[\=Z ';\4 -W]J %+\?2@!#+^% !O'TH 8'QQTH /,SSWH :S]J &F3'
MH :6H :TE ""6@0&7/>@8"3TI@(7VT (9LT )YOZT"!I: %\WB@!3)B@ $H'
M>@8GFT  DXQ[4@#SL4 ,\[%,0GFY_E0 HEP/I0 ADP*!BF4YI +YF?PI@-,V
M._\ G\:!$?F;_:@!5DP: &^9F@!/.Q0,42T"&^9F@ \[K2&*9O>@ \SC H /
M.S0 OFYH /,S3$/63O0,>)<F@!?-QTH /,S0(3S,4##S<4 ,,F* &^=0(3SJ
M #S<\4#%\R@ \W/7^= A1)0 >;B@8TR_E0(3SNN: (_-H&+YM B/SL4 )YWI
M3 /.I#&F8YZ\4@$,^>*  RT ,\WW_P _TH 4OGFF "8>M #A-^% #UFR*! 9
M1^5 #A/Q0 OFT )YV: $\W- "&;F@8OG9[T"(S-F@!&ESP: (_-S3 7S<T ,
M,M !YOZ4@ 39H G27/'6@#H[-L@>]62=';'_ #]:T1+.@MV_SQ6B)-V!OI0(
MT1FD,B<8SBI8",W>I*(^OX4,9(!@5($R<TAEJ/YL4 6$]J +*T 6%H LB@";
MM0!,M #U- #QQ0 ** %Z4 !H \6E3%069,T>.* *?W30(EC;FF!J02<_2@#6
MAYYH TT;WH L9X]Z8$@?MS3))5EP<]Z8#FDR/UH$4IACDTT!ER]*&!2D7-(#
M/EA I-%%(Q5 QVT=/:@"-XZ0RA*F* *C#/;CFF(9L_PI@*@YQVS0!HQ+5$EZ
M,4 3_P"?PH E ]J )8SCIT/6@H>'S2 D5\\T@'DY^E# 8R@_6D,K,,_6@"A*
M.:H"+&: %(S0 F/_ -= !MP.E A"E (:06H&*.10!(">M2!,1D4 3KGUI 6$
M&#_GWH F2@"0?RH E7_/YT .< #F@!3Q3$7+89/Y4P.NL4P,T =+#SS0!I1M
MBD,D:2@#.N)\4AG-W-_M[T 84NH=>?6F(S9;[/.: ,^:ZR: ,V:?.>U S+FF
MQWZ4",F:;- BB\V>2:!D/G8H$1F7C':@8T38Y!H$*9@*!CEGYH 3S<<T"'>?
MC\,T#$\['^?>D K34 ()10 WS@.?\]* $\W/2@ $^..W^>:8"^?N[_Y_S_.@
M!//[4" 7&*!B>=W- "_:* $\X&@!3-DT"#S<\4 (T^.] QIEQ0(9YO\ G\*
M S\<T 'G4#&M)CZ4@$\W% !YN>M "&7O0 AESU- !]HQ^- #3)ZT -\W^M !
MYV* !9,]* #S<4 'G?K0,/.]:!"&8>M #/,Q0 &7/]* &F44 (TM #?.S0 S
MS/\ .: $,@% ""2@!/.Q0 &3%,0@DSQ0,4R\\F@0IDS0 AFS2&()/UH 42T
M'F9H 0RT  ?.: $\W% ##+0 OFT  DVT"%\W% "&7%,!OF__ %J %\V@!OF]
M^] P\W% AGF9XH 7S.] #?-H& FV\T@$\WOF@ $M !YM !YN: '";/2@0X2\
M]:8"^::8P$WO0(?YN:5@ R4 1^=Q3 3S<?UI -,M ">9F@!/,SQ0,7S: '>=
MFG80AF- P,N*!"&:D TR>E "&7=0 PR^E ">;S3 9YM "^=2 3SO2@!GF9H&
M!EH$()<B@!3)B@ \S% #O,Q0,<)#WH$+YI- "B7%,!?-H 89J0 )LT .$F:
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M"3?2&.5@1S0!*&R:0!G;P*!D<C#I0!4=<?RH$1XP?I0 A&VF,0\4 .-(0PT
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M3  V* #?3 3?BI  U !OI@(6H 0O0 !J &ELT &_J*  -F@ S0 H:D!- W-
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M/% @- "$YH !Q18 H ;G% #E&:8#>E  #2 2@!: $QNXH 4<4 (* $6@ S0
MV@! ?6@ W4 .SF@!0<T )F@!X- !3 3-, S2 ;NI@)G-  .* $-( %(!5-
M30 !N:  TP"@!13 6D 9S0 P$FF &D E(!HH 4<4P"@ Z4  YH 6@!:8!0 4
M !- !TI -SBF WK0 I% "@8I +0 HH 3K0 8H 6F =:  4 31GFD!T]BWY52
M$==:?-UK1$,Z6U[?Y_S_ "K0@Z&W//\ G_/ZT :J,: &FI&-QFI93&]Z3&2+
M4@2#WH&6DYYI 6HSB@"RBXH G% %A: +"T 2@9H DQG\: 'YH .M !0 F":
M/,I^1FD!B7!["@HSV3\J &B+')H F5,4@)"-M,!S'/%(!A?%,",G//\ G^=
M#2Q- !NH GC/YTR2RO)]J +4#=J 'N.U %-Q@T 49AG_ #_G_/M2&9TN/\_Y
M]J!F3=R8&._]* ,=VQ]: *;/F@"->.* +<1VT@+\38Q3 NJV:8F64>D(M@T
M6,\T +_G\Z   TP''B@8I(I!<<K4#) =_%  5I 0L,4 5\TP(SQT_P *0$).
M*8$BGK2 F#9-(9*I[4 3BD!:4T 2 9]C]*!DP.<T  - B1>OXT .&/P- %R$
MX/..<?C3$=KISDBF!T41S0 _=BF!3G)-2!RNI_./:@9Y+K2\D_C3$<HX H K
M$&@!A!-("LQH J2<?2@"J^: (6YS^%, W4 1-Q0 T-2 * $9LT#$)- A<XH
M7?0 H;% #NM "T % "YQ0 OO0 I- " $&@ VYH 4<4 -H 4?-0 N<T +[4##
MI0(3% "$T */UH #S0 F* ',* &T &S% "#K3 3I2 !\U !C- "#- "@T .-
M PQF@04 ')I@)UH 8:0"=: #I0 S- !0 G(H ",4 &V@!<4 !% "=>* %Q0
MFW/6@!<8H&,Z4"$ZT +C- !B@!,4P%-  5S0 G6@!,9H8  32 0KF@!>M !S
MVH "M,!,9H :>:0"%: $S0 4 )U%, H ,T .S0 =* &D4 &:8!UH !Q0 9Q0
M W- !2 44 % !0 &@!<Y^M,!.O:D N* %'%,!!S0 N<T@&YH 2D 9I@-%,!P
M- !0  4@%'-,!*  #;2 7.*8"4 (>*0!0 8S0 'F@ QCK3 7% "XH =B@!:
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MI6 =]G;THL!&+=CU!H 7[*WH:+ +]F8]J+ !M&]#FBP!]C;TIV >MFWIBBP
M;1O0TK 'V5^XHL AM&/8T  M&/8_E2 /LC>AHL%Q19OZ&G8!#9.>QHL @L7]
M*+ *+%AV-,0AL']#0,46#_W30 AL'/;BBP"C3G]*+"N*=/<]N:+!<7^SG]#^
M5*P7&?V?)Z&BP7'G37],T[!<0:=)Z&E8+C?[-?L*87&G3I.PH"XS[ W3%%A7
M(3;%>M*PQAC([46&,VTP&^7F@!3'0 TQ4 *$XI +LH 3RR:8!LI !2F!&4H
M4C-(!I7-, VXZ4@#;0 =* #% "XI@&*0"[<T &*8 12 2@!6%(",B@!<4 )B
MF N*8#@*0#=M,!<8H 6@!*0"XQ0 8H 2F $9H * %"YH D"4 /\ *Q2 4Q8H
M 0I0 !,T +Y9%,!PAI *(: #RZ )8HLFF!T%HM,1T]H,5JB&=);DGBK)-V%L
M"F2:L9I#)?6I&&!ZFI8T-)_+VI#)AS2&/!I#+*4@+*B@"RG% %E10!.#[T 3
M*: )P>] #P* ' ^M #LYH 0T *#F@#R2Y?\ *@90R<_Y_2D,D2D!8C&<?XT
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M:WQV[4#*YAJ1D36X_P#K4AE.6U'7% &1/;[3TQ0(SI$QQ_G-,!F<4P%,F/\
M/^?2D [S-M,!PE!_G_G^5("96H B9L4 0-)B@",34P)DGQ0 _P [% $PF]:0
M$JR8_6J$/5L#% "9]*D9%TI@2#FD!*..*0RTH!I#1909Z>U RRHW4 2#FE<"
M3 _.@!<[: $)Q^%,3)1Q_+_/^<T"'H<4Q&_I[!?KVY_*@#J(9.A_S]*8R8R"
M@13GDIC.<NWW#_/:I$<'JP_QI@<LPYI -7C_ ":!B&@17E6@#/E7- Q\5IYA
MIB.AMM-X%581JPZ;GM3$6/[)SV/X4"*LVD9Y[_\ ZZ+ 8ESI6/7BBP&%/8["
M>/K4V**AM<'%%@N*+7% QZVY:D Y;>@"5;?% "?9N] #/(]J8#A#BD XV](!
MXAS0,>(* '>3GM0(7[/GZ4 )]G/2@!#;T -,% $9M\?TH 0P4 1F'/%- ,,)
MZT -\F@!OE4P 1T *(<4@%,/^<4 /\K- #Q"* 'K&<4P#R<T@'"#L:8&M96?
MF"@#J;/3BW:F2=79Z7VQ3 Z&VTT,.E &Q%I&1@_YY]*: D_L<>E4(;_9';!Q
M0 '2!QQ2N #1L<<\9[47 4:*!VHN U=(]N:+@/\ [']J+@']D=J3 7^R,]<F
MG< _LGD<>E%P$&CX'2BX"'2?:F [^R!WH 5=*]1]: $_LCB@ &E8[4@#^R*8
M!_9.>U #AI- !_9&.W0^E "_V3CM2L HTG.#18 _LK(]Z+ -_LG/44P'?V3^
M= "#2,=J %_LGVH >-+I6 ;_ &5M[4F@*<VDYSUI 4)=*Z\&F!F2Z90!BSZ4
M/3_/YT7 P+G2^M(9SMSIX'&.GO0!A7%G2 SVA(^E #?)]J %$.* #R,_Y_"@
M!1;@4 (8,<T -,- T0M%4C*S1XH @DCSS3 9MI ,*4 'EXI@*%Q0!((Z )-E
M "E,BD!'MV\T ,,8H KLF* (MN:0#2* &D4 )UIH!,XI@!%(!>M,!W6@!-N*
M0"[:8!C-(!,4 ,QB@!!3 G1<T 78DQ2 T8X<4P+0CQ2 :R9H C,5,!ABQ0 \
M1T 2K%FD!((J8#C#BD ](<TP->!.F:9)NVZ5:)9NP#U]O\_YXK1$&O$/YU0&
ME'VI 3$4F,;UYJ&-!T_"@9(K<5(QX^;^=(990T@+*\?A0!:7B@"PGMUH G6@
M"53N% %A30!,&S0 #F@!5H !0 N<#% '@[MN/IFI*)%DR10!:49_STI#+\=
MBR/2F!&X[F@"LP]* *;GTYH JR\"@"A*=OYT 4Y23Q3 :DF* -.WEP/P_I2
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M 1USS0!5DBS0!FSKC- &'<L%R/3_ .M0!@W4F<T#,.XYY_S_ )Q0!F_Q?C3
M[30[<(-QZ]J9+.A!+&F"+<5L7H OQ6.1DT ,FM 1^% 6.-UBR!Z=J0S@KV(K
MUZ>](#GY%V\T 0*-M,#3@DZ4"9L1'=3$75.*!ED#'2D,=C=2 <#[=J8%E!G]
M:D"R@[TAEE>?ZT#+8Y[T@% '^?>@!P%(8T#\OZ4P$ S3$)_^N@1(G/\ ^O\
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M IR)B@#.FC%(#(G04 8-T@H YN\';UH X^_'KZ4P.*U%<C\Z .5;G]:D8FW
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M- RT!CGMBD,F4=J! %_^O2&*?:F(9G_ZU,0W&: 'KUR:8&I:@&FA&W&,?C3
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M @\DT 1M$5H B9* (7&WM0!$JX/% &Q:<4 =%:MCD5HB6=!;G-:(@W(.?I3
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MTAH[/3U!Q4E'7V@ _*I TE% $I@SVH >(2!3 @ECH RIX\TQ%!HN] %=H^:
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ME;S@4@.0OA3 XN^^8\^_\O\ Z]-@<LY]Z@9$.,^O^?ZT /'&: 'CB@"3^=
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M4L:#\*3&*.!4C)5./K2&68N* +"C- %M3S0!,AQTH M=* +"'% $@- $R\4
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MLH)QE@.: /XX_$GB*Z\87USJ5])YMW=SRW$\FU5WRS.7D;:H"C+,3A0%'0
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M+G\JAC0S&?Z4F,E'6I&2 8I#)U% %A.?K0!:6@"RIS0!84T 3+0!.M $@&:
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M!<2@"_",T :D- S4CY_&@"VO'^% BRIW>] #LGM0,7-,!"<4P&YH 3- !DT
M&=W6@!2V3^E !0 T@#FD(&_6F!&>:0 X_P YIB&;<=!3$-(S_.@ V8H 786H
M < 6_#^5 %A$SQ5H3-"#Y:T1!K0BF(OQYH D4TACCZU#&AG3/O2&2*O-2,F!
MVT@)EH&64]* +*C'- %D4 6%&: +"B@"5* 'C_"@!_6@!P':@!,YH 3C_/-
M'S>LF/Y4BB99<4 2++0!+YH'2D!(LGI3 <\N1[>E %1WR.* *SOGTH IN: *
MK@]J8B%UXH&0A,T@+:C I /Z4 ;EC)G'X4,#I(3NQ_A2*-JU?:12&=5;,"*
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MGCUI@0.* (2*0R-CG_/K2 8#0-#NII#)EYH ?DB@!#0!$W]: *[<?2@"!FH
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M "(&D_\ ;W_Z63TA'U50!_/A\9O^1GUK_L)WO_I1)3 \YI@?;_[ O_(SW?\
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M%0 O2@!XYH E48H N1"@"_#S0!J1G\:!E^/% C0CX&:!DRG H D)Q0 X\]:
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MW(VES_.D%RA*^:8C*D7/Y_Y_I3 @*9]^U #Q%F@"9;;>,=*8&E#9 G)_K_\
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M(C-,#]4?V*OCW_;\">%K_P#U]M$S6<S29,L2G)A(=MQ>,']V$ROD(1M00Y=
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MJB2PLN* ';\'/%  S$TAB X- P:@!A44@%(XY]Z &[>] #QP?>@!ZKD8'YT
M31K@?I0QFC;S&/TQ2 WX;P#'T%(=S4M[_8>M(+F[%?+/U/X4Q7)!,(SUYQ5B
MN->_"]#ZT["N9<UYFJ2$5=^ZF(=NH$!YI#,RX4]*0S&E'4U)1F3'\*0&3-Q3
M S9.* *$@]:D!@- R9>OUI 6T2F,F*^O6F(9G- BH[XJA%"1L\4"(5.32 TH
M..E,#<MSD\B@#;@ H U8P .M %O=Q^% #"VW^= $;2]J5@(3/MZ46 C\_CV-
M  )\TP'+-0(M)-MH MK<8Z&@8JR[CB@!0_\ D_Y% $#-NH B SU_S_GUH D
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MK_A]K\7A36=/U&<,T5I>6\\BH 6*Q2J[!02 6(!P"0,]2.M(#]E?^&P? _\
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M*!#C>,G /% ")J;'_/\ A3N*Q<COR_?WJK@78IRXY.:9)<C:K MKR*0AY]Z
M()%]J0&)<19Y%2,PY^*15S&G&1S2&9DO'%,"D<GI2 F2 M18#1BM,?4>U.PK
MEA80G% 7 )QCH/I0!6<8X_S_ %I@49EW4",UJ (^M R];#- C?MFQ0!O6XXX
MH U8E!]J!%@)0!%)QP: *+O^/^?:@"F[;?\ /^- %=Y_0T 'G^GUH E6;C-
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MF3&F!CS&@#GKHT@.7OCC-,#BM0:@9QM[U..M ',OU_E4@,'7K0 Y5H D48H
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MCO0!\N$8J2B \9/>@"(\4 (#CVI@.%,0_<: )E.: )EI#)E^:D X8% #&XH
MB+?E0 S=GD4 6X3GG_/K0!=C%("VHS^5(8X*:8!L/2D!7D7/X4 4V&./>F Z
M.3!S^M C8@FX%6B36BDS^56(O1OC^E B<-F@!K** *<R9'- &%<0$\5-AG/7
M,!/:E8HSS!SS2&30V)>F(U(;( =,>E BPUI[4 (UMCKW_P _A0!6D@(Z#\:
M*,T% S)G% C-D7% %;&2* -&V7- &_:H10!O0+@4"-:-:8%@+B@"M,OZ4 9\
M_% &5*P% &;++2 B,N#0!/'-GG_(I@7XY"/QI@6 U #]V.?>D!:B;- $XR*
M)032 LJ30,G1MM &_9RYQ3 ZVR.!Q0(ZRUYQ3&=%;K@"D!=0XI /:7%,"N\U
M("E++FF!SEX?YTP.%U'DG]*0'#W[4,#+3KQ4E%V,XH M8SUH :: *[4@(CP*
M&,B///\ GFD(A:@9'C\J $#9^M R=!DYI#'4 -(S0! XQQ0!7- $3G.<\4"(
M@,#C_/I3)&F@9&3S]: &DXH$,P.E #,T +_*@8W.>AH&.4DTADP%,!ZGN>M
M$BG- %NWY84 >CZ5_*J1#/1=-4?G3).UL#D4P.FMZ -2/FF(D-( S3 2D 4
M%,!*0!3 0T % !TI !H 2F 4 +0 G6D 4 % !3 2D 8S3 * #I0 M(!* "F
M=: %I '2F!$]("G(* ,R:F!C7!S0!@7A- '+7QI <7>@<TQG&7X*YH YJ0=J
MD P* #;0!*!C% #L4 +MH&0$=^OO2&,9?K0!790:0R K2 85Q0 W&>M AVVD
M,C*XZ4 (PH&5GXH&59 #TH$RJPQ^5 BJ_/6@",KGB@!V<F@!0!D&@"0''!H
MF1\4 6T.><T 6XI*8C2C?% %M).GZ4T,MA\4P)B^>.U A=V:0"A\?Y_^O3 <
M&Z4@%W]J '^9VS0,3/O0(;C.<4#$*TQ#>E(!'.: &'VI@(30 TMB@ %  O'
MI .''TH G7K5$E^+GBJ0F:$38^G^?K6B)9HQ<51)HKSUH E%2,?UJ6-#=W-(
M8X<4ADRTADR&D!87D4 6E % $XR?PH L*,T 68^M $J\T 2#'^30 \9H <:
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MQ#3Q_2@8,=W'^?RH B/_ -:@0P\=*!C#STH$)G\J!@!CB@8_W_PI#)01_A0
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M,4ABJW3-(9(OZTADZD'K2 LJ* +(:@"RO'(H G7B@"=1F@"<<4 2 T .)Q0
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MT#&E<5($++0!#C)QSTH&1%?\]:0B)C0,KYQ_C2 7=WS0 F:!W&,* (&R.W-
MRJX[4"*C<TAD++2 B*8ZTQ"!,4 ,QBF(C;B@!F_% #U?%,"[$^*!%^.2@"]&
M_3TI@74DSWH F5Z8A=^/QH"XY6]: %+4AC@U #M^*8#]^.M #MV: #-(! WK
M3 :6Q0 F_G^M "DXI +D'IS0 @]J %W8(_"@!2<T 6D&*H1:C/I5(1HQL#6B
M(9J0]ZHDOK_.@"<4AC^GUJ6-#?;^E2,?2&/'(Q0!8'STAEA *0%H 4 3J<T
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ME6I&9,R8!^G^>: .>NX\T".:N(_Z4P,*=#Z4P(HK8^G-.PCHK.T*_P"/YT[
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M)I % #: %I@)0 &@!M "YH * $H .M !0 4@$ZT !I@% !2 * #.* $Q3 *
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M!H ,4 &: $H .E !2 !3 *0"4P#K0 A&:0!3 #2 * #K3 .M !G- !B@!!2
M*8"XH ADH I24 9LXH&8US0(YZZH YB^Z4 <=J!Q^% '&7H[TAF'CGK2 ?0,
M04AC_O4 .]OTH <!_P#JI &:8#&&#^% $3#(_&I&0GB@"H_% %9CSS2 3.V@
M ''2@!IH C<YH JR'C- RNYS2&5R?6D!'[4"&@;:!D3\U1)$U $#<4 18I@6
MHZ!&C%5 78_\\TR2^GO0!/@#_P#70 G6@ (H :./QH 4<]: )%/>@"P@H G
MQ0 TG'2D,K.<TAC#3 :&]: $#T .![>]("7- #UI@2K2 L*<?Y_^O5$EV XI
MH#3AYZUHB#5B;(K0DOH>N.*0%L'(]J3&**AC0T9H&/SFI&2J2:0$T9S2&3@&
M@"TA[4 6DX- $ZT 3(* )Q0!*"10 H.: '9_"@!,4 '6@#Y<)QUJ2B!CBF!
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M)J1E=B: &;J8# =U $^* )T&?;_/^?K2 </;I0!*!TS0!;0GM5$ER/'^?2J
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M23'Y4 7HF%("[&V#FD!?0\4 .WTP(6.,^M RG*<G\L_A0!3D."?SI 5'/UH
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M-)@T@,V24F@"DYW4P(5./I0 _% $J<]>E("44 2 YX-(!IYH C9R*8$);)H
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MGKLU3 Y6^/UI <9?#K2 Y"^;&:!F(QYI "]: 'C)H&B4"D,4<\4@'+Q3 ,4
M1-0,@D7% %=AMJ0*K?RH$5&:D,:.>?\ /^?>@!P- !G% $38H KO^M %5CF@
M"L] $8YH&-(S0#(S0(B/% $34 -!YI@6X@* -*(4Q&E'3 M#IZTR2>@!,XH
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M00/2&:J/Q3 EW9I"#=3 6@!* "@ H 3% !0 E "T )2 *8"=: % H 2D 4P
MT@$ZT  I@!H #Q0 @H 4T )F@ I !%, ZT *: (7YH HR\4@,N?BF!C7'%(#
MGKH8JF!RUYS4@<7J'?BF,X_4'W4@,4FD W&?K_\ 7H E% $N,4ABYI#' YI@
M!/\ G]* &-Z8I 5FH&5GI"*CG'YYH&52U(!1S0 =/YT )TH C8T 5GH JO\
M-S0!7+9H CS0 ,: (<\4 1GF@!AH 8!F@"Y'S3 T(SFF(TXUIH1:0TQ$H]J
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M_'_ZU KFHEP<<=*8R=;C\Z ()+DK0!GW,^ZF(YZYD&?2F!DR-CO^E %)P.*
M)[9L$8]: .QT[Y>GM2 [6QGV8I =3;7/YTP-2*XJQ&U:RYH W(),T ;434 6
M@F:FX!MH SKM=WY4 <1J2=:H#S;68><_A0!YGJD>T_C6;&C!QC^M26,84@&<
MG\Z0Q%&/:@"4*#0 X@TQ QVT 2*,=.],"PLFP<>G\Z (I)C@\TP*Y?\ *D(C
M:3/7M0,0XI -VXH L(G/- BVB$CWI#+B)M^E %I4Q0 I&V@8I'- R%EH$5I
M>U,"M(F*!%>09Z]* *3@B@"#D=J8$B/0!/&X/^?Z4")E.:8$@EI /#_YXH !
MSQ0 ]3B@ % "TP%Z_7I0!]6_![]E]/C+X1U_Q%::HD5]H$;33:<]N^)+98C*
M)!<AMJLXBN%2,(YWQ*':-)5=0+C/V1/V5I_VK-6NM/6Z>PM[2U\^2[%JUQ&)
M#(B1PMB6)49P9'3+;B(7PI 9E0,\W\2? N^T/QJ_@E6Q=_VHNG0S7$;P*_FS
M"*"=D_>,D4BLDPV^9^[<,I<$$H#[0M/^"=EEK/BK5O!MAXG275]-TZ&\"2:;
M+%'))+NW1.XF=8U0/9LTJ><6%T0L1:"1:=A7/C[]FCX#S_M'^);?P]#,]LDJ
M3R3W2VYN%@CBC9@[H'C 5G"0AF=0'E09)(5D,=^TO\"9_P!G#Q-<^'II9+E(
MD@DANF@-NMQ'+&KET0O)E5??#N5V!>)QD,&50#Z+\?\ [#]E\,/%/ASPCJ?B
M)%OM;3-RT=A*\=I))^[ME0^8OVA9[@/ K_N#&%$TJ(C 4["N?-GQH^!E]\'O
M%EWX2#?VA=PSQ10FWC<M/]H1)( L0!82,LJ!HEWXD)17D #LAGOO[8'[$T_[
M*<&G7*W\FJ6]\\\;RBS-ND$D81HT9_.F4M*&D**2A(A<@, VUV!,YJ+]F1=&
M^'4/C^^U1(C>71M['3UMW=IBLSQ-OGW!8F AN)<%'0I&@\P22[% /,?A]X2O
M_'M_;Z7I<#W-Y<OLAB0<L<9)). J@ L[L0B("[,%4D,#],Y/^"?T-JXTN#Q3
MI<GB,)&3I;X0AR@DD7<)7G*K&6D1OLX+H%8I&K%E9)\F6OPPU@ZW_P (XEOY
MNJB;R3;Q2Q38D RRF2)VC&SGS26 BVN)"FQ\,#[9C_8>V_\ $N_X2/2O^$A_
MZ!F__@?W]WG_ .I_>_\ 'O[?<_>4"/F#3/AS>IXB@\-ZBK65W+>06DH==QC,
MTBH'P& =<,'4JVV12&5MK!J!GTWK/[&TOA35FM=5UFPT_3./(OKJ2**2Y_=A
MG\FV,V3Y;E8Y/,DCX977=G;0!Y3\</@%>_!EH+A)DO\ 2;M$:UU")<1N67=L
M8!G"L1EHR&998_G5B1(L8!P_PO\ ACJGQ?OQIVE(KS!?,D9W5%CBWHC2,2<E
M5+KD('<C[J-TH$?3]Y^QD]U$\&D:[IVH:Q;JS7.G(ZJZ&,8D16$CL6$FV(&6
M.!<MEVC/RD \,^''PIM_$NLW>CZWJ4&BO:+*))9S&R^=%*L30@F:-"W+$%6;
M(0X!'( /T9_:B^$>E_$K5+:34O$MKI/DVH6.SN#&<[I'+3*KW$6-^ A(7GR@
M"QV@* ?!&@?#6ZUSP+?Z]_:,J6EC?*O]G;6,3RM]GC\[/F!5?;/MSY;-M7;N
MPW !\]^93 ]A^$7P1UCXV3R1:6L02#;Y\TL@2./>'*9 W2-N,;*-B/@XW;5Y
MI >U>)?V1VDLYKOPSK%GKQM5W7$%N5\Y0?N>6L<DP=B!(=K&-CLP@D<[0 ?+
MW@[P??>/KZ+3=-B\Z[FW^7'O1-VQ&=OF=E4852>2,XP.2!0!]>_\,6_\N'_"
M0:9_;W_0.W?\#^]N\[_5?O?^/?V^Y^\H ^:(_A9?6/B*W\-ZD/LEW+<VT$G*
M2^7]H*;6^1]K860-@,,]"0<X /I;4_V,4\,7TD6L:]8Z?8GBUGN-B2W)5(F<
MK TRJJ*9&0DRE]R ^7MD5J .0U?]C'Q/HEXEO,UF+8P2SR7YF9;2!(OOB9VC
M5T;[I'R$$$L"5CE,8!6^*_[+D_@'2O[>TW4;;5M)78'GB(4JS2&+*@/(CH'V
MH2LA<.Q!C"HST ?*@XI@% !0 E "D9H * &XH * %H *0!0 =*8$+T@*,IJ@
M,R89I 8MR* .;NSC- '*7OK[T#..OCU[T".+OS28S)8T@$#8- $@YY^E $@%
M!0_% #\T +G-2! ZB@"%B>E#&5G.*0%.3C\* *K\]Z0 M #NM $?\Z (R<4
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MV"__ $X2T#/FC]MG5);GQWJ,<CLZPI:I$K,2$4VT3E4!X52SL^!@;F9L9))
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M%UC+':K/;W0=@O0,P1 Q')"*#G:, 'PEB@ H 4&@!M, SBD M  :8"$T  I
M %, H ,9H @<XI 49.*I@9LYS2 Q+FD!SUW0!R-][4QG&WY_3V_E3$<;>CMT
MI,9BD<\5( I(H E!Q0!*.!04.% #\_C2 #2 B?)SZ4 0,!VH&56]?\_Y_P ]
M*0%20T 5#2 ?^- #3Q_^N@!"<#Z=J &9S0!789//6@"K)Q0!784 1GF@!IS0
M WI0 PT 0M@^] #AS0!;6F(T(..*8&I$*8%E..G6F22CD?2@ P#S0 AYZ]:
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MYN#0! Z?C0(JNE BLWS4 5G%,15D!H B4F@8X4 3*:8B=3CI3 L)QBD!,.:
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MTP.-OC0P,9AFI&+VH >,T 2K0-#Q0QBD=*0 PS2 8U,"N?FXI#*LG3%("HU
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M"B\F33 @\V@"C<R\4"//M8;.<&A@>7ZE\QJ&4C%:I*#^5(:'ACF@8H?'3^=
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MH4Q%I;G=2 G6YS0!.+C/>F!.L^* )A/FD,E6>F!*)LT 3K)0(D$F*0#_ #*
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M%OGG_&F!D3Q8H RIX>.*8&3.N#3),UQMH IRC% &;*A!H 8 3VH E530!=2
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M$10(9C'6@!X]:8#QG_ZW^?\ .:!$H% $PXJ@'BD [ -,!^V@!>:0#3Q3&(*
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MRKGUH$2=?QH < * '#GB@ % "EO6@!4'.: -2 XI%&S;/G%(#;MFI ;<+_\
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M]M]><T@%-W3 0W.: ,Z=MU(91>D!RU[)N;WJ644 W^?YU(QU !G_  H C/\
M]>@"/- "@[N!_+UI@7(1N[?YY^E &K <G^OXT :*4BBP.* %!H 0G H$-8C&
M/\]*8B*1L_Y_&@" MNI (#F@"9&H&6 W ]>>*!DE "X/^%(!AY]J (SQ2 @?
M_/UI@57&: *S  8_QI"(&.*8R(B@"*F2% #A_3_/^>E,!V<TQ$R\B@!XXZT
M2@=J '+0 N,]*8#0,4@&GCF@ Z_YZT .&#[TQB#CF@!P;%(!1R,4@)%&/SH
MVM.4MCZTP.VL(MV..>*9+.PLX=U,1TUK;YH VHK;-,"Y]FH$5WMLTT!5>V)[
M50%9[6D!5>U ]J5P*CVN:8%5K3;2 J268- %)[/9_6F@*<MD#28%.6QS0!1D
ML"W^>U %-[+%,"![<CO0!7:,K_GM0 G2@8*V#0 \/BD!.ET13 M1WQ%("]'?
MXQ0!>BO\T6 NI>YYI 7X[[=P<4P+B7H/>D(M)>4 7%O!ZT 6%N\^E RR+FF
MUKB@"![B@10>>D!F2RTAF-<OQ5 8%PV:!'-W6#2 YNY3\J ,<P8[=32&)LH
M4*: '8S0 \+04!]J0"$4 1,<<4@('.,T 5I/:D,IOD\4@(.E #AS0 _&*8A
M..G% Q#TI 5I* *3G%("LU #2.] "9I@1L: (R?2@"$FF +0(O14P-.*F!IQ
M?-0A%H-3$2]!B@ [T !&* &]* #KUH ES0!.AH D/.:!E:3'X4 5FI#(3Q2
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M0 W:10!( /RI"'A^*+#$+[C18"-GH C\WBAL")YJ5P*CW6VD,HM=YZX_S^5
M6+$$^12 L1S$=_2D.QHQ7A4?Y_PH"Q9^V[N/YT7"PTW!%%PL1K?;#C]?\_\
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MABSUH 390,"I'/\ D4AD9&?Z4@(33 K..:!D#]./K4@5)!2 @(H 44 2#K3
M, 4 1D8ZT@*\@S0!3DI 53QQVH CZT !%,"(\^U #&H @:F(<E %V+FF!J0C
M% &A&<<4T(M]>:8B4<'G\Z $ S0 [-  P].U "!: )5]S0!.!B@!S&@:*[@"
MD,JD9^E(",BF [&>GZ4@)%%,"<#MUZ_Y_P#KU(!BG8"7K0!,@Q0!:4_G5$EM
M1CI3$7$JT2S02M"2Y%Q3$6D.?>I*)EY-(!34E#>G2I&2BD!*G6D,M*VR@"P/
MFH G3(H LH<CG\Z )QS_ %H L#YJ '@[>E $@H <M  10 $[A0!\HRJ#Q0,S
MY5H"Y4.12L%QJG-,"PE $ZCVH$6%X_*@"93@T 2GGF@ 89H 49Q0 N<?6@!P
MSF@"]$,4F4:,)/3\Z3 OQ4AEL-_G]*0$@F- $B3X'M0!:6ZXI@+]L]*!"+=]
M,=Z0#S><4["&//D50ABOVI@2>8!30BN6_.J0$+-B@")FVYI@0-0!&6_.@!A;
M% #=X]:5P&&2BX$32X&*+@5GNQUI#*<EYBD!2DN\\YXI 57GW<^M*X#%F)H*
M-2VYX]^E %X<]?RI 6 /U_SVHN!*HQ_.@ 89/-,"(YH BDFV@"F2*LF[K0!<
MCDS^% &A'+F@!\L^W&* ,"ZG)H&8SG)_S_G\:D8@XI /W9H&,/'%(!.?2@!<
M8H&.$>: L3*Q_*F(TH3M&: -.-NM(HL+0 H;M0)C/>F(C;CWH @D- %5F_"@
M"$M@_P!* 'J^<T@+B/ZT#+0?- %A3S^/I0,>?>I 810(@DY_QH&4W]N:8BH_
M'^%(9 >_O_G- $!]J !N*8$>*9+'C)I@2 8I@2@T") *8#L;J '@XX^E "GF
M@!IS^5 Q"<T (>] "?>H  ,T *><4 .QF@!X% '1:2/YT >DZ8*9!W]BF*8C
MJK5*8S;ACI 6O+H$1F/%,"(Q9H B:&D!"8: (&M\4P(#;4 5FMZ *[V^: *K
M6V:: JO;9I@56M:5P*KVN>U %9K0TP*KVFWGUJ0*KVAI 5)+#;VH JM98[>W
MX4QE-['I3$4WLO;O3 J/9X]Z *S6Q% $?D]J &<T@%S^5 R5;@K2 G2[(I 6
MDO<8I@78[W-%@+0OOI0 &_SW_"@"%KO% %9[K-(10DFZ\T 9\LW'/2F!2=_R
MH HL* (RI/% Q/+[T@$,>: $,.: (F@]*0$+0_Y_&@"#RL4#()(MW)I#*TB8
M%("A**!E5ABD!6(P3BD!(O H <#S0 =: &OTH J/0!5D&3S2 K'F@"(K3 2@
M",\4 1GF@"$\=*8"QB@1?C/-,#3AI@7XCWH0BVK4Q$E "YXH 0#O0 N* &]>
M: )D.* )U&/TH <W- %1^*!D#+FI&-'^% "H: )=M $O2@!<\T .48H M+Q0
M!.@P:H1=2FB2['5HEEZ,\58BZG'/K3)+JBD,>#2&./S#FI*$'%2,<#VI 3 T
MADZG H MJ: )QTP?_KT 3ID_I0!:'- $R\4 2@8XH >#G_.:  T .'% #@Y6
M@#Y0=MPH HR 8H J2)MH @[T 3+0!;3U- %E5 ZT 3 Y&* 'A: '#]: ' 8^
MM "9Q0 J#F@"_$W>DRB_&Q_E2&:$1Q_GWI 62W&:0$$C<'/UH C+XZ4P W'/
MZ4"(WN:8#5NL'_/UIB+0NL]:!$OVDGC-,!WG T 2-<YYH$1^?_\ 6I@(9"*H
M")I*+@5VE%%P(C,*3 KO<YY]/\*5P(&O H(% %22\[]J0RB]\>A]^] 6*<MY
MGJ>U*X[%0W1/UI7&1BX/04K@/0[J8RROK0!J6D@% C7C&1Q2 G3Y?3_/XT#+
M&W- $;\=*8$+<4",Z=MYXYQ^%,"!)<"@1H)/N_S^M,1=CF*CB@"&6;(H S)3
MS0,@*U(Q, <GOQ0,<>*0 (^U(!H3^E!0X)CJ* ';,TQ#H^*!&A#Q0!IQC H&
M7$&>* )O))% AI0B@"I(2M %"7 IB*<I_/\ PH K;\4#)?-SWI6 M+)GK0"+
MD;4BBTKYQ_GVH$3ALTAB]J0$#8H INV3_GWH KN3C% %8^_X4 0L<T ,QZ4P
M%Q3)%7_)_P BF [.<TP)5Y'6F(D&1TI *>:8#QTR:0#B=W>@!F?2F ,,4#&E
MJ %W<?3F@ SV_6@ (';I0 [/.: 'KQ^E CHM'^4#L,T >DZ6,X-,D] L!3 Z
MZTXH VX:8%[K0(:5S0,;MH$1F/- #'CQ2 C:/%,"$Q4@(6BI@0M#B@"NT&?S
MH A>W[F@"N]MFD! ]MFF!5:VH KFUH K/:BD!5DM,FF!4:TQTH KO:[J *KV
MF* *TEF30F!3DLJH"H]G0!4>T_3^M %,V>. /\_Y]:0%9K6@"%H"M(9'M.:
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MS=Z8#DDP:0RTDGK2 N(] %U9,\DTAEE'Q4C)-Y_S_GI0 TMF@"LY)IB*CC%
M%8@4AE9AGI_G_P"M0 VJ$*.:!#P:8"H,?2F!*.*!$@&>?\_XTP'+2 <?3K0
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MIXY% #"Q'3_/I0!59\4 1M(6_P B@=B&68T@,V24F@93>0]Z0$62: &@9]J
M)$BQ2 L*E #EAH ?Y.!0 \1;: !8Z!D@XS0!:C4B@1HQK0,N1R$4AE@R'% $
M;OVH&0E-U,1+#;ECR#BF(U(K7;VIB+Z6^[KVQ3)+*6O?% $3VHQ^% &'<VX'
M^>] &.W4^M(H:ISZ?G0!,!28$P3-(8[9F@=QGEXI#(G7BF (-M F:]E 9#^M
M CKH(1$, ?4TP+1( SUI (?3TH$0N,T#*%P?TH Q;E N:H1@3F@#-=O6@ 60
M9I 6$<#BA@7(Y,T@+J28%247%DH&2A\4@%$F.:!$+G=U_.@96<XI@5W/O^E
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M;2&4)!C- $9;% #T?/X4@'AL8I@.!-(!X?/_ .N@!V\F@!Q:@!Q8=Z0#2W%
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M;V&"["N?*I/^?:D,CZ4QGTU^S;^RGX@_:CGO(M$:UB2QCC:>:ZE:.,-*6$2
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MH:EC'DYJ2A0:FPQ?O4@)EYZ>M(993\A0!80<T 3*N.E %I0&- $P&?I0!*M
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M_+ ^M(!KK_G_ #^= $$B8-2452F: +]L@'YTQ,W$7 ]Z8B18_6F(OQ)^?^%
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MP(UB;0];A\JYBPR.N3%/$Q(2:%R!OB?!P<!E8-&ZI*CHJ*/+2,T@/T%^%O[
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MQ(58TVJH!]':G^Q@GA>^DBUC7K'3[$Y%K<7&Q);DJD3.5@:955%,C(292^Y
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ML%X596&"&! ((P01D4 ?!Y6F!]V_\%!;N6;Q'90,[&%-.1UC+':KO/,'8+G
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MK30',W<./I0P.7NH=O-2!S%VI6F,YN<[3Q2 B64T@+"S\4 64N<>E,"PLW%
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M$ W.<4 <9?7INF]J ,X+F@"4+F@"9%H >JFD,=Y>* ).U $JC% A>M R3?\
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M_.@"E)\V<T 5\T -H !Q0 F,TP&-QF@17- %B(4P-NV'2J)-F 9Z=Z -R):
M-)!WH N*O>F A2F PH#0 TQYH B,>[G_ #_]:@!/*H #'2 KO&.U(#/DB[4
M0!.])E#E&*0#OK0P$Q2 0F@"#E:8 II@64&:"2Y&: +B?+^'-4A%J,8JT)EZ
M$U:(+T72J M"D!.M2QCL=N]24**3&.'%(9*O-)@6% I 64&<4 3+0!87C@4
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M7- &2TM("J\_% [%.>7=0!0<[NO>D,K/0,J.<4@#S/6F*Q-'*5YH$6_.XZT
M0329I 43+B@14DFS]!5#*<DN*!#XY,F@#4@% S8MQ0!JPC%4!LVZ<5(S82.@
M+$XCP/RH"Q%(G/>D,H2+MH RIQFD!@W(QS3 P[B,Y/% &0Z]Z &@9H G'K2
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MJ#\J8'*:G:"44T58\<U_3_+8D#O_ )XH86.)F&S(]*@DKE\4@!),T 6XY,T
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M(8I'%( ;@\4 2PZA)9G*'%-".ALOB-=V/&0?J/\ ZU6F38V#\6;EN@7/T_\
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M+/Q3&8US)^--,1SMT^:=P.3O7H XV_.* .0NA@U+ JT#&@U($H..G6@!X;:
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M0 9QTH D#<T 3QG'2@ !VT ,SB@"Y&212*+,8I 3D8I# DX% %=O2F(HN-U
M#@,4 3(: +:<4P-"(51)92J)+Z5HB6747C-,1;4YI,8\U($I! J2A V*!CEJ
M0)T&:0R9>/:@"TAYH L)S0!849_.@"91F@"8#'3K0!*.M $H- "XR* %Q0 "
M@#176"XZTS4G2^,GT_QI-C)'D!I 49.,\TP,N:I Q;E<TR68-U%YG'>F0<?>
MVHSGW_S_ #IB*BVO&/\ /6@1:6WVX].@- R<(<T@)%% %J,__KI%%H'/6D P
MG%2,"<_A0,KRM0!F3\'G\:D9E7&&YH Q9CZ?Y%424V;BF(=$^?K3 T8')X%
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MFD!6D;-4(JNW<4"(7H A- "!?UH >!B@!V* % S0 ]5QUH >J8XH E1>: )
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M AYH B89YH @?ZT 5G_QH KM0!"30!'TH ;VQ0!$3BF(B8YH @8YH DC.*:
MOQ'=0)F@G)JA&A$,4 6E0"@"0KN% #6_2@"/;^ H 0@T )R>* )%R: )%-
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M!4;GI3)$H 44 68S0!=C>@"VDG_ZJ +23YZT 3K/CTI#182XZ FD,>+@'K0
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MI")O[3P.O^?\]JH!3JON* &?VIZD4 ']JXH 0ZF/6@!HU3'7'2@!?[4_#\:
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MF_B@!?,H >&S2 F#[J ';\T@';L4 (3B@!A:@9 W% %)NM("%J (&/I0 TT
M1$_A3 A/% $3F@".@1*AQ3 T8CF@#2B&*H1I1<4"+B'=WH D _S^- B,M0 G
M3C_/^?YT#$X/;]: 'CCOS0!*!DT 3A>* (F6@"+% %H"D43@Y]Z0R4-0!-UH
M @SBF!28[:0A4.: )%'2@"TAZ8Z4P-& X%,@NI5H1;C&:T1)>09%,197BD,>
M128#JDH=G=S2&/0U($JC%(993B@"<#/UH LH>>* )Q[T 6!0!,.!0!-F@"3
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MWK4@&_'2G<! XZ^M,!PDSSWH <)/2@ !H 1FH'8B)[T 1%\_6@1$[4 1E^]
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MUZ4R2W&?YT 7X: --3FI*+4;8X%,"[&<FI&:R#CW[5)0$4@(7XH A7!_S_\
M6H [3290.M#*.EAEW=:0&U;')H&CJ[5!B@#1'% C)OI_UI@<U.Y;.:JXCF]0
MYS1<#R[70<\U9DSSBY7-,1G2$F@"%N!Q0 AYH 8: %((H 81F@!&!- #2O%
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MN*8 5H 0)GM0 ;>PH "M "%<4 &W'M0 N,4 -QB@!<>O% "@>M  RT )MS0
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M"9":0R>/WH L)_D4 65^6@"=#B@"=1CI0!.A- $P.* 'J,4 /R* $Q0  XH
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MS.6!]:8'F.MD$FM$9,X>9*HDS'BV].] $:QT #1 4 )Y?;% #O*H /*!]Z
MQT *(Z #810 ;#_D4  BH 0P@<B@ V4 !BQ0 HCH :(Z %V8H 3R\\>E  (\
M4 (8\4  CQTH !&,T 'EF@!_EXH :(OUH !'B@ ,?Y4 -,>: %"8X_I0 GEX
MX_S_ )_SUH 4)B@ \O'UH 4QT ($[XH -IH -F.U !L- ";* #9F@!-F/I0
M;* $\O;0 HC [T &SI0 NS- !Y?&* &[: $\O\J %,63]* &[<T !C]/6@ "
MYZ?SH 39WH "OI2&*(\4P$V[:!#=G?\ 6@ *^G>@ V;<T )B@!!&* !E_6@!
M&6@!"I_&@!NSF@!=O- Q OK2&(12 =U[TP$"_P#UZ0 ?FXJB1N,\4 &V@!=G
M]: $*XH 3[M "D4 )CM0 ;: &D8H 0<4  &* &XH ,8H ,8H 3%  !B@!,4
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M 9MQ/B@5SAM6.3@=,5JC)G+/#G_/:F(I21D>M $ CH 01D]J %\O/6@!_ET
M B H 41#G/?_  H /)Q0 GDX]J  Q!?_ -1H 88L]N: '>5GM0 ICSUH 3RJ
M $\G/)H 7RN.>>* !8\\4 -6'% "^5C]* #R>OK0 IBW=>E #O+S0 WRR* $
M$6.WI0 HBH 9Y5 #PN: &>5GM0 @@Q^/:@!VST[?A0 BI0 *F!0 NS'X]: $
M\J@ ,?7% #=F.: %"G''^?Z4 !BV]>M ">5C_/\ G_(H ;Y6.1UH 7RO;]*
M#RL=J %$6* %V4 -\O%  8@.* $V9H 38.W\Z %\OB@!#'S0 GEXH 85QQ0
MNR@!I3/6@!"@_P .: '%?2@!-N: $"9H 0+QCZ<T  3/- "%3VH :4H #'F@
M!A3% #63U% "]/;UH :%S_2D4!7% !LH 0+FBPA"E,0@3% #]N.M #=E #=M
M #@AH :RB@! M !B@ 4?A0 F.W_UJ %QB@!A6@!NW_/\J !5H :5_.@ V;J
M#&/PH 1ESTH 3;0 _P O=0 JH<^U !Y8.,]Z &E,T 0NE $&WF@!-M #@N?I
M2&)L_P XH&(U,0UEQ0(3% "$9H 9MH ",T@!5I@647% %Q!F@195,T[#'[ *
M (G3-("LRT ,(Q0!$1WH :PH&1'FD%QC+B@"&3C\*!E.5-M("HU,",<4A$R&
MJ$:,8H U8#0!I)S0!;'- #_\B@!.IH "<_Y_S_G\J!#<T#' YH G08% $V:
M(6- %4L/I0 [- R0-2&*&I *3[4 0N?RH K$X-,D>CYI@6HZ +\9Z4 ;-J,C
MVH U$SQ5(EEQ15H&6D'I5DDZC.*!",<U(QQ.*3*'#GV-2,<*D"8&D,L1X]J
M+"#'M0!94YH G3 Z?Y_#% %A,CF@"16Q0!, : )<^O- #NG0_6@ S0 'TZT
M?.>?7_/:H+(&Y- %27YA0(J2,6YH JB0BF!K6=U@\G^M*P&Y#-G_ /72&:D-
MUGB@9=6ZX]Z %$^1_C3$*+C<: +D$NWI0!LQ7!7FI*+JW1% RP)0: &[LC%
M!G'^?2D(K/S_ )[4P*[C=UI@4I8LYIDF?+:[J=Q%%X,'B@"HT.*8K#5CYZ4
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M_P ]?TZT -,6?\__ %J %$6* '&'% ">6?PH /+Y_P#K4 ,:+';Z4 /\O&*
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M $"T  &>*!B8H$(!0 F* (^E #<T  7- $J+0!;5/TH$6T7=S3&3XI@.VX%
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M,:HD8(_\: (70G_/:@"K-'M- #,4 ,V8H >$H 4IF@ V4 *%]NM #RA.1Z4
M-*8H 0I0 QD/UH =LS[\4 )LS^=  4S0 W;F@!2GM0 ;<4 &S\C0 !<4 ,V
M\4 +Y?>@!"IH 0)F@!Y3B@!H09.: %*4 !2@!"GYT -QMY_S_*@!S+Z4 -*8
M_P ]: #;B@!NW_\ 50 %* &[* ';/RH 0+GZ4 (4]J $*_RH 0IGZ"@!=F:
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MYI#+,?RCF@9*)"I^E("U%-D$&F ,W-,0\ =<T"' =/I0!$P% %.9: &_=%
M1MH ,4 & : #'\Z '$9ZB@!30 W.V@!HYH =CM0 G'Z4  % "&@!6YY_+_/-
M "%>/>@!AYH 7J: $(S0 ;=QQ0 FW/UH 0#- #AUXZT )B@!/O<T !XYH #S
MQ0 J\]: $*X'% "8S0  8H ;CUH "OYT )C)H ,<T ! H 3IQVH ;C/UH ".
M* $^]G\J $X- "X' H 3J<T *U #5H 7_/XT )TH ;M% #&Z_P Z % H 9MQ
M0 I&* &;* ';0/\ /TH 0# H 3;SQ0 FV@ V8H -N: &E<8_SVH "* &X_\
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MK9H >H_.@"51B@!^: $ZT +DB@#YO9:DHC(]* (73]*8$3Q9I 1%,TP%6,4
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M4V]* &L* (67'%("NRXH I2Q\4 4'CS2$5'7;0!79<T#(&&TT /1Z +"38I
M3":@!?.S0 PS9H ;YQZT7 3SZ8">=F@ \ZD QIL4 (9LT +YN:8$RM0!91J
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M0(I%:!E>9>* *&[!H D66D _S: '>;0 TRXI -\W%,!#+0 &7- #?,H 3S:
M$\R@!ZOBF!91O2@"VCT 65;% $V[/TH "U #E:@"W'QTH U8>:11J0G'?G_/
M% &_9C--"9M]:T))_P!:8F6%]*HDF4?E5 -D&>E2 Q>/K4L:)=P]*D9*@S[4
MF,E'-2,G% %E>E %A1NH F&* )UH F3GO0 \>M $_M0 I/K0 8H 5FVB@#Y_
M$;$4#+2V#S<[: &3:;*HR5./I2 SW0H>1S0,CS2 7=3 <O/\J0&C9KDCUXH
MZ."+C_/^?\1BD47T^2D,M*W&* &N*!%*3C/2@#GK^Z$(]33$SE);CS#S0(B+
MY% QIEH ;NIB'!L]/\\TP) =M("0-CGH: )-] !G% #A(: )!)[T 2"2@"02
M9^E #UEXS2 ?OV]* '&6@8&3% A1+GZ4 /6<M3 G2?'2F!,)0.G2D!&9.: *
M[R=J8$&_\Z ) W:F(F'R]J0R=7Q0 C/Q0!&[[30A,J%P<4Q#-V* %5\?E_*@
M!N_'M_G_ #Q0 ;\\9]: $$F: %#'\?Z4 -\V@!_F9Y^M !YO]: &&3.?K^=
M"%Z %+[OZ4 )OS^E  9=U "!]U #0_I0 !]IH 3>/\F@ #T  D/7\: %5SU%
M "[\4 ('Q0 N^@! ^* #=VH "X'2@!2V.AH :K\_6@!V_% !OH 3/&/\_P J
M %+4 )O[4 +O H 86S0 N^@!"^: $,F.E "[J '%\?Y_S_GF@ +#/- "[^W:
M@!0P% !NSUH  X% !OQTH <'_P#K4 )N_P#KT *9 O2@ \R@!/,H <9,T "R
M>E #]^* $\S% $GF8H 3?NZT 'F9Z4 !?K^E  9 : $W]Z $+T +YE  ),T
M/+A*  ,* '"3/6@!=WK0 !LT /#4 +N_QH -W&*  /0 %A[?YQ0 @EH 4-0
MX/F@!0^:  O0 &3'TH =NH 4OG\Z  -0 [?0 ;\GFF N_-(",O0!&6S[T 0.
MV* *4C9- &?*X.: *$S9_P#UT 4G(H 9C'TH -QH -U !Q0  T .&/I0 I%
M"K\M "CUH LIQ0!>B;MW_P B@"[%Q0!;7_/% #U&*  BF UQ_G]* ("N?R]:
M8#&3CBD!%M% $3 =*8$#@4 0,.>* &,F: *KK4@4WCH$49%Q0,H2';0!D3<&
M@"+S* #S:  2T +YE(!/,Q0 TR9H #)2 3S*8!OH 4/0!*'I@6D- %Z,YH N
M*V: )0<T +G;2 D6F!=BH U(!MI#-6']<T#-VS&.U-$LW .U:"'J<TP+49!]
MJI$$ZBJ ;(<XJ0$&.U2QH<*D9,@Q]:3&2KS2&6$.*0%@?K0!-'D\4 64.>*
M'CF@"UCVH E QB@"1?:@!>E "]* % S0!Q=AX?6'#/W'\J0S6,*H, <4#&D!
M^3_*@#-N]$@O@?X&]1T_S[T[@>::AIKV#E6&/>@11Q2&2(-Q%(#;TN+/X4F-
M'1@;1Q2&2 ?SH&/W4 ,9Z ,JY?KGI2 XK4I0QP/\CZ_Y]::$S$+?E3)%5]M
MQ0_/%,0X'-,"9!Z^U("P!BF X?CWH 1J #/K0 F<]: %#4@'ES_GFF [S* '
M>9GZ4@'>9S0 OFT6 7S,=_\ "D >;Z4P'J_:@"P#BF!./2@!CFD!7SFF J)2
M MHF[_/^-4(GZ4ABG^5("%GSS3L25I'H&5/,IB&F3/\ GO0 F[/';F@!A? H
M <),T -+T .9\^_^?\_Y% #?,S0 [?0 ADS0 F['2@ \R@!V^@!H?&>: &B7
MOZ4 *9-M #=^: #=G_/% "F2@!"] "^9C_/^?K0 >;C!H ;OQT[T *&SGTH
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M@!IDH <6 %  )?\ ZU ""3VQ0 IES0 F_O0 ]7I (9,?RI@(6S0 OG4 'F4
M(92: &^9CTH  _>@ $V* '>9W_SQ0 HE]* %\WWH !)VH 3S,T !ES0 TRT
M.,FV@!C2\]: #S<T (TF#0 OF^E #C-@8_2@!IDQWXH 7S<&@!?-XH 03>E
M#A..<8_S^-  9_I0 &;- "^=[T +YU "&;- !YV: %\Z@!!/CG- #TFH 3S\
MT .,^* '">@ %Q0 ><#WH =YV<T  GQD_6@!/.H <)J  SXH <)=U "B?K_G
MF@!1,.U "B?I0 IN* $,@_&@!!+R>U  T^?PH 7S: 'B?&/\XH 3S<8H !/@
M4 1O,!0!4DDSVH IR2;J *S24 5G>@!GM0 %PU "[L"@8SS*!"AL4  <YQ0
MY7_E0!(),4 /#9H FC84 6DDQTH O129% %I&Q0!*K#\: )=V10 H(% "@YH
M 7 /2F!!)0!3?F@"L>/QI@1GYJ ')Q0!(5ST_.D!7D3@4",J9<4@,2=>] S(
MF% C,D&*!D5 #LT@ FD 9I@)0 HXH #0 @H >#2 FCJ@+2T 7DH M+0!97BD
M Y>*0R9>*:$7D-,#5@]J -2+D?Y_QI#-VT&>E"$:R'/X5J(L(:!7+"G'-623
MHQ% #9!B@ !P1C_]52QHE4YJ1CT.:0R<<TF,G3YJ0$ZT 3CCI0!844 3 XH
MG0XH E6@"6@!>O7I0 _WH 1N?K0!HQIO/(YJ#022#;0!5*[J!E.6('IUH$9I
M^1B#UY% F>17T6QV7WIB(XHR3S0!UELF%J2C07F@9*!D4"$D-2,RKHX''>F!
MS5W)@$^U '$7#[B:HDJDYX[4 +TXIB)TXI@6D&?K0!=1,]:0%@+CCM0 %<4
M1'% #3S3 9@#^M(!AYI@(QQ2 @9^U42-WYH C)Q0!&9* '*_O0!JVW[PTAHZ
MNSL\_A_.I*1U%GI^><4BK&VEA@8IA8G.DY&,4 9]QIA'8TR3 FL-G8_2@13:
M''^?SI@1.I'OTI 9\X"TP,6:2F29<LOY4 5O,H 0R4 (7ZT &\"@!2: $\W-
M  7H 7?G]* #S,]Z $+8_.@!ID[&@!2]  '% "-)_P#6H ;OH #)F@!C29H
M<)* &F2@ +B@!0P'% !OH <7[?RH /,H -^?>@!OFC\?2@!0Y% $>Z@!?,R*
M %WB@!?,Q0 X2YXH 3S: #S>]  )<]Z $,N: %$O:@ \R@ \V@!/,H /-H 4
M2[AS0 OF4 'F9H /,SR* $#YH #)0 P29H !)B@!HDSQ0 \RY^E #/,)H 42
MYYH ;YN?_P!= "^9B@!@DH #-F@!!-GTH <9\4 *+CB@!//]Z %\WJ: #S\4
M 'G4 !E-  )\4 +YVV@ 6;.* '>:30 >=@T +YW84 *+C% !YV:  3_K0 OG
M8^E "^=0 OG'O0 \3YZT *)P<8H 434 (9^.M "F;\J #[10 AGW=.]  )Z
M$\^@ \[=UH >)=WU- "^;S[T 2;Z &M)B@"!G[=J *K-B@"N[XH @:04 1[L
MT *&H 0R4 -WYH ,T@)%.V@!P?% #E;- #LTP)4DSQ0!.DNV@"VDV?YT 65F
MS0!;6;- $JR=.U #U//O0!*7/X]: 'DT 5W;- %*3G_&@"#=C^5,!A_G_GM0
M \#TZ4P+0X% $,GZ4A&7,F#S2 P[A: ,6<9H RY10,KT .I '2@ H #0 @H
M#2 44P%'% $RFF!92@"ZM %E: +2FD!(.:!DZ#-,1?B- &I!0!KQ-F@#9LF[
M]: -4"K$6 >*9+)P"*H1..13 5Z &I^HJ6-$@XJ1DR'-)C)T8@\FI&3(2.*
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M7- "^;F@!OF9H 42YH !)0 [S2*  39]J 'B3'XT ()=M #A)LZ<4 'F8[T
M-$^/I0 ADS0 GFXH /-]Z )%DH 7S"30!9#\8H&!DS0!!(] ,A=N] BNST 5
MV8=J $,E #/,H 7S* $W4 .1LT@)@: "@!Y/?O2 ,DTP!7QUI@.$F?Y4 3I+
M0!92<C_.: +4=Q0!<BGH N))0!,'R?\ /^?Z4"$9NX^M R%I"U %>3GGK0!7
MQ0 \9%,!X7K3 G6@ 9<]^G]:0C,F7%(#$N5)^M &#<#F@9DRT 5\4 +2 *0
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M>U #LT *7H 3@4 'W: $+T -+=Z $)H -V* %#T ('H 4MF@ +$T *30 $T
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MO6F [=F@!<XXH 9NS3 =N[T *'H E1Z )EEP?>@"[%,?QH TH9<<^M %D24
M-+T &^@!IYH A9=W44 2(N.G2@"P!TI@*HVTP TA%.4'GGF@#"G3TH&84Z4
M8\RT@*A%)@-SFD 4 )3 *  T -H <.:0#@*8$B\4P+<= %I#0!;4_P J )TX
MH E4XH L1DT :,7- &K"M &G$?\ /^?YT ;5ESWI@::U9)-F@3)E%6(LIQQ0
M YP*0# <FDQHL 9XJ1DRTADR\4 3KGZU(R9* +"_+0!8!- $JT 3H* )D)H
MF'%  : '4 &_% '2V=VUL>.14&QI_:XI!SQ0(I37D<?>@9Q6L:J "J"@FYY3
M>YR2:!%" %33 UK=AP*D$7$YZT%%E7VT@%W_ *T@*\LG&.M '/W;;<GVJA'&
MW1W&J)*+\?C0!%T-,"91FD!<B^7\Z +OW>* '$T ([8I@1#BD %J8#,]J0#
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M '9H ;G% "[LT (#0 9H ;OQ0 TGUH 3(- "YS0 N<T -% "&@!<XH 3/Y4
M)GM0 9H 7K0 M " YH ?G% !UH 0F@!!S0 H- #J $'RF@ '% !0 TF@!":
M%W8H 3-  #0  X% "#!H =NR: #.* %!Q0 A:@!,T &<T &: %H !Q0 \'-
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M TCM0 O7K0 4 (O)H 7% "#- "8S0 M "4 .!W4  ]: %+9H 6@!.E "XQ0
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MB.=N#NZ]?\_Y% BH&SQ0(9G/6@"59=O2D46TGSUI#'239XZT 599MH.<="*
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M #90 ;* %"D=* '%<T  2@!"N* #R\4 &R@!ICQ0 I3=UH :$H 0IB@ V8H
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MFD ;* &XI@,(S2 1E_*F!'LS0(:4IB(\9H 85SQ0 S% #2* $- !M':@!<4
M+Q0 WIT[T &/6@!V*0!BF @.: $- "'B@")B30!$U #&H 0"@!<9H 7;0 ;<
M4 .Q2*'9XI +TH$%4(,4 *%S0!,%Q0 \#- "A,4 3** ' 9H >,T *1Q0 M
M#Z '!\4 7X'Q0!I1'B@#02@"PG% $H;_ #_G^E !0!&?FI@0=* ('XZ4P*4J
MT@,F:/- &/+'2 IO$* (C#0,;Y-*P7#R,4 ,:#- QC0XI -\J@!!%BF!/'%0
M!H114 7EBS0!.(^* (&BQ0(@9=OTIB%3Y: -*&@#6B.[\* -&$T ;%H,\T ;
M:'%4B2;H/_K50F2CCVJA%A6(I@/?D4 1H>A-(:)T/%0QDZG%242_7\Z0$PH
MM(<\T 3J<4 2J: )T.V@"930!*OO0!*IQS0 \4 *&H </K0!R?GY'%9&I!)=
M[:8C(NY]XQZTQ7,&=P3G^?UH RIGQ]*H14=B:0%5CFF!$6S0 \24@%WXI##<
M1_.@"L7P?>@"LYQ^5 $+-^5,179L4 ,#;NM %N,^M,"T,-0(>%IB)E7F@!>!
MS_G_ #VH ,!O>@!&P*10T**0#CQ0 W&>E,!XXH$.S3$'7B@"14R* &%=W^?Z
M4 - XH <!B@"TAVTAHF4D4@+*28.>*8R82D4 (TWZT 0O)F@1GRS&F(I'YOQ
MH CH <1B@! NV@!RC^= "E : #&.?\]J %X8^] "!<4 +C^7\Z &L* &A0U
M"[?_ *QH ,>O_P"J@!@7'7KT% "8H 7;F@!&% #67;DT &V@ *XH 0C-  5Q
M]:  C% "#ZT (5S0 C#;0 H7- !MH 79GB@! ,4 +LQ[4 ."4 'EF@!VS\Z
M$\O/.* %$=  (L?Y_P F@!WD_EF@",Q;J %\K]>* (6BXQ0 QA0 S;F@!30
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M,0QHOQH$1F/'UIB&>70 GE9H <(C0 TP_P#UZ!CQ#B@0_P D#_\ 70 @BQ0
MOEXI%$H@W=>](!PBS0*PY8-U,=@\@T$C6AR?Y4 ,:WS0@(#;TP$$% $@BQ0,
M;Y/X4AD314 1%<9 H @=* (MM(!,&F X"@1(!B@1*!FF!*HH D(XH 4B@ <4
M ,H C+4 ,+T /4T 2;LT 2QM0!H0OB@#4C;- %]'H >'H 7=GF@!C-D4 1[\
M4T!&:8%5R* *STF!59,T@(_*]J %$.10!((: $:&D40M!@^U $1A%(")HNE
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M]* ) : ';/UH$2#!Z4 .QF@"4+3 ?MSUH&/VT"% R??UH :5QF@"NXI 0$4
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M4 3(>] $W2@"PAVT 2*,4 2CUH D7GK0 O6@! VT_A0!YBPQ4%$+$T 1E,T
M5V0F@""2''XT 52F:!E*6/-,"G(N>,4 9<RX-,14)QQ0A#6/^%,1&W- ##WH
M ;M]* #;F@"0"@"5* +*KF@"9.* )^5H =C!H :S9_&D,3-(8F<T *6Q0 W%
M,"04 .4XH E4]J #<&IB8=:!"@YH 4D_Y_\ UT )UZT /8#H:10\'%,"/.*!
M#&;'ZT"(6;/% $1)- $++B@!<$T (1ZYZ4 .^[0!(#CI0!*M "[<4 .(Q[4
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MC_/K6B$3XIB% SUIC)%'ZU0B1N: *X&:E@3+\QJ6,MH<U($H.*0R5!0!:'-
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M=NM "B.@0X+F@8H4'K0(F6/TH D5,T *(_S-,!=F:8"&+CI2 :5SUI@1E,4
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M "X[4 ** %QB@ QF@!V>U $@.: %!Q0(D!H ?N[T#'+Q^% $X.:8$H..G2F
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M9VT!8 V*+B'JWK30#P<U0AX/;M3 4#'%,D/NT (>* #&?RH ;B@!/K0 8]:
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M!=A(% RR/\_C3L C' S18" L:+ 49CCI0(QISGBJ)(XUYH T83F@#7@4+TH
MTXQ2 TK;DTP-Z,9&*I"+6#VJP H:  #-4(<3FD! .:3 E7/6I&64!-2,F7GI
M2 G3F@"PI_&@"910!.G6@"P#^% $ZB@"=: 'T 28S0 4 +UH \^,?.14E#%3
M% $HBSS0,L*M(!"M(HKNN*!&=,E S"NNE,DQ9Q5"9F.IIDD>V@!R@=* )5/2
MD,=C%(8@7-,"8+0 TKCI0 W! IDB'.: &@9H 8>.: $QB@!A/K0 Q>: #&*
M'#FE88Y..E QY;- #ON\#^5 #@: #IUI /#4P),]Z0!FF H&*0 *8#AQBD G
M:@!2#GI0 'CIR* (RGK0!&128R(C%2V A&X>U24-Z<4!8AS0!(M AXS5(1(O
M-4(D7-4!(%Q3)#&Z@ QZ_2@!"OK0 !,4 ."$4 +Y= "&''^?\* %,6.U  8]
MU ""')H /*Q0 X14 !BV]J  IB@!/*P10 >2/6@!!%0 [R\4 *(Z '!,?G0
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M*(2?\_I3$2K%CM3 <8>V*9(I@H #!F@ ,/XT  AR: %\C;0 X0?S_P _Y[4
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MV5 &;<6V.E,##G3;3$8LGM^5# JL>N*3 D2D,M(,5 R=.*0$Z_6@"50%Y]:
M+*T 3(<=J )UH L+Z4 2K0!** ),B@ Z4 .!YH I?9,T /6UQC% P:U_D* (
M3;$\X^E(97>V[4AE1K?'%(+E*2#'2@+F3<P9]J8FS'>V[XIDE1[7!H&1FUQQ
MBF(C-K@9H A-MB@",VV* &M!N_S[T#$%MG]: %-L!S]: &FVYI#$^S8_/_ZW
M\J8AIM\?E0(/(S0 A@S0!&;;/% AIMJ %-O^8H :+;=_*@8Y+;(/'- #A;4
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M G V]* +"G- $P..>] $W7- $@% $F* 'ALT .'% &J+;=3 D^RYHL C6N*
M*Q@Q2&5)+?=Q0%RHT&XTK 9\UOC_ .O189FSV^:9)0>TH J-9Y]: (OL?M_G
MK0!&]D.U %=[3'- $+6N: (OLG]>* &_9-M ""TH <;3% #/L8]*  6P'%
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M^= $X&* )E8X^E %@<4 2K\M $@&>G6@!QY&!0 Y>* ']!0!V0BQ^-,!XBH
M8T6.: *KPT@*CP8.: *;Q<4 4WMP#Q0!5:US^8H JO94 0M8_P"?QH C:TH
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M/% #U.: )0: )!C.1_G% AC-0!"W% R,GO0!78YH ;UH =0!*AQT% %I..*
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M&L03QS2 C^Z..U,"I,PH&42],"(G;WI ,SBD!*HS0!:CH GZ=: &Y_6@!,T
M./- AF: &T#&G^5 "$8_&@1&W- #"N* *Y&V@">&;% S3CYH T(QCZT 6@@S
M0!96*@"3R">E &;=66X4 <M>6><_TH Y2]LLC@4F,YJYMS&<U(RJ1D8I#(SP
M>* %% $@H 0<4#&T /STH 6@!* &GF@!AH$2*<<T /SNH :3MI@*KT"%$F*
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M6V: (WM@: (6M!3 B-KBD!&;7% $1M<T )]FQ3 /L]("-8,4 -\@#F@8>12
M/L] "?9Q0 \0"@0>2/PI@.$'- "^3^= !Y6* &B "F "+(H /*SS0,40CZT
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MPH @;F@9%G;_ %H T(),=Z -N$YYH$:D8H&74CH LK%0!');9[4 85Y9;N*
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MM( +"@!"V*8",^*0#=PIB#?2 9OQ3 :'VT@$,E "-)0 S=BD,3S*8";_ ,*
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M/TH B9LTQ%<MMH$1;R>/6@!S-NH ,X- $H?% A%YH ?]?\YH&-//:@!-F!0
MNV@!S>] #QD8H L+UY_.@"84 !YXH :3C- RJW/-(979J &=>*0'5Z!I?FG)
M]JI(5SVW1=)XZ4["N>F:=IY3% '3I%L_"J0B>I :\I-,"/.Z@9$:!!B@8XT
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M R:8#@U,!0V*0"[LTP'"3M0 F_/'XT@(V:J$1DY- A>M "X]* %QWH >!ZT
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MO0!$;K;_ /KH #=9H ;]I]\4 *T^[B@",7'I0 W[3MH :;DT -:XQ0 GVDT
M)]HS0 TW!/% "&XS0 TW- #1<8_&@!OGY&* $\^@!C7&.?:@!/M)- "&XQP3
M0 PW'_UJ &^>1R.M ">?B@"-I_SH ;Y] #?.Q0 TS9- "&8GJ: (C+0 TS=^
MAH 0R_XT  FH 3S?;\: #S<4 (7H 19,_2@!OF8^E !YI- !OH 3?0 HDQ0
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M!#S3  #2$(>:!D9-,!2<4 .!Q0!84FF(M1-0(LCI0!,">: !ES0!(5H  "*
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M["?:,]30#$%R/_U4Q!YY:@ -Q0 T2T *)^>M(!OG\4 'GTP!9\_I18!GGYH
M/.I@!EP: &>;C- !YG:@!?M!&:& >;2 :)* #S?6@!-] ["&:@8WS3QZ?UH
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MZD#$N;>F!SEW;9I#.5N[8#\ZD#E+RUS]><9HL!REW:C\?\:EE&.>.#2&)C%
M"KD&@!5H 4'- #B* &OS0,8>!0(9]* &4 1,>>*8AF: (F?'6@"MU/I3 3&3
M0 _;BF @3'-(!FVF!&U #%7- $ZKDT@)]F:H183B@190YH L)SS0!+UH #DT
M +C' [T ,*T .H ,XZ4 +P* ) <_E0 [/>@H8>/PH A<T :&F1Y8?6@1[1H,
M6,>X% CT_3OD%,#?23%,1.&S2 4\TP$6@9(!0!(* )0NZ@#2A3;0(O14 2,M
M("BYS3 RK@XI 9DIH P[ILYJP.4OCB@#C[TY_P#UT <].<&F!GR#D4@)%YH
MMK4L"RII,"5.*0RPAH G' H G!R: )5YH L*,4 610 G2@"3KTH 4GTH 4KN
MH NEL5)1 6QS3 A9^](1$6%,0;P:0#?,I@-\PK[4P&+)B@")I<?6@"-I: (9
M).: (#-@?2@"(S$<T 1F7WI 1>;CTH 89.WZT -,U 6(FE_^M0,:9:!D?G4
M,-S2 C:?(IB&?:,&@0GG_P#Z_P"E #3<4 !N>] #//S2*&_:,<4P$:YY_P#K
M4@(S<XI@'VC!H)&&Y/K_ )_S_*@!HN]O3BF ?:,_A2 ;]HH 5Y^>M( :YS0
MTSTP%,_ISBD!']HS3 3SZ  W&:8#?M'YT -,V_@]J  3;J0 )A0,;YM AOGT
M#$^T4" S^_M2&1F<$TQ(0S4QV&F?- 6&^;GI_D4"$\XKU_SG_/TH ;]ISS2
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MM,0O2@!I7% $9% %?@<T ;%J: .LLCCM3$=/:\>U,#H8#0!J1>E $XXH :]
M%21,T 9LT=" R9XJ ,"XA[4@.:N[?C.* .2O+;K2&<M>6V.U2QG,7,&RD,S_
M &_.D,4Y/M0  9I *,_A3 4F@ SU^M #30!&PS0 C#WH AH C<8IB*S\4 ,(
MI@2*E #E7% #RE,"%TI 1%* &;<4P'H-M BPJD4Q$ZKCO0 ]>30!94XH E4Y
MH D/6@ R3U[T &-G]: &CB@! >* 'XV_A0 N-M !0 I'% R#.WU]J .FT:#>
M0: /9M&BQC\*!'=VQP*: TTDIB+229H E5J )!0,F!S2 D IB)HS0!IQMD4
M2*X4T (]QB@9GR7% &=-)F@1G.U(#(N6IC.6O.:8'(79'T_I3$<_-P:8&;(-
MQ^M("1?FH MH,TF!9!]ZE@3#'YTADR&@"RHS0!86@"8$ 4 3 XH E4T 39H
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M[/6D,;T/M2 <#B@!Q.: #'&!0 H%  .>:8$@&12 7.:8#B*8A47!X% A< T
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M;O",50')7WM3$<]-UI@9TF,]J %CXI 78S4@3KS2 L(Q'-(9,O/>@"PK%?\
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M'% %E* )0U $J#% $@H >.* '#B@!V[:: .-^T9-061FX]:=Q$1FWT -\XT
M1K-CIUI@,,@/% $<DN>M("N\U %<S<]*0#6D)'K0 GF'\OZ4 &\FF HD)H 7
M=NYH D#&D \=: #W_"@!C#'% #&YH KM0!7D)Z?Y_P ]:H"LQQ^'_P!>D!7<
MT 0%L4@(BW6F TMDYI@1[J0$>[/)I@-SC\O_ *U $6_B@!"_-(",X/- ";J8
MA-V:!";MW>@=A0V/J: L.#;J!CLXH 7[HQVH <* %W8H 7KWXIB$SM_E2"P9
MW4 -W?X4A",U,!"<?A_GWI@&=I!^E #2<4 )]* #?F@8WI2&)]*0#.OY4P$S
M3 8PH)$H 0T !&?K0 [?F@!XZ4  /I28R3/%(8N:8K"KUH"Q)NS3 <&H$2!J
M )E;M0 \'-)C'%J!C\8YI /!I@*M(!<9H -N.13$QXXH >!GF@8N* #'\J0#
MP.] #J8"X_*D Y>3_.@ Q_\ 7I@.5<4 **0#Q_G\L4 +GI3 ?GB@!V*"27<:
M '@4 "_E3 =@"@";&#0 ]5XH 4 CB@ *$4 (ZXH :8\<T 1LO>@!I![T"%Z4
MQEA6R<T 2+^=(I%B,XI,T3+Z<\5FT;Q9<50:@Z%(D"9J;&JF/$8J;&O,2HF*
M+#<B8<U5C)R%Q5)&+D-QBK,),3[M48,.@Q3,F.-,3&,<T"(SS]:8$+>G:@"N
M3G\Z -&U'^?_ -= '56G\Z8CI[7BF!T%J: -:(T 60*0"&F! U %9S2 H2T
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M4 2"@!010 8XH A*_E0!"Z[30!"_S?Y]Z8%-^] %9_7\J *[#/XT 0M_G\Z
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M_P#]:F9,;NQ3(#?FF(:9,T$D;/0!"S8I@0LV* -.S/YT =19D'I3$=3:'M3
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MH B9J8%8R4P&9H >30 H;- #XR10!8 "_A3)'9H 4\4 -R>] #E_E0 [)Z4
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MH :5YS2 % -, '/_ .N@!II (!F@!K4 *QSVH$,S5"&$8H 3&* &X)H &&*
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M#*;B@14D%,"OCI0 [B@"93GZT 3+UI@*..M("44Q,=N';\*8AV<\4 *!GO0
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M (,?A0 W/>F!&#CIQ2 #3 ;_ )_S_GFD '^=,!>?K2 :2.W- #AQ]*8#>O-
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M4 3=.:8#L$>_Z4Q'@NXU!8?>H ?GTI )NS0!'F@!=P% #L@=:8#PV:0"=32
MDW;?_P!5 #MQ;% $BF@"0'&* ) <?TH >* ) <CF@!":!BT"&[N_^<?Y% #M
M^.: (]QZ4 1-Q0!7<]: *[-0!6<TP*;"@9&QSU_"@1 5YYI@--( ;.:8!CM0
M F?7_.*0"Y(]Z %SSB@8=*!"8'2@ )QG%,!AH 48/\Z0"<D\T &=W- "YZT
M.SB@!:8#B<]:0"#^6/\ /_UJ8";<]?SI (1NI@+C% #<T@$*XXI@)C'%  1G
MK0 TK0 C8_I_G_"@!II$D96F T\T 1MS2&(>.G2@+#<4#&XR*8#<4@$(Q3 !
MSUI !.?K3 3=0!(&I /5L4P)0?PI@2*?\_\ ZZ0$X(^E $Z\]: +2GTI 3J*
M )EXH G44P)!ZT@'A >?\:8#OPH)'CD?7^E,!ZJ?PI,"7&: 'XI //-, VT
M&T4%#&_R*0"4 1L<TP$ QC%(!#R:8"YQWXI (3GV]J 'AN:8#E.!0!(&Q026
M4;%("S&: +\;9_S_ /JIE%N,YI 6$XH 4B@"(KG- %-DIB*3@#I3$5F^4T (
MPS5 1<<T +GK2 83CI_D4P*[MBI SY&Z_2@"B] $>[U[U)0JG'2@"U&:0%P-
M2&(6S0 W/>@!C?+_ (4P*;MBF(BB;!Z4 =5I]QC&?;-42=M83^_7K0!UUI-N
MIB.C@N*8&U'<8H MB;- QXES2$!D]* *\C9I@9LWZTP,6X/Y4P,&Y [=: .;
MNAF@#E[SY1FI Y>[&>1_^ND,SB,T@(V7 H 85Q0!&0 *11$5P.!2 9MQ2&1L
M.#2 8RYH C/R\4 -ZT ,SB@ '-,"=* +:'=0(F2@!6H K/\ _7H&474<U0%%
MNM B$C%(!R-D4 3!J )U:F!+UH 7=G% APIB'XH =UZT *.>] $F[/UH <!Z
M4 *,T ;6E+EOQH ]7TA,=/\ /^>:8'>V8VXI :&:8AW6F Y5I 3@9I@6DI 7
MDI@6UH DQF@!&6@"$\4@(F-,"NYH&5'H H3MB@1SUVU(#B]1FS[]?RH Y"XE
MS^)J@*X;BF!.K8H ;+STH $&ZDP+T0I 6%J1E@-@<T 2( * +"\4 6 <T 2@
M@4 6%X% $RCJ: )L[A0!*#MS0!(#5 . S0(\ 5L=*S+';N_7Z4 .SBF ;N@I
M (#B@!2_'^?I0 H_S_.F JT /SBI 4\T /QGF@"0'M0 ]6Q@4 /+'K0 X$"@
M!P;%  3F@ W8H 83GF@!=U #6D"_2@"(GB@")CCI0! S<^] %5CNH KMZ4QE
M<T"(R>* &-UI@ ;;2 3_ #]: '#Y: $(I#%-,!<XH$-)S3 >>: &>PI (?FH
MN $#M2 !WYSF@ S0 X#'% #PW^%.X!B@!PYR?>BX"'VHN 'GZ_E0 TC]: #K
M^5,!M !MS0 W/\J #&T]:0#: &;:8#6&:0"8Q0 T\].M #<9R30 A7-,!FW%
M #6XI &V@!@_G0 TTP&[J %!H <.#2 D#;>E $Z/BF!,O% %E3^E %D'CVI
M6%-,"VOS<46 G3C\*+ 3 9Y_SV^E #\&BPAVWGFF(DVT /"XXH D I /(_6@
M!2* #;C% #3S0 AXI#&]?:@!A!-,8TCWYI@,+4"$SC\:D8F0: %SB@"0#M3
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M8YYH&1,VVF(A8T ,H&)NSCWI %  #@8'- #QQ_C0(,[30,=F@0T&F IY_&F
MA ^OZ4F G!ZT@$!XZ4 +U_"@8$8H$/S0 <GZT#%H >30(": $^[TIC$H$&?Q
MH ":8"$?Y^M(!.IZT (.:8#2?SH 3']/\_YZT -/%( Y% $9% "?I3 :1Q[T
M@$VYI@,*XH 3&>: (C\M  % I ,(I@&,4 -H DZT@)E:@"=3G% %A&R,?YYH
M M+Q3 N1&A 6$]:8BVIS0(L1C/2@"=1B@"14H EV?Y_^O0 H2@!^,4 *%S_G
MVH 0 =*  #% #32 832 ::!W(]M,8G2@!O6@"+/>D N<]*8 .*!#AQ0,?G-
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M]*!%R)S^-,#1A;;SWI#+T39I#+:FD!(30!$>*8%604P*3C IDE4IVH JFF!
M:8$#GFD! 7_E_D4 56.*0B@_ H&0&@ W;?QI%"[J0 )*0QAEH A,VZ@0GF4
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MO'X]_I0 T-B@!Y.>U,!F_P#S_G\J &%J0"%\T 1EC0!&QH :9#UH A9L_7%
M$;&@")FS3 C-(!,"@!<4#%)H$.'% PSB@0[.ZF N<G- # <T +2 3(H 7I0
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MI 9\LV>] &'=ON__ %TP.9N25I 4,?\ ZZ0#2?TH 3.?\_Y^E #O\* &YS0
MTC- #&H B:@978?E2 B<4#(_:D!"0* )HP!@"@"ZAXQ^-("93GF@ ?I0!5DY
MH&49>.*!%%C0!7/!H 0'- #B: %R:8#@V:8$P- $P:D!(IYI@2J=U AP&13$
M"&@"04 3Q<D9]J /0-$CSC [T >I:8,#_P"MZ4 =.@X%,0XTP';J0$JBF!97
MFD!;CXI@7HNE %Q3B@!V[- R"1J ,N=J ,F4T",N>0K0,H/)2 SY)SS2 Y^\
MES^M '&WKXIH1BLU6 X8]>: +439H L 9H D3F@"['^M)@60,C%2,L#FD!*/
M6@"=30!.HS0!.AQ0!,.* )P<4 2 <T 3(<'FF!+C'2@0N: /FI7Q]*DLE#]_
M\_YYI .W9H D!SUH >&Q^GZT /1\<^U "@YI@29Q2 =F@!V<\4 (#^5%@'9Q
M_P#JH :#V]Z0#2<4 1F3'_ZZ $+9H ;NYI@)OHL N_/4\F@!F[% ",V32 9N
M_P ]Z $W "@"(M0 T\4 1;J &DYY'>@")A3 3.#2 8/>@!0: '9/% "CB@ '
M44 .%- !YH /K^- "8)ZT 'H3BD _&[_ #TH .O^% "C _SWH&)0(7K0 H_.
M@8Y10(7J.E-#'[Z8#\^_:@!I'\Z %Q2$-Z=*!BGBD(/:@8E AIH ",4#$* B
M@0W!-,!I7-,!.3^E( '6D F,T !&W\* &8SQV%,",C- $9XH B*T 1]:8"YQ
M2 4"F!*AQ2 G1: +R?Y_QIB+D9IB+D7'2@#2A&: -*,;N*8C0C7%,"XJYH F
M"?C2 =MI@,*<T 1%,<T 0.N>M("-A_G%("NPS0,8WS4 1%<T ,.>M(8TC% R
M,'% #",]:0",.U,".D(0-FJ$*10 [Z4 2 YH L*: +T;^M(HO1-B@"^C4@+"
MGT_*F N<T ,?F@"C(<4(3*,O%,12D//TH I2FF!68^M,"N3G\Z (&I"*[#'2
MD!$W7UH&1D4@&E*11 PI 0'GB@9 _/>@0SK3 F IB+<2]J8C1C3%,"R!BF >
M^>::$.I,">*<I3L!IPWII@:<5WGWH OQW=2!86ZQTZT@'_:>],8IN,=?\_A2
M BDFQ2 JO)ZTP,NZEZT 8-RU %,C-("/- #",\T *..M #Z $/- $9&: (V
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M!I:F TGG-,!"V.E !OI -W<4 -+>E #"QI@(S9%("(G':@!"V#[T@&DYZ]J
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M -)QS0 HYH .U $;KF@"(C- %=EH B I .P3B@H>HI 2CI^?% #US2 5N?\
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M!L?6@!^<<=J '=:0Q<YH$!Y_6@8_F@0N: 'Y/6@!RF@8\4 .ZT .QGZT *U
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MR:11 _TXJ0(&% $)H0$?6J L+QTIDER+I30%]!5")_\ )I@ 7% "D9H 0@4
M(!V- !BD F,<_P"?2D \$T .S0 A;'TH&29H 9GF@")G))S4@,(&<T - H B
MQGW_ ,_YS0 S;0 T4 (1Z4 +0 &@ QGG\* &"@!A]Z (R#F@!O- #QQTZ4BA
MQH =U%("$G%(""0T 4G.* *,G- $#C% #<TT $>O6F X#]:0#<<4P'8H 7%
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M] R04"'=>OX?6@!Q&/I0,,XYH 3VH$'>@8W&!0(0YZ4 (!^E "G!H 4'_/\
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M5/&: -C3>6'UI@>L:/VZ]:9)Z)9<#% &J#BF(%% $JG-,"910!:CXI 7XA3
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M )_6F!2DBS2*1FSP@U(&%<0"AC.=N8,=*D9A31XSBH91588Z4@*^V@ %,"=
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M 'JU "YS0 9H -^* $+8I@-W4@&D]: (R>] #2V: $S0 V@!/YT@%SB@! :
M$S0 ;J8#<T -SF@!2*8"9I **0"=: $SF@ SZ4#$)H$/W4 -'I0!(&I@*#0
MH.* %S0 H.:0#Z ' YH D!Q0!*#F@!V[- "EA0 HXH =UH >O% QP.Z@0[/\
MZ )NWM0!(!F@!>WM0,<*!#C_ /7H 7% Q!0(=Q0 W% QN<T"&YQTH "#V]*
M&D>M #L8H&(:!!C!_P ]* (3Q0,C<8H$5V!/2@!A'%,!H&#0 [%,"=1CDT")
MT[>M,1<CXH N(/6@#2AH TXCG%,#9@- C<MOUI@;<!S30&G'TH$7%6@!Y'%
MB)TS3 JR19^E(9GS1>E#&94D./\ /^?_ -5("C(F/\BD,J,F*0$+)B@"$IZ4
M -V?Y_6@"$F@!AXH K/P: (2<T 5W8'K0! [4 5R] #=^* '[\4 (&/U_E5
M/#4 6HY*$A&G;R9XJA&Q"0: -6!0>M C4BYIB+Z<TP)E^;Z4 -(Q0!7D6D4C
M-E2D!C7"<4F,YZ[CQ4C.9NT_G4,HS&XXI#(30 T'FF(E'%4B31@-- :*#%,"
M]&.*9);1:8%D+30AP7_]= APCI@ CQ2 <$QBF(3;F@8H2F \#- KDJI@\B@0
M[% (:4S4C('3% R!QFI**;KFAC*THZTAE)TS2 9LQ0!&8L=<T6 85HL S;0
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M E% $BT[@.7F@0[K0!\I5F:"'K0  9__ %4@#;BF @I *30 NZF N>*0#LT
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M/'% %CI0 \-FF!.E,1.IQ2 MI0!<3FF,MKQ0!(: *[C- %"7F@1F2B@9FRT
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M8H <#Z=: )58&@!^Z@9(&S0  YH D4YH$*#CK0,D4YXH$/#>E RP.:!$H.:
M' X^M QZCTH <"30(7&X8H .>] PZ4"$/Z=Z $*Y']*!C0I;B@0X#)H&)TH
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M0"4@&T -- "$YH 3=0 A-  &S0,:>*! ":  MF@!PJ@%#8-(!0: 'YI (&H
M<#CI0!(#B@!0:8#@:0#PU #U.*!CP<4"'!L4#'@XQ0(?G-(8X/\ SH F4YH
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M13L _I2 3.:8#A0 XF@!V:8#Q2 =TH >M(!P- #@V*!DJL:0$@.* )E8?K3
ML(1^= %A#F@1,.AH DX6@8[K0!*%W4"$(Q^% "D8XQ0 AXH&-(YI -/.*8A
M* '4 +T^M #0 : &"F!&RYH @)V\T 1-0!&3F@ QC\:8$B=J0%N/GK3 OQCU
M]:0&A$,&@#3B7/2F!HQ+CI0(T(UQ3$:,?'T_S_GZT :,+8I@:*3$?_7IB+L<
MW2@"47% "-<8H JO=4 9TUWUYIL#)GNL_E2&9,]SGO2 R9KG=0!GRW//!I 9
M\EQF@"DT_O0!7>?- R%I:0%??3$*3GI0 T-B@ (Q0 [.10!)F@!<XH <)!0(
M-V>E R4/V[\T 2A\G_Z],"7=BF!('S]>U("57I@2AL4[B)TFH MI/BF(LBYS
M0 AN,TAE1Y_SJ6,I224AF?+4#*SF@97;F@"$TQ#A[TP+,9Q3)+T+X^OO30&I
M&WH::$:$;XJ@-*.3\J0C1B.*I$EQ*8%H4 / I@! H ;]: (&.* *TAZT@*SO
M_G_.:0%&5L<TAE&5Z"C/E<#K28T5)'R>U("C(^3[?Y% $#28H 0/4@2>9B@!
MX?/^?_KT 2A\=^_K0!,KTP'*^:0!OSUH A:3_/\ DT 1E]W%(:(9#2&52,?2
MF!5;CZ4 0T@'@4P)TIB+0CZ4")%CXH CDCS0!7D3\J *CIB@949<FI&5S0 W
M- #UI@!YI (30 A.: .VT$8QTJA'L&D?S- CLX.!3 E'-,"9#F@1,N<=J +"
M?UH M(:0%Y:8%M10 M %:0T#,^6@#-EH$9LHH R9CF@#(F-(#%N30!A3G'/^
M>* .>N.AI 9>:H9-&,]*8B_'3 MH* )T%)@7(\'Z5(%I22: )EY^E("=1B@"
MPA_*@"PGO_GZ4P)TI@39H DSUIB)L4 2#F@!],0OTH ^8R,?2L34* &LM "E
M<4P&D>U(!A&10 T"@!I&* #%, QCZ4@& 9H ?BF P"@ QB@!N,]:0#&H 8:0
M#>E "8H 9G\Z '"@!2<4P&4P%/- #,9I )C-(!K"F F:8#30!&30 A.#4@-(
MQ0 F* $!J@'9Q0 H-(!ZTP%W4@%S0 H- #CQ0 ;N: #- #PW- "@T .)]* '
MA_2D _=F@8Y6S0!)NI 2[LT 3!L4Q$X.*!EE3^= BPIH E!H&2XH$2CG@4#'
M8S0(3;B@8CC\J &E=OM2 -F:8";>,T )B@0O7F@!![4 1@4T!&W% %<CVI@1
M'K2 AI@!.: )4- %N(8H T8O\^M(#1BX^E,#2BI :,1YIB9>5Q^O^?\ ]5"$
M6%EI@6XY: +*S'B@"Q]KQ_GM3$.^UX[T 1&\[4 5)+OWI@9\]Y[TV!DSW50,
MRYKK/3UH S9KK!X- &?)<$=Z *K38- %9I2U $(;U_ T *<B@!!QUH 5?EH
M,=OSH =0  YH ?G'_P"J@!!0 ^@!U #Q[4  ;O0!*#CM3 D#^E $H>@!Y:F!
M*KXH$3+)0 X2X^N*!@TE $329J0(2^*!E5CFH8R%CF@"LYI@1?Y_&@!13$6(
MSCI3$7(FYXH OQ2 _P#ZZ8C0C;'^33 T(Y,4Q&C')[T"9H1OZU0BXC8Q3 G1
ML?XT /)SS3 B9L4@*[-0!2<T@*CDGUQZ4#*<K>G^>*D9F2R?I0,SI'X]:0RA
M++@T@*CRXH @,N:0!YG;O0!*LF[K0!('H D26@"99L<4 2"2@!/,S0!&6S0
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M #30 VD TT ,ZT '6@!G2F ^@!PXH 6@!H-(!Y.* ' T %,!<TP'=Z0"$XH
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M@9F2M2 S96YSZ4#,V5Z0%1S2 AW4 ('Q0(>LN*!DJR^M $BO0!*'[B@"99:
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MP8\&@D>!3 ^9Q^M8&PM,!0,T@&[<TP$(S0 TC% #=OX4@$VXZ4P&[<T@$Q0
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M=V:!CE;-)C0$TAD8S^% $;F@"): +*<TQ,MJ/6F(OJ: +\5 %AN<4 1-QWH
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MN<4#%(VT"&D"@!I%,"-LGK3 KMUQ0!7?(H @?T_S^M %-L'K0! 6I ,&!]:
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M X#- "@4 &,TP%Z4 -/- "XH 3.:0 *8#\XI@)FD HH =2 <IZT 2!AZT@)
MU,"=#F@"=&H M T 6$?/3K0!=5L=* +2MC\:!DP)Q_\ KH$3@YH ESQ0 HQT
MH >0>M  1F@"/.: &EZ: A8]J8$##=]?6D!68D\T 0N,>M %5C3 KGYLT@&'
MB@!: ) V* +"L33 E\S%(!PDH D\VF(9YW/^?\^],0WS_K0!$TY/- $+28H
M86..] $9/% #30 #F@!#0!)G% "D[J %6@!P^:@!P.10 X-0 H]Z  4 .R:
M!?EZT /&5H 7I0 G4\4 '7I0 X&@ - #MW<T !H ,YZT +F@!0V* %S^>* %
MSQ0 [/K_ )_SWH$.)_#I0 W- R3\: 'Y]*10=>E #32&,<8ZT@*S4 0L:8@W
M4P)%IDC@<4 3!J )D?\ *@"9'S3 O(] BTKTP+*R8[TP)1+[T"'>:: &&3_/
M^?TH B+Y_P _XT7&1,Q^E("%FS0,B9L4@(6]*0%=CGI3 JN,T@*[K0! RT -
M,= $97)XZT ,9<&@"(KCK0 F/2@!A'I0!)&/6@"PG- $R9S2&2=*!AG%("-\
MTP(@<4@)HR*: M(QIDEJ-\<4 7(W% %E7VCTH <7Q0!"YY^E %1VS0!2E8'I
MTH SY.?\_P"- T4),=*D95(Q0  9I 2(3D8]: /1-$'3BK)/5]*X% '6Q-D9
MH E% B110!.IQ3 G44P+B>U("ZE,996@!QH K2&@10E.: ,N5L4AF9,:8C)F
MR/6D!D3\4P,2X- &)<F@#$G'%("@E,"Q%QTIH"PF*8$Z^M("=2,=Z8%R+)]:
ME@6UQ^- $R\4 6%.VD!82J0$RG/3K3 F'-(1.!0!(#3 ?022BF!(M #PM CY
MM K$W)#SB@!-H'6D N,4"%H&-88I@*: $*^E ";?SH 0+GZT (10!&5H ",F
MD PKBF TC\J0$9% $6*8#,<^U ",,T@(S2 ;B@!A% "8!H&% A"*!C2*! 5S
M0,C(H$-(Q0 PB@!"IH 8>:8"8H 3&* #I0 V@  I 2"@ Q0 8Q3 .M, I (1
M0 T\4@%SBF N: #-  6H ,^E(!V: '"@"4&@"16- %A6Q0!:C>@"RK4 6XS0
M!:5LT 6@^>*!DRMB@"97QZXH ?OH 0'- ">9B@0TM]* &%LT#(":!$+-CGO0
M! 6QQ0! [9H @S3 A(_G0 GT%  ,F@!W2F X9%(!VZ@ 9\<T &XB@!"V*8!F
MF(9C'- A"I:@! ,T & *0#10 GTI@&: %% #@* '*<4 .'% "\F@!<_6@!>:
M '?2@!P% #A]* %% "?>H 4'/2@!: %!S0 4 *O% "YR* "@ - "DT &XT .
MSF@!<XH 4F@!,T 28H >K8J2AX- $9.*0R-LT 5V- B&F =*8#AQQ3)'*<T
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MC4 , Q0 @&*!AB@!"* $/-(!,4 -(IB$(]: (PN* $Q0!'BF S%,! *  B@
MQ2 #2 <.?K0 @I@/[4 )C%, VYYH .E(!@&:0!3 .#0 A% "&A@ I /ZT *!
M0!(N* )AS0!*HYH&6%XH$6E:@"RC4 3J^*!EH/WH L!_K0 _S,T"'>9Q0,7S
M,<T -,OI0(8TM QCO0!%YFTT"(VD% %<M0!&S;OI0 PY)]J8#3EOQH ;UI@
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MN: ,N;B@#,G&: ,F?% &%<?J: ,>X'% &'<G(]J0%%#Q0,M+T]ZI"+,8["F
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M&3- #O.Q0 -)Q0(1GQ0 PRX^E QIEH C9\T ,9R* &,V:!$>[- "@@4P#I3
M0KF@!V* $Q0 O\J0"@8YH 7% "8H =TI@)MQ0 O^30 $9I --,!",T@&8I@(
MP_S^-"$-IB$!H 44 *.: '!LT .!H .M #MV,4 "T /![?\ UJ %!)H 4&@!
MR\_TQ0 @:@!>G% #@<T +G/-  /_ -= !NS0 =: '9S0 H.: &YW&@!_6@!<
MYH 3KUZ4 *M $U(:'@4#']?>I C(S0!%(<B@97-,1$U #3P:8 ".WI3)'B@!
M>E $JCVH$2@4 6XP: +2KGFF,L*.:8@(XYZ?_6H 4YH B)I# \_Y%(!AYY-
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MF@(SS0(CS3 >*9)(/FH D52: +*QYH$6 F* +*IMH L >O&!0!*!B@ *=N]
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M0#J %% "BD  8I@29Q0 9S0 8I .!QTZTP%%(!V,4P$S@T +G- " _G0 8I
M+TXH 8: &E<_RI@1D8I !]Z &D4 -8;J8A&&*8AU "9_.@!XYH 7/6@!3Q0
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M1YQB@ ^[_G\*0Q>E(8BTP 4@) V/:F!..>#UH G0;O\ /^?\\4 6%&>:0#P
M/\_A0 XK3 C84 1%<_\ UJ0$!%,"-^* (&YY_P :0$)'K2 A(Q0 S&*!D1(H
M$,!S0,.E #,^O.?RH$-(Q0,::!#30!'G% $9H 8<F@!A^:@!.M "8H -N.!T
MH 7'YT *%]* ' <T +C- #L9H 3&:  "@!1Q0 X"@!N,T +CF@!<4 *!0 E
M#@,T .Q0 H./PH 85S]: %QB@!YXQ0 A'I0 #BF O6F N,4@#% "]>M #L ?
MA0 $<T (%HL N* %/- #AQ0 XC%  6H 53FF [&.M(!<?SI@&?Y4 .6D!(>*
M8" XI  :F HI .QB@ I@*%I )UI@+B@!A.?\_2@!I!/2D S&#3 :RXI -^M
M"'B@!N<4R1,T  % #@<4P%% "CF@!Q- #J %4T  H !0 \<T +0  \\T /'
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M"(T ,ZT 1XH :3B@8PF@0A(H 86H 86H :PYI@-(_&A@-(S2 9MH 7% !MH
M-N* %"XZTP%VYH 4+CBD N,]* #&:  CTI@&* %ZT &?6D [% #10 _'I0 F
M* %(H 4#/- #J &<]J '8H "* %%, (Q]: % Q3 "* ';<\=:0"]*8!BD X#
M- ";<TP%Q2 * &@;O>@ )_2F \>]  >* '#F@ S2 4$T +G- #L4 .))H 4<
M4 .I@+_^ND 9H 4'-  * %S_ #I@(>:  BD WZ4 -I@1GZT@&GF@!IX-,!M(
M!N,4"#-,0X\TP#F@!1B@!1S0 H- $B_K0 #- "YH <* #- #L4  R: '9ZT
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MM0 F,T@%Q0 =.M !L- !MI@."FF N* %I +MS0!&%I@*:0";>U #@*8!P*D
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M0!$WZ4 1/S0!4:@!M #B#B@!A- !G% #EYH =0 _- #J &XQ0 II%#"<?SH
MBD-("L>* (\T (.:HDFS0!*AQ0!85L<4 *.: %P,8H .#UI@-XH C9/\FD!7
M<4 57&,B@"LPH 2W.&% 'J6A#% 'JVE' H Z=* 'YS0(D2@"9: +$=,9=C-
M%U.E,18% ",:0%5S3 SY30!FR\4 94M &5/]*!F+<<_UH PYZ ,>Z:@"B1NX
M'ZU(%Z%:8%\)@9H$,*8JD!"10(:>#0!,IH LCB@"U0!,@Q0!./2F(G49H$6$
MZBJ E49I"'YIC)1@4R6/%,1,*!"YQ3 \%W%JY3J$I ,+$4 1DXH B:@!I-,!
M/O4 -H 0\&@!RGUH D5L_2D!('S3 ?OH >)":0#"<G&* &[\<T@(F-,!A;%
M##0 PF@!N.>YI ,(H&)C/2@!K+0(CVT (PH 0B@",\?UH ,?RI@,V]J %"]J
M &E-M "[<4@ K0 [RZ8"!,4 .Q_G_(H  M "!<4P$Z?2D @YH ,8I@)C-  %
M]*0 !F@!V,4@$ H <!^= #\50#2/2@!V*0"XH 2@!-V* '9H 04 +B@ (Q0
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M:0$:F@">-@:8&E$,G\J8C4AH TXUSTH M <4R1<T@(R=M $/^?\ ]=,9&S4
M0,:8B%C0!6;GI0!6=J (2V/_ *U $#O@4 +O- #@V: ) ^* (]V/ZT 1L* (
M'_6@"LQ]* & T (.>*  F@ ZT /S0 X#=0!.D>: )A&.] #S"#^- RM(FW\_
MTJ1E8DBF!"[T@*K.0>: &[J8#5?%,DF!H E0]Z + ;_ZU AP;- R0C% !]*
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M #;F@ Q0 N,4 &,4 .'% "D<?E0 E "G'YTP$ _S[T !7/6D HYZTP#I_.D
M=,4 *1FF ;?Z]J0" 4  H 4G'0T +WH .N: $/- "<?2@!>E "9H 0\4  %
M >13 =B@!0:0#FXH 0&@!P:@ )S0 [- #@?Z4 (*8"CYJ  'M[4 2 9I (:8
M#^O% !T_"D,0^M(!@_SZ4Q#",?GUI@1$4 1FD TB@!O2F P]*0#LTP%QFA"
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MFD!0D&WFF!5D- %0M^= B+=3 <#0(F#4 6%XH$2+Q0!*,4 29+4#$SB@!P-
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MW9'6@!2=M !G- "AJ 'J,^M %M(LT 7DBH T(XJ +J0Y'-(HLK"#UQ_]?VI
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M7\:8"JAH D\O% "A?2@"4+D4@'!-M #@F: '^7CD=* #9FD HCH -E4 NVD
MACH 9L_R: $V9H C9,=N/I0 W;VI 1,OK0 ,N: (2@]/\_YS0 PJ.*H!N!0
MA4T ,QCI0 UABD W;C- #",T )][I0 W'&*8"$>E(!"* &,,?2@!O6@!"<4P
M$^E "9I .ZT !H #QS3 ?C% !2 2@ -,!I/:@ /M0 XGFD TG- "XH 4B@ W
MX)- "=.:8!0 8S2 6@!O6F '!ZT@%%, /I2 /SI@ .*0"$T *3FF AX% "GF
MD HYH  * %SVH 44 % "YH #S3 =[T .W$?2D O6@!X;_/\ G\*8 *0"=33
M,4@(SS2 8: (VYI@,H 8:8$=  ?>@ - "=.?>D ' I@!.*$(%)%,!W6@0O04
M *3BDQB[J!B;L4  >D!(I)I@7(_FH OQ+R*!6-*!,4AFI'$/PI@:<:9I 7$C
MQ0!9*@4 ,D7\:0&?*,>M S*G /2@#$G'6@1ER\T#*XZT 6XZ!%^,9I@:D38%
M,"_&3FD!8H B)SWI@1.V,4Q%?S*!$#R9H I/-0!0EFQS_GWH SIIJ ,Z6?%
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M!(!0!,HQQ0 \=L4@'8ICN2@4@%"4P'JO2D%R0+3 =M[4ACU4#G_]7^?_ *]
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M0 PMCK2 ;NQ3  U %B/CB@"_%\OX4@-.$9H UH10!J0CUZ\4 :,:XI 7TXH
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M0 : %/M3 .U( XI@)2 4<TP$ZT@"F ** %V^E( .!0 $$TP%_E2 0G%, )I
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M1X_E3)%*T -Z4")1Q0!*1G^E R04P$'O3 D% "]30 9I ,/ I 59#0!3?F@
MLR2X^M 'K6AD\=,4 >I:=P/I0!T*<4 2+Q0(D% $Z#&: +*\T 7$H MK3 GZ
MTP&O2 JRTQF;+S2 RY:!&9.<4P,J;GUI 8LYI@8<^,YI,#-DI#&QT :<*Y%,
M"V./\BF(<.:H0M("O-5$D$8H$6TH G48H E7C%,"=3BF(G7@T")E':F!,O\
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M4P!>: %SBD 8S3 ,8H 4B@!*0"@4 .!I@-SM^E #]U(!N[M3 =FD ,: &DT
M)NR: $H 4?G0 Y5W4P)E7% $PCH G5:0#@FZ@!X3 I -Q^= R!DH K2#- %*
M3IFF(HN<T 4WXH B/% #EYI@7H#2 UX#0!M04@->,4 :<7% %G.>M #R_'-
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M: &E\T *'H >IS0!(/:F!.@H M*M(">-,_GS3&2JN/K0 _:*D "YH$(>?QH
MK,/6@"I)P*!F?)QS3$4)1B@"DYI@1$4@)%/8T 78?2@#8A% &W!@4 ;,(S]:
M0&BG% $^V@!C/Q0!2DE- RC++BF!GO+GBD!4>3@T"*;MUH&57- %0G'- A-^
MZ@"5'Q30%Q9?4TP$\[%("M+<4 4I;BF!0EE!H$9TLM %=I*0R$MF@!-M, Q2
M 7%, QBD 8H GBXH OH*H1=CH$74Y^M %I>: )>U #30 8I@!- "9VT (>:
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MTH E##%(:)![T#)13$.#8_\ KT")!@T .7\*0$@&:8$@.!^M(!V[\Z8QW6D
MH-,8[I0 WGI2 0F@!C?6@!AYYS0 UN#2 8PH 1AGF@!'Y/\ ]:@")A0 C<TP
M&;?\_P"?UH BQ[4P&/S0!"W&:0#"* (\<8% #&7K0!$1CI3 90!'T_SWH 9M
MH :10 W;2 ;C% #":8"D8H #TH 0\_2D XF@!10 _I3 3&?PI &/\^U #,4P
M"D TB@ (S0 O)H ":8#@,]*0"#B@!2/2F ;<T@$(XH 4B@!,X_"@ . :8!F@
M!A.:0#L_G3 C+8H <7H :7Q2 86S0 A>@!A>@!-XH C+YI@)YF* &[\=Z0##
M)3 0R9H 87Q0 GF4@&&2@!HD]: %\V@"024 6(Y,TP+J-G\S0!=C:@"ZIQ2&
M3J: +(.30P%!S[4A"$XR*!D+'Z4#16- RI)0249!B@"E(*8BH1MI@0&F(44"
M+]O2&C?MQ2&;=NM,#9B []>HI :.,4@$- %&9L<T 94SXI@9DC@TP,Y^* (&
M?/2D,8:0B-FQ0!"U $;''I0!"QQTH 7=B@"-I* ,^9Z *;M0!$>: &8H  M
M$FV@!2M "XH :1Z4 +C-  !B@!Z"F!;3FF)ER,XIB+<9XH MK0!,.: $8T )
MG%,!.M  :8#.M "9(I &:8#2:0"9I"'YS0,>>: )%I 2'B@HC<T 5SR:9(E
M 3Z=*!#A0,D-, R<T %,!&I .S0 E $3CZT 0-2 IO0(LZ<</0!ZYHG3VSTH
M&>GV X% &T.* )%XH >E $\?% %M* +*<T 74YI@3CBF QAF@"G)S0!GR>]
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M0 C'DXH C+XH &DH ;YN*+@,+YH ;OS]*8#2^.E(!HD H 9OH ;YG:@!C/0
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M=:8#P<T"'4Q'SEFN([!V,4 .!SUI &<\4@'?6F W-, )P/\ &@!X.#0 \9H
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M +WH&2(2:0QPXI@2"D [K_G_ #^= "D4 (:8"GBD SI0 A%( /7'I0 P*:
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M&$T +3 2@!RTQ%A#3$6T.* +L9S0!;!H$2T#&GB@ -  * '!: #90 PB@!E
M .30!81.,]Z!%R)=U R_%#FD-%Q;>D,5H,"@"!XN* ,^XBIH3,EQMIB(#0(8
M#Q0 _- #@PH  V:!CLT &?PH ::  ]: *S4"*CT :.DD%OQ% 'K^B<8H&>FV
M- &P!F@0"@"0#C\J +$?>F!;CI@6T.:D"TIIC)0,4P&MTH J24 9TO- C,EY
MH R9>!0,RYS2$9,QQP>E,#'EZT 4I?2D!0D;'YTP+$)Y[$4[ ::=*9)-UIDB
MCBF@$;D4Q"(P/2F(M(* +*_K0(D'&* '#].],"<"@1(IQ^%- 3 YH$/ZTQ#P
M233&24$BTP%W$4 ?.8X^M<1V !CJ./:@"7-( /- "C@T@#'_ -:F =?I3 =G
M!H 6@"11MZTF ]>:0$JCGVI@/!Q042@T@)5;/Y4"'@TP'@XH >II!8=G=3&/
M!(H <K'M2 FZ"@!Y- !D']:8 #FD M(!/:G<! /SI +^G^>* #.3]: $/S4
M)C/'>@"*@!I.: &9S3 B:F!"S4@&%OSI@0DXH B89_I0(@?KZ4 (PQ2"Y'R>
MM,!O]*!D>W_)H 3;2 4C'3I3 BQFD!&>>E,!M(",C&* (\YH 9OS3 ;NI (S
M>E,!!)B@!WF'_&@!P?=0(<'R.*8B16]* 'B2@!K/D4 1O+DT 56E.* *[R"I
M&BLSY- R$O[T@(]V* $+T[@,+4 !.>M(",G- "9H 3- !G% "T .- !UH #Q
M0 E #3Z4 &:8#30 F: #%,!1Q2 ;0 M "XS0!(*8$@I 6%- %A#Q3 MIQ2 O
MQ\T#+*G%($6 :"B3!% "9[T *Q- #&!% $+8H$5)!B@13<4P&[*8A&XH >DF
M/:BP#UFQ0(D-QZ4AC#<T 5WN\4Q%*2[I#*$MX: (#<YH E27-("]&VZI8S3C
M% %I!Q3 E"XZT -9:!E1Q0(JL,T 0-[T 0N,4 18H #0 TG-  30 PG% $9.
M*8"9H 9F@0A- "9I@&: %#4T)EE#3$6XS0!<B- %Q#B@1*!F@8X"@ Q0!(H*
M]?\ )H$3*.] "X!H&0LF/Z4 0,F*!!&N: +T<>..U S0BB YI#->""D,NK#B
M@!'B[T 5I(1TH0&5<Q=::$SG[F,J>*8BH3B@" \4"%'K0 XM0!(&H 7)H =0
M $8H&-<T"('X^E %*6@9HZ2/FH ]BT0],CF@#TJQ7 H V%.*!#LT /'% %A*
M8%I*8%E*D9<4TP)\YI@1O2 J2<9IB,Z8T 9<ISFD!ER\_C3 R9Z0&5,<T 9$
MO6F!1E- &<XS3 F2@1J1_-5")\XH)#.[_/%,&2>],D1,&F!:CXH$6 <4 .'-
M,"4<<T 3*::$2+3$2#F@1(AQ3&2J<4"%S3 <* ' 8IDL^<AQS7"=HI'IVH >
M!GF@!PR:0"@XHL G6F Y?>@!1S0 O2@!YZ4 /4X_SWI 24 *M T2AL&@9(#_
M )_&D!)OQ0(>#0(<#3*)%;!H ?OS0 \' I 2*W%,!^['^?SH 4-2 7-  &S1
M8 W>E ";J $+Y_SS18!VZBP#&>@!I>BP#"W:BP$>ZBP#3Z_YYI@1L<T 1MZ?
MXT@(Z (F/'/6F!$PIDC2.3F@"/'IWH 0@&@!,<"D TC%%@&X%%AW&XHL%R(K
MGB@"-Q0,@=OYT 1%J0$);TI@0&2@!N^D QWQ0 P28I@.\RD!)YF*8#UDQ_\
M6H$/#$=*+A8>6HN(9OS3N.PPN#2"Q6D?-(94=NM("(M0!&30 PMB@!"<T  H
M :>: $- "B@!G6@!P% "F@!: %[4 % #>],!.M #: "F 8H 2@!,4 +2 * %
MZ4P'@YH D'- $RG-("RAS3 NQT@+D9QQ2&7%Z4#)P?SH&2]?TH 4#-  >.*
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M *4M C.EI 9<I_K3&9<I]: ,J<]:0C*G.*8&3*,&@#.E- BBY_PI@.0[>?\
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M0,U("!G'>@"L7H CS0 W=0 T&@!=U "[J0$JM3 =OH <9,B@",L: (RWIUI
M1L: (6- $)- "&@!F* $- "DYH ;B@ S0 WK0  8H 7K0 Z@!PXH 3M0 4 )
MUH :10 E "9H #0 4P$/-, H * ''@4@%6@!ZT 6%- %F,T 7$H O)^E(9;7
MB@9;48I /*XX- QX!/-,!HH 1O6@"O)[4 56- F5G.*8BHS9IB*LC8IB*VZ@
M1 \F* *KS8H IR34 5&?- #<T *#0!,E(:+\5)C->$5 S7BI#+J4#+#4"*[&
MJ IRG% BE(] %=FSS0! QS0!$3B@!N_'6@!I:@!A:@!A;-,!A- AA:@!NZF
MA.*8"DTA7&[J8A4/-,"VE %^,T 74XH O(.E %Q1Z4"+ 3UH&/5: )!'G^5
M",/S_6@"-EH @8;AQ0!$!S0!8B_"@"]&V* -& Y_S_GUI#-ZS/%)C-08'-("
M%S0!7=@:8&5<G(_SUIH3.0U'@TQ&2^* *IXH :M $R#'% $ZK0!-MS0 P#/-
M "8[&@!AXZT 5VXH K-0!J:*!N_&@#V'0QD?C0!Z19=!GWH U<T"'4 2 4 3
MJ<4 64P*8%M!2&6D/\J8$P%,!I.:0%*5L4Q&;.VW_/UH S)?:@#+EH&9LHW4
M",B<X']: ,F7(- BA+3 H2#)H %ZXIB-&(FF(L9S5"N*IQ023K[4P)DH$64-
M $R]:8$@R!VH$/Q0!/FF J\4R292!TI@2#F@0[.::&.!IB'X]*!"]>E 'SVO
M(_"N$[1.#]* #K^% "=: '=>* %'- "D_P Z '&@!V* %Z=*  '^5 "D\T &
M<4 .W_G0 X-FD!)G!I *6I@2!Z8#@^* '@YI!<>IR*0Q=U AY?-,!=] !OQT
MI 'F9I@-$@]:0">9WI@)OQ2&!>@8PR9I@(9:0#3)DB@0T2>OXTQ#=^: 'AJ!
MC"^1S_6@8UFSS0(1F!IB&L?\_P"?QH 0G- #&.: $]Q0 "@ &.] #'/:@"-O
MZT 0.<4 5F/K0!7=Z1159L4 5':D! 6XH :6S0 PM2 0L: ' XH <* '9Q0
MX4 .#4 (3B@!A- $7>@"$F@!AH 9F@!N: #- "4 % !G% "9S0 8Q0 "@!]
M"]: %Q0 &@!.E #,4 )TH 7K0!'0 HH ,TP$H 6@!<T  H D!I@6!Q2 M)3
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M:D*XPS9SZTP*SRDT#,VXEZTQ,YC47W&F(QWZT 1$4 +B@"55R* )U% $@R:
M#I_D4 ,84 0M0! S4 5'- &IHQYY]: /9M%/3ZT >C60XH T\T"'B@"94S0!
M,@S0!;08I@65XH&64X%,":@"-S2$4Y>*8&;)S0!GN.* ,N8>E S+F(H$9$_%
M &3+UIB*,@Q0!1E^6@!J]<4R2]'5(">F0*M,"P#^7% B=*8%E"!0!.M $RC-
M B5>*8#E/K3$2@4Q$B#/6@"3- @'ZTP)!B@0X>],0[O3 ^?5&*X#N# H ;0
MBC% ![>E #QS0 Y<#V_S_GZT  'I0 _/%  ?FH 2@!!0 4 .QC^5 #@<T 2
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M-,0F: &DT )FF HH E2@"\E %V.@"_%0!H1G- %H&@"13F@"["N\XYSZ#\J
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M(AF@1<2J0B?K5$CQQ0(F7\J8%E.>/YT 6D% $P&* )UYH$2+3 =FF22+3&3
MT$CSR?\ &F "F#'B@D<#_P#6H&*.*8CP#;7 =PHH ;M]* %(S0 WI]: ' &@
M!2,4 +C_ /50 _;F@!=N: ' <>] #-@H 7;_ )[T +B@ QLH <1^= #\_G0
M YH ?NQ0 [=TH ,_TH 3=^5(!-](!"V.E,",OGKU_P#K4 -W4P&EJ &%\\9H
M :9,]>] "&2@!@;% ";B: ';O2@!0<T +F@"0-S0 JM0 ;ORH =0 ?>H &;N
M: $#?K0 ;OY4 -/K0 TM0!"[!J (W:@"H^30!59J *S&I**['-,"LYJ0(\T
M)F@!I- !F@!10!(..: %!H DH 0-F@!K&@!C4 ,+<T 1,<T ,- ##S0 F0:
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MGZ4!81DI!83% AN,&@",C/UJ@*LAS0!2DH SY#B@#=T,Y/'K0![5HX QCUH
M]$M: - 8S0(F0=Z -"!<T 7HTH F6/- RP$H </YT /Q5 1D9H$59%H J/'0
M!2DBI 9L\-,9BSV].XC(FAH$94L.WK3 RKA<>](3,B0\TQ AYH N(:M$DPIB
M%ZB@1909IB+4?M0!<4>M R5:!$H% #^E,1(.:!$ZK5 .Z4"'@9^M,8@;-,DE
M!Q0 [I0(>HH ^?P<]ZX3N'D>E #0*  '/^>:  C(_P ^M "D$=* )-E #@N:
M0#U7/O0 I&: #% #0N>G>F W'/XT !% !D4 '2@!PH 3OF@!U "*<?6@!2:
M&]*3 -V:0#&?-,"/=3 ;NH C)/Y4 (3B@"/.* #?0 F?SH 3=F@ W9Z4 .W8
MH >'Q]: '>9B@"0';Q0  @T +G% "Y*T !(H ,T (/U]J &[J $'OTH A;B@
M"!FH JN<?TH K&D,KL:!E=CFD! 30!&<4@&9S0 E  : %% $A.* ' XH 4T
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M$6#3 I-'0!GW$= &8Z4@*K)3 K-'F@"!DQ3 C*XI$C"*8#<4 -Q3 >*0"XH
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M'<1_GUH YR[&/R]:8,P'Y- B9:8BTG/I5(EE@ 4Q#A3$3IQ0(N1B@"TN?PH
MFH F7\13 < *8B1:0$@JB23K0 X50,51B@D?TZT#'$^E,0H]J / E^E<!W#@
M>M #L9H 0T /QB@ "]J )>V?:D,=MQ_C0%A^,T# C\J0K#<4PL*.#[T"&,*
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M@1+&:8BZF: +*"@"<#- #\4P)5-,0]1B@1,#BF(</2F [K]:!#P:8"BF(7-
M#L9% 'S^K?Y__77 =Q,/FH >!0 Y:0["]:!C^M #^GM2 D%  !@^U,!>*0#?
MPI@& ?I0 A]*0#0M,DCZ4P%S0!&>>* %S0 ;NU #2<=:!C=V.](0F^@=B,M^
M5 6&DXH$1'FF TMB@!G>@!N: &;LT -)Q0 X'Z4 -SGI0!(IP* %7F@!^>:
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MM)HJYI_;8CTD4BI'<JSZM' .&R?TIV%<PI]4-SWXIB(4DH LH],!^:0 2#0
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MCZT@$QB@ :@!AH ;GUZ4 -/MTH$,/2J$1[\T !.: $SF@ SZ^E  #FD4,[T
M(3_.D!&Q^E,!K-_*D TU1)'[4 -8<4 1YH 90 =>: $Z4 .H 7- #P,?2@!X
MY]* '@XH E!I#$-,1(30 E ["Y)H ;UH$'6@!I8?Y]: (B: (6/Y4 0/QTH
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MD45BN* &;*0#=E,"%HZ (S$#0!"8O2@1&5S0!&5H KR1XHL,JE: ')3)+:4
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M'%" =R1S5"%'M0!(M A<4P%ZT +C-,#Y[0YKSSN)E-(9,I- QX.: 'D\4 2
MT 29Q0 H/^?\_P">M(!=V*8"$XH 9G/Y?K2 4\4P&Y_*D!'D4Q$9IB$:@!M
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M@57- %"6J S9CBD(YF]Y%,#C+VA$LQNAIB)5.*9);4TP+T JB2[?1A-N.XH
MJIQ3 M(*9):6@9*!Z4A$H%,!XI@3+0(<>:8F/&<4Q#L4 /H 4#'3_/2F O2@
M!^">*8CYW7GBO/.\G5N:0T29H&2@T 2#YJ0$@YZ4 2#F@!W6@!*8!0 A.,>M
M #3TI (>*8#,T"9&?\_Y_P _G3$(>: &XS0 [&WB@8A..G^?\_SI,!"30 C<
M"D!'BF,;FD WZ4P&'B@!I&?>@!AYH 9BD2,Z?Y_E0 UCDTT 9S3  <"@!V:
M';J 'C H ?TH 4&@!2* '[O6D,4<4 -Z4ACR=M "9H 9S3%8C<T!8B;K0%B!
MZ!$#"@"NYQUH&0-0,B:D!"U,!N:D!N: &9H 0T +F@!RT %  : !J &&@!M
M$1- #&YH ;UH 3&* "@!?:@  ]: $H =F@!!0 M  M $@.* %'% #^E  * $
M(QS0 8H ;F@!#S0 WK0 "F 4P#- "4 +TH 3.: 'B@"9* +L5(#2A&*8&I$!
MV_"@#01L4#+:<4@+ I"(FYZ4 4I3S3&9\QH$9<S4Q&>[9IB&8Q0!*M %A/>@
M"_'STH T(SWJ2C0A.:8%Y3FD!9!R/\_UH DSCTH ,4 !&*8#"II 1'%,"Q#+
MLI 3^;GKU_PH B,F.*0$#S4 4II<=ZH1D32AJ8BOOYZT . W4AHDVY^E(8I3
MUH :R9YI@1,N*0" 4R084P*SCUH SIEH I-0!7:@97>D,510A6+2K3$6UH G
M"T 3#F@"-N*!%63F@"F] R"@!E(!=U #@] $JO0!,LE("59*8#O-SWH 89,T
MP&M)0! [[J (F- $+&@!F<<4 21M0!<20CB@"P)!2*%,E(1"9*8B,MF@!I-,
M!K4 (30!$RYH CQ0!W7AP=/K0![5HZ8'TH ] M1@4D!=4XI@610!92@"TE $
MH&: 'YH <#0 _- "&@!IYZTQ#2*8$#T@*LE4@*4@H$9<_- '-WPR*8'&W@R:
M"68S ?K3)'J/2F(NH,U0%E'VTR26XF\W'/2@!1\M,19CS3 MIS2$3J: )!Q5
M /7F@1*!F@!2,TQ$@IB'8/XT#'4"'9I@+B@0_&?:@#YV7FO//0)EZ\T#) *0
M$PXH >.*8$PXI 2 TP'8Q_GTH 4_TI )_C3 :0/\_P"?_K4 ,)I !H CI@)G
M- K#.?:@+!0%A"W>F F?RI,0T\=*8 QW?Y]Z0Q#0(B)IC$-(!N,<TAD?TH ;
MUH C)I@,)Q18D9G-, % !UH =0 \"@8\# H$+G- #E/^10 XMW[4 (II +G-
M,!V>U(=Q>M QII )GUH 9UYI@,;FD! W%!)$RXI@52* (6%(H@*^E,"-N:0$
M1-(!M "'B@8F:!#NM !TH 7- "=:  T ,)S0 P\4 ,:@!AH 90 F: %QF@
MH .M !TH  : $Z4 !H <.* '9H <.* 'T +UH #S0 AH CS0 &@!* $/%,!<
MTP"D 4 (>:8 .:0#A3 G0YH N1&D!J0TP-2(XQB@"_&,?6@9=CY%("<# I 0
MGIS0!2E'YTP,Z8YIB,B9J9)2QNH 3'- #U- %M,=* +T- T6U-(9<C/TH U(
M>?KVH N+S2 E I .  H ::8$; TP("* (P2*"259>*0QC2?GTIA<JO)B@+E"
M63/% &?(V:8B/- %I?TI#184]*!D@]Z &$8H B9<<BD)D!3!JA#"<T 1.* *
M,YQ0!EN<4 0,:0T0L,T#)$6D!<051)904 6 N: %'% "$9H$5I%H HNN:!E8
MC% "8I -Q0  4 .'%("0&F!(#VI -S3 *8"$T -ZT ,)H C*YH 810 X#% $
MH- $@.* '&2D TGM3 3% #\4 (: #90 W% $>* .^T!,8ZTAGL^CJ5IB.^MJ
M0%I1G\*8$ZC% %A#0!<2@!Y.* !C0!(IH E49H ,4 (1NIB$)S3 K-Q2 KR5
M2 HRF@1ES\T <]? 'FF!R%ZO7/XTR3GRN*"2=!^=,1:C^6J EP13)$(S_P#7
MH N?=Y_G5"+*?+0!:7B@1,,4#)AS3)'CF@!P- #Q5 QV,4$DF?6@!0,TP%'(
MYH >HH$/% 'SLM>>>A8>.*!DHI 3#B@"4=/\_P"?2F _I2 G4XH 0T +G'O0
M 9]* &9YH 3&?\^U,!K<4@&$X^M #>E !T_SQ0 VF(:1GI_+FF%AVW% AF?I
M0 G>@!G^- #2: &Y]Z!H:>*D9&V* &9SZ50$;&@D3- $9- "8]* #I0 _&:0
MR4<4ABYJA,>*! .E "]..U "$T +NH  <4 *.<4#'$@TAC?>@!,4 ,.12 C8
M4Q,KNM(178 4 0.,=?I045VH A/-("-J &T -H ,4 +0 E #@* %H 7%,"%J
M &=:0#,YH 8: $H :: %% "=: #.*  T &: %H 2@!0: 'B@!U #LT *.: $
MS0 E #30 E "9H *8"YH .E, /2@!,4 +2 <HH ECYH NQ#;0!J1<FF!IP\4
M :4(*_Y_S^M S005($NW- $,@S0!3E%,#+G.,^M,1B3<4R2NE  W.,<T -H
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M ;S0 S% #>O2D SK04--(!AIB(R:8B-AS0 UN30 "@!10 X"@"1&Q0 X<]:
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M7(-+#GI0!U6E^$C>D +WII7$>M:+\&OMX&]>/?\ ^N#5V%<U=5^ D:1DQDY
MZ9_^M1H!\^^(? <FCD@CI^5)Q$F>?W&E%#TJ2S/-B0>12 %T[/;_ #^5,"E=
M:+NY H P9+!X3R,T@.WT'C'UH ]BT@8 S2 [BWZ4 :$>>],"Y'0!:6@"7K0
MZ@!VV@"3% $H % "DXH @? I@1,U $+-^M BF[XH H22"K RIWI".?O),\4Q
M,X^]:J1#,-B,TR2:-@: +Z<4P)13$3OR!3$+GBF(LQJ*8%Q?EH$3KQ0 X&@!
M],!^*8,<*!#^E A?PH <*8#UXIB#% #OYTP/G@>M>:>B2#M0 X<>F*0$P]Z
M)DH F%,"112 44 .Y]: $QD4 -QB@!,4 1D4 ,Z=:8"=Z!"#F@!* $!H$!Y^
MN*!V$(H 3&:!$?\ .D PG%,!IXH C;Y<4# T"(CQ3 C:@!C$\T (:  T (O-
M #L]Z ): '=: )!0 M  !0 8_.@!?\\T /'-  !BD4 &* '=* $QBD S'I0!
M$?:F)D#^U BK)3 JM2&5VYH&0FI 8: (Z &D8H * #I0 4 *IH 0<T -+9H
M8: &9H 0X- $?6@!210 A% !0 E #L4 -H 0T )TH 44 +0 M #L8H * '8H
M ": &DT )F@ -  .:8"T +B@!<8I@)2 7%,!>E(!1S3 FCH T8J ->%<4@-:
M)<4,9J1)MZTA&@B\4 2A>.:!D+@_Y- &7+B@1B3TP,*?K5$E-CB@!-U $P-
M$ZFD,L*:!C\T .1J0%E'QTH L))D8_.D!*LN* )HY?Y4 6//QWXH <+@^M,!
MHN/2F X3_P"-(!C7&* *K7&?\:8%*2:D!1EGHL!0:;%,!B2XH O138[T@+*W
M% #_ +1F@!#/NH KR2YIB93:;-,1%YA:D,-V:0R1#FF!8CCS4@64BH G6+/6
MF!(L7M0!:V8Y/2@ *9I@1>7FF(-F:!#2E $#P^U %9X<4 5Y(Z *3P&@"+[)
MF@"Q%9#TI :45OB@#0CA H NI&.*"B>-!2 LI'F@"TL>* )ECIB)T3N:0,F5
M0*0BP@!H OQ)TIH#IM)M!(1D=Q_GUIC1]+>!?#", S#H>:M.Q)[K!;+ , 8I
M-@0WN ISZ4 ?,/Q $3$].E:F9\TZD@4\?Y-9LM& \8)J1FM;V.^@9;ETX8/X
MT <AJ%J < 4 7=,M0IZ#K0!ZAI2D 4AG:P=*0C0C.:H"]&* +.,T 3 8- #P
M* 'XH <!0 YLB@"/- $#'-4!&^30(KN<T 4I#@4T!GRG%,#,F.12$<]=MMID
MG(W[YX]:HS9SY?\ "G8FY8B.:8TS5C.1_P#7H&6%7/%,18QFF(<*8BPHIB+2
MG- %@>V:8"]: '8Q3$.!]?YT")!0 _ZT .QCK3 <!B@0X#/3\*  G\J8!5$G
MSUWQ7EGIDI&!F@!5&3^5,"93G_/UI 3QC^5,";'-(!8SG- #^N?PH 7=_+-
M" Y&: $QR*8#9OEZ4@&#D4 -[9I@1@]*!,04 QV,?Y]J0A/_ *],$!_PI%#,
M\_A3$QI/.*!#2,4@(WZFF T'^5(!!WH B?@4P%/./?-" A?BF!&XYI@(.?TI
M -QB@!>F/>@"5>U)@/ R: )3P<4(8AIB),9/^?:@!P'6@0U.E QP[_Y]*!#B
M-IP*12%/6D, *8"CK_GUH C)X%(!H/?VH AS_.@3(NM,15>@"LW3- T5L9_6
M@9$PQ4@0GJ: (C0 E !UH <10 'K0 UN* %Z8H 810!$>* !J &4 )0 F*
MT (.E #CTH 2@!* "@!IH 0'- #EYH 6@ 4T /% "YXH <!0 PTQ"TAH * )
ME4$4P%51F@DG5!0%R<0KCI0 PQ@=J90T1C/2D UXP* (@M $D= %^&@#9A'.
M*8&Q ,YI#-)#MZ4@--5P10(13N/- #'&: ,J8=/P_G0!@7!P/PI@8US5(3,Q
MZ!#4ZT 3KS2 M+0-%E.F?I2&"\YI@'2D!,AYH E1N,T 3#_ T@%!_E0!(K&@
M!ZDMUH :3BF ;CG'M0 9S3 J2,: *LIY/TI 47.10!2E.* $4]*8%I3BD!90
M_P J0#LTP$=B*8%5W.30)D+&F(13DTAHD7D4#+BC- %Y!UJ0-!$%(8Y/O8_S
MTI@6%4 ?E0(?M% $;\#/M_A5 *Z@?G2 ;U_S[U0F"J#0(:PR/P)H J.* (VC
M&>G?^E %5QA@.W% " 4 2#B@"S$>:0$P8YQ2 E5B,4%%Z'G%,#4C7D4 6XE!
M_6@!ZC./PH$.(Q^M AZ\TF!.@QFD!I0#)Q3 [301R/J*:&CZU\%<1#ZG^M4Q
M'I(-(1SVO2M'&V#CBJ0F?(OC*Y=G.3VK1D(\1OW):LF6C,*@$4AG4V#$@>YH
M&:-VH /T- '"7XPX'M0!;T]<$CZ4 >B:0Q(!_P ]:0SMK<9%(1>0=:H"Z.!0
M!;7K0!*>* 'H: )\]* &DT /8T 0$TP(6[TP(V_I0(JR'%("HYR:I 4)#F@1
MF7 P* .<N>5/MFF2<5?,<U1DS&49Q]*H@FMVYH*1LQ# IE%U> ?I3$,!SF@1
M,C50BTG- BVB@"@"4&J 4'YJ0B4=J8"C_&@"0<_G_C0(5>30!.5 _6F U1S^
55,1,1C\Z &-\O3TIH&"_-S3)/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a2025half-yearfinancialrepa.jpg
<TEXT>
begin 644 a2025half-yearfinancialrepa.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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M1(?2D!68Y- $Z'- %V+K3 U[7F@#5 R*!%:7BF!BW1P.:0')WHQ0!CL:!C:
M)!0(GBXI@;MOS3 U4&!3$2YH$?-L?K3 DZ4 59?\\U0&5,<=/\]Z ,F4XI#,
MBY-(#'D?^O\ G_/\Z!E-AB@15?F@"%CCB@"+&/\ /K2 CQVI#'$?C2&.#Y]S
M0! Q [=*!F5<<"F!DS4 9\@)_P#KTK@-/% " 8IB'*,?I0,D09YH$S1A.[K0
MB3>M1T_/_)J@.IL5_P#K?Y_S]*!'1Q+B@"X' H ?Y^?K_P#K_P ]: )_. H
M6.^ [T 74N^AH O_ &@8P* $-SQ3 B9@U,#,N /S_P \U(&'.N!Z4 8\R^M
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MQF#=#O0!B3=N_P#G_/\ C4@9$O)H&5SW]J!$T0Y_^O0!IQC% %K)/XTP'=*
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M$^[06,+9_&@"":@1G3G- S&FY^E %0C)H B;F@!!_.@!RC- B9!F@3-"W'-
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MH :* %/% 6)5:@9-&] &W:M3).CMFS@4AF_;-4C)9'P*0'/7C=:D9S=P<<T
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M&3C_ #_^J@+&79W1) !Z4Q,[/3W\SW'_ -;\*9)V]CEL9_SFF!N^42/\^E#
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M,=3_ /KH'<I3:GMY[?CBF%S-DU'%(+E%]0[]J0%5KW<1CK_G_&D%R&2ZW47
MKFY]Z!B"Z(-%P&F\]Z (7O>>O2BXR$WM!1']NST/;_/M3&,^V]?;_/\ D<4
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M\_Y^E3<9ER>U RH_J* $!H ,_P"?\_RI 1MS_D_K3 JL>] %209H J,P'O2
M1/EYI@74&:0&A#S_ %YH V($S3 THDR<'TI#+JQTP+0CR/\ /^?\]:0"F+_/
MYTP&-#^=("+R030 V2#'/.* (7AYIB(/*V]O\XH 7RL_A0 SRQ_G_P#4?K2
M01X]Z '%/2F T(>] #P"* %H E1J0#]VWI0!*K9_&@!ZMZTP'H^/YT 3*W^?
M\_YZT 2"2@"3=Z^U("<OG/\ G_/_ .JF \-^.:0#U?M0 HD_G_G_ #_2@"Y
MV:8&_;MZ]: -:+YJ -2+UH L'F@"HQ/>D!1G[]Z!6,2\X_I0,RFYZT /5OUI
MB+<3=S_GU_S_ (4#+RO0 _S,T .$E !YGIU_SB@!QE]\4 *)<]* '>;NYH /
M,(H =YNW\*!#C-0 \2;^M "K+D4 'F8H&+YE #?,% A"] !OS0 F^@9$30(&
MY]J  F@!A.:  G(S0!)#P?\ /^?2F(Z"T./K[4".FM:&!O0G ZU QLK8%(9S
M]RW6D,P;EZ8&%*W/O3$/C?\ /I3 MJ^:8#M] $GFT ()>] "EZ '*U,1HPM0
M(W+9LTAHV8C2&6>U(96FXH SI3CK0!3:@"PAH OQ#% &U;KG'M0!JA<"F(KS
M4 8MRP'7I0!RMX<T 8##FD PKBD,3%,"W :8C<M^E4(UHS0(LCF@#\QAK8'0
MGH/_ *W\_P#/2IN8\PTZV/KQ_/G_ .M1<+D+ZX#_ %Y_S_GBBX7*3ZQ^/Y47
M'<IR:MCO[?I1<7,0_P!J@T7#F'#4QVI7%S#OMX% N8B^W?C0',1MJ% <Q$VI
M!O>@I2*SZKC_ #^M!HF5'U3-,L@_M;W_ %I@(NJ_K0.X_P#M+.>:=@N68[X'
MIV_PH"YHPW8_"BP&M#.#0!IP2Y/OQ_G_ #]:0S2#9'^?\_Y^E!(R1<4 4'D
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M_7)M^: /-O)P_L#0!NPC  Z?_6I 7U(6E8"THXQ_G_/_ -:@#.N;<#(['O5
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ME(#1MQG\* -BW&:!FQ"NVD!IQQ@C_(Q_.BX%Z*'B@"4PYX_STH 88>WUQ^-
M"?9^: (VA[=Z (C#WQCG_/\ G_&F(KM;X_#]:+@(8,?XTP&>1CM0 DD'>D!%
MY'%  T&![_Y_#_/2F SRB: $$1-(!?+(^GZ4 /"4 .V8I@.VT ."YH DVYH
M44 2KDT@'K0 \'!H 4>U #U;UI@7[9P>* -R!L4@-J"@#6BX[=: +#\4 5';
M)H J3<4 8%P<X_S_ )_^O0!EN=O^?\*8"9H LH] BQ')0,<)*0#]_-,!WFYI
M ()*8#E?;B@!_F;: %W_ )T *K9XZT"';]M #O,_2@8N_- AWF9H -^:  MG
MVH&"L!0(4-VH "W>@ #T (.: %)_*@!I% #2V:8B6%N: .BMCF@1TEHU)@:Z
M2<5(T)*X(I#,*YDQ2&<Y=.!30&.Y.:8AZG%,"8'_ /53 DWT *6H "] "A\B
M@!ZMS3$:-NV:!'16M#&;L7I_G_/_ .NI&7.HH KR#%(9F2#% %<KBD!/&II@
M7X4W''2@#H[6/ IB-$K3 IS+MH YR_.T$T".2NFR:0S*8=J (Q2 "N* )H:8
M&];U0C4BXH$6UH _&1]3<=Z@X;D+:L_K0-,B;57QUH&-.I,_4T#%%^6.2:"6
M2)?,.]!-RRM\30*Y*+Z@+BF_)I!<@>^(H'<J27Y-,M,H/J)3O0:1*$FID=ZJ
MQNBJVIDTRA@U%LYS0!:BU(GO3 UH=2SWH$:\.I@=Q^E SH+:_+=^*!HZ&"XS
M_G_/^<5)1LPW&!DXH)'O+FD(R9[C;01(Y^YO<YYJCDDS(>_VGK3L8\QL66IY
MX//\Z31K"1T<&H!1_G_/^12.N++"WGY4%D,D^\'O2&9\TA8X)]Z99F2N30!)
M:R[#S[T =C83C_/^-!-CL;*[P!]* L;7VSCK4@D1/?8ZGF@=BI)>>] %)[GW
M_P _Y_\ UT#&BX[T -64&F!#+)NR: .6U#GCM5(EG+W8SDTQ'.SK0!64;3[4
M ,F)Q0!G>27H$6Q:XX% R<6>.<4 1/IBR]1S1<"YH< MI*=P/<M&(^4_S_\
MK4@1ZOH]_P"6  ?PJ;E'?P:KN YJ1F=?ZQP>?\@TP/-M9U/=Q0QGF>HW/ZT"
M.9C^=J -6-/EXH LQ''UZ?Y_.F!:CRW%(!TP% "VZ[J .BMHL=/Z_P!*0'66
MD&X9Z TT!T]E:[\52$=[8:-P,BA@C:71<=12&4KG21V''^?Y4#.&UC2NO'^>
MM)B/,[ZS\EC]?\]:0&-+&30!F31'%4!!!:><P]*!'=Z389[&@3/1["V$?^?\
M_P"?K0QI'2P\=:D9#=R>6*8'$:C=&F)G-R/SFF26H7]Z8&[;38[_ .?\_P">
MM '16EQ@ 4P.@BN/I0!=^T9^E)@4YI=QS0!AW4WTJ0.9NKC'- T8<LH _E4C
M(TG(/^/^?\:!EM;CG/\ G_/^?JQ%Y+G!]Z!D_P!HQWI@,-QD?Y_S^% BN\VZ
M@DI/+]*"C.D..E %29MW'K2&5B,=:8 WS4A"#K3 :XW=/QI#*I&:8BO(F?6@
MDKF//]:8#E7%246XUH&7(5H$:\ S_2D,UX^G^?RH TXSF@#2BH L@\4@'+0
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M T[8X(IB.KMVR.:8$LC[N: ,VY>@#CM7?@T <8[<T@(R:  /^= ",: )X6H
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M:*O''O\ YSS_ )%2(T4T(-VJ@)6\/C'3^?\ 3M^M $0\/#!PH]>G^?\ /%
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M06\[-WIB)FE(ZGBI BEDX_S[4 8-Q+05<PKJ3M2&4=^>GY4P) _% $H?'UH
M<6[T .$I-(0QGS3&&_'7WI"'&3!ZTQ,<KG_ZU(HDW4")_,R,T#)0V:!$U $B
MM@9H&/)[T"%+!^:!B8_SBF(830 H<#BD XG- ""3%, :;'\J '"XR.M  +@C
MZ4 /%QZT 2K=[?I0!(+C:.O_ -?Z4#'BZS_G_P#52 E2\YH$2B[QWHL!,EWG
MO_G_ #[4@)8[K'^>W^>:!EE+J@"=+KMZ4 6XYZ +JSAN_I0-%E)0?3WI#+*3
M!J!%@2;J '>8#^M,0$^U #M^:!$D;8H&29VT +NST_K0 .<4 4;@XH$8MRV<
MT#*&ZF(FA?!H W+=O_KT,#?MN>: -('UH :_-,"A*=W/^%(#&GQ_G_/^- &+
M*<&@"HU "J<4 3H:!EA"0:8B9?7MF@9.O(I,"8#=Q2$3)0 \C%, (H =C-,!
M%H 0?+0("*!B$YH$-ZT#%&<4"'8H !0 NW% P'- #@U "#@4"%H 53DT 7(E
MWTQ,T57 IDEH<_Y_S_G\J0P+>E %263 H92*4C=34C(0: %H :#FF!)F@04
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M10 'BD H'^?P_P __J(I 6X1Z4R6;MM&&_S_ )_R:8BY]ES_ )Z4 )'  <4
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MH :3@T *3CZT -SF@0NZ@8!O>@!Q;/;TH 3=G_/X4 -SF@ +4"%W8H 4-VH
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M.Q__ %T .6_]Z!CQ?"F(>M]]:!DXO0O>D!,+_% $QOP!_G_/^?R0%*6[SWH
MR9KG)IH0R.?/I3 U+=MQI =%9G./Y4 =-;^M(#70YI@*W_ZZ *<ORB@#$N!^
MO^?2F!SLYQ0!F2OB@"NTN:D!ZW% $XGQ0!86YQ0!8%U0!92Z[T 3K<@TP'BX
M% $AN:8 +C- "K.* #SZ '^=^5 "^:#[4 *LE @$@% !YG/Z4#';Z!"&3- "
M%J!B>90 OF9H$)YE R1'YH$;5L<BJ)-=&S3$2@T 1R28I 85P](I&>7I#'[M
MU !DT 2=* $/- "@T *>* $W4 &[I0!,C\T ;%FW-,DZBR)- '10G-2RBSTI
M#*D](#+<T@$7FF!?CI@7[?@T =/#TH$$E,#+N: .3U3H?\]Z ..?K2&,!H 4
M<]* $:F!8@XH0C:M^*H1L)027$..E SYM4\?K_G%,";&/_UTQE6;%(#'E% &
M)<T 85R=OICO0!S=US_G_/YT 8LQ_.@"H3[T (K4 2 ]* )QQT_S_GB@!P7-
M( V4 1.N:8$1!% ##R* (RGX4F QAGZG_/\ 2D,84S_G_/\ DT!<B,6WM0.X
MTQ^W7_)H%<FA7!H$=%:CO_G^=.P&[&=PQW- %=UQ0!6(YH DQBD49LIZT#&1
M09[4A&K;0AC[>G^?\\_2J).PT^';_GVIB.QMACK2 LN^T4P,Z=J!F3,V>_>D
M!DRMWI@9THJ0,^5L?C29139<_P"?\_\ UJ0RL1_G_/\ ^N@"0+B@"1E]: &D
M8_3M^/XT , V_P"<T *@/U_S_GU^M $R9YSS02S1C0OQC%4(T8K7/04P-ZST
MTOVI@>D^'=+(:KL2>R:=H1EQQ0D!UEOX84CFG=#-0>&4'2E<+%"?0#'T%.XC
M!NM.V<$4QG/75KMZ4F!SMS&!4@<]=Q^90!R5W;9Y]:&!SM]:Y]/;VI <O=V/
M'^?_ -5*PSDKRU*GIU_SWH YNYBVYSS4V*N8I!!I#->SO2GUH Z""^+\<^U2
M,U[<M+T_S_G^7ZRP.JT[3SGOC_/Y4[C1WFFV&><?Y_S]:@JQU]M9 =1VI!86
MXL]O2@+'.W:8XJA',74NWC_/^?Y50'*7EQZGU_S_ (TR3GYY1*<&@1GW#;SQ
M5("!4!_SVI@*8_SIDLGBAR:8C?MK7VHL!TEG:8/M0(Z&SL^G^?T^M,#H;>QX
M''% %\6(]*&!0N++:.G7_/\ GI2&8]Q9]:D#G+JUQQV[]33 QY;3/;O1<"D;
M3::0"_9<_P"?\F@"9;:F!96UR.G_ ->F!<2SR,4@'-98[4P&&UP/ZT 9L]K@
MYQ2 SI8,T 4I$Q_^KM2*1 5Q2 >@YH&7T7.?>F(LJ,<T /QCFD TK@T 5RG;
M'0=:H">./?CTH)-%(\_Y]?\ /_ZJ +BV^_G_ #_G\J )4MO\_P"?\^] $ZV6
M?Y?K0(E2SSVY_P _SH L)IW- RZNG^W2@!?[/P.G3_)H @?3,'D4P*;Z<#VI
M 9<U@5/0T 4C;>U $3V^/:@8PPYI#&^3B@!#&: %$>Z@!=A%(!HR,"@!Y)(Z
M_I0 [>: '+(?6F!.)#WH 59J0#O.(Z4 .$Y'2@!XNC0 ]+DTK (UP33 K/(2
M: )XB0: .BM%- '4V?S8^F*8F=':C/X_X4AFJO%  !GG- %28T 8=WQ0!S5R
M=M &-*] &>9<=Z (Q)BBP#Q*6H F6<]:+ 3)/MHL!.MQ@\&@"47&:8$RSU($
MBSYH D\_% #Q/3 E6;- #UGI@/$] "^=Z4 2>:>M @\[(H 434##S,4 *)>]
M A/-Q0 >9B@8HDH EA?)H$=#:MD8JB385J8B?-%AE65N*&(P+E\_2I&4E?-(
MJY8C7- BXBT!<E2*F XP;: (3'@T 0-F@"N3B@0%_6@=R6.3M0!MV38H$=;9
M_P#UJ .@AJ646^U2,J3&@#-DH 1!S0,O1TP-&W'(H$=+!P* 'RFF(R+@X% '
M*:L.#0!QC]:0Q*0 !FF YFH DMSBF(W+=:H1KQG(H)+JT#/FT?U%,8\<\T 5
MI: ,B84T!AW/!I 8-US_ )_G0!S5TV: ,>;G_/O0!GL<=^O^?RH  >_XT 3(
M<@4 6UYH L(.WX5(#P,\4 ,=: *K+M__ %U0%<C% #?O9I (4% #"/\ /T^E
M " 9]NE, 5.] $J+M_R* ->V&,?Y_P ]J -I"<=^E #G^?K0!5?V]: &$Y^E
M2!69,=.O:@LLPP[OI02;-G#@Y^E4)G368]/\\4".@BDQ0 LDG'^%(#,F>F-&
M;,X_S_G_ #B@#-E.30!1D/:I I2#B@HJ;>E2,8PX_K0!)'QW_P _Y_'WH G*
M]3UH :RYH C\HF@!PCQU_P _Y_G0!;B@).::)9M6\.*L1OVL&>WK_G]: .LT
MVVQ@4 >M^&K#+<C_ #_GFK)/:;"V"@5+*-V..I L[* &.@<8I@<YJ5H"*H#S
MW4XMN?QH X:[^8T",:9>M &%=(* ,2:+(_S]?I0!EOI_F\5: S[GPX)^#28C
M@O$'A26R&X#<F>H_S_G]:FUQGGDD17J/YU!5R:V@YI6'<Z>QL]^#V]?\X';V
MJ6,[?2].S@''Y?Y]/\]*EC/0;#3]V/:H*1V-M;!!04:R@*/:I IWDV!U^OYT
MP./U*8<_Y_Q-42>=:G=XZ?Y_S^54)G(3W)?OU'^>E424GD+C S3L,<B%J8BP
M+8G'>D!<ALCZ<?Y_SZU9)K6]ASTS_P#6_P \_3VIH1T-K9;?3_/-6(Z2VM,#
M_/\ GZ4,#?MX/\YJ -R"(' H N"$4 4YH.W^>E(:,>Y@S2 YJY@#_P"?\]Z8
M&(\/Y>O^?\\5(%1[?IQ0 R&,=?\ /% %R.'/('TI@7HK<-[T :"V@H$2&RR*
M8RG+;;!_G_/^<4@,V>V!X_SZTP.?N(: ,N6+KGH?\_E4C*94"D,(QWH&7XQC
MI0(GV_I3 >1CZ4@%(H =Y>?\C_/_ .NJ$R6"'IG_ #WH$:T5L"*8C0CM_P#/
MXT 74ML?Y]:8%]++//Y?C0!=@LMY^O\ 6E8#333R*0%J/3<?3Z4#)O[.P:8$
M3V -,#+FL"*D#(N]/[=_IBF!A26F>G_UJ0%1[7:: (7M\?E0P&?9^OO^/^?_
M -5(H8;;\#_A0 XV^W_/^?\ ZU B/R<_Y_SZ4 ,:VI#(O)Q]* !XL"@!JQYX
MI@.5,BD %/PH /+H ;LH :$Q0 \+3 0C%(1&!0,T[:/=^-,#IK->U(#I;:/.
M/>@3.C@I@C25<CGO2&#4 4ICCZT@,.Z/%,#EKMN30!ASG;_GZTP,N1^*0%?S
M,TP'K)2 D$FVF \/FD!,DN13 E66@"82;: )!+CFD!*)<T .$E $BS;:8$@E
MP: '^=0 \3;J '+-0 IFQ0(<9>] Q?-S_C0 X2]J %\V@ \SM0 OFT"+,$F#
M0!U%GP*HDUHVJD!-NIB*L_':I8'-W#X[U(R%#N-(#109-,#1B2@"ZBT 2!-W
M3% %5D_2@"E-'M^E %&1<4 57S0 Z)L4 =!I_- '767(']: .C@YJ2B[TYI#
M*4_^?Y4@,]R#F@!L= %Z.F!HVW+"@#IXN0/I0 2&@#*N#3 Y+53Q0(XZ0YI#
M$Q0 G6@!": )H:8&] <]:HDU$H$7HC0!\W1C_/\ GI5#'MS0P*TG-(#+N!U]
MJH#"NA_GK2 YN[Y_QI <_<G\Z ,*4$_6@"F3F@!!_GF@"R@)H MH*3 M 8%(
M"8#?_2@!'7_.* *KKZ_Y_&F@*,OO^% $?4_6D,,Y_P#UT (3O/M_G_/UIB&Y
MS3 7'^?PH E VG% &C ?3Z?_ %_\* -F(\4 2G_/_P"H_P"?Z #/*).,]Z '
MQVW3_/- $GV3/OG_ #_G_(H L"VQT^E %^","@#7A.,>M &F)0G% $+3Y'O0
M!1EES_G_ .M0!2=_3OG\?\_E0!0>3=_G_/\ DT 4Y#N^E2!4DZT#3& ;NM!1
M&?\ &D!)%[4@+2@&G8!0,\&D ;13L ]4W'ZY%%@-"%!^']:&!NVT>/I_G_/6
ME<+'1V4&:.8?*=OI=OC&*.8.4]9\.P;<#'-6F2U8]3LEX'TJB3708J0)=M,"
M-A2 R[\9!J@/,M<(3- SSN[;)/UI 8$LI%%Q6,N64-3 J%-Y_P#K_P"?\XI@
M7DM^.1BJ$/\ L^1CK3 IS6'7C*GJ#0!Y]KWA9),R*HY[?Y__ %U+$CB6T@Q'
MH.N.G^?\*EE&W9:;@YXJ&-'<V%IMX[?3_/\ ];\J@H[2SC  _P ]JAEFTKA!
M2**US>B,?2A <U?:H$YS3L2>?:IJ]4!PM]J7F=^_^?\ /K^=,FYEKF3OC_$&
MG<#8@MBQ'U_S_GC^HEL=C6BL".U+F"QJ06 ;L,_Y_P __JIIA8V(-,![8_\
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M8R1Z99=!6IF:Z,*0AQ>@")Y-HIH9SNJW@3/-#'8\EUO4!(<9J;C.&O+H<X-
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M=O6@:+Y7 H&57]*8&=,: ,.ZXI <].P)XJA&5,O>D!0>#?2&-6#=3 >MMDT
M/^R8H%<:;:D GD"@8J19H E6WH$+Y6*!CO*SS0 X1Y% #1'FF _RJ0"F/\J
M&[30 ;3TI@*%Q0 NSO0 _&: '8H$(!2&*:8"@8H0C1LN2*9)U]KR*I :J=,=
M:H1*1B@91NCBI8'+7)YXJ0(XWV'- S9BD!Q0(UH6S0!J1'C% %Q3GTH @<4
M4GH&9LB_C0(HS#- $$:X.10!OZ>O\A0!V-D,B@9T,(J1EL]*0RI,*0&9)2&"
M#% ,NI5"-&U/- '31=* %E;% &5<'B@#D-8[T <@W6@!&XI (&_PI@-:@":
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MM*X'+W5]GZ4 <U<W5(9AS7&#CO\ 7_/^% !;7_DGCU'^?\\4T2T>DZ7JJWB
M<9'IP?R_SZUK%DLVU.>15B(VDQU- ',ZGJ'IUK-L9R\EV&.*0%-KT)_^O_/^
M?I2&,.H[?7H*5AW%&J;:7*%RA=:W@8_KS_GWI6&<_>ZP7X[<T <S<7AD)Q_.
MJ2);(%&3Z]?\_K18:-2VBZ5+&=7:6X4<?RK!FJ.DMX<=OTJ6:)'0V=ONQZ<=
M:5P.LLK(<5:(9U%M9@8X]#6Z,F;,%G@?Y[5JC(1[:@"B8,FJ0AOEX_G0(JS+
MBI*&)3 BG7(Z4F!CSCBD,Y^Z 'Y?Y_SS4@84V3_G^M(#/E&:H!4H V(?7]:
M-2#W&* --%Z?A0!.RYH S91UI@8UPN[_ #_G_P#70!@77I0!A7 !-24C.D0Y
MQZ_Y_P#KT@*[)NZ#]* (@1_+_/\ G^=,9"['I_\ 7H1-P#;J8A\;<_K3 UX#
MT%(#:MWQ3 VX3S3$7HY* +T4F?\ Z] &M;2 \4 =-ITG(SU)I#.VMFI"-5!G
MZ4#+"KQF@"-U[^N: ,6Y3- '-ZCP/\_Y_.@#D9 2: *K\"@"K(,T@'QT@)@
M?_K4 2A-WY4 1.F?P_Q]J!V#RLC%,8SR<4@*4D0&* *;Q@T 1M%W'Z?X4P&&
M*E<!?*R.:0P\OM0 _P H'T_S_.J$2K#COW_S_.D OE4P$,5,3)H(RW^?_P!?
M_P"K\J!&U:I_3]: -Z!-V/\ ZW_UZ0&Q",?Y]J0T3MS0,JO\O/:@#,F__73
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M;O2 <"0:8"G@@'_/^?\ Z] "$\4@(BW^?>D PMCZT##<?PH C8T )S_G_/\
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M 12\]?\ /^>*0&3<#K^- SGKG^G]/:I Q)ACZ4@,Z0X.:H 7Z?Y/X4 :UO\
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M$-2 UX?RI#(6@S3 A9,4 1>7MH 0QXH$-V9I@2K#D4P+*0TQ$WV?O0!*(,T
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M!G2:?VH ZZRZ4 =#","I&3$T 4YN./2D,R9#0(8M %U#ZTP+UMU% '11#(H
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M_P B;CS]>:!V(D\+:=<C_CWCSCT8?A\I_0"@##G^'VGWN=J/$W8(S$Y_X'N
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MRF* ("E $3K0!3D&:3&4W&*D"#&#2 8[8H JN^Z@"A*^:!F3.^* ,POF@"Q
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M)Z5:)9N)<Y%:$&9=3XI@9AG_ /U4Q 9NW^?\_P"% $ZR9H M XI ,?IG_/\
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M%=7LK D!HU;OMY(QZE>1^9-(99C\16TJ^8LN[!QT.[\NOZ>M0Y6*2N<]J/Q
M2RZV\SC/5MJX]Q]XX^H%9^U-/9E"?XDS0C,-LIYP TA!QZC$;4U,' 8?B5.F
MTRVI$AQD"1OYM&.W8X]@1S5J9#C8ZW1?&AU$9$1##^$MCCUSCGZ8J93L.,+F
MC>>)RHP(@?7#X_+Y3^E9^T+=,PX?%!N)-CPF/) 5MX8'/L!D?C6JG<S<;%V7
M7S 0I&<G )/!]<?XGI5W)*\FL,W4C'YFJ%85]<*_+D'T],50 FK-UX(/J.*
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MB<,0>.-Q'K@G*D@^]("*VNX[IF'E&,$?P.I4D_*-P!8J/9=PY]: ,[4_#O\
M:TBNSJ-I) \S<QSTRI51Z8PP '')IBN0KHT6FNS^8A.XMM!/F,>?X<<<\C'"
M\\GK18JY=TR*6:7=QE^-T@;!YX49./3J<#'/3;0)FC#"R[H%D8KN D<@A"Y.
M",?*K#@@!LY].<  U+;3FBRK;N1R"&.?0JBG) ]$"A!WR!0(D>PB@9I':&*4
MJ06'S2'C'!<LV>0 H7/3)VG)8$<$ L,Y^4'&TNA0X'4_/*@8=SD].@/9 7[K
M70N$1E9AT"8&T$@<X8X[98L2>.!CD OZ9J<>TD\!1G<S +D^F<$].P;H.<\
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MR0GWYI 6D39S_P#JIB+#$@52$S'>3:<51)HV9YZ_SH0,["R]Z8C84'%# '.
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MF?I69J?LM\+?V3_!GB30-+O;K3?,N+BPM9I7^TW2[I)(49VPLP49))P  ,X
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MA'3MD@?0].>F30QF?>&YL\#"B($ C."%(&<#C& >Y)^@K.Q5QD=ZR+C9Y8'
M Y8CTXSUR/Z9S0.Y?6T$BC=]U"Q(Y Z=&SUQWQ@=O>J%<='I2PI]X[BH"@GD
M9Y)/;)Z8XXZ<#FA%:%7CPH*C!QR-P'/H<C\^?S&&(VXKK9Q)R%!R1\O?   R
M<'IQC(_*@!3<_9T+8\J,#@$@CZ;1CK^G04@,R.YBNV$1PQY.!D].>5/7&.I)
MSP/:@"1?#A=C*^Z1V)P.6 SZX.,>Y( QV%, O-/CCYN6+'KL51MX' (RP],D
MD#C@X'(!!>ZDFH%?+1BP PJJ"!C!XY XQQU (&.@H 2TTB*[ :9)%&<;3(23
MC_@(['H6X ./="+M_I'EG(RJG[F<(B#C/'7=^))X!P.: ,J,"T!#,QY//(S[
M=?P[?04 94U_AA*06B4X1>09'/<8.=O8 ')'7'8&:)S+_I-P0G0!8AC:H&,+
M]X #D=R>S4@.7USQ*]P EN/)C!P/[Y'\7.3@GG<V-V.,@4#,*.\'AM$Y8RRM
MD+OP-O<D8/R@C'/+9.#ZR!J&(:A&)9(?+\P[E=20>IY*GS.>/NK@^G%,#=A\
M*6<X7SYI   =LV >X ..@_V003@G.>M"N;=IH[:?'\OECOM0D^8?4[1OX[#:
M N23DYH PYX8T5A.$^<Y<8.-V<])/F(Z9.?7 4TP,--*C8,%W[&)W' 0$9/"
M'=^'/'/3Y<4AC+^T6)D?'3_5Q*V[ (QO)/.<C_@6!RHYI 95K:2RR"6/*HN=
M[9X9NG&>I/) [#D<4#9VAF%RS$*#M)X+X &2,L<=\= RY'>F27]KQQ;KAQ;I
MTC,9="03QE$P".IY<GKACT(A$/VJXL4P[_N\=?,Y;M]PY)[<OM/J<YP#'7FI
MRO$&1 "!AY&!PB=>#M4<G[V%/H<X.4,9'XD^WJ9G0!%)5'.!GIDD= >1CAF
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M@_\ D>BP7.S^'7[)6A_#+5(-6L[B]>>W\S8LLD10^9&T9R%A0]'.,$<XZ]*
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M7$K":5L##%AM XP2<D8!^[R<_1@4P+$%V+PD1.5* *68_* "?N+SSSP?O''
M^]2 @TBVD5S/(Q>,,<;NF .<*1Z8/3D# XYI :HO9MF(V8[N"1DDE<C"_IDY
M )..<<,#8L+]\+$=T@ R7'\..H) 7=Z<]_NDY%4(GN8@6!G<@$9"A<-SSG!8
M$#/.<'\.S DM;41C]U$&7[S.2&P3ZXV!>G/)'\J0&BNEP18:8J& .%X)'/?'
M)QU'&.IY- &#/J7]F2J(&QD!L@+GK@L5/3@$\@9''?!38&S;:R$S*TA0[B-^
M%0D]R=N2V/0% !C)'%%QEA-5BU$CS%)!P=QQNY'# #)&1R=QY![C)HN(GN+"
M&929"\D;MSA5VGC^ZN\\8YX4\'D=:5P.)U=925/$<09OFW !1Z #VZ=,L<GM
M2 RK+=AO*8[-I )&=HZ$X/&2,>N!V)'#&-DU(6>,EMA7.<L#(W?)R&Q[]SWQ
MC:7 ]$TS6)K>-9'W,  "H);8.O&]GW$]@F<#J.BBA':0>+8H2</('7 9)&4+
M\W*C"@X]\LHR>5Z4@L1IXCMQ*^^V@5T.=VX9[<X91M)Z[LX]#TIW"QBKJ%J@
M)@41N?O>86=B0?NJZ;SC )X4L,G#9Z) <OK331A9 _R.> I(<94\$D#;@#.0
MP.>=W."QF'YMQ;X$@D/F$LD;2!V8 CDN"Q Z]21@&@#H[>V2=@0HDY)(+[=H
MY&5ZK@XS@ ^F.#0(V18R1$LKHK$8WRQEF SG'S*P)]R"#UR#BF!IF!Y8S'(T
MEP[*7#&,Q8QSE>AY7<,D#.0"3DT@,B6!G5%7R]YSM,DR*N 20I7>I&3P2K#A
MBVW.*0R#3O#DDTH)C0,PRR6^.^0<NQ9LY ')^8\X(!-"0CUNUTZZ=HT>)5CP
MQ89#98@G#?(#M).,$[<?WJH0\Z/<%@S2##-N9?*VL3R0.OW1G(C'R#&[=D\M
M("] ZV4C/&H3=L3S7EVQH#\S%8Q_%SM+MD*#@%5SA#-E?&-IGB:+:O ;>6#
M<$C;NW9P<8SU]C@&=I&=R?,4!)R 2%SGV;!ZGT] :0AX81/ZY'\CV_2J WK0
M!6&3^9H WD.SI^E %*YSD'MCD_\ UO\ )-# @DL4N &P"_3/?U'^>N/:D@)U
M41<,=W3L<YX[\_Y]Z8&S#*H5@I;=@+SSCWR.W?U[T 8.HZ1!XCB,-S&LT7)
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MLCN"0[QC;B,\YSDCCJ0 ?.J_M]>&&_Y==2_[]0?_ "10!.O[>7AEO^774O\
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M3VRR[ADYX'?G_9([\\4!<B.G_P!G@HX.3]YB21CITSDMQT/ /^UR0#,&D'5
MR';#'G).,#KP">>>>.!TZ=Z -:R\)0/EHRZJ<'<"-J^F >6).,D[ .O7%%@+
M.LZ;#Y>V/=M4@'D$C/=F!P,@X )!]3P2RL!YY87+[C%'GRSP68@$ YW?3KSC
MGUQTH*/0+"QCM]CO(H*J-J2 @H,<%47)#>YYS\YQBF2= BK"Q5BT@+'#<,4.
M.X' ]=K<Y.0.M,#&,-Q9N##'M&X@-(V=H'5F*A44'(VJ,\ \T@+3ZN=IQ<%5
M[E5C4D]21G#'C^$=01U!!8 J3*E_$S*-P ):0@Y)[KQE<G@D9+=^>@3$<G%(
MBR D_O#G!X&,_AQG@9QQ^9I%$_V6:\3!.S<7!#-U&/O-@;F&>F"=W\T!T-E<
MW.DQJL/.6P6<_+C)!ROWN.P!'USU -Q+:RUA )EEWDDX1LX//3=N)/4[3G'7
M S5$D::197K^6EPT:#.$,0SD].?F)SUS@ ]1UY!BW7@V+S 4FC;"G:G*N0 -
MN-Z[1D_>.#C.0#THL%RE<^'Y]/C$K]. 1$5DP%XY* 8('4G!7YB,9YH=S&_L
MF15/EDE'SR0>-I R ,<]N@ ^O!0&I%;10AE89=I,1Y+#CN25&"2>1G)Z] *3
M$=5;6(5"\S,J,=JI&H9BW8@[?3'WBQRQ&*: ?J=HJJK .=D@)V\$'!Y89X.,
M^@;IDY(# )[:"9D1Q\QR57&UVQTPNYF(ZDN1N/;&>4-'+74D\DK*HP,XV9(Q
M@\94$=N@.20"=IS2 Z**[N+@,268C"^A'7D(!N(Z>YSS3 LJ[Z9ON'*><-@
M(7@]0<9&">/0@ GYB<4".C.I1V>UXUC5)$! (&X9X(5FD!R.F-O3%,#/UG5C
MJ+*@*E<!3@LN2 " =RCJ"#D,<\'&,FD!>T[;81,\2*T_38[2*IQQE3YA3/'4
MC&00"!0!KVWBZZ8$SRPQ* @2)(R_'.0713M[[25Y_4,1H3YU%1.#(OE H$SM
M]M^#C P0,LHQST)H&.?5Q:JODJID4+NE5GD=V R3\G&.?E&5!/0=J!G._P!N
MW%B<O(Y?JR,H7=QPH7>S9Z#@%3GL"&I6&=7IVO7$!4SJOF/@X!.<=.4W,5_
ML>N57C*$=_I.M?:1E7#8..O'8]C_ /7R.E%P.TL[\3=3G&>>N>><]_?\>M4F
M(O2@R8QCKT _P_\ KTP+,"[!]?88_P ^QI 65B%R>>@[<"@"W,3:1E<G&#MP
M#^I'?\!0!CQ*P^8#:QZ_0\\9[\\>G//:@#FO$_A"U\7H(+K<N.8W0?,C<=\$
M8(^\I^4CL#@@$SY!\4>%)_!]R;>;#)UCE4$+(N>HST(XW+SM)ZD$&LFK%)W*
M=KE>OUI ;=N/3K_G_/\ 2@"9OZ?TH&9%T0#Z9% C*E4@<8]>:0"*N[J:15R]
M$^[U_.@+DF-H]S02 7/%,"L1GWI@=7H[$#-)E(]#MSMJ!FS&<8]STH&3^] %
M=N* ,6Z4DUH0/M#D^W^?_P!5,1V=D?\ /YTQ&Y%UX]A2 >XQ_GZTAF9+\I/^
M?\]J ,&[&>O^>.U,##N"1FH RI 0#3N!"IY]>*8&K;<]:8&K#Q0!K0#BF(LD
M8Y[TP,^8CM4@8=Q\N:0T8<[8Z>O/^?\ />@#"G!Z^E &:QS^-# JL<=/\_Y_
MSFI J/S3&4&.:8B(+_G_ #F@"S&"3^5 &M !^'K0!MVR[>O^?\\T :JIC_/?
M^= %V*, Y'7O0!KQ =?IZT ;L QBD!T-G\I'8U0'7P-D9I :49SQF@"ZIP*8
M$4K?G0!E7' R*5P.=O.: .8?K0!#D#^E,"O*./\ /K4@"#'Y4@)E_P#U50%B
M/(H F8[1Q2 4-T(]*+ 2#CITH 1GS2 8V?YBF.XH.:!B@XI#$W9_S_\ KH$/
M#4 2#T- #0VWF@3$8XX_S_G^M-"/W+_8Z_Y$;2_^WK_TKFIB/,_^"@!QX7M/
M^PG#_P"D]S0!^2*MN&12&74?.#^7^?\ /]:0T6PV1D4#'$YZ=/\ .* /H?\
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MIL2/P6C2I*+B)MJAGU3^QHO_ !76E^WVO_TDGH$S]VJ9 4 % !0!_.GY8/-
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M &TG /7.0#CY5'0A<[BV&))Z S7AO%TXF*!07[JIW$G(7!(&>ISP5QDDG/1
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M?:F@+B$GIS3 @E-(#)N#Q0!SU[P#Q0!SA/./<TP(2?\ /YT 5YA@5(#8VXI
M6 .#0.Q:CIW"Q+NXI@Q,XZ=/H*! K;@/\^W^?SH 1I,'GK_G_/\ 2DP$9Z $
M$H/]*0T+O!_S_G_"@8GF]/\ /O\ X4 .23O0 K38H :S_K_C0 TR9.::)/W4
M_8WX\"Z7_P!O7_I7/3$>9_\ !0,X\+VG_83A_P#1%Q0!^1D#_P"?ZTF4B_&=
MM(9:C;=[T 2$X% 'T5^R.?\ BM],_P"WK_TEFH$S]M*HD_G;^.1QXHUK_L)W
MO_H^2D6>0VMG-JDR6]O&\LTKJD<:*6=W<X554<LQ)PH ))P,4AG]'7PF^&-E
M\(M'M])LE4") 9I57:9YBH$DS@LQW.1G!9MBA8U.Q% HS/DG]I']M5?AC>C2
M= 2WN[V%R+N6;<T,1&1Y*B-T+2@_ZP[ML6/+(:0N(DV-(_/[Q!^U3XV\40B&
M?5[A%5PX,"QVK$@$ &2W2)RO)RI)4G!QD*0KE6.4'QO\5'KK6J?^!UQ_\72
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M/_1*5:(9^=W[</\ R,=M_P!@Z+_T=<5+&CXW%2,N(:8&Q8\FF!TZ=* (913
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M /FKXP>'OL5VEZBX$PV2>\B]"?=E//KM^M1)6&>7P\U($['%(#)N1GIT^O%
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M]@#Z9O+R+3HGFF=8XHU9W=V"JJJ,LS,<   $DG@#F@#\'_B!XQE^(VK76K7
MVO<R%@N0=B* L:955#;$"KNP"VW<>2:8')A/2F!.EJ* /W&^$OQ C^)NCVVH
MKM$KKMG1<?),G$B[=S%03\R!CN,;(QZU('RA^UC\!)]?F77M)MY)YWVI>1Q[
MG=L!4BDCC ). -D@4\ (X3 E>@#\Y'A"XQ_GZ4BBFRXI,9]#_ K]GJ_^+5RD
MLR26^EKAI+DKCS &*E("PP[DJRLW*Q8);+;8W8KFE\:_V<]0^$\DMS"K7&D[
MEV7/!9-Y(5)E'(8$!?, $;EDY5W\M0#P*'!J1GZ^?LKW<=SX2LEC=6:-KA7
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M-7<3));N.5 .%!) *M\Q QV&3C/  QGN >:JXB":^N0A\M^G !'(]>&R"3T
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M6K0M*-C#]X0#Y:@<<\ +E< #N>3DY(P,L"I/<?V>ZQLRD/P&Z]3P1P.!G ;
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MM'FBVQQA06/S;QWZ* /7##. "<YZG%,1V5A?_92#)MB:,IAE1SNW==V=V6.
M !C)/3T!'3O/%I\:YMYCO."HCQ@'\!TZC@MP.3UH 7^TQILCQ( L(!SD/OWD
M?PDMCWS@^@R: L<9/=CS/F48#DN)%(! .-V,#.<Y&<Y8C.>,R,L?V4;K:9)&
M#G@B3 W#@<_ICDY!X P,,#H[2!8%_>[&B53N)CW9[\$X)P.>1ZX/=6!!>%-2
MB^U0Q;2S_-T4D'^,N.1SC(4XW=0V<T@L8NHM)I\1,@<-N/SY5D(7L7R#NP,
M$MSWZU+&BEX=MA&X8 J[*VT-QQC)."<>^>>F1VH0SJ[/44LF9IUDDE((C50@
M'U8G'MU&3SN)XIW"QT>@:T]C)EHP3G<50[B.>3C\_3.:+CL='>6EGXB4G8HW
M\B6/,;_B1AB?9L@9Z&G<=CG!X%N+/!MY'DC4'"OL+'DY^]M!Z]B,_P!W)I7
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MT?/I2*1*OR_Y_P _04 )YNW _.@95>YV4"*QO>/Y47&5)+\CTZTK@5?[2YH
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M@+&5/\WZ_P"?\]ZH+'/7.&/M[T",)C@X_P X.: (ONY'KVI 59^F12&@A/\
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M/7KR@,N>)+A%^4*(U 2+RSM&T#!8[C@ 8SD_-C''- &9_8GDAI ,2,/FR#L
MSV.>IXZ\>](9A!\GYOE[8(]>3^ QU'?%(#8L;"6"-<J.%RH8CL>&(.#WP2?7
MK0 EO<F)@S % G*X)X!R3P>>F?7&>F<TP-&XO_L>3G:XV@,0,#=QD8 X';'0
MGMB@!EEJ#:?#E 79CC=UQGC [\9Z<'/.:0'0:?"UDAF(4NS,&=L,P;GA<DC(
M'4X/W<52$:TS6SR%Y\!OX>" ,X +(,_B!V4'!- $USH!U% 4!DR  00B\^K$
M;AUQMP#@XYH%<T%T3^PP"-C3'C#8,:^NW!^]][JV>K'!QA@9FI6J:IG 'GC
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MO0!G2KR: ,&Y^;Z4P,"<?Y_S_GM4@9DH)_+^=("N@S^G^?\ /_Z@#3@.[I5
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M^Q%^\[D*Q6- SM@A5)H _'']JO\ :37XS7D=IIX9=*LG<Q,VY3<2$ &9HR0
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M?QIDFG#S[4 6\X]ORH ^&+*_W_*I!P./\2?\YQQQC-- 5]1G6X4QXP6)ZX'
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M+4%KY*%3\V< ;0Q4'MN8DGIT!XI7+L6$C%HX7.3Q_P#J^G;\.:FY21J><T^
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MI0.Q+Y1F))55''/KS^))]_UJ6RDBREN4&X=">H'7!Y_SQ0A,T1.B@$#(]?\
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M!"Q#!%,#6AX_S_G_ #WI /;Y?\_Y_P _6F!0FYZT@,&Z&W\* .?N,'^G^?\
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M!D32?Y% &'<7@CY/7G_/_P!>@#G9M4"\C_/^?PH RY;LMSGK_GB@"L+@9IB
M38I#)EG+=^: )%FSZU0B;SO2@"8S<<T .^T[?84AENUN.::)9U=G)G\O\BJ$
M=19R$?2@1OP'-,"R3@<T 49.* *$PSUH P[F@#$G.*0R#S0O'% $B7&WC^E
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M5B-V!_\ 6_SW_.DQHZJW]Z11I*/S_P _CZTF!.C<4@(YCUJ@,B8@G'^?_K4
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M0!<2SQ0!)]DS0 ];'% "_8<4 1M8XH$57M/\:0[E5H/6@97,6*!B^5M_^L*
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MCAA(L8&2 ?)WBKPA?^ [^?3-3@>VO+9]DL3@;E/4'(RK*1AD=25="'5F5@2
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M/.\O[.\CX\GR]V_S(H\?ZQ<8W=#G'<L%SP?9MH&6[>W_ )4P-F*T_3_/^?\
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MI18"00?YYI -V!>10!7D@I7&5S'VIH0FW;U_G3L T1YXS_G_ #_GGD B89I
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M #UH A,7Y_E2 KB,#H*0RS''_GO0!9\O- #U3_/^>] $9CP>.?Y4 5W3'/\
MG_/]:!%*9<9- S*D0=*!E(KB@1#MQ_\ 7H >JYQ2"Y.BT :%O&*8&A&E %Q*
M + I"(I&R:"Q%8T 3*^* )1(: ) ^?\ /^<_Y]:!6'!S_G_/^?RH"Q*9#_G_
M #]* &AR?\_Y]Z0Q&DQ^- #TE- B[$^:0S0B:D,L TAGMWPS_9XU7XN6;WUC
M-:QQQS-"1,\BMN54<D!(W&,..^<@\4TB6S,^*W[.>K?"*RCO[Z:UDBDF6$"%
MY&;<R.^2'B08PA[DY(XQG#L%SP5,=Z0%R/YJ .FL!ZTQ&\IXH JSCB@9S=\<
M"J \WU4Y8Y'K2$9"^U(9)F@!QH ;F@1H6]4@-JW[4R35B% $X'^>* /S3FOU
M 1\<,QP""2<' SCN>HSCZUJ!?\WSWR.@52./7)/U].W\Z )H8Q/M67E">5/
M.#DCCL?N\<\D=^&!']J>8.SAU5 ,$XY/\1'!QCMVXZ\\H#)O[1KXH\709*XR
M0,9(!P.23_\ 6XYI,#G[:10'A.>G)S_%TZYY"]!SC(/&#2&3R7;)NCVYD.,,
M._'&1ST[_G@XQ0!7M/\ 1R689C1 ,CI\A!.2,]> 3TP1VI 9]P\M]\TA0;S@
M@' 4$>G3.W'IZD=26!N6EL+=&0JT43+F/^](^0"YQU )POJ22/8 2ST^/>9M
MQ+,".AP=O.,^O'..,#''=H"SJ$[3D1ACF.1B01P2H(Y]0N.>.![T 5M(M_*+
M2."XY4%A]YQC.TGG ^4,<#J![@L!(\,<3[1D_, 1C[S9!">XSR2<>W2F!#>;
M]7D-LBEY1R &^4' .[&WH,<<@=21R:D"E!X9N?#Z)*Y^=LAD((.6X Y'.>I(
MR  "3G%%@N2+/+!L'S*2O\(R.>QST_I0!T4?B@Z898E 8[]B+C ^;JQ_O=..
MF22.].X%:\MXO$.3:E8F)/#C"N5 R0>=N<_=QCC(/7!8#%&F76@/YDR,C,=N
M\\QC"XX8<$YSZ'KWY %SNK*T*Q(R,-H# CNV#GT((SN/)'# \XQ3$5/[597#
M"39&G! 53U[[0,9Y/)Z?7F@9KW<L=['B5HX\..%R,^@8A<#N>"<_W1]Z@#GQ
MIOV0AIL=\+D@ $' SSGC\^<<4 9FG27'VC*L/,(*H6SM Q]X'IC' ZX X6@#
MKK2 JT8R3$9,*0?G).%7.0<#[V,9/S#ZAB+VN6IO%W^4JE0,9&2V,X+#<3QT
MQT+ '+<"D!@Z=;O-,$C!8NFPX],$[1D\#AN>H!]\4 >A:%(FGVV]ON*6*LW\
M;#EL<<*N1@GJQ';- C@CYBS23-SAR, Y))[^YR0WT&>3C(,U;J\CO$".%RI&
MW< &QV &<G/4DC&TYZC% SFKB)HGD:,MDGED8D'<<X4CG(SSVSD=!28RQHOB
M&YT:1E&THP'ROT;><YW9 'N1Q]>H+CL=G8:E'>,$,8#,&&50;0V#CGKQR1[X
MSC.:$38PO$7@IKK]_8$D#.8CC<",9*8)#+ZXY!]ONE@.$.BRPL=X!;G+?=Y!
M.?O#GOGN>F.:0'2V7B9!$+>9?W)&WS#C>O7E3_=Z94D@]MO2E<#N=*\0SZ4P
MW_OX#T>,!B >Z\*3[J3QV/7(6>F*L>HQYR&W1Y#,<H0<=0?YX!'(QD8J["N>
M6>)-(.D,KQ\+QM( 4-@#E<9RH[Y.5(YZ9K&2L:IC-,\0(C!W)Y)!CS\N2/Q
M'MVSBH+.T@UV36\J04.3]PJ22#Q\N!^C=_?@&C4M+/RV 9@5PH0>I. 1M&&+
M$Y'.!SU]$T5<U_["CP2H!!^4$'CUR<#GGCCGH,&ERE<Q>?31=1D* N>YSCCC
MJ/Z9!(':IL7S$(@>S./O'N1TP3Q^']1D5+5BT[FT+L18W8W'&2!SG]#Z?_KI
M%)%:>T-VP*$ #J!U'49QT_'M2:*1U\ VA@&7)!^4#) +=B><=,CCG)QZ,DDM
M;#RE"@X . /7^7-*Q=S06!BVTX&1N_QYJ&BTS>M(NGH.V?\ /]*!FJJ&[/8
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M>UASWSG^M,5CHK:VW 9[@?Y_S_\ 6H!&Q%;8'/\ GV^GM307+PM=_7'^?RI
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M%]_X[OIM4U2=[B\N7WS2OU9N@   "JH 5$4*J(%10%   ,F(?E]?I_\ 7]:
M$923_GZT /\ K_2@"["F3F@#IK(@?EQ^'^?\\T =58@<?_KI%(Z>#@<?SJ1F
MBM %I./J*8$,^,@__6]OZT$E7_/^>E BA=8H+.=E.[Z5(R&(Y_S_ )_S^5 B
M^S C_/:D,GBX'ZTF-(61\_Y_IZ_6D,RKJ3U_SBJ X>[/FM_G_/\ ^JF236Z?
MYYIB-2.&F!<%O_G_ #]!0!7:/'7^7I47&D4)%V?2D#(F;M_GM5 1%2>M ACI
MNJ@(<$4#(Y!G_P#5_G_.*0BHP+4 ,10#Z4 =%9#IQ0![U\'_ (P:Q\'[IKK2
M9_+\S8)HF >*95;<%=#^(#J5D56<(Z[B2;"/6?BC^T[XA^,$'V2]DB@LSL+6
MULA1'9"Q#.79Y&Y(^0OY>41MF]=U%PL>'QGB@!3Q0!4DSW_SZTP*%Q_*@#!N
M!C_)H Y^Z7.?S_I0!G,F[T_S_G_]=)C$5,T 3F/;0!^_?[$W_(@Z3_V]_P#I
M9/5(AGS)_P %)$WG0?\ M_\ _;6AC1^9MO!TX]^G^?R_6D4;D$.,4Q7->"&F
M2;,$.!5"-.%,50B^GR]:!D3GFA@5WP/_ *]2! PS0!5E7VI 5]N:0R>$4 6D
M4#I0!(5Z4 1-%F@14=/\_P"30,S9_EH RIJ *.W- $>W]* 'HE %E%YH NPQ
MXH$7E&* )T- QV_%(96>3FD,%?ZT 2"3F@"59* )%DH F#@4 /$F:0@WT#&E
M]W2@!R/DT :D!H T$-(:+).*0S].?V*C_P 4]<_]A"7_ -$P5<2)%/\ ;C_Y
M%RU_[",7_HBXIL2/RS0 5!1<CH Z:P..U,1OK0,JS#%,#G-1Y% 'FFIGYJ!&
M4,4ADE #AQ0 T=<4Q&A;TT!NV_%,DU4H FW8H _,ZW=KAHE!&9&R6VC<J<<J
M,'_9'&.V!@'&@Q]SL<CR@4CP5"=3CH/P'KSDG/0BA@8[WDD#8"@$'#'/4 9(
M]NP^M(#:6W:4!IAC.,+U./N\8SU^;))Z<< 9JA#=5G^PLQ)7R]V%4-R .!T[
M\\XR .AR2:3&98/V=7DDCVKM 4M)RP./E50-P&,\_P /3&>"@,S4BD"1RN )
M6W.R_P!WIL ZYSD[NO! ]*&,IO*RV_D)CRSN9\'/S 93DY(!(Y ZYP>O((2
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MV/?@7J7[/N@W&EZI+;2SRWTERK6[R.@1X88P"9(XSNS&W &,$<YR "&_MB?
MG4OV@] M]+TN6VBGBOX[EFN7D1-B0SQD QQR'=F1<# &,G.0 0:/S8_X=B>,
M@<_;='_[_P!S_P#(M*Q5SS#XN_L'^)O@UHESKNH76FR6MKY7F)!+.TA\V5(1
MM#V\:GYG!.6'R@XR>"R3XG1L_P"?QH _29?^"8?C(?\ +[H__?\ N?\ Y$H
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M=R$7.2P% CZV\/?L!^(-3:(W]W9VD+KNDV&2>:,E20NP*D;$-A6VR[1RRL^
M&87.UD_X)P>;UUW_ ,D/_NJBP7/FGQU^PMXR\*1>?%#;Z@@21W%G*6= @!_U
M<JPN[,"0BPB1B05V@E0P%SXYU#3IM,FDM[B-XIHW*2QNI5D=?E964@%6!!!!
MP0<YYJ645=O.: )@!VI ?OM^Q3_R(6E?]O?_ *63U:(9\V_\%&TWG0L?]/\
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MVDL>9OF5<_>(2@#Y!U+1;GP].UM>0RV\Z8WQ2HT;KN 9=RN PR"",CD'/3%
MRJ#F@!X;% B)CFI911D;FD,^F_ _[(GBSQFHD:U6QB9697O&\HDJVW:8E5YE
M8\E=\:J5&[=RNYV%<^C/^'?)_P"@W_Y(_P#W33L%SR;Q5^Q%XHT/<UD;:_3S
M"J+'+Y4NSG$CK,$C7@ ,JR.0S8&X M2L%SY$NX)=,E>&9&CEC9D='4JR,IPR
MLIY!!R"#R",4AD*3X/- #Q-S0!ZG\)?A7??&6^?3]/D@CECA:<M.S*I171,
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M?UMOL:@!N(TX4]RS8'Y \GIGW-4!FVA:>4.3N/(''RCD<@'C)QN//)P,8XI
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MD1-MC!SA0,A1G@XZ,W'5R0<<*N.:$7=4TJWN44*K LH&2W)4GJQ_'([\ 46
MP](U*Z\)LT2']T"<YRR^A^AP.?;GVI+0-STG3+NQ\9(%NE!?;G/\8!Z[6ZX'
M]WD9.2,=:6I.Q1\1>![FXRR[#$K^8K D/N' 5AD]?[RX7/93Q2:*.)MAY<FY
MU"L"#EL\<9P1@C\N,G.":$!TUK=VD,3J\A8'YW?&YV8C&<X X&,8R,@\$C@$
M<7J&CE3YT"C]Y\PP5/'1=QZ!L<G&1QD'K0,Q7B>0YR0<A0/NG.>3GV.?RI6&
M:K3,RD'YUP,CU"Y'_P!?C'TH DU#Q/<6S+''\Q<9!"C.!C'3Y0#U/'?KQ1<#
M2TO6K>=VDD'E,#P=S'GN<<*H![XSGH :!&W9:>JN[-M.TADX)9R1D<Y;Y1T4
MC&3D>M,#)>2XT63Y%3<VU]A.1ST(/!&<9&<]._2@9UEIJ$>NHX(,9)RXZ;B.
M&V$]P3WW$#)QQ0(AU)$L$1!SYBJP3G?C&-S-D#&<X "GC '>DQH9I_BF358D
MAG.]X_NX.UFSP0.H8C@XP21TP>LWN.Q>T[4S;S@;W<'IU;:"#CY"#D#C!SCN
M<XIC-:?]Y\[*'9?E8@X!/X8&?4<9ZBF(\LUO0IH 9H\E=RLQ7HIY) ],<]?7
M!R1FLV45!%_:0PO923E1@$'&%&0<$]^OJ*AEFGHAN-*R0,+*!N7L5/3(!SS^
M!QSVH0['KGAW6A;QB.V=9&'!AD?;CKP#M.>^/IUJ[@T17'@L:RY,"/'*/F9&
M&5 )^\!N [<;6 // Q@JP[V,87K6I,$S%""%8-E7/\(P#V(YSR.<].:DM&W:
MOY8#(3A1T8]<>_'MGCVS6;-$=+INHECB4ALD$$<8(/<Y)8=/E/?!XQRQG=66
MR-R^0Y4;@Q!VC@].N3DYXZ'WH$8+D.^0<*Z@DD G##@9' ^@  QWS4FJ%1'U
M)P#C<@.">2>1Z9ZCD<GUQTI%;%N /O.P97(.1TX'OVQR/S]JDLZ#3I#[=,Y/
M(Y- '=6*+=#@;6*Y_G_7_P#73);L3;"^01R>AZ_A^>?YTBR[;Y1CN&!CJ?3G
MZ?K2 ;<2;QB/&>?P/^?PJ9%(JX)Y.3@=?;MQ^E240O;^9TR,?I2L5<KPPF+K
M^1_KG\_2I+-(,"=HZG\QD_E5$6)KE0R@[<D$X^O3\>G7ICIFJ8D45E#DI)DD
M8Z?S_P ^])#:ML37I,*CRP 22,D9]^E6]C-,Q;V!X -Q^;D\G'?M^'_UJFUC
M5.YIVETUU&4'# = ../3G\ZM&+5C-6]5?3G_ /7_ )ZT(JQ9L9O,XP,=C_D>
MU:Q,)FI>V7VB(%1CE2?QZ'\R*VL8)G3Z3I@L#D@, ,@8QST&?PS^54D9R=R]
M)*9"5<!<C QG'XC//;IB@5C'DT:"7'D%4*X/&=I;.>Y)';!SU'%- /GU&;:(
MRJOCDX.,CVS@YQS@]1R/2E<FQS%[)Y\3; P?& &'0]R3[CGGTZ8IB9RZZ<Z'
M&&X]>QZ_X46,R2[L#;VTK2D;?*DW<]@IS0!\WZ>-JC/T/UQ6(';6,61GG_\
M70!UEG"2/\\9JD!T5K!_]>@+FF(* 8\6^.>] )CA#LQ^5 $;Q8QG'^?_ -=
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M)&,#/)Y()"[0!GMQ0!BZTWEQ,K ^<R8<#D@L5P" .I)Z>G;;Q0!A:8)(9%/
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MI!5@0""""",@Y%%P(X7!/3FD!K0B@#]5?^";Q_Y#O_;A_P"W-5$F1]4_M?\
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M^-(#,FD SC\J0'V1^PI('\376/\ H&R_^C[>D!^BOQI_Y%?6?^P9>_\ HAZ
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M! QXGNO^P;+_ .C[>FA,_2GXR_\ (LZS_P!@V]_]$/5$'X'6M06=);C'?.:
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M?0C(YZC QSU3 S-0U&25(HG=O);I_P!]$9QUSNWD'&?:D!K)IPC,2Q#,I4A
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MS*LJ;@C@' =1(J/M;[PWJK8/*J>!!9^I'_!-HY&N_P#;A_[=5:(9]5_M@_\
M(CZG_P!NO_I7#38D?B3 ,=*@H_1G_@G[I$$]UJUZRYGBBMHD?)X25I6<8S@[
MC%&<D$C;@$ MFD)GUW^TYXEO/"/A'4KRPE:"X58465.&42SQQN5/\+;78!AA
ME/S*0P!%"1^"TW!_KW_S_G-248EQU_S[4 3>&O"M[XVO8=.TZ%[B[N'"1Q(.
M6."2<G 50 69F(55#,Q"@F@#^ECPIX<B\'Z?:Z;;EVAL[>*WC9R"Y2) BEB
MH+$*,D #/0#I5$'Y*_\ !07_ )&NT_[!</\ Z47-(I'Q-;\#WH0S]R_V/?\
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MY /Q2S0,D1L<9XH G0T ?M-^R!\()?A?H1N+V)HM0U!A+-&X*M'&F1#&R[B
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M1A@<XVDXXSR3DG\./YU#T-8NYL1W&S@9S[?_ %_SJ+E6N:5O?K<C&589SMD
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MB@Y3#L2)4#$*S@QR?)L&@3/A^?\ X)Z>*Y?^7O2_^_UQ_P#(U38JYZW\-?\
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MU4_X)LD$:[_VX?\ MS5HB1]6_M@?\B1J?_;K_P"E<--B1^)$1W$=_P#/^?\
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M2P!N"NU@ %)&.<'JN>W?KB@1>M=3&IL\,Q;SY."P'F #&"5.X$?+NX^; [T
M7[31$3$S1%3DA9,G=@$\[1T." 2?RXR6(P'O9=-E?$2JF.<<X[*,G..O/J#D
M<4F42^'_ !/=1Y9"N&?E6)V[>W .?;/8>M3<=CU;1]>@U1FCVJLCC!5LX9<<
M;.S#C@'&X=JLDQ]<LO)<MUE< $$A@%7T'&1T !) R>.X .0U/1)-4V;Q@9*J
MO0ELY."PW8(YZMC.#P<TK%%6ZLSIWR!B.0I P !TP<@<<GGZG [ &;9W4OAZ
M8RLNYTSL!#8(8<$@=1CD 8Y^O"$=9=:=%K<+3VW,Q_UJ#@\D9VJQ)P<_+UZ
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M74C:Q.]<<C/0'].YY-4,I:G LKKR3U+#TR/Y8!YYI 9./LJ;R, MU/\ = X
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MV,&&['4G/0=_Z]NW,W-+'<6<"JF7(V]%7[W)/X_X>W2@I(L:A8>=MPF2 H"
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MG5$G26LA_P _E0!LP-@?Y_S_ /KH O\ 2J$4W/!H S;C_/\ G]: ,&Z;\?\
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MC5".@@CQUZ4#-2)"*0&W:1'''6D!T-O'2 O*NVD43N: ,JXXH RF'- $D?-
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M^[']YE7H=P'.<G[N !TXQB@9F:AX=:S8LY39D@%OE&6R H+'YCCDX!*^H'%
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M(/MD5):8QY"O H&,:4D$^]("%I=^1D^E K$L<I'X<_YQ3&;5I.<X_P _Y_\
MU52).^T>\:$@@G_/T_3T/-,D]JT37LJ!G!_S_G_.:FQ=SLUU@,.M(9EWFI!A
MU]*!W.$U:^SNYH);/.-2N!V/^?\ /^>M,DYJ67/?\<T7$,5P?0C\/_UT[B:+
M<3YS_P#7IB-RWQ_]:J$;40VC'O0!KPKD9&?\_CU]_K30,NJ>,\<?Y_&F()#_
M )_S_G\S0!ES?3_)H PKD9Y]?3_/Z5(SF[H8].] &%.?RH RY  /K0!7+8&#
M_G_/ZTK#(F';_/\ GZT@0Y3D_6@+%A#C@4#L3;L\_3C_ "*!D,C9&#T_S^5
M%)WY.328%)Y/>D,J;SF@#7MOF'K0!T=L@!I ;\";QZU0C2A4$?A189<E QUY
MI ,48X]Z +@D]>W^?\F@"]')N^7^?^?\\4"-&+F@#3A7'3O0!TEM'O'/Z\T$
MW-+R<]OZ\C]: N9-U%MX]/UIH#G[I<46&CB[Y,<TAF0W/7\*8$12BX#%4]*0
M#@/Q_I0 C+@8_"J 9][K[4 4Y&VC^GX5+8(I-<8-26'V@\4 .2XP:0$@GQG/
M7_/:@"07'O0!>MKDGZ&FA,ZBSEW8JB3J;23- '06YQZX(H$:(/&?\_Y_R:8%
M208_'_/^?:F!FW!S_A0,P;H8!H$<_<MC_/7OFD!1:3'>D,3SL<4 !G [_P"?
MRH*)5NL<U(#_ #P/\_E0 XW-(!ZW I@2"< ?Y_R: )/M ./7_/- $J7>W/-
M%A;H"G<"3[1CCO\ Y_S]*8K"?:-W3B@0JRYH F+[N]("/?\ YS_G_/I3 B<Y
M_*D!&S#'^?\ ]=(=A%.XB@+ #Q0 \.!3 >#GC_\ 70!_1Q\#CGPIHG_8+L?_
M $GCK1&;/RZ_X*(MCQ5:?]@N'_THN:EE(^"R](8N_/6@!"] !YE 6%W4#';L
M\T"'>90 X29H ?OQ0 PR9_E0! [8H$0[Z8"(U,#=L$W&F!U=O'G% &I##[4A
M&[91XQ_G_/M2&;<,?%(9-WI#%/% &5.,&@#,/6@"1/>@"U%Q3$=7IXWXX_2@
M1O?>%,"K,<4 <U?C YH \SU,[35",@<5($AYH ?V% #$ZTP-NU&:8&Y;_G3)
M-6*@"4M@T ?F?=7/DXZC.._H0,^_^?K5#*$*+(Q3)VMR".I!&0,CGDCZ\GO0
M@.?UFQ2!5,8&P_*1Q[CU]C]2/I18#(N=.80F,(%8X 8=0N<DG\L?C18#&U+,
M*!=PW*<CV(Z?F:0$UJJZN/,7"S$<J3CZD#OTX'U H ]+T>(6F71LJI7<"/8C
MGWXJT!TFGSBSB40H6$RYV@A<$$ 'H>3VSZ#IU#$85U8B"0!&W2$_<'/(R<CD
MY/0+U)(R"!0!PFFZ2T$A>0D.F0^0<;CD#GT]<_0'GB1FW'>"R;RV!;<,L/3.
M=H)QU[Y[<=>E(#H["]W.LX!94D5B#R0!@[>^?PZY]: .PMM9/B<'[;(GFEL1
MSC(X;'5<XX(&W&,8[]12)9'KU@WA_:'83JH4J5]\K[\CC&."#GCI5,9PY(F9
M2[ %6W$MV#<8Z^N<9X]ZD9JI*45 VY6 8 ,.X!"G![$#.?52.<BF(XBWLA:
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M!QMDS@$] ,G /)QQQW''<\(9DI*<[E7Y5. .G3T]1Q[=1TZTAD3RCS."0G<
M]<GD?4@<]O?I@$79I@B[GW9..O\ =P!QC\/Q/MP 788X65Y8V97 &S<?O=NF
M.W;&>@QD]& ZUN3:X$Q96ZY/?D__ %NOZ<4(#1AD64%4[ D(> 3]2<?F?YT
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M4 /(Q[4P'XZ4 7[1L&@#K[$$].*8CKK)MW?F@#I+9\4 :J_,*H"N_/\ G\:
M,J9J ,*YYXH$<_='![$<4 9$O-2,J[J0$+?Y_2@H0G- $R&D [- #@<T /6@
M!W - #@U ";L&F!*C8ZT"+:R<4Q%I)_P_6F!9\T'I2 =Y@- $!?L:0"TBA,Y
M_&@!5.: '#T/>@!<^E #ER: !AS0 I.[I0 JY[T"%'/% PSVH$/% #B<T *.
M:  C_/\ GI0,F2(R&FA&FL>P;15$B[._I_\ 7H ;Y?\ G\*8#)(!UIB-+3UP
M?;/:@9U]O)BD!J12]J0&U;2]/>@#15^*0T-ZFD,>QR* ,V<4 9;<T .C'.*
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MYZ<=J8B]#,R295)(W7"\H5)[<9X////MQ3$:KROSO;&3T. #CKCL,<Y[GO3
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MA_"F!:$)//>F!.D1-( \MC]?3^= #BE "@;J10S/Y4@#I0 [/^?\B@!<XYH
M%- #@U "C_(H -V* #/>@"3.Z@ 5Z8$J'\*0 /EH$2YS0!K60X)^G:F@9: &
M:HD<JC/- $GE#J:8#XH@V,_Y_P _YZ4 $& U,1N0RX]J0R_%<8I ;=O-^(H
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M7)1@"3N !&>A[_EWH&+!=$D@'@@\'@=>OK]<]_PI ;>G^*GG*!T5$1U VJ"
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M-.%_S_\ 6H&57N./<4F,S+J?'Z__ *_Y4A&2\V>>_P#GG'YG'^30"12=?TH
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M)@C%(#8M3^7T/Z4F,V[6?803Q_G_ #BD!TT%QM'O3 V[6ZP1R?TH$SN[2\P
M/3_/M_2F9FK]LR"?\_Y_PH R[NY /^?\?\]* ,6>?;P32 \ZUV7<^3CTIEHY
M:0Y./U_'_/\ ^ND41[^<T 21MC\J +B28QWX_6F ]I-O3O\ Y_S_ )P"(O/
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M0,530,DW8Z>U #N/QH >* '9Q0 X@-2 7^M "J<$4P+T6#UIDEZ,8H M1K3
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M>@:'?:"O>@9<CNN/PH)+7V@^O^0: $\_@T 5WGR<T B>*<^O% [&M Y//^%
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M=9'#,NYP,CYB!QQGH2>G'3K0!3MPRDG.>$4@=P2 #S[XI 0:T6NI4#'=NC4
M\#:%4*%QZ\#/?I3 GC(FBA<'<P+#\!T/N>O^>@!4TVX>S;>.IX ]6+$_J/T/
M:@#N T=V3/&0-^ R]=I)&[W(/\LB@">3;?J5)+ED55VKR2P*CZ'L?FY)(QZ,
M#"O/#S:2X4'<$P"0>...!W!Z9_QI6 K07<VE[1D;@2>O7=U'N.#G/7\J0['1
M)Y.IN@8B,@<'JK<'C/4$$=^W!-4(T=3T^2S8R2KEMA*CD @\YYR#WQVY[8%,
M#(:UV.(68/\ NBSD D!LL /Y9]2?6@!MO#M4,J[%0YD&>#@$ \Y/<@+Z\<4
M=;;>*$#113*K-L#,V,XSTSQ\QP-P'3@>N*8B]X:\7+#@/&?*W2.Q!P4RVXY
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MJ6,SBQQCVJ1@'SF@"3<"<'_/7_ZU [@KE<4 65>@8OFDG&>?\_XT //S'WH
MDC.#CKG- &]"1C_/^?;Z4R2^JDXI"-"%: .BL5SGVI@:HB;_  X^GUI@75W4
M 1.S9X/K0!@7I(!S]/TZ?RH Y=W)//\ C0!"6H KR-L_S_3_ #WI 4,[N?\
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M$DY ;#?=49(!(&"<X. ".A)8<;MZ=)R.2M74/4^=O$_C74+V&1IIQMX.T1H
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M,9SMVP;IWI#.=FX]?Y?X?A0"*+$YY_S_ )_K4E%5QF@&1*0>!_+O0231CO\
MGVJA%K<,?3- R%U.:!%.<$"DRT8=R,5+ RW&>.G:I*%%(!<9XIB%VYI#)T'&
M/2@=R7.<>WO0,4&@":/G% '1VPX_SVH)-!1GZ ?Y_P ^E [&E"N[I_G^= 6.
MGTZ$ _Y[?Y]Z!&T(/;_/U_SBF(G$6SF@"%X_8\_YSW_2@#F=03@].#_G_/\
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MIV_PXPV[_=(.".AR.,<U@V=2B<[%X8N-38R,I))YZXX_/BN=JYV(ZRP^&[R
M;P1QQVQ_.G8&SLK;X<1J!N'YY_S_ )^M(DZ:T\%V\711G'.:=[$N-S5&C1VW
M10#["CF%R&8]NHS^G%%PL68[0(N1ZC/]?\:+B'.0>,<&JN(L&;'X4#*[SXYZ
M#_/^<T 46N@ ,\9Z&I*12NKP*.N!T%26<O=:LL1(R,D?7_/Z#ZT7*.1C@FUP
MEI&,5OU+E1EA_L ]<X^\00/K3,V9M_XEM-#S!9J-Q."<[B3SRS<^W' '88Q5
MI&,G8Q]/MKSQ5<!)V94&=PQ@=,XS_>[@$_-Q@8SCHC$Y)SN>C'P);^:$C5S*
MR_<8GH>_S# 7USQCU(YZ4D<C;/%/BYX37PU*(U.6,66QD#.3TSSZ9SC)!..:
MSJ;E0=SPG3D,EV4QTW>_ _K6<MAP=V>Q:5I,=P@5QDD GKC]"/U_.N-L].,3
MNK#1HX""!G!]2>GH6W8_IQ^*N:J)W>BZ=ER1R.0,_3CICGZ\'TILM'L6D:67
M^7&#UQG&??Z5([V.KM],.-S=...I_P X]<9XH%S"7:" >_3T_GG'^>U.Q-SX
M]U:Y_M>XGE0[E>1RI_Z9K\BGVR!N'^\#W%>I3C9'AUI<S;.+\06*@+$QRSGY
MRQ_N_,1VQT (]:MF5SI/!EK;VTPF<(^?, 3><Y5."0#G&6X['!ZXJ=AI'U=\
M3?%3SZE;6J &(^0X?.0?WB<#'! '4^]%RE$^#_VA;DQW]G#N#K'IUNVT9PAN
M=UT1SW_?<^G3/ %6C1;'2Z%<?VCHEG'WCW@?0LY/_LM8S):$;2SCI_A60R)]
M,/.1_DYH C.F$'&/\XIDLFBT_'Y_3_/_ .JF(U(K,KS_ )_S_P#6H THX,?Y
MS0!-Y>?\_P"?_P!= %"9.XI 8EPO/I_G]/\ /I5C*9!4<4$DL0Y_'C_/].*!
MF[;+@T".BMCD?Y_S_P#6H!G1V9Y'T_S_ )]ZHDZ6W&[IQZ_Y_P ]J -).33)
M+T0)-4 ^0\$T 9TIW?C[?Y]>](#&N0?2DQG-7@(SUZ\_Y_SZ^E(#GYQD' _+
M_&@#,;DU)9 Y+=: (7]\_0_A_G\*"2:$[NG7TJ@+JGM_G_/^>E A'7/7.?U_
MS^M %&9?\]ZDI&)=KQ2&8S#!]*D8Y%SS0,7;^=(1.JY'3_(H&&V@"9:!H7!S
M0,GA7D4 =#;# 'TH UHEQSTQ0!IV_7].?:@#K-.^;)_S_P#7[4$FXJ#.1_G%
M %CR^/\ /I0(IR+QGI_G_/X4QG-:JN%/^?\ /_ZJ!'$L1GM0!4D]O\_Y_P ^
MM RE+S0(J[<&D!+L_P#K4P$*D4 *%W4 .% #@IZXH <JX% $FR@ '/- #PO^
M?PH NVO%,1U5CQTI@=E8#L._^?\ /M0!U-G_ )_.A ;2\9I@,?GC_/\ D4",
MR<X/% #=!\+WOC6]AT[3H7N+N=PD42#ECU))X"J "SLQ"HH+,0H) !^N_P $
M/V#M&^'[I?:XR:K>A6_</&ILXRZJ&_=N&,S*=X223:I5@WD)(JL'8FY]ZTQ'
MAOQ?_:-\-? W:FM7>RYDA>6&VC1Y9I%3@8"@JF]LI&TS1QLP;Y\(Y57'8^(O
M%'_!473;.91I>BW-S!L!9[FY2V</DY 2-+D%<;2&+@DDC8 H9E<=@\,?\%1M
M-NY2-4T6YMH-A*O;7"7+E\C"E)$ME"D;CNWD@@#8025.8+'W/\(OV@O#GQPA
MWZ->)).$W2VC_N[F(80MNB;DJID5#+'OA+Y59&(IW%8]HIB/RG_:S_80MKBV
M?6_!UKY=Q'O>ZTZ/<5F4L7+VR$G9(N2/LZ81XP%A19$$<TM%)GX]=:@NPHXZ
MT .QB@0H% QX&:!#]O0_2F!^C7[*_P"PQ-\38;?7?$3/;Z8SJ\-IM*RW<6"=
MQ<,##"QV[2 9)8][)Y2F*9J2);/V,\%> ]+^'%FMAI%K#:6RX.R)0NY@JIO=
MOO22%54-(Y9WP"S$U1(OBCQ[I'@?R_[5O[2R\[=Y7VFXCAW[,;MGF,N[;N7=
MC.-PSU% 'RQXE_;^\"Z'"LMO=7%^[.%,5O:R*X&"=Y-R($VC ! 8MEAA2,D*
MX[&5X:_X*&^"M<F,5P;ZP4(6$MQ;AD8@@; +9YWW')()4+A3E@< EPL?6/@C
MXE:-\28?/T>^M[Q D;N(I%9XQ*"4$L>=\3'!^2158%6! *D!B.AUS0;3Q/;O
M:7\$5S;28WPS1K)&VU@R[D<%3A@&&1P0#U% 'X[_ +57[$7_  KBW?7/#0FF
MT^/>]W:N=\ELNXMYD9P&>!%(5PVZ6)5\QGD0R-%#1:9^<X%(8#I]* &]* &=
M#3 6@#]2?V?/^"?G]N6\&J^+'FA$F'734'ER;=RLOVB3[R;UWAX4"RH&4F:.
M0/&KL3<_5O0]!M/#-NEI8P16UM'G9##&L<:[B6;:B *,L2QP.22>IJB3G_B!
M\1M)^%MB=1UFY2UM0ZIO8,Q9WZ*B(&=VX+816(56<X56( /A_P 9_P#!1_0=
M*W)I-A=WTBRE=TI2VA>,;AYB-^]D.2%VH\4;;6);:R[3-RK'%6'_  4SADFC
M6XT)TA+J)'2]#NJ9&YE0VZ!V R0I= QXW+G(+ARGU7\*?VO_  G\6YA:V]P]
MG=LVV.WO0L+RY**OELKO$[,SA5C#^:Q5B(]HW%W%8^H*8CY(_:._9*TKXX0S
M7MNJ6FNE$\N[RP23RP0L=PBY#*00OFA3,@6/!=(_)96&F?A3XI\+7O@:^FTW
M4H7M[NW?9+$^,J>H((R&4@AE925=2'4E6!,E&$OR]* +D;BF@->V?-,1T%N*
MD9].?LG^!3XV\6V(PWE6;?;)64JI40$&,G=G(,IB1@H+;6)!4 LK0F?N75$A
M0 4 % !0 4 % !0!^&^NZY_PE.HW6H;/+^U7$LVS=NV>:[/MW8&<9QG SC.!
MT$E$5 RI<4".3U+I3&><:B-Q/^%2(R\T#)30 C#OF@!(SDT ;5M5"-^#)IDF
ME$/UH =(<^],1^7=A&;,QJ<$#EQG@ <MCU[@?7K6A0HUB;3F6Y3&\%C@\Y)9
MBP/M@D>X].,*XK'LWA368[U<QC".IPN3@."2\>?;AOH<] <6F0T<!XV\.(V;
MB%1E,[]O(9AQN"^QZ]^<\ 9,M%19Y]$2IC+ G>Q3WP,=<'GG\L&I*+TLB78*
ME1E68J<\,5&%!&,>GU ['- &#.GV2,@\8VJ<<YSCW[C]:H"Y8ZFR32')(WOE
M1G!VM^7''X4 :FM:;Y+GRN2YW#: <*1DC@]/G!SC&,"DP,<67E[%<X\L=L<E
ML%L^O8?_ *Z0%^YN7EB4*V\ A>>HR/\ ZW'^30!-93X4("5<C(!.?8?GR/TH
M 8SB5]L9P,Y;/08Z9/7WSB@#K[&[>42AD#1A%YSA0J J!D COUY)(Z<X+$8<
M.GIJ$GD@;<[0O&?O_,6..PW$_P"ZOL*0SJWT)M-1I=R[BH *Y; (*[AV/RJ2
M,?UXH5SB;2]O=*O',.-ZA5( ^7/<$'@@9ZD=LC ZR,]0BU*/68IHN(YY74E<
MXW,C#[O3.=NT]QDX!IW$+8W":3AK@!9"I^4@X/(Z$\<A<'';:ISCE@<7)9#5
M';Y JON+29[9) '/.,\8^\>X - SG[_17GGP1N)")D#H<XP<=\+S[=^*D95:
MREB3S,@H<*I/!!   P>>G<<9[T6"YIZ#JD^F2;TW+\K98'J.,@\8/7ISZYI@
MSUO1/B\A9([E.67F11D>V4ZCZ GOQGH7)L=;9IINLR(T,OW&WHN20#DL"RY!
MVACT.?3((XK<1B:QX#GM&3RI Z;0<'CD8/)[]..>P.*!F(FF7EHLGF1NX=B7
MR0?E;.X@@DXZ#@9QQGJ2@,=)(HW*$, 5VHN"1PQ RQP<\[<$8& <#I0,I6T[
MZ07N(YD568@#JKXZ$#ITX[=!SZH#U30O'!MHF+(H"A QSE6)Y7'MZCG.<TTP
ML=&OB;3/LSR3N@B<X?S#N4]VY'7V &<GVY.8+'RAXR\<60EVZ7YA7ONX3C@;
M <OC&?O'\*S>H]CSV]O[S7.)Y3L[+G@?0=*I(1#%%%8#/&?4_P"%624[K7,\
M 9/O2"Y%;:?=:PP ! /8 G].](:U.NM/ 1@ :7/.>V?Y<#\34.1:A<[O1X[7
M2<%(U+#J6&?RSQ^?-0V;*-CIX'DU<_N#SG)R>??'(&?KP.QJ2]BX+N6$[)"R
M$=0?3J/P^A_^L#3-8WY"@[ W')S_ %H&=?X:LU5O-!^0<D$'C(&<<YXZ8P?S
MIDMGNOPX-EKK,3AG1L/'GHO9@.X/?K@UM&QE-'2:E\,+-93-8 1H_P!]!R%;
MU7)X![CH.WLK(N,GU.+\5>$AHZ"2++-NVE,>HZY[_P!/6L9G33U*NA:6\D;A
MQN1U(;TP>/TX/L<5A>QT\MS9TSP9'9H@;D@=2.![ = ,\\8ZYK/F-U ZF/3%
MVC ''? S[5!5C3M[,'(X.#Q_D_I04/:W$@R1D#\L_P"- D,^S#H#R.HQG]?6
M@92N%R"/05#86,-H-Q^O^?Q_QHN0R;R"5VXZCM_C5$LIB$R<\]QQZU8B&ZA-
MN,XR,\C/7\L$?A_.@1$[[0, <>O/X8/;_.30!E75V\@.0@_W41?U"BI921RU
MS(7XS^/^?\_C4LU2.>FM$(,CLK*I'RY^;GN >6'KMR1W '-(3,+79WU-,1RE
M6SM*;&&%P=I#<C'8CY2,KMW#.-(F<R#P]X)WS()C\ISZ$$E2>>YZ$\X//M71
M$XZB/7=!T%(Y2%=D*KDE6*YX'!(QD# VY]_4BMXLY7&QMPZ=$9-DA$JCYE0J
MHVGURH!)XZ_XU:9FT>1?%C2EEDC=!PKHN,YX';G/&3CZYJ:FJ'#<^8=.T0VD
MLDJMOW X&,'YF'Z] .W-<SGS(Z(TN74]&TZ18)2$^90%0>^/ER/8D$]OTKF:
M.^)['IUI]K56 R,'KZYZ?Y^G:I1JCU/PMHAFP3UP3_\ 7_E_]>M(L4CUO3M+
M,3%P#M /7OTZX ..?]HC\*KE,[E^*R\F(D ?,WW1R<'I@]?R/3OUI6"YP7C?
M4?[%LI[C@;(V<#U(4X'X]/\ ' IQ6HI2LCYDM+%-(*[U#)&@E8$_P)\L:$CI
MYK8!QD!71NU>J>"]3R6\DFUV\*J09"WE)G(RY(WL< C[Q]_ZU+&>M?#WP@\K
MR";*A)(X5PV1NDVLQ'T'TSOQQWB1K!7/1O%ED-.E@BW;C96LSJ<??VR/CU_Y
MY@_RZ"DB[7.(^*?P0;Q0BSP/B[AACBVD +*L*"-1NS\K;5 SR&.,[<DUFJRO
MJ=CP[M='*^ ?#LEIIL<<RE)(G>-E(PP.YCS^ Y]L&G)G'8Z[^R%7GO\ 2H86
M(VTA5Z ?E]._-(")M)4'^5!-B+^RQ'T'^?\ /X8]JH5A!8*IX_E]?Q^E K#'
MM-PY_P _C_\ J_*F(J20;1_G_/;\.U &5<KV_P _S_R>U &-<PX-- 9;H3U&
M/Q_J<"F(F@381[]^M S9MQMP>W2@1T-J ?\ /^<4"9T=KP._Y]S0(Z" E?3B
MJ$:T0S_G_/\ ^NF#+R\G/)'O[4Q$C  <T 9DHP"/3Z_YX]^] &7< 'Z#/'YT
M,9S5VF"?Z?Y__5^-2!S-P<#/?\: ,UUQZU)5RFQVYSG% 7$W;3Q]/\>G^>]"
M$30_Y[@_Y_GWJ@+I'&,<'L?\_P#Z_6@0K],?Y/Y=/Z^U %6X7<!^7^?\_P J
M3*1B7!(%2,RY(LU(QOE\8_S_ )_S[4#)1!NSZ]:0$ZP#-,"18NG%%A (L4#0
M\1;L>WM2'<ECC.<>G]:8KG101X%(9>2/\!_]?M0,U(1CZ_3_ #_D]Z0'3:5R
M?I_]:F2=!&>Y]J +6X 8H&49G&.>,_Y_S_2@+'*:DVY#_3_/M_7Z,5CBI"3Z
MXI"(FST_S]: *\B9I@5A'^E "[>/YT / W?2@!"M #PN/I_]>F \(3Q2 ,;?
M\YH D(S0 !/;ZB@!Y7/'?_ZU %NV'^- '368P1G.>U,1V-B-P'OUH ZFT /Z
M50&TG(H B)Q_7\J!,K164VIRQP01O)-*RI&B LSLQPJJHR68D@  9)( % '[
MF_LX?LX67P(LM[E+C5IT N;H#@#@^3#D B($ DD!I6 =@ (XXZ);/I:@1^='
M[:?[7EW\(Y4T'P^R+J;(DMQ=$1R_9T)RL2QL'7SG #-YJX2%T958RJ\2;&D?
MB7J=_-JLTEQ<R/-/*[222R,6=W8Y9F8DEF)))8DDDDFH+,<K^E "[:0'0^$O
M%M_X"OX-3TR=[>\MG#Q2H1E3C!!!R&5@2KHP*.I*,K*2" ?T6?LM_M#0_M$Z
M)]L:-(-0MG$-[;JP(#E0RRQKN+K#)SL\SD.DD8:3R_,;1.Y#5CZ5IB/Q8_X*
M,_ N'PE?V_BC3X4BM]0=H;U4 4?:\-(LI&_EID#[]B*H>%I'8R39,2-(L_,W
M9Q4%,%7%,5B7:#0(510,_9C]C+]C+_A$?)\2^)H?]/XDLK*0?\>W=9IE/_+?
MO'&?]1PS#S\"WM(AL_3NJ)/@#]J_]M"'X1/<Z!HR.^N*L8:9T'D6PE7?N ;F
M68(49%VF$>8"SN4>%E<:1^*_BSQ7?>.KZ?4]2F>XO+E]\LKXRQX   P%4 !4
M50%1 %4!0 )*,'&*!DB]* -K0M?N_#%PEW87$MM<Q[MDT,C1R+N4J=KH0PRI
M*G!&5)'0T"/W!_9'_:XB^,\*Z1J[)%KL2'!P%2\11DR1C@+* ,RQ  $ RQCR
M]Z0TF2T?<U,1^(7[<?[-\/PJOH];TF%(=)OG$;Q*XQ#=G>Y6./ VQ.BED"EU
M1ED7$2>2AEHI,^!B=O6D4(10(8!GZT#/UR_8<_94M[>WMO%^M)YD\G[S3K9T
M8+"H)"W+AP-TC8WV^,HJ%9P6D9##21+9^I%,D^=/VF?C]#^S_HPNU19[^Y<P
MV<#, "^TEI77<',4?&_9R6:./='Y@D5-C2/P1\>?$;5OBG>G4M9N7NKHHJ;V
M"J%1!\JHB!41>2Q"*H+,SG+,Q,%''8VT#%QD4 .Q0!^R?[%'[4UQ\1<>&];?
MS-0AB+VMT[KNN8TQF.0$[GG0?,'7<98E=W >-I):3):/T4JB3X>_;G^"4/Q#
M\/R:S;Q)_:6EH9?,  >2T7+31,Q=1M0$SKD.P*,D:@S-E,:/PW05)181:8&S
M;+^5,#I;>+%2!^O?[!O@AM#T*YU60,K:A.%3+*5:&VW(K #YE;S'F5MQY"*0
MH'S-2)9]1_%#XH6'PCL/[1U'S#&9%B1(E#.[MDX&2JC"JS$LRC"D EBJEB/G
MQ?VW_#C?\NVH_P#?J#_X_2N.Q*O[;7AUO^7;4/\ OU#_ /'Z+CL2?\-K>'O^
M?;4/^_4/_P ?I<P<I _[;OAV/K;:C_WZ@_\ C]','*0?\-R^&_\ GVU'_OU#
M_P#'Z.8.4</VXO#A_P"7;4?^_4'_ ,?HY@Y3"\6?MG:+K.G7=O9Q:C%<S6\T
M<,NR)-DCHRHVY9RR[6(.Y06&,CFBXK'P#8"D4;)Z4 5)QG^E '*:CP*8CS;4
M>#^= S,ZT@'X- "DYS0 R.@#<MA30C>M^*HDTDYH <W':@#\NKJ(Y<* NV-C
MM/3H  /^^@,G'X5K8#GIQ]G(  .U2 .S9 (//Z^WXU(SI/#_ (DCT-A;SN1
MZJ&=?O)*=Q\U>^1D XY(]<4)B:/: ZRC,Z8(8"15YY(P<#/(8G@<C!!ZU1)Y
M)K_AZ30IGB&55@9$'8^8^,<=-I.".^!UW"DRDSG8X6MTE1AMDVMLY^\P(XSZ
MD#KQDX]:0S.BE=%4/AD+I)GW!R<J.<8.3TSB@"20AW22,_,<LY' &6^]SR=V
M #GIQS3 Z.S-O(9);P$;<K'@GY6^\#@<CT ' QTQDT <89&OE8Q#_5@*1NP"
M#GYN?Z^WH*0%<)*KY7."$!'8LJX_GU_2@#IH;F)44N "&VAASW+#/<XR>G;Z
M4 +- E[YBY7#8Y/R@8YSZ8YYZT =$([BTCD@V94LON2N".HXY(#>A/K3$4[5
MS;R,7W?,,<]<$X[]L$@]0232&6_$6J3Z?;D(P'"<Y[D$''?.0H_'T%-B1;L]
M"GL))+A\%%)QR,D@<L>G&3U /.*5AW,75-,(3S3PV&<%@=V$P!]"S$X]_3K2
M&;6BZ[/;1+'=XN$8G&X;F!P#@$^GOZ8!'=IBL:K6MMJA3[#+MR?F1LC!/.,-
M@,1SZ^M5N(Q[X7EBZ1+$,R @]LGD?+QCIWQC&03U !HDM]*:]G$11%4@ LN
M5*JKG*CY3SG&."W'ID VUT86EM),4C&]L+MR0.<$D@D8Z9Q]#B@FYQE]IAAG
M/S!D&.V-IZ'L.,CMT_G++,G57V#?R'1=HP2#U/ICGDT@)?\ A(IXPH9F;CY0
MW/7C'IV&,8QC'M1<1T.G^/YK?E-RX[[N./\ 9&,<_IFA,#KAXY@U)\W2JZ$
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M<^O/Z=OZTF6B&#0VG8%N<>H_S_3O6=BSIX=!"J>,X]NW0?3G]/2J417*][I
MBR5Z_P">F:8SGVT1@2=G!R>A'^?\:JX&?>:65C(QD^O^?K_G%6F)HY6XTWS"
M!CG.3[L 0#S[8%.YDT12:?'&T:OEA@!BH(X)SP6 ]^H(SV(QDN0XC?L.]=C#
M..5)[>P],<CZ 47%8YF:R:YVDKE@01GD],'!.2#V!'Y4AV.LTV#RU5^%QG#D
M?<.>">1N7(^93VY&".,V4D>MZ'?[E4C ?^)?[I&!@'N.X]B/>IO8;5SM?MYN
MB20,D#/OCN<_X_08Z5S$\ILQWGR9Z<<=L=?8?YZU7,3RGRW\8]1D-Q9Q[L*3
M,^#_ '@JIW[X9OYUM1.7$]$?,^KW37K+$1D*=Q ]>P^N#_+TKL/./4? -RVL
M206RH5\DAW(R 0BY^OS/@8[@GMD5,G9%TH<S/K*UTP1PA2 2>"3GUS@#I[UR
M-W/:A3L;\5HLMVD2_=6$RL>.&<A8\^C &93_ +N3[A74ZIM,&,;3]<'/N.#C
M\0/TK-Q-U(Q[K3MO'0_EG\#63-U(XC6]!$XZ8.#SC_/?H?TIIV,ZM%5$>9WE
MLUJQ!_SCT_SFNF+N>%5IN#L9VX&M#G96)S^E,1%3$-(W?C_G^?\ 6F25)8<Y
MQ_G_ #_]:F@,:XM>"33$S"N+?!H%<PIH3G_)IB(XXMI_S_G\>E%@N:MO'G'^
M?2D,U8%)Z_Y_S^54B6;MHN[B@#HK?G'^<T :<?'/4^M &I$IP*HDED7_ #_G
M'M0!1=,?3_/^<T 9=PG?I_GUH&<O=CD_Y]JD9RUV-QX/!_\ K_\ U_QH Q9A
MC\:3$5G&W_/^?ZTAC"?\_P"?\_R (FC^8^W^?\_XU0%Z-<D?G0!,J[^?:@"X
ML&1@CG\:!DGV#S.@_P ]?\YH$68]%+\\_E_(_P!?TH'<TD\-*>WU_P _A3L*
MY:B\-@#)'(^M%@N;4/A94/W<?GW_ ,XH$;,'A_O@_P"?\_I1<#4AT/';_/I_
M*@9;_L79V_S_ )X_PI +_8X';_/^>]#&03:;@'CC]/\ /OV]#TK,HQI[  ]/
M?_/^?6D,YZ>TYZ9_SV_R?TI %BNS/7FD-&FIQCIG_/-(HF!^M %&:3 JD!RV
MJ'*GZT 9-G!NY.:9!T$=O_3FJL(N+!N_.F UK3'^?\__ %J ()K$=@._;Z\8
M_+]10!C36FPY([T 0"#MC_/-*P#?+V^G^>/\XYI#%\O'&/R]\T"$6+U/% $;
M1XYQ2&18':@"(K^E %B$=Z8'0V0Q@?Y_S^=,1UEH,=/\_P"?\YH ZBR(Z8YI
M@;$1X_\ UT"&/Z4 ?I-_P3G&#KO_ &X_^W--$L_36F(^'/\ @H'XVA\.>#GT
M\[&FU.XAA1#(%<)$ZW#RJF"74&-(VQ@*9E);HK(:/P><8/\ G^5(HK,.OL:0
MRN8R![4 -"=_\_Y_SFD!*D= 'Z??\$QO"GVK5]6U7S,?9K2*V\K;][[5)YF_
M=GC;]FQC!W;\Y7;AJ1+/V4JB3R;X]\^$=>_[!-__ .DTE)C1_,QY)';_ #]*
M@TN1&//'^>E SJ/ O@>\^(NJ6ND6";KF[E2),ABJ[CR[[%9A&@R\C!3M16;&
M :!-G].'@/P59_#C2[72+!=MM:0K$F0H9MH^9WV*JF1VR\C!1O=F;&36AD=;
M0!^!_P"W!\2I/B)XON;9)=]EI?\ HD*KYBJ)%YN6*N<>9YNZ-G555XXHOO!0
MS(I'R3%;;?UI#+T=N">G-,"?[+]<_P"3_D4P)!:@_P"?2D X6F/6@!QM<=N*
M0'[^?LD:O<:WX(TB2Y;>Z120@X"_NX)I(8EPH ^6-$7/5L9)+$DT2?1M C\!
MOVT? G_"&^-+_9#Y4%[LO(OGW[_.7]\_+,RYG$WRMC'\*A-E2RD?*C0XH&?5
M'[$L>WQ]I7_;W_Z1STQ,_?RF2<7\1?&D/PZT>]U>;84M+>24(\@C$CJIV1!R
M#AI'VQKPQ+, %8D @'\S0AJ2QWE4@&B'^E ".O% R C'^'^?\XH$>\_LL>&?
M^$M\;:-;>9Y>RZ6XW;=V?LBM<[<97[_E;,\[=V[#8VD0,_HHJR H _F\^.*Y
M\5ZYG_H*WW_I1)2+1YQ#'@XH$;MC'S0,^OOV0/ Z^,O%=LT@5HK%6O'5F923
M%M6(KMZE9GB?#$*55@<_=9 S]IKR\BTZ)YIG6.*-6=W=@JJJC+,S'   !))X
M YJB#\$_&7BF7QUJEWJ<VX-=3/*%9S(44GY(]Q RJ+MC7@ *H   P)+,I!CI
M4C0]3S043=!2 S)^:"3,/7_/UH F44 78>33 ZS3^@/L*8C:!XH IS&@#E=4
MQ0!YO?\ !-,1F@9-(8[-  >/;_/^?PH 2(\T ;-L,TT(WX#FJ$:*<4 .<9]*
M!'Y>0J^E3!PIQM!SVQQQD?GGUQGK6B NZE ,*Z@%%8EA[<L1G^1[CB@9RZ:6
MQSO("_?W =ADD#UXY(^E("X->/AUEG[=74?Q E,J>V!G\#[T >IV>JBRF5BY
M>SNFRIX C!1CD=_X1QP.3W!JTR2IX\\(#7]URGRS*&4@9Q)LR3Z8.,'=T.0,
M#L,:/(OLQLMBL #("_L58<@YZ'&#WZ@\#DR,H16AN(FCS@"-7YQS\W(/^[G/
M8G&>,4@+]U<F*$(_S,NUL]P!\QZ^X7\L]Z ,VQO [8*@KDDJ3W7!&/SQ[Y/X
M &[!<R16ZQ1LP.'! !_BP>G3/<]\_2@!\7E*"-I 6W?DK_'O(W8YY[\'TYZF
M@#.&G>7$0>6:, #UVMMQ^O/^!H 9/ T<B],*(U^I;],^H[?A0!7DF^S'@9 (
M4D\@_P!.Q_G0!V>D:PUHXAX*[\D$9Z@=<\$\#T/TZT)@;**MY()HG+C:6$1.
M""BXPIXR.Q&,@>O-# NC795S+R7D3<S8P?783]6(S]>, T7&=1_PD"W< +I\
MP.1\V."P))XSNZ\@CZ=:+@BI;OIMXJB6.10QR"DA/X!=A]<8)/"^U,+&]'\.
M+/7H1):7+1';PK+YGKP1A6'I[=>W!85SS36/ NI:2-RJTBL< ISZ=NHZCIZX
MSD$!6"YB6>JO#\C;AA2<GY<#I_7_ #BIN J^)A<9\Q$(Q@9Y(&>H;&3SZ_X4
M[@:D7C$:5%OCEV,"N.2<CG(Z]P<?0=11<-CD]:\6?\)(QBTZU,<DF-[;MYQC
MG' "C/)/;U KHHT)579*YS5\1&@N:3LAVE?#Y5(DNGW'JT:]/H7S^@&/1J^A
MHY4EK)W\NA\AB<^;NJ:M_>>_W?\ !^1WBS0Z<FR-511T50 ,^_J?<\^]>U=0
M5EHNR/FN655W;N^[=S O=<QTZ?IC_/\ GUX:N+Y3T:&!<SR_68OMLSSN>./K
MV&*^3KU/:2;[GZ#A:*HP45T1H:./LQ^7Y2#R?7T_"N8[4;8U9YW*N-P!'UXS
MS_6D,Z_1KQKDJC)E6S@C)/7K@Y![?AFA =2OA9;L*8F!SDJ!WZ?K[&JL(;<Z
M%_9J?*F6.0!W!Z$GU&/3&/6E:PQEE&R*"5)5ANSW(#%>!SW].I^7I3 ]"AM[
M36A';SIY<C#8)2<L2W !S@8&>G/&. <T]P1TVF:)J/PRE\N.;="X##@&)E''
MW6R#U[8/N*6P]SO+/6=.UQ@EU;QQ/WE50ZD]R4(!4?BWY\TTPL>K:'X2%M-'
MY3J$!W;=@*\@_=;=T/4\'Z#-40V<I\5-1_MZX6T7R_,B^4Q@DDYZ-CCC@YZ\
M_+]<I,VIJQR&EV?_  C@!@=O,SG?TY_NXY&W@YSG]1C-Z&ZU/4[#Q8]_;AFV
MK*.K8)5OP!R/3(Z=>>E#F"@5I_$LTQ,0A$;CYL[]P/H0-HR/3G@\FN650[Z=
M*QHZ?$@CVKC(ZJ3@],Y]>?I7/<[29CC*D>G^>#^E3<T-"UB#],].HQC/J1Z=
MN/6J6HF:4<NP!0ORY[DG!XR1T_+L:JY%C3MK:2/)S@9!ZYR3UXZ_4?K5(S;-
M&&#RB9 XW@A^G/UP>,8SCZ$>F;1C)W-E;:.ZP<Y0Y]25/&3M XY(S^G'-697
ML4+>Q4-N0<GN?X<$<@'K_+V/-38ILY+68'15VAE5R .22<$^@SU4@8Y)YXZG
M.2L7$H6VH X1@<GC@<8)_GQW]<=J0-%[[/@D'@[23[8!8_R_6I*3&FW#Y! P
M!R#TVGC&.^>A_P YDLYMM!\LGR6P,#Y&R1G_ &3R0/8@^V.::&9DL)M\&2-D
MP<DXRN?J.@[\@5=QFO9M"W"NI/3&1[#ZCI2 Z:"VV#*\C)' _7],TT21W6G$
M9QDL>#[]/_K?E[T,:9RLT(Q@@GUP./P_R:DV1C7D*XS@' ^M V8;6H8Y[Y].
M.^?\??VQR$V*<UB) , #!)SSDY[=^G;U[]J9+1 ;)2<_IVI":,Q]/$1RG /;
M _K5$6(4CVG [X/]._\ G^@P.D\/L/NGG'_ZO\GTJ&,]"ABV\<=?K0%B\[\$
M=#G_ #_.@=CS#XC^ AXQA 5_+EB.Z-P,X/.0<D<'/(XZ=16D)\IA5H\Z/BW6
M? &K:9.0T+$DG#(V1DYY'3^E=RFF>>Z#1]7?"/P&VDVJR2\3.07! XP,;3G(
MXSS_ +1:L)RN=U"CRH]NU8_9BJ]NO&"<=^/S_6LCK.[\$:,VL0R73D>;<R;A
MD;0R1KL4CH</S(".GF'@]:UL<TIV9NVY$A7Y2NXL,8(V[=QPZG&">,<COW!6
MI-&R?4-#$W3Y3G()(8'KGL#V!!Y/;!QS#B.%2QPEW;%1ANI[<$>_(X/KWXY'
M'7!H[XL\_P!9TA;Y"NW!!X/H/8?Y^AHC+E)K4545CQS4K=M-?:W3H#VZ?Y]:
M[8NY\W5INF[,SQ-N[_Y_S^8^E:&!:13(0,\TT)EU;!I.,]1ZFJ2(N7X/#LMV
M/E R?;C^GU[?ATJ^45S7C^&]Q.,EU7USU_S_ /6HL*YE:A\-)HLE)%)Z_3VY
M_3^=.PCS'5/#4M@<,.,]Z5@.<,!7_P"O2&3PIG'0>O\ +_/3U^DE&E&,_IZ_
MSIHEFS:G!SGU_P _YX&._2F!T5NP'X<?Y_\ KT"-*,YQUYSF@9IP'M_G_/Z]
MZLDO-AAS_G- %*4A32 R[@ _Y_S_ )_.@9REZ,9.>><?Y_S_ (R!R5Y@=>W'
MK^?YB@9B2D$]N?;_ #_G]$Q%//8X]_\ /;_/!I 5Q*![CU_&J&6(GZ_7G_\
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ML10?YP?Q_P ]* -&&'Z>E %^.UR,4[B)TM<?Y-%P%%K@<CGVI@(;3!X'^?\
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M<GD'\\=:!D.I6I\O"'Y63\NA'YCMZ<=J0S'FA-^"C$&(D=!G 89X';D<^_-
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M?]*I$L[:TML_7T_S_P#6Q5D&T+3(!H 7[)CGO3 K2P;1T^M(#E;U0#_GI_\
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MT 1M;8XH _?#X(>&E\(^&M+LUA:!EM(FEB?<&6:5?,FW!_F4^8[DJ<;2=H
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M8XR.%"CMC..](HPFCDFB57 63[\>1]XIS@CUP.,^V*0%6)@'6%0<@OD=QO\
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M?IEMH*XA7!QRYY8_CV]P,#ZU])3HQHJT5\^I\77Q%3%/WG?R6B_KU([K4MO
M/^?U_P YY[UC5Q*B=%#!.?0K0Z;=:GG8CM[A21VX.!C/Y<5X-?%N74^LPN7*
M'0P)=#E:7]X,GJ 3SCU^G7D<5Y3DWN>[&FH[&M;:7'"I5E&X-P#G&,#@]/SJ
M;E<IZ5HUE;6BJ5127$:E0X!!&,G'4 L2 2><8Z=*3"Q5E,=_,R!$D4DI&74$
M+M)!.3R2 <\<GJ6P,5-P2+VF:46&(2L0#;7P_"-C/S;@.1QD=,\=<B@HGM?,
MTMBA,&65MQ CR03P5(R#CKMP 3_":8BQI5E;W+-]J"\KGA?*8,"0", *<$C
M P<XP:-P92N?#;V<A=<R0L,D@D[01_'M^[]>C'OVI,=Q+!9] (:'=&X(Y&X
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M= C(U!E QG\?\_Y[4#.!U%\$C_/7\J ,?.?KVS28T1\-CZ_Y[^E(HCX/'UH
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MG!5E/(((P0>0>.U2621'F@3.HL3BF(UP<TP*<QXI <KJ)PM C@-0/S'G'/\
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M^OUKSF[GL0C9&WI\FX$^_3\!G^=0;(Z2WF&0>O;Z9_S^%#+-='VGUS_A4@7
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M]1C\QU_7J:8$9N6:F!7=B?;_ "/?\J!,RKD@=3GW_2I Y*]&_./S'^?T[=*
M.>N7QR<_F/4_Y^E S,EFS0(C68@_Y_K0!IP2[\9]/T'XT#.@M1V_S_*@#J;
M9/7G_/\ /_\ 50(]!TU]O!Y_GZ<_A^M '=:<^_TS_2@9UUI\N!V_S_G/O0!T
M,$^,#W&: +L+A<<]/\_UH T+>7!P*3"Q=$^*12%%W@=: *TE[GI[?Y_SVH J
M2Z@/\_A0!E7=YO% '$W]P9. ?R_S_A4C.(NXSGG_ "/\_P!: )[)!V'Z?IV_
MSFD4A\L04\=*0PW9YZ\>_P#A4@59<8_S_G_.*L39@78!_.J1!-9$*.>G^?\
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MP7\$3<55I&1"Z[L@ _?GX?\ @6S^&FEV^D6 86ULA5-[;G8LQ=V8\#<S,S'
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MH3LORQ0S(#Y,8889Y$8;I.5C1L*3*2T*&?D[:VG?M0.YT=I;>U,1T5M;%<4
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MS:)XCM8U6:%ECO2  9(WPD4C'<,E&VQ\*SLLBY(2(8EE)GYO0]>:D9TUD13
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M@,>]3+:; K1E^H*Y4@8X([-C[R@YZ8H5BEJ&EI9[)T+&T;.V7@LIQG:0.1@
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MQ#]YV797M_P38ED,!YX/?H:Z).QPQ7,3:-H-_P"+7,=A$TA7[SDA47O\SD@
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MOVS0!GO+@G_/OUH 89BO\_\ /I_GB@!KR=J $\W/6@ W'_/^?RH DP?3'ZT
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M[MVSSI&?;NPN[&[&[ SC.!T%#,B&#9UI6$7$3'%("] ,<>E S4C[4 7U;TH
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M0QR)N9P-\8C"'&0R[<%ACJ, MQT')X'% ;]A?) LBS2QK#( OEY&XG 4!-O
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M&M%(PY#&BVW2>6X&UB<HX!4GZ?,/I^%:*5R)1L<[J/P^M)UW09@D[ 8,>1W
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MSBJ&=C93<\>G^?\ /^2,1T"R!L8/?]?\]?\ ]=(#<M;H?KC_ #_C3 TT<O\
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M1"9.:!V+4-MSS_G% 6+RV888'^?\FE<=B.6P,8SV[?Y_STIBL598MN?2@0L
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M(/0D'.9L.YG:?K+Z9(+5\[5W$/D$H2 003P>I5LG# XQD47&6=<TQ+6>.X*
M*S.6(SM5@ >W0$#.!RO7L!3$=!HTR- =.N9-UM*-R.2<@GCY<@9.X\9R .>
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MI'E&G'%_+MQ_D=/;]:8FRT(<=?SQ_D_YZT"N1RIGW_\ UT[!<SYK3_/U_K3
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M)HV\^3_GU_E_]>@#<MI^QQ^///\ G/\ /ZEPL:ZOO]>_^?\ ]>: +D1_3WH
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M[,9)0]P0?IQ_G_Z]24BWI5\9XXB?O%ANQV(.3_*E8H[*WD)&2*8%]%]#_C2
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M_G_/:@&=1;3B@#UOX7^![CXEZG%IUN=F_+22%698XUY9V _!5SM#.RKN7=D
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MV;@)T7.6(].OZXP/K77A:?M9)/;J>=CL1["FVM^GST_4]A-N54(HV@#  '
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M_P _C0(V(FS[_E_6@#:M&[?Y_P#KU1)OP'\NW^>_TZ_A0(VM/D*.,=_3_/\
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M^5 K&A'=X[]?_P!7K^/^>&(O)>E>>/PI@7AJ.,8//K^7X4 (-1_SZ_Y[^_%
M$PU+//\ 2@1(NHYP#GO_ (_X?YZ 'TE^RA\13X+\6V'S/Y5X_P!CE"*K%A<$
M+&#NQ@";RG9E(8*I'.2K '[HT ?-7[7'A(^+/!]\4B\V:T"747S;=GE']Z_4
M!L0--\IW9S\JE]M 'X:-J)I@0_;,_P!/S_R:0$3WG/X4#(3=XYXZ?Y_^O[T
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M '1RX'/I[TP%\PL.>@_2D!- ^!D_C_GG_/TIH8>9GDY]AW_S^5 A(Y<@]O\
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M_/\ GZFE>P'T;\,/&BMB-S@X]?\ /^?TENXDCZ0MKM;@ @U R^KXI 2;P.:
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M9;:XCQOAF1HY%W ,-R. PRI##/4$$<$4%$$&IE/PI#/O;]@SXBKIFNW.D2E
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M^9N>G-*Q5RAJ*>3*/XCGH1TP#^?Z5:&M31MK.+ /&/K6IDV;,6E+)P#Q]/\
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M[E)H ^//BB0TF!^(_P _A28SY]N;-AGOS4L:,=U,77]:11$T@7CWZ_Y_^O\
M6DP*+D*?S_S_ )_6D T'_/YT#'B7;TY'^?\ ZU %R.;''^?\^^:!%Q9L#K5
M3+*.1[_I^= $R2X[B@1I1''^?I0%C9@?F@9^R/[./['EK\/?LVL:V/.U9?WB
MV^Y6@MF.TIT!\R9,$[]QC5SE%9HTF+(;/NFF(* "@ H * "@ H * "@#QK]H
M?Q:G@?PCK-\T[VSI8SI#,A<.D\RF* J4^96,KH XQL)#$J 6 !_,YYI[]*0P
M$A X_P _YZTP)/-^OY_Y_P#UT#N3"0*:D9[9\"?CYJGP#U07]B?,MY-JW=HS
M%8[B,$\'KMD7),4H!*$G(:-I(W L?T(?"[XHZ7\8=+BU;29?,@DX93@212
MM%*H)VR+D9&2""KJS1LCM1 OQ/\ AAIGQ?TR72=6B\R"3E67 DBD .V6)B#M
MD7)P<$$%D96C9T8 _*7XG_\ !.K7-#>6;P]<1:A;#F."5A!=?-(0$RW[A]B%
M6:1GAWX?$0(565AGREK7[.7C/P[</;3:'J#2)C)AMY+B,Y ;Y98 \;<'!VL=
MIRIPP( ,[?PI^QKXY\6I#*FEO;PS/M\RZDC@,8W;2\D+OYZJ,$\1EF4;D5PR
MY /M'X.?\$[(])N/M/BNYBNXUWA;.U:58WRJA7DG_=2<'>?+15Y",92NZ,@C
M]-;"PATN&.WMXTBAB14CC10J(BC"JJC 50      ,#BF(\)^.W[2.B? 6W/V
MZ3S=0>)I+:Q3/F2X8*"S ,L49;/[Q^H23RUE="E 'X,?$KXIZI\7-4EU759?
M,GDX55XCBC!)6*)<G:BY.!DDDL[,SL[L#.$$O;F@"56% 'Z$_LH_L>1?%>U7
M7M==UTUFQ;6\3@/<&*3;(96&2D65>/:I65CN8-$JHTH!^Q5A81:7%';V\:10
MQ(J1QHH5$11A551@*H      &!0(MT % !0 4 % !0 4 % !0!_-?\8/&"^-
M?$>J:C'.]Q#/>W#P2N7R8/,80@!\,JB/8JJ0-B@)A<8"*/.A=;:!FOH7B2?P
MW=P7MJ^RXMY8YHGP&VR1L&1MK J<$ X((/0C'% ']"OP-^.6F?'?3!?6)\N>
M/:MU:LP,D$A!P#TW1M@F*0 !P",*ZR1HR#VF@#\U/VDOV*KGQ'=7.N>&W\RX
MN)1)-82,%W22,QEDBFD<*,L0YB? '[PK(!Y<- [GYS^+OAGKO@#<=5T^ZM46
M4P^;)"XB:0;OE27'ER9"L5*,P9064E>:0SDK:7::8'T=X9_9[\6>(9###I-V
MK!2Q,\9MEP"!@//Y:EN1\H)8C) (#$0%S[Z^$W[%MKX;DCO->F6\FC8,+:,?
MZ-E2V/,+@-,#\C;=L:A@R,)4/+L%S[HJB3Y>^-/[4.F?#)9+2S*WNI[7"HA#
M10R*VS%PRL""#N)B7Y_EVL8@ZO2;'8_([Q)XCN_%EW+?7TK3W,S;I)&ZD].
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M&AYR1FD4>F_"OXPZS\&;];[1[EXB'1I82S&"<)N 2:,$"1<.X!^\FXLC(^&
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M_0<TK_P/M_\ XY0 ?\+T\)_]!S2O_ ^W_P#CE "_\+T\)_\ 0<TK_P #[?\
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MA[YY)]J"ABQF;<PXQT_$\_7Z_7K2 WD00\= O3\/\_SH C>+[6V!CU_+J?\
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M.?0#_P#5_2G8+FBD$@Y"D],^O6G8+D$F^#.013),:[N,\?D/\_\ UZ +^BS
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M<?Y_S^E SB;GK@?Y_G_D_F 4"^[_ #ZT +GUZ<G_ #_4T 3(V!@=?K_G_.:
M)PVWCOZ=*8B6-MV>E,#2M_E_QH VK?T]: -ZV.>#T_S_ (?IZ4 ;$)Z'M0!(
MW/6@#.F.WK_G_/\ C028T_\ G_/].GYT 8$^'[YXX_SZ4#*+'_Z]!)"/FQSV
M_P ^].PP$6*+")@F1QT_SC_/\J+#&^5GFF(0Q[>E #]F#[T *4 H D$>>HY_
MI0 T#- %C;NJ1H41=LB@8GE^O&: %5,_TIV)$"8.<4P'XQR* 'E,4 2(N>?P
MH E1<<__ %OUH L(O]3Z4 6$&.>W^?\ /^/8 LE<CW_SS0 4 1L,'/\ GTH
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M#4-.\0LB32&.1>A*_(<D=6^Z,]LL/;.:MM,SBFC-'@AIGQ -R]220/K@ _\
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MK_GB@! E  8\#C_/- $AB- #C'@<=!0 ".@!QBVYX_S_ )^GUH =Y6?3U]*
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MO0 \R".#NK6,7#*I8DN=Q)Q@#. >AYY]\8QC)IC.KT?[/-O*OM;:JA43<Y)
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M!Y7_ #_G_/M0 N,<=>OTH =C/3C'^?7_ #F@!VSM_G_.:  Q@\<?Y_S[\<4
M/Z_7F@!0N/K_ )__ %T *1_2@!WT_P _Y_SB@ *]_3_/^?Z4 (5#?2@"(KCI
M_GO0 UP/\^G^?6@!F<_Y_P \?G0!&!DT ( .O^?6@ &3Q^'^?_U4 -_SZ4 .
M;G\* #']/YT )TZT -/X8XH 0?K0 A'I0 XC- "]\?YZ?Y_^O0 =: 'G\/\
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MZC_/^>* +0'K0(<B%^Y'^?\ /^>B&6E3\>U4(CD0_P"?\_YYI .C?')Y/^%
M#W]6/^?Y4F!!+-GIZ9I 5ICN']?\_2D!17 XZ"@"W"0PJ1,84\TD'N: -$,$
M^[VZ?S]*9)&DVT\<4AW+/VG!]/:@"-[P1_Y_S_GUJ;#.&UWQ(EH"2?\ ]>:<
M5<T2/G7Q1XODUUC'"Q1!D%C_ )XZ5UPA8RG.YY7?R+ V!\W<GC/^>O7GM6IS
ML[#P/IC:M>QYQLB*R-[;3P/J6 'T![5K&)PUZG*O4^HDEWUL>42(^#_GC_/X
MT 7A<M'R/QH&5;C698N ?\\5('%:QXNN8.X^N!_GK0!Y=J7BJXNR06QV_/\
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M\OU_^M0,T@^?IC]/\_I0!<M_E.:3 V(GQZ_Y_P _Y'(D9;347M\;6((XZ_\
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M 2MSP>U &=*>WK028=T?3_/--",*6F!$?E_7TH M1L/?_.?\XH O)D?_ %Z
M+B''T]?\_P">: %!_*@!V<_3Z4 /!"]?_P!5  >F10 \MF@!5?)H 4>OZ4 '
MF@?_ %Z  ,/\_6@!VX'_ /70 W<#0 TGCI0 P?X?Y_SGO0 P\=/RH C(Q_\
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M,#4MT#8/]/\ /^?K3N*QWFE1[5!ZY/U[_P!:D9V,-L' ('3_  J2D3+:[O\
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MK2&8TO% C-N!NZ8SZU2 QY!ST_'-4#*9/;K0(.E2,8>3U_6@",_/_6@ ^Z:
M#?OJA"ANF* )XI,TT!M6CY_S_A2 ZFR.X_Y_D?\ /6DP.LLOQHL!TD9I@2EJ
M ,^=LTR3!N6S_.F(PY_0_P"?\_Y]: (%.?\ Z_\ G_/MS0!,CC_#_/Z4 :$<
M@^O^?QH N"3 QD<4 )O_ /K?Y_R* '^>!_G_ #ZX^OUH 7SL$?AS^5 "^:*
M 39[]?\ /2@!YDS0 AE!^E "B49QZ_U_S^F: &M+W_SVH =YV./PH &EQ_G_
M #_GUH 02CM_G^5 ">9B@!/,W=OY_P"<4 )OH 87H -P/2@!RG)XH <&[X%
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MB*#8Z/3OA!-=NEQJ+L['JG! SGC'0?EGU]:T-$>O0> 8M/'E0[54*6X&WIU
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M< G$F/UH M1R[?\ /^?Z]Z )_,QC_/>@"19LD8_&D.POG9Z4!8:;CCM^'/\
M]:BX6'^?GZ_GVH"PK39![_C0@L,^T9[\]Z8A3/@<_G0 AG.._P#]>@!WG\_Y
M_P _RZ_6@!3/_G_/^<4 'G9ZXQ^G^?Z?CD 43;3[?Y__ %_X]P!#+_0T /\
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M4%VX&Y6& 1SMX]QQ@@?W3@9)&>E $^JV#P-F.0KA5WJW+?(=PQT''J<?='%
MT85EJ$FJ@S3$AU*K&ZH&QG.2P)Y4!>1@X)R/0L9T/V:6RB^RJV]YF\ZY<YR%
M9<1HW4@MR^WD@%1DDD4Q&VTZQPM'"S&0-)ND QN^4[FX/W59R@[%QW/-)B;.
M;L->_L.XGMFWO;(SA "1MPVU50].05//N^0,Y$!ZII^LP>7YI^1=J],N.@#=
M>OH>#UQDYY8K%9O D5Q)YUL3;S$C<%^52%;G&.5SDC(R/]FJL,\P\7Z'/ILE
MPTD9263>4S_JP@ !VM]ULCZXQS[0T-,\]LV2"!D.1'(2F>^&SM)Y'3N>G)XQ
MQ4E&=?G?(')VX(Z=3N48'''3^9H <L)C=N,QCGD]>I/T!X],"D!CZU8[T ;
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M&<'I_.D41)*6)&!Q_G_/M0,E9=H]3W%,:"-,<C@5(RX&W=,TB17(ZT 2XW4
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M_/\ GG]*D"I*5YZ9%(M%-G SD_Y_S^7H* *%Q(/7U^O^?\]J"3'FD+?Y_44
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M?C_/^?\ ]=,!ZMG]*!6#/'6F!.&#?KF@!5<'_P"M_G_/%*X6!7"4#)8VQQ2
M?YN.G>@ #=/\_6@"0-G^5 #UDQQ_G_/^?J /+_IUH 3>1_GUH A:3MV_S^=
MQK2=Z!$3/BF @D'X4@&9% "%LT *C?G0!;AXI@;MIU&/6D!T]J,U)2-V#C\/
M\_YZ\4F,T%Y_#O\ Y_.D!&Y]:!$(/I0,EY)_S]?\_G3 LQ=?;_/TIBL=79D'
M_/>@#18\?K0,S[C% CE-3Z''^?\ /^?8$SSN[.YC3$54-("PE R8=J8ARX.*
M -2 _A5HEF_;#C%,1J*,CWH >P!Z].U%@/BOP_X6,"SR2MA;C'0Y(7L,\CG
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MY7/W@>>5/!!!_7VJ@/*+WX(R^=OBE'D8!._[R\\@@##>V-I]1P<S9!J:%O\
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M.G;.<\'\!_\ JQ0,S)IPWIQ_G\/_ *_7K0!08$CW/M0!6D4ISG/I@C^6>*I
M9TUWZ>W7T_'_ #_1VN)R,YM1(P,9[9_SQ3L',5I=6(."1C_.::5@]H<Y?>*$
MBSTSC_$#_.>U;),F59(9H^I_VH2^,*,<^N?YXZ_B/6MX*QYF*J*6AUD#X.1P
M!S_G^?O6YYAV>G3DXYXH$SHBF\=* 1G7-L#_ (U0K'+7D! _#_\ 5VI <'K=
MB&&?KZ59)Y1J-MY#<<#T_P /\_K0,S2N1VQ^% $3$J?7'U[_ (9[]Z!,EAN"
M.![]O;Z?K5$FQ;WG&?\ /K_A0-&Q;:N4!(.>,_Y_7W]Q4E(Z>VUG/<9_/ _3
MW[YH&;7]I X&?\^G_P"OI4@5WO\ =T//IWZ_Y_SQ2 R)[@O[X_3_ #F@#+(W
M?7^5 $D: =/\G_/T_.@"SM'/3&3^7^?TYI 9=]"JY/;_ #TH X^^M1D^O/\
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M,E![T"'AJ!CRVWKQ0 \/@4"'AN] #]V!_G_/^?PH 52: )-^: '*V1^7^?\
M.: '!L<4 &^@!XDH 87R:!C-^: &[^*!#-Q:@",M0 @;=0 JO3 <&I 78B*
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MILIS_C_*BX#X%SQGBD!U^GQ9_P _C_6D,[C3(2"/7K_G_P"OVI@=M8V>1TH
MU$M,#_/^?YT 3_8\]O\ /I_^N@"C+9%NWZ9_S[__ *Z!%R'3L#I_G_/^-,1I
M?8"N#C_/^>/_ *]*PR%K3'^?\_X?6BQ) UIN.",_Y_STJ@*\ML>O?_.?TH Q
M+E6BZ4 8TL[?A^/^-*P[F7<L2#V_ST]__KU+*,.Y?!SQ[]^]("A]LV?Y/^/^
M?UI *NHJ.] $AOP_Y_\ UO\ /^-,"ONW^U,0QX=Q!Z>WXTP%2$CZ#T_SB@"T
MB8_6@"Y#$2>G^?TH$S8AM<\_3]*HDV(+8G^OZ?Y__50!HB+ ]*"BO-#[=O\
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M;GJ.I[TF,RSMOXY5(PY!SDGEBA"Y)XSD@@]2?KR 96G3RV,X;.X(P1AV "
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M_P _YZU:,V>:^(\Q@CVSQ^'6M8G-,\RRS'/.23_/_P#7^5=*.&9,MR8B%SD
MYSZGUK5(YI,ZW3;_ &G/^<?Y_P#U4S-'I>F7X; SS_GWJ6BCL+&X*D9S4C.]
MTV?=W_&J1)TH&ZF!EW=J".G^13)./O(?+/Z^M:(D\\UJT#=!_G_/^13)//;S
M3 Y.!0(S&L=G:E<I(RYH-W'^?Y?Y]<U-QV,&YB,?8Y_R:8S%>X:,]^W^><T
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M&6<M=DC.>H__ %U('/S.<<Y]Z!E SY_SS_G_ /52 L0OGU_SS3$;,)/'^?\
M/M5"-!!C\:8$@B&,\_G_ )_2@"W$,]LX_P _AF@#5BAZ'^E42S<MK?(Q]?\
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M4#*D]P(<D]!GH,^^?\YH8S#.J@@[=_;C@>O3_#CVK+F+2.7N=6DGW";8(>0
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M?Q@\?G5$'+W5H"?_ *W^>?\ /:H;*2*-Q9A^V3D_R]*EC,&YL0W SQ^/&/\
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MADN[;SC/^>G^>] Q-P//2@"8N/K2 59@W'O^5*Q-Q&?(X'^'Z4@*;<GC_/\
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M]A^E #)QQ_GG_.*!&%<C@^I_S_G_ .O28SG[A,@CVJ0,&>/&0.GT_P _Y[T
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MA7+<=?\ /^?RIB'LU %E'(H$60^?K_G_ #_^J@"1) #U[?Y__5T!IV L!_\
M]>?\YIC".Z\GC/YT6"Y.&*9/Y<?X4@N:$5UNS^6?P_S[TK%7+HE#9/3_ #_*
M@=R99@O/8\=O\]*11;%ULQG_ #^?;_/>I+N3"XWCKC_/>IL,G2X^E!:)XY02
M,\4F4B<.1_G_ #Q2&2/+2* R;.G7\Z +JS$8_P _YZT@N-67.,?C_GUI@3*V
M.^?2@8XL?7\*0B,RY/)XJ0(7E"=.<4@(UG_GS3 F/!)!_'_/X_YXJ +@42'
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M?- "D9XH <#@T #?+0 [.Z@!X.?K0 IX.:  'TH >!0 UEQS0 X>] "CKU-
M#C\M #A0 O\ ^J@!0*  #- "8QTYH > 10(V+;'%#*.DM.WI4LHZ:WJ1HW8>
M:D990T -)Q0 SK3 D'M3$RU%0(ZZR/'^?\_I3$:9Z?Y_S]:!F=.W^?\ .*0(
MY'53P?\ /UH$><77WCB@8R/GK0!8BXIB)F&#3 >HI@:=MS3)-J'@#IFJ$:"\
M"@0USCO0!X2T*S-\W'&,$9Y]?;Z#UK8@;-9!CN&!C R./\\T 4C&T6 ?\YH
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M$Y4X*KD'@@#.=F#]WKP<YI"%\-V0OL+.Q<CS&$A=68YV@KR2V"/O= AYYXP
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M0,MZ\9_*F(YG4+<@$\$'J._^?7^7HTR6CB-1@)/(Q_G_ #S6B,FCF9!LS_\
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M(0Q;/F@8X6>/\_X4 3)9XX_G0 ?92I^M "FUQVH ;]GZ9% #6@].: '>3NH
MD2VZ?C0!.MMCZ4 3K;Y[4 3_ &0+VZ4 .-EWQS0 @M30 PV9'6@!19GM0!*M
MICT_PH M)99.?T_I0!?ATLOT'K0!TEEH9)'3_/Y?Y-,#K;/PX1[TQ&\GAW Z
M?6@"G<:%CM0!S-YHH4T <K<Z;L(./\FI*0RWBV'FI8S:B7'3_/\ G\:DI&Q&
M3BI&6 ^>OIQ0 WJ?:@!!STZ4 /-,"W!S3)9UEF<BF(OL<T 4)CQCO2&CCM5S
MC- 'GMRW/'-,0D?(_P _Y_S^8,LI0(D_S_G_ #ZT 2Q<U0C6MAT_SZ4T(V8>
M *H1?2@!I(]:!'CDJF4''WO7_P"OZ>WTK8@CAQ(!T)'8],^_^?YTP%FB(SC.
M,\< ]/8T 8LUJ0>HV@$T 5 "A]O\_P"?_P!=("5H<#IG^M "8./\XH =/*2<
M@D'@CM_G\/H: N"W'GL2W$HZ,!DG '!SP2/U'%,=SG;&1_/D>;ELL$<_>V-\
MI&2/E &"!QU/H,@7,1F$:C8?*QR2?H,D#'/&,@<< 8ZT,$8$NL6]RJK$%0LR
MJY<<@ ]2,G&,#!P"<#!!V@R6>I:;KRVLOELV0=L:L3@@(H,K].OS* >GRD>M
M C=LF75XDR^ Z*<YP4# ;L>K ,W!Y!&3C&:8C/TVZ\VVN+B-PB.&2V  .R-,
M@OGCYG()YR0!U "X0[$L<JV5P[D*!#%W &9I&8J <9. =N?XB6/\)I6 \:=)
M;O).$BVX)S\V0"N.F,XXX/&,8/--C-2]MI=L$D<.005<<^^T=<_*3R2.!G.>
MR$7]-\/&WB$<BY4+W.WJ[/S@X(&<>_)(Z4QG?Z'I)C8RA0I QTYY]^O8?E^0
M*QNHI0__ *L_UH&/^Z<YYSW_ /K4 9>N7\>DVYDD&]S\J)P-S=1G'0>I]..I
M%0W8I*YS&@ZPUU;^9*<MN(/3)/&3@=!V]!CK4)EM'FOQ!U:X,GDH0D+I\P'5
ML,>-QR<="0.#Z&L:C-J:/-$S'V(/IU_QK$Z"W:WC18WC@8&>F/S(^IH Z&UU
M."XX\Q& Z=>OH1_];%(I'2VQA8X!;CT#'J>.O]*3+1H64AM'.T.RGG*[<Y[\
M,14LLZVTU"X8?*C\'JZ$=^N4W ?D*@I,OOKEU%\B)&Q;DD.W'J?FB7_'-38J
MY<M;NX<A@BL,=0""/IA@,>YHL6F=+87TESPR<D'[RNHQU^\J.H'U8>O%26F=
M5871E!\OC&!N!5T]ONDX^G4B@HL*SQ-M.#S@[<GKGE0,GCG*$!@,X3I0(Z9)
MTN47:5(['KC''4<'D<$9! SZTQE:)1'(>Q<;CQGE< ^G4$9]E'KF@!L\>_\
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M;AT.!_G\ZH"XFE8[<BJL(E&D!NWOQ_G\.*30$J:6<]!^7?\ SS2 >=''I_\
MJQVZX_G5) 6(])SCCCZ?Y_SQBF!971=@SCMC],=: *DFEX/3'-*P&<^F[<9'
MO_G_ #ZTK 4Y--QT'2D,I26&.V./\_Y_E4@5GL02<=SD4 +]B#T /%D3_G_/
M^>* '/:Y[=?04 0"TP1Q[4 -:V_S_P#6H C:WW'_ #_G^M #([?)Z<>W^?KU
MH F6WZ_3_/\ ^J@"Q%; ]/\ /I_G_"@"[':?_6H NI:;L9 _S_\ JH ?]CQV
MH 8;+'O_ )_Q_P /H ,^PXY H E6RSV- %A;'/..* +L%C@8(Z?Y% '5:9I.
M[!QV_P ^] '=:=HXXX_S^/\ G^5,#M['1%'0=O\ ZW^?Y4P-1M'VCI0!DW6D
MYSQ0(Y'4-,QVS_D4@//M0T_;GCGG^M2QG)B'#?Y_S_\ J[TF6:$2^E2,OIQ4
MC)]N* %H :.M $JCB@"U">:8F=59\#(]*8B\_'/8T 9]PW^?\_YXH&<=J0XI
MB.!N3\W- ABG&*!EI: )7.10(E@Y&*: UK:J1)MQ'%4(N"@!K$F@#QN&?<N_
M@'T[9[BMC,=*@X9.I[?Y]>E,"<2[R%8=,_Y- &88B'R1@>W/.>O^>: *\UEM
M.[I_7WX_6@!B'8 #W_I_G_ZU("-T&>,]#_\ J_SZT 5;HX(SV&<TP,-E9\MM
MSGC_ .O_ )Q0!FSV1)SG&#C@'W_^O],^] %6YLS=QE6?H2 _X\@GGT&1WH \
MXU?3Y)I,EEW!@/F!)<*%'!Y] ?09R2:0SI;>0@,BL6"K]X@D$GYN,]L#D8/!
MZB@&S<TV]10ZL3M*C<O)Z@@\>QXSP#F@1K"X>T#B-]N=Q.0#GH#CG '!XQUS
MG)R2%)E6X\W4FV7$JR<C:<]<[0VY1CMR.PP.U!1S^N^()/+BA1"TJD H!G!;
M(&.&^;!Q_$>20P.04P.\T:W$=O&\@V,0Q,8;(5PS'+$'!&>1]/04TB;G2K_Q
M,AN(&.>^<X^@X'7G-,$=!:6+; %^7(X)'7Z<=/USQ2*-"[M$48YW=>V,$^W^
M<_H@,CR1$"[G:B$_-D_IS^&.<_CP@//M:O1=D.X.!P%'\/&.<X_'^6,5A)FD
M4<Y:3+"N$.>I Y _'KSZ?K4W-&<_XYB2^\DE2"/,SZA?DP>^,\CTXQ6<S6F<
MA96RRL1DCT(_3@YQ^%9&QT<5D4(R<XZ?*O\ A058T)-$2] ,VYB ,'"]/3.W
M(Y[9_.@=BM#H(LB'4R>_1L8Z=1V[X_(\D)E)6-T9(R9'4J01D1D'MGA03P?K
MT^M24;MO9NOS%@ZCGD$\=_XAS^E3<HUK6%HLN50ENHSMQVQC;V_7/;-26C7@
M\B8_/&N3[#^8&1_7I292.KALX9!]P8_V21].GZ8J32QMV]O#D,V=XX&&8L?H
M2<_CP .33&;']FS["4<2G@[6.T]>@DQQ[%@ 3U*@XJ1&-9:@-/:0Y) .9HS\
MLL38&&9><AO5>".0"N"K!'=WD(\V+;@AGX(Y!'ER#CZY!S[=J+E#IX>O7TQ_
MD&FP,6>(MR?Y]O>J&<W=6P;I_+_Z_;FD0SE+^T!)ZXS5HEG.7-KM_KZ_R_6K
M3,V9K)CIW_S_ )Z4R1BR9Z'OBF@)MY' SVX_S_GK022LQS^OY4$D?F=/\_YY
MH >C@Y'O_3/^1Q0!,@_//3_/6K$3YR.#Q_7Z_P!#]:!#2W'U/^?\_P Z!BYS
MTS_6@HDQN&!UZ_Y_G0!$6V]/PI /+'O_ )Q_GI04 &.1_AZ8H 87.<'^?^?\
M\<4 /5R><T#N.CF(]/\ /U_R/?%*P7)4N0I]/Q_'_#WHL.Y(;T,<C_'_ #_G
MUHL',/\ M@/?GD_Y_P ]JFP<P@N=N3TY^@_SZ&@.84787@?C_+_/6BUPYB=;
MD9.,?Y_#'O\ @/I2L5S$R763[_ES_GIWI6"Y+'J*XR?\]>>GX?7-*Q7,:$5X
M6Y/8]!Z_Y_I4M%*1<_M,'OSVY_P_.IL5S%V!]N<_GT_2I+3+/VCT[@YJ66F7
M8I,<U):98CN"H^OO2'<L0WQ((./?VS]/_P!9HL4F5A>"0Y!Y^O\ GZT#'"<,
M.3GO3L2V59[G/N?3\0/7W_IWII$MW,VXO.HSZ_Y_7^5.Q#9S5[>;S@=!W_2M
M$K'/*1\]>-;L:M>N0"P3Y1GN !^0R#_G-=L%H>-5E=LYR"VS_GK5F1J0VP!X
MX'MQ_G_Z](#6AM>W !/3I^'^% '06=N <>O;C\1_GUQ30C=@BZ9Z^OOZ?X>N
M.*H"YY&!0!HP?Y_E_GZT :L#?Y]J -:($<'J?\_Y_IUH F(/7D=>O\__ *](
M"A=0E^>G^<=O\]>_5@<C?6/XX'3_ #]?;H?6I&<U<6VW\3FD!GR1#ZX_SV_7
MV]>: *CQXS_/\* *^P'..O?M_3\,]/QIH"%E+=/Q_'_/X]Z8AH_=\_3VZ\_Y
M_P :8"K#^?\ G]/;^=  4_S]._/^?TH ;LQUSQT_Q_S^=(!4X..>/\]?\]_Q
M8%R,X_+C^GI[5+&*R;>.W;_)_IZ=QT0B-H\\9_7_ #WH&(L&XX^GZT 6([?;
MC(]!V'T[>E,1;CBSZ \>WI[U0&S# %_R/Z_Y_E28&U;+M'J/\_Y_*I WK-R,
M9XS^'3/Z_P#U_6F!T]LV.._YU0'00,!SG^M2!KP2>O\ ]?\ "J =+)V_S^7Y
MC\/4&@#"O92,_4\?E_G\J$(Y*];DYZ_Y_P ^O JB3F[AL'\_T_SS4@5HS\W6
MFD!>50U,#1C7_/\ GZT 6XTQSQ_G_/- &BL>!^OMTH @DBZ_C_G_ #_*@1&R
M 9QZ<?\ ZZ *)C[_ )?_ *Z!B%.?\_Y]*!$P'/XG_/\ G_"@9+&O/;_/^?UJ
MA,E(]<$_S_S[?RH$,]<^G]: )3(1WQC/^>W].F: (Y)-HP?H,C_/:DQB1W/K
MV_SU_P \4AHG:XQ^'^?\X_\ K5)1EW$N_P"M S':3!["@16EEW'^?X4T)LNV
MPP/?/^?\:0D;]LN/R!_S[4%&Y!S_ )]* )B:!6*MP#WSS_GZ?Y[4"L8%V3SS
MR,]ZH1A.NZ@!\40/3ZT ;%O;9''X_P"1]* -V"RSZ\?TI@;<-B/3N.U5N!J0
MV7Y\520C1CT['^?ZT 74T_.!CI0 \:>,]J8$HT[C_/\ G\J0$\>FX- &F^E_
M)T[8H P)[ #/OTZ>] &7-88!X_*@"E)8?I4C,N>RQSQ_DU+ HM:8XI 1K;9/
M^?ZT /\ LV: (VML?Y_^M0! ;;OW^E $+6W'0?Y_S_GF@"L\ Y_+_/>@!@M^
MXH LK #[T 6$AS0!I16XH NK;9[9QZT 6!:]J (S;T ,%L,_3\: +*6OK0!/
M':4 7[:UP?I^'ZTF-'H&D6(;G'% ,]"TVPR!3$=I8Z?5 7GL !0!C7=B.128
M'(:C88S2 \RU>SV \>O]:0T>;W,>US^52,<@YXI%EJ.DP)<^M(!3^E "@XZT
M 28]*8%F [N*9)U5GQ0!?;)H S9V'7O04<;J? -,3.!N.32$(F: +"'- $Y;
M'M3$6(_8TT!IVXY]JI$F[%R*HDM*10!&_P#GK0,\$M)?(?:P(##I_GG\_K6Q
MF;P0]!_7O_GZTP'^64YX[?YY% #$D,?IQ_A[T ,=TSP""03@^O'^?>@"G*J]
M_FY'^?P]>_:@!CH7'RC)(SS0!4FL3*N[OQDT 9;6I4]O\/IGWH 9);N_0@$\
M#_&@"&YL=T9!&6)]!_7O_GWH Y&[L$&_?][Y7P1V3G@]B>F>/UH B\X.LKRC
M)^Z5/OC@#@@'/'IC.3D9 -&WT<3A&!Y"\J2,A@01R<97&>?7G% !:VAM5.3C
MI@D$C(.,<8(///\ ];E ;%EH+7UO@[#\P9"<C.!QD8#8/&X8R,=\"JM<+V*\
M%E)ITC*S!8QR(QD\=0", 8  Z=3VQS2!LZG2E-RW"#&<Y.3P>_;G/M_C0!UK
M *<G. /P YX_SU_*F4+'>M,/+#'< 0.><YZ^X_\ K5(RBK2;QG;M/<_YX..U
M(9ROB/5Q&2.<1D@#C!<\$_AP!GCJ>YK-LI'"W%_#%;)(=QPS8'&0<G\!G!R>
M?7GBLFS6*NSF;C74A7$60S'TZ=SCU/UK%R-U$R$,EX=TA#GG.[^A_+ _(UF:
MVL7+:S%QP"0?FP#Z'H>W3/\ ]>@9U-M+@!7(##[V[H?QYX./KSSZ%%HVTLDN
M5#@E/0K@CKW!XQ[<?A2>A0[RWBX="<'^'O@'G#=#[9.<]:D9%Y45T3'(""V>
M.5.1SQ_]8X]":!C].MV=0 Q8+S@KAMPXP2..OMG&.M(:.HME./G5@?0,1CWR
M0G'M^-(M&C"%/9R?9@1^K?SI%&C;J4;**Z<X/S1D?BH9L_H?2I91U%B&@QN)
MSZY'^/ ]N*11WFGW2S948! Y!(S]<=3['I0##6=)BU=$! 65#^[<\LK$$8Z\
MJ>-Z\!EST."$",'2IGC*PLN'1PQ&<C!C?E6X#*>1D[3G(8*P(#0SK&4S#(ZU
M0RG/%^!^G^?\:0&1+;EN_-5N!S=]:D?Y/_UO\^E-$LY2XM<]1^/^?\_UI,S:
M.?FM".?RJR+%%U'Y_P">_P!30(-N[TIB8H&/E_+_ !_QH((WP>O;V_S^% $@
M 3'I0 JOLZ]*:$/63/3KT_S_ )Q5 (6R.>W]?\]J!"-C!R<4@'&0]<?K_G^O
M6F6,,A;\O\_SH <!NX- #O-*\\]* &-A^<_K0 ]6QTI!<9G;QV_^O^O]* %W
M?_KQF@!I7:3Z?_7_ ,^E,5R1,^H[8H$(6+8IV)N*LF>/7_/:BP7(PP)Z].G'
M^?\ Z]-H+BF3'&??K_D?E2L%QZW1'3_&ERE*182Y)_#_ #_GVI<I7,7H[K.<
M=1_^NI:+4C1M[\KQR?\ /KQ_AW]JR<312-'[;D9'7I_]?WK.QIS%B.[&>#]/
M\C]*+%J1>-_M&.O7^7/^>OM2L5S%*>\(4Y/^?<]/K^5(.8I)?8'3'(Z_XT6'
MS%K^TBPY/I_GFG8.8ADU-0,G'U[T[$N1CW6J#'7G/7M_GZ=?PJDC*4SC-5UD
MV<32=Q@#IU/ Y].,X["MHQNSBJ3LCR;&\Y(')YKK/-+L$>[GUH UX(<GGD_Y
MYJ0-6"#;V_SZ_P!:0S>M8O2F@-:%=HY]/YT["+07 _#^E,"0<]>I_P#U_P"?
M>@">*3;W_3_]9_SF@#;MWW=* -6- PZ_IV'3]?I]*!#)%SR/\_C_ )-,##N[
M;<"1[_YXH Y"_@P3GK]?UY_SUJ!F#*NT'W]?\\_YXH&4&7)]?\^],149?7KS
M[\?2F ACV<X'^?Z_Y^@ X1$<#Z_Y_7_/0 <8,XS_ )]J &&//U)_S_3\: $V
M=_I[?_6_STH K%<#]/Z^E $J_-[U+ E9=N>,?_6-(9*L6[I].G^?3\?UH L)
M'@@#_/YT 3"/% C0ABS_ )_S_P#7Q^30&FD.?I0P+D?7CD$=/\_RI ;UJIX)
M]N3[>WTZGBF@.JLT P!_G_/3_P#4:H#=@C_'_/\ G_/) +D9*=Z '.=P'% &
M#=<?3\Z$(YJ[&W)'OCZ__7_PJB#F+DX/X?E0,I!O+8<@?KZ^] BZK^7^% S:
MMAQS0(TH4YXH&:D2[>,=* &R#''X4"*3#H.GM0,B\OW_ ,_Y_KVH$5G3GF@"
M9$ &?2@!HY/T!_E_^JF@+J)OP?6F(3R\G\/_ *] $K1A!U^G^?\ /YT 9MPP
M7D].])C,F2Y"'CKZ]J0RJ+[90%R"2\]_\^U*P[F5).7P1]?\YIB)K<$F@1M6
M_;Z4,:-ZUY'^1_G_ .M4E&S#Q_G_ #_C0!.1Q0!5F(_S_G].@H Y^Z&.O^?\
M_P ZHDQQZF@1HP1?S_E0!T=I!NH Z>WM<=*H#?M[;9Q_G_Z]4@-B*T/^?\__
M *J8C5@M ?I^7^>M %I;6@"46>.: )!:4 6$M,=*8&O]E^3]* .;NK7:>1TI
M 9<UKMZ\4 9DMMCMS4L$8]S",],?Y_S_ /6I#,N2'!/X_3_/^%("%8:0$GE9
MH @:#'U__70!5:'- $#)0!1ECV'G_/\ G_Z] $2*/\]Z +(7O^)_S_G\* +B
M1T :-M&#0!J10_Y^M $S1<4 1F+'UH 9Y/;K_*@">).* +*19XH UK:#'M29
M1WND(.*:$STK3(<XIB.WM(,BF!?>#B@#%O+;(I,#C]3AZT@/+-?AV$X[$TAH
M\>O%^<U(QF<TBD2Q>M(99Z=!_GZT@$/S?6@!5;?0!(>*: LP#!S3$SJ[4<9H
M$72: ,RYXH!''ZKP*!L\_N3\QSZG_/\ .@0B-MZT#+2G'^<_Y_S^ (E^]3 L
MP<TT(U8./PJD0;45,"X#3$1.V.?\_I0!\K:1XG.2DY,L?0,O^L4=N#C<.Q[^
MY[ZIB:/2;-Q<+E2& XR"?UZ8/J#@@_E5$FEV% %66,^G/IUH ECMB^ >/RH
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M/'YTP$#X'X4 ,9L\_A_G_/XFF*XG/./?_'_/XT"N.)V^W^?:@0_9CK^/^?\
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M'(QG..>_^>/ZTQ&A'+D8[U0$A?:,=O\ #_/\J $=O3^5 $"S;?H/T_P_S]:
M-^SFW8'O_G_ZU F=/"-P]>_:J0BPZY'^>_\ G- S.NHPW^?\:!,Y:_MQ_.DP
M3.+NHC'S^?\ ^O\ 2D49<F,XYH B(.>PZ>W^3]?PH D\K;UX_GZ]* )XX3Q@
M9&: )/)QCU/3_/;CGGW_   (9(@O^!_K_DT$W&F  ?AV_.@H@>,?Y]/SH @"
M;L^V?RI 2; II,99C&[KT_\ U?K_ /J]*0%F.+/Z_P"?\^M %M8R#0!H11[3
MCW_SW_SG\0"+R1G_ #_GK_GZ@$T*9.,<\<<_X?4T =':#;W]_P#(Z_S_ %H
MZRTCP._7K5)@;2+N'OS3 LJG7VR.M $<HQGT]_\ /^?PH Q[L8!]?\_Y_P #
M0!R=XN3Z#_/]/\CO1#.=F..?\_Y_*@"D#GKTYSB@1>1,<]#^5 &K;X44 :$7
M7K_G@^W^?3B@#6)P#W]?\_\ UOK0 T2=\_Y[T#(V&!Z#]* *X;'KW'^>AH S
MIC@T"%CEXR.GUH B#XZ]O\_Y[4 :L#8'.,?Y_P _Y-4(L$="?6@!&) _P_\
MU?Y_.@##NGSD#\.:0SF)YOZ]?_K_ )T@(&YY_'_/Z^^: (R2W^?\_I0!$5R/
MT_S_ (].E &C;+U _#_/Z_3K0!LPYX- S9M_EP?3G_/^1]:DHUXCG'^??Z4
M3%O:@"M,W'YT 8%V=W^--"9D,-I] ?\ /^?6F2;-HOX_Y]Z .IL_E^F/\G_/
M\Q0!UMF0U4!NVX]>0 /;_/\ GV- &Y;D8^G;^=4A&F@Q3 M@ B@"15Q[TP)N
MM $L8SZ4 :[CY:0'/7([<4P,6<#^O2I; S)USG_#_/\ ^LU((Q+C],F@9DSM
M@_T_S_GZ4F!"#QC]>*0#EX]Z *\F* *SG!H IRF@"C,!_G_/ZT 11M_G_)H
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M26_B6,F(;9%^]$V-P]P.X]^@Z>]:)W,VK'0EO;'^<TP$1]G]>/2@".X?S/\
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M=_\ .:H2-08< _Y_3US_ /6H*(9H^3_^K^7^?PXH),6\@W _Y]Z .(U"WST
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M##N#N/\ G_ZU("(+N^O//^?QH G\GO\ H?\ /X4 68( W'^?I_6@#3CM O\
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MMA_G_/\ GTJN4ASL31Q%^/SXZ\^_]/6KY2'4+"VA/;/_ .NCE)]J,;3&8<C
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M!0!>\K/X9X_S^.<G^=-$V$-OG/\ G_#^E,=AIMO7K]?J?\_RH&030?Y_S_\
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MU&[UZX_&F3<Q3=22GK@#TXH"Y( S]S_]>@5RP;=B#GGC_/OGZ>E.Q%RN;?\
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M^E C/DEZ#_/MQ_GI[T#&)-CG/&?U/I0(MPOQS_GFF!HHWX?I_G_/X,0UGV4
M4)I@!CZXZ>_^?\G QHR)YL?Y]./\_P"14@-BES_G\?YD?Y/(!IQ=!_GO^% &
MA"!ZC_\ 7^'T- %U%SZ>Y/:@#1B&3CU_&@"S$-W3]?;^?3_]=# M#Y?\_C4E
MDR@CITXH <3N'\L_Y_S[4 4IN/UZ_P"?\\TT2S$N#D'O@_K_ )^M,1DN=IH
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MGGO[$ _I2N58ZJUT<Q8*X!P,G<YZ?[R_IT_*IN78T6:2T/[U/EX.]>1^('S
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M> ?;_/\ G]* )@<T :=LV: ->%N/:@"VS#H*8#0WY4P'BD!=B^:D!:@&>O%
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MQ@9].?I3((#:D#."/7=GC\^WL.?7TI@)_9TA&T?,<Y. <>O?&>.F.M T,VM
MP0HW'^SC\^@'/ID'\J +#6Q(R5Z^N0?_ -?US0(Z30-2;1F;?@QR<L!G(/8@
M9 /H1W'T%.X'HH*RJ"IR" 0W(!'MTS_GT(H R=PGY5FQGUSG_/;G/H12 @FD
M9,CU!.1_,YQZ<]O?-2QHY"ZNC<-M4G'8\<@=#TQ[^_/3@U%S2QFW,@C)_O,/
M?/3O_+O_ %H8%!M;ATU2Y[#U&..F<C\.,_UJ6[#M<\IUC7Y]9;DD+S@?X@?_
M *NP]\&[FZ5B6"VV*,#GL#69JC>M+<D;CC ]?TX[GV/U-(I&];1@$GN.G3/X
M_G_]?%!1NQQ^<-H )/?M2&7[?3$E4\$DCH<XSD\<=_\ >Z5#8TC?LK!(>.-N
M0",XY/<>_H3SG'U$W+Y3H(91$RC.1T!'X=?U^O?D?,C1&_''NP0.!CG'./\
M/^<4AFM;IMS@$?K_ %S_ )]Z!B&T!QM QC.#R.GZ'W'XYI@$:[N"I7!_O?X<
M?_6QT[ %I-.R,%\>V ?\/Y4@(%T@@Y!!) &<8_7F@9HVEHZ??Y!QTZ^W& /Q
MS0-&Q#$C8&"/8G_ T,9HP68?Y><^QH O0V>]>3\RYSG\_P"7/XT#+_V1XQD$
M''^?\_TH T(80X&3UQP?K0,MHC >X_F.#_G_ /50!<B0/]Y?KUY^E T2"#.<
M>GY__7H*)N<=,]CGZ?YZ_P#ZX&(6 _AQT^E,HC^^<XY[_P">:8$$L0'7'X_Y
M_P \4P*++M[_ (YS_+_/6@9&06'S<_6@1$UMZ#/^?\^](13D@(R1^(/^?\_S
M!&-<VH/3D'L>W^-5<AF!/IY/3T^F/PIW),&XL,]1D>W_ .KZ5=R#GKFR--,#
M&GA93]>_/;\J9FS/.9.U(1!D*>.W^?\ /OTH :S[N:8R-FSTH %(Y':J1#)E
M?:/\_P"?QIDDRCO@=..^?\^W'XTQ$B'./3Z_Y_D:9),&Y_S_ )_#BF(MVEH]
MZX2-2S'' &??)]![\#IS5*-R92L>AZ9X!<G=<, .NU&Y_$D<'Z _U.J@8.KV
M.E&C1V Q$H4CC('/XGJ?Q/\ A5V,6[E=D,/3_/\ G_.#5$E.2<'J#G'^?>@#
M(NKS;DC\?_UCZ_7]:!&!-.3Z_P"?\_\ ZJ0BHSFF(8%)IB-."$8[8_G3%<TH
MH=@&,]/\_P">E.Q+9HQ)CZT#1HA=X_2F,@:(+C_(H AV]\4Q,85V]^G^>_\
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MW_S_ )_.F!G2H<^XH&C&NFR,_C_G\_\ />0,=VY_I_G% T6(VZ$?U_\ U8H
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M9#T/4]#Z]O\ $]:11TVGP< 8)4=SP,\=B<]S_P#7J&4D;4,?& 0/IVZ\]O\
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M3)R>K9]R2>?Z<XXX&G+8YF[D\M@5R?\ /X_Y^F:+ 8-Y;8'YT@.:NDV@Y_\
MUT <S,=I].#^E*X&!>RE3G\J!&.10)BJ-WI_G_/UIDEQ(=O]?\]*:$:<:9XJ
MD2S0"X_/_/\ G^?2F22B0*,$\_Y__70-$PF]<"@L&EQ^'^?K0!&) ?QIA83G
MM_G_ #^O\@EDZ =C022OR 1_GO\ A[4 5"N,Y_#_ #T_SVH*3(=F/\_7_/I2
M'<KRKG\OSH"Y2:'/T_R?ZTPN8-Y:\<#'^?7_  J0.:N;<IP1R<__ *ZAHM,P
MYHO\_G_G_)J;%F;*GK_G_/K4,":,YX/^'^>.U(9J*>Y[G/\ G_"@9=CN=HYZ
M?Y[<X_SBI*+B7/!'^?\ ]?OZX]*!EM+O'^>* -"UU+8<>G^?\_\ UJ .EM-3
MQC)_#I_^KL*!'1Q7.['?_/\ GZ9H&7-^\?E^M "2+N&#T]*+DLI2V^\=/US[
M=_\ .<T C'G@(S]:!W,^1=I_S]./Z?G@F@96=_7C\: *$LFTX[_Y_P DT@,J
M=\?3'\O\]: *32XZ_P"?\_Y[T .# G/'7K28&A;D#O\ Y''_ .OUJ2D:JC=S
MW_S_ )[U+*)E'Y?Y_P _E2 F#'CCGL,?Y_2J0%A/D/\ GC_"F)FC =W0<TR3
M;MSDCT_S_GZ55A'4V9SS3 WHAD#U_P _Y&: !UVCCD_Y_*@#/NB/\\=O\_K0
M!REZ-W3_ /5_GVH X^^&#SZ4[F9S4F">G^?K3&11N<C_ .MC_)_SB@"WD'@?
MGC_'\.U %J-P>..F/SI@3\\G&!_+I_\ 7I@5I1P?\^O/^?\ "F!2F&/PS^'^
M?\^T 57.>G;_ #VZ_P"/- $!?CI_G_/^<]0!JH9#[9_SR:!&_:VW_P"K_/\
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M<UF:HWX4VD9SV/K@CCCWY].12+1T=O""?ER%SZ=OY?YZ5!9OV\:(IPN..O\
MD4BK'069,8V[<<]>WT]3T J2T;<$ .>AZ'.>_P"OI2+-""(%FV]N<?4C!]OZ
MT :-I:")B.H;+*?PP0.PSU/<Y- T;\,6WC_/^?SI%%@J"<#G_/YT#*SVI;IV
MY% $XMN/?M3))5MRF.?\_P"?TIV$2QQ[^H[_ .?\_IQ18"[%"1TZ=N^/\^U(
MI%Q58'D9_P _G04.\G,@)XRH[GN2/\: -J*,'&?YG^M &E!$OH!Z]/3Z?XT
M6T4QG;N_K_G'3WI 3QISG)_'^E,9,R[<D_T_S_6@HD3D\8S[_P"?_KT#)_+"
M\$8]P/\ Z]("G):@C@Y/&!2L.Y2W;>W3_/&*6P$3LKG^N/\ /'^<4)C)8X\=
MP<U5QA(A].#QC!_S^O\ A2$0M&3U'0_Y_P _I0! P8=2 /;C\??_ #S3$1&,
M8)SQQT_S_G%!+,V6W#9Y#+Z]*8C(FML#(P>OI_G_ #QFFB68%U:C!P,'_(_S
M^E6B3E+RT*Y_P!!_*J0CE[NWVY]QV_E_D_SIB:,608/7/X_4?YS004B>V/\
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M?M_G_.: &'Y?\: (V)!SZ_X4 (),#B@!YF)Z\GOWH L+=8__ %T 6$O<=>U
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MG'44 6PW%4 N^E8 )[=1Z4@&F7G% "QS?G0-$T<^WC_]52,ZBQO=F.>G^>*
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M.*/9PHPN,G Q^=("+[(;AMH[\Y[ ?Y_(4 =18Z0NGKN(Y_(GKP,\@''7^E
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M4FJ?;26V[ .A&#QQ[ ?Y_.1FE;:CLPJ$*>AY!S]3QCT'?!.1BD!K07+7[&&
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MH+%4[>.O_P"J@!P('/7O03<8Q4#E>G^?\_\ ZJ0B)I%!YX]Z8%@3+C'4=\T
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MZ?T]O3]/K0,U(1CW_ T["-6-"P_S_7_)I@6UAR/\_P">M B<(%^G^?\ /X4
M*C_3K_A0! \FWC^O^1[?TH&B*2XVT@,R:Y _+_/^32&85W-NJ1I&!-ESS_GZ
MT#(2N/P]?\_GTH&.:/Z_Y_R:$2Q I'!_E5$CBN[_ #_G\: $.1V_STXH KA,
M'CM_G_/I0!KVXZ8_SQ_G_P#50!O6ZCH.GX\5)2-F ^PH&:D*C'J#C_ZU %D#
M;_G%!!7FZ>W^?;Z4T!C7 ]/?_/\ GKZ>K P)EZGMU_S_ )% %:*$+QV_SVH
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M&X_S_+_#- &I$M %Y%QV_'_/;_/- %N,9 'UR/TH M(@["@"XJYJ@+<<0ZT
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M .O0!0$8!_3%*P$\?//TI@:UL2#QU^M,#M],FV<'V_E_G^=4,[6WN-P_3/\
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M1*MH'[?Y[_YXJ2B.33\]!Q_G\3Z?_JJ *4MCM!QC'X?6@=RH]EZ<_I_GUI6
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M]#_G]/QIDD>=HQ_G^G^-,0UGXR>._P#B: (D.6Q_C]/\G]* .DLT#8)'U_\
MU4F,Z*V3)^G^?\]:0(W+>+<<GUZ_GG^=!1JQQ;#SQ0 2+@X/X]_\?\B@"C.@
MQFFB3!NS@=\?_KSUI@8DW3J..O'^?\\4"([?/_U_Y?RH U(>3UZ_S_S_ "H
MTHR/IG/^?3_..U $\8\OZT 6A_D]?\]J +\9W8Y&:H#4C4CG'KV_^M^OI^&
M1<0>M %Y(\GZ?SH&:-O#D@^X_P _Y]*8'0&U"#('Z?Y__70!E7%OG\^/_K4@
M,*XA[X_S_6@#*EBYS_G_ #_]>@#%N8Z0&8RYY[T@)[>3FA@:B/D>O^?YU($\
M;]_I_G_/TJ@)B-WU%)#&D[>F/SIB*TO(QB@"F1GI_G_/^0: #J??F@!RC% %
MR(=/6@#1B'\J +&,# _S_G\* *<AV]_RH JR\?6@"@TG7]: *$OO0!ER19/3
MG_)_S[X]* (1%0 ]H#C_ #_G_P#50 >01ZY_S_\ 7H >L##MZ4 6(XCZ=* -
M&WX[?Y_S_D4#1NV? 'IBI&;T8H8%Z''Y?Y_S^M2,O!<4P&O'F@0@7BBP$BQX
M_&F(D4>U,1/$<&F!K)* * (99\4 9D]R#^-#&CF;^ZSQ4C.5FFW9Q0!4F?\
MS_GZ_P">E %,OV_S_.@"5'W>_K3 <1FD ]!S[TP$/%("-Y,TP'))[XH ^))?
MAM=6Q&^,KGCYF7UP>A_STJTR1@\,&V)!*9&!]Y<G]?Y9],=:H"]_93Q'(/8'
MY2H'/J6(R?T^E%Q#3$EHVX+\_?+<9]3GD_3C^I *XMGOE+XP,X'&%_$]?RY/
MK5 =1I?A>:7@*SMQ[8'U;&![]/3-!!WVG?#(S#,[B/'102Q[>G 'T_\ K47
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MMUX,.,X'MQWQ]?Y_RSF;#N<GJ'A'(X['T_P_S]:FPSSS5/#6WH.G7'^'^/\
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M3_\ 7_A0!*"3Q^?^??\ R* +4;D<G_/^3W_GS0!JPN,#_/O5 :*2]1_G_/\
MGZ@B_$X)H U(&W<8_P _Y]: -BU&6 /K_G_/2@9U9BRH]<>__P"O]: ,*[ 0
MYH Q90#_ )S0!C3PT <_>+28&#,^WCGZ_P#UO\_A2 9"^WO_ )Q0P-B*3^E2
M!:0Y/K[_ (TQEE3N^E(H"0.?K0!!*,?A_7_/^<51)4QC^M A/O<CD?Y_S[T
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MI@/- %*5L'_/ZTF JY[4AG':@0H./7G'T_R/Q-62SS^XDPY8 $@]" 1S]?\
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M('  %TT9U&>TVS"%"<')(  ZD]@.G/U..Y(&36K,4:RZ4[,9=P$Y)+. -IX
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M^><50B2-=Q_K_GM_2@9V>F1[0#[9]_>DQ'66@['MWI%'00)C\?3_ /5_]?\
M*I&:2QX_I0,S[MMO;C_/^1^!IDLQISNS_P#6Y_SZTR3E[\X'7CK_ $J@.=G8
MIG''O^5 $,4G<?S]O?/TH THY2GX?YS0,NI<8[_Y_P _UH$6([O'^- %A;OK
M]/Z]* -*WO ?7WI@:D=W_P#K_P _UIB-:&X#=3T[8H V;><#VQ_G]* -VQ?)
M!]QS_G\/Q% ':J<J/\^] '/7;@G(ZT#.>FDSG% &3<R#'O0!@WC_ (=?\_\
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M)P,=U"%]3BKSMH-O+^2VC(=2W;<JL.HQRIR5(ZYW,/I7HMV/-2N6+=#-#P"
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MO^12'<E5<?X4#%9L\FF "(;N.,]Q3 L1 (/KWH >1Y?0YQ2&/'7@?3T_7]*
M'[L<Y]/\_P"?_P!3&-"'Z4A%!T#<9'TS0,@=MO51S]?RH$4V3=SS_G_/Y>]
M%1Y-PP?\XH HRKU_IP?\_P">] &=M#'D\^_^?_K4 5VE[GGZ<_AQ^=!)EW,N
M[.0,'_/^>:H1S>H-O.  ?7L,?YZ4T)G"ZW(N.O8G_/\ GM]*N)C(X"5_Y_\
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M>_\ GL/TIH@L+>X[_C18"O-?@\#'/;_/^?6F!G/>C'!&?0?_ *_\_J0#*GO
M?KD?J?\ /Z4T!D7%QN_PS_G_ #FF!F23;>O7_//^?6I @%QSP/P_7_ZU %1K
MS9QGK_G^E %-[SMT_3\?U_SW ,J?4!U]L_Y_S_.@+&-<:B5S[\?Y[?YZGK1<
M+&)/?$_Y_.E<:17^U%AR>W]?\_A^%(=AINMGT]?\_7].] R83]A]!Q_G_/Z
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M&G3^5P,@ 8P02,<<<]L#'7& .*&061?O"2B!G@4@&,Y8]SM0MDG *GRV^4Y
M5]H*%6'<W-/U:.\3S1GRQD\@C.WKG.,'U![]?2BQ=SJ;24S$2;6!QM"D] >3
MP#UX&>H&, CDM+&B^8FT\;XL!<$M&3A2QZ$$ ["3P< AO[H8AA)6QL60BU1
MK[LQ@ Q$A61O5MI8;NA4C*\9!-3L4CI49D*ER .Y  P?[QP.GKC.T '!&<0S
M5'G6I>"_M;L]GA4_YYL"!NST3(^Z><9.WL#@8'E5\#S:QT\CVL/C^727WG#8
M>-BI+*RD@AN<$<$<^E>'*+B[,]Z,E)71.C;QSQ[XS_G]:DHF SSG/;@_Y_SB
M@:)2"M2,@[\<"F \_NZ 9(K%0&QP?6F2:"RE?N\^_ICO^7;O_( D@7(_F?\
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MY!SSG/X5)9=MY]N /\_Y_3K28'4V=WMQZ=/PJ1G5VU\3^?\ G_/O2'8VX+_
MZ\T!8U(;[/7&?\]L?_KIB+AN%/3K_A_G^= BN]QGK_G_ #^7\Z: J&]V$$>O
M\_\ /2J(*W]H=O;U_P _Y-4 _P#M'W[T 59-3(]O\_Y]J ,U]2QG]/Z?Y_\
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MI-WIG^?^/^>U &K"?R_SQ2 O*=W3\:8QV[OW]?\ /^?:@+D3\_6@0(>G^>M
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M /JZ?A4--%J297EC[5+15SG;V'<">]0T,XG4XL_3_.<]NG\Z0SC[B'&?7_\
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M_/2@#1@NN.3_ )]__K4Q,LB^SS[GF@DA>]STIB*,U[MS@_7\_P#.35@5C?\
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M,"MY_/.?\]_I0%Q?MFX8/XCZ?G_GVH%<KO.6Z_YQ_G^?6FA#=OF=_P NGO\
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M22<\Y))R<]2>YK%F\2U<#8/,&?, PA R3G^$@D @^A( ^]E<9$EB)+YDNV3
M?GRSDD%1W7('S_W@,E5QR5&:+!<LW$<<X*S -$5 (.>V<'@@^@XY&._2I<;H
MN,G%W1Y/J^A?V:Q"Y>+. WIGL<=^.,=1S@ XKY_$X5T]5L?487%JHK/<R3'G
M@]N,^U>=8]*Y$P$7(_PH&+$H'3CDD?G_ )% F6XT*\_G0278TV\''7TH MJ
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M) QGW'#\$<Y 2&SK=&)N'+>ORKQV'!/?J?P("]Z;)1ZG=)''#LD0.9#A5/\
M$V,C'3!&">#D8SD8S7,=)S7V>3102Y,T9Y9QRZ\8)(_C4  #'S@#)\QBS5HB
M36AN!/M\L!R_((.5*]"Q89&/0=6/''4)H":YTE53"\8Z<\_F>2<^O?%"D#B>
M3:CH[64@2)=Z;@S0X7  [)G &3R%.0V"%V$5J<[1*&6\^=>F<'C!SU(*G!4^
MQ -,17@CWEV]3M'<87(/!XY)8>A  S3$8DT9LAMC!,9X,0Z@$'B,Y'8$[2<'
MHI7A2V".LT>^2=-ZD%<GD>HZ@CJ"#U!P1GD"I8T>C:)<?:FX^ZIXZ_,PR">V
M0O( YYSZ UA)6-X.YV)M3 6DAX9N64G",<Y+'@[7/]X=3C=NK#<Z;$MO??;>
M%#1[3B3(&Y.. /<\$-RI [DD L5<T5B15,84",C 7'R[?3'\_?WYI#L59IET
MI=\A_<*!\YY*<\!N[+R #R5_BR"2H&Q81WD)#KM4_P#+,X/;&6XX8@D'!("G
M&3DY30T['!Z_X5%HOGPG@D90]OSYY_O<#MCAGKRL1A$]8[]CV\-CG>TMNYQ!
M4D^_(.?7_P"MZ=J\-JQ[J=S4M9"HR?\ .*0&BKAAN].*!CHV-P,@?TI#+*0#
MKCFF(<J@GGBA"&. *8#<A,_K0,;N!R#T_&BX#?IC'_U^_P"52,E,BYQ0 F\2
MY]1U'U_I0,59,Y'T'^?2@0]X@0>../\ (H SS:AL^_\ G_./TH RY(L],>OZ
M_P"<XH*N8TUL?0X]CZ^] 7,J2U*'ID_2FB2!=++G<PZ=,=SUZC\_\BF!I6VG
M!CEN@]^O^?Z=Z&!HNX7IP #CG_\ 54C,Z^3[2N.W/3\O\_GVH&>1^*+(X;TQ
M_G/^?QK2)SR/G#Q?9AXI$/0@COQ7139RU%='RRQ:T<J>H-=\78\YJYI1710Y
M%=*J6.24+G<:9J/G #O7H1G<\^4+,]M\$7_G*8OQ/X_YZ?RQ64S6*.QN4VN!
MU!.??U_R.G:DAG-:[ RR J,A@<_7GW_+W["M8F,@TR1FRK,00>WIGUQ_G'%6
M2=I9PKT([8Y_R/7\J8':Z-<G:%!Y''^'^?>J2 [BVD$@V]OR_P _Y-60R[]C
M2]0@G:1P>1_G\^35IV,64[:U%O\ +QE3_A6L3GDK&HKD CUSW_S^G/2M40:U
MAK1@RK'D=OZFDU<%*QNIKSS\*/7D_P"?\YJ>0KG-_3=5,HQ(W(/X=*AP*4SJ
M4U!)!MP!_GT_R?PK+E-N8NQM%>K@XXX/%2]"[IG*:[X(L]5!+*#QZ#/^>M)I
M2W12DX[,\?U;X1H!FV=L^AY&/3U_G_AA+"I['1'%/J>4:KX3O-()WKD#H1T]
MJXIT)1.ZG7C,YI[DQL1W'8\'\1_CQ7*]#IW!;DJ!FH+L(TY[>OOUJ;CL(+G;
M@]3^'^?\^U3<982<MZ^V/7_ZW?\ ^O4C-*#YN?KC^?\ ]>DQHTD8)R/\_K^%
M2RR4S>]2,I;2Y/T_S_\ 6H LQ0#OCO\ X?Y[?K1<#=LXMC>_7^6/3BA"/4]"
MDV$?3_/M6J)9[+HU[@#G_/\ G_ZU.Y)Z7IU]3N,Z^UOLU5Q&K'>YI#+ O?>D
M UK['>@#.NK\CO3 YN[OCSS4L#FKJX+]Z0'.73;1G/2@1RE[=9Z?Y_.@9S%Q
M+G.,^O\ GFI8&!=D-G.*"SE[V';U[C_/^>_Z4T(XN]B'Y?Y_S_2E(2.6NH:@
MHPI%QW]?\_C[4 ,88./Z<]OY=*0R]",\>QQ_3_//^* M(=O^?\_Y/:F 28__
M %4P,>X;CI5",V=MV?\ //\ DGVZ>U4A&!.3G/3^7^>M,DRY9>O^/^?\BD-%
M:9R,@>_'^?I2**;2<_7I_2@!F0._^?\ /_Z^* !6+<'.,YR/\?3GVH 1I>/\
M]?;_ #_.D!7DEVY]Z0%!Y,T 59'YJ@*S/B@ 4D_XT@+,1STZ\?X^E,"]&N?\
M_P#ZZ +BC'2@"S%\O7I_3_/^>]4265;;]<4"984_+_GIC_/\\4#&CC/Z_P!*
MDHF1\<=OP_K_ )_2@0Z)S'TZ<<^O^?UZ?0&6XI,=?\_Y[4"-.PFP<'_/X'Z?
MYS0,["WF[=/\_P"?T^E &A%,1T_S_G^M(!?/W#W'^?\ /YT +]IR, 8'Y=_\
M_P"![LAE^V!.,8/M30CJK&WZ$^O'^?T/_P!>J0CK;=!C_/\ G_.?6F-$SY4Y
M''^?\_CBDV J1?E]/2D,GQLZ?C0(<(^_;/Y?YYI7 LV5B;MPO3I_GC_'_&F(
M^GO#ENMC$(T''?Z_X53&=E$F: )C'0!BZA""IQ_GB@#YY\>J+4-[=!TQ^/:I
M8'S)JLNYCCG/?U_#\O\ Z]26CEG;'^>W^?\ ]= #4;/^?K_G^N: -&"3'3_/
M^?\ /- &JC$B@"RKG'^?\_Y^M #P_P"70?2@@J2C<3Z?T_E5 9CK0!$4Z'CZ
M4 /C]O3^?X4 :-J>WI_G_/Y4#-R <8J1FHN#U_&@9(1C/^?PIDD+<_Y]/\_Y
M-,$2I@<?E_G_ /74E$BG_P"O0!=C.RFA&M;Y ]/YTP->(8^OZT 6B,_Y_P#K
M\T"*C<B@0*/S_P XH NKQ]?Y]O\ "@I$BX%2,U++K^7^?\_UH ](TH9QTJD(
M]#TT8H).VLS3 MMR*0&%>=Z .&U4\$]<T#1XUXD) (]SUQ_G_/Y 'ANH9$C?
M6D,I9&:0%VU.#[?XTF,VX>!TJ0--><T 2ITY[4 38% %^U.2/K30'9V'%4(U
MMV.* ,^Y; ^G^>E '%ZLV!S2N!YG?'!/\_QI@4E.:0"DYX_SB@"!FH =&/\
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MTE.JJBNB]" W&,'^=9FI<1 O3M2L,G[9Q^5+81&1GMQUI@,*%1R,_P"?\FF
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M_?B :1!G)'(+*.X!P#W^O?1*Z,WH<Y>)O ##D<Y]?\_TIHAF=Y'EE6!'N/\
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MZ]O\_P N?7\6A,V+; ';_/YTP-J$_I0!9;GCKZT 5<4$B;N>>GK^E %M6]:
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MN-%\-%V4R*23C:@ZL3TSGH.?\]#W4J'5G%4K]CT81BP&Q=HD/  X'KCCL/\
M.3C/J(\UNX&%(5).#W9B.O3)/^> ,8P,46)9GB'!SP"?;&!Z=.I_SD46)-"U
M"P9VYW=^_P"9/&?\X[5HD9O4?/>2@')4 ]AQ_B3^ 6K)'V&E/J#;V'R$]OXL
M=.?\DT[BL=C9R+;$)R0#M^52V#Z-M!Q]3_\ 7I C5:YVR!#&V&_CRFW/KRP;
M].U*P[CVUGYO)3B0#[W!VCJ"/X02.@?CV;&TG(/G-^RB_M9#%(A".IWJ[!MR
M]"A^9MS-_$S<A,XYY67[I2U(Y_"IM]K6C;2O2)\^4W.<$#[I!^ZRCY<GY6'
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M^32 Y.YC.#_3^?\ G/Y5)9S-VN.@SQQCO_GTH RY,8/I_G_]=(9/&/\ )^M
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M #_]>DQH\;\3'AL4 >%W_P#K&^O^?K4C*';/?M0!=@.1^/\ G_/2D,V[<XH
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MQ"B\O@^8@_BW8 #C'4+\^,95L;JZ%+F.64>70RS,T$2R$^?;,3L*DM(,\KN
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MM^]&< AOD93D$&=!#<+=*'4[E;.#[YY'/.1T.<$$$$ \5+12&W4FU=H +/D
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MW_S]* *\AW?YQ0!7#'U_.@")N?H: &9SS0!=M>&Y_P#K>] CK;-__K_Y^G-
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M<_YS0!,AS@=\_P _\_E0!L6XR/Y?E0!JPG'^?\_K0(O-5 0OS0(:!S_G_/\
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MMY)OSSC]!0!B2D-G(YX_7K^E2694S>6>/4\_Y_\ U\]: -"RU39][_/J.:3
MZ)=111U//^?\]:D9BZMJH8%0>/YC'K^=%RTCBKFZWYYYJ;FEC+=\_6G<5AB$
MD\?A_G_.:$Q&W; 'G_/^>WO5(R9T-NO ]!5"+I7UH ?LXQZ=J:)9ES>IZ>M,
M1",@^] $L77C\* -.!?UQ28T:<9X_'K[4BAS9_44 0.V/IC_ #_GZ4 *OZT
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M&!CCYQ@M\PSMK<C8GM)A+B8'/F '(Y&.P7VYY/\ $0#T"A1@C;ANL<^WI_\
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M^4;&4?EJS,[SP1X@.ERJC?=+ XKHI2Z&%1=3[0T*Z$R1C/!Y!_#I_GK_ #]
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M)[ =\]L9S]*(H<Y6*EE9RZIEF)BMW )&?G<XYQ_='3)&<]=Q!P:;L3%7.HM
ML06,*%"C"@  8]A_,>OK698^YM_MQ\H' &"[#A@"#\H]V[GLONRTKA:YJVS"
M/Y,!<#@=!@<<=@!Z=0/;FI9<4/N6$6 @'F-PF>Y]\<[1U;V!QS@%(IE%;<6
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MSW0(Y]<U(C/MKW/^?Y4#.CM[P>O2LRS6CN=Q_I_]?\_TZ50$OFEA^'U_R?\
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M_D4P-.._ H KW%^ .M*XSE]1U  &DQ' :KJ%(9Y3K5Z#GZTP/.;IP6/^>O\
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M.<':OIQZ\%O?C)"@T,:1:>/=@#DTALRHXOM9\X\#_EEM8_=."6)&,[R 1G/
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M+1MAAAL';D8(7@CK_>X8]#T!Z4YL4$=/]E,7SHP5V.2#RK8'\0SP<<;EVG
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M#DM3UD'O_G_/^>U4(\]U+5/-Z?YZ\4@.#U&]\S/- '.2'<2:0R(G/ S_ )-
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M-@Q)R0S ;U"[63.,9X."<*>,BN6MB>31'51PW/JSE+7XNQ:G(TC(Z,V%9D"
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MR*\\[RG+)WS^=2QF9(^[GWI%(H/(!S^5 RI*_8=N/Y?_ %^*!%!KG/3\<_\
MZZ!E"2?!)QG/X?Y_SS0!GSW/X=?Y?Y]*+"N8UW,1D=^/SZ>E%@.6OKC\<?R^
ME 7.;N7.>>>_3_/X_A0D284XYQ]>/?UJ@+EM<'!.>X^OT^M.P$SWW'4>O^?\
MFG8#F[N[(_SS_G_/I3L!S<MP6)[>_J.GUH \;\5:R&?"\]_SJ62<(]V7I -\
M_%.P MT5Z46 T;?6&BX/2F.Y=.NDCC_ZU,92N=:>7I2$8AE+<YYJ0)[>Y*4
M=597^!UH Z>UOCGC% '0V]UN]OSHL.YIQW6.6_7_ #_GK4EDK3@?A_GO]<T
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M3-$B_)<@8)RQ9AM&<$GKQ[ 98GLH)I(T(XE^RKLE.Z1VW,_12QQP,],8PH]
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M* *+-G/^?2@ !% $\;8/TY_S[T 7(CD\T ;EL<CZT ;<7N/\: +;''X_Y^M
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M_4]SQV%4R4S;3#@E>#_GM4FA6:X:[;;'QC[S^G/*KV)]^B_44Q'2Z1*L0$>
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M%Q<_U_G_ "H Q[FYQZ]?7_ZP_#_.$!SEUJ!'?]1_C1<#&N-0 [_R^O\ ]?\
M_73)9GM?= #D_P">GMTS[T"(TN/M# <X/^?3_.*N(CJHK<0#:!Z9_P Y_P Y
M[5HD(8Y.,\Y_ST].*8C$NEV\?AW% C@-;3@X[#W[_P!>>?\ ]= T>-ZK,P/!
MX_E_G\/RJ&6>=ZE>-,3DY%(3.=E.30(I/0!&10 4P#-( %,!V*0!C- "4 .
MH 7'-)@7(KDBD!LVUYC@GK0.QK)=YH LQ71- S0CNLD8]* +@N WO['_ .O_
M )_2@"\C?X?_ *Z ) A;@?C]/2@#1A3=USU_G_GZ=Z!&I!&6_+T_'_.* -9%
MX'0GMQD?_6'- S1C. /J>!_G/]* +\?&/7Z?Y]* +:MC&1V_G]?_ -7L.@ (
M)5[_ .<^_P"=*Q5S'N!^6*0S%E@)R/3_ #_2@"O$H!&?\]?\_K0!KQ2XZ'M0
M!HQ3[S@=?\_Y]J - /GO_P#6_P \TF KINZ<9]/Z?S]*D"6&+=R?\^] &DD
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M3'*I'WFDUIO^(3P[!R".,]_<?S'\ZY'AYKH_N9WK$0?5?>BEY.T9(/3@X/\
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M*I(&!ST&?\__ %J@T//[B8MFD)F<U,1%2 :1F@!F,T +C- #CQ0 HH .O%
M!0 HH "*3 <!2&7(WQ5#+D<V*5A%Z.?%(1H0S=*!FK%+NH VH.#D_G0%S148
M''^?\_\ UZ -*!3G_#_ZU &E N[G@'K0,TTP/3' _P ]OK0!?B.S_/\ A^'7
M]*!%U#C^M R3?OZ=ACMW/- "L>,?X=OQ_P ]?2@:*,B_Y_\ KTF,RI8O;'^?
MT_R?JAE22'R^GM_GUH <I_S_ )_SZ4 6,X&?\_K_ )_H :EO-D?Y_P _7\*
M-",Y_+Z?7_/>DP+T0Q^/^/\ G\ZD#4ADSQUI#+<?S'_/^30!HQ=??_/O_P#6
M% %K:",'_/I0!5E3>/I[_P"?KZ4 85U#V/O_ )_S]*H1SEXF\$\50,YB>+-
MBGY?Y=* +$:;30!KVQYP.H_I_P#KH Z"&,G&1_\ JH V(!Q0!9QM_P _Y_#U
MH H3C=0!01=I([__ %Z -"+CCZ4 ;%NO0X]/\_I0!K6_R_3_ .M]* -.'Y*
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M0M]1!/RJ6],?_KJ6BU(NO),2)% 4=#GW^E18J[-R.U9Q\[D^PXK)LV2%-E'
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M -:@HTXB#Z"@"^C>W^?\_P"<4 3JQ7!]^GZ4K@6@^./P/_U_3_\ 5058E64
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MV^OK0!M0)C&?\\4#N::IZ9Y[_G_G_)HL.Y<"[P./\_YYI!<8T93&/T_S]?\
M]=(94D7<<=3T_G_GT^E &:YR/\_E_G\Z ')\W^?\_P"?:@"PGX?Y[T :%OS_
M "% '1V;9&?\_P"&>?YTQ&VF#0QDYYZ_Y_S_ )S0A >O^?\ /\J8$B'/^?\
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M?[1Z#N?\^M(IF0HED.'.T'LO7\_\,59!T4*J  ."O0_U_'O4&B+RWHA!\P@
M#KVQ2L.Y5L8FNY1,PP =R(>#[,1Z^@[=\G[HQ+4] M95E&5_S[&N=JQTK49<
M@S-Y2'&1\Y[ $$#I_$>BXZ<MSBD-EHL44 K@#@8Z8'3CL/\ "D6CR7QH4D+,
M, H57^IYP/4=S7529QUD<+IUZ;"195/*/GCVYKJDKHXXNS/JJUN RA5&  ,=
M^/\ /?UKQVM3VD]#.NK?[<0S8VJ<K[G^]^?W0>#C<<_+MM.Q#5SG]30PG=_#
MCKZ?7V]__K5O%F$E8RDNH]X4L,G^OKZ?C5V(N:UM>"T(#D >I(&/S_SBI:N-
M.PZ>/^T,2' B_@ 'W]P(+,,=.NT=/XCG*;1:#>I=LI3&FT\K_>ZE3V!/H?S!
M]>R92.<N6WS%5R(P?F8<9.?N \'UW$$8^[PQ.W5;&+W/0[.);U!M&T*?EQ@8
M&.,=AQQCICBL;F]KF:-3:'; @V\*=[#@*PRI(/\ $YR5'W<9)R05-+45S9LT
M18Q'MP5'0G.?4@GDDDDDY)SR2<YIL2.=U)7VJ[, )'W;#V+!F.WOUSQR/<'[
MVL&8S.&UE2L,H[E'[^JG_/\ G%="U.26AV>DWOVA=P/I^O-936IM!W1EJG]B
MWA53^YN%+8_NN/IT!R!QGO\ *<8J_B7H3\+]2231X[^29SE9 P3>K8.W8I&>
M2K $D@,&'H".6E3L-QN>>Z5X1N8+\HDA\M6C=W=00%#;MH">7R2O&=W<X('/
M7*::.2,&F>N0WT%@71I%4!LC<P!Y ^AZY]ZX6KGH)V(+N[BNXR8RSD@[=L3.
M,CH>%YY]Q0A-A]K$@#I'*0>1^[;I3%<S)X\.<1R ,,\IW[\9_P XZ52)9G+?
MOHYW+O50<\HP XZ@XQ]>?I5VN9['3VFK1:DA' /!!4]QA@<CIR/Q[^E9.%C9
M3N=%%MN%#CD'D>OT/?/KZ'BLWH:HQM01;!Q(,KD_-Z<?=)'0\X7GL1G[M6M2
M'H6;/6HKZ3YI(MK#"[3T88XR"0,^^,'N1TCE+4[B:38F^8R2C#,2<="@'11C
MD''WAG[Q<]"!0W8:U+EW<'1%)=OW0!)9NH'7)/ (]^,8R2>30E<&^4A6(7*K
M=-E9#R" !A?X5.0<\8)!R ^Y@1FJ6FA#UU*\TYNP?-W;%YPOZ8&>2>P[G II
M)$MME@2-I,2ME?O+YF.,%B ?7<.BCN  #D#(EZE;%OQ3K2>%+2:[==_E+\JC
M.6D)"1H, _>9@N<' )/:N><N57.B$>9V/'M%L;_Q3<7$UK*O#&)K]E5V!3*N
MMLK*Z10AMRHJ+YL@7>UPF0K80I>T5Y/0ZZE7V;M%:_@CT%O"NHZ8@-MJ]W*S
MG:T-Z4GMY0025*%,J" 3\I).,9!PPKV"Z77S(6(?5+[C9T>WENEDB@BCM[R,
M"0V4:[;>XC&<M:Y/[F1ACY-S1,5Y5'>61(YW2>NJ[]2N155IHR*[NXVB^5UV
M2X *X(*,,EL]#E.A.1E@#D$UZ1Y;T-NVN?M"A@,;NGT_PX_R,5#1:,C5-,CN
M77;E7/S,R$JQV$8#$$9.XJ5W9X5@,4T#+-G"T)'[QV(Z!@I _P"^0C'OR6R<
MYH8S:L6G!#W"[@N5&P9P. 3LW,WS,#T9L*%  )DK)EHT5DBO<[&R>XZ,/JN,
MCZD=C2U*([1A*3(,%22J=#P#R<_[1_ JJG YRQ6)I42Y 60;AG..^3QD$8*G
M'<8- S"C$J^8\<WF<F-1(N54*PWKN&'Y96!8[L )A#M^9I$C1KJQD)(ICD()
MVL00WJ58<, .3T8#J@)&;L3S&/86T^IL+H^7L)81IC($1QDJP/5R-W/!7R\!
M7\POI=(QLWJ6-7L(=8A-I=QQRQO]Z&0;@3TW1YQZ\%,21]#@_.9-%H>.W7PH
M58BUE*8Y"[E8YB2I0L=@5P-WW<,"V\_, 2I!W:)DN7<\ROM*GT@B.YC>)L'
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MH J+[$R7<Y;5/#R3?<>5/H[,/P#[P/Y?J#O&1A*)R?A\2VT<6VX9AL4?/&I
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M@"$7(_#K_GWH >ET5Q0!>CGSS_D\?_K^M &U;WFT#_/\J -6*Z)Z?X\4 /\
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M^/<U29$D$AE1?F3)_P!A@?T.T_D6/US5;DO0P[/4(IT*[MC>9-\K#8W^M?.
M0,_ATZ=:ID%](!IBC.0'R6SD8/4=?;C\*'[PEH<MJDL-PK[I$'RD?>'IZ9_H
M:VBK&4G<@.I17',>Z0GG"(SXS[J,#\33$8MW*\KQCRG0AC@MM'\##HK,P_$
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MV?;- # ^.?TH 02XI 0&;'X4 0O.2.: (6EW4 1>;MHL(>LV:D8SS,4 2*]
M$D;]*8RPK9P.U(0\@GI3$,,6:H!C6V331(1V^[M3$;MK;[,4#.SL,#Z9Y_/K
M0!U]F^,?RY_S_D?6@1OV\^P8Q^/\JJP#+F?C'K2 YVZD)S_G^5)C1SDTI4_7
MC_/4?S_#MF643<$>]2,;YQ/^?\_K3$6HKDK^%,"^ER",>W^?\_\ ZZ=P)Q?\
M>XZ47%8#>X/7D4@*S7Q/4\_Y_P F@")IR:!D9G)YYZ_TH :9,^HH E\[UZT
M3+.2>M BPLQH G2X)QU__70!)]I(_P _Y_S]: (VN\]?\_Y_QH&0M<XP/\_Y
M_P#KT 1+.<?A_G\.*!$GG'TH&1-*7%("OR>: %Y% $?F%>^,T  D- "K+ZT"
M9:63/]?\_P">] &G;/FF!J1R=ZH#1BY_S_\ KH V[48Z]_\ /^?>I Z*V&*
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M@UDW<U0Y[5(T$.-R_P"T <G.22",<DD]N2> *:8C*OX4L8RD$AA=SM4[MP&
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M94YZ@4 /-J%YQ2 /LX'^?>@",VY]/\_Y_P * (7@ _S_ )__ %T 1&,#MTH
M@,0I 5R* &...*8#U;TYQVH$:=N<TP-J#WIH#5A!88_SQ_G^?2F!T%LH(QC_
M #]:D#H+<8 _S_G_ #Q2&;D+<8% %Y7&,9H D7Z_Y_2@1(IP<4P.JTUORYS_
M )_S^6*H1TR'% %>3CM]*3&<EJ/2@#R_6EVL>G7_ #]::$82G(H&.ZBD!3G
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M52RD7GL@W7K_ $I%%4V 7/\ ^K]/\_T !']@';W_ *^W\O2@ :R'H!_D?K3
M:UCZ ?Y^O^?YT@*TEH'[8^O^?\_C3 IM8''(Z#_/^% %.2R [<?U_P : ,^6
MQ]OTH SWL<^G^?\ /_UJ!%![+';/YT[!<A>W]>I_K_G\/6D,SY(-AYZ=* *Y
M@_PJ0&^3]*0$ZCI0,M(F>E %Z)3CCM_G]:H1;6$'_/\ GWIB+:1<9]Z!CT3%
M BW!\ASSCZT =+9-Z'/^?\_YX !V-E(&_+_/^?QZU5Q6.BC.>??_ !Z__6H)
M9:"=C_G_ #_GF@1$UL",_P"?S[>M4!2FL QX^G^?T_QI6&9DVG[LU+129GM:
M 5F4)Y [?S_6D,8(<<?Y_P ]: '& '/_ .J@!C0CTQ]>/K_]:@ :VQS_ )S0
M(:(.?3_/6F,>;;/ _P ]?\_I3$-6 >O/4?Y_S^% #_)XZT "Q9_R?\_3VH 3
MRPN<_P">U AY0'CM_GZT#%*X^M #57''>D ;10 BJ/Y9H @^[UZT@$9<TP*I
M&* *C_+_ )_S]:D"$X/O0!68YH KL:=P(PW>@#9MCN%4(VK;_"F!LP'<>/\
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MGMSVQ4@R\LF>OY8I )!,)G+=E^4?U_I3 GDN!%D^@S0 EBVU 6ZL=Q_'I^@
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M&P32 [6VN.F!W'X5+ W;)-QS2$=;:#I[?R_SQVJ&6:;(%X[5(RFT0'<>_/\
M]?\ SZT (T9';D?Y^G7^G6F >7M^GY8IW C,&., ?Y_R:+@0M'QCWY^O^2?\
M\4 5I( !D#_/^?RI@4)(<_IZ_P!/\_K0!2:#H1C- %*2WSR>1]: ,F6'_/Z_
MY_E0!1>$-0!1FM\X]1Q2 H/!@GN1_GZU(#3%Q_G_ #_G\* '+%GZ?K0!:2$-
MU[<4 6HTQU_S_G\OK5@7XQUQQ[4 60,\G_.>G\__ *PH <HST^M $JCGUS^/
M^?\ /XJX&A;.5_'W]Z5P.GM+G'^?\_EU]J+@=59W/?K[<<U:9+1LH_MQ_G\:
M9!H  ^^/7^?6J 5H,_3I_G_/Y=*!D$EKNS_A_GZ?TI,9E3VV.WTK-HI&1,FP
MY_I4V*N1GZ\Y_/\ S_A2&-% - RX//3]/UH"PHCSVY[^_% A'4<G]<?Y_.@!
MZC()]_Z?3_/ZTQ#2@ R/R_\ UTP&DX_SV]* $";O_K_YY_K0!&X"C\>U #/\
M_EV_6@!K'\3]/Y_Y_6@!#QUXQ_DT@%+;OQ_ES_G_ !I ,W@]/2@!A/O^/'^>
MW\Z8%=Y,D#\/\_YQ2 IR29&:0$#DM0!3:3MUH AD?- %/=G_ /5_*F N: -6
MV?(I@=%;<8]*8C>M^?\ /^?I0!OV0Q_G_/\ ^N@#?MQ^'^?\^](9M0G')Z_G
MT_S_ )ZD M 9'TH %;'% "CCJ>.O]?\ "F(Z+3?F_7VJ@.KC;CZ_Y_S_ )-
MB*9O\_Y- '.7RYYQCUI,9YEK3$D_6A <YG\_KWXH 4<C_/TH KRKQ_C2 RI1
MGO0!0DZTP("=M( \S'_UJ0#6<TP/JJ*1D'WN2>3W)_S_ #KZD^7N*]S(YV*V
M,]3Z"@+FQ!>_9E"@<#I_GO2L4I6"?4!=D1IQD_,>N!_B:+6!RN=!;[(P!D=
M.OIVK)FR&7+"X=8QC:OS,?Y#TZ]?:A:"N3A=Q/K_ )[T#&6<7FNSGD [5^@Z
MG^GX4,21I28B1F/& 32+"VM-BJ#P<9/U/7_#_P"O2;!(2Y@5RJ=F(S]!R?T%
M"8FB=XL]J:"Q02W$\G3[O\S57$CI;:U"^U9MFEB*:R^UN3C*KP/<^OX?YZ4)
MV%:YF3EK-MPR*T6IF]!AN/[0.V(D*/OG/.?0>GKGTXXJDK$MW%EM5C7Y1@#M
M5ID-6/-/'=D'M7)Y7'XY]JU3,;:GS=X<O,2[CU]/0?C^H_G5Q,JA](>$-1$;
M*F<;ACGU]?PY/ZU-6-QT96/H"Q4)&%0X4  #\*\UGKHS+N8W/R1\'^)O3V';
M/\JTBK&<G<Y#4+%;;E1R>I]?K71!G--6,)<*Q'8_Y_S_ )QL9&E%<^2NS&X]
M@.WUS@ ?7\*SL6F<_%J$]H[HR@\Y4+R>O3GVXYP!D<UM8Q;L>G/I:W$9+,)/
MF+ 9RJ^W^UCH&('L%J.:QK:YFV<[%7A8D#*X)R2 6 _0\?B.]:25S.+Z%7Q?
M=B&YCD )95=F [$X ./H3TSQ^-%-#F]3Y@\?>)UNW,(?#-_">&ZG/'!'Y?SK
MHB<TMSZ!TW43=Z59S(NY6MHU9AZJ #^1ZUA;4U>Q;TN\6%4/S$@#HC'G\JMH
MF++,6M"%=@BF)#./N;?XC_?V_P#UNF*CE'S'*:QJMQ*4VQ!<L/O..P/9=WUZ
MUO"-C"4C%FO;IU;+QJ,'.U2WY9=?3O@>U:61%ST6UT![^$>:SL2,Y+LN<^R;
M1T]OQ-<LIV9U1C=&3/H4%NZYB#'GEAN].[$\]?\ ]54F2U8U(XF9<<A0!QV_
MS^%)L=C$*,7D R1N!'_?M!_3I5DDJV32'IQ_A_GI^E.XK!;:5)&BK@G"@9]<
M"E<87"1VRDRN%&5SN('!(!Z_7)[ #D@<TKA8FAGLY>/M$+=\>:GU]?\ 'CUZ
MT78[#Y1 'B') <],L#\C=AU[= 3CGH"15F(W[?4;>$?ZN7@_\\)OZI[?2L7%
MFJ:+T&L9EW)#*P$> " @)+#CYBISC)['@].2,FC1%W4=9N<Y6$;SQ^\E4<#@
M<1J^ .P& /09J$K%WN9EE)=2,Q,4(.[DB1V[#_IDO;'YXZYI,:+UQ-=1HWR1
M$8SD2,N"O((!3'& >H'K4#"YFD63=)$5!Q]U@P^F#M/\Z:!L;8Z;%=C<R*Q;
M)W8&[DYX88;Z8QQT]*<G8$6SHH1D5&D0!CSN+D_*>/WF\?H<=MM3<HLIIK1<
M^?*?]X1=/3Y8UHN.Q4NM/D<N&:)D.W*O 6!SG&?WH!Z>BCIUZU2E8AQN>;ZK
MX6^PL7LXXX)&QA[=FBX7D@PMNB/&><E@,],5T0D82@<E=^)I(9Q%JL4C <-<
MP)N.T X\U(]P^4E2&;</3:3QM<SY22YNY-6!DBFCN(%P$$1!<=>'C'((X'R@
MXP>%(&=(LPDC0\.>'_MJM=SD(B ,V<JP[A<'YN.AX +[L#M3<B>4LZEXDAM0
M1'\V,@ ?>8^@S^&2<*O)8@9IBN>=W,\;.9>%F8?-(F,GV)((95YV!PV!DC!-
M4A'-74MQ-@,RL >XVY'H<%@/P'3L.["Q625@=KHP?MCYEZ9SE1D#ZA>?;.$,
MMBWD?Y86 '&6V%BW/LRX_D/2DP1RNK^+[?P_N0%9[K& B9(7GJYR,#/& <\?
M,T?WAC*I8VC3N>:7E]=:XPDNG+8& N0<#TZ< ]#M&3QECUKE;YMSLC'EV/:?
M@VS032A<_*@;.2>,XP<DGGIVY_&B)-1'V9X?G68 CO\ T_SCVJ)%0->^D:,E
M8%WM_%Z)W)8^O(.S[Q'H.:E&C*<=FMNN!R6.23U8],GM],< = *JY*1S>MVI
M. @_>Y_=^Q]>_ '+#G@'C.*UBS&<3@IPVD7."?WN S/_ ,]&[MC)QR,$=@ .
ME=*]Y'%+W6>KV&K?VJ@6$A9< N?[B\_-CN3C"C(R<GHK5R2CRGH1GS&O!:C3
MQ^[^YDE@<EMQY+=.2>A'0#&, 8K&]S<T3,D:AF8;3@ D]2>F/7/;N3C%2,YB
M]L'F8R8,<9ZQJ3YC=MSX^[Q_"GS8P2P.5K12,6BK'9I"NU %'!!'\R>I/?)S
MGWJKDV+EE<E#Y3GO\I]>_'OUX]>@Q6<HFD6:+Q'&"0?[I /Y8J#2QGS3)#]Y
ML$>M6B&68=520$+EW'0(,Y'KZ#W]/6G8+DALWO,^<<*>-BGMWRPP3^&/QIW$
M3VRK /*( 7M[_P#U_7OWI#,^_L N64<<U460T9\&HA6QG/'/0X/H?\\]LU5A
M&I;W #$@C#?3K2L.YJ)=*H^8@?4TQ$%K?(NY <D'MSUH%<@O)WE!"H>>F>*I
M(ELJ12SRJ.%7UIDD<T<J[6+]#V Z?C3 T39@_>9C^-3<JQF2:>BN< \\CDT@
ML4&BD@<C/&!UH*([AG .5_+FD L%RK*.<?7BIL,GC;+GG/>@9'?0JXR0*:!@
MUL<<$\^IIW),N-7M<C&1GM5$;$T,X=SSU%4*Y7NX &!Z>^* ,!X/(F!_S_G_
M #]$P.KMKS=P>_\ G_/%9M&J9EZE8B[R?;&/\_C0-H_/7X]^"CI%S]JA7Y'&
M6]C]?R_#ZBO,Q5.VJ/3PM6^C/EV7GFO.:/1*4A]>E58"BQI 0-TI,".I 3-
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M"+T9SQ]/\_Y_K0,FVY/U_7_//_UZ %#>O_ZJ '!\]?\ /^>E2P)XI,_7^O\
MG%(#2MY-OX?Y_P _7VI#.@MK\GJ?Q_2G<5CH;6^R>3^'O6B)9OVUR'&/\]*H
M@T5PW7O^?^-,"8*/RI,H@FC!_K_G_/YT@.;ND[CI_P#6]_TJ&BC)8A<C\?\
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MWUX/M:+;H)-V2S9(4$8Q@J>3D@XZ ]>HK5+34R;UT.*U_4, RL=TK;RV1@
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ME492. >#0%S5DPWTI 48EVDKVZC\:9(EPJE2N0#BF@(X[M'4'=0.Y2GNU&"
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M3OXZ_P">?KW]:X<5"ZN=F%J6T9\)F/UKR6>P59$V\U(%4\T ,QBF PF@!I-
M#2: (B<T@&DXH C:F PF@!M #:0"9H 0&@!10 M $B+NI@:=NF*0&];Q=*D9
MOP F@$=+:IM&1^'^?\\?6E<:-J&7(]N/UYI%EO[43_\ K_S_ )XJ;@(;C _S
MT_G3 C:XY_\ UT7 8)B./2E<!YN#D#I_G_/I2&-%P1SGT_PIW$(;C''/^?\
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M&@#8D0R99/O>GK]?YBD,C>[2+ 8X/]WJW'7Y1S3 P-0M9G/GPIMZ<,<$_P#
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MWK_D]OZ>M9M%IG,W"[#[5!I<@\W\O?\ R:E@B-IJ8RG)<8H)*DES[T"*CW-
M%9KCF@9#]HQ0 >;GZ]:!#!)_]:F UGQ3 424 -W8I 2!LT@%"GTI@/9#0 @0
MT@%V$TP&B,T 3) 10!<CAQ3$;EG$2>E '76*[* .FMDV_E_G_P"O0!TULN>/
M\_Y]: -Z+L>U %].W:D,MK]* "0X_*F(A- &W8#)X_S_ $J@.HB3</;/^?\
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MPY(8W)/7H,]<#_'Z5K$QGL>W^#YRERB!N'ZCUXSBE66@479GT[92$J-WO_\
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M!/8T"V,+4G>>3RHL@A1N<?P@YQCKECZ?P_>/8-:,WJ6HX!#@( N!@+T7:.@
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MV\]/KB@"SY';'^?\_P"%,8TPGIC'K_\ J_SS2 :T6/3U_P#K4 -$1^O^>O\
MG_"@!OEX- #C$"?\?\_XT -,!'^?\_X4 0-%CWH %AW<_P">E #3%^?Y_P"?
M\\T -:+;Q0!%Y6* %V9_S_GVH !#G_\ 50(/(/\ .@9&8BO/KU% #O(_S^%
M$R1%>M("[&GF<_Y[?_KXI@6(HR3[_P"?PH NK!Q]/\/\_A0(#'V_S_\ 6H 4
MQY'^?RI@1K&203VIL!_V(MZG_/\ GTJ0(WT\@_\ ZO\ /^%(8ITT]C^?^?\
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MDVC@'BG<5B6VL II@=-;6V*0S8B2D!<#!:0%.5P>M RF7!H$3J0*0$R,%_\
MU4%'DFGJ,F0@C/2OIFSYI(UFF$2YZ8]JDHLV,?DH,_>/)^I[?EBAC1<RD8+'
M\/K2*)H(7C QUZ_C2&B.\=D0G )/ 'O30F101?9U /WNI/J3_G'T IDH9<S
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M0!S<T&#029DL>VJ&9LBXIB(",4@(&&* (>M,!IH ;UH E5<T 2A*0#@N* '
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M"Q (XIB%%CG\?Z_Y_P#UT 7(H G04 ;4$(6I UX%]J -FV'0?TH UH\'_/\
MG_/I2 N(N.G^?7_/]<4#+J\\#_/^?\]J '?C_DT (%&,?YZTQ'0Z7'YA ./\
M_P">]- =YIB%OIUI@=?:V>0./_K?6I V8K,4 0W%G0!GFV"FF!.C^73 :VHJ
MG4X-("F^M)_>%("HVJJ>X_S_ )_"@"+^T@<<T#)TU(''-(9<74 >^/\ /X4
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MX)_0_P"17H0=C@FC\^_&FB'0[^6) 4YRH^N>WID-[_T]")YD]SG(;PAE$@P
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MP6;YB 0JX99!2T)>H^RB:TC*D?)RP;).">SDY+'I\_)(QGD%B]Q6,>]B\]"
M2#U!'4'/!_KZ=NA-:(S9CW%]$1\[*A[J2!@^G(&>G!Z$8/3%!!<TF43NQ4@Y
MQD@Y]/3Z4,:9?&HI"3M!<C^&,;B&ZX..%SU&[ '.3TJ;7*O8Z#[*VI -<;=N
M,K$O*CW9N-Y[8P$'(P_!&;T-5J:D5P9?E8C>!^!'8CV]NQJ30Q-5FY\M1O=@
M,)['^)C@[5XZ^O ^;BKB9LI06O\ 9W );=C>YP6)48&<<8XR,< DYY8L;;N+
M8EEDW?)&1O8<=PJX^^<'IUQ_>;"YYS4A<LPV20]CG<26S\Q;H6)Z9..F-H
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MOJ.X_*@")K09((_S_GZT )Y'4?3M_G_/X4@,NYM-N<?Y_P _SIC(19Y_^O\
MYZT 2K; ]J '?9#_ )_S_G\L #_LWY_X4")(X2O&,T :$$>!C'2DQEN)-OI_
MG_.*0C5@'^?:@9HQBD!<0\4 7(ACU_S_ )]Z ',H[?Y_S^GO0 ]%SUX_R*8C
MJ-)0?Y[=*:$>BZ:O3M0QG:6B=S2*-< "@17GXH&9,I%!)C7<^T4 <-J=_C*@
M_P"?\_I0!P]WJ# YR:H9CMJKJ.IYH$-3Q!*G\1_S_DT")!XEEC_B_P ]*3&7
M(O%LJ=_UI#-JV\3;#R/Z?E_2OI>4^:4CH]/USS)"2., 8SZ__JJ;%IG40:BL
MG48J32Y-9J F>[<_AVI@BV[")2W^?Q]J0,?;0;%YZDY/^']*8(KW:^6I/X?Y
M_"A$L?9V[0H!WZGZGDTFP2+\TAC4G&>,8ZU)9HVBB%%7T')]3U)_$U++1:N7
M\M,_Y_SS4HHFB3RU"GM_/J?UIB*EX_DJ2O';ZTT+89',8AANH'Z__K_6G897
ME/V@JOOD_2GL3N321"(?7BB]P:L5]6(2,^@Z_2K@]2)['RGXI&V]\SHS[2WT
MP,#\OUKV:6QX-;<]9\(2,2 HP".,^H_^M7/5.BB=%K]@TL9RQ(]!]*QB;R1\
MV^.].^P%9$Y7T[Y/_P!>MS$S=$G692.AQS6\3FFCZ%^'%]Y:%#DYQ@=\]/6N
M3$1N=F&D>W& VR[LY+ ;O\^@_P \UYQZ9P>MJ"<]./;_ #_^NNNF<E0X6(R:
MJ?D)50?O>I]!6[T.5:GH.F0+;Q[4'0<_7W]ZYI'9!&O:2^7@'IV/Y<5FS1,D
MNE_M4%5.(^[=S]/\?7I5)V"2YCG(M.^SS+%M&W/&>X_Q_P YKK4KHXW&S/G?
MXZ_#L7F;ZVR9(5^=,9+)DDX]QDX[X)'>NZC.YY]>G9GQS$XW,5Z<#]#WKM6I
MP%Y+=0=R$H?4'M]._&?ZT D?1/[,6I-;:K-&QRMQ;R'/3'E\#@<<CT_E7)B(
MZ'9AI:_>?7KWJQL0 Q!/4*>#]?>O.L>I<MF^"@-M8LI^Z%Y.>.!GU(^GM2L.
M]SI[=YYX\!1%UP3\S_ERH/U+_P"[6;5BUJ.TBSCL"\8!+9!#MRQ4YX)[X((Q
M]T#' S0QHUYE612I&%(Y XQ[CW]*DIE.+<PPWW@2#CID=_Q'S>V<<]:H@I;!
M%,[8^\BC\59\_P U_P ];Z$=2C(JWT@60MLQ\VT9)'Y@ ?[1X&>,D@$>BT#?
M<VX+A;Q%= 0".GI[9XZ=,^U9LV6J*DW[F16;H^%_$9*_S8?E31+)9(>U -&*
MSC<Z="I!'KAAG/XMN'X=,4Q%%T)Z9XQS_P#7_KVH RX(,1#OM^4D8/"\#G)/
M0 ]2?7FJ1)SNLW$(1XY)8URK#YF4=NN"?QK1&4BE9>+;>9%8RH2P!*AMQR1D
M@[030U<E,BO]80 .!*2C*W$4F,9&[EDQRI(X-4D)L[?2_$+3@ 6\O3@_NU_]
M"D'Y^M8R@;1G<N7=Y<1R)+Y.W/R',B<GJO0X[-CUR>G>+&C-9@UY\R+M.,;6
MX]^JE^/PR?;&*G8;U.?D+Q2C?&V7  *LI7Y2> "RMU.?N@>YK1&;1:2>-/O;
MUY_B1@.>>I&.N>XI BK;/ Z!#)'\HV@;AD@<#@XX(P<<^G:F%BW<:,)(2F,C
M;SCOCZC';'3\C33L)Q(HM&&&V]7!YZX![_UJ^<7*65M?/4':0",XVGCV/'4=
MP>XYYH&,@>VLT6WDE16X !==V0>H!.2<C(]Q^-2Q(ZW2=2,C;1$1M.&+@H,>
MJJWSMGCL!U&_(.,9(VBRX=/\UA-*Q:9"=K@8"9S]U>< Y^;<26X!; &)N:<I
M#O,IPXP<$=>"OJ#T ]<G*G(Y&&+$,$K:DI\O"Q8P)#R6)Z[%],'AVX/&$=#D
MO86YQ,^B);MY<Y:9<;1YKEP<?[!.S.!G(&3ACQ@YUYKF35B6"U2TXC 0'C"
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MQ)>,8&9#P1V_/_/6OG&K'T2.?N7!SZ4AF++'UH),BZBR<T#,:9*JXS-D'6I
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M2%7;]YCUV@=QU)!^51EF*KDTT*16LX-C$RC,Y!+'D@+G[J'^X,#/1B<,P!P
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M>I[?Y]*!LYZ=C,-T<9)[Y^4#_OH GZ@?G5(S8Z%O.&UQM;ZY_P ^U &9?/\
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MG%<?3GK^?'XU2$-^M4!KVV%Z^W^?\:HDW8R#U^F?\_T_K0(MJV/;_/\ ]?-
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M3[3'DDDXY&:YDSKM<\D\2:1O238.5_EW(]/2NE,Y6>"6UR(G8< @GC'Z>O\
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MDG[M/E=<$J1@@$XY'K[]Q56(N6&LVN5+JP)7!*XP:8&=-'L(<##+U_S_ (T
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M3_\ 7]10%RP+8H/4?Y_PH"Y>2SY_'_/_ .KZ^M 7)/L6>: N2KIV_P"O^?\
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M6.<?GTIV$S0C8J?THN27$?&2.E,"QNV=>W^?\]Z0[DF_=^'^?\_G18JX_?\
MY_P_.D QAG_/^?\ /Z #MN,4 ,D^7GT_S_\ K]Z (,Y- !NVG_/_ -;_ #S0
M!&KASQ0!85LD'_/K^7^>U)C+H.X?Y_S_ )_"D(M1/Z4BD: - 7+2&@1,/EH
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M);DDY)).:=@,6X\60R?NXP)'8'" CD#KDX.%]20?10S%5+L*YI6JL@+9#LP
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MN0:Q:.A.XB_-(3Z+C\R/\* '.N*11#:OOW,>YZT#3+4\FQ#W)X^M(=QZP^6
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M $N<LY YVEV);D< 9QDUDU<T3L==;WJ7:AE(96Y!'((Z^]9-6-E*Y#<P88.
M2K8#=>,=&QSP.C>QR>%IK4EHRKF7SUQ"&FW@X*8QZ9\S(12#C@,6!Z"C8"&W
M,KDK*RAL<! 21GOEQAATS\@&21VJA$\=BJX$FZ53UW?, <9SL&%QGT&5XP,
MT7&6'T^)!NC54W#(91CC/!X_0COSGBIN.QMIK@509S@@'GN2!G/OGCIW//)-
M0XEJ9=B1[].OEAB-I1@6P,D[G&57.>1&68<8E'*TMBMR)K1(5,39V%F*X&-C
M'GG P<Y/SD!CCYRS')+@T<]'FU?@=.&_#K^(_P 1Z5H9V+6%;!8 NO0D<\=.
M?\XZ\9.9&3A\\9.WTR?S_P <U28%3;Y+;1G!'!/UY'L/3D\9] *>Y%K'0I/'
M&%.&,H ("8W88D=#P%)& 6*ID<L,5BT;7)4C:Z*^?C<O.U>4R#PW/+LN.&.
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MK0%BH;< <>G^?2@$A&MSW[_Y_P _TH&0F @<<XST_P B@5B$Q]?_ *^>>_\
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M[/P/XNF\P0W,C/G[O)"^P90<MD''S;EX& #C*BS243UOQEX&A^(-B;:(+'<
M;H3T!8#[C=,*0=N>BDANJUNX\R,%.S/RF\6Z=_94SJP*L&(VD8.?0@\@CD$=
MJ\BI&QZM-G,P:A-9;A$[1AP58*Q&0<@AL8W YZ'*^U<YTE*WNWT^198SAT((
M(X.0<C!Z]>_6IV&U<^P?A?\ '@^#;B-905L;TJ[QJ %1_NO)"/FPX((9#A64
M <*8V@[*57E^9QU*/-ZGUWXS\?+:1K;Z;=-)]JC#M(I7"Q/PH7:BX=QG=R#&
MHY7+Y7Z'"T/::O8G#TKZL\JL^5 ]/3T' _#_ #TKWDCV(FNL?3]/\C_Z]6BQ
M&>K2 :Y+55AD,B?Y^E R73]2FT.9;FU;;(GKR"IZJP.,J>XR.Q!# $85:2J*
MS,:D%-69]2>$O$MOXFMQ/ HC/W9(N,HW?I@'KD-CYAZ$$#Y>K2=-V9\]4INF
M[,[( U@08MY,@;8@+D]E[$^IZ ?YYJT9LQ+O3Y9NI"$=EY_4X_E_]>[DV)[:
M7"[7Y _,=:!%ZWMPI4@Y4?H357)L:\B[AVQ0#,>*S67<>^>H[4V)(IWL+1;<
M'(STQ30F5GFR/F&/\]J ,Z2+RV$B]P,X[U+*1<N+@.N1CO\ Y_SBD49FFVY5
MR6'#=,]N/K_]?ZT$I%;7;#[)\PZ&FA-'#R7<FBL)%'&>>OU]*M*YE>QZ=X>\
M61:N@3HW'!_'UK.<+&L)W-'Q!X:378#&W7L>O;^5<E2"FK'93GR.Y\K:YH;:
M+*T3]OKV_3_/XUX52#@[,]RG/G5S-@AW'_\ 569J:,4>!_\ 6_S^9_.G<1)(
MF/\ /T_S_P#JI#(O+'?_ #_G_/L 1-%GZ_Y_S[TQ%21-V<?X_P"?\]>:8%9T
M_P#K4 5<8X_SP.E $+ ')_S_ )__ %T$C <8_']._P#GU[F@"6-<#CI_A_\
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ML%Q)C,_$:A0/O$X+..X1>GT+D'=P8]N<@$"::D:Y1W8, 268L#GG(SP,]?E
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M_K7'.!VPJ#/%/A=?$4!90/- X]>G\_Z'%<%>ESH]&A5Y&?-<MNUD^QQA@?\
M./J.A&*\-JQ[:=QZ2@>GZ?T.*0QK2AAGOF@"(R9X'4=?P_SC\: *SR8!Y[?Y
M_P _3IB@"I,X;_.?\^E %(RXS],=?RQ_]>BX$3S<<GCW_P __KH$0O-@9/\
MGI3)(Q+CGTIC'K)D^_KQV- K%D2X^F>.OT_SWXH LI< =#S[4 6HK@ Y/3]/
M\\?YXH OI<XX]J!W)3<CUZ=_\_R^OX Q3< _U[8_+/YT 123[N>: (GN.>/\
M_P"?\BI K-<?YQ_A3L!!Y^!S^>>?S_G2&57E'?D4@(/-(Q[<#\OY=?\ /5 0
M/-^(_P _3T_GQ2 J23C/;_\ 70,I2S<4 47D]^?K0!4DGYP#S_G_  QWH 9Y
M_P#@!]#_ )^O\@!5E#'KCW]/P_SZU5A$HF'!^G?_ #_*BP$)N0.>W^''^?\
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MLY.8;3[_ -?\_P!*LDH[\<#_ #_D4 3*I:@1I6VE2R<XX[9_SS0!>DTR2,9
M/_Z_S_7% &1*A7M_D]>] &---LS_ )]CS0 R*[QQWH THKH/_GB@#1AGQC!_
MR<4T)EZ.3=UQC_/TIBN6OO XZ\_IT_S^M24)C)^O^?\ /I0!=C7WS28S0C^:
MI&C0A7.,\?Y_I0,T$3BI8$RG;0 _<3_GTH 4#\?\]:H3)U.?_P!7^<_S_*@1
MK::=K8)XQCK_ )_P-,1Z#:R9'IF@"P\VT?Y_Q]Z ,.]DXS3 \VUY^#V_SWH0
M'G<@R30P J.#_GFD C"@"DZ;C_D_Y% '2Z3I>X9 P2?QQ5H3.ZL])Z<?Y_S_
M $JB3IX-&W#IQ]/\_P"/Z4P)WT,+V]?:@#I[*X(F([%?\/\ '_/2O>/ 9U$<
MHH&-M7"LX]_YTR2\P$@(/O0#*=HHD0?E38)'%>-O#$>JVT@(P=IZ8[U6XK6/
MDW6M#.D2[2..,<T-6)N8TN"!WP0?UI =KHM[\OEDX]/_ *]:IF4M#Z,\(ZL9
M %!_"IG$=.1ZM#=>841_7/Y<_P!*Y['7<T6H&9ENOSR$>HS^M D274F(SGK0
M-LOI$ H'L/\ "@"H(R)1CH%/ZTQ%R1AM..N*0V>0?&33OM6CR]<JA;\AFNJA
MN<E=:'@'P4N#);R(3A4G_0A3_G\OIZLM4>-#<^Q])0*!Q@?Y_P BO-F>M SO
M$$?/U%:4C*ML>17Z8@?/J?\ ZQKT6>2CRKPJK"Z0=RV!^?\ GVK-G3N?;>@J
M(HU4]0*\:IJSVJ2LC7G<SG:G3N2.!62-64_LPT\?+]TGGU_&J%89<1+.I!Z$
M529,D>67J$3;>=@ZGU[XS^7ZBNV)P-6/2[)@ZAT].E<K.M&IM#P[GX!Z55P>
MQBZ<4GE07(. 1M'^/^'3ZUH]M#*.^IY]\;-0.FJ98_XE8*.>26 4$?2MJ&QE
M65V=MID?V&SM;;^Y#&I^H49/YYK-ZLM;&=N",1^-605?[2$+[(QO8]0.@^I[
M46%S6+TL4ETAWMMXZ)_4_P#UJ@LT;.S2 !D')&<]_P Z5RD7?*,4@/\ >!'3
M/3G_ #[U-[E;&RD6*DHY^:7[%(6!P5.1S_GWJTKD/0UI(FU)=S/M7.0(S@D?
M[38_1=O^]Z+8=KF*8UT.0,ORQMA6 '  ^Z?;'0^Q[U?Q&?PG2+*NW<2,#G)/
M'YUDT:7*#ZHK_-$K2CN5'R_]]=/U[TK#N0W4KD$&$X/JRU0C.M;YXR5>-@5[
M@J>.QX.?8G'K2:N-%I]66%MY5PC</^[; ;IG[O?@=^<>M*Q2D: OEDZ1R,#_
M +!Z'ZXJ+%W*D-R6'EF*0E1ZID YVY&[(Z8Z=NU%A%.[F>V.\12  <CY3QGV
M/Y5HB"U#J**P.<'T8%3^O?V[]*30&C*Q7$J$],X'<$YZ#\QQ[=":2&S1BN#.
M.3^N>.U2QHI1V@B 3KL&,]R/X23GKC@D]P:&PL075H+A2IR,C:#SQGC/U'4=
MP<&FF#1EI;+=H&(P[#YAZ,,A@?<'(],C\:NY#5SG-=LH+=2DK+&W!0$@,6!!
M4@<LW(!( )ZBM%(RE%%2#?<#,,3'('S./*7H#_'^\QVRL;9_+%7%8FFLYS$Y
M=@N/G58QEP1V$CX7/'0ICKDFIN.PLNA078W2#SCVDD_>'_@(;*KCOL"YZD9
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M&, 2@OC_ ($"'/?O^%<D\%&7D<53!QEY>AZ1H'CRWU<[''V>7CY&8%6/^RV
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MZ80*IPHP/3_/^>U.PKBG3Q+VHL%SD]9T?:-P'^?\DY^GYR-'FNH0=2/4^_\
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M<Y=J1ZY_/\^M(DY2>7)^O\_\\_A3()H%#'UXST_SC_(H W[:/' _S^'^?QH
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MYZ<*.P XJ+E6);6,Q,T>#C[R'L%/WEZD_*>W "LJCH0!@BTQ5%+MA5 )+$@
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M<9]A^7K3-HLZ%921CMU H*)T//\ G_/K3L!I6TIC(/\ *DP+[2^9S_GG_/\
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M &3?$X]!_P#7^G'KWH XZ^CW]?T_S^%4,XN[MBO/Z?J:8'/R6C9. ?3/^?\
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M>_7_ #[TRXG60@@#/!QT_/TJC0T%';_/^?\ />A@68SCIS^OY5(RPLN>?SH
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MMP>>?\_G3*%D.: .<U5!.K C((((XY!&",_Y[=ZM$2/.H)_M%V%)RT:<_P#
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M( -W]:8##<@<]Z0AIN_>F QKK&#GBD C7>>?\\TP 7AZ_P _\_UH :;G/XT
M)]JQ[_C_ /J_QI  N\<]?Y46&(+S\OZ4K 213@X!Z'_/_P"JF!L0R;>>U %H
M3YX'TX_S_@/8T6 =]HW<GT_R<46 A,Q<=_Q_S_G^8!3DE)'O_G_/TI@9[S$<
MTF!GO<9/''^?UJ0$\P]",= /Y?YQ0 &;_/\ G\Z &>:>Y_Q_2@!ZRD_YS^5
M&O8N6;_/^?>G8#UO09/, !Z8_P _Y_PJ&4CL[;(Q4C-B&3/^?Q_SVH&7U<=>
M>,T -D.?IVXIH#S[Q%=A!M_S_GM_G-60SEXIN><_I^7^>*HDVK7#=?\ /^>G
MK0,W8)L=_P!?;\O\_2F(O))M Z]/\_X_K0!-Y^.>OM_GTH J7,N>#^?^?SH
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M+<[62,J3QB1C@$<KS&/0X&>G P%K3<R5S2TZY#'#)MD7I\HR5[8()Y'0YY.
M< XS++3-%PT;;AR#][G/7G/)Q]1QGKG(P9&/COUMR@)Y;&T8;//=5 +<9R2!
M\HR20,D)HI,U[>1[L_O,A!@>7N!8D<?-M)#C_9S@X)8R[]B9O0U3N;#(LF1G
ME1AAGH .F.W'KC ]!BHN6REY/]I[=O\ JAR7!PQ!&2J/Q@'JSDD%1\H(;S4=
M[!:X]K46J#8, C")M., 9 4#:Q/;>W"]> 5I7N%CE]=CFME8SO&J@$;&D8*
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M^'UH C\PD^Y/ZT -\T]^/0T !ER1_G_/^10 "7G/O0 [S.?\\?Y_G0!.H)H
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M./N+(QD@_P"?\]..M.P7,>XA"?Y_S]:8KF/<-S2&8\[8Y_SQ_D^W%,9D7$X
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MB!Z8,/5F#=V>BZ<PX'L./3M[U9JCJK5@XXZ_Y_S^-)E&W$?T'K_GWK, EF"
MC@<8H PKRX/.#WJQ'.W=V!GUX_S_ #K.3$V<5JVM"U!8GM7)4J\I-SB!K7F9
M=CU_S_+\/:N55+F;9T>B7/FJMVP#?-B",@_O&4_>;./W:'\V&,_+6\'?7[@.
MG9!+$8W^92I#9/)!&"?<GG!]<'VHJ04U9[/<H\K\5>$SX=F!C+-;R9,3MC/
M&Y6QQN&1SP&!#8'W1\1F& >%:MK%[/\ 09RYM\_Y->385R1;0G_/I185QR60
M//%%ABM:>Q_S_6D,K-;[1_GCC_\ 52 @>'U[=?\ /% %81%>:8$)!7UXY_P_
ME0!"RGI^7^'\Z (L'_/^?\^] $JK0!:3D9],X'_UZ )T3 ^M &C%#GM_G\Z
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M)+'WR<G\L5++2-*4^7\_/H?I_G]*D;*%RG4?Y(-4B&8L8,?RDY(_D>GX]O\
MZU:D#/\ 5/N/1NOU_P#U=:0$LEJCG<$5F!!&0/7W_P _6@#;MTAG7<J)CO\
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MQGZ,6ZT7':YSPM5TE@B*JJ<[-JA<8YVG'3@?+[ C'RC.J=S%JQ7N8-[;^6!
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MZ4 =1;MM//''^?ZTK!<U3)^%38=Q_F ' [TAB";-  +C'UIV%<!.&_SG]?\
M(II"N7+>YIV$:\=WP.V?\_Y_"@"4W0_'_/\ GUI#N4YI]WT_S]13"YA7'S"F
M(H^1@_U_S_/^?8 F6WSU_P FF!H0Z;O(_P ^O2BP'4Z=I.T]/Y^G^?SJK"/4
M=(L/+%4!WEI:8J6!T4,.!2&+(A'2@#R*)B_<U[QX(_3R=AYP0Q'4_7^M#$BV
M\9<<GI2&062DH.?48_&FP)Y5RAY[4D.P6J$H#D]!3"PMY 70\\T!8L6R.%!W
M=0/Y4A"W:,-A/9A33$QQ;'!JT)F));I>))$W(YX/H?PJ[V,SX:^)?AMM"OCQ
M\C'@_AT_K^=-DG%:??MIDZN#T89(^O--:$O4^N?"NIJVV0=&4'CZ5M-7.>$K
M,]FTERTFY3PHS^)Z?UKED=L7<[B&[+]16%CHN16VV1W;Z#G\?_K50D.G7 .1
MV-"$+IJ^6J8_SS38(\U\9>(E\+ZF"Q 6X3@_[2G^9R1^'I7927,K'#6?([F+
M<>)VO,'=SV'^?\]NM:\ECF]K<Z/0M8$W)Z^G?_/_ .JLIQ-J<ST^QM]L>7P6
M/X@?3M^-<C.^** D\HG/ %43<:T)OEW-]T?='K]?\_E1L%KF-)<YX;J/Y59#
M9GB[,C[$ZGOZ55B$[G4:?;BR4[1P>O\ ^JLF[FR5A\]FK1L3^=7&1G)&IIQ8
MA 5VQXX_VO?_ .O0RD-O8UGG@"G #@\<?Y_K^-5'1$RW/%OC5%%:W]A>/@[)
M@N?]]2*[<,]+'%B5J>DFXD?85'RNN5Y[?2N9HZ4S0\QY%&5R?;C^O^<5FC2]
MS$U;P9%XUA:WO8U,9Z;N><=1^>,]1V(-#L]&"NM5H?/]E\&?[()+K%L1B%)Y
M)&>,\=?KD]S4JA$J6(DCWOPYI:Z%9B).#SNP,<_X 8K6UM$8W;U9T2'RE1_[
MK<_0]:3 UII-G)/ ]Q22*N8EQJ*,ZA,NP.WY<GD^^,=JJQ-S2@-Q*>R+^9_2
MI&5;W3@K .SN&7ID@9'? -6F)H33U6R8JHP#Q^-*0(KZA, 3$%+N1]W X'N3
MP!Z#OC@4D-LR;",H^9FWR#'7[JC'&T=CZG[Q]NE-B1URXQ61N4OM<=@?+=N3
MDJO4X] !Z46N',6UGFEX"!!TRYS^@_QJ!WN49[*3&TR<CIA0./S_ ,XIIDM&
M+<6<BD.)6&.HP.1W]_?TS6A ]K64C D!'NO]<\4R2>UDG<?=1B#@\GKWZ@_Y
M[4F-$PNY;5\>7\K<\,!SSZ_G]>]25L6)IY+A2OE$'MAUX/;T_P#U9HL5N0)>
M22C=Y+#U^9.O?^('KFF0-6Y96P8F^;IRG)QR!\_IS^=, N&=?F5'W#D?=/U'
M#=^G;FA :UI/YV"58$]BI_\ U?A^%0T4F7X;EK4[!&Q4YV'Y0,=<<MQCM[<
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M&.<_Y_SQ2*.7N^N* ,*9P12 J$8[?SI#+L$9D/L>M*P[FJD!'^?4U5A7)""
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M2&&.M,S9ZS\,/$GGQ^2Q^:,G'7ID?Y_ ^O&T'<YY*VI]6^#]4\Z/&>6.>/\
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ML>A_^O\ Y_G0(AW8X_SSQ_A0,:K].V/4_E_GITH$:4''^'^?ZTF,V(!GO_\
M7Q_G_/:1E@QX';/KC_/^10 J+MZ=*!$5R[+T/Y<?_7H 9%>.HY/([G.#^'0?
MYZ4PL;]G=@FM$0SI[>;?^7^?P_/FM2&;*M[]_I2$3DAO\_E0!E7<'F \>W\Z
M5AG%ZE:8!^O/Z_Y_QS4-%7.,NU*FI*N8SVI8_I0,T+31-^,G_/\ GI3L*YNP
MZ:(QTXHL*Y*;0@?Y_P _YYIA<JS0G'^/^<__ %Z ,>Y3U_7_ !_R* 9S\O%
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M\_C57 R]4UTI!*J#,ICD\M2/O-M.T>GS' YQU]JIR(E(\'^%-M(X=W4@*VT
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M1N<, 01GG(./YU>'W^1Z=+?Y'H'VH_<4@+GCU_+^O2O0/0B:MDGF8P/Q^O\
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MSZY_+H::)9REW&0>!_G/3V%,DSH8_FH&=WI=L<#CC_/--$G;V$1'_P"O_/\
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M?':@;1/;@3#/6DQH6%&B^0].Q/IZ?A_GH:0T:HCW 8X(Z?Y]#4ECX[U%&68
M^F:FQ5R)KP.=T89C@#A3@CZ],CUS[4("19I9!E%"_P"^<G\ES^()% BO=6[,
M,[CN[A<*#^/)'M@U1+(+54080  =1WS[^M,0YYDF!1<NWHO.#]>@]B:!CXYI
M6.)-J9SCNQ'MT4'U^]S^LC+#:<DPQ)N<?[3$C\AA?TI7*)K?]V3&  >,8 &1
MGV[CO^?>@1(YW @]>H/H>QI(926?@[N"IP?J/3]*NQ-SGM0UBW@;S"Z;A\K
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M33&36^I%>AX./<?C5)DM'3V.H>8 23^/YU=R+'56DIX_7T^M4(WH"&_+_/\
MGZT C8MXQWZ_XTQG5Z;;AST_K4L#J!8@ 8%2,S9;0+_G_/\ A2L,Q+JWQ[<U
M)1R6HP[012"YYUJ<.<\9Z_\ ZOI5DLXV[A Z]_7_ "?_ -7K3L(@L+3YLGOT
M_P ]/_UTT@/0].L\XP/\GUS3L(ZRW@"X_P ]Z+"N;4)S[T6&:,<&X50%6>RW
M#VJ1'):A:; 3_G^M)@<M+'R0:@8R*+=^?I0!?@./_K4P-6*7&.E,"5Y<=?7'
M7]*0%)Y=O6D ^*;/^?\ /_UZ11?CES_G_/YTAV+T<F*!FG;OM(XH$=SIE_@
M=N,?S_K_ )S5$G>65[QCM0!?^UDT 5)K[;_G\* ,R:^VFF!VLA5Z]T\(Y+4+
M-3*I'?/?V_\ K5I%F;B<SJ%@K>G/^?\ .:U3,G$Y:>S7S#SV_P *NY#10F/V
M<G/^>O\ GVJTR&94<H\YAGC /ZG_ #_]:@1;6]5!G- "6%Z SX['K_GZ4#.H
MMM0(&.M18I,Z;0[_ 'I@]B?UYJ&C2+.TBG)0_2LF;(U[#F)>>U2RD17 PRFF
MA/0I:QIJ7\+1N.&!!JD2T?GE\6?!DGANY=O^6<G*^@XY'Y_I6UC+<ZCX7>(_
M[7M]C?ZR( '/7'^>:WCJ<LU9GONF7809Y[?Y_P#UUFXEIGH.@-NC!!Y.?Y]?
M\\?A6,D;PU.I,SPJ3UQ_GM6=C8T-%U<0H-W?G\^?_K5+149'1RW2NA(I(NYX
M'XTL1H6L03C[LL6P\]U)Q_/_ #Q7?2E='G5H69Z?H9-R0Q^X1P/Z_3T]:QGH
M;0.P( XZ"L$;&!J)-PNT\*./J:TB3(\TN7!? Q[5UHXF00J8I?DZ'J?3^G^?
MI2EJ-'L^APB%0%Y+8Y]?\_X5RR.N!U5_B1$)&-@QCOT'8?0?C]*A&C.3E@>]
M8#&(<@GU..:UO8RM<B\0^7IJ^:6V(H&!ZD8. #P2><=,YQTHCJ$E8R]&D>>(
MW$@"M,<A?11P!GN>.O.:TEV,T42_[\,2/T]ZT2,A;NZ0 \_YZ4P9 ]^D@!R>
MO^?Z5-@N66U% <C.,>E+E'S%JVU/<WRJ2#WX _\ U4^4.8N0Q3,YQA>GUH L
MWVE&52TC,Y&#@\#CV%2F78U8(EVC:  >E)L20M[%L4$?PD&A,;1(L'FAF!"A
M%R6)P /P]>P[T7L"5S GFY5HU)VGD]!SUY/_ .NJ%<NWUM.I5F8#GH ,?3.,
MU!1:NE\U1S@\$'Z>M2:,SUNVU%2(QQG!8X(!'4#'4C\O>EL+<M16"0@@<EOO
M,>I/KG^G0>E*Y21>MF)&T_>'7_'Z5)16-\LQ,:#>>Y'"C([GI_,^U%A7&6]M
M)+\DCD8[)D<>['DGGGMQ2&6QI,+#&P$^IY/YFBX[%.6 =0!D'GCO5)DV,UX%
M5^5&&_G5DM%QK".49"J".G'Z?2IN.PL-G$XSM'H1CN.QI D21:;#&<!  22.
M.,^G^%%QHNOID4F/D4,.G&?\^]3<JQHVEO&1P@!'!X'7_#TJ&6B]L\L[UXQG
MCU]OKZ5(R5'#@8Z4#*L\BVQ+D@*>O3\_\:=A%%KW[3_JP6'9NBGIW[_@#5)$
M-E233?M9#2-EAT'\(_#O^.?8<FG<FQL0R@_+T(XQ_AGM29:(Y[F/[I;+=@O)
MSV./\B@=Q(;B23C9AO\ :(&?P&3^!Q2L*Y3N(I9AAG5.F"JY/YMQ^GK30F55
MA,RY=G8]^=HSGT7'X53)1GRVT5LPD5%"\!N 2/0Y//!_0^M4A-FB3Y1'IW%
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M4#)EGQWXZ_Y_^M0!9$YP/\]/_P!5 B;[1QGOZY_SU_+% R;S@/S_ %_SU]:
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MSZU@V=$5H6-*\4IHC-'+PZ\J<=0>>,?YYJ7"Y49V._L=2&J_.W1N<>N>3_\
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M_([_ /ZOZF@DXB_RN>.>W7_/?UQ^AH$<I.N>!S_G_P#5T_6@8GE#()]?KG%
M%E>,^O\ 3G'^??TH LH2G8@<?Y[#_.* )]Q' Z__ %__ -= "^8?0?IS_G_Z
MU #'D)'N/Q[_ .?:@"A-<>7W^GZ'_/\ 6@#)WY&/3T[_ (4")$;;SGI0,>,-
M_G_"@"<''3UZ_P"?_P!?ZT 'F;N1UQ0 \OGOQ_GVI7*L)YYZ4KA83S]W\_2B
MX6-:T?;SGF@9TMC,4SSGO_GK_3BI8&_'AR#Z^V.YJ2DBV@[9S042J-O7';\?
M\_U^M(#/OGXR#QW],U1+.6N')'?C'UH$9@_6J "?Z_Y_S[T 1MQZ8'].O]:8
MBI*WIZ^O^?PH SI%]/T^E $2DYSZ4 3 ;@!_G_/TJB62*03S^/\ G_/'XB@1
M;B.[I@__ %Z +2OGF@0\G;UQT_S_ )]\<"@!"W_U_KV_S_\ KH&,XW>WI_\
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M@#A-7TX@9QS]/PI >+Z_8E&)[5('"RY@.>:0R=;S P3Z\?7^=(#/>8QL??\
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M %>_^>U,DF0XQC_/M0!=7/0'Z<?C_GM0(?MXYZ_C_G_/Y@#&^7]?_KX_Q_\
MK4#)(U$AQG_/X4 =;I\&/7_/^<T".\L(QCM_^OO^/^<TF-'46PQ]?\_Y^N:E
ME&FI"C_/^?\ ZU("K,_&1QQ]/\]?Y4@.=O9.O/7K0,Y&]?\ /_/^>E4@,&8;
MO8?3_/\ 2F!F/$#^/]/\_P"30(6-<GGJ:!F_IT6,'KWIHEG;6*D8YY_^M_G^
M5,1UEIQ_G_/^104=?IJ[C]/0_2FB#M[5"!P?\_Y]:8%EAZT 4KCFJ Y?44QS
M5(1QE[[_ .>*8F8#GMT^G^?\XIF9KZ8-Q'K_ )]?_K_A2*2/4='@W8'L#_G-
M%RCTC3; -CUI =M;V.1G'84#)FLL=O:@"A/99% '$:QI_! I >,:]IFXGO\
MY_S_ /JYH \OU#2NO';^OK_^OUYI-#.$FS;L5S4,"#/F#GKZT@)%^<=JDL5>
M!0!(C_Y_E2N,T('Z>W^?\_3VI@S;@DV_E0(Z"TESCV_E28&M$<4@+H;WJ@'&
MX*4 59;TG_/;_/% &--?;?3% 'UI;MLD(]1G]?\ Z]?0GSQ>9-X(]J!LCLF(
M7'H:&A(6\B!*GT(-"!HHW5H#G@&J0K'+7-L!,OK@_P!:T1FRK>688< 4R6CS
MJYM!%.00.G^%:IF+&M$&[51)1M+7:[]>H_K1L)FW;0A3UI#1T^DD.@_SW/\
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M_G_.0#5@DQ]*H1MVTV._^?\ /Y4F!N1R8^E("PLN.?2J BEEH SKB<8SGZT
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M78$^_P#^NI OZ>N6S[>WK3*2.OTY2F/TH&==;DO_ /J_SZ_UI :\,>WC_/\
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M^/\ +/-5>2\QW:.\T?QM;ZH LHV2=,$8Y]O\FJ4[FBE<Z<Z=%<C<A'J,<_\
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M_P">F:"QX;:OJ/\ ']* '].O7^OI_/VJ '$A1CIV_P ]O\_A0!4<X&>?I_\
MJ_S]: *,GR]>O^>>W'^<52$RDP]^_P#G_)JB1RC=TJQ#T&<8'^3W_P Y_I31
M+)4.[T^GUIB)UZ9R>/7_ #]: $+>O3UZ?Y[T"+$"DYZY^G^?QH&=38+@\_Y_
M+_/I[ F=;9L!^/\ G\Z .IMC^?Z?Y_E4LM%F:3"XQV_2I;&<Q>2;O;G_ #]?
MK69:,%SNY_S[]O\ .#0,SW^0_I[]JH3(F./KC'X_7'UIDCF'?L:8BI(02/\
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MR0#S['%7T(-)K0S?ZQLCT' _^O6=S6PSRQ:M\HPI[#U_SBF!;=Q&,DX''/\
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M'J<_GZ_RHN!9^Q2]1)@]1\H_+- [%^"'S!EG8YXZX%2QV&/81Q'<%SZ]>?\
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M+ =;I$&W![<9XHL*YW-E.5QGH/S]?\_7THM<1Z'I-TTW3VJ@N>A:4V#GI_\
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M_P"?\^E*Y1BWHR"3T.:RD)GGNMVP(/\ /CG_  KAJHE'"-&2?;H.._\ +_\
M7Z5R#-S1),-QSSG_ #U]:T@,]\\/S$8[<C\_\_YXKU*9K$Y;XP^&EN[?^T(Q
M\R!5E/J!]QLCT^X?8CGU\?-</=<ZZ;_H95H=3Y,FM2G+=<G-?'N)A%DVD6%O
M=,PNIC$ I(VKN)([<E0![YXJ#6YK>!_$W_"&:E'=J"T:Y61<XW(PPP_#[P]P
M*[\%B/J\U+IL_1Z%)GW\CK. R'*, 5;U!Y!_S^5?I47=:'3N5[NQ2;DKD_\
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ME; 3',IWGTZ*/H/ZU-RDBQ&QB^0] .#[?_6H&073 J=QP.Y]*:);/-M0\1Q
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M-:JPAZ8Y'K^F.W;]?? )G$7SEB,^GY_Y_.J1)GX#<$]Z=@(?O#_'K_\ 6HL
M@!Y'/^?I18!YZ>_^118"L[8_^M4@9TK]_P"G_P!;VJK 4W^;_P#7G_ZWX_X4
M"(P,]3U_S_G^7:F F2HQT^O^?SH G)QVP/\ &FB6/C.WC_\ 5Q_^K_ZU,1+U
M]_4?E_G_ #F@!QZ\_P"?\_\ UZ )T..H_P C_(]J -2V;:?KU_SG_/\ ),#M
M--//UXZ\^O\ @*AEG>V?(XZ?Y_QJ&".DMXMXXQ_GI_G\*0RS+9[AT_R* ,J2
MR#Y^I]_?_P"M30F85YI^/P_E_*J0CFKK3=Q]<]J=QF+):8YQD#U]_;'M3 J2
M#:<$=.N.V"?;\/\ ZU %"9?3.<?T[?H?PI@8=QQZ?S_S]/PIHEF/+[^WY_Y_
M#\*8C*NWQ_G'^>U &/$Q4G\C[_2@:+*/0,FB?FI&;,3GKU_S[]>_3\*H@T5?
M?T_7\OS_ ,35 4Y5W'CID']/I5B+5K:YY/IZ9_G_ /K%-(EL] TR/:.O3\_P
M_P _7WHBYZ)HUL'(S_GGZG/_ .OL: 3/7-*LP!WS@=!_G\Z3+.@,.SCT[_Y_
ME2&=/HTNS&>GK_G\J3 ]+TNX[=^/Y5%P-R>\ '7_ #_G]*!V.=N+WK3 QKJX
MR"<\?2D!X_XN?<N>O^?\\XIB/EGQ7+EFQSG&/\_C^'KVJ&7$X1^?7W/K6)H@
M S_GT_SUH*+: ;1_D4 ///3\A_G_ #S0 _.>?\]>/\]J!,:%W?IZ^O?_ "*9
M))Y>_P#IZ_Y]/ZT /"_A_G_.?SH FCM\\_YZ4 3+"/3\.GI_G_)H $MO\_\
MZ\?Y]>M(#[%UBS! ;N/\FOJSY9EBQC"K@],4R33LW$3%< 9P1_+_  JD!T,3
M9&/:F(V]%O.-IZJ<?AUJ9(:=CLXI!,N#Z5D:W+5E-\H]J!IERZC\Y#CK2&]3
M+DRPR1VJB3FKAML_3JO]1^/^>U:HR9E7N2,;35HEG!W4>V64A3T4\?Y_S]*M
M'.S%NI .,'-:HAG-PW"AWSG[W?\ 'VJB2W)<* 1_^O\ S_GK0!/I%R @ /\
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MD>7ZC,9<HG)[D=!_]?T%=D3BD=%HZK&BX[@9]364C2)UL.(@K=!GGZ=_\?\
M/'*SJ0R]F65E 8$_7\*2*9%*/[/.[.%/7/K^-&X]C1CO(I ,D=.>]2T:)W)8
MKYFRBJ20>">!BIL5<>UL]P/G/X#C]>M%PL+8VZ1_+@ ^O//^>W_UZ 2"2$$<
M]#UH$9D=T$/ECYV'''\\_E^=,1,UJ]Q_K#@'^%<@?B?_ -=%PL/L(_LI\L<
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M ]#V_P _Y]L8[ %;^QL#A>>GIBG<"!]$_E_GT_2F@(7T0#/'X]_P)_SZ<XH
MKR:)@8'^/?/^?K^8!3DT+/&*0&?)H0;G'TQG_/O3 S9M% '3U/\ AG'_ -?\
M.X!ERZ(%)P/P_#(_S_\ JJ0,UM'P20,]O0_IW/\ D'% %$:4&/ _3M_GU]*
M1TUEHAD (R .OT[\?T_R,F:HZF"Q\K'^?3G_ #C_ !1:-*)!QZ#W_7_/:F!:
M;*^G^>W^?SZTA%%[GKCI]/I_G_)H YG5FW?0?Y_/F@3./DR2?P[>U6B"+MU_
MST_S_P#6I@5G3=PW'^>G^>E $8'/N#_GM_C_ #H 1GW?E_GI0!29LCV]Z ,R
M7YCSCGG'IQWH JN>V>O/^?\ /X4 -+YH F5@Q]O2FA OI]33)9.I_/\ S_6@
M"<#;R>@H =NV\4 2=?\ /^?\_E0(N6\NS_/^?K0,[#36S@#G\_?_ ".]9LL]
M L9^]0".PM7XZ<8';_/^<&AC.@CB4]/PQ^&/Y4@)?L>_T_S_ )_SW!%"YT[C
M&/R_S_GID47 P+K2P,D_YZ_Y]*H9S=YI>W/'7US_ )_6K$<I=V>PD]QG\Z .
M>N83%^7^?\.WZ4 <]=]"2/\ /U_SBK1+,"4X/Y_Y_KU_$]*!&'<8//% &.),
M9_S_ )_&@"16&<=^U T7(G/\ZDHV87SC .>WXU1+-F"(N ?7'X#VJT2:L-AO
MQGD?Y[_Y_3BQ&[;V.WGW[^O^'^<51FS=MHA&0!3$>@:(H4CU//\ 7/\ GIDT
M >OZ6X"_E_G_ #^-)FAL-@=,?E_GZ_G4C+FGS"/FI8';6FH^63W]?Q_S_GO!
M1:DU;/UIH1E37H8DYH&49;O(Z_Y_SQ_^NF!YIXJD,BG'>F(^7O% WO\ 3_/-
M92*1Q6WYO?\ SU]JR+) ^*"AX<'N.G'K_GJ?QQ0,D#_D>_X_YQ^'M0 A;GGC
M_#_"@"RK GKZ_A_GZTR"Q&N[\<_3_/\ GF@"VL8//_UJ +HBV]J0%A82?\!_
MG_/TH 5H0HY/'8Y_S_G]$!]D7L092#U_KC-?6'RYG66./R_'FA$L6[E\IPP'
M'\Q5"-FWNFZ8JA$UM.\,Q'][^?\ G(^M,3.SL9V8?,V*AH:.AL_O%2>O3\/\
M_I6;-$;B.8^E(T1.B"0<4@,2\@\N5#]1^E6B&C-N8<#]:I,EG'36NZ9Q[#_/
M^??KVU3,6CGKRQYK1,RDCB!9Y>3(Q\W^?7_/XUJ96*T]HO/';M_G\Z8BGI2
M(>WS'_/^??Z4 ;FW"M@]O\_YZ?A2 O:(SPHNUOZ]S2:-$SN(YW9#DYK&QLF=
M99SR* 1@\?B/2LVC2+/GW]H3X=#78'U:!3Y\*_O%5<EDR,]Q@CEP>XW+CH0H
MZ%/WM#Y-\-W36@!!ZG(S_GZ>W.<9KL@[')-'K=U<+K=OL;'3()_+D?YXK62N
M8)V/G6Q@;P;K'F#B*4[' ' .,9]^_7CK[9Y%'E9TN7,CW2YL/* VGD\D\=2.
MOTK<A,8EW]E&#P<=?RH)9=B'VE?,8?,1P3Z?Y^G&!ZBJ0BU;8VLV<!>/SI@<
M/X=CW>:@8[ ^0/KGC_/>L$;HZ,+Y)SN/7Z9I@=OH6N&S.>N>W_UNG\_Z5=KF
M;/I?P+XRCU!-AP"/0_Y_*L90-(SL>EW2_:$XK'8VW&+'M ;U% K'+7LJ[R&X
M+#KG'X?YQ70CGD8MVK6L<:,N1G[U:HS9;M80=PXYZ?Y_&DV"+NF6VQFP._TZ
M_2IDRXHZEU17&]LD#IZ=OTK$V-&&_;[@4GT/3-9M%IG(^(TF=,D[,'.!C...
MI_P__7<-R9['(SH(P .G^>:Z4<DB]IUT9!L09(ZGM4R146=;;Z?]HB.\[B/P
M'0?Y_P#K&N5NQUQ5RS/ BE"HQG'3_/O4EV+8TR.8?.-V>YJ+E\MRM%;"R;:
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MI$LYQ6R/KU_KCT_IZ]*HD1GQ_P#K_P#U_P#U\4P*3N<?YZ4 0AN3SS_G_/\
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MYV.Y2@BY&1BI*.RTUMI [?Y__76T#1,]&TR0I]?Y\?YQ]?RZX%HZQ'W#_/\
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MU:KV/-QE6RY>Y[>J@$$=3U_S_G%<!XIU&GJ(6/<$?Y_K4/49LA&W C 7_/\
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M7:Q (X^OI292(+V[C*XSD@Y&.>?PIH&00WLER#M3;C(RQ_I0*XZ2V>;AW]"
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M 4T0W<ALK=4)#G>XZD\Y].* L:4T>\$=L>@H&5H9\ @G!7KG% 7*\UY]I!5
M6/KVS]:8KC;:&6<?O7VD<%5_QH L-8+M("\_F?SI7&2P_O![C@_Y_P ]Z &S
MQC!SQ]3B@&9\.HB3A<NPX..QIDW'S0S7(P"$].YH!ZDT%FTRY9V/KVY_SS2N
M-(EDL$@(?;GL<]2/\^E!5C2C 3[H ^E(90N!Y+;QWX/]#0B25AW[#UJ@,N2]
M6)\@%L\';Z^M KEIHII^@"#WY/;\* W*XTSR6W.S,&Z@D@9^@]OS[T7"QI)
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M@8H <;G/Y^O^?\: 'BYQ^A_S^7M0!(D^/\_Y_P F@"3SMN* )%?(H DW=?\
M/X_Y_GF@!I'M_P#6_P _X4 498N/<_YX_P _TH$<Y>V^,Y'7I_G_ .O0,XO4
M+3//;T_EV_S]:: X*_MPO;Z9_#O0P.+O(,9S_G_.?\YJ6!S<ORGCO[_TI@0L
M_4C^GMV_I0 PDD<<F@"L3G\L_P"<_P"?P- %=N>F/_U?YQ0!4E/Y4 49%Z]S
M0!7ER_/?K0!+"/0?Y_PH U$7&/\ /^?UZ4 6T_S^OUH L*/4=!0 BMCZ_A_]
M;_/:@0,<>YH&,B8 X_SSZ>E &[;GZ_Y_S^G;I4EF_:\8_P ^G^?\\RQF[&1C
MW/\ G_/K^538"O+RN1W_ ,^_^?>F!GR,<>V/Z&@#,N6SSW_(Y_G_ /7]\52)
M9@RGDX_SU_S_ %JR2[%*0/2@"5F9?4?I_A_^N@"-I6'7V_SS0!6FNR/?_.:!
M%5[POWZ_U[]#_GO0.Q0NM0+C!I7*L<]<:BS<YS^/O2"QG27KL3S^M %=YF?C
MTXI#!(RW7MWJ0)Q9X_K0!-'9>@H E^RX]: )4@V\_P!/\YH&:5OD=.G_ -;W
MH W[9F&3_G_/KZT =':WC*.,\?Y]J15BT]^V/SXH"QFW$IF).?\ /6@+%6&V
M,S#W[U=R6;]KI87KZ_Y_I_\ KJD2V;<6E!<>H'_UO\Y__4R2>33>./\ /^?2
M@#EM0M/*/3T^H_S_ "H"YSS,4^7IU_3_ #[?6I+!%S_GC]<?X>U("P(]WI4C
MN/-L&YQ_G_/U[TBK@T9.2?\ /2@94,>#_G_/^?I3 U[*/S2 ._8_K_GUYR*"
M#T_2M/%L,GD^GICZY_S[BG8#>.%_2D!%-\XSQ]>E &+<KLYZ?A0!]<7R?+UY
M!KZL^61'YX=03Z"BP7,*YF\N16 ]C^/^10.Y;(9EX Q_G_)_R:I$%*R#1R,I
M/N/PX_S]*8&X+?>"">HQ^E @T\! 5]#_ #_R:9+-"4!P1[?E[T"%TNX 7 [$
M_P Z;!&HMP&X[D>U(=S2TFZ$J;?[IQ_A4M%Q9T2R;U(/I46+-*RN0R_3C_"I
M:*3'.JLV<]>* 9E7]OUQZ?\ ZZTBS.2.1MX2$/KD_P A6IB<]JL0VG([&M8F
M4SD(;8&,''K_ #/^>GXUH8F-?VJA&^G?_)_I_A1)+;0;57:<<"D,MRHVT?-G
ME<?G4C.MMHY%Z,/IBLV;Q-/,BNF0/O?Y_P ]:S+-?[1)#VXHL5<S-7TJW\?6
M<EE>H""2 <\CN"#V(/(/8^N34-6+4KGYI?$WX77_ ,/I2DZEX-V$E P"/?D[
M3[$XQT+4TQ./8\BTO56M9P/X3P?QHC*S):NCZ:T;7R459#SU# UZ5S@1OMJR
MS79QTV <>GY_XUC+5FT2CJ$IW[D!()YZ8_ST]ZP-B6WMR?O'G'TIH9V7AF-8
MVXQR>_TYK1&$CV733YC"HD5$]&TR6*WC#'&>3^O^?\FL&=")[C6O,!Q@#%'*
M#9B7-P&0?,"?K5I$2.3GE029SSCTK=',Q_VD2X10<YJT2ST+0--E+)A\  ]%
M]L^OUK";-J:.UGM"%W.Y.!]*YTSK:/-]0A$;MQC.,5U1.21F^;N("\D'\JHS
M.XL+(3$;^>G;BN>3.B".KQ]E92!@$;?3_/:L-SIM8??DE.?7_/\ GUHB#.;L
M'\MO?.*UD9H[ MN6L#<SA<+8_*QXZC_#O_2JL BSR77"#:/[Q_H/\_X(1';V
M2V[_ #?,3R": -N.7:/I4ED4-T+=\8&#R#_D46%<D;5DZ*"Q]NE%A\Q$DLCG
M:3L!SCN?I0!=%K'SQN/J:0[#(?W9*=AR/I1N(+@C'S8QWH0C(@U!I/DC4MC^
M(\#%4*XZ:P:YXE;((^Z!Q_\ 7]LT#L.M1Y0V  ;?;\C0"+3#>,&D,JI=K$N'
M/(X-.PKD$MV;I2L:$Y[G@>WK0)L@AAEF'SL% X(48_6FP+ALT5>!D^IYYI#L
M:,%QYB@_GBD-$-RX."!RIR* +$=T"-V?EQWHL%RE>:D@(9,LP[ =1Z?Y^OI1
M8+COMDLPX4*#SDG/%%@N9]Q S$.SGT.. 1V_*F*Q(+5(Q]T?CS0%BIO(<CJ#
M\P_E56),C5SOC;Z9_*JB1,XF^;?SZ\]#71$YY&/I48 &[ '.:T9"1T]A/$!A
M,L5XX&>G_P!:LI:FB.GT=I3(5V! QW*6/;'/ [_CTK*1K$[IM'2<?O6,A[$@
M #_@/^)/X5CS'1RG/70$;LO&5[# _$?7M6B,6CC=4N1;[N.OS?CW_E6J(9Y!
M<S><Y[?-_7_/6NA&5SJ?#MS'!*X+;F*K\J\MD9'09/IUQ43'$]'M'F8%0FP<
ME2QR>?\ 8'O_ +7H365RQ1IRA@9R90QP5/" GI\HZY]6R<]^:+@;$\) 4C^'
MH/;N!_3Z8Z$T;C($"S*3V8>O/_Z_ZT 9DFHBV<Q'+2#!VJ.3[^BGCG) 'J:J
MPBJRW$AQD1JQ/ .]_7&3E1T/ 4@8QG)!H$9SV<=G)YBK\S<%S\S_ /?1R<=@
M!A1Q@<U8,P-1A#,3ZCTZXX)_+'\\4RD?-?Q5\+KJT!D7'F0GV.5Y]R<8Z]^,
M^@K.:N;PE8^0[R%6&&/S 8QW]OZ5S,ZS M;IM.D/!"D '\.AQZ__ %_6M:-1
MTV6CN;+4EN!QWS^/3_.?:O;IU%,LUEE+8_/'7_/\^>HXK0:"8=Q^(_R/\\TA
ME-FV_P#UQZT#+]M/SUX]/\Y_R::*3.EC?Y>/7I6Z-$5+J<P88=B/\_G2;L)L
M[G1-0\]1GT],_P"<>_KTKJIRN:QD:\RK*.GK6K+,>0[#@]?\_P!*AL0[[1GD
M]3[\?Y]:FX )0?QZ?Y_SWS33&2K-@\&G<=R=;G//^?\ /%%QW)Q+0%R02X_^
MO2N42K-ZGV_.@8]I,]?\BE<!F_\ S[T -9QU']?\_P#UZFX 9?3VI7 @\S _
M#_/\Z3 KLVWVJ6(KL^T\'\ZD9'';&9N/\YK.1)TGAN5'NF@095$)8C^\Q 'Z
M;O?\JTH[_P!>A+,KQ1)X8^'R#6;J)+S4IW=XX6DWDMYA#[5(,<:(=PWNC'<I
MVY8&OG,9.-*3=KMOU/(J*=25MD>*_$;]H:_\3-&+.[EMXS&OFQQ PA7RWR;P
M[23 #:=S>6-Q91$H 9O#J8B51G1##1AYGM_[,UUJ>I)/-<3336&P!!*20)MP
M^YN)X"[M^.Y7.3BO1PT'%7?4X<7:Z2W/K[3[L'(]*ZV<"8^XU);9^O446"YA
MWUX]P">@%,FY1DDXX_$T 1I=9&3Z_P"<T"L4#J!.2...M)CL8DFI R9SD_YZ
M?K5)$MB_VM\P![^U%A'86.H>>,<T2129BZN?).[&,\?_ *Z^=Q5/E=^Y]!A:
MG,K=D8/VXGT_SUZ]O\:X3O'B^+'^M (?]NST_P _YQ[^M VA!>8Y!_S^&?\
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M (?_ %J ,V89S^GY8_\ K?G5",MS\V1U[?Y]ZM$,N1H&_P : ', G]<X'Z4
M491_G^M &=<+C_/^?_KT 5V7 X]^Q_"DRD94\>X?6D,QY82QH K?9R#C_/-
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M>/OA<9SSBF%RD;1PP,S9!.-B?*H//4CYB#[L%S_#R:JXK$DEJ(%'E*J8;.T
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M_P _2@3(S!@X_P _Y_7% B%K?/XT#(S:DGW[?Y^O^'7H!<K"T[#T_P _Y]J
M'_9\^_\ GZ_6@"3R\<'\^*!CO)!&.V>W\O\ /_ZP!"G8]* &8(YY^G]* '#Y
M ,?Y^G2@"2,9.#T_S_G\/R -R)<C^7]>GYTF4;\"''KZ?YP>M2QFU%R/\3_/
M]?QS4C(I^1^?I_G_ #F@#+?O_G\/PI@9LXXY].?\*H1FGKSU[9]">OO3)9?0
M#_/2F(2;!Z],$4 9SX?@=1GI^5 $#0[L^G^?\YH!#6M\_P!>.^/\_C045I+'
MCG'.?7_/3U_PH%<H26&#CMZ?YZU-ACTTX+C'I_G_ #_2@9<BM.W!_P _Y^E
M$_V7OS[_ .?\_P"" /LI;!(X_P _YY[TP)!9XY_(_IS0!86S]NG7I_G_ #^0
M*Y/'8\]LCK@?G^/_ .NG85S6M;+GMU^O^>>?P_-6'<U/L_8]N<]?_K_YZT -
M>'@\?_J_S].M)H9DS1<G/\O\]OY5!=QUG$ >?\_Y_P ^X)L[6UAW+QCL0?S_
M !_^L*LDNPP\YZ>GKC_/Z4Q,Z"WBSCTH)-E+?(]?4?Y__7Q5 <IK4)_3 _'^
M7X4T!Y+JR!'R,>I]NV1^O<]?K2$0QH6&/S[_ .>F/PI,LF$>>OT_S_GI4E#E
MY/Y'G_/![^]2(41;NQ'OG_/_ ->@9+%:D$?Y_P ^W^<NPCL]/7Z#T]O\C_\
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MN><'O6,F:Q1VH48K Z#/0YC8=QQ_G^54)F7$H$@X[8K4R-_3G\DE>QY']?\
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M?M>VRU/*Q&*<=$OO/L'S8[ (D8"HB*BJ,X"J-H SDX &.>>.M=21X[=S)O\
M4#*<#C-4(RKBY"CKDY^G^<T!<)=2\I<9[8_S_GI3L%S$GOFG&,D9_P _Y]?T
MJK$EG3K<A>G)_P ]?:DT([W2K NJX7T_SS_]:@1U=IITF[@?U[_A_GFD,M7N
MDSJ,C/>E<&B1=%EN[1U/.%/'_P"K_P#77/57,FCIHMIIGRW>W!M9'0]02#^H
M_IWZ?I7R<M&?71U1$+[=SD#_ #W%2,D6[/<]?0^U FAXOB.O]>V/\_XU0B\E
M[OR"?\GO_/VH$;$-WD#\??\ #]:"S?M9@?\ /^?ZU(SH+:3=W_I_G_/- &U"
MV<8]/\CO0!K1)GK[?ES_ )Q0!9$>WUS_ )XH$&W'OVQ]1_\ KH)&D'&*H"E(
MF?Q_IF@#!O8]^2/3T_S_ )Q0!Q>I1=?0=?S]_P!!^.: .&OX^,'T_P _G_GV
M8')747'7CZ__ *J0&')#S[#_ #_GWJK ,6'.>GI_]>F!'Y07K_\ 7_\ KG^E
M(1'Y(;IQQ_\ J[>U*PB"2W![?Y_R/\YS2 88-V?\_P"?\^E $1MLGI0!(+?)
M'^?\_P!3CI0 \6V[G_/X4#&M;YX_^M_G]:!D;0;>HH IFVZYH C>(KSTY_S_
M )]Z '1QX;![_P#ZO\]*!'06B;.0./Z^_P#G/XTF6C7M5Q_^JI8S<B!QZGM_
MG_/\L2,BG7 ]?\]/\_XT 9$I(/2J SIQCZ_A]/\ .?K3$9BG#51#-.(8_P Y
M^E ".../\_Y]: *)3 _/_/Z4 .6+/./\_P"?\\4#1/\ 9MW;/K_A0#'/ 3VZ
M>W]/\\?C0(:;,MTX_P YH!#/L)!Z?S_0=_\ )J2Q3:\<C/\ GT[?K0 X1C&/
M2@"PEKG!P>A[<_\ UZ!-EN*TZ9&?PZ_Y_P \T[$W+8L@>V?\_P"33$65LBQZ
M']?T_P ^E %V&U)QGIQ_GGM3 O-:\=_\_P">G^%3811E@QGCIZ_Y_P ^GJF:
M)F+.G>H&);\''^>IY&?T[<T#.FMY/7_/^?:J)9T5K#R.<8_Q_P _YYIDG201
M$?Y_^M^=-"-)$R/;T'?K_G'%,#C]?; Y^O;\_P#/\NC0SQS4GS(?7Z?Y'^/O
M2 +?IW'I_G\./\:3&BU*F<XSZ?RI%%=1^//_ .OBE8"]''N/^';-%@+UO%MP
M?\?Q_6@#I+ ;?K_]:F!T"<#\Z!C'P.O'^?\ />@#-N9=N2?RZ?A4@<U/(9#S
MEOP!_I18#[<\O';-?5'RAGNGERJ<<'@T 7^O6@#)CB\N1E/ 89Y^O_U_?/Y4
M 69TP#Z&F@,2RNO+)4G&#_/_ .OFJ)-DS!T//(_S_GO0 6]_F,;<\<?EQ3)*
M]Y?O*A 7MGFF(?9:A(\8SQV)SZ<4["9!>3M*A&>OXU2%<+*]#("?IGZ>_P#G
M^H+!<UQ-'(F._IV_SSVH'<ZG3+U753[8/X<&LVBU(Z W6]#[5%B[FY:78F4'
MU_R:S:-$R.]M5O%*GC/?C\Z:=@DKG!W=JVGCRV&<#@^M="=SGDK'!:^P6,YR
M.GIVKHB<LC(FE5.._P#G\OI5D%9[@.4&<_,O\Z&!U=I-GBLV:)EEGW2)]3_*
ML[&MSI+1R/\ /_UZAEEA1F4C_8_K_P#KI#L23QC;^7^?\]J L9FLD)"6QV&:
M:$S\T?BMJ2P:ZJ#&<9/T.?ZGKTJXNS,Y1NK_ -:F?;7?SKD=">1GI_4=_P#]
M=;&)WMEJ8'!//^>GMT_PJ#=%E[EI1P.#2&>D^#QNA < _>_S_GK6D=C"6YZ*
MENFP\>^?\_Y]A2&CU+1;%&B''0#O_G\O_P!=<\C>!=N[%!C SZ\G_/\ ^NE<
MMFM;6:MVI7"QS6J($E88 X[?A6L3"1V/A:T ;Z#_ .M4U&:4SMY&"CGI7.CH
M9YY<7X8;1DD$C'XUND<TG<X^2$S3*S]CT';G_/%;W,;'>VH&,?Y_SQ7.SHB7
M8[E8).3C(^N:AFB+Z7SOPBD^A-18TN0K%-(Y&0H9?U_R:H11-F\9R7/6JN9V
M+L-D\G5SQZ>E2V-1-Z"V2WY4=:S-DAUPG 8=5Q_G_/\ *@;0QY% W9X_6BP[
ME"XG:<?N@!CG<<X_3FFB;A%:>?\ -(Q.>W84-@69;=47Y !CFD!.CAQGGF@=
MRG=72V^#GY@>!_2A!<ECO)+H?*-BGN>OY46$5I;, AV^8CU_S^/UH"QIHV,>
MG]*11$_[M@XZ'K0)D4M\J?*OS-Z"F%RFT<KODG8K<8'K]?S[=?:@FQ;BLX[?
MMD^IY-#8[#%_=L1CAN:8B;/M0,R3J"6KE>G.0/KU_P _XT6 L+>2RCY4VY[L
M?\__ *J &PVTARDDF0.< 8H$3+91Q\!<\8R>3]?:BXQUHQ4;#U4X_#M_GZ4F
M,EE D4@_Y_.@9&LN]1G]:87,B>]2.0'</?'/\LT[$DHOFE^Y&Q^O _K185S
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ME,J:*."WE..!W],]Z4F7%'YT>([\/=SD9QYKCU[D8KYJ>K/I(;&/]I/3_/\
M*HL5<='=E<'_ #_G\N_>F%RREYGW_+OQ0!<2[/T]Z -RVNJ N=/:77&1C\/\
M_P"?YIE'7V<F[_ZW]:0SJ+5]Q_,8H W(>* -%8RW&* &,OI_G_/-"((W7_&J
M SY%_P B@#&O$XY[?Y[_ .?KW .,U%>??US0!QM\N0>O':J Y2:'CD?Y_E0(
MQI(">@Z_Y%,!!:GJ1_GUIV 0V/U_+]<?Y_2G8"%[/9_G_/YBDT(J/;^7Q2 C
M$0?C/^?8?SH ?Y>#S_\ J_E2 >L.[G_/^?\ /2BP$@ML8/7\/\C_ /5Z5(#?
M(ST!''_U^/\ /2@:%-H,]_U_S_7W% $!ML_@/\_XT#(6M-O3_/;_ #^5 #4M
M=O;&/Y?Y[^P]: -&"UW ?7]/\XI,$:L$&,=N_P"'^?7O4LLUHE/^?\]ZD95N
M%PH_SG% &+,N#Z]_\\?Y]JI 9DP(/&<?Y_+],?2F(J>66/\ GUZ?_J[>]40S
M1C0L..>AQ_D_GT[4 (4QG_/X#O\ XF@" KNH D6/(QUH M10@\<<=,\_G]:&
M-%^.VSU]OQ_S^GO4CL3K;9!QS0 _[-_G_'^M S9T[P\^J,$0')X7\::1+9[S
MX7^ QOANE; ],9_#M].G-;))$-W/7[+X&:9;C##)QS[T^85C/U;]G^TN%)@8
M@X^O]?\ /M1=,+,\&\3?#"X\-D\9'/.,<?G_ ) Q0XV"YP+V6TX/4>OY5 $B
M6O?/I[#_ #TX]Z0R4J![?IZT 95TH'3'X_X?ACV_&I&<[<Q[*S9:,H/M/3_/
M^<_6BPSH-/N,XY_^O_GU_/WHEG<:?)N'7\?\_P"?YT$G1P28Z_7G/Z_K30BV
MUTJY]_Y?Y_SZ,#SCQ%=[\X]?7O\ Y_SF@9Y3=MN;C\\?B#_G/7F@9/&>N>_-
M %]6W=><_P"<_P!/\\*P7%'/)Y'T]O\ ]?\ ]>E8:9L0(..,]OU_SG^=.P[F
MDD>/\]:+!<T(D*CO]>?\_P ^U(9IPOMX[T $TP4=?SI <[>703)/Y?Y_S]:8
MCS_5O$IM&Q&!UP:!GZ(O*KC/J,BOJ3Y4Q[Z0;=W=3FG8"19B1\HZC(^E%@*M
MQN1U;OD_KQ_6DP- PDCG/O0!S]U8A)<]F'^?_P!=4(T;)%4X_.@"S9J(Y&3'
M!Y_7_#%,@FN8O\FF!D6PV,R>G(X_S[4R 858FS*M'VLRDX&<_P#ZL4$&G%<H
M#R>/\GH*H+ES3+X1ED]\C^7^%)H:.NM=0+#&./>LFC6YLZ9<R#*YQC!J&C1,
MZ%-\@P6Z5)HBTD OTVOR?Z_E2V&U<\P\6Z>;9"I'OG_]7>NJG(XZD;'%WD&>
MPX_#%=*9S'.W%N Z <9;M_G^5,#9MXB>C'\__KU#*1J0HQE3YCT)Z^V/3Z5F
MS1;G26XE0CFLV:FE TAEYP?D/I[>]2QER7>01[4AF%JTQDM6.W@*?TXIDGY$
M?$74SJ.NW,F>$D* ^RFL(O4ZIKW;'6:5<>:%.>A*@_KS_G\*[SSHGH,1V $<
M'_/UJ2RXMQN')[>OL/\ /_Z^45<]2\'S_N0>V3T_S_GTK2.QB]ST%+Y-G.1T
M['^=)@D>I^']11@!NZC_ #_GUK"2-X,Z:>>.3;R.3_G_ "*@U-1;R.,'#?H?
M\/\ &D-G"7-S]NN6V>H KH2T.66IZ!H=G)$V2Q&1VX_STK*;-Z<3HIK:, ER
M6^IK)&K1PLQ%L[JN .HP*V1SV,&1A'G'+>GI5LS.EL[>2X().![>_P#GZ5E)
MFT5<Z;[%'$ V!D$9)ZUDV;VL:9^7&/\ /^<U)9#(=A5O>FA$4\8#<=,52(98
MM' .6X]?2ID.)9-TD9*YSCICN*DHC=I)N  J].>O^/\ GZ4#((+183M;YCV)
MYX_S_7\6"+F2*117C;R25/W><?\ UJ"=AC7Z'A?F/M0%RE%'+(VUCL'4 =?T
MZ50B_';)#T R>YZG\3G^E(+#[=MA9?J1]#Z?YZTAHGF<*/F(Q0-LS(;_ ,S*
MQ L5.,]!0*Y.UH]R,2-P?X1T]LT#L6K5 BX  (XX_P _YZT ATB>8I'^>*0R
M#[8L8RQ /ZTQ7,VYGEE&8EY[$\#WXIHD2*T:?!D8G/\ ".!3"Q.]HD."J@;3
MG@#I_.D!=SGG\J!E6=O+*O[X/TH$/DO(HOO,/H#G^5%AF;+?N7!C0D$8R>![
M&@1-Y4TOWFV#V'-(JQ3CLEWLK$MSGD_Y_G3$3FR0@X4#\/I0!?5]XR?;]?\
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MPI"'F/&#CKZ_GST]?Q_"I E6')!'IS^/3Z4#)##G&1T_#_ZU QYMB_7'\O\
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M9Y<X('T_S]?SI.;95S(*O<-@]3^E9B-JTLDMAEL<_P"?Y592$FOUA''4=?\
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M*Q:5":!$4O&12 ^;/BE&I#-[Y_//^-62?.<LP5L9]>_.:0%.2X!Z$8Z_U_\
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MPZ'V_P /\_X52)9F>>N/<@'\ZL1#<R?*"!R.:"32@NG8 @=1Q2*+,L\F V<
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M:N*%)E/1XY)MI' )_K6LF<\3TXZ<[Q?,Y/L*Y;G:EH8>H6D9(.,G Z_Y^O\
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MTBC*N&_S^GZ8[4@*>_T_R?\ /^/T +B2[3QVX_S_ )[4$V+3S'MTQ^O^>?\
M/+$8-Q=[/TIV%8QKF\_/&?P_S_DTQ&:UQN/!_G_2@#?TY\'D?A^/^>G;CK0,
M[6PBW#OV[_Y_S].6AG6VB[>3P?\ /^<TV([73^ !QQU_^MGI4EG10@''0X^G
M^?\ /UI7 )5/&>G^?\_AW[(9@76 /S/Z?Y_PH Y/44R#R#QST[4 <)J,?7U]
MO\_Y]J .,G7G)&?;(]/?\?SQ0!^J*,B2K_M#%?4'RY;N-J\XH&8+NJS^FY3^
M?']*9-QMS!NI!8YF-?L\K+V/^-,1)+,HSD],50KF;:7JQ%E)Z&@#0-X'&,$T
MQ7$L)F9-H'*DCUZ_A0(OJKOWZT#%LH<J0<DJ<<_G_GV% 6)Y;56!%"!HP[:W
M^7&/NG'Z5=S.Q)Y.X'Z=^*=P)+*/*>X)'/;TI 7>JD>WI2 U]+N?,C&3T.#^
M%2QHT9I@5(/I06V6++4E"C)Y'%)H%(N2WOF+QG([U-B[EV>WCUZ#9*N<COZ^
MOU';TH3Y6#7,CPOQ#HC^'W(<'9GY6]?RXS_^OL:[X3YCSYP<#&M+S?/Z_*.G
MN1_D?6J:,TSKD/FC_/X?_6K,V0W3OEF<]  /\_\ ZJEE(ZRWDQZUE8V*]NP;
M?_O&@1Q/C?2%U"(G&X@'/N/\YK.:+@S\Q?'>A_\ ",WI &V-^5QT[9_S]:SB
MS2:[&/!>[O\ /_ZZUYC%(V["\#]^<XY[\_Y_^MV5RFCZF^&C[K%?^NC?KCV]
MNM=<-CEGN>GG 7D#_/;^E,5SJM.0 @$>G;TI,#TNVC5<?*,;:YF=)7U! J],
M?A5Q(F:.DC&SZU4B8GJ.=J@'TKC.WH>=WEZJ,Z9R0Q  [_YYK=&$F<Y>*95W
M-PH[?E5DFK"BQ<+Q4L:1T: 0A7_ _0_A6+-T275XL.<GI4CN<MJ5Z=RLBDCI
MD].?\Y-6B64(VF<_.VWZ'D59G<Z33X49E8Y)/4Y[U++1UXA1EQA?I@5!I8AM
M)?*;;W_#I0U<2+MQA<2#IQ_G_/\ 2I&QLERL8R3@'^5%@N94\TLX#1K@ ]3Z
M4P+T-H)0&9BV><$\4AV'/"(#E>,=<>G]: +3<]*0S/FG6V<%B #U_I_GZT[7
M$1M=/-_JES_M'BBPBI'8['S(=VX=.V:JXK&Y&@3H,5!:(E;RW*]CS_G\J8#9
M[Q(>"<GT'6@&S.C::X8K]Q.H]?ZX_P#UU0BVMBB\'D]R>:FX[$EH3M*?W3_G
M_/\ ]:A@ATT?F @_K3$5DO4  )Y]N?Y<4K 4[]I+E?W:8P<@M_A3$$-FS_ZU
M]V<=.!^E,98:RBCPZJ,@\\<\_P"<>W6BXBVR@=.G7BD,@6,+)GIN'Z_YS0,E
MDVH-K8 H!E&WOX]H7.2#VS0)#YY9& 9(S@'.6('3_/Y4@+L4$MR,EPH(!P!S
MS2&/_LY8V#-ENV6/_P!?^5.X6.AA18ONJ!TZ<?A4EHB#F!B/X3T]O6@+F+K6
MJ1VJ%68#C_/X_P#UO6JBC.<K'SMK>KG4/EC#,!D$D8'''4]:[HQL<;=S2T2S
MGF 8[4'';)]_;UZTI,:._@TOY?F9G/N>,]L <?S^OIG<T1N64*(,J OK@8J1
MBI*(B5/3J/IZ?A2 IW<P@</T_A/YX!_/\OPJA&->ZI&P*QDNPY&T9YSZ_=YQ
MCK32);,B[NI[I#TC4]/XFP>_3 _6J2)9S\%E',%,@+L1G+G>1],].?0 >U:$
MFE9.=H)[#^G^?Y4!<YV[?S<CTR/R)%4B3.%Y':QIO;:Q"X4 ECD X"XR<^P)
MIA:Y=-Q*&38F,GEG.T'<< 8&7SGD@@<=Z3&C8BMV+AI)&8YZ ;%]_E!R>WWB
M_7'09I#,_4HDLU&Q0J;ONJ !\Q]!@=2#G\*!H\_U-?+<$]_E_P"^OQ]@/IQ4
MFL2I&1#EO3&X]@#T)]L]^O.>G-!3.-\2Z(-3!GMU\P]#M^[]=Q(7 QSMWDY4
M'L*RJ1OL:0E;<\RN]!E4'SOD'8*V.AQRQY_+;T[UC:QOS7,(6>X9"@$_> P.
M1D'..IR/?IS3L,P+ZU*,,]^/Q']<?R^E-%(^>]$*N-I]:]'#,U:.MCU&;32.
MC+Z-S^O7]:]&Y.QUUEK\=R!D*K8&1T_QH-5(VS*9N_Y8Q_GM^-0RTR$R#@'\
M?\__ *J112N),<\C_/\ G\*0&:T_G-M7KV^G^>:87.CT3P_-J9W*/EXR3_A_
MGI6D*;D-(]+AMH-$0 8STW?7'M_/I^&:Z[*"+2L<)K>OM='"'@^G^<^U<E2I
M<#E$0W!ZY]S_ #KG&=)8V&!T('Y?Y[U:IEW.CM[''S$?48Q_G^6.M;1A8#72
M+8.W^?I_D9ZUKL-&%J5XMO@ Y8]AWQZ]<?\ Z^]<\AE;3[!K@[GY]L^G^<8^
ME1&-P.MC@6 >_//_ .L?YQ71:PR$6[W1^;H/\_\ ZOSJ&ADMTZ6@VCKCT[\_
M_J]JAC,YI<DYZ9^O_P"OZ\=:0C3L4.IS1VR\@D-)S_ #R.>H)POT.>@-;4H\
MSL2><?M 065K+"P_X^V7++M/S1CY0Q/&#N#*!R3@],<^1G/*FN_Z SD?#7P=
MU'6K7SF\F ,-T8E8EV!Q@X4-L!ZC< ?;!S7%1RN<XWT7;K_PQ))=>"_$'BJ3
M_2I3<F%!$#+<%]J*2%5=QR$'.T#@<X'6LUE=1]OO ^N?V9_#J_#J>XN;F8H9
M8A"4#,Z;MRN2WR]5P,=1\Y^88P?1IY:Z:WU[7.'$0<MNA]K_ -OVI'+[LCUX
M(]NV/S[U/L9(\B4TCG++Q_:V,15< H2#\O;.1^AX_P YU^K29S?6$CS?Q3\1
M)Y71X)"A61& '?YAQ[__ %ZZX89):]CDEB+O0]A\<^#U\801W2;8[@H"6 P"
M<9PV,<=>>W3N<^2GRZ'ISC>S/F&+0;J28QRC:!_^KCU[^V>U%R;'OGA+3EM$
M"H!G&,XY/U_2LV:(N^+_  TNMP,C<G''J/S_ /K9Z5C.'.K&T)N#N?#_ (H\
M.2>'I2C\*<X.1]?3G].O>O"JTG39[E.HIK0Y>0<_X?YZ5B;#9%],]_SZ_A["
M@"-SS_/_ #_GI0 PI^GM_G_/M0!'D+TZ_P"?S_#CWYH 0GG/^'^?7CV/% "%
MMGTH MVI^8<]P/\ /Y_X4 >IZ*.G\NO\O\_SH$>K:;D_I_G\OZT#.YL%R!_G
M_P"M_GKVH Z.$# Q_GB@""3B@"JZ_6@"A,O\J!&%=\C_ #C_ #VH&<?=C .>
M/\_YY_#- %"*<(>3CGGI3N!Z+I$X; Z\?YY_S_6KN!ZAI+=..:; ]-TM^.M0
M!V*,,4"*ES@CCF@#F[U,_ES3*2. U>'%4BT?.OC?2A=;L $\^AZ]_P#]=4RF
MCYTUC3'M6/!*\]^O//\ ]:LF8G*LQ7K^?X#WX']>P.*D":&[Z?X_Y_KF@#?M
M[D8P>G?G^OK^?.* -N.;.?I_D?J?QH V[8Y_S[T :29/)[CO_G_.:D:)0.,_
MX_Y_3TJ641GT]Q^/^?\ .*0$-QP./3.?3]*0SF[]N_T_^OZ4#L<U<ML'U_ST
MIH1FM-MY!P<?Y_QJQ#8WR<?A_G\_\\TT2S=M6[<Y_E3$:]M(/0#T_7_/I^%
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M_A[UR2DY#N9T5L9&X''7..*BUQG5:?IFT9QSG_ZW^>];1@!T]G8L_4$X_/\
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M1SCK4<Q+1X9XA\*M:$F/)4Y^OX_S/X9I&-K'",I0X/4=O\__ %J!%ZUEZ>M
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M=B0\+],GK3 CDC9F5@,#(_S^IH T3 T?4YI 49[E8)%8GV_S^= KFZ2AQW%
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MJ8KW'6EHI&YSN;H3[TBDBS<@,F%[<BA RU"1,H/M0%S*O;A+=@6/0@8[X/\
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M=/I0A-F:-4CF'RY8XZ <<^_3VI\HKF3Y\]P,*HC4$C)Y;VX^F/SK2Q-RC:6
M=I-[%R/[Q..1GIT_G5"+-M:+$S  #." /R_PH$A)DVOCL1_+_P#70!3FN([$
M[G( *]_4'W^M,5S)EOFE8"*-FW*<%AL48(P?F&X]2>!_.@1!;6;S2[I78[AR
M$)0#GU'S'KZ@>U &Q;VD=K(3&BIN&3M4 G'7) R3SWS1<#7A4*Y)[@8'^?\
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M64BP&Q_GD<?@/Y8/TJ&41AR?Q^G?KVJ2D13'C [>_P#^KWI%'/7TGY_7^O\
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M;0&_VL=NX_\ U?YYH*N%M%R",YP1[^O]*!"3WT43CG<RD@JN689']U<MV Y
MZ]<4RB:"6>Y*LD8C!.T-*><'OL4YZA1@LK#).,9I,#H;ZTW8,KLZC&Y.%7&<
M=% ) XX)/ ZUFF:%BY"PQX4!0G(P,  9S@#VR.W7-"!GG?B&?Y">ZX.?<'Z'
MMD<>_<\62<I?/L1G8@;%+9[<9/OP<8_'MUH*N4[G4/DS K2L<%=OW2 <C+D%
M3GH=FYNV,\A@T='91221AG<*QP1Y7IU'S-DGORH0\^M(+&_ID26<>R-0O)W$
M=6P>"Q))8D8(W$D>M24<9XDT\7)D7^\F0/7!VMCIV*_B*M:B1^<_BJSVW5PA
MZB64$>X8_P"?\BO*>Y[,6>4V;>4V/>NVC*QJ=UIUP>!7L4YB.LBF#=#77<2+
MT4A'^?\ (JAFC!+GKR/\_P"?Z]ZT0TS?LIHWP/3WSC_/Z^U:HLWXK=6'!'?O
M[?Y]/\:+L6/(]?\ /^>](LC\O'7CCZ<^OZ_E4V S;B/./\_T_P ^U(".&W]?
M\_Y_KZU'*!M6T 3&.N*I1L6;,2=O\_Y^AK1(HL2N(ADG@]_\Y_\ K&DP. U"
M277Y3!#]T'#L/3T[_D,]!UK!WF[(3/0/#_@>+3UZ$GJ2>YYKNIT%'<N,3T:"
MS6,<<5U;%V*EQ.EKDCEC_G-1(#DKT&Y.XG'^'<<?TKGD2SSWQMHC7]H5C'SY
M&/J/3'^?YUY^)I<T="&>"Z%%/\2;V.VN[ETMHEQN)&0!D@)GC<1U8Y^7N<!3
M\K3@\7/ED]$1>YZ!JGPQTZQDBCC5@C*26+DOD<@D_=Z>P'L*[ZN IQLDNG<H
M2R^&=E*0_FW.0>#YBC/X;/\ //XYQP$//[U_D(]NTBS33(A#$"%'KU)/7.,<
MG_#&*]BC35-60T=+"<?Y]?\ /I_*NN)JC9MI:[(,HGN?N_3WJV3(Y>+67TJ\
M!SD;%P/J2"?TQV[XX->?4C<^6Q^DCWKPOXH#'?&X4L.0?NGZC@Y'J#G\*\NK
M2.*$SVOPYXA_M;:[X49RJ?WO]O/\0[KC&/O'G;CS*E/E.R$^8[R0"X&>N:YM
MC<XK6;<-F*-=X(P^>0N?[WUSP.O?UQLC&2/A7XF^"'\)W6Y!FVE)*,!P"?X3
MC@>WM@5XF*H<CNMF>SAJ_.K/='F0Q_\ J']/\G]:X#N&']/3/_ZZ (BN?\_Y
M_P ^E #&&?SS_G_]9H C9=O_ .OK^/\ GOZT 1G"]10!/:C<V![<?3'^?\:
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MW\70?0=.N/6D47+^<0*NW@ C ' ],8_&F#9C7$NYE/8-^G3FBQ Z[N%C7<Q
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M$S[[B1QN.0HC3RH96+G<2 5 P"21CG:..4]]/Z]!F=;?&&"%E4V[*G3<) W
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MD_X9Z?R_^O0!1:]Y_P _Y_SUH CCU0V_W2>OOT'^>?2@1K+XR*#:_/Y=._\
MGK^% %I?$PFX Z\^O^?\\4P+(NVN0/?U[]_\*+C-/3K/=UZ?X_TJDQ6.TL[
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M_K0#/3=*)('MC_/O]?SJA'I.F'&!GC''KQ_GKQ0!Z!8]/I_GO2 Z"W.?\_\
MU_>F UO2@"-\XH S+CD>] ',7AV#Z?Y[YH XR[?!/U]/S_SSWH8T8<LVWO\
MYYK.Q14-T/7]:0[E,WVWO_7I2*N"W>>,]NF?\_SI!<8]WTY_S_4?Y]:9)F37
M0(P/\]?\]?2F!FR7>> ?\_S_ ,CTH RY;K'<^_IQST]?2@#&FN=W7_.?\]_R
MH$;^E2[]I)S@<_X?A0!Z18N& ^G/\A_G_("['9:>V?\ /^?\_JP:/1-.Q(HR
M.]49LV2@4?Y_2J$R!E&?;]*!$$B%<GB@#!OH]V?SS[]^])E)'&ZE#P3^/!]!
M^%0V4>=:O#M)/J/PJ2S@;Y,G'3T]: .:N(.,^OIZ_E008-S 4Z#\#R1[?E^M
M6A&7Y(4YI@7(OR_+O_G\JH@U+<;2!U'OCZ_Y_'M0!T5HY Y]._\ G_&DQHV[
M9]N,4BC:M7Y'X8J&-'3H-P^O;_/]*S-"*9L?Y_S_ )Z=. "@' /8_P"?P_SU
MXH ]"\.WPC7T_P ^M)E(]+T^\$GT_P ]/\_IB@9Z9H,RGOG_ #_GZTBCNLA1
MNH$SDM9NM^!G)YZ?I5)B9PM^-P//7W/^?\X^E7$>)>-$^0].G'?_ #_A[52,
MI'S#K28<\C&?\_YSWK4R.0E'.?Z?_6^E %=T(Y'7_/?\* &&,\_YXH C5,]N
M?IZ?YQ^5 ">7F@!/)SWH ;Y!3&!U_P C^M @\DM_GM0,0PE>: '"''^?\_\
MU\T (T6[Z]: '>25[?Y_SQUZ4 -$9'/^?\_YXH 3R3V_6@!0G8?Y]O\ /K0
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MC%.P#O-FN>F$!]>O^?K]:8%>"S"2G/S=""?\*&P-<#'&*D"M:YVX_NDC^O\
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MWS^=+<1KH-U&P$5H FY?0Y_.@$.N&5EQFD,HZ1=X4C'()_7D?J:8BQ=SM(C
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M@<?3\JW1@QTEO))AG? SC"CUXZU1(Z73XT4LHR1SD\\CG^E,EH?*F1M[8/\
MG_Z]-$C;1!*0&_N_T_S_ )--C0";" MP!W/ XX-/83,B#4QY>V)3(1E25X P
M?4X'^<4 -LX)KXE=^P9;(3[W7^\?Z >HXI-V!*YTVG6$.EY5%&[)RQY8YY')
MYQSBI>ILD0:DN)L^JJ<>_(_H/\YI1)D4XFVNRX/9L=_?^5404Y]5CMYFCR6<
M@'8H+-GIT'; ')P.^: (A-<3-G8L>1@;CO;Y3W52!U;CYOJ/0 :NA+<.K3,T
MW!!#<+U!X08&.#][=]>Q0S=NU^S[6 X4XQT^]E>!^(Z4QM6,^\. K8X##/\
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M:;Z6] -G2?AU;6K^8TDD@'1&(*_CD?RP1GJ*UI8&,7?7YD\MSTF%0GW0 ,8
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M[E)W1F=3 ?E'^?Z5T@:$7./0?R_SZ52 NQ]B?3-6-%P'8>>W^?QH+%;G_/\
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MKGN.X/?D#DXK#$T?:QNMT:8:K[*5GL_S/D? 7C_/^?\ ]5?/L]Y$;(6R._\
MG_/I2-!C)^O^?I^6,4 26^=PZ'/^?\_YP =QIO\ G_/Y9],^E40>BZ6>>GZX
M_GCV_*@#N[%L8S0!TT'S 8Q0!8/'- $3?+0!E3_IC^7]: .9OA@4". U%>OX
M_ICI_G\\T#. U#@G_"@#B[[(Z#U_0_Y_GVH YR:38<C_ /7_ $_R?P #>?\
M//\ GWZTF4ARMWZ]OP_R*0QV_ Z_U_KQU_#T'9 -D.1Q_/\ IC\?_P!=2,S)
M9 3S_G]#_GMZ &)+P/I_G_/^33$4H;DPGK_^K_/]*=@.UT[4AC!]O\XJ;#.L
MM=1V=#VZ_P!/\^]%BD;,>L@<9[^G;'?I_GBBPFR;^T,#KZ_C_GK^M-"+EM=Y
M_'_/I2 ZRSO& &,_F:EEFTE\PXSVZ?E4C+GVH/D=N._L<_Y[XH DW[_\]/\
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M!CV@>X'SN0#V7C]36FQFT5+6T2-1P"?4\]#[U1 D$NW<H[$]/SIB)+279O\
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M:8R_YHY J; 95].8Y$8#/.,_7CV]:H"WO=O:D!ESQL)5)/4XS]>/ZTP-F*T
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M!?2)8URW0]>?PJ0*MO?HBA1EB"> /K18!\XFN5.%"^[=?TI@6([ W #2N3D
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M\_6@ X<\\C\* /O)I0?I7TY\P4[,YW)Z'^?_ .JD!:' Q0!<TZ<F,9ZCC\J
M)+B0%3FF!0BOE*#U Q^5%@*UW*)$. 3C_)_K5 64E=XU(QT&2?I0!1O8G9#S
M0(NV<!F56[D#O^= RS=V89#QZ4@-*- P#8'(S2 SM2CW)D=130$RG< ?4 T7
M JWT15=P['-%P-)9%8 ^V: *M_.I7)Z@@_D* +45R#R!P>12 AO)67:P7D&D
M,UE\Q^.!0!2N8=KJQ/4XXYZ\4!85[8&F%C(E@$4H..JD?Y_*F(5Q@''%,3.=
M:+RY6/0$9_*K1!.LA)Q3$:&D77DEE]#G\#_GM2 Z%I?-4\]J0RK;3*Z#)Z<?
ME5"*,TP64$<CI]:M&;"XN"ZG )S5HEF)J>E+XDM'@G161E*E6Y]N1^GT.>M,
MA'Y\:]X7E\&7TMI*N$W'RV[%,\'/J.A]_J"916YI6)(&%)'X_P#UO\?J*H9V
M&E7,BY'7D]?\_P"?Q% ([NUFD+*=O-2:'0+<R <+T_S_ (5 S-2YE#,,#ZY_
MPI,:-$0/&068].<<?Y%0RS9TIE.>.0>GU_\ KYI#.IC?:/Z4$W(EN !@GI_D
M4P99:XBE&,Y^@_S_ )]J9)-I\[L@"K]TGK_GZ4@+L\,LZX8X'M_DTAC[>U4*
M-Q)XYSF@""^C"CY/TH U+5QZ]?\ /^?I0-%N8>5M<=B/R[_I_.D4;::A'&.2
M,U#1I<234"Y!C4G!Y)I6!&JL<DWWFP/:@9";58W5L>Q)^F/\:!FN1P*0%5T*
M2*?J* )S<)%U//I_^K_Z] %5KEY&Q&N 1U/% %H60DYD);V[4 2P*$8J, <'
MI0!<XH S5O$@!4GH?K_*@D@F:2Z!"C"D=3U_+K3&26=FK*"V6/?=^72@"S<)
ML3(XQCI2&7#("* ,J:_2.0;26.",#]*=@'E9[D\D(/;K_G]:!#+>S2-FW#<3
M@C///?\ SUH TR H(Z"D,IVT@"X_N\?Y_P :!;%._N%C4@D#IBF@&1ZD+@9C
M4L#T[4 0NDSLI8[ >..3T)%,#5BLHU&6^8]]U2%B6)0K$* !U&!0!<[5*&1P
ML%!&>%)&?QIV R-9O46)AD9&" .?Y9_SVJXF<F8$EW),!Y2$9[MQ^G!_S]*Z
M$<S,RVTQ[MF$\AV@GY5X&/KS6C9-KFNEE;VL@"HHRO!/7(]SS1<35A;B4JZM
MZY'^?Q'_ .JFB64I?O!O<_J,#]:8C48I"NYB %(/Y<G],U#+,[5=12Y#"(,_
M'4# _,X%-#EJ8:QS7R?.VQ2/NIU]OF_P Z=:HDV=-M(U7?M!;'4\G/?D\\4F
M",JV?;QV!(_ 'BF(=$25XXQD?ED?TH$V9EM?H,HAW,I(^49Z'CG[OYD5/,(;
M )YAM!6)0Q!_C?J3Q_"N!C^]]!4MC)[?38QE6!DVD_ZPE^ISWR!QCH%I7 T(
M?G9D]QCZ8 _F&X_^M0,;+]_;WPI_/C^@_.J3"Q7O+R.S<^8P56"D>YY&!W)Q
MM& #GT/- $'VYQ*!%$Y,BGYG_=H-I[C!D!^;NO(QCOAB-*:PDN#')-*3@@!8
M\QJ-W ^8$R'DKG#(,#..U!2+,UM' KF-%5OO950"Q7##)XSR!]X_C0BCFM3D
M#HS 9 &_(Z?*<Y_3W]<&J)/ OB/Y<5R@)RVP?*!N.-S=@"<<]^.3Z5SU3OH[
M'S3J$! ^;@@#J>N .>OMQ^OMR'H1.*UFV$B/]/T_'_)]:5C2)XW8OLX/J:VP
MLK?>.H=K8R>G->Y%F".IA8#\?\G_ #WK0U1LPMQ_7_.:HHL=>?Z_Y_2@I"DA
MAZ'_ #Q[?_6[=P9)LP: $QSQ0 C/MY^N<?Y_^O2&-Z\#I_\ KS_3]:D"-UQW
M_P G_/\ 3WK-FA7"ENO^34%(=G&!4C(PFX\?7Z9H O6ML!R:=BC:6;RA[?YZ
M5:=@&-=%S]>Q_P _YXH;N!QOB?6I+,I#;AO/D.1C.>3A0/0GG)'8>]>;BZSC
M:,=V(DT+X<27N9+V8[CR4C(S_P "<YY[]\^M94<M<M9OY+_/4#JKOX5PO@Q3
MMD<*LJ[QUZ=5XSVP?7FMY95'[+M\A6.B\*> U\-R>>VQI?FPR!EP"".F<$<]
M,#&>IQ@]>%P"HN[U8T>E1KT]O\_Y]?PKUD,V+1.?7/Z_Y]OZ5O M(WK<;:["
MQT[A5QVQ2;$<],=QYSWYZ]2?\_K6#,6:FBR!GW=N.W^?;Z<U<#&:N>IZ]X*D
MMH8K^*/Y9E#O@KP6X'L >OX\CM7DJIJUYGRN(IV?S.G^'>K,LZ0?, 7#GM@)
MR.W<@ ]>I!'>N;$QTN+#RUL>H_&#PJOB/2W8*"RJ2..>F>O^>M>=AJEI6.W$
MT^>)^3T%H4!Y^Z?_ -?\J^BB?(3W.W\,SLD@F!QC@<]3GG/KZ>]:-A3NCWGP
MYJ/V4^8G5N3[]N?PKEG&YZ4)'T5X;\0_9@C("^[C8#C)Z\=@3CJ>#SDC[P\J
MK3/3ISL>PVT2ZE%YC[6D8$,?[HZ;1G& ,<]-Q&<8V@>?+W3M6I\O?&SP42HN
MH%&Z/.\ =4/TZXQT]"?:N7%T?:+F6ZW.K"UN1\KZ['S&R_Y_SW_G]*\$]H=#
MR0?\X]: .OTX<Y_I0!V^FG;C_/\ C_G\*H#N[ D >O\ G_/_ .J@#JK<[1_G
M]?\ /X<4 7 ?Q_S_ )_ST (9,D=J!&3<'U_S_G_/N#.;O\$$?7'].M '"ZBN
M[/?KSZ>] '$7W'^'Y_Y_R:D:./O!CZ_2@HYR<8.* *AY]J &L 21Q_GCG_$_
ME0 A'3_Z_'Y_RX_6@"/8>O?@=<\_I_2@"-H\]?RY_P ^E $)@_I_G_/Z4 ,%
ML,X_G]/\_G0 HBV_Y^G%("6.$GKUSV/_ .J@#L=,M0%&>O?\?_U9J0.[APRC
MTQ_GV_SF@99:(2 ?Y]/\]Z *LEOMY_7_ ": ,>X/E]>!]??_ #Q0!R]]<[$Y
M[GBF!BP:@RG(//K[4@-6WU;'?C\?\_X8H'<THM3#]^?I_A0.X_[8&Z>G^?\
M/Z>@%QHO>2/PS_\ 7_\ UT";&?;-N?3C% APO/?]<?S[_P!* -"VU+;T//\
MG_#_ .OQ0!T-IJP  /\ 7\?ZT =!'JBOW^F<_P"?Z?6@!\FH#L1WH R;F]!Z
M'M^E C#EF#<$]^?\_I^-4@*APWX_2F!<B7C^7X=OZ4 #+@=?K2N!4D//I3 H
M%OSY^G^1Z4"8QI2/3/KW_P _K0B"[%,6ZGG_ #_G\\U0R\)<=>IH K2S8'/
M_/\ S^OK[4 99DR?\/\ /^?I0 /)F@!/,'^?\_Y]30 &7=Z\4 .:7'?B@!HE
M&/?Z?Y_7\S0 &4$<<]L?G]* $9]WX]>/3_/>@!#+W_SF@!IER/\ /I_G_(%
M"B4$?S_I_2@",/@G'_U_\]: '&0GOS_G^M $32\]3U_#_P"MVH ;YO\ G/\
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MU("P>.*0&6)<(1QP3W[=?\^XH R+B_7I]XX[<X_6@0ZPNI95&Q< <9;\OI3
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MP/T_R?K0!:@C\P@=C_(?Y/\ .D!V]G#S[=/R_/W_ $]*D9UUM'N ]_J?\?\
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M1U45M),O+=>O^363-!\NB'*OG)#9Z_Y%0T4CN+33E7&!R<4#-0Z87VMV4]*
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M8?5;L:1Z;:Q9YKU8HM(Z"V7'(KK@:%Y2 O'3_/\ GZUH!@WTAR1W_P _Y_\
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M_/\ G_Z_TH F67\_Z?GS_GTH G2?/-(">.XP/ZYZ_G18"7S]N,_Y_#_/^*L
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M)>&XNG8-B%" >,-*<<'DY1> HX$G^]GHP.(O[58W? ].3R3QDDGDD^Y)/0=
M  U3/G_QF@6/)QPQY[?>(_SU_I7+4/1I'C=_"3R>F,<<^V3QS_GK7,=2/$?$
M\0AO&QCE0>/Q']*J.YHMAMF.:]:!B==IY(Q75$:.F@EZ9XXS^=:EHU1@\#KW
M]?\ /2G8I#U^7IQT]O6D,'!4=?\ /^>OL* $9<9P:"D(2%QGU_'_ #^E2 H.
M>W8?Y_S^%(L0'(X_.H&(%YR?Y?Y_R:12)%P..PZ?7_./RI%CB>F.GI2L !=Q
MR3G^6?\ /TJ0+<"_Y[]/\_\ ZJI :D('X?GC_/;^M,#S;Q3'/X6N_MMMC$YP
M5['J7!7T+8((Z$#!! QX6*<J$^>/4FQW?AWQS;:K+'#-LM6?(9Y7Q$O&>657
M?!Q@?*3SCWKKAF<7NG^@R&Y^*UKIT[1&/S$5R!+$^5('=0R*W/4;@"!U .:/
M[6BNC^\=SUGPWK$'B&(3VS;T!()(((/!VD?B,8X]^M>[A:T:ZO'8%J=C:IMQ
MG^O^?RKO2-$:\0*@ ]>_^?\ .*Z$BBY=.(ES^/\ 3%-NPF<?=S!<N3_G]*XI
M.YSMF;:<G/=NI_SW_P XK-$'86*E6!!/ SCOZ_Y%=\-!GVKX;\.1G3[;!Q)Y
M49R.5+,NY@5_'L0>/PKY>O6;D_4\"K&[;\R>[M<2JYXQ@<=L9_S^E0I:'-;4
M[71(/,MGN&)&_P"X.F%&<'''+9R>Q&WTKAGN=L-CYQ\3>&T$A;8/G'7&3GZ]
M>F>>]>E"1YLT?/GB#P\;)RP''^3[>GU]Z[X2.*43A;<^8Y5>$SR?4 \A?Y<=
M/7G-;HYVCL;*\%OC)PHXQZ?A3!':^%K]M/D3).UR,^Q)SCK_ )Z5C4C<VA*Q
M]?:'JX"*H&YV'"CO@<D^@&>2?7U->!4C8]J$RQ)I2VN2Y#%^-^/NDG.U1V7]
M2>3_  @9J0W$^>/BMX :0&\@3]['_K !]]0.OU';N<!:Y,50]HN9;HZ\+6]F
M^5[/8\,TX[CCL0,'CGG'^?K7@GNG<Z>PX^GO_GWI@=GIXSUZYS_A_D\T =A:
M_,/YT 75% $;T 9,_2@1S5X,>G4__JX_SF@9Q.H C(SGM_G%2!Q-[R?Z?YS]
M/\YJK <E=KN]/I_D]_ZU)9SLZ\XQ_CV_STX^O0 B2$GGTZ_2@#4M; S,,=?_
M -?^?\FF(]P\(>%Q OG.H)_AR/\ /\^/0<5-QG826I;\\]?TXICL4VL&7D?Y
M_P _Y-(+%?9M[XSQ@\^_/K^/Y4 >+>/?#RV,GVB) (WZ <8/<?X=.N33)L>=
MQKCWQ@X^F/\ )_QH&=?X<@^<L0> !_G\ORJ6-'=+'G'^?KWJ2RR8<>X_D* *
MLN4Y_P G_/7FE<#F]2G" D\X''_UJ0SQ?6+@LYYSVZY_S_GM5(S9@^9ZTP'*
MY8_R_P _TJA%N-#UI@:<2;?\_P Z +7EX_S_ )_J* $9=W'4'_"@!C COC]/
M\]O\]0!O"]?\_P"?\]* $W8]N* '^9C]#0*XWS=O(]/\X['\:+ V(+G'4FBP
M7)#/MH"Y(+C=_+_/-(9HVD9.#V_G0,Z2VL&DQ@9S@'_/^<?A1<1;;1W8 8X]
M!Q1<#.ETUER>??\ _5C_ #[FF R*T(Y/7_/^>U %\1=O\_U_I3$*4]OT)_S_
M )[TAF7-)L/)_P /\_Y]:H@QKF?W]?\ Z_\ +Z4",]KG(]NW]*!D7GX//;_'
M_/X=* $-UGV_&@!JW'O_ (4 *;@#G(^O^?\ Z_:@ $O(].G^?PH$!NMW/3OW
M_3/^>U Q!<8_'_/^?6@!#< _3_/?_/YT +]J],]?\^G^?2@0GVC.,4#&_:-I
M_P#U=/\ /\J &FYVD_3_ #_G^5 "B[__ %?R_P _RH :+K/?Z]^G^?\ ]5 "
M&X)_S^M  ;C.>?\ ]5 #M_F<9]_6@#])+:$C<OH?T/\ ^JOJ#Y@=<6OF@CVH
M JZ=;$K_ +I(_+F@":_ @7D_R_/_ #VH U[>X$Z ^PS^(_\ U]:8BEJ$NQ-R
M]1S^5 %O[7OQQ]/\_P"?PH K75PX4,!C!R* .G\QFYSUY_.H'<PM439ANZG-
M4@-*-%;G%("M=QA-K= &!_S^5- )<7@A'&/\_P#Z_P"M.PKG)W^ZY=&]&^G6
MJ)9U=K;B$=JDJQ4O)! Z-Z'^?']: !]1"C^>* ,Z:X,<BN%Z\9^O%,#5@DDD
M^;'^?UI#%&GK<RC<<94_X_TH;%8O+H+6IW*Q(].OY>W^3VJ;W*L7+>(1R8;J
MR]_7K_C04D;<3QBI&4O[4$3LJX['\O\ ]?\ *CEN3S#3JK2>W^?QI\H<QGV<
M[$LI)X.?Z?TJFB1UTOF(U"$S/MXA(@;/;^7']*8%6Y"1,AZ\X_I_G_\ 75$E
ML2*AR%YIB*L4Y,C*!CH:8A]V9,!N!@YJDR&)<V[.K'/K_G\:I,AJYEW-J+F(
M@DG*G/Y?Y_QK1&;1\9>.?#@\/7[KC]U+\Z>Q/WA_7\>U#5BD[HFTF-)%!(SU
M%,1U>G%;:3!X#?EQ[?Y[5FS1'J^CS1C& ,\<_P"?UJ6BDST+2M361=A_A/!]
MCZ_YS[5DT67VN@1[4#N+87.5(]"1C]?ZT@N27=PFT@D=^/\ /^>M S+BU&/8
M!R3R.,GOC_(]^E &9J-R]RA"H0,'DTQ&/Y<TF&+8SSQ_G_/\BPA\MBNT%N2#
MGD^]4!IHBQ]!Z?Y_S]:0$<DACP1Z\_Y]J&-&IG!)XJ0&27 @96)Z9'7U_P Y
MH O2:L2,1KD^II&A7$,D[J6(7/''X]Z0S>@LXXN>ISWH$2*0'^H_E2+N:$;X
MXI#(&NUMW.3C(S^7^?\ /6D PZ@TW^K7/N:=@$AMVD=A(W4]!Q_GMTH U(+9
M8.@Q2N!'"Y.0>QI@3-<@ @G'&#Z_A0!1M=29P%C7//7' YHL!:EMC=C,A)XZ
M#@4 :]N %&..*0%.[X*GMG%" I75^L R3S56$V<[]HFN'.T;5(')YZ'%,@LP
M:2'Y<EC[\C\OY]OZ%Q\IOZ=9@+C'0D8[5+921>N(,*?S_P _Y_6I&1W6II"N
M20..GUIV%>QS%QK!D93&I;G&>W/%78ELOI8S7@^9P@]%_P :6P[7)K71(X9#
MG+9YY/>I;"QOI:CL,4KE6'VD BRG]T\4KC+;PAA@],4@*$=VL2 $\CC\JHFY
MQ.IW<DK*84XSU;@<_P"?\XKHB<\B\;!KJWP[GOPHP.?U_6K3U(:NC*LK-(T!
M &>A/?CCDUK<RL36W!*^] D6['_6L!W /Y<4F-%C4&6(!V(&#]#SQ4HMG%7^
MH&=U,2E\-US@=".IK5(R9;C@EN"H=]N2>$ !Z9Y)R>W08I :T^CPV4+,H^8
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MG !(("C!_3W->#1I?6Y-R>W8E:GID/POT^=%38P./O*Y#9]3G</PQC\J]?\
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MUAE%\V0D7(%%QV,V6W[8I#,NZM,]L'_]=,+'GGB^,/9R*?X3N'Y=OKQ0B&>
MK%ELBJ$=]H5J$4<=OI_A^GXUFRDCJT.1GT'_ -;M04667'^?_P!5*X&7>D$?
MYXZU(S@-5G(W9X !_P#K_A^M,#QJ^F,SDG//7_/_ .NK1F9^[UI@6(^3S_G_
M #S5"-*%?\_Y_P#UT ;<$>?_ *W^?>@"QY?&/P_I_G_. !KC_/\ ^J@"!US0
M!&5Q^'X_Y_SG I 0D8I@5I9-I_S[4T2RN)<C_/\ C3$1-(4_S]:!$0N"3UZ_
MUI :MBWG$#N?;VHL.YZEHVDB;&>G^3_GZ=JS;-%J>H:;X?'<4B['1Q^'!(/\
M^N/P_*F%BC?>%]@/'-.Y+1PUUHGD< <?Y_S_ %IDF/\ 90F>_P#G/^?\X8C/
MN(\?A_G_ #_A0,X^]FVGC%40<Q=71)_ES[T 4/M&/PH ;YW^'Z9_E0 --M]:
M '&7'/X_YQQ0(:+@GGUS0,;YV* )!+D@?TH 9YN/KCO_ )_STYH /M&>E #?
M/ H 1I_\_G0 T3_7_)H 07)[4 -\_C_/^?Y_2@ ,WY>U ">?GZ]?\_G_ /7H
M =Y_XXS0 DER,<C- 'ZFQ;I)6"CJ/ZU]0SY@UOL3_>.!47'8I6R&$L!QS_\
M6_I5",+4K?[1_GO5(3,C2;OR1@\A21^O^?\ Z],5SN8U2[C.W_&I&16</[M?
M;C\J "Y4,I'M_P#7I@36,N^)?88_+BDQBW@$B'V'-,0^SN5$:DGD#'Y=:5AF
M)KNJ81E4$G\?Y\^_^>*8FS%MKB2Y4'U'^?\ /ZTR#7:T=DSGTH'8V4@W@'/4
M?SJ2C+U2V79QVYI@310 '('I0 V[4+M]B/\ '_"@#<CC!%2QD%Q\C*_H:+@;
MRW@B3YCQBIL5<X^]UY#*NT]\5:1-RQ)J([$TP*!NFDE7@\Y'^?TH$:<6\] !
M0 Z!'\UAD<KGOV/_ -<T#-7[$7ZFE<"M96012I[$TQ#K^T"QYP./\BBX6)D0
M,,@4 4)%Q-GU'3Z?_JJD2Q\_S*1_G\_Z5:):(B 4 '.1C\A3)96B 9,'GK_G
M]:LR/G[XR:,;JU2Z0 O;L0Q_V&Y(_7=^%6R5H>+Z/=$9!!Z9[=:0T=(;DX!
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M^O\ SZ4 !; SZ8_S^E #&;9GOT!Q^8_S]* (7.T?04 ,(P>G3CKG\L4 5W)
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M0PX'T_\ KU9)6U;$<;9X P3^!S]>Q]* /.=0WRR,D9"X"[F(W$9ST&0,D>O
MR#@YH-4<+XITY6C9^6=3@$L3U49( .U<\\J%X]JB:-Z;LSYQU(".1AQC<?QR
M/Z^W-<!Z)Y+X[4O"K'H).?Q!_P :TB:Q."@C(QZ&O2@)G2VHSCN/\_Y__574
M@.CMR6Y';\ZT19KQCOTYZ>U4-%Y#D>H_KT^GXT%$N?Y_Y]^] "8S_G_/^?PI
M#'D9&1^%(H:5R/\ /K2&AA_K[?Y_/C^LC'P_>SW]?YTAHOHH./8\_E_G\*91
M: &<#CVX_I0-$BPYSG .!^''^?UHL,O1V_F9'_UO_K?AWJU&X%K4EDLK2>6$
M?O4C8J<=#CD@>JC)_7%363C%M;V$SA/A=X5L=7C:XG"S7 ?_ %;D$(A *G;T
M.[/4@CC& :\[*\-"I[TM6NCZ"BKGN-SX%T_6"#/:Q,>.@V'\2FT_F:^@GA*=
M3>*_+\K%\B)[/X6Z3:$.MOM/;$LGY8W_ .>/QRCEM)=/Q?\ F#@=>L"6PVH
MJ@\ < ?A^I]:[5%1T125B"XN!$N!U/\ G_&DY6!LY:>\\TYX.3D>V/\ //\
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MQZ#@=/;/UYH 6(9!'NWZDF@!890I=>RL>GN W]: *<NHQVK,KMSGA0,L> >
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M_(% #2 : $(/IZ]>E "@8S[4 09VT -R>E #?\_Y_K0(8U QV: $88'^?Z4
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MX]?;U[]Z]2E \BO4.&T:S-RQ>7J#T/;(]N_/T]*ZJDK')3C<TM9OOLR,$.,
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MR@'D4@,NUO53*<\&F MW<;U.!_GBF(L0W3R*& Z@=?UH$ROM?>5)P&'\C_\
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M3@ =/\_U_P#UT$LN YP>W!%,#$U*Z2+!SDY!P.>_^?:D49CWTKYV+CU+'_\
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MKI1HC8A8-V_+_/\ ];\:8%M./P_S_C3!$F"?\_R_^M04A@.T_P!>_P"/;/%
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M+;G4UO[T[CB.#<SD\C*C!_ 9Y]"/8XZ$K(Y'*[]#S/4;_P#M&9F.[<Y)"<9
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MZ4 :T<Y'^>H_SU_PY*&7OM8?D'_'F@93FOR.GX?E_D4 <]>7AQ_G_P#7U_\
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MG/4>GL?\^GTH$&-IQQ^5 QFWD<4 1R>_6@!O4\4 (HQS_G_/6@!I3GGO_D4
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M;YCP!_GTI 2F6:?H-H]_UIC%MK7<,,Q)4G('^?\ /YT 78HECSA?7G]/\_\
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MJKB(5G#D@'H3_3'^?Y4@%N;Y+(.2<?*#S[ ]*!H\]M]0=V8Q#))^\>!_C_\
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M^7^?U -*-N#]?\_6@"X#[=OY_P"?RH  PZ^W^?\ /Z4,$0YSRN>GXU)8[/\
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M?K0!8(#XZ?Y_R?RH "N[_/\ GW- #G![]O2@!A3'3_/^?\]Z $*__J_7_/\
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MSC SS_G^GM0!,EW(W*KM'J?R^E,5B[;6PGD'F$L2.!TY_P _YZ4Q'3QQA0,
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M."3]>.OL.-.87*8M[\6K&!3M+R$ \*G7\3WZ5GN5L<#=^/SJ6=RM\QY (Y'
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MVO"Y!R.1D=/\^E7SHGD8V?64A"L'&0<_YS]/_KTN87*SK[7Q<HXSD?A_G_\
M72N4KHOMK'GLK+@\X_Q_G3 U@\C=?\_Y_G3 R"ICFP6X9?U[?R-,"UY !ZT
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M_.:;$BDLRPL2Y )48'<\G.!C)_#\J0V6K6XDE+"-=HS@L^0?NK@A0,_@2/\
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M^?\ /ZJP[B _H/\ "D42;B.W3_/;_.* '9R?_P!?TH =')OY_K[4 3B0@^E
M$R/V_P _UH%8D!^N>WH?P_S_ (@#N,9SWSGO_+O0,<#T_P ]?U]J '9]/\^G
M^3B@ !&0.X_"@! 2P_S_ )_S^- #&C[],]>/\_\ ZJ=R;$+QD<_Y/XT7"Q4Q
MZ?Y_+-(=B(YZ?YX_SBIN,4C'TJ6QCFDQP#QV[=:5QV /CZ<GW_R?SS1<+$ZR
M[NI_^M_G%4F(>),^_P#G_"K$3 CK[?\ UOS_ #JB6+T_7^7^?T[4"(R?6@!N
MWD&@!H.[K0 O!Z].<>O]/\F@!1Z?Y_SU]N/R $/7^= "*N.!G_/- #,?R_2@
M0AY_SZT#$9?\_P"?Y_X4 ,&",?RH _82YB++7TESYID=HS%0,\CC\J 16O-Z
MD..JFA :.XGTI%7,\[HY0>,-P:8BZV[&*DHHQHR.1D\@'\O\_I3$6'CVCDTB
MCS;7=<335E7=VR.?_P!7_P"OTQFHE*Q:5SX8^)_Q"_M"4QQ,=@)[XKRZDVST
MZ5.Q\SW^I&X))_G61TF>LN[M0!964#FF!;25?\GFD!NV4BY Y_I0)G<Z5"LW
M< <9!_SZ_P#UZH$CT>STM7&./\_U_*E<3%O-&P"!U.?3_/\ A[47&<1J<3VQ
MW*3Z_P#ZO_U47"US'A\03VYQN..#S^M7SLS=-,[.R\5W,8')Z>I'M^56JC)=
M)&W%XO;'0YSUS_CSZU2K$.@=59^/A@9'OVK98@PEAC>A^( XVGOSS_GM6GMT
M9/#,]+TGXDI,.3S_ )_"MU71A*@T:\GC:.1E.1D'UQ_GJ36GM$9^S9NP^)DF
MQD8]:OF1/*R\-:B#HV<<XZ_@?YT<PN4W1J,;YVD&FF(JI<;9>G48/\_Z'_/5
M@::,\PQCZT 4[)' 8%L<_P _\XH$27MEO0Y.:8F5E03J,]2,T"L91"HS#Z51
MFS'X$A [BM2"W!%^] ]?\12;!&WJ!\MD_$<?3_)__526I;,^+B7VP>_ZU1!\
M[>/?#_\ 9-[YX_U<S8QT ;ICZ$<_7.<DU=R3*@@0CH?;G_#Z^]#*)+:S101C
M.#Z^HJ2KDLMLJ@\=.:EH997'7';N/\<U(P9MS ],Y'3CU%("X#MH&5XY!N/N
M?U[_ %H&/^V(@QN'X?\ Z_\ /\DP*UK?[EVJ"<$^P]O\_P JD=B>1Y)P>@^I
MSG/^?;ZB@=A+2!IU#,Q/MTZ4AEA[9%4\>GZ<T 7(IO, QZ?YXIB9+*/ER.O6
M@#034$3J>?3_ #_G^C1)1NY3,047(!ZT,9,L$LGWFP/;K0(TK"Q594<G=R0<
MYZX],U+*B=O, .@XQ4&YE^:(7.XXX_/%24.>_>3A1@>I)_\ K4",2&W,SMO8
MGD$CH/Y_UH&=&Z*JG  'K2N!S4VJK%W&?3\>_P#D?TI@2I=-<J?+7/\ +_/T
MH$RW'!).H); ([=.?\_C0(6:R2W4MCD'.3^/K^&?Y4#1IB?8<T")FU7R@-_'
MU]Z=P'-KK/\ <7/&,GI1<+&?#<>:[%OF.1].G^?\]$.QI&X+KR*HD>MPJ@$D
M @#O[52(*\VO6\:\GD$=,D=?I^M42RXNL1OR%8].Q_PJR":+6&9UVQD\D?F.
M.U)B.DMFDDP1'C/J?6H*0ADN(2P*J,^I-!1PGB0R.#O?&,Y  _G_ )ZTR#DU
MA2!20".,$]^G^?2@17,G 'M_GV_.D58PY;KIC)/)QP?\?:@LTH[5YD&6VCC(
M'4CZU21+9T46D(HR1N('?GMUY_\ K55B+FQ8P @!>.!Q_G%(39HFTV7&/5%/
MYDC^E CL;.+:,^A'^?UJ66D0ZZ?*4'H,&B(2/&;Z[^UL5C(X8\^F">.V33&B
M?3;00EFQDDC+$<GI_G':D#-. ;-WIG^@^E BU;SK 79C@<9)X'2J)94;51?R
MA85:0X;E1A>H_B.%^N": .OM8)@A&Q% *L/F+GY2#G "^G9J3*1Z/;:=)$N9
M9CGTC C_ #ZO^3#K[5DV;I6.:O;6&.=\(I;".&?+L-V5X+DD<IGC Y[U<3.1
MCWS<!CDX:,\GT=?T_2M#,S;O]Z"@[@_R--".;O+Q1$K'G<1M ZMSG ]>.3Z#
MDX +!C1CP0?,LC\OAL?[(..!UZ]SU/\ NX !EJ4_NS[%OH,9/O\ _6].E &1
MJLXN,+%R1D.P&0IR,Y.",C!X)R#UI,J)QNJ68"X X!_'YOJ*BQK<\2\76Y\F
M96Z$>A]O\\?_ *N61TK8\3TK3OM/'3 J"4=E%IHAX/)_SS[?CTZU)=C7@TU5
M.[/S=O;V_P 3Q[=Z8FK&L%6-22,<=?I[?Y_+BF(<9$DY''J1U/\ 7\^HJD!S
M.H:/#J#_ "_)( 3N7'([Y'?O713J-%*HT<[,[Z<=L@R. &'0_4?A]*[E4N;Q
MJ7)%U% <$8^O_P"H_P!:U4C12)TO$8X4C^7^>E7S%W+3<<XY[T[C'C [_P">
M>*!HE" ]/\_YZ4BBPD([CISGM_GK185S)O/$-I:G9YF6_N1@NWZ?*/SI-V)Y
MCRK7=25KO[3$6B<8XX)STSQTSW'/-?+UZGOWCH:HUM%\9VXNT?5(I;RW7=F!
M)A 3QP0_ER 8//W3GID=::QDKZARC[#Q1+%,'CAWP@\1.<\<D LN,D?3D]L<
M52Q<OD0T?7GPUO8_%BBZC0HH4J4/\)!7(!],$<\9ST&*[J4^?4\>NN1V/IW1
M8(-.0AV&['W>2?R&3GMQ^?IVG S<CUUUB10C[M@!)PHSCGJ2?S%0%SR'XAV1
MU9%E(5'5EYSN_B[\+3;'$\N_L=\\L?H!C_'^?:BY5BY;>'A [R2LP0JO+-M4
M8SWR!WX].U,1IVMUIR-Y<3B:7^[$ID.?]X?+V]<XJD[D,NS_  MO/&*(EWNM
M8%9F6('+,6)Y8@X& <*!G'S'/.*M(RE(];\!_#G2?#B#9 )'7Y6?^+C@_P L
M_C],:-VV,UJ>NWVCP0JDMMB/:OS;A_#_ !'C'*_>]QD9YKGYK[G5R]BS! +4
M<'<2!EB<Y_ICT X'UK%NYHCF_$$>T>> <KUQW4]?\1]*U@931S+,;C[IS'U)
M_O>P]O4\5J8&K:8LI@_ 5]JM[8Z'CZX/X<\5+*6AUJ-O^10&/?VSQG///IU.
M:Q9T(S9H#8N9LEBW#].F0,COQWZY !XQ2&,DD#G.>._TZTKC/"/$5^;^X=R.
M <#!Z#M^/Z=?:N*3N=D8V1PDXVG<,9_S_D5C)G1%'#W>HBXN&Q_#QQ_]88__
M %UY51W9Z5-61Z'H-QG'I_GUK%FQ[#H=QTSU''I_G_ZW>F@/5=+NA@>E4!W-
MI,*8'00O_DT :B>U" EV50BK-%FF(Y^^B'2I8'#:I;#/T_\ UU)1YQJUJ"#_
M )_S]:3 \_O[8<@_Y_G2 YFXM\$@_3^G^?2@:,B6W(_S^ _SZXJ2B@UJ5_S_
M )]*5@)EMBPR>WZ=_P"7Y4K#+RQYS_G_ #TI#1'+%C^5(HR+F(L.1TZ_A_GW
MH XS4UXXZ'H1T_P_QIHEG%7D9;.,]/3^M6B&8#0$=L_TQ]/\XJB1HB(['^M
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M_P#J_P <FO/J3N>A3IV/E[4]1>Y)_P _XURIG;8R0I?%7<1?CBR!0!8$'M0
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M+UX0\^A.,?U__75(3-6]LC<OZX7)Z]6&,?SZXQ6R9*T,Y](5P00?P/MZ=/\
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M?6HCCGT_S^5%Q6-2._23N#_G_/MUI@/,BL.,?A^% %:11[?Y_#I3&1F->?\
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M_.M$B+G765LL.  %^@ _^O5".JT"U#?>YVEAS]:R;'%&WK"+#+$WKE?TR/U
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M/KV./\^_X5M];,OJ=C.A\0N!C(SVY_H?Y4UC&+ZFC<A\0/(.H&?_ *W/^?\
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MQ)^E(#K-!T*&W16=1(Q ^9_F_('@?A5I&;=SL(GPTB$GAE(Y)P"J].3CD$\
M#O0(M6UOY[C']].G^\!_7_Z^*3-$CL-00OQZ#%9HN1ST7REP,\.3^?SGGIC+
M?SJR#(OM4AE**K;G5R2J N1\C#G:#CKWQ^E&P%:V:56!$.U<]7=0QX[*N_\
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M_6G<#HX+X47 TTNJ &R7= &5<W6ZD!S=[<]QV[_Y_P ]J0'-3DGG\_\ /X4
M-CAWGV_PS0(W(8!U/^?\]*H9KQV?^<=Z0%U;,#BG< DM<G_/^?\ /:@#-FLL
M]JD1C3VG!]_UZT#,JXLQ_D_Y_2@#&GT[/3C_ !_S_D9Q0!ER:-R1@=: *)T;
M;QC]/:@"M)I&?<]/\Y]_RH SI-)]O\_Y]/3ZT 9[Z5@8'/X>_P#G_P#70!4.
MD[?7KZ>GU_\ U4 -;1L]/P/%  -*.<8QTQ_G_.: &KI6?\_T_P _ATH /[)Q
M_GW^OM],^W% "?V3D_3K^'^?\]:!#1I/?^7^?I0 [^R,<8_S_G^M QYTDG@
M]/Y]?I_.@0G]C^G6@8Y=(]!_G_/2@"8Z.>HZ'Z_Y_IUH)'KI)'/^30 '1B#T
MP>!_D_RZ4%$G]D[NO7K_ )[T (NE8XX[<8H D;2-O7GGK^ H 0:2>X^G^>:
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M<Y_S_7_#0S.@TJP42G=ELC/)J6:([JTC$ X K(V1SMU(%=@ 6() ^OI_GTI
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M P!'NV5''!ZC/J.F.U:*!G*I8]:T/X,+:@238:51D#G:#]/T[_G0[(SYFSZ
M\/:7!:1#RD"CT QC'7^8XK.3-8JYT=](L 5P1O4\+GJI^\!_GGC/:H1JS?L;
MT7"@J&(.,$C (Q_+\.E KD'[VQD#878_!YR!GIU&?4<>OXBKH1>6&:0]57D=
M 3_5:5QV!--:$$M)N5FQM8 9)&>GO@D]\Y/>H;+L8MK="4- %X .S<>W0^^
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M*=@#^S0N/Y46 #IH.<CU_P _G]*0#AIP[>N?RZTQ#O[/!Z_Y[TADJ:?C_/\
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M==-*E<[:5!O<YR/7#/@ \<#MV_SZ]OR]:%-(]:%)(LI?;N<UTI'9&):63/\
MG_/YU1?*6U?/0_Y- ^4L*0?\_P"??_/-4.PICX_"DXID.%R7>7!5B<'CCC\B
M,'\B*Y:E!2.2IATPCN([%1L55.T<@#/;N>?U_P :Y5ACC>%,276&F8MG'^'^
M2:[Z=!(ZX45$9'<[\<\UU*)T*-BVA#4]C1(F\K%0QV)1*\9X)QD$?GG_ #^%
M9.FF1*FF:,>LS* JD#W.3W]./\]ZXYX5,XIX1,M1@7:LL[O)ECG)VCIG&%"@
MC.<A@1SWZUYM6C8\NK0Y2I.XC..BAE&.@ XZ<\#\JXFK'-8CEG$8*@%F.,*.
MN#P,]E4XQN.!P>_!1-B P;=KN0[#E<#"K_NC^3'<PYP0"10(E9<QOZX;'X9Q
M2$<P 9-P/W1P0,@]>3D8/Y'UYH M7D*HH50  "<#@#IT'^?QIV ^,?'B>1JL
MW49V'_QQ1_2N">YV1,J*X!P._IZ5!I<T(Y"@.3DGJ?\ /:@+DDESSR?6@#0L
MF,Q&\\<%1C]>?\_I0(Z$KOZ_G_\ 7I@5)0TAVY)7O_AW'UX]/7%,#:TJYV2*
MC#^+@<?E^O\ ];%5$B1VPT])>@_%<CW['_/XUM8QYK$=OX?+.YRPV[1D8/8^
MH[9]><C%+E*YQ+K3'M\ L3Z\#CCZ?X?C4M6*4KG+RV+>8.3T/ISTYK!FR=C;
ML]-+D#)_3\.W^>E4D3<^:_B=JJPZJKP.3-;JH# _=96+ Y]LCZ$&N"M+7T.Z
MBM/4Z:S^&<^KPI=W.HP@2JK*S'<OS=BS'!(QR!G!XZYK>-*ZNV9.JEHD2_%O
M0-5NY5U2YL[7R D<9DL8A'"0HP&98_E5FZDC )Z =*QG3<==S:-52TZGK7PF
M\#1>);2.^TV%0>5D.XLR..&'.>O48ZJ1UKOH035T>?B)M.S/9C\&KNX*O(Q5
M>A( X!_7KC_/3M43B<['867PBTZQ_P!://;TSD#ZXX^M;*"1SN;9U5KX+@LI
M 50(K>F"<@'UX!/X]N]:)V,[7.K@\.V]NV]4&[U/)';\/P^E3S%J)92%;63;
MP%<9 _VAZ?7^GK2O<=C6M$9F^5< YY;@?EUK-LTBBS;V!A=HW)PWS#!('/!Q
M@Y[=,]_RSN:I&_!;)",* H]O\\_4U%R^4GTEC&60C[C8_ \K_4?A3"QT<L"W
M"<\@8Y'L:=Q6,"[\1VFFCF1>^-Q4'\L_Y_"K2N0Y6.:NO&]L[(SE&16P<-TW
M?+D =^GX9]*?(3SW(;V1%;[1 VY5.1@YX_B'&<Y&1CUQZ"IL5<;J-]'(HDR#
MGH?7/8>IZ?X4(=SSW5+K[.OGR$!4^Z#QZ\M[YQ@'TYYXK&H[&M-7/G#QEXKQ
MN.\;CDDCC_\ 5@8%>;5K=CT:-&[U/G^ZG:Y8LYSSG_/^?PKS&[GII6,]AMS^
ME2QB=>E(:%1L?3'^1042JY SZ?\ UO\ /]:0&S9W.S'K_G\?UI@=?INH8QD_
MY_S]:=B&=YINH_Y_S_G-(1WNGZCNQ@T&AU]GJ''6G<FQT]O=[LTQ%];@..?\
M]:5QV$D?=3$5'4'\:5RK%8QXZ?\ UO\ /'_ZJ5Q6+D*[<50C5MG[_P">?\YH
M VH)L?Y_S_GUH T5EST- #'FW4 4)6X^O^?6@" \T 1E0?3_ #_G\Z !8L_2
M@1*L JD(L+;CJ1^M,!PM1W'^?\_6D QK//:@"M)8CKCGWI@5I;$#MZ_Y_P ^
ME("J]F/3_/- R'[$/3]?PH$1-9@<4K@0FU [4#&?912& M #TH 7[)[>W3_/
M^10 >2/\_2@0[R /2G<0_P"SCT_S_G\:8#?LX%  8,T 'V?]?\_Y_*F4(D'?
M_//\Z  6X':@0@M0!2&-,//2E<0\0X[47 7R,CI3 40C_/\ D_Y]:0 (0/P_
MS_GO1<8GD]?\*+@(8@>WX_\ UZ0#EC_3_.*! (@?3\J:&/$(_P _X50">7C_
M #_G_/ZH!WE"F TH* #8!Z?6@ "#\/R]J0!LQ0 [;FF(;M!Z4#$*]AU_^O\
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M.8U5\7*W!_S_ #_7^M,+FE!XK5OI]?Z4PN:,7B53WH*+Z>(%?N/Z_P"?PI7
ML)K"D^GIG-,"]%JB/[?AG_/TH%8U(KQ''7_//^?_ *W4$6@HD/M_G]/UIW&7
M5M@U "_9E_GW]J";$ZZ6C \=/YT[A8#I ;I_GI_G\Z?,3RE>2P8# ;_/^?\
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M JL@/ZT%%)P#FI$5R@_S^5(&5F4"@+#,"@8S:!0 !<^] #3C'3_]5 ";0.E
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M67MM+*Y!^\A!Z'CS,+33=W\CU<1-QCIU/T3U?0[?4(=EQ#%-$,;DD177:?\
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M?K_G\/TH*.KMKS'3GT_S_GZT@-^*YS[TQFLDF?I]:!%I"3SGG\J ) /\_C0
M\$D^U438#+M_7% A#<8H C-QG//^?\__ *Z '>>1Q_G_ #_GI0 \7&!0(G6?
M9W].GY_Y_G0!86XQQ]?QH$7([L+^&*!ER.Z!XSW_ ,_Y_E3N!=^U47$/-T/7
M_/Y^M,")I_?'^?\ /Y4 5'N >_:F459+C=_^JH J&;;^6* (FGQ0!%]JXH$1
M^?C.>/QH&)]HQWXH C-P/RH 7S\]Q0 V2YQU[?TH C%T/7Z<_P"?\^U A/M
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M+X/?W_\ KY[\5JL28O#'2Z?\3]^< G)ZLRCZ>I_3WIK$7,WAFC;'CJ6Z7K&
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MCZ?_ %J31)974QP@.6[Y]/7^E*PKDS7I7.WH>O\ G_"@8J7+/R,D^G?/X?\
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MU_#_ #_2O)/58TGO^?\ G'_ZOPH AQR..OY4 ,<#MW__ %?T^E $+?Y_SZ4
M0M_2@!GMC^>/Z5-@ #.,_P"?PH ESV'X?Y[_ ,J"KEZ-\?Y__50,UK:<K[<8
MQZ\?X?YQ0!U%A=[,<_7_ #V]_P O0@ [.PNRV/3O[?Y.:0'9V%UTST_/_/\
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MY^G\_2BX$9U+;SGVP/\ /^?4]F(3^TL8.?;_ #_GGZ4#(SJ87N![?SH 8-0
M[]?\_2@!IU'(P3_GZT (=0![\=1_G_)[T 1G4\]_Y4 ,_M+ISWXH 1M3P1[?
MY[CV]* (_P"TB/XAQ_G_ #U]: &C4S_GI_\ 6_S[T -&H[.3_/\ E_G_  +
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M?\Y_R?G<;A+ZH\ZK3<3R'1-9:WS$^<]*\1:GFR5MCOX(0X'K]* 1H0KW.?\
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MC4R>OTH &U+)_K0!&VIAA_C^6/Y4 -_M#'Z9SS0(A_M G@GG_(YH& U+/?\
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M3>^QGGC\?IQ0!6:])Y)_SSW/UI 5'N>N?\_Y[47 B>[QQFD!$][Z?_K]NO\
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MU(IO;9;-38?,7?(##BBP[F-):A6R.E%A7&&'M0,A,% 7&,@'% 7&D8H 9S2
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MVJ2M*^<GH/0#H/\ ]74\\YKRIRYG<]6$>56(T./\_P"%063#!_ST_P __7H
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M\OP].M"*CWA''\_S_P _YP 1->DCU_S_ )_.D! ]]Q_3V_3Z]_QIB*4NH_\
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M&2V<6V@"Y>/D4@,?K2*'1<'F@#TSP_JRVHYQ_G_/TJHNPFCKUU])!M[G_/\
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M\O\ /XU]'3CRG7"-CT"WB&*Z"RRJXH DP!UH$T(1G _SSS_G^=!)7EAW=?\
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MY'7K_3V/N/UI ,:ZW=\_F/\ /Z_6@"(W7ZT[@,:XV<$_Y^E.X%=KK=_G_/\
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MAV(_BC\1K37HH8;9D:.,EF8$DDD#@]!U%3)W$?'OB>=6)V\@G/ZU0SAB<FF
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M]../\_YXS0!$3_\ 6H  <].XH >SYZ]./\_TH (V]^/\:EE(G#\T#'*_^?\
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M;CL*Z;T.25)'%3:>T6?I_GG_ #CI[UX;F1[,IR6;-P<X'84>T%[,HO8 '(4
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MQ0!(#NZ\#Z=\_P"<T 1GC@]L?US0!59>G?M^M %.9=W;\_T_S_*@#,E0C/\
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M[JUDWXYZTQM&DN&'^?\ /^12$02@TT!D7:X! _S_ )_*F%CCKS<I)7GG_/\
MG\*:9FRS9Z@PP#^7^?\ ]5:HDFO+87*[L9KGKT541+1Y1K.FFU;=CC_/^?\
M.*^ QV&=)^1D8!7;SCC_ #_G\/K7DC(R@?J!GKGW_P __KH L1VL;]0,#V_S
MZT7%84Z4C' &/_U_0T[L7*A?[#5^G]./7K^?_P!:GSL7(C+G\-G.<#J3[<\$
M\_AU_P#UTIDN!SQ\)K:R><JX8Y/7^]SZ]OSXJH3L1.G<N0VS*06'T].#[?YZ
M]*W54Y72-*.5EXYQZU7M!>S-W3[>.1PTA&!@[>@;TS]..O\ ABE5(=&Y[-H>
MOV%B<JJ CV]_3Z_TKK5:)RRHR.BG\>6=Q\F1M'7(ZGMQZ>W?I3=>/<GV$C)N
M/'$2?ZEOEQPIX'?I_05+K(:H,Y6]\12:HV"<*.N&&#C./\^V>QK&57F.B%+E
M./U?Q$MNA6,[I/7T_P _GTKDJUK:(ZZ=&^YYS/,UPQ=VR3U)_E_+ [=*\Z3N
M>A%)%0IM_(_GSZG_ !_"I+&F@"%CQQ^?I_G^M $17_\ 50!#(H'&/\^U("!O
ME'U_SBF ]?Q_S_D4 7(QGMSP/U_S[=Z +T?KT_\ K=?I]:0%A>O/2F!&?\^U
M("I)D_S]Z$!FRM_+%,"G)D 8/% %0DK_ $]O\_UH A_*@!W7_/\ G_/:BY!(
MCX/?M_.@"96Q]?\ &@:9:1O\C_/^?:@HMJ_'/0^G]:0%A)/>F!<#$@^O^?\
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M7*)?-YSWJ;E(%?<!Z?TQ_G_&D,"=I_S_ )_G4B*$SE>E,1S6HS;$)SC'^?\
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M^?\ /M[?E0 JC(Q_G_/)H ?_ $Z?YZ_Y[T +G_/^?UH CP3TSG_&@!,9X!H
M0C')_#U[T 1FD #W'-,0TKC&.WO0,88<]NG7_/ZT[BL1&/VI$D;C_/\ G_/M
M0!"4Y_S_ )_S^;N!%C//I2'8AV#/^?Z<4#2(R,@_Y]_\^E P((_S_C0 W.:
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MUH MH_/Y_P">_K_G- %I7[]<9- %B-MW<>F/\\_YS[T 6"^XCWH MJ^?\_\
MUL4 7%?''O0!,']/IV_SUY]Z 'Y!'N?7O_GZT .W;L?K_G'^<T /#Y'7H?\
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M.PTM1<+#2](9&9*!V O3"PA?!I!859*06'EJ86(6DS2&1@TBD*": +J$KT-
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MP<'\Z0$V[I_G_/XT 3 X]OQH LHV>:8%A7[_ .?6@"=7'Y?Y_P#K4 3J^/\
M/TH LI)T^M %I)=O'?% %M) ?I^7\_\ /UH G23=QT/^/UH F1O\CO\ Y_ST
MH F63/&#0 _?GIZ=: 'E]W;]<_I0!,IS]/\ /^?P]>H!)O\ S/O_ )__ %4@
M'%O7I_G\?K28#]VW_"D JMN[]/\ /^?RH 0O_G_Z_P#D?7- QGF^O8XZ4"#S
M2.O^>O-  \V!ELGUY]J &&;)_3]?_KTP(C+MXS_]:@!AFW?Y_P ]/\].$!6,
MV>>W^?\ /^30! \F?3M_G_"@"M(=W?C_ #_D>U %-WZ?A_G\Z: JN=O^<50%
M<OGZXJ %!_GCTH 4'&?3_.*!C@>_:@"0-_G_ #_G\Z!!G%4 XG\* &*:3 &)
MS_G^N:0P!P/KQ0 X-B@0\\9S_G_/^- P4[C^?^/^- $@;'/^?:@!X;(X_P _
MY[T (".W^>/_ -?KVJP' 9% A0!C/>@",'- "*.U #<8^OZ?Y_G4W 9M].GT
M_P _XT7 0_E_/M_+-,!C\\4P&$?I_GU_SB@!A'OW_P G_/2D A''T]O\_P"1
M2N W;D?Y'^?3-,"%EQ^G^?\ ]5,"N8R>@R/;.?RH ^>8YRAKI3L<LHG46]E)
M<(& ZUUJ-SA<K$,MJT75:3B-2N4\XJ2QI%-H8P\5(P!S0,<#B@1+F@D<.*!#
MLXH*0Z@H1VQ4C(?,S1<!ADI!8C+T 0;S4E6$#4BK#@V*+A87?0 GF8I#&F7-
M #?,Q0%AIDHN%B/S,TKC'>9FBX#UDQ3!D_F TR6/5ZI,DD1N: )E;'2F23 Y
MHN XX-,!CIFD!5<%:!HHL:DI%)GS4EC-] #=U QX<T"%\R@!I<F@9'OI!8"^
M* L)YE [#E>F(EW\4K@(,4%)"XH!DH.*!#S)MH"Q \M R!OGH E4;:!B[L50
MQ,YH 4-F@!"U $>:0$@H :5!H B:/% $17-,#T7PCIYD8&O:P<+"/==+N#9L
MNW@#C_./\]??'M0E8$=D/$+$8Z'Z_P"?Z]*ZO:LH<NH&<^O^>]+FN,L!B?3U
MX]?QHN4('(Z=^G\O_KTKC&B3GC_/- Q#(3SDXZCWQ^//^% %*9L>G'_ZO\]*
MD9BW$X Z_P"?\_YS6;$<]<76W(J0..UK4%"X'3_/^?\ )I-F;9Y9=R&Y>O.J
M:F5[G9>&M%,S D5TT:=BK'O.B>'5'4=/\_\ U_6O7A %$[==)BA R!^/;_'_
M #WJ[6+Y30TZTBW< #IU[?YQ^M7$=B;6-($Z +Z54XW'8Y/3-,:T9E[>OT__
M %USQC85CM8%/0C_ #_G_P#56IJC408[]Z118 Y'UYH!"QC:/\_Y]*H9,/E_
MS_C_ )_E0,E!YX_S_G-!0OYU0F.49YIH0]$S5V)-BUB_#^M=,16+$T&1S_G_
M #TJQ6,N9!Z?Y- [&3.H':L6Q&)/(!_G_/Z>M9-DF)/)CGBN>3$9S'<#GM^G
M7/\ GTXK)@4KAASCI[?S^ON:AB.%UB%[D\9W8X]_;_ZU)(AF39Z.Q)(^_P"A
M'Y?2M5"XCT'2TE0D,.W7U_S_ )Q6R-$=Y"=PH-190"/_ *W^?:D44Y'SWJ6)
MF)<S;.1U_+_..E<TF!R.H7(0<>G_ -;_ .O7'-DMGEFL:^+9QD$\]/\ /^<4
MD[&3D=KX9\16^ 3QW].G^>/_ *]>M0FDC*Y[7H^OQ'@8[=\9_P#K?I7;[1,V
MB=I%?>< 1TQ_G_/X?1W-4$LA/OQ_6BXS,N6(_E6;$SP/XG %/K_]?_ZU?.9E
ML<[/G1CNKY @:10!(!B@!IS0 NV@!P6@!",T 1M2 ,T +B@!XH 0FF  D4 &
MZ@"[8C>:0T=9$ @_2DRBVI"<8'Y>U,9!*%?L/PH S+BTC?C%*PCFY]%5^E.P
MC(GT/;T%2!D2Z>T/2D!OZ!?O:.H/TI ?2F@71N803D$?R[?Y_E63-4;N?3I_
MGV_#\Z0R!SCCU_SF@#*N#V^I^G'% &)*N[_'_/\ GWH$9TO/TH HN.U4! <]
M/7_/^?:F!$?2@"5>.32 DW'Z4P)D/% $X/- %B-L<]/7_/Y?S% #HW*9_P 3
MZ_Y]* +*OLZ_Y^E %F*7GZ]: +,;GCW_ ,_Y_.@"TC+Z_P"?\D4 61)_GVH
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M >I_QH :!@_YX_S^/TH&!<G/% $V<=^/ZT .9_IV_'_.:: E&&[U0 <\YZ4
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M?ET_R>.:VN;HTRY'(ZX_R/\ /_ZV49MS/_G]*ALEG@WQ'F_=GU[_ )?YX_\
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M)M^OM_CW_P \4@(VD_S_ (?Y-,")Y=W6@"%FV],X_P __J__ %TF!&7[>O\
M+^?_ -:D! WU_P _Y_E0!&3DT -R: '9 _.@9(&YY_G0!(I Y_GU% #6;/7U
M'^?\_P JH!S2;R.?\]/Z_J/6F(;TJ6 H8CGKZ?Y_SZ>M(!4]?\_Y_P#K]Z )
M<4 )W_S_ (T#)!Z\=!_+_/O0(D!!_P _Y_SQ0,>/F[=_\]__ -= $@].O2J
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MG5 2;<\?E4@,V_GG'_UZ $//2@!,X_3'^'^- %<\<C'>@!2A'X<T *3Q0 W
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MY/I]/\__ *JS8R$R!^,\8I,"G=1D@$?E_P#KJ1,YN:0H<'O0(@%P7XQG_/\
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M_P _YXH :9>F* (3+CKR!_*@9%YA %("L9=O/K^% AAD[_\ ZN: $:0CZ]J
M&F0=J $+\?C_ (?Y]*8$(ES_ /6_S_DU0!OVG)]J (R^?\\XZT@!I,_CV^O^
M?\]:5@(N@YY_K2 "] "@GI_G\*!CT<$^O?\ S_C0 X-D?E0 \,>_^?\ /^?<
M 3..OI_7B@0P-NY_S]*: 4.3C'^?\]O>J D4X/'6@"4G'!_SUZ_YZT 3'KZG
M_/\ ];KZU-@'$XY [_Y_S_C2&/'Z]* %!VC'^>?\C\J!$G!]C^7^?\CVH&2A
M@/\ /Y?U_P ,TP)0>/\ ZW^?K]*!$H/;'X?3TH &&[^61_G_ #F@8?TH 8,
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M:=RBR),]>O\ 3_/Z_2JN!-'.#5)C+:3YXR2*I,9;CGS_ )^M4F,N)=@#_/\
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ML*8(Z.$G.>E(LW[;Y1CG_/K_ %_QJ@+I;/O0!2E&>E2P.;O1UI 8VW% $#T
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MQ%(IY_''^?\ /TIDEF*3S#Z=ORI#-,(&/-,""7,1SSQ_3K_];\Z9+,8ZRX8
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MU^M2,KR=?KG_ /5_+\*!E5VVYXS0!4<X/(_6F(J,* *CY/0?Y_SBD!5=>U4
MQA^=,!C<4 ,QB@! IZ?I_.@!G7UH 4#%%R;#]OIQ3N.PA&?SI!83&>.3_C0,
M81D?YZ4 *#@?Y_S_ )_"@!ROW/\ DT .!SP/PH F5L?3WH L(V[Z4F!(K@5(
M$J2<>M,!XDH  ^: %$F?_KT &_''M0!&7QUQ2&1L^.*!$#G'2@"/?Z?3_/\
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MN^G^?\_ICIFM5(#5CNOK_G_/\JT4BC5CN@A/MWJ^<=QDMZ%[]N/_ *WM]/\
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MA.Z@!-V:!#]] #P<"JL \/V[?YQ3 <'Q]:0#U.?PJ0'A]@_&@"8/^7^?\]Z
M)E.>A^E $P>F!*&[?YZT .SW_P \T 2*0* 'A@: + RO2@9..F/;_/\ *D!9
M4YS_ )^M #E!8X]O7_/% B8?-Z?7_/O_ (4#$ [>G2@!Q'.?;]* !O;G_/X^
MG]: (V4_C[?Y]Z!$6W//;_ZU Q^ 3Z#/;\#T_P ]^* $4;O\]* '+QWP/6@#
MT62(.<<YKZ4^;9B7-N"1[8/^?I_GVHDK3Q!1^?\ G]: .7O(=S\<#G'M5HAF
M'<GRSSR#5&;'0KDCO04C0ME%PWL!4&L3<6VW $<-VQ4E" LK#(X&.A_ET_\
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M9J@#% ![_K0 A7'L.] "$8]O6@!0* %8?I_G_(H 0K0 ASG\: (W&* $'O0
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M[<T *3_GI_G_ #S0,0G;CFI0"-\],0X?-_A0 C^_2@!F=QH 9@BAL!2 N/\
M/UJ+@*.#1<:&D?Y_G_2D4 R:+@. Q_GBE< QSGO1<D9M!I QF,_Y]J!#&7L,
MT[@)LS[4@&[,].G% $;)O/Y\T7 0ICZ_SHN!:@X/'^<528&DZ!QZBM>8#/5=
MO'^?\_E7-*87+ 7&,>I_S_G_ .O6#J!<4G\JP=87,,+Y!^AKGE4N1<C#9//^
M?\YK%L5R/.ZIN-!M[?Y_QJ2B0@X]:D8\';4L88Q[YI / SQ0 TCVH 51S0 N
M2.O% "CVQ0 A?;_G^M %*XU6*WZD9HN!JZ>XO5WCIT_R:D#F?'2^1;9''/%
M'@N235"+< !ZT"+?V=KKA 30!WF@^#&DPT@I7&>K:;X=BM1]WGFI;&CJX;<)
MR.G_ -;Z?Y_6E<JQ<1:!EI><=J (YK5;H889^O\ C0(PY/#L;'.!G_/^3^E/
MF%8GBT1(^W3\_P!*+A8T5MQ .!^/^?\ Z]0RB&0_Y_S_ )Z4@*,O)_#@\T#*
M#X)]_P#/_P!;\J8%8GH?\_Y]: *S@-UZ?YX__55"*S#]/\BD!78[?\_Y_E2
M@'/Y4P&"@"+%#  ,4@',,?Y_S_GUH 4#'7M0 $ ?Y_SQ5 .(H 9R* ' 8H ,
MY]J %Z4 &.GK_P#6H 5>O^>E ";: &;: (W&: &E0>O^>U #%]#_ %H <1CK
M0 G3CK0 IH 0@#TI,",Y _"@!&I@1<T 0YQ4L!.G2D F<B@!H/&:H!1BF WK
MWI,"(DFI C8"J0#&I@,+8ZT --2!$6Q0 N[- #EXH <'Q5 /W8YJ6 H;)YH
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M%!(W&X?Y_P _X4K@#>H]*=P$(]*0 R[O\_G2N >5_G_/:BX#Q&*AR <ZJ/\
M/XU#G8FY#@(/2LW5)YA!<%>E8NNQ<PB,=W05DZC8<Q+O_P ]:AR%<C.14B%)
M_/\ ^M4C$W_YZ_Y_R*0"A<_Y_P _Y[U+&AQ'Z=/I4ECL]NU2R@^_2 .GO[4
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MT 1!=WXT -(]Z (P,<?UH 9MV_E0 <B@ Q^.* &]?\_C0 BG''^>M "9Q^%
M#-N: (\YJ6P(C\W^?2D!&>>: &Y_/K0 \<?_ %ZH"(\&F I...U $>*D"(C%
M- '%,"(XH A8YI,!II ,S0 H.:H!U $@.>* ),]Z0"C Z?C_ )_G0P'@Y.*
M'[A^?I3 7=]* )0P_#_/^?\ "@"3?W_SZT@)D?%2 _=@_P"?\_A0,F5^,_G_
M /KI 64;C_/^?\^E,"S$V>G3Z?\ Z_\ /YT 74?_ #_G_/Z4P+R,/\_Y_.@1
M<CI#)E6@"VJ^G^>E $>W^7O_ )[_ .1T! 4SWS_G_/U]Z!C"AZ^U(!C1AC3
M>$S0 W!7G//^?8T >C/ HKZ0^<,WR!O;VH$5[B(#@50CC;FW#EN?UJKD-7.3
MN(S;L?2K,7H-C?=S2*1-(0!4,U1+&H _#_&I92+B$IT/T_K]/\YQ4EFA:,8P
M<@9SGCT_S_\ 6I#+DTN5./3% '7:1%E !V_"F(T[A3;\C@>AS_G_ #^0(XG5
MI=X)'0?X4P/"%G O<GH'%,AK0]\CL%O(ACOC]?\ /O4&B((?#[(2<_IZ>O\
MG\*D9NPZ<5PO3'^>E2RR<VS(?\G^=)C%>1DX(I#0IFXQR32+&(03D?Y__52&
M/E/Y]Z (R..O^?Y4 95Y!OZ<4 94MJ>WZ9IDE)Y6BX/Z?Y_'FF)D,B"9>/\
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M_2D41YYXZ_I4@,R2?\_E]*0QQ84C08\H!QCFI8Q$F#\>^#_.D!-N!Z@9/X4
M+N[#F@"C<WB6O+-BI Y+4O&4<0VIR?P- C@;WQ!+=D\X!I@9*R%SFF(M*,T#
M/5? .DD'SVXQTJ6"/Z!_V./^">UM;VT>O^-[7S;F79)::9+N58%#!UDND!&^
M1L ?9GS&D999D>1S' K#;/URTW38-&@CMK:-(8(46.**-0B1H@"JB*H"JJ@
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M':F UN.O^?>F KC/UXH 8W/-)@1LQQGZ&D@(V';M5 18ZT@(R,4@(SQ0 AH
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M\\B@8Z4;%Y'Z?TH SBWX4P,V:6F29FX2MD@XZ9_S_GIS31(KQ=<4Q&5+G/\
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MVDRR_P"34-%$^Q3^-( ">O\ G_/^<5($BKCIS_\ 6H FSL''%# C:3/^%("
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M,9=4)8H&"%W*[VYY*S-T[GO-24?R\_\ !17GXGZW_P!N/_I!;5TPV,9;B_\
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M (*.?M"^)_@-_87_  CE]]C^V?;_ +1^X@EW^3]E\O\ U\4FW;YC_=VYSSG
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MAB@!E(!K<TP(BN>:!$96@"$K3 :>*8#: $"4 (!4@/% "CBF@''_ !I@-VT
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M0S0L)=XYZU)2-08/MF@8@7;2N,> >V>.O^?\YZ4Q#QT_S_G_ .N: &R ,,4
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MZ4BQ,$G\>/\ /]: /Z"?^"48(\$W^?\ H-3_ /I+9TT0S].*9)_/W_P59/\
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M^E %=UZFDP(2,_UZ4@(F4^] Q/+Q0!&4_E0 NW/% "&/-("(C''2F!'MQ^5
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M "-W3_/^?0_TH :H/?KT_/\ S_*@!7&>O/\ G_/O0 C4 +C- #A_GM]?\YH
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M 'J  #TYH 1_8?A_G_/TH 80.O\ GKG_ #^5 "=?\_A0 #VH  NWJ* $QW-
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MS#C_ #_^N@!V-W_ZO>F(.O3-,!&&: ,RY78<T"+MK+Y@XH O;L^M "-QU[T
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M XYYS0 OWNE $GWLCO0 #F@!!@?XT (XQG_/2@!,=O\ /^?\* %Z"@!I7O\
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M3!L8YJS%:,]?\(N)8D]P/\*PF=5/8WM7C(!/L<>_^>O^><S:YB";SHB!G/\
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M<<D:HBQR2[]WFLS,639L7 ?>2G,=)^:K\?Y_3I_G^8,A>DP/U@_97_;]\/\
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M.._^?Z4F4;*_/G'0<?3^M(9>M\(X_P _Y]* .J@"M4&J)98P1TI#$55P,8H
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M_E[U469M'7BY\Q?F=CT/WL>G88]ZU$;5O%#"?E5?QY_GFK1F:$U^ RJO PW
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MYH KDY'^?QI6 ADZ>_\ G_.:18T#/^':@",<T '6@!/SIHD<!@TQ"C ]^M
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MP&!3F@"UNV]>.@S0!.4W#G\:8C%N80Y_&@#G[RSR?\_Y_P :LS,-U.<?Y_\
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MU%2 \G\O\_Y_&@9*IS04*IS^= $@;% $N=QYH  =P]J $+Y^O^30 XO@].:
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MU]* #;2L X# ]: ' 4P#;0 H/2@!"*  +B@!=N/\_P"?>@!P- "%<4 !!6@
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MJ'''^?\ /:BY1FRP&+YA5IDM$UO<YZT F:J-N'%(LG7Y>* %4^_^?\_YZ4
MQG-*X%2XMA*/?_/^?I33 Q03;-5[DFS!="48J!W+@/?K4@,!S2 3\* $W9_I
M0(4_,*!C NXX- $;#'^?\_A0 FXI_DT 2>8/PH 1L,.O7F@#-GM@W;- &-/I
MH?/'TI6N38PYM)]JS<!6,]],*]JS<16(O[-:IY!\H/8^7R:.0+6*<L?H*EQ(
M)K>R+FJC"P'7V&E%B,CBG*=AG>66GK; 'W'\_P#]?%>=.=S)LV=O7\JQ((HA
MDGZG_'O0!/(-V#_GUH :S;.O'Z4P*PNU7/.>>W/I3)9').9/X3P5Y-(!^)']
M!]>?\_C0!&D+;CESR!T&/6F!H1*J\D9^O^>O^?H ;MCJ 51CT^G^?_K55Q&[
M#J&67GUJDQ-'51WVU&]E/X<'W_SBM4S!HZE-06,<D#_/Z_A6MS.PD5RTZ@QK
MQVW<?EW/Z=*!6(5M<A2Y+-\O)^Z.GW1^F>2?6D,NR2@,22  .23Q_GCO5"+-
MONE4"+&.FYL@<9Y ')_\=!'(8TR67(+98E65R9&P"&?!Y/HH^5>N,CG_ &B*
M!%*++PY.2=A^O3_/Z]* (=0N A7N6)PHZG'7 _$$DX [GFD49QB-PQ\T @ 8
M7JN>>3TR?PP.U(9<SA1CC@<=/3_/^-(I&;=2$[E3KCD^G_U\=/SZ=9&ARH(Q
M@< 'I^'/U_G2&5Y&\[H,)\P;U)!Z#\>_MC'H%$-TVV/ ZA3GV%9SV*AN>8Y.
M/I_GVKQSUQ&?':I&D5G;L,<TPL5W(';_ #_GC\* L1[]F?K_ )_2D41,../Y
M4 )G- "@8^O^?\_X4"&D8Q0)B+_G^54(<30 A.?\_P"?\_J -+9]?_UT &[;
M]:  G H F)'TXY_S_G\J (L^O_UJ (#+QC_/^?\ Z] $+-2*1 >!2&1%<4 ,
M'/\ G\/\_P#ZZ (B<4 31#\>/\C_ #_.@3+0!Q^7TQ5$DR\?Y_S]: $V\4 1
M2?,/K4L:&9'8_P">E!0X>X_S_G^E40(?Z?\ Z_Z4 (>?\CVH C#Y/M0,<&SU
MJ1V%#[C0,<).WIG\C_G]: )!)VSV_G0!)YN#GL>WXT !DP?\^] ">;GJ3TH
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MSUH 0C'YT )C- #L9Y% " '\* 'D=Z $4=* #&* %S0 <&@!,B@!,4 .SC-
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M[J07/0_=Q_/K]/3K5)D-'96#(AR .O4Y/\\GVK:)BSI].?Y!ZD#^5:HR8C7
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M/>F())693A<<=S0(DVN_0@9]!ZT (8,L"22.>_T]/I0!=BMDAQ@#CO\ Y[T
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M.>P0.V>GO0!"[\XH B+[O\^U #2W^?2@!FX&@!3Q_G_'\?K0 N[=0 TL1WH
M3?QC_/\ G_/:@! V[GT[U1!'N/'Y_P"?\_E0 W=_]?\ E4C2';J"A,^GI3N*
MP_/:F2&>^?\ .*!C&!J1D!7U_P ^E QA&: '"//X4 -$1/X4 /\ +W?7_/\
MG_Z] $BID?Y_^L?_ -5 %I4[&J):)?+W>] AVS% $93/7I2L,A*GL*10GE<>
M]-"(2A'^?\?ZTR2-X\C(H&BJ5QU'^?\ /%245W.* (B<]: &&3O0 WS,\=:
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MV6[GZ>G^?\FJN18I7!*\XZ=Z86.<*')X[_\ ZZM,S:,BX!8'CK5D,Y+4M/\
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MI+G%;IFB-VWFP*9JF7PV[ZT%W(9(L^O^?\_K0,KJ3$>: +\<H?FD42-$)13
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M*NX>O'^?_KT[@S!,)()]ZH@R+J+:*I$-&&\.X8-418X77-)\S)'4_P"?\_\
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MB@!3(N>O]33$R%I23PI.1Z4Q"XDEX  _S_G_ .M0 D5NQ"Y8X_S^- R8VRY
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MBF V'[H)I7&2,ZH1D_K[&D \2Y.%!/'I0 Q&<IV7J>N?Y4 +%;LQPS'O[=J
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M -8!(J?Y]Z ) ,4 2J!P?2@ V;: %\O_ .O0!'L_S_G_ #_*@!X7% $BC_\
M5_GZ4 2*.* 'JE $Z*,_Y]* +T:9Z>U-"9<1:9):2/VH&#0C^= BM+ &H IF
M//?_ #_A292*_EBD,HRIM_6J),Z:/'T_E0(R)HPO';I]*DHRI$Q5"96=<_6@
M1$PSTH&-(SU% ";/3]/\_C0 [;B@ V_Y_3_Z] "8W=* %QB@!P],\4 *.30
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M5?3GK_A0 U;H-ZT *)F=A@ <'J?I_GF@"<*S\LV/I_GT_*@!;6W!4;B3^/\
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M/Y4P' _Y_P _Y_2@!.O3\.] "XS^HH 4C=C]/\_XT &/3_/'T_SWH 4KCF@
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M%ACB@"'I0!$PH :10!$<#F@!A&?RH 3% !C% "T  H #S0 [&<T +TH 3I0
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MQ B@"XG&?UH  1F@"<..?7OTH 2.3RSP::$T:D5P'';IBK3(L(JAB?\ ]?\
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MX_Y_S]* #MS3 7%,0\/F@995Z0$ZMC_/^?\ )I 6%/7_ #^?YB@9.O\ G\Z
MN2@YZ_Y_&@DD!Q^.<4 3+B@9+]<__KH$.4XH*L3*/Y4##/.#[?Y_SB@!=N*
M C_/Z?XT 1%<_6@",].?Q^O^?\^@ S\JD!!CGV'^?\B@!C CGM0!&R<D?S_E
M3 C*\8I@0D9S_G^= $+I^- %=TS^- $9&/K0! 0#]* (&7U/- $9X_I0!$0
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MR/R\'M4M7'%V/3=$\3B7"2=?7ZUC*-CJC.YV*E)0&4Y%9EDXC!H 5$ .#S0
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M?/N,G^=  [YQ]10!(S9XH B2103DCK]>U $CONQM!/(_SV_S^@,=M=_0?J:
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M_/\ GZT '3\J %##M0 \&@!#[?Y% !MYQ0 [M_D4 *#]?\_Y_P \T /4YX%
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M, G@=3^E R.0! >/\_E0!1A&%'TI .?A33 LQ)_+_/\ D4K@2YRP_/\ _72
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M?6I;*.2?]X22.3G/^1692&JH7IC&?\\TRALJ@K]*3 D"T@(67!_"@ >4)W%
M%6.8$#J3CTIB'M(S=!W_ ,^E,88<]<#Z4@%,1).23TI .-LI[<T 31@8% #A
M\I'/K_C0!.#B@1%'TQZ9_G_G_)H&,E<+C)[^M #C.,?+DF@!B2,Q.!W[_@:
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M!7%>6>F,/- $9P,XH ;QS0 !OK0 HYH 7]* #- #@=U !F@!1\U #AQ0 H-
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M7(:.?N+3!^OX59-C#N[4KTH$50Q'8_Y_"@"6VO9+%\J<"I<;C4K'H.F^(EE
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M921IE/*Z]LU%RAROYO'I_G_/TH M-B,<\4#.9U*Y,Y*AC@?_ %JS;-$C):(
M\]\\_C4E$F![<^M @4Y'XT#L.=S@FA@&ZD!7E?!!/O\ RH &N0._Y?\ ZJ (
M8I2V0H)Y[#VH )6=@< ?G_G\*8$X#-R6_+_/^10 -"">YZ]Z0$PC7T'^?K0
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MU)H&1-;J".M("58]O:@!T?4T 2LO:D BGC\* !N,<]?6F >>I[_RI@1+(02
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MHL >;NH <6S18=R,M3$!<CKU_P _6@!N<]* $- #2.WZT .- #&;/- $#'%
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M%(YG7I-Y49]:X:[.R@CG20*Y3J(7/^>] %<\?SH B>@",\F@!JT  XH 3@4
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MX&@"QC% QB'(/U/\Z8QDKC&,CJ#^M,!//'49/'I2 $9B3@8SZT@)60D<G\*
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MV>@"+S-M "ELT ,+4 +O_P _Y_S^5 $N[% #A)0!(K9^M #@<#'I_2@!V:
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MTH"P]4I#'8_^M0 XJ3_GUH ;S_G\*! PS0%B/%,0F*8"'F@ ]Z $S^O/^>M
M",<T -QWH C+9I ,+_G0@(=P'_UZ8#'>@",G/2@!FZ@!H.: #I0 \<B@!RT
M.!Z4 2 CUH E7K0 Y1B@!>M  &_2@!N: &DXH A<YZT 59#0!3D- %61L5(T
M4Y*8R!O:D!$:0#,T@$ Q0 N[% "BF X&@!<T (30!$YI 0L:8$;'- 'TZZ8
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M $S0  YYI ,9L>E [#<TAC&- #*!,@8YJA#>M $;<4 ,W4 ,SB@!U #@3@4
M2 T /!SQ0!8&*0 3CI0  8I@/!H 3=0 $\4 1N: ('.: *DG'6@"M(* *KFI
M&BHYS3&5VI ,-)@1F@ I *>*8"T@%%,!* $)I 1,: (F-,"(G'6@#Z6FN=^,
M D_X5Z[/)1"9V?D+QZU)17C,ASP.OO\ Y_S]:!D<_F)Z?E_G_/O0!+ CD8R.
MW;\Z )6B8D#<:D"1H<\$F@9$ELH'/J: '26ZX/% #Q$H[4 -9!D4 /  H ;_
M ! ^U B3&*!C >3]: )J (H^0/\ /TH )3D'Z?\ UJ  C\^: ('ZCZT 2]*
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MB/I0 N:10=._K2 &?B@0W?@<?2F(:'Q3 !)D5(["F;/UH&!E[4 ,\_- !YU
M#3-0)C?/_E3L HG-%A!]J]?\_P"?RH 3[1W_ ,^G^>] "_:=M(!&FS3 %FY)
M[TP+22T 7H;C;W[4 71.33$5I9L4AF9,YH R9FV^U %7S: %\V@ \S- ";J0
MQF_/^?\ ]=(+"!J!DF: '*U-"'H<?6F(F5Z +"&@"=3BI*)0: ) U $RMB@!
MXXH 7/:@!"U # ?>@!#QQ0!$6Q3)(P,FF S% "@9- "'G\: $;@9I#&D8_S_
M )_.D,CVY% #" : &D9YY_7]?\]JH1&3GO0!$X_6D(;GF@!I- !FF \F@!]
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M F,\WDYJA#3-BD T34BAIFYH 89?RIBN-,WO_DT"N-,QI# S4 1^=5" SYH
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M5''84P'2HJCH .* 'E1Z4@&/@$<?YQ3 EZ4 1X^;\/\ "D!*1FF!'&W)^O\
MA2&29Q3$)$W H ;,?E-  30! QZ>Q% $XXH 8YW'\* '$YH K?Q'IFD,=G%
MQL;!LXYYH 1FS0!!&V5% $4K@#MT]:0#8Y %Y(_/_/\ G]*$*\X/?O0(=]H4
M=Z &M<*".:0R4W"@<&F(A:8;NO8T@ S+ZBF! ER 2,]Z0$QF YR.M,"!)@!U
MI ->11_%Z]Z !)%VCFF!#+(N.30,<)5'M2&1RS+CK0 [SP.G\J &M/R, GKQ
M^%(!QE)YP:8#0[%AQV/?Z4"%W.>U QB[R3T'2@!ZHQ[T""&,GJ>YH&2F+CDG
MI2 (X0 * '/& #0!($ '3B@!KJ&('^>* )/PH 8/O9H D)"_Y^O^>U $*2CG
MZFD IN ,_P"%, 60] #0!"[,V..] $NUG[_E0!$82S=3T]: )1$!0 B*!GZF
MD!(QVC(IE #Q0 C';CZTB1I.:8$+2 -U'2D,?YJ]N?PH 9$Y89 _S_GM2 5]
MQXX )H&3%,]2?Y4P&^4,G^M  0%&,8I (AP!]* (Y#R/K_C0 _.:!$:.%YS@
M<_SH&!D!(Y[_ -#^% $C.S=!^9_PH 1$9Q\QZCL/ZT  @&XD\_7GUH >_;Z_
M_7I,8,P /T/\J!"/,J__ %J &*S$?*.YY/UH :L77.3_ "X_S_G- R1% ) P
M.!_6D \'+<T *&R>.<8_S_\ JH 7;GD\G_/^?6@9:1<+SZ8JB28/NX7GW[?_
M %_PJA%ZWBYR3DC_ #Q30F:L)QGZY]:LADPNMRX0;CT]OSZ?ED^U5<DOPVA9
M@TG.><=A^'3/UYJB66IW" ] /_K"A@9K_O#DCCM_B?\ /%9LM%:63GV%0S1'
M-L:\]G<B!C2*(F;;0!$7_6@!F^@!IDS0(C+Y_P _Y_R*!C"V: (B_:F2,+[*
M8$);% $32T@(VDR:0[D#2XH&,\V@"/S2*8">92 ;YU #?,H)8PR4#(C+CF@+
M#/,S0,3S,T -,N:!6&M)0 I?- QN^@!OF8H 0M3)'9I@)F@!X- $H; H >C4
M 6TH N1G'- %P-F@ =J *4G&>: ,RXYH H$\T /S0 Z@!V:!B$TAB 4@)5H
ME!H DQBF22*,4P)QQ4E$P- $PH F% $ZT /- "YSS0 F,?6@!A- #3B@",_Y
M_E0 P\4 !./\_P#ZZ:$-+4Q!G_/TH CR: &DX_6@!C4 -)I#0PTAD5,!C'%
MKD;4Q#?I0 A.: '@T 2J*0Q:8A_2@!2<T  - "YQ0 N[B@8?RI#&D^M(!A%
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M^<4 -DMQCWQ0 )" !Q3 CEBP#0 ]8QBD,CD&.WI0!)MH C+[2/2D!,,GVXH
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MS0!.D8/:@!40#/\ GM0 ]>E #4Z#_/:@ D&?TH G*T 02#YU_'^5 #NM #$
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M $4 1F@!C?UI 18I@1 9% $6* &GD4 1L,9_SWH :10 WI0 P_U% "$8S]*
M%Q3 :!0 H% $;?X_TH$,/^%,0X<DTF IZ4%#3TH <.IH :: %49H 9WIB%%
MAX%  G^?UH LK0!..* '4 /48- %L<XH %H 0_UH @D'- &<QI( ZTP%Q@T
M.'(H 1N!2&/ XI#'Q<T 2K_C3 E7_"@"0#FD!*HYH <@H GCZ4 65&<T 2+W
M^M #\_Y_"@!3QG\: $:@! .WM0!&HX_$T ,QF@ (P?SH$1MP30 T=*!"O\O3
MUH&,(P/PH!C,<TQ XI ,(I@0]_QI , R?PI@,(_S^% $ &2?K0 8X/X4P' ?
MRH ='R328$@[4@)@,C\Z8Q2*8$I7&* &J,_G_6@!R#-(!N>E(9(PP?\ /O0
MP]Z !QWH KR<4Q,KO0(K,N*!HI..M RN3S4@0&@!IH 7O0 W.10 4  H 8*
.&'F@!IH :: &&D!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANOFI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001121404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">&#8364; 9,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 10,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">40,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">3,563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsNoncurrent', window );">Non-current income tax assets</a></td>
<td class="nump">541<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,967<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">87,942<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">37,017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">9,618<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">7,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">3,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Current income tax assets</a></td>
<td class="nump">397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">15,359<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale</a></td>
<td class="nump">238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">124,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">132,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>Equity and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to equity holders of Sanofi</a></td>
<td class="nump">70,008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">271<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">70,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions and other non-current liabilities</a></td>
<td class="nump">7,116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,166<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">25,621<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">7,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilities', window );">Current provisions and other current liabilities</a></td>
<td class="nump">13,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="nump">252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">29,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities related to assets held for sale</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 124,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 132,798<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;569 million and a current portion of &#8364;72 million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Income Statements - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit (loss) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 19,889<span></span>
</td>
<td class="nump">&#8364; 18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,881)<span></span>
</td>
<td class="num">(5,966)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,460<span></span>
</td>
<td class="nump">13,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,717)<span></span>
</td>
<td class="num">(3,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,506)<span></span>
</td>
<td class="num">(4,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">533<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,476)<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(210)<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(430)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5],[6]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5],[6]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[7]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(711)<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[7]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the&#160;equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,837<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5,812<span></span>
</td>
<td class="nump">&#8364; 2,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,225,500,000<span></span>
</td>
<td class="nump">1,249,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares after dilution (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,230,700,000<span></span>
</td>
<td class="nump">1,253,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent', window );">Basic earnings per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 4.74<span></span>
</td>
<td class="nump">&#8364; 1.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent', window );">Diluted earnings per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.72<span></span>
</td>
<td class="nump">1.79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.40<span></span>
</td>
<td class="nump">1.64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings (loss) per share from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.34<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings (loss) per share from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.33<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2.39<span></span>
</td>
<td class="nump">&#8364; 1.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BasicEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">&#8364; 5,837<span></span>
</td>
<td class="nump">&#8364; 2,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">5,812<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses)</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments', window );">Change in fair value of equity instruments included in financial assets and financial liabilities</a></td>
<td class="nump">222<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax', window );">Change in fair value of debt instruments included in financial assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Change in currency translation differences</a></td>
<td class="num">(5,203)<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(95)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="num">(5,318)<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeFromContinuedOperations', window );">Other comprehensive income from continued operations</a></td>
<td class="num">(5,077)<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive income from discontinued operations</a></td>
<td class="nump">303<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations', window );">Comprehensive income, attributable to owners of parent, continuing operations</a></td>
<td class="num">(2,097)<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations', window );">Comprehensive income, attributable to owners of parent, discontinued operations</a></td>
<td class="nump">3,173<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="num">&#8364; (13)<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive income, attributable to owners of parent, continuing operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive income, attributable to owners of parent, discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) On Remeasuring Debt Instruments, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeFromContinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income from continued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeFromContinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income from discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Attributable to equity holders of Sanofi</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserves and retained earnings</div></th>
<th class="th"><div>Stock options and other share-based payments</div></th>
<th class="th"><div>Other comprehensive income</div></th>
<th class="th"><div>Attributable to&#160;non-controlling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 74,353<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 74,040<span></span>
</td>
<td class="nump">&#8364; 2,530<span></span>
</td>
<td class="nump">&#8364; 313<span></span>
</td>
<td class="num">&#8364; (1,184)<span></span>
</td>
<td class="nump">&#8364; 67,499<span></span>
</td>
<td class="nump">&#8364; 4,944<span></span>
</td>
<td class="num">&#8364; (62)<span></span>
</td>
<td class="nump">&#8364; 313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 72,997<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72,690<span></span>
</td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="num">(1,371)<span></span>
</td>
<td class="nump">65,093<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,355<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(492)<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">154<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Change in non-controlling interests without loss of control</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,857<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77,507<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="nump">68,185<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,774)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,772)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(3,988)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,868<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(34)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 70,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 70,008<span></span>
</td>
<td class="nump">&#8364; 2,456<span></span>
</td>
<td class="nump">&#8364; 11<span></span>
</td>
<td class="num">&#8364; (975)<span></span>
</td>
<td class="nump">&#8364; 65,689<span></span>
</td>
<td class="nump">&#8364; 5,430<span></span>
</td>
<td class="num">&#8364; (2,603)<span></span>
</td>
<td class="nump">&#8364; 271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2024-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee share ownership plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effects of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of services obtained from employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareBasedPaymentPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareBasedPaymentPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parenthetical)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 3.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Taxes on Share Cancellations</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="num">(34)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember', window );">Reserves and retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="num">(3,794)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="nump">3,868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Taxes on Share Cancellations</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Attributable to equity holders of Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Taxes on Share Cancellations</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2024-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxesOnShareCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes on Share Cancellations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxesOnShareCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from (used in) operating activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5,812<span></span>
</td>
<td class="nump">&#8364; 2,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForLossesGainsOnTransferOfBusiness', window );">Adjustments for losses (gains) on transfer of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,881)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod', window );">Share of undistributed earnings from investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset', window );">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains and losses on disposals of non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Net change in deferred taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(539)<span></span>
</td>
<td class="num">(749)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Net change in non-current provisions and other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of employee benefits (stock options and other share-based payments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue', window );">Impact of the workdown of acquired inventories remeasured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other profit or loss items with no cash effect on cash flows generated by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,980<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile profit (loss) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(785)<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities', window );">Net change in other current assets and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">620<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations', window );">Cash flows from (used in) operating activities, continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">3,367<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows from (used in) operating activities, discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">188<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">3,555<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Acquisitions of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,420)<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisitions of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">(538)<span></span>
</td>
<td class="num">(1,885)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisitions of other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(423)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">434<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposals of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherNonCurrentAssets', window );">Net change in other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashProvidedByusedInContinuingInvestingActivities', window );">Net Cash Provided by/(used in) Continuing Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,979)<span></span>
</td>
<td class="num">(3,355)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities', window );">Net Cash Provided by/(used in) Discontinuing Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flows from (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,727<span></span>
</td>
<td class="num">(3,413)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashInflowFromDiscontinuedOperations', window );">Net Cash Inflow from Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issuance of Sanofi shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsPaidAbstract', window );"><strong>Dividends paid:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,772)<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities', window );">Dividends paid to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Additional long-term debt contracted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares and related tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,003)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Cash flows from (used in) financing activities, continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,441)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash flows from (used in) financing activities, discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,489)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of exchange rates on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale', window );">Cash and Cash Equivalents Reclassified to Assets Held for Sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,918<span></span>
</td>
<td class="num">(1,915)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,441<span></span>
</td>
<td class="nump">8,710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 15,359<span></span>
</td>
<td class="nump">&#8364; 6,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes non-current financial assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Of which:</span><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025 and June 30, 2024, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2025, this amount includes &#8364;(667)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;3,353&#160;million, compared with &#8364;6,060 million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForLossesGainsOnTransferOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on transfer of business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForLossesGainsOnTransferOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for noncurrent provisions and other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents Reclassified to Assets Held for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashInflowFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Inflow from Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashInflowFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashProvidedByusedInContinuingInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by/(used in) Continuing Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashProvidedByusedInContinuingInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by/(used in) Discontinuing Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashProvidedByusedInDiscontinuingInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1,355)<span></span>
</td>
<td class="num">&#8364; (1,434)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities', window );">Dividends received from non-consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,359<span></span>
</td>
<td class="nump">6,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,353<span></span>
</td>
<td class="nump">&#8364; 6,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;3,353&#160;million, compared with &#8364;6,060 million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received from non-consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Introduction<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General Information About Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Introduction</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i06f57da0e5ba4e0c866be66a8e0b007c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2025 were reviewed by the Sanofi Board of Directors at the Board meeting on July 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information About Financial Statements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iff95aeb1cacb4d618b9870fd263c70dd"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A/ Basis of preparation of the half-year financial statements and accounting policies</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7688eda8a7014a69b04b189c74427e4d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2025 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2025 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2025 are identical to those presented in the consolidated financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment became applicable on January 1, 2025, and does not have a material impact on the Sanofi financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2025 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. The effective tax rate also includes a one-off impact from the 2024 component of the exceptional contribution in respect of French corporate income taxes (see Note B.19.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i3ba3e8d2d67d4839a3ee18f4455ccac9"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2. Use of estimates and judgments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. </span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0833d134ca4f467aa2d44022496a4589"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3. Seasonal trends</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5d091607f6cd4770b1e2ba57b80d1097"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2025, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1d2d8abdbdca4cb1ad5f11223ac03852"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i594cdfc2671541919a399905ebafffb7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.6. New pronouncements issued by the IASB and applicable from 2026</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026. Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments clarify the application of the &#8216;own use&#8217; exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and will not early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in Note D.21. to the consolidated financial statements included in the 2024 Form 20-F for the year ended December 31, 2024 (the &#8220;2024 20-F&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock', window );">Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i59b3a64f982a4997abb93c9d6139ad1b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Significant transactions for the first half of 2025</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i59a51ad9042b4cd4977c803f9630832f"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.1. Opella - Loss of control and equity interest in OPAL JV Co</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, Sanofi and CD&amp;R closed the Opella transaction following the signature of the share purchase agreement (SPA) on February 18, 2025. Sanofi retains a significant shareholding in Opella, through a 48.2% equity interest in OPAL JV Co (formed in Luxembourg), which indirectly holds 100% of Opella. Bpifrance owns a 1.8% equity interest, and is represented on Opella&#8217;s Board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Completion of the deal resulted in the loss of control of Opella by Sanofi and the derecognition of Opella&#8217;s assets and liabilities. This resulted in a net gain of &#8364;2.7&#160;billion, reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated income statement. The proceeds from the divestment of Opella, determined on the basis of a &#8364;16 billion enterprise value, reflected the estimated share price. That price is subject to adjustments following finalization of the Opella completion accounts, expected at the earliest in the fourth quarter of 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the closing date of the transaction, the carrying amount of Opella&#8217;s assets and liabilities in the Sanofi consolidated balance sheet was &#8364;11.3&#160;billion. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The gain took into account the following components: (i) a reclassification of unrealized foreign exchange losses amounting to &#8364;0.5&#160;billion associated with Opella operations, in accordance with IAS 21 (&#8220;The Effects of Changes in Foreign Exchange Rates&#8221;); (ii) recognition of the retained 48.2% equity interest in OPAL JV Co (over which Sanofi exercises significant influence as defined in IAS 28 &#8220;Investments in Associates and Joint Ventures&#8221;), reported within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> at an amount of &#8364;3.2&#160;billion (representing the fair value of the equity interest at the date of initial recognition in accordance with IFRS 10 and included in the estimated share price, plus capitalized transaction costs); and (iii) other items, mainly comprising compensation as agreed under the separation agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella transaction generated a net cash inflow of &#8364;10.7&#160;billion, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash inflow from the Opella transaction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a reminder, on October 21, 2024, Sanofi and CD&amp;R entered into exclusive negotiations for the transfer of a controlling interest in Opella. As of December 31, 2024, completion of the transaction was considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), all assets of Opella and all liabilities directly related to those assets were classified from October 21, 2024 in the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, respectively, in the consolidated balance sheet (see Notes D.8. and D.36. to the consolidated financial statements for the year ended December 31, 2024). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information" to the consolidated financial statements for the year ended December 31, 2024). Consequently, Opella met the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), as a result of which the net income from that business was presented separately within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated income statement. This presentation in a separate income statement line item applied to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business were also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented.</span></div>B.1.2. Acquisition of Dren-0201, Inc.<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 27, 2025, Sanofi announced the completion of the acquisition of 100% of Dren-0201, Inc., adding SAR448501 (formerly DR-0201) to Sanofi&#8217;s immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. This potential first-in-class targeted bispecific myeloid cell engager targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent pre-clinical and early clinical study data in autoimmune diseases suggest that deep B-cell depletion has the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price was $600&#160;million. Of that amount (plus acquisition-related costs), $562&#160;million was allocated to in-process development in respect of SAR448501, and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, potential future payments totalling $1.3&#160;billion contingent on attainment of certain development and launch milestones have been recognized as off balance sheet commitments. These milestones will be added to the value of the SAR448501 intangible asset if and when attained.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of $602&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ie03a56ead74e44b3aa28ab44ba3c23df"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.3. Agreed transactions expected to be finalized in the second half of 2025</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieed73ef4674a4d15af5f8915f5773e86"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Vigil Neuroscience, Inc. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vigil Neuroscience, Inc. (&#8220;Vigil&#8221;), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi&#8217;s four strategic disease areas, enhances Sanofi&#8217;s early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer&#8217;s disease. VG-3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer&#8217;s disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of a share purchase agreement (including the exclusive right of first negotiation for an exclusive license to VG-3927 or for transfer of the rights to research, develop, manufacture, and commercialize VG-3927) entered into by Sanofi and Vigil in June 2024 for an amount of $40&#160;million, Sanofi already held an equity interest in Vigil Neuroscience, Inc., representing approximately 12% of Vigil&#8217;s share capital. That equity interest was remeasured at market value as at June 30, 2025 through </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VGL101, Vigil&#8217;s second molecule program, is not being acquired by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash at closing. Based on $8.00 per share, the total equity value of Vigil represents approximately $470&#160;million (on a fully diluted basis).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Vigil&#8217;s shareholders will receive one non-transferable and non-tradeable contractual contingent value right (CVR) per Vigil share entitling the holder to receive a deferred cash payment of $2.00, contingent upon the first commercial sales of VG-3927.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition is expected to close in the third quarter of 2025 subject to closing conditions.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i10b85b18c19a4029849164666a084b38"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Blueprint Medicines Corporation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 2, 2025, Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, entered into an agreement under which Sanofi agreed to acquire Blueprint.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition included a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint&#8217;s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi&#8217;s growing immunology pipeline.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the acquisition, Sanofi agreed to pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1&#160;billion for 100% of the shares. Blueprint shareholders also received one non-tradable contractual contingent value right (CVR) per share which entitles the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5&#160;billion on a fully diluted basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2025, Sanofi obtained control of Blueprint after all tender offer and merger conditions had been met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ied518a2a4a454270b2de2daf0c8e1b8d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Property, plant and equipment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation, see Note B.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;732&#160;million as of June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if2b2a5097a884347b340e8351a4610b7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Goodwill and other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;40,283&#160;million as of June 30, 2025, versus &#8364;43,384 million as of December&#160;31, 2024. The movement during the period was mainly due to the impact of changes in exchange rates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2025 were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:45.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,866</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,348</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,852</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,066</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(199)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(228)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,159)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,297</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61,048</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,830</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75,175</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,497)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52,507)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,433)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58,437)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(852)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,249)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,064)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(54,744)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,369</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,841</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">419</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,629</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2025</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,048</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,984</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">399</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">See Note B.4.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;11.0 bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2025 (versus &#8364;12.7 billion as of December 31, 2024) and a weighted average amortization period of approximately</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 10 years</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;1.0 billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus &#8364;1.1 billion as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock', window );">Impairment of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5cb600bbe3954f83a819a319c757b93a"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Impairment of intangible assets</span></div>The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;210&#160;million in the first half of 2025 linked to research and development projects.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impairment of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2024), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,239</span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,563</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">316</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#8364;241&#160;million loan to OPAL JV Co being in substance part of the investment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#8364;2.89 as of June 30, 2025, and &#8364;2.88 as of December 31, 2024). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed net income of &#8364;85&#160;million for the first half of 2025 (versus a net loss of &#8364;22 million for the first half of 2024), including &#8364;11&#160;million for Sanofi&#8217;s share of profits from OPAL JV Co for the period from May 1, 2025 through June 30, 2025. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">333</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#8364;189&#160;million (and was also &#8364;189 million as of December 31, 2024).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key items from the OPAL JV Co 2025 unaudited half-year consolidated financial statements, as provided in accordance with Sanofi&#8217;s consolidation timelines, are presented below: </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:83.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated income statement</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net sales and other revenues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated statement of comprehensive income</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:83.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated balance sheet</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,179&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,116</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of OPAL JV Co</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,754&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,295</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,039&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,821</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,116</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Other Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,109</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,753</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTradeReceivablesTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iaf6d41da42f0471b8c814bb674ed84ba"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.7. Accounts receivable</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,777&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,810</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2025 was a net expense of &#8364;4 million (versus a net expense of &#8364;3 million for the first half of 2024).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:18.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">386</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">122</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">103</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As of December&#160;31, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2024 and hence were derecognized was &#8364;12 million as of June&#160;30, 2025 (versus &#8364;14 million as of December 31, 2024). The residual guarantees relating to those transfers were immaterial as of June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfTradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfTradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Consolidated Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7de095be9bd34777b07065d8d9446fb6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieb1db694e9274ef49646dccbed6532bf"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;2,455,512,548 and consisted of 1,227,756,274 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.66</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.868</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.755</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.211</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 171,150 shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 2,682,051 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2025, of which 1,156,205&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,525,846</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i25296d69bf8543698f51f58a59381631"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.2. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2024, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 39,344,633 of its own shares during the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for a total amount of &#8364;3,988&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#8364;5&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#233;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#8217;s share capital, equivalent to 29,556,650 shares, for a total amount of approximately &#8364;3&#160;billion, representing a price of &#8364;101.50 per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2025.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="iab53d79b00614867aa54dfaeaac8fdef"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.3. Reduction in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, treasury shares amounting to &#8364;3,868 million were cancelled further to decisions taken by the Sanofi Board of Directors on March 13, 2025 and April 23, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity, except for the impact of the tax on share cancellations.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i8f51ca431f464eb6984626bf2fabb13e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.4. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2024. The principal features of the plans awarded in 2025 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:82.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.541%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 April, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,021,370&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,599,478&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;83.94&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,421,892&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,331,892 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;79.25&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (90,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;75.10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">331</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,550,347&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,192,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,020,451&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,110,089&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,498,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,313,588&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,652,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">106,219&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,031,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,463&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="idc68e16f4a53438286d6b02e26a98749"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.5. Capital increases</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 29, 2025, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;72.97 per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of 2,260,776 shares, and this capital increase was supplemented by the immediate issuance of a further 116,794 shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2025 was &#8364;31 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;72.87 per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of 2,124,445 shares, and this capital increase was supplemented by the immediate issuance of a further 119,951 shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#8364;45 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="if776696deda84ae0905c147f47bfbc13"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.6. Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2025 or in 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No further stock option plan expenses were recognized through equity in either the first half of 2025 or 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.98</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.86</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">725,044</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">725,044</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i92d70e7ae645487f86bdd2b833ba9524"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.7. Number of shares used to compute diluted earnings per share</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,230.7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,253.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, December 31, 2024 and June 30, 2024, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i2ea5e4740dbf4078bbff62d9a657d829"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.8. Other comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5,017)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;2&#160;million in the first half of 2025, immaterial in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#8364;5&#160;million profit in 2024, and immaterial in the first half of 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Treasury Shares Held</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7de095be9bd34777b07065d8d9446fb6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieb1db694e9274ef49646dccbed6532bf"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;2,455,512,548 and consisted of 1,227,756,274 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.66</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.868</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.755</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.211</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 171,150 shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 2,682,051 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2025, of which 1,156,205&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,525,846</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock', window );">Debt, Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5d93f704479c4f44b67be7e205d2d7a8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9. Debt, cash and cash equivalents</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,791&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,519</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,102</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,772</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ic4f08bedb155434a888a0d64f5305f78"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.1. Net debt at value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2025 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:28.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,311&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,519</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,560</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,171</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,102</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,806</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,581&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,876&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,905&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,317</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,560</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,940</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,231</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,171</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,317</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,174)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,940</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,134)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,806</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, 2025, current other bank borrowings include &#8364;4,535&#160;million related to the US commercial paper program and &#8364;230&#160;million related to the Negotiable European Commercial Paper program in France.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span id="idb1ea718ea754a00bb46d85600fe6342"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi carried out the following bond issues during the period:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">March 2025: a bond issue of &#8364;1.5&#160;billion in two tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;850&#160;million of floating-rate bonds maturing March 2027, with quarterly coupons and bearing interest at an annual rate of 3-month Euribor plus 30 basis points; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;650&#160;million of fixed-rate bonds maturing March 2031, with annual coupons and bearing interest at an annual rate of 2.750%.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">June 2025: a bond issue of &#8364;1.5&#160;billion in two tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;750&#160;million of fixed-rate bonds maturing June 2029, with annual coupons and bearing interest at an annual rate of 2.625%; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> &#8364;750&#160;million of fixed-rate bonds maturing June 2032, with annual coupons and bearing interest at an annual rate of 3.000%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Two bond issues were redeemed in 2025:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">the &#8364;1&#160;billion fixed-rate bond issue from April 2020, which was redeemed at maturity on April 1, 2025; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the &#8364;850&#160;million fixed-rate bond issue from April 2022, which was redeemed at maturity on April 6, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, neither facility was drawn down.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two short-term debt programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">a &#8364;6 billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a $10&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">the average drawdown under the US Commercial Paper program was $2.63 billion; and </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;0.02 billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2025 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="icd19a6965fa84d6a8acb50e70115a9d2"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.2. Market value of net debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,143&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt instruments issued explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5ee764af394a41d98996a14bec414e96"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10. Derivative financial instruments</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i850ed5d10c524593866e3ac094f18038"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.1 Currency derivatives used to manage operating risk exposures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,619</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">133</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,619</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">133</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which pound sterling</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,418</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(84)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,418</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(84)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,037</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,037</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="id95d9cb34ad843deb2eeb9cd2820d2ca"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.2. Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,476</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,723</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">176</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,007&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;of which Japanese yen </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,609</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,808</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#8364;5&#160;million, with &#8364;18&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#8364;77 million; the opposite entry was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#8364;25 million, with &#8364;0 million&#160;credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to recognize the hedging cost.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and beyond</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive 1.17%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3m</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">848</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">650</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,348</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,498</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock', window );">Non-Current Provisions And Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i66ef10b1748b4d4696f08a72f348bef5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.12. Non-current provisions and other non-current liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,003&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,762&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,116</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,096</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes &#8364;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,293 million.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:29.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,992</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">799</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,150</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,762</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(378)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(616)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(178)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(197)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,705</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">765</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">802</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,731</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,003</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i298b3c160c444f929e628ff6396043d5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2024, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2025 to take into account changes during the first half of the year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2025, Sanofi completed a further buy-in (amounting to &#8364;101&#160;million) to cover the remaining uninsured liabilities arising under the main defined benefit pension scheme in the United Kingdom. Consequently, all scheme members are now fully insured as a result of buy-in transactions, except for liabilities rising from guaranteed minimum pension equalization (as described in Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:65.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025     (6&#160;months)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024     (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes actuarial gains/ (losses) related to Opella of &#8364;(4)&#160;million for the first half of 2025 and &#8364;(6)&#160;million for the first half of 2024 .</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off Balance Sheet Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OffBalanceSheetCommitmentsAbstract', window );"><strong>Off-Balance Sheet Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock', window );">Off Balance Sheet Commitments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if13b4d11bd91484d826b9b625505475d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13. Off balance sheet commitments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2024 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into, amended or discontinued during the period are described below: </span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In April 2025, Sanofi entered into a license and collaboration agreement with Earendil Labs for two bispecific antibodies in the field of autoimmune and inflammatory bowel diseases: HXN-1002 (targeting &#945;4&#946;7 and TL1A for potential treatment of moderate to severe ulcerative colitis and Crohn's disease) and HXN-1003 (targeting TL1A and IL23 for potential treatment of colitis and skin inflammation). Under the terms of the agreement, Earendil Labs received an upfront payment of $125 million, is eligible to receive up to a total of $1.7 billion in development and commercial milestone payments, and is eligible to receive tiered royalties on product sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2024 Form 20-F.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of off-balance sheet commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OffBalanceSheetCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OffBalanceSheetCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and Arbitration Proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock', window );">Litigation and Arbitration Proceedings</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1c221f089c9a4af9901d6cb4e4acaee3"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14. Litigation and arbitration proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i562e9106bf0241498655b78496fddfab"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.1. Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="iee905ab161554e27ac58988037567eef"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zantac product litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards the ongoing Zantac product  litigation in the US, the Separation Agreement (see Notes D.1 and D.22 to the consolidated financial statements in the 2024 Form 20-F) entered into between Sanofi and Opella specifies that Sanofi will indemnify the Opella group in respect of liabilities relating to (i) the commercialization of any Zantac branded products (i.e. products containing ranitidine as their active pharmaceutical ingredient) prior to closing, and (ii) all personal injury claims resulting from the manufacturing or handling of Zantac prior to closing.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2025, Sanofi reached several settlement deals that in total resolve a majority of the Delaware State Court consolidated litigation. In addition, in May 2025, Sanofi reached settlements with the City of Baltimore and the New Mexico Attorney General, amicably resolving both those matters. Other cases are pending in various state courts.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 10, 2025, the Delaware Supreme Court unanimously reversed the Superior Court&#8217;s denial of Defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">motion based on the lack of reliability of plaintiff&#8217;s experts on causation and remanded its findings back to the Superior Court for proceedings consistent with the rulings in the opinion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i705e5b570c5f4f11b9bf3e2e13c2c5f8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talc product litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, Sanofi was named as a defendant in approximately 900 ongoing product liability actions. To date, no cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i3b1346ea9ebb45569d3dcaf9303a1d2e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.2. Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="ic6e991b615794cb48c76d24520e17825"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Praluent (alirocumab)-related Amgen patent litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Regarding Amgen&#8217;s EP 3 666 797, in April 2025, the Opposition Division of the European Patent Office ruled in Amgen&#8217;s favor and decided to maintain the patent as granted. Sanofi has appealed this decision to the Technical Board of Appeals of the European Patent Office, and the appeal hearing is scheduled for April 2026. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="ia6627e68f8924c1fbed2173501177e82"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) Litigation (Commonwealth) Litigation in Australia </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This matter has been finalized with no possibility of appeal. The matter is closed.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i3a96cd4646e3420c91ee3a27281ff538"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.3. Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i9d56b9e5932441cf91443bf4641a4ec5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) - Attorney General action in Hawaii</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2025, the parties agreed to settle the Hawaii action, with Sanofi US to pay $350&#160;million pursuant to its settlement agreement and Bristol-Myers Squibb to pay $350&#160;million pursuant to its separate settlement agreement. The appeal and the underlying case were dismissed pursuant to the settlement. This matter is closed.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i5d5243e109504bcd98fabc418f1c66c3"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel)-related litigation in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the claim filed by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Caisse Nationale d&#8217;Assurance Maladie</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8211; CNAM</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (French Social Security), hearings were held in June 2025. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="id7f1b070fc274121b83d6d00bc45251c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B drug pricing program in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the action filed by Sanofi against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA) and their respective administrators, following a joint hearing held on April 29, 2025 in Sanofi&#8217;s case and the similar cases filed by Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos, the district court held on May 15, 2025 that, although Section 340B does not categorically prohibit the use of manufacturer rebates, it does not allow HRSA to require preapproval of a manufacturer rebate program. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The district court also held that HRSA&#8217;s letter determining that Sanofi would violate Section 340B if it launched its Credit (rebate) Model was arbitrary and capricious and remanded the Sanofi matter back to HRSA for further consideration. Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos appealed the district court&#8217;s decision to the Circuit Court. Those appeals, along with a similar appeal by Johnson &amp; Johnson, have been expedited and consolidated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2025, Sanofi received notice that Hudson Headwaters Health Network (Hudson Headwaters) had filed a petition for monetary relief against Sanofi before the HRSA ADR (Administrative Dispute Resolution) Panel. Hudson Headwaters alleges that Sanofi has violated Section 340B by allowing only one contract pharmacy to be selected and utilized per covered entity, if the covered entity does not have an in-house pharmacy capable of dispensing its drug. Hudson Headwaters alleges that this Sanofi policy is an &#8220;overcharge&#8221; under Section 340B. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">State Litigation in the US </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In lawsuits filed by PhRMA and certain other manufacturers challenging a contract pharmacy law passed by the State of Mississippi, the court denied for each of the plaintiffs their preliminary injunctions in their respective lawsuits. The plaintiffs appealed the denials of the preliminary injunction motions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Various other challenges to similar state laws have been filed by PhRMA and/or certain manufacturers in a number of other states, including in Colorado, Kansas, Louisiana, Maryland, Minnesota, Missouri, Nebraska, North Dakota, Oklahoma, Tennessee, Utah, South Dakota, and Vermont.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Legal And Arbitral Proceedings [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Other Operating Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7c36aaced6214a41ba3422866e6c16dd"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.15. Other operating income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;533 million in the first half of 2025 (versus &#8364;563 million in the first half of 2024), and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;2,476 million (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">versus</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8364; 1,977 million in the first half of 2024).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main items included in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were: in the first half of 2025, (i) income from pharmaceutical partners of &#8364;87&#160;million (versus &#8364;121 million in the first half of 2024), of which &#8364;70 million came from Regeneron (versus &#8364;96 million in the first half of 2024, see table below) and (ii) gains on disposals of assets and operations of &#8364;344 million, primarily on divestments of non strategic products (versus &#8364;319 million in the first half of 2024). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 included &#8364;2,331 million of expenses related to Regeneron (compared with &#8364;1,841 million in the first half of 2024), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024       (6 months)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,327)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,837)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,261)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,745)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">96&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock', window );">Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">430</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,060</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div>Restructuring and similar costs decreased by &#8364;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;D operations to make Sanofi a leader in immunology<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringTextBlock', window );">Disclosure Of Restructuring</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i006acb851dac4f99bae83d4ef197fbbd"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16. Restructuring costs and similar items</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">430</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,060</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div>Restructuring and similar costs decreased by &#8364;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;D operations to make Sanofi a leader in immunology<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of restructuring costs and similar items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Restructuring [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Gains and Losses, and Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock', window );">Other Gains and Losses, and Litigation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7ee99a522aa34d97b31f94cdb6dc313a"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17. Other gains and losses, and litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2025, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;57 million, mainly related to major litigation. That compares with a charge of &#8364;450 m</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other gains and losses, and litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial Expenses and Income</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i3f2720f484d742c9ae4964b2d83dbd0c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.18. Financial expenses and income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(67)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(177)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(583)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">277</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(25) million in the first half of 2025 and &#8364;(24) million in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(4) million in the first half of 2025 and &#8364;(18)&#160;million in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Includes a financial expense of &#8364;50</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">million for the six months ended June 30, 2025 and &#8364;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2025 or 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5300777f87c6406e8545c0c1004331b2"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.19. Income tax expense</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,108)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(379)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,462</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this line includes a tax expense of &#8364;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, and &#8364;52&#160;million for the six months ended June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i557cf676139c4011ad72a0e3d410b685"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21. Segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment: Biopharma.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella, which constitutes a related party with effect from the deconsolidation date (April 30, 2025). Those revenues, which before that date represented intragroup transactions classified within continuing operations, are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ice051a960b0f48668ab8553db2de5368"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the portion attributable to non-controlling interests related to continuing operations and excluding the effects of the above reconciliation items, is deducted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:27.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-7.8</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+15.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-5.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-3.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,753)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.6</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-0.1</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+14.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+0.2</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,716)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,447)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,943)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,347</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.0</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.6</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+10.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.9</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">27.0</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:50.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6 months) (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(110)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,335)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,916</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,938</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,938</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(987)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(527)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,768</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(583)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,462</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">See Note B.17.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i742dec16cfa84e3b9d7429184f7f1072"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments in joint ventures and associates accounted for using the equity method with which Sanofi has entered into a collaboration agreement; (ii)&#160;acquisitions of property, plant and equipment; and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:61.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i7e465b35c3514c8eba9eaaae5e6df42e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.3. Information by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:60.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (a)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,072&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,535&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,996&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"></td><td style="width:30.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.169%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,438&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,167&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,725&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,056&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,574</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40,283</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,091</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,384</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,629</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2024, goodwill is not allocated by geographical region.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i118884e44be846e89e084fafd4dfd51b"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.4. Disclosures about major customers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 35% of net sales in the first half of 2025. Sanofi&#8217;s three largest customers respectively accounted for approximately 18%, 12% and 5% of consolidated net sales in the first half of 2025 (versus approximately 13%, 9% and 7% in the first half of 2024).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events Subsequent to June 30, 2023<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events Subsequent to June 30, 2023</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i23ea087f4ae74ebaa993bb45daf2618f"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C/ Events subsequent to June 30, 2025</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vicebio Ltd (&#8220;Vicebio&#8221;), a privately held biotechnology company headquartered in London, UK. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands Sanofi&#8217;s capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology. Under the terms of the agreement, Sanofi would acquire all of Vicebio&#8217;s share capital for a total upfront payment of $1.15&#160;billion, with potential milestone payments of up to $450&#160;million based on development and regulatory achievements. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Disclosure of revenue [text block]</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i52a8186c44054bbe8274d7f029df5eba"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20. Revenue from contracts with customers</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i5a65fe3ac5364662bb96cd50b9aad65c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1. Analysis of net sales</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2025 and June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,072</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,292</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccine (Beyfortus) </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,072</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,292</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i159fef8eaf084bf697cb00fb8e4ea868"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.2. Other revenues</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,246</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,352</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,452</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,529</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current asset held for sale and discontinued operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract', window );"><strong>SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Disclosure of non-current assets held for sale and discontinued operations [text block]</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1731ee5f715a4ab4931699f4917632dc"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.22. Information related to Opella, presented within assets held for sale and discontinued operations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30 2025, the Opella transaction was closed (see Note B.1.) triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. As of December 31, 2024, all Opella assets and associated liabilities were classified as held for sale, in accordance with IFRS 5.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total  assets held for sale</span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,489</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale </span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,131</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, were measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.  </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,736</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,645</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(85)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">202</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below presents basic and diluted earnings per share from discontinued operations (Opella), in accordance with IAS 33 (Earnings per Share):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">202</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,230.7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diluted earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock', window );">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block</a></td>
<td class="text">As of December 31, 2024, all Opella assets and associated liabilities were classified as held for sale, in accordance with IFRS 5.<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total  assets held for sale</span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,489</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale </span></td><td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,131</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, were measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.  </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,736</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,645</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(85)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">202</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below presents basic and diluted earnings per share from discontinued operations (Opella), in accordance with IAS 33 (Earnings per Share):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">202</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,230.7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diluted earnings per share (in euros)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">International Financial Reporting Standards (IFRS)</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2025 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2025 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2025 are identical to those presented in the consolidated financial statements for the year ended December 31, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment became applicable on January 1, 2025, and does not have a material impact on the Sanofi financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2025 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. The effective tax rate also includes a one-off impact from the 2024 component of the exceptional contribution in respect of French corporate income taxes (see Note B.19.).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div>For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock', window );">Seasonal Trends</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory', window );">Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2025, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1d2d8abdbdca4cb1ad5f11223ac03852"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.5. Fair value of financial instruments</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New Pronouncements Issued by the IASB and Applicable from 2024</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026. Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments clarify the application of the &#8216;own use&#8217; exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and will not early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in Note D.21. to the consolidated financial statements included in the 2024 Form 20-F for the year ended December 31, 2024 (the &#8220;2024 20-F&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about financial reporting in hyperinflationary economies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 29<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=29&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS29_g39-40_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Seasonality Or Cyclicality Of Interim Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of Measurement Principles Applied to Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock', window );">Summary of Acquisitions and Capitalized Interest by Operating Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation, see Note B.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock', window );">Schedule of Movements in Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2025 were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:45.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,866</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,348</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,852</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,066</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(199)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(228)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,159)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,297</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61,048</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,830</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75,175</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,497)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52,507)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,433)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58,437)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(852)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,249)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,064)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(54,744)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,369</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,841</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">419</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,629</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2025</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,048</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,984</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">399</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">See Note B.4.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of changes in other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock', window );">Summary of Investments in Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i087622ce136040f7a63e1598eff62e6b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5. Investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2024), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,239</span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,563</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">316</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#8364;241&#160;million loan to OPAL JV Co being in substance part of the investment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#8364;2.89 as of June 30, 2025, and &#8364;2.88 as of December 31, 2024). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span> showed net income of &#8364;85&#160;million for the first half of 2025 (versus a net loss of &#8364;22 million for the first half of 2024), including &#8364;11&#160;million for Sanofi&#8217;s share of profits from OPAL JV Co for the period from May 1, 2025 through June 30, 2025.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Principal Transactions and Balances with Related Parties</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">333</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#8364;189&#160;million (and was also &#8364;189 million as of December 31, 2024).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of investments in associates and joint ventures explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock', window );">Summary of Other Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib826488bd111450d94e97cf9c6e8d771"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6. Other non-current assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,109</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,753</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of components of other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,777&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,810</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock', window );">Summary of Gross Value of Overdue Receivables</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:18.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">386</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">122</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">103</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As of December&#160;31, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of current trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCurrentTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Treasury Shares Held</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7de095be9bd34777b07065d8d9446fb6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ieb1db694e9274ef49646dccbed6532bf"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, the share capital was &#8364;2,455,512,548 and consisted of 1,227,756,274 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.66</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.868</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.755</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.211</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 171,150 shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 2,682,051 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2025, of which 1,156,205&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,525,846</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock', window );">Summary of Principal Characteristics of Restricted Share Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2024. The principal features of the plans awarded in 2025 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:82.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.541%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 April, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,021,370&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,599,478&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;83.94&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,421,892&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,331,892 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;79.25&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (90,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;75.10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">331</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock', window );">Summary of Number of Restricted Shares Not Yet Fully Vested</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,550,347&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,192,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,020,451&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,110,089&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,498,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,313,588&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,652,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">106,219&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,031,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,463&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Summary of Options Outstanding and Exercisable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.98</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.86</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">725,044</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">725,044</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock', window );">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,230.7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,253.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock', window );">Summary of Movements within Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5,017)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;2&#160;million in the first half of 2025, immaterial in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#8364;5&#160;million profit in 2024, and immaterial in the first half of 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of restricted share plans Not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of shares used to compute diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock', window );">Summary of Changes in Financial Position</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,791&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,519</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,102</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,772</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock', window );">Summary of Reconciliation of Carrying Amount to Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2025 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:28.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,311&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,519</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,560</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,171</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,102</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,806</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock', window );">Summary of Net Debt by Type Valuation of Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,581&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,876&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,905&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,317</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,560</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,940</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,231</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,171</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15,359)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,317</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,174)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,940</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,134)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,806</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock', window );">Summary of Market Value of Net Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,165&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,143&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in financial position [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt net of cash and cash equivalents by type at value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of market value of net debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMarketValueOfNetDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock', window );">Summary of Operating Currency Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,619</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">133</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,619</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">133</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which pound sterling</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,418</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(84)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,418</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(84)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,037</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,037</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock', window );">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,476</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,723</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">176</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,007&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;of which Japanese yen </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,609</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,808</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#8364;5&#160;million, with &#8364;18&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#8364;77 million; the opposite entry was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#8364;25 million, with &#8364;0 million&#160;credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to recognize the hedging cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock', window );">Disclosure of Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2025:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and beyond</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive 1.17%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3m</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">848</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">650</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,348</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,498</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest rates hedging instruments with notional amount by expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock', window );">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:45.279%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">568</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">641</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">564</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;569 million and a current portion of &#8364;72 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock', window );">Summary of Non-Current Provisions and Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,003&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,762&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,116</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,096</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes &#8364;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,293 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock', window );">Summary of Movements in Non-Current Provisions</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:29.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,992</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">799</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,150</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,762</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(378)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(616)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(178)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(197)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,705</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">765</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">802</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,731</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,003</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:65.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025     (6&#160;months)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024     (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes actuarial gains/ (losses) related to Opella of &#8364;(4)&#160;million for the first half of 2025 and &#8364;(6)&#160;million for the first half of 2024 .</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncurrent provisions explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingExpensesTableTextBlock', window );">Schedule of Other Operating Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2025 included &#8364;2,331 million of expenses related to Regeneron (compared with &#8364;1,841 million in the first half of 2024), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024       (6 months)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,327)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,837)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,261)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,745)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">96&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock', window );">Summary of Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">430</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,060</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restructuring costs details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock', window );">Summary of Analysis of Financial Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(67)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(177)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(583)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">277</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(25) million in the first half of 2025 and &#8364;(24) million in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(4) million in the first half of 2025 and &#8364;(18)&#160;million in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Includes a financial expense of &#8364;50</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">million for the six months ended June 30, 2025 and &#8364;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock', window );">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,108)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(379)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,462</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock', window );">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this line includes a tax expense of &#8364;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, and &#8364;52&#160;million for the six months ended June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of allocation of income tax between current and deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of average effective tax rate and applicable tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Segment Results</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:27.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2024 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+8.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-7.8</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+15.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-5.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-3.9</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,753)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.6</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-0.1</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+16.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+14.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+0.2</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,716)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+11.5</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+12.3</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,447)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.4</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+4.7</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.9</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,943)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,347</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.0</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.3</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.6</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+10.8</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">26.9</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">27.0</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:50.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6 months) (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(110)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,335)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,916</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,938</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock', window );">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6&#160;months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 (6&#160;months) (a)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,938</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(987)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(527)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,768</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(583)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,462</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">See Note B.17.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock', window );">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:61.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Geographical Information on Net Sales and Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"></td><td style="width:30.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.169%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,438&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,167&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,725&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,056&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,574</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40,283</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,091</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,384</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,629</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments reconciling items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Disclosure of disaggregation of revenue from contracts with customers [text block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2025 and June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,072</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,292</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccine (Beyfortus) </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,072</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,292</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherRevenueTextBlock', window );">Disclosure of other revenue</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024  (6&#160;months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,246</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,352</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,452</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,529</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1],[2]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,452<span></span>
</td>
<td colspan="2" class="nump">&#8364; 1,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AR', window );">Argentina</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_TR', window );">Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Consumer Price Inflation Rate Over The Last Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)<br> $ / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 27, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 02, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 538.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,885.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfAcquiree', window );">Name of acquiree</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,563.0<span></span>
</td>
<td class="nump">&#8364; 316.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashInflowFromDiscontinuedOperations', window );">Net Cash Inflow from Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,742.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,774.0)<span></span>
</td>
<td class="nump">&#8364; 1,199.0<span></span>
</td>
<td class="nump">1,233.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,881.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 202.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashInflowFromDiscontinuedOperations', window );">Net Cash Inflow from Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Assets (liabilities)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember', window );">Assets Acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">562,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">602,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PotentialFuturePayments', window );">Potential Future Payments | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_VigilNeuroscienceIncMember', window );">Vigil Neuroscience, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Equity interests of acquirer | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityInterestsOfAcquirerPerShare', window );">Equity Interests Of Acquirer, Per Share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DeferredCashPayments', window );">Deferred Cash Payments | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_BlueprintMedicinesCorporationMember', window );">Blueprint Medicines Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9,100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Equity interests of acquirer | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashTransferredPerShare', window );">Cash Transferred, Per Share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 129.00<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2025, this amount includes &#8364;(667)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashTransferredPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Transferred, Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashTransferredPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DeferredCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DeferredCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityInterestsOfAcquirerPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Interests Of Acquirer, Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityInterestsOfAcquirerPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashInflowFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Inflow from Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashInflowFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PotentialFuturePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PotentialFuturePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_VigilNeuroscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_VigilNeuroscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_BlueprintMedicinesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_BlueprintMedicinesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">&#8364; 702<span></span>
</td>
<td class="nump">&#8364; 591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsCapitalised', window );">Interest costs capitalised</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">&#8364; 39<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FirmOrdersOfPropertyPlantAndEquipment', window );">Firm orders of property, plant and equipment</a></td>
<td class="nump">&#8364; 732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FirmOrdersOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Firm orders of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FirmOrdersOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Billions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="nump">&#8364; 11.0<span></span>
</td>
<td class="nump">&#8364; 12.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember', window );">Technological platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="nump">&#8364; 1.0<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[4]</sup></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 332<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,339)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(40)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,297<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">12,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">500<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">201<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,048<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,249)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">13,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">302<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(199)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,159)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(244)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,048<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">66,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,772<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">281<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">9<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,984<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49,064)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(52,507)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,830<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">399<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,431)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(1,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(777)<span></span>
</td>
<td colspan="2" class="num">&#8364; (898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,431<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">22,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">676<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(228)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,547)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(292)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,175<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">81,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">500<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,239<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">287<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">852<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">210<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,431<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (54,744)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (58,437)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">See Note B.4</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Scope Of Consolidation Through Business Combination, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="nump">&#8364; 210<span></span>
</td>
<td class="num">&#8364; (371)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,563<span></span>
</td>
<td class="nump">&#8364; 3,563<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the&#160;equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td colspan="2" class="num">&#8364; (22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts payable, related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">637<span></span>
</td>
<td class="nump">&#8364; 637<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">82<span></span>
</td>
<td class="nump">&#8364; 82<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">&#8364; 3,239<span></span>
</td>
<td class="nump">&#8364; 3,239<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LoansToAssociates', window );">Loans to Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 241<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockPrice', window );">Stock price (in euro per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2.89<span></span>
</td>
<td class="nump">&#8364; 2.89<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.0288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company | MCM Vaccine BV</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember', window );">Infraserv GmbH &amp; Co. H&#246;chst KG</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.20%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">&#8364; 93<span></span>
</td>
<td class="nump">&#8364; 93<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">79<span></span>
</td>
<td class="nump">&#8364; 79<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Other investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 70<span></span>
</td>
<td class="nump">&#8364; 70<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#8364;2.89 as of June 30, 2025, and &#8364;2.88 as of December 31, 2024). </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#8364;241&#160;million loan to OPAL JV Co being in substance part of the investment.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Total for all joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LoansToAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans to Associates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LoansToAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherAssetsRelatedPartyTransactions', window );">Other Assets, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubordinateHybridBondRelatedPartyTransactions', window );">Subordinate Hybrid Bond, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Sales (c) (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">&#8364; 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions', window );">Royalties and other income (c) (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">63<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Amounts receivable, related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherAssetsRelatedPartyTransactions', window );">Other Assets, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases of goods and services (including research expenses) (c) (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">371<span></span>
</td>
<td class="nump">&#8364; 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts payable, related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#8364;189&#160;million (and was also &#8364;189 million as of December 31, 2024).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and other income, related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubordinateHybridBondRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subordinate Hybrid Bond, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubordinateHybridBondRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details) - Associates and joint ventures - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Sales (c) (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">&#8364; 29<span></span>
</td>
<td class="nump">&#8364; 59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeRelatedPartyDisclosures', window );">Other Comprehensive Income, Related Party Disclosures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ComprehensiveIncomeRelatedPartyDisclosures', window );">Comprehensive Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAndLiabilitiesRelatedPartyTransactions', window );">Amounts payable, related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentAssetsRelatedPartyTransactions', window );">Current assets, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsRelatedPartyTransactions', window );">Assets, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions', window );">Equity Attributable to Equity Holders, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions', window );">Equity Attributable to Non Controlling Interest, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRelatedPartyTransactions', window );">Equity, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedPartyTransactions', window );">Non Current Liabilities, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedPartyTransactions', window );">Current Liabilities, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilitiesRelatedPartyTransactions', window );">Liabilities, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentAssetsRelatedPartyTransactions', window );">Non Current assets, Related Party Transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetIncomeRelatedPartyDisclosures', window );">Net Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures', window );">Net Sales and Other Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">&#8364; 887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ComprehensiveIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ComprehensiveIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAndLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity and Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAndLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Attributable to Equity Holders, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAttributableToEquityHoldersRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Attributable to Non Controlling Interest, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Sales and Other Revenues, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Other financial assets at fair value through profit or loss</a></td>
<td class="nump">&#8364; 965<span></span>
</td>
<td class="nump">&#8364; 1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LongTermPrepaidExpenses', window );">Long-term prepaid expenses</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLoansAndReceivables', window );">Long-term loans and advances and other non-current receivables</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">3,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 362<span></span>
</td>
<td class="nump">&#8364; 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LongTermPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LongTermPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non current loans and receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Assets At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PreFundedPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PreFundedPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Summary of Accounts Receivable (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 7,810<span></span>
</td>
<td class="nump">&#8364; 7,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">7,896<span></span>
</td>
<td class="nump">7,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 86<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccountsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounts Receivable [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccountsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</a></td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerecognizedReceivables', window );">Derecognized receivables</a></td>
<td class="nump">&#8364; 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerecognizedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognized receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerecognizedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 386<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Overdue by less than 1 month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Overdue by 1-3 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">Overdue by 3-6 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">Overdue by 6-12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Overdue by &gt; 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="nump">&#8364; 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OverdueReceivablesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OverdueReceivablesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Feb. 02, 2025</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,455,512,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,756,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease', window );">Number of restricted shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,682,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease', window );">Number of restricted shares alloted in regards of capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,525,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,318,000,000)<span></span>
</td>
<td class="nump">&#8364; 1,067,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CancellationOfTreasuryShares', window );">Cancellation of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,868,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember', window );">Employees share ownership plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubscriptionPricePerShare', window );">Subscription price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesSubscribed', window );">Number of shares subscribed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,124,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution', window );">Number of shares issued immediately for employer's contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember', window );">Share Repurchase 2024 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,344,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,988,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareProgramAxis=sny_ShareRepurchase2025ProgramMember', window );">Share Repurchase 2025 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,556,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,000,000,000<span></span>
</td>
<td class="nump">&#8364; 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PerShareValueOfSharesRepurchased', window );">Per Share Value of Shares Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 101.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions', window );">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease', window );">Capital increase by issuance of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,156,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,017,000,000)<span></span>
</td>
<td class="nump">&#8364; 1,067,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Other comprehensive income | Foreign Currency Translation | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CancellationOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of treasury stock cancelled during the period. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CancellationOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmountOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmountOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Further shares as an employers contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IssuanceOfFurtherSharesAsAnEmployersContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares alloted in regards of capital increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares issued in regards of capital increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Restricted Shares Vested In Regards Of Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in regards of capital increase by exercise of stock subscription options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PerShareValueOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per Share Value of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PerShareValueOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PeriodOfShareRepurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of share repurchase program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PeriodOfShareRepurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareProgramAxis=sny_ShareRepurchase2025ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareProgramAxis=sny_ShareRepurchase2025ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesHeld', window );">Number of shares (in shares)</a></td>
<td class="nump">10,660<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
<td class="nump">15,330<span></span>
</td>
<td class="nump">13,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfShareCapitalForThePeriod', window );">% of share capital for the period</a></td>
<td class="nump">0.868%<span></span>
</td>
<td class="nump">0.755%<span></span>
</td>
<td class="nump">1.211%<span></span>
</td>
<td class="nump">1.063%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfShareCapitalForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfShareCapitalForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">4,021,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="nump">&#8364; 331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025 | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">2,599,478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 83.94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025 | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,421,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025 | With market condition | Excluding General Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,331,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 79.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025 | With market condition | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 75.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueOfPlanAtDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of plan at the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueOfPlanAtDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share awarded to a three year service period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfYearsServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Years, Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfYearsServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithoutMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithoutMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total expense for restricted share plans</a></td>
<td class="nump">&#8364; 146<span></span>
</td>
<td class="nump">&#8364; 128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">11,550,347<span></span>
</td>
<td class="nump">11,192,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">3,313,588<span></span>
</td>
<td class="nump">3,652,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">106,219<span></span>
</td>
<td class="nump">3,031,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">4,110,089<span></span>
</td>
<td class="nump">4,498,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Restricted Share Plan 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">4,020,451<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesNotYetFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesNotYetFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">725,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">725,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember', window );">From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">2 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember', window );">From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">299,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 76.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">299,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 76.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember', window );">From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">257,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 88.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">257,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 88.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">&#8364; 90.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,225,500,000<span></span>
</td>
<td class="nump">1,249,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for stock options with dilutive effect (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares', window );">Adjustment for restricted shares (in shares)</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares used to compute diluted earnings per share (in shares)</a></td>
<td class="nump">1,230,700,000<span></span>
</td>
<td class="nump">1,253,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive effect of share options on number of restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 241<span></span>
</td>
<td class="nump">&#8364; 166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,318)<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures', window );">Actuarial gains/(losses) excluding investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures', window );">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges', window );">Equity risk hedging instruments designated as fair value hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures', window );">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(5,266)<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures', window );">Currency translation differences (investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations', window );">Hedges of net investments in foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">390<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnTaxEffects', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,017)<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments included in financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Foreign Currency Translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;2&#160;million in the first half of 2025, immaterial in the first half of 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#8364;5&#160;million profit in 2024, and immaterial in the first half of 2024.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation before tax excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnTaxEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnTaxEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Risk Hedging Instruments Designated At Fair Value Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">&#8364; 13,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 11,791<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">20,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="num">&#8364; (6,795)<span></span>
</td>
<td colspan="2" class="num">&#8364; (8,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">5,102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 1,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 13,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 11,791<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="num">&#8364; (6,795)<span></span>
</td>
<td colspan="2" class="num">&#8364; (8,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember', window );">Adjustment to debt measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,317<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,560<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5,143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 4,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="num">&#8364; (6,795)<span></span>
</td>
<td colspan="2" class="num">&#8364; (8,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,560<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5,143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,317<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,359)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,134)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,317<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,322<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(68)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 4,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current | Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current | Commercial paper program in France</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;1,776 million as of June 30, 2025 and &#8364;1,906 million as of December&#160;31, 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, 2025, current other bank borrowings include &#8364;4,535&#160;million related to the US commercial paper program and &#8364;230&#160;million related to the Negotiable European Commercial Paper program in France.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=sny_NonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=sny_NonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=sny_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=sny_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Additional Information (Details) - 6 months ended Jun. 30, 2025<br> $ in Millions</strong></div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember', window );">Commercial paper program in France | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs</a></td>
<td class="nump">&#8364; 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown</a></td>
<td class="nump">20,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member', window );">Four Billion Facility Maturing December 2027 | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2030Member', window );">Four Billion Facility Maturing March 2030 | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2020Member', window );">Fixed Rate Bond Issue from April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2022Member', window );">Fixed Rate Bond Issue from April 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member', window );">One Billion Five Hundred Million Bonds, Issued In March 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfTranches', window );">Number Of Tranches</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2027Member', window );">Fixed Rate Bond Maturing March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2031Member', window );">Fixed Rate Bond Maturing March 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingJune2029Member', window );">Fixed Rate Bond Maturing June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2032Member', window );">Fixed Rate Bond Maturing March 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member', window );">One Billion Five Hundred Million Bonds, Issued In June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfTranches', window );">Number Of Tranches</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingAverageDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Average Drawdown</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingAverageDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromApril2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">&#8364; 20,519<span></span>
</td>
<td class="nump">&#8364; 16,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="nump">8,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">20,560<span></span>
</td>
<td class="nump">16,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RedemptionOfDebtInstrumentIssued', window );">Value on redemption</a></td>
<td class="nump">&#8364; 5,143<span></span>
</td>
<td class="nump">&#8364; 8,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RedemptionOfDebtInstrumentIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of debt instrument issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RedemptionOfDebtInstrumentIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtMarketValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 11,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">11,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInCanadianDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInCanadianDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInRussianRoubleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInRussianRoubleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInRussianRoubleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInRussianRoubleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (23)<span></span>
</td>
<td colspan="2" class="num">&#8364; (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember', window );">Forward currency sales in US dollar</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember', window );">Forward currency purchases in US dollar, US bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member', window );">Cross Currency Swap, Expiring 2029</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">870<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member', window );">Cross Currency Swap, Expiring 2032</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">870<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember', window );">Cross Currency Swap</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,808<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,723<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in US dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6,007<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,609<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in US dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,289<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Singapore dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,094<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Chinese yuan renminbi | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">601<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Sales In Canadian Dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Hungarian florint | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">639<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cross Currency Seller Swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,476<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cross Currency Seller Swaps In US Dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,476<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">137<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">176<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in US dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Singapore dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Chinese yuan renminbi | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Sales In Canadian Dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Hungarian florint | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cross Currency Seller Swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cross Currency Seller Swaps In US Dollar | 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#8364;77 million; the opposite entry was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, with the impact on financial income and expense being immaterial.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#8364;25 million, with &#8364;0 million&#160;credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span> to recognize the hedging cost</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#8364;5&#160;million, with &#8364;18&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments to manage financial exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstrumentsToManageFinancialExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInCanadianDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInCanadianDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Disclosure of Instruments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 2,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2029 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Notional amount | 2029 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay 2.08% / receive Euribor 3m | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">&#8364; (3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.92%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2029 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2029 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateSwapsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Swaps, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateSwapsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock', window );">Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="iaa43e806f1aa45c983dc11f10a287070"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.11. Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2024. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:45.279%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">568</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">641</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">564</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;569 million and a current portion of &#8364;72 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2025, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;563 million as of June&#160;30, 2025, compared with &#8364;568 million as of December 31, 2024. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 10%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture was extinguished during 2024 in accordance with the contractual terms. Sanofi has no further liability in respect of this contingent consideration following settlement of the milestone linked to 2024 sales.</span></div><span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(77)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European Vaccines business)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(76)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;569 million and a current portion of &#8364;72 million.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to business combination and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences business combinations and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 564<span></span>
</td>
<td class="nump">&#8364; 641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European Vaccines business)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 563<span></span>
</td>
<td class="nump">&#8364; 568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#8364;569 million and a current portion of &#8364;72 million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageIncreaseInFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in fair value liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageIncreaseInFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5,003<span></span>
</td>
<td class="nump">&#8364; 5,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,116<span></span>
</td>
<td class="nump">&#8364; 8,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">a)&#160;&#160;&#160;&#160;Includes &#8364;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,293 million</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Provisions [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 5,762<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(615)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(616)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(255)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(255)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">United Kingdom | Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember', window );">Provisions for pensions &amp; other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(69)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(167)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(17)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember', window );">Provisions for other long-term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(78)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(61)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">765<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember', window );">Restructuring provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(175)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(158)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">802<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember', window );">Other provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(293)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(378)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(93)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(83)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">&#8364; 1,731<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Of Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains and losses on defined-benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest related to employees benefits and unwinding of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember', window );">Eurozone | Actuarial assumption of expected rates of inflation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_UKZONEMember', window );">UKZONE | Actuarial assumption of expected rates of inflation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">&#8364; 152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 373<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember', window );">Plan assets | Pensions and other post-employment benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (138)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes actuarial gains/ (losses) related to Opella of &#8364;(4)&#160;million for the first half of 2025 and &#8364;(6)&#160;million for the first half of 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_UKZONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_UKZONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and Arbitration Proceedings (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>proceeding</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember', window );">Plavix Attorney General action in Hawaii | Action For Which Sanofi Are Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PenaltyFeeIncurred', window );">Penalty Fee Incurred</a></td>
<td class="nump">&#8364; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PaymentOfDamagesClaimedByCounterparty', window );">Payment Of Damages Claimed By Counterparty</a></td>
<td class="nump">&#8364; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember', window );">Gold Bond Product Litigation In The US | Action for which we are defendant | Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number Of Class Action Lawsuits | proceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal and arbitral proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PaymentOfDamagesClaimedByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Damages Claimed By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PaymentOfDamagesClaimedByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PenaltyFeeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penalty Fee Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PenaltyFeeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefendantAxis=sny_ActionForWhichSanofiAreDefendantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefendantAxis=sny_ActionForWhichSanofiAreDefendantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 533<span></span>
</td>
<td class="nump">&#8364; 563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expense</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsOnDivestmentOfProducts', window );">Gains on divestment of some mature products</a></td>
<td class="nump">&#8364; 344<span></span>
</td>
<td class="nump">&#8364; 319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsOnDivestmentOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on divestment of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsOnDivestmentOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">&#8364; (2,476)<span></span>
</td>
<td class="num">&#8364; (1,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expenses), net related to Regeneron</a></td>
<td class="num">(2,261)<span></span>
</td>
<td class="num">(1,745)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(2,327)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(2,475)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Additional share of profit paid by Regeneron towards development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Reimbursement to Regeneron of selling expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember', window );">Other (mainly Zaltrap and Libtayo)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other related parties | Reimbursement to Regeneron of selling expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">&#8364; (2,331)<span></span>
</td>
<td class="num">&#8364; (1,841)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_OthersCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses', window );">Employee-related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 201<span></span>
</td>
<td class="nump">&#8364; 810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories', window );">Charges, gains or losses on assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">109<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts', window );">Costs of transformation programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRestructuringCosts', window );">Other restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 430<span></span>
</td>
<td class="nump">&#8364; 1,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of restructuring activities related to property plant and equipment to inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Of Restructuring Activities, Transformation Programs Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities', window );">Decrease in total expense of restructuring activities</a></td>
<td class="nump">&#8364; 630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Total Expense Of Restructuring Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Gains and Losses, and Litigation (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and litigation</a></td>
<td class="nump">&#8364; 57<span></span>
</td>
<td class="nump">&#8364; 450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties', window );">Liability Recognised For Estimated Future Royalties</a></td>
<td class="num">&#8364; (50)<span></span>
</td>
<td class="num">&#8364; (176)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Recognised For Estimated Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognisedForEstimatedFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Cost of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (219)<span></span>
</td>
<td class="num">&#8364; (306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">162<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CostOfDebtNet', window );">Cost of net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonOperatingForeignExchangeGainsLosses', window );">Non-operating foreign exchange gains/(losses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Unwinding of discounting of provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestCostRelatedToEmployeeBenefits', window );">Net interest cost related to employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Net interest expense on lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income/(expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties', window );">Liability Recognised For Estimated Future Royalties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember', window );">Interest rate and currency derivatives used to hedge debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageDebt', window );">Gain on derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents', window );">Gain on derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (4)<span></span>
</td>
<td class="num">&#8364; (18)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(25) million in the first half of 2025 and &#8364;(24) million in the first half of 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(4) million in the first half of 2025 and &#8364;(18)&#160;million in the first half of 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Includes a financial expense of &#8364;50</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span>million for the six months ended June 30, 2025 and &#8364;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CostOfDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of debt net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CostOfDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent detailed information about finance income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Recognised For Estimated Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognisedForEstimatedFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetInterestCostRelatedToEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest cost related to employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetInterestCostRelatedToEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonOperatingForeignExchangeGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-operating foreign exchange gains/(losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonOperatingForeignExchangeGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current taxes</a></td>
<td class="num">&#8364; (1,202)<span></span>
</td>
<td class="num">&#8364; (1,108)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total</a></td>
<td class="num">(711)<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 3,582<span></span>
</td>
<td class="nump">&#8364; 2,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Standard tax rate applicable in France</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Difference between the standard French tax rate and the rates applicable to Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(7.30%)<span></span>
</td>
<td class="num">(15.50%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes', window );">Revisions to tax exposures and settlements of tax disputes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19.80%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,202<span></span>
</td>
<td class="nump">&#8364; 1,108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentTaxExpenseRelatedToPillarTwo', window );">Current Tax Expense Related to Pillar Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span>For the six months ended June 30, 2025, this line includes a tax expense of &#8364;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, and &#8364;52&#160;million for the six months ended June 30, 2024</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentTaxExpenseRelatedToPillarTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax Expense Related to Pillar Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentTaxExpenseRelatedToPillarTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revisions to tax exposures and settlements of tax disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentTaxExpenseRelatedToPillarTwo', window );">Current Tax Expense Related to Pillar Two</a></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentTaxExpenseRelatedToPillarTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax Expense Related to Pillar Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentTaxExpenseRelatedToPillarTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 19,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,966)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,717)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(158)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,753)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,716)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,334)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,247)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,941)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Dupixent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Aubagio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,361<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Influenza Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">214<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Nexviazyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Sarclisa</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">227<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Altuviiio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">542<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Rezurock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Cablivi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Xenpozyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Tzield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | RSV Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(128)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(110)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(56)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember', window );">Other Products Segment | Industrial Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Dupixent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">944<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Aubagio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Influenza Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Nexviazyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Sarclisa</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Altuviiio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Rezurock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Cablivi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Xenpozyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Tzield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | RSV Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member] | Other Products Segment | Industrial Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Dupixent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Aubagio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Influenza Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Nexviazyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Sarclisa</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Altuviiio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Rezurock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Cablivi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Xenpozyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Tzield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | RSV Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">UNITED STATES | Other Products Segment | Industrial Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Dupixent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Aubagio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Influenza Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">142<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Nexviazyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Sarclisa</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Altuviiio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Rezurock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Cablivi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Xenpozyme</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Tzield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | RSV Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">185<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other Countries [member] | Other Products Segment | Industrial Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_DupixentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_DupixentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AubagioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AubagioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_NexviazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_NexviazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RezurockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RezurockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_CabliviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_CabliviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_XenpozymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_XenpozymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_TzieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_TzieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Results (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 19,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(5,881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,966)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,717)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Reportable segments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">19,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(5,881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,959)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,717)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,303)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="num">(1,943)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,414)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business Operating Income</a></td>
<td class="nump">5,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">19,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(5,753)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,716)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,334)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,247)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business Operating Income</a></td>
<td class="nump">5,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(128)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(110)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(59)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(56)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Miscellaneous Other Operating Income (Expenses)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business Operating Income</a></td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill', window );">Impairment Loss on Intangible Asset Other Than Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(430)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,347<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,363<span></span>
</td>
<td class="nump">4,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember', window );">Material reconciling items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit (loss) of associates and joint ventures accounted for using equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill', window );">Amortization and impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="num">(987)<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories', window );">Expense arising from the impact of acquisitions on inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="num">(430)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="num">&#8364; (57)<span></span>
</td>
<td class="num">&#8364; (450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.16.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[12]</td>
<td style="vertical-align: top;" valign="top">See Note B.17</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and impairment of intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses arising from the impact of acquisitions on inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss on Intangible Asset Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">483<span></span>
</td>
<td class="nump">&#8364; 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">845<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 575<span></span>
</td>
<td class="nump">&#8364; 922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 19,889<span></span>
</td>
<td class="nump">&#8364; 18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">9,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 10,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">40,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember', window );">Reportable Geographical Zones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">19,889<span></span>
</td>
<td class="nump">18,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">9,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">40,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,144<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">5,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">3,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,535<span></span>
</td>
<td class="nump">8,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">16,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember', window );">Other Countries, Excluding Europe And North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,210<span></span>
</td>
<td class="nump">5,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">&#8364; 1,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Principal Customers and Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember', window );">Certain wholesalers in the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember', window );">Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember', window );">Customer two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember', window );">Customer three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about major customers and credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events Subsequent to June 30, 2023 (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 22, 2025</div></th>
<th class="th"><div>May 27, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember', window );">Assets Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PotentialFuturePayments', window );">Potential Future Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_VicebioLtdMember', window );">Vicebio Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalMilestonePayments', window );">Total Milestone Payments</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PotentialFuturePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PotentialFuturePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_VicebioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_VicebioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,452<span></span>
</td>
<td class="nump">&#8364; 1,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromVaxServeSalesOfNonSanofiProducts', window );">Revenue from VaxServe sales of non-Sanofi products</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">842<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations', window );">Revenue from intragroup sales from continuing to discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">61<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherRevenue', window );">Miscellaneous other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">275<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">&#8364; 206<span></span>
</td>
<td class="nump">&#8364; 177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous other revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from intragroup sales from continuing to discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromVaxServeSalesOfNonSanofiProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from VaxServe sales of non-Sanofi products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromVaxServeSalesOfNonSanofiProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Non-current asset held for sale and discontinued operations (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems', window );"><strong>Disclosure of analysis of single amount of discontinued operations [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 711.0<span></span>
</td>
<td class="nump">&#8364; 379.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations', window );">Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations', window );">Right Of Use Assets, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations', window );">Goodwill, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations', window );">Other Intangible Assets, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,928.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations', window );">Inventories, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations', window );">Accounts Receivables, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations', window );">Other Assets, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations', window );">Assets Of Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,489.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations', window );">Lease Liabilities, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations', window );">Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations', window );">Accounts Payable, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations', window );">Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations', window );">Other Liabilities, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations', window );">Liabilities Of Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations', window );">Revenue From Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736.0<span></span>
</td>
<td class="nump">2,645.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations', window );">Operating Revenue, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266.0<span></span>
</td>
<td class="nump">277.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations', window );">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations', window );">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,039.0<span></span>
</td>
<td class="nump">278.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158.0)<span></span>
</td>
<td class="num">(85.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,881.0<span></span>
</td>
<td class="nump">&#8364; 202.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225,500,000<span></span>
</td>
<td class="nump">1,249,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Adjusted weighted average number of ordinary shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230,700,000<span></span>
</td>
<td class="nump">1,253,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings (loss) per share from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.34<span></span>
</td>
<td class="nump">&#8364; 0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings (loss) per share from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.33<span></span>
</td>
<td class="nump">&#8364; 0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems', window );"><strong>Disclosure of analysis of single amount of discontinued operations [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 88.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net (income)/loss of the exchanged/held-for-exchange Animal Health business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivables, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Of Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GoodwillDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GoodwillDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InventoriesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InventoriesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Of Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Revenue, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Intangible Assets, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right Of Use Assets, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>628</ContextCount>
  <ElementCount>433</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>190</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Income Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedIncomeStatements</Role>
      <ShortName>Consolidated Income Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Introduction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Introduction</Role>
      <ShortName>Introduction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements</Role>
      <ShortName>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Impairment of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofIntangibleAssets</Role>
      <ShortName>Impairment of Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Investments Accounted for Using the Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod</Role>
      <ShortName>Investments Accounted for Using the Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Other Non-Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssets</Role>
      <ShortName>Other Non-Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Consolidated Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquity</Role>
      <ShortName>Consolidated Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Debt, Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalents</Role>
      <ShortName>Debt, Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Off Balance Sheet Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffBalanceSheetCommitments</Role>
      <ShortName>Off Balance Sheet Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Litigation and Arbitration Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LitigationandArbitrationProceedings</Role>
      <ShortName>Litigation and Arbitration Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Other Operating Income And Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses</Role>
      <ShortName>Other Operating Income And Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Restructuring Costs and Similar Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItems</Role>
      <ShortName>Restructuring Costs and Similar Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Other Gains and Losses, and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherGainsandLossesandLitigation</Role>
      <ShortName>Other Gains and Losses, and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Financial Expenses and Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncome</Role>
      <ShortName>Financial Expenses and Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Income Tax Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpense</Role>
      <ShortName>Income Tax Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952180 - Disclosure - Events Subsequent to June 30, 2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/EventsSubsequenttoJune302023</Role>
      <ShortName>Events Subsequent to June 30, 2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952181 - Disclosure - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Revenuefromcontractswithcustomers</Role>
      <ShortName>Revenue from contracts with customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9952182 - Disclosure - Non-current asset held for sale and discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations</Role>
      <ShortName>Non-current asset held for sale and discontinued operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Investments Accounted for Using the Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables</Role>
      <ShortName>Investments Accounted for Using the Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Other Non-Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssetsTables</Role>
      <ShortName>Other Non-Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherNonCurrentAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/AccountsReceivable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Consolidated Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables</Role>
      <ShortName>Consolidated Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/ConsolidatedShareholdersEquity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Debt, Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsTables</Role>
      <ShortName>Debt, Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/DebtCashandCashEquivalents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Other Operating Income And Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables</Role>
      <ShortName>Other Operating Income And Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Restructuring Costs and Similar Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables</Role>
      <ShortName>Restructuring Costs and Similar Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/RestructuringCostsandSimilarItems</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Financial Expenses and Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncomeTables</Role>
      <ShortName>Financial Expenses and Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialExpensesandIncome</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Income Tax Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseTables</Role>
      <ShortName>Income Tax Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/IncomeTaxExpense</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/SegmentInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenue from contracts with customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables</Role>
      <ShortName>Revenue from contracts with customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Revenuefromcontractswithcustomers</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails</Role>
      <ShortName>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Impairment of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails</Role>
      <ShortName>Impairment of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/ImpairmentofIntangibleAssets</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails</Role>
      <ShortName>Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Other Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssetsDetails</Role>
      <ShortName>Other Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherNonCurrentAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable - Summary of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Accounts Receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails</Role>
      <ShortName>Accounts Receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails</Role>
      <ShortName>Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails</Role>
      <ShortName>Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Disclosure of Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Litigation and Arbitration Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails</Role>
      <ShortName>Litigation and Arbitration Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/LitigationandArbitrationProceedings</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails</Role>
      <ShortName>Other Operating Income And Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails</Role>
      <ShortName>Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails</Role>
      <ShortName>Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails</Role>
      <ShortName>Restructuring Costs and Similar Items - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Other Gains and Losses, and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails</Role>
      <ShortName>Other Gains and Losses, and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherGainsandLossesandLitigation</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Financial Expenses and Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncomeDetails</Role>
      <ShortName>Financial Expenses and Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialExpensesandIncomeTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails</Role>
      <ShortName>Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails</Role>
      <ShortName>Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical</Role>
      <ShortName>Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/IncomeTaxExpenseTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails</Role>
      <ShortName>Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Segment Information - Schedule of Segment Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails</Role>
      <ShortName>Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails</Role>
      <ShortName>Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails</Role>
      <ShortName>Segment Information - Principal Customers and Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Events Subsequent to June 30, 2023 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/EventsSubsequenttoJune302023Details</Role>
      <ShortName>Events Subsequent to June 30, 2023 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/EventsSubsequenttoJune302023</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Revenue from contracts with customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails</Role>
      <ShortName>Revenue from contracts with customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="sny-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Non-current asset held for sale and discontinued operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails</Role>
      <ShortName>Non-current asset held for sale and discontinued operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20250630.htm">sny-20250630.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20250630_d2.htm">sny-20250630_d2.htm</File>
    <File>sny-20250630.xsd</File>
    <File>sny-20250630_cal.xml</File>
    <File>sny-20250630_def.xml</File>
    <File>sny-20250630_lab.xml</File>
    <File>sny-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1052">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sny-20250630.htm sny-20250630_d2.htm": {
   "nsprefix": "sny",
   "nsuri": "http://www.sanofi.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "sny-20250630.htm",
      "sny-20250630_d2.htm"
     ]
    },
    "schema": {
     "local": [
      "sny-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sny-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sny-20250630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sny-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sny-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 230,
   "keyCustom": 203,
   "axisStandard": 38,
   "axisCustom": 7,
   "memberStandard": 52,
   "memberCustom": 133,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 628,
   "entityCount": 1,
   "segmentCount": 190,
   "elementCount": 996,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1052,
    "http://xbrl.sec.gov/dei/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://www.sanofi.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
     "longName": "9952152 - Statement - Consolidated Income Statements",
     "shortName": "Consolidated Income Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GrossProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952153 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:TaxesOnShareCancellations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sanofi.com/role/Introduction",
     "longName": "9952158 - Disclosure - Introduction",
     "shortName": "Introduction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies",
     "longName": "9952159 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements",
     "longName": "9952160 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
     "shortName": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipment",
     "longName": "9952161 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets",
     "longName": "9952162 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sanofi.com/role/ImpairmentofIntangibleAssets",
     "longName": "9952163 - Disclosure - Impairment of Intangible Assets",
     "shortName": "Impairment of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod",
     "longName": "9952164 - Disclosure - Investments Accounted for Using the Equity Method",
     "shortName": "Investments Accounted for Using the Equity Method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssets",
     "longName": "9952165 - Disclosure - Other Non-Current Assets",
     "shortName": "Other Non-Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sanofi.com/role/AccountsReceivable",
     "longName": "9952166 - Disclosure - Accounts Receivable",
     "shortName": "Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquity",
     "longName": "9952167 - Disclosure - Consolidated Shareholders' Equity",
     "shortName": "Consolidated Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalents",
     "longName": "9952168 - Disclosure - Debt, Cash and Cash Equivalents",
     "shortName": "Debt, Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstruments",
     "longName": "9952169 - Disclosure - Derivative Financial Instruments",
     "shortName": "Derivative Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "longName": "9952171 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sanofi.com/role/OffBalanceSheetCommitments",
     "longName": "9952172 - Disclosure - Off Balance Sheet Commitments",
     "shortName": "Off Balance Sheet Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sanofi.com/role/LitigationandArbitrationProceedings",
     "longName": "9952173 - Disclosure - Litigation and Arbitration Proceedings",
     "shortName": "Litigation and Arbitration Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses",
     "longName": "9952174 - Disclosure - Other Operating Income And Expenses",
     "shortName": "Other Operating Income And Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItems",
     "longName": "9952175 - Disclosure - Restructuring Costs and Similar Items",
     "shortName": "Restructuring Costs and Similar Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sanofi.com/role/OtherGainsandLossesandLitigation",
     "longName": "9952176 - Disclosure - Other Gains and Losses, and Litigation",
     "shortName": "Other Gains and Losses, and Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncome",
     "longName": "9952177 - Disclosure - Financial Expenses and Income",
     "shortName": "Financial Expenses and Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpense",
     "longName": "9952178 - Disclosure - Income Tax Expense",
     "shortName": "Income Tax Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sanofi.com/role/SegmentInformation",
     "longName": "9952179 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sanofi.com/role/EventsSubsequenttoJune302023",
     "longName": "9952180 - Disclosure - Events Subsequent to June 30, 2023",
     "shortName": "Events Subsequent to June 30, 2023",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sanofi.com/role/Revenuefromcontractswithcustomers",
     "longName": "9952181 - Disclosure - Revenue from contracts with customers",
     "shortName": "Revenue from contracts with customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations",
     "longName": "9952182 - Disclosure - Non-current asset held for sale and discontinued operations",
     "shortName": "Non-current asset held for sale and discontinued operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentTables",
     "longName": "9955513 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables",
     "longName": "9955514 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables",
     "longName": "9955515 - Disclosure - Investments Accounted for Using the Equity Method (Tables)",
     "shortName": "Investments Accounted for Using the Equity Method (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssetsTables",
     "longName": "9955516 - Disclosure - Other Non-Current Assets (Tables)",
     "shortName": "Other Non-Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sanofi.com/role/AccountsReceivableTables",
     "longName": "9955517 - Disclosure - Accounts Receivable (Tables)",
     "shortName": "Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables",
     "longName": "9955518 - Disclosure - Consolidated Shareholders' Equity (Tables)",
     "shortName": "Consolidated Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables",
     "longName": "9955519 - Disclosure - Debt, Cash and Cash Equivalents (Tables)",
     "shortName": "Debt, Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables",
     "longName": "9955520 - Disclosure - Derivative Financial Instruments (Tables)",
     "shortName": "Derivative Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables",
     "longName": "9955521 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables",
     "longName": "9955522 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables",
     "longName": "9955523 - Disclosure - Other Operating Income And Expenses (Tables)",
     "shortName": "Other Operating Income And Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables",
     "longName": "9955524 - Disclosure - Restructuring Costs and Similar Items (Tables)",
     "shortName": "Restructuring Costs and Similar Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncomeTables",
     "longName": "9955525 - Disclosure - Financial Expenses and Income (Tables)",
     "shortName": "Financial Expenses and Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseTables",
     "longName": "9955526 - Disclosure - Income Tax Expense (Tables)",
     "shortName": "Income Tax Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.sanofi.com/role/SegmentInformationTables",
     "longName": "9955527 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables",
     "longName": "9955528 - Disclosure - Revenue from contracts with customers (Tables)",
     "shortName": "Revenue from contracts with customers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
     "longName": "9955530 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherRevenueTextBlock",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
     "longName": "9955531 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)",
     "shortName": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NameOfAcquiree",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
     "longName": "9955533 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "shortName": "Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
     "longName": "9955535 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-111",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
     "longName": "9955536 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-108",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails",
     "longName": "9955537 - Disclosure - Impairment of Intangible Assets (Details)",
     "shortName": "Impairment of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
     "longName": "9955538 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)",
     "shortName": "Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "9955539 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "shortName": "Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherAssetsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "link:footnote",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherAssetsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "link:footnote",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
     "longName": "9955540 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details)",
     "shortName": "Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-137",
      "name": "ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "sny:OtherComprehensiveIncomeRelatedPartyDisclosures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails",
     "longName": "9955541 - Disclosure - Other Non-Current Assets (Details)",
     "shortName": "Other Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
     "longName": "9955542 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)",
     "shortName": "Accounts Receivable - Summary of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - Accounts Receivable - Additional Information (Details)",
     "shortName": "Accounts Receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
     "longName": "9955544 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "shortName": "Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
     "longName": "9955545 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)",
     "shortName": "Consolidated Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails",
     "longName": "9955546 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails",
     "longName": "9955547 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-165",
      "name": "sny:NumberOfYearsServicePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "sny:NumberOfYearsServicePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
     "longName": "9955548 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
     "longName": "9955549 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-203",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-203",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails",
     "longName": "9955550 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
     "longName": "9955551 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-204",
      "name": "sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
     "longName": "9955552 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
     "longName": "9955553 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
     "longName": "9955554 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:InterestRateAndCurrencyDerivativesUsedToManageDebt",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "ifrs-full:BondsIssued",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
     "longName": "9955555 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-239",
      "name": "ifrs-full:CommercialPapersIssued",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-239",
      "name": "ifrs-full:CommercialPapersIssued",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
     "longName": "9955556 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMarketValueOfNetDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
     "longName": "9955557 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "shortName": "Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-331",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-331",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
     "longName": "9955558 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "shortName": "Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-358",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
     "longName": "9955559 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)",
     "shortName": "Derivative Financial Instruments - Disclosure of Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-331",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-331",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
     "longName": "9955560 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
     "longName": "9955561 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-412",
      "name": "sny:PercentageIncreaseInFairValueLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
     "longName": "9955562 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
     "longName": "9955563 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ChangesInOtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
     "longName": "9955564 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-434",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-434",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails",
     "longName": "9955566 - Disclosure - Litigation and Arbitration Proceedings (Details)",
     "shortName": "Litigation and Arbitration Proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-443",
      "name": "sny:PenaltyFeeIncurred",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-443",
      "name": "sny:PenaltyFeeIncurred",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
     "longName": "9955567 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)",
     "shortName": "Other Operating Income And Expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-444",
      "name": "sny:GainsOnDivestmentOfProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails",
     "longName": "9955568 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)",
     "shortName": "Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherOperatingIncomeExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:OtherOperatingExpensesTableTextBlock",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails",
     "longName": "9955569 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)",
     "shortName": "Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails",
     "longName": "9955570 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)",
     "shortName": "Restructuring Costs and Similar Items - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-460",
      "name": "sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-460",
      "name": "sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails",
     "longName": "9955571 - Disclosure - Other Gains and Losses, and Litigation (Details)",
     "shortName": "Other Gains and Losses, and Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherGainsLossesAndLitigation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
     "longName": "9955572 - Disclosure - Financial Expenses and Income (Details)",
     "shortName": "Financial Expenses and Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
     "longName": "9955573 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "shortName": "Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails",
     "longName": "9955574 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "shortName": "Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical",
     "longName": "9955575 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)",
     "shortName": "Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:CurrentTaxExpenseRelatedToPillarTwo",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails",
     "longName": "9955577 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "shortName": "Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-473",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
     "longName": "9955578 - Disclosure - Segment Information - Schedule of Segment Results (Details)",
     "shortName": "Segment Information - Schedule of Segment Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-591",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
     "longName": "9955579 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "shortName": "Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
     "longName": "9955580 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "shortName": "Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-598",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
     "longName": "9955581 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "shortName": "Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-606",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails",
     "longName": "9955582 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)",
     "shortName": "Segment Information - Principal Customers and Credit Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-620",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-620",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
     "longName": "9955583 - Disclosure - Events Subsequent to June 30, 2023 (Details)",
     "shortName": "Events Subsequent to June 30, 2023 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-73",
      "name": "sny:PotentialFuturePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-628",
      "name": "sny:UpfrontPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-7",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
     "longName": "9955584 - Disclosure - Revenue from contracts with customers (Details)",
     "shortName": "Revenue from contracts with customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherRevenueTextBlock",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "sny:RevenueFromVaxServeSalesOfNonSanofiProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherRevenueTextBlock",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
     "longName": "9955585 - Disclosure - Non-current asset held for sale and discontinued operations (Details)",
     "shortName": "Non-current asset held for sale and discontinued operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxExpenseContinuingOperations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20250630_d2.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "AR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Argentina",
        "label": "ARGENTINA"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AccountsPayableDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AccountsPayableDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable, Disposal Group Including Discontinued Operations",
        "label": "Accounts Payable, Disposal Group Including Discontinued Operations",
        "documentation": "Accounts Payable, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivables, Disposal Group Including Discontinued Operations",
        "label": "Accounts Receivables, Disposal Group Including Discontinued Operations",
        "documentation": "Accounts Receivables, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization and impairment",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67",
      "r107",
      "r121",
      "r124"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "sny_AcquiredRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AcquiredRDMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R D",
        "label": "Acquired R D [Member]",
        "documentation": "Acquired R D"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AcquiredResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AcquiredResearchAndDevelopmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R&amp;D",
        "label": "Acquired Research And Development [Member]",
        "documentation": "Acquired Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest in acquiree held before acquisition date",
        "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, acquisition-date fair value",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Acquisitions through business combinations, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "sny_ActionForWhichSanofiAreDefendantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ActionForWhichSanofiAreDefendantMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Action For Which Sanofi Are Defendant",
        "label": "Action For Which Sanofi Are Defendant [Member]",
        "documentation": "Action For Which Sanofi Are Defendant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActionForWhichWeAreDefendantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ActionForWhichWeAreDefendantMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Action for which we are defendant",
        "label": "Action For Which We Are Defendant [member]",
        "documentation": "Action for which we are defendant."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of discount rates",
        "label": "Actuarial assumption of discount rates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflationMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of expected rates of inflation",
        "label": "Actuarial assumption of expected rates of inflation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of inflation used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [axis]",
        "label": "Actuarial assumptions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_ActuarialAssumptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [domain]",
        "label": "Actuarial assumptions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses)",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) excluding investments accounted for using the equity method",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AdditionalLaunchAndSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AdditionalLaunchAndSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Launch And Sales Milestone Payments",
        "label": "Additional Launch And Sales Milestone Payments",
        "documentation": "Additional Launch And Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional paid-in capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions other than through business combinations, property, plant and equipment",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average number of shares after dilution (in shares)",
        "totalLabel": "Average number of shares used to compute diluted earnings per share (in shares)",
        "terseLabel": "Adjusted weighted average number of ordinary shares outstanding",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "sny_AdjustmentToDebtMeasuredAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AdjustmentToDebtMeasuredAtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to debt measured at fair value",
        "label": "Adjustment To Debt Measured At Fair Value [Member]",
        "documentation": "Adjustment to debt measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in deferred taxes",
        "label": "Adjustments for deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets",
        "label": "Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset",
        "documentation": "Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in accounts payable",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains and losses on disposals of non-current assets, net of tax",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "sny_AdjustmentsForLossesGainsOnTransferOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AdjustmentsForLossesGainsOnTransferOfBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for losses (gains) on transfer of business",
        "label": "Adjustments for losses (gains) on transfer of business",
        "documentation": "Adjustments for losses (gains) on transfer of business"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in non-current provisions and other non-current liabilities",
        "label": "Adjustments For Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "Adjustments for noncurrent provisions and other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile profit (loss) [abstract]",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of employee benefits (stock options and other share-based payments)",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of undistributed earnings from investments accounted for using the equity method",
        "label": "Adjustments for undistributed profits of investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AggregatedIndividuallyImmaterialAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Aggregated individually immaterial associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the aggregation of associates that are individually immaterial. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK",
        "label": "Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy [Policy Text Block]",
        "documentation": "Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment",
        "verboseLabel": "Other",
        "label": "All other segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for business activities and operating segments that are not reportable."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r227"
     ]
    },
    "sny_AllergyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AllergyMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allergy [Member]",
        "label": "Allergy [Member]",
        "documentation": "Allergy, Cough And Cold [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllowanceForCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AllowanceForCreditLossesMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances",
        "label": "Allowance for credit losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an allowance account used to record impairments to financial assets due to credit losses."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "sny_AlprolixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AlprolixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alprolix",
        "label": "Alprolix [Member]",
        "documentation": "Alprolix"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AltuviiioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AltuviiioMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altuviiio",
        "label": "Altuviiio [Member]",
        "documentation": "Altuviiio"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization expense",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization and impairment of intangible assets",
        "label": "Amortization And Impairment Of Intangible Assets Other Than Goodwill",
        "documentation": "Amortization and impairment of intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizedCostNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AmortizedCostNettingMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Amortized Cost, Netting [Member]",
        "documentation": "Amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmountOfSharesRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AmountOfSharesRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of shares repurchased",
        "label": "Amount Of Shares Repurchased",
        "documentation": "Amount of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable, related party transactions",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r83"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts receivable, related party transactions",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r83"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AntibodiesAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monoclonal Antibodies Alliance",
        "label": "Antibodies Alliance [Member]",
        "documentation": "Antibodies Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AntibodiesCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibodies Collaboration Agreement",
        "label": "Antibodies Collaboration Agreement [Member]",
        "documentation": "Antibodies Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard tax rate applicable in France",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r163",
      "r164",
      "r167",
      "r230",
      "r233"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsAcquisitionAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition [Axis]",
        "label": "Assets Acquisition [Axis]",
        "documentation": "Assets Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsAcquisitionDomain",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition [Domain]",
        "label": "Assets Acquisition [Domain]",
        "documentation": "Assets Acquisition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsAcquisitionMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition",
        "label": "Assets Acquisition [Member]",
        "documentation": "Assets Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsAcquisitionNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition Nominal Value",
        "label": "Assets Acquisition Nominal Value",
        "documentation": "Assets Acquisition Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsAcquisitionPurchasePricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition, Purchase Price Per Share",
        "label": "Assets Acquisition, Purchase Price Per Share",
        "documentation": "Assets Acquisition, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAndLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [Axis]",
        "label": "Assets and liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r242"
     ]
    },
    "ifrs-full_AssetsAndLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAndLiabilitiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [Member]",
        "label": "Assets and liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r242"
     ]
    },
    "sny_AssetsOfDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Of Disposal Group Including Discontinued Operations",
        "label": "Assets Of Disposal Group Including Discontinued Operations",
        "documentation": "Assets Of Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssetsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets, Related Party Transactions",
        "label": "Assets, Related Party Transactions",
        "documentation": "Assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssociatesAndJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AssociatesAndJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates and joint ventures",
        "label": "Associates And Joint Ventures [Member]",
        "documentation": "Associates and Joint Ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AstraZenecaMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r123",
      "r147",
      "r163"
     ]
    },
    "sny_AtMarketValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AtMarketValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value",
        "label": "At Market Value [member]",
        "documentation": "At market value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AtNotionalAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AtNotionalAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "At Notional Amount [member]",
        "documentation": "At notional amount."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r307"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [domain]",
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r307"
     ]
    },
    "sny_AubagioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "AubagioMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aubagio",
        "label": "Aubagio [Member]",
        "documentation": "Aubagio."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank credit balances",
        "label": "Bank overdrafts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "sny_BasicEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BasicEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share (in euros per share)",
        "label": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)",
        "label": "Basic earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings (loss) per share from discontinued operations",
        "label": "Basic earnings (loss) per share from discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer contingent consideration arising from acquisition of Genzyme",
        "label": "Bayer Contingent Purchase Consideration Arising From Acquisition Of Genzyme [Member]",
        "documentation": "Bayer contingent purchase consideration arising from the acquisition of Genzyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BiopharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BiopharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharma Segment [Member]",
        "label": "Biopharma Segment [Member]",
        "documentation": "Pharmaceuticals segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BlueprintMedicinesCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BlueprintMedicinesCorporationMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blueprint Medicines Corporation",
        "label": "Blueprint Medicines Corporation [Member]",
        "documentation": "Blueprint Medicines Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BondsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond issues",
        "label": "Bonds issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_BorrowingAverageDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BorrowingAverageDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, average drawdown",
        "label": "Borrowing, Average Drawdown",
        "documentation": "Borrowing, Average Drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "verboseLabel": "Market value",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Member]",
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r169",
      "r183",
      "r189",
      "r271",
      "r273",
      "r330"
     ]
    },
    "sny_BusinessCombinationNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BusinessCombinationNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination Nominal Value",
        "label": "Business Combination Nominal Value",
        "documentation": "Business Combination Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BusinessCombinationPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, purchase price",
        "label": "Business Combination, Purchase Price",
        "documentation": "Business Combination, Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BusinessCombinationPurchasePricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in USD per share)",
        "label": "Business Combination, Purchase Price Per Share",
        "documentation": "Business Combination, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations [Member]",
        "label": "Business combinations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r203"
     ]
    },
    "sny_BusinessOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "BusinessOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business operating income",
        "totalLabel": "Business Operating Income",
        "label": "Business Operating Income",
        "documentation": "Business operating income."
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CabliviMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CabliviMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cablivi",
        "label": "Cablivi [Member]",
        "documentation": "Cablivi"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CancellationOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CancellationOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of treasury shares",
        "label": "Cancellation of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of treasury stock cancelled during the period. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r107",
      "r114",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r202",
      "r217",
      "r218"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [Member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r114",
      "r120",
      "r122",
      "r123",
      "r202",
      "r217",
      "r218"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "negatedLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r134",
      "r157"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashAndCashEquivalentsDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CashAndCashEquivalentsDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, discontinued operations",
        "label": "Cash and cash equivalents, discontinued operations",
        "documentation": "Cash and cash equivalents, discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CashAndCashEquivalentsReclassifiedToAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents Reclassified to Assets Held for Sale",
        "label": "Cash and Cash Equivalents Reclassified to Assets Held for Sale",
        "documentation": "Cash and Cash Equivalents Reclassified to Assets Held for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashFlowAndFairValueHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CashFlowAndFairValueHedgeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow and fair value hedge",
        "label": "Cash Flow And Fair Value Hedge [Member]",
        "documentation": "Cash Flow And Fair Value Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash flow hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Types of hedges [domain]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r212",
      "r213",
      "r214"
     ]
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals of consolidated undertakings and investments accounted for using the equity method",
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities [abstract]",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from (used in) financing activities, continuing operations",
        "label": "Cash flows from (used in) financing activities, continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) financing activities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities, discontinued operations",
        "label": "Cash flows from (used in) financing activities, discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt and other financial instruments",
        "label": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments",
        "documentation": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) investing activities [abstract]",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from (used in) investing activities, continuing operations",
        "label": "Cash flows from (used in) investing activities, continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) investing activities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) operating activities [abstract]",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from (used in) operating activities, continuing operations",
        "label": "Cash flows from (used in) operating activities, continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) operating activities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) operating activities, discontinued operations",
        "label": "Cash flows from (used in) operating activities, discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r327"
     ]
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of consolidated undertakings and investments accounted for using the equity method",
        "terseLabel": "Net cash flow on acquisition",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash transferred",
        "label": "Cash transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "sny_CashTransferredPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CashTransferredPerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Transferred, Per Share",
        "label": "Cash Transferred, Per Share",
        "documentation": "Cash Transferred, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for related parties [Member]",
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "sny_CerezymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CerezymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cerezyme",
        "label": "Cerezyme [Member]",
        "documentation": "Cerezyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CertainWholesalersInTheUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CertainWholesalersInTheUnitedStatesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain wholesalers in the United States",
        "label": "Certain Wholesalers, In The United States [Member]",
        "documentation": "Certain Wholesalers, In The United States"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)",
        "label": "Change In Currency Translation Before Tax Excluding Associates And Joint Ventures",
        "documentation": "Change in currency translation before tax excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences (investments accounted for using the equity method)",
        "label": "Change In Currency Translation Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in currency translation net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges of net investments in foreign operations",
        "label": "Change In Currency Translation On Hedges Of Net Investments In Foreign Operations",
        "documentation": "Change in currency translation on hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnTaxEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInCurrencyTranslationOnTaxEffects",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Change In Currency Translation On Tax Effects",
        "documentation": "Change in currency translation on tax effects."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Debt Instrument Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax",
        "documentation": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets",
        "label": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets",
        "documentation": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "label": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "documentation": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ChangesInOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases in provisions and other liabilities",
        "label": "Increase (decrease) in other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "sny_ChangesInProfitLossFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ChangesInProfitLossFromDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Profit Loss from Discontinued Operations",
        "label": "Changes in Profit Loss from Discontinued Operations",
        "documentation": "Changes in Profit Loss from Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [Axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r168",
      "r178"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Member]",
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r168",
      "r178"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of Contingent Liabilities [Axis]",
        "label": "Classes of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r201"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of contingent liabilities [domain]",
        "label": "Classes of contingent liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r201"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [Axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r222",
      "r223",
      "r240",
      "r241"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class [Member]",
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r222",
      "r223",
      "r240",
      "r241"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions [Member]",
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [Axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [Axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "sny_ClinicalStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ClinicalStudyMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Study",
        "label": "Clinical Study [Member]",
        "documentation": "Clinical Study [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementWithGSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CollaborationAgreementWithGSKMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement with GSK",
        "label": "Collaboration Agreement With GSK [Member]",
        "documentation": "Collaboration Agreement With GSK"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsDevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CollaborationAgreementsDevelopmentMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, development milestone payment",
        "label": "Collaboration Agreements, Development Milestone Payment",
        "documentation": "Collaboration Agreements, Development Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsRegulatoryMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CollaborationAgreementsRegulatoryMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, regulatory milestone payment",
        "label": "Collaboration Agreements, Regulatory Milestone Payment",
        "documentation": "Collaboration Agreements, Regulatory Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CollaborationAgreementsUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, upfront payment",
        "label": "Collaboration Agreements, Upfront Payment",
        "documentation": "Collaboration Agreements, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CommercialPaperProgramInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in France",
        "label": "Commercial Paper Program In France [Member]",
        "documentation": "Commercial paper program In France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CommercialPaperProgramInUSAMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in USA",
        "label": "Commercial Paper Program In USA [Member]",
        "documentation": "Commercial paper program in USA."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommercialPapersIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CommercialPapersIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper programs",
        "label": "Commercial papers issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_CommercializationRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CommercializationRelatedExpensesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement to Regeneron of selling expenses incurred",
        "label": "Commercialization Related Expenses [Member]",
        "documentation": "Commercialization related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to potential milestone payments for projects under collaboration agreements",
        "label": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement",
        "documentation": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments Related To Research And Development License Agreements, Discontinued Operations",
        "label": "Commitments Related To Research And Development License Agreements, Discontinued Operations",
        "documentation": "Commitments Related To Research And Development License Agreements, Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r37",
      "r139",
      "r141",
      "r153",
      "r269"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r40"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to equity holders of Sanofi",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r41"
     ]
    },
    "sny_ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income, attributable to owners of parent, continuing operations",
        "label": "Comprehensive income, attributable to owners of parent, continuing operations",
        "documentation": "Comprehensive income, attributable to owners of parent, continuing operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income, attributable to owners of parent, discontinued operations",
        "label": "Comprehensive income, attributable to owners of parent, discontinued operations",
        "documentation": "Comprehensive income, attributable to owners of parent, discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ComprehensiveIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ComprehensiveIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Related Party Disclosures",
        "documentation": "Comprehensive Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "sny_ConsumerHealthcareSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ConsumerHealthcareSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consumer Healthcare Segment [Member]",
        "terseLabel": "Consumer Healthcare Segment [Member]",
        "label": "Consumer Healthcare Segment [Member]",
        "documentation": "Consumer Healthcare segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ContingentConsiderationArisingFromAcquisitionOfAmunixMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arising from acquisition of Amunix",
        "label": "Contingent Consideration Arising From Acquisition Of Amunix [Member]",
        "documentation": "Contingent Consideration Arising From Acquisition Of Amunix"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Fair value of contingent consideration payable",
        "label": "Contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sny_ContingentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ContingentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Milestone Payments",
        "label": "Contingent Milestone Payments",
        "documentation": "Contingent Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractDurationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractDurationAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract duration [axis]",
        "label": "Contract duration [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ifrs-full_ContractDurationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractDurationDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract duration [domain]",
        "label": "Contract duration [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all durations of contracts with customers. It also represents the standard value for the 'Contract duration' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "sny_CoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Core Assets [Member]",
        "label": "Core Assets [Member]",
        "documentation": "Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CostOfDebtNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CostOfDebtNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Cost of net debt",
        "label": "Cost Of Debt Net",
        "documentation": "Cost of debt net."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "negatedTerseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r52"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Member]",
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CreditFacilitiesExtensionOptionNumber",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, number of extension options",
        "label": "Credit Facilities, Extension Option, Number",
        "documentation": "Credit Facilities, Extension Option, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CreditFacilitiesExtensionOptionPeriod",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, extension option period",
        "label": "Credit Facilities, Extension Option, Period",
        "documentation": "Credit Facilities, Extension Option, Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySellerSwapsInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CrossCurrencySellerSwapsInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross Currency Seller Swaps In US Dollar",
        "label": "Cross Currency Seller Swaps In US Dollar [Member]",
        "documentation": "Cross Currency Seller Swaps In US Dollar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySellerSwapsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CrossCurrencySellerSwapsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross Currency Seller Swaps",
        "label": "Cross Currency Seller Swaps [Member]",
        "documentation": "Cross Currency Seller Swaps [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapExpiring2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CrossCurrencySwapExpiring2029Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross Currency Swap, Expiring 2029",
        "label": "Cross Currency Swap, Expiring 2029 [Member]",
        "documentation": "Cross Currency Swap, Expiring 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapExpiring2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CrossCurrencySwapExpiring2032Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross Currency Swap, Expiring 2032",
        "label": "Cross Currency Swap, Expiring 2032 [Member]",
        "documentation": "Cross Currency Swap, Expiring 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CrossCurrencySwapMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross Currency Swap",
        "label": "Cross Currency Swap [Member]",
        "documentation": "Cross Currency Swap [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CumulativeConsumerPriceInflationRateOverTheLastThreeYears",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative consumer price inflation rate",
        "label": "Cumulative Consumer Price Inflation Rate Over The Last Three Years",
        "documentation": "Cumulative Consumer Price Inflation Rate Over The Last Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency and interest rate derivatives",
        "label": "Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents",
        "documentation": "Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r149",
      "r269"
     ]
    },
    "sny_CurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Assets [Member]",
        "documentation": "Current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets, Related Party Transactions",
        "label": "Current assets, Related Party Transactions",
        "documentation": "Current assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt and current portion of long-term debt",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r151",
      "r269"
     ]
    },
    "sny_CurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Liabilities [Member]",
        "documentation": "Current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities, Related Party Transactions",
        "label": "Current Liabilities, Related Party Transactions",
        "documentation": "Current Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Current portion",
        "label": "Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentProvisionsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentProvisionsAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions and other current liabilities",
        "label": "Current Provisions And Other Current Liabilities",
        "documentation": "The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations",
        "label": "Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations",
        "documentation": "Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax assets",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax assets",
        "label": "Current tax assets, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current taxes",
        "terseLabel": "Current tax expense (income)",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "sny_CurrentTaxExpenseRelatedToPillarTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CurrentTaxExpenseRelatedToPillarTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Tax Expense Related to Pillar Two",
        "label": "Current Tax Expense Related to Pillar Two",
        "documentation": "Current Tax Expense Related to Pillar Two"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax liabilities",
        "label": "Current tax liabilities, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r249"
     ]
    },
    "sny_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer one",
        "label": "Customer One [member]",
        "documentation": "Customer one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer three",
        "label": "Customer Three [member]",
        "documentation": "Customer three."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer two",
        "label": "Customer Two [member]",
        "documentation": "Customer two."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Debt Instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DebtInstrumentDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Domain]",
        "label": "Debt Instrument [Domain]",
        "documentation": "Debt Instrument [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DebtInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments included in financial assets",
        "label": "Debt Instruments [Member]",
        "documentation": "Debt Instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DebtNetOfCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net debt",
        "label": "Debt Net Of Cash And Cash Equivalents",
        "documentation": "Debt net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272"
     ]
    },
    "sny_DefendantAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DefendantAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Axis]",
        "label": "Defendant [Axis]",
        "documentation": "Defendant [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DefendantDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DefendantDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Domain]",
        "label": "Defendant [Domain]",
        "documentation": "Defendant [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DeferredCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DeferredCashPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Cash Payments",
        "label": "Deferred Cash Payments",
        "documentation": "Deferred Cash Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r59"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred taxes",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r59"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability (asset)",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Axis]",
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ifrs-full_DefinedBenefitPlansDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansDomain",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Member]",
        "label": "Defined benefit plans [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "sny_DerecognizedReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DerecognizedReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognized receivables",
        "label": "Derecognized Receivables",
        "documentation": "Derecognized receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial assets",
        "label": "Derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_DerivativeFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DerivativeFinancialInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating currency hedging instruments in place",
        "label": "Derivative Financial Instruments",
        "documentation": "Derivative financial instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstrumentsToManageFinancialExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DerivativeFinancialInstrumentsToManageFinancialExposure",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial currency hedging instruments in place",
        "label": "Derivative Financial Instruments To Manage Financial Exposure",
        "documentation": "Derivative financial instruments to manage financial exposure."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Pronouncements Issued by the IASB and Applicable from 2024",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sny_DevelopmentRegulatoryAndLaunchMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DevelopmentRegulatoryAndLaunchMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Regulatory And Launch Milestone Payments",
        "label": "Development Regulatory And Launch Milestone Payments",
        "documentation": "Development Regulatory And Launch Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DigestiveWellnessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DigestiveWellnessMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Digestive Wellness [Member]",
        "label": "Digestive Wellness [Member]",
        "documentation": "Digestive Wellness [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DilutedEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in euros per share)",
        "label": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)",
        "label": "Diluted earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings (loss) per share from discontinued operations",
        "label": "Diluted earnings (loss) per share from discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for stock options with dilutive effect (in shares)",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for restricted shares (in shares)",
        "label": "Dilutive Effect Of Share Options On Number Of Restricted Shares",
        "documentation": "Dilutive effect of share options on number of restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "sny_DisclosureOfAccountsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAccountsReceivableLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Line Items]",
        "label": "Disclosure Of Accounts Receivable [line items]",
        "documentation": "Disclosure Of Accounts Receivable [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccountsReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAccountsReceivableTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Table]",
        "label": "Disclosure Of Accounts Receivable [Table]",
        "documentation": "Disclosure of Accounts receivable Table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements within Other Comprehensive Income",
        "label": "Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information of accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]",
        "documentation": "The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Acquisitions and Capitalized Interest by Operating Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]",
        "documentation": "Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes",
        "label": "Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]",
        "documentation": "The disclosure of allocation of income tax between current and deferred taxes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Line Items]",
        "label": "Disclosure of analysis of other comprehensive income by item [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Table]",
        "label": "Disclosure of analysis of other comprehensive income by item [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of other comprehensive income by item."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of single amount of discontinued operations [line items]",
        "label": "Disclosure of analysis of single amount of discontinued operations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of single amount of discontinued operations [table]",
        "label": "Disclosure of analysis of single amount of discontinued operations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of the single amount of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "sny_DisclosureOfChangesInFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfChangesInFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Financial Position",
        "label": "Disclosure Of Changes In Financial Position [Table Text Block]",
        "documentation": "Disclosure of changes in financial position [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]",
        "documentation": "The disclosure of changes in liabilities related to business combinations and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquity",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Treasury Shares Held",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Non-Current Assets",
        "label": "Disclosure Of Components Of Other Non-Current Assets [Table Text Block]",
        "documentation": "The disclosure of components of other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities in business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfCurrentTradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfCurrentTradeReceivablesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accounts Receivable",
        "label": "Disclosure Of Current Trade Receivables [Table Text Block]",
        "documentation": "The disclosure of current trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Cash and Cash Equivalents",
        "label": "Disclosure Of Debt Instruments Issued Explanatory [Text Block]",
        "documentation": "Disclosure of debt instruments issued explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Debt by Type Valuation of Redemption",
        "label": "Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt net of cash and cash equivalents by type at value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Disclosure of derivative financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Line Items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about finance income expense [Line Items]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [Line Items]",
        "documentation": "Line items represent detailed information about finance income expense."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "documentation": "Schedule disclosing information related to details of finance income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Measurement Principles Applied to Financial Instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r224"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block",
        "label": "Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Text Block]",
        "documentation": "Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Characteristics of Restricted Share Plans",
        "label": "Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]",
        "documentation": "Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events Subsequent to June 30, 2023",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Expenses and Income",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]",
        "label": "Disclosure of financial assets that are either past due or impaired [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Table]",
        "label": "Disclosure of financial assets that are either past due or impaired [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated",
        "label": "Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]",
        "documentation": "The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Financial Income and Expenses",
        "label": "Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]",
        "documentation": "The entire disclosure for financial income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r224"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Introduction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Introduction",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Geographical Information on Net Sales and Non-Current Assets",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfHyperinflationaryReportingExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies",
        "label": "Disclosure of information about hyperinflationary reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about financial reporting in hyperinflationary economies."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
        "label": "Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]",
        "documentation": "The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of impairment loss and reversal of impairment loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Intangible Assets",
        "label": "Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]",
        "documentation": "The entire disclosure for impairment of intangible assets and property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to credit exposures designated as measured at fair value through profit or loss."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information about major customers and credit risk [line items]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Line Items]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information About Major Customers and Credit Risk [Table]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Table]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the terms and conditions of hedging instruments and how they affect future cash flows."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [line items]",
        "label": "Disclosure of initial application of standards or interpretations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [table]",
        "label": "Disclosure of initial application of standards or interpretations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the initial application of standards or interpretations."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Other Intangible Assets",
        "label": "Disclosure of intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Instruments",
        "label": "Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]",
        "documentation": "The disclosure of interest rates hedging instruments with notional amount by expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Accounted for Using the Equity Method",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments in Associates and Joint Ventures",
        "label": "Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]",
        "documentation": "The entire disclosure of investments in associates and joint ventures explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Line Items]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Line Items]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTable",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Table]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Table]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation and Arbitration Proceedings",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Text Block]",
        "documentation": "Disclosure Of Legal And Arbitral Proceedings [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]",
        "documentation": "The entire disclosure for liabilities related to business combination and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMarketValueOfNetDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfMarketValueOfNetDebtTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Value of Net Debt",
        "label": "Disclosure Of Market Value Of Net Debt [Table Text Block]",
        "documentation": "Disclosure of market value of net debt [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Line Items]",
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Table]",
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Sales by Segment and Geographical Area",
        "label": "Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]",
        "documentation": "Disclosure of net sales by segment and geographical area."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfNonCurrentProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-current Provisions [Line Items]",
        "label": "Disclosure Of Non-Current Provisions [Line Items]",
        "documentation": "Disclosure Of Non-current Provisions [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfNonCurrentProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Noncurrent Provisions [Table]",
        "label": "Disclosure Of Non-Current Provisions [Table]",
        "documentation": "Disclosure Of Noncurrent Provisions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfNonCurrentProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Non-Current Provisions",
        "label": "Disclosure Of Non-Current Provisions [Table Text Block]",
        "documentation": "Disclosure of noncurrent provisions explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Noncurrentassetheldforsaleanddiscontinuedoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Restricted Shares Not Yet Fully Vested",
        "label": "Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]",
        "documentation": "Disclosure of number of restricted share plans Not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off Balance Sheet Commitments",
        "label": "Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]",
        "documentation": "Disclosure of off-balance sheet commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Line Items]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "documentation": "[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Table]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "documentation": "Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Currency Hedging Instruments",
        "label": "Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]",
        "documentation": "The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Results",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Line Items]",
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method",
        "label": "Disclosure Of Operating Segments Reconciling Items [Table Text Block]",
        "documentation": "The disclosure of operating segments reconciling items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherGainsandLossesandLitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Gains and Losses, and Litigation",
        "label": "Disclosure Of Other Gains And Losses, And Litigation [Text Block]",
        "documentation": "The entire disclosure of other gains and losses, and litigation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherNonCurrentAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non Current Assets [Line Items]",
        "label": "Disclosure Of Other Non-Current Assets [Line Items]",
        "documentation": "Disclosure of other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherNonCurrentAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non-current Assets [Table]",
        "label": "Disclosure Of Other Non-Current Assets [Table]",
        "documentation": "Schedule disclosing information related to other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Current Assets",
        "label": "Disclosure of other non-current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income and Expenses",
        "label": "Disclosure of other operating income (expense) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "label": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "documentation": "Disclosure of other operating income (expenses)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesTable",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Other Operating Income Expenses [Table]",
        "label": "Disclosure Of Other Operating Income Expenses [Table]",
        "documentation": "Disclosure of other operating income expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOtherRevenueTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other revenue",
        "label": "Disclosure of other revenue [Text Block]",
        "documentation": "Disclosure of other revenue [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Gross Value of Overdue Receivables",
        "label": "Disclosure Of Overdue Receivables Gross Value [Table Text Block]",
        "documentation": "The disclosure of overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfPrincipalAgreementsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Principal Agreements [Line Items]",
        "label": "Disclosure Of Principal Agreements [Line Items]",
        "documentation": "Disclosure Of Principal Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfPrincipalAgreementsTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Principal Agreements [Table]",
        "label": "Disclosure Of Principal Agreements [Table]",
        "documentation": "Disclosure Of Principal Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-Current Provisions and Other Non-Current Liabilities",
        "label": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Provisions And Other Non-Current Liabilities",
        "label": "Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate",
        "label": "Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]",
        "documentation": "Disclosure of reconciliation of average effective tax rate and applicable tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [line items]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [Table]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Carrying Amount to Value on Redemption",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]",
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Other Intangible Assets",
        "label": "Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]",
        "documentation": "Disclosure of reconciliation of changes in other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Remeasurement of Net Defined Benefit Liability Asset",
        "label": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]",
        "documentation": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs And Similar Items [Text Block]",
        "documentation": "The entire disclosure of restructuring costs and similar items."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfRestructuringCostsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs Details [Table Text Block]",
        "documentation": "The disclosure of restructuring costs details."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfRestructuringTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Restructuring",
        "label": "Disclosure Of Restructuring [Text Block]",
        "documentation": "Disclosure Of Restructuring [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Revenuefromcontractswithcustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of revenue [text block]",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options Outstanding and Exercisable",
        "label": "Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]",
        "documentation": "The disclosure of share based compensation shares authorized under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Shareholders' Equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Shares Used to Compute Diluted Earnings Per Share",
        "label": "Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]",
        "documentation": "The disclosure of shares used to compute diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "sny_DisclosureOfTradeReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DisclosureOfTradeReceivablesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Disclosure Of Trade Receivables [Text Block]",
        "documentation": "The disclosure of trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Transactions and Balances with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsAndGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals and other decreases",
        "label": "Disposals and retirements, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals and retirements, intangible assets other than goodwill",
        "label": "Disposals and retirements, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "sny_DividendsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DividendsPaidAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid:",
        "label": "Dividends Paid [Abstract]",
        "documentation": "Dividends Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend paid per share (in euros per share)",
        "label": "Dividends paid, ordinary shares per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid to equity holders of Sanofi",
        "label": "Dividends paid to equity holders of parent, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid to non-controlling interests",
        "label": "Dividends paid to non-controlling interests, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends received from non-consolidated entities",
        "label": "Dividends Received From Nonconsolidated Entities Classified As Operating Activities",
        "documentation": "Dividends received from non-consolidated entities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of dividends to non-controlling interests",
        "label": "Dividends recognised as distributions to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend paid out of earnings",
        "label": "Dividends recognised as distributions to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DupixentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "DupixentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dupixent",
        "label": "Dupixent [Member]",
        "documentation": "Dupixent [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EUROZONEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EUROZONEMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eurozone",
        "label": "EUROZONE [Member]",
        "documentation": "EUROZONE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of exchange rates on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129"
     ]
    },
    "sny_EloctateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EloctateMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eloctate",
        "label": "Eloctate [Member]",
        "documentation": "Eloctate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EmployeeShareOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EmployeeShareOwnershipPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees share ownership plan",
        "label": "Employee Share Ownership Plan [Member]",
        "documentation": "Employees share ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EnjaymoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EnjaymoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enjaymo",
        "label": "Enjaymo [Member]",
        "documentation": "Enjaymo"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r31",
      "r138",
      "r140",
      "r163",
      "r164",
      "r167"
     ]
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAndLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityAndLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable, related party transactions",
        "label": "Equity and Liabilities, Related Party Transactions",
        "documentation": "Equity and Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAttributableToEquityHoldersRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityAttributableToEquityHoldersRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Attributable to Equity Holders, Related Party Transactions",
        "label": "Equity Attributable to Equity Holders, Related Party Transactions",
        "documentation": "Equity Attributable to Equity Holders, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityAttributableToNonControllingInterestRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Attributable to Non Controlling Interest, Related Party Transactions",
        "label": "Equity Attributable to Non Controlling Interest, Related Party Transactions",
        "documentation": "Equity Attributable to Non Controlling Interest, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_EquityInstrumentsIncludedInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityInstrumentsIncludedInFinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments included in financial assets",
        "label": "Equity Instruments Included In Financial Assets [Member]",
        "documentation": "Equity Instruments Included In Financial Assets[member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityInterestsOfAcquirer",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interests of acquirer",
        "label": "Equity interests of acquirer"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "sny_EquityInterestsOfAcquirerPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityInterestsOfAcquirerPerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Interests Of Acquirer, Per Share",
        "label": "Equity Interests Of Acquirer, Per Share",
        "documentation": "Equity Interests Of Acquirer, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Related Party Transactions",
        "label": "Equity, Related Party Transactions",
        "documentation": "Equity, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity risk hedging instruments designated as fair value hedges",
        "label": "Equity Risk Hedging Instruments Designated At Fair Value Hedges",
        "documentation": "Equity Risk Hedging Instruments Designated At Fair Value Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EuroapiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "EuroapiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euroapi",
        "verboseLabel": "EUROAPI",
        "label": "Euroapi [Member]",
        "documentation": "Euroapi"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe [Member]",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendPercentageOfShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExceptionalSupplementaryDividendPercentageOfShareCapital",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceptional supplementary dividend, in percentage",
        "label": "Exceptional Supplementary Dividend, Percentage Of Share Capital",
        "documentation": "Exceptional Supplementary Dividend, Percentage Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi",
        "label": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent",
        "documentation": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExcludingChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExcludingChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excluding General Director",
        "label": "Excluding Chief Executive Officer [Member]",
        "documentation": "Excluding Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of outstanding options (in euros per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sny_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac80.00 to \u20ac90.00 per share",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac70.00 to \u20ac80.00 per share",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac60.00 to \u20ac70.00 per share",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExpenseArisingFromTheImpactOfAcquisitionsOnInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expense arising from the impact of acquisitions on inventories",
        "label": "Expense Arising From The Impact Of Acquisitions On Inventories",
        "documentation": "Expenses arising from the impact of acquisitions on inventories."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unwinding of discounting of provisions",
        "label": "Expense arising from passage of time on other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognized",
        "netLabel": "Total expense for restricted share plans",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_ExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseOfRestructuringActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restructuring costs and similar items",
        "totalLabel": "Total",
        "label": "Expense of restructuring activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation for early termination of contracts (other than contracts of employment)",
        "label": "Expense Of Restructuring Activities Compensation For Early Termination Of Contracts",
        "documentation": "Compensation for early termination of contracts (other than contracts of employment)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related expenses",
        "label": "Expense Of Restructuring Activities Employee Related Expenses",
        "documentation": "Employee related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges, gains or losses on assets",
        "label": "Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories",
        "documentation": "Expense of restructuring activities related to property plant and equipment to inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ExpenseOfRestructuringActivitiesTransformationProgramsCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of transformation programs",
        "label": "Expense Of Restructuring Activities, Transformation Programs Costs",
        "documentation": "Expense Of Restructuring Activities, Transformation Programs Costs"
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "FR",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FabrazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FabrazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fabrazyme",
        "label": "Fabrazyme [Member]",
        "documentation": "Fabrazyme [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FairValueHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hedges",
        "label": "Fair value hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to changes in fair value of a recognised asset or liability or an unrecognised firm commitment, or an identified portion of such an asset, liability or firm commitment, that is attributable to a particular risk and could affect profit or loss. [Refer: Types of hedges [domain]]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r212",
      "r213",
      "r214"
     ]
    },
    "sny_FairValueOfInvestmentsInEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FairValueOfInvestmentsInEquityInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Investments in Equity Instruments",
        "label": "Fair Value of Investments in Equity Instruments",
        "documentation": "Fair Value of Investments in Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition",
        "label": "Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value at the date of the derecognition of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "sny_FairValueOfPlanAtDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FairValueOfPlanAtDateOfGrant",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan at the date of grant",
        "label": "Fair Value Of Plan At Date Of Grant",
        "documentation": "Fair value of plan at the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures",
        "label": "Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures [Member]",
        "documentation": "Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period",
        "documentation": "Fair value per share awarded to a three year service period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial income",
        "terseLabel": "Financial income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net financial income/(expenses)",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "sny_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FirmOrdersOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FirmOrdersOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm orders of property, plant and equipment",
        "label": "Firm Orders Of Property Plant And Equipment",
        "documentation": "Firm orders of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondIssueFromApril2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondIssueFromApril2020Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Issue from April 2020",
        "label": "Fixed Rate Bond Issue from April 2020 [Member]",
        "documentation": "Fixed Rate Bond Issue from April 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondIssueFromApril2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondIssueFromApril2022Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Issue from April 2022",
        "label": "Fixed Rate Bond Issue from April 2022 [Member]",
        "documentation": "Fixed Rate Bond Issue from April 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingApril2024Redeemed2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondMaturingApril2024Redeemed2024Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing April2024 Redeemed2024",
        "label": "Fixed Rate Bond Maturing April2024 Redeemed2024 [Member]",
        "documentation": "Fixed Rate Bond Maturing April2024 Redeemed2024"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingJune2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondMaturingJune2029Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing June 2029",
        "label": "Fixed Rate Bond Maturing June 2029 [Member]",
        "documentation": "Fixed Rate Bond Maturing June 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMarch2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondMaturingMarch2027Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing March 2027",
        "label": "Fixed Rate Bond Maturing March 2027 [Member]",
        "documentation": "Fixed Rate Bond Maturing March 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMarch2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondMaturingMarch2031Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing March 2031",
        "label": "Fixed Rate Bond Maturing March 2031 [Member]",
        "documentation": "Fixed Rate Bond Maturing March 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMarch2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FixedRateBondMaturingMarch2032Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing March 2032",
        "label": "Fixed Rate Bond Maturing March 2032 [Member]",
        "documentation": "Fixed Rate Bond Maturing March 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForeignCurrencyTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForeignCurrencyTranslationMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Translation [Member]",
        "documentation": "Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInCanadianDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInCanadianDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Canadian dollar",
        "label": "Forward Currency Purchases In Canadian Dollar [Member]",
        "documentation": "Forward Currency Purchases In Canadian Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Chinese yuan renminbi",
        "label": "Forward Currency Purchases In Chinese Yuan Renminbi [Member]",
        "documentation": "Forward Currency Purchases In Chinese Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInHungarianFlorintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInHungarianFlorintMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Hungarian florint",
        "label": "Forward Currency Purchases In Hungarian florint [Member]",
        "documentation": "Forward Currency Purchases In Hungarian florint"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Japanese Yen",
        "label": "Forward Currency Purchases In Japanese Yen [Member]",
        "documentation": "Forward Currency Purchased In Japanese yen [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInKoreanWonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInKoreanWonMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Korean won",
        "label": "Forward Currency Purchases In Korean Won [Member]",
        "documentation": "Forward Currency Purchases In Korean Won"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInRussianRoubleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInRussianRoubleMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Russian rouble",
        "label": "Forward Currency Purchases In Russian rouble [Member]",
        "documentation": "Forward Currency Purchases In Russian rouble"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Singapore dollar",
        "label": "Forward Currency Purchases In Singapore Dollar [Member]",
        "documentation": "Forward currency purchases in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInTurkishLiraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInTurkishLiraMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Turkish lira",
        "label": "Forward Currency Purchases In Turkish lira [Member]",
        "documentation": "Forward Currency Purchases In Turkish lira"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInUSDollarCommercialPaperMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, commercial paper",
        "label": "Forward Currency Purchases In US Dollar, Commercial Paper [Member]",
        "documentation": "Forward Currency Purchases In US Dollar, Commercial Paper"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar",
        "label": "Forward Currency Purchases In US Dollar [Member]",
        "documentation": "Forward currency purchases in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarUSBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesInUSDollarUSBondMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, US bond",
        "label": "Forward Currency Purchases In US Dollar, US Bond [Member]",
        "documentation": "Forward Currency Purchases In US Dollar, US Bond"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencyPurchasesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases",
        "label": "Forward Currency Purchases [Member]",
        "documentation": "Forward currency purchases."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInCanadianDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInCanadianDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Canadian Dollar",
        "label": "Forward Currency Sales In Canadian Dollar [Member]",
        "documentation": "Forward Currency Sales In Canadian Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Chinese yuan renminbi",
        "label": "Forward Currency Sales In Chinese Yuan Renminbi [member]",
        "documentation": "Forward currency sales in Chinese Yuan Renminbi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Japanese yen",
        "label": "Forward Currency Sales In Japanese Yen [Member]",
        "documentation": "Forward currency sales in Japanese Yen."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInMexicanPesoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInMexicanPesoMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Mexican peso",
        "label": "Forward Currency Sales In Mexican Peso [Member]",
        "documentation": "Forward Currency Sales In Mexican Peso"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInPoundSterlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInPoundSterlingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Pound sterling",
        "label": "Forward Currency Sales In Pound Sterling [Member]",
        "documentation": "Forward Currency Sales In Pound Sterling"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInRussianRoubleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInRussianRoubleMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Russian rouble",
        "label": "Forward Currency Sales In Russian rouble [Member]",
        "documentation": "Forward Currency Sales In Russian rouble"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Singapore dollar",
        "label": "Forward Currency Sales In Singapore Dollar [member]",
        "documentation": "Forward currency sales in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in US dollar",
        "label": "Forward Currency Sales In US Dollar [Member]",
        "documentation": "Forward currency sales in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ForwardCurrencySalesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales",
        "label": "Forward Currency Sales [Member]",
        "documentation": "Forward currency sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingDecember2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FourBillionFacilityMaturingDecember2027Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Billion Facility Maturing December 2027",
        "label": "Four Billion Facility Maturing December 2027 [Member]",
        "documentation": "Four Billion Facility Maturing December 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingMarch2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FourBillionFacilityMaturingMarch2030Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Billion Facility Maturing March 2030",
        "label": "Four Billion Facility Maturing March 2030 [Member]",
        "documentation": "Four Billion Facility Maturing March 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FulcrumTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FulcrumTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fulcrum Therapeutics",
        "label": "Fulcrum Therapeutics [Member]",
        "documentation": "Fulcrum Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FutureRoyaltiesReceivableValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "FutureRoyaltiesReceivableValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future royalties receivable, value",
        "label": "Future Royalties Receivable, Value",
        "documentation": "Future Royalties Receivable, Value"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GainLossOnDerivativesUsedToManageCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage cash and cash equivalents",
        "label": "Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents",
        "documentation": "Gain (loss) on derivatives used to manage cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GainLossOnDerivativesUsedToManageDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage debt",
        "label": "Gain (Loss) On Derivatives Used To Manage Debt",
        "documentation": "Gain (loss) on derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) on benefit obligations",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on Disposal of Opella, Disposal Group Including Discontinued Operations",
        "label": "Gain on Disposal of Opella, Disposal Group Including Discontinued Operations",
        "documentation": "Gain on Disposal of Opella, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains/(losses) on disposals of financial assets",
        "label": "Gains (losses) on available-for-sale financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnCashFlowHedgesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of cash flow hedges",
        "label": "Gains (losses) on cash flow hedges, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in currency translation differences",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gain (loss)",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78"
     ]
    },
    "sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GainsLossesOnRemeasuringDebtInstrumentsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of debt instruments included in financial assets",
        "label": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax",
        "documentation": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity instruments included in financial assets and financial liabilities",
        "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)",
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "sny_GainsOnDivestmentOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GainsOnDivestmentOfProducts",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains on divestment of some mature products",
        "label": "Gains On Divestment Of Products",
        "documentation": "Gains on divestment of products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralInformationAboutFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GeneralInformationAboutFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information About Financial Statements [Abstract]",
        "label": "General Information About Financial Statements [Abstract]",
        "documentation": "General Information About Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralMedicinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GeneralMedicinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Medicines [Member]",
        "label": "General Medicines [Member]",
        "documentation": "General Medicines"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r255",
      "r275",
      "r284"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Member]",
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r255",
      "r275",
      "r284"
     ]
    },
    "sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GlobalPenaltyFeeIncurredByDefendantsAmountVacated",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Global penalty fee incurred by defendants, amount vacated",
        "label": "Global Penalty Fee Incurred By Defendants, Amount Vacated",
        "documentation": "Global Penalty Fee Incurred By Defendants, Amount Vacated"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GoldBondProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GoldBondProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gold Bond Product Litigation In The US",
        "label": "Gold Bond Product Litigation In The US [Member]",
        "documentation": "Gold Bond Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r100",
      "r101",
      "r202"
     ]
    },
    "sny_GoodwillDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GoodwillDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Disposal Group Including Discontinued Operations",
        "label": "Goodwill, Disposal Group Including Discontinued Operations",
        "documentation": "Goodwill, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant recognised as deduction from development expenses",
        "label": "Government Grant Recognised As Deduction From Development Expenses",
        "documentation": "Government Grant Recognised As Deduction From Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r107",
      "r121",
      "r124",
      "r202",
      "r218",
      "r220",
      "r288"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_HedgedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Axis]",
        "label": "Hedged items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_HedgedItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgedItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Member]",
        "label": "Hedged items [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Instruments [Axis]",
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r212"
     ]
    },
    "ifrs-full_HedgingInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [Member]",
        "label": "Hedging instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r212"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identifiable intangible assets recognised as of acquisition date",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287"
     ]
    },
    "sny_ImmunoOncologyAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ImmunoOncologyAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-Oncology Alliance",
        "label": "Immuno-Oncology Alliance [Member]",
        "documentation": "Immuno-oncology Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImmunoOncologyCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ImmunoOncologyCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno Oncology Collaboration Agreement",
        "label": "Immuno Oncology Collaboration Agreement [Member]",
        "documentation": "Immuno oncology collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of the workdown of acquired inventories remeasured at fair value",
        "label": "Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value",
        "documentation": "Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ImpairmentLossOnIntangibleAssetOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment Loss on Intangible Asset Other Than Goodwill",
        "label": "Impairment Loss on Intangible Asset Other Than Goodwill",
        "documentation": "Impairment Loss on Intangible Asset Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ImpairmentLossOnIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment Loss On Intangible Assets Other Than Goodwill",
        "label": "Impairment Loss On Intangible Assets Other Than Goodwill",
        "documentation": "Impairment Loss On Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses, net of reversals",
        "label": "Impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss",
        "label": "Impairment loss recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment loss on other intangible assets",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables",
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before tax and investments accounted for using the equity method",
        "terseLabel": "Income before tax and investments accounted for using the equity method",
        "label": "Income Before Tax And Investments Accounted For Equity Method Investments",
        "documentation": "Income before tax and investments accounted for equity method investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations",
        "label": "Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations",
        "documentation": "Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeResultingFromOutLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeResultingFromOutLicensing",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from out-licensing",
        "label": "Income Resulting From Out-Licensing",
        "documentation": "Income Resulting From Out-Licensing"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations",
        "label": "Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations",
        "documentation": "Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTotalLabel": "Total",
        "terseLabel": "Tax expense (income)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r55",
      "r57",
      "r58",
      "r84",
      "r158",
      "r229"
     ]
    },
    "sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments",
        "documentation": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income tax relating to cash flow hedges included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56"
     ]
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments",
        "documentation": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method",
        "documentation": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r262"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of contingent consideration",
        "label": "Increase (decrease) in contingent consideration asset (liability)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in total expense of restructuring activities",
        "label": "Increase (Decrease) In Total Expense Of Restructuring Activities",
        "documentation": "Increase (Decrease) In Total Expense Of Restructuring Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Increase Decrease Of Unused Provision Reversed, Other Provisions",
        "documentation": "Increase Decrease Of Unused Provision Reversed, Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on defined-benefit plans (B.12.1.)",
        "label": "Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions",
        "documentation": "Actuarial gains and losses on defined-benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in non-controlling interests without loss of control",
        "label": "Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes arising from issuance of restricted shares",
        "label": "Increase (Decrease) Through Issuance Of Restricted Shares, Equity",
        "documentation": "Increase (decrease) through issuance of restricted shares, equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests",
        "documentation": "Increase decrease through net exchange differences business combinations and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions",
        "documentation": "Net interest related to employees benefits and unwinding of discount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase through remeasurement of financial liability",
        "label": "Increase (Decrease) Through Remeasurement, Other Current Liabilities",
        "documentation": "Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share ownership plan",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans",
        "documentation": "Employee share ownership plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted shares and vesting of existing restricted shares",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares",
        "documentation": "Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effects of share-based payments",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options",
        "documentation": "Tax effects of the exercise of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of services obtained from employees",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees",
        "documentation": "Value of services obtained from employees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements (b)",
        "label": "Increase (decrease) through other changes, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers and other changes, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "sny_IndustrialSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IndustrialSalesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industrial Sales [Member]",
        "label": "Industrial Sales [Member]",
        "documentation": "Industrial Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfluenzaVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InfluenzaVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Influenza Vaccines [Member]",
        "label": "Influenza Vaccines [Member]",
        "documentation": "Influenza Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfraservGmbhAndCoHochstKGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InfraservGmbhAndCoHochstKGMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infraserv GmbH &amp; Co. H\u00f6chst KG",
        "label": "Infraserv Gmbh And Co Hochst KG [member]",
        "documentation": "Infraserv GmbH and Co. Hochst KG."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InhibrxIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InhibrxIncMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inhibrx, Inc",
        "label": "Inhibrx, Inc [Member]",
        "documentation": "Inhibrx, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "terseLabel": "Carrying amount of intangible assets",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r114"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill [member]",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r281"
     ]
    },
    "ifrs-full_InterestCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestCostsCapitalised",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest costs capitalised",
        "label": "Interest costs capitalised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of debt",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "sny_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income",
        "documentation": "Interest Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "sny_InterestRateAndCurrencyDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateAndCurrencyDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate and currency derivatives used to hedge debt",
        "label": "Interest Rate And Currency Derivatives [Member]",
        "documentation": "Interest rate and currency derivatives used to hedge debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage cash and cash equivalents",
        "label": "Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent",
        "documentation": "Interest rate and currency derivatives used to manage cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage debt",
        "label": "Interest Rate And Currency Derivatives Used To Manage Debt",
        "documentation": "Interest rate and currency derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsInterestRate",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Interest Rate Swaps, Interest Rate",
        "documentation": "Interest Rate Swaps, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive069Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive069Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay 2.08% / receive Euribor 3m",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive092Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive092Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 0.92%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive3.56Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive343Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive343Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 3.56%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD / receive 1.17%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD / receive 1.32%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32%"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "sny_InterestsInOtherEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InterestsInOtherEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]",
        "documentation": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r77",
      "r247"
     ]
    },
    "sny_InventoriesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InventoriesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, Disposal Group Including Discontinued Operations",
        "label": "Inventories, Disposal Group Including Discontinued Operations",
        "documentation": "Inventories, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r159",
      "r231"
     ]
    },
    "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in associates",
        "label": "Investments in associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, ownership percentage",
        "label": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage",
        "documentation": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in joint ventures",
        "label": "Investments in joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Total for all joint ventures [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_IrrevocablePurchaseCommitmentsDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IrrevocablePurchaseCommitmentsDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Irrevocable Purchase Commitments, Discontinued Operations",
        "label": "Irrevocable Purchase Commitments, Discontinued Operations",
        "documentation": "Irrevocable Purchase Commitments, Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IrrevocablePurchaseCommitmentsGivenDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Irrevocable Purchase Commitments Given, Discontinued Operations",
        "label": "Irrevocable Purchase Commitments Given, Discontinued Operations",
        "documentation": "Irrevocable Purchase Commitments Given, Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IrrevocablePurchaseCommitmentsReceivedDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Irrevocable Purchase Commitments Received, Discontinued Operations",
        "label": "Irrevocable Purchase Commitments Received, Discontinued Operations",
        "documentation": "Irrevocable Purchase Commitments Received, Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IssuanceOfFurtherSharesAsAnEmployersContribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "IssuanceOfFurtherSharesAsAnEmployersContribution",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued immediately for employer's contribution (in shares)",
        "label": "Issuance Of Further Shares As An Employers Contribution",
        "documentation": "Further shares as an employers contribution."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ItemsNotSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Items Not Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items not subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ItemsSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Items Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_JevtanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "JevtanaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jevtana",
        "label": "Jevtana [Member]",
        "documentation": "Jevtana."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_JointVenturesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "JointVenturesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [Axis]",
        "label": "Joint ventures [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r161"
     ]
    },
    "ifrs-full_JointVenturesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "JointVenturesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for joint ventures [Member]",
        "label": "Joint ventures [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r161"
     ]
    },
    "sny_LantusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LantusMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lantus",
        "label": "Lantus [Member]",
        "documentation": "Lantus."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r184",
      "r292",
      "r299",
      "r301"
     ]
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and beyond",
        "label": "Later than four years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r184",
      "r292",
      "r301",
      "r307"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 1-3 months",
        "label": "Later than one month and not later than three months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r294",
      "r301"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than one year and not later than five years [member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r301"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than one year and not later than three years [member]",
        "label": "Later than one year and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297",
      "r301"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r184",
      "r292",
      "r301",
      "r307"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue by > 12 months",
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 6-12 months",
        "label": "Later than six months and not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r296",
      "r301"
     ]
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 3-6 months",
        "label": "Later than three months and not later than six months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r295",
      "r301"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than three years and not later than five years [member]",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r298",
      "r301"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Later than three years and not later than four years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r184",
      "r292",
      "r301",
      "r307"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Later than two years and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r184",
      "r292",
      "r301",
      "r307"
     ]
    },
    "sny_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Lease, Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LeaseExtensionOptionsNumber",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, number",
        "label": "Lease, Extension Options, Number",
        "documentation": "Lease, Extension Options, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LeaseExtensionOptionsTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, term",
        "label": "Lease, Extension Options, Term",
        "documentation": "Lease, Extension Options, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "sny_LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities, Disposal Group Including Discontinued Operations",
        "label": "Lease Liabilities, Disposal Group Including Discontinued Operations",
        "documentation": "Lease Liabilities, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LeaseTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, term",
        "label": "Lease, Term",
        "documentation": "Lease, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LegalAndArbitralProceedingsAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Axis]",
        "label": "Legal And Arbitral Proceedings [Axis]",
        "documentation": "Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LegalAndArbitralProceedingsDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Domain]",
        "label": "Legal And Arbitral Proceedings [Domain]",
        "documentation": "[Domain] for Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to assets held for sale",
        "label": "Liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r207"
     ]
    },
    "sny_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities Of Disposal Group Including Discontinued Operations",
        "label": "Liabilities Of Disposal Group Including Discontinued Operations",
        "documentation": "Liabilities Of Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Related Party Transactions",
        "label": "Liabilities, Related Party Transactions",
        "documentation": "Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset)",
        "label": "Net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sny_LiabilityRecognisedForEstimatedFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LiabilityRecognisedForEstimatedFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
      "http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Recognised For Estimated Future Royalties",
        "label": "Liability Recognised For Estimated Future Royalties",
        "documentation": "Liability Recognised For Estimated Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LoansToAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LoansToAssociates",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to Associates",
        "label": "Loans to Associates",
        "documentation": "Loans to Associates"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LongTermPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LongTermPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term prepaid expenses",
        "label": "Long Term Prepaid Expenses",
        "documentation": "Long term prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_LovenoxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "LovenoxMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lovenox",
        "label": "Lovenox [Member]",
        "documentation": "Lovenox."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MCMVaccineBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MCMVaccineBVMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Vaccine BV",
        "label": "MCM Vaccine BV [Member]",
        "documentation": "MCM Vaccine BV"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MSDContingentConsiderationEuropeanVaccinesBusinessMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSD contingent consideration (European Vaccines business)",
        "label": "MSD Contingent Consideration European Vaccines Business [Member]",
        "documentation": "MSD contingent consideration European vaccines business."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSPVaccineCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MSPVaccineCompanyMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSP Vaccine Company",
        "label": "MSP Vaccine Company [Member]",
        "documentation": "MSP Vaccine Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorBusinessCombinationMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major business combination",
        "label": "Major business combination [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major business combinations. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "sny_MajorCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MajorCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major collaboration agreement",
        "label": "Major Collaboration Agreement [Member]",
        "documentation": "Major Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [Axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_MajorCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [Member]",
        "label": "Major customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "sny_MajorFinancialLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MajorFinancialLiabilityMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major financial liability",
        "label": "Major Financial Liability [Member]",
        "documentation": "Major Financial Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MajorTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MajorTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major territories",
        "label": "Major Territories [Member]",
        "documentation": "Major Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManufacturingAndSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ManufacturingAndSupplyMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing &amp; Supply",
        "label": "Manufacturing And Supply [Member]",
        "documentation": "Manufacturing and supply"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MarketConditionAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Axis]",
        "label": "Market Condition [Axis]",
        "documentation": "Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MarketConditionDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Domain]",
        "label": "Market Condition [Domain]",
        "documentation": "Market Condition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MarketedProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed Products Trademarks And Other Rights",
        "label": "Marketed Products Trademarks And Other Rights [Member]",
        "documentation": "Marketed Products Trademarks And Other Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MarketsOfCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MarketsOfCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Markets of customers [axis]",
        "label": "Markets of customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_MarketsOfCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MarketsOfCustomersDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Markets of customers [domain]",
        "label": "Markets of customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all markets of customers. It also represents the standard value for the 'Markets of customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material reconciling items",
        "label": "Material reconciling items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [Axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r173",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r211",
      "r221",
      "r257",
      "r292"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [Member]",
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r173",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r211",
      "r257",
      "r292",
      "r300"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MazeTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MazeTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maze Therapeutics",
        "label": "Maze Therapeutics [Member]",
        "documentation": "Maze Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [Axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r123",
      "r163"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement [Member]",
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r123",
      "r163"
     ]
    },
    "sny_MeningitisTravelAndEndemicVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MeningitisTravelAndEndemicVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Meningitis Travel And Endemic Vaccines",
        "label": "Meningitis Travel And Endemic Vaccines [Member]",
        "documentation": "Meningitis Travel And Endemic Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "terseLabel": "Other operating expense",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Miscellaneous other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_MiscellaneousOtherOperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MiscellaneousOtherOperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous Other Operating Income (Expenses)",
        "label": "Miscellaneous Other Operating Income (Expenses)",
        "documentation": "Other operating income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Miscellaneous other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for miscellaneous other provisions. [Refer: Classes of other provisions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "sny_MiscellaneousOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MiscellaneousOtherRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous other revenue",
        "label": "Miscellaneous other revenue",
        "documentation": "Miscellaneous other revenue"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MyozymeLumizymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "MyozymeLumizymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Myozyme/Lumizyme",
        "label": "Myozyme/Lumizyme [Member]",
        "documentation": "Myozyme/Lumizyme"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NameOfAcquiree": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NameOfAcquiree",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of acquiree",
        "label": "Name of acquiree"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets (liabilities)",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r307"
     ]
    },
    "sny_NetCashInflowFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetCashInflowFromDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Cash Inflow from Discontinued Operations",
        "label": "Net Cash Inflow from Discontinued Operations",
        "documentation": "Net Cash Inflow from Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetCashProvidedByusedInContinuingInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetCashProvidedByusedInContinuingInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Cash Provided by/(used in) Continuing Investing Activities",
        "label": "Net Cash Provided by/(used in) Continuing Investing Activities",
        "documentation": "Net Cash Provided by/(used in) Continuing Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetCashProvidedByusedInDiscontinuingInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetCashProvidedByusedInDiscontinuingInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Cash Provided by/(used in) Discontinuing Investing Activities",
        "label": "Net Cash Provided by/(used in) Discontinuing Investing Activities",
        "documentation": "Net Cash Provided by/(used in) Discontinuing Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other current assets and other current liabilities",
        "label": "Net Change In Other Current Assets And Other Current Liabilities",
        "documentation": "Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetChangeInOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other non-current assets",
        "label": "Net Change In Other Non-Current Assets",
        "documentation": "Net change in other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Axis]",
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetDomain",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Member]",
        "label": "Net defined benefit liability (asset) [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange loss",
        "label": "Net foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r315"
     ]
    },
    "sny_NetIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income",
        "label": "Net Income, Related Party Disclosures",
        "documentation": "Net Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetInterestCostRelatedToEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetInterestCostRelatedToEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net interest cost related to employee benefits",
        "label": "Net Interest Cost Related To Employee Benefits",
        "documentation": "Net interest cost related to employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetReversalOfImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetReversalOfImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Reversal of Impairment Loss",
        "label": "Net Reversal of Impairment Loss",
        "documentation": "Net Reversal of Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NetSalesAndOtherRevenuesRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Sales and Other Revenues",
        "label": "Net Sales and Other Revenues, Related Party Disclosures",
        "documentation": "Net Sales and Other Revenues, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NexviazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NexviazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nexviazyme",
        "label": "Nexviazyme [Member]",
        "documentation": "Nexviazyme"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Core Assets [Member]",
        "label": "Non-Core Assets [Member]",
        "documentation": "Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Assets [Member]",
        "documentation": "Non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Current assets, Related Party Transactions",
        "label": "Non Current assets, Related Party Transactions",
        "documentation": "Non Current assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Liabilities [Member]",
        "documentation": "Non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Current Liabilities, Related Party Transactions",
        "label": "Non Current Liabilities, Related Party Transactions",
        "documentation": "Non Current Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Non-current portion",
        "label": "Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLoansAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentLoansAndReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term loans and advances and other non-current receivables",
        "label": "Non current loans and receivables",
        "documentation": "Non current loans and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current provisions and other non-current liabilities",
        "totalLabel": "Non-current provisions",
        "label": "Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations",
        "label": "Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations",
        "documentation": "Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentRestructuringProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonCurrentRestructuringProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring provisions",
        "label": "Non-Current Restructuring Provision [Member]",
        "documentation": "Restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonOperatingForeignExchangeGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NonOperatingForeignExchangeGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating foreign exchange gains/(losses)",
        "label": "Non-Operating Foreign Exchange Gains/(Losses)",
        "documentation": "Non-operating foreign exchange gains/(losses)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [Axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [Member]",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r142",
      "r144"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to\u00a0non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r150",
      "r269"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets [abstract]",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Non-current assets or disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial instruments",
        "label": "Non-current derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instruments at fair value through other comprehensive income",
        "label": "Non-current financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r152",
      "r269"
     ]
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "sny_NotEligibleForHedgeAccountingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NotEligibleForHedgeAccountingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not eligible for hedge accounting",
        "label": "Not Eligible For Hedge Accounting [Member]",
        "documentation": "Not eligible for hedge accounting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneMonthMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by less than 1 month",
        "label": "Not later than one month [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r293",
      "r301"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r179",
      "r180",
      "r184",
      "r292",
      "r301"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_NovavaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NovavaxMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novavax",
        "label": "Novavax [Member]",
        "documentation": "Novavax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfBondIssuesRedeemed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfBondIssuesRedeemed",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of bond issues redeemed",
        "label": "Number Of Bond Issues Redeemed",
        "documentation": "Number Of Bond Issues Redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfCases",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Cases",
        "label": "Number Of Cases",
        "documentation": "Number Of Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClassActionLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfClassActionLawsuits",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Class Action Lawsuits",
        "label": "Number Of Class Action Lawsuits",
        "documentation": "Number Of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfDismissals": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfDismissals",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Dismissals",
        "label": "Number Of Dismissals",
        "documentation": "Number Of Dismissals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total number of shares awarded (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r329"
     ]
    },
    "sny_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number Of Operating Segments",
        "documentation": "Number of operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, number\u00a0of options (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r189"
     ]
    },
    "sny_NumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfPlaintiffs",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Plaintiffs",
        "label": "Number Of Plaintiffs",
        "documentation": "Number Of Plaintiffs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesAlloted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfRestrictedSharesAlloted",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares alloted (in shares)",
        "label": "Number Of Restricted Shares Alloted",
        "documentation": "Number Of Restricted Shares Alloted"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares alloted in regards of capital increase",
        "label": "Number of restricted shares alloted in regards of capital increase",
        "documentation": "Number of restricted shares alloted in regards of capital increase"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase by issuance of restricted shares (in shares)",
        "label": "Number Of Restricted Shares Issued In Regards Of Capital Increase",
        "documentation": "Number of restricted shares issued in regards of capital increase."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesNotYetFullyVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfRestrictedSharesNotYetFullyVested",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares not yet fully vested (in shares)",
        "label": "Number Of Restricted Shares Not Yet Fully Vested",
        "documentation": "Number of restricted shares not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares vested (in shares)",
        "label": "Number Of Restricted Shares Vested In Regards Of Capital Increase",
        "documentation": "Number Of Restricted Shares Vested In Regards Of Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, number of options (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "sny_NumberOfSharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfSharesHeld",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares Held",
        "documentation": "Number of shares held."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital\u00a0increase\u00a0by\u00a0exercise\u00a0of stock subscription options (in shares)",
        "label": "Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options",
        "documentation": "Number of shares issued in regards of capital increase by exercise of stock subscription options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares repurchased (in shares)",
        "label": "Number Of Shares Repurchased",
        "documentation": "Number of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfSharesSubscribed",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subscribed (in shares)",
        "label": "Number Of Shares Subscribed",
        "documentation": "Number of shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Tranches",
        "label": "Number Of Tranches",
        "documentation": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfYearsServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "NumberOfYearsServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period",
        "label": "Number Of Years, Service Period",
        "documentation": "Number Of Years, Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OffBalanceSheetCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OffBalanceSheetCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance Sheet Commitments [Abstract]",
        "documentation": "Off-Balance Sheet Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionBondsMaturingJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OneBillionBondsMaturingJune2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1 billion bonds maturing June 2023",
        "label": "One Billion Bonds Maturing June 2023 [Member]",
        "documentation": "One Billion Bonds Maturing June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionFiftyMillionBondsMaturingApril2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OneBillionFiftyMillionBondsMaturingApril2025Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Billion Fifty Million Bonds Maturing April 2025",
        "label": "One Billion Fifty Million Bonds Maturing April 2025 [Member]",
        "documentation": "One Billion Fifty Million Bonds Maturing April 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionFiveHundredMillionBondsIssuedInJune2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OneBillionFiveHundredMillionBondsIssuedInJune2025Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Billion Five Hundred Million Bonds, Issued In June 2025",
        "label": "One Billion Five Hundred Million Bonds, Issued In June 2025 [Member]",
        "documentation": "One Billion Five Hundred Million Bonds, Issued In June 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionFiveHundredMillionBondsIssuedInMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OneBillionFiveHundredMillionBondsIssuedInMarch2025Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Billion Five Hundred Million Bonds, Issued In March 2025",
        "label": "One Billion Five Hundred Million Bonds, Issued In March 2025 [Member]",
        "documentation": "One Billion Five Hundred Million Bonds, Issued In March 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1.75 billion bonds maturing March 2023",
        "label": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]",
        "documentation": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OpellaBusinessMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Business",
        "label": "Opella Business [Member]",
        "documentation": "Opella Business [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OpellaMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella",
        "label": "Opella [Member]",
        "documentation": "Opella"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OperatingRevenueDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Revenue, Disposal Group Including Discontinued Operations",
        "label": "Operating Revenue, Disposal Group Including Discontinued Operations",
        "documentation": "Operating Revenue, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segments",
        "label": "Operating segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other profit or loss items with no cash effect on cash flows generated by operating activities",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "sny_OtherAssetsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherAssetsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets, Disposal Group Including Discontinued Operations",
        "label": "Other Assets, Disposal Group Including Discontinued Operations",
        "documentation": "Other Assets, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets, Related Party Transactions",
        "label": "Other Assets, Related Party Transactions",
        "documentation": "Other Assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherBankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherBankBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other bank borrowings",
        "label": "Other Bank Borrowings",
        "documentation": "Other bank borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income for the period",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r36",
      "r47",
      "r156"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeFromContinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherComprehensiveIncomeFromContinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income from continued operations",
        "label": "Other comprehensive income from continued operations",
        "documentation": "Other comprehensive income from continued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherComprehensiveIncomeFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income from discontinued operations",
        "label": "Other comprehensive income from discontinued operations",
        "documentation": "Other comprehensive income from discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherComprehensiveIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income, Related Party Disclosures",
        "label": "Other Comprehensive Income, Related Party Disclosures",
        "documentation": "Other Comprehensive Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "sny_OtherComprehensiveIncomeFromContinuedOperations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items subsequently reclassifiable to profit or loss",
        "terseLabel": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "sny_OtherComprehensiveIncomeFromContinuedOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "sny_OtherCountriesExcludingEuropeAndNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherCountriesExcludingEuropeAndNorthAmericaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Countries, Excluding Europe And North America [Member]",
        "label": "Other Countries, Excluding Europe And North America [Member]",
        "documentation": "Other Countries, Excluding Europe And North America"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherCountriesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Countries [member]",
        "label": "Other Countries [member]",
        "documentation": "Other countries."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets at fair value through profit or loss",
        "label": "Other Financial Assets At Fair Value Through Profit Or Loss",
        "documentation": "Other Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherGainsLossesAndLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherGainsLossesAndLitigation",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other gains and losses, and litigation",
        "negatedNetLabel": "Other gains and litigation",
        "label": "Other Gains, (Losses) And Litigation",
        "documentation": "The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Other intangible assets, beginning balance",
        "periodEndLabel": "Other intangible assets, ending balance",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "sny_OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets, Disposal Group Including Discontinued Operations",
        "label": "Other Intangible Assets, Disposal Group Including Discontinued Operations",
        "documentation": "Other Intangible Assets, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherIntangibleAssetsExcludingSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherIntangibleAssetsExcludingSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets excluding software",
        "label": "Other Intangible Assets Excluding Software [Member]",
        "documentation": "Intangible assets excluding software."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "sny_OtherLiabilities1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherLiabilities1Member",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities1 [member]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities, Disposal Group Including Discontinued Operations",
        "label": "Other Liabilities, Disposal Group Including Discontinued Operations",
        "documentation": "Other Liabilities, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other movements",
        "label": "Other Movements, Contingent Liabilities Recognised In Business Combination",
        "documentation": "Other movements."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherNonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherNonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Core Assets [Member]",
        "label": "Other Non-Core Assets [Member]",
        "documentation": "Other Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other non-current assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_OtherOperatingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherOperatingExpensesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Operating Expenses",
        "label": "Other Operating Expenses [Table Text Block]",
        "documentation": "Other Operating Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income/(expenses), net related to Regeneron",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "sny_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income (expense)",
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Other Operating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherProductsSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Products Segment",
        "label": "Other Products Segment [Member]",
        "documentation": "Other Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "label": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "sny_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other restructuring costs",
        "label": "Other Restructuring Costs",
        "documentation": "Other restructuring costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (d)",
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sny_OtherTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OtherTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other territories",
        "label": "Other Territories [Member]",
        "documentation": "Other Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OthersCounterpartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OthersCounterpartyMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (mainly Zaltrap and Libtayo)",
        "label": "Others Counterparty [Member]",
        "documentation": "Others Counterparty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OthersMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Others [Member]",
        "documentation": "Others"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OverdueReceivablesGrossValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "OverdueReceivablesGrossValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue receivables gross value",
        "label": "Overdue Receivables Gross Value",
        "documentation": "Overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PainCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PainCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pain Care [Member]",
        "label": "Pain Care [Member]",
        "documentation": "Pain [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euros per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "sny_PaymentOfDamagesClaimedByCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PaymentOfDamagesClaimedByCounterparty",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Of Damages Claimed By Counterparty",
        "label": "Payment Of Damages Claimed By Counterparty",
        "documentation": "Payment Of Damages Claimed By Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PaymentToSaleOfBusinessPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PaymentToSaleOfBusinessPeriod",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to sale of business period",
        "label": "Payment To Sale Of Business Period",
        "documentation": "Payment to sale of business period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of treasury shares and related tax effect",
        "label": "Payments to acquire or redeem entity's shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "sny_PenaltyFeeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PenaltyFeeIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalty Fee Incurred",
        "label": "Penalty Fee Incurred",
        "documentation": "Penalty Fee Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PenaltyFeeIncurredByDefendantsInterestsAmountVacated",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalty fee incurred by defendants, interests, amount vacated",
        "label": "Penalty Fee Incurred By Defendants, Interests, Amount Vacated",
        "documentation": "Penalty Fee Incurred By Defendants, Interests, Amount Vacated"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PensionsAndOtherPostEmploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PensionsAndOtherPostEmploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pensions and other post-employment benefits",
        "label": "Pensions And Other Post-Employment Benefits [Member]",
        "documentation": "Pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PerShareValueOfSharesRepurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PerShareValueOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Share Value of Shares Repurchased",
        "label": "Per Share Value of Shares Repurchased",
        "documentation": "Per Share Value of Shares Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageIncreaseInFairValueLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PercentageIncreaseInFairValueLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of liability",
        "label": "Percentage Increase In Fair Value Liabilities",
        "documentation": "Percentage increase in fair value liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PercentageOfDevelopmentCostsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of development costs arising from commercial operations",
        "label": "Percentage Of Development Costs Arising From Commercial Operations",
        "documentation": "Percentage Of Development Costs Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue",
        "label": "Percentage of entity's revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "sny_PercentageOfNetSalesArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PercentageOfNetSalesArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales arising from commercial operations",
        "label": "Percentage Of Net Sales Arising From Commercial Operations",
        "documentation": "Percentage Of Net Sales Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfProfitsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PercentageOfProfitsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profits arising from commercial operations",
        "label": "Percentage Of Profits Arising From Commercial Operations",
        "documentation": "Percentage Of Profits Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in actuarial assumption",
        "label": "Percentage of reasonably possible decrease in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in actuarial assumption",
        "label": "Percentage of reasonably possible increase in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "sny_PercentageOfShareCapitalForThePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PercentageOfShareCapitalForThePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% of share capital for the period",
        "label": "Percentage Of Share Capital For The Period",
        "documentation": "Percentage of share capital for the period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests acquired",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "sny_PeriodOfShareRepurchaseProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PeriodOfShareRepurchaseProgram",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of share repurchase program",
        "label": "Period Of Share Repurchase Program",
        "documentation": "Period of share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PharmaLaunchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PharmaLaunchesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharma Launches",
        "label": "Pharma Launches [Member]",
        "documentation": "Pharma Launches"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharma Segment",
        "label": "Pharma Segment [Member]",
        "documentation": "Pharma Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PlanAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets",
        "label": "Plan assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "sny_PlavixAttorneyGeneralActionInHawaiiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PlavixAttorneyGeneralActionInHawaiiMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix Attorney General action in Hawaii",
        "label": "Plavix Attorney General Action In Hawaii [Member]",
        "documentation": "Plavix Attorney General Action In Hawaii"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PlavixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix",
        "label": "Plavix [Member]",
        "documentation": "Plavix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PolioPertussisHibVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PolioPertussisHibVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Polio Pertussis Hib Vaccines [Member]",
        "label": "Polio Pertussis Hib Vaccines [Member]",
        "documentation": "Polio Pertussis Hib Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PotentialFuturePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PotentialFuturePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential Future Payments",
        "label": "Potential Future Payments",
        "documentation": "Potential Future Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PotentialPaymentsRelatedToPercentageOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PotentialPaymentsRelatedToPercentageOfSales",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentiel payments related to percentage of sales of alemtuzumab",
        "label": "Potential Payments Related To Percentage Of Sales",
        "documentation": "Potential payments related to percentage of sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PreFundedPensionObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PreFundedPensionObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded pension obligations",
        "label": "Pre-Funded Pension Obligations",
        "documentation": "Pre-funded pension obligations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PrincipalAlliancesAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Axis]",
        "label": "Principal Alliances [Axis]",
        "documentation": "Principal Alliances"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PrincipalAlliancesDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Domain]",
        "label": "Principal Alliances [Domain]",
        "documentation": "Principal Alliances [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax",
        "label": "Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Sanofi shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional long-term debt contracted",
        "label": "Proceeds from non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "sny_ProductLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ProductLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Liabilities",
        "label": "Product Liabilities [Member]",
        "documentation": "Product Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r274"
     ]
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [domain]",
        "label": "Products and services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r274"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products, trademarks and other rights",
        "label": "Products, Trademarks And Other Rights [Member]",
        "documentation": "Products, trademarks and other rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r35",
      "r126",
      "r139",
      "r141",
      "r230",
      "r232",
      "r269",
      "r282"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit (loss) [abstract]",
        "label": "Profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to non-controlling interests",
        "terseLabel": "Attributable to non-controlling interests",
        "netLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r143"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from continuing operations",
        "label": "Profit (loss) from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r154",
      "r230",
      "r232"
     ]
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (income)/loss of the exchanged/held-for-exchange Animal Health business",
        "label": "Profit (loss) from discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r51",
      "r155",
      "r204"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r312"
     ]
    },
    "sny_PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations",
        "label": "Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations",
        "documentation": "Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment owned",
        "verboseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r65"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [Member]",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r260",
      "r281"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in associate",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r146"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointVenture",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in joint venture",
        "label": "Proportion of ownership interest in joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r146"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in subsidiary",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r145"
     ]
    },
    "sny_ProventionBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ProventionBioIncMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio",
        "label": "Provention Bio, Inc [Member]",
        "documentation": "Provention Bio, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provisions utilized",
        "label": "Provision used, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "sny_ProvisionsForOtherLongTermBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ProvisionsForOtherLongTermBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for other long-term benefits",
        "label": "Provisions For Other Long Term Benefits [member]",
        "documentation": "Provisions for other long term benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ProvisionsForPensionsAndOtherPostemploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for pensions &amp; other post-employment benefits",
        "label": "Provisions For Pensions And Other Postemployment Benefits [member]",
        "documentation": "Provisions for pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of other equity investments",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of other intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of property, plant and equipment and intangible assets",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase program",
        "label": "Purchase of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of goods and services (including research expenses) (c) (d)",
        "label": "Purchases of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "sny_QRIBIntermediateHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "QRIBIntermediateHoldingsLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QRIB intermediate Holdings, LLC",
        "label": "QRIB intermediate Holdings, LLC [Member]",
        "documentation": "QRIB intermediate Holdings, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RSVVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RSVVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSV Vaccines",
        "label": "RSV Vaccines [Member]",
        "documentation": "RSV Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r169",
      "r183",
      "r189",
      "r271",
      "r273",
      "r330"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [Member]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r169",
      "r183",
      "r189",
      "r271",
      "r273",
      "r330"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [domain]",
        "label": "Ranges of exercise prices for outstanding share options [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sny_RareDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RareDiseasesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rare Diseases",
        "label": "Rare Diseases [Member]",
        "documentation": "Rare Diseases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReclassifiedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReclassifiedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Axis]",
        "label": "Reclassified items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_ReclassifiedItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReclassifiedItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Member]",
        "label": "Reclassified items [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for items that have been reclassified when the entity changes their presentation or classification in its financial statements. It also represents the standard value for the 'Reclassified items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "sny_RecludixPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RecludixPharmaMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recludix Pharma",
        "label": "Recludix Pharma [Member]",
        "documentation": "Recludix Pharma"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInOtherProvisionsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in other provisions [abstract]",
        "label": "Reconciliation of changes in other provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RedemptionOfDebtInstrumentIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RedemptionOfDebtInstrumentIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Redemption Of Debt Instrument Issued",
        "documentation": "Redemption of debt instrument issued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReductionOfIssuedCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction in share capital",
        "negatedTerseLabel": "Reduction in share capital",
        "label": "Reduction of issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "sny_RegeneronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RegeneronMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron",
        "label": "Regeneron [Member]",
        "documentation": "Regeneron"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegeneronPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RegeneronPharmaceuticalsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron Pharmaceuticals, Inc",
        "label": "Regeneron Pharmaceuticals, Inc [Member]",
        "documentation": "Regeneron Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RegularMilestonePaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regular milestone payments",
        "label": "Regular Milestone Payments For Projects Under Collaboration Agreements",
        "documentation": "Regular Milestone Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of long-term debt",
        "label": "Repayments of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "sny_ReportableGeographicalZonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ReportableGeographicalZonesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Geographical Zones [Member]",
        "label": "Reportable Geographical Zones [Member]",
        "documentation": "Reportable geographical zones."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reportable segments [member]",
        "label": "Reportable segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r230",
      "r256",
      "r285"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "negatedTerseLabel": "Research and development expense",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Projects And Technology Platforms",
        "label": "Research And Development Projects And Technology Platforms [Member]",
        "documentation": "Research And Development Projects And Technology Platforms [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "sny_RestrictedSharePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2020Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2020",
        "label": "Restricted Share Plan 2020 [Member]",
        "documentation": "Restricted Share Plan 2020"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2021Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2021",
        "label": "Restricted Share Plan 2021 [Member]",
        "documentation": "Restricted Share Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2022Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2022",
        "label": "Restricted Share Plan 2022 [Member]",
        "documentation": "Restricted Share Plan 2022"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023AdditionalSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2023AdditionalSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2023, additional shares",
        "label": "Restricted Share Plan 2023, Additional Shares [Member]",
        "documentation": "Restricted Share Plan 2023, Additional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2023Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2023",
        "label": "Restricted Share Plan 2023 [Member]",
        "documentation": "Restricted Share Plan 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2024AdditionalSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2024AdditionalSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Plan 2024, Additional Shares",
        "label": "Restricted Share Plan 2024, Additional Shares [Member]",
        "documentation": "Restricted Share Plan 2024, Additional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2024Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Plan 2024",
        "label": "Restricted Share Plan 2024 [Member]",
        "documentation": "Restricted Share Plan 2024"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharePlan2025Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Plan 2025",
        "label": "Restricted Share Plan 2025 [Member]",
        "documentation": "Restricted Share Plan 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RestrictedSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares",
        "label": "Restricted Shares [Member]",
        "documentation": "Restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and retained earnings",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r246"
     ]
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses) on plan assets",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RevenueFromDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue From Disposal Group Including Discontinued Operations",
        "label": "Revenue From Disposal Group Including Discontinued Operations",
        "documentation": "Revenue From Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from intragroup sales from continuing to discontinued operations",
        "label": "Revenue from intragroup sales from continuing to discontinued operations",
        "documentation": "Revenue from intragroup sales from continuing to discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty income",
        "label": "Royalty income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales (c) (d)",
        "label": "Revenue from sale of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "sny_RevenueFromVaxServeSalesOfNonSanofiProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RevenueFromVaxServeSalesOfNonSanofiProducts",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from VaxServe sales of non-Sanofi products",
        "label": "Revenue from VaxServe sales of non-Sanofi products",
        "documentation": "Revenue from VaxServe sales of non-Sanofi products"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill, reversal amount",
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RevisionsToTaxExposuresAndSettlementsOfTaxDisputes",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revisions to tax exposures and settlements of tax disputes",
        "label": "Revisions To Tax Exposures And Settlements Of Tax Disputes",
        "documentation": "Revisions to tax exposures and settlements of tax disputes."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RezurockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RezurockMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rezurock",
        "label": "Rezurock [Member]",
        "documentation": "Rezurock"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right Of Use Assets, Disposal Group Including Discontinued Operations",
        "label": "Right Of Use Assets, Disposal Group Including Discontinued Operations",
        "documentation": "Right Of Use Assets, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177"
     ]
    },
    "sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "RoyaltiesAndOtherIncomeRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and other income (c) (d)",
        "label": "Royalties And Other Income, Related Party Transactions",
        "documentation": "Royalties and other income, related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SAR44425Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SAR44425Member",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAR44425",
        "label": "SAR44425 [Member]",
        "documentation": "SAR44425"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesChannelsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesChannelsAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales channels [axis]",
        "label": "Sales channels [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_SalesChannelsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesChannelsDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales channels [domain]",
        "label": "Sales channels [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all sales channels. It also represents the standard value for the 'Sales channels' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_SanofiEuroMediumTermNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SanofiEuroMediumTermNotesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Euro Medium Term Notes",
        "label": "Sanofi Euro Medium Term Notes [Member]",
        "documentation": "Sanofi Euro Medium Term Notes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SanofiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi",
        "label": "Sanofi [member]",
        "documentation": "Sanofi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SarclisaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SarclisaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarclisa",
        "label": "Sarclisa [Member]",
        "documentation": "Sarclisa"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ScribeTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ScribeTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scribe Therapeutics",
        "label": "Scribe Therapeutics [Member]",
        "documentation": "Scribe Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SeasonalSymptomsAndPainReliefMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SeasonalSymptomsAndPainReliefMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal Symptoms And Pain Relief",
        "label": "Seasonal Symptoms And Pain Relief [Member]",
        "documentation": "Seasonal Symptoms And Pain Relief"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal Trends",
        "label": "Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]",
        "documentation": "Seasonality Or Cyclicality Of Interim Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentConsolidationItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment consolidation items [Axis]",
        "label": "Segment consolidation items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_SegmentConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentConsolidationItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for segment consolidation items [Member]",
        "label": "Segment consolidation items [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r172",
      "r230",
      "r256",
      "r285"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Member]",
        "label": "Segments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r172",
      "r235",
      "r256",
      "r285"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and general expenses",
        "negatedTerseLabel": "Selling, general and administrative expense",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made",
        "label": "Settled liabilities, contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sny_ShareBasedPaymentPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareBasedPaymentPlansAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment plans:",
        "label": "Share Based Payment Plans [abstract]",
        "documentation": "Share based payment plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the\u00a0equity method",
        "label": "Share of profit (loss) of associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit (loss) of associates and joint ventures accounted for using equity method",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r228",
      "r234"
     ]
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance",
        "label": "Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]",
        "documentation": "Share of profit or loss from commercialization of monoclonal antibodies member."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareOfProfitOrLossFromCommercializationOfZaltrapMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional share of profit paid by Regeneron towards development costs",
        "label": "Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]",
        "documentation": "Share of profit or loss from commercialization of Zaltrap."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareProgramAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Program [Axis]",
        "label": "Share Program [Axis]",
        "documentation": "Share Program [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareProgramDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Program [Domain]",
        "label": "Share Program [Domain]",
        "documentation": "Share Program [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2022ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareRepurchase2022ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2022 program",
        "label": "Share Repurchase 2022 Program [Member]",
        "documentation": "Share Repurchase 2022 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2023ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareRepurchase2023ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2023 program",
        "label": "Share Repurchase 2023 Program [Member]",
        "documentation": "Share Repurchase 2023 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2024ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareRepurchase2024ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2024 Program",
        "label": "Share Repurchase 2024 Program [Member]",
        "documentation": "Share Repurchase 2024 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2025ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShareRepurchase2025ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2025 Program",
        "label": "Share Repurchase 2025 Program [Member]",
        "documentation": "Share Repurchase 2025 Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration arising from acquisition of Translate Bio",
        "label": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]",
        "documentation": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [Axis]",
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r162"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for associates [Member]",
        "label": "Associates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r162"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r160"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [domain]",
        "label": "Subsidiaries [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r160"
     ]
    },
    "sny_SpecialtyCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SpecialtyCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Care [Member]",
        "label": "Specialty Care [Member]",
        "documentation": "Specialty Care."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of comprehensive income [abstract]",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Financial Reporting Standards (IFRS)",
        "label": "Statement of IFRS compliance [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "sny_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan",
        "label": "Stock Option Plan [member]",
        "documentation": "Stock Option Plan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "StockPrice",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in euro per share)",
        "label": "Stock Price",
        "documentation": "Stock Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]",
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstractAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]",
        "documentation": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SubordinateHybridBondRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SubordinateHybridBondRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinate Hybrid Bond, Related Party Transactions",
        "label": "Subordinate Hybrid Bond, Related Party Transactions",
        "documentation": "Subordinate Hybrid Bond, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubordinatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubordinatedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinated liabilities",
        "label": "Subordinated liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are subordinate to other liabilities with respect to claims."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sny_SubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SubscriptionPricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription price (in euros per share)",
        "label": "Subscription Price Per Share",
        "documentation": "Subscription price per share."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SwedishOrphanBiovitrumABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SwedishOrphanBiovitrumABMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swedish Orphan Biovitrum AB",
        "label": "Swedish Orphan Biovitrum AB [Member]",
        "documentation": "Swedish Orphan Biovitrum AB"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityCanceledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SyndicatedCreditFacilityCanceledMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility canceled",
        "label": "Syndicated Credit Facility Canceled [Member]",
        "documentation": "Syndicated Credit Facility Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SyndicatedCreditFacilityOneMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility, expires in 2027",
        "label": "Syndicated Credit Facility One [Member]",
        "documentation": "Syndicated credit facility one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "SyndicatedCreditFacilityTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility, expires in 2028",
        "label": "Syndicated Credit Facility Two [Member]",
        "documentation": "Syndicated credit facility two."
       }
      }
     },
     "auth_ref": []
    },
    "country_TR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "TR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turkey",
        "label": "T\u00dcRKIYE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of contingent consideration liabilities",
        "label": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations",
        "documentation": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between the standard French tax rate and the rates applicable to Sanofi",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments",
        "label": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments",
        "documentation": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxesOnShareCancellations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TaxesOnShareCancellations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on Share Cancellations",
        "label": "Taxes on Share Cancellations",
        "documentation": "Taxes on Share Cancellations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxotereProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TaxotereProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxotere Product Litigation In The US",
        "label": "Taxotere Product Litigation In The US [Member]",
        "documentation": "Taxotere Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TechnologicalPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TechnologicalPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological platforms",
        "label": "Technological Platforms [Member]",
        "documentation": "Technological Platforms"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]",
        "label": "Temporary difference, unused tax losses and unused tax credits [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [axis]",
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [domain]",
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r169",
      "r183",
      "r189",
      "r271",
      "r273",
      "r330"
     ]
    },
    "sny_TotalMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TotalMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Milestone Payments",
        "label": "Total Milestone Payments",
        "documentation": "Total Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalOffBalanceSheetCommitmentsDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TotalOffBalanceSheetCommitmentsDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Off-Balance Sheet Commitments, Discontinued Operations",
        "label": "Total Off-Balance Sheet Commitments, Discontinued Operations",
        "documentation": "Total Off-Balance Sheet Commitments, Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ToujeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ToujeoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toujeo",
        "label": "Toujeo [Member]",
        "documentation": "Toujeo."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r311"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradingEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradingEquitySecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading equity securities",
        "label": "Trading equity securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that (a) are acquired or incurred principally for the purpose of selling or repurchasing it in the near term; or (b) on initial recognition are part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272"
     ]
    },
    "sny_TransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TransactionCost",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Cost",
        "label": "Transaction Cost",
        "documentation": "Transaction Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_TypesOfAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TypesOfAgreementAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Axis]",
        "label": "Types Of Agreement [Axis]",
        "documentation": "Types Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TypesOfAgreementDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Domain]",
        "label": "Types Of Agreement [Domain]",
        "documentation": "Types Of Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfContractsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfContractsAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts [axis]",
        "label": "Types of contracts [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r283"
     ]
    },
    "ifrs-full_TypesOfContractsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfContractsDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts [domain]",
        "label": "Types of contracts [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r283"
     ]
    },
    "ifrs-full_TypesOfCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of customers [axis]",
        "label": "Types of customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_TypesOfCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfCustomersDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of customers [domain]",
        "label": "Types of customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of customers. It also represents the standard value for the 'Types of customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_TypesOfHedgesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfHedgesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of Hedges [Axis]",
        "label": "Types of hedges [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214"
     ]
    },
    "ifrs-full_TypesOfHedgesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfHedgesDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges [Member]",
        "label": "Types of hedges [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [Axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payment [Member]",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "sny_TzieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "TzieldMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tzield",
        "label": "Tzield [Member]",
        "documentation": "Tzield"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UKZONEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "UKZONEMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UKZONE",
        "label": "UKZONE [Member]",
        "documentation": "UKZONE"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "sny_USGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "USGovernmentMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government",
        "label": "US Government [Member]",
        "documentation": "US Government"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unwinding of discount and gains (losses) arising from revisions of expected cash flows",
        "label": "Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost",
        "documentation": "Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "UpfrontPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payments",
        "documentation": "Upfront payments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "UpfrontPaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments",
        "label": "Upfront Payments For Projects Under Collaboration Agreements",
        "documentation": "Upfront Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average amortization period",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "sny_VaccinesCoExclusiveLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "VaccinesCoExclusiveLicensingAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaccines Co-exclusive licensing agreement",
        "label": "Vaccines Co-exclusive licensing agreement [Member]",
        "documentation": "Vaccines Co-exclusive licensing agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_VaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "VaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "documentation": "Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfHedgeRecognizedInEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ValueOfHedgeRecognizedInEquityMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of hedge recognized in equity",
        "label": "Value Of Hedge Recognized In Equity [Member]",
        "documentation": "Value Of Hedge Recognized In Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ValueOnRedemptionMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Value On Redemption [Member]",
        "documentation": "Value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_VicebioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "VicebioLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vicebio Ltd",
        "label": "Vicebio Ltd [Member]",
        "documentation": "Vicebio Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_VigilNeuroscienceIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "VigilNeuroscienceIncMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vigil Neuroscience, Inc",
        "label": "Vigil Neuroscience, Inc [Member]",
        "documentation": "Vigil Neuroscience, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise\u00a0price per share, options exercisable (in euros per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average residual life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails",
      "http://www.sanofi.com/role/NoncurrentassetheldforsaleanddiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of shares outstanding (in shares)",
        "verboseLabel": "Average number of shares outstanding (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "sny_WellnessBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "WellnessBrandsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellness Brands",
        "label": "Wellness Brands [Member]",
        "documentation": "Wellness Brands"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "WithMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "With market condition",
        "label": "With Market Condition [Member]",
        "documentation": "With Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithoutMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "WithoutMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Without market condition",
        "label": "Without Market Condition [Member]",
        "documentation": "Without Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_XenpozymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "XenpozymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Xenpozyme",
        "label": "Xenpozyme [Member]",
        "documentation": "Xenpozyme"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ZantacProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20250630",
     "localname": "ZantacProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zantac Product Litigation in the US",
        "label": "Zantac Product Litigation in the US [Member]",
        "documentation": "Zantac Product Litigation in the US"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_p&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "29",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS29_g39-40_TI",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2024-01-01",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2024-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2024-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2024-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2024-01-01",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2024-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "11B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_11B_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24G&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2024-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2024-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001121404-25-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001121404-25-000022-xbrl.zip
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M_#LH+M@M-B  3P:_",2]N;^#00R4?U'"\8  N,1>QROA,C;@HAI,S"TSR?$
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M U;&7P_W_I3%-*7_RDE\3N,9BZ^8\3+/  ]8JX8.//(ACTM#AI@\&S^S/ML
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M 5:T#=4:+ O@TM5!UVDFJJY'.5PBNZ%<$\(K8,7]%:B?Y3R8DM0\IO0YG(>
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MU['* 06P_O=C4"ZFC--G8!EQ)@Z='/)D-@K^DXL_Y+>GXTM.XC02(?<C2_!
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MYUD$5H(%2P,J(F%,DSS57NE^7SP8 -9IX(<'"$J;#5C4 1=+0  &6.(!%GA
MP 5.'0(<I4  !D[9P132*BI#;7!Z!^ H514&6*6 6BN>4A' 6/<#J'A*Q0!P
MW7]"LT_"I\0T7#B7Y7S:W4A@\VC=YYF 0FTH<9GI9YI,.)E/64"B$:=D08)
M:K+\;N_S1P00.X"%!0 0/[R^O,)JO'LB[SAH22GM !9##&_6X(V[/F_<,GD#
M6(*!#UI=@QVP# ,?M+I&&F Q9B3*$L*92)O2-)_-LZ<RZ"?V.1U_$FFU3*_D
M0QTV=M<IS_;.23RA"\*(/X]9S&;Y#$V&[@ 6<.""3&YQ@0Q8$'HSR >W<QID
M-%0@GXZ/XG&D%LE47I[)N/#U'_\^/3G 0P# :A3<4;X%5^Z6"3)@P0LNR%MP
MY:6"#%A1P^G*#[Z>GU;NS,ND@ M8<;M@DUB<)!"=.XJO:9K),Z1'\45^E;*0
M">17%YF>SJ7"O>:M/8TJZ6JJPUW HINA#F@UP 6GNTE$!%RB5^3!8U@"&3H.
M$_Z'\/;3/ZAP]_=[;9Q B/-_H1,10^)PQ*]8QDETQI. TI#%DQ6F?$ZB\&,2
MAV)CF ?9%Y:QB0II1_'EE'Z]*'$!_W(JL;AC;^7&L =SZ[HE]]O05"\N./5P
M+>I=D#@9LUKH)_S6-;L=95G"8WKW63@FL:=NW5'\&[DAC%4?X+SU YRWLL1V
M,R\%6;/,,LZN\B+EC<6X_7AW(N^#H9>)\ N,'^:Q0NF[6SU%M)-W ,D'U0;)
MC"X.+M&)"(-/$AEA3\?G5-['&YZMWA%4[*F:\W"7AJ9*D(51PR1,F1-D]14N
MDYZK!T9IF@1,*@5%@\[I1,:XIBZ+=B'+MX9!&'P09&WX30S:3V8SR@6,$?M3
M55:+4+(\ 8Z0AIS-=?E#R"*X83-6-M?DFSW >O[;V'PQ)9RJQ>UCEIWR+TF:
MRB=&/2+YZ?@XB9,@4L],CI>/O"ACEF_EL1:BL3.ZHM'<7V?YW(UF^D@/L-1O
M6(765X&;!=@>J_Y-HHR3><.(5)=[ J?I&R+A]$B-4_RKK@6 \:8N!]0X?;]E
MO*G+WX!3\X'A4M=X!J>1 \.EKO$"3GG^,2Y*]4I7MS=TO(#34('A4M-X\2M7
M U]K"+O;ZZ]I"*=,0P 6L-3[QL*CC,Z>>5_T* [U4U2"NT^BT]<B'[MNZDH9
M'[ F!!.HNEP+8,WEN1LT1$S0KP(I<>I)-V^%$!]9,I\2/B.+30T=IX"5DA>>
MA//UP@"_ ?" I8X?W)BE,CZ5\/%RIY[;2@-PRD4[W7]=T1^<0-(V]U\7\. 4
MF':[_[IH $[P,9CT 2_]PA227W&MQ7V0\A[>"\JOV8/W+GW*Y^RVL0E@'["B
MAB,#,#Q;BV> !4&,"8=AW5JL ZQNE@$+IG2J+@K@4SA-.H4W><<GJYIT"B//
M$.JV)IU"SSK <G';TJFZ*(!0.&YR.C6*LOR:,98T-'L'+%"W*Y]J.-$&"%7W
M-B143:<=8/F]%%PPI51U<0"A-&Y2*K09_ "P)FY2JB81#:'R;E(J_+0#+,&W
M+J6JBP,(Y?$FIU0G]/::D3_O9@V]T7P 6!AO5T[5>*8AU-_;D%0UGG> A?AR
M@,&45M5$@B%"D=RD57C3^"%@==RD58UB&D(-WJ15#> =8#&^?6E5721 *)0W
M.:W:)U<1N]["V_!JR>$!R^/MRJF:33.$"GP;$JIFDPZP#%\"*IA2J;H8@% >
M-ZD4UKP=L"9N4JFFT,SK(53=32J%G72 I?>6I5)U,0"A)-[D5.J?-)XGC5U@
MX/4 *^'M2J::3C2$:GL;TJFFTPZP[EX*+IA2JKHX@% 4-RD5W@P>L!QN4JHF
M$0VAZFY2*ORT ZR_MRZEJHD#%D)QO,DIU2B_(I.&/JW%LP"+XNU*J)I-,X3*
M>QO2J6:3#K#^7@(JF%*INAB 4!@WJ136O!VP'&Y2J>;0#*'B;E(I[*0#K+NW
M+)6JBP$(!?$FIU(7A <12TE#$W? .GB[<JEF\\Q&J+6W(9EJ..L B^YEP((I
MG:J+ @@%<9-.84W>;<!*N$FG&L0SA'J[2:?0LPZP\-ZV=*HN"B 4Q9N<3IW3
M/T77@F\-3=X!J^'M2J<:SC.$FGL;TJF&LPZP]EX&+)C2J9HHX""4Q4TZA35Y
M=P#+X2:=:A#/$&KN)IU"SSK VGO;TJFZ*(!0%F]R.G7Y)Z-1V-#4'; 8WJYD
MJM$L0ZBWMR&5:C3G *ONFX."*8VJBP (Y7"31B%-V0&+X":-:@K+7(0ZNTFC
MD',.L-K>KC2J+@(@E,&WDD8IM[:DX'8=SE$<YJGPIB2Z(-&++A5I_NX"5L)K
MRJD,Y2JF'$+E?:L)EB%@Q00$+,>7B,ZV.8B5#0AE<Y-Z-2'G!ZR=F]2KF91#
MJ-:;U*M)! 0LX;<X]:J)#1Y"J;W)DX=G2<22,\JS/$U9^AN[^IT$ 8N;6@=Z
M@%7W=LTGMHUX"-7^-DPQMHV&@+7_2G#:)B>Q<@*A.&]2LN94!("E>9.2-9EX
M"&<!3$K6/!H"GA-H?4I6%R<0BO9-3LF.:<SB"<M8>LG)-8W$3@=Q2&<L:'BY
M"%B[;U=NUE8&^@CG"]J0I+66CX G$*H%#%/:5A<Y$(K\)FUK7OG@ U;Y3=K6
M"@8BG%,P:5N#^0AXDL&D;763 ^%$0)/3MO.+WQM>1 *6_-N5GS6?:@AG$MJ0
MB#6?>("G#DI"!E-J51,+^@CE>Y-:(<[E^X#U>9-:-8MJ"-5^DUHU@7B Y?T6
MIE9UL0"AQ-[DU.HH'D<YC?\DS:[K^H"5]'8E6&TA'$)UO@UI5EOH!UBK+Q4?
M3"E775Q **:;E M_I@]82C<I5P,)-T"HVIN4JSGT ZSAMS;EJHL+"$7V=5,N
MI%GP +#\_/9T!"L8"%7@UX9JK-#@4TJWYKKJBB;XM,0MN*ZZP "LK$%Q775!
M UCH>IP)G\YI%)&/>2I3[J8&$\ :4,V(U#1&AH!%DH>(%-^/HDBYK^7V9HZ5
M(6#]X#EDSND\X1FYBFC#L0%<SP,9-77Y,\!E/9A14Q<V@*O\A>7WDSA-(A:2
M3&P_RNCL$5@B*>!B:SQIN(<#7/:#Q:JN<058#U@;JV/1??F6DG,J>A>P2*"F
M]FOH\ *L&D"'K*Y1ADI-J'Y>C<7"\F+?QR-CN>5M9D8E$6S5S&YY9O9[@.O^
M%S3DP_.&10._![C4KP^,>OR\WP-<VZ\MZ!_<!E$>BH"LY\%&<7@B2LSI:"8L
M$9!&YE1^#W#ICP.XND8<8%W@!?>W?]*X402X\*\/C+I&!N#*_@<NK1 T5W?Z
M=]+4VVO\'N!R'B1.=8TGP#5\#8N9JBGA_1[@$KY>*[M=R^XZ5BE6MDP%7RF+
M+5.45\M??'5V-:L8J^(OOG*X<ON6RE]\56O]<D-57,=7M(+"HM1Q@:]FK49
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M+U(,O\(40Z_KD3W>I*U%BN%7F&)X6G;U-EH<[!<IAE]ABN%I4=C;2!3N%PE
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M]#$342M"NU=)>"=^3+-9].'_ U!+ P04    "  =7/]:T!RTB>,X  !KYP(
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M*/!-^MURR<(IUU_(KV"B_9S-MC&=9FMO9>])=ZHW'SY\>*U^E<NTZDR$)WA
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M2+T$:CV.IE-Y41.&APZKOABHS$W\V2EW^"!/[]179Z>T8.6$BGM].6T[A76
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M?$F"P3'2W!$S?4:G8XN.F.D[@:4FH'XW(C=[8Z#TG#U2'VP',*>R*35<"A9
M@"N<)65[WQP([ X'@?,>^%"G2THFHPSU4^HI/"7&/YK2L#D!P4UVNFL<&8(_
M7" @(+C8.1JWRTQ5#1'272 A8,#:[%3)O< 1+</4)&R[SNC)- 2@679&0&99
M">]I>A LJV*6OBT[ SHHM1L\!,RHW7@R1$U+MU5?Y$0>&0(0[?IB)3(]W7_H
M0.-F5ZPD9K)P69\:^R(@TGHY2074U^JT"0X!*S;<R%JRE=2U1).L9!VY]EPE
M]6TQ7'5TV86S1,BKIL^2!12VN>:QR;YI[(:!MBOR)[V=4T&65,+V#"0UM<9
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M\$[E03_@RX6Z?,Z20'ERP.F5)*$WMZ?;&0Y6A@Q]7SV#DD"C+FG0N6^L6>$
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M.NPKI#ZSE/5;1UT[L?5T<VP,Z3)O!3!CZ& .52/;[$'G()T.Q7,Q@IOC4X]
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M/3W\QN9_X#?#UW[S<(?H!$0>[S:=FK,-KH:?/UK>VL2]5H%0[3)9QSZ!9UH
MESYQ$Q@O9I_$S&>_N.5(GYM73G@LAGED8)66V_X06AK0R:12E(I6#U=F]Q"%
M8W"X^D?*UT;Q'"BMUF;]#4&[BY3&"L=4 9ZR(HH*@U"P@"G(D!C@[-V<JN%F
M83VZ>T[C])T"18TDUZ-Z[EH,7Z;UY;*.,5^LUE41O)V>3V=A^9KX>*,TGOSF
MX>JW!R*.5Z]]<Z99;'([#.;L-AT[HUR="L%WGB=&@AK/##SG$8QPVC$ZQ<J
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M)5?[#*K]@[!? _:S-2:IM59@$H4__7BNXT,Z9SXH-A.[*?GV#<N3^;"\ANS
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M\C-5N=H_/,NWZ_Y&6 XSS$6CHH_/]?V9Z?MU!<I<XS.J\;>4:"XI #AW)Y+
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M@+:<O?00PIV.DF1R>7'Q\O(BO@ZCL1A&3Q>*)*D7$7G[8O995AYOE4>*:%M
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MGBT@6D/_MVF !57J"HJDZ$(\"J=C5QAB(<+(A6I\<IT_ID%J1J#^7DB?CAY
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M^35EHC=,'D]Q( &0]J6P%*JP%)/[W663LQ<)&H[Q+$NY-$KG&45/?M"#:B!
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MMT''[&"^%BV\Z]1,7I/ H)CR3BNW4(RC9P<+50<]1J>O[U(;>*Y&Z)RZL?V
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MM$T%59-LZ:SPC%PZO)!X;1.<3L1/4?$$A2ZTTM/-2C0%D+PDG5R<;K=VPJ>
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M1Q'1G"L]W+LTOD Y:+.]W(^O/[$B!87$\!-\>T!1RI8X5X4B+)R@)V;]H&0
MR(VXF@+RT<$2 .[Y%;C4FU\OYO1K&431DL=55"D,O05O6BUIL !;Y-H;CV/D
M)66[R4!<^ ,VZB\B,S*/BQ:\=!CE6DW8'9+=!/["![V(;W62.3)D;4*EF9U0
M6>I?[N15R$-+)H8MV9IN*X9LPD]$-,:*HJHC\,_,]G@5$L_] >(7($> Q&>T
M8@E9[9\+^Z4@R[&'\YQ:$G^'9S-B';CVE_BUA5ZS7N UZW6\YK8Q\G/>5"Q4
M;CZ6[>"8:%9C$POR&3 JFNH!\ $RX"K2+% ,LSDS]C%0'PV]3*+1&5LK"K_8
M3 20$O/49[^@M4?(UZBIRU\YLY:<1?D^BCNB:8H"B!:B4HW#JJ'[2:<"K3OR
MT6%91 \DOW"H+%-*90>+M$%"7,%:TT2FYCKS:>:=D3&:0"#Z-XM>Q3\5Z@]0
MD!98Y>R5Y:"(Q-R'BNHFEUX_6&7IME[3/!T7QW0.VVU:C9O6^TT5"HF8VL >
M7(S"N-LTL*91+>;<]_Y)Z"_89SX)%[X+- 46BO]"L!L1T8<6ZD]&G<,$Q7.0
M>D@F4?XB^-CA]^CX17/!\>,IP'/T,?UPV>=0>["T!HK.-,D!5@U8G@X5>E0N
M=$@[/M)0GOZTIHM$Z;UXGOT*YB6+4JW\%C\!PQ4,"!#98RJ<:2>73SIDM@:9
M:\.X2SL66<\_-3E8<-$EF=@BQ2$H<A"T81KMW_2\N;6D]5\=VMN ]O5U$11]
MZ8<K%E>(=J ?TC+VD1>$'0I/@\*H+0QU)V#AFH UZRVC0(Q+Q@[\:@A M3H#
MIQ5(RO(0LUY_.D%4FN%CY ,\X!%8L/ 8=*O""'-]%G=Q@A_!2@BO.##"'"KB
M_G1\ST5:P,P"?O<C_J*C@1/3@$W&Q$?SAX;?F*0%S"^F8=KO#K^)%V<D3CY2
MR,CR_>4U_.L5<S:LBYBZ+_@'X-4B-?A+T,'@N&/LC-2*D6:"8&V+M R *VB"
M#.&$4Q PT<FNF<0:L^&,76.!;;MW\?*)*&Y&NR"+ LAI'G&^  D1Q#(!YTI@
M-@Z(;^%B<1FF$F1E)<J<Y /LC%") SEQ4'X85X  4&*8)['=?+ X3NY@&#%S
M3#PU!J+ FF!"+$TY@7!+1EYX\;"9^$#SZ2+(/";ZE-;  9RROXKC3^SZ0Y9G
MQT9^6@(UP9 8<SM!4[Y'CL,?'3=CP;(X)ZL!X!9T) 6]).OCGY%PXMEI>S^.
ML8B/$[*H-N5=N$XT(2OTO>F4W87-=@NB$'L$19L"B2&T )).)A:(YXA_$;#0
M/W7"ABOI%QQ,D 1)YCZV7/R*;DQUT-J"GBA0]Q-^]@"4^,?_!'T4V,XH#H:Q
ME2DQS3#L4(Y;'X'#56;";J]Z@Y7>W5[U;J]ZMU?]PO:JBT*W6+UKR>T6J[=+
MFG6+U;O%ZMUB]8,WY)8YR;0EHZ!10]JK&\^095N4E9&EC!5-MRS)5A1!DA13
MP_:4%I4#R3P\E%:73+G0QS&O.]3_X&B>^"G@7CWXM\L1^I;TAW%4\OX0[QT/
M'K%X=/D,#_HT]48_TN(?XWS+?-9=A&3F+:VIP1+&8#'\)ZV46:W=#V+HCZ<8
MUHVF=AZH3$VU!1.,$WVLC6Q%UX6A2*2AI>I#0[!%P=3;0Y<*%0D1^\=)XG@8
M4E)L2KL=IBLU^(5^&/QNI5,3G+S)$MLBW#'[-D9$"5"W-\-?-U8"]]OZ2Y)F
MC\+B-_-\Z?_>C<IVHP?'$I6."(A+3#$^MH('%J<";/Q)7/+O!3BYF?@9C02.
M5HB Q=+ZJR%&5M"*%>2^0\N#61B<Q='0!<=:439#%]Z$S0O,0A<%[NHVJV+2
MGIRTM>\=Y5\ +IP%WLX"<2OEJ!'=)3=P5Z^83DC8$BN FSBSN,#YC,N6!SYF
M\>&&K(!]M)@M6.R"12=I\'0<\RQ8)_2OIE: ./0)J^YGT*!3SP@+N)9.D',7
M&%K)#9'3LT/DI)49<LF!$/G(U8]8Y'4?'PKKX!_@7(#HKW"J9SS4/_!,R30X
ML UBEC4$=*OSP^#^TD]CL%9V(#.[OPTOS$Q58SGV#%QHA-7"4@A@&W_)9"'Y
MUP( .UVNA.*O BQ=HTVT$55CB$DTWJ$VI\26X(.-C"Z3>VS@+#XRCJ\G?6N2
MR<@^+KJ/:R?C?!2&J(O)&(L HL/BP/\Y-\6&]#,F[N>%_X,L3TK9QI$H6VP)
M9;-F@PQQ2U)*W P?9T?9V^PTT99LPQK:0QL\B-%0M&QU+(J2)%LC0394J3UV
MFLIS=Y;CTVH^LEHAE)E;O=F<K6M@@8WD.W/6C9\V&3"OXLXK'/-99&X94M[Q
M,Z1S[C7X@R5LL3U3E+DKBI@_*6)^3\NXV)P+^D<Z_$V"K@RT/G"I$8LM8>,4
MPYEZL(";8;_:$"1ALO8C,M^ &1WP]OS19+F:BW3<^2+,RP=J[JV0$?OC^$31
MM-3TH<C-3*A2O@NZNOOCEZQ\1<ASX@?N7PN/)8ZI[*<=\%0KLFDSK&XI[0"-
MREDPK9RI=+K"1)NW"+F99U/7F*D4+'@"T?S#>L$&^:XX[518EJIA.7#@8)9?
MC.,^_IQ6?8=D-'&=?RU(IE[ FM+63G"1+3K(G@H+=,#H,.*XM<,;P@59B3%[
M.?;T6%WEVBD)1/ZP!;48 ML'O5M"8AMW*W63HBNFPKM)T5U:N@5IZ3<\*5HL
M3?MU:?ANZG-K,]+=U.>J2>9=4T6?26@Y4]QH4C)+=ELT0\[%+4I2WC3&L2DA
M7A 7@4_E<XJ$/-.Z9Q0[0X*K H.)]\JV"&:'"$0S%Y)*=Q83R7;/K+? @?<#
MR*#C #)EZ(4QK[VCW$<7FX8IUB_%E+5F2C%%C9?%9NQ/DY>DS<5+59^D\::X
MN3RT^IED76^FRHO7M6;@I/.FN5GE5;^=*C>%NZ:>A+?;7 RW4PG;_EY*@4B,
M-A,W;7$*\:#^]5W);^-FS\OY:LJ![HM*17!SMX[LVY;<.Q/,IS=.E-);O3 +
M,3EN-D>0Y +>ZJ7_S(?32J^*RT]7#84-^\^CO\#$8X7UZ.T%T.^LL2[.):5#
M"E,J60%8'7&_"LQMH&)%S(7=8[''+&^TD(LVW>61+-4]5_M1F,9W*Z!*$C:@
MZDQT5LK5,\\FTTW"ZXWA^DMV;&CIO;4+%&3W49OO9LCD*.("(/.GAZXX2Q\6
M"8CF>69C)/E0S;!EH0P*@T^\QA]43+3ORG?K4X:B$(R-55<9&_ JRDE'G?:9
MX,N[$PC6$\.LV.BYA*N+%W?CR&XZ/+K;)QO^A[%\5!E JU'*W:*<Q9SH3.GP
M2O.T</KV?K"SQBP SEG1R"XJ\]SO7%=GVF08[J4QZP&LC2RRN\H\_[N+JQ&'
MB[GW/IKSW$7$D53G^1-)ISLOBS$JZ\Z%VYS'>?YL<LGZ4[Z\*P]6ICF_YQX)
M\>G:'IP+Z+G<%6@4T"WPYG)>V)"H:E:MM$_(W(\IW+@1R!;6%XY#&+&_A6U"
M8YVD<4<4IK43]J+[O:*%@--,G3UKK4K 3G<VKR'%8<U6?*?/3J//=JQU/*92
MJS#*_]V6U.2;E7F=BKNH*S^QQ5373+!:\[GO6:-).[797K74#<#J.=>S6VDG
MR,KTZ.&2LVQ:"A'-?"E]1#3BA;!M(>FV,3K FNXWSDR.B48NV[11?,CFOM E
M@)]Y'2=>59[)LMO&T2TU'9WV?=MW_NJY+]=(XMS4PR?2J>KV3UP('JV[P7W>
M;-@W'6059A@DN#RAN^I77-[]UZ--%W_I%JC5DVG4U95)=!_,7N*DBN*,5C;'
MHVVFZ7*0=$DOZ/E4V7?>Y"7ILZJ.Y(1,HZ$N9&6E5-1=5;9\"EO9+E#K7;)G
M6;M@Y_ROW.4=N[QCEW?L-.MFS6H3' U-XQ&U=&NR+PXC_\0-HM6IG6:]M+MW
MFO6B!$BG63O-6D&SFA>G6>\S^QD=EYLMZ&K0\2*[W^)B)&2G$"_JRI>L$+_!
MQ:DMO>7ZG3+LE.$%,<6+%SHT_;[>]=%'CW%&?.J$SJTY\?OTUSB?U1K1%04V
MH<-/6:Z!YB'B3RY/M':IRBY5V9Y4Y8DE*1E9BX#.[@^RL_H#;F+]Q,K6F14N
M?*R2QR0F2I)P L>4N1D\>H+KUE=3G0[.XWNQ?"RRP5T=+A5 <S8%CY9B_7)F
MR::13&P,%]*SH7ZLT@=SG*X7UMB]=,GY3%"'6*?TB1>E2Z^3S<RJ/T:]ZPY#
MBY,]W2W0?IOF1>]SENRV^PW'V7FWO76QQ<R=]NZT=QH@8ZH1^&)U:U-V*0ON
M9#FN(F>U23OK<8[JLCO/KWXA.#M9OU"39UJK>"8.K=8:+N&QM,1J1/!1_\H'
M\BN5;L7=_-E&1%RS,EQ2FRA:C16MTPRQL0@P/N'&4QR'G&QF*MZX4>G]24=D
M]@3\%C0D+_YI^<POG5M+!JU@@6M@ .C>TIJRK3$9;*S"<F4+*)PPOC$28GQ+
M@*6':W=7M^I>I)EW85&/K]AG5VC378SNZ\(5G<&SQ>!Y&[Q^QW3;E+)\HDOH
M9JE4)Z3]08X[8N.302\!''SOE2[[!)5]R2I"%"Y.1X")\@J&:KI0GF[VMD:7
M&-N^Y"RQ=-K(5_R*U;4=^)#LDN B,)X 8%*%1ME31<U.0CR/;'Y#9@7RNJ=U
M>0SU.QP]JD/X/O?*3<_R<<]O/PW_UVD8+>43:8/Q!_8#!9WGDF4$0.I+__6E
M]&__/^)[W*VWF'ONY='999<R7*#%MC(KG0M>K?D%2M?.5+NH*]><2O)&.;\S
MLSHSJUDS*_I'QM:B-6Y?%CY\]"MD$]<27</(+>"*[3&N,\4Z4^RR!/*M[P7!
M=1(ZZVRQB[M[%S;KPF:ML.<NR)SI3+[&(FNGL/8N" N[&815M]J=N_@#DU&L
M83)>"EB^9LK$:&$O6^XZQ.0]EAZ.O-G0<:/A%[0CR6.CSS!QZTVGF,B/.7D7
M!?+FN7(7>_5RH%-CYO'E *6YJ<AO7'C]08?QW ^^<[+4+Y]E/+>6;!:RRUF%
MD@WK7*V"VMDES^6G+M.*V6QU[6E'+.?U&M7[[VGY=V9(\IKS%KMJ\=YL1.X'
M>)*LK"(]VIO-/G( WF[XX3KZNP.BG3[R@Q/"(485_+Q,DTDK3K0*5HDW#836
M6@\ [0W.3J!"(IP0^P6Q&Y(9H]>5H53V"RV<HPTX0$L39]Z/'NG[2_R5-</B
MN[AR?J58?FA-<88I%TQPII7CCJ8+>#G'ED33J1W9,OPP!#);L!Z"J/0^.IKO
M!#^NL.9\U8MV?GU@E,YV991] K;#M\4,@#S:$%)0<X1I5*%*(R')HEG@F;=%
MF%(,7C3Q5;G.IE?'#B>1D,E^,1:LZ5>L(4!X$99_I2@6PL"Z*K.!5J?6/" ?
MXG]\M)U@/K66'QR7DA?]TL<\H-;GZ>+[V*_3,_$".U?D#41OCG[-PZ_>YS^7
M>4$R"G\C\&+AYV5/,A5>UZ6-C]KBJ^RZ;'['+L===VA3621*E>-+YW2M[X-O
M#W?WNTO9O>)X+!C _LME?_AM\/7N^A]?!D_<W?VWP;?;^\%7[NG+X\/3\Z9V
M2=T0)*(5'Q7/!V?=Z9B2(*EE"PA6%7+VOQ,_I8<7L/I\8OVXML8@*CY8TU=K
M&2"#9&4E\']B!NF\+L'9RJ3/JKB0UN6JRFMZYC.?/C3Z,&\DE]@ 9R'-5-X0
MBJ5676EFJ+Q@:HT\"@\E5Y&+:XI+E!C@5X6*[[VR?TLY 2.@>(G>4Q"QW'43
M2H&.HR14;!C6YSIC1W/PRZ^),W1"SC1YL8P?\T#5<T ]-H1V%*'\UOYMIIAX
M[M9#[D6O<F)-Q]=TS<K6CLHZ$FW-YN,<^__VQM>*KE[+FP23O)9#DE+G I_@
MJ*8RLL<C2=-%51%-T;1DTS0%E0RM\7@\U'LWC4I[4=R1\ :\QG/?".V"=,$2
M'R4]J<&"^89H2(/#^HFM%9C/X;E4?-*Y_Z _M%5HKUC,U)4$0GHB8[C<M=CC
M7&L&]W3&?G ]7DRG'SY3]W".H'\8?_DU)R- ZOUL;HW"A_&]"R:K-1VPE[*_
M@;-^#^$HEF\'#SXM]IO[)&3N12]&GZ'T.'BR-4=*]A<;TX%JH:7>O*MH5*3Z
M!Y<;S'UGRIEL?5 _14&$E?N[I^^<:'!7C\EB0/3. 3^?V9@3S)*!>Y0.KOB>
M\,:[?@Z)?[> ^/TEQ]85Z=Q5L!AB1RRZ4>#K>WY V#Q^1@R8#YD3 ,T?+KSV
M'<\-@.8IQNA@M2"@?^P$4<],.%U&,XC!,N"Y"%JOSG1*=TH 0T\Q .'-,;B
MBR: &(,(P_G-26>#PM^M)2<+91@$+G!MQFD 9(I/DR*0_E./'&:,I$1-Y%,
MK3..N(#^9;1C@0)[I3]_97A7!M>N1X'M$)]ULZ^B74M08WN$K?L@E!WA9<MD
M\T>$Z#X]00D.<=A/>K\S1N'?%W KT2C#X9_@1L\()XH(_K_^AR%)PL>!Z^(8
M41!@OO>3K""8_H7X<1O[U<)#O'S%P_E*:^_$SGEO$22\!,3P.G&P=QZ$ W I
M_!U;Y1(/+;#":*TH$)N?T%JP&=>S,\9OLJBM',>]6R]J]TNF,2!7,EA=VV1.
MJ'/!D2E@"!2>$RY[_<W<S=Q O0(=L&T_R:,86I@,ME*5&(=BD;Y$[:/WZN(^
M5_J3_A%HA\RH=L63/'JO<-O'A3^:8$1O\.*3B%ZN'A\'P3LV_6(^609H&7(V
MF3I@)M(A&'!S\DK/FKDJ(XV99\?'H@$W'.81CY7P<0VVG]F5E[1/TG=YB[#@
M=5=_TM/48H3J\HA[2J_B$O]ER<UC@*2'H^XCC5EC:G$9G\2B4R1R"_Y8'W'!
M+D%)K+%*, IP)E-$Z)/O/!^MK.N[2IL&N:N8$D 6T0_PJY'D*0J 9H.;^?#G
M;LQ<%LJD=K$R&@J"K8G:<"PK1!^9BJ"/Y;&M#RU+40WE_\G4--XL2[89WR-#
M-"5-5N$M1#$-;2C;DF9H]G!HCH;J<+31^-[-I<$S5(A)?7K/?0>(4>E*H]Z
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M]+O2Z3;P#<;H#@Z_<J,1--%IT[Z;>N:$LLV<H/8!=JK[!,QKA,<]K2VJ;0F
M1E&VQ%E263@%Q@8.HS66B(M\FUF9S.MS*UTZ=-O!+]HP ]*N%#1P_B')MVNH
M6>C<?[LK:&('!&(-U@MY&/_IA4D?4KSG.(B2!G8"DFLIA8G.QCNOP>0OB=I+
MF)81>-3>$_4MKP/EE;H&T> YVG,\8VN2HA'L 7Y$"2>>69',?6B1R\ "+Z,L
MP475;">V]GGN7"V./__V5<2@VQI),<LRT4; )R^^-:.."H;)AX15W$6!GT00
MG:OB^)X9;1D;3JB.P1.C0_BBMK<9B 7*;4%J?**,_4^#%P2LY(MX$400=>2
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MB<#P'4[/10\-%L/ L1W+=TC 3:R?!#=%P"F)O3+D$X PMO#V6+B)*W0L%[\
MT!A:[H^ >W7"B;>@@T&]A1\0GL/R3]96@T[DRK,F5LC-2$AK08&=;(=.G@8V
M"D:^,X0W.R[WS0,,?.(-7!<*+X_^E)(V[N+-3/ +0OB [?V)"WB7Q/(Y0B?
MQ]XK%SNN=*+IA+@CPKT2P#VP#RLH_C?\-59Z[U#BO"$&\SGS^,W%R28F4?*Y
MO:0ZV4K*!")//*H52(JU=SCX!B^EQL$E'+&\[> Y1+QC-.(3H+\%X/%E8?D6
M'(X$C &1TBCFO0 X%-<NC^&>#&G.; 9(]]EBDUSUQ!I?;A!7$5LH!B^:P#IS
M+Z"T^($=X">)RG<CO9#Y8BQPTZ]80R#.15C^E761>_0B9#@2+[!CU:E"-A5>
MUS</,*GZ*)D7MDQ5.= HE,UHJ"^&=XWO,O$[^/9P=[\AK-K,RXME/Y,=[+]<
M]H??!E_OKO_Q9?#$W=U_&WR[O1]\Y9Z^/#X\/7,;CEI_8E2U8ZX403$NWFF2
MRL:@:JNH0M0+[EMD?&7^6WV(F28F0\PF?@JW%W)-YT5=6V,0IQ^LZ:NU#) /
ML[8,B)G$/M9Y78+KE,FX5:F$?QGAYAH1\4'E-3WS&85T_&$& R-0YL1GGSB@
MQ=WPP[4H\K(R/[[0-$U>,;3:,M/@36'S**IF)5WHS7O1AN]&N-38<:S;EU\3
M9^B$'(!-+*/G(UUZ1V:M:$.+/'?K(6UB;Q*VBEU3HW.KC5J'R2MUF:7M<]E>
ML^\3RR>WUAP1]T3@DC\)CAZG0R?9^N-[Y#$2A%]^ 9^X%ICVR]2BDYFAZ+@+
M8@_"Z#-\YUHSVAXGO)WB2KI@]:B%AU&:FXZHVT0PU2$QA[:LZ+H^%'1!4VW#
M-A5%&P^U]DQ'-"A]I;04()0FWA2D74 '*.L?.4(16=$)70.-N089,A3M(<":
MF)*ND+%B:HIFCT;@C6FJ+ W'&R&S&ZN)0B7%B+  ;J-DPHT8G9RIXUU0Z=VG
M#FN0O5PC7JA0T%X;!,#.$:=5ZY(74BY4<3^VHJI]593Z:D'Y"G6L4?XY 1(L
M7+3T\/2ZP<;SWW^[*YA%OD /,A(9 ;M/[8MHN&!/DO2^KFI](/;\1=CQN"O$
M3(B#M3F7OACO%/W.6X0@TUW45N]H\(.SN+D5[]6LUBC]2'QZD?IP>+38OL'T
M"?EKZH"OW-7.-6+U#$8JJ(UE#/X)F=H8O8O>@\QSML-.=W3+-8575;F9+E6-
M%_0&'Z4T8?@*: &6.FFK%'E#&XS:YR\>LDKLVYI(*B7Z1ES;)GJ <VV_>^"I
M505[?TFPD-@G2(]Q-'H.#_7LKN&MYJ3<KNRSNK6$0U8R*Z=6S*3?0%<61>UQ
M1:O :UV76U>'7),@F36\D2#5E76SQ,>0GO6R%IBX\_SG"1JQ(!X3"L7GQ"1J
M]FX$WM#*2^6/125MDIY_J:-)SJK>>.=*XS=595(L[N7]Q#V04N_&Y L6Q1QT
MZ]8%H*M8&,I-"T-=$%$8ZJI:51@V+M0.#^2W*]JR)F\GT1B+"/N*-*P[47FY
MDVE'DFE"\T(-YUGSDBAV0NU-=I#]W7(7EK_DNJ:Q6J)1W-O:4X"O9%[)&PM=
M'?GID5XL7L4#V(PJBE=!*Q^!T#P!M$\(%0C@U6J+LTF##:)T9/W<JJ@:)5G%
MO$QA>=5[]XF\6+X=/(PC:KMW1YB&(Y^67WX!03H!4F/HC7Y\7PRQ<GN.!WF@
M_ZTXA%U(*16SLKK8%PMZ7..D'ZO\I8?;,*R;SNJ&/U],:>$Y_A6)CHL_QV7O
M>&Y:_!X?G//8R1M-D98.\3LBT=R['/(L7JZ_>PU'(T>I3;45:/:)!*'OC$)B
M,^K]DV#Y03GUUJ9,3*3W-4/J"VK>3"VLC6T#UB.>.3'"?U)D )I!J\2LYR<(
MBW)F6/(5</:"]I84<W4?__$Z<4:3PPB^=2+:)@)K$Q$F6T"X:7U)V&:3M8V2
MJ-@=+Z9C9SHEM.H"93#N4T"DN.0UEL]8_W-B>FNHXF@3:> *LV8%C(FTH0*1
M&TJU9%P;J +I !=KA%C5BH1 ?CD![=F)J&'L$TH@(_CQA9R8+JIW!-4JFI14
MR=1LS1R.#561-=,8J^)8-2S5E U1D\73%DU*//=$Y@L?,+!J^VRN%VFW"?S@
M<H.Y[TR38"HKH!RX+O:0_8VXQ(?__9T02HMKEX[J9SEK$4X\GW;\69$2\E-(
MS7WOQ;=FM)O0BJHW,B9W2;6S:JYY;/"MR*).L?#('KTB(K"M] -H/]I[FD@%
M$4=]&NN4&@U/YKD_J$:EG931<?NI?HW?9M=6EII0V4M(+U6W!%,7@3%DLR\K
M2E\KB-XBK!WLTGUU8V%2:ART53QF*UM.96PS^F4>8]J)N\O>(FW#2$;64[TS
M5:0Q*U$"JNB;1C[;O[(UXEQ+6#^G)#Q+I1/^^,D#.X*VR#H^[3 /<-E-'#J5
MS&RA./O;C/R*CAEZ60F&?WE+F[27_R>(>*C/Z,&-2<'U<+'3B! ,Y^Q&%:L3
M$<T&J<),J4+NW919S$-&$?W(OZ#EVL2?!7$E>MQ8'I 0S17\?8&"6%4G&%E
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MV%!"4)_AC)C\Z(,J+7*6V&#_B3-T0@[ )M8?!-SHI7?DNXHVCLASMQ[2)OK
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M$?^XR\;NJ>(8])\ ^+\QV&?DTN<$\H,PD5^_4:C7$3[Z>>BOMT\&&]34$<C
MV)$,.E73J9HNTWF2*,T&O5&0F<J;NN/R>$W6HBV2%F;O1MLG0M.Y.L>*W!V+
M)@P!5SQV0;L3=@@=LD7K/B2S@',]./YB&)!_+8 TIN 6D-'4"@)G[-#6T=#C
MYCZ\+^0\G\.2SK.:MWU(^#52PY*.<2IK=WZ>6.'_.M/I-R_\1)X2Y.!:CT>*
MF <?:Q+2($6>C;$01<D/W=M@+30#MT;F.5W4P._VT&M)C<Q1Z%7JW8B:=A[T
M>CRRO##5=W@[[#,9AI5K<+J.V:YCM@L*M+0J:-,TLWWNJ/#JUJDM])JY&8/(
M4=<2KRCYL2FXHA"? (Z@U>6+*Y@B1JUD'TKUU-?=J5S%$.3>3<TAU5U Y&@!
M$7.W4J9&"$/IW>Q3TO]6(R*=,FV7,NW*F-JMEIKH<32$KDZI[3224U5'IY&N
M$*G376W571>?'6Y,X51+!)98P 7-A]7ERYG4&G4Z:*.[U#3]Y.G$:&#BQUO5
M0%5O>@:=K;=6,.'&4^\U*A9EK:OK):1=V^J)J*(S6%H6N5Z5@&<6OAY>:)R@
M7KQ2%':+5Z(HO0-)R@I_=XQ7FC@ML*OJ:Q]1B*<C"B#(F_QB]2Z(W>G5=NG5
M+HA]<.<PKYMJ2)]F1_89(!*[4$*[J26GM!JGECQ52%W@H--8K=-87>BZ41<H
M+2LNBD2NR)&'<5GE<9'TD'LW^4+B3INT@BBVN4 '(PJE4RF-JY331)L3OV&T
M\'WBCI9<Z,/CIFPAH^V A,:/R7[EVV\_UMP9$B=S?;<0+@<_@@L%CW'_?_;>
MM;E1)%L;_2N$]YYY77%DF;O M4,1KMNTYZVV*ZJJ9\Z<+SL0I"RZ$&@ E<OS
MZ\]:F2 A 1(@0$BBI\=MZP+D6D^N6ZX+K=.S+=OP;7B]EC:*IQ5PYJ[-"W7J
M&XPXQP#\OL;?.X*( W5;*+Z8=/#=Y?S&\L*;Z.Y9RE>Y&BL#,:.\JP]*=\X@
M.SY:5##5!H*:;GO=FVN]XNZVXBX?OU[7,?7:K3GM5C40.;H:B[W6ZB >RARE
MUHB'S(RV_A2UUTC'TD@L%(;GGW@,FM0^]MJ']!;$I[ /+E39U'X^FB%2GMPX
M+ G")9$8^^!^8FQX6G$A2[+H5V-)3_?BZL/69Z%O#@.'R(/:.<@.Z15/KWCZ
MP]!..3 %Y0;&6!B9LP2#@",V#K%(>X5QG'/. _DN@K5P<+.*<U4*48.CB1>&
MWCRSQ]$Y-7-LNY%C/63M?NN\F@-4Q9OH%>N@5RZF+DIX L,+AXR2; (&M;=M
MO!1TUG+(<V1,8DK.@,\XY^EPT\=NP+Y%-7L;HB:)C?N$WS0W_&?;I<O%C;+A
M) C"4)(W=\^?RR"TIZ^;KE7TN09-.GK).SN$AS!W0T"D0G_=G0TP.?6\T/5"
MPA#KWD@"8IR]]M7#1YV%X>+N]O;EY67X:^([0\]_OA5Y7KKUX>W;^+-=6=\F
MD\2AKB'M'U@'S"!A/)A1M#!E/]QQ]ARV.,'1R)P'6.4,Q^$6\+=G!</5UDG0
M[F*0,]F)'/',D".61\Y?_TN35/EM.<TE=E)S*5D]\IGZ &XXN"S;I6>]4]L/
M0FYF.%.,T8N\J R26RCO4_)E[R5SYUZ2&$QL=XG#<J+7;LY*-DM#23TH4]#P
M"3<W;!=\0FM)'4'$F;& ;8*GG7@9K)F#U_[XQEF>XQC^3LC!2Q'-V9=7O "Z
MGS\@.;:WTS_+24"CF@R4VI&!:3&G7HUE14\).BZ6<;BJ?$''^5'B?HP^6 00
M!HWB%0"?%@2@QUT'A'"/N,??#87AF^&@*JD.GKA0E52CK!ZAFQHA0@/0"P7\
M@'9)*:<*6'Q]:RN.X]L^+N=P)3/K$[@_\4EMV9SPO*4*ZF0JR61DZC(_FDI3
M:S0Q#%G1Y/]5P2E;;_GU5;<H+23CF!_LP 0H+/U4NZ#@(0A 2'_\!7Z%:X2>
M__H=KO'.\<P?:])IV^(<7\,[$"#S NX!%R.90B9RQB38U4FQ(ZY%!UVT8NG2
M=,3+\D@WY:DL3]31A(R(R"N6:(T,[6J7PSG2>)&HV>(&I0M(FBTA(P@5I<R[
MH3[DD( #SL26.@@0^@LFC/T$Q+G;9RV56,3"SGCT&+>[_Q*E9G]'5R^#0WIQ
M7BB9XKU^2:X-]R:=B^MJD6"SNW^<B@ZJT8^3\I@/P[V 8J43,$$E>B_;38O*
M+YMZSULQ!!/5[2(@=_$O;V//&_0UKH!^Z6WZ#ENQ 7I#]O;;%]L*9W>Z/M1T
M <-#470\NC%[5Q@"16[3KX_XH2AGO\4/A<S7\RXE2$-1U&N[E)3]E?A2]1X.
M,TH>[3@QTG>Q<DW%9:L4+Q6-8NY:>I-1S+\O7<))_(#:"P46?"KK^D!,,I\0
MGQD DD 7*&\L\()FKGSVP $ *V<.MMDD/*E98AT[5MYGW2*ED=#O/-_W7H 4
MI8LO)$PUD@;@)]>4BG89,[RZA9.]#F,-.,',$V$PTLL653<+AW,J=/XV\_QP
M+3>9.T#C02%8L'[L0CNU2==SWQ9[Q2>+MH7K77'O6M%K7QC!GZ:/GFMN?ZST
MYA&OQJ.!Q*=#*UU*]SUW..R5DJW!0;H:RZ!R2\*AEY6)5"A@K$^"D/.-D"0D
MI?D*//;MG[3@/."6 ;$P&CDW7..9] *SK,#,["+.*/\5"+_:'^;KAS75_P@P
MD/H[)3E&M[)V *:"=+OXX=QYG9*&C?%:00^C9'%WP[+N//)!OWNAX9R>C]V9
M-+E]]L !&EZ]&HO\0!'2*KZ3N6Z7[<QW!9![#=0# #G"<=N#+#G<24 >-6IP
M3K'8]WL/%D]!972MNFNO)PG$1H,)_O-Q3?+2FQ:[#R@#*2,EHVH6_YE+\H[A
M9'_$H1Z<Z!A>DN42=8%]5+;92,/^?(X+"3_4(5?+NZ*9^RICY\C\U5C1NEI.
M>XK\/FX(HC#?!9"8)7M&-VUTIK 59:+5/1\NJ@)NQ-MY)"$[N]KA5%2[?T;7
MT:Q'J#SFRCBDZ6@&I^K9KTWRJB;!C%$_FBA;CRTCBUBX*O#I<HO:(=5(X"1[
MTS;67^'LD9=C0C>!/.EJK U&HPM'WF47@7;BB;++-C-+H^2J15 K36UYX+W
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MJ53K7-H#[XR!UTH>I[(CC[,'WF4"KY6:<&5'37@/O,L$7GO=/A6Y]R%Z\&V
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MRP9)CQ)A&<(?A$GZI>_]QW/)@)(P\.8$]QI[4.H&C=X&,<'P!K!M?X*L(<&
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MECYYFGZVC8GMV*%-@J_$ 98 $]XM \!$$+SWYA/;I8\4 !>^>X^>BY?U/0=
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M8QXIW-SWN_:4;4,R48D=7>(&/W\G"$-)CJ]CNQ8(G+N;Z,7B2/XG7 ^O>9@
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M7?CN&U*6F W6I4ELGV"5<&/#-9S7P [B48H!+CRT?^)\2GC)F\#3&DP@@SY
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M8>Y<0+"F*T+_>E0[W?$_:7H^EA.'L,_M:90JGWQYK0+HCD+#R[T!;1.0]8U
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MY$ ?C:IL^5,U2C_9S]AF8]4X@A:LTZXED=,>=9-;6Z,^N5DW+L+RQ&1MX<2
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MU(9FUQY/*<6LC7W&$]5+9E\S>DB2=8R"W'[%L)TQ)3<]9Z1/KNY$<G4!!HY
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MD^T6[M&T&GQBV:)D6\G<8E-R;CN!^96\/'G.7Z\3\B[]TX4_CZFMO'SI9'B
M:.&B3I65QUYS[';YG*Y\9%C :5R::;.J2>.<9LSIRNGA DZKG5Y!.Q5G=",8
MS3"#"]YY3[7*5OW4R^F+9ZC-,-%J82=#217-V5:-;0S3GN"0]62S9 ,*YULU
MOE7.3A;PS>ST])(9"<ZV:FQCF$ $7ZFG*B4=')XQ.$7&X'RU*1^=@>\]><=7
MIER^Z#',X8+WVM-Y#-E01C/,VH)7VS/+)NLYHVMB-,,$H(T)0)XL:"BC&>;_
M;,S_J:RJ>+@;7(VA#--\X%+WM)+-ZIQMU=C&,&D'[ECI["QG6Q6VZ1+#U!PX
M5Z7M)&=;-;8Q3,W9F)J3SZ@E>:[@_+F"_Y\$T_"O?%D!SQ9L%3Z&^54;-V:P
MFLO$8PO&C&:8D06WMJ<U^QSRBAG-,/\'CG!/+ENZRQE=$Z/9Y?_@;M!O:G9>
MZ/(9RB[/IX%3W5/X$74M;&.7M=/ '>N5G>O#V5:-;>QR<QHX5Z ^.=OJ8!N[
MW)P&KE*O8.\+3Q8T\0;YIQH&CG;.3/H*2H4O!>#SDEH^+^FDV55ZR2.&)NV5
MJ#829??HI-G >?1"/CCI:/].9G>(ITEZIZ>Q2FKP028- PJ[8T--,B 0X!-O
M+A0H[(ZX-,GL])26#[SA0-D&%'9'9)ID8?E=V9&\#4/*U0."W5&:)MGE>_TX
MV\_#=H8':^#.]@K6K'*V-Y#M#(_?9"RS;_! =L[V)=L9'M^!J]E3I ;/.FM\
MYJR=2>7[8,ASRCRGW/*<<E/3R=>42/[N1$/?BQV!IY*/M^P,*SQDM=/CJT(O
M%2@,:TID#4N!6-7,<J0T"RD*P],I6>_TRDX1XD!I"U 8GD[)!D25;3^>NGI
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M#P@)A(C<3.'3P#[B"J!('%0>L1<G\(HP<. O(0GA4R.?#!,A&1-AZ#MQ[(T
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M_A@2T$PNF&\(5 3G,2)D D^:*K'LYD$% 6B?/#>/;R"=  _QY W3BCZ 8+1
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M3#,,BYV5).IKF@S(YV/39,=2HR)!:>+FS6IN^"TF:\*8+.Y__FL# D0@:5:
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MZL[$X2AYIBX:7"Q]/35<-$8/4#W-T"IC?!HMPQ-<TN:@[_LVC5.([TW 90*
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M,V$\ U8I Q;#$\!?<X,8!Z_O?_7B(5A#)R#A+*847^Q1OJ/TSHQAA;)G.C3
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MR<=9-F2<Y<4#<; 3B-:% 5%!VM,) \)3-F* .KS.8@)!.AGS>>P-QT)V<V,
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MCS[N"H\9Y 0O%H(P$1S?#X?THH-7X3&W7D"(R&/QZH1LP8*3P@WIB[#TM.%
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M%@P#WVQX9LUJ7IAXKNN3QA7<I)3<:9;NOG[>%/9_TZL3-^/-]^PR90V1B=V
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M\NW;KN (T\A[<A("/TYG)L.["1F. WCVQU= [62*TXC'Q''_.W.B^<\*7\+
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M&$^8*ATHI</SP-NX9CC]A&_+@L,U$3F_@R^+L.P*H@R84B ":V$=&7+D <0
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M*$=2T[+&HC)]16X>\U(X6[+3P<*S6O:V3.24^#F\9GN)_[R[GJ8+F.';<O<
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MGV\9K)W8\I"+?6BMEVL*;9"N+G6UP3IXJ:SV^(]5/*L?+NQ%N0,4>6SR%5O
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M0":A)E#2%=I<$:(BZQ!TFT/#K0.<DHZ[D^16JW>(7%*87?P\;GZ?]99%NGF
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MRK2;>5U@.%M@^+J)1SZ"WTL-O1"BXZJ.6MGBC%(LNT0.%7E4+/BD68U$96M
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M3K <A*B>7F 0;,6$:++#B&+ YC_/M(Q(+]'"PW31X?G;-DSK.K<M4/U1->0
M3;:K#+&/&H:K&B)D*=D6\IDTIW=!)*"5$@03O.@8N,O.#'AT\:RKAO3 C5VD
MWVO5D"R*+R X#9_K-<@@F/>8&9)M!);FZK"-<? \JX;L).6M54-V$5$O1L#&
MZXQG8$-R(=<6=2XSC9Y8Z95CMI(R>!N)L8.]P!LA'OLV<E]WY@[71T_!T/^^
M'LV6M2-V*!E1#Q76EZ*3LED56>WEK&FE"YEY+3DKUCHM?'9@!VSK=_!\3I6
M VNZ%Z.DXS(G%I-,69#/%^C%HT4ZLV@2K?RU(6PV*9DX7/>8TZI\TQN+C\>
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MUGQHP?52YWQA8D!:G,_^A//?$2?O<7&7Z]TR#>OFQ;%"091D8X0B:$,7:%@
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M[27#\3U^PLDU_DQ2^0!CVI]K@YG9UDBA,\YSG0U3BY(/UOEEB<84P0(HP_V
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M4+W/NNP\J=6Z-#I;K^AH8MF2X55\(*&B!YU"P:"8+_<SRHYB+]]IDB^5\L?
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MLZ"5]6*\DM3WT;T8[C124./Z$*O I]=A^N];YIA59(Z1XP>N.'+[T)$Y1LC
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MQRBBW\"77G>'&UV?-<"U@<L(G5/* E]YP9&H[7GQ8$.LS=N-=[[+17&7L4Z
M!\U%ND'GO:X-'P,H^=J>#2J)X!2(6BA3H6,0A"*G1H3HO453.D6G=QGKQ'6^
MET@WZ+S7O>%&@%?/DOX*'T=+%HLW()4F<P4+F2O%(UB3&++D#98NC9@Z#'6J
M&N\AT T*;W]]N&;DVE(A"@KI'$(4]='*"P>.T<GC MFJP1F>[E>&W'V1GZCU
MUT*D&W3>KXMD5PODBJ=K R1Y5T(Q#*04JW#?FDA5 J"+1<;BI'6II>UW=_@3
M8,88@M] EEY7AS6)XK?I8CF_N&[1$T0)+DD#U@4%2A0!7G(!#IUF(BON1)<J
MXP\_^?0CCAM(M''\QUTTZW*:'?!LCC#NH.E#1 :WD/M6%?806N.PK8VX8D(7
MLO.@<^+5AR![4I4,0J%D9&D6+W=?K@>(W!U#A[O(JG7(W2I[[=>+^>QWS).+
MKY]P_O6/V?*Z.8%PRJE4S4+G")J,')QQ>77H9.Y]%J)++>8GAADY8[.W#F;#
M"+!Q$.W.+\=*DLU/Q(94S0R%U>_74I.'D+/'J*T-791]O(_TS;4_J(B'J<)?
M,Y%Q_BW,KQL1.<\9MX&!29$\0<.P=LV3H)-%SQ(S7HY7=.LAOM.WSYII9Y@&
M'W<P72V8+JC&[^^Q >G!VGOTU.03U.BAAA&VE74ETV2M-#F#=D+6.\4:8*X%
MT#Z'R*T(/L03),?3K3U&X<8NTF]L5?X>_@<_?<%Y^(87RTE:VT*(QHA$4\O.
MTBG+4X$8O(8LHE*9"R]<Z&!?;/[T@[2%Z"WW65.A-38@_[BH"-Z5ZP?EQ=JB
M.=.Q!(,8P.6:)82^NCY>0G($**LLA>]R';]]A$.H<\R*! WE.TCG8?)A5J5*
M+DO7G(F0@G&*U; !K.5I#'DPG$BID*'S)OK[2W? K?PNME-G2A.=M"[4?SOI
MA+:^7VO!FGKZO5N5-;HD]AD2!%_+"V.6OC:KU!"+5."5Y;0Y&N=DEQ><3H.=
M.@N&D7KC:]TG +['^626SZS!X'G(D .15]64A>BE!>NQY%2,P$Z-8#L-]I,6
M^TA](#_R3D++NMI\\ 5M634YL(E..F*J0UWC$&N$HHU!WX_M&M1)V(3QU$G4
M5$>-TPBOY_CJ.YG&G_&7>?@KS_Z:GL7H4LUR F=DO8%W9!?7_Y1LM<Z!V9B[
M7%9N^_Q3UWDSV3;.(?SS&TEFNGP??GQ=U2_$B-9H)$]8E%J_4$1PVB)([9/
MDECB77S&>Q_[$K3;1Y*-TP77CLZGFJCZ!1=GS):4E YDE*P.HQK+@*74_)1L
M<W*,J2X57NY_[DM0:R]9;LWW&Z7"Y\>+KU_#_,>L_![F_\;EJAKJK/R!R_I/
MAJCTV6G  2M^[C[A@U?^%)D5%60!CHFXJ9B#R+P&+%8F%<AV1#F:.?:L*G_J
M[(TUT8)P6=1N:K2@50D@@O7DJ!>!]U]/CT9RSZ3RYR[<;%/Y<Q>='D_ES]\Q
MU&E>!ZL@B[J@%N!BJ3D<JQMI.B$$ZHS<%Z[->)=W]\ ]K]?=G?CP@(%]]#+(
MJ]TM0%>/%UT@C?ZN^P#FH1YU>RGP,3KTD/Y(Q!"&<^MK]+&J>6"Z:(@1$5(,
MT4G)G;X?AOW\"?'D0^[0?-A%Z(UO^%\M;]FLZY01&C;R&&MQTEI91)"343#1
M]%S4'EUBG1+S-WST(1RWGN*>M9-5XV?;!UTFUFE]GJ&V->%7ROJF*&,MZDBX
M4BA!6Z*GZ9(UM^7CG[<*6\ALX ++9RDQ+9EWP%CMUEGO#GRH@<<QAN1L4BGE
MT;;@0S0+.[0'L:<N&B_O&X[6N=\.9KVZK?=(VTN6"I*M%WVY5O -N@ C\U3*
MH(P276(SGAKGU/7>7-9;]X>FEV_K3E%O)],PK2\Y-YAO[J/>D:=$?VOZ>=UA
MZC\Q?Z9O;_W=/O=QK3$TN*(;5"R#W-K=Y_7E,^^O?W];_9Z +":?I[4"Z*O%
MU3F87RW?ALE\=99]^C*?77S^\GY.<EB^F_]SMKBU'%BIU\*6 9=Y518TTBF9
M+23T/(4<HR^'N:H:;LYM[P2;X[R\7HBJ%"&$I?7$-2BC T3!'1@TJ5@MT=C#
M7+X.,]_#W#@>R;IZ_(+R" AVO/>9@JM<&)WA"HL'9:6$(%@ 8X)TWOBH<+RX
M\J.\SSP&^CQY_;F+&L>ZY>H Z>?UYUX*['+=M8?T1R)&TEXH37QGI;;G##&!
M\UX F?^6%6:+%>/U7C[6Z\_6?-A%Z,VO/^\&6Z_3-YTJS+$(W/ ,JF@&H4@!
M2FC: "5&[KK$K6S^]..X0=M)Z+.F$ALDD>'6N;:^FK7"8"X97!0TP\0C!%_O
M9]'+* MG',=K3O8 WO-E02N9-U[*EU>[I;KR6!LT?YY._J?>&M4XG>6/=2W]
MY*0S@4/2LJ;IUPK)(2C0WN80DG8\E,YWXX^/=0@%]U3(@XORAM(<Y #_1']S
M<87R,L&2D7UJK+%01'7-.!FQ7JL(128GK(E8DAIMT3^ ]]-KV+J7]%-EPP27
M+9"N-LPNH$;W'#8 /93OT%.-C].BAPZ&WW[6Y=NREXD1N) M&4(VTX9;Z%NA
M2O8Q"-IV]>D1XTD?8@Q>["+Z8:HCA,67M^>SORY171V2/F:74R++&&N$0.W1
MY&HY;F6B$5X;F=)X9N@FA(<P5'JK[V%*4U_9MTZJGRU_/9]\GM#)^'8V7Z%Z
ME5+UF&K!SJL>7L5I@3$0\6,$%4W]BMN:NJ>+1QE1=VF'TF&HYZSC(:0YR/)_
M^(JXVN@*QH(YTX(T-5JL]EPE6]P!,A>CIIDK;T;; #9C_&F7;MU7&BAUD#3;
M#4_6ETNL"[+1+=1M: ]EIK;0:@>J]%#)2#O4%4)N@Q/><T#C"BBE/7B%&HS/
M24EO72SCA?V.2Y8G3==QN;*+)AK?H-')^E>8YW50S,=P?FU()>UL#I).5)[I
MW*9S&B*+#J(I)06K,=M.1=JWCG ( Z6-#F;-!=BZ/N@&5+6_Z"^S\_,P7P?
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M9PNW2107]C  GQCUQ#G16]##.@.WD/YO(FZ8_NLZ'SI'8JDC9P5EE87WQ-O
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M^&_*CV(^V.MR"Q5O)TX[_1R"1Y:1@:E$AN0Y!Z4#@WB%6&FMO=3(3YH_3S]
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MW'$(3!D@M($Q'[VTXVT]NZ(_UA# ?8)E1M+A,/;YIL!G&YA#J35P+FH[6._
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M8!J-J]]9/-Y@A!Q2B8V[W3R4(^C(V2Q)&^#1L'HG9L#IH"'13FZ,H:W];KS
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MFK!-1B\?[0JEYFR-O-/7Y2.&GCY_>@902P,$%     @ '5S_6N"6"-6R[P$
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M9^"+EXRH6^HFD)Y*5OK%5GG+#2 M._I[MC:NXX;,K%A9J04%TC[;0/$ 6B;
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MA1PO2[EJU<8S;/S $HV701FNQSCPGJUBJ*]\/D@AFBS4_ND+\F-7.HLQ9#3
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MH+X3RR#SR5X\RW0G?3'-,IW."S*4WO3=&^OE-)UG]2B1Z<(CTV(/F[RHZK;
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MOOPI),8C'!/E<STL[(OF$:\X):-]8&*BK'X1"%>9G>(- Q(-!!9./;58!&&
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MBE=D6XDN>HCC))<"Y3!'E$ 4$0PQ3U)8RDAF+&,X=[V>9$\\N,U[(.B=P^L
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MFVH;_\E$EK,TXS"-)8&HU W2RC*&<<%Q@;)(I'91-%\& F^L#^0))#]%Y;^
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MV2_F 8#&==L\8KNIM#,2>^BQ ='MU=<\$/AI+6\HG%35N(0#&FK@X<44T[@
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M0)(I6XQ(G$"*M7V.PQC1*,UH')I7K9N-Q[>='B+L^JR]F0P.[W/B-50WB[3
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M_H5S&$@9D%"&.6=&10EF(_%L/?[:)@,<),\*7+'@UV57[(FU.9M@<H $_G'
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M*KW:(S]4-=G^>5<]/GQJJJXI">=3,S8R2$0NA"*/ZZ(ML7)&<I3E4(:(1;E
MF32_69T#Q+.3UT#3 9?Z3*Y%]P;T^$ #$!P0@B%$<,1HOKN;-2736^&UB+:S
M&?^3.#;?6J_%M=N>VR_G5COR)8@:V:K/&GZU/?P2) PW]XN,YY"V495]9<:*
ME&TMAT.5^TV@7PX,I3"+.57[_D3 7"(,HRBDC#"1<)08)VV,2?)]T%F5MU ]
M=P^V6G9SM4#X=UW5N[Y0:&G0KL$B<V&4S6ESOQA'=O;\-UTVMJ^D?2#( P,6
MF1M+,>&8M^',B%W6AHF68SD;H\^OE[%AHL9)OH;1 \[9&F+_L=JIK7S9M^O6
MM6@V <Z$##(*(\FEVGOG$E*11,T&/,<)3HEUUL9909YMF1(*9"L5B$YL4Z+)
M.HWC/$VFF]/YREL:*6N]7?([1I7RG^=Q7OS:^1ZC))S)^QC_O+U3\DF9AN]J
MMI0UZ O,O:ON[XM]%_&F387@%QS^E 4TPTQM; G3Y^V$0!+3!%(I&(T2',6!
M45S:7"">S<  &C@4I!R  SVZ-_,W8+/F8]KK68ME.WOS/X9@<Z=J+:+=?"Z/
MA%LY94NP-.*SS1I^-9=N"1*&'M\BX]F_28911$J(TKO8%ET.S#NRVSWIQJ1-
M29N;ZF_Z5/^ZU"7$[A_T1]JB4"CA:40YAK$@3?9@!@G+)$P"F::"RDQFQGO@
M^7 \OU5.X_)V)Q";GB0=R+Z0U+[JFH2H7^\.2,'O-Q;UNQ::I^GWS+KLV[UM
M!L0WQ0).B%<_Z?&!%J!NU]- !-<E^/JZQ)N_?]:= +>WT%(K8*DR:LOR-O)>
M6D#(:F^GY0@9OJ,6'-6ALW73">*JY";Q@E$:$IIC#I,HE!"E@80TS@BD/ Z2
M))4LYMBX[[6%8-\!6@VYM<Y\U&R^.12T?6AB"_=.\9=6Q$Z_1'S19?>Z:%$T
MAY*+!ZQ:$6;1L]L3<8X=O9<CT*[EMP,+8PW!;89;KUVX@Y(GS<1=GG<]+?Y5
M#=L43+LNQ7\+LE-B?ZOVAY]^5/L2_>.Z;U*?9CC)PP#B6/V! IK!'.G2DB**
M<"@(2[!E-5\[ +YORK38MCZASOI]4H*;15)6>[ ]_DXJ4,TOZ^F\P&5X-SV6
M]L>FG87V0*3#>;8;&][/N2UAK7S^[4;:RW-QQW&<^TBW@0.7<Y>R#,<Y5D8K
M3973&$@&:18)F.8ARWD:YI@(RP[1XQ(]FZIW)RV1EO%]S)B<]A(7Y\?.^+P>
M-=9->Y>CR+$,QGRJ7#K1FJD]W6-V8IRUN\>:J76F+ZSA@PYWB><;,C:A_6_5
M_WE7+4/7PJT_W#]LJR?1!OY?_RB54;HK'II?;?(LRUD4IY &A$,DXQ#2B">0
M9TJF2%+,0F/SN10HSQ:VE]RFIH"JE]U4I+:XW5IJ"@RN$E^!6,MKQ4._V/>'
M?K$=RK8P+&QP]O5V0 ,''&:B^0@X@&U__0I387'I^ I3XG@F,/9U7ZH3^=)T
MC-TT+B5JO5O'A<DYN8%<>FS7 X=WU?W#3MR)LE8; (6JNA=7^_VNH(_-G4'3
M]IR=:7N^26B21CB-8,*YT-&X".9!AJ' -(]B(H,TM<S"=87B^QQX@$%?L#1Q
MN4<8NJMJB\/VS,&9>M/3AS4(M=P*#!$IYC2D-X#,9MCA,&(N.=Z/)9P!KGQ
M,9?(ET<5LT=T<LR5E*^B?MSJC&A=BO3Z<?]KP32(\G;#TS01(LQ@0E,"41#'
MD)!$]TZ+F) RQSP-+/SM,5F^0_4:Z6U!W^I1S6\OU\IO&R7+R#->B@)KAU=K
M?Y ,M&B@9,-?E^?!RBU=B@_'<+<9O-AZG"::CCN2HR.LZ1^:J/+,[3-ZQ-6
MO14Z*/V&_+PJ^;&3==V5K!+\8[5KK[,^B_U=-?S()N,Q#K(PA2R/ XAX0&$>
M<Z8K2E$A@H D8692#& ),%8FT+YX0/=EIPV^IC^MO@LYMKVO^QIP:N>K/@)T
MTZ);L+\33<NK_1.X;P#;&HH9DQ-C'2DN4DBP#B-G+((Y4M,4BDQ*K%9(3(Q*
M%ZX^.<[OI_]!DV/ZNEN'<J?W80L-*&Q @0,#T>  #RA\H(M4:!$./[<BW[:O
MU75XG_7>-?ZVGWS'AY];[D!H$<8FW]\S1*S\@I]/QDL/8($Q[5V$YOCHJWCH
M(M[UQ'S95;<[<M]%-:02!4*B$$:Q4&^9/,HA$8A 1@51N]18"O/@\BEAGM\B
M[<GT43[0 $"'P-Q635(V;?N7),+.MH]R '[_;!,I8T2&N6%>DA0WPSN3'"NC
M:JKMB-&<'&(UHVBJS-#H&3]C;]3^+$JQ(]M/I3*H]VTW EH][C\6)2E90;;?
MU/>BJ]%+ZZ:US(8E*:<93F$@(@I1Q@6D7#=Y2=,HPPD/X\#HY-I-O&?#UP$"
M T2@@00.F, 1%/B]AV5A!QPHGS:3?HFT,YQ_3 [-K:M?+MWL[?*<6IE@=TI&
MC++#H*N9:7>%AX9[QBCVIORZ%&^+[58)T<&(?WDL^4[PS^U/WE8EKS_5]:-0
MSO!G->R=GHW.[TC"*!2!R"%%/(8HR1)( REAFO \9(F(&#<N)N<*PK-95[!
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MIW^QSM!Z TK1>)G*US#NS[W<K!GL]->>"\M#@'8:/I5  SP68-<8@08)6I1
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M8M="^5*I7SX=TQTDIG&LB]GC. QTP3<&<40C&,J$9%1@%'*C-E_S8'A^]_;
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MAO)?;3N'+[,HC!VL-:EW<\1F?NL7NM1:BJ<1IVZVB-6<OZ7(&#J)BXWI4(6
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M9T3Y<8'(( Z3#":"R 3%G,><;KZ+':W,+?<E838K?"C2>*$?!8.ZDVS9G<>
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M:<_]WG5_]"M1R^;FCI0Z0ON_!6G*U?U6[8\_5TY8\_-^I4=IEDF2P91Q#%'
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MO(.92MJ^L'O]M#SP>R_1ZHUY3E.;E]A,C=W>*Z>:+V7G1U09-;WGGEO1&H[
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M2[G8BN6_R-\(8]5RGWD6*MJ (BN D!D&ZB<**$GUF7664,4@:@UK?07L@HS
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M_05$/YFR:]7RYZC>:1B1O8IO3&7C_6"K'9ELH@[JGR/FA]UMP@B-N$\\XP1
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M"\2LG'->DU>DG%YH^AFG_U6?%%KW8KVIOHF_B\5B*=:[2TA($%9D"0$%Y1S
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MM6NX3 B4)R0!12J*)E<JHCP&#*<L*ZCDT#7.K%]@X,%CA$>TE1ZQ@WC7.6X
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MNLQD]X)'_NCZ\5&L6$46G\F36+6Y,JZ7'U>:_MK[;T*M9TF28Y @HORCHL"
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MH3TRH&462UYRD+!,D7]92$ 9%(#C,LGBC.6L<$Q0<%Y08'9O&&C=B'3=3[@
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M8,NO72W!UG2+@@G637D'PO)_;-ORE1_KU7NAUD<KLPS2.=R6:W&7L3(C%$,
M>1P#F(L$4(0E$!G'<9FDC""KG71[D3-0/MLO$G@K7N\RN-^]'43/UH>?$A,W
MKNY(-M5KNX"8K))*^J01HY:6AH\='5)D[BA22V#.Q)/:ONE36$7QT5KO=JN6
M3=#JIWIY?RM6CVVA[MV9,10Y(CQ3O$!ULK(B10!14H),D(S'),ZH?<T#6Z&!
MB>*@AAD8333U0FD"5&./NPKT#KZ*-9C#+E\(B-QXHX..4J&]]*25B+06T4X-
MC^QHUC"YU'&9'B[?NBX7/JKHZ*.:Z-*2J]V]-5\LFYJQ!HR;<<<U81S?#548
M]8JN-RO"AK*LNC<XUX&.<[5.TBHX:\'.EZB\>LW.O4(_6-G.ET"Y5^X\:6%,
M_9+J7Z;1]@B^]6?V_"\YRJ 4($DRM3[)RP0@@6(@XS@6L:!8_8][!9,^D8$]
MCB^B>J1;]9K):;"IHR_B7M'1JDG<OA;-.4;KE.M=<'/3U2'.V1+88?]C>KC<
M..A$_CX,9J?!J.(F_9^=1WF3J5 :6^!DA]:J16OW+4U>X,3&8*L2)[T-O4*1
M$QO#SI<YL7K3G2R_",6WE4ZW__6!K(3.2JW@S-J/-66XU%7G@$AP"B"*(4!E
M+ #,J X9DK# V)8C>R4%I\:=[&BMA3?9S;5X^_'=C]0PZ4UFOQO7=4PW<IM4
M]UJR!\?U8V!/;9-AX<=HES&9ALBLS.OAK_[W9Z,M*S.Z;&7W@L<)Y#Z=PV'E
M=;7D+U(]?*H(K1;- 0T519HE!0>8R5@1ET" P#0#/,MDAE*:R1C;Y1OPDN_R
M"7LE(=#Y87:)2IX.FP*'A)#+S@.+@V(.1V/.F"-$!1%0@I)A J H,H#BG(.B
M+$0.RU0RB>XV.DGW*R-^T&$DWB'1M#BX#8F1XY%M)UU19X]*:7,FG]&G>3Y'
MAS/:D$#Z9RLBC_5V:6IQ+2^/]NZ?VNW @YY-9).^(*?^7&V>(UZK7^HPI[5X
M(KHN[^)YEQ1)[.[2K<FCT"6^-LTZLM9<LIFJ9H,WU'T'O<YMSG?$ZVONT>&N
M=R/N,ZUI]*_UMR8AZCMS>'Q_W/H7P>K[964.F,_LX-Q!#E-4%B5@4JII &48
MX#Q+0)I(@AG.4P3I+@OSK=W28;Q65B/V."GSK?LRH^&ZQYVB]NPV >S#\\5,
M*'I-( UR>^7>1 ?UNO-%=%!0W\[<J1AU=)P5=/LY9E[P_2:=%Y_O1)0_G>4]
M<\ $0F:;%*8#I#M+3-BJ?XH4?<&-/2CG*XXIS5G* 4*D ) 4.@L_5\NQ))6%
ME(6@TCDQRJ[QT!$^^V08.X'NF4#V.%AX\2.L<W32IS3,/;&)CX%CTYD,&NJ5
MPN2E)1:)2_:OS)ZNY*6RYY*4G#SCS@!?MU0]JIE$_.69KBJN$Y]<O">-18XS
M6&*0ZIT9*&$.*&4<I%PP!2&*>6)-#TZ2 W-'1Y>H4<9DU)GF[KD;Q,/,$PPX
M-UKZ@3"S)[5@V/DQWI08.E&B%PX]?.G6WFQDZF5FEVG]&I@B;&A?IZG-A/Q
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M<IKE]._5YD&M I5DLK@RQ6MOVP 577'NMOZP7=7KJ\T[U:1Z<7>Z_47]V21
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MS^>2?U6?A"FX=B.O/W[YJA?&BTJMH,4576]6BEOO"HP@8;%:P#*J_D-*"+"
M"*2(X$+F,,Z%E3\Y7I70/N9.K:BCESD7V6MFJJ(IW:*#<M'O._6<4Q-[=XGM
M1N <0#MZIWN,C_(1*XS7>XSK%F/6P9@,8NRQXS<6GN#;?-X*SKRW-Q;(TPV]
MT2WZTN2UFB.7]Q5=B&81;XA97P;^I:ZY+N=]1R@B)$,,)#A5?)C%*2"E=@TE
M$R4ML:1%YGK]?E"JRXCTNXEOIOIJKX=G3J!A^"1,J8AC" B&F8(O1P I-QH(
MDJ.4E1 12=VFDTG!\YDWR&KUK-VCMFJ&XJ\9<+2= R9%QXWLKU^BT)[DF+P'
M]ZWX*0G=VM;@S#VLR<P4;0W-*1?;OSI%S8Q;L7K4B57>U4O>E'%LX\$I6>ME
M_[.F_ZO52I?O>#1; [N*#3HW DUI#E!&<EU[G@ J& 4H(12G<091ZIC#:1*]
M K//<;D''4#:I"EB>SWW5RB 435Z:G2-R$%9NP(007O/EL]F[Q,WSINQ.T;6
MXQ@-WJS5.?RU?<5:':,A[J_<,;YY][U2Y8^O5.NK;[\\T@<C^R\U>UAO_NN7
M=H.+\3)-!&.@S$H,8)G$@$+. ,.%B,LDR=5?;;=*AX0%CP]JQ4=*_E^B_R"/
M3_^I5OY_BO[R'_]7"HO_U*I$__6+_?;@('C#^Z530N+JS770>##[(N_JJ)&N
M4!B^Z^T.A_UFZ92P^.V5OOA8B('G3P=\)KJ3:&MHSU[I8!.S;97:&M/=*;5^
MQ]<9O54O*B)]MUUOZD=%&E=_5.N[ B62$2@!Y(EBM1AB@$I* ,*\$ (*R*AC
M=N1S8@+SF1&IW0^V$QK]3I189X_O+$2V#MQ8P]U8R]UF#[>JSZ3@7M)9X3,[
M/7T G/HPO4^[#5L3L+UZOGOWZUT*!1&$QD"6*050Y\^C)&,@D3QF/,<TYJG-
M$#TT&7K?Z*%:$KNAUS&S?YCY*>^XA_^7ZU^OQ@^?4U7/#)6U8'^ZK[_]N7VX
M2337_N.09Z[3U"P?_JGJNX_\S%]\YZ&KQ:+^KO>V/]:K=RNA//SF0D+K&^5,
MQW+)!%"*!8!%@@!)>:;^4T)"4Y)C8I4DTE9@X,&P%^Z\53J D^VT-)WU;J-I
M+S>2]2IB1G+47.\,DC[)SL[@L]: &C//7W:@G,YDEN]YG]FW)PM-0>,KIM8E
M6Q/]]%X\K02KFF,Q<Y=HO3LBNWY\(M7*K/R7_)>54N=%*]I7DZ6 ,(YSP$FL
M2V\6.2 0YZ!,9"($YSEW+38<2M5YSV[>1.2@><0[JK_13^R5-\N[:J]^<S-;
M&Q"Q%X=!OU_Y.-C!.MZ6#7^$[G3T2H+WY.3+AM @AX]/"&7 W/$+@3OB3'Q#
M:(E^RZBK+W<YPA#K\(8,Z=N@N*  822!Q"2AC$J2$ZM+2X<F0WN.JWNA:P@Z
M+J64J79+*3<#')V_+[]\^/5VTN740=W1RRG5U*S+J8/J+Y=3G;]XW)VI%^K'
MNJDN>76_$N8P9/W;D])@N6F/2>YRDI0\YA2D$B4 LB(!.,F0SCH9DT3@DCA<
MF[&1&#R:L:-#1/9*O(FVC1J[@T>'&R!60 Z?84P.CZ.G<(3,50>95H/H<QAD
M'*[%3(V0YXV8T4BYW85QL;KO&HQ5._/=@'$QZ^CRB].+[L3X:[U\URV\UNZ8
M")8G*"$<9+ED );*^2,L)2"G,*:RY"G&5ANIET4$IKY.E3_[(7P!C&$V&V^B
M&WWI! J[JVKM?5WWBRH7K+5GJ/%6^U'2KR<5'"<Z6.TWJ(=M+KPX&[WT*][E
MDX$GO3>JS>IC_44P47W3^5@OW@M-<BES3',0XTP 2(L8J,4&! 6AB/.T+'"<
M.>Y9V\H.O0AI]- I\%M%WJB?F\V')W-U=.-\Z=8'8>O=[A"X.:Y]IH',9PO<
MU?CPN^'6&LV],>X*U9D]<N<F/*H-""F6G"PW;:J-3*(B2](<2,E3 +-4WUD3
M'(B"90DO4)PF5I<,SK0=F$CVTCP2C[Q$8=AW&6&;VV"?TBR'A/?^YOEY)PYF
MNF6B/V](7U+Y%V_,EQ_^O*I'J=XO/.(^[K^JIQ?5FK3N:XRRN) %!T6F4[27
MB*N52UP (DM8%JPD1%H=:YTV'7C4[X39#XH7E@\/=7][W$;Z3H['HN2%3?;C
MW-\VOV$^V%U.@_N\]CUC^\4+LPWM\XIV1_:%)[PO8Z[76YUC\ZG:D,5=$1<D
MQC@&/)400!1S@'/UDX02QD@*0815"O$+[8<>XJ9:#&MD.5\'/ +"ULGW-L]M
MQ#=B!DWSN<]WSH#P=_>.I,Y]3^^<R6?NY)U];$Q=4:&\\<^J7_7AXH=_;JLG
M<]"XRSB0" @A*DJ0J8D4J.%& "IX DJ<Y3CC."9VJ0P=9 8>CSOY;Z(GK8$Y
M^!<['6P2#GAC:3M\)T7(;4B/!L>S.JB5N;/4!.W7Y!4J@5I!<[[^I]VK[M[W
MV^VZ6HKU^EW]2*NE<:%^K1_53PN3</5.)C&-2X5P3 H*($PDP"B'@,<RSP0D
MRB//;=WQ 5F!R6(G/>J(CUKYD5' WLL=0FW8E9\0"S=:F!,&>^]_0CC\E@,C
M8'%:*%@:VK-R&&IAMJ6$I2G=M87M*^X\]D4H*JQT.O^F\%R[_H10,E(2G>^O
MY !F4@):%@)(5"8Y37)(F%4^@<LB K/606A;0M%^=%Z 9)B;QAOJ1DD=&]O:
MG>[[#A>,M6>@\4;[$<])!T]T%MIO3P^_7'AQ-EKI5[S+)@-/^JZDM'NU>;[:
MJ+;I=F.*4]9-V?4;^9GHH]==,73.\I3(#.1(AYME,00HCI&^-4]%%N<\RZQ\
M(W?1H4]".PKH:JW"J!4]U NN+U_JBL9D6<O*=5UEC:SM\BH$7F[<U6@0D1>(
MU48)C=2342/(-2!7ZX,ONJP5FGGMY0K4Z1+,N07O0 S^C^U:,=K?177_H/[W
MZIM8D7O1$-R=()3FNN0B3A#5U2B4.\,Q 8(EBHABD664NN:MZY7H,G"\<M:U
MTJ+EOEAZ6RF:2$5<37UH[8K_5"W;OU@F-[:%-*6XD#1F0"2Y\A!3K(M:YB7(
M&5.,KGZI?,2[3;TAB]D!/4@=#Z=]X>UP4!.))2PQ!;G@^KHK)X"2A*M)D^:9
M*&D:(\<-R.F@]I@D6]G1]U9X1$[ 5V-?+6Y6S[M>J+>;]8:86F730FL[84X&
MF-LL^7=[B,R'JKY 1A9,7Z?1M[<N?ZR3AA398!,^C*A7B[E#AVP@.1,N9/6:
M]Q1I A^5]YW!6" (\A26BK@I!YCE&&293'"6P"+3QQE.Q&T:#LS0M_H5SXRB
MK>76@]W9'K=1?=5OA,\0/-(X_%AKQ,T]J(Z,/#-ZCO_N7U%R\XELFBR?-TOQ
MWXH\=VDG<HSCA)4 DT3-PRP6 &<I!K3,DB+-4986CHF0+LH*/ ?KS0OW*HZ7
M<+$=5Y-8ZS;4E,A(1URVB7?KI8B>E=@@R\I!\V8HC7A)@]D+'@Y <:Z,X= K
M'I=\Q$87J;U>ZA+PNHJM*7.K+\QN!6\K3NC(\9PERHV6.4!%KO,VQCD@HH@!
M8VD&,U)@!KGUK1\[F8$'N-*BJ4_=Z!'I3HJZFD0'51QNSECB.;Q5'@ E1V)X
M58 <[AI-#Y3GY:,I '.[E>1F>M\U)<N6YKNWY&;:T44FQU=''PGJZ F%:+R[
M(5FRI,!2 BZR5&>#% "1% &*>4(E%C&ROU[0*VGF T(3[1-I\=Z'9R^0&F;!
MR>QWX[Z7YX;1YYWIXP\07V#@?8[HC\7HX\07F 0Y5CQOGOWIXHOW7^N0\;P9
M/6>-%U[P/G)LRH1I&FQ.&M0*<+-H974S@7?O6ETO__Y0L0==P6%]L_HJ5M\J
M)MH[6H*_K[AR1?_/EBPJ^?RQ7JG?U_=+DV+\:MUN)"2H%)#',4 \+Y2_R I
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M)=,R4N0L@Y;9&PX!Z#O^TZ%BG'WB5:,NN9)M>=^M""*<%PF-(A G!9=."&:
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M3;D5W8L7$%[-P;A&QIB+<?4=A[U3OBN_86DW^/&"PB"=SR9+292+(@0<L@)
M##' 6$0 A9E<5, XBQ@UWC,=%>5YJ)\RZ1PCW;YR=M]N< UR3E7JRA*U*"HS
M0:#!)NEBM%ANCA[E!J>[*0/)BU%@L0VZ&!6.)T4G2L21DM/GL=#.II&28SN:
MXPVLMY-II,C9#J;9&_96[+<O?Z^_\5VEVNGRP!0H#O,,1X#02&7DI2D@$"&
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MQP+/III8+Q;-4)FS\#33=YR+KPU2\@]O.+SE^S\YKP87($K>%87@<1BQ+.9
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M5W\K&W6_Z*9B^AKERTI/9R'Y'RNZ/:BX19W35L4"'3B[?>R"ZIH-1!SC$')
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M&2D^,/O/0Z/N[GSXIHIXW@@Y'#_SQWJG?O=)7V'LOO:"4IY%- -"71"$(64
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MF3C7KI&\#*T7ZB8OU+#]!L[-@TJ^]=^<O:N;_:]\K\1V*VP2(<KB) 4HSV(
M:90!PA+I36).<0(C(KC16<^X&,\&[R@X4-7&S;<@1GB9WI%91EL[*W125 E]
M$W1B'79?1E0WWW19A@*WO9;S/E^HR,BT0B/;*",OK[9[,JW <-/$X&GGO9(V
M[_D=_CY(?:XR7+2_WQ N"I@D!2 B)0!F*0,DR3!@A*1Y%!>80\LSY@F)GDV0
M3KK250TH3T$K<W*/3S!HO#Q;CA?+=5I'QS,>W@35B:M%EVQFBOI?NTW@6'L1
M9T;+A=6<X8L.!TH7UXGG\2XW3</WS;_R+9.ND:IKM(FB&&6%=%!PG$0 1J'\
M":8I8 6#<19*6\R-EG'."-;:@-4_#& %GY\%KK7( @5-KSL4.(N#%R?V#8ZH
M?'/JN$WTEZ33XF3+-ZV.9UU^Z+4[_II#S=B!F%.[ZQV1S5'[[-!L5D.S*V]^
MDI_65U6ZY5(]1![#"*<B SR.L+3V7"Y,18$!+7*19G*-FI@YB)9R?6_-/2^9
M^-AC>5XVT;G"Y"BKTU;<$U=VMOM%-<XCC.4K<H[RY5R5<RG>YE7F?,$?.^/O
M2?&W6)B7(POFE3I'6WNM:ITF*HY4[#1ZW=[2OMT>^..N5,7D64E+V>R[>O?8
M59KOOFV:HK!@&($,"F5AXP*@1 B01"$DL2 )1<86UD">9\MZ1! <(00##.;F
MP82Z:3.Z,"%VYG.""P>;:4**N:U<F!PW&SF;)"O#:*'RB$$T:64U0VBATM
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M6],WNU(NE.]_DAK=T/\ZR/]H(_GO=KAJU%KZ;5GW"90P1PCB!(A,Y'*Q&J6
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M5I\>FG<H^U,V=%NK65I=Q\2,?^:4E]\PD4#N^/?]6\G&/S:B@)"&'(&4Q F
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M0J6AW;-Y;?F$&;I"K%S&/^BOY%.;/:9Y5S?[9H.0("DD"4@0SP#,0E4;,H8
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M:DW6)=K.^ Q+(8[RNW9IDN5(6[',HC/45RO(.)?<L=*-L]MVN*IXEIOG??V
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M:+DMM4MX*][AW>Y)759\4+4![^HVL6'UF4M70P^WGZ6K\7'/'YH-YCS-4$%
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MT%BPNOWPEK(XR'./0$I] J,H2R *2 "3(.$!#S,<)8:FM;'N9MX8N@383;(
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MEX#QGG&7%!AKR<.*49 [3AN"6:%0)<]8[DX"CVGKY[*L103=V:1&E-'CH?5
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M@K%7G>IYA/!/3$M_/VGJ=?,^<:!V(CB?Y=$DW#W6?L39\HL++8,I7%M@OA;
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M8Q"0VKO]I\VNH#8)F%'+[K$%G-7+N:!.\^B0Q^Z<KD8GA+38<J0EZ+6BM$'
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M&XIMO.?HMUK7OU%2_=)!4*1VII!C(WR(H!2OMQ>UB,\:Z2S76H<.4UB/96.
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MJX;G5YS0H3A^BI9[B_*0PG:?PV-LXH)S"3YY!HI1P.U-,5""-,)2S&W%/I.
M#E^YV8O2_==__^UF'";UP[]?8/"*?(,"M2,Z*)M2'83.00?II<9BF.RRF]^)
M[/37IK)EW#U_:]J^ZH=IV-Z$^6@^+1]G2 I:?M:TD/_PES N_XUAMH7_,,EG
M*4UO:_+QY4=RKE.--PZWB4VMW( Y;44(C67NOIW.;J9$%FZ"<Y(WDBH__/+I
M\]LIR7Q$=.+][N"A*.16@@N2T!F8@* Q@4X2LTLZ<]EA"?J17#1KX9>:/M_4
M],: VNU[/#C+C3,>HG?D-.NE&Q,]&)6TS+(&B]T59YW&2]_O")T@^7D[WS(
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M%C)7<Y># QY](1CEE/VAM^YMT'EZ%ZE[A>'\8QAE@N(M$7#?MDTD9HDADH!
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M /\?>V^ZY5:.G(L^4=B8AY\JU="ZKB[IEM3MY?LG%X: DNX4MP[)5)7.T]\
MR4RE<MPD]P"6O;RL5DJE#43$AQB &+8UM=>8NYW+<E.F<F2!YI%K#5.B.02A
M0PR[.K*HXQ;/.5@FF/-U&I^M=6BDCW+R@");B580#/M<;9^ZCQ'0^$-8+]8=
M17%(9WW[K:Z0J/X6KLI_85C=)@^]IX6V92DUX6X_SY.\Z7?=U2+13O=9DD=
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M&"EJ_0L7$"Q'P"!1$,RQ&'4,).8N"QA 8,^)_PCNM0: FZ@N:O31*M",4YR
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M6!+$+)&$X#H6ARI-9K%Z;[NEQO=C.53CR+ )>+X.Z\L/J[!<[]:_""DR:YP
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MC&?D]LH^L#Q\Y68?H$Y'W\AB: ADO^'F?:!C]1)Y.MK@>+U^#I63VM8^=LD
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MVCZ_$+>2*U+6/N4^SM-MI#\-\S2>G]'&32#J)B!]V]O4UAP.G3/H4,>5*U;
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M/">_B1M!E&<"T1N_WEE1LB^0LB;*5""E&YD!)(T;Z9ASYJ=[I^B[Z[EO;,9
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MB=5-Z+9;<W!_$%@];39&+P-%&G2V-*@ZD=/;3+P2%(AXE K-=.VGGMOIW.4
MT^38#"6JIH%WXQK3OG)Q$I(SL6;!&?"Q.')HF><YLL0;@%X;QG,X7/2&W!%"
MFKO[*L;-F^5ZL[K>VH&;6FP=*5(6 2*7I+.]41 5^136)*.=0)>PSZBW1S_>
M*BR.D5TW)"-G1L+KL+[\^:K[X]4RW\ZZ_!OFCS=)%\9Q9BCZAN"9 !6(.[Y(
M"0Y=U-)%R4N?BX@7EID[7V$D= S)W)EQ\G.WPL7'_3RH]/4#.9'KJZV$;FE)
M.:@LH((?E*!?0JD.7RJ187#6R3Z/'R^M,_=CZ$A(&92]37@TOV.JK%J4!>9M
M.=/6 )=@E5"D#XVJI:'6<(A6<3+ CO N6+9L.D?FT2W.,^]O8N?Y=.&TB;']
M*71!V<QC@B!K4YG,"[CL$7P(B#8QR=-T_;^?V.3<#M$ $'@95D?(8V8[M]WV
M^^NXQO]S37R\^OJ-IFTC_NYN:]V;5.G:MD@)"3;Y7-,AB#P9 F )/*,0I=QO
M>_>HZ3MBZ>9 =(S N^FXWX36>E'#_WI; :R<Y%ABAI #'4>5%-'F I@@DB6J
M6=1Q,D76?]_SS#"=V(:.),8F(/I=0<@%2YJ51#M'5/69@1F(P7I(P025?%(N
M33?N[+NMS:W_QL+ \Q4Z!PFD"3S]=EU5]9XUZQTQ%XYY)TQ D%;7>@Z4=;X(
MQ37"^YBE3+5<?2I8/;;#N6\E)D/7R>)I F3OPNZ&Y1VNMH1<:.V]X758(%)$
MKHP,$$+A8+@KPJ9M%ZK) '9_=W-?9$P&KI/$,G,T\-C!>+/\'3^&529V[3GU
M9IE6&-;XP]>?_L156JR)I>\W7?I7]633:O&Y2O7M]E=B)L576D<'I?#ZV!H8
MA)))E7/N$F?U)=_U"!:&WUGS:3FG ;(!<38"YM]QO5DMTDU#F?4_Z>?G^'"!
M@=M@5"357^IS!A*-U@;07DFE&!,\'P+90]=O_CE[.&".*II&X??2,;S@.1>=
M+ -KD&AD',$E.F)9!&=9EJF4/B\+QZ[?_(7P>/ ;5#2-PJ^.5*4?+J)T+$C#
M:^=Q5\L*6+T,L."+08'&^.S-"2C;+]/\S<AX8#J&T3-CAES619?W#/J68;[/
M+K]@2*C7I'>SJA.=,07P,GIR:;-$G4K04O: S/.K]$*,.VO$#,CF1I3,#O'?
M2,D77B3CA10@'=9R-N/!"4LZ,V45"U>>N3YO!$\NT LF_JQA,@QS9T;(;ACX
M8T2$&)(K7$+4EL#-O(4@2P%D2C.>@\CWIYL^BI G%^AW5\K.&B+#<'?NXK [
M8>8[LJ#?;DZ*5"8Z)4&3IP^*>P'>LPC.R.0R,Y8L:P^(/+E /XB<[WWZ<-QM
MRL[L28H$\QR256@UV"!J!R99Q^EP#B5Z6XRG6/%^HG /,_/M^_T <KY7XH/Q
M=NXL!@K<PC+5UM/7J]I5:^^"KU\M]T4;J_7K;DG^>;RNTKM '77FN09R7H&J
M.68^80:1HE$R:48>>I\4A@/7[8>G\[T%'UT633R\_/3G9URN\6?B[ZXQW!HW
MFZM]W'>W]FB;UAC2]N;TS?(_+Q?I\I>NR^NWJ_>X^D*Z>#_&%O./BSI9Y/^]
M#E>+\O7G;K4?;KU%QGJ7<7D19!!\^T"E:S=^RPKQB0ZE)1,?.<LNQNF2(^;A
M0;_S<[Z7]G/S]R",-7$6;ZS7=SVU;^L3;AXT\MO5S=7R<P6"%S8DIIS)8)%
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M9ANOR\73>SU>A;]9S#_1,?CR<K%<+OZJ$Y(O4C0JHDL0D Z]8APA2H' /5U
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M$V2/M?>$9A +*C"&+-\8<O1YO!>3SML^T[C78+?E2<0[\5W:HWL%:F,,>6.
MQ0M0SF0(J#0@,J8$4>MPPA8C[;D/Q]_$)Q92>RU&HB\J295 B[ I?*,#%*2%
ME$5"SK*Q^_&R=EJ,M%Q<?ZR[T$M 350W/U*E+8WD6OKZ.NHBT:$*!')XP&/0
MRL>2;!IQ%.7/66%_'.@&$-SDK1J&Z$VA"N<1LX#BU::GBH18"T*2#@)3%")T
MFGLT5HN1EDOOQ[F&CQ?CY+A]KL>%<<I(9S1H5\?=::_ IXV;YH57SO.BN@1=
MAF@QTG(%?U^\#<G^P2[AD:KY7^2\F1 ?+G^;E\7R2SA5W?Z3"YVT0K\[B6/5
MXM<)--H[A(2X*0G3X)T10.9<$KSHJ,W4#=>.K<7_\?W;A_N:ZYAO">)%7%S=
M:AQZ_08D<Q%&.#IQZ"VHQ%R=UAZ@D&?/HK4FI/'\DAX$3)T?,"#^[EN*IQ9H
M&S'&AQ)PHA;"8E9@1)UJK)0'QQ@'SS(:491T>HJAT@=FS)T0=R>'1K=$N4/D
MU"3:MCD:6=I"1H8",EH3L<9$<KZTAIAU85RXR/28S[EGDRAWD/R[)LH=(HRI
M'V[G^')V>4E"^(#?</[/JWFF#;R>E?7WWZ]_?_,B_7M87RWK%"#:Z&>2N]QE
M[\B<,W)+3KXCWTE'6>>3:A!:,2F4JX^37=YXC]I%:\#J@X+%)")I!GQW*/KW
MJSG>(DA)%9-F 7((I/4=&@@B._ 956!$J=X?_O8,QIY8K-$,O..A-!2#)T;,
MA^_S/$LUDO**%IZM7X?J_Z^_$Z%;8DRP:#>C,D)]Z).\)BN65*,YQOD22@Y=
MBK*?76CJ<4T#(V58QC:*DH]_+79*DB4NL9!'DZPF8K('SQT'$S*=!JE1IRZA
MVV<7FN9]?G24]&-LHRAY5;.3R1O94E1$E#JY""77[&=';G",/D PF;.0N2C[
M4VX/@LK=U:9Y3Q\=+T>P^!Q*!FQ6B?-$3H4CPTME1>SB5H$LY&M$*U3(7=(Q
M!BL9&/S]^V2 &9R]C<+E1[F,9M8*3G087<UUD>N0Q82@G<M"U9%W_!BL'%:'
M-/B;]>A Z<?8B5'R>O8WYOJ$6:WTG9'^XNMR=EE#+/7]"K]@KC_?V6):.<5%
MK(&PS52$5(MF"NC$9!2>,9ZZE) <NNXTS\PGP]!)V3XUI!97RZWKM[MT=Q3^
M@FE##A%FMX3E1"?#$SG9L)J:)HEYV@K@JF J/,N0N[C8!RTZS1ORZ<!T,H:W
MBZ1MZ$FR7;,#K[-)$<GDKT.&:D-[)WD 4Y!<1&58DD?":&_%;I$_]C. Z!A>
M-Q/F>S2(N=.Z>DM=31Q3WFEPM1V<"D*"=\) J:W #"_"8Y<+[O"5NR'J'(/)
M)^']U+KI]@V^J9I[32S=$;0[*K1JYK:Z"K7SBJI]$+Q@&KAD3I;"%*HNH\ Z
M+=8-/^<301Z>PTU#1NSN9XDY>9\AI&)J_:6N+X("&.I4F.3%=/+@.RW6#3+G
M$TH>GL,-W5_?</L>=UN37M?K_C;?/<7M-&EAC-0GBR"+KQG1V8"O5S:3R:&5
M 9/KHGCZKM\-6.<3?1Y%#BVII_TGWIWWP(@8IY0%O@EM1#I%GA</-L3 A37>
M^2ZO%UW6ZH:A\XE(#\[?AO$B^<Y7""J)X!2(VCY7H6,0A")O4X3HO453.A4J
M=%FK&U[.)R ].'];Q,LV'\!OR>%H:^&" :DT67-8R)HK'L&:Q) E;VC;?>%R
M=ZEN:#F?J/30W&T1+#OP[PPY0KN0SB%$45]\O7#@&%VN+I ;$)SA:;_5\.'*
MY2!+^<P#T,?P]UP,Y>V1T#>Q+%=",0RD%!Z4\;5RL 1 %XN,Q4GKTI!V\MWE
MNZ'J?"+18TAAZDYL&->_S5?KY=7-.*X@2G!)&K N*%"B"/"2"W#H-!-9<2>Z
MS%VX_^6I4P+'2I0?@*]-H6)[BF)"%[+SH'/BU98GVTR5#$*A9&2U%2\/Q\64
M">U#R.E1D?=@VM197)OBOE^OEHO?,<^NOGS$Y9<_%NN;(2+"*:=2M:^<(U)D
MY.",RQLMFKGW68@NW>N?6:85*/21W^(TS&S1=GWJ<5])VB0=(DCUSE58G7XM
M-9GI.7N,VMK0!2@GR:DX32^[(9%S4G8W47CUJA:5XY+X>C,@S7G.N T,3(KD
MRAF&=?ZC!)TL>I:8\7*\SG7W]S=UBOKX)7Y'RJA!G.U:,"=KI<D9M!.R1IAJ
M\KT60 <%D5L1?(@3(:V-XKYC)?\,E'J(8>+[[_?P+_SX&9?A*UZM9VEW@R,:
M(Q*Q(CM+^IVG C%X#5E$I3(77KC0X99[^.MM@:"/S!:#,K )?7*8%GYSTR)%
MDB$0-R6$+&S" 8E\"2*9"XN:1V+I?B%5,XT5WAS4W?R$#Z#CWX!C2'OJ,657
M]2"^+3?I!:N=>7FA8PD&,8#+M9(1??5_O83DZ%QFE:7P75XN'E]A:@TWBG@7
M@_.Z"45(CNRFM<]U>Z@+$5(P3K&:@(*U!90A-Y:37E?(T'D3_?Y->$+]=G=O
MYQ5R/ YE@\AGZBJ?V\5M9'G\6IM#K6I/LDW;L>M#=(&T95\;M6.6ODXWUA"+
M5."5Y62;&.=DEX>R3HN=E^MWO)X:7@)M0^H=+F>+?&$-!L]#AASHH*A:WA2]
MM& ]EIR*$=AI GFGQ<[+ECHYI'I(H(E;<*]P;C=K)/B"MFPF.]E$MSF="H>Z
M9O#6W%X;@]Y/53QI@.&A/4Y=&SW-K3B O"9693<\>?&-O.E/^,LR_)47?\TO
M8G2I5F*",[(^63ERI>L/)5NM<V VYBX1]\>^/W5I]-@*:Q ^3XR5/[\2)^?K
M=^'[ETT_58QHC48)6I3:3U5$<-HB2.V3P))8XEW"57N?G;H6>FQD',/51IS]
MC[4!P&=<73!;4E(ZD-&VN7!K5@R64LO@LLW),::Z=!S;_^[4I<U3.?:]^#H8
M)D;J7/SAZLN7L/R^*+^'Y7_C>M,7>E'^P'7])Z?H8-QIP9-V,CZ<Y+$Z&G/F
MHZS=HUR1@?QZQR#&Y,!*JY04HD0S7L/>%CL:Z^R--=&"<%G4 ;ITI%4)((+U
M*9@B<#\1H9G ^SET-#X$?\-T-#Y$H$WXB+]CJ!3>Y)8AB[J@%N!BJ?53FR<T
MNAL$ZHS<%Z[->*'2O<U-C;:3 ^(>!(^13FOPVK[1"L.Y]3756=4"/5TTG4E$
M2#%$1X?5Z?T$\'$ UD9NPU$"?PH^/;@_L3OP8GW+GMD5U- V(X^Q-FZN77D$
M&:T%$['#1>W1)=:I5\0#GVY(\'U$M1B.;Q.+_=XDEUVAIF>H;2T=E[*^0<I8
MF]82'2F4H"T=!=.EL/&1ST_]##><^(?@7Q-71U\W66165) %.";RE15S$)G7
M@,7*I$)0#&6C-O6;@Y)9FGD5'L+2&4/:3<#Z]CCOQ+1DW@%C=9QW#>WX4(LY
M8@S)V:12RJ,A]< YF\V8V3VA\-1XS4/DTAM3WW 9%P/<ES\4?>76[33_[?.1
M1[K?LU20;(T YSHN(.@"C$ZDE$$9);HD2CVWSGFIK.-0,SC?6XVR[D8KOI[-
MP[P^3/Z@\D?8\>U77-+?FG_:C63\)^9/],M;?_>8P.O0>Q@D%GM2QAP9GKVN
MT;F_KYNP6$1>8B)O(*3ZD% ,F8*U/9-5@A<GE'&YRTO;4VL,:_[MG^/K?(U?
M__ZZ^7-BXFKV:5Y;C[]8;0WI_&+].LR6&V/XX^?EXNK3YW=+DN'Z[?+-8K6U
M6*(J10A!%@OC&I31 :+@#@R:5*R6:.PTEN)IZ)VN<'$P-#YM-S8 DR9,S/T@
MDN J%T87F\)"'+920A L@#%!.F]\5#A>15'#,=T6\/-L"/@08;:&QFUH(VDO
ME"8VL%(G\H9(GJ+W LA@LJPP6ZP8;^Q[\R'@@P3>(01\"/<G#P'?313?U1,[
M59AC$;CAF6X,S2 4*4 )30=*8N2N2U[(PU]O2/Q]!+88E'M-*)!;.G87SK;"
M8"X97!3$D<3)>/ UIHU>1EDXXSC>!,Q[VYO:$QX&04/QOXGGA%(]+ZQ#Y#_-
M9_^J@8&:+K#^OIL?DIQT)G!(6M9>%[7!.GG^H+W-(23M>"B=WQ:>7FMJ]7*D
M,.\]- S(V2:4S4?ZFZLM5=>UY8QL-&.-A2)RK0(F0\YK%:'(Y(0U$4M2HRF;
M>]N;6MDT;S\?)]#V,+GK&)>]3(R("-G2+6XSG=I"OQ2J9!^#H+.KIT%E&U;T
MD6)_&D8]9- $D&J>W.O+Q5_75&Q5M(_9Y93('L2:&U"GJ[G:HEV9:(371J8T
MGC'UT Z;@E(?T=\O]#E6#E-GZB_6OU[./LU(.[]>+#=4O$BI^ABUJ>EV<E]Q
M6F ,=,AB!!5-_1FWM7A.%X\RHNXR(*C#4E-?@4/AXQ2<;4+MW'_VV"CD@K%@
MSJ0(3,UMJU.IR0)U@,S%J(E3RH_7=>3A/;946]VD=36 :!N%Z/8@<QN<\)X#
M&E= *>W!*]1@?$Y*>NMB&2]=];%=3GU##H&"#M#J(9*I.U,NEG^%9=Z]_WX(
MES?7/?F^Y )+TMT\TPU!-P)$%AU$4TH*5F.VG7JI/[I">Z#H([_%X,QL$!)U
MENTOB\O+L-PE:PJ9@LX6;.V[J@0G6Y 7!.199B5+Q/T7DL[@V%]KPE?A@>3Y
M#$2.8FZ38'GU>38G,?W759B_Q_F7V3S.=N$V5[)(RM-9,H*.EA#$04<W2516
M2,>-ZS1A^L!EI^MK.QJ$AF%YDVCZ]_ U;&C#7:JX840!4QQJOT10'AVX6BT@
M.;-15!W-<V\4W5MN&AM[5/0<Q^(F4?,[_CU+8?X.5XN;(>S:>JTCI%@?F9AS
M1)R+8(Q)&1D*NN1[H^;><M.T*!H5-<>QN$G4?""#,'Q=+/'.A9Q=E$%Q!+89
M*6JP0$A,02@J6H$BE_U8]@'(>7#):?H+C8J>XUG=%H+>72W3Y["ZX9;1/F;4
M$EQ4B;@5R+ETF0/SSF26:S)A#Q-Y;Y6I0XNG]J&.86JC\+AG[GO-&=9&)PF+
MHZNVADM%T&3N"[J!O8\F]W"T'UVO&7_J*-EV@,Q1C&X6/ ^KS:"EM#&2:5]#
M<TK65KB1B+29D_:L4S2Z3=4\;-EF_*K30^EXMC>+J%=A'O(LS.]0)EDPNE[!
M)=9JW( 67$H&A+.%VR2*"SV,Y6=6;<;3.CV>CF9ZLW#Z7W1(POP_;^JZ<Z03
MX<B)1%EYYSV=D< 0G*Q\I'U9V:4E0N<%FW&\3@^B8UC=+'X>CV09%7/)7(*0
MIO8:4429D ),"JD4)D/D1^JDHP*(8[AC(RBF0=C?%KJV'N?[J]6*5.[[Q56\
MW"67>BQ"&Y- U[H%128@A&P\G: LC) N&M]EW&OG!:=^L!_ET>MX5K>%GUO'
MX^/5\K]GJ\]O9LNPLP&1H8D;+5L?D8E/$ M1&:6S0A@M4SG.]+ZWY-3=ST=S
M^H]E=[,H>NAXR)RMU\J K9EUBI-CZFOWU#KCR9'EQZ4X#D=]M=$)VYB/B*1C
M6=Y$%M!)TZW>W+2<8*7VV+4,N*R9R XCQ)@M)/0\!;(R?9FFZ^?I:)Y:IS:?
M2-<@]"8?\?U4DXV+4HHV,5@HWI,*D\D!&>6">$ZF<^VV$GB7>2A/KS)U#E6+
MJ%B<1$3GV 'GAW06Y>;/'^_U,IN_NPP)_YJM/]\MS*V-V5>7572GZI-SNIV>
MO)O.2$P^=<\=B[69(R^053#DG4FRL)T(@(&Q8.CP\>*ZF)^3]=RI\^%7M=?V
M8DYJAWYW6_*PE_<[S_]<_/7Q,WY_40JF]>NK-7UM5^^RO2G)+!2:JP)TSNL@
M@Q# ,9T@R!288$&Z$?L_C$-SH[UW#D'E83;+1'!IPHW8[^#ADG QYTRW'UVJ
MJG@&,4D+F(64C!433!D-[V?4?V<J##W;@^<0@;:&R&T$P NK+ L(1F,"I:.&
MH!-!)B,Y*I%)X<8;S=%\#YZ#!-ZA!\\AW&^S!P_RRH5"MKT.F0Y4,>0RU)0R
MK9CSL:C0*;!_+CUX#A+8\SUX#N%>$PKD?ML0KXHN7GLPZ%4E(9-?EPL8YKWG
MZ)27X[7%.(,>/'T0-!3_FX#0(T6"'J,H@>YCY=SF**0:)*[I\-QXDV+!_?;$
M;58!3]1CI1D;:0#Q-@K3[0&66=<,(0M1":)$>;(&I&. #KGUP4H>Q[/BSZP2
M^" 4=*\$/D0D;3U6WL[[CTJ638_PH'VZ?CAPS"I(2M#50%N-O,MLW#.L!#Y(
M?MTJ@0]A9H.0N)]4':)((JI:"A)K48@ IQ,='QE<-143JA[I?>=3"7R0/ ^M
M!#Z$N4V"Y>&TZ5B*(>\TT#FJ4;V$=,!2\L 99V0L9F0I]L9,VYGJIX/.\:QN
M$D'OR"O-'VB%RQ\-AF0Q6GCR3500Q#B6Z5@X:2"E(&PVY,#XOJTI'ERPF;ST
MTZ'G6#:WA9W]-%GFC,]<.M"6U8Y4MH +I%$UN11*(A-YOX7<SU2+-Y 5<PQ3
M&X7'_=8;4F4Z.QEB\):< :D@Y$B_+$BJLJ *LDM3N+.OQ3M(MGUJ\0YA=+/@
M>?C*U=Z'C*2)A99TW&3TX+5!",(I%*4D[XXI_&W=PCD]E(YG>[.(NM^(@]MH
M;0YU,JHB]F$.X*U18%/4/'N;K>Q1H/#4DLU8.Z='TG'L;A9%.UW[YX>7BWG>
M^9)9R,*U![3%U#$='+R('!)S,C!C7-$]FE@\LVJSY2Y#VT0#,+UY.+U:?/F"
MRYJJ\RY\Q9W>Y9S7?HD>$D:ZR:TUX)DO$&7401IEK#RN*N_)Y:?.VYX 8,>+
MH2VD/=O!+/%0.Z,',!:)E=H)".CHEX'7-L6Z"-\W_MQ<S>?(0>FAV-XFHAZJ
ML5>V\&)"!FEK%_-@!#@?:LV/(IH"M\X<T8&P;U,#<_XX.I;9;4'HEM[]YQ6Y
M&TLB[?7E8CG[,::JYD7D5)M4&4?L<X5<C6RA2):"S+E(TVE(Z8'K=H*3/5\X
M#<OXB4'U:KE8K6X.RE_AZZ]_?YT1*9\(!GX7Q\W::T4.#;$OU#',"GQ.='OS
MR)VVJ(/M\H#68:E.T'%G!)VAV=LN6J38D>-*M,)F8)J1F5<[=&[RXZ7-TC#'
MDF)=GCXZ+-4)+?[G0$LO]K:&EET3&.E\8>1MBE3JO'CGZ<Y%4H_6LAR%(QAT
MN9<>^7RWB#4[9UCTX&-34,#+2UQ60FZ:Q#COK,,:A @*5(RLMNP4$#&7&".2
MU]AE>N#3JW0#QCDE\0S(U4;Q<>]51GN&FQS@'+TFEZ]V>)6BWIW.1,%2R?YP
MW?'X>MTP<TY/IB?A=!-II[^']=5RMOZ^29<TJD@=382"M=R$,PU18P'ND_!>
M!ZW4B,4YMW8V=;SY+#*A>XNR*2!N3RJZI*0@:&CC(BA+AS3$Y.K!#<E&P_F(
M<R;O[FWJM-;^<GX4,CV8W@1H_EBLWP3ZX,?/8?YVCO^%/QJ.6YVX%PYR"?IZ
MVCBI9E%?_4(P7F@GPVCX>72;K4"IC_SO@6D8832!JWTZ2'O?IN[C7XOZNSN3
M,1 M= X]L)BKVJYG4!D-5IM@0R5N/U?ZA%@[:.M3Y[8-BK_3":T)3)[<!GES
MTY?'!!E2HO/*8^W+PU3U@0P#<H!*XBF$Z,:KC1N/[JD?G<_"RFP4ADTW#?NX
M^#W,PZ<??[;KGG5!]II/JHK!Z]H()08(B!&L38G4GT63NW2'[+G\U.9'JUCJ
MW&IL&,$V<;W<[1=P@:88S#J#-(GX96P"9WBJ=EMR0:)F(8]I/]_:V]1&2^.H
M'42D34#R@;/W8K7"]>I"N#KGG)OJ\-(10R?!>9= 6F>E=%%R$<<S4![;YD\?
MM1H*J,,(NE7,OIF%.+LD)N/JP@IOI+8.BJ(;05FO(:A0H!#O1"Q&V_U7O'&!
M>VNO/[TU?$+T]A5Y$Q#^![GBJ]JH%5=OYSMN5>[BZB62'/!C^/O".U?(&V=@
M:S2'O'8%KI)F6!3!BFC#B%TINNQXZKS/LX'SX.(_]Q:[MW][A#ZY#RPW:K/;
MY\@]=<?:XG0.IM2F9!G)<_(*"%&6?HB)^U20V4X)F*-UK'W0,=Q$6H3,*FDA
M(#"?R7H)9'$KLKT=-XD.B28O<$0SM<N6&^T7>P@FG@Y9#2.L)N[I1WH>197(
MJ_,6/!I>Y_$01<5EB*JD5 1:)<=[.3VBL=E(<:>! -&U+]DATFD49=O'FI*]
M,!@C2+KY:P9N >^%ARB<U,8+E\1XKUYGUI?L(!1T[TMVB$@F#IC_-J?OX&K]
M/JQQDTKU+GQ_%;[.UN%R]B_,']Z^?O_GAU_>8T(R63B3N\++Q".3S(%-ABX"
M;QFXFO8ME?1*RX#1YP[&0;_5VP-3'[DO1A7"6<'L)E_<RJ)3L@&L*$0AN5"D
M^B6')*(36F7KL4LGJWZK3QW?GAAFO830-LQ^7=$?;^EC9E?"PB4S6BL%68MJ
MU.H ?E/'XLC@$$ID70;090^N/75D>FR('2^ ,P*8WQT@4LIDM$I+S#2:#E#V
MX&S*('R.V7&EA.G28Z3/VE,'CR<%6"\!G _ Z)K?9;M75<PB&:_6*2";5M#9
M\0X$YZ2>L]4A=FFKU6?MJ<.Y4P*LGP#:!MB>$?!O;'>&I,O,,D.'QFA1XS^1
MK( 0095B+=?&N= E0Z;G\LU6^8]CB_430]M(NW.2_DV;+8%%HU!&DX;.U24W
M3H,K">F7UC#'BXRV2WNW7HLW6_P_AC+K)X(F8F/[XWJ"M@ZCUI!T3?KBQH&O
MLS8469)2,<&-VNM'VMC K9&RIDX5<SU&'JT!:GL"-9J,PC!(WA()AOS?4+O7
M*6950"49J9\I(-5&>/4H@7>8EW4(]]N<EQ6Y%B:@!!XK!4*3>QNC!FFRM9*4
M.'8:5WPN\[(.$MCS\[(.X5X3"N3^O";K2U1:9[ UM*%<1@B*(="-JIDUD;R'
M\1)YSV!>5A\$#<7_B57(9MO7F4=(UMGBT[P::[_-?_V_5[/U]YLV35%P%@,8
M7VOY1*YU4TH ,2V7$I-+JDMZ1I>UIHY2#J=>!N=L$\KF3B%RC,+K0):;S9:,
M]]I<-P07H6B/I02#@8]H^S;:.^!DAF]?232%H^TA2R$5S,X#V7"E]H.V$(H5
MP"P*=#$DOO\N\C^S]/\@.3]7^G\(TYL S>/5YJB52 X59!.1;EQEZ[LAT6,<
MCYGTJK/C=3$YE]+_@^1_0.G_(<)H E>'59$G)HH2W ,F0V9 D Q<T!ZR"(8%
M(L^S\:;1GG/I_W'X.YW0VL+DCI!]^@A:>)M"9,)%61!TL$1AR06\#1X8&E<'
M9ECZX_%AV7'W4QMLIT'F*437&#AO2-FC\?7B:GF;1)X2][9D$)D.H1*ZCI!V
M"$QC;=Z:4O3CQ30/WO[4J0TG@N<IA-<6/F\HV:=P]NW."2R^%DIK!:A4JO7[
M$6+B ;CC/ F3PKTQEF/ L^/NI\Z+. TZ3R&Z)L#YD?[FMM@/KU/#N66)9\S
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MB-PRL#Y:*4T17(Z8W#!0RO0)P7I:U/3*H3Y$A.> RYLQ\\(DI2I%H8"2=>Z
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M'EVCPTINZF#<<>]<,:>RRZ2X%?EQRKC:Z-'6- G46(PIHL@IH'&WW^G']T:
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M]:"/V>*"?J:?UK-\&R0H3,C"965NR:#\MMDY]R"#],PH%-TJNX[<1NOA!J,
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MA)9!:!H@0MYG[6WW72&*MD4E2,F9&I8EH]D18Y/4UCB4PO,1@^=]R6C]@-,
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M PAJVKB[:6"J.8JB$A3&:PH2*G H)/W$2RR<VR@F@+Q)9;@/ 8WNL.LAITD
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M3:(_8N A*C+MNU3&?W>A:4&CCR27IV)K2XRL-C=NXMO5SDG<'AMA3#'2!-+
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M'N9N>C"$(I0NY)[5ILC*L%1#3UB'TGM6!^ZR$2/&>S;86LD=*?;G8=1#!M,
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M,C R-3 V,S N:'1M4$L! A0#%     @ '5S_6M <M(GC.   :^<" !
M         ( !2#0  '-N>2TR,#(U,#8S,"YX<V102P$"% ,4    "  =7/]:
M9C#M3*@S  !=& ( %               @ %9;0  <VYY+3(P,C4P-C,P7V-A
M;"YX;6Q02P$"% ,4    "  =7/]:Z$8!K7:- 0#@I1< $P
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4!08     !P ' ,4!  "63P8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>sny-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sny="http://www.sanofi.com/20250630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sny-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-27</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-27</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VigilNeuroscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VigilNeuroscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-22</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-02</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-29</startDate>
            <endDate>2025-01-29</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-02</startDate>
            <endDate>2025-02-02</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionFiveHundredMillionBondsIssuedInMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionFiveHundredMillionBondsIssuedInJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingJune2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromApril2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromApril2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:UKZONEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:EUROZONEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichSanofiAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:VicebioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="proceeding">
        <measure>sny:proceeding</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-4">0001121404</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-6">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-7">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-8">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">SANOFI</dei:EntityRegistrantName>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-6" id="f-9" unitRef="eur">9574000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-10" unitRef="eur">10091000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-2" decimals="-6" id="f-11" unitRef="eur">1433000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-6" id="f-12" unitRef="eur">1510000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-13" unitRef="eur">40283000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-14" unitRef="eur">43384000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-6" id="f-15" unitRef="eur">20431000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-16" unitRef="eur">22629000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-17" unitRef="eur">3563000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-18" unitRef="eur">316000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-19" unitRef="eur">4109000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-20" unitRef="eur">3753000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-2" decimals="-6" id="f-21" unitRef="eur">541000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-3" decimals="-6" id="f-22" unitRef="eur">560000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:DeferredTaxAssets contextRef="c-2" decimals="-6" id="f-23" unitRef="eur">8008000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-3" decimals="-6" id="f-24" unitRef="eur">7967000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-6" id="f-25" unitRef="eur">87942000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-6" id="f-26" unitRef="eur">90210000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-2" decimals="-6" id="f-27" unitRef="eur">9618000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-3" decimals="-6" id="f-28" unitRef="eur">9431000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-29" unitRef="eur">7810000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-30" unitRef="eur">7677000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-6" id="f-31" unitRef="eur">3595000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-6" id="f-32" unitRef="eur">3826000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-2" decimals="-6" id="f-33" unitRef="eur">397000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-3" decimals="-6" id="f-34" unitRef="eur">724000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-35" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-36" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-37" unitRef="eur">238000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-38" unitRef="eur">13489000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentAssets contextRef="c-2" decimals="-6" id="f-39" unitRef="eur">37017000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-6" id="f-40" unitRef="eur">42588000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-2" decimals="-6" id="f-41" unitRef="eur">124959000000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-6" id="f-42" unitRef="eur">132798000000</ifrs-full:Assets>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-2" decimals="-6" id="f-43" unitRef="eur">70008000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-3" decimals="-6" id="f-44" unitRef="eur">77507000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c-2" decimals="-6" id="f-45" unitRef="eur">271000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-3" decimals="-6" id="f-46" unitRef="eur">350000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-47" unitRef="eur">70279000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-48" unitRef="eur">77857000000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-49" unitRef="eur">13200000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-50" unitRef="eur">11791000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-51" unitRef="eur">1524000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-52" unitRef="eur">1645000000</ifrs-full:NoncurrentLeaseLiabilities>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-53" unitRef="eur">564000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-54" unitRef="eur">569000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-55" unitRef="eur">7116000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-56" unitRef="eur">8096000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-2" decimals="-6" id="f-57" unitRef="eur">1502000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-3" decimals="-6" id="f-58" unitRef="eur">1512000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-2" decimals="-6" id="f-59" unitRef="eur">1715000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-3" decimals="-6" id="f-60" unitRef="eur">2166000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-61" unitRef="eur">25621000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-62" unitRef="eur">25779000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-2" decimals="-6" id="f-63" unitRef="eur">7075000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-6" id="f-64" unitRef="eur">7551000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-65" unitRef="eur">0</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-66" unitRef="eur">72000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-2" decimals="-6" id="f-67" unitRef="eur">13697000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-3" decimals="-6" id="f-68" unitRef="eur">14241000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-2" decimals="-6" id="f-69" unitRef="eur">724000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-3" decimals="-6" id="f-70" unitRef="eur">697000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-71" unitRef="eur">252000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-72" unitRef="eur">261000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-73" unitRef="eur">7309000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-74" unitRef="eur">4209000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-75" unitRef="eur">2000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-76" unitRef="eur">2131000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentLiabilities contextRef="c-2" decimals="-6" id="f-77" unitRef="eur">29059000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-6" id="f-78" unitRef="eur">29162000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-6" id="f-79" unitRef="eur">124959000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-6" id="f-80" unitRef="eur">132798000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-81" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-82" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-83" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-4" decimals="-6" id="f-84" unitRef="eur">1529000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-6" id="f-85" unitRef="eur">5881000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-4" decimals="-6" id="f-86" unitRef="eur">5966000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c-1" decimals="-6" id="f-87" unitRef="eur">15460000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-4" decimals="-6" id="f-88" unitRef="eur">13923000000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-89" unitRef="eur">3717000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-6" id="f-90" unitRef="eur">3335000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-91" unitRef="eur">4506000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-6" id="f-92" unitRef="eur">4303000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-93" unitRef="eur">533000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-94" unitRef="eur">563000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-95" unitRef="eur">2476000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-96" unitRef="eur">1977000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-97" unitRef="eur">777000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-98" unitRef="eur">898000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-99" unitRef="eur">210000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-100" unitRef="eur">-371000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-1" decimals="-6" id="f-101" unitRef="eur">61000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-4" decimals="-6" id="f-102" unitRef="eur">66000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-103" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-104" unitRef="eur">1060000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-105" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-106" unitRef="eur">-450000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-107" unitRef="eur">3759000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-108" unitRef="eur">2768000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-109" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-110" unitRef="eur">583000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-111" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-112" unitRef="eur">277000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-113" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-114" unitRef="eur">2462000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-115" unitRef="eur">711000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-116" unitRef="eur">379000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-117" unitRef="eur">85000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-118" unitRef="eur">-22000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c-1" decimals="-6" id="f-119" unitRef="eur">2956000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c-4" decimals="-6" id="f-120" unitRef="eur">2061000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-121" unitRef="eur">2881000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-122" unitRef="eur">202000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-123" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-124" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-125" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-126" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-127" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-128" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="INF" id="f-129" unitRef="shares">1225500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="INF" id="f-130" unitRef="shares">1249400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="INF" id="f-131" unitRef="shares">1230700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="INF" id="f-132" unitRef="shares">1253800000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="INF"
      id="f-133"
      unitRef="eurPerShare">2.40</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="INF"
      id="f-134"
      unitRef="eurPerShare">1.64</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="INF"
      id="f-135"
      unitRef="eurPerShare">2.34</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="INF"
      id="f-136"
      unitRef="eurPerShare">0.16</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="INF"
      id="f-137"
      unitRef="eurPerShare">4.74</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-4"
      decimals="INF"
      id="f-138"
      unitRef="eurPerShare">1.80</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="INF"
      id="f-139"
      unitRef="eurPerShare">2.39</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="INF"
      id="f-140"
      unitRef="eurPerShare">1.63</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="INF"
      id="f-141"
      unitRef="eurPerShare">2.33</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="INF"
      id="f-142"
      unitRef="eurPerShare">0.16</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="INF"
      id="f-143"
      unitRef="eurPerShare">4.72</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-4"
      decimals="INF"
      id="f-144"
      unitRef="eurPerShare">1.79</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-145" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-146" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-147" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-148" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-149" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-150" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-6" id="f-151" unitRef="eur">-111000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-4" decimals="-6" id="f-152" unitRef="eur">-235000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-1" decimals="-6" id="f-153" unitRef="eur">222000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-4" decimals="-6" id="f-154" unitRef="eur">-10000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-155" unitRef="eur">92000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-156" unitRef="eur">59000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-157" unitRef="eur">241000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-158" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-1" decimals="-6" id="f-159" unitRef="eur">3000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-4" decimals="-6" id="f-160" unitRef="eur">-5000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1" decimals="-6" id="f-161" unitRef="eur">-23000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-4" decimals="-6" id="f-162" unitRef="eur">-3000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-6" id="f-163" unitRef="eur">-5203000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-4" decimals="-6" id="f-164" unitRef="eur">1040000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-165" unitRef="eur">95000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-166" unitRef="eur">-35000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-167" unitRef="eur">-5318000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-168" unitRef="eur">1067000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:OtherComprehensiveIncomeFromContinuedOperations contextRef="c-1" decimals="-6" id="f-169" unitRef="eur">-5077000000</sny:OtherComprehensiveIncomeFromContinuedOperations>
    <sny:OtherComprehensiveIncomeFromContinuedOperations contextRef="c-4" decimals="-6" id="f-170" unitRef="eur">1233000000</sny:OtherComprehensiveIncomeFromContinuedOperations>
    <sny:OtherComprehensiveIncomeFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-171" unitRef="eur">303000000</sny:OtherComprehensiveIncomeFromDiscontinuedOperations>
    <sny:OtherComprehensiveIncomeFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-172" unitRef="eur">-23000000</sny:OtherComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-173" unitRef="eur">1063000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-174" unitRef="eur">3496000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-175" unitRef="eur">1076000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-176" unitRef="eur">3471000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations contextRef="c-1" decimals="-6" id="f-177" unitRef="eur">-2097000000</sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations>
    <sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations contextRef="c-4" decimals="-6" id="f-178" unitRef="eur">3264000000</sny:ComprehensiveIncomeAttributableToOwnersOfParentContinuingOperations>
    <sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-179" unitRef="eur">3173000000</sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations>
    <sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-180" unitRef="eur">207000000</sny:ComprehensiveIncomeAttributableToOwnersOfParentDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-181" unitRef="eur">-13000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-182" unitRef="eur">25000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-5" decimals="-6" id="f-183" unitRef="eur">2530000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-6" id="f-184" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-185" unitRef="eur">-1184000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-186" unitRef="eur">67499000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-6" id="f-187" unitRef="eur">4944000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-6" id="f-188" unitRef="eur">-62000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-6" id="f-189" unitRef="eur">74040000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-6" id="f-190" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-6" id="f-191" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-14" decimals="-6" id="f-192" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-15" decimals="-6" id="f-193" unitRef="eur">1059000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-16" decimals="-6" id="f-194" unitRef="eur">1225000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-17" decimals="-6" id="f-195" unitRef="eur">8000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-4" decimals="-6" id="f-196" unitRef="eur">1233000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-14" decimals="-6" id="f-197" unitRef="eur">2246000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-16" decimals="-6" id="f-198" unitRef="eur">2246000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-17" decimals="-6" id="f-199" unitRef="eur">17000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-200" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-14" decimals="-6" id="f-201" unitRef="eur">2412000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-6" id="f-202" unitRef="eur">1059000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-6" id="f-203" unitRef="eur">3471000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-17" decimals="-6" id="f-204" unitRef="eur">25000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-205" unitRef="eur">3496000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-4"
      decimals="INF"
      id="f-206"
      unitRef="eurPerShare">3.76</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-14" decimals="-6" id="f-207" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-16" decimals="-6" id="f-208" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-4" decimals="-6" id="f-209" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-16" decimals="-6" id="f-210" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-17" decimals="-6" id="f-211" unitRef="eur">31000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-212" unitRef="eur">31000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-18" decimals="-6" id="f-213" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-16" decimals="-6" id="f-214" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-4" decimals="-6" id="f-215" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-19" decimals="-6" id="f-216" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-20" decimals="-6" id="f-217" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-16" decimals="-6" id="f-218" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-4" decimals="-6" id="f-219" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-19" decimals="-6" id="f-220" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-20" decimals="-6" id="f-221" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-18" decimals="-6" id="f-222" unitRef="eur">115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-14" decimals="-6" id="f-223" unitRef="eur">-115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-16" decimals="-6" id="f-224" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-4" decimals="-6" id="f-225" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-21" decimals="-6" id="f-226" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-16" decimals="-6" id="f-227" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-4" decimals="-6" id="f-228" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-21" decimals="-6" id="f-229" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-16" decimals="-6" id="f-230" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-4" decimals="-6" id="f-231" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-14" decimals="-6" id="f-232" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-16" decimals="-6" id="f-233" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-4" decimals="-6" id="f-234" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <ifrs-full:Equity contextRef="c-22" decimals="-6" id="f-235" unitRef="eur">2533000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-6" id="f-236" unitRef="eur">317000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-6" id="f-237" unitRef="eur">-1371000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-6" id="f-238" unitRef="eur">65093000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-6" id="f-239" unitRef="eur">5121000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-6" id="f-240" unitRef="eur">997000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-6" id="f-241" unitRef="eur">72690000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-6" id="f-242" unitRef="eur">307000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-6" id="f-243" unitRef="eur">72997000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-31" decimals="-6" id="f-244" unitRef="eur">-194000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-32" decimals="-6" id="f-245" unitRef="eur">1379000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-33" decimals="-6" id="f-246" unitRef="eur">1185000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-34" decimals="-6" id="f-247" unitRef="eur">14000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-35" decimals="-6" id="f-248" unitRef="eur">1199000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-31" decimals="-6" id="f-249" unitRef="eur">3314000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-33" decimals="-6" id="f-250" unitRef="eur">3314000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-34" decimals="-6" id="f-251" unitRef="eur">41000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-35" decimals="-6" id="f-252" unitRef="eur">3355000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-31" decimals="-6" id="f-253" unitRef="eur">3120000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-6" id="f-254" unitRef="eur">1379000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-33" decimals="-6" id="f-255" unitRef="eur">4499000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-34" decimals="-6" id="f-256" unitRef="eur">55000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-35" decimals="-6" id="f-257" unitRef="eur">4554000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-34" decimals="-6" id="f-258" unitRef="eur">13000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-35" decimals="-6" id="f-259" unitRef="eur">13000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-36" decimals="-6" id="f-260" unitRef="eur">0</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-33" decimals="-6" id="f-261" unitRef="eur">0</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-35" decimals="-6" id="f-262" unitRef="eur">0</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-37" decimals="-6" id="f-263" unitRef="eur">12000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-38" decimals="-6" id="f-264" unitRef="eur">492000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-36" decimals="-6" id="f-265" unitRef="eur">-530000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-31" decimals="-6" id="f-266" unitRef="eur">26000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-33" decimals="-6" id="f-267" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-35" decimals="-6" id="f-268" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-37" decimals="-6" id="f-269" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-38" decimals="-6" id="f-270" unitRef="eur">25000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-33" decimals="-6" id="f-271" unitRef="eur">26000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-35" decimals="-6" id="f-272" unitRef="eur">26000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-37" decimals="-6" id="f-273" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-38" decimals="-6" id="f-274" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-36" decimals="-6" id="f-275" unitRef="eur">1000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-31" decimals="-6" id="f-276" unitRef="eur">-1000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-35" decimals="-6" id="f-277" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-37" decimals="-6" id="f-278" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-38" decimals="-6" id="f-279" unitRef="eur">150000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-33" decimals="-6" id="f-280" unitRef="eur">154000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-35" decimals="-6" id="f-281" unitRef="eur">154000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-39" decimals="-6" id="f-282" unitRef="eur">132000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-33" decimals="-6" id="f-283" unitRef="eur">132000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-35" decimals="-6" id="f-284" unitRef="eur">132000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-39" decimals="-6" id="f-285" unitRef="eur">7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-33" decimals="-6" id="f-286" unitRef="eur">7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-35" decimals="-6" id="f-287" unitRef="eur">7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c-31" decimals="-6" id="f-288" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c-33" decimals="-6" id="f-289" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c-34" decimals="-6" id="f-290" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c-35" decimals="-6" id="f-291" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:Equity contextRef="c-40" decimals="-6" id="f-292" unitRef="eur">2526000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-6" id="f-293" unitRef="eur">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-42" decimals="-6" id="f-294" unitRef="eur">-840000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-6" id="f-295" unitRef="eur">68185000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-6" id="f-296" unitRef="eur">5260000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-297" unitRef="eur">2376000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-298" unitRef="eur">77507000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-299" unitRef="eur">350000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-300" unitRef="eur">77857000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-6" id="f-301" unitRef="eur">2526000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-6" id="f-302" unitRef="eur">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-42" decimals="-6" id="f-303" unitRef="eur">-840000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-6" id="f-304" unitRef="eur">68185000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-6" id="f-305" unitRef="eur">5260000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-306" unitRef="eur">2376000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-307" unitRef="eur">77507000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-308" unitRef="eur">350000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-309" unitRef="eur">77857000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-48" decimals="-6" id="f-310" unitRef="eur">243000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-49" decimals="-6" id="f-311" unitRef="eur">-4979000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-50" decimals="-6" id="f-312" unitRef="eur">-4736000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-51" decimals="-6" id="f-313" unitRef="eur">-38000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-314" unitRef="eur">-4774000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-48" decimals="-6" id="f-315" unitRef="eur">5812000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-50" decimals="-6" id="f-316" unitRef="eur">5812000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-51" decimals="-6" id="f-317" unitRef="eur">25000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-318" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-48" decimals="-6" id="f-319" unitRef="eur">6055000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-49" decimals="-6" id="f-320" unitRef="eur">-4979000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-50" decimals="-6" id="f-321" unitRef="eur">1076000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-51" decimals="-6" id="f-322" unitRef="eur">-13000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-323" unitRef="eur">1063000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-1"
      decimals="INF"
      id="f-324"
      unitRef="eurPerShare">3.92</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-48" decimals="-6" id="f-325" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-50" decimals="-6" id="f-326" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-1" decimals="-6" id="f-327" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-50" decimals="-6" id="f-328" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-51" decimals="-6" id="f-329" unitRef="eur">32000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-330" unitRef="eur">32000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-52" decimals="-6" id="f-331" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-50" decimals="-6" id="f-332" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-1" decimals="-6" id="f-333" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-53" decimals="-6" id="f-334" unitRef="eur">74000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-52" decimals="-6" id="f-335" unitRef="eur">-3868000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-48" decimals="-6" id="f-336" unitRef="eur">3794000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-1" decimals="-6" id="f-337" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <sny:TaxesOnShareCancellations contextRef="c-52" decimals="-6" id="f-338" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-50" decimals="-6" id="f-339" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-1" decimals="-6" id="f-340" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-53" decimals="-6" id="f-341" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-54" decimals="-6" id="f-342" unitRef="eur">14000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-50" decimals="-6" id="f-343" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-6" id="f-344" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-53" decimals="-6" id="f-345" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-54" decimals="-6" id="f-346" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-52" decimals="-6" id="f-347" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-48" decimals="-6" id="f-348" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-50" decimals="-6" id="f-349" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-1" decimals="-6" id="f-350" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-55" decimals="-6" id="f-351" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-50" decimals="-6" id="f-352" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-1" decimals="-6" id="f-353" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-55" decimals="-6" id="f-354" unitRef="eur">-7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-50" decimals="-6" id="f-355" unitRef="eur">-7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-1" decimals="-6" id="f-356" unitRef="eur">-7000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-48" decimals="-6" id="f-357" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-50" decimals="-6" id="f-358" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-1" decimals="-6" id="f-359" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-48" decimals="-6" id="f-360" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-50" decimals="-6" id="f-361" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-51" decimals="-6" id="f-362" unitRef="eur">-34000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-1" decimals="-6" id="f-363" unitRef="eur">-34000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:Equity contextRef="c-56" decimals="-6" id="f-364" unitRef="eur">2456000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-57" decimals="-6" id="f-365" unitRef="eur">11000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-58" decimals="-6" id="f-366" unitRef="eur">-975000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-59" decimals="-6" id="f-367" unitRef="eur">65689000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-60" decimals="-6" id="f-368" unitRef="eur">5430000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-61" decimals="-6" id="f-369" unitRef="eur">-2603000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-62" decimals="-6" id="f-370" unitRef="eur">70008000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-6" id="f-371" unitRef="eur">271000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-372" unitRef="eur">70279000000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-6" id="f-373" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-4" decimals="-6" id="f-374" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <sny:AdjustmentsForLossesGainsOnTransferOfBusiness contextRef="c-1" decimals="-6" id="f-375" unitRef="eur">-2881000000</sny:AdjustmentsForLossesGainsOnTransferOfBusiness>
    <sny:AdjustmentsForLossesGainsOnTransferOfBusiness contextRef="c-4" decimals="-6" id="f-376" unitRef="eur">-202000000</sny:AdjustmentsForLossesGainsOnTransferOfBusiness>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-377" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-378" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-379" unitRef="eur">15000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-380" unitRef="eur">-96000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-1" decimals="-6" id="f-381" unitRef="eur">1779000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-4" decimals="-6" id="f-382" unitRef="eur">1242000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-1" decimals="-6" id="f-383" unitRef="eur">-266000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-4" decimals="-6" id="f-384" unitRef="eur">-229000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-1" decimals="-6" id="f-385" unitRef="eur">-539000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-4" decimals="-6" id="f-386" unitRef="eur">-749000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1" decimals="-6" id="f-387" unitRef="eur">-212000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-4" decimals="-6" id="f-388" unitRef="eur">1002000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-6" id="f-389" unitRef="eur">171000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-4" decimals="-6" id="f-390" unitRef="eur">157000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-1" decimals="-6" id="f-391" unitRef="eur">0</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-4" decimals="-6" id="f-392" unitRef="eur">7000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-1" decimals="-6" id="f-393" unitRef="eur">106000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-4" decimals="-6" id="f-394" unitRef="eur">21000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-6" id="f-395" unitRef="eur">3980000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-4" decimals="-6" id="f-396" unitRef="eur">3608000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-6" id="f-397" unitRef="eur">-635000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-4" decimals="-6" id="f-398" unitRef="eur">-917000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-6" id="f-399" unitRef="eur">-785000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-4" decimals="-6" id="f-400" unitRef="eur">81000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-1" decimals="-6" id="f-401" unitRef="eur">187000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-4" decimals="-6" id="f-402" unitRef="eur">78000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-1" decimals="-6" id="f-403" unitRef="eur">620000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-4" decimals="-6" id="f-404" unitRef="eur">-1612000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="c-1" decimals="-6" id="f-405" unitRef="eur">3367000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="c-4" decimals="-6" id="f-406" unitRef="eur">1238000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-407" unitRef="eur">188000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-408" unitRef="eur">184000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-409" unitRef="eur">3555000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-4" decimals="-6" id="f-410" unitRef="eur">1422000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-411" unitRef="eur">1420000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-412" unitRef="eur">1804000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-413" unitRef="eur">538000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-414" unitRef="eur">1885000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-415" unitRef="eur">423000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-416" unitRef="eur">208000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-417" unitRef="eur">434000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-418" unitRef="eur">516000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-419" unitRef="eur">0</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-420" unitRef="eur">42000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-1" decimals="-6" id="f-421" unitRef="eur">-32000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-4" decimals="-6" id="f-422" unitRef="eur">-16000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetCashProvidedByusedInContinuingInvestingActivities contextRef="c-1" decimals="-6" id="f-423" unitRef="eur">-1979000000</sny:NetCashProvidedByusedInContinuingInvestingActivities>
    <sny:NetCashProvidedByusedInContinuingInvestingActivities contextRef="c-4" decimals="-6" id="f-424" unitRef="eur">-3355000000</sny:NetCashProvidedByusedInContinuingInvestingActivities>
    <sny:NetCashProvidedByusedInDiscontinuingInvestingActivities contextRef="c-1" decimals="-6" id="f-425" unitRef="eur">-36000000</sny:NetCashProvidedByusedInDiscontinuingInvestingActivities>
    <sny:NetCashProvidedByusedInDiscontinuingInvestingActivities contextRef="c-4" decimals="-6" id="f-426" unitRef="eur">-58000000</sny:NetCashProvidedByusedInDiscontinuingInvestingActivities>
    <sny:NetCashInflowFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-427" unitRef="eur">10742000000</sny:NetCashInflowFromDiscontinuedOperations>
    <sny:NetCashInflowFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-428" unitRef="eur">0</sny:NetCashInflowFromDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-429" unitRef="eur">8727000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-4" decimals="-6" id="f-430" unitRef="eur">-3413000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-6" id="f-431" unitRef="eur">29000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-4" decimals="-6" id="f-432" unitRef="eur">21000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-433" unitRef="eur">4772000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-434" unitRef="eur">4704000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-435" unitRef="eur">27000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-436" unitRef="eur">25000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-437" unitRef="eur">2993000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-438" unitRef="eur">0</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-439" unitRef="eur">1859000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-440" unitRef="eur">638000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-441" unitRef="eur">124000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-442" unitRef="eur">136000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-1" decimals="-6" id="f-443" unitRef="eur">3322000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-4" decimals="-6" id="f-444" unitRef="eur">5876000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-1" decimals="-6" id="f-445" unitRef="eur">4003000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-4" decimals="-6" id="f-446" unitRef="eur">302000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="c-1" decimals="-6" id="f-447" unitRef="eur">-4441000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="c-4" decimals="-6" id="f-448" unitRef="eur">92000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-449" unitRef="eur">-48000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-450" unitRef="eur">-3000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-451" unitRef="eur">-4489000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-4" decimals="-6" id="f-452" unitRef="eur">89000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-453" unitRef="eur">-42000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-454" unitRef="eur">-13000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale contextRef="c-1" decimals="-6" id="f-455" unitRef="eur">167000000</sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale>
    <sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale contextRef="c-4" decimals="-6" id="f-456" unitRef="eur">0</sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-457" unitRef="eur">7918000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-458" unitRef="eur">-1915000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-459" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-13" decimals="-6" id="f-460" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-461" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-30" decimals="-6" id="f-462" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-463" unitRef="eur">1355000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-464" unitRef="eur">1434000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-465" unitRef="eur">206000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-466" unitRef="eur">320000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-467" unitRef="eur">170000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-468" unitRef="eur">261000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-469" unitRef="eur">5000000</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-470" unitRef="eur">0</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <ifrs-full:CashAndCashEquivalents contextRef="c-64" decimals="-6" id="f-471" unitRef="eur">667000000</ifrs-full:CashAndCashEquivalents>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-65" decimals="-6" id="f-472" unitRef="eur">3353000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-66" decimals="-6" id="f-473" unitRef="eur">6060000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-474">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i06f57da0e5ba4e0c866be66a8e0b007c"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Introduction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi, together with its subsidiaries (collectively &#x201c;Sanofi&#x201d;, &#x201c;the Group&#x201d; or &#x201c;the Company&#x201d;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements for the six months ended June 30, 2025 were reviewed by the Sanofi Board of Directors at the Board meeting on July 30, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-475">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="iff95aeb1cacb4d618b9870fd263c70dd"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A/ Basis of preparation of the half-year financial statements and accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7688eda8a7014a69b04b189c74427e4d"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.1. International financial reporting standards (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2025 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2025 are available via the following web link: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2025 are identical to those presented in the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment became applicable on January 1, 2025, and does not have a material impact on the Sanofi financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In its 2025 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. The effective tax rate also includes a one-off impact from the 2024 component of the exceptional contribution in respect of French corporate income taxes (see Note B.19.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i3ba3e8d2d67d4839a3ee18f4455ccac9"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.2. Use of estimates and judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of financial assets and financial liabilities at amortized cost;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of post-employment benefit obligations;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i0833d134ca4f467aa2d44022496a4589"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.3. Seasonal trends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5d091607f6cd4770b1e2ba57b80d1097"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2025, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i1d2d8abdbdca4cb1ad5f11223ac03852"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.5. Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i594cdfc2671541919a399905ebafffb7"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.6. New pronouncements issued by the IASB and applicable from 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026. Sanofi does not expect any material impact, and will not early adopt these amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026. Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments clarify the application of the &#x2018;own use&#x2019; exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and will not early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in Note D.21. to the consolidated financial statements included in the 2024 Form 20-F for the year ended December 31, 2024 (the &#x201c;2024 20-F&#x201d;).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-476">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2025 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2025 are available via the following web link: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2025 are identical to those presented in the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment became applicable on January 1, 2025, and does not have a material impact on the Sanofi financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In its 2025 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. The effective tax rate also includes a one-off impact from the 2024 component of the exceptional contribution in respect of French corporate income taxes (see Note B.19.).&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-477">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of financial assets and financial liabilities at amortized cost;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of post-employment benefit obligations;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock contextRef="c-1" id="f-478">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;</sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock>
    <ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory contextRef="c-1" id="f-479">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2025, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i1d2d8abdbdca4cb1ad5f11223ac03852"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.5. Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-67" decimals="2" id="f-480" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-68" decimals="2" id="f-481" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-482">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c-1" id="f-483">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-484">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026. Sanofi does not expect any material impact, and will not early adopt these amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026. Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments clarify the application of the &#x2018;own use&#x2019; exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and will not early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in Note D.21. to the consolidated financial statements included in the 2024 Form 20-F for the year ended December 31, 2024 (the &#x201c;2024 20-F&#x201d;).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i59b3a64f982a4997abb93c9d6139ad1b"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.1. Significant transactions for the first half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i59a51ad9042b4cd4977c803f9630832f"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.1.1. Opella - Loss of control and equity interest in OPAL JV Co&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, 2025, Sanofi and CD&amp;amp;R closed the Opella transaction following the signature of the share purchase agreement (SPA) on February 18, 2025. Sanofi retains a significant shareholding in Opella, through a 48.2% equity interest in OPAL JV Co (formed in Luxembourg), which indirectly holds 100% of Opella. Bpifrance owns a 1.8% equity interest, and is represented on Opella&#x2019;s Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Completion of the deal resulted in the loss of control of Opella by Sanofi and the derecognition of Opella&#x2019;s assets and liabilities. This resulted in a net gain of &#x20ac;2.7&#160;billion, reported within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in the consolidated income statement. The proceeds from the divestment of Opella, determined on the basis of a &#x20ac;16 billion enterprise value, reflected the estimated share price. That price is subject to adjustments following finalization of the Opella completion accounts, expected at the earliest in the fourth quarter of 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of the closing date of the transaction, the carrying amount of Opella&#x2019;s assets and liabilities in the Sanofi consolidated balance sheet was &#x20ac;11.3&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The gain took into account the following components: (i) a reclassification of unrealized foreign exchange losses amounting to &#x20ac;0.5&#160;billion associated with Opella operations, in accordance with IAS 21 (&#x201c;The Effects of Changes in Foreign Exchange Rates&#x201d;); (ii) recognition of the retained 48.2% equity interest in OPAL JV Co (over which Sanofi exercises significant influence as defined in IAS 28 &#x201c;Investments in Associates and Joint Ventures&#x201d;), reported within the balance sheet line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; at an amount of &#x20ac;3.2&#160;billion (representing the fair value of the equity interest at the date of initial recognition in accordance with IFRS 10 and included in the estimated share price, plus capitalized transaction costs); and (iii) other items, mainly comprising compensation as agreed under the separation agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Opella transaction generated a net cash inflow of &#x20ac;10.7&#160;billion, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net cash inflow from the Opella transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a reminder, on October 21, 2024, Sanofi and CD&amp;amp;R entered into exclusive negotiations for the transfer of a controlling interest in Opella. As of December 31, 2024, completion of the transaction was considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), all assets of Opella and all liabilities directly related to those assets were classified from October 21, 2024 in the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, respectively, in the consolidated balance sheet (see Notes D.8. and D.36. to the consolidated financial statements for the year ended December 31, 2024). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information" to the consolidated financial statements for the year ended December 31, 2024). Consequently, Opella met the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2024), as a result of which the net income from that business was presented separately within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated income statement. This presentation in a separate income statement line item applied to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business were also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented.&lt;/span&gt;&lt;/div&gt;B.1.2. Acquisition of Dren-0201, Inc.&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 27, 2025, Sanofi announced the completion of the acquisition of 100% of Dren-0201, Inc., adding SAR448501 (formerly DR-0201) to Sanofi&#x2019;s immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. This potential first-in-class targeted bispecific myeloid cell engager targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent pre-clinical and early clinical study data in autoimmune diseases suggest that deep B-cell depletion has the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition price was $600&#160;million. Of that amount (plus acquisition-related costs), $562&#160;million was allocated to in-process development in respect of SAR448501, and recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, potential future payments totalling $1.3&#160;billion contingent on attainment of certain development and launch milestones have been recognized as off balance sheet commitments. These milestones will be added to the value of the SAR448501 intangible asset if and when attained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition, as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows, is a net cash outflow of $602&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ie03a56ead74e44b3aa28ab44ba3c23df"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.1.3. Agreed transactions expected to be finalized in the second half of 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ieed73ef4674a4d15af5f8915f5773e86"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of Vigil Neuroscience, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vigil Neuroscience, Inc. (&#x201c;Vigil&#x201d;), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi&#x2019;s four strategic disease areas, enhances Sanofi&#x2019;s early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer&#x2019;s disease. VG-3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer&#x2019;s disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of a share purchase agreement (including the exclusive right of first negotiation for an exclusive license to VG-3927 or for transfer of the rights to research, develop, manufacture, and commercialize VG-3927) entered into by Sanofi and Vigil in June 2024 for an amount of $40&#160;million, Sanofi already held an equity interest in Vigil Neuroscience, Inc., representing approximately 12% of Vigil&#x2019;s share capital. That equity interest was remeasured at market value as at June 30, 2025 through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;VGL101, Vigil&#x2019;s second molecule program, is not being acquired by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash at closing. Based on $8.00 per share, the total equity value of Vigil represents approximately $470&#160;million (on a fully diluted basis).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, Vigil&#x2019;s shareholders will receive one non-transferable and non-tradeable contractual contingent value right (CVR) per Vigil share entitling the holder to receive a deferred cash payment of $2.00, contingent upon the first commercial sales of VG-3927.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition is expected to close in the third quarter of 2025 subject to closing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i10b85b18c19a4029849164666a084b38"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of Blueprint Medicines Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On June 2, 2025, Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, entered into an agreement under which Sanofi agreed to acquire Blueprint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition included a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint&#x2019;s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi&#x2019;s growing immunology pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the acquisition, Sanofi agreed to pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1&#160;billion for 100% of the shares. Blueprint shareholders also received one non-tradable contractual contingent value right (CVR) per share which entitles the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5&#160;billion on a fully diluted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July 2025, Sanofi obtained control of Blueprint after all tender offer and merger conditions had been met.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-69" decimals="-5" id="f-486" unitRef="eur">2700000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:NetAssetsLiabilities contextRef="c-70" decimals="-5" id="f-487" unitRef="eur">11300000000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-69" decimals="-5" id="f-488" unitRef="eur">500000000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-70" decimals="-5" id="f-489" unitRef="eur">3200000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sny:NetCashInflowFromDiscontinuedOperations contextRef="c-71" decimals="-8" id="f-490" unitRef="eur">10700000000</sny:NetCashInflowFromDiscontinuedOperations>
    <ifrs-full:NameOfAcquiree contextRef="c-1" id="f-491">,</ifrs-full:NameOfAcquiree>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-72" decimals="-6" id="f-492" unitRef="usd">600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-72" decimals="-6" id="f-493" unitRef="usd">562000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <sny:PotentialFuturePayments contextRef="c-73" decimals="-8" id="f-494" unitRef="usd">1300000000</sny:PotentialFuturePayments>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-73" decimals="-6" id="f-495" unitRef="usd">602000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-74" decimals="-6" id="f-496" unitRef="usd">40000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-75"
      decimals="INF"
      id="f-497"
      unitRef="number">0.12</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <sny:EquityInterestsOfAcquirerPerShare
      contextRef="c-75"
      decimals="INF"
      id="f-498"
      unitRef="usdPerShare">8.00</sny:EquityInterestsOfAcquirerPerShare>
    <ifrs-full:EquityInterestsOfAcquirer contextRef="c-75" decimals="-6" id="f-499" unitRef="usd">470000000</ifrs-full:EquityInterestsOfAcquirer>
    <sny:DeferredCashPayments contextRef="c-74" decimals="0" id="f-500" unitRef="usd">2.00</sny:DeferredCashPayments>
    <sny:CashTransferredPerShare
      contextRef="c-76"
      decimals="INF"
      id="f-501"
      unitRef="usdPerShare">129.00</sny:CashTransferredPerShare>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-76" decimals="-8" id="f-502" unitRef="usd">9100000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-76"
      decimals="INF"
      id="f-503"
      unitRef="number">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:EquityInterestsOfAcquirer contextRef="c-76" decimals="-8" id="f-504" unitRef="usd">9500000000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-505">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ied518a2a4a454270b2de2daf0c8e1b8d"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2. Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella (discontinued operation, see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Firm orders for property, plant and equipment stood at &#x20ac;732&#160;million as of June 30, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella (discontinued operation, see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-507" unitRef="eur">702000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-77" decimals="-6" id="f-508" unitRef="eur">591000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-78" decimals="-6" id="f-509" unitRef="eur">663000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-79" decimals="-6" id="f-510" unitRef="eur">535000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-80" decimals="-6" id="f-511" unitRef="eur">453000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-81" decimals="-6" id="f-512" unitRef="eur">366000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-82" decimals="-6" id="f-513" unitRef="eur">39000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-83" decimals="-6" id="f-514" unitRef="eur">56000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:InterestCostsCapitalised contextRef="c-1" decimals="-6" id="f-515" unitRef="eur">22000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised contextRef="c-77" decimals="-6" id="f-516" unitRef="eur">22000000</ifrs-full:InterestCostsCapitalised>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-517" unitRef="eur">732000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-518">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="if2b2a5097a884347b340e8351a4610b7"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3. Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill amounted to &#x20ac;40,283&#160;million as of June 30, 2025, versus &#x20ac;43,384 million as of December&#160;31, 2024. The movement during the period was mainly due to the impact of changes in exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,866&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,348&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,066&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,297&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;61,048&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,830&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;75,175&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(54,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,369&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,841&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,629&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,048&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,984&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;See Note B.4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Products, trademarks and other products&#x201d; mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;marketed products, with a carrying amount of &#x20ac;11.0 bil&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;lion as of June 30, 2025 (versus &#x20ac;12.7 billion as of December 31, 2024) and a weighted average amortization period of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 10 years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;technological platforms brought into service, with a carrying amou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;nt of &#x20ac;1.0 billion as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (versus &#x20ac;1.1 billion as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and a weighted average amortization period of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18 years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-519" unitRef="eur">40283000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-520" unitRef="eur">43384000000</ifrs-full:Goodwill>
    <sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,866&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,348&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,066&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,297&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;61,048&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,830&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;75,175&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(54,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,369&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,841&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,629&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,048&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,984&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;See Note B.4.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-522" unitRef="eur">12866000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-523" unitRef="eur">66348000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-524" unitRef="eur">1852000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-525" unitRef="eur">81066000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-88" decimals="-6" id="f-526" unitRef="eur">500000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-89" decimals="-6" id="f-527" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-90" decimals="-6" id="f-528" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-91" decimals="-6" id="f-529" unitRef="eur">500000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-530" unitRef="eur">332000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-531" unitRef="eur">302000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-532" unitRef="eur">42000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-533" unitRef="eur">676000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-534" unitRef="eur">22000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-535" unitRef="eur">199000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-536" unitRef="eur">7000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-537" unitRef="eur">228000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-538" unitRef="eur">-1339000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-539" unitRef="eur">-5159000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-540" unitRef="eur">-49000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-541" unitRef="eur">-6547000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-542" unitRef="eur">-40000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-543" unitRef="eur">-244000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-544" unitRef="eur">-8000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-545" unitRef="eur">-292000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-546" unitRef="eur">12297000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-6" id="f-547" unitRef="eur">61048000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-6" id="f-548" unitRef="eur">1830000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-6" id="f-549" unitRef="eur">75175000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-550" unitRef="eur">-4497000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-551" unitRef="eur">-52507000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-552" unitRef="eur">-1433000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-553" unitRef="eur">-58437000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-554" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-555" unitRef="eur">-800000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-556" unitRef="eur">-52000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-557" unitRef="eur">-852000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-558" unitRef="eur">-201000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-559" unitRef="eur">-9000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-560" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-561" unitRef="eur">-210000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-562" unitRef="eur">-22000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-563" unitRef="eur">-199000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-564" unitRef="eur">-8000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-565" unitRef="eur">-229000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-566" unitRef="eur">427000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-567" unitRef="eur">3772000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-568" unitRef="eur">40000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-569" unitRef="eur">4239000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-570" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-571" unitRef="eur">281000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-572" unitRef="eur">6000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-573" unitRef="eur">287000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-574" unitRef="eur">-4249000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-105" decimals="-6" id="f-575" unitRef="eur">-49064000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-106" decimals="-6" id="f-576" unitRef="eur">-1431000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-107" decimals="-6" id="f-577" unitRef="eur">-54744000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-108" decimals="-6" id="f-578" unitRef="eur">8369000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-109" decimals="-6" id="f-579" unitRef="eur">13841000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-110" decimals="-6" id="f-580" unitRef="eur">419000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-581" unitRef="eur">22629000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-104" decimals="-6" id="f-582" unitRef="eur">8048000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-105" decimals="-6" id="f-583" unitRef="eur">11984000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-106" decimals="-6" id="f-584" unitRef="eur">399000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-107" decimals="-6" id="f-585" unitRef="eur">20431000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-111" decimals="-8" id="f-586" unitRef="eur">11000000000.0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-112" decimals="-8" id="f-587" unitRef="eur">12700000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-113" id="f-588">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-114" decimals="-8" id="f-589" unitRef="eur">1000000000.0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-115" decimals="-8" id="f-590" unitRef="eur">1100000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-116" id="f-591">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock contextRef="c-1" id="f-592">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5cb600bbe3954f83a819a319c757b93a"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4. Impairment of intangible assets&lt;/span&gt;&lt;/div&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;210&#160;million in the first half of 2025 linked to research and development projects.</sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock>
    <sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill contextRef="c-117" decimals="-6" id="f-593" unitRef="eur">210000000</sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill>
    <sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock contextRef="c-1" id="f-594">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i087622ce136040f7a63e1598eff62e6b"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5. Investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2024), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;OPAL JV Co &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#x20ac;241&#160;million loan to OPAL JV Co being in substance part of the investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#x20ac;2.89 as of June 30, 2025, and &#x20ac;2.88 as of December 31, 2024). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt; showed net income of &#x20ac;85&#160;million for the first half of 2025 (versus a net loss of &#x20ac;22 million for the first half of 2024), including &#x20ac;11&#160;million for Sanofi&#x2019;s share of profits from OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c-1" id="f-595">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2024), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;OPAL JV Co &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#x20ac;241&#160;million loan to OPAL JV Co being in substance part of the investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#x20ac;2.89 as of June 30, 2025, and &#x20ac;2.88 as of December 31, 2024). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; showed net income of &#x20ac;85&#160;million for the first half of 2025 (versus a net loss of &#x20ac;22 million for the first half of 2024), including &#x20ac;11&#160;million for Sanofi&#x2019;s share of profits from OPAL JV Co for the period from May 1, 2025 through June 30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services (including research expenses)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#x20ac;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#x20ac;189&#160;million (and was also &#x20ac;189 million as of December 31, 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Key items from the OPAL JV Co 2025 unaudited half-year consolidated financial statements, as provided in accordance with Sanofi&#x2019;s consolidation timelines, are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated income statement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated statement of comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,116&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to equity holders of OPAL JV Co&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,295&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,821&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,116&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-118" decimals="3" id="f-596" unitRef="number">0.482</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-119" decimals="-6" id="f-597" unitRef="eur">3239000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-120" decimals="-6" id="f-598" unitRef="eur">0</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-121" decimals="3" id="f-599" unitRef="number">0.296</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-122" decimals="-6" id="f-600" unitRef="eur">82000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-123" decimals="-6" id="f-601" unitRef="eur">82000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-124" decimals="3" id="f-602" unitRef="number">0.312</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-125" decimals="-6" id="f-603" unitRef="eur">93000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-126" decimals="-6" id="f-604" unitRef="eur">102000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-127" decimals="3" id="f-605" unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-128" decimals="-6" id="f-606" unitRef="eur">79000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-129" decimals="-6" id="f-607" unitRef="eur">81000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-130" decimals="3" id="f-608" unitRef="number">0</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-131" decimals="-6" id="f-609" unitRef="eur">70000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-132" decimals="-6" id="f-610" unitRef="eur">51000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-611" unitRef="eur">3563000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-612" unitRef="eur">316000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sny:LoansToAssociates contextRef="c-118" decimals="-6" id="f-613" unitRef="eur">241000000</sny:LoansToAssociates>
    <sny:StockPrice
      contextRef="c-133"
      decimals="INF"
      id="f-614"
      unitRef="eurPerShare">2.89</sny:StockPrice>
    <sny:StockPrice
      contextRef="c-134"
      decimals="INF"
      id="f-615"
      unitRef="eurPerShare">0.0288</sny:StockPrice>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-135" decimals="2" id="f-616" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-617" unitRef="eur">85000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-618" unitRef="eur">-22000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-136" decimals="-6" id="f-619" unitRef="eur">11000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-620">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services (including research expenses)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#x20ac;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#x20ac;189&#160;million (and was also &#x20ac;189 million as of December 31, 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-621" unitRef="eur">29000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-622" unitRef="eur">59000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-623" unitRef="eur">63000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-624" unitRef="eur">33000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-625" unitRef="eur">371000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-626" unitRef="eur">333000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-627" unitRef="eur">299000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-628" unitRef="eur">184000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-629" unitRef="eur">189000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-630" unitRef="eur">189000000</sny:OtherAssetsRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-631" unitRef="eur">637000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-632" unitRef="eur">160000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <sny:SubordinateHybridBondRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-633" unitRef="eur">200000000</sny:SubordinateHybridBondRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-2" decimals="-6" id="f-634" unitRef="eur">189000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-3" decimals="-6" id="f-635" unitRef="eur">189000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures contextRef="c-137" decimals="-6" id="f-636" unitRef="eur">887000000</sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures>
    <sny:NetIncomeRelatedPartyDisclosures contextRef="c-137" decimals="-6" id="f-637" unitRef="eur">24000000</sny:NetIncomeRelatedPartyDisclosures>
    <sny:OtherComprehensiveIncomeRelatedPartyDisclosures contextRef="c-137" decimals="-6" id="f-638" unitRef="eur">-1000000</sny:OtherComprehensiveIncomeRelatedPartyDisclosures>
    <sny:ComprehensiveIncomeRelatedPartyDisclosures contextRef="c-137" decimals="-6" id="f-639" unitRef="eur">23000000</sny:ComprehensiveIncomeRelatedPartyDisclosures>
    <sny:NonCurrentAssetsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-640" unitRef="eur">16179000000</sny:NonCurrentAssetsRelatedPartyTransactions>
    <sny:CurrentAssetsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-641" unitRef="eur">2937000000</sny:CurrentAssetsRelatedPartyTransactions>
    <sny:AssetsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-642" unitRef="eur">19116000000</sny:AssetsRelatedPartyTransactions>
    <sny:EquityAttributableToEquityHoldersRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-643" unitRef="eur">5754000000</sny:EquityAttributableToEquityHoldersRelatedPartyTransactions>
    <sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-644" unitRef="eur">541000000</sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions>
    <sny:EquityRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-645" unitRef="eur">6295000000</sny:EquityRelatedPartyTransactions>
    <sny:NonCurrentLiabilitiesRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-646" unitRef="eur">11039000000</sny:NonCurrentLiabilitiesRelatedPartyTransactions>
    <sny:CurrentLiabilitiesRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-647" unitRef="eur">1782000000</sny:CurrentLiabilitiesRelatedPartyTransactions>
    <sny:LiabilitiesRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-648" unitRef="eur">12821000000</sny:LiabilitiesRelatedPartyTransactions>
    <sny:EquityAndLiabilitiesRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-649" unitRef="eur">19116000000</sny:EquityAndLiabilitiesRelatedPartyTransactions>
    <sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock contextRef="c-1" id="f-650">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ib826488bd111450d94e97cf9c6e8d771"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6. Other non-current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,109&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,753&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="c-1" id="f-651">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,109&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,753&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-142" decimals="-6" id="f-652" unitRef="eur">2105000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-143" decimals="-6" id="f-653" unitRef="eur">1559000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-144" decimals="-6" id="f-654" unitRef="eur">362000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-145" decimals="-6" id="f-655" unitRef="eur">357000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-2" decimals="-6" id="f-656" unitRef="eur">965000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-3" decimals="-6" id="f-657" unitRef="eur">1027000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:PreFundedPensionObligations contextRef="c-2" decimals="-6" id="f-658" unitRef="eur">146000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-3" decimals="-6" id="f-659" unitRef="eur">156000000</sny:PreFundedPensionObligations>
    <sny:LongTermPrepaidExpenses contextRef="c-2" decimals="-6" id="f-660" unitRef="eur">143000000</sny:LongTermPrepaidExpenses>
    <sny:LongTermPrepaidExpenses contextRef="c-3" decimals="-6" id="f-661" unitRef="eur">152000000</sny:LongTermPrepaidExpenses>
    <sny:NonCurrentLoansAndReceivables contextRef="c-2" decimals="-6" id="f-662" unitRef="eur">382000000</sny:NonCurrentLoansAndReceivables>
    <sny:NonCurrentLoansAndReceivables contextRef="c-3" decimals="-6" id="f-663" unitRef="eur">502000000</sny:NonCurrentLoansAndReceivables>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-2" decimals="-6" id="f-664" unitRef="eur">6000000</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-3" decimals="-6" id="f-665" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-666" unitRef="eur">4109000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-667" unitRef="eur">3753000000</ifrs-full:OtherNoncurrentAssets>
    <sny:DisclosureOfTradeReceivablesTextBlock contextRef="c-1" id="f-668">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="iaf6d41da42f0471b8c814bb674ed84ba"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.7. Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,810&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of allowances against accounts receivable in the first half of 2025 was a net expense of &#x20ac;4 million (versus a net expense of &#x20ac;3 million for the first half of 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;386&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amounts overdue by more than one month relate mainly to public-sector customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2024 and hence were derecognized was &#x20ac;12 million as of June&#160;30, 2025 (versus &#x20ac;14 million as of December 31, 2024). The residual guarantees relating to those transfers were immaterial as of June 30, 2025.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfTradeReceivablesTextBlock>
    <sny:DisclosureOfCurrentTradeReceivablesTableTextBlock contextRef="c-1" id="f-669">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,810&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfCurrentTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-95" decimals="-6" id="f-670" unitRef="eur">7896000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-87" decimals="-6" id="f-671" unitRef="eur">7777000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-146" decimals="-6" id="f-672" unitRef="eur">86000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-147" decimals="-6" id="f-673" unitRef="eur">100000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-674" unitRef="eur">7810000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-675" unitRef="eur">7677000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-1" decimals="-6" id="f-676" unitRef="eur">-4000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-4" decimals="-6" id="f-677" unitRef="eur">-3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock contextRef="c-1" id="f-678">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;386&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock>
    <sny:OverdueReceivablesGrossValue contextRef="c-2" decimals="-6" id="f-679" unitRef="eur">386000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-148" decimals="-6" id="f-680" unitRef="eur">122000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-149" decimals="-6" id="f-681" unitRef="eur">103000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-150" decimals="-6" id="f-682" unitRef="eur">73000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-151" decimals="-6" id="f-683" unitRef="eur">48000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-152" decimals="-6" id="f-684" unitRef="eur">40000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-3" decimals="-6" id="f-685" unitRef="eur">650000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-153" decimals="-6" id="f-686" unitRef="eur">316000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-154" decimals="-6" id="f-687" unitRef="eur">194000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-155" decimals="-6" id="f-688" unitRef="eur">87000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-156" decimals="-6" id="f-689" unitRef="eur">9000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-157" decimals="-6" id="f-690" unitRef="eur">44000000</sny:OverdueReceivablesGrossValue>
    <sny:DerecognizedReceivables contextRef="c-2" decimals="-6" id="f-691" unitRef="eur">12000000</sny:DerecognizedReceivables>
    <sny:DerecognizedReceivables contextRef="c-3" decimals="-6" id="f-692" unitRef="eur">14000000</sny:DerecognizedReceivables>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-693">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7de095be9bd34777b07065d8d9446fb6"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8. Consolidated shareholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ieb1db694e9274ef49646dccbed6532bf"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.1. Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the share capital was &#x20ac;2,455,512,548 and consisted of 1,227,756,274 shares (the total number of shares outstanding) with a par value of &#x20ac;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10.66&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0.868&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.755&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.063&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A total of 171,150 shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 2,682,051 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;vested under Sanofi restricted share plans during the first half of 2025, of which 1,156,205&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;were fulfilled by issuance of new shares and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,525,846&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; by allotment of existing shares free of charge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i25296d69bf8543698f51f58a59381631"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.2. Repurchase of Sanofi shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, 2024, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 39,344,633 of its own shares during the first half of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for a total amount of &#x20ac;3,988&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#x20ac;5&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#xe9;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#x2019;s share capital, equivalent to 29,556,650 shares, for a total amount of approximately &#x20ac;3&#160;billion, representing a price of &#x20ac;101.50 per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ot use that authorization during the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="iab53d79b00614867aa54dfaeaac8fdef"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.3. Reduction in share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2025, treasury shares amounting to &#x20ac;3,868 million were cancelled further to decisions taken by the Sanofi Board of Directors on March 13, 2025 and April 23, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Those reductions have no impact on shareholders&#x2019; equity, except for the impact of the tax on share cancellations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i8f51ca431f464eb6984626bf2fabb13e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.4. Restricted share plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2024. The principal features of the plans awarded in 2025 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30 April, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,021,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,599,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;83.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,421,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,331,892 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;79.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (90,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;75.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;331&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,550,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,192,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2025 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,020,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,110,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,498,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,313,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,652,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;106,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,031,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="idc68e16f4a53438286d6b02e26a98749"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.5. Capital increases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January 29, 2025, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#x20ac;72.97 per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of 2,260,776 shares, and this capital increase was supplemented by the immediate issuance of a further 116,794 shares for the employer&#x2019;s contribution. The total expense recognized for this capital increase in the first half of 2025 was &#x20ac;31 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#x20ac;72.87 per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of 2,124,445 shares, and this capital increase was supplemented by the immediate issuance of a further 119,951 shares for the employer&#x2019;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#x20ac;45 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="if776696deda84ae0905c147f47bfbc13"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.6. Stock subscription option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No stock subscription option plans were awarded in the first half of 2025 or in 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No further stock option plan expenses were recognized through equity in either the first half of 2025 or 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average residual life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;725,044&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;725,044&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i92d70e7ae645487f86bdd2b833ba9524"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.7. Number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,230.7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,253.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, December 31, 2024 and June 30, 2024, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i2ea5e4740dbf4078bbff62d9a657d829"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.8. Other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: &#x20ac;2&#160;million in the first half of 2025, immaterial in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#x20ac;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#x20ac;5&#160;million profit in 2024, and immaterial in the first half of 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-694">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7de095be9bd34777b07065d8d9446fb6"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8. Consolidated shareholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ieb1db694e9274ef49646dccbed6532bf"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.1. Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, the share capital was &#x20ac;2,455,512,548 and consisted of 1,227,756,274 shares (the total number of shares outstanding) with a par value of &#x20ac;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10.66&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0.868&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.755&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.063&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A total of 171,150 shares were issued in the first half of 2025 as a result of the exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 2,682,051 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;vested under Sanofi restricted share plans during the first half of 2025, of which 1,156,205&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;were fulfilled by issuance of new shares and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,525,846&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; by allotment of existing shares free of charge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="0" id="f-695" unitRef="eur">2455512548</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssued contextRef="c-2" decimals="INF" id="f-696" unitRef="shares">1227756274</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-697"
      unitRef="eurPerShare">2</ifrs-full:ParValuePerShare>
    <sny:NumberOfSharesHeld contextRef="c-2" decimals="-4" id="f-698" unitRef="shares">10660000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-2" decimals="5" id="f-699" unitRef="number">0.00868</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-3" decimals="-4" id="f-700" unitRef="shares">9530000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-3" decimals="5" id="f-701" unitRef="number">0.00755</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-30" decimals="-4" id="f-702" unitRef="shares">15330000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-30" decimals="5" id="f-703" unitRef="number">0.01211</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-13" decimals="-4" id="f-704" unitRef="shares">13450000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-13" decimals="5" id="f-705" unitRef="number">0.01063</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-158"
      decimals="INF"
      id="f-706"
      unitRef="shares">171150</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease contextRef="c-1" decimals="INF" id="f-707" unitRef="shares">2682051</sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-158"
      decimals="INF"
      id="f-708"
      unitRef="shares">1156205</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease contextRef="c-2" decimals="INF" id="f-709" unitRef="shares">1525846</sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-159" id="f-710">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:NumberOfSharesRepurchased
      contextRef="c-160"
      decimals="INF"
      id="f-711"
      unitRef="shares">39344633</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-160" decimals="-6" id="f-712" unitRef="eur">3988000000</sny:AmountOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-161" decimals="-9" id="f-713" unitRef="eur">5000000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-162"
      decimals="INF"
      id="f-714"
      unitRef="shares">29556650</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-163" decimals="-9" id="f-715" unitRef="eur">3000000000</sny:AmountOfSharesRepurchased>
    <sny:PerShareValueOfSharesRepurchased
      contextRef="c-163"
      decimals="INF"
      id="f-716"
      unitRef="eurPerShare">101.50</sny:PerShareValueOfSharesRepurchased>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-164" id="f-717">P18M</sny:PeriodOfShareRepurchaseProgram>
    <ifrs-full:CancellationOfTreasuryShares contextRef="c-1" decimals="-6" id="f-718" unitRef="eur">3868000000</ifrs-full:CancellationOfTreasuryShares>
    <sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock contextRef="c-1" id="f-719">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2024. The principal features of the plans awarded in 2025 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30 April, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,021,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,599,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;83.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,421,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,331,892 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;79.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (90,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;75.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;331&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock>
    <sny:NumberOfYearsServicePeriod contextRef="c-165" id="f-720">P3Y</sny:NumberOfYearsServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-166"
      decimals="INF"
      id="f-721"
      unitRef="shares">4021370</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-167"
      decimals="INF"
      id="f-722"
      unitRef="shares">2599478</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-167"
      decimals="2"
      id="f-723"
      unitRef="eurPerShare">83.94</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-168"
      decimals="INF"
      id="f-724"
      unitRef="shares">1421892</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-169"
      decimals="INF"
      id="f-725"
      unitRef="shares">1331892</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-169"
      decimals="2"
      id="f-726"
      unitRef="eurPerShare">79.25</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-170"
      decimals="INF"
      id="f-727"
      unitRef="shares">90000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-170"
      decimals="2"
      id="f-728"
      unitRef="eurPerShare">75.10</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-166" decimals="-6" id="f-729" unitRef="eur">331000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock contextRef="c-1" id="f-730">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,550,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,192,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2025 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,020,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,110,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,498,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,313,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,652,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;106,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,031,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-171" decimals="-6" id="f-731" unitRef="eur">146000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-172" decimals="-6" id="f-732" unitRef="eur">128000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-173"
      decimals="INF"
      id="f-733"
      unitRef="shares">11550347</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-174"
      decimals="INF"
      id="f-734"
      unitRef="shares">11192984</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-175"
      decimals="INF"
      id="f-735"
      unitRef="shares">4020451</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-176"
      decimals="INF"
      id="f-736"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-177"
      decimals="INF"
      id="f-737"
      unitRef="shares">4110089</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-178"
      decimals="INF"
      id="f-738"
      unitRef="shares">4498109</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-179"
      decimals="INF"
      id="f-739"
      unitRef="shares">3313588</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-180"
      decimals="INF"
      id="f-740"
      unitRef="shares">3652352</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-181"
      decimals="INF"
      id="f-741"
      unitRef="shares">106219</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-182"
      decimals="INF"
      id="f-742"
      unitRef="shares">3031060</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-183"
      decimals="INF"
      id="f-743"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-184"
      decimals="INF"
      id="f-744"
      unitRef="shares">11463</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:SubscriptionPricePerShare
      contextRef="c-185"
      decimals="2"
      id="f-745"
      unitRef="eurPerShare">72.97</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-186"
      decimals="INF"
      id="f-746"
      unitRef="shares">2260776</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-186"
      decimals="INF"
      id="f-747"
      unitRef="shares">116794</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-187" decimals="-6" id="f-748" unitRef="eur">31000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:SubscriptionPricePerShare
      contextRef="c-188"
      decimals="2"
      id="f-749"
      unitRef="eurPerShare">72.87</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-189"
      decimals="INF"
      id="f-750"
      unitRef="shares">2124445</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-189"
      decimals="INF"
      id="f-751"
      unitRef="shares">119951</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-190" decimals="-6" id="f-752" unitRef="eur">45000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average residual life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;725,044&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;725,044&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-191"
      decimals="INF"
      id="f-754"
      unitRef="eurPerShare">60.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-192"
      decimals="INF"
      id="f-755"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-193"
      decimals="INF"
      id="f-756"
      unitRef="shares">168784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-194" id="f-757">P2Y10M2D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-193"
      decimals="2"
      id="f-758"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-193"
      decimals="INF"
      id="f-759"
      unitRef="shares">168784</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-193"
      decimals="2"
      id="f-760"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-195"
      decimals="INF"
      id="f-761"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-196"
      decimals="INF"
      id="f-762"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-197"
      decimals="INF"
      id="f-763"
      unitRef="shares">299250</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-198" id="f-764">P2Y11M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-197"
      decimals="2"
      id="f-765"
      unitRef="eurPerShare">76.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-197"
      decimals="INF"
      id="f-766"
      unitRef="shares">299250</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-197"
      decimals="2"
      id="f-767"
      unitRef="eurPerShare">76.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-199"
      decimals="INF"
      id="f-768"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-200"
      decimals="INF"
      id="f-769"
      unitRef="eurPerShare">90.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-201"
      decimals="INF"
      id="f-770"
      unitRef="shares">257010</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-202" id="f-771">P1Y10M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-201"
      decimals="2"
      id="f-772"
      unitRef="eurPerShare">88.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-201"
      decimals="INF"
      id="f-773"
      unitRef="shares">257010</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-201"
      decimals="2"
      id="f-774"
      unitRef="eurPerShare">88.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-203"
      decimals="INF"
      id="f-775"
      unitRef="shares">725044</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-203"
      decimals="INF"
      id="f-776"
      unitRef="shares">725044</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock contextRef="c-1" id="f-777">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,230.7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,253.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-778" unitRef="shares">1225500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="-5" id="f-779" unitRef="shares">1249400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-1" decimals="-5" id="f-780" unitRef="shares">100000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-4" decimals="-5" id="f-781" unitRef="shares">100000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-1" decimals="-5" id="f-782" unitRef="shares">5100000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-4" decimals="-5" id="f-783" unitRef="shares">4300000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-784" unitRef="shares">1230700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="-5" id="f-785" unitRef="shares">1253800000</ifrs-full:AdjustedWeightedAverageShares>
    <sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-786">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: &#x20ac;2&#160;million in the first half of 2025, immaterial in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#x20ac;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#x20ac;5&#160;million profit in 2024, and immaterial in the first half of 2024.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-204" decimals="-6" id="f-787" unitRef="eur">105000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-205" decimals="-6" id="f-788" unitRef="eur">235000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-204" decimals="-6" id="f-789" unitRef="eur">1000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-205" decimals="-6" id="f-790" unitRef="eur">0</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-204" decimals="-6" id="f-791" unitRef="eur">25000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-205" decimals="-6" id="f-792" unitRef="eur">57000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-206" decimals="-6" id="f-793" unitRef="eur">222000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-207" decimals="-6" id="f-794" unitRef="eur">-10000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-206" decimals="-6" id="f-795" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-207" decimals="-6" id="f-796" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-206" decimals="-6" id="f-797" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-207" decimals="-6" id="f-798" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-206" decimals="-6" id="f-799" unitRef="eur">60000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-207" decimals="-6" id="f-800" unitRef="eur">2000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-204" decimals="-6" id="f-801" unitRef="eur">243000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-205" decimals="-6" id="f-802" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-208" decimals="-6" id="f-803" unitRef="eur">3000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-209" decimals="-6" id="f-804" unitRef="eur">-5000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-208" decimals="-6" id="f-805" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-209" decimals="-6" id="f-806" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-208" decimals="-6" id="f-807" unitRef="eur">0</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-209" decimals="-6" id="f-808" unitRef="eur">-1000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-809" unitRef="eur">-23000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-810" unitRef="eur">-4000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-811" unitRef="eur">0</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-812" unitRef="eur">1000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-210" decimals="-6" id="f-813" unitRef="eur">-6000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-211" decimals="-6" id="f-814" unitRef="eur">-1000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-815" unitRef="eur">-5266000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-816" unitRef="eur">1167000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-817" unitRef="eur">-26000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-818" unitRef="eur">-1000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-210" decimals="-6" id="f-819" unitRef="eur">390000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-211" decimals="-6" id="f-820" unitRef="eur">-126000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-210" decimals="-6" id="f-821" unitRef="eur">101000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-211" decimals="-6" id="f-822" unitRef="eur">-33000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-210" decimals="-6" id="f-823" unitRef="eur">-5017000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-211" decimals="-6" id="f-824" unitRef="eur">1067000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-212" decimals="-6" id="f-825" unitRef="eur">2000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-213" decimals="-6" id="f-826" unitRef="eur">459000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-214" decimals="-6" id="f-827" unitRef="eur">5000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock contextRef="c-1" id="f-828">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5d93f704479c4f44b67be7e205d2d7a8"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.9. Debt, cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,519&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,102&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,772&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Net debt&#x201d; is a non-IFRS financial measure used by management and investors to measure Sanofi&#x2019;s overall net indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ic4f08bedb155434a888a0d64f5305f78"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.9.1. Net debt at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2025 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,519&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,560&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,171&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,102&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,806&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,317&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,560&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,940&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,231&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,171&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,317&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,940&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,806&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) As of Ju&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;ne 30, 2025, current other bank borrowings include &#x20ac;4,535&#160;million related to the US commercial paper program and &#x20ac;230&#160;million related to the Negotiable European Commercial Paper program in France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span id="idb1ea718ea754a00bb46d85600fe6342"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal financing and debt reduction transactions during the period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi carried out the following bond issues during the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;March 2025: a bond issue of &#x20ac;1.5&#160;billion in two tranches:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt; &#x20ac;850&#160;million of floating-rate bonds maturing March 2027, with quarterly coupons and bearing interest at an annual rate of 3-month Euribor plus 30 basis points; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt; &#x20ac;650&#160;million of fixed-rate bonds maturing March 2031, with annual coupons and bearing interest at an annual rate of 2.750%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;June 2025: a bond issue of &#x20ac;1.5&#160;billion in two tranches:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt; &#x20ac;750&#160;million of fixed-rate bonds maturing June 2029, with annual coupons and bearing interest at an annual rate of 2.625%; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt; &#x20ac;750&#160;million of fixed-rate bonds maturing June 2032, with annual coupons and bearing interest at an annual rate of 3.000%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Two bond issues were redeemed in 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;the &#x20ac;1&#160;billion fixed-rate bond issue from April 2020, which was redeemed at maturity on April 1, 2025; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the &#x20ac;850&#160;million fixed-rate bond issue from April 2022, which was redeemed at maturity on April 6, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, neither facility was drawn down.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi also has two short-term debt programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;a &#x20ac;6 billion Negotiable European Commercial Paper program in France; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a $10&#160;billion Commercial Paper program in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;the average drawdown under the US Commercial Paper program was $2.63 billion; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the average drawdown under the Negotiable European Commercial Paper program in France was &#x20ac;0.02 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financing in place as of June 30, 2025 at the level of the holding company (which manages most of Sanofi&#x2019;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="icd19a6965fa84d6a8acb50e70115a9d2"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.9.2. Market value of net debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock>
    <sny:DisclosureOfChangesInFinancialPositionTableTextBlock contextRef="c-1" id="f-829">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,519&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,102&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,772&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInFinancialPositionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-830" unitRef="eur">13200000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-831" unitRef="eur">11791000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-832" unitRef="eur">7309000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-833" unitRef="eur">4209000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-834" unitRef="eur">-10000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-3" decimals="-6" id="f-835" unitRef="eur">-137000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-836" unitRef="eur">20519000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-3" decimals="-6" id="f-837" unitRef="eur">16137000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-838" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-839" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-840" unitRef="eur">58000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-3" decimals="-6" id="f-841" unitRef="eur">-76000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-842" unitRef="eur">5102000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-843" unitRef="eur">8772000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-844" unitRef="eur">1776000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-845" unitRef="eur">1906000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock contextRef="c-1" id="f-846">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2025 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,519&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,560&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,171&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,102&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,806&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-847" unitRef="eur">13200000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-215" decimals="-6" id="f-848" unitRef="eur">39000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-216" decimals="-6" id="f-849" unitRef="eur">78000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-217" decimals="-6" id="f-850" unitRef="eur">13317000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-218" decimals="-6" id="f-851" unitRef="eur">11940000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-852" unitRef="eur">7309000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-215" decimals="-6" id="f-853" unitRef="eur">2000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-216" decimals="-6" id="f-854" unitRef="eur">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-217" decimals="-6" id="f-855" unitRef="eur">7311000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-218" decimals="-6" id="f-856" unitRef="eur">4218000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-857" unitRef="eur">-10000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-215" decimals="-6" id="f-858" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-216" decimals="-6" id="f-859" unitRef="eur">78000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-217" decimals="-6" id="f-860" unitRef="eur">68000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-218" decimals="-6" id="f-861" unitRef="eur">-13000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-862" unitRef="eur">20519000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-215" decimals="-6" id="f-863" unitRef="eur">41000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-216" decimals="-6" id="f-864" unitRef="eur">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-217" decimals="-6" id="f-865" unitRef="eur">20560000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-218" decimals="-6" id="f-866" unitRef="eur">16171000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-867" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-215" decimals="-6" id="f-868" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-216" decimals="-6" id="f-869" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-870" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-871" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-872" unitRef="eur">58000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-215" decimals="-6" id="f-873" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-216" decimals="-6" id="f-874" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-217" decimals="-6" id="f-875" unitRef="eur">58000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-218" decimals="-6" id="f-876" unitRef="eur">-76000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-877" unitRef="eur">5102000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-215" decimals="-6" id="f-878" unitRef="eur">41000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-216" decimals="-6" id="f-879" unitRef="eur">0</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-880" unitRef="eur">5143000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-881" unitRef="eur">8806000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-882" unitRef="eur">1776000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-883" unitRef="eur">1906000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock contextRef="c-1" id="f-884">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,317&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,560&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,940&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,231&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,171&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,317&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,940&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,806&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-219" decimals="-6" id="f-885" unitRef="eur">13259000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-220" decimals="-6" id="f-886" unitRef="eur">2322000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-217" decimals="-6" id="f-887" unitRef="eur">15581000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-221" decimals="-6" id="f-888" unitRef="eur">11876000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-222" decimals="-6" id="f-889" unitRef="eur">2716000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-218" decimals="-6" id="f-890" unitRef="eur">14592000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-219" decimals="-6" id="f-891" unitRef="eur">58000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-220" decimals="-6" id="f-892" unitRef="eur">4847000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-217" decimals="-6" id="f-893" unitRef="eur">4905000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-221" decimals="-6" id="f-894" unitRef="eur">64000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-222" decimals="-6" id="f-895" unitRef="eur">1290000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-218" decimals="-6" id="f-896" unitRef="eur">1354000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-219" decimals="-6" id="f-897" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-220" decimals="-6" id="f-898" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-217" decimals="-6" id="f-899" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-221" decimals="-6" id="f-900" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-222" decimals="-6" id="f-901" unitRef="eur">3000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-218" decimals="-6" id="f-902" unitRef="eur">3000000</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-219" decimals="-6" id="f-903" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-220" decimals="-6" id="f-904" unitRef="eur">141000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-217" decimals="-6" id="f-905" unitRef="eur">141000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-221" decimals="-6" id="f-906" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-222" decimals="-6" id="f-907" unitRef="eur">209000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-218" decimals="-6" id="f-908" unitRef="eur">209000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-219" decimals="-6" id="f-909" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-220" decimals="-6" id="f-910" unitRef="eur">68000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-217" decimals="-6" id="f-911" unitRef="eur">68000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-221" decimals="-6" id="f-912" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-222" decimals="-6" id="f-913" unitRef="eur">-13000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-218" decimals="-6" id="f-914" unitRef="eur">-13000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-219" decimals="-6" id="f-915" unitRef="eur">13317000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-220" decimals="-6" id="f-916" unitRef="eur">7243000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-217" decimals="-6" id="f-917" unitRef="eur">20560000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-221" decimals="-6" id="f-918" unitRef="eur">11940000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-222" decimals="-6" id="f-919" unitRef="eur">4231000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-218" decimals="-6" id="f-920" unitRef="eur">16171000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-223" decimals="-6" id="f-921" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-922" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-923" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-924" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-925" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-926" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-223" decimals="-6" id="f-927" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-224" decimals="-6" id="f-928" unitRef="eur">58000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-217" decimals="-6" id="f-929" unitRef="eur">58000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-225" decimals="-6" id="f-930" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-226" decimals="-6" id="f-931" unitRef="eur">-76000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-218" decimals="-6" id="f-932" unitRef="eur">-76000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-223" decimals="-6" id="f-933" unitRef="eur">13317000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-934" unitRef="eur">-8174000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-935" unitRef="eur">5143000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-936" unitRef="eur">11940000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-937" unitRef="eur">-3134000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-938" unitRef="eur">8806000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:OtherBankBorrowings contextRef="c-227" decimals="-6" id="f-939" unitRef="eur">4535000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-228" decimals="-6" id="f-940" unitRef="eur">230000000</sny:OtherBankBorrowings>
    <ifrs-full:NotionalAmount contextRef="c-229" decimals="-8" id="f-941" unitRef="eur">1500000000</ifrs-full:NotionalAmount>
    <sny:NumberOfTranches contextRef="c-229" decimals="INF" id="f-942" unitRef="eur">2</sny:NumberOfTranches>
    <ifrs-full:NotionalAmount contextRef="c-230" decimals="-6" id="f-943" unitRef="eur">850000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-231" decimals="-6" id="f-944" unitRef="eur">650000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-232" decimals="-8" id="f-945" unitRef="eur">1500000000</ifrs-full:NotionalAmount>
    <sny:NumberOfTranches contextRef="c-232" decimals="INF" id="f-946" unitRef="eur">2</sny:NumberOfTranches>
    <ifrs-full:NotionalAmount contextRef="c-233" decimals="-6" id="f-947" unitRef="eur">750000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-234" decimals="-6" id="f-948" unitRef="eur">750000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-235" decimals="-9" id="f-949" unitRef="eur">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-236" decimals="-6" id="f-950" unitRef="eur">850000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-237" decimals="-9" id="f-951" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-238" decimals="-9" id="f-952" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:CommercialPapersIssued contextRef="c-239" decimals="-9" id="f-953" unitRef="eur">6000000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued contextRef="c-240" decimals="-9" id="f-954" unitRef="usd">10000000000</ifrs-full:CommercialPapersIssued>
    <sny:BorrowingAverageDrawdown contextRef="c-241" decimals="-7" id="f-955" unitRef="usd">2630000000</sny:BorrowingAverageDrawdown>
    <sny:BorrowingAverageDrawdown contextRef="c-242" decimals="-7" id="f-956" unitRef="eur">20000000.00</sny:BorrowingAverageDrawdown>
    <sny:DisclosureOfMarketValueOfNetDebtTableTextBlock contextRef="c-1" id="f-957">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfMarketValueOfNetDebtTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-243" decimals="-6" id="f-958" unitRef="eur">4589000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-244" decimals="-6" id="f-959" unitRef="eur">8165000000</ifrs-full:Borrowings>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-245" decimals="-6" id="f-960" unitRef="eur">5143000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-246" decimals="-6" id="f-961" unitRef="eur">8806000000</sny:RedemptionOfDebtInstrumentIssued>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-963">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5ee764af394a41d98996a14bec414e96"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10. Derivative financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i850ed5d10c524593866e3ac094f18038"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.1 Currency derivatives used to manage operating risk exposures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which United Arab Emirates dirham&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="id95d9cb34ad843deb2eeb9cd2820d2ca"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.2. Currency and interest rate derivatives used to manage financial exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#x2019;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#x2019;s debt once those instruments are taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maximum expiry&#160;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cross currency seller swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,476&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,723&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;176&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;of which Japanese yen &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,808&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp;amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#x20ac;5&#160;million, with &#x20ac;18&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#x20ac;77 million; the opposite entry was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#x20ac;25 million, with &#x20ac;0 million&#160;credited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.17%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 2.08% / receive Euribor 3m&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;848&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,348&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,498&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-962">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5ee764af394a41d98996a14bec414e96"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10. Derivative financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i850ed5d10c524593866e3ac094f18038"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.1 Currency derivatives used to manage operating risk exposures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which United Arab Emirates dirham&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="id95d9cb34ad843deb2eeb9cd2820d2ca"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.2. Currency and interest rate derivatives used to manage financial exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#x2019;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#x2019;s debt once those instruments are taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maximum expiry&#160;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cross currency seller swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,476&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,723&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;176&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;of which Japanese yen &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,808&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp;amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#x20ac;5&#160;million, with &#x20ac;18&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#x20ac;77 million; the opposite entry was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#x20ac;25 million, with &#x20ac;0 million&#160;credited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.17%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 2.08% / receive Euribor 3m&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;848&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,348&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,498&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock contextRef="c-1" id="f-964">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,619&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,418&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which United Arab Emirates dirham&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,037&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2025 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock>
    <sny:DerivativeFinancialInstruments contextRef="c-247" decimals="-6" id="f-965" unitRef="eur">6619000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-248" decimals="-6" id="f-966" unitRef="eur">133000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-249" decimals="-6" id="f-967" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-250" decimals="-6" id="f-968" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-251" decimals="-6" id="f-969" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-252" decimals="-6" id="f-970" unitRef="eur">6619000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-253" decimals="-6" id="f-971" unitRef="eur">133000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-254" decimals="-6" id="f-972" unitRef="eur">3351000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-255" decimals="-6" id="f-973" unitRef="eur">100000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-256" decimals="-6" id="f-974" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-257" decimals="-6" id="f-975" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-258" decimals="-6" id="f-976" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-259" decimals="-6" id="f-977" unitRef="eur">3351000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-260" decimals="-6" id="f-978" unitRef="eur">100000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-261" decimals="-6" id="f-979" unitRef="eur">539000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-262" decimals="-6" id="f-980" unitRef="eur">10000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-263" decimals="-6" id="f-981" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-264" decimals="-6" id="f-982" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-265" decimals="-6" id="f-983" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-266" decimals="-6" id="f-984" unitRef="eur">539000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-267" decimals="-6" id="f-985" unitRef="eur">10000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-268" decimals="-6" id="f-986" unitRef="eur">480000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-269" decimals="-6" id="f-987" unitRef="eur">14000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-270" decimals="-6" id="f-988" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-271" decimals="-6" id="f-989" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-272" decimals="-6" id="f-990" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-273" decimals="-6" id="f-991" unitRef="eur">480000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-274" decimals="-6" id="f-992" unitRef="eur">14000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-275" decimals="-6" id="f-993" unitRef="eur">253000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-276" decimals="-6" id="f-994" unitRef="eur">9000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-277" decimals="-6" id="f-995" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-278" decimals="-6" id="f-996" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-279" decimals="-6" id="f-997" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-280" decimals="-6" id="f-998" unitRef="eur">253000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-281" decimals="-6" id="f-999" unitRef="eur">9000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-282" decimals="-6" id="f-1000" unitRef="eur">173000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-283" decimals="-6" id="f-1001" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-284" decimals="-6" id="f-1002" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-285" decimals="-6" id="f-1003" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-286" decimals="-6" id="f-1004" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-287" decimals="-6" id="f-1005" unitRef="eur">173000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-288" decimals="-6" id="f-1006" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-289" decimals="-6" id="f-1007" unitRef="eur">4418000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-290" decimals="-6" id="f-1008" unitRef="eur">-84000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-291" decimals="-6" id="f-1009" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-292" decimals="-6" id="f-1010" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-293" decimals="-6" id="f-1011" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-294" decimals="-6" id="f-1012" unitRef="eur">4418000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-295" decimals="-6" id="f-1013" unitRef="eur">-84000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-296" decimals="-6" id="f-1014" unitRef="eur">2540000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-297" decimals="-6" id="f-1015" unitRef="eur">-55000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-298" decimals="-6" id="f-1016" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-299" decimals="-6" id="f-1017" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-300" decimals="-6" id="f-1018" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-301" decimals="-6" id="f-1019" unitRef="eur">2540000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-302" decimals="-6" id="f-1020" unitRef="eur">-55000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-303" decimals="-6" id="f-1021" unitRef="eur">610000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-304" decimals="-6" id="f-1022" unitRef="eur">-15000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-305" decimals="-6" id="f-1023" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-306" decimals="-6" id="f-1024" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-307" decimals="-6" id="f-1025" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-308" decimals="-6" id="f-1026" unitRef="eur">610000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-309" decimals="-6" id="f-1027" unitRef="eur">-15000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-310" decimals="-6" id="f-1028" unitRef="eur">277000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-311" decimals="-6" id="f-1029" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-312" decimals="-6" id="f-1030" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-313" decimals="-6" id="f-1031" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-314" decimals="-6" id="f-1032" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-315" decimals="-6" id="f-1033" unitRef="eur">277000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-316" decimals="-6" id="f-1034" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-317" decimals="-6" id="f-1035" unitRef="eur">159000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-318" decimals="-6" id="f-1036" unitRef="eur">-4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-319" decimals="-6" id="f-1037" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-320" decimals="-6" id="f-1038" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-321" decimals="-6" id="f-1039" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-322" decimals="-6" id="f-1040" unitRef="eur">159000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-323" decimals="-6" id="f-1041" unitRef="eur">-4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-324" decimals="-6" id="f-1042" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-325" decimals="-6" id="f-1043" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-326" decimals="-6" id="f-1044" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-327" decimals="-6" id="f-1045" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-328" decimals="-6" id="f-1046" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-329" decimals="-6" id="f-1047" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-330" decimals="-6" id="f-1048" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-331" decimals="-6" id="f-1049" unitRef="eur">11037000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-332" decimals="-6" id="f-1050" unitRef="eur">49000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-333" decimals="-6" id="f-1051" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-334" decimals="-6" id="f-1052" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-335" decimals="-6" id="f-1053" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-336" decimals="-6" id="f-1054" unitRef="eur">11037000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-337" decimals="-6" id="f-1055" unitRef="eur">49000000</sny:DerivativeFinancialInstruments>
    <sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock contextRef="c-1" id="f-1056">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2025. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maximum expiry&#160;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cross currency seller swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,476&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,723&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;176&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;of which Japanese yen &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,808&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp;amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#x20ac;5&#160;million, with &#x20ac;18&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#x20ac;77 million; the opposite entry was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#x20ac;25 million, with &#x20ac;0 million&#160;credited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-338" decimals="-6" id="f-1057" unitRef="eur">1476000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-339" decimals="-6" id="f-1058" unitRef="eur">5000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-340" decimals="-6" id="f-1059" unitRef="eur">1476000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-341" decimals="-6" id="f-1060" unitRef="eur">5000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-247" decimals="-6" id="f-1061" unitRef="eur">7723000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-248" decimals="-6" id="f-1062" unitRef="eur">176000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-342" decimals="-6" id="f-1063" unitRef="eur">6007000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-343" decimals="-6" id="f-1064" unitRef="eur">148000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-344" decimals="-6" id="f-1065" unitRef="eur">601000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-345" decimals="-6" id="f-1066" unitRef="eur">7000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-346" decimals="-6" id="f-1067" unitRef="eur">303000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-347" decimals="-6" id="f-1068" unitRef="eur">9000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-289" decimals="-6" id="f-1069" unitRef="eur">3609000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-290" decimals="-6" id="f-1070" unitRef="eur">-44000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-348" decimals="-6" id="f-1071" unitRef="eur">1289000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-349" decimals="-6" id="f-1072" unitRef="eur">-14000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-350" decimals="-6" id="f-1073" unitRef="eur">1094000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-351" decimals="-6" id="f-1074" unitRef="eur">-33000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-352" decimals="-6" id="f-1075" unitRef="eur">639000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-353" decimals="-6" id="f-1076" unitRef="eur">7000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-331" decimals="-6" id="f-1077" unitRef="eur">12808000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-332" decimals="-6" id="f-1078" unitRef="eur">137000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <ifrs-full:NotionalAmount contextRef="c-354" decimals="-6" id="f-1079" unitRef="eur">870000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-355" decimals="-6" id="f-1080" unitRef="eur">870000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-356" decimals="-6" id="f-1081" unitRef="eur">5000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-357" decimals="-6" id="f-1082" unitRef="eur">18000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:NotionalAmount contextRef="c-358" decimals="-6" id="f-1083" unitRef="usd">3615000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-358" decimals="-6" id="f-1084" unitRef="eur">77000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-359" decimals="-6" id="f-1085" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-359" decimals="-6" id="f-1086" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-359" decimals="-6" id="f-1087" unitRef="eur">25000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-360" decimals="-6" id="f-1088" unitRef="eur">0</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock contextRef="c-1" id="f-1089">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.17%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 2.08% / receive Euribor 3m&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;848&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,348&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,498&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-361" decimals="-6" id="f-1090" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-361" decimals="-6" id="f-1091" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-362" decimals="-6" id="f-1092" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-362" decimals="-6" id="f-1093" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-363" decimals="-6" id="f-1094" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-363" decimals="-6" id="f-1095" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-364" decimals="-6" id="f-1096" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-364" decimals="-6" id="f-1097" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-365" id="f-1098" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-365" id="f-1099" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-366" decimals="-6" id="f-1100" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-366" decimals="-6" id="f-1101" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-367" decimals="-6" id="f-1102" unitRef="eur">-54000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-367" decimals="-6" id="f-1103" unitRef="eur">-54000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-368" decimals="-6" id="f-1104" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-368" decimals="-6" id="f-1105" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-369" decimals="-6" id="f-1106" unitRef="eur">-54000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-369" decimals="-6" id="f-1107" unitRef="eur">-54000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-370" id="f-1108" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-370" id="f-1109" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-371" id="f-1110" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-371" id="f-1111" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-372" decimals="-6" id="f-1112" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-372" decimals="-6" id="f-1113" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-373" decimals="-6" id="f-1114" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-374" id="f-1115" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-375" decimals="-6" id="f-1116" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-376" decimals="-6" id="f-1117" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-377" decimals="-6" id="f-1118" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-378" decimals="-6" id="f-1119" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-379" decimals="-6" id="f-1120" unitRef="eur">-7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-380" id="f-1121" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-381" id="f-1122" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-382" decimals="-6" id="f-1123" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-383" decimals="-6" id="f-1124" unitRef="eur">-7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-384" decimals="-6" id="f-1125" unitRef="eur">-3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-385"
      decimals="INF"
      id="f-1126"
      unitRef="number">0.0092</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-386" decimals="-6" id="f-1127" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-387" decimals="-6" id="f-1128" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-388" decimals="-6" id="f-1129" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-389" decimals="-6" id="f-1130" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-390" decimals="-6" id="f-1131" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-391" decimals="-6" id="f-1132" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-392" decimals="-6" id="f-1133" unitRef="eur">-27000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-393" decimals="-6" id="f-1134" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-394" decimals="-6" id="f-1135" unitRef="eur">-27000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-395" decimals="-6" id="f-1136" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-396" decimals="-6" id="f-1137" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-397" decimals="-6" id="f-1138" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-398" decimals="-6" id="f-1139" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-399" decimals="-6" id="f-1140" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-400" decimals="-6" id="f-1141" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-401" decimals="-6" id="f-1142" unitRef="eur">848000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-402" decimals="-6" id="f-1143" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-331" decimals="-6" id="f-1144" unitRef="eur">2348000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-332" decimals="-6" id="f-1145" unitRef="eur">-88000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-403" decimals="-6" id="f-1146" unitRef="eur">1498000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-404" decimals="-6" id="f-1147" unitRef="eur">-81000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-333" decimals="-6" id="f-1148" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-334" decimals="-6" id="f-1149" unitRef="eur">-7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-335" decimals="-6" id="f-1150" unitRef="eur">-3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock contextRef="c-1" id="f-1151">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="iaa43e806f1aa45c983dc11f10a287070"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.11. Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of the nature of the liabilities reported in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;MSD contingent consideration (European Vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;568&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;641&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;564&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2025, this comprised a non-current portion of &#x20ac;569 million and a current portion of &#x20ac;72 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#x20ac;563 million as of June&#160;30, 2025, compared with &#x20ac;568 million as of December 31, 2024. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture was extinguished during 2024 in accordance with the contractual terms. Sanofi has no further liability in respect of this contingent consideration following settlement of the milestone linked to 2024 sales.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock>
    <sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock contextRef="c-1" id="f-1152">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;MSD contingent consideration (European Vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;568&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;641&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;564&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2025, this comprised a non-current portion of &#x20ac;569 million and a current portion of &#x20ac;72 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-405" decimals="-6" id="f-1153" unitRef="eur">72000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-406" decimals="-6" id="f-1154" unitRef="eur">568000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-407" decimals="-6" id="f-1155" unitRef="eur">1000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-3" decimals="-6" id="f-1156" unitRef="eur">641000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-408" decimals="-6" id="f-1157" unitRef="eur">72000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-409" decimals="-6" id="f-1158" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-410" decimals="-6" id="f-1159" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-1160" unitRef="eur">72000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-408" decimals="-6" id="f-1161" unitRef="eur">1000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-409" decimals="-6" id="f-1162" unitRef="eur">71000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-410" decimals="-6" id="f-1163" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1" decimals="-6" id="f-1164" unitRef="eur">72000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-408" decimals="-6" id="f-1165" unitRef="eur">-1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-409" decimals="-6" id="f-1166" unitRef="eur">-76000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-410" decimals="-6" id="f-1167" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-1168" unitRef="eur">-77000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-411" decimals="-6" id="f-1169" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-412" decimals="-6" id="f-1170" unitRef="eur">563000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-413" decimals="-6" id="f-1171" unitRef="eur">1000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-2" decimals="-6" id="f-1172" unitRef="eur">564000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1173" unitRef="eur">0</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1174" unitRef="eur">564000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-1175" unitRef="eur">569000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-1176" unitRef="eur">72000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-412" decimals="-6" id="f-1177" unitRef="eur">563000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-406" decimals="-6" id="f-1178" unitRef="eur">568000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-412"
      decimals="2"
      id="f-1179"
      unitRef="number">0.10</sny:PercentageIncreaseInFairValueLiabilities>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock contextRef="c-1" id="f-1180">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i66ef10b1748b4d4696f08a72f348bef5"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.12. Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,116&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,096&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes &#x20ac;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,293 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,992&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,762&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans (B.12.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,705&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly transfers to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i298b3c160c444f929e628ff6396043d5"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provisions for pensions and other post-employment benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2024, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2025 to take into account changes during the first half of the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2025, Sanofi completed a further buy-in (amounting to &#x20ac;101&#160;million) to cover the remaining uninsured liabilities arising under the main defined benefit pension scheme in the United Kingdom. Consequently, all scheme members are now fully insured as a result of buy-in transactions, except for liabilities rising from guaranteed minimum pension equalization (as described in Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025     (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024     (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes actuarial gains/ (losses) related to Opella of &#x20ac;(4)&#160;million for the first half of 2025 and &#x20ac;(6)&#160;million for the first half of 2024 .&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1181">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,116&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,096&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes &#x20ac;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,293 million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1182" unitRef="eur">5003000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1183" unitRef="eur">5762000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-1184" unitRef="eur">2113000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-1185" unitRef="eur">2334000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-1186" unitRef="eur">7116000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-1187" unitRef="eur">8096000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-414" decimals="-6" id="f-1188" unitRef="eur">1756000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-415" decimals="-6" id="f-1189" unitRef="eur">1027000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-416" decimals="-6" id="f-1190" unitRef="eur">2293000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:DisclosureOfNonCurrentProvisionsTableTextBlock contextRef="c-1" id="f-1191">&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,992&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,762&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans (B.12.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,705&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly transfers to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNonCurrentProvisionsTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-417" decimals="-6" id="f-1192" unitRef="eur">1992000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-418" decimals="-6" id="f-1193" unitRef="eur">821000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-419" decimals="-6" id="f-1194" unitRef="eur">799000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-420" decimals="-6" id="f-1195" unitRef="eur">2150000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1196" unitRef="eur">5762000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-421" decimals="-6" id="f-1197" unitRef="eur">-69000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-422" decimals="-6" id="f-1198" unitRef="eur">-78000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-423" decimals="-6" id="f-1199" unitRef="eur">-175000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-424" decimals="-6" id="f-1200" unitRef="eur">-293000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1" decimals="-6" id="f-1201" unitRef="eur">-615000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-421" decimals="-6" id="f-1202" unitRef="eur">167000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-422" decimals="-6" id="f-1203" unitRef="eur">61000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-423" decimals="-6" id="f-1204" unitRef="eur">10000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-424" decimals="-6" id="f-1205" unitRef="eur">378000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1" decimals="-6" id="f-1206" unitRef="eur">616000000</ifrs-full:ProvisionUsedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-421" decimals="-6" id="f-1207" unitRef="eur">17000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-422" decimals="-6" id="f-1208" unitRef="eur">0</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-423" decimals="-6" id="f-1209" unitRef="eur">2000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-424" decimals="-6" id="f-1210" unitRef="eur">178000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1" decimals="-6" id="f-1211" unitRef="eur">197000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-421" decimals="-6" id="f-1212" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-422" decimals="-6" id="f-1213" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-423" decimals="-6" id="f-1214" unitRef="eur">-158000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-424" decimals="-6" id="f-1215" unitRef="eur">-93000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1" decimals="-6" id="f-1216" unitRef="eur">-255000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-421" decimals="-6" id="f-1217" unitRef="eur">37000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-422" decimals="-6" id="f-1218" unitRef="eur">1000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-423" decimals="-6" id="f-1219" unitRef="eur">2000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-424" decimals="-6" id="f-1220" unitRef="eur">20000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-1" decimals="-6" id="f-1221" unitRef="eur">60000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-421" decimals="-6" id="f-1222" unitRef="eur">-94000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-422" decimals="-6" id="f-1223" unitRef="eur">-74000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-423" decimals="-6" id="f-1224" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-424" decimals="-6" id="f-1225" unitRef="eur">-83000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1" decimals="-6" id="f-1226" unitRef="eur">-255000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-421" decimals="-6" id="f-1227" unitRef="eur">-111000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-422" decimals="-6" id="f-1228" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-423" decimals="-6" id="f-1229" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-424" decimals="-6" id="f-1230" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-1" decimals="-6" id="f-1231" unitRef="eur">-111000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-425" decimals="-6" id="f-1232" unitRef="eur">1705000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-426" decimals="-6" id="f-1233" unitRef="eur">765000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-427" decimals="-6" id="f-1234" unitRef="eur">802000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-428" decimals="-6" id="f-1235" unitRef="eur">1731000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1236" unitRef="eur">5003000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-429" decimals="-6" id="f-1237" unitRef="eur">101000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock contextRef="c-1" id="f-1238">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025     (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024     (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes actuarial gains/ (losses) related to Opella of &#x20ac;(4)&#160;million for the first half of 2025 and &#x20ac;(6)&#160;million for the first half of 2024 .&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-430" decimals="-6" id="f-1239" unitRef="eur">45000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-431" decimals="-6" id="f-1240" unitRef="eur">138000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-432" decimals="-6" id="f-1241" unitRef="eur">152000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-433" decimals="-6" id="f-1242" unitRef="eur">373000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="c-434"
      decimals="4"
      id="f-1243"
      unitRef="number">0.0000</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-435"
      decimals="4"
      id="f-1244"
      unitRef="number">0.0030</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-436"
      decimals="4"
      id="f-1245"
      unitRef="number">0.0030</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-437"
      decimals="4"
      id="f-1246"
      unitRef="number">0.0040</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-438"
      decimals="4"
      id="f-1247"
      unitRef="number">0.0065</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-439"
      decimals="4"
      id="f-1248"
      unitRef="number">0.0010</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-440" decimals="-6" id="f-1249" unitRef="eur">-4000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-441" decimals="-6" id="f-1250" unitRef="eur">-6000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock contextRef="c-1" id="f-1251">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="if13b4d11bd91484d826b9b625505475d"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13. Off balance sheet commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments to third parties as of December&#160;31, 2024 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal commitments entered into, amended or discontinued during the period are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;In April 2025, Sanofi entered into a license and collaboration agreement with Earendil Labs for two bispecific antibodies in the field of autoimmune and inflammatory bowel diseases: HXN-1002 (targeting &#x3b1;4&#x3b2;7 and TL1A for potential treatment of moderate to severe ulcerative colitis and Crohn's disease) and HXN-1003 (targeting TL1A and IL23 for potential treatment of colitis and skin inflammation). Under the terms of the agreement, Earendil Labs received an upfront payment of $125 million, is eligible to receive up to a total of $1.7 billion in development and commercial milestone payments, and is eligible to receive tiered royalties on product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2024 Form 20-F.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock>
    <sny:DisclosureOfLegalAndArbitralProceedingsTextBlock contextRef="c-1" id="f-1252">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i1c221f089c9a4af9901d6cb4e4acaee3"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.14. Litigation and arbitration proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i562e9106bf0241498655b78496fddfab"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.1. Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="iee905ab161554e27ac58988037567eef"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zantac product litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As regards the ongoing Zantac product  litigation in the US, the Separation Agreement (see Notes D.1 and D.22 to the consolidated financial statements in the 2024 Form 20-F) entered into between Sanofi and Opella specifies that Sanofi will indemnify the Opella group in respect of liabilities relating to (i) the commercialization of any Zantac branded products (i.e. products containing ranitidine as their active pharmaceutical ingredient) prior to closing, and (ii) all personal injury claims resulting from the manufacturing or handling of Zantac prior to closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In April 2025, Sanofi reached several settlement deals that in total resolve a majority of the Delaware State Court consolidated litigation. In addition, in May 2025, Sanofi reached settlements with the City of Baltimore and the New Mexico Attorney General, amicably resolving both those matters. Other cases are pending in various state courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 10, 2025, the Delaware Supreme Court unanimously reversed the Superior Court&#x2019;s denial of Defendants&#x2019; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;motion based on the lack of reliability of plaintiff&#x2019;s experts on causation and remanded its findings back to the Superior Court for proceedings consistent with the rulings in the opinion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i705e5b570c5f4f11b9bf3e2e13c2c5f8"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Talc product litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2025, Sanofi was named as a defendant in approximately 900 ongoing product liability actions. To date, no cases have proceeded to trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i3b1346ea9ebb45569d3dcaf9303a1d2e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.2. Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="ic6e991b615794cb48c76d24520e17825"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Praluent (alirocumab)-related Amgen patent litigation in Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Regarding Amgen&#x2019;s EP 3 666 797, in April 2025, the Opposition Division of the European Patent Office ruled in Amgen&#x2019;s favor and decided to maintain the patent as granted. Sanofi has appealed this decision to the Technical Board of Appeals of the European Patent Office, and the appeal hearing is scheduled for April 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="ia6627e68f8924c1fbed2173501177e82"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plavix (clopidogrel) Litigation (Commonwealth) Litigation in Australia &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This matter has been finalized with no possibility of appeal. The matter is closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i3a96cd4646e3420c91ee3a27281ff538"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.3. Other litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i9d56b9e5932441cf91443bf4641a4ec5"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plavix (clopidogrel) - Attorney General action in Hawaii&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In May 2025, the parties agreed to settle the Hawaii action, with Sanofi US to pay $350&#160;million pursuant to its settlement agreement and Bristol-Myers Squibb to pay $350&#160;million pursuant to its separate settlement agreement. The appeal and the underlying case were dismissed pursuant to the settlement. This matter is closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i5d5243e109504bcd98fabc418f1c66c3"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plavix (clopidogrel)-related litigation in France&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the claim filed by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Caisse Nationale d&#x2019;Assurance Maladie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013; CNAM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (French Social Security), hearings were held in June 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="id7f1b070fc274121b83d6d00bc45251c"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;340B drug pricing program in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the action filed by Sanofi against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA) and their respective administrators, following a joint hearing held on April 29, 2025 in Sanofi&#x2019;s case and the similar cases filed by Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos, the district court held on May 15, 2025 that, although Section 340B does not categorically prohibit the use of manufacturer rebates, it does not allow HRSA to require preapproval of a manufacturer rebate program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The district court also held that HRSA&#x2019;s letter determining that Sanofi would violate Section 340B if it launched its Credit (rebate) Model was arbitrary and capricious and remanded the Sanofi matter back to HRSA for further consideration. Eli Lilly, Bristol Myers Squibb, Novartis, and Kalderos appealed the district court&#x2019;s decision to the Circuit Court. Those appeals, along with a similar appeal by Johnson &amp;amp; Johnson, have been expedited and consolidated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ADR Proceedings in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June 2025, Sanofi received notice that Hudson Headwaters Health Network (Hudson Headwaters) had filed a petition for monetary relief against Sanofi before the HRSA ADR (Administrative Dispute Resolution) Panel. Hudson Headwaters alleges that Sanofi has violated Section 340B by allowing only one contract pharmacy to be selected and utilized per covered entity, if the covered entity does not have an in-house pharmacy capable of dispensing its drug. Hudson Headwaters alleges that this Sanofi policy is an &#x201c;overcharge&#x201d; under Section 340B. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;State Litigation in the US &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In lawsuits filed by PhRMA and certain other manufacturers challenging a contract pharmacy law passed by the State of Mississippi, the court denied for each of the plaintiffs their preliminary injunctions in their respective lawsuits. The plaintiffs appealed the denials of the preliminary injunction motions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Various other challenges to similar state laws have been filed by PhRMA and/or certain manufacturers in a number of other states, including in Colorado, Kansas, Louisiana, Maryland, Minnesota, Missouri, Nebraska, North Dakota, Oklahoma, Tennessee, Utah, South Dakota, and Vermont.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfLegalAndArbitralProceedingsTextBlock>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-442"
      decimals="INF"
      id="f-1253"
      unitRef="proceeding">0</sny:NumberOfClassActionLawsuits>
    <sny:PaymentOfDamagesClaimedByCounterparty contextRef="c-443" decimals="-6" id="f-1254" unitRef="eur">350000000</sny:PaymentOfDamagesClaimedByCounterparty>
    <sny:PenaltyFeeIncurred contextRef="c-443" decimals="-6" id="f-1255" unitRef="eur">350000000</sny:PenaltyFeeIncurred>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c-1" id="f-1256">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7c36aaced6214a41ba3422866e6c16dd"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.15. Other operating income and expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; amounted to &#x20ac;533 million in the first half of 2025 (versus &#x20ac;563 million in the first half of 2024), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; to &#x20ac;2,476 million (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;versus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &#x20ac; 1,977 million in the first half of 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main items included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; were: in the first half of 2025, (i) income from pharmaceutical partners of &#x20ac;87&#160;million (versus &#x20ac;121 million in the first half of 2024), of which &#x20ac;70 million came from Regeneron (versus &#x20ac;96 million in the first half of 2024, see table below) and (ii) gains on disposals of assets and operations of &#x20ac;344 million, primarily on divestments of non strategic products (versus &#x20ac;319 million in the first half of 2024). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for the first half of 2025 included &#x20ac;2,331 million of expenses related to Regeneron (compared with &#x20ac;1,841 million in the first half of 2024), as shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025       (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024       (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total: Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Other (mainly Zaltrap and Libtayo)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which amount presented in &#x201c;Other operating income&#x201d; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-1257" unitRef="eur">533000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-1258" unitRef="eur">563000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-1259" unitRef="eur">2476000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-1260" unitRef="eur">1977000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-444" decimals="-6" id="f-1261" unitRef="eur">87000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-445" decimals="-6" id="f-1262" unitRef="eur">121000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-446" decimals="-6" id="f-1263" unitRef="eur">70000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-447" decimals="-6" id="f-1264" unitRef="eur">96000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:GainsOnDivestmentOfProducts contextRef="c-444" decimals="-6" id="f-1265" unitRef="eur">344000000</sny:GainsOnDivestmentOfProducts>
    <sny:GainsOnDivestmentOfProducts contextRef="c-445" decimals="-6" id="f-1266" unitRef="eur">319000000</sny:GainsOnDivestmentOfProducts>
    <sny:OtherOperatingExpensesTableTextBlock contextRef="c-1" id="f-1267">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for the first half of 2025 included &#x20ac;2,331 million of expenses related to Regeneron (compared with &#x20ac;1,841 million in the first half of 2024), as shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025       (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024       (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total: Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Other (mainly Zaltrap and Libtayo)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which amount presented in &#x201c;Other operating income&#x201d; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:OtherOperatingExpensesTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-448" decimals="-6" id="f-1268" unitRef="eur">2331000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-449" decimals="-6" id="f-1269" unitRef="eur">1841000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-450" decimals="-6" id="f-1270" unitRef="eur">2475000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-451" decimals="-6" id="f-1271" unitRef="eur">1934000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-452" decimals="-6" id="f-1272" unitRef="eur">494000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-453" decimals="-6" id="f-1273" unitRef="eur">389000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-454" decimals="-6" id="f-1274" unitRef="eur">346000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-455" decimals="-6" id="f-1275" unitRef="eur">292000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-456" decimals="-6" id="f-1276" unitRef="eur">2327000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-457" decimals="-6" id="f-1277" unitRef="eur">1837000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-458" decimals="-6" id="f-1278" unitRef="eur">66000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-459" decimals="-6" id="f-1279" unitRef="eur">92000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-1280" unitRef="eur">-2261000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-4" decimals="-6" id="f-1281" unitRef="eur">-1745000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-446" decimals="-6" id="f-1282" unitRef="eur">70000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-447" decimals="-6" id="f-1283" unitRef="eur">96000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:DisclosureOfRestructuringTextBlock contextRef="c-1" id="f-1284">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i006acb851dac4f99bae83d4ef197fbbd"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16. Restructuring costs and similar items&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;Restructuring and similar costs decreased by &#x20ac;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;amp;D operations to make Sanofi a leader in immunology</sny:DisclosureOfRestructuringTextBlock>
    <sny:DisclosureOfRestructuringCostsDetailsTableTextBlock contextRef="c-1" id="f-1287">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsDetailsTableTextBlock>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-1286">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;Restructuring and similar costs decreased by &#x20ac;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;amp;D operations to make Sanofi a leader in immunology</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-1285">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;Restructuring and similar costs decreased by &#x20ac;630 million between June 30, 2024 and June 30, 2025. In the first half of 2024, restructuring and similar costs mainly comprised the impacts of (i) the renewal of the Job Management and Career Paths (GEPP) program in France to cover the 2024-2026 period, including scope extensions in the job profiles affected by transformations and (ii) a voluntary redundancy program announced in 2024 in connection with the reorganization of R&amp;amp;D operations to make Sanofi a leader in immunology</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-1" decimals="-6" id="f-1288" unitRef="eur">201000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-4" decimals="-6" id="f-1289" unitRef="eur">810000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-1" decimals="-6" id="f-1290" unitRef="eur">109000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-4" decimals="-6" id="f-1291" unitRef="eur">-27000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-1" decimals="-6" id="f-1292" unitRef="eur">80000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-4" decimals="-6" id="f-1293" unitRef="eur">114000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:OtherRestructuringCosts contextRef="c-1" decimals="-6" id="f-1294" unitRef="eur">40000000</sny:OtherRestructuringCosts>
    <sny:OtherRestructuringCosts contextRef="c-4" decimals="-6" id="f-1295" unitRef="eur">163000000</sny:OtherRestructuringCosts>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-1296" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-1297" unitRef="eur">1060000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities contextRef="c-460" decimals="-6" id="f-1298" unitRef="eur">-630000000</sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities>
    <sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock contextRef="c-1" id="f-1299">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7ee99a522aa34d97b31f94cdb6dc313a"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17. Other gains and losses, and litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For the first half of 2025, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is a charge of &#x20ac;57 million, mainly related to major litigation. That compares with a charge of &#x20ac;450 m&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;illion in the first half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-1300" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-1301" unitRef="eur">-450000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-1302">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i3f2720f484d742c9ae4964b2d83dbd0c"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.18. Financial expenses and income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;(25) million in the first half of 2025 and &#x20ac;(24) million in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(4) million in the first half of 2025 and &#x20ac;(18)&#160;million in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;Includes a financial expense of &#x20ac;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;million for the six months ended June 30, 2025 and &#x20ac;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of the ineffective portion of hedging relationships was not material in either 2025 or 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-1303">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;(25) million in the first half of 2025 and &#x20ac;(24) million in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(4) million in the first half of 2025 and &#x20ac;(18)&#160;million in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;Includes a financial expense of &#x20ac;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;million for the six months ended June 30, 2025 and &#x20ac;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-6" id="f-1304" unitRef="eur">219000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-4" decimals="-6" id="f-1305" unitRef="eur">306000000</ifrs-full:InterestExpenseOnBorrowings>
    <sny:InterestIncome contextRef="c-1" decimals="-6" id="f-1306" unitRef="eur">162000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-4" decimals="-6" id="f-1307" unitRef="eur">239000000</sny:InterestIncome>
    <sny:CostOfDebtNet contextRef="c-1" decimals="-6" id="f-1308" unitRef="eur">57000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-4" decimals="-6" id="f-1309" unitRef="eur">67000000</sny:CostOfDebtNet>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-1" decimals="-6" id="f-1310" unitRef="eur">1000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-4" decimals="-6" id="f-1311" unitRef="eur">0</sny:NonOperatingForeignExchangeGainsLosses>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-1" decimals="-6" id="f-1312" unitRef="eur">22000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-4" decimals="-6" id="f-1313" unitRef="eur">19000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-1" decimals="-6" id="f-1314" unitRef="eur">37000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-4" decimals="-6" id="f-1315" unitRef="eur">39000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-6" id="f-1316" unitRef="eur">22000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-4" decimals="-6" id="f-1317" unitRef="eur">20000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1318" unitRef="eur">-40000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1319" unitRef="eur">-161000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1320" unitRef="eur">-177000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1321" unitRef="eur">-306000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1322" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1323" unitRef="eur">583000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1324" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1325" unitRef="eur">277000000</ifrs-full:FinanceIncome>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-461" decimals="-6" id="f-1326" unitRef="eur">-25000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-462" decimals="-6" id="f-1327" unitRef="eur">-24000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-461" decimals="-6" id="f-1328" unitRef="eur">-4000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-462" decimals="-6" id="f-1329" unitRef="eur">-18000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-1" decimals="-6" id="f-1330" unitRef="eur">-50000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-4" decimals="-6" id="f-1331" unitRef="eur">-176000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-1332">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5300777f87c6406e8545c0c1004331b2"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.19. Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the&lt;br/&gt;                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;For the six months ended June 30, 2025, this line includes a tax expense of &#x20ac;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#x2019;s current understanding of Pillar Two rules, and &#x20ac;52&#160;million for the six months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock contextRef="c-1" id="f-1333">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;(6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1334" unitRef="eur">1202000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1335" unitRef="eur">1108000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1336" unitRef="eur">-491000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1337" unitRef="eur">-729000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-1338" unitRef="eur">711000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-1339" unitRef="eur">379000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1340" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1341" unitRef="eur">2462000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock contextRef="c-1" id="f-1342">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the&lt;br/&gt;                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;For the six months ended June 30, 2025, this line includes a tax expense of &#x20ac;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#x2019;s current understanding of Pillar Two rules, and &#x20ac;52&#160;million for the six months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-1343" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-4" decimals="3" id="f-1344" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-1" decimals="3" id="f-1345" unitRef="number">-0.073</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-4" decimals="3" id="f-1346" unitRef="number">-0.155</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-1" decimals="3" id="f-1347" unitRef="number">0.023</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-4" decimals="3" id="f-1348" unitRef="number">0.023</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="3" id="f-1349" unitRef="number">-0.010</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-4" decimals="3" id="f-1350" unitRef="number">0.028</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-1351" unitRef="number">0.198</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-4" decimals="3" id="f-1352" unitRef="number">0.154</ifrs-full:AverageEffectiveTaxRate>
    <sny:CurrentTaxExpenseRelatedToPillarTwo contextRef="c-1" decimals="-6" id="f-1353" unitRef="eur">17000000</sny:CurrentTaxExpenseRelatedToPillarTwo>
    <sny:CurrentTaxExpenseRelatedToPillarTwo contextRef="c-4" decimals="-6" id="f-1354" unitRef="eur">52000000</sny:CurrentTaxExpenseRelatedToPillarTwo>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-1355">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i52a8186c44054bbe8274d7f029df5eba"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.20. Revenue from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i5a65fe3ac5364662bb96cd50b9aad65c"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.1. Analysis of net sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2025 and June 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,072&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,292&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare diseases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme/Nexviadyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cablivi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Xenpozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Neurology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aubagio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tzield &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccine (Beyfortus) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,072&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,292&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i159fef8eaf084bf697cb00fb8e4ea868"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.2. Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe sales of non-Sanofi products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales to Opella &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biopharma Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,246&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,352&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales / Revenues from Opella products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,452&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-1356">&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2025 and June 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,072&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,292&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare diseases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme/Nexviadyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cablivi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Xenpozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Neurology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aubagio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tzield &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccine (Beyfortus) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,072&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,292&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-463" decimals="-6" id="f-1357" unitRef="eur">4144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-464" decimals="-6" id="f-1358" unitRef="eur">9535000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-465" decimals="-6" id="f-1359" unitRef="eur">6210000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-78" decimals="-6" id="f-1360" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-466" decimals="-6" id="f-1361" unitRef="eur">4072000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-467" decimals="-6" id="f-1362" unitRef="eur">8292000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-468" decimals="-6" id="f-1363" unitRef="eur">5996000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-469" decimals="-6" id="f-1364" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-470" decimals="-6" id="f-1365" unitRef="eur">944000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-471" decimals="-6" id="f-1366" unitRef="eur">5283000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-472" decimals="-6" id="f-1367" unitRef="eur">1085000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-473" decimals="-6" id="f-1368" unitRef="eur">7312000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-474" decimals="-6" id="f-1369" unitRef="eur">770000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-475" decimals="-6" id="f-1370" unitRef="eur">4437000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-476" decimals="-6" id="f-1371" unitRef="eur">931000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-477" decimals="-6" id="f-1372" unitRef="eur">6138000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-478" decimals="-6" id="f-1373" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-479" decimals="-6" id="f-1374" unitRef="eur">456000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-480" decimals="-6" id="f-1375" unitRef="eur">86000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-481" decimals="-6" id="f-1376" unitRef="eur">542000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-482" decimals="-6" id="f-1377" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-483" decimals="-6" id="f-1378" unitRef="eur">259000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-484" decimals="-6" id="f-1379" unitRef="eur">21000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-485" decimals="-6" id="f-1380" unitRef="eur">280000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-486" decimals="-6" id="f-1381" unitRef="eur">132000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-487" decimals="-6" id="f-1382" unitRef="eur">195000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-488" decimals="-6" id="f-1383" unitRef="eur">60000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-489" decimals="-6" id="f-1384" unitRef="eur">387000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-490" decimals="-6" id="f-1385" unitRef="eur">95000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-491" decimals="-6" id="f-1386" unitRef="eur">174000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-492" decimals="-6" id="f-1387" unitRef="eur">51000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-493" decimals="-6" id="f-1388" unitRef="eur">320000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-494" decimals="-6" id="f-1389" unitRef="eur">55000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-495" decimals="-6" id="f-1390" unitRef="eur">71000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-496" decimals="-6" id="f-1391" unitRef="eur">10000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-497" decimals="-6" id="f-1392" unitRef="eur">136000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-498" decimals="-6" id="f-1393" unitRef="eur">43000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-499" decimals="-6" id="f-1394" unitRef="eur">60000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-500" decimals="-6" id="f-1395" unitRef="eur">10000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-501" decimals="-6" id="f-1396" unitRef="eur">113000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-502" decimals="-6" id="f-1397" unitRef="eur">44000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-503" decimals="-6" id="f-1398" unitRef="eur">47000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-504" decimals="-6" id="f-1399" unitRef="eur">19000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-505" decimals="-6" id="f-1400" unitRef="eur">110000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-506" decimals="-6" id="f-1401" unitRef="eur">24000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-507" decimals="-6" id="f-1402" unitRef="eur">37000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-508" decimals="-6" id="f-1403" unitRef="eur">11000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-509" decimals="-6" id="f-1404" unitRef="eur">72000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-510" decimals="-6" id="f-1405" unitRef="eur">40000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-511" decimals="-6" id="f-1406" unitRef="eur">76000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-512" decimals="-6" id="f-1407" unitRef="eur">22000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-513" decimals="-6" id="f-1408" unitRef="eur">138000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-514" decimals="-6" id="f-1409" unitRef="eur">95000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-515" decimals="-6" id="f-1410" unitRef="eur">96000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-516" decimals="-6" id="f-1411" unitRef="eur">18000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-517" decimals="-6" id="f-1412" unitRef="eur">209000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-518" decimals="-6" id="f-1413" unitRef="eur">83000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-519" decimals="-6" id="f-1414" unitRef="eur">119000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-520" decimals="-6" id="f-1415" unitRef="eur">74000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-521" decimals="-6" id="f-1416" unitRef="eur">276000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-522" decimals="-6" id="f-1417" unitRef="eur">64000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-523" decimals="-6" id="f-1418" unitRef="eur">100000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-524" decimals="-6" id="f-1419" unitRef="eur">63000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-525" decimals="-6" id="f-1420" unitRef="eur">227000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-526" decimals="-6" id="f-1421" unitRef="eur">23000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-527" decimals="-6" id="f-1422" unitRef="eur">220000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-528" decimals="-6" id="f-1423" unitRef="eur">20000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-529" decimals="-6" id="f-1424" unitRef="eur">263000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-530" decimals="-6" id="f-1425" unitRef="eur">12000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-531" decimals="-6" id="f-1426" unitRef="eur">188000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-532" decimals="-6" id="f-1427" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-533" decimals="-6" id="f-1428" unitRef="eur">207000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-534" decimals="-6" id="f-1429" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-535" decimals="-6" id="f-1430" unitRef="eur">27000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-536" decimals="-6" id="f-1431" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-537" decimals="-6" id="f-1432" unitRef="eur">29000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-538" decimals="-6" id="f-1433" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-539" decimals="-6" id="f-1434" unitRef="eur">20000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-540" decimals="-6" id="f-1435" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-541" decimals="-6" id="f-1436" unitRef="eur">21000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-542" decimals="-6" id="f-1437" unitRef="eur">241000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-543" decimals="-6" id="f-1438" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-544" decimals="-6" id="f-1439" unitRef="eur">9000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-545" decimals="-6" id="f-1440" unitRef="eur">251000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-546" decimals="-6" id="f-1441" unitRef="eur">273000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-547" decimals="-6" id="f-1442" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-548" decimals="-6" id="f-1443" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-549" decimals="-6" id="f-1444" unitRef="eur">274000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-550" decimals="-6" id="f-1445" unitRef="eur">223000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-551" decimals="-6" id="f-1446" unitRef="eur">320000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-552" decimals="-6" id="f-1447" unitRef="eur">818000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-553" decimals="-6" id="f-1448" unitRef="eur">1361000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-554" decimals="-6" id="f-1449" unitRef="eur">248000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-555" decimals="-6" id="f-1450" unitRef="eur">311000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-556" decimals="-6" id="f-1451" unitRef="eur">789000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-557" decimals="-6" id="f-1452" unitRef="eur">1348000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-558" decimals="-6" id="f-1453" unitRef="eur">96000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-559" decimals="-6" id="f-1454" unitRef="eur">319000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-560" decimals="-6" id="f-1455" unitRef="eur">194000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-561" decimals="-6" id="f-1456" unitRef="eur">609000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-562" decimals="-6" id="f-1457" unitRef="eur">97000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-563" decimals="-6" id="f-1458" unitRef="eur">301000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-564" decimals="-6" id="f-1459" unitRef="eur">185000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-565" decimals="-6" id="f-1460" unitRef="eur">583000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-566" decimals="-6" id="f-1461" unitRef="eur">85000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-567" decimals="-6" id="f-1462" unitRef="eur">68000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-568" decimals="-6" id="f-1463" unitRef="eur">203000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-569" decimals="-6" id="f-1464" unitRef="eur">356000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-570" decimals="-6" id="f-1465" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-571" decimals="-6" id="f-1466" unitRef="eur">116000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-572" decimals="-6" id="f-1467" unitRef="eur">77000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-573" decimals="-6" id="f-1468" unitRef="eur">200000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-574" decimals="-6" id="f-1469" unitRef="eur">52000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-575" decimals="-6" id="f-1470" unitRef="eur">54000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-576" decimals="-6" id="f-1471" unitRef="eur">108000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-577" decimals="-6" id="f-1472" unitRef="eur">214000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-578" decimals="-6" id="f-1473" unitRef="eur">30000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-579" decimals="-6" id="f-1474" unitRef="eur">16000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-580" decimals="-6" id="f-1475" unitRef="eur">142000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-581" decimals="-6" id="f-1476" unitRef="eur">188000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-582" decimals="-6" id="f-1477" unitRef="eur">4144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-583" decimals="-6" id="f-1478" unitRef="eur">9535000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-584" decimals="-6" id="f-1479" unitRef="eur">6210000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-1480" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-585" decimals="-6" id="f-1481" unitRef="eur">4072000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-586" decimals="-6" id="f-1482" unitRef="eur">8292000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-587" decimals="-6" id="f-1483" unitRef="eur">5996000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-1484" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:DisclosureOfOtherRevenueTextBlock contextRef="c-1" id="f-1485">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025  (6&#160;months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6&#160;months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe sales of non-Sanofi products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales to Opella &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biopharma Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,246&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,352&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales / Revenues from Opella products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,452&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOtherRevenueTextBlock>
    <sny:RevenueFromVaxServeSalesOfNonSanofiProducts contextRef="c-78" decimals="-6" id="f-1486" unitRef="eur">842000000</sny:RevenueFromVaxServeSalesOfNonSanofiProducts>
    <sny:RevenueFromVaxServeSalesOfNonSanofiProducts contextRef="c-469" decimals="-6" id="f-1487" unitRef="eur">854000000</sny:RevenueFromVaxServeSalesOfNonSanofiProducts>
    <sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations contextRef="c-78" decimals="-6" id="f-1488" unitRef="eur">61000000</sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations>
    <sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations contextRef="c-469" decimals="-6" id="f-1489" unitRef="eur">95000000</sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations>
    <ifrs-full:RevenueFromRoyalties contextRef="c-78" decimals="-6" id="f-1490" unitRef="eur">68000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="c-469" decimals="-6" id="f-1491" unitRef="eur">62000000</ifrs-full:RevenueFromRoyalties>
    <sny:MiscellaneousOtherRevenue contextRef="c-78" decimals="-6" id="f-1492" unitRef="eur">275000000</sny:MiscellaneousOtherRevenue>
    <sny:MiscellaneousOtherRevenue contextRef="c-469" decimals="-6" id="f-1493" unitRef="eur">341000000</sny:MiscellaneousOtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-78" decimals="-6" id="f-1494" unitRef="eur">1246000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-469" decimals="-6" id="f-1495" unitRef="eur">1352000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-588" decimals="-6" id="f-1496" unitRef="eur">206000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-589" decimals="-6" id="f-1497" unitRef="eur">177000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-1498" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-4" decimals="-6" id="f-1499" unitRef="eur">1529000000</ifrs-full:OtherRevenue>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-1500">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i557cf676139c4011ad72a0e3d410b685"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21. Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The segment information presented by Sanofi consists of a single operating segment: Biopharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella, which constitutes a related party with effect from the deconsolidation date (April 30, 2025). Those revenues, which before that date represented intragroup transactions classified within continuing operations, are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ice051a960b0f48668ab8553db2de5368"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.1. Segment results&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%"&gt;Sanofi reports segment results on the basis of &#x201c;Business operating income&#x201d;. This indicator is used internally by Sanofi&#x2019;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Business operating income&#x201d; is derived from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, adjusted as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts reported within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;other gains and losses (including gains and losses on major divestments), presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;other costs and provisions related to litigation, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the portion attributable to non-controlling interests related to continuing operations and excluding the effects of the above reconciliation items, is deducted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-6.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+16.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+15.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+16.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+14.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+11.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+11.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,347&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+8.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+11.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;-27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;-27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+8.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+10.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;26.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;27.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.924%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months) (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,916&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,938&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6&#160;months) (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,938&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,759&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,768&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#x20ac;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See Note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;See Note B.17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i742dec16cfa84e3b9d7429184f7f1072"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.2. Other segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the split by operating segment of (i)&#160;the carrying amount of investments in joint ventures and associates accounted for using the equity method with which Sanofi has entered into a collaboration agreement; (ii)&#160;acquisitions of property, plant and equipment; and (iii)&#160;acquisitions of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp;amp; Co. H&#xf6;chst&#160;KG (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i7e465b35c3514c8eba9eaaae5e6df42e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.3. Information by geographical region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,574&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40,283&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,091&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,384&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,629&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2024, goodwill is not allocated by geographical region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i118884e44be846e89e084fafd4dfd51b"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.4. Disclosures about major customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 35% of net sales in the first half of 2025. Sanofi&#x2019;s three largest customers respectively accounted for approximately 18%, 12% and 5% of consolidated net sales in the first half of 2025 (versus approximately 13%, 9% and 7% in the first half of 2024).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c-1" id="f-1501">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2024 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-6.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+16.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+15.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+16.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+14.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+11.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+11.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+4.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,347&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+8.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+11.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;-27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;-27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+8.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+10.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;26.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;27.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.924%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months) (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,916&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,938&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-78" decimals="-6" id="f-1502" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-590" id="f-1503" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-591" decimals="-6" id="f-1504" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-78" decimals="-6" id="f-1505" unitRef="eur">1246000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-590" decimals="-6" id="f-1506" unitRef="eur">206000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-591" decimals="-6" id="f-1507" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-78" decimals="-6" id="f-1508" unitRef="eur">5753000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-590" decimals="-6" id="f-1509" unitRef="eur">128000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-591" decimals="-6" id="f-1510" unitRef="eur">5881000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-78" decimals="-6" id="f-1511" unitRef="eur">3716000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-590" decimals="-6" id="f-1512" unitRef="eur">1000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-591" decimals="-6" id="f-1513" unitRef="eur">3717000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-78" decimals="-6" id="f-1514" unitRef="eur">4447000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-590" decimals="-6" id="f-1515" unitRef="eur">59000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-591" decimals="-6" id="f-1516" unitRef="eur">4506000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-78" decimals="-6" id="f-1517" unitRef="eur">-1941000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-590" decimals="-6" id="f-1518" unitRef="eur">-2000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-591" decimals="-6" id="f-1519" unitRef="eur">-1943000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-78" decimals="-6" id="f-1520" unitRef="eur">77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-590" decimals="-6" id="f-1521" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-591" decimals="-6" id="f-1522" unitRef="eur">77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-78" decimals="-6" id="f-1523" unitRef="eur">-8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-590" decimals="-6" id="f-1524" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-591" decimals="-6" id="f-1525" unitRef="eur">-8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-78" decimals="-6" id="f-1526" unitRef="eur">5347000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-590" decimals="-6" id="f-1527" unitRef="eur">16000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-591" decimals="-6" id="f-1528" unitRef="eur">5363000000</sny:BusinessOperatingIncome>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-469" decimals="-6" id="f-1529" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-592" id="f-1530" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-593" decimals="-6" id="f-1531" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-469" decimals="-6" id="f-1532" unitRef="eur">1352000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-592" decimals="-6" id="f-1533" unitRef="eur">177000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-593" decimals="-6" id="f-1534" unitRef="eur">1529000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-469" decimals="-6" id="f-1535" unitRef="eur">5849000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-592" decimals="-6" id="f-1536" unitRef="eur">110000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-593" decimals="-6" id="f-1537" unitRef="eur">5959000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-469" decimals="-6" id="f-1538" unitRef="eur">3334000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-592" decimals="-6" id="f-1539" unitRef="eur">1000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-593" decimals="-6" id="f-1540" unitRef="eur">3335000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-469" decimals="-6" id="f-1541" unitRef="eur">4247000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-592" decimals="-6" id="f-1542" unitRef="eur">56000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-593" decimals="-6" id="f-1543" unitRef="eur">4303000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-469" decimals="-6" id="f-1544" unitRef="eur">-1426000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-592" decimals="-6" id="f-1545" unitRef="eur">12000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-593" decimals="-6" id="f-1546" unitRef="eur">-1414000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-469" decimals="-6" id="f-1547" unitRef="eur">66000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-592" decimals="-6" id="f-1548" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-593" decimals="-6" id="f-1549" unitRef="eur">66000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-469" decimals="-6" id="f-1550" unitRef="eur">-6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-592" decimals="-6" id="f-1551" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-593" decimals="-6" id="f-1552" unitRef="eur">-6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-469" decimals="-6" id="f-1553" unitRef="eur">4916000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-592" decimals="-6" id="f-1554" unitRef="eur">22000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-593" decimals="-6" id="f-1555" unitRef="eur">4938000000</sny:BusinessOperatingIncome>
    <sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock contextRef="c-1" id="f-1556">&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6&#160;months) (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,938&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,759&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,768&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#x20ac;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See Note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;See Note B.17.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock>
    <sny:BusinessOperatingIncome contextRef="c-594" decimals="-6" id="f-1557" unitRef="eur">5363000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-595" decimals="-6" id="f-1558" unitRef="eur">4938000000</sny:BusinessOperatingIncome>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-596" decimals="-6" id="f-1559" unitRef="eur">-77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-597" decimals="-6" id="f-1560" unitRef="eur">-66000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-596" decimals="-6" id="f-1561" unitRef="eur">8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-597" decimals="-6" id="f-1562" unitRef="eur">6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-596" decimals="-6" id="f-1563" unitRef="eur">987000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-597" decimals="-6" id="f-1564" unitRef="eur">527000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-596" decimals="-6" id="f-1565" unitRef="eur">61000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-597" decimals="-6" id="f-1566" unitRef="eur">66000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-596" decimals="-6" id="f-1567" unitRef="eur">0</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-597" decimals="-6" id="f-1568" unitRef="eur">7000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-596" decimals="-6" id="f-1569" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-597" decimals="-6" id="f-1570" unitRef="eur">1060000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-596" decimals="-6" id="f-1571" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-597" decimals="-6" id="f-1572" unitRef="eur">-450000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-1573" unitRef="eur">3759000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-1574" unitRef="eur">2768000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1575" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1576" unitRef="eur">583000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1577" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1578" unitRef="eur">277000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1579" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1580" unitRef="eur">2462000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill contextRef="c-117" decimals="-6" id="f-1581" unitRef="eur">210000000</sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-1582" unitRef="eur">-371000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock contextRef="c-1" id="f-1583">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-598" decimals="-6" id="f-1584" unitRef="eur">483000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-599" decimals="-6" id="f-1585" unitRef="eur">229000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-78" decimals="-6" id="f-1586" unitRef="eur">845000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-469" decimals="-6" id="f-1587" unitRef="eur">882000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-78" decimals="-6" id="f-1588" unitRef="eur">575000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-469" decimals="-6" id="f-1589" unitRef="eur">922000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-582" decimals="-6" id="f-1590" unitRef="eur">4144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-585" decimals="-6" id="f-1591" unitRef="eur">4072000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-600" decimals="-6" id="f-1592" unitRef="eur">835000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-601" decimals="-6" id="f-1593" unitRef="eur">855000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-583" decimals="-6" id="f-1594" unitRef="eur">9535000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-586" decimals="-6" id="f-1595" unitRef="eur">8292000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-602" decimals="-6" id="f-1596" unitRef="eur">6210000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-603" decimals="-6" id="f-1597" unitRef="eur">5996000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-604" decimals="-6" id="f-1598" unitRef="eur">1388000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-605" decimals="-6" id="f-1599" unitRef="eur">1406000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-606" decimals="-6" id="f-1600" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-607" decimals="-6" id="f-1601" unitRef="eur">18360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-1602">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.165%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,574&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40,283&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,091&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,384&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,629&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-608" decimals="-6" id="f-1603" unitRef="eur">5438000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-608" decimals="-6" id="f-1604" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-608" decimals="-6" id="f-1605" unitRef="eur">3167000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-609" decimals="-6" id="f-1606" unitRef="eur">5550000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-609" decimals="-6" id="f-1607" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-609" decimals="-6" id="f-1608" unitRef="eur">3307000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-610" decimals="-6" id="f-1609" unitRef="eur">2953000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-610" decimals="-6" id="f-1610" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-610" decimals="-6" id="f-1611" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-611" decimals="-6" id="f-1612" unitRef="eur">3112000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-611" decimals="-6" id="f-1613" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-611" decimals="-6" id="f-1614" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-612" decimals="-6" id="f-1615" unitRef="eur">2080000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-612" decimals="-6" id="f-1616" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-612" decimals="-6" id="f-1617" unitRef="eur">16725000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-613" decimals="-6" id="f-1618" unitRef="eur">2411000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-613" decimals="-6" id="f-1619" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-613" decimals="-6" id="f-1620" unitRef="eur">18711000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-614" decimals="-6" id="f-1621" unitRef="eur">2056000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-614" decimals="-6" id="f-1622" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-614" decimals="-6" id="f-1623" unitRef="eur">539000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-615" decimals="-6" id="f-1624" unitRef="eur">2130000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-615" decimals="-6" id="f-1625" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-615" decimals="-6" id="f-1626" unitRef="eur">611000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-616" decimals="-6" id="f-1627" unitRef="eur">83000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-616" decimals="-6" id="f-1628" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-616" decimals="-6" id="f-1629" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-617" decimals="-6" id="f-1630" unitRef="eur">96000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-617" decimals="-6" id="f-1631" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-617" decimals="-6" id="f-1632" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-618" decimals="-6" id="f-1633" unitRef="eur">9574000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-618" decimals="-6" id="f-1634" unitRef="eur">40283000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-618" decimals="-6" id="f-1635" unitRef="eur">20431000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-619" decimals="-6" id="f-1636" unitRef="eur">10091000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-619" decimals="-6" id="f-1637" unitRef="eur">43384000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-619" decimals="-6" id="f-1638" unitRef="eur">22629000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-620"
      decimals="2"
      id="f-1639"
      unitRef="number">0.35</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-621"
      decimals="2"
      id="f-1640"
      unitRef="number">0.18</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-622"
      decimals="2"
      id="f-1641"
      unitRef="number">0.12</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-623"
      decimals="2"
      id="f-1642"
      unitRef="number">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-624"
      decimals="2"
      id="f-1643"
      unitRef="number">0.13</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-625"
      decimals="2"
      id="f-1644"
      unitRef="number">0.09</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-626"
      decimals="2"
      id="f-1645"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory contextRef="c-1" id="f-1646">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i1731ee5f715a4ab4931699f4917632dc"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.22. Information related to Opella, presented within assets held for sale and discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30 2025, the Opella transaction was closed (see Note B.1.) triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. As of December 31, 2024, all Opella assets and associated liabilities were classified as held for sale, in accordance with IFRS 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment owned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total  assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,489&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total liabilities related to assets held for sale &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,131&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, were measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the main items presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,645&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; In 2025, this line includes an expense of &#x20ac;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below presents basic and diluted earnings per share from discontinued operations (Opella), in accordance with IAS 33 (Earnings per Share):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding (million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares after dilution (million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,230.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Basic earnings per share (in euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share (in euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock contextRef="c-1" id="f-1647">As of December 31, 2024, all Opella assets and associated liabilities were classified as held for sale, in accordance with IFRS 5.&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment owned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total  assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,489&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total liabilities related to assets held for sale &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#661de8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,131&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#661de8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, were measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the main items presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,645&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; In 2025, this line includes an expense of &#x20ac;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below presents basic and diluted earnings per share from discontinued operations (Opella), in accordance with IAS 33 (Earnings per Share):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding (million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares after dilution (million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,230.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Basic earnings per share (in euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share (in euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock>
    <sny:PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1648" unitRef="eur">760000000</sny:PropertyPlantAndEquipmenetDisposalGroupIncludingDiscontinuedOperations>
    <sny:RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1649" unitRef="eur">116000000</sny:RightOfUseAssetsDisposalGroupIncludingDiscontinuedOperations>
    <sny:GoodwillDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1650" unitRef="eur">7255000000</sny:GoodwillDisposalGroupIncludingDiscontinuedOperations>
    <sny:OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1651" unitRef="eur">2928000000</sny:OtherIntangibleAssetsDisposalGroupIncludingDiscontinuedOperations>
    <sny:InventoriesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1652" unitRef="eur">600000000</sny:InventoriesDisposalGroupIncludingDiscontinuedOperations>
    <sny:AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1653" unitRef="eur">989000000</sny:AccountsReceivablesDisposalGroupIncludingDiscontinuedOperations>
    <sny:OtherAssetsDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1654" unitRef="eur">841000000</sny:OtherAssetsDisposalGroupIncludingDiscontinuedOperations>
    <sny:AssetsOfDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1655" unitRef="eur">13489000000</sny:AssetsOfDisposalGroupIncludingDiscontinuedOperations>
    <sny:LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1656" unitRef="eur">112000000</sny:LeaseLiabilitiesDisposalGroupIncludingDiscontinuedOperations>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1657" unitRef="eur">204000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations>
    <sny:AccountsPayableDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1658" unitRef="eur">797000000</sny:AccountsPayableDisposalGroupIncludingDiscontinuedOperations>
    <sny:CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1659" unitRef="eur">570000000</sny:CurrentProvisionsAndOtherCurrentLiabilitiesDisposalGroupIncludingDiscontinuedOperations>
    <sny:OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1660" unitRef="eur">448000000</sny:OtherLiabilitiesDisposalGroupIncludingDiscontinuedOperations>
    <sny:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations contextRef="c-2" decimals="-6" id="f-1661" unitRef="eur">2131000000</sny:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperations>
    <sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1662" unitRef="eur">1736000000</sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations>
    <sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1663" unitRef="eur">2645000000</sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations>
    <sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1664" unitRef="eur">266000000</sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations>
    <sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1665" unitRef="eur">277000000</sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations>
    <sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1666" unitRef="eur">2781000000</sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations>
    <sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1667" unitRef="eur">0</sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1668" unitRef="eur">3039000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1669" unitRef="eur">278000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1670" unitRef="eur">-158000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1671" unitRef="eur">-85000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1672" unitRef="eur">2881000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1673" unitRef="eur">202000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-627" decimals="-6" id="f-1674" unitRef="eur">88000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1675" unitRef="eur">2881000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-1676" unitRef="eur">202000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:WeightedAverageShares
      contextRef="c-1"
      decimals="INF"
      id="f-1677"
      unitRef="shares">1225500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c-4"
      decimals="INF"
      id="f-1678"
      unitRef="shares">1249400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c-1"
      decimals="INF"
      id="f-1679"
      unitRef="shares">1230700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c-4"
      decimals="INF"
      id="f-1680"
      unitRef="shares">1253800000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="INF"
      id="f-1681"
      unitRef="eurPerShare">2.34</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="INF"
      id="f-1682"
      unitRef="eurPerShare">0.16</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="INF"
      id="f-1683"
      unitRef="eurPerShare">2.33</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="INF"
      id="f-1684"
      unitRef="eurPerShare">0.16</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1685">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i23ea087f4ae74ebaa993bb45daf2618f"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;C/ Events subsequent to June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 22, 2025, Sanofi announced that it had entered into an agreement to acquire Vicebio Ltd (&#x201c;Vicebio&#x201d;), a privately held biotechnology company headquartered in London, UK. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands Sanofi&#x2019;s capabilities in vaccine design and development with Vicebio&#x2019;s &#x2018;Molecular Clamp&#x2019; technology. Under the terms of the agreement, Sanofi would acquire all of Vicebio&#x2019;s share capital for a total upfront payment of $1.15&#160;billion, with potential milestone payments of up to $450&#160;million based on development and regulatory achievements. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <sny:UpfrontPayments contextRef="c-628" decimals="-7" id="f-1686" unitRef="usd">1150000000</sny:UpfrontPayments>
    <sny:TotalMilestonePayments contextRef="c-628" decimals="-6" id="f-1687" unitRef="usd">450000000</sny:TotalMilestonePayments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-142"
          xlink:label="f-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-120"
          xlink:label="f-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-132"
          xlink:label="f-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-128"
          xlink:label="f-128"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-88" xlink:label="f-88" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-114"
          xlink:label="f-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1680"
          xlink:label="f-1680"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-110"
          xlink:label="f-110"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-100"
          xlink:label="f-100"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-144"
          xlink:label="f-144"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-94" xlink:label="f-94" xlink:type="locator"/>
        <link:loc xlink:href="#f-84" xlink:label="f-84" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-104"
          xlink:label="f-104"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-98" xlink:label="f-98" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-138"
          xlink:label="f-138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1301"
          xlink:label="f-1301"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-92" xlink:label="f-92" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-136"
          xlink:label="f-136"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-90" xlink:label="f-90" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-130"
          xlink:label="f-130"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-102"
          xlink:label="f-102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1582"
          xlink:label="f-1582"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1673"
          xlink:label="f-1673"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-124"
          xlink:label="f-124"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-126"
          xlink:label="f-126"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-82" xlink:label="f-82" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-134"
          xlink:label="f-134"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1678"
          xlink:label="f-1678"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-618"
          xlink:label="f-618"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1676"
          xlink:label="f-1676"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-118"
          xlink:label="f-118"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1684"
          xlink:label="f-1684"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-116"
          xlink:label="f-116"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1258"
          xlink:label="f-1258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1260"
          xlink:label="f-1260"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-140"
          xlink:label="f-140"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-86" xlink:label="f-86" xlink:type="locator"/>
        <link:loc xlink:href="#f-96" xlink:label="f-96" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-108"
          xlink:label="f-108"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1682"
          xlink:label="f-1682"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-122"
          xlink:label="f-122"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-106"
          xlink:label="f-106"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-112"
          xlink:label="f-112"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-142"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-120"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-132"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-128"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-88"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-114"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1680"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-110"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-100"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-144"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-94"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-84"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-104"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-98"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-138"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1301"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-92"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-136"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-90"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-130"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-102"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1582"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1673"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-124"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-126"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-82"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-134"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1678"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-618"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1676"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-118"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1684"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-116"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1258"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1260"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-140"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-86"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-96"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-108"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1682"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-122"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-106"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-112"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-148"
          xlink:label="f-148"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-174"
          xlink:label="f-174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-170"
          xlink:label="f-170"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-146"
          xlink:label="f-146"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-160"
          xlink:label="f-160"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-166"
          xlink:label="f-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-154"
          xlink:label="f-154"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-158"
          xlink:label="f-158"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-176"
          xlink:label="f-176"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-156"
          xlink:label="f-156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-180"
          xlink:label="f-180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-182"
          xlink:label="f-182"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-150"
          xlink:label="f-150"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-152"
          xlink:label="f-152"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-164"
          xlink:label="f-164"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-162"
          xlink:label="f-162"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-172"
          xlink:label="f-172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-168"
          xlink:label="f-168"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-178"
          xlink:label="f-178"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-148"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-174"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-170"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-146"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-160"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-166"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-154"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-158"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-176"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-156"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-180"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-182"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-150"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-152"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-164"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-162"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-172"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-168"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-178"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-348"
          xlink:label="f-348"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-214"
          xlink:label="f-214"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-332"
          xlink:label="f-332"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-350"
          xlink:label="f-350"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-262"
          xlink:label="f-262"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-347"
          xlink:label="f-347"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-215"
          xlink:label="f-215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-213"
          xlink:label="f-213"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-346"
          xlink:label="f-346"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-261"
          xlink:label="f-261"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-331"
          xlink:label="f-331"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-345"
          xlink:label="f-345"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-333"
          xlink:label="f-333"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-260"
          xlink:label="f-260"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-349"
          xlink:label="f-349"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-348"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-214"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-332"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-350"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-262"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-347"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-215"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-213"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-346"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-261"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-331"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-345"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-333"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-260"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-349"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-339"
          xlink:label="f-339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-338"
          xlink:label="f-338"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-340"
          xlink:label="f-340"
          xlink:type="locator"/>
        <link:footnote id="fn-4" xlink:label="fn-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-339"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-338"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-340"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-234"
          xlink:label="f-234"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-233"
          xlink:label="f-233"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-232"
          xlink:label="f-232"
          xlink:type="locator"/>
        <link:footnote id="fn-5" xlink:label="fn-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-234"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-233"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-232"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-358"
          xlink:label="f-358"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-359"
          xlink:label="f-359"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-357"
          xlink:label="f-357"
          xlink:type="locator"/>
        <link:footnote id="fn-6" xlink:label="fn-6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-358"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-359"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-357"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-360"
          xlink:label="f-360"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-361"
          xlink:label="f-361"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-363"
          xlink:label="f-363"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-362"
          xlink:label="f-362"
          xlink:type="locator"/>
        <link:footnote id="fn-7" xlink:label="fn-7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-360"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-361"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-363"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-362"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-402"
          xlink:label="f-402"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-442"
          xlink:label="f-442"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-424"
          xlink:label="f-424"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-460"
          xlink:label="f-460"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-378"
          xlink:label="f-378"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-456"
          xlink:label="f-456"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-444"
          xlink:label="f-444"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-446"
          xlink:label="f-446"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-452"
          xlink:label="f-452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-450"
          xlink:label="f-450"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-390"
          xlink:label="f-390"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-386"
          xlink:label="f-386"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-400"
          xlink:label="f-400"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-408"
          xlink:label="f-408"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-434"
          xlink:label="f-434"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-416"
          xlink:label="f-416"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-392"
          xlink:label="f-392"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-418"
          xlink:label="f-418"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-406"
          xlink:label="f-406"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-420"
          xlink:label="f-420"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-436"
          xlink:label="f-436"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-432"
          xlink:label="f-432"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-394"
          xlink:label="f-394"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-412"
          xlink:label="f-412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-382"
          xlink:label="f-382"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-430"
          xlink:label="f-430"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-428"
          xlink:label="f-428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-398"
          xlink:label="f-398"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-440"
          xlink:label="f-440"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-384"
          xlink:label="f-384"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-410"
          xlink:label="f-410"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-380"
          xlink:label="f-380"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-396"
          xlink:label="f-396"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-462"
          xlink:label="f-462"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-414"
          xlink:label="f-414"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-426"
          xlink:label="f-426"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-448"
          xlink:label="f-448"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-388"
          xlink:label="f-388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-454"
          xlink:label="f-454"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-404"
          xlink:label="f-404"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-438"
          xlink:label="f-438"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-376"
          xlink:label="f-376"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-374"
          xlink:label="f-374"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-422"
          xlink:label="f-422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-458"
          xlink:label="f-458"
          xlink:type="locator"/>
        <link:footnote id="fn-8" xlink:label="fn-8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-402"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-442"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-424"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-460"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-378"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-456"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-444"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-446"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-452"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-450"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-390"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-386"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-400"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-408"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-434"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-416"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-392"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-418"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-406"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-420"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-436"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-432"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-394"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-412"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-382"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-430"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-428"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-398"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-440"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-384"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-410"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-380"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-396"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-462"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-414"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-426"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-448"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-388"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-454"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-404"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-438"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-376"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-374"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-422"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-458"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-383"
          xlink:label="f-383"
          xlink:type="locator"/>
        <link:footnote id="fn-9" xlink:label="fn-9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes non-current financial assets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-384"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-383"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-387"
          xlink:label="f-387"
          xlink:type="locator"/>
        <link:footnote id="fn-10" xlink:label="fn-10" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item includes contributions paid to pension funds (see Note B.12.).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-388"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-387"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-393"
          xlink:label="f-393"
          xlink:type="locator"/>
        <link:footnote id="fn-11" xlink:label="fn-11" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-394"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-393"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-405"
          xlink:label="f-405"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-407"
          xlink:label="f-407"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-409"
          xlink:label="f-409"
          xlink:type="locator"/>
        <link:footnote id="fn-12" xlink:label="fn-12" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Of which:</xhtml:span><xhtml:div style="margin-bottom:5pt;text-align:justify"><xhtml:table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><xhtml:tr><xhtml:td style="width:1.0%"/><xhtml:td style="width:70.240%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.229%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.231%"/><xhtml:td style="width:0.1%"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td colspan="3" style="padding:0 1pt"/><xhtml:td
              colspan="3"
              style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025  (6&#160;months)</xhtml:span></xhtml:td><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:bottom"><xhtml:div style="text-align:right"><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2024</xhtml:span></xhtml:div><xhtml:div style="text-align:right"><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;(6 months) </xhtml:span><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,355)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,434)</xhtml:span></xhtml:td><xhtml:td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(206)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(320)</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#x2014;&#160;</xhtml:span></xhtml:td><xhtml:td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr></xhtml:table></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-408"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-406"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-405"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-410"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-407"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-409"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-413"
          xlink:label="f-413"
          xlink:type="locator"/>
        <link:footnote id="fn-13" xlink:label="fn-13" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-413"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-414"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-417"
          xlink:label="f-417"
          xlink:type="locator"/>
        <link:footnote id="fn-14" xlink:label="fn-14" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025 and June 30, 2024, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-418"
          xlink:to="fn-14"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-417"
          xlink:to="fn-14"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-427"
          xlink:label="f-427"
          xlink:type="locator"/>
        <link:footnote id="fn-15" xlink:label="fn-15" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2025, this amount includes &#x20ac;(667)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-427"
          xlink:to="fn-15"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-428"
          xlink:to="fn-15"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-443"
          xlink:label="f-443"
          xlink:type="locator"/>
        <link:footnote id="fn-16" xlink:label="fn-16" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#x20ac;3,353&#160;million, compared with &#x20ac;6,060 million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-443"
          xlink:to="fn-16"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-444"
          xlink:to="fn-16"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-570"
          xlink:label="f-570"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-545"
          xlink:label="f-545"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-571"
          xlink:label="f-571"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-542"
          xlink:label="f-542"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-544"
          xlink:label="f-544"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-573"
          xlink:label="f-573"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-543"
          xlink:label="f-543"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-572"
          xlink:label="f-572"
          xlink:type="locator"/>
        <link:footnote id="fn-17" xlink:label="fn-17" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-570"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-545"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-571"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-542"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-544"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-573"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-543"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-572"
          xlink:to="fn-17"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-529"
          xlink:label="f-529"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-527"
          xlink:label="f-527"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-526"
          xlink:label="f-526"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-528"
          xlink:label="f-528"
          xlink:type="locator"/>
        <link:footnote id="fn-18" xlink:label="fn-18" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the intangible asset recognized as part of the Dren-0201, Inc. acquisition (see Note B.1.)</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-529"
          xlink:to="fn-18"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-527"
          xlink:to="fn-18"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-526"
          xlink:to="fn-18"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-528"
          xlink:to="fn-18"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-561"
          xlink:label="f-561"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-558"
          xlink:label="f-558"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-559"
          xlink:label="f-559"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-560"
          xlink:label="f-560"
          xlink:type="locator"/>
        <link:footnote id="fn-19" xlink:label="fn-19" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note B.4</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-561"
          xlink:to="fn-19"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-558"
          xlink:to="fn-19"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-559"
          xlink:to="fn-19"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-560"
          xlink:to="fn-19"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-597"
          xlink:label="f-597"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-613"
          xlink:label="f-613"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-598"
          xlink:label="f-598"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-596"
          xlink:label="f-596"
          xlink:type="locator"/>
        <link:footnote id="fn-20" xlink:label="fn-20" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a &#x20ac;241&#160;million loan to OPAL JV Co being in substance part of the investment.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-597"
          xlink:to="fn-20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-613"
          xlink:to="fn-20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-598"
          xlink:to="fn-20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-596"
          xlink:to="fn-20"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-599"
          xlink:label="f-599"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-600"
          xlink:label="f-600"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-601"
          xlink:label="f-601"
          xlink:type="locator"/>
        <link:footnote id="fn-21" xlink:label="fn-21" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (&#x20ac;2.89 as of June 30, 2025, and &#x20ac;2.88 as of December 31, 2024). </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-599"
          xlink:to="fn-21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-600"
          xlink:to="fn-21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-601"
          xlink:to="fn-21"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-603"
          xlink:label="f-603"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-602"
          xlink:label="f-602"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-604"
          xlink:label="f-604"
          xlink:type="locator"/>
        <link:footnote id="fn-22" xlink:label="fn-22" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-603"
          xlink:to="fn-22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-602"
          xlink:to="fn-22"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-604"
          xlink:to="fn-22"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-607"
          xlink:label="f-607"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-606"
          xlink:label="f-606"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-605"
          xlink:label="f-605"
          xlink:type="locator"/>
        <link:footnote id="fn-23" xlink:label="fn-23" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-607"
          xlink:to="fn-23"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-606"
          xlink:to="fn-23"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-605"
          xlink:to="fn-23"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-627"
          xlink:label="f-627"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-628"
          xlink:label="f-628"
          xlink:type="locator"/>
        <link:footnote id="fn-24" xlink:label="fn-24" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-627"
          xlink:to="fn-24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-628"
          xlink:to="fn-24"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-630"
          xlink:label="f-630"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-629"
          xlink:label="f-629"
          xlink:type="locator"/>
        <link:footnote id="fn-25" xlink:label="fn-25" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#x20ac;200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was &#x20ac;189&#160;million (and was also &#x20ac;189 million as of December 31, 2024).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-630"
          xlink:to="fn-25"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-629"
          xlink:to="fn-25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-625"
          xlink:label="f-625"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-623"
          xlink:label="f-623"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-624"
          xlink:label="f-624"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-621"
          xlink:label="f-621"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-626"
          xlink:label="f-626"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-622"
          xlink:label="f-622"
          xlink:type="locator"/>
        <link:footnote id="fn-26" xlink:label="fn-26" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-625"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-623"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-624"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-621"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-626"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-622"
          xlink:to="fn-26"
          xlink:type="arc"/>
        <link:footnote id="fn-27" xlink:label="fn-27" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-625"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-623"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-624"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-621"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-626"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-622"
          xlink:to="fn-27"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-636"
          xlink:label="f-636"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-637"
          xlink:label="f-637"
          xlink:type="locator"/>
        <link:footnote id="fn-28" xlink:label="fn-28" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-636"
          xlink:to="fn-28"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-637"
          xlink:to="fn-28"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-723"
          xlink:label="f-723"
          xlink:type="locator"/>
        <link:footnote id="fn-29" xlink:label="fn-29" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-723"
          xlink:to="fn-29"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-728"
          xlink:label="f-728"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-726"
          xlink:label="f-726"
          xlink:type="locator"/>
        <link:footnote id="fn-30" xlink:label="fn-30" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-728"
          xlink:to="fn-30"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-726"
          xlink:to="fn-30"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-803"
          xlink:label="f-803"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-804"
          xlink:label="f-804"
          xlink:type="locator"/>
        <link:footnote id="fn-31" xlink:label="fn-31" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-803"
          xlink:to="fn-31"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-804"
          xlink:to="fn-31"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-809"
          xlink:label="f-809"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-810"
          xlink:label="f-810"
          xlink:type="locator"/>
        <link:footnote id="fn-32" xlink:label="fn-32" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#x20ac;2&#160;million in the first half of 2025, immaterial in the first half of 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-809"
          xlink:to="fn-32"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-810"
          xlink:to="fn-32"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-816"
          xlink:label="f-816"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-815"
          xlink:label="f-815"
          xlink:type="locator"/>
        <link:footnote id="fn-33" xlink:label="fn-33" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</xhtml:span><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#x20ac;459 million loss in the first half of 2025 relating to the deconsolidation of Opella (see Note B.1.)., a &#x20ac;5&#160;million profit in 2024, and immaterial in the first half of 2024.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-816"
          xlink:to="fn-33"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-815"
          xlink:to="fn-33"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-842"
          xlink:label="f-842"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-843"
          xlink:label="f-843"
          xlink:type="locator"/>
        <link:footnote id="fn-34" xlink:label="fn-34" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-842"
          xlink:to="fn-34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-843"
          xlink:to="fn-34"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-879"
          xlink:label="f-879"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-878"
          xlink:label="f-878"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-877"
          xlink:label="f-877"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-881"
          xlink:label="f-881"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-880"
          xlink:label="f-880"
          xlink:type="locator"/>
        <link:footnote id="fn-35" xlink:label="fn-35" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net debt does not include lease liabilities, which amounted to &#x20ac;1,776 million as of June 30, 2025 and &#x20ac;1,906 million as of December&#160;31, 2024</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-879"
          xlink:to="fn-35"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-878"
          xlink:to="fn-35"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-877"
          xlink:to="fn-35"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-881"
          xlink:to="fn-35"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-880"
          xlink:to="fn-35"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-892"
          xlink:label="f-892"
          xlink:type="locator"/>
        <link:footnote id="fn-36" xlink:label="fn-36" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of Ju</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, 2025, current other bank borrowings include &#x20ac;4,535&#160;million related to the US commercial paper program and &#x20ac;230&#160;million related to the Negotiable European Commercial Paper program in France.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-892"
          xlink:to="fn-36"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1059"
          xlink:label="f-1059"
          xlink:type="locator"/>
        <link:footnote id="fn-37" xlink:label="fn-37" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash &amp; cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of &#x20ac;5&#160;million, with &#x20ac;18&#160;million debited to </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1059"
          xlink:to="fn-37"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1063"
          xlink:label="f-1063"
          xlink:type="locator"/>
        <link:footnote id="fn-38" xlink:label="fn-38" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2025, the fair value of these forward contracts represented an asset of &#x20ac;77 million; the opposite entry was recognized in </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, with the impact on financial income and expense being immaterial.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1063"
          xlink:to="fn-38"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1073"
          xlink:label="f-1073"
          xlink:type="locator"/>
        <link:footnote id="fn-39" xlink:label="fn-39" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of &#x20ac;25 million, with &#x20ac;0 million&#160;credited to </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</xhtml:span> to recognize the hedging cost</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1073"
          xlink:to="fn-39"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1173"
          xlink:label="f-1173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1156"
          xlink:label="f-1156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1174"
          xlink:label="f-1174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1168"
          xlink:label="f-1168"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1172"
          xlink:label="f-1172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1160"
          xlink:label="f-1160"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1164"
          xlink:label="f-1164"
          xlink:type="locator"/>
        <link:footnote id="fn-40" xlink:label="fn-40" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2025, this comprised a non-current portion of &#x20ac;569 million and a current portion of &#x20ac;72 million.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1173"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1156"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1174"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1168"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1172"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1160"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1164"
          xlink:to="fn-40"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1162"
          xlink:label="f-1162"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1163"
          xlink:label="f-1163"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1161"
          xlink:label="f-1161"
          xlink:type="locator"/>
        <link:footnote id="fn-41" xlink:label="fn-41" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(b&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1162"
          xlink:to="fn-41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1163"
          xlink:to="fn-41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1161"
          xlink:to="fn-41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1164"
          xlink:to="fn-41"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1185"
          xlink:label="f-1185"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1184"
          xlink:label="f-1184"
          xlink:type="locator"/>
        <link:footnote id="fn-42" xlink:label="fn-42" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">a)&#160;&#160;&#160;&#160;Includes &#x20ac;1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,027&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,293 million</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1185"
          xlink:to="fn-42"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1184"
          xlink:to="fn-42"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1202"
          xlink:label="f-1202"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1197"
          xlink:label="f-1197"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1207"
          xlink:label="f-1207"
          xlink:type="locator"/>
        <link:footnote id="fn-43" xlink:label="fn-43" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1202"
          xlink:to="fn-43"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1197"
          xlink:to="fn-43"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1207"
          xlink:to="fn-43"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1213"
          xlink:label="f-1213"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1214"
          xlink:label="f-1214"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1216"
          xlink:label="f-1216"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1215"
          xlink:label="f-1215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1212"
          xlink:label="f-1212"
          xlink:type="locator"/>
        <link:footnote id="fn-44" xlink:label="fn-44" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1213"
          xlink:to="fn-44"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1214"
          xlink:to="fn-44"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1216"
          xlink:to="fn-44"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1215"
          xlink:to="fn-44"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1212"
          xlink:to="fn-44"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1241"
          xlink:label="f-1241"
          xlink:type="locator"/>
        <link:footnote id="fn-45" xlink:label="fn-45" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1241"
          xlink:to="fn-45"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1242"
          xlink:label="f-1242"
          xlink:type="locator"/>
        <link:footnote id="fn-46" xlink:label="fn-46" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1242"
          xlink:to="fn-46"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1239"
          xlink:label="f-1239"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1240"
          xlink:label="f-1240"
          xlink:type="locator"/>
        <link:footnote id="fn-47" xlink:label="fn-47" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes actuarial gains/ (losses) related to Opella of &#x20ac;(4)&#160;million for the first half of 2025 and &#x20ac;(6)&#160;million for the first half of 2024 </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1239"
          xlink:to="fn-47"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1240"
          xlink:to="fn-47"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1241"
          xlink:to="fn-47"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1242"
          xlink:to="fn-47"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1289"
          xlink:label="f-1289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1293"
          xlink:label="f-1293"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1291"
          xlink:label="f-1291"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1294"
          xlink:label="f-1294"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1292"
          xlink:label="f-1292"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1295"
          xlink:label="f-1295"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1296"
          xlink:label="f-1296"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1297"
          xlink:label="f-1297"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1288"
          xlink:label="f-1288"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1290"
          xlink:label="f-1290"
          xlink:type="locator"/>
        <link:footnote id="fn-48" xlink:label="fn-48" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;text-align:justify"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1289"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1293"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1291"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1294"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1292"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1295"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1296"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1297"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1288"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1290"
          xlink:to="fn-48"
          xlink:type="arc"/>
        <link:footnote id="fn-49" xlink:label="fn-49" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1291"
          xlink:to="fn-49"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1290"
          xlink:to="fn-49"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1305"
          xlink:label="f-1305"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1317"
          xlink:label="f-1317"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1325"
          xlink:label="f-1325"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1311"
          xlink:label="f-1311"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1319"
          xlink:label="f-1319"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1315"
          xlink:label="f-1315"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1307"
          xlink:label="f-1307"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1321"
          xlink:label="f-1321"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1313"
          xlink:label="f-1313"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1323"
          xlink:label="f-1323"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1309"
          xlink:label="f-1309"
          xlink:type="locator"/>
        <link:footnote id="fn-50" xlink:label="fn-50" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1305"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1317"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1325"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1311"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1319"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1315"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1307"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1321"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1313"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1323"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1309"
          xlink:to="fn-50"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1304"
          xlink:label="f-1304"
          xlink:type="locator"/>
        <link:footnote id="fn-51" xlink:label="fn-51" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;(25) million in the first half of 2025 and &#x20ac;(24) million in the first half of 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1304"
          xlink:to="fn-51"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1305"
          xlink:to="fn-51"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1306"
          xlink:label="f-1306"
          xlink:type="locator"/>
        <link:footnote id="fn-52" xlink:label="fn-52" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(4) million in the first half of 2025 and &#x20ac;(18)&#160;million in the first half of 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1306"
          xlink:to="fn-52"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1307"
          xlink:to="fn-52"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1312"
          xlink:label="f-1312"
          xlink:type="locator"/>
        <link:footnote id="fn-53" xlink:label="fn-53" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1312"
          xlink:to="fn-53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1313"
          xlink:to="fn-53"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1318"
          xlink:label="f-1318"
          xlink:type="locator"/>
        <link:footnote id="fn-54" xlink:label="fn-54" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">Includes a financial expense of &#x20ac;50</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </xhtml:span>million for the six months ended June 30, 2025 and &#x20ac;176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1319"
          xlink:to="fn-54"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1318"
          xlink:to="fn-54"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1339"
          xlink:label="f-1339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1337"
          xlink:label="f-1337"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1341"
          xlink:label="f-1341"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1335"
          xlink:label="f-1335"
          xlink:type="locator"/>
        <link:footnote id="fn-55" xlink:label="fn-55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1339"
          xlink:to="fn-55"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1337"
          xlink:to="fn-55"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1341"
          xlink:to="fn-55"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1335"
          xlink:to="fn-55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1350"
          xlink:label="f-1350"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1352"
          xlink:label="f-1352"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1346"
          xlink:label="f-1346"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1348"
          xlink:label="f-1348"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1344"
          xlink:label="f-1344"
          xlink:type="locator"/>
        <link:footnote id="fn-56" xlink:label="fn-56" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1350"
          xlink:to="fn-56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1352"
          xlink:to="fn-56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1346"
          xlink:to="fn-56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1348"
          xlink:to="fn-56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1344"
          xlink:to="fn-56"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1345"
          xlink:label="f-1345"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1347"
          xlink:label="f-1347"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1343"
          xlink:label="f-1343"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1351"
          xlink:label="f-1351"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1349"
          xlink:label="f-1349"
          xlink:type="locator"/>
        <link:footnote id="fn-57" xlink:label="fn-57" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1345"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1347"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1343"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1351"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1349"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1350"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1352"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1346"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1348"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1344"
          xlink:to="fn-57"
          xlink:type="arc"/>
        <link:footnote id="fn-58" xlink:label="fn-58" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</xhtml:span><xhtml:div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2024 component of the temporary exceptional corporate income tax contribution, introduced under the 2025 French Finance Bill, is included in the<xhtml:br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1345"
          xlink:to="fn-58"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1346"
          xlink:to="fn-58"
          xlink:type="arc"/>
        <link:footnote id="fn-59" xlink:label="fn-59" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</xhtml:span>For the six months ended June 30, 2025, this line includes a tax expense of &#x20ac;17&#160;million, representing the estimated impact of Pillar Two based on Sanofi&#x2019;s current understanding of Pillar Two rules, and &#x20ac;52&#160;million for the six months ended June 30, 2024</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1349"
          xlink:to="fn-59"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1350"
          xlink:to="fn-59"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1468"
          xlink:label="f-1468"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1380"
          xlink:label="f-1380"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1388"
          xlink:label="f-1388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1476"
          xlink:label="f-1476"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1372"
          xlink:label="f-1372"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1420"
          xlink:label="f-1420"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1412"
          xlink:label="f-1412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1396"
          xlink:label="f-1396"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1452"
          xlink:label="f-1452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1428"
          xlink:label="f-1428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1460"
          xlink:label="f-1460"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1484"
          xlink:label="f-1484"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1436"
          xlink:label="f-1436"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1364"
          xlink:label="f-1364"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1444"
          xlink:label="f-1444"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1404"
          xlink:label="f-1404"
          xlink:type="locator"/>
        <link:footnote id="fn-60" xlink:label="fn-60" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1468"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1380"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1388"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1476"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1372"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1420"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1412"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1396"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1452"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1428"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1460"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1484"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1436"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1364"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1444"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1404"
          xlink:to="fn-60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1497"
          xlink:label="f-1497"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1495"
          xlink:label="f-1495"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1499"
          xlink:label="f-1499"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1489"
          xlink:label="f-1489"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1491"
          xlink:label="f-1491"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1487"
          xlink:label="f-1487"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1493"
          xlink:label="f-1493"
          xlink:type="locator"/>
        <link:footnote id="fn-61" xlink:label="fn-61" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1497"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1495"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1499"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1489"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1491"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1487"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1493"
          xlink:to="fn-61"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1488"
          xlink:label="f-1488"
          xlink:type="locator"/>
        <link:footnote id="fn-62" xlink:label="fn-62" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1488"
          xlink:to="fn-62"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1489"
          xlink:to="fn-62"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1492"
          xlink:label="f-1492"
          xlink:type="locator"/>
        <link:footnote id="fn-63" xlink:label="fn-63" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1492"
          xlink:to="fn-63"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1493"
          xlink:to="fn-63"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1496"
          xlink:label="f-1496"
          xlink:type="locator"/>
        <link:footnote id="fn-64" xlink:label="fn-64" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1497"
          xlink:to="fn-64"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1496"
          xlink:to="fn-64"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1512"
          xlink:label="f-1512"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1518"
          xlink:label="f-1518"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1509"
          xlink:label="f-1509"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1506"
          xlink:label="f-1506"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1524"
          xlink:label="f-1524"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1503"
          xlink:label="f-1503"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1515"
          xlink:label="f-1515"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1527"
          xlink:label="f-1527"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1521"
          xlink:label="f-1521"
          xlink:type="locator"/>
        <link:footnote id="fn-65" xlink:label="fn-65" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1512"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1518"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1509"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1506"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1524"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1503"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1515"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1527"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1521"
          xlink:to="fn-65"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1551"
          xlink:label="f-1551"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1539"
          xlink:label="f-1539"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1530"
          xlink:label="f-1530"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1534"
          xlink:label="f-1534"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1553"
          xlink:label="f-1553"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1537"
          xlink:label="f-1537"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1545"
          xlink:label="f-1545"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1536"
          xlink:label="f-1536"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1542"
          xlink:label="f-1542"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1552"
          xlink:label="f-1552"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1541"
          xlink:label="f-1541"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1554"
          xlink:label="f-1554"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1531"
          xlink:label="f-1531"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1538"
          xlink:label="f-1538"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1540"
          xlink:label="f-1540"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1532"
          xlink:label="f-1532"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1543"
          xlink:label="f-1543"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1544"
          xlink:label="f-1544"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1529"
          xlink:label="f-1529"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1533"
          xlink:label="f-1533"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1546"
          xlink:label="f-1546"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1547"
          xlink:label="f-1547"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1535"
          xlink:label="f-1535"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1550"
          xlink:label="f-1550"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1548"
          xlink:label="f-1548"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1555"
          xlink:label="f-1555"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1549"
          xlink:label="f-1549"
          xlink:type="locator"/>
        <link:footnote id="fn-66" xlink:label="fn-66" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1551"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1539"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1530"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1534"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1553"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1537"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1545"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1536"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1542"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1552"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1541"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1554"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1531"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1538"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1540"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1532"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1543"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1544"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1529"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1533"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1546"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1547"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1535"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1550"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1548"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1555"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1549"
          xlink:to="fn-66"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1580"
          xlink:label="f-1580"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1560"
          xlink:label="f-1560"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1576"
          xlink:label="f-1576"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1558"
          xlink:label="f-1558"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1574"
          xlink:label="f-1574"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1566"
          xlink:label="f-1566"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1572"
          xlink:label="f-1572"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1578"
          xlink:label="f-1578"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1562"
          xlink:label="f-1562"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1564"
          xlink:label="f-1564"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1570"
          xlink:label="f-1570"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1568"
          xlink:label="f-1568"
          xlink:type="locator"/>
        <link:footnote id="fn-67" xlink:label="fn-67" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1580"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1560"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1576"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1558"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1574"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1566"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1572"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1578"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1562"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1564"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1570"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1568"
          xlink:to="fn-67"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1559"
          xlink:label="f-1559"
          xlink:type="locator"/>
        <link:footnote id="fn-68" xlink:label="fn-68" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1560"
          xlink:to="fn-68"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1559"
          xlink:to="fn-68"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1561"
          xlink:label="f-1561"
          xlink:type="locator"/>
        <link:footnote id="fn-69" xlink:label="fn-69" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1561"
          xlink:to="fn-69"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1562"
          xlink:to="fn-69"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1563"
          xlink:label="f-1563"
          xlink:type="locator"/>
        <link:footnote id="fn-70" xlink:label="fn-70" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;210&#160;million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to &#x20ac;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1563"
          xlink:to="fn-70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1564"
          xlink:to="fn-70"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1567"
          xlink:label="f-1567"
          xlink:type="locator"/>
        <link:footnote id="fn-71" xlink:label="fn-71" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1567"
          xlink:to="fn-71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1568"
          xlink:to="fn-71"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1569"
          xlink:label="f-1569"
          xlink:type="locator"/>
        <link:footnote id="fn-72" xlink:label="fn-72" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.16.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1569"
          xlink:to="fn-72"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1570"
          xlink:to="fn-72"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1571"
          xlink:label="f-1571"
          xlink:type="locator"/>
        <link:footnote id="fn-73" xlink:label="fn-73" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note B.17</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1571"
          xlink:to="fn-73"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1572"
          xlink:to="fn-73"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1585"
          xlink:label="f-1585"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1584"
          xlink:label="f-1584"
          xlink:type="locator"/>
        <link:footnote id="fn-74" xlink:label="fn-74" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1585"
          xlink:to="fn-74"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1584"
          xlink:to="fn-74"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1599"
          xlink:label="f-1599"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1591"
          xlink:label="f-1591"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1601"
          xlink:label="f-1601"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1597"
          xlink:label="f-1597"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1593"
          xlink:label="f-1593"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1595"
          xlink:label="f-1595"
          xlink:type="locator"/>
        <link:footnote id="fn-75" xlink:label="fn-75" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1599"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1591"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1601"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1597"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1593"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1595"
          xlink:to="fn-75"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1664"
          xlink:label="f-1664"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1665"
          xlink:label="f-1665"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1663"
          xlink:label="f-1663"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1662"
          xlink:label="f-1662"
          xlink:type="locator"/>
        <link:footnote id="fn-76" xlink:label="fn-76" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1664"
          xlink:to="fn-76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1665"
          xlink:to="fn-76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1663"
          xlink:to="fn-76"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1662"
          xlink:to="fn-76"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-1671"
          xlink:label="f-1671"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-1670"
          xlink:label="f-1670"
          xlink:type="locator"/>
        <link:footnote id="fn-77" xlink:label="fn-77" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> In 2025, this line includes an expense of &#x20ac;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1671"
          xlink:to="fn-77"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-1670"
          xlink:to="fn-77"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
